<SEC-DOCUMENT>0001193125-13-438247.txt : 20131112
<SEC-HEADER>0001193125-13-438247.hdr.sgml : 20131111
<ACCEPTANCE-DATETIME>20131112160857
ACCESSION NUMBER:		0001193125-13-438247
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20130930
FILED AS OF DATE:		20131112
DATE AS OF CHANGE:		20131112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		131210246

	BUSINESS ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9640 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d610136d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For quarterly period ended September&nbsp;30, 2013 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-36112 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS,
INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>06-1591613</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State of organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9640 Medical Center Drive, Rockville, Maryland 20850 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices and zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(301) 251-5172 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports)
and (2)&nbsp;has been subject to such filing requirements for the past 90
days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required
to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting
company&#148; in Rule 12b-2 of the Exchange Act. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> <U></U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of the registrant&#146;s common stock outstanding on October&nbsp;31, 2013 was 25,020,288. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page<BR>Number</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PART&nbsp;I.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>FINANCIAL INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_12">Financial Statements </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_1">Consolidated Balance Sheets at September 30, 2013 and December 31, 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_2">Consolidated Statements of Operations and Comprehensive Income (Loss) for the three and nine months ended September
 30, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_3">Consolidated Statements of Cash Flows for the nine months ended September 30, 2013 and 2012</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_4">Notes to Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_5">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;3.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_6">Quantitative and Qualitative Disclosures about Market Risk</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;4.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_7">Controls and Procedures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>PART&nbsp;II.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>OTHER INFORMATION</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;1A.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_8">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;2.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_9">Unregistered Sales of Equity Securities and Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Item&nbsp;6.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_10">Exhibits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx610136_11">Signatures</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART I. FINANCIAL INFORMATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx610136_12"></A>ITEM&nbsp;1. FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx610136_1">
</A>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,<BR>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,<BR>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B></B>(unaudited)<B></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,569,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,281,282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,046,219</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,103,449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">137,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,953,929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,927,008</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,469,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,975,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Liabilities and stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,798,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,739,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">939,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability &#150; current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,229,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,768</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue &#150; current</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,298,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,123,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,265,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,728,094</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,378,184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,445,171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,888,688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,801,653</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">679,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,947</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue, net of current portion</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,812,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,956,343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,024,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,984,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 convertible preferred stock, $0.01 par value &#150; 26,874,792 shares authorized, 26,874,792 shares issued and outstanding
at September&nbsp;30, 2013 and December&nbsp;31, 2012; aggregate liquidation preference of $27,000,000 at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">268,748</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 convertible preferred stock, $0.01 par value &#150; 7,364,582 shares authorized, 7,364,582 shares issued and outstanding at
September&nbsp;30, 2013 and December&nbsp;31, 2012; aggregate liquidation preference of $7,000,000 at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B convertible preferred stock, $0.01 par value &#150; 71,401,237 shares authorized, 71,401,237 shares issued and outstanding at
September&nbsp;30, 2013 and December&nbsp;31, 2012; aggregate liquidation preference of $31,000,000 at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C convertible preferred stock, $0.01 par value &#150; 110,952,217 shares authorized, 110,952,217 shares issued and outstanding
at September&nbsp;30, 2013 and December&nbsp;31, 2012; aggregate liquidation preference of $45,000,000 at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,109,522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-1 convertible preferred stock, $0.01 par value &#150; 30,000,000 shares authorized, 14,446,227 shares issued and outstanding
at September&nbsp;30, 2013 and December&nbsp;31, 2012; aggregate liquidation preference of $9,400,000 at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144,462</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 convertible preferred stock, $0.01 par value &#150; 75,000,000 shares authorized, 63,681,176 shares issued and outstanding
at September&nbsp;30, 2013 and December&nbsp;31, 2012; aggregate liquidation preference of $41,500,000 at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,812</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.01 par value &#150; 425,000,000 shares authorized, 2,124,624 and 1,098,914 shares issued and outstanding at
September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Treasury stock, at cost; 14,381 shares at September&nbsp;30, 2013 and December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57,742</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">165,569,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,334,646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(172,528,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(175,472,403</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,048,414</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,237,308</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">41,975,907</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,746,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx610136_2"></A>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenues:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,111,173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,532,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,015,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,283,510</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">120,895</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">548,864</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,112,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,744,047</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total revenues</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,232,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,081,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,128,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,027,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Costs and expenses:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,087,919</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,968,253</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,233,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,924,987</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,986,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,514,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,322,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,640,740</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total costs and expenses</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,074,474</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,482,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,556,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43,565,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Income (loss) from operations</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,157,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,598,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,571,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,461,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income (expense)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(553,612</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(627,281</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,752</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net comprehensive income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,603,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,600,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted net income (loss) per common share</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average number of common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,242,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,502,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,908,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx610136_3"></A>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">834,615</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">722,496</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">393,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">628,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair value adjustment of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">626,349</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(235,063</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,713,429</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(965,815</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(69,231</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,940,897</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,444,288</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(297,214</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,860</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lease exit liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(466,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(395,694</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,968,859</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(27,935,268</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">87,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,988,440</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,281,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,036,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(530,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,036,700</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(530,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from issuance of common stock</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net change in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,173,957</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24,767,276</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,743,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,218,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,569,198</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">30,451,085</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>See accompanying notes.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MACROGENICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx610136_4"></A>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>1. Overview and Basis of Presentation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MacroGenics, Inc. (the &#147;Company&#148;) was incorporated in Delaware on August&nbsp;14, 2000. The Company is a clinical-stage
biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The Company generates its pipeline of product candidates from its proprietary
suite of next-generation antibody technology platforms which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which the Company has identified through its understanding of disease
biology and immune-mediated mechanisms, may address disease-specific challenges which are not currently being met by existing therapies. The Company creates both differentiated molecules that are directed to novel cancer targets, as well as
&#147;bio-betters&#148; which are drugs designed to improve upon marketed medicines. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying unaudited interim consolidated
financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics West, Inc. All intercompany accounts and transactions have been eliminated in consolidation. These financial statements have been prepared
pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the
United States of America (GAAP) have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these consolidated financial statements should be read in conjunction with the financial statements and
notes thereto included in the Company&#146;s Prospectus filed with the SEC pursuant to Rule 424(b)(4) on October&nbsp;11, 2013 (the Prospectus). In the opinion of the Company&#146;s management, the consolidated unaudited interim consolidated
financial statements reflect all adjustments necessary to present fairly the results of operations for the three and nine months ended September&nbsp;30, 2013 and 2012, the Company&#146;s financial position as of September&nbsp;30, 2013, and the
cash flows for the nine months ended September&nbsp;30, 2013 and 2012. These adjustments are of a normal recurring nature. The results of operations for the three and nine months ended September&nbsp;30, 2013 are not necessarily indicative of future
financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise
about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in
one segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;16, 2013, the Company completed an initial public offering (IPO) of its common stock, which resulted in the sale of 5,750,000 shares, including all additional shares available to cover over-allotments, at a price of $16.00 per share.
The Company received net proceeds before expenses from the IPO of $85.6 million after deducting underwriting discounts and commissions paid by the Company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>2. Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use
of Estimates </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the financial statements in accordance with GAAP requires the Company to make estimates and
judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made
its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values
of assets, convertible preferred stock and common stock, preferred stock warrant liability, income taxes, pre-clinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various
other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, through September&nbsp;30, 2013, the Company utilized estimates and assumptions in
determining the fair value of its common stock. The Company granted stock options at exercise prices not less than the fair value of its common stock as determined by the board of directors, with input from management. Management uses
contemporaneous valuations in estimating the fair value of its common stock. The board of directors has determined the estimated fair value of the common stock based on a number of objective and subjective factors, including external market
considerations affecting the biotechnology industry and the historic prices at which the Company sold shares of its preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash and Cash
Equivalents </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company considers all investments in highly liquid financial instruments with an original maturity of three months
or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of certificates of deposit and investment in money market funds with commercial banks and financial institutions. Cash equivalents are stated at amortized
cost, plus accrued interest, which approximates fair value. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accounts Receivable </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding
amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors
including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. No allowance was recorded as of
September&nbsp;30, 2013 or December&nbsp;31, 2012, as the Company has a history of collecting on all outstanding accounts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Deferred Initial Public
Offering Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred IPO costs as of September&nbsp;30, 2013, consisted of legal, accounting, printing and filing fees were
capitalized. The deferred costs are included in prepaid expenses on the consolidated balance sheets. The deferred offering costs were offset against the IPO proceeds received upon the completion of the offering in October 2013. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Cash </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is
required to maintain certificates of deposit that serve as collateral for various operating leases and corporate credit card accounts. Amounts classified as restricted cash on the consolidated balance sheets are $404,850 at September&nbsp;30, 2013
and December&nbsp;31, 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fair Value of Financial Instruments </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair market values of the financial instruments included in the financial statements, which include cash equivalents and money market
accounts, approximate their carrying values at September&nbsp;30, 2013 and December&nbsp;31, 2012, due to their short-term maturities. The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial
Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, <I>Fair Value Measurements and Disclosures</I> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair
value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value, and requires assets and liabilities carried at fair
value to be classified and disclosed in one of the following three categories: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 1&nbsp;&#150; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 2&nbsp;&#150; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active
markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market
data. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Level 3&nbsp;&#150; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting
entity&nbsp;&#150; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate
level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial assets and liabilities subject to fair value measurements were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at September&nbsp;30, 2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active&nbsp;Markets&nbsp;for</B><br><B>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other</B><br><B>Observable&nbsp;Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,522,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,522,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,047,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,047,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,974,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,974,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(679,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(679,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair Value Measurements at December&nbsp;31, 2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Quoted&nbsp;Prices&nbsp;in</B><br><B>Active&nbsp;Markets&nbsp;for</B><br><B>Identical Assets</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant&nbsp;Other</B><br><B>Observable&nbsp;Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Significant</B><br><B>Unobservable</B><br><B>Inputs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level 3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,695,197</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,047,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">404,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">48,148,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Liabilities:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preferred stock warrant liability</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&nbsp;31, 2012, the Company transferred its money market funds from Level 2 to Level 1 because
the inputs are now based upon a quoted market price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Level 1 securities primarily consist of restricted cash, cash
equivalents and money market funds. The Company determines the estimated fair value for its Level 1 securities using quoted (unadjusted) prices for identical assets or liabilities in active markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines the estimated fair value for its Level 2 securities using the following methods: quoted prices for similar
assets/liabilities in active markets, inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves volatilities, default rates, etc.) and inputs that are derived principally from or corroborated by
other observable market data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table provides a rollforward of the Company&#146;s preferred stock warrant
liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as defined in ASC 820: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(52,947</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total unrealized gains (losses) included in earnings</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(626,349</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at September&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(679,296</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to estimate the fair value of the preferred stock purchase warrants, the business enterprise value
was established based on a discounted cash flow model (income approach). The Company utilized an option pricing method to value the shares using a contingent claims analysis, which applies a series of call options whose inputs reflect the
liquidation preferences and conversion behavior of the different classes of equity. After the equity value of the business enterprise was determined, the total equity value is allocated to the various equity instruments such as preferred stock,
stock options and preferred stock purchase warrants. Key management estimates relate to the time period to liquidation and conversion behavior of a particular class of stockholders. The business enterprise value includes assumptions related to
product approval, market penetration and costs to develop the product. Significant changes to these assumptions would result in increases/decreases to the fair value of the outstanding warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total unrealized gains (losses) on the preferred stock warrants included in earnings is included as a component of other income (expense)
in the consolidated statement of operations and comprehensive income. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Concentration of Credit Risk </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Substantially all of the Company&#146;s cash and cash equivalents are maintained with major financial institutions in the United States.
Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents,
and accounts receivable. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three and nine months ended September&nbsp;30, 2013 and 2012, all of the Company&#146;s grant revenue was related to contracts and
research grants received from U.S. government agencies. Collaborations with Les Laboratoires Servier and Institut de Recherches Servier (collectively, Servier), Boehringer Ingelheim GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc.
(Pfizer) and Eli Lilly&nbsp;&amp; Co. (Eli Lilly) account for all other revenue. All outstanding receivables are due from Gilead, Pfizer, Boehringer, Eli Lilly, and U.S. government agencies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents the percentage of all significant revenue earned in the periods indicated: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="52%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Servier</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents the percentage of all significant accounts receivable: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gilead</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Pfizer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boehringer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eli Lilly</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Government Agencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Property and Equipment </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are
removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following
estimated useful lives: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">3 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">10 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Laboratory and office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">5 years</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Shorter&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;useful&nbsp;life</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Impairment of Long-Lived Assets </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, <I>Property, Plant and
Equipment</I>. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by
a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of
the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the
carrying amount or fair value, less costs to sell. As of September&nbsp;30, 2013 and December&nbsp;31, 2012, the Company determined that there were no impaired assets and had no assets held-for-sale. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Revenue Recognition
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based
therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i)&nbsp;licenses, or options to obtain licenses, to the Company&#146;s technological platforms, such as its Fc
Optimization and Dual-Affinity Re-Targeting (DART) technologies, (ii)&nbsp;rights to future technological improvements, (iii)&nbsp;research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and
(iv)&nbsp;the manufacture of pre-clinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development
activities, payments for the manufacture of pre-clinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements
include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of the FASB ASC Topic 605-25, <I>Revenue Recognition&nbsp;&#150;Multiple-Element
Arrangements</I>, and ASC Topic 605-28, <I>Revenue Recognition&#150;Milestone Method</I>, in accounting for these agreements. In order to account for these agreements, the Company must </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the
delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the periods presented, the Company had the following two types of agreements with the parties identified below: 1) exclusive development
and commercialization licenses to use the Company&#146;s technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) Option/research agreements to secure on
established terms, development and commercialization licenses to anticancer and other therapeutic product candidates to collaborator selected targets developed by the Company during an option period (referred to herein as right-to-develop
agreements). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material
financial consequences to the Company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Exclusive Licenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The deliverables under an exclusive license agreement generally include the exclusive license to the Company&#146;s DART technology with
respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and pre-clinical development activities to be performed on behalf of the collaborator. In some cases the
Company may have an option to participate in the co-development of product candidates that result from such agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally,
exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i)&nbsp;at the collaborator&#146;s request, provide research and pre-clinical development services at
negotiated prices which are generally consistent with what other third parties would charge, (ii)&nbsp;earn payments upon the achievement of certain milestones, (iii)&nbsp;earn royalty payments, and (iv)&nbsp;in some cases grant the Company an
option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company&#146;s intellectual property rights and whether the Company exercises
any co-development and co-commercialization rights. The Company may provide technical assistance and share any technology improvements with its collaborators during the term of the collaboration agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements
to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the partner and the availability of technology
platform and product research expertise in the general marketplace. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated
selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company&#146;s previous collaboration agreements,
recent pre-clinical and clinical testing results of therapeutic product candidates that use the Company&#146;s technology platforms, the Company&#146;s pricing practices and pricing objectives, the likelihood that technological improvements will be
made, the likelihood that technological improvements made will be used by the Company&#146;s collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value. Prior
to the adoption of Accounting Standards Update (ASU) No.&nbsp;2009-13, <I>Revenue Arrangements with Multiple Deliverables</I>, on January&nbsp;1, 2011, the Company determined that its licenses lacked stand-alone value because it did not have
vendor-specific objective evidence of selling price (VSOE), and were combined with other elements of the arrangement and any amounts associated with the license were deferred and amortized over a certain period, which the Company refers to as the
Company&#146;s period of substantial involvement. In making the determination of the length of the period over which to defer revenue for contracts entered into prior to the adoption of ASU No.&nbsp;2009-13, significant judgment and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
estimation is used by the Company and can have an impact on the amount of revenue recognized in a given period. Historically, the Company&#146;s involvement with the development of a
collaborator&#146;s product candidate has been significant at the early stages of development, and lessens as it progresses into clinical trials. Accordingly, the Company generally estimates this period of substantial involvement to begin at the
inception of the collaboration agreement and conclude at the end of the Company&#146;s substantial involvement. ASU No.&nbsp;2009-13 amends the criteria for separating and allocating consideration in a multiple element arrangement by modifying the
fair value requirements for revenue recognition and eliminating the use of the residual value method. The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price
(BESP), if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management&#146;s
judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market
opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions
used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has
value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the
Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition
model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In determining the separate units of accounting, the Company evaluated whether the exclusive license had standalone value to the collaborator
based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination included the research and development capabilities of the collaborator and the availability of relevant research expertise
in the marketplace. In addition, the Company considered whether or not (i)&nbsp;the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii)&nbsp;the value of the license was dependent on
the undelivered items and (iii)&nbsp;the collaborator or other vendors could provide the undelivered items. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company reassesses its
periods of substantial involvement over which the Company amortizes its upfront license fees and makes adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target
license, but retains its right to use the Company&#146;s technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there
is substantial pre-clinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, the Company would recognize as revenue any
portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has
stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of pre-clinical and clinical materials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes revenue related to research and pre-clinical development services that represent separate units of accounting as they
are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection of the related receivable is probable. The Company recognizes revenue related to the rights to future technological
improvements over the estimated term of the applicable license. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company typically performs research activities and pre-clinical
development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and pre-clinical testing stages of drug development under its exclusive licenses. The Company records amounts
received for research materials produced or services performed as revenue from collaborative research. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s license agreements have milestone payments which for reporting purposes are
aggregated into three categories: (i)&nbsp;development milestones, (ii)&nbsp;regulatory milestones, and (iii)&nbsp;sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical
trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries&#146; regulatory authorities or on receipt of actual marketing approvals for the
compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the inception
of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether
(a)&nbsp;the consideration is commensurate with either (1)&nbsp;the entity&#146;s performance to achieve the milestone, or (2)&nbsp;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the
entity&#146;s performance to achieve the milestone, (b)&nbsp;the consideration relates solely to past performance and (c)&nbsp;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company
evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone
consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Non-refundable
development and regulatory milestones that are expected to be achieved as a result of the Company&#146;s efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the
milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to the achievement of such milestones are generally achieved after the period of
substantial involvement and are recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman"><I>Right-to-Develop Agreements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize
in specified geographic territories product candidates developed by the Company under agreed upon research and pre-clinical development product programs. The product candidates resulting from each program are all directed to a specific target
selected by the collaborator. Under these agreements, fees may be due to the Company (i)&nbsp;at the inception of the arrangement (referred to as &#147;upfront&#148; fees or payments), (ii)&nbsp;the selection of a target for a program,
(iii)&nbsp;upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv)&nbsp;some combination of all of these fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered
substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in
evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront
consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at
the inception of the agreement. For those right-to-develop agreements entered into prior to the adoption of ASU No.&nbsp;2009-13 where the options to secure development and commercialization licenses are considered substantive, the Company has
deferred the upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration
agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option, generally 12 months. Subsequent to the adoption of ASU No. 2009-13, the Company&#146;s evaluation
of whether the option is substantive is consistent with pre-adoption of ASU </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
No.&nbsp;2009-13. How the Company determines the selling price of the option is the only difference between pre and post adoption of ASU No.&nbsp;2009-13. Post adoption of ASU No.&nbsp;2009-13,
the selling prices of deliverables under an arrangement may be derived using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the
right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management&#146;s judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in
negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product
candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration
between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i)&nbsp;the delivered item has value to the customer on a standalone basis and (ii)&nbsp;if the arrangement includes a general right of return
relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company&#146;s control. The arrangement consideration that is fixed or determinable at the inception of the
arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management
exercises significant judgment in determining whether a deliverable is a separate unit of accounting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a collaborator exercises an
option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon
exercise, through management&#146;s best estimate. Management&#146;s determination of selling price includes such factors as stage of development, market potential and cash flow models used during the negotiation with the collaborator. There have
been no option license exercises to date for any period presented. Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee to the development and
commercialization license and apply the multiple-element revenue recognition criteria to the development and commercialization license and any other deliverables to determine the appropriate revenue recognition, which will be consistent with the
Company&#146;s accounting policy for upfront payments on exclusive licenses event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as
revenue, but was classified as deferred revenue, at the date of such termination. The Company&#146;s right-to-develop agreements have been determined to contain substantive options. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered
substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition.
The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and
Development Costs </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenditures are expensed as incurred. Research and development costs primarily consist
of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company&#146;s clinical trials, the cost of acquiring and
manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and
regulatory approvals. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Comprehensive Income (Loss) </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective January&nbsp;1, 2012, the Company adopted ASU2011-05, <I>Presentation of Comprehensive Income, </I>which amended ASC Topic 220,
<I>Comprehensive Income. </I>The amendments in ASU 2011-05 require the presentation of the comprehensive income (loss) and its components as part of the consolidated financial statements. Comprehensive income (loss) is comprised of the net income
(loss) and other changes in equity that are excluded from net income (loss). Comprehensive income (loss) equals net income (loss) for the three and nine months ended September&nbsp;30, 2013 and 2012. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock-based Compensation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based payments are accounted for in accordance with the provisions of ASC&nbsp;718, <I>Compensation&nbsp;&#150; Stock Compensation</I>.
The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance
condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the
Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend
yield, expected volatility and the expected life of the award. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Net Income (Loss) Per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income (loss) per share is calculated under the two-class method under which all earnings (distributed and undistributed) are allocated to each
class of common stock and participating securities based on their respective rights to receive dividends. In the event that the Board of Directors shall declare a dividend payable in cash or other property on the then-outstanding shares of common
stock, the holders of the Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock shall be entitled to receive the amount of dividends per share of Preferred Stock that would be payable on the largest number of whole shares of Common
Stock into which each share of Preferred Stock could then be converted. Therefore, the Series A-1, A-2, B, C, D and D-2 are participating securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic net income (loss) per common share is determined by dividing the net income (loss) allocable to common stockholders by the
weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per share is computed by dividing the net income (loss) allocable to common stockholders by the
weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#146;s stock option grants and the if-converted method is used to determine the
dilutive effect of the Company&#146;s Series&nbsp;A-1, A-2, B, C, D, and D-2 convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Basic and diluted income (loss) per common share is computed as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,603,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,600,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undistributed earnings allocated to participating securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,434,756</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,600,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,944,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,466,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">169,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Basic income (loss) per common share</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.14</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,603,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,600,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,944,149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,466,582</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,403,843</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,600,514</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,944,149</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,466,582</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net income (loss) allocable to common shares</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">200,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,184,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,092,307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,463,798</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078,145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Effect of dilutive securities</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,058,471</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,410,117</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,445,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,334,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Diluted weighted average common shares outstanding</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,242,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,502,424</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,908,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,412,848</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Diluted income (loss) per common share</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>0.01</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>&#151;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following common stock equivalents are included in the calculation of diluted net income (loss) per share:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-1 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,156,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series A-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392,274</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,336,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,909,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">769,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,391,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants to purchase Series D-2 Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,784</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock Options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,910,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,910,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,276,516</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recently Issued Accounting Standards Adopted </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May&nbsp;2011, the FASB issued ASU No.&nbsp;2011-04, which amended ASC Topic 820 to achieve common fair value measurements and disclosure
requirements in U.S. GAAP and International Financial Reporting Standards (IFRS). The amendments in ASU No.&nbsp;2011-04 result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRS. Consequently, the amendments change
the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. This amendment is effective for fiscal years beginning after December&nbsp;15, 2011. The
adoption of this amendment did not have a material impact on the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2011, the
FASB issued ASU No.&nbsp;2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The amendments in ASU No.&nbsp;2011-05 require that all nonowner changes in stockholders&#146; equity be presented either in a single
continuous statement of comprehensive income </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and its components followed consecutively by a second statement
that should present total other comprehensive income, the components of other comprehensive income, and the total of comprehensive income. This amendment is effective for fiscal years beginning after December&nbsp;15, 2011. The adoption of this
amendment did not have a material impact on the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated all ASUs
through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company&#146;s consolidated financial statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>3. Property and Equipment </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and
equipment consists of the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,&nbsp;2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,&nbsp;2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,172,535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,003,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,323,081</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">599,650</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,603,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,747,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,893,770</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,881,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,643,994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,607,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Less accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,174,112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,339,497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,469,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,267,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the three months ended September&nbsp;30, 2013 and 2012 was $316,852
and $235,543, respectively, and $834,615 and $722,496 for the nine months ended September&nbsp;30, 2013 and 2012, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4. Stockholders&#146;
Equity (Deficit) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During 2002 and 2003, the Company issued a total of 34,239,374 shares of Series A-1 and Series A-2 convertible
preferred stock (Series A preferred stock) for $1.00 per share resulting in net proceeds of approximately $34,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On
October&nbsp;12, 2004, the Company entered into a series of transactions raising $30,261,672, net of related offering costs of approximately $238,000, from the sale of 71,401,237 shares of its Series B convertible preferred stock (Series B preferred
stock). In connection with the Series B preferred stock offering, 13,604,016 shares of common stock were allocated to holders of Series&nbsp;A-1 preferred stock as an anti-dilution measure but remained unissued at September&nbsp;30, 2013. Upon
completion of the IPO in October 2013, these allocated shares were converted into shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&nbsp;16, 2006, the
Company raised $44,898,754, net of related offering costs of $101,246, from the sale of 110,952,217 shares of its Series C convertible preferred stock (Series C preferred stock). In connection with the Series C preferred stock offering, 10,003,300
shares of common stock were allocated to holders of Series B preferred stock as an anti-dilution measure but remained unissued at September&nbsp;30, 2013. Upon completion of the IPO in October 2013, these allocated shares were converted into shares
of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company issued 12,466,039 shares of its Series D convertible preferred stock (Series D
preferred stock) in exchange for all of the outstanding capital stock and convertible notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently, in March 2011 a settlement was reached with the former Raven stockholders bringing the total
Series D preferred stock issued in connection with the Raven acquisition to 14,446,227 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;19, 2008, the Company
raised $24,843,211, net of related offering costs of $156,788, from the sale of 38,337,678 shares of its Series D-2 convertible preferred stock (Series D-2 preferred stock). The Company also issued preferred stock warrants for the purchase of
2,875,327 shares of Series D-2 preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stock. The preferred stock warrants are exercisable at any time prior to September&nbsp;2018, but expire upon an IPO, and have a stated exercise price of $0.65 per warrant. On May&nbsp;16, 2010,
the Company exercised a put notice to Lilly in accordance with the Series D-2 preferred stock purchase agreement, resulting in the issuance of 6,916,110 shares of Series D-2 preferred stock and a warrant to purchase 518,708 additional shares of
Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January&nbsp;11, 2011, the Company raised gross proceeds for $12,016,500 from the sale of 18,427,388
shares of its Series D-2 preferred stock. Issuance costs associated with the sale were not material. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to certain provisions in the
Series D-2 convertible preferred stock warrant agreement, these warrants are required to be classified as a liability. Management believes that the circumstances requiring cash settlement of the award are remote. The Series D-2 preferred stock
warrant liability is recorded at fair value, which is adjusted at the end of each reporting period using the Option-Pricing Method, with changes in value recorded as &#147;Other income (expense)&#148; in the accompanying consolidated statements of
operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock are entitled to vote,
together with the common stockholders as one class, on all matters as to which common stockholders are entitled to vote. In any such vote, each share of Series A, Series B, Series C and Series D preferred stock shall entitle the holder to the number
of votes per share that equals the number of shares of common stock into which each such share of preferred stock is then convertible. For so long as at least four&nbsp;million shares of each of the Series A, Series B and Series C preferred stock
remain outstanding, the holders of each of the Series A, Series B and Series C preferred stock, each voting as a separate class, shall each be entitled to elect two members of the Board of Directors of the Company. The holders of a majority of the
common stock, voting as a separate class, shall have the right to elect one member of the Board of Directors of the Company. The holders of a majority of the common stock and the holders of at least 66 2/3% of the preferred stock, each voting
separately as a single class (and on an as-if-converted basis to common stock with respect to the preferred stock), shall be entitled to elect all remaining members of the Board of Directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dividends are noncumulative and accrue on the Series A-1, Series A-2, Series B, Series C, Series D and Series&nbsp;D-2 preferred stock at a
rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum, respectively, and are payable when and as declared by the Board of Directors. Dividends must be declared so that the Series A, Series&nbsp;B, Series C and Series D preferred stock are paid in
like-kind and participate equally to those of the Series&nbsp;D-2 preferred and common stock. No dividends have been declared and none are accrued at September&nbsp;30, 2013 or December&nbsp;31, 2012. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#146;s Series A-1, Series A-2, Series B, Series C, Series D and Series D-2 preferred stock are initially convertible into 1.506,
1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively, of common stock at the option of the holder. The conversion ratio of certain series of preferred stock is subject to change in the event specified dilutive transactions occur. These dilutive
events are considered to be the sale of common stock at a per share price less than the applicable preferred stock conversion price. There are no anti-dilution protections for the Series A-2 preferred stock and no adjustment to the Series A-1
preferred stock conversion price is made if a common stock issuance is at a price per share greater than the conversion price of the Series C preferred stock. The conversion price shall be $12.39, $18.77, $6.95, $7.70, $12.20 and $12.20 for each
share of Series A-1, A-2, Series B, Series C, Series D and Series D-2 convertible preferred stock, respectively. The Company has reserved 17,129,782 shares of common stock for the potential conversion of the Series A-1, Series A-2, Series B,
Series&nbsp;C, Series D and Series D-2 preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series A-1, Series A-2, Series B, Series C, Series D and Series D-2
preferred stock automatically converts into shares of the Company&#146;s common stock upon closing of a firm commitment underwritten public offering of common stock registered under the Securities Act of 1933 which generates net proceeds to the
Company of at least $40&nbsp;million. The holders of two-thirds of the Series&nbsp;A-1, Series&nbsp;A-2, Series&nbsp;B, Series C, Series D and Series D-2 preferred stock, voting together as a single class, but separately from the common
stockholders, shall have the right to elect to convert all outstanding shares of Series A-1, Series&nbsp;A-2, Series&nbsp;B, Series C, Series D and Series D-2 preferred stock into shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In liquidation, the holders of Series D-2 preferred stock are entitled to receive $12.20 per share prior to any distribution to the holders of
any Series C and Series D preferred stock. The holders of Series C and Series&nbsp;D preferred stock are entitled to receive $7.70 and $12.20 per share, respectively, on a <I>pari passu</I> basis, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to any distribution to the holders of any Series B preferred stock. The holders of Series B preferred stock are entitled to receive $6.95 per share prior to any distribution to the holders
of any shares of Series A preferred stock. The holders of Series A preferred stock are entitled to receive $12.39 per share prior to the holders of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with preparing for its IPO in October 2013 (see Note 11, Subsequent Events, for additional information), the Company&#146;s
Board of Directors and stockholders approved a 1-for-18.7739 reverse stock split of the Company&#146;s Common Stock. The reverse stock split became effective on September&nbsp;26, 2013. All share and per share amounts in the consolidated financial
statements and notes thereto have been retroactively adjusted for all periods presented to give effect to this reverse stock split, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.
In addition, in September 2013, the Company&#146;s Board of Directors and stockholders approved an amendment of the Company&#146;s certificate of incorporation to, among other things, change the definition of a designated public offering to remove
the per share price requirement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>5. Shared-Based Payments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Plan </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s 2000 Stock Option and Incentive Plan (the 2000 Plan) allowed for the grant of awards in respect of an aggregate of 130,725 shares, which was increased to 150,297 shares, of the Company&#146;s common stock in the form of incentive
stock options, non-qualified stock options, stock appreciation rights, restricted stock and restricted stock units and other performance awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Effective February&nbsp;2003, the Company implemented the 2003 Equity Incentive Plan (the 2003 Plan), and it was amended and approved by the
Company&#146;s stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of 2,051,644 shares of the Company&#146;s common stock. During the year ended December&nbsp;31, 2006, the maximum number of
shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 460,746 shares to 2,512,390. During the year ended December&nbsp;31, 2008, the maximum number of shares of common stock authorized to be issued by the
Company under the 2003 Plan was increased by 745,716 shares to 3,258,106. During the year ended December&nbsp;31, 2010, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 532,654
shares to 3,790,760. During the year ended December&nbsp;31, 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased by 545,970 shares to 4,336,731. As of September&nbsp;30, 2013, a
total of 8,171 shares were available for issuance under the 2003 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock options granted under the 2003 Plan may be either incentive
stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following stock-based compensation
amounts were recognized for the periods indicated: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111,888</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">284,281</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">353,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">274,940</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">135,936</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">209,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">393,561</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">628,796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Employee Stock Options </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the
following table: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="75%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">0%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">53%&nbsp;-&nbsp;58%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">51%</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">1.24%&nbsp;-&nbsp;2.05%</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">1.18%</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected average life of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7&nbsp;years</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7&nbsp;years</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fair market value of common stock at:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="white-space:nowrap">$1.50&nbsp;-&nbsp;$7.51</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$1.50</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected forfeiture rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.06%</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.57%</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Fair Value of Common Stock&nbsp;&#150;&nbsp;</B>Before our entry into the public market on October&nbsp;10,
2013, the Company&#146;s Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. In the absence of a public
market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date. The factors include:
(1)&nbsp;the achievement of clinical and operational milestones by the Company; (2)&nbsp;the status of strategic relationships with collaborators; (3)&nbsp;the significant risks associated with the Company&#146;s stage of development;
(4)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (5)&nbsp;the Company&#146;s available cash, financial condition and results of operations;
(6)&nbsp;the most recent sales of the Company&#146;s preferred stock and (7)&nbsp;the preferential rights of the outstanding preferred stock. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and
assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Volatility</B>&nbsp;&#150; Volatility is a measure of the amount by which a financial variable such as a share price has
fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. The Company does not maintain an internal market for its shares and its shares are not traded publicly. The Company has been able to identify
several public entities of similar size, complexity and stage of development; accordingly, historical volatility has been calculated using the volatility of these companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Dividend Yield</B>&nbsp;&#150; The Company has never declared or paid dividends and has no plans to do so in the foreseeable
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Risk-Free Interest Rate</B>&nbsp;&#150; This is the U.S. Treasury rate for the week of each option grant during the year,
having a term that most closely resembles the expected life of the option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Term</B>&nbsp;&#150; This is the period of time
that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years. The Company estimates the expected life of the option term to be seven years. The Company uses a simplified method to calculate the
average expected term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Expected Forfeiture Rate</B>&nbsp;&#150; The forfeiture rate is the estimated percentage of options granted
that is expected to be forfeited or canceled on an annual basis before becoming fully vested. The Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were
granted. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Equity instruments issued to non-employees are accounted for under the provisions of ASC&nbsp;505-50,<I> Equity Based Payments
to Non-Employees</I>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the services required are completed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes stock option activity under the Plan during the period then ended:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of</B><br><B>Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average&nbsp;Exercise</B><br><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average</B><br><B>Contractual&nbsp;Term</B><br><B>(in Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,249,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,025,933</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Forfeited or expired</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,949</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Outstanding, September&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,877,003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">September&nbsp;30, 2013:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercisable</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vested and Expected to Vest</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">918,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value of options outstanding and options exercisable as of September&nbsp;30, 2013 is
approximately $17.4 million and $12.2 million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted for the nine
months ended September&nbsp;30, 2013 was $2.00. Total cash received for the options exercised was $851,183 for the nine months ended September&nbsp;30, 2013. The total fair value of shares vested in the nine months ended September&nbsp;30, 2013 was
$402,084. As of September&nbsp;30, 2013, the total unrecognized compensation expense related to non-vested stock-based compensation arrangements granted under the 2000 Plan and 2003 Plan, net of related forfeiture estimates, was $1.5 million, which
the Company expects to recognize over a weighted-average period of approximately four years. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>6. Lease Exit Liability </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On July&nbsp;16, 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the
development of monoclonal antibody therapeutics for treating cancer. Raven was considered a development-stage enterprise as defined in ASC&nbsp;915, <I>Development Stage Entities</I>. In connection with the acquisition, the Company issued 12,466,039
shares of its Series D convertible preferred stock in exchange for all of the outstanding capital stock and convertible notes payable of Raven. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company undertook restructuring activities related to the acquisition of Raven. These restructuring activities included reductions in
staffing levels and the intended exit of leased facilities. All severance-related payments were completed in the year ended December&nbsp;31, 2009. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with these restructuring activities, as part of the cost of acquisitions, the Company established a restructuring liability
attributed to an existing operating lease. The terms of the operating lease extend through 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in the lease exit liability are
as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2011</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,607,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(533,560</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at December&nbsp;31, 2012</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,073,939</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Principal payments</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(466,301</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrual balance at September&nbsp;30, 2013</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,607,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future principal payments to be made under the lease agreement for the next five years and
thereafter as of September&nbsp;30, 2013 are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Twelve Months Ending September&nbsp;30,</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,229,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,589,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,808,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,049,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,315,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">616,356</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,607,638</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The purchase agreement provides for a specified total of certain contingent milestones that are based on the
achievement of certain product sales derived from the acquired Raven technology. Also, a onetime payment of $5.0&nbsp;million will be made to the Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any
product derived from the Raven &#147;Cancer Stem Cell Program.&#148; No payment shall be made if the Phase 2 trial start date has not occurred on or before July&nbsp;15, 2018. Other consideration includes a percentage of revenue (excluding
consideration for research and development and equity) received by MacroGenics for license of a product derived from the Raven &#147;Cancer Stem Cell Program&#148; and a onetime payment ranging from $8.0&nbsp;million to $12.0&nbsp;million dependent
upon a specified level of sales of products derived from the Raven &#147;Cancer Stem Cell Program.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The contingent consideration
will be accounted for as additional purchase price and recorded as incremental in-process research and development expense when it is deemed probable that the contingencies will be attained. No additional amounts have been recorded during the nine
months ended September&nbsp;30, 2013 and 2012. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>7. Collaboration and License Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Les Laboratoires Servier </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
November 2011, the Company entered into a right-to-develop collaboration agreement with Servier for the development and commercialization of MGA271 in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Servier made a nonrefundable payment of $20 million to the Company. The Company is eligible to receive up to
$30 million in license grant fees, $47 million in clinical milestone payments, $140 million in regulatory milestone payments and $208 million in sales milestone payments if Servier exercises the option, obtains regulatory approval for and
successfully commercializes MGA271. The Company concluded that the license grant fees are not deliverables at the inception of the arrangement. The Company has determined that each potential future clinical, development and regulatory milestone is
substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would
preclude revenue recognition at that time. In the event Servier exercises its option to continue development of MGA271, Servier must pay a license grant fee. Under this agreement, Servier would be obligated to pay the Company from low double digit
to mid-teen royalties on product sales in its territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Servier
and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that the option is substantive and that the license fees for this option is not a deliverable at the inception of the
arrangement as there is considerable uncertainty that the option would be exercised and the additional fee to be paid upon exercise of the option represents its estimated selling price (i.e. no substantial discount was given). The Company&#146;s
substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement and
participation on an executive committee and a research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and development committee. The Company determined that these performance obligations represent a single unit of accounting, since the license does not have stand-alone value to Servier without
the Company&#146;s technical expertise and committee participation. As such, the initial upfront payment was deferred and is being recognized ratably over the initial 27-month period, which represents the expected period of development and the
Company&#146;s participation on the research and development committee. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2013 and 2012 the Company recognized revenue of $12.3 million (including a $10.0 million
milestone payment) and $2.3 million, respectively. During the nine months ended September&nbsp;30, 2013 and 2012 the Company recognized revenue of $18.9 million (including a $10.0 million milestone payment) and $6.8 million, respectively, under this
agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, $3.1 million of revenue was deferred under this agreement, all of which was included in current
liabilities. At December&nbsp;31, 2012, $10.0 million of revenue was deferred under this agreement, $9.1 million of which was included in current liabilities and $0.9 million was included in long-term liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2012, the Company entered into a second right-to-develop collaboration agreement with Servier and granted it options to obtain
three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by the Company as MGD006 and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico,
Japan, South Korea and India. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Servier made a nonrefundable payment of $20 million to the Company. In
addition, the Company will be eligible to receive up to $65 million in license grant fees, $98 million in clinical milestone payments, including $5 million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule, $300 million in
regulatory milestone payments and $630 million in sales milestone payments if Servier exercises all of the options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these
milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered
substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this
agreement, Servier would be obligated to pay the Company between high-single digit and mid-teen royalties on net product sales in its territories. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Servier and has determined that it is a revenue arrangement with multiple
deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The
Company&#146;s substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan during the first year of the agreement
and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the pre-clinical development represent a single unit of accounting, since the license does
not have stand-alone value to Servier without the Company&#146;s technical expertise and committee participation. As such, the initial up front license payment was deferred and is being recognized ratably over the initial 29-month period, which
represents the expected development period. The Company further concluded that each potential future clinical, development and regulatory milestone is substantive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three and nine months ended September&nbsp;30, 2013 the Company recognized revenue of $2.2 million and $6.5 million, respectively.
No revenue was recognized under this agreement during the comparable periods in 2012. No milestones have been recognized under this agreement during the three and nine months ended September&nbsp;30, 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, $11.6 million of revenue was deferred under this agreement, $8.6
million of which was included in current liabilities and $3.0 million of which was included in long-term liabilities. At December&nbsp;31, 2012, $18.0 million of revenue was deferred under this agreement, $8.6 million of which was included in
current liabilities and $9.4 million of which was included in long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Gilead Sciences, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2013, the Company entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, the Company retains development and commercialization rights outside of North America, the European Union, Norway,
Iceland, Turkey, Australia and New Zealand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company received an initial $7.5 million license grant fee for the first DART-based
molecule. The Company may be eligible to receive additional license grant fees of $22.5 million, $200 million related to pre-clinical and clinical milestones, $355 million related to regulatory milestones and $500 million related to sales milestones
if Gilead exercises all four of the options and successfully develops, obtains regulatory approval for, and commercializes a product under each option and license. The Company has determined that the other licenses are conditional deliverables,
which are substantive options that were not granted with a substantial discount. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered
substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Gilead also
provides funding for the Company&#146;s internal and external research costs under the agreement. Additionally, Gilead would be obligated to pay the Company high single digit to low double digit, but less than teen royalties on product sales in its
territories. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the research collaboration agreement with Gilead and has determined that it is a revenue
arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research collaboration include a license to its technology and research and development services. The Company
concluded that the deliverables do not have stand alone value and therefore, represent a combined single unit of accounting. Due to the lack of standalone value for the license and research and development services, the combined unit of accounting
(the upfront payment and the expected research and development reimbursements) is being recognized ratably over a period of 21 months, which represents the expected development period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Gilead have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. Had management considered participation on the joint committee as a
deliverable, it would not have had a material impact on the accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Receivables of $1.1 million as of
September&nbsp;30, 2013 relate to amounts due to the Company from Gilead for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company recognized revenues of approximately $2.2 million and $5.9 million under this agreement for the three and nine months ended September&nbsp;30, 2013, respectively. No milestones have been reached under this agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, $4.4 million of revenue was deferred under this agreement, all of which was included in current liabilities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Boehringer Ingelheim International GmbH </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010 the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize up to ten
DART-based molecules which span multiple therapeutic areas. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DARTs
generated under the agreement, or the Boehringer licensed products, throughout the world. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, the Company received an upfront payment of $15 million. The
Company subsequently received two annual maintenance payments and anticipates receiving a third annual maintenance payment in the fourth quarter of 2013. The first two maintenance payments were solely attributed to the passage time. Because
Boehringer has the option to cancel the program after the second anniversary of the agreement, the third maintenance payment will be recognized over the remaining obligation period once received. The Company has the potential to earn milestone
payments of approximately $41 million related to pre-clinical and clinical development, $89 million related to regulatory milestones and $83 million related to sales milestones for each of the DART programs under this agreement in the case of full
commercial success of multiple DART products. The Company has determined that each potential future clinical, development and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized
upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer also provides funding for the Company&#146;s
internal and external research costs and is required to pay the Company mid-single digit royalties on product sales. From the commencement of the collaboration through September&nbsp;30, 2013, the Company has received $39.0 million under this
agreement, including upfront, annual maintenance and milestone payments as well as research funding. In addition, Boehringer purchased $10 million of the Company&#146;s Series D-2 Preferred Stock in January 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be
performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional
period is not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company concluded that the undelivered element of
research and development services had fair value. The Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore does not represent a separate unit
of accounting. The Company concluded that because the drug candidate has not yet been developed, the license is of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the
Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research and development services were treated as a combined unit of account and recognized over the
expected obligation period associated with the research and development services through September 2015, which represents the estimated period of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Boehringer have also agreed to establish a joint research committee to facilitate the governance and oversight of the
parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint
committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the organization period for the research and development services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Receivables of $246,375 and $355,568&nbsp;as of September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively, relate to amounts due to the
Company from Boehringer for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $2.3
million and $2.5 million under this agreement during the three months ended September&nbsp;30, 2013 and 2012, respectively, and $6.9 million and $9.3 million during the nine months ended September&nbsp;30, 2013 and 2012, respectively. One milestone
payment of $2.0 million was recognized under this agreement through December 2012. No milestones have been recognized under this agreement during the three and nine months ended September&nbsp;30, 2013. A milestone was earned under this agreement
subsequent to September&nbsp;30, 2013. See Note 11, Subsequent Events, for additional information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, $10.3 million of revenue was deferred under this agreement, $5.0
million of which was included in current liabilities and $5.3 million of which was included in long-term liabilities. At December&nbsp;31, 2012, $14.0 million of revenue was deferred under this agreement, $5.0 million of which was included in
current liabilities and $9.0 million of which was included in long-term liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Pfizer, Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2010, the Company entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based
molecules. The Company granted Pfizer a non-exclusive worldwide, royalty-bearing license and received an upfront payment of $5 million and has received milestone payments and funding for the Company&#146;s internal and external research costs under
the agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is eligible to receive milestone payments of approximately $17 million related to pre-clinical and clinical
development and $195 million related to commercialization and sales milestones for each DART program under this agreement. The Company has determined that each potential future technical and development milestone is substantive. Although sales
milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition
at that time. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay the Company mid-single digit to low-teen royalties on product sales. Under this collaboration, one DART
program is currently being pursued and the Company will complete its research obligations under this program in January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
has evaluated the research collaboration agreement with Pfizer and has determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company&#146;s substantive performance obligations under this research
collaboration include an exclusive license to its technology, research and development services and manufacturing services. The Company concluded that the manufacturing services were optional and were subject to further negotiation upon reaching
regulatory approval. As such, the manufacturing services are not included in the expected obligation period to perform services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company determined that it had fair value of the undelivered element of the research and development services. However, the Company concluded that the license does not have value on a standalone basis (e.g. absent the provision of the research and
development services) and therefore does not represent a separate unit of accounting. Facts that were considered included the development of the candidate noting that because the drug candidate has not yet been developed, the license is of no value
to Pfizer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Pfizer could not sell the license to another party (without the Company agreeing to provide the research and
development activities for the other party). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Therefore, the upfront license fee and research and development services were treated as a
combined unit of accounting and recognized over the expected obligation period associated with the research and development services through January 2014, which represents the estimated period of development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $5 million upfront payment received by the Company is non-refundable; therefore, there is no right of return for the license. The Company
is recognizing revenue associated with this non-refundable up-front license fee through January 2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and Pfizer have also
agreed to establish a joint research committee to facilitate the governance and oversight of the parties&#146; activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined
that it was not a deliverable because it is a participating right and not an obligation of the Company. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the
accounting for the arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on
January&nbsp;1, 2011. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Receivables of $501,794 and $896,285 as of September&nbsp;30, 2013 and December&nbsp;31, 2012,
respectively, relate to amounts due to the Company from Pfizer for reimbursement work performed under the collaboration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
recognized revenues of approximately $0.9 million and $1.2 million under this agreement during the three months ended September&nbsp;30, 2013 and 2012, respectively, and $3.2 million and $4.0 million during the nine months ended September&nbsp;30,
2013 and 2012, respectively. Included in the 2012 revenues are milestone payments totaling $500,000. No additional milestones have been recognized under this agreement through September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013 and December&nbsp;31, 2012, $58,000 and $1.3 million of revenue was deferred under this agreement, all of which was
included in current liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Green Cross Corporation </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June&nbsp;2010, the Company entered into a collaboration agreement with Green Cross for the development of the Company&#146;s anti-HER2
antibody known as MGAH22, or margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the agreement, Green Cross made a nonrefundable payment of $1.0&nbsp;million to the Company. The Company is eligible to
receive clinical development and commercial milestone payments of up to $4.5 million. The Company has determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on
net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has evaluated the collaboration agreement with Green Cross and has determined that it is a revenue arrangement with multiple
deliverables or performance obligations. The Company&#146;s substantive performance obligations under this agreement include an exclusive license to its technologies and participation in a joint steering committee. The Company concluded that the
license does not have value on a standalone basis and therefore does not represent a separate unit of accounting. Likewise, Green Cross could not sell the license to another party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The $1 million upfront payment received by the Company is non-refundable; as such, there is no right of return for the license. Therefore, the
upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through June 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no material modifications to this agreement since the adoption of ASU 2009-13 on January&nbsp;1, 2011. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognized revenues of approximately $25,000 under this agreement during each of the three month periods ending September&nbsp;30,
2013 and 2012, and $75,000 during each of the nine month periods ending September&nbsp;30, 2013 and 2012. No milestones have been recognized under this agreement during the three and nine months ended September&nbsp;30, 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At September&nbsp;30, 2013, $675,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and
$575,000 of which was included in long-term liabilities. At December&nbsp;31, 2012, $750,000 of revenue was deferred under this agreement, $100,000 of which was included in current liabilities and $650,000 of which was included in long-term
liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Eli Lilly&nbsp;&amp; Co. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October&nbsp;2007, the Company entered into an exclusive license and collaboration agreement (together, the Agreements) with Eli Lilly to
jointly develop and commercialize teplizumab, a humanized anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly acquired the exclusive rights to the molecule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon execution of the Agreements, Eli Lilly made a nonrefundable payment of $41.0&nbsp;million to
the Company. In May&nbsp;2008, Eli Lilly paid the Company a milestone payment of $50.0&nbsp;million and in May&nbsp;2010, Eli&nbsp;Lilly paid an additional milestone of $5.0&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;28, 2010, Lilly notified the Company of its decision to terminate the agreement after review of one year of clinical data from
the PROT&Eacute;G&Eacute; trial in Type 1 diabetes patients treated with teplizumab. Such data failed to support the primary efficacy end point in the study. During the year ended December&nbsp;31, 2012, Eli&nbsp;Lilly satisfied its obligation
related to the cost of monitoring patients under the PROT&Eacute;G&Eacute; and ENCORE trials. The Company&#146;s obligations continued through September 2012, which represented the follow up period for enrolled patients and the Company&#146;s final
reporting of the trial&#146;s results. There is no additional clinical trial activity under the Eli Lilly Agreements as it relates to such trials. In February 2011, the Company reacquired the commercial rights to the molecule from Eli Lilly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Receivables of $244,542 and $558,516 as of September&nbsp;30, 2013 and December&nbsp;31, 2012, respectively, relate to amounts due to the
Company from Eli Lilly for reimbursement work performed under the above mentioned clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended
September&nbsp;30, 2013 and 2012, the Company recognized revenue of $190,833 and $9.5 million, respectively, under this agreement. During the nine months ended September&nbsp;30, 2013 and 2012, the Company recognized revenue of $673,927 and $30.1
million, respectively. No milestones were recognized under this agreement during the three and nine months ended September&nbsp;30, 2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>8.
Commitments and Contingencies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company leases office and laboratory space over periods extending through January&nbsp;30, 2018. Several of the leases contain rent
escalation clauses. Rent expense for the three months ended September&nbsp;30, 2013 and 2012 was $806,275 and $783,462, respectively. The Company incurred $2.4 million of rent expense for each of the nine-month periods ending September&nbsp;30, 2013
and 2012. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Future minimum lease payments under noncancelable operating leases at September&nbsp;30, 2013 are as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Twelve Months Ending September&nbsp;30,</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2014</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,460,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2015</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,396,780</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2016</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,385,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2017</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,486,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">2018</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,035,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thereafter</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">625,540</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">17,390,144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>9. Product Milestone Payments and Royalty Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with an Asset Purchase Agreement with Tolerance Therapeutics, Inc. (Tolerance) entered into during June 2005, the Company may be
required to issue Tolerance additional consideration as follows: (i)&nbsp;$10,950,000 if certain milestones are met, including the initiation of Phase 3 trials and filing of various regulatory product license applications; (ii)&nbsp;36,135 shares of
common stock; and (iii)&nbsp;royalty payments between 1.75% and 4.0% of net sales of products acquired from or patented by Tolerance or other product fees earned by the Company. Any additional consideration required to be paid under the Asset
Purchase Agreement will be recorded as research and development expense when incurred. No payments related to the additional consideration have occurred during the three and nine-month periods ended September&nbsp;30, 2013 or 2012. Additionally,
certain agreements require the Company to pay royalties. Currently, the Company is not obligated to pay royalties, as no other revenue from product sales is being generated by the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>10. Employee Benefit Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;25, 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section&nbsp;401(k) of the
IRC. Under this Plan, all employees at least 21 years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to 100% of their salary, subject to government maximums. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Employees are 100% vested in their contributions to the Plan. The Company&#146;s contribution to the Plan, as determined by the Board of
Directors, is discretionary. The Company&#146;s contributions to the Plan totaled $55,311 and $48,891 for the three months ended September&nbsp;30, 2013 and 2012, respectively, and $194,498 and $179,966 for the nine months ended September&nbsp;30,
2013 and 2012, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, the Company completed its IPO, in which 5,000,000 shares of the Company&#146;s common stock were sold at a price of
$16 per share. Additionally, the underwriters of the Company&#146;s IPO exercised the full amount of their over-allotment option resulting in the sale of an additional 750,000 shares of the Company&#146;s common stock at a price of $16 per share.
The Company received net proceeds of $83.8 million from the IPO, net of underwriting discounts and commissions and other estimated offering expenses. Upon consummation of the IPO, all outstanding shares of preferred stock automatically converted to
common stock at the applicable conversion ratios then in effect. Subsequent to the IPO, the Company had 25,020,288 issued and outstanding shares of common stock and no outstanding shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, Boehringer nominated a bi-specific antibody therapeutic candidate generated by the Company&#146;s DART technology for
pre-clinical development. This formal selection of a development candidate triggered a $5.0 million milestone payment to the Company under the October 2010 agreement described in Note 7, Collaboration and License Agreements. In addition, Boehringer
will pay a research maintenance payment of $4.0 million to the Company in the fourth quarter of 2013. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx610136_5"></A>ITEM&nbsp;2. MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion of our financial condition and results of operations is based upon our unaudited consolidated financial statements
included in this Quarterly Report on Form 10-Q, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America, (GAAP), for interim periods and with Regulation S-X promulgated under the
Securities Exchange Act of 1934, as amended. This discussion and analysis should be read in conjunction with these unaudited consolidated financial statements and the notes thereto as well as in conjunction with our Prospectus filed pursuant to Rule
424(b)(4) under the Securities Act of 1933, as amended, with the Securities and Exchange Commission, on October&nbsp;11, 2013 (Prospectus). This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many
factors, such as those set forth under the section entitled &#147;Risk Factors&#148; and elsewhere in this report, our actual results may differ materially from those anticipated in these forward-looking statements. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage
biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. We generate our pipeline of product candidates from our proprietary suite of
next-generation antibody technology platforms which we believe improve the performance of monoclonal antibodies and antibody-derived molecules. These product candidates, which we have identified through our understanding of disease biology and
immune-mediated mechanisms, may address disease-specific challenges, which are not currently being met by existing therapies. The combination of our technology platforms and antibody engineering expertise has allowed us to generate promising product
candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. These collaborations provide us with funding and allow us to leverage the additional expertise of our collaborators to advance the
development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have two oncology product candidates in clinical development. Additionally, we have
several proprietary product candidates in pre-clinical development and we expect to commence Phase 1 clinical trials on two of these product candidates in 2014. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Margetuximab</I>, also known as MGAH22, is an Fc-optimized monoclonal antibody that targets HER2-expressing tumors, including breast, gastroesophageal and other cancers. HER2, or human epidermal growth factor
receptor 2, is critical for the growth of many types of tumors. We currently are enrolling a Phase 2a clinical trial in metastatic breast cancer and anticipate commencing a Phase&nbsp;3 potential registration clinical trial in advanced
gastroesophageal cancer in the second half of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGA271</I> is an Fc-optimized monoclonal antibody that targets B7-H3, a member of the B7 family of molecules and is over-expressed on a wide variety of solid tumor types. We have initiated a Phase 1 clinical trial
that we expect to complete by the end of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD006 </I>is a humanized DART molecule that recognizes CD123, the Interleukin-3 receptor, or IL3R, alpha chain which is expressed on leukemia and leukemic stem cells, but not on normal hematopoietic stem cells, and
CD3, which is expressed on T cells. We expect to commence a Phase 1 clinical trial in the first half of 2014. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>MGD007</I> is a humanized DART molecule that recognizes both the glycoprotein A33, expressed on gastrointestinal tumors, including more than 95% of human colon cancers, and CD3, which is expressed on T cells. We
expect to commence a Phase 1 clinical trial in the second half of 2014. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We commenced active operations in 2000, and have
since devoted substantially all of our resources to staffing our company, business planning, raising capital, developing our technology platforms, identifying potential product candidates, undertaking pre-clinical studies and conducting clinical
trials. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the private placements of our convertible preferred stock, collaborations and government grants and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
contracts. From inception through September&nbsp;30, 2013, we have received $151.3 million from the sale of convertible preferred stock and warrants. We have received an additional $190.0 million
of upfront, milestone and annual maintenance payments from our collaborators and have been reimbursed $219.4 million through our collaborations and government grants and contracts. As described more fully in Note 11 to the financial statements, we
raised $85.6 million ($83.8 million net of expenses and deferred financing costs) in October 2013 through the sale of common stock in connection with our Initial Public Offering (IPO) and exercise by the underwriters of their over-allotment option.
Although it is difficult to predict our liquidity requirements, based upon our current operating plan, we anticipate that the net proceeds from the IPO, together with our existing cash and cash equivalents, and a significant portion of the $100
million in collaboration payments we anticipate receiving through 2015, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007 and MGD010 through 2015, assuming all of our collaboration programs advance as currently
contemplated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Through September&nbsp;30, 2013, we had an accumulated deficit of $172.0 million. Due primarily to upfront fees paid by our
collaborators, we realized a profit of $6.6 million and $2.9 million for the three and nine months ended September&nbsp;30, 2013, respectively. We expect that over the next several years we will increase our expenditures in research and development
in connection with our ongoing activities with several clinical trials. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Strategic Collaborations and Licenses </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have entered into several strategic collaborations which provide us with significant additional funding in order to continue development of our pipeline and
to extend our technology platforms and on-going programs. Our collaborations have allowed us to speed up the progress of our on-going pre-clinical and clinical stage programs. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Servier</I>. In November 2011, we entered into a collaboration agreement with Servier under which we granted Servier an option to obtain an exclusive license to develop and commercialize MGA271 in all countries other
than the United States, Canada, Mexico, Japan, South Korea and India. We have received a $20 million option grant fee and a $10 million milestone payment, and may be eligible to receive up to approximately $415&nbsp;million in license grant fees,
and clinical, development, regulatory and sales milestone payments. In the event Servier exercises its option, Servier must pay a license grant fee, which we estimate to be $30 million, based on the number of different indications represented within
the planned Phase 1 patient population. We and Servier will share Phase 2 and Phase 3 development costs. </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">In September 2012,
we entered into a second agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART-based molecules, consisting of those designated by us as MGD006 and MGD007, as well as a third DART
molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India. We received a $20 million option grant fee. In addition, we will be eligible to receive up to approximately $1 billion in additional license grant
fees, and clinical, development, regulatory and sales milestone payments if Servier exercises all three of its options and successfully develops, obtains regulatory approval for, and commercializes a product under each license, including
$5&nbsp;million upon IND acceptance for each of MGD006, MGD007 and a third DART molecule. In addition to these milestone payments, we and Servier will share Phase 2 and Phase 3 development costs. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Additionally, under both agreements, Servier would be obligated to pay us low double digit to mid-teen royalties on product sales in its
territories. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:Times New Roman; font-size:10pt"><I>Gilead.</I> In January 2013, we entered into an agreement with Gilead to grant it an exclusive worldwide license to research, develop and
commercialize up to four DART-based molecules. Gilead has exclusive worldwide rights for three of the programs. For one program, we retain development and commercialization rights outside of North America, the European Union, Norway, Iceland,
Turkey, Australia and New Zealand. We received an initial $7.5 million license grant fee for the first DART-based molecule, and are eligible to receive up to an additional $22.5 million in grant fees on the remaining three DART-based molecules. We
are </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:Times New Roman; font-size:10pt">
further eligible to receive up to an additional $85 million in pre-clinical milestones across the four DART programs and up to approximately $1 billion in additional clinical, regulatory and
sales milestone payments if Gilead exercises all four of the options and achieves all of the requisite milestones under each option and license. Gilead also provides funding for our internal and external research costs under the agreement. We are
also eligible to receive tiered royalties on the net sales at percentages ranging from the high-single digits to the low double digits, but less than teens, subject to reductions in specified circumstances. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Boehringer</I>. In October 2010, we entered into an agreement with Boehringer to discover, develop and commercialize up to ten DART-based molecules which may span multiple therapeutic areas. We granted Boehringer an
exclusive worldwide, royalty-bearing, license and received an upfront payment of $15 million. We subsequently received two annual maintenance payments and anticipate receiving a third annual maintenance payment in the fourth quarter of 2013. We have
the potential to earn development, regulatory and sales milestone payments that can reach up to approximately $210 million for each of the DART programs under this agreement. Boehringer provides funding for our internal and external research costs
and is required to pay us mid-single digit royalties on product sales. From the commencement of the collaboration through September&nbsp;30, 2013, we have received $37.9&nbsp;million under this agreement, including upfront, annual maintenance and
milestone payments as well as research funding. In addition, Boehringer purchased $10 million of our Series D-2 Preferred Stock in January 2011. Subsequent to September&nbsp;30, 2013, Boehringer nominated a bi-specific antibody therapeutic candidate
generated by our DART technology for pre-clinical development. This formal selection of a development candidate triggered a $5.0 million milestone payment to us under the agreement. In addition, Boehringer will pay a research maintenance payment of
$4.0 million. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Pfizer.</I> In October 2010, we entered into a three year agreement with Pfizer to discover, develop and commercialize up to two DART-based molecules. We granted Pfizer a non-exclusive worldwide, royalty-bearing
license and received an upfront payment of $5 million and have received milestone payments and funding for our internal and external research costs under the agreement. We are eligible to receive technical, development and sales milestone payments
that can reach up to approximately $210 million for each DART program under this agreement. Pfizer is responsible for all pre-clinical and clinical development costs for the program. In addition, Pfizer is required to pay us mid-single digit to
low-teen royalties on product sales. Under this collaboration, one DART program is currently being pursued and we will complete our research obligations under this program in January 2014. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Green Cross.</I> In June 2010, we entered into a collaboration agreement with Green Cross for the development of margetuximab. We granted Green Cross an exclusive license for all indications for all pharmaceutical
forms of margetuximab in South Korea. Under the terms of this agreement, we received an upfront, nonrefundable payment of $1.0 million and are eligible to receive clinical, development and commercial milestone payments up to $4.5 million as well as
royalties ranging from the low-single digits to the low-twenties on net sales of margetuximab in South Korea. In addition, Green Cross purchased $2.0 million of our Series D-2 Preferred Stock in January 2011. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Financial Operations Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Revenues
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue consists of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for
licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreement with our strategic collaborators, including Servier, Gilead, Boehringer, Pfizer and Green
Cross. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other educational institutions on behalf of the U.S. government, primarily with respect to research and development activities related
to infectious disease product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses consist of expenses incurred in performing research and development activities. These expenses include
conducting pre-clinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and
development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expenses: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related expenses such as salaries and benefits; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Employee-related overhead expenses such as facilities and other allocated items; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stock-based compensation expense to employees and consultants engaged in research and development activities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Depreciation of laboratory equipment, computers and leasehold improvements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our pre-clinical and clinical trials including but not limited to investigator
grants, laboratory work and analysis, database management, statistical analysis, and other items; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Amounts paid to vendors and suppliers for laboratory supplies; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">License fees and other third party vendor payments related to in-licensed product candidates and technology; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Costs related to compliance with regulatory requirements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is difficult to determine with
certainty the duration and completion costs of our current or future pre-clinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our
product candidates that obtain regulatory approval. We may never succeed in achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a
variety of factors, including the uncertainties of future clinical trials and pre-clinical studies, uncertainties in clinical trial enrollment rate and significant and changing government regulation. In addition, the probability of success for each
product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical
success of each product candidate, as well as an assessment of each product candidate&#146;s commercial potential. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative
Expense </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance,
legal and intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other Income (Expense) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other
income (expense) consists of interest income earned on our cash equivalents, offset by interest expense and other expense, including changes in the fair market value of the preferred stock warrant liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our
consolidated financial statements. Management has determined that our most critical accounting policies are those relating to revenue recognition and stock-based compensation. There have been no significant changes to our critical accounting
policies discussed in the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Results of Operations </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Revenue </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development revenue for the three and nine months ended September&nbsp;30, 2013 and
2012: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="65%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>20.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>16.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>4.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>26</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Revenue from collaborative research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Grant revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(70</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total revenue</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>43.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>54.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(10.9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(20</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)%&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The increase in collaboration revenue of $4.6 million for the three months ended September&nbsp;30, 2013
compared to the same period in 2012 is due to the receipt of a $10.0 million milestone payment under our agreement with Servier and the addition of our collaboration with Gilead. These increases are partially offset by a decrease in teplizumab
clinical trial-related reimbursement revenue from our former collaborator, Eli Lilly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The decrease in collaboration revenue of $8.3
million for the nine months ended September&nbsp;30, 2013 compared to the same period in 2012 is primarily due to the conclusion of the teplizumab clinical trial-related reimbursement from Eli Lilly. Aside from reimbursing us for the continued
monitoring expense of one on-going trial, Eli Lilly&#146;s participation in the development of teplizumab concluded in the first quarter of 2013. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Grant revenue decreased in the three and nine month periods ended September&nbsp;30, 2013 as compared to the same periods in 2012 due
primarily to the completion of grants to study H5N1 influenza virus, small pox and West Nile virus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Research and Development Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our research and development expense for the three and nine months ended September&nbsp;30, 2013 and
2012: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margetuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGA271</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(43</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DART-based product candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teplizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(82</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other discovery and pre-clinical programs, collectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expense</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>11.1</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>12.0</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(0.9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Margetuximab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MGA271</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DART-based product candidates</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Teplizumab</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(86</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other discovery and pre-clinical programs, collectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40</TD>
<TD NOWRAP VALIGN="bottom">%)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total research and development expense</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>32.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>36.9</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(4.7</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(13</B></TD>
<TD NOWRAP VALIGN="bottom"><B>%)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the three months ended September&nbsp;30, 2013 our research and development expense decreased by $0.9
million compared to the same period in 2012 due to the reduction in spending on teplizumab related clinical development, offset by an increase in spending on DART-based product candidates. During the nine months ended September&nbsp;30, 2013, as
compared to the same period in 2012, our research and development expense decreased by $4.7 million. This decrease was due primarily to the reduction in spending on teplizumab-related clinical development as we ended trial enrollment and began
closing down the trials during this period. In addition, we significantly reduced our Cancer Stem-like Cell (CSLC) related activities. These decreases were partially offset by an increase in spending on MGA271 and our various DART-based product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>General and Administrative Expense </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following represents a comparison of our general and administrative expense for the three and nine months ended September&nbsp;30, 2013 and
2012: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine Months Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Increase/(Decrease)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">General and administrative expense increased for the three and nine months ended September&nbsp;30, 2013 by $0.5 million and
$0.7 million, respectively, compared to the same period in 2012 primarily due to an increase in professional fees and other costs associated with preparations for public company operations, including extensive studies performed for potential tax and
other credits. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Cash Flows </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table represents a summary of our cash flows for the nine months ended September&nbsp;30, 2013 and 2012: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Nine&nbsp;Months&nbsp;Ended&nbsp;September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(dollars in millions)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net cash provided by (used in):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(13.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(24.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net increase (decrease) in cash and cash equivalents</B></P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(14.2</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(24.8</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Operating Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities reflects, among other things, the amounts used to run our clinical trials and pre-clinical activities,
including toxicology studies. The difference between net cash used in operating activities during the nine months ended September&nbsp;30, 2013 and 2012 was primarily due to receipt of a $10 million milestone from Servier in the third quarter of
2013. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Investing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities was primarily due to the acquisition of additional lab equipment needed to further our research and
development activities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Financing Activities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other than stock option exercises, we had no financing activity in the nine months ended September&nbsp;30, 2013 or 2012. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity and Capital Resources </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception through September&nbsp;30, 2013, we have raised an aggregate of $560.7 million to fund our operations. Of this total
amount, we have received $151.3 million from the sale of preferred stock, $354.9 million from our collaborators, including payments in the form of upfront, milestone and annual maintenance payments and reimbursement for research and development
services performed, and $54.5 million from government grants and contracts. As of September&nbsp;30, 2013, we had $33.6 million in cash and cash equivalents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;16, 2013, we completed the IPO of our common stock, which resulted in the sale of 5,750,000 shares, including all additional
shares available to cover over-allotments, at a price of $16.00 per share. We raised $85.6 million ($83.8 million net of expenses and deferred financing costs). In connection with the closing of the IPO, all of our outstanding redeemable convertible
preferred stock automatically converted to common stock at various ratios as disclosed in our Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to our existing
cash and cash equivalents, we expect to continue to receive additional reimbursement from our collaborators for research and development services rendered, additional milestone, opt-in and annual license maintenance payments and grant revenue.
However, our ability to receive these milestone payments is dependent upon our ability to achieve certain levels of research and development activities and is therefore uncertain at this time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Funding Requirements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not
generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval of and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development,
it will be some time before we expect to achieve this and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials and pre-clinical
development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from
the U.S. government in order to further our research and development. Based upon our current operating plan, we anticipate that the net proceeds from the IPO together with our existing cash and cash equivalents, and a significant portion of the $100
million in collaboration payments we anticipate receiving through 2015, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007 and MGD010 through 2015, assuming all of our collaboration programs advance as currently
contemplated. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contractual Obligations and Contingent Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There were no material changes to our contractual obligations during the three months ended September&nbsp;30, 2013. For a complete discussion
of our contractual obligations, please refer to our <I>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</I> in the Prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not
have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx610136_6"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Quantitative and Qualitative Disclosures about Market Risk </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary objective when
considering our investment activities is to preserve capital in order to fund our operations. As of September&nbsp;30, 2013, we had cash and cash equivalents of $33.6 million, of which $26.0 million was invested in money market funds. Our primary
exposure to market risk is related to changes in interest rates and our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies and money market instruments. We do not believe that
our cash and cash equivalents have significant risk. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx610136_7"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Controls and Procedures </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Disclosure Controls and Procedures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls
and procedures as of September&nbsp;30, 2013. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this Quarterly Report on Form 10-Q has been appropriately recorded,
processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#146;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and
principal financial officers, to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the
reasonable assurance level. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Changes in Internal Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No change in our internal control over financial reporting has occurred during the quarterly period ended September&nbsp;30, 2013 that has
materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements include statements
that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in
particular, under the headings &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;. Forward-looking statements can often be identified by the use of terminology such as
&#147;subject to&#148;, &#147;believe&#148;, &#147;anticipate&#148;, &#147;plan&#148;, &#147;expect&#148;, &#147;intend&#148;, &#147;estimate&#148;, &#147;project&#148;, &#147;may&#148;, &#147;will&#148;, &#147;should&#148;, &#147;would&#148;,
&#147;could&#148;, &#147;can&#148;, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but
they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and
factors, among others (including those set forth under &#147;Risk Factors&#148;), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate and degree of market acceptance and clinical utility of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our commercialization, marketing and manufacturing capabilities and strategy; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant competition in our industry; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of litigation and the failure to successfully defend lawsuits and other claims against us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic, political and other risks associated with our international operations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to receive research funding and achieve anticipated milestones under our collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our intellectual property position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss or retirement of key members of management; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to successfully execute our growth strategy, including any delays in our planned future growth; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to maintain effective internal controls. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consequently, forward-looking statements should be regarded solely as our current plans,
estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. We do not undertake and specifically decline any obligation to
update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II. OTHER INFORMATION </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx610136_8"></A>Item&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Risk Factors </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Our business and results of operations are subject to numerous risks,
uncertainties and other factors that you should be aware of, some of which are described below. The risks, uncertainties and other factors described below are not the only ones facing our company. Additional risks, uncertainties and other factors
not presently known to us or that we currently deem immaterial may also impair our business operations. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Any of the risks,
uncertainties and other factors could have a materially adverse effect on our business, financial condition or results of operations and could cause the trading price of our common stock to decline substantially. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business and the Development and Commercialization of Our Product Candidates. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>All of our product candidates are in pre-clinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and we
may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and non-U.S. regulatory authorities, which regulations
differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable
regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing
approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a lengthy, expensive
and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the products, manufacturers or manufacturing process; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">warning letters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">civil and criminal penalties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injunctions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizures, detentions or import bans; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">voluntary or mandatory product recalls and publicity requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">total or partial suspension of production; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">imposition of restrictions on operations, including costly new manufacturing requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal to approve pending BLAs or supplements to approved BLAs. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval
process. The number of pre-clinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations
applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be deemed safe or effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results may not confirm the positive results from earlier pre-clinical studies or clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies may not find the data from pre-clinical studies and clinical trials sufficient; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agencies may change their approval policies or adopt new regulations. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any delay in
obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact
our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our
product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently enrolling a Phase 2a clinical trial of margetuximab in patients with metastatic breast cancer and anticipate commencing a
Phase 3 potential registration clinical trial of margetuximab in advanced gastroesophageal cancer in the second half of 2014. We have initiated a Phase 1 clinical trial of MGA271 that we expect to complete by the end of 2014. We expect to commence a
Phase 1 clinical trial of MGD006 in the first half of 2014 and expect to commence a Phase 1 clinical trial of MGD007 in the second half of 2014. The commencement of these planned clinical trials could be substantially delayed or prevented by several
factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our
product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to obtain sufficient funds required for a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical research organizations, or CROs, the terms of which can be subject to
extensive negotiation and may vary significantly among different sites or CROs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The completion of our clinical trials could also be substantially delayed or prevented by several factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">slower than expected rates of patient recruitment and enrollment; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of patients to complete the clinical trial; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of efficacy during clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of our clinical trials by one or more clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">inability to monitor patients adequately during or after treatment by us and/or our CROs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect
these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a
clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a
number of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our
ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The results of
previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no products approved for sale and we cannot guarantee that we will ever have marketable products. Clinical failure can occur
at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or pre-clinical
testing. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek regulatory approvals for their
commercial sale. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to
the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in
subsequent registration clinical trials. Similarly, the outcome of pre-clinical testing and early clinical trials may not be predictive of the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final
results. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical
trials. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the design of a clinical trial can determine whether its results will support
approval of a product and flaws in the design of a clinical trial may not become apparent until the clinical trial is well advanced. We may be unable to design and execute a clinical trial to support regulatory approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. We
do not know whether any Phase&nbsp;2, Phase&nbsp;3 or other clinical trials we or any of our collaborators may conduct will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration
trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from pre-clinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for
the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial that has the potential to result in FDA or other agencies&#146; approval. In addition, any of these
regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S. regulatory
authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that
utilize these technologies. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our products in development are based on new technologies, such as Fc Optimization, bi-specific DARTs
and CSLCs. Given the complexity of our technologies, we intend to work closely with FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product
candidates. It is possible that the validation process may take time and resources, require independent third-party analyses or not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these
technology platforms, the regulatory approval path and requirements may not be clear, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the products that we develop would adversely affect our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress
these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at&nbsp;various
cancers and autoimmune disorders, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for
clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not
continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock
price. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or
indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we have limited financial
and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later
prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs
and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that
product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or
commercialize our products outside of the United States, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted
by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing
and validation and additional administrative review periods. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional pre-clinical studies or clinical trials which would be
costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming,
uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates
approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain
and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek fast-track designation of margetuximab and may seek fast track designation for some of our other product candidates. There is no assurance
that the FDA will grant such designation and, even if it does grant fast track designation to margetuximab or one of our other product candidates, that designation may not actually lead to a faster development or regulatory review or approval
process and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek fast-track designation of margetuximab and may seek fast track designation and review for some of our other product candidates. If
a drug is intended for the treatment of a serious or life-threatening condition or disease, the drug sponsor may apply for FDA fast track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a
particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Moreover, even if we do receive fast track designation, we may not experience a faster development process, review or approval
compared to conventional FDA procedures. In addition, the FDA may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development program. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may seek breakthrough therapy designation by the FDA for any of our product candidates but that is not assured and may not, in any event, lead to a
faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval in the United States. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may apply for breakthrough therapy designation for some of our product candidates. The FDA is authorized to designate a product candidate as
a breakthrough therapy if it finds that the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products designated as breakthrough therapies, interaction
and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Products designated as breakthrough
therapies by the FDA are also eligible for accelerated approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Designation as a breakthrough therapy is within the discretion of the
FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough
therapy designation for a product candidate may not result in a faster development process, review or approval compared to product candidates considered for approval under conventional FDA procedures and, in any event,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no
longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may be unable to
obtain orphan product designation or exclusivity for some or all of our product candidates. If our competitors are able to obtain orphan product exclusivity for their products that are the same as our product candidates, we may not be able to have
competing products approved by the applicable regulatory authority for a significant period of time. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Regulatory authorities in
some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, FDA may designate a product candidate as an orphan drug if it is a drug intended to
treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for
which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the European Medicines Agency (EMA) or the FDA from approving another marketing application for the same drug for that time period. The
applicable period is seven years in the United States and ten years in Europe. The European exclusivity period can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently
profitable so that market exclusivity is no longer justified. Orphan drug exclusivity may be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity
of the product to meet the needs of patients with the rare disease or condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain orphan drug exclusivity for a product,
that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA can subsequently approve the same drug for
the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our product candidates may have undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be
taken off the market, require them to include safety warnings or otherwise limit their sales. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although all of our product
candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved by
regulatory authorities, after the approved product has been marketed. All of our product candidates are still in clinical or pre-clinical development. While our clinical trials for our initial product candidates to date have demonstrated a favorable
safety profile, the results from future trials may not support this conclusion. The results of future clinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical
trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential
product liability claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates receives marketing approval and we or others later identify undesirable or
unacceptable side effects caused by such products: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require us to take our approved product off the market; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to limitations on how we may promote the product; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales of the product may decrease significantly; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may be subject to litigation or product liability claims; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our reputation may suffer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these events could prevent us, our collaborators or our
potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from
the sale of our products. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the
medical community, and third-party payors our revenue generated from their sales will be limited. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The commercial success of our
product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations or warnings contained in the approved labeling for a product candidate; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the standard of care for the targeted indications for any of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limitations in the approved clinical indications for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">demonstrated clinical safety and efficacy compared to other products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">lack of significant adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sales, marketing and distribution support; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability and extent of reimbursement from managed care plans and other third-party payors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timing of market introduction and perceived effectiveness of competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the degree of cost-effectiveness of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular diseases; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse publicity about our product candidates or favorable publicity about competitive products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">convenience and ease of administration of our products; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential product liability claims. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved, but do not
achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community
and third-party payors on the benefits of our product candidates may require significant resources and may never be successful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs
and limit supply of our products. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process of manufacturing our products is complex, highly regulated and subject to several
risks, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The process of manufacturing biologics, such as margetuximab, MGA271, and our other product candidates, is extremely susceptible to product loss due to contamination, equipment failure or improper installation or
operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could
result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such
manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The manufacturing facilities in which our product candidates are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures and numerous other factors. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We must comply with the FDA&#146;s current Good Manufacturing Practice, or cGMP, regulations and guidelines. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages
in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. Any failure to follow cGMP or other regulatory requirements or delay,
interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory
requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials
or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines,
injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and
criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or
criminal prosecution. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other
interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing
alternatives. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and
distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have no marketing, sales and distribution capabilities and we have no sales or marketing experience within our organization. If
any of our product candidates are approved, we intend either to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates, or to outsource this function to
a third party. Either of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to hire a sales force in the United States that is
sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our
products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to certain of our existing and future product candidates, we have entered into
collaboration or other licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower
than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our
control. If we are unable to enter into these arrangements on acceptable terms or at all, we may not be able to successfully commercialize any approved products. If we are not successful in commercializing any approved products, either on our own or
through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We
face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing
therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently
be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research
institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical
testing, obtaining regulatory approvals, recruiting patients and in manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been
approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and
development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or
discovering, developing and commercializing products in our field before we do. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Specifically, there are a large number of companies
developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by
using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen, Inc., or
Amgen, is in late-stage clinical development of cancer product candidates which work by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells. In addition, other companies are developing new
treatments for cancer and autoimmune diseases that enhance the Fc regions of antibodies to create more potent antibodies, including F. Hoffmann-La Roche Ltd., or Roche, and Xencor, Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more
effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain
approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking
to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products may be approved prior to margetuximab. Even if our product candidates achieve
marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, or collectively,
ACA created a new regulatory scheme authorizing the FDA to approve biosimilars. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is &#147;biosimilar to&#148; or &#147;interchangeable with&#148; a
previously approved biological product or &#147;reference product.&#148; Under this new statutory scheme, an application for a biosimilar product may not be submitted to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
FDA until four years following approval of the reference product. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was approved. Even if a
product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#146;s own pre-clinical data and data
from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. Furthermore, recent legislation has proposed that the 12 year exclusivity period for each a reference product may be reduced to seven
years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well
as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable
to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for
our products, it is less likely that our products will be widely used. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if our product candidates are approved for sale by the
appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health
insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels. We cannot be certain that reimbursement will be available for any products that we develop. Also, we cannot be certain that
reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize any of our approved products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act,
or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation established Medicare Part D, which expanded Medicare coverage for outpatient prescription drug purchases by the elderly but provided authority for limiting
the number of drugs that will be covered in any therapeutic class. The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals
to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been
significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health
maintenance organizations and additional legislative proposals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2010, the ACA became law in the United States. The goal of ACA
is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. While we cannot predict what impact on federal reimbursement policies this legislation will have in general or
on our business specifically, the ACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval. We
also cannot predict the impact of ACA on our business or financial condition as many of the ACA reforms require the promulgation of detailed regulations implementing the statutory provisions, which has not yet occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If any product liability lawsuits are successfully brought against us or any of our collaborators, we may
incur substantial liabilities and may be required to limit commercialization of our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We face an inherent risk
of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability
claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend
ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">termination of clinical trial sites or entire trial programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increased regulatory scrutiny; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">significant litigation costs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to or costly settlement with patients or other claimants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product recalls or a change in the indications for which they may be used; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">diversion of management and scientific resources from our business operations; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize our product candidates. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are
approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any
of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse
effects resulting from patients&#146; use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently hold $15 million in product liability insurance coverage in the aggregate, with a per incident limit of $15 million, which may
not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be
unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly
if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our business may become subject to economic, political, regulatory and other risks associated with international operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative and clinical
trial relationships are located outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic weakness, including inflation, or political instability in particular foreign economies and markets; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">differing regulatory requirements for drug approvals in foreign countries; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potentially reduced protection for intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties in compliance with non-U.S. laws and regulations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. regulations and customs, tariffs and trade barriers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in non-U.S. currency exchange rates and currency controls; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in a specific country&#146;s or region&#146;s political or economic environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">negative consequences from changes in tax laws; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">workforce uncertainty in countries where labor unrest is more common than in the United States; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">difficulties associated with staffing and managing foreign operations, including differing labor relations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products
approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of September&nbsp;30, 2013, our
accumulated deficit was approximately $172.0&nbsp;million. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for,
our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred
to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders&#146; deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of
our expenses and our ability to generate revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the numerous risks and uncertainties associated with pharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in
addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will
require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those
products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we
may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or
continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will require substantial additional funding, which may not be available to us on acceptable terms, or at
all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are
advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting pre-clinical studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to
conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in the initial public offering, or IPO, of our common stock completed in October 2013 to complete
the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our
liquidity requirements, based upon our current operating plan, we anticipate that the net proceeds from the IPO, together with our existing cash and cash equivalents and a significant portion of the $100&nbsp;million in collaboration payments we
anticipate receiving through 2015, will enable us to fund the clinical development of margetuximab, MGA271, MGD006, MGD007 and MGD010 through 2015, assuming all of our collaboration programs advance as currently contemplated. Because successful
development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including but not limited to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of other product candidates that we pursue; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope, progress, timing, cost and results of research, pre-clinical development, and clinical trials; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense
and enforcement of any patents or other intellectual property rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need and ability to hire additional management, scientific, and medical personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of competing products that may limit market penetration of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any
milestone or royalty payments under these agreements. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Until we can generate a sufficient amount of product revenue to
finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on
acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to
relinquish substantial rights. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that we raise additional capital through the sale of equity or convertible debt
securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve
agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic
alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that
we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We have broad discretion in the use of the
net proceeds from our IPO and may not use them effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management has broad discretion to use our cash and cash equivalents to fund our
operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a
material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use to fund operations, we may invest our cash and cash equivalents in a manner that does not
produce income or that loses value. <B><I>Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</I></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to utilize our federal net operating losses, or NOLs, and federal tax credits is currently limited, and may be limited further,
under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Internal Revenue Code. The limitations apply if an ownership change, as defined by Section&nbsp;382, occurs. Generally, an ownership change occurs when certain
shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to
Section&nbsp;382 limitations due to an acquisition we made in 2008. As of December&nbsp;31, 2012, we had federal NOL carryforwards of $100.9 million, state NOL carryforwards of $64.2 million and research and development tax credit carryforwards of
$21.8 million available. Future changes in stock ownership, may also trigger an ownership change and, consequently, another Section&nbsp;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit
carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax
credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Dependence on Third Parties </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to
maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. Accordingly, we have entered into collaborations with other companies that we believe can provide such capabilities, including
our collaboration and license agreements with Servier, Gilead, Boehringer, Pfizer and Green Cross Corp., or Green Cross. These collaborations also have provided us with important funding for our development programs and technology platforms and we
expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical
trial results, changes in the collaborators&#146; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new
formulation of a product candidate for clinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are
more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the
commercialization of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or
products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual
property or proprietary information or expose us to potential litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product
candidates. For example, each of our collaboration and license agreements with Servier, Gilead, and Boehringer may be terminated for convenience upon the completion of a specified notice period. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators
terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our technology platforms
and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development, regulatory approval and commercialization described in this
report also apply to the activities of our program collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, subject to its contractual obligations to us, if one of
our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with
us, we may find it more difficult to attract new collaborators. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For some of our product candidates, we may in the future determine to
collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive
agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United
States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our
ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or
technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business
combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may
have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and
undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be
available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our
product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential
collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with
third parties for specified periods of time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Independent clinical investigators and CROs that we engage to conduct our clinical trials may not
devote sufficient time or attention to our clinical trials or be able to repeat their past success. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to
depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise
required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be
our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient
resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of
third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly
referred to as current Good Clinical Practice, or cGCP, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects
are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with cGCP procedures could adversely affect the clinical development of our product candidates and harm our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Failure of our third party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could harm
our ability to commercialize our product candidates. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to develop companion diagnostics for our product candidates where
appropriate. Companion diagnostics are used to identify patients who could potentially benefit from our therapeutic product candidates. We expect that, at least in some cases, the FDA and similar regulatory authorities outside the United States may
require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on
third parties to perform these functions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We plan to outsource the development, production and commercialization of companion diagnostics
to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not perform their obligations as expected; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may encounter production difficulties that could constrain the supply of the companion diagnostic; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may not commit sufficient resources to the marketing and distribution of such product; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">may terminate their relationship with us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any companion diagnostic for use with one of our
product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into
arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or
commercialization of such product candidate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We expect to contract with third parties for the manufacture of our product candidates for clinical
testing in the future and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable
cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently have a manufacturing
facility located in Rockville, Maryland. We manufacture drug substance at this facility that we use for research and development purposes and for clinical trials of our product candidates. We currently have capacity to produce Phase 2 material for
our antibody product candidates and all clinical and commercial material for our DART therapeutics, but our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for
commercial quantities of such candidates. We do not have experience in manufacturing products at commercial scale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We anticipate
engagement of contract manufacturing organizations in 2014 to supplement our clinical supply and internal capacity as we advance pre-clinical product candidates into clinical development. We expect to use third parties for the manufacture of certain
of our product candidates for clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We plan eventually to
enter into long term supply agreements with several manufacturers for commercial supplies. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract
manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other
regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA&#146;s requirements for the manufacture
of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities&#146; cGMP requirements, our product candidates will not be approved or, if
already approved, may be subject to recalls. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reliance on third-party manufacturers entails risks to which we would not be subject if we
manufactured the product candidates ourselves, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or
prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and
at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be
unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant
regulatory authorities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in
the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with
patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because
publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file
for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States
and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending
patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business
objectives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and
time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to
protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. The issuance of a patent does not ensure that it is valid or enforceable, so even if we obtain patents, they may not be
valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product
and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our
products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid
and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and
factual considerations. The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform,
worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. The laws of some </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting
their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the
United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide
competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference
proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for
adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive
advantage. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after they have issued, our patents and any patents which we license may be challenged, narrowed, invalidated or
circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect
our competitive business position, business prospects and financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following are examples of litigation and other
adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or
patents licensed to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may initiate opposition or reexamination proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend
the validity and scope of our patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. Patent&nbsp;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors
to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing
lawsuits alleging patent infringement. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits and proceedings would be costly and could affect our results of
operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party&#146;s activities, or that the scope of
certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or
other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive
business position, business prospects and financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection for our proprietary rights is uncertain because legal means
afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to make the inventions covered by patents or pending patent applications; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we might not have been the first to file patent applications for these inventions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we may not develop additional proprietary technologies that are patentable. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our commercial success
depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or
import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells.
Although we believe that these patents are invalid, if they cover margetuximab or MGA271 and we are unable to invalidate their patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps
materially. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid
and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and
results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.
Invitrogen, Inc., for example, has asserted that we are required to obtain a license for use of a cell line. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the pharmaceutical
industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or
proceedings include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not
infringe those third parties&#146; patents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the
priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that
we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These lawsuits would be costly and could affect our results of operations and divert the
attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party&#146;s patents and would order us or our collaborators to stop the activities covered by the
patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition,
there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the
technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry
participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent
infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For
example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs
and divert management&#146;s time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an
infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a
license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product
candidates to market and be precluded from manufacturing or selling our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The cost of any patent litigation or other
proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties
resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant
management time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license
rights that are important to our business. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently party to various intellectual property license agreements. These
license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements which
grant us the right to use a certain technology related to biological manufacturing to manufacture margetuximab and MGA271. These licenses typically include an obligation to pay an upfront payment, yearly maintenance payments and royalties on sales.
If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination
of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our
business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be
adversely affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on other proprietary rights, including protection of trade
secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of
their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#146;s relationship with us be kept confidential and not
disclosed to third parties. Our agreements with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not
obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or
disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees,
consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to
assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#146;s
assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Adequate remedies may not exist in
the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and
time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may
independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at
research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade
secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their
former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed
by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the
USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally,
the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help
us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we
are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any
costs and consequences of any resulting loss of patent rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign
legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be
eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a
patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we
are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market
competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Legal Compliance
Matters </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely
affected. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and
chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the
risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and
workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we
maintain workers&#146; compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not
provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations
may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to
civil or criminal penalties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state
and federal healthcare laws commonly referred to as &#147;fraud and abuse&#148; laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback
statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment
to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying,
soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed
healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and
regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to
scrutiny if they do not qualify for an exemption or safe harbor. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and
services reimbursed by private insurers. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of
promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by
federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our
future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these &#147;fraud and abuse&#148; laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our employees may engage in misconduct or other improper activities, including noncompliance with
regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk of employee fraud or other misconduct.
Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information
or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks,
self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee
misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible
to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions
or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business, including the imposition of significant fines or other sanctions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Relating to Employee Matters and Managing Growth </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our
President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their
employment with us at any time. We currently maintain $1 million in &#147;key person&#148; insurance coverage for Dr.&nbsp;Koenig. The loss of the services of our executive officers or other key employees could impede the achievement of our
research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success.
In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future
product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required
to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the
competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on
consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have
commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, we had 160 full-time employees. As our development and commercialization plans and strategies develop, we expect
to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain,
motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may
not be able to effectively manage the expansion of our operations which may result in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our
expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product
candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks
Relating to Our Common Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Our stock price may be volatile and fluctuate substantially. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our stock price is likely to be volatile. The stock market has experienced significant volatility, particularly with respect to pharmaceutical,
biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock. Some of the
factors that may cause the market price of our common stock to fluctuate include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">results and timing of our clinical trials and clinical trials of our competitors&#146; products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure or discontinuation of any of our development programs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issues in manufacturing our product candidates or future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#146; products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competition from existing products or new products that may emerge; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments or disputes concerning patents or other proprietary rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">introduction of technological innovations or new commercial products by us or our competitors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements by us, our collaborators or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in estimates or recommendations by securities analysts, if any cover our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fluctuations in the valuation of companies perceived by investors to be comparable to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">public concern over our product candidates or any future approved products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">litigation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">future sales of our common stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additions or departures of key personnel; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the structure of health care payment systems in the United States or overseas; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure of any of our product candidates, if approved, to achieve commercial success; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">economic and other external factors or other disasters or crises; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">period-to-period fluctuations in our financial condition and results of operations, including the timing of receipt of any milestone or other payments under commercialization or licensing agreements; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general market conditions and market conditions for biopharmaceutical stocks; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overall fluctuations in U.S. equity markets. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in the past, when the market price
of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the
lawsuit and divert the time and attention of our management, which could seriously harm our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>An active trading market for our common stock
may not be sustained. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we closed our IPO. Prior to the IPO, there was no public market for our common stock.
Although we have completed our initial public offering and shares of our common stock are listed and trading on The NASDAQ Global Market, an active trading market for our shares may not be sustained. If an active market for our common stock does not
continue, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares or sell their shares at or above the prices at which they acquired their shares or sell their shares at the time they would
like to sell. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our
shares as consideration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Insiders have substantial control over us which could delay or prevent a change in corporate control or result in the
entrenchment of management and/or the board of directors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our directors, executive officers and principal stockholders, together
with their affiliates and related persons, beneficially own, in the aggregate, approximately 78% of our outstanding common stock. As a result, these stockholders, if acting together, may have the ability to determine the outcome of matters submitted
to our stockholders for approval, including the election and removal of directors and any merger, consolidation, or sale of all or substantially all of our assets. In addition, these persons, acting together, may have the ability to control the
management and affairs of our company. Accordingly, this concentration of ownership may harm the market price of our common stock by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delaying, deferring, or preventing a change in control; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entrenching our management and/or the board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impeding a merger, consolidation, takeover, or other business combination involving us; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We are an &#147;emerging growth company&#148; and as a result of the reduced disclosure requirements applicable to emerging growth companies, our common
stock may be less attractive to investors. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth company,&#148; as defined in the Jumpstart Our Business
Startups Act of 2012, or the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not &#147;emerging growth companies&#148; including, but not
limited to, not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and
exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In addition, the JOBS Act provides that an emerging growth company
can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of some accounting standards until those standards would otherwise
apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We cannot predict
whether investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock
price may be more volatile. We may take advantage of these reporting exemptions until we are no longer an &#147;emerging growth company.&#148; We could remain an &#147;emerging growth company&#148; until the earliest to occur of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of the fiscal year in which we have total annual gross revenue of $1 billion or more; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the last day of our fiscal year following the fifth anniversary of the date of the first sale of common equity securities pursuant to the prospectus filed with the Securities and Exchange Commission on October&nbsp;11,
2013; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we have issued more than $1 billion in non-convertible debt during the previous three years; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which we are deemed to be a &#147;large accelerated filer&#148; under SEC rules and regulations. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time
to corporate governance standards. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a public company, we will incur significant legal, accounting and other expenses that we did
not incur as a private company. In addition, our administrative staff will be required to perform additional tasks. For example, in anticipation of becoming a public company, we will need to adopt additional internal controls and disclosure controls
and procedures, retain a transfer agent and adopt an insider trading policy. As a public company, we will bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the
securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, regulations and standards relating to corporate governance and public disclosure, including the
Sarbanes-Oxley Act and related regulations implemented by the Securities and Exchange Commission and the NASDAQ Global Select Market, have increased legal and financial compliance costs and will make some compliance activities more time consuming.
We are currently evaluating these rules, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. We intend to invest resources to comply with evolving laws, regulations and standards, and this
investment will result in increased general and administrative expenses and may divert management&#146;s time and attention from our other business activities. If our efforts to comply with new laws, regulations and standards differ from the
activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed. In connection with our IPO, we increased our
directors&#146; and officers&#146; insurance coverage which will increase our insurance cost. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept
reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and
compensation committee, and qualified executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the corporate governance standards of the NASDAQ Global Select Market, a
majority of our board of directors and each member of our audit committee must be an independent director no later than the first anniversary of the completion of our IPO. We may encounter difficulty in attracting qualified persons to serve on our
board of directors and the audit committee, and our board of directors and management may be required to divert significant time and attention and resources away from our business to identify qualified directors. If we fail to attract and retain the
required number of independent directors, we may be subject to the delisting of our common stock from the NASDAQ Global Select Market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Provisions of our charter, bylaws, and Delaware law may make an acquisition of us or a change in our
management more difficult. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our restated certificate of incorporation and restated bylaws that became
effective upon the completion of our IPO could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your
shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these
transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or
remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">allow the authorized number of directors to be changed only by resolution of our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a classified board of directors, providing that not all members of the board of directors be elected at one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a &#147;poison pill&#148; to dilute the stock ownership of a potential hostile
acquirer to prevent an acquisition that is not approved by our board of directors; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">limit who may call stockholder meetings; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware
General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This
provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We do not anticipate paying cash dividends, and accordingly, stockholders must rely on stock appreciation for any return on their investment.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently intend to retain our future earnings, if any, to fund the development and growth of our businesses. As a result,
capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>A significant portion of our total outstanding shares of common stock is restricted from resale but may be sold into the market in the near future. This
could cause the market price of our common stock to drop significantly, even if our business is doing well. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Sales of a substantial
number of shares of our common stock in the public market could occur in the future. These sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of
our common stock. After the IPO in October 2013, we had 25,020,288 outstanding shares of common stock. This includes the shares sold in the IPO, which may be resold in the public market immediately and the remaining shares are currently restricted
under securities laws or as a result of lock-up agreements but will be able to be resold as described in the &#147;Shares Eligible for Future </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Sale&#148; section of the Prospectus. Moreover, holders of an aggregate of 15,504,104 shares of common stock, which includes 15,130,610 shares of common stock issuable upon the conversion of all
our outstanding shares of our preferred stock have rights, subject to certain conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or
other stockholders. We also intend to register all 1,920,168 shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance and once vested,
subject to the lock-up agreements described in the &#147;Underwriting&#148; section of the Prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Future issuances of our common stock or
rights to purchase common stock pursuant to our equity incentive plans or outstanding warrants could result in additional dilution of the percentage ownership of our stockholders and could cause our share price to fall. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of September&nbsp;30, 2013, we have options to purchase 2,877,003 shares outstanding under our equity compensation plans. We are also
authorized to grant equity awards, including stock options, to our employees, directors and consultants, covering up to 8,170 shares of our common stock, pursuant to our equity compensation plans. We plan to register the number of shares available
for issuance or subject to outstanding awards under our equity compensation plans. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>If securities or industry analysts do not publish research or
publish inaccurate or unfavorable research about our business, our share price and trading volume could decline. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading
market for our common stock will depend on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide
favorable coverage. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly
publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx610136_9"></A>Item&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Unregistered Sales of Equity Securities and Use of Proceeds </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Sales of Unregistered Equity
Securities </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, upon the closing of our initial public offering, all 294,720,231 shares of our then-outstanding
convertible preferred stock were automatically converted into 16,955,790 shares of common stock. The issuance of such shares of common stock was exempt from the registration requirements of the Securities Act of 1933 (Securities Act), pursuant to
Section&nbsp;3(a)(9) and Section&nbsp;4(s) of the Securities Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Use of Proceeds </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2013, we issued and sold 5,750,000 shares of our common stock, including 750,000 shares of common stock sold pursuant to the
underwriters&#146; full exercise of their option to purchase additional shares, in our initial public offering (the &#147;IPO&#148;) at a public offering price of $16.00 per share, for aggregate gross proceeds of $92.0 million. All of the shares
issued and sold in the IPO were registered under the Securities Act pursuant to a Registration Statement on Form S-1 (File No.&nbsp;333-190994), which was declared effective by the SEC on October&nbsp;9, 2013. Merrill Lynch, Pierce,
Fenner&nbsp;&amp; Smith Incorporated and Leerink Swann LLC acted as representatives of the several underwriters. The offering commenced on October&nbsp;10, 2013 and did not terminate until the sale of all of the shares offered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B><A NAME="tx610136_10"></A>Item&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Exhibits </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Restated Certificate of Incorporation of MacroGenics, Inc. (Incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form 8-K, filed on October&nbsp;17, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Amended and Restated By-Laws of MacroGenics, Inc. (Incorporated by reference to Exhibit 3.4 to Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-190994) filed on October 1, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certificate of Correction to the Restated Certificate of Incorporation of MacroGenics, Inc. (Incorporated by reference to Exhibit 3.3 to the Company&#146;s Current Report on Form 8-K, filed on October 17, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Executive Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Financial Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Executive Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Financial Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Definition Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Labels Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed to be &#147;furnished&#148; and not &#147;filed&#148;. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U><A NAME="tx610136_11"></A>SIGNATURES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MACROGENICS, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BY:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="91%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">BY:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President and Chief Financial Officer</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">(Principal Financial Officer)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;12, 2013 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">EXHIBIT INDEX </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Exhibit Page Number </U></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Restated Certificate of Incorporation of MacroGenics, Inc. (Incorporated by reference to Exhibit 3.1 to the Company&#146;s Current Report on Form 8-K, filed on October 17, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Amended and Restated By-Laws of MacroGenics, Inc. (Incorporated by reference to Exhibit 3.4 to Amendment No. 2 to the Registration Statement on Form S-1 (File No. 333-190994) filed on October 1, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;3.3</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Certificate of Correction to the Restated Certificate of Incorporation of MacroGenics, Inc. (Incorporated by reference to Exhibit 3.3 to the Company&#146;s Current Report on Form 8-K, filed on October 17, 2013).</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Executive Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Rule 13a-14(a) Certification of Principal Financial Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Executive Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.2</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">Section 1350 Certification of Principal Financial Officer.</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Schema Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Calculation Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Definition Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Labels Linkbase Document</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE*</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top">XBRL Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">In accordance with Regulation S-T, the XBRL-related information in Exhibit 101 to this Quarterly Report on Form 10-Q shall be deemed to be &#147;furnished&#148; and not &#147;filed&#148;. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>d610136dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Scott Koenig, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2013 of MacroGenics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">President and Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Principal Executive Officer)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;12, 2013 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>d610136dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 31.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Karrels, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2013 of MacroGenics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Vice President and Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">(Principal Financial Officer)</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: November&nbsp;12, 2013 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>d610136dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.1 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Executive Officer</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 18 U.S.C. 1350</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Section 906 of the Sarbanes-Oxley Act of 2002</B>) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#147;Registrant&#148;), certify, to the best
of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2013 of the Registrant (the &#147;Report&#148;), that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Scott Koenig</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: Scott Koenig, M.D., Ph.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: November&nbsp;12, 2013</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>d610136dex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXHIBIT 32.2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certification of Principal Financial Officer </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to 18 U.S.C. 1350 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Section 906 of the Sarbanes-Oxley Act of 2002) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, James Karrels, Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#147;Registrant&#148;), certify, to the
best of my knowledge, based upon a review of the Quarterly Report on Form 10-Q for the period ended September&nbsp;30, 2013 of the Registrant (the &#147;Report&#148;), that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The Report fully complies with the requirements of Section&nbsp;13(a) of the Securities Exchange Act of 1934, as amended; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name: James Karrels</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Date: November&nbsp;12, 2013</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>mgnx-20130930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version:  6.21.0 -->
<!-- Round: 7 -->
<!-- Creation date: 2013-11-12T20:03:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31" xmlns:mgnx="http://www.macrogenics.com/20130930" xmlns:us-types="http://fasb.org/us-types/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="mgnx-20130930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="eol_PE179294--1310-Q0003_STD_0_20041031_0" unitRef="shares" decimals="INF" id="id_2787876_368FCEED-783A-4624-A454-175370AC7D1D_2001_3">13604016</us-gaap:CommonStockSharesSubscribedButUnissued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE179294--1310-Q0003_STD_0_20100530_0_932980x1165094" unitRef="shares" decimals="INF" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_2003_6">518708</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20131031_0" unitRef="shares" decimals="INF" id="id_2787876_213C6852-500A-4BE7-BF3A-D570AECEB64B_2_500005">25020288</dei:EntityCommonStockSharesOutstanding>
  <mgnx:AdditionalPaymentUponAchievementOfMilestone contextRef="eol_PE179294--1310-Q0003_STD_0_20050630_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_3001_0">10950000</mgnx:AdditionalPaymentUponAchievementOfMilestone>
  <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="eol_PE179294--1310-Q0003_STD_0_20060531_0" unitRef="shares" decimals="INF" id="id_2787876_04ECB415-C29F-4F1F-98CA-0B614727AF0E_2001_3">10003300</us-gaap:CommonStockSharesSubscribedButUnissued>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20080716_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_32F2441E-5662-4D57-B46F-AA0E03E43BAF_1_0">5000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreement>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts contextRef="eol_PE179294--1310-Q0003_STD_0_20080716_0_926437x923140" unitRef="iso4217_USD" decimals="-5" id="id_2787876_32F2441E-5662-4D57-B46F-AA0E03E43BAF_1001_2">12000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts>
  <mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts contextRef="eol_PE179294--1310-Q0003_STD_0_20080716_0_926437x932953" unitRef="iso4217_USD" decimals="-5" id="id_2787876_32F2441E-5662-4D57-B46F-AA0E03E43BAF_2001_1">8000000</mgnx:OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE179294--1310-Q0003_STD_0_20080930_0_932980x1165094" unitRef="shares" decimals="INF" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_2001_3">2875327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-Q0003_STD_0_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1002_26">30451085</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock contextRef="eol_PE179294--1310-Q0003_STD_0_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_1004_4">1.50</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_63">2124624</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_3001_6">1855178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_62">2124624</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_7001_6">17129782</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_3001_5">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_3001_5">2877003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_1006_9">8171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_3001_7">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_3001_7">918600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:TreasuryStockNumberOfSharesHeld contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_65">14381</us-gaap:TreasuryStockNumberOfSharesHeld>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_3001_6">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_61">425000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_60">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_14">1229454</us-gaap:RestructuringReserveCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_13">939811</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_1">3396780</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_1_7">15174112</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_66">165569134</us-gaap:AdditionalPaidInCapital>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_6">17390144</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_12">1798228</us-gaap:AccountsPayableCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_3">3486881</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_16">25265811</us-gaap:LiabilitiesCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_5">625540</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_68">-4048414</us-gaap:StockholdersEquity>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_4">3035013</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_19">679296</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:ImpairedFinancingReceivableRelatedAllowance contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_AED7DD18-38FA-4FDD-ABEE-5151CBC9A0B3_1_0">0</us-gaap:ImpairedFinancingReceivableRelatedAllowance>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_67">-172528254</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_15">21298318</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_18">2888688</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_59">21246</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_69">41975907</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RestructuringReserveNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_17">8378184</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_21">46024321</us-gaap:Liabilities>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_2">3385321</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2001_7">679296</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_20">8812342</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_57EF7F73-918F-4648-844A-3C50F964790C_1001_0">3460609</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_5">36953929</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_8">147246</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_4">1103449</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_6">404850</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2001_2">7522029</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:Assets contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_9">41975907</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2001_5">33974048</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_2">33569198</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_3">2281282</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_1_6">19643994</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8031FE81-0DCF-4B7F-BAA6-D28D7E128B63_1001_1">12200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8031FE81-0DCF-4B7F-BAA6-D28D7E128B63_1001_0">17400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:TreasuryStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_64">57742</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1_7">4469882</us-gaap:PropertyPlantAndEquipmentNet>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2001_4">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2001_3">26047169</mgnx:MoneyMarketFundsFairValueDisclosure>
  <mgnx:PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="shares" decimals="-6" id="id_2787876_9AD1D1E0-1A81-471B-BA99-1437F4A6E8B1_1001_0">4000000</mgnx:PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold>
  <mgnx:RevenueRecognitionMilestoneMethodRevenueReceivable contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_3_7">5000000</mgnx:RevenueRecognitionMilestoneMethodRevenueReceivable>
  <mgnx:ResearchAndMaintenanceAmountReceivable contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_3_8">4000000</mgnx:ResearchAndMaintenanceAmountReceivable>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926437x923140" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_1002_4">7.51</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926437x932953" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_1001_4">1.50</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_1">1589410</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_6">9607638</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_5EF377F7-EC84-4D48-9940-2B776A570667_6001_5">9607638</us-gaap:RestructuringReserve>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_3">2049273</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_5">616356</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_4">2315026</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_2">1808119</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_129DD59A-640C-485A-A334-CC88AC0F804A_1001_0">1229454</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_927592x929614" unitRef="iso4217_USD" decimals="0" id="id_2787876_32387351-DF92-45CD-A47C-B41F9198D8A0_4001_5">679296</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A86010D7-4CAF-4590-ABAE-2320C4E8DEAB_1002_0">11600000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A86010D7-4CAF-4590-ABAE-2320C4E8DEAB_1002_1">8600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A86010D7-4CAF-4590-ABAE-2320C4E8DEAB_1002_2">3000000</us-gaap:DeferredRevenueNoncurrent>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_310C5680-5400-40FB-A957-C56097578569_2001_4">300000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_310C5680-5400-40FB-A957-C56097578569_2001_3">5000000</mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement>
  <mgnx:LicenseGrantFeesReceivable contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_310C5680-5400-40FB-A957-C56097578569_2001_1">65000000</mgnx:LicenseGrantFeesReceivable>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929038x1220599_930809x1218846" unitRef="iso4217_USD" decimals="-5" id="id_2787876_7D91C121-F31A-44B5-89FB-D5E86D3F956D_1001_3">1500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925736" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2002_7" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2002_2">7522029</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2002_5">33974048</us-gaap:AssetsFairValueDisclosure>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2002_4">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2002_3">26047169</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2003_7" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2003_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2003_5" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2003_4" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2003_3" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x929831" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2004_7">679296</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2004_2" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2004_5" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2004_4" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_2004_3" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x923192" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_1001_4">51360</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x923325" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_2001_5">4893770</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x928802" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_3001_3">10603598</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x929134" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_4001_1">1323081</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x931760" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_5001_0">2172535</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x932226" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_6001_2">599650</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_930809x1108152" unitRef="shares" decimals="INF" id="id_2787876_6AC3516C-BBFA-4E19-AC04-AF5AB2FC5EA4_2001_0">130725</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1001_45">110952217</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1001_43">110952217</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1001_42">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1001_44">110952217</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1001_41">1109522</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1001_46">45000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2001_39">71401237</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2001_37">71401237</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2001_36">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2001_38">71401237</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2001_35">714012</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2001_40">31000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockLiquidationPreference contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1165094" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_52838CDE-F0A3-4967-9890-22E85D1E08AB_1001_0">12.20</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1165094" unitRef="shares" decimals="INF" id="id_2787876_5EF224A7-A5C9-4B21-A277-B270D8262E38_1001_5">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1165094" unitRef="iso4217_USD_per_Warrant" decimals="2" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_2002_4">0.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3001_27">26874792</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3001_25">26874792</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3001_24">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3001_26">26874792</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3001_23">268748</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3001_28">27000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4001_33">7364582</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4001_31">7364582</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4001_30">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4001_32">7364582</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4001_29">73646</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4001_34">7000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1184171" unitRef="shares" decimals="INF" id="id_2787876_5EF224A7-A5C9-4B21-A277-B270D8262E38_2001_0">1.506</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218712" unitRef="shares" decimals="INF" id="id_2787876_5EF224A7-A5C9-4B21-A277-B270D8262E38_3001_1">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5001_57">63681176</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5001_55">75000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5001_54">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5001_56">63681176</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5001_53">636812</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5001_58">41500000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6001_51">14446227</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6001_49">30000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6001_48">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6001_50">14446227</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6001_47">144462</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6001_52">9400000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockLiquidationPreference contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x929177" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_52838CDE-F0A3-4967-9890-22E85D1E08AB_2001_2">12.20</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x929177" unitRef="shares" decimals="INF" id="id_2787876_5EF224A7-A5C9-4B21-A277-B270D8262E38_4001_4">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockLiquidationPreference contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x930400" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_52838CDE-F0A3-4967-9890-22E85D1E08AB_3001_1">7.70</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x930400" unitRef="shares" decimals="INF" id="id_2787876_5EF224A7-A5C9-4B21-A277-B270D8262E38_5001_3">1.00</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:PreferredStockLiquidationPreference contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x930435" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_52838CDE-F0A3-4967-9890-22E85D1E08AB_4001_4">12.39</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:PreferredStockLiquidationPreference contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x932774" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_52838CDE-F0A3-4967-9890-22E85D1E08AB_5001_3">6.95</us-gaap:PreferredStockLiquidationPreference>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x932774" unitRef="shares" decimals="INF" id="id_2787876_5EF224A7-A5C9-4B21-A277-B270D8262E38_6001_2">1.14</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_0FE629E8-8134-406C-BD27-E416C76BC312_1002_0">10300000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_0FE629E8-8134-406C-BD27-E416C76BC312_1002_1">5000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_0FE629E8-8134-406C-BD27-E416C76BC312_1002_2">5300000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="0" id="id_2787876_29AE0681-F93E-47D7-A12A-DC9DFC111F6F_1001_0">246375</us-gaap:AccountsReceivableNetCurrent>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-6" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_2002_3">89000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_2787876_49809704-B319-43D5-B16F-F15B02345391_1_0">4400000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_2787876_75BE03A1-62C3-4EEB-B123-6DFDC9EA5410_1_0">1100000</us-gaap:AccountsReceivableNetCurrent>
  <mgnx:AdditionalPaymentUnderLicensingAndCollaborationAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_2787876_4011512C-62F0-4DEF-BAEA-D33749CCE2CB_1001_1">22500000</mgnx:AdditionalPaymentUnderLicensingAndCollaborationAgreement>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_2787876_4011512C-62F0-4DEF-BAEA-D33749CCE2CB_1001_3">355000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_2787876_4011512C-62F0-4DEF-BAEA-D33749CCE2CB_1001_2">200000000</mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement>
  <mgnx:LicenseGrantFeesReceivable contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_2787876_4011512C-62F0-4DEF-BAEA-D33749CCE2CB_1001_0">7500000</mgnx:LicenseGrantFeesReceivable>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_AE06C6B2-3870-4B78-9698-2D3C030F1B61_1002_0">675000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_AE06C6B2-3870-4B78-9698-2D3C030F1B61_1002_1">100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_AE06C6B2-3870-4B78-9698-2D3C030F1B61_1002_2">575000</us-gaap:DeferredRevenueNoncurrent>
  <mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A5FB727B-5249-45AF-B90A-4DC897D6932B_1001_1">4500000</mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_2001_2">58000000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="0" id="id_2787876_4753E236-364D-4661-8B31-4B0511BAD057_1001_0">501794</us-gaap:AccountsReceivableNetCurrent>
  <mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="-6" id="id_2787876_04D8518E-EFD4-4F16-B5E3-6EE1827C3DE0_1001_0">17000000</mgnx:AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1218715" unitRef="iso4217_USD" decimals="0" id="id_2787876_B00BF36B-BE5C-40F5-8BD1-788DF6F80A36_2001_600000">244542</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_DC4E113B-A1C0-4AAA-89B4-2F67F72C8205_2_0">3100000</us-gaap:DeferredRevenue>
  <mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_B2F44DBC-B6A6-4DA8-B93A-2F1E9B6669DB_1001_3">140000000</mgnx:AdditionalRegulatoryMilestonePaymentsUnderAgreement>
  <mgnx:LicenseGrantFeesReceivable contextRef="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_B2F44DBC-B6A6-4DA8-B93A-2F1E9B6669DB_1001_1">30000000</mgnx:LicenseGrantFeesReceivable>
  <us-gaap:SharePrice contextRef="eol_PE179294--1310-Q0003_STD_0_20131016_0_931707x926487_932504x931597" unitRef="iso4217_USD_per_shares" decimals="0" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_1002_1">16</us-gaap:SharePrice>
  <mgnx:AdditionalCommonStockIssuePricePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20131016_0_931707x926487_932504x931597" unitRef="iso4217_USD_per_shares" decimals="0" id="id_2787876_4F874131-ED1D-47E9-B3FD-4D6B3ECF07AF_1002_1">16</mgnx:AdditionalCommonStockIssuePricePerShare>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20131016_0_932504x931597" unitRef="shares" decimals="INF" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_2_5">25020288</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20131016_0_932504x931597" unitRef="shares" decimals="INF" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_2_4">25020288</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20131016_0_932504x931597" unitRef="shares" decimals="INF" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_2_6">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20031231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_1_0">2051644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharePrice contextRef="eol_PE179294--1310-Q0003_STD_0_20031231_0_932980x930435" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_4F476A18-7ECD-444C-93B8-96787978ACA4_2001_2">1.00</us-gaap:SharePrice>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-Q0003_STD_0_20111231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2001_25">55218361</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1310-Q0003_STD_0_20111231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_5EF377F7-EC84-4D48-9940-2B776A570667_1001_1">10607499</us-gaap:RestructuringReserve>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_63">1098914</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_62">1098914</us-gaap:CommonStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_1001_1">0.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_1001_1">3249702</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:TreasuryStockNumberOfSharesHeld contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_65">14381</us-gaap:TreasuryStockNumberOfSharesHeld>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_61">425000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_60">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:RestructuringReserveCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_14">628768</us-gaap:RestructuringReserveCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_13">1237025</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_2_7">14339497</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_66">164334646</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_12">3739125</us-gaap:AccountsPayableCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_16">29728094</us-gaap:LiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_68">-8237308</us-gaap:StockholdersEquity>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_19">52947</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:ImpairedFinancingReceivableRelatedAllowance contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_AED7DD18-38FA-4FDD-ABEE-5151CBC9A0B3_2_0">0</us-gaap:ImpairedFinancingReceivableRelatedAllowance>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_67">-175472403</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_15">24123176</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRentCreditNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_18">2801653</us-gaap:DeferredRentCreditNoncurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_59">10989</us-gaap:CommonStockValue>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_69">53746900</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:RestructuringReserveNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_17">9445171</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:Liabilities contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_21">61984208</us-gaap:Liabilities>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1001_14">52947</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_20">19956343</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AssetsCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_5">49927008</us-gaap:AssetsCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_8">147246</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_4">137634</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:RestrictedCashAndCashEquivalents contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_6">404850</us-gaap:RestrictedCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1001_9">18695197</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:Assets contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_9">53746900</us-gaap:Assets>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1001_12">48148005</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_2">47743155</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_3">2046219</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_2_6">17607293</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:TreasuryStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_64">57742</us-gaap:TreasuryStockValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2_7">3267796</us-gaap:PropertyPlantAndEquipmentNet>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1001_11">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1001_10">29047958</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:RestructuringReserve contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_5EF377F7-EC84-4D48-9940-2B776A570667_3001_3">10073939</us-gaap:RestructuringReserve>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_927592x929614" unitRef="iso4217_USD" decimals="0" id="id_2787876_32387351-DF92-45CD-A47C-B41F9198D8A0_1001_3">52947</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A86010D7-4CAF-4590-ABAE-2320C4E8DEAB_1001_0">18000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A86010D7-4CAF-4590-ABAE-2320C4E8DEAB_1001_1">8600000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A86010D7-4CAF-4590-ABAE-2320C4E8DEAB_1001_2">9400000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1002_14" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1002_9">18695197</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1002_12">48148005</us-gaap:AssetsFairValueDisclosure>
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1002_11">404850</mgnx:RestrictedCashFairValueDisclosure>
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925736" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1002_10">29047958</mgnx:MoneyMarketFundsFairValueDisclosure>
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1003_14" />
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1003_9" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1003_12" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1003_11" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925851" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1003_10" />
  <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" decimals="0" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1004_14">52947</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1004_9" />
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1004_12" />
  <mgnx:RestrictedCashFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1004_11" />
  <mgnx:MoneyMarketFundsFairValueDisclosure contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x929831" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_C18D42D9-A657-4E01-9763-50A83D9BADAF_1004_10" />
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x923192" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_1002_4">51360</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x923325" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_2002_5">4881706</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x928802" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_3002_3">8747790</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x929134" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_4002_1">1323081</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x931760" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_5002_0">2003706</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x932226" unitRef="iso4217_USD" decimals="0" id="id_2787876_F82DFBD0-EE03-4D86-BEA1-62A6EFCDEF72_6002_2">599650</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1002_45">110952217</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1002_43">110952217</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1002_42">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1002_44">110952217</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1002_41">1109522</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_1002_46">45000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2002_39">71401237</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2002_37">71401237</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2002_36">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2002_38">71401237</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2002_35">714012</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_2002_40">31000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3002_27">26874792</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3002_25">26874792</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3002_24">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3002_26">26874792</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3002_23">268748</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_3002_28">27000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4002_33">7364582</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4002_31">7364582</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4002_30">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4002_32">7364582</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4002_29">73646</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_4002_34">7000000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5002_57">63681176</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5002_55">75000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5002_54">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5002_56">63681176</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5002_53">636812</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_5002_58">41500000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6002_51">14446227</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6002_49">30000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6002_48">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370" unitRef="shares" decimals="INF" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6002_50">14446227</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6002_47">144462</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370" unitRef="iso4217_USD" decimals="0" id="id_2787876_115C3CD3-D93C-4BBD-8A1E-46E7B39578F6_6002_52">9400000</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_0FE629E8-8134-406C-BD27-E416C76BC312_1001_0">14000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_0FE629E8-8134-406C-BD27-E416C76BC312_1001_1">5000000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_0FE629E8-8134-406C-BD27-E416C76BC312_1001_2">9000000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="0" id="id_2787876_29AE0681-F93E-47D7-A12A-DC9DFC111F6F_1002_0">355568</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_AE06C6B2-3870-4B78-9698-2D3C030F1B61_1001_0">750000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_AE06C6B2-3870-4B78-9698-2D3C030F1B61_1001_1">100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_AE06C6B2-3870-4B78-9698-2D3C030F1B61_1001_2">650000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_2005_2">1300000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1115783" unitRef="iso4217_USD" decimals="0" id="id_2787876_4753E236-364D-4661-8B31-4B0511BAD057_1002_0">896285</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1218715" unitRef="iso4217_USD" decimals="0" id="id_2787876_B00BF36B-BE5C-40F5-8BD1-788DF6F80A36_2005_800000">558516</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:DeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_DC4E113B-A1C0-4AAA-89B4-2F67F72C8205_1_0">10000000</us-gaap:DeferredRevenue>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_DC4E113B-A1C0-4AAA-89B4-2F67F72C8205_1_1">9100000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_DC4E113B-A1C0-4AAA-89B4-2F67F72C8205_1_2">900000</us-gaap:DeferredRevenueNoncurrent>
  <dei:EntityRegistrantName contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_213C6852-500A-4BE7-BF3A-D570AECEB64B_1_400001">MACROGENICS INC</dei:EntityRegistrantName>
  <dei:AmendmentFlag contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_B6A6E516-05D1-43E5-B395-E586BAA6A9AE_1_1">false</dei:AmendmentFlag>
  <dei:EntityFilerCategory contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_213C6852-500A-4BE7-BF3A-D570AECEB64B_1_400004">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_B6A6E516-05D1-43E5-B395-E586BAA6A9AE_1_3">2013</dei:DocumentFiscalYearFocus>
  <dei:DocumentType contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_B6A6E516-05D1-43E5-B395-E586BAA6A9AE_1_0">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_B6A6E516-05D1-43E5-B395-E586BAA6A9AE_1_2">2013-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityIncorporationDateOfIncorporation contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_A3669A0E-2303-4751-B86C-F76B4F6B89D5_1_0">2000-08-14</dei:EntityIncorporationDateOfIncorporation>
  <dei:EntityCentralIndexKey contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_213C6852-500A-4BE7-BF3A-D570AECEB64B_1_400002">0001125345</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_213C6852-500A-4BE7-BF3A-D570AECEB64B_1_400003">--12-13</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_B6A6E516-05D1-43E5-B395-E586BAA6A9AE_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_3BD003A0-98DA-443B-8AD2-B07E2C7330C4_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;5. Shared-Based Payments&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s 2000 Stock Option and Incentive Plan (the 2000
 Plan) allowed for the grant of awards in respect of an aggregate of
 130,725 shares, which was increased to 150,297 shares, of the
 Company&amp;#x2019;s common stock in the form of incentive stock
 options, non-qualified stock options, stock appreciation rights,
 restricted stock and restricted stock units and other performance
 awards.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Effective February&amp;#xA0;2003, the Company implemented the 2003
 Equity Incentive Plan (the 2003 Plan), and it was amended and
 approved by the Company&amp;#x2019;s stockholders in 2005. The 2003 Plan
 originally allowed for the grant of awards in respect of an
 aggregate of 2,051,644 shares of the Company&amp;#x2019;s common stock.
 During the year ended December&amp;#xA0;31, 2006, the maximum number of
 shares of common stock authorized to be issued by the Company under
 the 2003 Plan was increased by 460,746 shares to 2,512,390. During
 the year ended December&amp;#xA0;31, 2008, the maximum number of shares
 of common stock authorized to be issued by the Company under the
 2003 Plan was increased by 745,716 shares to 3,258,106. During the
 year ended December&amp;#xA0;31, 2010, the maximum number of shares of
 common stock authorized to be issued by the Company under the 2003
 Plan was increased by 532,654 shares to 3,790,760. During the year
 ended December&amp;#xA0;31, 2012, the maximum number of shares of
 common stock authorized to be issued by the Company under the 2003
 Plan was increased by 545,970 shares to 4,336,731. As of
 September&amp;#xA0;30, 2013, a total of 8,171 shares were available for
 issuance under the 2003 Plan.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Stock options granted under the 2003 Plan may be either incentive
 stock options as defined by the Internal Revenue Code (IRC), or
 non-qualified stock options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following stock-based compensation amounts were recognized for
 the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,888&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;284,281&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;353,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,647&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;109,280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;274,940&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;135,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209,599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;393,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Employee Stock Options&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;53%&amp;#xA0;-&amp;#xA0;58%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;51%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.24%&amp;#xA0;-&amp;#xA0;2.05%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.18%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected average life of options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Fair market value of common stock at:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;$1.50&amp;#xA0;-&amp;#xA0;$7.51&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;$1.50&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.06%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.57%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Fair Value of Common Stock&amp;#xA0;&amp;#x2013;&amp;#xA0;&lt;/b&gt;Before our
 entry into the public market on October&amp;#xA0;10, 2013, the
 Company&amp;#x2019;s Board of Directors determined the fair value of the
 common stock. The Board of Directors made determinations of fair
 value based, in part, upon contemporaneous valuations to determine
 fair value. In the absence of a public market, and as a
 clinical-stage company with no significant revenues, the Company
 believes that it is appropriate to consider a range of factors to
 determine the fair market value of the common stock at each grant
 date. The factors include: (1)&amp;#xA0;the achievement of clinical and
 operational milestones by the Company; (2)&amp;#xA0;the status of
 strategic relationships with collaborators; (3)&amp;#xA0;the
 significant risks associated with the Company&amp;#x2019;s stage of
 development; (4)&amp;#xA0;capital market conditions for life science
 companies, particularly similarly situated, privately held,
 early-stage life science companies; (5)&amp;#xA0;the Company&amp;#x2019;s
 available cash, financial condition and results of operations;
 (6)&amp;#xA0;the most recent sales of the Company&amp;#x2019;s preferred
 stock and (7)&amp;#xA0;the preferential rights of the outstanding
 preferred stock. The contemporaneous valuations were performed in
 accordance with applicable methodologies, approaches and
 assumptions of the technical practice-aid issued by the American
 Institute of Certified Public Accountants Practice Aid entitled
 &lt;i&gt;Valuation of Privately-Held Company Equity Securities Issued as
 Compensation&lt;/i&gt;.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Expected Volatility&lt;/b&gt;&amp;#xA0;&amp;#x2013; Volatility is a measure of
 the amount by which a financial variable such as a share price has
 fluctuated (historical volatility) or is expected to fluctuate
 (expected volatility) during a period. The Company does not
 maintain an internal market for its shares and its shares are not
 traded publicly. The Company has been able to identify several
 public entities of similar size, complexity and stage of
 development; accordingly, historical volatility has been calculated
 using the volatility of these companies.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Expected Dividend Yield&lt;/b&gt;&amp;#xA0;&amp;#x2013; The Company has never
 declared or paid dividends and has no plans to do so in the
 foreseeable future.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Risk-Free Interest Rate&lt;/b&gt;&amp;#xA0;&amp;#x2013; This is the U.S.
 Treasury rate for the week of each option grant during the year,
 having a term that most closely resembles the expected life of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Expected Term&lt;/b&gt;&amp;#xA0;&amp;#x2013; This is the period of time that
 the options granted are expected to remain unexercised. Options
 granted have a maximum term of ten years. The Company estimates the
 expected life of the option term to be seven years. The Company
 uses a simplified method to calculate the average expected
 term.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Expected Forfeiture Rate&lt;/b&gt;&amp;#xA0;&amp;#x2013; The forfeiture rate is
 the estimated percentage of options granted that is expected to be
 forfeited or canceled on an annual basis before becoming fully
 vested. The Company estimates the forfeiture rate based on turnover
 data with further consideration given to the class of the employees
 to whom the options were granted.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Equity instruments issued to non-employees are accounted for under
 the provisions of ASC&amp;#xA0;505-50, &lt;i&gt;Equity Based Payments to
 Non-Employees&lt;/i&gt;. Accordingly, the estimated fair value of the
 equity instrument is recorded on the earlier of the performance
 commitment date or the date the services required are
 completed.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table summarizes stock option activity under the Plan
 during the period then ended:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&amp;#xA0;Term&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding, December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.19&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,025,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Forfeited or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,949&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding, September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,877,003&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 September&amp;#xA0;30, 2013:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercisable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,855,178&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Vested and Expected to Vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;918,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The aggregate intrinsic value of options outstanding and options
 exercisable as of September&amp;#xA0;30, 2013 is approximately $17.4
 million and $12.2 million, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The weighted-average grant-date fair value of options granted for
 the nine months ended September&amp;#xA0;30, 2013 was $2.00. Total cash
 received for the options exercised was $851,183 for the nine months
 ended September&amp;#xA0;30, 2013. The total fair value of shares
 vested in the nine months ended September&amp;#xA0;30, 2013 was
 $402,084. As of September&amp;#xA0;30, 2013, the total unrecognized
 compensation expense related to non-vested stock-based compensation
 arrangements granted under the 2000 Plan and 2003 Plan, net of
 related forfeiture estimates, was $1.5 million, which the Company
 expects to recognize over a weighted-average period of
 approximately four years.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_A062C0D0-73EF-4D19-806B-17F736F7530B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In May&amp;#xA0;2011, the FASB issued ASU No.&amp;#xA0;2011-04, which
 amended ASC Topic 820 to achieve common fair value measurements and
 disclosure requirements in U.S. GAAP and International Financial
 Reporting Standards (IFRS). The amendments in ASU No.&amp;#xA0;2011-04
 result in common fair value measurement and disclosure requirements
 in U.S. GAAP and IFRS. Consequently, the amendments change the
 wording used to describe many of the requirements in U.S. GAAP for
 measuring fair value and for disclosing information about fair
 value measurements. This amendment is effective for fiscal years
 beginning after December&amp;#xA0;15, 2011. The adoption of this
 amendment did not have a material impact on the Company&amp;#x2019;s
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June&amp;#xA0;2011, the FASB issued ASU No.&amp;#xA0;2011-05, which
 amended ASC Topic 220 regarding presentation of comprehensive
 income. The amendments in ASU No.&amp;#xA0;2011-05 require that all
 nonowner changes in stockholders&amp;#x2019; equity be presented either
 in a single continuous statement of comprehensive income or in two
 separate but consecutive statements. In the two-statement approach,
 the first statement should present total net income and its
 components followed consecutively by a second statement that should
 present total other comprehensive income, the components of other
 comprehensive income, and the total of comprehensive income. This
 amendment is effective for fiscal years beginning after
 December&amp;#xA0;15, 2011. The adoption of this amendment did not have
 a material impact on the Company&amp;#x2019;s consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&amp;#x2019;s
 consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NumberOfOperatingSegments contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="Segment" decimals="INF" id="id_2787876_3DA46293-E181-4792-B97C-83469A0F1260_1_0">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_E24EDB9F-707A-4B6C-B85F-97A1CF9B8CA9_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;8. Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company leases office and laboratory space over periods
 extending through January&amp;#xA0;30, 2018. Several of the leases
 contain rent escalation clauses. Rent expense for the three months
 ended September&amp;#xA0;30, 2013 and 2012 was $806,275 and $783,462,
 respectively. The Company incurred $2.4 million of rent expense for
 each of the nine-month periods ending September&amp;#xA0;30, 2013 and
 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Future minimum lease payments under noncancelable operating leases
 at September&amp;#xA0;30, 2013 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Twelve Months Ending September&amp;#xA0;30,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,460,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,396,780&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,385,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,486,881&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,035,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;625,540&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,390,144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_3296DC37-F811-4F2C-8162-5B7EEFB57D5F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&amp;#xA0;rights to future technological improvements,
 (iii)&amp;#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&amp;#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, &lt;i&gt;Revenue
 Recognition&amp;#xA0;&amp;#x2013;Multiple-Element Arrangements&lt;/i&gt;, and ASC
 Topic 605-28, &lt;i&gt;Revenue Recognition&amp;#x2013;Milestone Method&lt;/i&gt;, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&amp;#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Exclusive Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&amp;#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&amp;#xA0;at the collaborator&amp;#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&amp;#xA0;earn payments upon the
 achievement of certain milestones, (iii)&amp;#xA0;earn royalty
 payments, and (iv)&amp;#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&amp;#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&amp;#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&amp;#x2019;s technology platforms, the
 Company&amp;#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&amp;#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update (ASU)
 No.&amp;#xA0;2009-13, &lt;i&gt;Revenue Arrangements with Multiple
 Deliverables&lt;/i&gt;, on January&amp;#xA0;1, 2011, the Company determined
 that its licenses lacked stand-alone value because it did not have
 vendor-specific objective evidence of selling price (VSOE), and
 were combined with other elements of the arrangement and any
 amounts associated with the license were deferred and amortized
 over a certain period, which the Company refers to as the
 Company&amp;#x2019;s period of substantial involvement. In making the
 determination of the length of the period over which to defer
 revenue for contracts entered into prior to the adoption of ASU
 No.&amp;#xA0;2009-13, significant judgment and estimation is used by
 the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&amp;#x2019;s
 involvement with the development of a collaborator&amp;#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&amp;#x2019;s substantial involvement.
 ASU No.&amp;#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if VSOE is not available. The objective of BESP is to
 determine the price at which the Company would transact a sale if
 the element within the license agreement was sold on a standalone
 basis. Establishing BESP involves management&amp;#x2019;s judgment and
 considers multiple factors, including market conditions and
 company-specific factors, including those factors contemplated in
 negotiating the agreements, as well as internally developed models
 that include assumptions related to market opportunity, discounted
 cash flows, estimated development costs, probability of success and
 the time needed to commercialize a product candidate pursuant to
 the license. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&amp;#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&amp;#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&amp;#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&amp;#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&amp;#xA0;the value of the license was dependent on
 the undelivered items and (iii)&amp;#xA0;the collaborator or other
 vendors could provide the undelivered items.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&amp;#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&amp;#xA0;development milestones, (ii)&amp;#xA0;regulatory milestones,
 and (iii)&amp;#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&amp;#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&amp;#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Right-to-Develop Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&amp;#xA0;at the
 inception of the arrangement (referred to as &amp;#x201C;upfront&amp;#x201D;
 fees or payments), (ii)&amp;#xA0;the selection of a target for a
 program, (iii)&amp;#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&amp;#xA0;some
 combination of all of these fees.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&amp;#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No. 2009-13, the Company&amp;#x2019;s evaluation of whether the option
 is substantive is consistent with pre-adoption of ASU
 No.&amp;#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&amp;#xA0;2009-13. Post adoption of ASU No.&amp;#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&amp;#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&amp;#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&amp;#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&amp;#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&amp;#x2019;s
 best estimate. Management&amp;#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 There have been no option license exercises to date for any period
 presented. Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee to the development and
 commercialization license and apply the multiple-element revenue
 recognition criteria to the development and commercialization
 license and any other deliverables to determine the appropriate
 revenue recognition, which will be consistent with the
 Company&amp;#x2019;s accounting policy for upfront payments on exclusive
 licenses event a right-to-develop agreement were to be terminated,
 the Company would recognize as revenue any portion of the upfront
 fee that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&amp;#x2019;s right-to-develop agreements have been
 determined to contain substantive options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_12">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_14">21908859</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_B79AB6FF-C1CA-40E4-9A68-137CBC94606C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table summarizes stock option activity under the Plan
 during the period then ended:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="59%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Number&amp;#xA0;of&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Options&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&amp;#xA0;Exercise&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Price&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Weighted-&lt;br /&gt;
 Average&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Contractual&amp;#xA0;Term&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;(in Years)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding, December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,249,702&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;687,183&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.19&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(1,025,933&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.75&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Forfeited or expired&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(33,949&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.13&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Outstanding, September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,877,003&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.50&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 September&amp;#xA0;30, 2013:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Exercisable&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,855,178&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.94&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Vested and Expected to Vest&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;918,600&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.44&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_4ADD117F-40D4-4D15-81A3-5318ADE7C86B_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Effective January&amp;#xA0;1, 2012, the Company adopted ASU2011-05,
 &lt;i&gt;Presentation of Comprehensive Income,&lt;/i&gt; which amended ASC
 Topic 220, &lt;i&gt;Comprehensive Income.&lt;/i&gt; The amendments in ASU
 2011-05 require the presentation of the comprehensive income (loss)
 and its components as part of the consolidated financial
 statements. Comprehensive income (loss) is comprised of the net
 income (loss) and other changes in equity that are excluded from
 net income (loss). Comprehensive income (loss) equals net income
 (loss) for the three and nine months ended September&amp;#xA0;30, 2013
 and 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_3_11">20445061</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_459EF587-1239-47C2-A594-57E61FCF7643_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at September&amp;#xA0;30, 2013
 and December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
  <us-gaap:StockholdersEquityReverseStockSplit contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_190F7446-E182-4184-A9F6-6E76EC8BBD86_1_0">1-for-18.7739</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_5001_4">1.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_33D7CCF2-04E6-4D62-A323-DE1AFA3C4C3C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Property and equipment consists of the following:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,172,535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,003,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,323,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,323,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,603,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,747,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,893,770&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,881,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,643,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,607,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,174,112&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,339,497&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,469,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,267,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_11">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_DBDC3536-24CC-400E-9F4D-D0419E679F92_1_0">&lt;div&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following common stock equivalents&amp;#xA0;are included&amp;#xA0;in
 the calculation of diluted net income (loss) per share:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,910,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276,516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,910,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276,516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_5AB0F7F6-C655-44B5-A7C0-C41DF5637656_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;3. Property and Equipment&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Property and equipment consists of the following:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,172,535&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,003,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,323,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,323,081&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;599,650&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Lab equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,603,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8,747,790&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,360&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,893,770&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,881,706&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Property and equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;19,643,994&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,607,293&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less accumulated depreciation and amortization&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(15,174,112&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(14,339,497&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Property and equipment, net&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,469,882&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,267,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Depreciation and amortization expense for the three months ended
 September&amp;#xA0;30, 2013 and 2012 was $316,852 and $235,543,
 respectively, and $834,615 and $722,496 for the nine months ended
 September&amp;#xA0;30, 2013 and 2012, respectively.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_2511AA34-ABD5-4DB1-A8AB-3538A2F86E8B_3001_3">P7Y3M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_29560B2A-31A5-4813-A616-FDF3A32E9A82_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of September&amp;#xA0;30, 2013
 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Twelve Months Ending September&amp;#xA0;30,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,229,454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,589,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,808,119&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,049,273&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,315,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;616,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,607,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_5001_2">687183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_3_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_442131D2-D15A-4CEC-A922-2FB9724F3204_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&amp;#xA0;Markets&amp;#xA0;for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&amp;#xA0;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,522,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,522,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,974,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,974,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&amp;#xA0;Markets&amp;#xA0;for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&amp;#xA0;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_FF7AC915-C2B7-4F12-91B0-28160EC4ED23_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Changes in the lease exit liability are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrual balance at December&amp;#xA0;31, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,607,499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(533,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrual balance at December 31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,073,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(466,301&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrual balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,607,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_E2098E25-5AA1-41DD-9BCB-0E8A267033BB_1_0">&lt;div&gt;
 &lt;div&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,603,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,434,756&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;169,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,184,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,078,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Basic income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;0.14&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,603,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,403,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,184,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,078,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,058,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,410,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,445,061&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,334,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,242,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,502,424&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,908,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,412,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Diluted income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;0.01&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;
 &lt;/div&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_873C8AD7-6E58-48EF-A25B-4E8B0AD5DF1D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;4. Stockholders&amp;#x2019; Equity (Deficit)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During 2002 and 2003, the Company issued a total of 34,239,374
 shares of Series A-1 and Series A-2 convertible preferred stock
 (Series A preferred stock) for $1.00 per share resulting in net
 proceeds of approximately $34,000,000.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On October&amp;#xA0;12, 2004, the Company entered into a series of
 transactions raising $30,261,672, net of related offering costs of
 approximately $238,000, from the sale of 71,401,237 shares of its
 Series B convertible preferred stock (Series B preferred stock). In
 connection with the Series B preferred stock offering, 13,604,016
 shares of common stock were allocated to holders of Series&amp;#xA0;A-1
 preferred stock as an anti-dilution measure but remained unissued
 at September&amp;#xA0;30, 2013. Upon completion of the IPO in October
 2013, these allocated shares were converted into shares of common
 stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On May&amp;#xA0;16, 2006, the Company raised $44,898,754, net of
 related offering costs of $101,246, from the sale of 110,952,217
 shares of its Series C convertible preferred stock (Series C
 preferred stock). In connection with the Series C preferred stock
 offering, 10,003,300 shares of common stock were allocated to
 holders of Series B preferred stock as an anti-dilution measure but
 remained unissued at September&amp;#xA0;30, 2013. Upon completion of
 the IPO in October 2013, these allocated shares were converted into
 shares of common stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On July&amp;#xA0;16, 2008, the Company issued 12,466,039 shares of its
 Series D convertible preferred stock (Series D preferred stock) in
 exchange for all of the outstanding capital stock and convertible
 notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently,
 in March 2011 a settlement was reached with the former Raven
 stockholders bringing the total Series D preferred stock issued in
 connection with the Raven acquisition to 14,446,227 shares.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On September&amp;#xA0;19, 2008, the Company raised $24,843,211, net of
 related offering costs of $156,788, from the sale of 38,337,678
 shares of its Series D-2 convertible preferred stock (Series D-2
 preferred stock). The Company also issued preferred stock warrants
 for the purchase of 2,875,327 shares of Series D-2 preferred stock.
 The preferred stock warrants are exercisable at any time prior to
 September&amp;#xA0;2018, but expire upon an IPO, and have a stated
 exercise price of $0.65 per warrant. On May&amp;#xA0;16, 2010, the
 Company exercised a put notice to Lilly in accordance with the
 Series D-2 preferred stock purchase agreement, resulting in the
 issuance of 6,916,110 shares of Series D-2 preferred stock and a
 warrant to purchase 518,708 additional shares of Series D-2
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On January&amp;#xA0;11, 2011, the Company raised gross proceeds for
 $12,016,500 from the sale of 18,427,388 shares of its Series D-2
 preferred stock. Issuance costs associated with the sale were not
 material.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Due to certain provisions in the Series D-2 convertible preferred
 stock warrant agreement, these warrants are required to be
 classified as a liability. Management believes that the
 circumstances requiring cash settlement of the award are remote.
 The Series D-2 preferred stock warrant liability is recorded at
 fair value, which is adjusted at the end of each reporting period
 using the Option-Pricing Method, with changes in value recorded as
 &amp;#x201C;Other income (expense)&amp;#x201D; in the accompanying
 consolidated statements of operations.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Holders of the Series A-1, Series A-2, Series B, Series C, Series D
 and Series D-2 preferred stock are entitled to vote, together with
 the common stockholders as one class, on all matters as to which
 common stockholders are entitled to vote. In any such vote, each
 share of Series A, Series B, Series C and Series D preferred stock
 shall entitle the holder to the number of votes per share that
 equals the number of shares of common stock into which each such
 share of preferred stock is then convertible. For so long as at
 least four&amp;#xA0;million shares of each of the Series A, Series B
 and Series C preferred stock remain outstanding, the holders of
 each of the Series A, Series B and Series C preferred stock, each
 voting as a separate class, shall each be entitled to elect two
 members of the Board of Directors of the Company. The holders of a
 majority of the common stock, voting as a separate class, shall
 have the right to elect one member of the Board of Directors of the
 Company. The holders of a majority of the common stock and the
 holders of at least 66 2/3% of the preferred stock, each voting
 separately as a single class (and on an as-if-converted basis to
 common stock with respect to the preferred stock), shall be
 entitled to elect all remaining members of the Board of
 Directors.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Dividends are noncumulative and accrue on the Series A-1, Series
 A-2, Series B, Series C, Series D and Series&amp;#xA0;D-2 preferred
 stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum,
 respectively, and are payable when and as declared by the Board of
 Directors. Dividends must be declared so that the Series A,
 Series&amp;#xA0;B, Series C and Series D preferred stock are paid in
 like-kind and participate equally to those of the Series&amp;#xA0;D-2
 preferred and common stock. No dividends have been declared and
 none are accrued at September&amp;#xA0;30, 2013 or December&amp;#xA0;31,
 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s Series A-1, Series A-2, Series B, Series C,
 Series D and Series D-2 preferred stock are initially convertible
 into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively,
 of common stock at the option of the holder. The conversion ratio
 of certain series of preferred stock is subject to change in the
 event specified dilutive transactions occur. These dilutive events
 are considered to be the sale of common stock at a per share price
 less than the applicable preferred stock conversion price. There
 are no anti-dilution protections for the Series A-2 preferred stock
 and no adjustment to the Series A-1 preferred stock conversion
 price is made if a common stock issuance is at a price per share
 greater than the conversion price of the Series C preferred stock.
 The conversion price shall be $12.39, $18.77, $6.95, $7.70, $12.20
 and $12.20 for each share of Series A-1, A-2, Series B, Series C,
 Series D and Series D-2 convertible preferred stock, respectively.
 The Company has reserved 17,129,782 shares of common stock for the
 potential conversion of the Series A-1, Series A-2, Series B,
 Series&amp;#xA0;C, Series D and Series D-2 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Each share of Series A-1, Series A-2, Series B, Series C, Series D
 and Series D-2 preferred stock automatically converts into shares
 of the Company&amp;#x2019;s common stock upon closing of a firm
 commitment underwritten public offering of common stock registered
 under the Securities Act of 1933 which generates net proceeds to
 the Company of at least $40&amp;#xA0;million. The holders of two-thirds
 of the Series&amp;#xA0;A-1, Series&amp;#xA0;A-2, Series&amp;#xA0;B, Series C,
 Series D and Series D-2 preferred stock, voting together as a
 single class, but separately from the common stockholders, shall
 have the right to elect to convert all outstanding shares of Series
 A-1, Series&amp;#xA0;A-2, Series&amp;#xA0;B, Series C, Series D and Series
 D-2 preferred stock into shares of common stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In liquidation, the holders of Series D-2 preferred stock are
 entitled to receive $12.20 per share prior to any distribution to
 the holders of any Series C and Series D preferred stock. The
 holders of Series C and Series&amp;#xA0;D preferred stock are entitled
 to receive $7.70 and $12.20 per share, respectively, on a &lt;i&gt;pari
 passu&lt;/i&gt; basis, prior to any distribution to the holders of any
 Series B preferred stock. The holders of Series B preferred stock
 are entitled to receive $6.95 per share prior to any distribution
 to the holders of any shares of Series A preferred stock. The
 holders of Series A preferred stock are entitled to receive $12.39
 per share prior to the holders of common stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In connection with preparing for its IPO in October 2013 (see Note
 11, Subsequent Events, for additional information), the
 Company&amp;#x2019;s Board of Directors and stockholders approved a
 1-for-18.7739 reverse stock split of the Company&amp;#x2019;s Common
 Stock. The reverse stock split became effective on
 September&amp;#xA0;26, 2013. All share and per share amounts in the
 consolidated financial statements and notes thereto have been
 retroactively adjusted for all periods presented to give effect to
 this reverse stock split, including reclassifying an amount equal
 to the reduction in par value of common stock to additional paid-in
 capital. In addition, in September 2013, the Company&amp;#x2019;s Board
 of Directors and stockholders approved an amendment of the
 Company&amp;#x2019;s certificate of incorporation to, among other
 things, change the definition of a designated public offering to
 remove the per share price requirement.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_5001_2">3.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="pure" decimals="4" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_3_5">0.0506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_EDE7E034-97AF-4950-BAA4-FB75082B501C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table provides a rollforward of the Company&amp;#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total unrealized gains (losses) included in earnings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(626,349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_8AF80531-C3A0-43BA-8A64-B936F9CB8ED6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Deferred Initial Public Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Deferred IPO costs as of September&amp;#xA0;30, 2013, consisted of
 legal, accounting, printing and filing fees were capitalized. The
 deferred costs are included in prepaid expenses on the consolidated
 balance sheets. The deferred offering costs were offset against the
 IPO proceeds received upon the completion of the offering in
 October 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_3F2E69CD-0CAB-46EA-9ED2-EBA3CDB2AEF7_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;6. Lease Exit Liability&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On July&amp;#xA0;16, 2008, the Company acquired Raven Biotechnologies,
 Inc. (Raven), a private South San Francisco-based company focused
 on the development of monoclonal antibody therapeutics for treating
 cancer. Raven was considered a development-stage enterprise as
 defined in ASC&amp;#xA0;915, &lt;i&gt;Development Stage Entities&lt;/i&gt;. In
 connection with the acquisition, the Company issued 12,466,039
 shares of its Series D convertible preferred stock in exchange for
 all of the outstanding capital stock and convertible notes payable
 of Raven.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company undertook restructuring activities related to the
 acquisition of Raven. These restructuring activities included
 reductions in staffing levels and the intended exit of leased
 facilities. All severance-related payments were completed in the
 year ended December&amp;#xA0;31, 2009.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In connection with these restructuring activities, as part of the
 cost of acquisitions, the Company established a restructuring
 liability attributed to an existing operating lease. The terms of
 the operating lease extend through 2018.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Changes in the lease exit liability are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrual balance at December&amp;#xA0;31, 2011&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,607,499&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(533,560&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrual balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,073,939&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Principal payments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(466,301&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Accrual balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,607,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of September&amp;#xA0;30, 2013
 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="85%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Twelve Months Ending September&amp;#xA0;30,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,229,454&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,589,410&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,808,119&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,049,273&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,315,026&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;616,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;9,607,638&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The purchase agreement provides for a specified total of certain
 contingent milestones that are based on the achievement of certain
 product sales derived from the acquired Raven technology. Also, a
 onetime payment of $5.0&amp;#xA0;million will be made to the Raven
 stockholders upon the initiation of patient dosing in the first
 Phase 2 clinical trial of any product derived from the Raven
 &amp;#x201C;Cancer Stem Cell Program.&amp;#x201D; No payment shall be made if
 the Phase 2 trial start date has not occurred on or before
 July&amp;#xA0;15, 2018. Other consideration includes a percentage of
 revenue (excluding consideration for research and development and
 equity) received by MacroGenics for license of a product derived
 from the Raven &amp;#x201C;Cancer Stem Cell Program&amp;#x201D; and a onetime
 payment ranging from $8.0&amp;#xA0;million to $12.0&amp;#xA0;million
 dependent upon a specified level of sales of products derived from
 the Raven &amp;#x201C;Cancer Stem Cell Program.&amp;#x201D;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The contingent consideration will be accounted for as additional
 purchase price and recorded as incremental in-process research and
 development expense when it is deemed probable that the
 contingencies will be attained. No additional amounts have been
 recorded during the nine months ended September&amp;#xA0;30, 2013 and
 2012.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_03C26CB3-6F43-4E2E-86EB-D254F77F4299_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation and
 amortization are computed using the straight-line method over the
 following estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 Shorter&amp;#xA0;of&amp;#xA0;lease&amp;#xA0;term&amp;#xA0;or&amp;#xA0;useful&amp;#xA0;life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_3_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_9256EFE9-D347-4C73-BE0A-8B5799ED7A22_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investment in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_16">-12988440</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_01644EC4-CA24-4049-B0B8-BE8285356635_5001_3">0.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_CC2C623D-8DA5-48D9-A42B-8632F96B7AB3_1_0">&lt;div&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;11. Subsequent Events&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On October&amp;#xA0;16, 2013, the Company completed its IPO, in which
 5,000,000 shares of the Company&amp;#x2019;s common stock were sold at a
 price of $16 per share. Additionally, the underwriters of the
 Company&amp;#x2019;s IPO exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 750,000 shares of the Company&amp;#x2019;s common stock at a price of
 $16 per share. The Company received net proceeds of $83.8 million
 from the IPO, net of underwriting discounts and commissions and
 other estimated offering expenses. Upon consummation of the IPO,
 all outstanding shares of preferred stock automatically converted
 to common stock at the applicable conversion ratios then in effect.
 Subsequent to the IPO, the Company had 25,020,288 issued and
 outstanding shares of common stock and no outstanding shares of
 preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In November 2013, Boehringer nominated a bi-specific antibody
 therapeutic candidate generated by the Company&amp;#x2019;s DART
 technology for pre-clinical development. This formal selection of a
 development candidate triggered a $5.0 million milestone payment to
 the Company under the October 2010 agreement described in Note 7,
 Collaboration and License Agreements. In addition, Boehringer will
 pay a research maintenance payment of $4.0 million to the Company
 in the fourth quarter of 2013.&lt;/p&gt;
 &lt;/div&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:LeaseExpirationDate1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_A29B278F-DB51-4F64-81F4-9D7953868844_3_2">2018-01-30</us-gaap:LeaseExpirationDate1>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_13">1463798</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_7304AF03-1E5E-4153-A221-6EA1A4DE0886_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&amp;#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_8E41F651-C41B-4D6A-9E1D-74D9D008EA75_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Future minimum lease payments under noncancelable operating leases
 at September&amp;#xA0;30, 2013 are as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="83%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Twelve Months Ending September&amp;#xA0;30,&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,460,609&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,396,780&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,385,321&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2017&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,486,881&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 2018&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,035,013&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Thereafter&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;625,540&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,390,144&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_7F7B80C2-6264-43D9-B0AA-479424983B50_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;10. Employee Benefit Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On September&amp;#xA0;25, 2002, the Company established the MacroGenics
 401(k) Plan (the Plan) for its employees under Section&amp;#xA0;401(k)
 of the IRC. Under this Plan, all employees at least 21 years of age
 are eligible to participate in the Plan, starting on the first day
 of each month. Employees may contribute up to 100% of their salary,
 subject to government maximums.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Employees are 100% vested in their contributions to the Plan. The
 Company&amp;#x2019;s contribution to the Plan, as determined by the
 Board of Directors, is discretionary. The Company&amp;#x2019;s
 contributions to the Plan totaled $55,311 and $48,891 for the three
 months ended September&amp;#xA0;30, 2013 and 2012, respectively, and
 $194,498 and $179,966 for the nine months ended September&amp;#xA0;30,
 2013 and 2012, respectively.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_5001_3">1025933</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_3D9E36BF-4CE0-4DB5-AE59-460C3963A80E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Substantially all of the Company&amp;#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the three and nine months ended September&amp;#xA0;30, 2013 and
 2012, all of the Company&amp;#x2019;s grant revenue was related to
 contracts and research grants received from U.S. government
 agencies. Collaborations with Les Laboratoires Servier and Institut
 de Recherches Servier (collectively, Servier), Boehringer Ingelheim
 GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc.
 (Pfizer) and Eli Lilly&amp;#xA0;&amp;amp; Co. (Eli Lilly) account for all
 other revenue. All outstanding receivables are due from Gilead,
 Pfizer, Boehringer, Eli Lilly, and U.S. government agencies.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table represents the percentage of all significant
 accounts receivable:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_FA0A5F4B-FCFC-47CF-9E86-FC423402DB05_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&amp;#xA0;718, &lt;i&gt;Compensation&amp;#xA0;&amp;#x2013; Stock
 Compensation&lt;/i&gt;. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_E236FEBE-2758-45C2-8873-B2AC1774170E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;2. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of the financial statements in accordance with GAAP
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In addition, through September&amp;#xA0;30, 2013, the Company utilized
 estimates and assumptions in determining the fair value of its
 common stock. The Company granted stock options at exercise prices
 not less than the fair value of its common stock as determined by
 the board of directors, with input from management. Management uses
 contemporaneous valuations in estimating the fair value of its
 common stock. The board of directors has determined the estimated
 fair value of the common stock based on a number of objective and
 subjective factors, including external market considerations
 affecting the biotechnology industry and the historic prices at
 which the Company sold shares of its preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investment in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 September&amp;#xA0;30, 2013 or December&amp;#xA0;31, 2012, as the Company
 has a history of collecting on all outstanding accounts.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Deferred Initial Public Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Deferred IPO costs as of September&amp;#xA0;30, 2013, consisted of
 legal, accounting, printing and filing fees were capitalized. The
 deferred costs are included in prepaid expenses on the consolidated
 balance sheets. The deferred offering costs were offset against the
 IPO proceeds received upon the completion of the offering in
 October 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at September&amp;#xA0;30, 2013
 and December&amp;#xA0;31, 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012, due to their
 short-term maturities. The Company accounts for recurring and
 non-recurring fair value measurements in accordance with the
 Financial Accounting Standards Board (FASB) Accounting Standards
 Codification (ASC) 820, &lt;i&gt;Fair Value Measurements and
 Disclosures&lt;/i&gt; (ASC 820). ASC 820 defines fair value, establishes
 a fair value hierarchy for assets and liabilities measured at fair
 value, and requires expanded disclosures about fair value
 measurements. The ASC 820 hierarchy ranks the quality of
 reliability of inputs, or assumptions, used in the determination of
 fair value, and requires assets and liabilities carried at fair
 value to be classified and disclosed in one of the following three
 categories:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#xA0;&amp;#x2013; Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2&amp;#xA0;&amp;#x2013; Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#xA0;&amp;#x2013; Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&amp;#xA0;&amp;#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&amp;#xA0;Markets&amp;#xA0;for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&amp;#xA0;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,522,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,522,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,974,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,974,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&amp;#xA0;Markets&amp;#xA0;for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&amp;#xA0;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of December&amp;#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table provides a rollforward of the Company&amp;#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total unrealized gains (losses) included in earnings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(626,349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Substantially all of the Company&amp;#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the three and nine months ended September&amp;#xA0;30, 2013 and
 2012, all of the Company&amp;#x2019;s grant revenue was related to
 contracts and research grants received from U.S. government
 agencies. Collaborations with Les Laboratoires Servier and Institut
 de Recherches Servier (collectively, Servier), Boehringer Ingelheim
 GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc.
 (Pfizer) and Eli Lilly&amp;#xA0;&amp;amp; Co. (Eli Lilly) account for all
 other revenue. All outstanding receivables are due from Gilead,
 Pfizer, Boehringer, Eli Lilly, and U.S. government agencies.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table represents the percentage of all significant
 accounts receivable:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation and
 amortization are computed using the straight-line method over the
 following estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 Shorter&amp;#xA0;of&amp;#xA0;lease&amp;#xA0;term&amp;#xA0;or&amp;#xA0;useful&amp;#xA0;life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC 360, &lt;i&gt;Property, Plant and
 Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets be reviewed
 for impairment whenever events or changes in circumstances indicate
 that the carrying amount of an asset may not be recoverable.
 Recoverability of the long-lived asset is measured by a comparison
 of the carrying amount of the asset to future undiscounted net cash
 flows expected to be generated by the asset or asset group. If
 carrying value exceeds the sum of undiscounted cash flows, the
 Company then determines the fair value of the underlying asset
 group. Any impairment to be recognized is measured by the amount by
 which the carrying amount of the asset group exceeds the estimated
 fair value of the asset group. Assets to be disposed of are
 reported at the lower of the carrying amount or fair value, less
 costs to sell. As of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Revenues&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&amp;#xA0;licenses, or options to obtain licenses, to the
 Company&amp;#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&amp;#xA0;rights to future technological improvements,
 (iii)&amp;#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&amp;#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, &lt;i&gt;Revenue
 Recognition&amp;#xA0;&amp;#x2013;Multiple-Element Arrangements&lt;/i&gt;, and ASC
 Topic 605-28, &lt;i&gt;Revenue Recognition&amp;#x2013;Milestone Method&lt;/i&gt;, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&amp;#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Exclusive Licenses&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&amp;#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&amp;#xA0;at the collaborator&amp;#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&amp;#xA0;earn payments upon the
 achievement of certain milestones, (iii)&amp;#xA0;earn royalty
 payments, and (iv)&amp;#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&amp;#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&amp;#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&amp;#x2019;s technology platforms, the
 Company&amp;#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&amp;#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update (ASU)
 No.&amp;#xA0;2009-13, &lt;i&gt;Revenue Arrangements with Multiple
 Deliverables&lt;/i&gt;, on January&amp;#xA0;1, 2011, the Company determined
 that its licenses lacked stand-alone value because it did not have
 vendor-specific objective evidence of selling price (VSOE), and
 were combined with other elements of the arrangement and any
 amounts associated with the license were deferred and amortized
 over a certain period, which the Company refers to as the
 Company&amp;#x2019;s period of substantial involvement. In making the
 determination of the length of the period over which to defer
 revenue for contracts entered into prior to the adoption of ASU
 No.&amp;#xA0;2009-13, significant judgment and estimation is used by
 the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&amp;#x2019;s
 involvement with the development of a collaborator&amp;#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&amp;#x2019;s substantial involvement.
 ASU No.&amp;#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if VSOE is not available. The objective of BESP is to
 determine the price at which the Company would transact a sale if
 the element within the license agreement was sold on a standalone
 basis. Establishing BESP involves management&amp;#x2019;s judgment and
 considers multiple factors, including market conditions and
 company-specific factors, including those factors contemplated in
 negotiating the agreements, as well as internally developed models
 that include assumptions related to market opportunity, discounted
 cash flows, estimated development costs, probability of success and
 the time needed to commercialize a product candidate pursuant to
 the license. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&amp;#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&amp;#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&amp;#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&amp;#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&amp;#xA0;the value of the license was dependent on
 the undelivered items and (iii)&amp;#xA0;the collaborator or other
 vendors could provide the undelivered items.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&amp;#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&amp;#xA0;development milestones, (ii)&amp;#xA0;regulatory milestones,
 and (iii)&amp;#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&amp;#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&amp;#xA0;the consideration is commensurate
 with either (1)&amp;#xA0;the entity&amp;#x2019;s performance to achieve the
 milestone, or (2)&amp;#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&amp;#x2019;s performance to achieve the milestone,
 (b)&amp;#xA0;the consideration relates solely to past performance and
 (c)&amp;#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&amp;#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt"&gt;
 &lt;i&gt;Right-to-Develop Agreements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&amp;#xA0;at the
 inception of the arrangement (referred to as &amp;#x201C;upfront&amp;#x201D;
 fees or payments), (ii)&amp;#xA0;the selection of a target for a
 program, (iii)&amp;#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&amp;#xA0;some
 combination of all of these fees.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&amp;#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No. 2009-13, the Company&amp;#x2019;s evaluation of whether the option
 is substantive is consistent with pre-adoption of ASU
 No.&amp;#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&amp;#xA0;2009-13. Post adoption of ASU No.&amp;#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&amp;#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&amp;#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&amp;#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&amp;#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&amp;#x2019;s
 best estimate. Management&amp;#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 There have been no option license exercises to date for any period
 presented. Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee to the development and
 commercialization license and apply the multiple-element revenue
 recognition criteria to the development and commercialization
 license and any other deliverables to determine the appropriate
 revenue recognition, which will be consistent with the
 Company&amp;#x2019;s accounting policy for upfront payments on exclusive
 licenses event a right-to-develop agreement were to be terminated,
 the Company would recognize as revenue any portion of the upfront
 fee that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&amp;#x2019;s right-to-develop agreements have been
 determined to contain substantive options.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Research and Development Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&amp;#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Comprehensive Income (Loss)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Effective January&amp;#xA0;1, 2012, the Company adopted ASU2011-05,
 &lt;i&gt;Presentation of Comprehensive Income,&lt;/i&gt; which amended ASC
 Topic 220, &lt;i&gt;Comprehensive Income.&lt;/i&gt; The amendments in ASU
 2011-05 require the presentation of the comprehensive income (loss)
 and its components as part of the consolidated financial
 statements. Comprehensive income (loss) is comprised of the net
 income (loss) and other changes in equity that are excluded from
 net income (loss). Comprehensive income (loss) equals net income
 (loss) for the three and nine months ended September&amp;#xA0;30, 2013
 and 2012.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&amp;#xA0;718, &lt;i&gt;Compensation&amp;#xA0;&amp;#x2013; Stock
 Compensation&lt;/i&gt;. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Income (loss) per share is calculated under the two-class method
 under which all earnings (distributed and undistributed) are
 allocated to each class of common stock and participating
 securities based on their respective rights to receive dividends.
 In the event that the Board of Directors shall declare a dividend
 payable in cash or other property on the then-outstanding shares of
 common stock, the holders of the Series&amp;#xA0;A-1, A-2, B, C, D, and
 D-2 convertible preferred stock shall be entitled to receive the
 amount of dividends per share of Preferred Stock that would be
 payable on the largest number of whole shares of Common Stock into
 which each share of Preferred Stock could then be converted.
 Therefore, the Series A-1, A-2, B, C, D and D-2 are participating
 securities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic net income (loss) per common share is determined by dividing
 the net income (loss) allocable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 net income (loss) per share is computed by dividing the net income
 (loss) allocable to common stockholders by the weighted-average
 number of common stock equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&amp;#x2019;s stock option grants and the if-converted method
 is used to determine the dilutive effect of the Company&amp;#x2019;s
 Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred
 stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,603,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,434,756&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;169,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,184,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,078,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Basic income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;0.14&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,603,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,403,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,184,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,078,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,058,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,410,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,445,061&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,334,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,242,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,502,424&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,908,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,412,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Diluted income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;0.01&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following common stock equivalents are included in the
 calculation of diluted net income (loss) per share:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,910,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276,516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,910,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276,516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Recently Issued Accounting Standards Adopted&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In May&amp;#xA0;2011, the FASB issued ASU No.&amp;#xA0;2011-04, which
 amended ASC Topic 820 to achieve common fair value measurements and
 disclosure requirements in U.S. GAAP and International Financial
 Reporting Standards (IFRS). The amendments in ASU No.&amp;#xA0;2011-04
 result in common fair value measurement and disclosure requirements
 in U.S. GAAP and IFRS. Consequently, the amendments change the
 wording used to describe many of the requirements in U.S. GAAP for
 measuring fair value and for disclosing information about fair
 value measurements. This amendment is effective for fiscal years
 beginning after December&amp;#xA0;15, 2011. The adoption of this
 amendment did not have a material impact on the Company&amp;#x2019;s
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June&amp;#xA0;2011, the FASB issued ASU No.&amp;#xA0;2011-05, which
 amended ASC Topic 220 regarding presentation of comprehensive
 income. The amendments in ASU No.&amp;#xA0;2011-05 require that all
 nonowner changes in stockholders&amp;#x2019; equity be presented either
 in a single continuous statement of comprehensive income or in two
 separate but consecutive statements. In the two-statement approach,
 the first statement should present total net income and its
 components followed consecutively by a second statement that should
 present total other comprehensive income, the components of other
 comprehensive income, and the total of comprehensive income. This
 amendment is effective for fiscal years beginning after
 December&amp;#xA0;15, 2011. The adoption of this amendment did not have
 a material impact on the Company&amp;#x2019;s consolidated financial
 statements.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&amp;#x2019;s
 consolidated financial statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_19C52C16-FF5C-4E6F-A297-3350DD6BB091_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Accounts Receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 September&amp;#xA0;30, 2013 or December&amp;#xA0;31, 2012, as the Company
 has a history of collecting on all outstanding accounts.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_2787876_BE0C4AFC-646F-44E0-8FBD-35C298BB3D0F_5001_4">33949</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_1C6230D7-246F-4872-9FC9-B96909316575_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC 360, &lt;i&gt;Property, Plant and
 Equipment&lt;/i&gt;. ASC 360 requires that long-lived assets be reviewed
 for impairment whenever events or changes in circumstances indicate
 that the carrying amount of an asset may not be recoverable.
 Recoverability of the long-lived asset is measured by a comparison
 of the carrying amount of the asset to future undiscounted net cash
 flows expected to be generated by the asset or asset group. If
 carrying value exceeds the sum of undiscounted cash flows, the
 Company then determines the fair value of the underlying asset
 group. Any impairment to be recognized is measured by the amount by
 which the carrying amount of the asset group exceeds the estimated
 fair value of the asset group. Assets to be disposed of are
 reported at the lower of the carrying amount or fair value, less
 costs to sell. As of September&amp;#xA0;30, 2013 and December&amp;#xA0;31,
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_716B86FC-1EA6-47B7-90B7-612CF6C8DE93_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following stock-based compensation amounts were recognized for
 the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended&lt;br /&gt;
 September&amp;#xA0;30&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Nine Months Ended&lt;br /&gt;
 September&amp;#xA0;30&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;111,888&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;117,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;284,281&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;353,856&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;24,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;91,647&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;109,280&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;274,940&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;135,936&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;209,599&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;393,561&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;628,796&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:UseOfEstimates contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_F90B95C3-6DC8-4178-8EB1-CE7E4B4A4673_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The preparation of the financial statements in accordance with GAAP
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In addition, through September&amp;#xA0;30, 2013, the Company utilized
 estimates and assumptions in determining the fair value of its
 common stock. The Company granted stock options at exercise prices
 not less than the fair value of its common stock as determined by
 the board of directors, with input from management. Management uses
 contemporaneous valuations in estimating the fair value of its
 common stock. The board of directors has determined the estimated
 fair value of the common stock based on a number of objective and
 subjective factors, including external market considerations
 affecting the biotechnology industry and the historic prices at
 which the Company sold shares of its preferred stock.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_2D4DC6FB-0B73-4E48-9839-CAC011D93AAF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;1. Overview and Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 MacroGenics, Inc. (the &amp;#x201C;Company&amp;#x201D;) was incorporated in
 Delaware on August&amp;#xA0;14, 2000. The Company is a clinical-stage
 biopharmaceutical company focused on discovering and developing
 innovative monoclonal antibody-based therapeutics for the treatment
 of cancer and autoimmune diseases. The Company generates its
 pipeline of product candidates from its proprietary suite of
 next-generation antibody technology platforms which it believes
 improve the performance of monoclonal antibodies and
 antibody-derived molecules. These product candidates, which the
 Company has identified through its understanding of disease biology
 and immune-mediated mechanisms, may address disease-specific
 challenges which are not currently being met by existing therapies.
 The Company creates both differentiated molecules that are directed
 to novel cancer targets, as well as &amp;#x201C;bio-betters&amp;#x201D; which
 are drugs designed to improve upon marketed medicines.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The accompanying unaudited interim consolidated financial
 statements include the accounts of MacroGenics, Inc. and its wholly
 owned subsidiary, MacroGenics West, Inc. All intercompany accounts
 and transactions have been eliminated in consolidation. These
 financial statements have been prepared pursuant to the rules and
 regulations of the Securities and Exchange Commission (SEC).
 Certain information and footnote disclosures normally included in
 financial statements prepared in accordance with accounting
 principles generally accepted in the United States of America
 (GAAP) have been condensed or omitted from this report, as is
 permitted by such rules and regulations. Accordingly, these
 consolidated financial statements should be read in conjunction
 with the financial statements and notes thereto included in the
 Company&amp;#x2019;s Prospectus filed with the SEC pursuant to Rule
 424(b)(4) on October&amp;#xA0;11, 2013 (the Prospectus). In the opinion
 of the Company&amp;#x2019;s management, the consolidated unaudited
 interim consolidated financial statements reflect all adjustments
 necessary to present fairly the results of operations for the three
 and nine months ended September&amp;#xA0;30, 2013 and 2012, the
 Company&amp;#x2019;s financial position as of September&amp;#xA0;30, 2013,
 and the cash flows for the nine months ended September&amp;#xA0;30,
 2013 and 2012. These adjustments are of a normal recurring nature.
 The results of operations for the three and nine months ended
 September&amp;#xA0;30, 2013 are not necessarily indicative of future
 financial results.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company currently operates in one operating segment. Operating
 segments are defined as components of an enterprise about which
 separate discrete information is available for the chief operating
 decision maker, or decision making group, in deciding how to
 allocate resources and assessing performance. The Company views its
 operations and manages its business in one segment, which is
 developing monoclonal antibody-based therapeutics for cancer,
 autoimmune and infectious diseases.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On October&amp;#xA0;16, 2013, the Company completed an initial public
 offering (IPO) of its common stock, which resulted in the sale of
 5,750,000 shares, including all additional shares available to
 cover over-allotments, at a price of $16.00 per share. The Company
 received net proceeds before expenses from the IPO of $85.6 million
 after deducting underwriting discounts and commissions paid by the
 Company.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_FCD6755F-8508-419F-A9C4-49867CB4C8A2_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Net Income (Loss) Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Income (loss) per share is calculated under the two-class method
 under which all earnings (distributed and undistributed) are
 allocated to each class of common stock and participating
 securities based on their respective rights to receive dividends.
 In the event that the Board of Directors shall declare a dividend
 payable in cash or other property on the then-outstanding shares of
 common stock, the holders of the Series&amp;#xA0;A-1, A-2, B, C, D, and
 D-2 convertible preferred stock shall be entitled to receive the
 amount of dividends per share of Preferred Stock that would be
 payable on the largest number of whole shares of Common Stock into
 which each share of Preferred Stock could then be converted.
 Therefore, the Series A-1, A-2, B, C, D and D-2 are participating
 securities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic net income (loss) per common share is determined by dividing
 the net income (loss) allocable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 net income (loss) per share is computed by dividing the net income
 (loss) allocable to common stockholders by the weighted-average
 number of common stock equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&amp;#x2019;s stock option grants and the if-converted method
 is used to determine the dilutive effect of the Company&amp;#x2019;s
 Series&amp;#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred
 stock.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Basic and diluted income (loss) per common share is computed as
 follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="51%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,603,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less: undistributed earnings allocated to participating
 securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,434,756&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;169,226&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,184,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,078,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Basic income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;0.14&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,603,982&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(6,403,843&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,600,514&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,944,149&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,466,582&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Net income (loss) allocable to common shares&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;200,139&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Basic weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,184,507&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,092,307&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,463,798&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,078,145&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Effect of dilutive securities&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,058,471&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,410,117&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,445,061&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;20,334,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Diluted weighted average common shares outstanding&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,242,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,502,424&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,908,859&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21,412,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;Diluted income (loss) per common share&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;0.01&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;b&gt;$&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&lt;b&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&lt;b&gt;&amp;#xA0;&amp;#xA0;&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following common stock equivalents are included in the
 calculation of diluted net income (loss) per share:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series A-1 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,156,114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series A-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;392,274&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series B Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,336,037&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series C Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,909,906&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series D Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;769,468&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,391,991&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Warrants to purchase Series D-2 Preferred Stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;180,784&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Stock Options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,910,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276,516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,910,952&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276,516&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_79627653-21F3-40D1-BE82-3D0ED5681DD5_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="75%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected dividend yield&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;0%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected volatility&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;53%&amp;#xA0;-&amp;#xA0;58%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;51%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;1.24%&amp;#xA0;-&amp;#xA0;2.05%&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;1.18%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected average life of options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;7&amp;#xA0;years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Fair market value of common stock at:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;$1.50&amp;#xA0;-&amp;#xA0;$7.51&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;$1.50&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Expected forfeiture rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.06%&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="center"&gt;5.57%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;


 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_E8B300B3-1F88-48BB-8895-B3492505A801_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012, due to their
 short-term maturities. The Company accounts for recurring and
 non-recurring fair value measurements in accordance with the
 Financial Accounting Standards Board (FASB) Accounting Standards
 Codification (ASC) 820, &lt;i&gt;Fair Value Measurements and
 Disclosures&lt;/i&gt; (ASC 820). ASC 820 defines fair value, establishes
 a fair value hierarchy for assets and liabilities measured at fair
 value, and requires expanded disclosures about fair value
 measurements. The ASC 820 hierarchy ranks the quality of
 reliability of inputs, or assumptions, used in the determination of
 fair value, and requires assets and liabilities carried at fair
 value to be classified and disclosed in one of the following three
 categories:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 1&amp;#xA0;&amp;#x2013; Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 2&amp;#xA0;&amp;#x2013; Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="5%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" width="2%" align="left"&gt;&amp;#x2022;&lt;/td&gt;
 &lt;td valign="top" width="1%"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;Level 3&amp;#xA0;&amp;#x2013; Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&amp;#xA0;&amp;#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Financial assets and liabilities subject to fair value measurements
 were as follows:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="49%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 September&amp;#xA0;30, 2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&amp;#xA0;Markets&amp;#xA0;for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&amp;#xA0;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,522,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,522,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,047,169&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,974,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;33,974,048&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td height="16"&gt;&lt;/td&gt;
 &lt;td height="16" colspan="16"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements at
 December&amp;#xA0;31, 2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom" rowspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&amp;#xA0;Prices&amp;#xA0;in&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Active&amp;#xA0;Markets&amp;#xA0;for&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Identical Assets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&amp;#xA0;Other&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Observable&amp;#xA0;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Significant&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;br /&gt;
 &lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Cash and cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,695,197&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Money market funds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;29,047,958&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Restricted cash&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;404,850&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;48,148,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Liabilities:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt"&gt;
 Preferred stock warrant liability&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 As of December&amp;#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company&amp;#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table provides a rollforward of the Company&amp;#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="86%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at December&amp;#xA0;31, 2012&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(52,947&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Total unrealized gains (losses) included in earnings&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(626,349&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Balance at September&amp;#xA0;30, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(679,296&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_3">43128232</us-gaap:Revenues>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_3_3" />
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_9">-627281</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_1">42015994</us-gaap:LicensesRevenue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_3_9" />
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_2">1112238</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_8">3571430</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_8">965815</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_7">235063</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_10">2944149</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_18">2036700</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_5">626349</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_7">39556802</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_6">7322974</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_23">851183</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_14">-13968859</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_4">393561</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_24">-14173957</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A29B278F-DB51-4F64-81F4-9D7953868844_3_1">2400000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_786A1F41-8B84-485F-8C90-2FEFCE4DEA73_3_1">194498</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_12">-297214</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_11">-1940897</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_22">851183</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_19">-2036700</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_3_5">32233828</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_3_2">2944149</us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_37BCABB3-BAFF-4350-97CD-CDB60E3A1101_3_0">834615</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_13">-466301</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_3_8">2944149</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings>
  <us-gaap:Depreciation contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_3">834615</us-gaap:Depreciation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_3_2">393561</us-gaap:AllocatedShareBasedCompensationExpense>
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_1_15">87035</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_D5D60FA2-BDEB-45D8-B580-CD9AC98EB52C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Depreciation and amortization are computed using the straight-line
 method over the following estimated useful lives:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="60%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Computer equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Software&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;3 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Furniture&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;10 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Laboratory and office equipment&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;5 years&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Leasehold improvements&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 Shorter&amp;#xA0;of&amp;#xA0;lease&amp;#xA0;term&amp;#xA0;or&amp;#xA0;useful&amp;#xA0;life&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_2511AA34-ABD5-4DB1-A8AB-3538A2F86E8B_3001_2">P7Y</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
  <mgnx:RoyaltyAgreementDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_6458A40D-1D39-4900-9838-0919FD4ECFB8_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;9. Product Milestone Payments and Royalty Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In connection with an Asset Purchase Agreement with Tolerance
 Therapeutics, Inc. (Tolerance) entered into during June 2005, the
 Company may be required to issue Tolerance additional consideration
 as follows: (i)&amp;#xA0;$10,950,000 if certain milestones are met,
 including the initiation of Phase 3 trials and filing of various
 regulatory product license applications; (ii)&amp;#xA0;36,135 shares of
 common stock; and (iii)&amp;#xA0;royalty payments between 1.75% and
 4.0% of net sales of products acquired from or patented by
 Tolerance or other product fees earned by the Company. Any
 additional consideration required to be paid under the Asset
 Purchase Agreement will be recorded as research and development
 expense when incurred. No payments related to the additional
 consideration have occurred during the three and nine-month periods
 ended September&amp;#xA0;30, 2013 or 2012. Additionally, certain
 agreements require the Company to pay royalties. Currently, the
 Company is not obligated to pay royalties, as no other revenue from
 product sales is being generated by the Company.&lt;/p&gt;


 &lt;/div&gt;</mgnx:RoyaltyAgreementDisclosureTextBlock>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_0B827F48-2FE4-4825-B785-465AB206B661_1_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" id="id_2787876_4D86E490-1A94-4132-AE4C-52D3574AA30F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;7. Collaboration and License Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Les Laboratoires Servier&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In November 2011, the Company entered into a right-to-develop
 collaboration agreement with Servier for the development and
 commercialization of MGA271 in all countries other than the United
 States, Canada, Mexico, Japan, South Korea and India.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20 million to the Company. The Company is eligible to
 receive up to $30 million in license grant fees, $47 million in
 clinical milestone payments, $140 million in regulatory milestone
 payments and $208 million in sales milestone payments if Servier
 exercises the option, obtains regulatory approval for and
 successfully commercializes MGA271. The Company concluded that the
 license grant fees are not deliverables at the inception of the
 arrangement. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. In the event Servier exercises its option to continue
 development of MGA271, Servier must pay a license grant fee. Under
 this agreement, Servier would be obligated to pay the Company from
 low double digit to mid-teen royalties on product sales in its
 territories.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that the option is substantive and that the license fees
 for this option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised and the additional fee to be paid upon exercise
 of the option represents its estimated selling price (i.e. no
 substantial discount was given). The Company&amp;#x2019;s substantive
 performance obligations under this research collaboration include
 an exclusivity clause to its technology, technical, scientific and
 intellectual property support to the research plan during the first
 year of the agreement and participation on an executive committee
 and a research and development committee. The Company determined
 that these performance obligations represent a single unit of
 accounting, since the license does not have stand-alone value to
 Servier without the Company&amp;#x2019;s technical expertise and
 committee participation. As such, the initial upfront payment was
 deferred and is being recognized ratably over the initial 27-month
 period, which represents the expected period of development and the
 Company&amp;#x2019;s participation on the research and development
 committee. The Company further concluded that each potential future
 clinical, development and regulatory milestone is substantive.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During the three months ended September&amp;#xA0;30, 2013 and 2012 the
 Company recognized revenue of $12.3 million (including a $10.0
 million milestone payment) and $2.3 million, respectively. During
 the nine months ended September&amp;#xA0;30, 2013 and 2012 the Company
 recognized revenue of $18.9 million (including a $10.0 million
 milestone payment) and $6.8 million, respectively, under this
 agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At September&amp;#xA0;30, 2013, $3.1 million of revenue was deferred
 under this agreement, all of which was included in current
 liabilities. At December&amp;#xA0;31, 2012, $10.0 million of revenue
 was deferred under this agreement, $9.1 million of which was
 included in current liabilities and $0.9 million was included in
 long-term liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In September 2012, the Company entered into a second
 right-to-develop collaboration agreement with Servier and granted
 it options to obtain three separate exclusive licenses to develop
 and commercialize DART-based molecules, consisting of those
 designated by the Company as MGD006 and MGD007, as well as a third
 DART molecule, in all countries other than the United States,
 Canada, Mexico, Japan, South Korea and India.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20 million to the Company. In addition, the Company
 will be eligible to receive up to $65 million in license grant
 fees, $98 million in clinical milestone payments, including $5
 million upon IND acceptance for each of MGD006, MGD007 and a third
 DART molecule, $300 million in regulatory milestone payments and
 $630 million in sales milestone payments if Servier exercises all
 of the options and successfully develops, obtains regulatory
 approval for, and commercializes a product under each license. In
 addition to these milestones, the Company and Servier will share
 Phase 2 and Phase 3 development costs. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Under this agreement,
 Servier would be obligated to pay the Company between high-single
 digit and mid-teen royalties on net product sales in its
 territories.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that each option is substantive and that the license fees
 for each option are not deliverables at the inception of the
 arrangement and were not issued with a substantial discount. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusivity clause to its
 technology, technical, scientific and intellectual property support
 to the research plan during the first year of the agreement and
 participation on an executive committee and a research and
 development committee. The Company determined that the performance
 obligations with respect to the pre-clinical development represent
 a single unit of accounting, since the license does not have
 stand-alone value to Servier without the Company&amp;#x2019;s technical
 expertise and committee participation. As such, the initial up
 front license payment was deferred and is being recognized ratably
 over the initial 29-month period, which represents the expected
 development period. The Company further concluded that each
 potential future clinical, development and regulatory milestone is
 substantive.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During the three and nine months ended September&amp;#xA0;30, 2013 the
 Company recognized revenue of $2.2 million and $6.5 million,
 respectively. No revenue was recognized under this agreement during
 the comparable periods in 2012. No milestones have been recognized
 under this agreement during the three and nine months ended
 September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At September&amp;#xA0;30, 2013, $11.6 million of revenue was deferred
 under this agreement, $8.6 million of which was included in current
 liabilities and $3.0 million of which was included in long-term
 liabilities. At December&amp;#xA0;31, 2012, $18.0 million of revenue
 was deferred under this agreement, $8.6 million of which was
 included in current liabilities and $9.4 million of which was
 included in long-term liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Gilead Sciences, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In January 2013, the Company entered into an agreement with Gilead
 to grant it an exclusive worldwide license to research, develop and
 commercialize up to four DART-based molecules. Gilead has exclusive
 worldwide rights for three of the programs. For one program, the
 Company retains development and commercialization rights outside of
 North America, the European Union, Norway, Iceland, Turkey,
 Australia and New Zealand.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company received an initial $7.5 million license grant fee for
 the first DART-based molecule. The Company may be eligible to
 receive additional license grant fees of $22.5 million, $200
 million related to pre-clinical and clinical milestones, $355
 million related to regulatory milestones and $500 million related
 to sales milestones if Gilead exercises all four of the options and
 successfully develops, obtains regulatory approval for, and
 commercializes a product under each option and license. The Company
 has determined that the other licenses are conditional
 deliverables, which are substantive options that were not granted
 with a substantial discount. The Company has determined that each
 potential future clinical, development and regulatory milestone is
 substantive. Although sales milestones are not considered
 substantive, they are still recognized upon achievement of the
 milestone (assuming all other revenue recognition criteria have
 been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Gilead also provides
 funding for the Company&amp;#x2019;s internal and external research
 costs under the agreement. Additionally, Gilead would be obligated
 to pay the Company high single digit to low double digit, but less
 than teen royalties on product sales in its territories.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated the research collaboration agreement with
 Gilead and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include a license to its technology and
 research and development services. The Company concluded that the
 deliverables do not have stand alone value and therefore, represent
 a combined single unit of accounting. Due to the lack of standalone
 value for the license and research and development services, the
 combined unit of accounting (the upfront payment and the expected
 research and development reimbursements) is being recognized
 ratably over a period of 21 months, which represents the expected
 development period.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company and Gilead have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. Had
 management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Receivables of $1.1 million as of September&amp;#xA0;30, 2013 relate to
 amounts due to the Company from Gilead for reimbursement work
 performed under the collaboration.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognized revenues of approximately $2.2 million and
 $5.9 million under this agreement for the three and nine months
 ended September&amp;#xA0;30, 2013, respectively. No milestones have
 been reached under this agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At September&amp;#xA0;30, 2013, $4.4 million of revenue was deferred
 under this agreement, all of which was included in current
 liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Boehringer Ingelheim International GmbH&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2010 the Company entered into a collaboration and
 license agreement with Boehringer to discover, develop and
 commercialize up to ten DART-based molecules which span multiple
 therapeutic areas. Under the terms of the agreement, the Company
 granted Boehringer an exclusive, worldwide, royalty-bearing,
 license under its intellectual property to research, develop, and
 market DARTs generated under the agreement, or the Boehringer
 licensed products, throughout the world.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon execution of the agreement, the Company received an upfront
 payment of $15 million. The Company subsequently received two
 annual maintenance payments and anticipates receiving a third
 annual maintenance payment in the fourth quarter of 2013. The first
 two maintenance payments were solely attributed to the passage
 time. Because Boehringer has the option to cancel the program after
 the second anniversary of the agreement, the third maintenance
 payment will be recognized over the remaining obligation period
 once received. The Company has the potential to earn milestone
 payments of approximately $41 million related to pre-clinical and
 clinical development, $89 million related to regulatory milestones
 and $83 million related to sales milestones for each of the DART
 programs under this agreement in the case of full commercial
 success of multiple DART products. The Company has determined that
 each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Boehringer also provides
 funding for the Company&amp;#x2019;s internal and external research
 costs and is required to pay the Company mid-single digit royalties
 on product sales. From the commencement of the collaboration
 through September&amp;#xA0;30, 2013, the Company has received $39.0
 million under this agreement, including upfront, annual maintenance
 and milestone payments as well as research funding. In addition,
 Boehringer purchased $10 million of the Company&amp;#x2019;s Series D-2
 Preferred Stock in January 2011.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company determined that the deliverables under the Boehringer
 agreement include the license, the research and development
 services to be performed by the Company, and the
 co-promotion/manufacturing services. The Company concluded that the
 co-promotional activities were optional and were subject to further
 negotiation upon reaching regulatory approval. As such, the
 co-promotional period is not included in the expected obligation
 period to perform services.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company concluded that the undelivered element of research and
 development services had fair value. The Company concluded that the
 license does not have value on a standalone basis (e.g. absent the
 provision of the research and development services) and therefore
 does not represent a separate unit of accounting. The Company
 concluded that because the drug candidate has not yet been
 developed, the license is of no value to Boehringer without the
 ensuing research and development activities using the DART
 technology, which is proprietary to the Company. Likewise,
 Boehringer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of account and recognized
 over the expected obligation period associated with the research
 and development services through September 2015, which represents
 the estimated period of development.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company and Boehringer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. However,
 had management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement as the period of participation in
 this committee matched the organization period for the research and
 development services.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&amp;#xA0;1, 2011.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Receivables of $246,375 and $355,568&amp;#xA0;as of September&amp;#xA0;30,
 2013 and December&amp;#xA0;31, 2012, respectively, relate to amounts
 due to the Company from Boehringer for reimbursement work performed
 under the collaboration.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognized revenues of approximately $2.3 million and
 $2.5 million under this agreement during the three months ended
 September&amp;#xA0;30, 2013 and 2012, respectively, and $6.9 million
 and $9.3 million during the nine months ended September&amp;#xA0;30,
 2013 and 2012, respectively. One milestone payment of $2.0 million
 was recognized under this agreement through December 2012. No
 milestones have been recognized under this agreement during the
 three and nine months ended September&amp;#xA0;30, 2013. A milestone
 was earned under this agreement subsequent to September&amp;#xA0;30,
 2013. See Note 11, Subsequent Events, for additional
 information.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At September&amp;#xA0;30, 2013, $10.3 million of revenue was deferred
 under this agreement, $5.0 million of which was included in current
 liabilities and $5.3 million of which was included in long-term
 liabilities. At December&amp;#xA0;31, 2012, $14.0 million of revenue
 was deferred under this agreement, $5.0 million of which was
 included in current liabilities and $9.0 million of which was
 included in long-term liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Pfizer, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October 2010, the Company entered into a three year agreement
 with Pfizer to discover, develop and commercialize up to two
 DART-based molecules. The Company granted Pfizer a non-exclusive
 worldwide, royalty-bearing license and received an upfront payment
 of $5 million and has received milestone payments and funding for
 the Company&amp;#x2019;s internal and external research costs under the
 agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company is eligible to receive milestone payments of
 approximately $17 million related to pre-clinical and clinical
 development and $195 million related to commercialization and sales
 milestones for each DART program under this agreement. The Company
 has determined that each potential future technical and development
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Pfizer is responsible
 for all pre-clinical and clinical development costs for the
 program. In addition, Pfizer is required to pay the Company
 mid-single digit to low-teen royalties on product sales. Under this
 collaboration, one DART program is currently being pursued and the
 Company will complete its research obligations under this program
 in January 2014.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated the research collaboration agreement with
 Pfizer and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, research and development services and manufacturing
 services. The Company concluded that the manufacturing services
 were optional and were subject to further negotiation upon reaching
 regulatory approval. As such, the manufacturing services are not
 included in the expected obligation period to perform services.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company determined that it had fair value of the undelivered
 element of the research and development services. However, the
 Company concluded that the license does not have value on a
 standalone basis (e.g. absent the provision of the research and
 development services) and therefore does not represent a separate
 unit of accounting. Facts that were considered included the
 development of the candidate noting that because the drug candidate
 has not yet been developed, the license is of no value to Pfizer
 without the ensuing research and development activities using the
 DART technology, which is proprietary to the Company. Likewise,
 Pfizer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of accounting and
 recognized over the expected obligation period associated with the
 research and development services through January 2014, which
 represents the estimated period of development.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The $5 million upfront payment received by the Company is
 non-refundable; therefore, there is no right of return for the
 license. The Company is recognizing revenue associated with this
 non-refundable up-front license fee through January 2014.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company and Pfizer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&amp;#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable because it
 is a participating right and not an obligation of the Company.
 However, had management considered participation on the joint
 committee as a deliverable, it would not have had a material impact
 on the accounting for the arrangement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&amp;#xA0;1, 2011.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Receivables of $501,794 and $896,285 as of September&amp;#xA0;30, 2013
 and December&amp;#xA0;31, 2012, respectively, relate to amounts due to
 the Company from Pfizer for reimbursement work performed under the
 collaboration.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognized revenues of approximately $0.9 million and
 $1.2 million under this agreement during the three months ended
 September&amp;#xA0;30, 2013 and 2012, respectively, and $3.2 million
 and $4.0 million during the nine months ended September&amp;#xA0;30,
 2013 and 2012, respectively. Included in the 2012 revenues are
 milestone payments totaling $500,000. No additional milestones have
 been recognized under this agreement through September&amp;#xA0;30,
 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At September&amp;#xA0;30, 2013 and December&amp;#xA0;31, 2012, $58,000 and
 $1.3 million of revenue was deferred under this agreement, all of
 which was included in current liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Green Cross Corporation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In June&amp;#xA0;2010, the Company entered into a collaboration
 agreement with Green Cross for the development of the
 Company&amp;#x2019;s anti-HER2 antibody known as MGAH22, or
 margetuximab. This arrangement grants Green Cross an exclusive
 license to conduct specified Phase 1 and Phase 2 clinical trials
 and commercialize margetuximab in South Korea.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon execution of the agreement, Green Cross made a nonrefundable
 payment of $1.0&amp;#xA0;million to the Company. The Company is
 eligible to receive clinical development and commercial milestone
 payments of up to $4.5 million. The Company has determined that
 each potential clinical development and commercial milestone is
 substantive. The Company is also entitled to receive royalties on
 net sales of margetuximab in South Korea. The Company and Green
 Cross have formed a joint steering committee to coordinate and
 oversee activities on which the companies collaborate under the
 agreement.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company has evaluated the collaboration agreement with Green
 Cross and has determined that it is a revenue arrangement with
 multiple deliverables or performance obligations. The
 Company&amp;#x2019;s substantive performance obligations under this
 agreement include an exclusive license to its technologies and
 participation in a joint steering committee. The Company concluded
 that the license does not have value on a standalone basis and
 therefore does not represent a separate unit of accounting.
 Likewise, Green Cross could not sell the license to another
 party.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The $1 million upfront payment received by the Company is
 non-refundable; as such, there is no right of return for the
 license. Therefore, the upfront license fee and participation on
 the joint steering committee were treated as a combined unit of
 accounting and will be recognized over the term of the agreement
 through June 2020.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&amp;#xA0;1, 2011.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The Company recognized revenues of approximately $25,000 under this
 agreement during each of the three month periods ending
 September&amp;#xA0;30, 2013 and 2012, and $75,000 during each of the
 nine month periods ending September&amp;#xA0;30, 2013 and 2012. No
 milestones have been recognized under this agreement during the
 three and nine months ended September&amp;#xA0;30, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 At September&amp;#xA0;30, 2013, $675,000 of revenue was deferred under
 this agreement, $100,000 of which was included in current
 liabilities and $575,000 of which was included in long-term
 liabilities. At December&amp;#xA0;31, 2012, $750,000 of revenue was
 deferred under this agreement, $100,000 of which was included in
 current liabilities and $650,000 of which was included in long-term
 liabilities.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 &lt;b&gt;&lt;i&gt;Eli Lilly&amp;#xA0;&amp;amp; Co.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 In October&amp;#xA0;2007, the Company entered into an exclusive license
 and collaboration agreement (together, the Agreements) with Eli
 Lilly to jointly develop and commercialize teplizumab, a humanized
 anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly
 acquired the exclusive rights to the molecule.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Upon execution of the Agreements, Eli Lilly made a nonrefundable
 payment of $41.0&amp;#xA0;million to the Company. In May&amp;#xA0;2008, Eli
 Lilly paid the Company a milestone payment of $50.0&amp;#xA0;million
 and in May&amp;#xA0;2010, Eli&amp;#xA0;Lilly paid an additional milestone
 of $5.0&amp;#xA0;million.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 On October&amp;#xA0;28, 2010, Lilly notified the Company of its
 decision to terminate the agreement after review of one year of
 clinical data from the PROT&amp;#xC9;G&amp;#xC9; trial in Type 1 diabetes
 patients treated with teplizumab. Such data failed to support the
 primary efficacy end point in the study. During the year ended
 December&amp;#xA0;31, 2012, Eli&amp;#xA0;Lilly satisfied its obligation
 related to the cost of monitoring patients under the
 PROT&amp;#xC9;G&amp;#xC9; and ENCORE trials. The Company&amp;#x2019;s
 obligations continued through September 2012, which represented the
 follow up period for enrolled patients and the Company&amp;#x2019;s
 final reporting of the trial&amp;#x2019;s results. There is no
 additional clinical trial activity under the Eli Lilly Agreements
 as it relates to such trials. In February 2011, the Company
 reacquired the commercial rights to the molecule from Eli
 Lilly.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 Receivables of $244,542 and $558,516 as of September&amp;#xA0;30, 2013
 and December&amp;#xA0;31, 2012, respectively, relate to amounts due to
 the Company from Eli Lilly for reimbursement work performed under
 the above mentioned clinical trials.&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 During the three months ended September&amp;#xA0;30, 2013 and 2012, the
 Company recognized revenue of $190,833 and $9.5 million,
 respectively, under this agreement. During the nine months ended
 September&amp;#xA0;30, 2013 and 2012, the Company recognized revenue of
 $673,927 and $30.1 million, respectively. No milestones were
 recognized under this agreement during the three and nine months
 ended September&amp;#xA0;30, 2013.&lt;/p&gt;


 &lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
  <mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_4_4">0</mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement>
  <mgnx:DefinedContributionPlanEmployeesContributionAnnualVestingPercentage contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="pure" decimals="INF" id="id_2787876_786A1F41-8B84-485F-8C90-2FEFCE4DEA73_3_0">1.00</mgnx:DefinedContributionPlanEmployeesContributionAnnualVestingPercentage>
  <mgnx:PreferredStockMinimumHoldingPercentageForElectionOfDirectors contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="pure" decimals="INF" id="id_2787876_9AD1D1E0-1A81-471B-BA99-1437F4A6E8B1_1_1">0.6667</mgnx:PreferredStockMinimumHoldingPercentageForElectionOfDirectors>
  <mgnx:NetProceedsFromPublicOfferingOfCommonStock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-6" id="id_2787876_EE20ECBD-A4A8-4C7E-A9B1-51C5AFA090B4_1_0">40000000</mgnx:NetProceedsFromPublicOfferingOfCommonStock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x923140" unitRef="pure" decimals="4" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_2_2">0.0205</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x923140" unitRef="pure" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_2_1">0.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x923140_930809x1218846" id="id_2787876_5A62D52C-211A-4329-B8E1-589E2391D229_1001_0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x932953" unitRef="pure" decimals="4" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_1_2">0.0124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x932953" unitRef="pure" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_1_1">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_1003_1">109280</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_2003_0">284281</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060404_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_1001_2">0.111</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_1003_1">0.159</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060690_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_2001_0">0.512</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060690_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_2003_2">0.137</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1074019_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_3001_4">0.040</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_3003_4">0.026</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1115783_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_4001_1">0.226</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_4003_3">0.073</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1218715_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_5001_3">0.110</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_5003_5">0.016</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1218717_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_6003_0">0.588</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_927592x929614" unitRef="iso4217_USD" decimals="0" id="id_2787876_32387351-DF92-45CD-A47C-B41F9198D8A0_5001_4">-626349</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_77B9F842-971D-4E15-A1C6-FF2E2FEC4D11_1003_0">6500000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_310C5680-5400-40FB-A957-C56097578569_1001_0">20000000</mgnx:NonRefundableFees>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879" id="id_2787876_E1CCDAA0-2324-42A6-B5D5-9EBE8755E2BF_1001_0">P29M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879" id="id_2787876_6DDD85AB-B003-44AB-AF07-362B3A192099_1001_0">September 2012</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:SalesMilestonePayments contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_310C5680-5400-40FB-A957-C56097578569_1001_5">630000000</mgnx:SalesMilestonePayments>
  <mgnx:ClinicalDevelopmentMilestonePaymentsReceived contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_310C5680-5400-40FB-A957-C56097578569_1001_2">98000000</mgnx:ClinicalDevelopmentMilestonePaymentsReceived>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1031975" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_1003_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1124615" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_2003_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1166280" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_3003_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1166416" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_4003_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1218718" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_5003_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x924898" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_6003_7">2910952</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x929614" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_7003_6">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x997107" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_8003_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x1203065" id="id_2787876_B289BBDE-32E9-449E-A496-2B337E2610BF_1001_3">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x923325" id="id_2787876_B289BBDE-32E9-449E-A496-2B337E2610BF_2001_4">Shorter of lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x931666" id="id_2787876_B289BBDE-32E9-449E-A496-2B337E2610BF_3001_1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x931760" id="id_2787876_B289BBDE-32E9-449E-A496-2B337E2610BF_4001_0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x932226" id="id_2787876_B289BBDE-32E9-449E-A496-2B337E2610BF_5001_2">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930526x926068" id="id_2787876_2FE83A00-081B-46A3-B760-790A5B2B7AC9_1_0">&lt;div&gt;
 &lt;div&gt;
 &lt;p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="52%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="10%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;September&amp;#xA0;30,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Servier&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;71.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;14.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;58.8&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;10.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.3&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.5&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0.9&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;59.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;55.7&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/div&gt;
 &lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
  <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930526x932533" id="id_2787876_C9231768-1DA0-4F47-B5BA-63AC4BF20D44_1_0">&lt;div&gt;
 &lt;p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt"&gt;
 The following table represents the percentage of all significant
 accounts receivable:&lt;/p&gt;
 &lt;p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"&gt;&lt;!-- Begin Table Head --&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="16%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2012&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Head --&gt;&lt;!-- Begin Table Body --&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Gilead&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;&amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Pfizer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22.6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;45.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Boehringer&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.1&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Eli Lilly&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;28.2&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt"&gt;
 Government Agencies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;8.4&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;!-- End Table Body --&gt;&lt;/table&gt;
 &lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1108152" unitRef="shares" decimals="INF" id="id_2787876_6AC3516C-BBFA-4E19-AC04-AF5AB2FC5EA4_1001_1">150297</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1218846" id="id_2787876_5A62D52C-211A-4329-B8E1-589E2391D229_1_1">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1218846" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_7D91C121-F31A-44B5-89FB-D5E86D3F956D_1_0">2.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1218846" id="id_2787876_7D91C121-F31A-44B5-89FB-D5E86D3F956D_1_4">P4Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1218846" unitRef="iso4217_USD" decimals="0" id="id_2787876_7D91C121-F31A-44B5-89FB-D5E86D3F956D_1_2">402084</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1218846" unitRef="iso4217_USD" decimals="0" id="id_2787876_7D91C121-F31A-44B5-89FB-D5E86D3F956D_1_1">851183</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1165094" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_3ED0C1F0-FD1B-4432-AED9-E3926AE32F9C_1001_5">0.0522</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1165094" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_1001_5">12.20</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1184171" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_3ED0C1F0-FD1B-4432-AED9-E3926AE32F9C_2001_0">0.08</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1184171" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_2001_0">12.39</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1218712" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_3ED0C1F0-FD1B-4432-AED9-E3926AE32F9C_3001_1">0.08</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1218712" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_3001_1">18.77</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x929177" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_3ED0C1F0-FD1B-4432-AED9-E3926AE32F9C_4001_4">0.0522</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x929177" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_4001_4">12.20</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x930400" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_3ED0C1F0-FD1B-4432-AED9-E3926AE32F9C_5001_3">0.0324</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x930400" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_5001_3">7.70</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:PreferredStockDividendRatePerDollarAmount contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x932774" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_2787876_3ED0C1F0-FD1B-4432-AED9-E3926AE32F9C_6001_2">0.0341</us-gaap:PreferredStockDividendRatePerDollarAmount>
  <mgnx:ConvertiblePreferredStockConversionPrice contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x932774" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_C3DC4B8B-C1DA-4D08-8014-37A74C2EE4AE_6001_2">6.95</mgnx:ConvertiblePreferredStockConversionPrice>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B0DCCEE5-9359-409E-B55D-7230969CA2AA_1003_0">6900000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-6" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_2_2">41000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-6" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_2_0">15000000</mgnx:NonRefundableFees>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" id="id_2787876_189ED1C3-5B70-47FD-BF3B-7DB21F989AB2_1_0">October 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:PaymentReceivedOnCollaborationAgreement contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_2_5">39000000</mgnx:PaymentReceivedOnCollaborationAgreement>
  <mgnx:SalesMilestonePayments contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-6" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_2_4">83000000</mgnx:SalesMilestonePayments>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="Molecule" decimals="INF" id="id_2787876_189ED1C3-5B70-47FD-BF3B-7DB21F989AB2_1_1">10</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NumberOfAnnualMaintenancePaymentReceived contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" unitRef="Payments" decimals="INF" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_2_1">2</mgnx:NumberOfAnnualMaintenancePaymentReceived>
  <mgnx:ResearchObligationCompletionDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404" id="id_2787876_B26F3918-8C9D-4C88-A5F5-268B15068E89_1_0">2015-09</mgnx:ResearchObligationCompletionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A34B2E43-8B42-4F47-AE26-6424A695904A_2_0">5900000</us-gaap:LicensesRevenue>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" id="id_2787876_154B00C8-38B2-4242-B8AF-B76A460D5D33_1_0">P21M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" id="id_2787876_ECB75CDA-7A34-4EC0-832C-1468A10F7E8C_1_0">January 2013</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:SalesMilestonePayments contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-6" id="id_2787876_4011512C-62F0-4DEF-BAEA-D33749CCE2CB_1_4">500000000</mgnx:SalesMilestonePayments>
  <mgnx:NumberOfLicensedProgramsTypeUnderCollaborationAgreements contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" unitRef="Molecule" decimals="INF" id="id_2787876_ECB75CDA-7A34-4EC0-832C-1468A10F7E8C_1_2">3</mgnx:NumberOfLicensedProgramsTypeUnderCollaborationAgreements>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" unitRef="Molecule" decimals="INF" id="id_2787876_ECB75CDA-7A34-4EC0-832C-1468A10F7E8C_1_1">4</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <mgnx:NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690" unitRef="Program" decimals="INF" id="id_2787876_ECB75CDA-7A34-4EC0-832C-1468A10F7E8C_1_3">1</mgnx:NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_13242280-5928-4811-B200-F93F127B9E9D_1003_0">75000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A5FB727B-5249-45AF-B90A-4DC897D6932B_1_0">1000000</mgnx:NonRefundableFees>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1064508" id="id_2787876_4242D4F2-E8CB-4EFC-8768-BC3F2C26CBB9_1001_0">June 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:UpfrontFeeAndParticipationRecognitionDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1064508" id="id_2787876_12B41187-641A-434E-99EE-854E414CB327_1_0">2020-06</mgnx:UpfrontFeeAndParticipationRecognitionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_1003_0">3200000</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="-6" id="id_2787876_AD3A5DB4-DDC3-47C8-AFC8-30B23756D325_1001_0">5000000</mgnx:NonRefundableFees>
  <mgnx:NumberOfPrograms contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1115783" unitRef="Program" decimals="INF" id="id_2787876_04D8518E-EFD4-4F16-B5E3-6EE1827C3DE0_1_2">1</mgnx:NumberOfPrograms>
  <mgnx:SalesMilestonePayments contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="-6" id="id_2787876_04D8518E-EFD4-4F16-B5E3-6EE1827C3DE0_1_1">195000000</mgnx:SalesMilestonePayments>
  <mgnx:ResearchObligationCompletionDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1115783" id="id_2787876_04D8518E-EFD4-4F16-B5E3-6EE1827C3DE0_1_3">2014-01</mgnx:ResearchObligationCompletionDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218715" unitRef="iso4217_USD" decimals="1" id="id_2787876_B00BF36B-BE5C-40F5-8BD1-788DF6F80A36_1003_600001">673927.0</us-gaap:LicensesRevenue>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_2787876_ED4B36DB-215E-4039-920F-98D47C76DD1D_1001_1">41000000</mgnx:NonRefundableFees>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218715" id="id_2787876_ED4B36DB-215E-4039-920F-98D47C76DD1D_1001_0">October 2007</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_F664745D-171D-4C74-AA93-6DB0B8CD35F2_1003_0">18900000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_F664745D-171D-4C74-AA93-6DB0B8CD35F2_1003_1">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_B2F44DBC-B6A6-4DA8-B93A-2F1E9B6669DB_1_0">20000000</mgnx:NonRefundableFees>
  <mgnx:UpfrontPaymentRecognitionPeriod contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" id="id_2787876_11912A05-B59D-4385-9DCC-24A52F0B783A_1001_0">P27M</mgnx:UpfrontPaymentRecognitionPeriod>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" id="id_2787876_3015AFD0-409E-443E-A9B6-4D0A84224173_1001_0">November 2011</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:SalesMilestonePayments contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_B2F44DBC-B6A6-4DA8-B93A-2F1E9B6669DB_1_4">208000000</mgnx:SalesMilestonePayments>
  <mgnx:ClinicalDevelopmentMilestonePaymentsReceived contextRef="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-6" id="id_2787876_B2F44DBC-B6A6-4DA8-B93A-2F1E9B6669DB_1_2">47000000</mgnx:ClinicalDevelopmentMilestonePaymentsReceived>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="pure" decimals="4" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_4_2">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_12">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_14">21412848</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="pure" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_4_1">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_4_11">20334703</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_11">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_4_3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="pure" decimals="4" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_4_5">0.0557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="pure" decimals="2" id="id_2787876_049F1474-BF37-46EC-9A84-D3E2E39DDE39_4_0">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_16">-24281449</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_13">1078145</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_3">54027557</us-gaap:Revenues>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_4_3" />
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_9">4752</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_1">50283510</us-gaap:LicensesRevenue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_4_9" />
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_2">3744047</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_8">10461830</us-gaap:OperatingIncomeLoss>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_8">69231</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_7">2713429</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_10">10466582</us-gaap:NetIncomeLoss>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_18">530136</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_5" />
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_7">43565727</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_6">6640740</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_23">44309</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_14">-27935268</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_4">628796</us-gaap:ShareBasedCompensation>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_24">-24767276</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A29B278F-DB51-4F64-81F4-9D7953868844_4_1">2400000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_786A1F41-8B84-485F-8C90-2FEFCE4DEA73_4_1">179966</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_12">53860</us-gaap:IncreaseDecreaseInAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_11">-5444288</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_22">44309</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_19">-530136</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_4_5">36924987</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_4_2">10466582</us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_37BCABB3-BAFF-4350-97CD-CDB60E3A1101_4_0">722496</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_13">-395694</us-gaap:IncreaseDecreaseInRestructuringReserve>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_4_8">10466582</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings>
  <us-gaap:Depreciation contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_3">722496</us-gaap:Depreciation>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_4_2">628796</us-gaap:AllocatedShareBasedCompensationExpense>
  <mgnx:IncreaseDecreaseInDeferredRent contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_5F4D31B3-8D36-40C1-8C81-8D9A2D3964A3_2_15">404727</mgnx:IncreaseDecreaseInDeferredRent>
  <mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_0B827F48-2FE4-4825-B785-465AB206B661_2_0">0</mgnx:ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense>
  <mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_5_4">0</mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_1004_1">274940</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_2004_0">353856</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_1004_1">0.172</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1060690_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_2004_2">0.000</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_3004_4">0.069</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_4004_3">0.074</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_5004_5">0.557</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1218717_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_6004_0">0.126</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_77B9F842-971D-4E15-A1C6-FF2E2FEC4D11_1004_0">0</us-gaap:LicensesRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1031975" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_1004_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1124615" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_2004_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1166280" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_3004_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1166416" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_4004_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1218718" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_5004_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x924898" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_6004_7">3276516</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x929614" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_7004_6">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x997107" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_8004_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B0DCCEE5-9359-409E-B55D-7230969CA2AA_1004_0">9300000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_13242280-5928-4811-B200-F93F127B9E9D_1004_0">75000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_1004_0">4000000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B00BF36B-BE5C-40F5-8BD1-788DF6F80A36_1004_700001">30100000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_F664745D-171D-4C74-AA93-6DB0B8CD35F2_1004_0">6800000</us-gaap:LicensesRevenue>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_30_20100530_0_932980x1165094" unitRef="shares" decimals="INF" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_1003_5">6916110</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <mgnx:NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement contextRef="eol_PE179294--1310-Q0003_STD_30_20050630_0" unitRef="shares" decimals="INF" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_1_1">36135</mgnx:NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement>
  <mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement contextRef="eol_PE179294--1310-Q0003_STD_30_20050630_0_926437x923140" unitRef="pure" decimals="INF" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_1001_3">0.040</mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement>
  <mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement contextRef="eol_PE179294--1310-Q0003_STD_30_20050630_0_926437x932953" unitRef="pure" decimals="INF" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_2001_2">0.0175</mgnx:RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement>
  <mgnx:LeaseExpirationYear contextRef="eol_PE179294--1310-Q0003_STD_30_20080716_0" id="id_2787876_A466F1D5-45F4-495D-A7EA-8851ECBFAB76_1_0">2018</mgnx:LeaseExpirationYear>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="eol_PE179294--1310-Q0003_STD_30_20080716_0_932980x1010406" unitRef="shares" decimals="INF" id="id_2787876_83F30792-6B44-439F-9DDF-627743D26CBB_1001_0">12466039</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="eol_PE179294--1310-Q0003_STD_30_20020930_0" unitRef="pure" decimals="INF" id="id_2787876_6F348845-155C-4F36-8D33-A8DD29F27261_1_1">1.00</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <mgnx:EmployeeEligibleAgeToParticipateInBenefitPlan contextRef="eol_PE179294--1310-Q0003_STD_30_20020930_0" unitRef="Age" decimals="INF" id="id_2787876_6F348845-155C-4F36-8D33-A8DD29F27261_1_0">21</mgnx:EmployeeEligibleAgeToParticipateInBenefitPlan>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_30_20080930_0_932980x1165094" unitRef="shares" decimals="INF" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_1001_2">38337678</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-Q0003_STD_30_20080930_0_932980x1165094" unitRef="iso4217_USD" decimals="0" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_1001_0">24843211</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1310-Q0003_STD_30_20080930_0_932980x1165094" unitRef="iso4217_USD" decimals="0" id="id_2787876_1B74BFEB-E244-4273-96EF-F02C4219FEE8_1001_1">156788</mgnx:StockIssuanceCosts>
  <mgnx:ClinicalDataReviewPeriodForAgreementTermination contextRef="eol_PE179294--1310-Q0003_STD_30_20101028_0_933025x1218715" id="id_2787876_F47B85B0-3FA8-4C66-A392-5F8573B9C7C8_1001_0">P1Y</mgnx:ClinicalDataReviewPeriodForAgreementTermination>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_31_20041031_0_932980x932774" unitRef="shares" decimals="INF" id="id_2787876_368FCEED-783A-4624-A454-175370AC7D1D_1001_2">71401237</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-Q0003_STD_31_20041031_0_932980x932774" unitRef="iso4217_USD" decimals="0" id="id_2787876_368FCEED-783A-4624-A454-175370AC7D1D_1001_0">30261672</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1310-Q0003_STD_31_20041031_0_932980x932774" unitRef="iso4217_USD" decimals="0" id="id_2787876_368FCEED-783A-4624-A454-175370AC7D1D_1001_1">238000</mgnx:StockIssuanceCosts>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_31_20080731_0_928576x1218824_932980x929177" unitRef="shares" decimals="INF" id="id_2787876_20E2E480-D537-4907-920D-BB06EB00749C_1001_0">12466039</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <mgnx:NonRefundableFees contextRef="eol_PE179294--1310-Q0003_STD_31_20101031_0_933025x1115783" unitRef="iso4217_USD" decimals="-6" id="id_2787876_68F36200-6602-4B9B-BD3A-9229DE2A2EB5_1_3">5000000</mgnx:NonRefundableFees>
  <mgnx:CollaborativeAgreementPeriodOfContract contextRef="eol_PE179294--1310-Q0003_STD_31_20101031_0_933025x1115783" id="id_2787876_68F36200-6602-4B9B-BD3A-9229DE2A2EB5_1_1">P3Y</mgnx:CollaborativeAgreementPeriodOfContract>
  <mgnx:CollaborationAndLicenseAgreementEnteredDate contextRef="eol_PE179294--1310-Q0003_STD_31_20101031_0_933025x1115783" id="id_2787876_68F36200-6602-4B9B-BD3A-9229DE2A2EB5_1_0">October 2010</mgnx:CollaborationAndLicenseAgreementEnteredDate>
  <mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations contextRef="eol_PE179294--1310-Q0003_STD_31_20101031_0_933025x1115783" unitRef="Molecule" decimals="INF" id="id_2787876_68F36200-6602-4B9B-BD3A-9229DE2A2EB5_1_2">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_31_20110131_0_932980x1165094" unitRef="shares" decimals="INF" id="id_2787876_F9829CD8-2492-435C-A00B-7DCB4FF706DE_1001_1">18427388</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-Q0003_STD_31_20110131_0_932980x1165094" unitRef="iso4217_USD" decimals="0" id="id_2787876_F9829CD8-2492-435C-A00B-7DCB4FF706DE_1001_0">12016500</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="eol_PE179294--1310-Q0003_STD_31_20110131_0_932980x1218718_933025x1060404" unitRef="iso4217_USD" decimals="-6" id="id_2787876_298FE587-0E1D-40D2-9C91-B90A65F4DC91_1001_6">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_31_20131031_0_931707x926487_932504x931597" unitRef="shares" decimals="INF" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_1001_0">5000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE179294--1310-Q0003_STD_31_20131031_0_931707x926487_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_1001_3">83800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="eol_PE179294--1310-Q0003_STD_31_20131031_0_931707x926487_932504x931597" unitRef="shares" decimals="INF" id="id_2787876_98A058F1-B906-4D02-A771-86FD0270DD7F_1001_2">750000</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
  <mgnx:StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment contextRef="eol_PE179294--1310-Q0003_STD_31_20131031_0_931707x926487_932504x931597" unitRef="shares" decimals="INF" id="id_2787876_4F874131-ED1D-47E9-B3FD-4D6B3ECF07AF_1001_0">5750000</mgnx:StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment>
  <mgnx:ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses contextRef="eol_PE179294--1310-Q0003_STD_31_20131031_0_931707x926487_932504x931597" unitRef="iso4217_USD" decimals="-5" id="id_2787876_4F874131-ED1D-47E9-B3FD-4D6B3ECF07AF_1001_2">85600000</mgnx:ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued contextRef="eol_PE179294--1310-Q0003_STD_31_20110331_0_928576x1218824_932980x929177" unitRef="shares" decimals="INF" id="id_2787876_20E2E480-D537-4907-920D-BB06EB00749C_1002_1">14446227</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_31_20060531_0_932980x930400" unitRef="shares" decimals="INF" id="id_2787876_04ECB415-C29F-4F1F-98CA-0B614727AF0E_1001_2">110952217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-Q0003_STD_31_20060531_0_932980x930400" unitRef="iso4217_USD" decimals="0" id="id_2787876_04ECB415-C29F-4F1F-98CA-0B614727AF0E_1001_0">44898754</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <mgnx:StockIssuanceCosts contextRef="eol_PE179294--1310-Q0003_STD_31_20060531_0_932980x930400" unitRef="iso4217_USD" decimals="0" id="id_2787876_04ECB415-C29F-4F1F-98CA-0B614727AF0E_1001_1">101246</mgnx:StockIssuanceCosts>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-Q0003_STD_31_20080531_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_2787876_ED4B36DB-215E-4039-920F-98D47C76DD1D_1002_2">50000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_365_20061231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_2_1">460746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-Q0003_STD_365_20061231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_2_2">2512390</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_365_20101231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_4_5">532654</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-Q0003_STD_365_20101231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_4_6">3790760</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE179294--1310-Q0003_STD_365_20111231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_5EF377F7-EC84-4D48-9940-2B776A570667_2001_2">533560</us-gaap:PaymentsForRestructuring>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_366_20081231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_3_3">745716</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-Q0003_STD_366_20081231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_3_4">3258106</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_5_7">545970</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0" id="id_2787876_2511AA34-ABD5-4DB1-A8AB-3538A2F86E8B_1001_1">P7Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0" unitRef="shares" decimals="INF" id="id_2787876_F4A41947-8640-4C44-942C-9BA439842F4F_5_8">4336731</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
  <us-gaap:PaymentsForRestructuring contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_926911x929956" unitRef="iso4217_USD" decimals="0" id="id_2787876_5EF377F7-EC84-4D48-9940-2B776A570667_4001_4">466301</us-gaap:PaymentsForRestructuring>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1060404_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_1002_2">0.180</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1060690_931007x926523" unitRef="pure" xsi:nil="true" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_2002_0" />
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1074019_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_3002_4">0.084</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1115783_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_4002_1">0.454</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1218715_931007x926523" unitRef="pure" decimals="3" id="id_2787876_1350E185-6932-4750-864E-BD138CF6DAB9_5002_3">0.282</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B0DCCEE5-9359-409E-B55D-7230969CA2AA_1005_1">2000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-Q0003_STD_366_20121231_0_933025x1115783" unitRef="iso4217_USD" decimals="0" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_1005_1">500000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE179294--1310-Q0003_STD_730_20031231_0_932980x930435" unitRef="shares" decimals="INF" id="id_2787876_4F476A18-7ECD-444C-93B8-96787978ACA4_1001_0">34239374</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE179294--1310-Q0003_STD_730_20031231_0_932980x930435" unitRef="iso4217_USD" decimals="0" id="id_2787876_4F476A18-7ECD-444C-93B8-96787978ACA4_1001_1">34000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_12">0.00</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_14">21502424</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_2_11">20410117</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_11">0.00</us-gaap:EarningsPerShareBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_13">1092307</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_3">16081544</us-gaap:Revenues>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_2_3" />
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_9">1557</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_1">15532680</us-gaap:LicensesRevenue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_2_9" />
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_2">548864</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_8">2598957</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_10">2600514</us-gaap:NetIncomeLoss>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_7">13482587</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_6">1514334</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_A29B278F-DB51-4F64-81F4-9D7953868844_2_0">783462</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_786A1F41-8B84-485F-8C90-2FEFCE4DEA73_2_1">48891</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_2_5">11968253</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_2_2">2600514</us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_37BCABB3-BAFF-4350-97CD-CDB60E3A1101_2_0">235543</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_2_8">2600514</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_2_2">209599</us-gaap:AllocatedShareBasedCompensationExpense>
  <mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_3_4">0</mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_1002_1">91647</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_2002_0">117952</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_1002_1">0.156</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1060690_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_2002_2">0.000</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_3002_4">0.035</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_4002_3">0.077</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_5002_5">0.590</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1218717_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_6002_0">0.142</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_77B9F842-971D-4E15-A1C6-FF2E2FEC4D11_1002_0">0</us-gaap:LicensesRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1031975" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_1002_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1124615" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_2002_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1166280" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_3002_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1166416" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_4002_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1218718" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_5002_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x924898" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_6002_7">3276516</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x929614" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_7002_6">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x997107" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_8002_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B0DCCEE5-9359-409E-B55D-7230969CA2AA_1002_0">2500000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_13242280-5928-4811-B200-F93F127B9E9D_1002_0">25000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_1002_0">1200000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1218715" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B00BF36B-BE5C-40F5-8BD1-788DF6F80A36_1002_500001">9500000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_F664745D-171D-4C74-AA93-6DB0B8CD35F2_1002_0">2300000</us-gaap:LicensesRevenue>
  <us-gaap:EarningsPerShareDiluted contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_12">0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_14">21242978</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_1_11">20058471</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
  <us-gaap:EarningsPerShareBasic contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_11">0.14</us-gaap:EarningsPerShareBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="shares" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_13">1184507</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:Revenues contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_3">20232068</us-gaap:Revenues>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_1_3">169226</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_9">-553612</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_1">20111173</us-gaap:LicensesRevenue>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_1_9">200139</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:RevenueFromGrants contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_2">120895</us-gaap:RevenueFromGrants>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_8">7157594</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_10">6603982</us-gaap:NetIncomeLoss>
  <us-gaap:CostsAndExpenses contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_7">13074474</us-gaap:CostsAndExpenses>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_6">1986555</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_A29B278F-DB51-4F64-81F4-9D7953868844_1_0">806275</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_786A1F41-8B84-485F-8C90-2FEFCE4DEA73_1_1">55311</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_B0D36152-43E4-498E-897E-F15D0F38CEEA_1_5">11087919</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_1_2">6434756</us-gaap:UndistributedEarningsAllocatedToParticipatingSecurities>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_37BCABB3-BAFF-4350-97CD-CDB60E3A1101_1_0">316852</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="INF" id="id_2787876_2AEAEDD6-4098-44B5-84BE-969DE51EEFF3_1_8">6403843</us-gaap:ParticipatingSecuritiesDistributedAndUndistributedEarnings>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_1_2">135936</us-gaap:AllocatedShareBasedCompensationExpense>
  <mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0" unitRef="iso4217_USD" decimals="0" id="id_2787876_D1DC73A1-11B3-459F-BC56-793728427436_2_4">0</mgnx:AmountOfAdditionalConsiderationPaidUnderAgreement>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927015x925832" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_1001_1">24048</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927015x928963" unitRef="iso4217_USD" decimals="0" id="id_2787876_DE2C39D6-52B9-4A97-B124-7522A4A0E917_2001_0">111888</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1060404_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_1001_1">0.115</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1060690_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_2001_2">0.109</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1074019_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_3001_4">0.006</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1115783_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_4001_3">0.045</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1218715_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_5001_5">0.009</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1218717_931007x926597" unitRef="pure" decimals="3" id="id_2787876_6C4DEA1D-A29E-4E5D-8550-27F88DF9F140_6001_0">0.713</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928294x1218880_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_77B9F842-971D-4E15-A1C6-FF2E2FEC4D11_1001_0">2200000</us-gaap:LicensesRevenue>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1031975" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_1001_3">5909906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1124615" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_2001_2">4336037</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1166280" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_3001_0">2156114</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1166416" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_4001_1">392274</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1218718" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_5001_5">3391991</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x924898" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_6001_7">2910952</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x929614" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_7001_6">180784</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x997107" unitRef="shares" decimals="INF" id="id_2787876_A207B5A9-C88B-4D93-8833-E7E6B8FF2DA6_8001_4">769468</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1060404" unitRef="iso4217_USD" decimals="-5" id="id_2787876_B0DCCEE5-9359-409E-B55D-7230969CA2AA_1001_0">2300000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1060690" unitRef="iso4217_USD" decimals="-5" id="id_2787876_A34B2E43-8B42-4F47-AE26-6424A695904A_1_0">2200000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1064508" unitRef="iso4217_USD" decimals="0" id="id_2787876_13242280-5928-4811-B200-F93F127B9E9D_1001_0">25000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1115783" unitRef="iso4217_USD" decimals="-5" id="id_2787876_8333AA51-90F2-41F9-93FE-E77FBF342901_1001_0">900000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1218715" unitRef="iso4217_USD" decimals="1" id="id_2787876_B00BF36B-BE5C-40F5-8BD1-788DF6F80A36_1001_400001">190833.0</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_F664745D-171D-4C74-AA93-6DB0B8CD35F2_1001_0">12300000</us-gaap:LicensesRevenue>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1218879" unitRef="iso4217_USD" decimals="-5" id="id_2787876_F664745D-171D-4C74-AA93-6DB0B8CD35F2_1001_1">10000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1218717_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1060690_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1218717_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1060690_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_92_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-07-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_730_20031231_0_932980x930435">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2002-01-01</startDate>
      <endDate>2003-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1218715_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1115783_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1074019_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1060690_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_927195x1060404_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_366_20081231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2008-01-01</startDate>
      <endDate>2008-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_365_20111231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_365_20101231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2010-01-01</startDate>
      <endDate>2010-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_365_20061231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2006-01-01</startDate>
      <endDate>2006-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20080531_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-05-01</startDate>
      <endDate>2008-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20060531_0_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2006-05-01</startDate>
      <endDate>2006-05-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20110331_0_928576x1218824_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-03-01</startDate>
      <endDate>2011-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20131031_0_931707x926487_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20110131_0_932980x1218718_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20110131_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2011-01-01</startDate>
      <endDate>2011-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20101031_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-10-01</startDate>
      <endDate>2010-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20080731_0_928576x1218824_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-07-01</startDate>
      <endDate>2008-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_31_20041031_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2004-10-01</startDate>
      <endDate>2004-10-31</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20101028_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-09-29</startDate>
      <endDate>2010-10-28</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20080930_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-09-01</startDate>
      <endDate>2008-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20020930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2002-09-01</startDate>
      <endDate>2002-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20080716_0_932980x1010406">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:ConvertiblePreferredStockSeriesDMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2008-06-17</startDate>
      <endDate>2008-07-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20080716_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2008-06-17</startDate>
      <endDate>2008-07-16</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20050630_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20050630_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20050630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2005-06-01</startDate>
      <endDate>2005-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_30_20100530_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2010-05-01</startDate>
      <endDate>2010-05-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1218717_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1060690_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_274_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1218712">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesATwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1184171">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesAOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1218846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlanTwoThousandThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_930809x1108152">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockOptionPlan2000Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_930526x932533">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CreditConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_930526x926068">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x931760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x931666">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_929865x1203065">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x997107">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x924898">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928305x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1218717_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1218715_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1218715_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1115783_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1115783_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1074019_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1074019_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentAgenciesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060690_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060690_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060404_931007x926597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927195x1060404_931007x926523">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927015x928963">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_927015x925832">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x923140_930809x1218846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlanTwoThousandThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_932980x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x931760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x929134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x928802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929865x923192">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20111231_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20111231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2011-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20031231_0_932980x930435">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20031231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2003-12-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20131016_0_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20131016_0_931707x926487_932504x931597">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1218715">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:EliLillyMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1115783">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:PfizerIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1064508">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060690">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GileadSciencesIncMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_933025x1060404">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x932774">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x930435">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x930400">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x929177">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1225370">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218718">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesD2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1218712">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesATwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1184171">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesAOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166416">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA2ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1166280">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesA1ConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1124615">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_932980x1031975">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_930809x1108152">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockOptionPlan2000Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x932226">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x931760">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x929134">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x928802">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x923325">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929865x923192">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x929831">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925851">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929790x925736">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_929038x1220599_930809x1218846">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgnx:EquityIncentivePlanTwoThousandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlanTwoThousandThreeMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_928294x1218880_933025x1218879">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:LesLaboratoiresServierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:SecondRightToDevelopCollaborationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_927592x929614">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_926911x929956">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20120930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2012-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20080930_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-09-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20080716_0_926437x932953">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20080716_0_926437x923140">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20080716_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2008-07-16</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20060531_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2006-05-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20050630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2005-06-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20131031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20100530_0_932980x1165094">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:SeriesDTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2010-05-30</instant>
    </period>
  </context>
  <context id="eol_PE179294--1310-Q0003_STD_0_20041031_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001125345</identifier>
    </entity>
    <period>
      <instant>2004-10-31</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="iso4217_USD_per_Warrant">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>mgnx:Warrant</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="Segment">
    <measure>mgnx:Segment</measure>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Molecule">
    <measure>mgnx:Molecule</measure>
  </unit>
  <unit id="Payments">
    <measure>mgnx:Payments</measure>
  </unit>
  <unit id="Program">
    <measure>mgnx:Program</measure>
  </unit>
  <unit id="Age">
    <measure>mgnx:Age</measure>
  </unit>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mgnx-20130930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Schema, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 7 -->
<!-- Creation date: 2013-11-12T20:03:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<schema xmlns="http://www.w3.org/2001/XMLSchema"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:us-gaap="http://fasb.org/us-gaap/2013-01-31"
  xmlns:us-types="http://fasb.org/us-types/2013-01-31"
  xmlns:mgnx="http://www.macrogenics.com/20130930"
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2012-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2013-01-31"
  xmlns:exch="http://xbrl.sec.gov/exch/2013-01-31"
  xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
  targetNamespace="http://www.macrogenics.com/20130930"
  elementFormDefault="qualified" attributeFormDefault="unqualified">
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation" id="DocumentandEntityInformation">
        <link:definition>101 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified" id="Role_StatementOfFinancialPositionClassified">
        <link:definition>103 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical" id="Role_StatementOfFinancialPositionClassifiedParen">
        <link:definition>104 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative" id="Role_StatementOfIncomeAlternative">
        <link:definition>105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect" id="Role_StatementOfCashFlowsIndirect">
        <link:definition>106 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <link:definition>107 - Disclosure - Overview and Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
        <link:definition>108 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
        <link:definition>109 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" id="Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
        <link:definition>110 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <link:definition>111 - Disclosure - Shared-Based Payments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
        <link:definition>112 - Disclosure - Lease Exit Liability</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" id="Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
        <link:definition>113 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
        <link:definition>114 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" id="Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
        <link:definition>115 - Disclosure - Product Milestone Payments and Royalty Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <link:definition>116 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock" id="Role_NotesToFinancialStatementsSubsequentEventsTextBlock">
        <link:definition>117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
        <link:definition>118 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" id="Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
        <link:definition>119 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
        <link:definition>120 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" id="Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
        <link:definition>121 - Disclosure - Shared-Based Payments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
        <link:definition>122 - Disclosure - Lease Exit Liability (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" id="Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
        <link:definition>123 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" id="DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
        <link:definition>124 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
        <link:definition>125 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
        <link:definition>126 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
        <link:definition>127 - Disclosure - Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
        <link:definition>128 - Disclosure - Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" id="DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
        <link:definition>129 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" id="DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
        <link:definition>130 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare">
        <link:definition>131 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Income Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" id="DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
        <link:definition>132 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" id="DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
        <link:definition>133 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation" id="DisclosurePropertyAndEquipmentAdditionalInformation">
        <link:definition>134 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation" id="DisclosureStockholdersEquityDeficitAdditionalInformation">
        <link:definition>135 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation" id="DisclosureSharedBasedPaymentsAdditionalInformation">
        <link:definition>136 - Disclosure - Shared-Based Payments - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" id="DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
        <link:definition>137 - Disclosure - Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" id="DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
        <link:definition>138 - Disclosure - Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" id="DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
        <link:definition>139 - Disclosure - Shared-Based Payments - Schedule of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation" id="DisclosureLeaseExitLiabilityAdditionalInformation">
        <link:definition>140 - Disclosure - Lease Exit Liability - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" id="DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
        <link:definition>141 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" id="DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
        <link:definition>142 - Disclosure - Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
        <link:definition>143 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation" id="DisclosureCommitmentsAndContingenciesAdditionalInformation">
        <link:definition>144 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" id="DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
        <link:definition>145 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" id="DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
        <link:definition>146 - Disclosure - Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation" id="DisclosureEmployeeBenefitPlanAdditionalInformation">
        <link:definition>147 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation" id="DisclosureSubsequentEventsAdditionalInformation">
        <link:definition>148 - Disclosure - Subsequent Events - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:href="mgnx-20130930_cal.xml" xlink:title="Calculation Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:href="mgnx-20130930_def.xml" xlink:title="Definition Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:href="mgnx-20130930_lab.xml" xlink:title="Label Links, all"/>
      <link:linkbaseRef xlink:type="simple" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:href="mgnx-20130930_pre.xml" xlink:title="Presentation Links, all"/>
    </appinfo>
  </annotation>
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://fasb.org/us-types/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-types-2013-01-31.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2013-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2012-01-31" schemaLocation="http://xbrl.sec.gov/currency/2012/currency-2012-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2013-01-31" schemaLocation="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2013-01-31" schemaLocation="http://xbrl.sec.gov/exch/2013/exch-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <element name="AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" id="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalCommonStockIssuePricePerShare" id="mgnx_AdditionalCommonStockIssuePricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPaymentUnderLicensingAndCollaborationAgreement" id="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalPaymentUponAchievementOfMilestone" id="mgnx_AdditionalPaymentUponAchievementOfMilestone" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AdditionalRegulatoryMilestonePaymentsUnderAgreement" id="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="AmountOfAdditionalConsiderationPaidUnderAgreement" id="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="BoehringerIngelheimMember" id="mgnx_BoehringerIngelheimMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalDataReviewPeriodForAgreementTermination" id="mgnx_ClinicalDataReviewPeriodForAgreementTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ClinicalDevelopmentMilestonePaymentsReceived" id="mgnx_ClinicalDevelopmentMilestonePaymentsReceived" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" id="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementEnteredDate" id="mgnx_CollaborationAndLicenseAgreementEnteredDate" type="us-types:dateStringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborationAndLicenseAgreementsDisclosureTextBlock" id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="CollaborativeAgreementPeriodOfContract" id="mgnx_CollaborativeAgreementPeriodOfContract" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" id="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockConversionPrice" id="mgnx_ConvertiblePreferredStockConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ConvertiblePreferredStockSeriesDMember" id="mgnx_ConvertiblePreferredStockSeriesDMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" id="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DepreciationAmortizationImpairmentLineItems" id="mgnx_DepreciationAmortizationImpairmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="DocumentAndEntityInformationAbstract" id="mgnx_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EliLillyMember" id="mgnx_EliLillyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EmployeeEligibleAgeToParticipateInBenefitPlan" id="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlanTwoThousandMember" id="mgnx_EquityIncentivePlanTwoThousandMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="EquityIncentivePlanTwoThousandThreeMember" id="mgnx_EquityIncentivePlanTwoThousandThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="FutureMinimumLeasesPaymentsUnderLeasesTable" id="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="GileadSciencesIncMember" id="mgnx_GileadSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="GreenCrossCorporationMember" id="mgnx_GreenCrossCorporationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="IncreaseDecreaseInDeferredRent" id="mgnx_IncreaseDecreaseInDeferredRent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LaboratoryAndOfficeEquipmentMember" id="mgnx_LaboratoryAndOfficeEquipmentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LeaseExpirationYear" id="mgnx_LeaseExpirationYear" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LesLaboratoiresServierMember" id="mgnx_LesLaboratoiresServierMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsLineItems" id="mgnx_LicenseAndCollaborationAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="LicenseAndCollaborationAgreementsTable" id="mgnx_LicenseAndCollaborationAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="LicenseGrantFeesReceivable" id="mgnx_LicenseGrantFeesReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="MoneyMarketFundsFairValueDisclosure" id="mgnx_MoneyMarketFundsFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NetProceedsFromPublicOfferingOfCommonStock" id="mgnx_NetProceedsFromPublicOfferingOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NonRefundableFees" id="mgnx_NonRefundableFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfAnnualMaintenancePaymentReceived" id="mgnx_NumberOfAnnualMaintenancePaymentReceived" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfLicensedProgramsTypeUnderCollaborationAgreements" id="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfPrograms" id="mgnx_NumberOfPrograms" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" id="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" id="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnetimeMilestonePaymentToBePaidUnderAgreement" id="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" id="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndNatureOfBusinessLineItems" id="mgnx_OrganizationAndNatureOfBusinessLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="OrganizationAndNatureOfBusinessTable" id="mgnx_OrganizationAndNatureOfBusinessTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="PaymentReceivedOnCollaborationAgreement" id="mgnx_PaymentReceivedOnCollaborationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PfizerIncMember" id="mgnx_PfizerIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockMinimumHoldingPercentageForElectionOfDirectors" id="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" id="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" id="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" id="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RavenBiotechnologiesIncMember" id="mgnx_RavenBiotechnologiesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchAndMaintenanceAmountReceivable" id="mgnx_ResearchAndMaintenanceAmountReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ResearchObligationCompletionDate" id="mgnx_ResearchObligationCompletionDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RestrictedCashFairValueDisclosure" id="mgnx_RestrictedCashFairValueDisclosure" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RevenueRecognitionMilestoneMethodRevenueReceivable" id="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementDisclosureTextBlock" id="mgnx_RoyaltyAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementLineItems" id="mgnx_RoyaltyAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="RoyaltyAgreementTable" id="mgnx_RoyaltyAgreementTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" id="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SalesMilestonePayments" id="mgnx_SalesMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SecondRightToDevelopCollaborationMember" id="mgnx_SecondRightToDevelopCollaborationMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA1ConvertiblePreferredStockMember" id="mgnx_SeriesA1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesA2ConvertiblePreferredStockMember" id="mgnx_SeriesA2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesAOnePreferredStockMember" id="mgnx_SeriesAOnePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesATwoPreferredStockMember" id="mgnx_SeriesATwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesBConvertiblePreferredStockMember" id="mgnx_SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesCConvertiblePreferredStockMember" id="mgnx_SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD1ConvertiblePreferredStockMember" id="mgnx_SeriesD1ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesD2ConvertiblePreferredStockMember" id="mgnx_SeriesD2ConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesDConvertiblePreferredStockMember" id="mgnx_SeriesDConvertiblePreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="SeriesDTwoPreferredStockMember" id="mgnx_SeriesDTwoPreferredStockMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ServierMember" id="mgnx_ServierMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityLineItems" id="mgnx_StockholdersEquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockholdersEquityTable" id="mgnx_StockholdersEquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
  <element name="StockIssuanceCosts" id="mgnx_StockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" id="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" id="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="StockOptionPlan2000Member" id="mgnx_StockOptionPlan2000Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontFeeAndParticipationRecognitionDate" id="mgnx_UpfrontFeeAndParticipationRecognitionDate" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="UpfrontPaymentRecognitionPeriod" id="mgnx_UpfrontPaymentRecognitionPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
  <element name="USGovernmentAgenciesMember" id="mgnx_USGovernmentAgenciesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mgnx-20130930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 7 -->
<!-- Creation date: 2013-11-12T20:03:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureStockholdersEquityDeficitAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_LicensesRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1600" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1300" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.0500" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.0600" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0700" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.0800" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve" order="1.0900" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1000" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="mgnx_IncreaseDecreaseInDeferredRent" order="1.1100" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="mgnx_RestrictedCashFairValueDisclosure" order="1.0300" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" order="1.0200" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLoss" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" order="1.0400" weight="-1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0300" weight="-1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" weight="1.00" priority="2" use="optional"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" weight="1.00" priority="2" use="optional"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mgnx-20130930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Definition Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 7 -->
<!-- Creation date: 2013-11-12T20:03:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureStockholdersEquityDeficitAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalCommonStockIssuePricePerShare" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OrganizationAndNatureOfBusinessTable" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_OrganizationAndNatureOfBusinessTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_AdditionalCommonStockIssuePricePerShare" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_RestrictedCashFairValueDisclosure" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.1000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_ServierMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0500" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DepreciationAmortizationImpairmentLineItems" xlink:label="mgnx_DepreciationAmortizationImpairmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_DepreciationAmortizationImpairmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_DepreciationAmortizationImpairmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_DepreciationAmortizationImpairmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NetProceedsFromPublicOfferingOfCommonStock" xlink:label="mgnx_NetProceedsFromPublicOfferingOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" xlink:label="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" xlink:label="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesATwoPreferredStockMember" xlink:label="mgnx_SeriesATwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesDTwoPreferredStockMember" xlink:label="mgnx_SeriesDTwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockholdersEquityLineItems" xlink:label="mgnx_StockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockholdersEquityTable" xlink:label="mgnx_StockholdersEquityTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesDTwoPreferredStockMember" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesAOnePreferredStockMember" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesATwoPreferredStockMember" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockholdersEquityTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockIssuanceCosts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_NetProceedsFromPublicOfferingOfCommonStock" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EquityIncentivePlanTwoThousandMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_EquityIncentivePlanTwoThousandThreeMember" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockOptionPlan2000Member" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mgnx_EquityIncentivePlanTwoThousandMember" order="1.1600" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="1.0800" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_LeaseExpirationYear" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RangeAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0300" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:label="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0100" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" xlink:label="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ClinicalDevelopmentMilestonePaymentsReceived" xlink:label="mgnx_ClinicalDevelopmentMilestonePaymentsReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LesLaboratoiresServierMember" xlink:label="mgnx_LesLaboratoiresServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseGrantFeesReceivable" xlink:label="mgnx_LicenseGrantFeesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NonRefundableFees" xlink:label="mgnx_NonRefundableFees"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" xlink:label="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" xlink:label="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PaymentReceivedOnCollaborationAgreement" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SalesMilestonePayments" xlink:label="mgnx_SalesMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember" order="1.2800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableFees" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseGrantFeesReceivable" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ClinicalDevelopmentMilestonePaymentsReceived" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_SalesMilestonePayments" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" order="1.1300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.1400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" order="1.1500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" order="1.1600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" order="1.1700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived" order="1.1900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_PaymentReceivedOnCollaborationAgreement" order="1.2000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.2100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.2200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract" order="1.2300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfPrograms" order="1.2400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionDate" order="1.2500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ClinicalDataReviewPeriodForAgreementTermination" order="1.2600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_LesLaboratoiresServierMember" order="1.2700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.3000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.3100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_PfizerIncMember" order="1.3200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.3300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_EliLillyMember" order="1.3400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyAgreementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="us-gaap_RangeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ResearchAndMaintenanceAmountReceivable" xlink:label="mgnx_ResearchAndMaintenanceAmountReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" xlink:label="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_ResearchAndMaintenanceAmountReceivable" order="1.0900" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="1.0000" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0700" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1.0800" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="100.0000" xbrldt:closed="true" xbrldt:contextElement="segment" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0200" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0300" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1.0400" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0500" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0600" priority="2" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" priority="2" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mgnx-20130930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Labels Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 7 -->
<!-- Creation date: 2013-11-12T20:03:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_2787876_928978_1_1">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" id="id_2787876_928978_2_1">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_2787876_933775_1_1">Accounts Payable Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" id="id_2787876_933775_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_2787876_926523_1_1">Accounts Receivable [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US" id="id_2787876_926523_2_1">Accounts Receivable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_2787876_938700_1_1">Accounts Receivable Net Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_2787876_938700_2_1">Accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" id="id_2787876_938700_12_1">Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2787876_933113_1_1">Accrued Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2787876_933113_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_2787876_933479_1_1">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_2787876_933479_14_1">Less accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1175455_3_1">Aggregate potential remaining clinical milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1175455_1_1">Additional Clinical Development Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1175455_2_1">Clinical milestone payments under agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalCommonStockIssuePricePerShare" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare_lbl" xml:lang="en-US" id="id_2787876_1096799_3_1">Additional common stock issue price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare_lbl" xml:lang="en-US" id="id_2787876_1096799_1_1">Additional Common Stock Issue Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare_lbl" xml:lang="en-US" id="id_2787876_1096799_2_1">Initial public offering price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalCommonStockIssuePricePerShare" xlink:to="mgnx_AdditionalCommonStockIssuePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_2787876_933723_1_1">Additional Paid In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" id="id_2787876_933723_2_1">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" xlink:label="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement_lbl" xml:lang="en-US" id="id_2787876_1098092_3_1">Additional payment under licensing and collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement_lbl" xml:lang="en-US" id="id_2787876_1098092_1_1">Additional Payment Under Licensing And Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement_lbl" xml:lang="en-US" id="id_2787876_1098092_2_1">Additional license grant fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" xlink:to="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_2787876_959178_3_1">Additional payment upon achievement of milestone.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_2787876_959178_1_1">Additional Payment Upon Achievement Of Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl" xml:lang="en-US" id="id_2787876_959178_2_1">Additional consideration of asset purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1155390_3_1">Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1155390_1_1">Additional Regulatory Milestone Payments Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1155390_2_1">Regulatory milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:to="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_929248_1_1">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_929248_2_1">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_2787876_940280_1_1">Allocated Share Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" id="id_2787876_940280_2_1">Stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_2787876_921947_1_1">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" id="id_2787876_921947_2_1">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1218876_3_1">Amount of additional consideration paid under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1218876_1_1">Amount Of Additional Consideration Paid Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1218876_2_1">Payments related to the additional considerations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_2787876_931668_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" id="id_2787876_931668_2_1">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_2787876_928305_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" id="id_2787876_928305_2_1">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_2787876_923482_1_1">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" id="id_2787876_923482_2_1">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_2787876_927484_1_1">Antidilutive Securities Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" id="id_2787876_927484_2_1">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_2787876_930670_1_1">Arrangements And Nonarrangement Transactions [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" id="id_2787876_930670_2_1">Arrangements and Non-arrangement Transactions [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_2787876_938186_1_1">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" id="id_2787876_938186_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_2787876_928450_1_1">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" id="id_2787876_928450_2_1">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_2787876_937150_1_1">Assets Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" id="id_2787876_937150_6_1">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_2787876_926145_1_1">Assets Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" id="id_2787876_926145_2_1">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_938194_1_1">Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_938194_6_1">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_926213_1_1">Assets Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_926213_2_1">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_2787876_929038_1_1">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" id="id_2787876_929038_2_1">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_2787876_1060404_3_1">Boehringer Ingelheim International GmbH.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_2787876_1060404_1_1">Boehringer Ingelheim [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_BoehringerIngelheimMember_lbl" xml:lang="en-US" id="id_2787876_1060404_2_1">Boehringer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_BoehringerIngelheimMember" xlink:to="mgnx_BoehringerIngelheimMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_2787876_926379_1_1">Business Acquisition Acquiree [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US" id="id_2787876_926379_2_1">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_2787876_928576_1_1">Business Acquisition [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US" id="id_2787876_928576_2_1">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_2787876_928408_1_1">Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xml:lang="en-US" id="id_2787876_928408_2_1">Shares issued to acquire entity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2787876_938283_1_1">Cash And Cash Equivalents At Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2787876_938283_4_1">Cash and cash equivalents at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2787876_938283_5_1">Cash and cash equivalents at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" id="id_2787876_938283_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_938170_1_1">Cash And Cash Equivalents Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_938170_2_1">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_2787876_938600_1_1">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US" id="id_2787876_938600_6_1">Net change in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_928679_1_1">Cash And Cash Equivalents Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_928679_2_1">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_2787876_925153_1_1">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" id="id_2787876_925153_2_1">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_2787876_932584_1_1">Class Of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" id="id_2787876_932584_2_1">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_2787876_932954_1_1">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" id="id_2787876_932954_2_1">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_2787876_925087_1_1">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" id="id_2787876_925087_2_1">Purchased shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl" xml:lang="en-US" id="id_2787876_1218977_3_1">Clinical data review period for agreement termination.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl" xml:lang="en-US" id="id_2787876_1218977_1_1">Clinical Data Review Period For Agreement Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl" xml:lang="en-US" id="id_2787876_1218977_2_1">Review of clinical data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:to="mgnx_ClinicalDataReviewPeriodForAgreementTermination_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ClinicalDevelopmentMilestonePaymentsReceived" xlink:label="mgnx_ClinicalDevelopmentMilestonePaymentsReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ClinicalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" id="id_2787876_1175461_3_1">Clinical development milestone payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ClinicalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" id="id_2787876_1175461_1_1">Clinical Development Milestone Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ClinicalDevelopmentMilestonePaymentsReceived_lbl" xml:lang="en-US" id="id_2787876_1175461_2_1">Clinical milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ClinicalDevelopmentMilestonePaymentsReceived" xlink:to="mgnx_ClinicalDevelopmentMilestonePaymentsReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:label="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl" xml:lang="en-US" id="id_2787876_1074447_3_1">Clone 1 Of Future Minimum Leases Payments Under Leases (Line Items)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl" xml:lang="en-US" id="id_2787876_1074447_1_1">Clone Of Future Minimum Leases Payments Under Leases [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl" xml:lang="en-US" id="id_2787876_1074447_2_1">Clone 1 Of Future Minimum Leases Payments Under Leases (Line Items)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_2787876_1095244_3_1">Collaboration and license agreement entered date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_2787876_1095244_1_1">Collaboration And License Agreement Entered Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl" xml:lang="en-US" id="id_2787876_1095244_2_1">Collaboration agreement date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_1218875_3_1">Collaboration and license agreements disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_1218875_1_1">Collaboration And License Agreements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_1218875_2_1">Collaboration and License Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:to="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_2787876_1054969_3_1">Collaborative agreement period of contract.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_2787876_1054969_1_1">Collaborative Agreement Period Of Contract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract_lbl" xml:lang="en-US" id="id_2787876_1054969_2_1">Period of agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_CollaborativeAgreementPeriodOfContract" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_930041_1_1">Commitments And Contingencies Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_930041_2_1">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_923990_1_1">Commitments And Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_923990_2_1">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_2787876_925879_1_1">Common Stock Capital Shares Reserved For Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" id="id_2787876_925879_2_1">Reserved common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_2787876_931741_1_1">Common Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_2787876_931741_2_1">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_930676_1_1">Common Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_930676_2_1">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_2787876_925763_1_1">Common Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" id="id_2787876_925763_2_1">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_923588_1_1">Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_923588_2_1">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US" id="id_2787876_932891_1_1">Common Stock Shares Subscribed But Unissued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US" id="id_2787876_932891_2_1">Shares of common stock allocated but unissued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_2787876_935685_1_1">Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" id="id_2787876_935685_2_1">Common stock, $0.01 par value - 425,000,000 shares authorized, 2,124,624 and 1,098,914 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_929610_1_1">Compensation And Retirement Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_929610_2_1">Compensation and Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_930849_1_1">Compensation Related Costs Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_930849_2_1">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_925034_1_1">Comprehensive Income Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_925034_2_1">Comprehensive Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_931760_1_1">Computer Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_931760_2_1">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US" id="id_2787876_931666_1_1">Computer Software Intangible Asset [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US" id="id_2787876_931666_2_1">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="id_2787876_932519_1_1">Concentration Risk Benchmark [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" id="id_2787876_932519_2_1">Concentration Risk Benchmark [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="id_2787876_931007_1_1">Concentration Risk By Benchmark [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" id="id_2787876_931007_2_1">Concentration Risk Benchmark [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_2787876_930526_1_1">Concentration Risk By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" id="id_2787876_930526_2_1">Concentration Risk Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_2787876_930739_1_1">Concentration Risk Credit Risk</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" id="id_2787876_930739_2_1">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="id_2787876_932490_1_1">Concentration Risk [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" id="id_2787876_932490_2_1">Concentration Risk [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_2787876_931347_1_1">Concentration Risk Percentage 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_2787876_931347_2_1">Percentage of all significant revenue earned</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" id="id_2787876_931347_12_1">Significant Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="id_2787876_929058_1_1">Concentration Risk [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" id="id_2787876_929058_2_1">Concentration Risk [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_2787876_927911_1_1">Concentration Risk Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" id="id_2787876_927911_2_1">Concentration Risk Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2787876_1218865_3_1">Contingent consideration recorded as incremental in process research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2787876_1218865_1_1">Contingent Consideration Recorded As Incremental In Process Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2787876_1218865_2_1">Additional amounts recorded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" id="id_2787876_929956_1_1">Contract Termination [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US" id="id_2787876_929956_2_1">Contract Termination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_2787876_1042584_3_1">Convertible preferred stock conversion price.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_2787876_1042584_1_1">Convertible Preferred Stock Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice_lbl" xml:lang="en-US" id="id_2787876_1042584_2_1">Conversion price of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ConvertiblePreferredStockConversionPrice" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_2787876_1010406_3_1">Convertible preferred stock series D.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_2787876_1010406_1_1">Convertible Preferred Stock Series D [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember_lbl" xml:lang="en-US" id="id_2787876_1010406_2_1">Convertible Preferred Stock Series D [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ConvertiblePreferredStockSeriesDMember" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_2787876_931255_1_1">Convertible Preferred Stock Shares Issued Upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" id="id_2787876_931255_2_1">Convertible preferred stock series</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_2787876_937189_1_1">Costs And Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US" id="id_2787876_937189_6_1">Total costs and expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_2787876_927176_1_1">Costs And Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesAbstract_lbl" xml:lang="en-US" id="id_2787876_927176_2_1">Costs and expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_2787876_933025_1_1">Counterparty Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xml:lang="en-US" id="id_2787876_933025_2_1">Counterparty Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="id_2787876_932533_1_1">Credit Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CreditConcentrationRiskMember_lbl" xml:lang="en-US" id="id_2787876_932533_2_1">Summary of Significant Accounts Receivable[Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditConcentrationRiskMember" xlink:to="us-gaap_CreditConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_2787876_922004_1_1">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" id="id_2787876_922004_2_1">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="id_2787876_926068_1_1">Customer Concentration Risk [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US" id="id_2787876_926068_2_1">Summary of Significant Revenue [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_928138_1_1">Deferred Charges Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_928138_2_1">Deferred Intial Public Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US" id="id_2787876_930500_1_1">Deferred Compensation Arrangement With Individual Share Based Payments [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US" id="id_2787876_930500_2_1">Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_2787876_935667_1_1">Deferred Rent Credit Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" id="id_2787876_935667_2_1">Deferred rent liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_2787876_935260_1_1">Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US" id="id_2787876_935260_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_2787876_935460_1_1">Deferred Revenue Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_2787876_935460_2_1">Deferred revenue - current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US" id="id_2787876_935460_12_1">Deferred revenue included in current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_2787876_936354_1_1">Deferred Revenue Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_2787876_936354_2_1">Deferred revenue included in long-term liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US" id="id_2787876_936354_12_1">Deferred revenue, net of current portion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_927219_1_1">Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_927219_2_1">Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_2787876_1218878_3_1">Defined contribution plan, employees contribution, annual vesting percentage.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_2787876_1218878_1_1">Defined Contribution Plan Employees Contribution Annual Vesting Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl" xml:lang="en-US" id="id_2787876_1218878_2_1">Percentage of employee vested contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:to="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_2787876_938911_1_1">Defined Contribution Plan Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" id="id_2787876_938911_2_1">Company's contribution to plan total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_2787876_926177_1_1">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US" id="id_2787876_926177_2_1">Percentage of employee contribution to salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_2787876_940263_1_1">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US" id="id_2787876_940263_2_1">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DepreciationAmortizationImpairmentLineItems" xlink:label="mgnx_DepreciationAmortizationImpairmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DepreciationAmortizationImpairmentLineItems_lbl" xml:lang="en-US" id="id_2787876_1006656_3_1">Depreciation Amortization Impairment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DepreciationAmortizationImpairmentLineItems_lbl" xml:lang="en-US" id="id_2787876_1006656_1_1">Depreciation Amortization Impairment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DepreciationAmortizationImpairmentLineItems_lbl" xml:lang="en-US" id="id_2787876_1006656_2_1">Depreciation Amortization Impairment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DepreciationAmortizationImpairmentLineItems" xlink:to="mgnx_DepreciationAmortizationImpairmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_2787876_939791_1_1">Depreciation Depletion And Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" id="id_2787876_939791_2_1">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_2787876_930617_1_1">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" id="id_2787876_930617_2_1">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_2787876_923166_1_1">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" id="id_2787876_923166_2_1">Shared-Based Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="mgnx_DocumentAndEntityInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_2787876_951207_3_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_2787876_951207_1_1">Document And Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" id="id_2787876_951207_2_1">Document And Entity Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="mgnx_DocumentAndEntityInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_2787876_922019_1_1">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" id="id_2787876_922019_2_1">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_2787876_921974_1_1">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" id="id_2787876_921974_2_1">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_2787876_921989_1_1">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" id="id_2787876_921989_2_1">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_2787876_921984_1_1">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" id="id_2787876_921984_2_1">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_2787876_925621_1_1">Earnings Per Share Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_2787876_925621_2_1">Basic income (loss) per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" id="id_2787876_925621_12_1">Basic net income (loss) per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_2787876_924397_1_1">Earnings Per Share Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_2787876_924397_2_1">Diluted income per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" id="id_2787876_924397_12_1">Diluted net income (loss) per common share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_931897_1_1">Earnings Per Share Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_931897_2_1">Net Income (Loss) Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_2787876_1218715_3_1">Eli Lilly &amp; Co.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_2787876_1218715_1_1">Eli Lilly [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EliLillyMember_lbl" xml:lang="en-US" id="id_2787876_1218715_2_1">Eli Lilly [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EliLillyMember" xlink:to="mgnx_EliLillyMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_2787876_1055795_3_1">Employee eligible age to participate in benefit plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_2787876_1055795_1_1">Employee Eligible Age To Participate In Benefit Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl" xml:lang="en-US" id="id_2787876_1055795_2_1">Eligibility of employee participation plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" xlink:to="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_2787876_932976_1_1">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" id="id_2787876_932976_2_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_2787876_940160_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" id="id_2787876_940160_2_1">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_2787876_929567_1_1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" id="id_2787876_929567_2_1">Unrecognized compensation expense recognition period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_2787876_924898_1_1">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" id="id_2787876_924898_2_1">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_2787876_921997_1_1">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" id="id_2787876_921997_2_1">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_922042_1_1">Entity Common Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_922042_2_1">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_2787876_921955_1_1">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" id="id_2787876_921955_2_1">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US" id="id_2787876_921996_1_1">Entity Incorporation Date Of Incorporation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xml:lang="en-US" id="id_2787876_921996_2_1">MacroGenics incorporated date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_2787876_921937_1_1">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" id="id_2787876_921937_2_1">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_2787876_928802_1_1">Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" id="id_2787876_928802_2_1">Lab Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_2787876_932367_1_1">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" id="id_2787876_932367_2_1">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_2787876_927325_1_1">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" id="id_2787876_927325_2_1">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EquityIncentivePlanTwoThousandMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EquityIncentivePlanTwoThousandMember_lbl" xml:lang="en-US" id="id_2787876_1220599_3_1">Equity incentive plan two thousand.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EquityIncentivePlanTwoThousandMember_lbl" xml:lang="en-US" id="id_2787876_1220599_1_1">Equity Incentive Plan Two Thousand [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EquityIncentivePlanTwoThousandMember_lbl" xml:lang="en-US" id="id_2787876_1220599_2_1">Equity Incentive Plan Two Thousand [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EquityIncentivePlanTwoThousandMember" xlink:to="mgnx_EquityIncentivePlanTwoThousandMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl" xml:lang="en-US" id="id_2787876_1218846_3_1">Equity incentive plan two thousand three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl" xml:lang="en-US" id="id_2787876_1218846_1_1">Equity Incentive Plan Two Thousand Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl" xml:lang="en-US" id="id_2787876_1218846_2_1">Equity Incentive Plan 2003 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:to="mgnx_EquityIncentivePlanTwoThousandThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_2787876_937097_1_1">Fair Value Adjustment Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" id="id_2787876_937097_2_1">Fair value adjustment of warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_2787876_928161_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" id="id_2787876_928161_2_1">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_2787876_932133_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" id="id_2787876_932133_2_1">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_926674_1_1">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_926674_2_1">Summary of Fair Value Measurement Financial Asset and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_2787876_929790_1_1">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" id="id_2787876_929790_2_1">Fair Value, Hierarchy [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_2787876_925736_1_1">Fair Value Inputs Level 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" id="id_2787876_925736_2_1">Quoted Prices in Active Markets for Identical Assets Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_2787876_925851_1_1">Fair Value Inputs Level 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" id="id_2787876_925851_2_1">Significant Other Observable Inputs Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_2787876_929831_1_1">Fair Value Inputs Level 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US" id="id_2787876_929831_2_1">Significant Unobservable Inputs Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" id="id_2787876_934853_1_1">Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl" xml:lang="en-US" id="id_2787876_934853_2_1">Total unrealized gains (losses) included in earnings</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_2787876_925195_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xml:lang="en-US" id="id_2787876_925195_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_2787876_927929_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US" id="id_2787876_927929_2_1">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_2787876_927992_1_1">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US" id="id_2787876_927992_2_1">Summary of Preferred Stock Warrant Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_2787876_930398_1_1">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" id="id_2787876_930398_2_1">Fair Value Hierarchy [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_2787876_934561_1_1">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_2787876_934561_16_1">Balance end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xml:lang="en-US" id="id_2787876_934561_17_1">Balance beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_2787876_931938_1_1">Fair Value Of Financial Instruments Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" id="id_2787876_931938_2_1">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_2787876_932226_1_1">Furniture And Fixtures [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" id="id_2787876_932226_2_1">Furniture [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_2787876_1079572_3_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_2787876_1079572_1_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl" xml:lang="en-US" id="id_2787876_1079572_2_1">Future Minimum Leases Payments Under Leases [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_2787876_937408_1_1">General And Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" id="id_2787876_937408_2_1">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_2787876_925832_1_1">General And Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" id="id_2787876_925832_2_1">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_2787876_1060690_3_1">Gilead Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_2787876_1060690_1_1">Gilead Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GileadSciencesIncMember_lbl" xml:lang="en-US" id="id_2787876_1060690_2_1">Gilead [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GileadSciencesIncMember" xlink:to="mgnx_GileadSciencesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_2787876_1064508_3_1">Green Cross Corporation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_2787876_1064508_1_1">Green Cross Corporation [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_GreenCrossCorporationMember_lbl" xml:lang="en-US" id="id_2787876_1064508_2_1">Green Cross Corporation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_GreenCrossCorporationMember" xlink:to="mgnx_GreenCrossCorporationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairedFinancingReceivableRelatedAllowance" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance_lbl" xml:lang="en-US" id="id_2787876_935402_1_1">Impaired Financing Receivable Related Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance_lbl" xml:lang="en-US" id="id_2787876_935402_2_1">Allowance Recorded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairedFinancingReceivableRelatedAllowance" xlink:to="us-gaap_ImpairedFinancingReceivableRelatedAllowance_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_931752_1_1">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_931752_2_1">Impairment of Long-Lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_2787876_927850_1_1">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" id="id_2787876_927850_2_1">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_2787876_927015_1_1">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" id="id_2787876_927015_2_1">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_2787876_931901_1_1">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" id="id_2787876_931901_2_1">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_2787876_938987_1_1">Increase Decrease In Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" id="id_2787876_938987_2_1">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_2787876_935454_1_1">Increase Decrease In Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" id="id_2787876_935454_14_1">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_2787876_938916_1_1">Increase Decrease In Accrued Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" id="id_2787876_938916_2_1">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_2787876_947179_3_1">Increase decrease in deferred rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_2787876_947179_1_1">Increase Decrease In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" id="id_2787876_947179_2_1">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_IncreaseDecreaseInDeferredRent" xlink:to="mgnx_IncreaseDecreaseInDeferredRent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_2787876_938117_1_1">Increase Decrease In Deferred Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US" id="id_2787876_938117_2_1">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_2787876_924543_1_1">Increase Decrease In Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" id="id_2787876_924543_2_1">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_2787876_934983_1_1">Increase Decrease In Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" id="id_2787876_934983_14_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl" xml:lang="en-US" id="id_2787876_939820_1_1">Increase Decrease In Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl" xml:lang="en-US" id="id_2787876_939820_2_1">Lease exit liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_2787876_926487_1_1">I P O [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" id="id_2787876_926487_2_1">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_1203065_3_1">Laboratory and office equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_1203065_1_1">Laboratory And Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_1203065_2_1">Laboratory and Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LaboratoryAndOfficeEquipmentMember" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_2787876_929765_1_1">Lease Expiration Date 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US" id="id_2787876_929765_2_1">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_2787876_1088217_3_1">Lease expiration year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_2787876_1088217_1_1">Lease Expiration Year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LeaseExpirationYear_lbl" xml:lang="en-US" id="id_2787876_1088217_2_1">Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LeaseExpirationYear" xlink:to="mgnx_LeaseExpirationYear_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_2787876_923325_1_1">Leasehold Improvements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" id="id_2787876_923325_2_1">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LesLaboratoiresServierMember" xlink:label="mgnx_LesLaboratoiresServierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LesLaboratoiresServierMember_lbl" xml:lang="en-US" id="id_2787876_1218879_3_1">Les Laboratoires Servier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LesLaboratoiresServierMember_lbl" xml:lang="en-US" id="id_2787876_1218879_1_1">Les Laboratoires Servier [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LesLaboratoiresServierMember_lbl" xml:lang="en-US" id="id_2787876_1218879_2_1">Les Laboratoires Servier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LesLaboratoiresServierMember" xlink:to="mgnx_LesLaboratoiresServierMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_2787876_936129_1_1">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" id="id_2787876_936129_6_1">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_2787876_935778_1_1">Liabilities And Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" id="id_2787876_935778_6_1">Total liabilities and stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2787876_924388_1_1">Liabilities And Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2787876_924388_2_1">Liabilities and stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2787876_934201_1_1">Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" id="id_2787876_934201_6_1">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_2787876_929787_1_1">Liabilities Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" id="id_2787876_929787_2_1">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_929095_1_1">Liabilities Fair Value Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US" id="id_2787876_929095_2_1">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_2787876_1007346_3_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_2787876_1007346_1_1">License And Collaboration Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl" xml:lang="en-US" id="id_2787876_1007346_2_1">License And Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_2787876_1051041_3_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_2787876_1051041_1_1">License And Collaboration Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable_lbl" xml:lang="en-US" id="id_2787876_1051041_2_1">License And Collaboration Agreements [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseGrantFeesReceivable" xlink:label="mgnx_LicenseGrantFeesReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_LicenseGrantFeesReceivable_lbl" xml:lang="en-US" id="id_2787876_1218877_3_1">Aggregate potential remaining license grant fee payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_LicenseGrantFeesReceivable_lbl" xml:lang="en-US" id="id_2787876_1218877_1_1">License Grant Fees Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_LicenseGrantFeesReceivable_lbl" xml:lang="en-US" id="id_2787876_1218877_2_1">License grant fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_LicenseGrantFeesReceivable" xlink:to="mgnx_LicenseGrantFeesReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_2787876_934341_1_1">Licenses Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_2787876_934341_2_1">Recognized revenue under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicensesRevenue_lbl" xml:lang="en-US" id="id_2787876_934341_12_1">Revenue from collaborative research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="id_2787876_927195_1_1">Major Customers [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MajorCustomersAxis_lbl" xml:lang="en-US" id="id_2787876_927195_2_1">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_2787876_923140_1_1">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US" id="id_2787876_923140_2_1">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_2787876_932953_1_1">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US" id="id_2787876_932953_2_1">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_1138489_3_1">Money market funds fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_1138489_1_1">Money Market Funds Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_1138489_2_1">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_MoneyMarketFundsFairValueDisclosure" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="id_2787876_925477_1_1">Name Of Major Customer [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NameOfMajorCustomerDomain_lbl" xml:lang="en-US" id="id_2787876_925477_2_1">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="us-gaap_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_2787876_937453_1_1">Net Cash Provided By Used In Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" id="id_2787876_937453_6_1">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_924600_1_1">Net Cash Provided By Used In Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_924600_2_1">Cash flows from financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_2787876_939292_1_1">Net Cash Provided By Used In Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" id="id_2787876_939292_6_1">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_924425_1_1">Net Cash Provided By Used In Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_924425_2_1">Cash flows from investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_2787876_928832_1_1">Net Cash Provided By Used In Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" id="id_2787876_928832_6_1">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_930909_1_1">Net Cash Provided By Used In Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_930909_2_1">Operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_935636_1_1">Net Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_935636_32_1">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_935636_2_1">Net income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_935636_6_1">Net comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_935636_12_1">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_2787876_933727_1_1">Net Income Loss Available To Common Stockholders Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" id="id_2787876_933727_6_1">Net income (loss) allocable to common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_2787876_934779_1_1">Net Income Loss Available To Common Stockholders Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US" id="id_2787876_934779_6_1">Net income (loss) allocable to common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NetProceedsFromPublicOfferingOfCommonStock" xlink:label="mgnx_NetProceedsFromPublicOfferingOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NetProceedsFromPublicOfferingOfCommonStock_lbl" xml:lang="en-US" id="id_2787876_1223311_3_1">Net proceeds from public offering of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NetProceedsFromPublicOfferingOfCommonStock_lbl" xml:lang="en-US" id="id_2787876_1223311_1_1">Net Proceeds From Public Offering Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NetProceedsFromPublicOfferingOfCommonStock_lbl" xml:lang="en-US" id="id_2787876_1223311_2_1">Net proceeds from underwritten public offering upon closing of firm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NetProceedsFromPublicOfferingOfCommonStock" xlink:to="mgnx_NetProceedsFromPublicOfferingOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_923522_1_1">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_923522_2_1">Recently Issued Accounting Standards Adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NonRefundableFees" xlink:label="mgnx_NonRefundableFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NonRefundableFees_lbl" xml:lang="en-US" id="id_2787876_980010_3_1">Initial fee received from collaboration or license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NonRefundableFees_lbl" xml:lang="en-US" id="id_2787876_980010_1_1">Non Refundable Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NonRefundableFees_lbl" xml:lang="en-US" id="id_2787876_980010_2_1">Non-refundable upfront payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NonRefundableFees" xlink:to="mgnx_NonRefundableFees_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_2787876_1218889_3_1">Number of annual maintenance payment received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_2787876_1218889_1_1">Number Of Annual Maintenance Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl" xml:lang="en-US" id="id_2787876_1218889_2_1">Number of annual maintenance payments received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" xlink:label="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements_lbl" xml:lang="en-US" id="id_2787876_1200246_3_1">Number of programs for which collaborator has worldwide rights.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements_lbl" xml:lang="en-US" id="id_2787876_1200246_1_1">Number Of Licensed Programs Type Under Collaboration Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements_lbl" xml:lang="en-US" id="id_2787876_1200246_2_1">Molecules having exclusive worldwide rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" xlink:to="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_2787876_1218881_3_1">Number of molecules to be developed and commercialized as per collaborations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_2787876_1218881_1_1">Number Of Molecules To Be Developed And Commercialized As Per Collaborations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl" xml:lang="en-US" id="id_2787876_1218881_2_1">Commercialization of molecules</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_2787876_923679_1_1">Number Of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" id="id_2787876_923679_2_1">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_2787876_994023_3_1">Number of programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_2787876_994023_1_1">Number Of Programs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfPrograms_lbl" xml:lang="en-US" id="id_2787876_994023_2_1">DART program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfPrograms" xlink:to="mgnx_NumberOfPrograms_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" xlink:label="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights_lbl" xml:lang="en-US" id="id_2787876_1218887_3_1">Number of programs for which company retains development and commercialization rights in certain countries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights_lbl" xml:lang="en-US" id="id_2787876_1218887_1_1">Number Of Programs Under Foreign Development And Commercialization Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights_lbl" xml:lang="en-US" id="id_2787876_1218887_2_1">Number of programs Company retains development and commercialization rights outside</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" xlink:to="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_2787876_1218874_3_1">Number of shares which could be issued as additional consideration under asset purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_2787876_1218874_1_1">Number Of Shares Issued As Additional Consideration Under Asset Purchase Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl" xml:lang="en-US" id="id_2787876_1218874_2_1">Common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:to="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_923192_1_1">Office Equipment [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" id="id_2787876_923192_2_1">Office Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1088486_3_1">One-time milestone payment to be paid under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1088486_1_1">Onetime Milestone Payment To Be Paid Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl" xml:lang="en-US" id="id_2787876_1088486_2_1">Onetime purchase payment under purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_2787876_1218863_3_1">One-time milestone payment to be paid under agreement upon specified level of sales of products.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_2787876_1218863_1_1">Onetime Milestone Payment To Be Paid Under Agreement Upon Specified Level Of Sales Of Products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl" xml:lang="en-US" id="id_2787876_1218863_2_1">Onetime payment paid under license of product</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_934856_1_1">Operating Income Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" id="id_2787876_934856_6_1">Income (loss) from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_2787876_933732_1_1">Operating Leases Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_2787876_933732_2_1">Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" id="id_2787876_933732_6_1">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_2787876_936689_1_1">Operating Leases Future Minimum Payments Due Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" id="id_2787876_936689_2_1">2014</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_2787876_935061_1_1">Operating Leases Future Minimum Payments Due In Five Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US" id="id_2787876_935061_2_1">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_2787876_934077_1_1">Operating Leases Future Minimum Payments Due In Four Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US" id="id_2787876_934077_2_1">2017</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_2787876_936161_1_1">Operating Leases Future Minimum Payments Due In Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" id="id_2787876_936161_2_1">2016</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_2787876_933250_1_1">Operating Leases Future Minimum Payments Due In Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" id="id_2787876_933250_2_1">2015</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_2787876_934235_1_1">Operating Leases Future Minimum Payments Due Thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US" id="id_2787876_934235_2_1">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_930013_1_1">Operating Leases Of Lessee Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_930013_2_1">Schedule of Minimum Future Lease Payments Payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_2787876_938759_1_1">Operating Leases Rent Expense Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" id="id_2787876_938759_2_1">Rent expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_2787876_971196_3_1">Organization And Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_2787876_971196_1_1">Organization And Nature Of Business [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl" xml:lang="en-US" id="id_2787876_971196_2_1">Organization And Nature Of Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_OrganizationAndNatureOfBusinessLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OrganizationAndNatureOfBusinessTable" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable_lbl" xml:lang="en-US" id="id_2787876_986628_3_1">Organization And Nature Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable_lbl" xml:lang="en-US" id="id_2787876_986628_1_1">Organization And Nature Of Business [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable_lbl" xml:lang="en-US" id="id_2787876_986628_2_1">Organization And Nature Of Business [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="mgnx_OrganizationAndNatureOfBusinessTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_2787876_927825_1_1">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" id="id_2787876_927825_2_1">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_931858_1_1">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_931858_2_1">Overview and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_2787876_937594_1_1">Other Assets Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" id="id_2787876_937594_2_1">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_2787876_934087_1_1">Other Nonoperating Income Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" id="id_2787876_934087_2_1">Other income (expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings_lbl" xml:lang="en-US" id="id_2787876_940189_1_1">Participating Securities Distributed And Undistributed Earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings_lbl" xml:lang="en-US" id="id_2787876_940189_14_1">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PaymentReceivedOnCollaborationAgreement" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement_lbl" xml:lang="en-US" id="id_2787876_1095988_3_1">Total cumulative payments received to date under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement_lbl" xml:lang="en-US" id="id_2787876_1095988_1_1">Payment Received On Collaboration Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement_lbl" xml:lang="en-US" id="id_2787876_1095988_2_1">Received including upfront, annual maintenance and milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PaymentReceivedOnCollaborationAgreement" xlink:to="mgnx_PaymentReceivedOnCollaborationAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" id="id_2787876_936416_1_1">Payments For Restructuring</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRestructuring_lbl" xml:lang="en-US" id="id_2787876_936416_14_1">Principal payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRestructuring" xlink:to="us-gaap_PaymentsForRestructuring_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_2787876_936514_1_1">Payments To Acquire Property Plant And Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" id="id_2787876_936514_14_1">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_930605_1_1">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_930605_2_1">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_2787876_1115783_3_1">Pfizer Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_2787876_1115783_1_1">Pfizer Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PfizerIncMember_lbl" xml:lang="en-US" id="id_2787876_1115783_2_1">Pfizer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PfizerIncMember" xlink:to="mgnx_PfizerIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_2787876_930809_1_1">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" id="id_2787876_930809_2_1">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_2787876_931386_1_1">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" id="id_2787876_931386_2_1">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="id_2787876_924435_1_1">Preferred Stock Dividend Rate Per Dollar Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl" xml:lang="en-US" id="id_2787876_924435_2_1">Accrued noncumulative dividends on preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" id="id_2787876_925867_1_1">Preferred Stock Liquidation Preference</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreference_lbl" xml:lang="en-US" id="id_2787876_925867_2_1">Earning per share received by the shareholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreference" xlink:to="us-gaap_PreferredStockLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="id_2787876_934823_1_1">Preferred Stock Liquidation Preference Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xml:lang="en-US" id="id_2787876_934823_2_1">Aggregate liquidation preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" xlink:label="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors_lbl" xml:lang="en-US" id="id_2787876_1219046_3_1">Preferred stock minimum holding percentage for elect to convert all outstanding shares of preferred stock into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors_lbl" xml:lang="en-US" id="id_2787876_1219046_1_1">Preferred Stock Minimum Holding Percentage For Election Of Directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors_lbl" xml:lang="en-US" id="id_2787876_1219046_2_1">Percentage of preferred stock holders with voting rights of board members</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" xlink:to="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_2787876_932596_1_1">Preferred Stock Par Or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" id="id_2787876_932596_2_1">Convertible preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_929540_1_1">Preferred Stock Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_929540_2_1">Convertible preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_2787876_932934_1_1">Preferred Stock Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" id="id_2787876_932934_2_1">Convertible preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_926142_1_1">Preferred Stock Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_926142_2_1">Convertible preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_926142_12_1">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_2787876_933055_1_1">Preferred Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" id="id_2787876_933055_2_1">Convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" xlink:label="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold_lbl" xml:lang="en-US" id="id_2787876_1219045_3_1">Preferred stock voting rights as separate class holding percentage threshold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold_lbl" xml:lang="en-US" id="id_2787876_1219045_1_1">Preferred Stock Voting Rights As Separate Class Holding Percentage Threshold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold_lbl" xml:lang="en-US" id="id_2787876_1219045_2_1">Outstanding stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" xlink:to="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_2787876_937707_1_1">Prepaid Expense Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" id="id_2787876_937707_2_1">Prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_2787876_939370_1_1">Proceeds From Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" id="id_2787876_939370_2_1">Proceeds from initial public offering net of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl" xml:lang="en-US" id="id_2787876_961833_3_1">Proceeds from issuance initial public offering before offering expenses.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl" xml:lang="en-US" id="id_2787876_961833_1_1">Proceeds From Issuance Initial Public Offering Before Offering Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl" xml:lang="en-US" id="id_2787876_961833_2_1">Proceeds from initial public offering before offering expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:to="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_2787876_938994_1_1">Proceeds From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" id="id_2787876_938994_2_1">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_2787876_940632_1_1">Proceeds From Issuance Of Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xml:lang="en-US" id="id_2787876_940632_2_1">Proceeds from issuance of convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_2787876_939698_1_1">Proceeds From Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" id="id_2787876_939698_2_1">Total cash received for the options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_2787876_928864_1_1">Property Plant And Equipment [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" id="id_2787876_928864_2_1">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_2787876_929865_1_1">Property Plant And Equipment By Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" id="id_2787876_929865_2_1">Property, Plant and Equipment, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_925725_1_1">Property Plant And Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_925725_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_1037793_3_1">Property plant and equipment estimated useful life.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_1037793_1_1">Property Plant And Equipment Estimated Useful Life Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_1037793_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_2787876_927780_1_1">Property Plant And Equipment Estimated Useful Lives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" id="id_2787876_927780_2_1">Leasehold improvements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_2787876_938855_1_1">Property Plant And Equipment Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" id="id_2787876_938855_2_1">Property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_2787876_925379_1_1">Property Plant And Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" id="id_2787876_925379_2_1">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_2787876_940861_1_1">Property Plant And Equipment Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_2787876_940861_2_1">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" id="id_2787876_940861_6_1">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_928618_1_1">Property Plant And Equipment Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_928618_2_1">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_2787876_925467_1_1">Property Plant And Equipment [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" id="id_2787876_925467_2_1">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_2787876_930445_1_1">Property Plant And Equipment Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" id="id_2787876_930445_2_1">Property, Plant and Equipment, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_2787876_928464_1_1">Property Plant And Equipment Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" id="id_2787876_928464_2_1">Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_2787876_1072861_3_1">Property Plant and Equipment Useful Life And Values [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_2787876_1072861_1_1">Property Plant And Equipment Useful Life And Values [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xml:lang="en-US" id="id_2787876_1072861_2_1">Property Plant and Equipment Useful Life And Values [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_2787876_926437_1_1">Range [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US" id="id_2787876_926437_2_1">Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_2787876_930818_1_1">Range [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RangeMember_lbl" xml:lang="en-US" id="id_2787876_930818_2_1">Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_2787876_1218824_3_1">Raven Biotechnologies, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_2787876_1218824_1_1">Raven Biotechnologies Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RavenBiotechnologiesIncMember_lbl" xml:lang="en-US" id="id_2787876_1218824_2_1">Raven Biotechnologies Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RavenBiotechnologiesIncMember" xlink:to="mgnx_RavenBiotechnologiesIncMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_2787876_924049_1_1">Repurchase Agreement Counterparty Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" id="id_2787876_924049_2_1">Counterparty Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2787876_939407_1_1">Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" id="id_2787876_939407_2_1">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_2787876_928963_1_1">Research And Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" id="id_2787876_928963_2_1">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_2787876_929876_1_1">Research And Development Expense Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" id="id_2787876_929876_2_1">Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ResearchAndMaintenanceAmountReceivable" xlink:label="mgnx_ResearchAndMaintenanceAmountReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ResearchAndMaintenanceAmountReceivable_lbl" xml:lang="en-US" id="id_2787876_1226211_3_1">Research And Maintenance Amount Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ResearchAndMaintenanceAmountReceivable_lbl" xml:lang="en-US" id="id_2787876_1226211_1_1">Research And Maintenance Amount Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ResearchAndMaintenanceAmountReceivable_lbl" xml:lang="en-US" id="id_2787876_1226211_2_1">Research Maintenance Payment Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ResearchAndMaintenanceAmountReceivable" xlink:to="mgnx_ResearchAndMaintenanceAmountReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_2787876_1219855_3_1">Research obligation completion date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_2787876_1219855_1_1">Research Obligation Completion Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ResearchObligationCompletionDate_lbl" xml:lang="en-US" id="id_2787876_1219855_2_1">Research obligation completion date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ResearchObligationCompletionDate" xlink:to="mgnx_ResearchObligationCompletionDate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_2787876_938076_1_1">Restricted Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_2787876_938076_2_1">Amounts classified as restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" id="id_2787876_938076_12_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RestrictedCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_1089936_3_1">Restricted cash fair value disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RestrictedCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_1089936_1_1">Restricted Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RestrictedCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_1089936_2_1">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RestrictedCashFairValueDisclosure" xlink:to="mgnx_RestrictedCashFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_932808_1_1">Restructuring And Related Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" id="id_2787876_932808_2_1">Restructuring and Related Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_928489_1_1">Restructuring And Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_928489_2_1">Lease Exit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_2787876_926911_1_1">Restructuring Cost And Reserve [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US" id="id_2787876_926911_2_1">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_2787876_926104_1_1">Restructuring Cost And Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" id="id_2787876_926104_2_1">Restructuring Cost and Reserve [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_2787876_934071_1_1">Restructuring Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserve_lbl" xml:lang="en-US" id="id_2787876_934071_2_1">Accrual balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserve" xlink:to="us-gaap_RestructuringReserve_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_2787876_933081_1_1">Restructuring Reserve Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" id="id_2787876_933081_2_1">Lease exit liability - current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveNoncurrent_lbl" xml:lang="en-US" id="id_2787876_935871_1_1">Restructuring Reserve Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveNoncurrent_lbl" xml:lang="en-US" id="id_2787876_935871_2_1">Lease exit liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveNoncurrent" xlink:to="us-gaap_RestructuringReserveNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_2787876_935451_1_1">Retained Earnings Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" id="id_2787876_935451_2_1">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_2787876_934838_1_1">Revenue From Grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromGrants_lbl" xml:lang="en-US" id="id_2787876_934838_2_1">Grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" xlink:label="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable_lbl" xml:lang="en-US" id="id_2787876_1226208_3_1">Revenue Recognition, Milestone Method, Revenue Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable_lbl" xml:lang="en-US" id="id_2787876_1226208_1_1">Revenue Recognition Milestone Method Revenue Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable_lbl" xml:lang="en-US" id="id_2787876_1226208_2_1">Milestone Payments Triggered</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" xlink:to="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_2787876_934577_1_1">Revenue Recognition Milestone Method Revenue Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US" id="id_2787876_934577_2_1">Milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_924259_1_1">Revenue Recognition Policy [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US" id="id_2787876_924259_2_1">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_2787876_933119_1_1">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" id="id_2787876_933119_6_1">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_2787876_929243_1_1">Revenues [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US" id="id_2787876_929243_2_1">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_1203629_3_1">Royalty agreement disclosure.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_1203629_1_1">Royalty Agreement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_1203629_2_1">Product Milestone Payments and Royalty Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:to="mgnx_RoyaltyAgreementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_2787876_1086595_3_1">Royalty Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_2787876_1086595_1_1">Royalty Agreement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementLineItems_lbl" xml:lang="en-US" id="id_2787876_1086595_2_1">Royalty Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyAgreementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_2787876_1081226_3_1">Royalty Agreement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_2787876_1081226_1_1">Royalty Agreement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyAgreementTable_lbl" xml:lang="en-US" id="id_2787876_1081226_2_1">Royalty Agreement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="mgnx_RoyaltyAgreementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_2787876_1164792_3_1">Royalty payment as percentage of net sales under licensing agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_2787876_1164792_1_1">Royalty Payment As Percentage Of Net Sales Under Licensing Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl" xml:lang="en-US" id="id_2787876_1164792_2_1">Maximum royalty payments percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_2787876_931590_1_1">Sale Of Stock Name Of Transaction [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" id="id_2787876_931590_2_1">Sale of Stock, Name of Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" id="id_2787876_926597_1_1">Sales [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesMember_lbl" xml:lang="en-US" id="id_2787876_926597_2_1">Sales [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesMember" xlink:to="us-gaap_SalesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SalesMilestonePayments" xlink:label="mgnx_SalesMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SalesMilestonePayments_lbl" xml:lang="en-US" id="id_2787876_1113355_3_1">Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SalesMilestonePayments_lbl" xml:lang="en-US" id="id_2787876_1113355_1_1">Sales Milestone Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SalesMilestonePayments_lbl" xml:lang="en-US" id="id_2787876_1113355_2_1">Sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SalesMilestonePayments" xlink:to="mgnx_SalesMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_2787876_928220_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" id="id_2787876_928220_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_2787876_925701_1_1">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" id="id_2787876_925701_2_1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_927124_1_1">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_927124_2_1">Schedule of Dilutive Securities Excluded from Computation of Diluted Net Income Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_2787876_925602_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" id="id_2787876_925602_2_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_2787876_931816_1_1">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" id="id_2787876_931816_2_1">Schedule of Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_926102_1_1">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_926102_2_1">Future Principal Payments Under Lease Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_2787876_931140_1_1">Schedule Of Property Plant And Equipment [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" id="id_2787876_931140_2_1">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_2787876_924950_1_1">Schedule Of Restructuring And Related Costs [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" id="id_2787876_924950_2_1">Schedule of Restructuring and Related Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_2787876_926756_1_1">Schedule Of Restructuring Reserve By Type Of Cost [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl" xml:lang="en-US" id="id_2787876_926756_2_1">Changes in Lease Exit Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_2787876_930578_1_1">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" id="id_2787876_930578_2_1">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_924843_1_1">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_924843_2_1">Schedule of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_931898_1_1">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" id="id_2787876_931898_2_1">Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="id_2787876_924499_1_1">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xml:lang="en-US" id="id_2787876_924499_2_1">Summary of Percentage of Customer Concentration</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_2787876_1218880_3_1">Second right to develop collaboration.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_2787876_1218880_1_1">Second Right To Develop Collaboration [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SecondRightToDevelopCollaborationMember_lbl" xml:lang="en-US" id="id_2787876_1218880_2_1">Second Right to Develop Collaboration [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SecondRightToDevelopCollaborationMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1166280_3_1">Series A1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1166280_1_1">Series A 1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1166280_2_1">Series A-1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1166416_3_1">Series A2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1166416_1_1">Series A 2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1166416_2_1">Series A-2 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1184171_3_1">Series A- 1 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1184171_1_1">Series A One Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesAOnePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1184171_2_1">Series A- One Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesAOnePreferredStockMember" xlink:to="mgnx_SeriesAOnePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_930435_1_1">Series A Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_930435_2_1">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesATwoPreferredStockMember" xlink:label="mgnx_SeriesATwoPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1218712_3_1">Series A- two preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1218712_1_1">Series A Two Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesATwoPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1218712_2_1">Series A- Two Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesATwoPreferredStockMember" xlink:to="mgnx_SeriesATwoPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1124615_3_1">Series B convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1124615_1_1">Series B Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1124615_2_1">Series B Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesBConvertiblePreferredStockMember" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_932774_1_1">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_932774_2_1">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1031975_3_1">Series C convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1031975_1_1">Series C Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1031975_2_1">Series C Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesCConvertiblePreferredStockMember" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_930400_1_1">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_930400_2_1">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1225370_3_1">Series D1 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1225370_1_1">Series D 1 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1225370_2_1">Series D-1 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1218718_3_1">Series D2 convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1218718_1_1">Series D 2 Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1218718_2_1">Series D-2 Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_997107_3_1">Series D convertible preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_997107_1_1">Series D Convertible Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_997107_2_1">Series D Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesDConvertiblePreferredStockMember" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_929177_1_1">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_929177_2_1">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesDTwoPreferredStockMember" xlink:label="mgnx_SeriesDTwoPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_SeriesDTwoPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1165094_3_1">Series D-2 preferred stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_SeriesDTwoPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1165094_1_1">Series D Two Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_SeriesDTwoPreferredStockMember_lbl" xml:lang="en-US" id="id_2787876_1165094_2_1">Series D Two Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_SeriesDTwoPreferredStockMember" xlink:to="mgnx_SeriesDTwoPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_2787876_1218717_3_1">Servier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_2787876_1218717_1_1">Servier [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ServierMember_lbl" xml:lang="en-US" id="id_2787876_1218717_2_1">Servier [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ServierMember" xlink:to="mgnx_ServierMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_2787876_938471_1_1">Share Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" id="id_2787876_938471_2_1">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_2787876_926550_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" id="id_2787876_926550_2_1">Options granted, maximum term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US" id="id_2787876_927740_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Discount For Postvesting Restrictions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl" xml:lang="en-US" id="id_2787876_927740_2_1">Expected forfeiture rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_2787876_928648_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" id="id_2787876_928648_2_1">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_2787876_926378_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_2787876_926378_2_1">Expected average life of options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" id="id_2787876_926378_12_1">Expected life of option term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_2787876_925061_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" id="id_2787876_925061_2_1">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_2787876_924177_1_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" id="id_2787876_924177_2_1">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_2787876_926498_1_1">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" id="id_2787876_926498_2_1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_923350_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_923350_2_1">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_929330_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" id="id_2787876_929330_2_1">Aggregate of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_2787876_993610_3_1">Share based compensation arrangement by share based payment award number of shares authorized after increase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_2787876_993610_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl" xml:lang="en-US" id="id_2787876_993610_2_1">Increase in aggregate of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_2787876_928178_1_1">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" id="id_2787876_928178_2_1">Shares available for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_2787876_939053_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" id="id_2787876_939053_2_1">Aggregate intrinsic value of options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_2787876_924337_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" id="id_2787876_924337_2_1">Number of Options, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_930255_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_930255_2_1">Weighted- Average Exercise Price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock_lbl" xml:lang="en-US" id="id_2787876_1103375_3_1">Share based compensation arrangement by share based payment award options fair market value of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock_lbl" xml:lang="en-US" id="id_2787876_1103375_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Fair Market Value Of Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock_lbl" xml:lang="en-US" id="id_2787876_1103375_2_1">Fair market value of common stock at:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_2787876_931512_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" id="id_2787876_931512_14_1">Number of Options, Forfeited or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_2787876_1138394_3_1">Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_2787876_1138394_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US" id="id_2787876_1138394_2_1">Weighted Average Contractual Term, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_2787876_926164_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" id="id_2787876_926164_2_1">Number of Options, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_2787876_928357_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="id_2787876_928357_2_1">Weighted-average grant-date fair value of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_2787876_939707_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" id="id_2787876_939707_2_1">Aggregate intrinsic value of options outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_2787876_928127_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_2787876_928127_4_1">Number of Options, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" id="id_2787876_928127_5_1">Number of Options, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_927714_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_927714_4_1">Weighted- Average Exercise Price, Outstanding, Ending Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_927714_5_1">Weighted- Average Exercise Price, Outstanding, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_2787876_925836_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" id="id_2787876_925836_2_1">Weighted Average Contractual Term, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_2787876_929888_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" id="id_2787876_929888_2_1">Number of Options, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_928214_1_1">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_928214_2_1">Weighted- Average Exercise Price, Vested and expected to vest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_2787876_933472_1_1">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" id="id_2787876_933472_2_1">Fair value of shares vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_2787876_928585_1_1">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" id="id_2787876_928585_2_1">Equity Award [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_929456_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_929456_2_1">Weighted- Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_925340_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_925340_2_1">Weighted- Average Exercise Price, Forfeited or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_927283_1_1">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="id_2787876_927283_2_1">Weighted- Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_2787876_928548_1_1">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_2787876_928548_2_1">Convertible Preferred Stock Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" id="id_2787876_928548_12_1">Initial public offering price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_2787876_931089_1_1">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" id="id_2787876_931089_2_1">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_2787876_929134_1_1">Software And Software Development Costs [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" id="id_2787876_929134_2_1">Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_2787876_932980_1_1">Statement Class Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" id="id_2787876_932980_2_1">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_2787876_927592_1_1">Statement Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" id="id_2787876_927592_2_1">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_2787876_926570_1_1">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" id="id_2787876_926570_2_1">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_2787876_932756_1_1">Statement Of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" id="id_2787876_932756_2_1">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_2787876_924693_1_1">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" id="id_2787876_924693_2_1">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_2787876_926771_1_1">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" id="id_2787876_926771_2_1">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_2787876_934682_1_1">Stockholders Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" id="id_2787876_934682_2_1">Total stockholders' equity (deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2787876_925186_1_1">Stockholders Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" id="id_2787876_925186_2_1">Stockholders' equity (deficit):</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockholdersEquityLineItems" xlink:label="mgnx_StockholdersEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockholdersEquityLineItems_lbl" xml:lang="en-US" id="id_2787876_1086872_3_1">Stockholders Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockholdersEquityLineItems_lbl" xml:lang="en-US" id="id_2787876_1086872_1_1">Stockholders Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockholdersEquityLineItems_lbl" xml:lang="en-US" id="id_2787876_1086872_2_1">Stockholders Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockholdersEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_927127_1_1">Stockholders Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" id="id_2787876_927127_2_1">Stockholders' Equity (Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_2787876_925324_1_1">Stockholders Equity Reverse Stock Split</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xml:lang="en-US" id="id_2787876_925324_2_1">Reverse stock split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockholdersEquityTable" xlink:label="mgnx_StockholdersEquityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockholdersEquityTable_lbl" xml:lang="en-US" id="id_2787876_976939_3_1">Stockholders Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockholdersEquityTable_lbl" xml:lang="en-US" id="id_2787876_976939_1_1">Stockholders Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockholdersEquityTable_lbl" xml:lang="en-US" id="id_2787876_976939_2_1">Stockholders Equity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockholdersEquityTable" xlink:to="mgnx_StockholdersEquityTable_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_2787876_1065608_3_1">Costs related to the issuance or offering of stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_2787876_1065608_1_1">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuanceCosts_lbl" xml:lang="en-US" id="id_2787876_1065608_2_1">Related offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuanceCosts" xlink:to="mgnx_StockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_2787876_929323_1_1">Stock Issued During Period Shares Acquisitions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US" id="id_2787876_929323_2_1">Shares issued in connection with acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_2787876_932873_1_1">Stock Issued During Period Shares New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_2787876_932873_2_1">Initial public offering number of share sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" id="id_2787876_932873_12_1">Number of shares issued or sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl" xml:lang="en-US" id="id_2787876_953379_3_1">Stock Issued During Period Shares New Issues Including Underwriters Over Allotment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl" xml:lang="en-US" id="id_2787876_953379_1_1">Stock Issued During Period Shares New Issues Including Underwriters Over Allotment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl" xml:lang="en-US" id="id_2787876_953379_2_1">Initial public offering number of share sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:to="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_2787876_930668_1_1">Stock Issued During Period Shares Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" id="id_2787876_930668_14_1">Number of Options, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_2787876_952345_3_1">Stock issued during period, shares to underwriters for exercise of over allotment option.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_2787876_952345_1_1">Stock Issued During Period Shares To Underwriters For Exercise Of Over Allotment Option</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl" xml:lang="en-US" id="id_2787876_952345_2_1">Additional shares sold under over-allotments Option to underwriter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_2787876_936512_1_1">Stock Issued During Period Value New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" id="id_2787876_936512_2_1">Preferred Stock purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_2787876_1108152_3_1">Stock option plan 2000.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_2787876_1108152_1_1">Stock Option Plan 2000 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_StockOptionPlan2000Member_lbl" xml:lang="en-US" id="id_2787876_1108152_2_1">Stock Option Plan 2000 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_StockOptionPlan2000Member" xlink:to="mgnx_StockOptionPlan2000Member_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_2787876_924078_1_1">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" id="id_2787876_924078_2_1">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_2787876_931597_1_1">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" id="id_2787876_931597_2_1">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_2787876_925770_1_1">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" id="id_2787876_925770_2_1">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_2787876_929519_1_1">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" id="id_2787876_929519_2_1">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_2787876_930713_1_1">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" id="id_2787876_930713_2_1">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_2787876_932504_1_1">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" id="id_2787876_932504_2_1">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_2787876_929873_1_1">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" id="id_2787876_929873_2_1">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_2787876_931707_1_1">Subsidiary Sale Of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" id="id_2787876_931707_2_1">Subsidiary, Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_2787876_931202_1_1">Text Block [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TextBlockAbstract_lbl" xml:lang="en-US" id="id_2787876_931202_2_1">Text Block [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TextBlockAbstract" xlink:to="us-gaap_TextBlockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="id_2787876_931282_1_1">Trade And Other Accounts Receivable Policy</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US" id="id_2787876_931282_2_1">Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld_lbl" xml:lang="en-US" id="id_2787876_930050_1_1">Treasury Stock Number Of Shares Held</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld_lbl" xml:lang="en-US" id="id_2787876_930050_2_1">Treasury stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockNumberOfSharesHeld" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="id_2787876_940705_1_1">Treasury Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" id="id_2787876_940705_14_1">Treasury stock, at cost; 14,381 shares at September 30, 2013 and December 31, 2012</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_2787876_928294_1_1">Type Of Arrangement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" id="id_2787876_928294_2_1">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_2787876_923475_1_1">Type Of Restructuring [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US" id="id_2787876_923475_2_1">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xml:lang="en-US" id="id_2787876_939773_1_1">Undistributed Earnings Allocated To Participating Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities_lbl" xml:lang="en-US" id="id_2787876_939773_14_1">Less: undistributed earnings allocated to participating securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:to="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl" xml:lang="en-US" id="id_2787876_1218973_3_1">Upfront fee and participation recognition date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl" xml:lang="en-US" id="id_2787876_1218973_1_1">Upfront Fee And Participation Recognition Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl" xml:lang="en-US" id="id_2787876_1218973_2_1">Term of the agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionDate_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_2787876_1001330_3_1">Upfront payment recognition period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_2787876_1001330_1_1">Upfront Payment Recognition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod_lbl" xml:lang="en-US" id="id_2787876_1001330_2_1">Expected period of development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_UpfrontPaymentRecognitionPeriod" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_2787876_931855_1_1">Use Of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" id="id_2787876_931855_2_1">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="mgnx_USGovernmentAgenciesMember_lbl" xml:lang="en-US" id="id_2787876_1074019_3_1">U S government agencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="mgnx_USGovernmentAgenciesMember_lbl" xml:lang="en-US" id="id_2787876_1074019_1_1">U S Government Agencies [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="mgnx_USGovernmentAgenciesMember_lbl" xml:lang="en-US" id="id_2787876_1074019_2_1">Government Agencies [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="mgnx_USGovernmentAgenciesMember" xlink:to="mgnx_USGovernmentAgenciesMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_2787876_929614_1_1">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US" id="id_2787876_929614_2_1">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_2787876_935273_1_1">Warrants And Rights Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US" id="id_2787876_935273_2_1">Preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_936341_1_1">Warrants Not Settleable In Cash Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US" id="id_2787876_936341_14_1">Preferred stock warrant liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" id="id_2787876_925122_1_1">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl" xml:lang="en-US" id="id_2787876_925122_2_1">Effect of dilutive securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_924805_1_1">Weighted Average Number Of Diluted Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_924805_2_1">Diluted weighted average number of common shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" id="id_2787876_924805_6_1">Diluted weighted average common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_2787876_929768_1_1">Weighted Average Number Of Shares Outstanding Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_2787876_929768_32_1">Basic weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_2787876_929768_2_1">Basic weighted average common shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" id="id_2787876_929768_12_1">Basic weighted average number of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mgnx-20130930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- RR Donnelley Xcelerate Taxonomy Presentation Linkbase, based on XBRL 2.1  http://www.rrdonnelley.com/ -->
<!-- Version: 6.21.0 -->
<!-- Round: 7 -->
<!-- Creation date: 2013-11-12T20:03:48Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DocumentandEntityInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureOrganizationAndNatureOfOperationsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosurePropertyAndEquipmentAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureStockholdersEquityDeficitAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityChangesInLeaseExitLiability" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureEmployeeBenefitPlanAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#DisclosureSubsequentEventsAdditionalInformation" roleURI="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
  <roleRef xlink:type="simple" xlink:href="mgnx-20130930.xsd#Role_NotesToFinancialStatementsSubsequentEventsTextBlock" roleURI="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="mgnx_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.3500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.3600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RestructuringReserveNoncurrent" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstanding" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TreasuryStockNumberOfSharesHeld" xlink:label="us-gaap_TreasuryStockNumberOfSharesHeld"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD1ConvertiblePreferredStockMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockNumberOfSharesHeld" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="us-gaap_CostsAndExpensesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="us-gaap_RevenueFromGrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="mgnx_IncreaseDecreaseInDeferredRent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="us-gaap_IncreaseDecreaseInRestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="1.1100" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInRestructuringReserve" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="mgnx_IncreaseDecreaseInDeferredRent" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalCommonStockIssuePricePerShare" xlink:label="mgnx_AdditionalCommonStockIssuePricePerShare"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2013/dei-2013-01-31.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:label="mgnx_OrganizationAndNatureOfBusinessLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OrganizationAndNatureOfBusinessTable" xlink:label="mgnx_OrganizationAndNatureOfBusinessTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" xlink:label="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" xlink:label="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_AdditionalCommonStockIssuePricePerShare" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessLineItems" xlink:to="mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OrganizationAndNatureOfBusinessTable" xlink:to="mgnx_OrganizationAndNatureOfBusinessLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_OrganizationAndNatureOfBusinessTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairedFinancingReceivableRelatedAllowance" xlink:label="us-gaap_ImpairedFinancingReceivableRelatedAllowance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairedFinancingReceivableRelatedAllowance" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalents" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_MoneyMarketFundsFairValueDisclosure" xlink:label="mgnx_MoneyMarketFundsFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RestrictedCashFairValueDisclosure" xlink:label="mgnx_RestrictedCashFairValueDisclosure"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_MoneyMarketFundsFairValueDisclosure" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="mgnx_RestrictedCashFairValueDisclosure" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" order="1.1000" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ServierMember" xlink:label="mgnx_ServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_ServierMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_USGovernmentAgenciesMember" xlink:label="mgnx_USGovernmentAgenciesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_MajorCustomersAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_PfizerIncMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_EliLillyMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="mgnx_USGovernmentAgenciesMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DepreciationAmortizationImpairmentLineItems" xlink:label="mgnx_DepreciationAmortizationImpairmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="mgnx_LaboratoryAndOfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DepreciationAmortizationImpairmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_DepreciationAmortizationImpairmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="mgnx_LaboratoryAndOfficeEquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="mgnx_DepreciationAmortizationImpairmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" xlink:label="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" xlink:label="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss_2" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings" order="1.0700" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA1ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA1ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesA2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesA2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesBConvertiblePreferredStockMember" xlink:label="mgnx_SeriesBConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesCConvertiblePreferredStockMember" xlink:label="mgnx_SeriesCConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesDConvertiblePreferredStockMember" xlink:label="mgnx_SeriesDConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA1ConvertiblePreferredStockMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesA2ConvertiblePreferredStockMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesBConvertiblePreferredStockMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesCConvertiblePreferredStockMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesDConvertiblePreferredStockMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:label="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0800" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ConvertiblePreferredStockConversionPrice" xlink:label="mgnx_ConvertiblePreferredStockConversionPrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NetProceedsFromPublicOfferingOfCommonStock" xlink:label="mgnx_NetProceedsFromPublicOfferingOfCommonStock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockDividendRatePerDollarAmount" xlink:label="us-gaap_PreferredStockDividendRatePerDollarAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="us-gaap_PreferredStockLiquidationPreference"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" xlink:label="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" xlink:label="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="mgnx_RavenBiotechnologiesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesAOnePreferredStockMember" xlink:label="mgnx_SeriesAOnePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesATwoPreferredStockMember" xlink:label="mgnx_SeriesATwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="us-gaap_SeriesCPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="us-gaap_SeriesDPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesDTwoPreferredStockMember" xlink:label="mgnx_SeriesDTwoPreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockholdersEquityLineItems" xlink:label="mgnx_StockholdersEquityLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockholdersEquityTable" xlink:label="mgnx_StockholdersEquityTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuanceCosts" xlink:label="mgnx_StockIssuanceCosts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="mgnx_RavenBiotechnologiesIncMember" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesDTwoPreferredStockMember" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesAOnePreferredStockMember" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesATwoPreferredStockMember" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="mgnx_StockholdersEquityTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_SharePrice" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_StockIssuanceCosts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePerDollarAmount" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_ConvertiblePreferredStockConversionPrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="mgnx_NetProceedsFromPublicOfferingOfCommonStock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreference" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_StockholdersEquityTable" xlink:to="mgnx_StockholdersEquityLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EquityIncentivePlanTwoThousandMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EquityIncentivePlanTwoThousandThreeMember" xlink:label="mgnx_EquityIncentivePlanTwoThousandThreeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockOptionPlan2000Member" xlink:label="mgnx_StockOptionPlan2000Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_EquityIncentivePlanTwoThousandThreeMember" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="mgnx_StockOptionPlan2000Member" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="mgnx_EquityIncentivePlanTwoThousandMember" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="1.0300" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="1.0400" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" xlink:label="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ConvertiblePreferredStockSeriesDMember" xlink:label="mgnx_ConvertiblePreferredStockSeriesDMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LeaseExpirationYear" xlink:label="mgnx_LeaseExpirationYear"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:label="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_ConvertiblePreferredStockSeriesDMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" xlink:to="mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_LeaseExpirationYear" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RangeAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="us-gaap_PaymentsForRestructuring"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="us-gaap_RestructuringReserve"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserve" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_PaymentsForRestructuring" order="1.0200" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:label="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="us-gaap_ContractTerminationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:label="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" xlink:to="mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="mgnx_FutureMinimumLeasesPaymentsUnderLeasesTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" xlink:label="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" xlink:label="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_BoehringerIngelheimMember" xlink:label="mgnx_BoehringerIngelheimMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ClinicalDataReviewPeriodForAgreementTermination" xlink:label="mgnx_ClinicalDataReviewPeriodForAgreementTermination"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ClinicalDevelopmentMilestonePaymentsReceived" xlink:label="mgnx_ClinicalDevelopmentMilestonePaymentsReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborationAndLicenseAgreementEnteredDate" xlink:label="mgnx_CollaborationAndLicenseAgreementEnteredDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborativeAgreementPeriodOfContract" xlink:label="mgnx_CollaborativeAgreementPeriodOfContract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EliLillyMember" xlink:label="mgnx_EliLillyMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GileadSciencesIncMember" xlink:label="mgnx_GileadSciencesIncMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_GreenCrossCorporationMember" xlink:label="mgnx_GreenCrossCorporationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LesLaboratoiresServierMember" xlink:label="mgnx_LesLaboratoiresServierMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:label="mgnx_LicenseAndCollaborationAgreementsLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseAndCollaborationAgreementsTable" xlink:label="mgnx_LicenseAndCollaborationAgreementsTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_LicenseGrantFeesReceivable" xlink:label="mgnx_LicenseGrantFeesReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="us-gaap_LicensesRevenue"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NonRefundableFees" xlink:label="mgnx_NonRefundableFees"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="mgnx_NumberOfAnnualMaintenancePaymentReceived"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" xlink:label="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" xlink:label="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfPrograms" xlink:label="mgnx_NumberOfPrograms"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" xlink:label="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PaymentReceivedOnCollaborationAgreement" xlink:label="mgnx_PaymentReceivedOnCollaborationAgreement"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PfizerIncMember" xlink:label="mgnx_PfizerIncMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ResearchObligationCompletionDate" xlink:label="mgnx_ResearchObligationCompletionDate"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SalesMilestonePayments" xlink:label="mgnx_SalesMilestonePayments"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SecondRightToDevelopCollaborationMember" xlink:label="mgnx_SecondRightToDevelopCollaborationMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_SeriesD2ConvertiblePreferredStockMember" xlink:label="mgnx_SeriesD2ConvertiblePreferredStockMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_UpfrontFeeAndParticipationRecognitionDate" xlink:label="mgnx_UpfrontFeeAndParticipationRecognitionDate"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="mgnx_UpfrontPaymentRecognitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="mgnx_SecondRightToDevelopCollaborationMember" order="1.2800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="mgnx_SeriesD2ConvertiblePreferredStockMember" order="1.2900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborationAndLicenseAgreementEnteredDate" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NonRefundableFees" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_LicenseGrantFeesReceivable" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ClinicalDevelopmentMilestonePaymentsReceived" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_SalesMilestonePayments" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontPaymentRecognitionPeriod" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_LicensesRevenue" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenue" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights" order="1.1600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement" order="1.1700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.1800" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfAnnualMaintenancePaymentReceived" order="1.1900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_PaymentReceivedOnCollaborationAgreement" order="1.2000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.2100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ResearchObligationCompletionDate" order="1.2200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_CollaborativeAgreementPeriodOfContract" order="1.2300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_NumberOfPrograms" order="1.2400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_UpfrontFeeAndParticipationRecognitionDate" order="1.2500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsLineItems" xlink:to="mgnx_ClinicalDataReviewPeriodForAgreementTermination" order="1.2600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_LicenseAndCollaborationAgreementsTable" xlink:to="mgnx_LicenseAndCollaborationAgreementsLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_LicenseAndCollaborationAgreementsTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_LesLaboratoiresServierMember" order="1.2700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GileadSciencesIncMember" order="1.3000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_BoehringerIngelheimMember" order="1.3100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_PfizerIncMember" order="1.3200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_GreenCrossCorporationMember" order="1.3300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="mgnx_EliLillyMember" order="1.3400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseExpirationDate1" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AdditionalPaymentUponAchievementOfMilestone" xlink:label="mgnx_AdditionalPaymentUponAchievementOfMilestone"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" xlink:label="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" xlink:label="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementLineItems" xlink:label="mgnx_RoyaltyAgreementLineItems"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementTable" xlink:label="mgnx_RoyaltyAgreementTable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" xlink:label="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="mgnx_RoyaltyAgreementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AdditionalPaymentUponAchievementOfMilestone" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementLineItems" xlink:to="mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="us-gaap_RangeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="mgnx_RoyaltyAgreementTable" xlink:to="mgnx_RoyaltyAgreementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:label="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" xlink:label="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" xlink:label="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_ResearchAndMaintenanceAmountReceivable" xlink:label="mgnx_ResearchAndMaintenanceAmountReceivable"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" xlink:label="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="mgnx_ResearchAndMaintenanceAmountReceivable" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="11.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="1.0900" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="1.1000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="1.1100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="1.1200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="1.1300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="1.1400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="1.1500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CreditConcentrationRiskMember" xlink:label="us-gaap_CreditConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="1.0700" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CreditConcentrationRiskMember" order="1.0800" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1.0400" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="1.0500" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0600" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="1.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="100.0000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0300" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="1.0200" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="mgnx-20130930.xsd#mgnx_RoyaltyAgreementDisclosureTextBlock" xlink:label="mgnx_RoyaltyAgreementDisclosureTextBlock"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_TextBlockAbstract" xlink:label="us-gaap_TextBlockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TextBlockAbstract" xlink:to="mgnx_RoyaltyAgreementDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2013/elts/us-gaap-2013-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="1.0100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" use="optional"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EABAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The preparation of the financial statements in accordance with GAAP
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In addition, through September&#xA0;30, 2013, the Company utilized
 estimates and assumptions in determining the fair value of its
 common stock. The Company granted stock options at exercise prices
 not less than the fair value of its common stock as determined by
 the board of directors, with input from management. Management uses
 contemporaneous valuations in estimating the fair value of its
 common stock. The board of directors has determined the estimated
 fair value of the common stock based on a number of objective and
 subjective factors, including external market considerations
 affecting the biotechnology industry and the historic prices at
 which the Company sold shares of its preferred stock.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investment in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 September&#xA0;30, 2013 or December&#xA0;31, 2012, as the Company
 has a history of collecting on all outstanding accounts.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Intial Public Offering Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Deferred Initial Public Offering Costs</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Deferred IPO costs as of September&#xA0;30, 2013, consisted of
 legal, accounting, printing and filing fees were capitalized. The
 deferred costs are included in prepaid expenses on the consolidated
 balance sheets. The deferred offering costs were offset against the
 IPO proceeds received upon the completion of the offering in
 October 2013.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at September&#xA0;30, 2013
 and December&#xA0;31, 2012.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 September&#xA0;30, 2013 and December&#xA0;31, 2012, due to their
 short-term maturities. The Company accounts for recurring and
 non-recurring fair value measurements in accordance with the
 Financial Accounting Standards Board (FASB) Accounting Standards
 Codification (ASC) 820, <i>Fair Value Measurements and
 Disclosures</i> (ASC 820). ASC 820 defines fair value, establishes
 a fair value hierarchy for assets and liabilities measured at fair
 value, and requires expanded disclosures about fair value
 measurements. The ASC 820 hierarchy ranks the quality of
 reliability of inputs, or assumptions, used in the determination of
 fair value, and requires assets and liabilities carried at fair
 value to be classified and disclosed in one of the following three
 categories:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1&#xA0;&#x2013; Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2&#xA0;&#x2013; Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3&#xA0;&#x2013; Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&#xA0;&#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Financial assets and liabilities subject to fair value measurements
 were as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active&#xA0;Markets&#xA0;for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable&#xA0;Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,522,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,522,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,974,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,974,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active&#xA0;Markets&#xA0;for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable&#xA0;Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 As of December&#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table provides a rollforward of the Company&#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total unrealized gains (losses) included in earnings</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(626,349</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance at September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Concentration of Credit Risk</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Substantially all of the Company&#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For the three and nine months ended September&#xA0;30, 2013 and
 2012, all of the Company&#x2019;s grant revenue was related to
 contracts and research grants received from U.S. government
 agencies. Collaborations with Les Laboratoires Servier and Institut
 de Recherches Servier (collectively, Servier), Boehringer Ingelheim
 GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc.
 (Pfizer) and Eli Lilly&#xA0;&amp; Co. (Eli Lilly) account for all
 other revenue. All outstanding receivables are due from Gilead,
 Pfizer, Boehringer, Eli Lilly, and U.S. government agencies.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table represents the percentage of all significant
 accounts receivable:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.1</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation and
 amortization are computed using the straight-line method over the
 following estimated useful lives:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Computer equipment</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Software</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">
 Shorter&#xA0;of&#xA0;lease&#xA0;term&#xA0;or&#xA0;useful&#xA0;life</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC 360, <i>Property, Plant and
 Equipment</i>. ASC 360 requires that long-lived assets be reviewed
 for impairment whenever events or changes in circumstances indicate
 that the carrying amount of an asset may not be recoverable.
 Recoverability of the long-lived asset is measured by a comparison
 of the carrying amount of the asset to future undiscounted net cash
 flows expected to be generated by the asset or asset group. If
 carrying value exceeds the sum of undiscounted cash flows, the
 Company then determines the fair value of the underlying asset
 group. Any impairment to be recognized is measured by the amount by
 which the carrying amount of the asset group exceeds the estimated
 fair value of the asset group. Assets to be disposed of are
 reported at the lower of the carrying amount or fair value, less
 costs to sell. As of September&#xA0;30, 2013 and December&#xA0;31,
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Revenues</i></b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&#xA0;licenses, or options to obtain licenses, to the
 Company&#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&#xA0;rights to future technological improvements,
 (iii)&#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, <i>Revenue
 Recognition&#xA0;&#x2013;Multiple-Element Arrangements</i>, and ASC
 Topic 605-28, <i>Revenue Recognition&#x2013;Milestone Method</i>, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <i>Exclusive Licenses</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&#xA0;at the collaborator&#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&#xA0;earn payments upon the
 achievement of certain milestones, (iii)&#xA0;earn royalty
 payments, and (iv)&#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&#x2019;s technology platforms, the
 Company&#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update (ASU)
 No.&#xA0;2009-13, <i>Revenue Arrangements with Multiple
 Deliverables</i>, on January&#xA0;1, 2011, the Company determined
 that its licenses lacked stand-alone value because it did not have
 vendor-specific objective evidence of selling price (VSOE), and
 were combined with other elements of the arrangement and any
 amounts associated with the license were deferred and amortized
 over a certain period, which the Company refers to as the
 Company&#x2019;s period of substantial involvement. In making the
 determination of the length of the period over which to defer
 revenue for contracts entered into prior to the adoption of ASU
 No.&#xA0;2009-13, significant judgment and estimation is used by
 the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&#x2019;s
 involvement with the development of a collaborator&#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&#x2019;s substantial involvement.
 ASU No.&#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if VSOE is not available. The objective of BESP is to
 determine the price at which the Company would transact a sale if
 the element within the license agreement was sold on a standalone
 basis. Establishing BESP involves management&#x2019;s judgment and
 considers multiple factors, including market conditions and
 company-specific factors, including those factors contemplated in
 negotiating the agreements, as well as internally developed models
 that include assumptions related to market opportunity, discounted
 cash flows, estimated development costs, probability of success and
 the time needed to commercialize a product candidate pursuant to
 the license. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&#xA0;the value of the license was dependent on
 the undelivered items and (iii)&#xA0;the collaborator or other
 vendors could provide the undelivered items.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&#xA0;development milestones, (ii)&#xA0;regulatory milestones,
 and (iii)&#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&#xA0;the consideration is commensurate
 with either (1)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (2)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (b)&#xA0;the consideration relates solely to past performance and
 (c)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <i>Right-to-Develop Agreements</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&#xA0;at the
 inception of the arrangement (referred to as &#x201C;upfront&#x201D;
 fees or payments), (ii)&#xA0;the selection of a target for a
 program, (iii)&#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&#xA0;some
 combination of all of these fees.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No. 2009-13, the Company&#x2019;s evaluation of whether the option
 is substantive is consistent with pre-adoption of ASU
 No.&#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&#xA0;2009-13. Post adoption of ASU No.&#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&#x2019;s
 best estimate. Management&#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 There have been no option license exercises to date for any period
 presented. Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee to the development and
 commercialization license and apply the multiple-element revenue
 recognition criteria to the development and commercialization
 license and any other deliverables to determine the appropriate
 revenue recognition, which will be consistent with the
 Company&#x2019;s accounting policy for upfront payments on exclusive
 licenses event a right-to-develop agreement were to be terminated,
 the Company would recognize as revenue any portion of the upfront
 fee that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&#x2019;s right-to-develop agreements have been
 determined to contain substantive options.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Research and Development Costs</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Comprehensive Income (Loss)</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Effective January&#xA0;1, 2012, the Company adopted ASU2011-05,
 <i>Presentation of Comprehensive Income,</i> which amended ASC
 Topic 220, <i>Comprehensive Income.</i> The amendments in ASU
 2011-05 require the presentation of the comprehensive income (loss)
 and its components as part of the consolidated financial
 statements. Comprehensive income (loss) is comprised of the net
 income (loss) and other changes in equity that are excluded from
 net income (loss). Comprehensive income (loss) equals net income
 (loss) for the three and nine months ended September&#xA0;30, 2013
 and 2012.</p>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Stock-based Compensation</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&#xA0;718, <i>Compensation&#xA0;&#x2013; Stock
 Compensation</i>. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.</p>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Share</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Net Income (Loss) Per Share</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Income (loss) per share is calculated under the two-class method
 under which all earnings (distributed and undistributed) are
 allocated to each class of common stock and participating
 securities based on their respective rights to receive dividends.
 In the event that the Board of Directors shall declare a dividend
 payable in cash or other property on the then-outstanding shares of
 common stock, the holders of the Series&#xA0;A-1, A-2, B, C, D, and
 D-2 convertible preferred stock shall be entitled to receive the
 amount of dividends per share of Preferred Stock that would be
 payable on the largest number of whole shares of Common Stock into
 which each share of Preferred Stock could then be converted.
 Therefore, the Series A-1, A-2, B, C, D and D-2 are participating
 securities.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic net income (loss) per common share is determined by dividing
 the net income (loss) allocable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 net income (loss) per share is computed by dividing the net income
 (loss) allocable to common stockholders by the weighted-average
 number of common stock equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&#x2019;s stock option grants and the if-converted method
 is used to determine the dilutive effect of the Company&#x2019;s
 Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred
 stock.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic and diluted income (loss) per common share is computed as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,603,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,600,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,944,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,466,582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,434,756</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,600,514</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,944,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,466,582</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">169,226</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,184,507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,092,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,463,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,078,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>Basic income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>0.14</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,603,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,600,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,944,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,466,582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,403,843</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,600,514</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,944,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,466,582</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,184,507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,092,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,463,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,078,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,058,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,410,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,445,061</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,334,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,242,978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,502,424</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,908,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,412,848</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>Diluted income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>0.01</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following common stock equivalents are included in the
 calculation of diluted net income (loss) per share:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,910,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,276,516</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,910,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,276,516</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards Adopted</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Recently Issued Accounting Standards Adopted</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In May&#xA0;2011, the FASB issued ASU No.&#xA0;2011-04, which
 amended ASC Topic 820 to achieve common fair value measurements and
 disclosure requirements in U.S. GAAP and International Financial
 Reporting Standards (IFRS). The amendments in ASU No.&#xA0;2011-04
 result in common fair value measurement and disclosure requirements
 in U.S. GAAP and IFRS. Consequently, the amendments change the
 wording used to describe many of the requirements in U.S. GAAP for
 measuring fair value and for disclosing information about fair
 value measurements. This amendment is effective for fiscal years
 beginning after December&#xA0;15, 2011. The adoption of this
 amendment did not have a material impact on the Company&#x2019;s
 consolidated financial statements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In June&#xA0;2011, the FASB issued ASU No.&#xA0;2011-05, which
 amended ASC Topic 220 regarding presentation of comprehensive
 income. The amendments in ASU No.&#xA0;2011-05 require that all
 nonowner changes in stockholders&#x2019; equity be presented either
 in a single continuous statement of comprehensive income or in two
 separate but consecutive statements. In the two-statement approach,
 the first statement should present total net income and its
 components followed consecutively by a second statement that should
 present total other comprehensive income, the components of other
 comprehensive income, and the total of comprehensive income. This
 amendment is effective for fiscal years beginning after
 December&#xA0;15, 2011. The adoption of this amendment did not have
 a material impact on the Company&#x2019;s consolidated financial
 statements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&#x2019;s
 consolidated financial statements.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122427<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Subparagraph a<br><br> -Article 9<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (b),(f(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationRelatedCostsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for credit risk.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61082-112788<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 825<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6480020&amp;loc=d3e61044-112788<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskCreditRisk</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredChargesPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2144384<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerSharePolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for determining the fair value of financial instruments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155942<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueOfFinancialInstrumentsPolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2127266<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpensePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18823-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionPolicyTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3, 4<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TradeAndOtherAccountsReceivablePolicy</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UseOfEstimates</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0";/64!!P(``"8=```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F=UJVS`8AL\'NP>CTQ$K
M^EG7C3@]V,_A5EAW`:K])3:Q)2&I77+WDYVVC)*EA`;VGL0DEK[WB<#/@=_%
MU7;HBWL*L7.V8J*<LX)L[9K.KBOVZ^;;[)(5,1G;F-Y9JMB.(KM:OGVSN-EY
MBD7>;6/%VI3\)\YCW=)@8ND\V7QGY<)@4OX:UMR;>F/6Q.5\?L%K9Q/9-$OC
M#+9<?*&5N>M3\76;?]Z3!.HC*S[O%XY9%3/>]UUM4B;E][9YEC)[2"CSSFE-
M;#L?WV4,Q@\FC'?^'?"P[T<^FM`U5%R;D+Z;(6/P;<]_N["Y=6Y3'A]R@-*M
M5EU-C:OOAGP"9?2!3!-;HC3TY70M!]/91^XC^=/BR*>+.#/(^/^FP2=R2!`.
M!<*A03C>@W!<@'!\`.&X!.'X",(AYB@@*$85*$H5*$X5*%(5*%85*%H5*%X5
M*&(5*&:5*&:5*&:5*&:5*&:5*&:5*&:5*&:5*&:5*&:5*&95*&95*&95*&95
M*&95*&95*&95*&95*&95*&95*&;5*&;5*&;5*&;5*&;5*&;5*&;5*&;5_\NL
M*;=0Q*?/US^XTY@7:I"8=CW%,[^ZW`]]*;DU@9J?*>2^[NP`?\\^QI';K.O@
M?,R]7J#33^&QN!MWSWP>1"%U]%3=':K`GA)S)WAZX+,.CL;6L:'F0#:?6L[E
M'P```/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`"`)?<F5L<R\N
M<F5L<R"B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````",DL].PS`,QN](O$/D^^IN
M2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][NYFE4'QQB+T[#
MNBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7^ZBRBXL:NI3\
M(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(!WL'JC[Z//FR
MMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1R?LB8P.>)MI<
M3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X8<'%#U1?````
M__\#`%!+`P04``8`"````"$`53TUZ"P"``!?'```&@`(`7AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````O)G=;MI`$(7O*_4=K+T/9F86DE0QN8DJY;9-'\#""T8!V_)N
M?WC[KE`$16I/<V&=&R3;8OUI/?/-,3P\_CKLBQ]AC+N^JYS,YJX(W;IO=MVV
M<M]>/M_<N2*FNFOJ?=^%RAU#=(^KCQ\>OH1]G?*78KL;8I%7Z6+EVI2&3V49
MUVTXU''6#Z'+5S;]>*A3/ARWY5"O7^MM*'4^7Y;CGVNXU=6:Q7-3N?&Y$7/%
MRW'(M_[_XOUFLUN'IW[]_1"Z])=[E#_[\36V(:2\:#UN0ZK<^50L3U?$9IG9
ME?_`R?O!Q;E#.+HDX^@2X=@]&<?N$8X*&4<%X9@GXYA'.%[).%XASBT;YQ;A
M++()IVOTV-9C:+ZF,7LUYH7?W'-U&M&P]P9N#;MN8-D(VX`"#:AL`RHTH+`-
M*-"`RC:@0@,:NY(-EK*QN]Q@F_M)#7B.61?[G4^])2\_1PKTBRF%?+XWP%D@
M'#8-A!$VC4`<96=VA9E=V9E=868W]L0R.+'\I!,KIN,^OR)>$L[I&#62L#4C
M4#,RZ7:\0S,"![BQ![C!`>[9`]S#`4ZG087,+AQ8-\+>&H$/2ME)2V'24G;2
M4IBTC*U`@PHT=IHPF"8\.TUXF";\I&DBY5]*PV5<G@[+TR?T\*0,[QA2.-"0
M@SE\/,(VC4#3"-LT`DVC[-96V-K&;FV#M6/LMC+85Y[]HN#ABX*RIY3"*>79
MR=A#([-I(`R[<,YU4U[]+;CZ#0``__\#`%!+`P04``8`"````"$`C^8ZX#4$
M``#.#@``#P```'AL+W=O<FMB;V]K+GAM;)2776_:2!2&[U?:_X!\OP5_0)LH
MI$HHU49*&[1DV\O18`]X%'O&'8]#V%^_KTTQQQ^QDIN0@SDOY^,Y9X:KSR]I
M,GH6)I=:S1WWP\09"17J2*K=W/GW\>M?GYQ1;KF*>**5F#L'D3N?K__\XVJO
MS=-&ZZ<1!%0^=V)KL\OQ.`]CD?+\@\Z$PI.M-BFW,,UNG&=&\"B/A;!I,O8F
MD]DXY5(Y1X5+\Q8-O=W*4'S189$*98\B1B3<(OP\EEGN7%]M92)^'#,:\2S[
MSE/$_9(XHX3G=AE)*Z*Y,X6I]Z+QABFRVT(F>'KA3WQG?%TGN3*C2&QYD=A'
MI'=21[V\P/-FY2?+4OR08I^?G4IS]/)3JDCORX^BM(?:\A'`OGKT4T8VQO/)
M9%*_][>0N]B>WH3\F.A7%<3W5*\C5:5WJ@A#I]A266D/[$X=JR\U6EA6_0Z9
MN<[(7$K\8^XBMPR<JBQ01)W(B*-$[)8G7(6"K4O7G$AX1,)[AP1;<:+B$Y6J
MUJ\&LK:(IVQWSO26/62"J`1$)1B,I:FRX#0CU+TNRK2M\H#I>$8KJ]+>\EQ6
M8:R,R!$2S2C`J-0R%10TI761IMP<RA36<J<D..;*LILPU(6R-*4+(O.Q'<W*
M8+(,NELU^E<AL[(RQ'T*S.HH/K7=UU:'3[%.(LP'6\(=2E\$8I$-#4K)14<C
MYD9$J`0@6?%#U1D:`.7#G;2][P4<V?)%6G8O^48F"(%Z4R[<'D*3A&^TJ0:^
MJL$]]H&"XLW.4#"FE`RW!],TE?8(55E)D&^Q\K#Z)!;<>5RF%`VWPRFZ$16A
M9=^P<G*+!5D7I(R-ZLQ(5]P.J<LT2_1!"'8K%+IAV0JS1]T_4O<.HNMBDXM?
M!4!@RV?\;61`J73?B24XJ!@N-\>4<NEVP!SF&TS40C-*J-M!M)]P]L@WJ#&5
MH9"Z;Z*T1X3"B@W=6HA]L/:(4&:]'F8'6&,T(\JLUV'VP>RXDO^=T?_.;6%$
M=RG.*+1>!]KA3B&7NE->(Z`.M<-"\#T+-2+JX7=H-\+W+$3GZ'CR5L]^'X/#
M$<'W+$0GRGLGS?`]"]'Y\CHT#T=47JY.)[-'YPM&"\5A(?C60CZ=+Q@MH7]$
MJ'&D87FORZ^F(^[3D8+1\GQE,M=A+*("]ZMS!'2J_`[(K^C<1+B;-2XK/ATL
M&*UX!@XS=D.W[XQ2XW<Y[CG0(%!%HSC-BV*,&UP[GCZ=W]41=-#]1CS=G3RH
MTV@8I=CO4CPH1'>R3RF&T<JL=P_V5HA"['<@[M59Q!PG;\XDJ71`&8;QEGB^
M%M4Z7!FJ0XD..D0O]-!U@E9Z1BL==)!>Z*$=3X4"RC2,5F;#0K1E`5W.,%I"
MPU>31D24ZJ!#=>_=I!X/4NL992CH4MV^I-0:/&%W5(<R%%10CZO5@M\\(4]"
M_!@K7\H[207&^/13]/I_````__\#`%!+`P04``8`"````"$`<Y]2<C`%``".
M$@``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)286V^K.!#'WU?:[X!X
M;["-S25*<E0(W3W266FUVLLS)4Z"&B`">OOV.\8DL2<G:=*'MB$__I[_C"\#
MLV\?U<YYDVU7-O7<I1/B.K(NFE59;^;N/W\_/42NT_5YO<IW32WG[J?LW&^+
M7W^9O3?M2[>5LG=`H>[F[K;O]U//ZXJMK/)NTNQE#=^LF[;*>_C8;KQNW\I\
M-=Q4[3Q&2.!5>5F[6F':WJ+1K-=E(9=-\5K)NM<BK=SE/<3?;<M]=U"KBEOD
MJKQ]>=T_%$VU!XGG<E?VGX.HZU3%]/NF;MK\>0>^/RC/BX/V\.%,OBJ+MNF:
M=3\!.4\'>NXY]F(/E!:S50D.5-J=5J[G[B.=9C1TO<5L2-"_I7SOC/^=;MN\
M_]:6JQ]E+2';4"=5@>>F>5'H]Y6Z!#=[9W<_#17XLW56<IV_[OJ_FO??9;G9
M]E!N`8Z4L>GJ<RF[`C(*,A,FE%+1["``^.U4I9H:D)'\8_C[7J[Z[=SU@XD(
MB4\!=YYEUS^52M)UBM>N;ZK_-$1'*2W"1A&X8Q2A;,(B047PM8JG(QH,+O,^
M7\S:YMV!60-C=OM<S4$Z!67ES(?\Z#B.7B]9!8]*Y%&IS-W0=>#V#NKSM@CI
MS'N#E!8CDOP$83:2'A"50"6[/%PXR2+5[$"HZH&CHRU(EFGKYX4Z1*]@%?UA
MW$1?`.VC'1SJ.1'ZMIOE.8)$LG/"$+'L^/?843!4T8@^Y'9LB4:X@0B;2+\D
MEE\2V37"L@>!W%XM!<]=R-VQ."$*/M%(-$Q$1BC\&(D=IE9J(E0(GP41L5.P
M-!$.,B*.41XS$Q&$1;Z@)Q7+(JRMVRTJ&%D,[.`2C02#1<I(%*,<I"8@>!0%
M*/:E"4"&&/,C>XS,)/R0<\+#(V&9"^XQIV!D[B0[%"?1B#;'"/,9"5!LJ8G0
M@$14<&S01#ALM1$('>,?!LI,1'#"0B%.L5@686^[O7X*1BL0Q9]H!.;/<1;C
M`GY)++\DLFN$94]U*L8Q<'V_5#"J8&PG-M'(.#TIB<*8(B2UD3B(F,!;J(GX
M,$']B*$\9A82Q(S'T84*QO=85+!M$6\/B49&BW$4"($K:!&"<M_'4]0D0G`8
MXYTZ,XD@X"3D%S88"J?V[24<:&00G:W)R(P.?1B:X_!2Q'`HHI'_\117D<U=
MK>/'0L!6BQ>BI<-]$8B07:@C56?^S7-UH)%1-'@R,CK`D(I0X(T^M1`F8MAO
M3^&--G4O,MH4(=3[5"J]W5@JE/"`1@9C+4BJFH/;7>I6PCP4([28DD'Q4(8'
M./("BA*16@B<BF<6]3#:XD/`0A:A29-9$CP4IR%L>ZHWN-V>[B0L>V@I)50S
M^M`/`N+'T6GL(?VIA;"`$%B3]KZUM)&8<\K1OI59B"IB((R1;)>J/S!<'KKK
MZ]LKU5V%Y19M+<G(Q,/Y3R:4$^L'524=<9T<-"N7U[[,+GQIVU2-POTV=7MA
MV<1=CGK(@JWC8).<^=+?7_!UY<ML5,9WVKY4>W"_+]U46+[00DJHV7A0&G%!
M$)+:"(D9;,!XLEHJ//##&!^/2"6,*#]-)=NLZA7N-ZL[#,LLBB&!)_/3_L\H
MXW#,(29%#/32G)VM35LG)E$DSA:GS7#H^OAI+&U8/^;KI^!*MAN9RMVN<XKF
M53W"^["DCE>/KQ<>F7HZ1-<3.H5GUO/K2_4Z0EWWCC?`VX!]OI%_Y.VFK#MG
M)]<P%)F$,$5;_3Y!?^B;_?!,_MST\!Y@^'<+[WTD/`V3"<#KIND/']0`QS=)
MB_\!``#__P,`4$L#!!0`!@`(````(0!(+2G=E`,``%L,```9````>&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;(R7VVZ;0!"&[ROU'1#W,>>393N*C=-6:J6J
MZN%Z#6M[%6#1[CI.WKZSK+%92"`WB=E\\S/_S(`GB_N7LC">,>.$5DO3F=FF
M@:N,YJ0Z+,T_OQ_O8M/@`E4Y*FB%E^8KYN;]ZO.GQ9FR)W[$6!B@4/&E>12B
MGEL6SXZX1'Q&:US!7_:4E4C`)3M8O&88Y4U065BN;8=6B4AE*H4Y^X@&W>])
MAE.:G4I<"27"<($$Y,^/I.:M6IE]1*Y$[.E4WV6TK$%B1PHB7AM1TRBS^;=#
M11G:%>#[Q?%1UFHW%P/YDF2,<KH7,Y"S5*)#SXF56*"T6N0$',BR&PSOE^:#
M,]\ZMFFM%DV!_A)\YIW/!C_2\Q=&\N^DPE!MZ)/LP([2)XE^R^41!%N#Z,>F
M`S^9D>,].A7B%SU_Q>1P%-#N`!Q)8_/\-<4\@XJ"S,P-I%)&"T@`?AHED:,!
M%4$OS>\SR<5Q:7KA+(ALSP'<V&$N'HF4-(WLQ`4M_RG(N4@I$?<B`A$7$<>=
MN7'@!.&TBJ4R:@RF2*#5@M&S`5,#]^0UDC/HS$%9.O.@/BJ/J]?WK()'*?(@
M599F9!H0SJ$_SZL@]A;6,]0TNS#K(1.Y.K)I$5E!J9NV!S==1P_9MH1L'UBZ
M^H)J=7V]W:DV?0G+]-O[KM4!:%_]]%,=$E'/<#I$>B+;(=$1T>QXNAW9)O_=
M`6QMR2!H9\=%$/MZ_=:*\;N,3FPFB722V(X1FD](Y.-MD_#2A")>NQ3$@9[]
M6C%Q,Y..%R1>J`.;+N#:29`D.I!V`2_Q@K`_@ET@=.,HN=U"\P;]ZGIK'[7Q
MT91!?8\W_>8I62L&TKC50?>PF23226([1F@^PZ'/Z5F505.SJI@QGY-$.DEL
MQPC-)[SNNOT<[Z.$^WWLSZIB0C6KCA/'<:^-.A`E0>^%DG8!-_;=N#^K7<`+
MO#BXS9+F36XN;WPMC'N407V/D6YAK9BQ'DX2Z22Q'2,TG\G0Y_2LRJ"I657,
MF,])(ITDMF.$YA.V(ZVAXXULZ'XG^]-Z@=2KU?5MOS^M&I`XH=^;A50#'#MQ
M8UN?%KG4R5)?[A'YB7\CE#^ULZF5IL3L@#>X*+B1T9/<QSQXEJZGUUWQP97?
M]+WSM3.'_6-XGLK=4IY;UP!8[6ITP#\0.Y"*&P7>PZWL601O2*:60W4A:-TL
M6#LJ8*EK/AYAB<>PV=@S@/>4BO9"WN#Z;\'J/P```/__`P!02P,$%``&``@`
M```A`-C'2=4/!```7P\``!D```!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
ME)==CZ)(%(;O)]G_0+AOH%!4C#IIZ>W=27:3R61F]QJA5-)`&0K;[G\_YW``
MJ9*FT0L5>.O44^>KJ-77MRPU7GDA$Y&O368YIL'S2,1)?EB;OWX^/RQ,0Y9A
M'H>IR/G:?.?2_+KYX\OJ(HH7>>2\-,!"+M?FL2Q/2]N6T9%GH;3$B>?P9"^*
M+"SALCC8\E3P,*X&9:GM.L[,SL(D-\G"LAAC0^SW2<2?1'3.>%Z2D8*G80G\
M\IB<9&,MB\:8R\+BY7QZB$1V`A.[)$W*]\JH:631\MLA%T6X2V'=;VP:1HWM
MZN+&?)9$A9!B7UI@SB;0VS7[MF^#I<TJ3F`%Z':CX/NU^<B6`?-->[.J'/1?
MPB^R\]^01W'YJTCB?Y*<@[<A3AB!G1`O*/T6XRT8;-^,?JXB\+TP8KX/SVGY
M0US^YLGA6$*X/5@1+FP9OS]Q&8%'P8SE>F@I$BD`P+>1)9@:X)'PK?J])'%Y
M7)N3F>7-G0D#N;'CLGQ.T*1I1&=9BNQ_$K':%!EQ:R,3H*^?NY:[\)@W^]R*
M3435`I_",MRL"G$Q(&M@3GD*,0?9$BSCRF;@'^)HU_K14F&-:.01K:S-N6G`
M<`GQ>=UXB\7*?@6?1K5F>ZMAJB)H%!@*P&L98>5=QGZO-R@H1A2,`K)MZ0;8
M;ME<;=Y;Q7S22A02\%"7!+TU_3`/&B(<!!'O`'@+O[5/D*29=C6J(AA2*(Q@
MI,LX["T4KTUP0.N<B7-=.[&19N96<74TK`\>*D3@H?%$*-:)INJD6]+`U"VU
MIRH"4C3,EG=--85L=@\9BG6RF3KOEC1#9*2HR9C%%G\^7/-1@8-R&N\V%.MP
M>@621H&;:8D8#&L4/MS=.JUC.-%0K/$Q+9>VI%'X5/<&I/"K3&36->@*EW\/
M%XIUKFL\J`!(4X?,LQS/5S[=`%8#`FV`-^]*%%8&O7:\$RNU2NOYNA=KT9`;
M!R4J'_;D3I#'=3Q&G7RXY=6B04ZRTR]1.;&'=SB'DY%1QU?;GMYD:M&UAVA]
M,:@%8^BP>8^GHU:OTNF-AI&H[2/NM)MCE(:U9@P@:.X`1+6:AI.;8F8DFM[4
M:LW6/.[KX6IH[]H^\+5,8_/\:_>G@JY%@/#A!C(H4?FT361DB=`^\$F)?+Z=
ML"&)RGG7?L+Z-I2;$B'1M43F2F/TM:0-:J/]?E=A[]I<6,_NXFB3;VM1#>M"
M&W>Z']93/T,;DHI[UYX#1Q4]1WOJAT14/_/N&TQ=0,WSOAPF.#K/T.M^QHL#
M#WB:2B,29SRKX/M<>[<]1SVZ^.:LW=_B^0KOV^T#.-Z<P@/_-RP.22Z-E._!
MI&/-H?P*.B#112E.U2%C)THXV%1_CW"0Y?!F[E@@W@M1-A<XP:4Y&F]^`P``
M__\#`%!+`P04``8`"````"$`K/Z1@AT$``"2#P``&0```'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6R<EUMOJS@4A=]'FO^`>"_8$"!$(4>%JC-'FI%&H[D\
M$W`25,`(.TW[[V>;32B83`]I'VB)EU<_+U]VO/WV5I7&*VM%P>O(I!8Q#59G
M/"_J8V3^_=?SP]HTA$SK/"UYS2+SG0GSV^[GG[87WKZ($V/2`(=:1.9)RF9C
MVR([L2H5%F]8#2T'WE:IA-?V:(NF96G>=:I*VR'$MZNTJ$UTV+1+//CA4&3L
MB6?GBM4235I6IA+XQ:EHQ-6MRI;856G[<FX>,EXU8+$ORD*^=Z:F466;[\>:
MM^F^A'&_T56:7;V[EYE]560M%_P@+;"S$70^YM`.;7#:;?,"1J!B-UIVB,Q'
MNDEH:-J[;1?0/P6[B-'?ACCQRR]MD?]6U`S2AGE2,[#G_$5)O^?J(^ALSWH_
M=S/P1VOD[)">2_DGO_S*BN-)PG1[,"(UL$W^_L1$!HF"C>5XRBGC)0#`TZ@*
MM30@D?2M^WTI<GF*3->WO("X%.3&G@GY7"A+T\C.0O+J7Q31W@I-G-[$!7IL
M=UQKY7C!>H&+C43=`)]2F>ZV+;\8L&K@?XHF56N0;L#Y.C+D&,;Z?T.%,2J3
M1^42F8%IP"@$S,_KS@N=K?T*F6:])D8-/`<-G2J2N6(5K@>-#<0#-H0QQKX]
M$5<Z)59T:F(4;HP?C%$TV.2&PKM-`J&-252`+BRPSXE4)]"-LG!"=_!'2-2L
M1IH/@DZ1?*:8I`4F]S.J3I$)00SSY<T84>-W,^XZJS`@>I"H@.>'RS#."2-L
MA#'CY_DIL<ZV&GPQ/]0@F[\.Z%H+.$'!`C3_'C0EUM&TB8M1@V@/E#@0K`Z'
MD@5PL.G&N2U;?ZJ3#NEK^:&FAW3=<!5.!0D*%B"J,JB=,3_>(JJ3CAA,"6+4
M(**S#@)"]!C'"GV!3I9?.&7\?/DIL<[V<5#A\D,-LM&UY]%`4R2H6)`?A?/D
M_@"[7CJE-H=Q+T+,D*Y]0J89)[UB":8ZO^^>9XJG_OB<F4'$O2CL#AIBA=I>
M3_KV)9#J9+\?$NO!%%(K7S%%$4*Z%M6R3OKV)9#J9+\?$NO!%%([CV.*HFN2
M@78T)7W[$DC0?`%2]9JN2E_?M3%%$4)2BSKAY$=?H:B&YX]JC/K.]@7D>;7Q
MB;8"X\XZ,J_(LUC1XQK[:`%/3B&JE9IEIWG72\]4(XA[T0T"_#+1MR])\4LE
MA\YKCD_TFM.+$-*Q5EK*2=^^!/)+18?.JXY/]*K3BR80_FRSH]-$-*S;Z9QK
MI6?AG,]KD$^T"A/#G4AMMC&$3V:D-T3THPH@*UZ-\.90L?;($E:6PLCX65U[
M*)S+PZ?#E>S1Z2Y50P/<B)KTR'Y/VV-1"Z-D!^A*K`"V1HMW*GR1O.GN)7LN
MX2[4_7F"NR^#;^[$`O&!<WE]4;>VX3:]^P\``/__`P!02P,$%``&``@````A
M`#W\T"WC`P``/`\``!D```!X;"]W;W)K<VAE971S+W-H965T,SDN>&ULG)=;
MCYLZ%(7?*_4_(-X+F`1R49)J`IJV4H]T5/7R[("3H`&,L#.9^??=&Q.*26HF
MS4,2R.>5M?8V&*\^OA2Y]<QJD?%R;1/'LRU6)CS-RL/:_O']\</<MH2D94IS
M7K*U_<J$_7'S_MWJS.LG<61,6J!0BK5]E+):NJY(CJR@PN$5*^&7/:\+*N&P
M/KBBJAE-FT%%[OJ>%[H%S4I;*2SKMVCP_3Y+6,R34\%*J41JEE,)_L4QJ\1%
MK4C>(E?0^NE4?4AX48'$+LLS^=J(VE:1++\<2E[370ZY7\B4)A?MYN!*OLB2
MF@N^EP[(N<KH=>:%NW!!:;-*,TB`9;=JME_;#V09D\!V-ZNF0#\S=A:][Y8X
M\O.G.DN_9B6#:D.?L`,[SI\0_9+B*1CL7HU^;#KP?VVE;$]/N?S&SY]9=CA*
M:'<`B3#8,GV-F4B@HB#C^(V-A.=@`-ZM(L.I`16A+\WG.4OE<6U/0B>8>1,"
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M][95C,%;="'P0O?TT?'MWS3'<)_HU]WL&&'=<;`8_.=6,2;'HT1L(C3W^&@P
MN&..7[LX:.S:58PIQ2@1FP@MQ>)?4N`@O1<AF>O]WRHF;.;^_.;<5X0A9VPB
MM!0$;IK]9IBG4D/K_H/%8('9MI#!7C2.Q$9$CX`KVMWSB:AUT+P8M)`QBM(Q
M(+%118^""^#]4=2RJ:\,PUE%%*1NJ00>HO&ES[RH98Q9E,QM1,^"J^#]6=3:
MJ6=9Z#ZWQ+3`-@MA-([$1D2/`G'_(0J.&KME$07=KF<;912)C2IZ%%P5[^^*
M6DNUKOB#V;/%70'D53<NXD_#T)L,.A>UC"$N;F90YC:BLJC-BGH*+UA]8!'+
M<V$E_(0;$1_NG-W9;I/TX./#ZN!\A)NG9OO3_0![EXH>V'^T/F2EL'*V!TG/
MF8&K6NU^U('D5?/LO^,2=BW-UR/L4AD\#'L.P'O.Y>4`'[6[?>_F-P```/__
M`P!02P,$%``&``@````A`*,^<-.I!@``N"8``!D```!X;"]W;W)K<VAE971S
M+W-H965T,S4N>&ULE)I;;Z,X%(#?5]K_@'B?!),`2=1T-%P,*^U*J]5>GBDA
M#9H0(J#3F7^_QY@D',/XT#ZT#?E\L#]\.XF?/G\OS\:WO&Z*ZK(WV<(RC?R2
M58?B\KHW__F;?]J81M.FET-ZKB[YWOR1-^;GYU]_>7JOZJ_-*<];`R)<FKUY
M:MOK;KELLE->ILVBNN87>.=8U67:PLOZ==E<ZSP]=(7*\]*V+'=9IL7%E!%V
M]9P8U?%89'E896]E?FEED#H_IRW4OSD5U^86K<SFA"O3^NO;]5-6E5<(\5*<
MB_9'%]0TRFSWV^NEJM.7,[3[.UNGV2UV]V(4OBRRNFJJ8[N`<$M9T7&;M\OM
M$B(]/QT*:('0;M3Y<6]^8;O$]LSE\U,GZ-\B?V\&_QO-J7J/Z^+P>W')P38\
M)_$$7JKJJT!_.XA+4'@Y*LV[)_!G;1SR8_IV;O^JWI.\>#VU\+@=:)%HV.[P
M(\R;#(Q"F(7MB$A9=88*P&^C+$37`"/I]^[O>W%H3WMSY2X<SUHQP(V7O&EY
M(4*:1O;6M%7YGX18'TH&L?L@T*GZ(,Q>V!N'.2X=92EKU#4P3-OT^:FNW@WH
M-7#/YIJ*/LAV$/G6,EF/>UM_UE1HHPCR1439FYYI0"L:>#[?GAUG^[3\!DZS
MGO''#,-$<".$0!$VO%UXA%UO-[A0=&-NA;AZ(58O)/)"9W<)&NXNP/#0Q?33
MO359P*+)M_OZ\@+$OCNP<56#,>&M,!*.$=O!2#1&'-?"#)]B%-OQ%*/4.)E@
M;.]^+R1OA>6)CK3^Z1"Y212%8#`,G#FNHL27S'K(W&O0=9.`)$*2B$B"DT1,
M$HF.0#:AN?.[HH#W)CRK>\]SW#5VY$M&9Y$D0I*(2(*31$P2B23<;IZQ+8>Y
MZT=KD47H?_,M"EBUJ(P]7S)P_X=I[#D@B5`2LO;KU<KU5LK(C(;$RMM:WFA\
M(\)V-LQR<3WB(6$[S%YME3DBD<1T6Y!%]R,6!:Q:5.KF2V;ZSG)$DT0H"6G1
M63M;3VE>A("5[3J//M+=@P\!;^UX3*EF/`36KN6M%2"1P'0[D$%8&.?W0P&K
M!A]S;E=W7S*R]1OF*1THD&]/5ZP+$))$1!*<)&*22'0$4BBVTH-]BGYM%K"J
M4-DW^))!CEQERQ+,8,()!@_%B"0X2<0DD>@(9'*+38J%>@4[8KU144@QJHXX
M7S*;;EIFWMH2/UA%(!$D'1,A240DP4DB)HE$1R"=#-P->^8\GUTI5:@RC/T>
MDL.<V9#TC8WVC$XIC40TPFDDII%$BV"O8I<^>\0SN:='>R!/V<WZ/:1Q%=!(
M2",1C7`:B6DDT2)8I]C*#W3.VY\SF0#`MO6QX1EMT'M(JU7&T2`A'26B$4XC
M,8TD6@1K%3OZ@5;]+,KD_A_U4E==F'H(N1JM3%.0,I/22$0CG$9B&DFT"!8*
M[1X*G3F=BE+J=*HFDDQ"<H%2YH:@?Q-95X7*\AHDHJ-P&HEI)-$B6*C8YP]Z
MZ$RA,CM`/=53=M"^^`@,K/?;4(>QC:(\Z`F-LI!&(AKA-!+32*)%L%6Q]Q]8
M)<:]S!2P336W9"C?L&QKH_@.>D)K4Y>3=%O_B([":22FD42+8)LB#1C8G-E'
M9?*`K2HYFL\F,@Q/2:>"*4@=_!-Q,!+143B-Q#22:!$L5F0%BECZ4SDF<PDL
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M6.=$/C5CD9*IDG[M%U_C@WNM5A()Z2@1C7`:B6DDT2)8ZX<2*GLBH1I]Y=E#
M_<>G*\M3OTH/>D(C/*21B$8XC<0TDF@1;%-)J(@Q/Y%(N6IZ"N=K'LD^<RQ[
MJV91/:&U26=1=!1.(S&-B`-#/Q]MTJ8\$"3/RY1Y_9H'^?G<&%GU)@[[K.";
MCOO5^T&D+[8X$J)<]]D.3K>,KX=L!\=3X/KR7@#.#5W3U_R/M'XM+HUQSH]P
M*VOAP<"OY<DC^:*MKMWIG9>JA1-#W;\G."&6P[D9:P'PL:K:VPMQ@_N9L^?_
M`0``__\#`%!+`P04``8`"````"$`U]X[6\H)``!#00``&0```'AL+W=O<FMS
M:&5E=',O<VAE970S-"YX;6R<W-ERVDH7!>#[4W7>@>(^@":FLGTJH'D>_N&:
M8-FF8I`+2)R\_6FI):S>8"V(+^RX_;'5DI:D1HUR]\^O[6OO9[X_;(K=?5\:
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MJ@WTOTW^?FC]NW=X*=ZM_>;1W^QRMK79?BKWP+>B^%Y2Y[%L8B\>GKW:K/9`
MO.\]YD^K'Z_'M'BW\\WSRY'M;HVM4;EB\\??>GY8LRW*R@QDK:RT+EY9!]CW
MWG931H-MD=6OZN?[YO'X<M]7Q@-M,E(DQGO?\L/1W)0E^[WUC\.QV/Z?(ZDN
MQ8O(=1'VLRXB:0-5UB;36ZHH=17VLZG".CW5)&U\0U_4N@K[V51AW;IR1=@J
M5UMC<GJQ(M^\-=BA5169?111;RXBL23P'</Z5*_('^P9:=R4:?5&OGK?#'E:
MJO#IJ^/JX6Y?O/?8$<WR<'A;E><':2ZQTDWL>$A.0?PLARR`996O99G[/MO:
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M3(A]A7&N,.X%HY`SO'>%\:\PP14FO&3($1]=,N2(CR\9LB^2*TQZR9!]D74;
M(9ULU".DLSN5I19221N6O*&=2DH,WL`'A.75UZ0-%FVPFX:/,[>F?%PCJFNX
M<X5Q&],<,AYM\&E#0!M"VA#1AI@V)+0AI0U9JT'8/6PL=\/N*34[N;0NV9I*
MK@@+;MCR3I=U<II>0J%#84!A0F%!84/A0.%"X4'A0Q%`$4(101%#D4"10I%U
M"2&\[*W$#>$M]7V?758_@JF28WS!35=XH="A,+@8\T&@*BLS94*N0"8L8D%A
M0^%`X7+!NRI-57G"ABKBA=EKD_%,&DL2.27X;:%,%64RGI`B`>Q)"$4$1=SN
MR$121Y*LD,MH`HND[2)L76>:+$ND2M9518@P>ZLF1/BZP5OY*AIE,L!<<-,5
M92AT*`PNIG641]67F`\3%K&@L*%PH'"YX%V5Y)$TUD8DJ!XLXK>+R.I4562)
MG$,"6"2$(H(B;G=$&<EC:3PA"4A@D;1=1%6GL^E$(R>BK*N(D.3R_FW[!DSW
M0*_4-,'D/>&"FZX$0Z%#87!1QX)$%[[:@L*&PH'"A<*#PH<B@"*$(H(BAB*!
M(H4BZQ)";-FMPAMB6VH:6W+$++CIBBT4.A0&%"84%A0V%`X4+A0>%#X7]3!$
M8\,'.GZ`)4(H(BCB=C=D9<JN=N()(X$ETG8)B0U`5/)>/^LJ(22WO"$O1/>Z
ML4/U,IIA\A9M4:.N$->DWB=L4R@*W1RZ:)3QB`VYR/H:>%$F)A8F-B8.)BXF
M'B8^)@$F(281)C$F"28I)EDG$:-=WK&_?C`A\1O\XEL[DK-%C3HCS>MT$!U7
M,3`Q,;$PL6M2'X&JJHYE.@_@B(:=;<8CA=S-<_&B/$Q\3`),0DPB3&),$DQ2
M3+).(D:ZO)]_0Z3Y[7\QTN1=YD+BJ".O2TQT3`Q,3$PL3&Q,'$Q<3+R:\&-'
MDZ:3$1E1^(*0V3LCA1Y<`5Y.B$F$28Q)@DF*2=9)Q#R7<P`WY)E/&8AY)IM\
M(7'4F6=(=%S%P,3$Q,+$QL3!Q,7$P\3')#B1\H,/HP']Z$!X^GOK'JHX`HXP
MB3%),$DQR3J)F&:6N5O27'(ZAB:7U87$$3_%J)=NC2UKTA%X'1,#$Q,3"Q,;
M$P<3%Q,/$Q^3`),0DPB3&),$DQ23K).(@2XG4=JGYRO?'/*Y%^$TK9$WN8OR
MTWPL_6.YNNO+3A/L:];Z(B/O9>T[4]XUYU--OQJXBHF)A8F-B8.)BXF'B8])
M@$F(281)C$F"28I)UDG$E)?S+'^0<CX](Z:<W,9?E!]49"GO2.T2$QT3`Q,3
M$ZLFL^J8U`8R^]1SZTLQOI#9`1O7=#!Q,?$P\3$):G+U^H7""T8#.KZ/P-]C
MW*=$**$,U%'K)#B;3<^V>8IK9J0FFQQN?PDUQ4.AG*AI'PK=\R\2G]<1#P$2
MD46-.@^!KOFA^K.OD!AX028FUHF4HU=R.-NG/WXZ='4P<3'Q,/$Q"4[DPKJ$
MXA\'VHA<<2,1B"/T^/3'3[=$<B+5T@>2&$(RT$U/^M."V8F(JR,FN)RSN2'!
M?(I'3#"=0I2ZYH&J>"XQT3$Q,#$QL6K"3W*2/"`'I(U+.)BXF'B8^)@$-?EL
M=4+Z=WIG,A+!=#`A=\!BW(E$J#$>S,A41XI+9$*)R>"C$V)^RYF;&_++)WK$
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MP,3$Q,+$QL3!Q,7$P\3'),`DQ"3"),8DP23%I'SF_//[:?SDS)\IYX_U;O/]
M<[[,7U\/O77QHWQ>O!P$GUI/S[)_K9Y/(^VV-&?/K+*'<$A[(,W9<ZCG[0MY
MOKA49RG/V0-'YUZ7YWK5/CPM@#W"_K9ZSH/5_GFS._1>\R?6Y=%@PFYL[_E#
M\/R78_%6/:S\K3BRA]>K?[ZP_ZP@9\\IC08,/Q7%L?F%+7AX^N\/'OX%``#_
M_P,`4$L#!!0`!@`(````(0#&6OEPP`(```8'```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;(R576^;,!2&[R?M/UB^+P0()$4A51/2K5(G3=,^KATP
M8!4PLIVF_?<[QH'RL;6]"=AY_?B\Y]B'S<US5:(G*B3C=80=:X$1K1.>LCJ/
M\*^?=U=KC*0B=4I*7M,(OU");[:?/VW.7#S*@E*%@%#+"!=*-:%MRZ2@%9$6
M;V@-_V1<5$3!4.2V;`0E:;NH*FUWL0CLBK`:&T(H/L+@6<82&O/D5-%:&8B@
M)5$0ORQ8(SM:E7P$5Q'Q>&JN$EXU@#BRDJF7%HI1E83W><T%.9;@^]E9DJ1C
MMX,9OF*)X))GR@*<;0*=>[ZVKVT@;3<I`P<Z[4C0+,*W3GA88GN[:?/SF]&S
M'+PC6?#S%\'2!U932#:421?@R/FCEMZG>@H6V[/5=VT!O@N4THR<2O6#G[]2
MEA<*JNV#(>TK3%]B*A-(*&`LU]>DA)<0`/RBBNF3`0DAS^WSS%)51-@++'^U
M\!R0HR.5ZHYI)$;)22I>_3$BYX(R$/<"@147B.-:[MIW_.!]BFTB:@W&1)'M
M1O`S@D,#>\J&Z"/HA$#NG)DX>J__LPH>->164R*\P@A<2"C/T]9WW8W]!#E-
M+IK=7+.:2/:=1&=0<^-NXI7KC*F'3J'+!Y9Z7Y"MH:]_5ZH+7XMU^-V^.S,!
M[-[/--2Y8N6-0XOGD@GD,%<,(",[WMB.+I,'Q_AM6WH1Z(8N@F`<Y,YHE@.-
M/U;LWU7$[RH.;RE&/B&08=D^YE,OBC`DLZ^6[TZ*L3.:=7LV/2=8^Y-:[(<"
MU_/]Y800#P5K;QDXDT1!`])AF"U6KKN\?LVU\6CZB[E^%14YW=.RE"CA)]T[
M/(BMG^W;VJVK3^5D?N>$<%?F\S&TP7;>[A=`&VI(3K\1D;-:HI)FL-7"6L%=
M%Z:1F8'B3=L,CEQ!`VI?"_C>4+B%"PO$&>>J&^B[UG_!MG\!``#__P,`4$L#
M!!0`!@`(````(0"0NXXP100``*X1```9````>&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;)2878_:.A"&[RN=_Q#E?DF<[R"@*JSVG$JM5%7GM-<A&(B6Q"C.
M+KO__HPS7HB=U`DW0.#QY/6\]DS,XO-;>;)>:<T+5BUM,G-MBU8YVQ7586G_
M]^_30V);O,FJ779B%5W:[Y3;GU=_?5I<6/W,CY0V%D2H^-(^-LUY[C@\/](R
MXS-VIA7\LF=UF35P61\<?JYIMFL'E2?'<]W(*;.BLC'"O)X2@^WW14X?6?Y2
MTJK!(#4]90WHY\?BS#^BE?F4<&56/[^<'W)6GB'$MC@5S7L;U+;*?/[U4+$Z
MVYY@WF\DR/*/V.U%+WQ9Y#7C;-_,()R#0OMS3IW4@4BKQ:Z`&8BT6S7=+^TO
M9+[Q?-M9+=H$_2KHA7<^6_S(+G_7Q>Y;45'(-O@D'-@R]BS0KSOQ%0QV>J.?
M6@=^U-:.[K.74_.37?ZAQ>'8@-TAS$A,;+Y[?Z0\AXQ"F)D7BD@Y.X$`>+7*
M0BP-R$CVUKY?BEUS7-I^-`MCUR>`6UO*FZ="A+2M_(4WK/R-$)&A,(@G@_B@
M7O[NS;PD)&$T'L5!1>T$'[,F6RUJ=K%@U<`]^3D3:Y#,(;*86?#'F<&4Q)@O
M8E`[%&@.=KRN0I(LG%=(82Z9=9_Q5&(S0(17Q`%]5Y$P=5VD#R8.I_]#I!@$
MB;:MCLCT&K^=R!J9H,NHQ,9$*!KA1EV-9FT"7MH0^ZK-BXEZYS4R29M>DD:!
MGZ:!BFP4)([<V$O]*Z*H@REVU0F;QS,H!NDJ-1/7R$2MR@<2DC@@1&,V*A/X
M?AJD\;!.6'I=G>8L"EC5YVNW7B."\H(@2I-$(S9=PO>B.$ZC86G1/=($K$H+
M7=U@9"`YUT5P6_[M\MR8",7>6-4VS5XQ:&R#(&/2:"(4C:(9=BJ-V5H!J_GK
M;Q!DT%N/Q%[HZ_E3"-?U8_</WJ;W:!.PJBUTM9VY1L:4-Q.AY(U`I>LF;IJY
M[:@Q=R5DDFE$5)U:*S$;3+#ZFTN@A-!BXGN^FVB;:&-$5'VBE$]>@`0+?U=?
MZ&KK:RTA8_XPSC"BZM,ZR$2?L0?`ZZV*$+W-$82&16"I,2*J3@AS1QX%K>Z6
M_DXF"*'/89I&H7NMP5*>@5#5W=5!Q$.<IB[TM'NO)00*;BG6Y6&<8435I[61
MB2YC)QAQV=0N9!I-B*I3:RDCNQF[0'>W#+B,D-S-;N3Z8:H]-6Y(ETGB`-KQ
MS0Y5X%W]A/0;2NAIM60MH6$790(QSC"BZM-ZRD2CL2V,&&WJ'5*G"5%T>EI[
M,1O=TF/;64)R.Q,_NEF(Z@R`JNVNEN+U6TKHZJ500L,&2G489QA1]8GBWFDI
MTSSVL"68/9;0L`BI<W)K@;.QHG/$8T&/>HP0'D^")/7CN.>RBB2D__B%)VX\
MD)ZS`_V>U8>BXM:)[J'6NK,8ZFJ-YVV\:-BY/7AN60/GY/;C$?X7H7`J=6<`
M[QEK/B[$B?[Z3\OJ?P```/__`P!02P,$%``&``@````A`+\/@=LU!0```!L`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,S$N>&ULE)E;;ZLX$(#?5]K_@'@_
M(8;<B)(<-=C=/=*NM%KMY9D2)T$-.`+:M/]^QYBDV'1GTI?3AO-Y\.<9R-1>
M?7\K3MZKK.I<E6N?C<:^)\M,[?+RL/;__NOQV\+WZB8M=^E)E7+MO\O:_[[Y
M^:?5157/]5'*QH,(9;WVCTUS7@9!G1UED=8C=98E_,]>547:P,?J$-3G2J:[
M=E!Q"L+Q>!84:5[Z)L*RNB>&VN_S3'*5O12R;$R02I[2!N9?'_-S?8U69/>$
M*]+J^>7\+5/%&4(\Y:>\>6^#^EZ1+7\<2E6E3R?P?F.3-+O&;C\,PA=Y5JE:
M[9L1A`O,1(?.<1`'$&FSVN5@H)?=J^1^[3^PI0AG?K!9M0OT3RXO=>]WKSZJ
MRR]5OOLM+R6L-N1)9^!)J6>-_MCI2S`X&(Q^;#/P1^7MY#Y].35_JLNO,C\<
M&TCW%(RTV'+WSF6=P8I"F%$XU9$R=8()P+]>D>O2@!5)W]J?EWS7'-=^-!M-
MY^.(`>X]R;IYS'5(W\M>ZD85_QJ(=:%,D+`+`B.Z("P<A8LIF\[H*(&942O(
MTR;=K"IU\:!JX)[U.=4UR)8069M-X*>9Q\WU_U3!40=YT%'6_MSW8'@-^7G=
M3%FT"EYA3;..V0Z9>6@CR171*ZCC\NN%C[C,'B*NA$X?*-V\8+7Z7I]GZCI]
M#>OI7^^[-1<@]LW'G>J0F#O"?(@X0<20Z`6Q=");1Z<I@C+&M?2@M0\WN5E,
MG3EN#3+I(_8")R3!24)@A*4)$^EG[5J-N*8>!,O1=V`3VV)K&,R3)#A)"(RP
M/.$)ZWOB?AIVTLBFCI]A9NVC%\(;@;DKD)`$)PF!$9;?S/:[KUSU(,?3U30(
MED:2X"0A,,+2A!=>/XWWE:L>1)6K83!/DN`D(3#"\M1]3.]+`B]7#3MI')2K
M84RY1G$8SIWG-:$`3@$"`2RWV':[KU3U(,=QYCR1!L%22!*<)`1&6)H,OBWZ
M.;RO5MM15+%V$*9*(YQ&!(K8MKHMN+MBF6DBK"_*0<EVD*G9213-QM'<3GE"
M(YQ&!(K8EKI_Z%G>5[O,=!V6K6.R[1@TI28,@G`ZBD`16U8W$8ZL[E3QEQ$S
MK0?>''00HI+0"*<1@2*V+4RF;TM8:MIY'PT+V$"F@*?Q.(['SCLK823":42@
MB&VI&PHGIW1;J__R&M@Z*ML.`J&/YM=]7$T<!.%T%($BMJWN*QS;.RK8="-$
M!6,M2_NG5,)(A-.(0!';5G<7/5NB@DTO8KV4AA5L(%/!\UD\F2W<E%($9Q0A
M,,(VU"U&S_#.UZ]I3"S3V-;8,L,@E9G0"*<1@2*VK.XT'-D[BM?T)T3Q8DU,
M5[PDPAF)"!2Q;$.G6\*+MZ6IUV\'=3UO%+,X=O8R$AKA-")0Q+;\4I<4#KND
MR<+IV[<=A%4NC7`:$2AB6^I&Y<N5&YKV!J_<#D)M31P$X704@2*V+<RX;TM4
MKJ;)RC60J5RV&,_=K"<A17"2$!AA&\):?L%0TZZAV^Z&!D*2E-`(IQ&!(K;E
M)ZT1_;[5&\%@"^GXZ'K<G:!M!Z&V=&M$1Q$H8MLZK1%1M::5L;Y"!\T"G`?H
MI3!5&\9L'$^=[=?$0J)P/ILRIXWD%O)I%'WP\'$C-XJQ-`<+9M^]D-5!)O)T
MJKU,O>A#@PAV[6Y7;P<:#Z'>CG:N;]D2-LF'USD<@+37@]L`.'\XIP?Y>UH=
M\K+V3G(/MQJ/YI#9RIQ@F`^-.K>G`$^J@9.']M<CG#1)V'X?CP#>*]5</^A-
M]MO9U>8_````__\#`%!+`P04``8`"````"$`WET7$X@$``#T$```&0```'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6R<F%UOJS@0AN]7VO^`N&^PP7Q%28Y*
M2'>/=%9:K?;CFA`G004<`6G:?[]C'"B>L"3=7C0!'K_,Z[''=A;?WHO<>.-5
MG8ER:=(9,0U>IF*7E8>E^=>?+T^!:=1-4NZ27)1\:7[PVORV^OFGQ454K_61
M\\8`A;)>FL>F.<TMJTZ/O$CJF3CQ$I[L154D#5Q6!ZL^53S9M8V*W+()\:PB
MR4I3*<RK1S3$?I^E/!;IN>!EHT0JGB<-Q%\?LU/=J17I(W)%4KV>3T^I*$X@
ML<WRK/EH14VC2.??#Z6HDFT.OM\I2]).N[VXD2^RM!*UV#<SD+-4H+>>0RNT
M0&FUV&7@0':[4?']TGRF\PUU36NU:#OH[XQ?ZL%WHSZ*RR]5MON1E1QZ&_(D
M,[`5XE6BWW?R%C2V;EJ_M!GXO3)V?)^<\^8/<?F59X=C`^EVP9$T-M]]Q+Q.
MH4=!9F:W8:0BAP#@OU%D<FA`CR3O[><EVS7'I>EX,]<G#@7<V/*Z><FDI&FD
MY[H1Q3\*HC*H7L2^BD"+JPBU9W;@4M>[KV*IB%J#<=(DJT4E+@:,&GAG?4KD
M&*1S4);.&'RJ.'JO_V45PI,BSU)E:?JF`<UKR,_;RJ5T8;U!GZ97)KIE?%M'
MUATB;4O=N+OQJ8M4-QTATP>6>E_06T-?XYGJPI>P#+][;Z1N@';O!X=Z2_B.
M[B:^19#(YI88B&AVG*_8D3`,L4'T]"8;BF$#QM7#7]\EXKO$9HK0_$$@CZ=+
MPDL3.N\S.TZH1Q\I)FC'HN<1)PQ0YZ^'A.T1XE*F:\0:$3)&&7K+9DA0PCS/
M';Q&,PAS:FA0SC,'ZM#TN)2-D%%&]"`CQ7BMT2>/.<QW/1U9:\BX51T9]:HA
MTV:]_V-6-L)FT9B,%*/,4B^T;6Q5`9"6?FB$"(GO(YM)1$LKE+ROIU4VPDY1
ME)%BKDYIP%SBHZQJ!`EM!Q.Q1C#/\<-`U]AH!/$#RCY[7/,I=S*#96)ZV$H8
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M%_2_5ZS^!0``__\#`%!+`P04``8`"````"$`K$0+&.,"``#B!P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970T,"YX;6R4E5UOFS`4AN\G[3]8OB_?D!"%5$U0
MMTJ;-$W[N';`!*N`D>TT[;_?,0XTD"YI;Q)L'K]^SSGV87G[7%?HB0K)>)-@
MUW(PHDW&<];L$OS[U_W-'".I2).3BC<TP2]4XMO5YT_+`Q>/LJ14(5!H9()+
MI=J%;<NLI#61%F]I`V\*+FJB8"AVMFP%)7FWJ*YLSW$BNR:LP49A(=ZCP8N"
M933EV;ZFC3(B@E9$@7]9LE;V:G7V'KF:B,=]>Y/QN@6)+:N8>NE$,:JSQ<.N
MX8)L*XC[V0U(UFMW@S/YFF6"2UXH"^1L8_0\YMB.;5!:+7,&$>BT(T&+!-^Y
MBS3"]FK9Y></HP=Y\HQDR0]?!,N_L89"LJ%,N@!;SA\U^I#K*5ALGZV^[PKP
M0Z"<%F1?J9_\\)6R7:F@VB$$I.-:Y"\IE1DD%&0L+]1*&:_``/RBFNF3`0DA
MS]W_@>6J3+`?6>',\5W`T99*=<^T)$;97BI>_S60>Y0R(MY1)`#WQ_>>Y<U#
M-XRNJ]C&41=@2A19+04_(#@TL*=LB3Z"[@*4=60^Y,?X&&+]7Z@0HQ:YTRH)
MGF$$RR64YVD5>>[2?H*<9D=F?<X$\7S,;'I&IU`+IV:B2X0-C@?;D(Q3VV\7
MHG>G8>VN5UV;"=`>['KAQ,DY$GG>F$G/F5=BY-;_B%L-)QBT!W.1YX]W7AL&
MZC4P4_]7B?02,7(/VYSFNC\BEW.N%\%1.G$8N=,H#',IBJM$>HD810$7[32*
MR^XU/*U!,*F!8>;=:7<=9^;'?CQ&-F,D<F9!/$'24R0&(O)?[\3(?_01_QH>
M^_>#R<YKPQC_-T$4^<[DQFY&1.C[8>2,`X2>J_=YNX+&O>FIIN745.SHAE:5
M1!G?ZW[I0?:&V:&5WWGZJD[FU^X"V@/,V\,+:+$MV='O1.Q8(U%%"Y!TK!GD
M5)@F;0:*MUVCVW(%S;5[+.%;2J'!.!;`!>>J'^@-AJ_SZA\```#__P,`4$L#
M!!0`!@`(````(0"](BUB<`,``+T+```9````>&PO=V]R:W-H965T<R]S:&5E
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MI8!QAU"1+&R1?SP1GD%'@6;FA9(I8Q4D`'^MFLK5@([@=_6YI;DH4]N/9N'<
M]1'`K37AXIE*2MO*7KE@]3\-0H9*DWB&!#X-"?)F7ARB,+K,XNB,5(%/6.#5
MLF-;"[8&-'F+Y0ZB!3#+RH*3E4%)\LR#/*2.`IK#.-Y6D,+2>8,69@;S>(CQ
M]@@'Q/<9@.HT`Q\F=+RWNPSD(>BB;0TRB/;\*LM'C0D&F#['409`,\S@O+($
MI[:GJO9<%$Q$=3A683^(W,A-]HB1*.1UO:@$#T3[.G2E.AQI43^)YK%[7!0F
M>[VH!`]$I^W5X9UH'/H>.BX:W2(JP0/1^9Y25ZK#1C2(HS@^(3J_152"!Z+Q
M1%2'C:CKAR[R]XC13*7?#UZF\XLDP5*T7V$_G/988[0RO&)A<&*NR2W"$CP6
M1D'?1=UGC='":.XGL.C]IH]J1O"N7E^T0H_%(Z_OIA8WH"O>7'3$OBZ;ASIU
MR3T,Z)HD)@YV?NQ(V]))`S%QTWK/2X+P5.=O\BTT,:ZIAYBXT0WC)$`GE@U)
MN[EZS15Z\')-5]S$C6[LQ@B=<$SYBWN#[L2^IDZBV%);ZWIND'CS?@_'&WZ3
M@:&)@TW-Q,2-KH]"U^M;,M:]R</0SL3.^8D!:?$(14/'&6O?9&5P][IL*0:D
M?QJ3R)U'?M\;+:XO8/I^TN(-^8&[#6VX59$"?N?=V1QFVNGKEWX0K%7WD#43
M<&U27TNX)A.XI+@S`!>,B=V#O.#M+]ZK_P```/__`P!02P,$%``&``@````A
M`'([J]"<%P``<L$``!D```!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG)U9
M<]LXUH;OOZKO/[A\/[&UVG(EF8+V?=_OW(Z2N#JV4K:[,_/OYU`D)0%$\!QW
M+KH3\.$+D,"+0X"`^/'?_WGZ<?'W[N7U<?_\Z3+WX?KR8O?\L/_R^/SMT^5B
MWOS7[>7%Z]O]\Y?['_OGW:?+_^Y>+__]^?__[^.O_<N?K]]WN[<+47A^_73Y
M_>WMY]W5U>O#]]W3_>N'_<_=LQSYNG]YNG^3?[Y\NWK]^;*[_W(XZ>G'5?[Z
MNGSU=/_X?!DKW+UH-/9?OSX^[.K[A[^>=L]OL<C+[L?]FY3_]?OCS]=4[>E!
M(_=T__+G7S__];!_^BD2?SS^>'S[[T'T\N+IX:[S[7G_<O_'#[GN_^2*]P^I
M]N$?&?FGQX>7_>O^Z]L'D;N*"YJ]YLI5Y4J4/G_\\BA7$-WVBY?=UT^7)G=G
MQH7\Y=7GCX<[M'S<_7H]^_O%Z_?]K];+XY?^X_-.;K=45%0%?^SW?T9HYTN4
M)"=?9<YN'JI@_'+Q9??U_J\?;]/]K_;N\=OW-ZGODEQ2=&5W7_Y;W[T^R"T5
MF0_Y4J3TL/\A!9#_7CP]1FU#;LG]?P[___7XY>W[I\M"^4/IYKJ0$_SBC]WK
M6_,QDKR\>/CK]6W_M(JA7"(5B^03D;*4/CF>_Y"_+>5*Y7>HW*1%D<S2LOP#
MF5Q:FMRI./_@FG+'XHA7TJMZ_ZW)59*KRA>.,OGK#S>YZTKAYAUWN)C*R%_2
MF_/^TD2U<:CNO!0KO:C2A]M2J5B^?4=Q"M).#SK17U*=\H=BOG1S^YZ&4TB;
M7T$*EEZ6W"AENRM(#1^*490Z/Q5#>SE7L1<.UJK?O]U__OBR_W4A'9:4ZO7G
M?=3]Y>XBZ=14L06.-ON=R\1>D8J)9#Y=2CL2`[U*W_#WYW+^YN/5WV+GAX2I
M9IF;O(W44B0R;Z1;3Q-.NCG[E$9*I*<TXX38M9%&*R5.&FZ^[11)13IIPND<
M)]]N2J2G].*$4[[]E#AIN/D.4B05&:8)IW.<?$<ID9XRCA-.^4[2A).&F^\T
MBSC9S-)L?B\R3Y&T)(LTX72.H[I,B?2459P@_SVVFV+EUJ[A=7K2&5,NV<PF
M95+A;9IP.LF]">;8:-.3C*>).E=@,DW4)&TT>`WFV$P#Y4E:[LTAWAQ<Y6FZ
M;GDR3=<D;??4(,RQK9XR+[IWT"3M]RQW10,VF19LN`F;3!LVYXWX2GJF8_<D
M/9+5/?EC?=H+1734"Z456DT33A?N]CA9XJ9@MZUZ%G%$&EG"%6EFD;S3AELQ
M<MZ.G'S:6<+-IY-%')%NEG!%>EG$+6S?@]BW;9`EW'R&6<0I["A+N"+C+.(6
M=N)![,).D9@A,<\2;ED76<2YX&66<$566<2]X'46*16<9KW),F67V689I[S&
M9!&WP":Q8:!EFYI")C&B)>-XR"16M!B[JDUBQ7,D4V+VHE&8T?C<Z);8X\=R
MP8421Y8+AT>K0J54J3A7Q88T"D<:MJ11>-*$36GU\/((_(X>/J*M'MY-J+D)
M=3>AX28TW816G'#>0LIYYZFDK6`Z"J:K8'H*IJ]@!@IFJ&!&"F:L8"99IEAQ
MNJFI@IGY&*>CFBN8A8)9*IB5@EDKF(V/*=K&WRH88S1050,E]CJW1K'B%,DD
ME@M#B0W/H7+!54JL&89\=LTH^?R:@7R&S4`>QQ8K9;M6C,>R6<CCV2SD,6T6
M\K@V"WELFX4\OCV'K*Y;YF>LKCN:.XAF2<(/Z=%95A?N)M3<A+J;T'`3FFY"
M*TXX#8+:;D+'3>BZ"3TWH9\FG(83Y;P3B`<*9JA@1@IFK&`F*9..B:9IPME%
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M"\YS1#5FI.\ZSH\Z0\,:$G4D&D@TD6@AT4:B@T07B1X2?20&2`R1&"$Q1F*"
MQ!2)&1)S)!9(+)%8(;%&8H/$%@EC&&'7&;:=8=\9-IYAYQFVGF'O&3:?8?<9
MMI]A_QDVH&$'&K:@"7K0ZN+EU:;5Q8>?BR+ZTZ7,:1Z[[7+!?1T:,Z&N'8DZ
M$@TDFDBTD&@CT<D2Y8(SI=;-,DZPZR'11V*`Q#!+E`O.L&2499RRCI&8(#'-
M$N6B.U;+,DY)YD@LLD2YZ`R.EEG&R6>%Q!J)39;(E&2;99R2&,-(E9$:(^Q`
MPQ8T[$'C,6&YZ(P!#/O0>(SHWCSVH6$C&G:B82L:GQ>+SA2Q83.:H!NMCCY:
M+GB^(";<T4>TT]$7G4G,:LR$.GHDZD@TD&@BT4*BC40G)FX/+ZIDA>3ACSV[
MU$61'A)])`9(#&,B5-01BHR1F"`Q16*&Q!R)14S$EYLK^6IFB2(K)-9(;,X+
MXBW'%C6,820Q7GS!WGQ,C578>H:]9]A\)G%?4C^^ZC%L/Y/X+]#;&/:?80,:
M=J!A"QK+@\6<]ZK9A";H0JM[E\6@[^C>(]KMWIUP68V9P`VO(5%'HH%$$XE6
M3)3C-03QK78>)MLHTF&1+HKTD.B?9U/VFG>`(D,6&:'(&(G)>38W<5GMB#=%
M8H:YS)%8(+%$8H7$&HD-$ELDC&&$G6?8>H:]9]A\AMUG$OL%.@K#]C.)_T(J
M[#_#!C2)`T,9L0--8L&0"EO0!#UH=>\Y>?W\CO[]@+L=O#L'GT"!:Z@Q4F>D
MP4B3D18C;48Z"1('B^*-+S!W6:;'2)^1`2/#!(G+6[GUE7?$,F-&)HQ,&9DQ
M,F=DP<B2D14C:T8VC&P9D47YD8,_70;<)LOTF5%84E;NLX["E$;A2J.PI5'X
M4E;W<YD5QI3E_JRCL*9L`&"=U)RA.E684W8)A/*RXX`L&7M/'(AP-PZX$_:Y
M&`I<18V1.B,-1IJ,M!(D[A%S1?_S/NMT-#I=UNDQTK>R*B0E=H8H`]89:G1&
MK#-F9&)G5?*.5*8::&9!MQ5?!)MS@18*F27+K!A9,[)A9,N(Q`1TGL0$9A3V
ME)C`.@J#2DQ@G=2B@1Y%8@+KI!8-Z2@<*C&!\TH]&LI+85'9)L9Y*2PJ,2&D
M8\>$:(^)?FH_VER=B0G.*\MJ`@7N1HV1.B,-1IJ,M!AI,]))D#BRY*^]#]M=
MUNDQTF=DP,@P0>("R_)17]\Z8ITQ(Q-&IE9IDH!Q[42Y&>O,&5E86=TF%V[/
M32U99L7(FI$-(UM&)!C$O@Q83H)!S"3//A5O5):MO*RDL*;L[64=A3EEB,`Z
M"GO*$(%U%/:4<,`Z"H/*$(%U4HN&:E7A4`D'H;SL<!#M=WE'.(BWQXC\:4U/
MT5D54LW%4.`J:HS4&6DPTF2DQ4B;D8X'D1E[NY?I>B#G14J/D3XC`T:&'J1<
M<I:[C#R04^`Q(Q-&IAZD7')6=LP\D%.:.2,+1I:,K!A9,[)A9,N(1`-TG$0#
M9A2VE*$!ZRB,*4,#UE%84X8&K.,SI]-PY.<A6$=A3J-PI\0"SLOG3[?,"GM*
M+`CE9<<"Z;'?$PLBW)DN*CFKDJJY&$J?DG/RQ]UG7K.87*E4R)=OG9ZS;C'%
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M7)3CQ9M"Q?T!,?G=H'.9PG6\7,C1"7O2[O6CO6SO&`'$6]^L$4#)Z8FKT0\2
MAE]?U1BI,])@I,E(*T&2@?+!8FZ3;;-,1R'399D>(WU&!HP,&1DQ,F9DPLB4
MD1DC<T86"1+7M7^MW9)E5I9,LL+7]N":53:,;!F1_A_M)OT_,PI/2O\?Z\3W
MSQ=?I?OGK!2NE)D@UE'84F:"6$?A2YD)REZZVTU('.#,%-Z4-P.LHW"G//Z'
M=.Q`$.T)?$<@B+<0G@<"]T<+J]$OLE(<0*3.*@U&FHRT$B1NVP5?8&VS2H=5
MNJS2LU22)<'.8U3?9G)ES\/A@+,:*F1&+#.V9;SO0R8L,V5D9N=T[7L^G[/,
M0B&S9)F5+>-];%ZSS(:1+2,2"]!/$@N8J2D8A3$E&,1YQ9XJ^Q[3%<Z46(`R
M"FM**#B7B5<IVU%;YH'XYJ3F#`T:4G.&&(4Y)1!P>13NE$`0TK$#0;3C[SP0
MZ'[)(?H![<Q\D#,14$V@N#GD<_G*;2'GO$ZN)4S@SM45,@V6:=HR19GLR=TX
M"U];+--FI,-(EY%>@L1WK^(+4'T+N?6'!-S1.625$1=WS"H3"RG&G:?MR"DC
M,PN)'TJ=6#E/D$"C6K#*DE56K+)FE0TC6SNC)-YFYUH,2TE$B)M$W+!*O]52
M6%-&".=:.5]PEJA@,9[G%GD_@*U4H@+**+PI40%E%.:4\0&7.+5GH!G*/!'K
MI`8-Z2@<*E$AE)<=%:)=@O\@*L2;"\^'">62T\=6<S$4-[];^:)`P=W574N0
MP`776:7!*DU+)5>IE.0'&9VW&BV6:3/28:3+2"]!DIC@L5+?(F(_.KWC@/,9
MLLJ(5<:62L77WT]89<K(S,JHY.N%YJRR8)4EJZPL%>^:UC6K;!C9,B(#!-[M
MF_HQ8#99-\0ZJ2-#.JDED]#C'R!P5JDE`S(*2THH..^)XG=A]N.(#!"X-*DI
M0Q>>VC+$*'PI`P0NC\*9$@I".G8HB+8E_H-0$.]FM$-!9G\!;GFL19_8"<\J
MU1EI,-)DI,5(FY$.(UU&>HST$R1QR2%89$(!WMTAJXRX+&-&)E9&R2R[.^4Z
MU4`SSFS.R(*1)2,K1M:,;!C9)DA<VSGO]D6)!UC?,CR(F:"0PI8R-N#,4F/&
MF16]KQ@4SI3!P7FA_3H*;TI(X#(KW"G#`]9)_1F.":R3.C2DH["HQ(107E9,
MR$>[TLYC0O@G@PZXNWC(F0BJ)E#@*FJ,U!EI,-)DI,5(FY$.(UU&>HST&1DP
M,F1DQ,B8D0DCTR,2K7)RUB3,C@=_NTIISLCBB$19N*O+EL>CO\UCQ<B:D<T1
MB8KA+)/='@_^MA3RP9K0)M+X:W8*^\D7:UA'84#Y8@WK*"QH%!Z4;]9P7@H7
M&H4-C<*'1F%$^6H-EUEA1?EL#>N$S6AW^M&VL_-.7_>F(!_O5K,'`NXN@@0*
M=OZA76_QIQ-9I<%(DY$6(VU&.HQT&>DQTF=DP,B0D1$C8T8FC$R/2-0E.A-V
ML^/!WW:)<T86C"P963&R9F3#R)81B0-H(?EP&3,U!5-7,`HSRJ?+N#P*.TH<
M8!V%(24.L(["DA('6$=A2OEZ&>LH;"F?+POIV'%`NO),'"C*RB,8!$2G.8.`
MLC,?4<W'4#`.(%)GE08C349:C+09Z3#29:3'2)^1`2-#1D:,C!F9,#(](H<G
M='OR=G8\&(@#V)@6K+)D9,7(FI$-(UM&)`[@54L<8*:F8!1>E/$`YZ5PHXP'
M6$?A1_F&)>LH'"GC`=91>%+&`ZRC<*6,!U@G[$L[#D1[S<['`]#_QUO3I`BG
MW<1E9PMJ-1_:OW9XR*\Q4F>DP4B3D18C;48ZC'09Z3'29V3`R)"1$2-C1B8)
M$L\-YP];BS+O`Q3,C+.:,[)@9,G(BI$U(QM&MHQ('$"W21Q@1F%)H_"DQ`'.
M2^%*B0.LH_"EQ`'643A3X@#K*+PI<8!U%.Z4.,`Z87_:<4">UM\3!R+<'0<X
MLYK5?`REUI=%0K<.4DN0P%"ASBH-5FG:*M?%<C[G3%^U6*7-2(>1+B,]1OJ,
M#!@9,C)B9,S()$&2%Y*^A;!31F86DB_*UXF<Y<IS+LH"198LLK)$"J52J>R\
M"UNSR(:1K95/Z3IWXVZBEP@0^RQ@(HD`YU[TRBB\*`'@7.:V(I\7=^Z_]/]<
MFM2-H1(K["CS09R7PI`R'\0Z"DO*?%"LD_1XQ6+)710IW3]GE9HR(*,PI<P&
MG9>F5+HMY4ZK..W./]IQ=CX(4+X4B#>JV8,!9QZWF@_M9DL&`XC46:7!2).1
M%B-M1CJ,=!GI,=)G9,#(D)$1(V-&)HQ,&9DQ,F=D<40\+V27QX.G<:[3T:T8
M63.R863+B(0`M)"$`&9J"D;A10D"G)?"C3((8!V%'V40P#H*1\H@@'44GI0H
MP#H*5\H@@'7"OK3C0+3A[!_$@7B?FAT'G,4<U7QH,UL2!Q"ILTJ#D28C+4;:
MC'08Z3+28Z3/R("1(2,C1L:,3!B9,C)C9,[((D'BAZV"=ZW_DF56C*P9V3"R
M943"`3I)P@$S-06CL*2$`\Y+84H)!ZRCL*6$`]91&%/"`>LHK"GA@'44YI1P
MP#IA>]KA(-II=AX.X-U`O#'-#@/.4U,U']J]EH0!1.JLTF"DR4B+D38C'4:Z
MC/08Z3,R8&3(R(B1,2,31J:,S!B9,[)@9,G(BI%U@EC?2W164&Q89LN(A`%T
MDH0!9FH*1F%)"0.<E\*4$@981V%+"0.LHS"FA`'645A3P@#K*,PI88!UPO:T
MPT"TR^P=82#>E&:'@=/$TZ&/K^9#.]>2,(!(G54:C#09:3'29J3#2)>1'B-]
M1@:,#!D9,3)F9,+(E)$9(W-&%AZD7'9V/"X]D/.<LV)DS<B&D2TC$@?02A('
MLDS9?:4AFP>RE'/E\HZ`&84M9=$HZRB,*2\)6$=A37E)P#H*<\I+`M91V%,6
MC;*.PJ#RFB"D8T>":&_9.R)!O!7-C@3.6]=J/K1?+8D$B-19I<%(DY$6(VU&
M.HQT&>DQTF=DP,B0D1$C8T8FC$P9F3$R9V3!R)*1%2-K1C8^Y-IYT[;U0?9B
M6HD$:"6)!,S4%(S"DS(BX+P4KI01`>LH?"DC`M91.%-&!*RC\*:,"%A'X4X9
M$;!.V)]6'"A$6]+T<>"`.XN%;IPA;S6!Y)7U<66I\V118Z3.2(.1)B,M1MJ,
M=!CI,M)CI,_(@)$A(R-&QHQ,&)DR,F-DSLB"D24C*T;6C&P8V3)BC((Y^=&S
M*<,HK&@47C0*,QJ%&XW"CD;A1Z,PI%$XTB@L:12>-`I3&H4KC<*6)NQ+N_^/
MMIF]H_^/=Z59XX`;=]-`(;1U+1X',%)GI,%(DY$6(VU&.HQT&>DQTF=DP,B0
MD1$C8T8FC$P9F3$R9V3!R)*1%2-K1C:,;!F1_A^]9JH*IJ9@%(Z4*,#E47A2
MHD!6IWSC+#F7.)"EG"=-B0/,*)PI<8!U%-Z4.,`Z"G=*'&"=L#_M."!=^GOB
M0(2[XP!G%%LMQ%!P'(!(G54:C#09:3'29J3#2)>1'B-]1@:,#!D9,3)F9,+(
ME)$9(W-&%HPL&5DQLF9DP\B6$8D#:"2)`\S4%(S"D1('."^%)R4.L(["E1(%
M6,?GR_*-L_A1X@`K*;PI<8!U%.Z4.,`Z87_&<>#J]?MN]U:_?[O__/%I]_)M
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M]//_!````/__`P!02P,$%``&``@````A`)L4>I'*"P``GVH```T```!X;"]S
M='EL97,N>&ULU%W_;^+(%?^]4O\'R]M6=U(3P)@`N9#30N+>2MOT=)NJE7I5
M9<`D;OR%&K.;7-7_O>^-O[T!;(_QP.P=N@T8YKW/^SIOGL?VS?>OOJ=]=J*-
M&P83O7?9U34G6(1+-WB:Z']]M"Y&NK:)[6!I>V'@3/0W9Z-_?_O;W]QLXC?/
M^?3L.+$&)(+-1'^.X_5UI[-9/#N^O;D,UTX`WZS"R+=C^!@]=3;KR+&7&QSD
M>QVCV[WJ^+8;Z`F%:W\A0L2WHY?M^F(1^FL[=N>NY\9OC):N^8OK#T]!&-ES
M#Z"^]DQ[D=%F'_;(^^XB"C?A*KX$<IUPM7(7SC[*<6?<`4JW-\'6M_QXHRW"
M;1!/=",_I"7??%A.]"M=2T2>A4L`\8?_;,/XN]\E?][]\=V[[K^^_>X?/SG+
M?_[\S?YW/W^K=S(VA";8H)KF9;>2+'R=4.ZD$MS>K,*`"`(,F(*N7X+P2V#A
M=^`,(![^[/9F\XOVV?;@2`_A+4(OC+08K`SRL2.![3O)+V:VY\XC%W^VLGW7
M>TL.&WB`.4;Z.]\%,^'!3L+AO'SFB":3:80P.)GZ>(3*Y(-(-AZLELG^]P&9
M.%Z#>EYM],?Q8E)4RR6-U[Y?[.FP#:_<5H1/]#2?Z)8%.:37[:):J<%.Q&P\
MZP*_LS&[&IQ-LK[5MX92)>-\<=]NR+!OR51E#4/K_?#N;.J4SZQ,NC0-GRL"
M,.#D:M&%T*V([Z&%KW/XR9DGM--8C%'EDCX+O2(W/KJ^L]$>G"_:3Z%O!ZA8
M.JFQ7W-S,N=XIR'/N8!\%KEWH;!5NFE7O)Q)"I:D3R=%KBQ6LIV>SW[U)=-A
MY5//]5/G3`T"C<7;!@+1];Q\<=$WL?R&([<WL,Z)G2BPX(.6OG]\6T/Q'<"2
M#'%TDM_5_/HILM]Z!BM!Q09L0L]=(HJG&2OYTY)K=G5OS>X97X),%$4)4<N:
M#4]`]'XZGLE'.AN/91,U+'A))OI^@"_)1"WX;R9-I^FD:\H"F=/38A>7Z-W+
MX7@\'O6N1J/1V.SW3),I>9YZM!LLG5<'5^W2U+2/8``(QOW1^,H`(%USQ%B=
M%4$?``P'@]&@-S9,^)^EV-,CD*W3@:[:J@2!(JL2!(JLR@J0CH3,GT8*-,P4
MQRI!H,BJ!($BJPXE9^"A<JL2!(JL2A`HLBJK?R7&*O2)%<<J0:#(J@2!(JM*
M*S[3##Q6;E6"0)%5"8)S6S5;5LWN[RW6Z=JOS,KK8[:2@[7C/(R6<!8O.S75
MP]5C<NSVQG-6,:P2(_?I&?_&X1K^G8=Q#.>\;F^6KOT4!K8';SO9B.QOQ4@X
M*P@G`"=Z_.PN7H`9URI(\"8L3L4AST0F5OCFT.P.S8%QE2RB)+'VG:6[]?>E
MRWD?]!50(^JV7G"BPR!GDKI#T?CLH!52\PF.8*9FEA8<`#Z1N83@"!DR%B<!
M1&4D(\1D)`,$920C1&6$T#D47)DFE^$63DCO&MBR1MUNTF\5Y5--D``_X#&'
M09`Q^_JL'7)`H[5CFLH*^64O-J8&OEC%>D#2FA'[<M8,."!ES0A1&7F_R:S+
M$<_;"9B>#R#9T3?W\^-@`*-D8(9G)PFF^0G/`R5G@H33W6%Q:\D3J8%"L^DJ
MDV%'3?LRR&#21)(,6.V8*B.F\S5,_PO'\S[AA/SW55X#0*OK]N9U1?:1P.8>
MW&B!VU3P+?23T[?)?)]\`!V7#3)*!VGV>NV]/6S]N1-9;,</8\&.8M^Z^#1E
MA4KQ^;WG/@6^PYIU>D+FQRB,G47,=B2QTT%E>/HE>'HI(1$\;?B;)?Q!3\+Z
M:,,?FD$'C0AZ4<H?G$N8OTQ_P+U7J5.#":A35^&1B0"6_!D",((*!+`\S1"`
M>ZI``$NI#`$X:($`X%1X19LXZ)%L!CY0L`3^IV().2:3DF-Y0BG+TB_PKY#2
MXM)O*S63?`N.7J@9/E0`:,6R+,6J2C'$[!!IA0K@0X4*+)AUY4QYO;*<KTPA
M).D"AD(CD`:J-"+/*TG.!9X%@&J-3"76(<0I,!6IA@!PE$`@AN@IFG][%(.B
M&9AZ@Z(IF$+@YN`SQ@2U!#=#*L(`>)1$15$G]+@9XXQJ(!!494CB#8:J%$DQ
MJ,J1A2D,52F20%"5(:DE5*5(BD%5CB2F4)4B"030B)(,22VA*D52#*IR9&&*
MOJH422"HRI#$$OT3I\@.;9LF3532/X4]@>6M4#!0MOS?M=7KJK:1VBM;-`&M
M;'BR>DI6CF`+MI8B2VF\.L_.>J?:<QBYO\`B$Z_26T`SU8ETO*HS=A?TR)?(
M7C\ZK[`43<X[O:Y:"5B#J>`/S75=:\)<NGY:8!&P=(TB:B5GB_K:QOR.9_#-
M[5H/J06!S1W5&%#7*0;I+B`I1#!R5:L))DGE&*BI8,*L2X:-LEFMKU+FJ(RT
MZ0^'N0+FJ%3:A#GB$.)=FKA;)"9<1XEQM\!A,>>WS5-$[0904\8<%]+-F%><
MU&Q.K$:---'@]@0Z$S>?"1N+6H.NC<-5])Y/'FI&6<F$'=<J[M.TT5OK_M1N
M60W5)!E01^KOKJRK$%JL%]X(7ZU?:7AI2Q+UX/N=JDKOU+B/U2'8M7TVIT85
M5QJ[>\&^TDB)1)56#?1PG2:8DBE\MG&I81TM.WM(Q//UA$@S:]?@%C'W$0'?
MTO@UH'EOS.`)3II'T:Z9I5KZF4&:"-71R4M>6J8UR6&ES.'V.7)FJD9HR*1]
M"DLUPE)F%CQ=6#5#"L_A3="(IW!!)Z%.*S[7U+=BOO[2!ZXJ;UB0U\1_$SN6
MJJ>F,"P-=FK'8PK!4D#2$D!KA&7VDH90B@%[4'!)20MM]24]53113X^T5TZ1
MP:ER9*:M4^/^6G5X3*G6UL15I1JA+:46.H>_2`?:TBAB>"JL``3$.E:EL]*Q
M[BX&7>9\+"RK8%W51'*E?4D#&P1"_>!32%ZQ5;9J$I7B<+B9Y;R28U;+3A61
M+D?-!'FBU?DQ5:+TFH+F96%`)6JL3AHB6BQUJZ-@8DII;FT^RK*V1DVJ.PH?
MNP*A.4`119X2-@;.KP]UF;*_-J>E.(7GQ,,N41I-M7,CW5L@?D[],`H^GDHQ
M'8J@XK23<&KZ52%G6XE@\Q"Y%)._$#/?:J3AS3CAYN'=WVL7VOL%JB/O"^*2
M:;YU/;C)"NXAPFU@B^T&[B4P30ZF&W>J:.6=-"Q&*"TH#YK2RI??V-*DM"!O
M-*4%[),JI`_2$EIPE6IC6M"]2&G!.TH+SA$VQ05#4EJ\[@>"NC</V9%M<29V
M!)%%<%%:A1U!<T3&/HC<E%9A1S`<I04B-Z55V!$0$EHF,&E*J[`C6('2`G=K
M2BNWHXG30*'[@:#NKP[:D?=5W(\H@HO2*NS(^VI?T%<IK<*.O*^BR$UQ%78$
MJD1?)GS1E%9A1SY/F()Y@LI8V)'7_4!0][L9E?=X0]#C$RJ%[>`=T1$N,D1T
ME%`IK,9[>5_0RQ,JA;UX_S8%_3NA4E@*Z!&)3/A"7*+<1GU>NZ:@=J?V,LNZ
MO,/@/","`^[4O-AZ\/B/$!\>PO;;8N>:"(0+4B%*S\[B19O![1-R0GP\X#0J
M0NC^=>W9@1V'T9N&>VQS<KS1!X+D_A2&N8YX"GAV0030#_"H%7B*BP9Z233$
M^S#6@DW(Y+'`JP<ON&M"!D8G:'C_P\5P$S(P.B'#)U6LGT3(?`C6V]Q"?"[%
MJ5N$Q$<W>'&6O.?P&C8`I`BE!V<;1W;N?WQ(&8**><";;N0T^!21W%(]NT-(
M6G\^P#TV,B5BI4UB!]<M(L#_LHV)&G$4(8*-.!$BCVX,]T;*@I@C@;"$2(2P
M[STGL9-1!&G\S8X"C!8N='=\M$2BXBH"J/Z7K\4-6)C>8WP8$;LU2[X>`$4M
MG96]]>+'_,N)7KS_,[OK&#A3^JL?W<]AS$A,].+]1[R=&T0Q-)TAW7S<P"W"
MX*^VC=R)_M_[Z7!\=V\9%Z/N='1A]IW!Q7@PO;L8F+/IW9TU[AK=V?]`9?CD
MIFMX]$^+)R.Q)SC!=00]\WKCP?.3HE38%/RGXMA$)Q\2^.P>3@`;MJAE0G0V
M^9.E;O\/``#__P,`4$L#!!0`!@`(````(0!BQ&WDA8<``%;8`0`4````>&PO
M<VAA<F5D4W1R:6YG<RYX;6SLG>MN'%>VW[\'R#L4!">F`)(2*=ECSWAT0%.2
MCQ+;THC4!,%!/C2[BV2/FUT]7=V2.9_\#LF7`.<`0AY%C^(GR>^_UKY553=%
M:<:>7`:8B]A=M2_K^E^7O?NK?_KQ:E:]KI?MM)G__L[!_OT[53T?-Y/I_.+W
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M@_M[?^A_>`0!)D:$I[/11?_;3\]'LW8P4)KE1;V<-B+=I'H\6FU_[NFT'8]F
MU7^M1\OJ*41O!_-L(EJ:)KP>9ML\P!\&-`\,?5E?3$4^V/S]Z&JPQD^_.SI^
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M=_*X/J\1[0FD?UW/U_7V)[L4CD.S@_Z0FQ;0?Z:8%JV*@PVT`:Z'Y;62\>K-
M:&E68.L+Q;BV'>->U9S'[5>+9KG:X!=\<W'8#9LR';ML9A/\X:<F'0C*SJ0^
MGXZGJ[M#T7?-M%7O5I_<W[]_4"VPG"B`T?CAX6>[6!O]MVI=;T?KU66SG/ZE
MGN!B=@\.'^Y^?OC09/%@]_Z77^Q^>?`P/CIM6TF`Y+3)VEZ-5A4>;%5?G2&<
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MOAM-RC8:O/_-&TAR='&QK"^P(#@:W#KP!\M3^1*(:`98HR,V)RM>%!!HY4:>
M@Q#L]=;L!6QGF$L0"7848#ENKNIJY]NF;;<*U(-;1R`#N/727?00,H0OJO-E
M<X6EGLU&9XV6R9HP\R#V\0#L?&-^-#C]/I_=H(8O!_[]&%?@VX\09.#^0%HV
MJQ%IPK)GC8&I_D3?U'/H.;/'1I.KZ=Q@OA;>?S*@C\'4_><B#V;&`R.(4)WS
MK/^PP[AI8%O8S0`"?U_+_96,CF_8)/U!OQZUT[%`8]5YK&(5&D:`W52E_][C
MZ6PM:/KA;_J,;^KIQ:4&&.&)1A=U-5\;$!#X*:8=L#/.^['OWZ`MQ\+]3V?-
MFZWA1="G^45%;#Q];8BX3QC1WTG9_^9H\J=UNW+E7#7(^KB9CXF72AKRN2AJ
M(<ABV;R>3B#1&=AMW?*/Z?QN%>2CLX:!1#^N4?3QU$U'D)3^<DX$Y/;.@-\$
M&`@,9L&>[S_W=#2-2'"4=B#K\EYX^^F[M^_>]H<[OAS-+\`A8*AB*Q:2F6(5
M(&?#MKKPOS]V@:?G@RA(C#&Z!E*6TV_EILG$N<F$:><4T]ZN"%9OD(`7:RP8
M9#43#!,WA&G]A0_6=IMY^FL[G\X)D=^SMF4SKNM)Z\97_LNBZD+K!`*W+J\4
MR=M,9_LRAHO?1GV%`?:/&R)LV]FF!Q4TG)%>F<^U358-;<D']==[X_MDG[:_
M^1QK]'I:OS%1E*4R)KZ07YKC6C?$8B$`UGI>D*T8"V-OSY\=[%<?/L5WH_&R
MP?E,Q^VNW/9^M0,2K'[^Z5^/T=O1_/KGG_[M+NHHI1HW2X)&BS^@^.-Z-D)-
MZPHS?K2^P/R\>TM41,;P_OW]ZI1!P@@5&QU5XQD^#7RY1TH&DWPV;188B:O1
MN%X;[C0[P7S5N5)JV`V&G9!I:Z":R1VD#?Y3?\*FYC5$P['C1YHQB5?SG@0>
MS>0ZF![E)D8+FP"I;):5MK8BI#-+*4Z-):+D+QB<J+.97EVMY[7F5>J@[6[C
MPEST2O8%K[^8+FJVQ/:1E&4S68]E`N83RRE%'=!S*"G!T6JD('(]!7KQPKS^
M<;47QA,"(Y]GZZY6]?ARWLR:B^MJ0:2G[&U;O;F<CB^9%/&<38$0+``?#&%L
M/XBI)7F5P6+H(34D-;;!,,D>D3MTF_#HK!ZO9V&?I$J&^]@-DXMPD9W8GPK?
MP6CG4T9972Z;]876UY*<5E9`F?"@0X&28K=M2NMP(N]=U1.<B);!GD?@G2LD
M\&I$TFDR02?:R(4]1>=,-:YX;$;63!;>22+IFS?0W9-=LVLHI(FO,,<X-C(_
M;D]=#J!#EZ%C20*#G36K2V8[QP%H5[ZH2!OVAV'03),I?D\+EB.%^B397'K@
M[059OUW28-6;>@:(:Z5`['GOK%ZMH`A*5"QYLEQ?L+VZG5[,?;C(S_4"8;@:
M+7^HG3`3='[.LOM&Z!1VC$@5FH9JQ^OY:$T>@=&F<R:<"OP6&<Y@3]$0F!-!
M/`H]6T]<B#38.B#[H4DPKL'>-R05('+S1LMNUV?M%!8NKW>KXI7JO^#$@BDY
M@A:VGK!26[--HQ&5QFX%=EAI=0E6@WOUO$+&@;_&!-GUM`T>,_8AIQNWDT<`
MGQ">LL3%>BDGM!+'),%+";OI`E&0,BDV-4JC+T_0A:7!+GOBR8^22BP58G^%
M,Y.:[IP\.;Z[7QV3WQBQMFFNKM@KYTVS0AS-?F"0R!LQVUP5'E$MD%L<VKR!
MM&P>$#^6$_.?;Z9(9^"/6(TUP1,OM!.W(!J<[Y7OLL&UF5=S$P8+V<S-4!DA
MX3NJ=KXY.GIQMR`W!$:7S>`NJ^9JBKQ.W(.O+C'<D)(\H8DV?V%KPA.H5[O&
M*FTDZ7YU9.MGN3.D@P7!M,Q)3>!XHBN0[66SG@%)%:N-;"N\\Z?UW$2D,CIH
M;QO?E4")]JUF6]8PO*2W7@OFZ^>?_F=+8JJQG-\:0PU*GN3!X7!';%XB,M7#
MPX<[9W=W'H*0YQ75KX:T(LXN5,#<8^8AD9!G<Q.I9H'/XY4@8>4*KD9SW*"G
MU;6Z#G4^1IM)FV'-L52R/PE+(W\D/-M6W@>:(&("&]4YN!NIT<1\LIZAVZPQ
M8&:I8W*6E\L:4R/BRM?A7%0R!.9`LY1A??>VDV*E^D56M4_RS+5%TUK&4V:2
M63<,@[C)/H@LBIL"1@[^^\,6$DU&21(#+>=@$M=-2"`'(MW"[*"T[B7^QH0)
MKBJR8VH6`?ON&`8ZG*\U=R'=80$;C7\0I<+S.?.0?ZP'1>C(3#;5UA>2,]`A
MZLMT^2-LH?P:J7L9=-@QQJ/P<G`$(XRQO`D6!_TED[)>!2_6RL!BHN6C\:+\
MH[2%PGNO1U-R+^A.E*3QY;1.(L82)CAU,ZI7HQ_JY6X%=\N/M,H+@,5B5QO2
M-P8I+ILWDF.$O(%R)KT-(1';EL2HU(2EYM4"%#DW(\$$P!W`%=*N=UTA_:NS
M-8,(@@1:!@I&,,3^"B0Z!%Q;X:?C!:0[0TU-#>U4?VBP1@EY]CW^\]+P?.ZE
M]XZ2&>]FAAO@&W8'($-)87U&W(":@6U$EYUG+YYCQ<X-K<%M%A]+&PZI7.B0
M!K8N!6RI4^KYSW9_\UE9I!%;!!\TJ)N<5,9H0Q4GB0`,,QA?"<OOB7>>J8`0
MV"LYM+'-\<G!Y_M4@>"=YX6ZG$-+J8BR,B4Q0*H>:Y[5")B*?%X,C9Z+%.2+
MYUKW)U]\MO]Y=36=S62(1^>(,\P36M?*#:^^D=?G#\FR@R`Q1<1QMX_;4[T5
MCU?8M(%6GJRO`&Z`(RP:N$Z`5<A#CG`-J&3\&,+U67NX7WW\RZ_03*9\TJZF
M-)(,2Y"G\!"K;^I:N*)LC3N`<(`[O@$M8!_)%2,8Y?ZEA=+<2BD+F]DT\$_K
MB1D;4QTB*\-)X^F2RI7"`BFJXVD$$F<E@CK"D/VY2A#4:\:[J1P*=%>=S@J9
MKNJ1X>XJEL2BPBUBH0,O$06?*L)CP\PRX.3$V"()9([:J2,&L9K;X!1%*=%Y
M`Z1:_IQ@`!G^#&)L)8@6%`@2=]J'*)NXLEM=D`V4>%(N%4H@]/(DKK-`:']$
M`?T:^ZY`$N-_T>AYLF]3J%;(;%6KZ"HIL=4FSI6Z3.45&D1ZPN1`=?Y_W"#6
M@LR[AA^\@FLN/+*+Y:'A7ON#K-@<H7`K)1KINP:G_\0@YV?K4AUA-?I1`L`+
M>S&-P*CKB3<HI(]H:<#D`867:QI];$8B.TLV!T%0!F6?:"6Q3RG*'C6$\4"^
M*RK0:O.1H!&_6W0-0)ZS;=)":_9M0[/U]=7"`PF3[#),AWQG(N:H)3LA9VCV
MQEC2T0GAY15KYE$'8]@,@+"'I,FDP9?$LH'Y>0;O0R59//>0?".T*@6"U,M,
M=?8\L%&MW)1Y7X1,)0G7D8+[TC()?LG8KM6^4'4E"4$3*(7=KW^LER``62?,
MO^(DNA_D<Z&BNQZ!U-`FL&$:P94)[DX+8_Q@G<^:T=)2<!ZL-TO$Q@*'Z7P!
M>K$\:];>CBBL)0DR&348B%778K(K##)O!BV0_T/H,%R0F8QBY>)'Y"N!46?3
M^JZDK92:S<J3%46-YNQ/P@\$T+)OQ.7QSW.B:R-!]M4DGNJE4F6>9>A:%'3&
M['+<(!F,(B$UG4_6M`VYTFEE44LB"^&J@XA2Q&BS8DT."0(;>XH_D.648K5_
M/-G>+77*(HX]"9(VPAXLZZ!<NM=#D.!+"D(`;B]Z%A![.F=#UC5)<L/B;.SG
M<DH2V"@$(%<7)<M&HXB#0O@#5#5)9;_:*554\\%D&T@9(-&N]A:Z%(EH\@8*
M9@Q;Z!_%5[YX?`<SR4<8>)"9YN\)`3CQDKWGF7OM2O",U=37D8_GF):P!PF,
M=(LMG(WF/[@AS*Y%>YZNT'R$.JRI7(HB`L,$.&1FO5*7D"R$VEXPP3.4PBPL
M'UEJ!S)'7#Q:`,M^#&@@"_*`OP$3M=7+K4UNZ1%'?68\S;QFY34]$OVU#+EX
M9-][R2S45?%7$$/[21`#JND-N='4_7<6NO^L\9;-P86RD\A!"5!$M@G+)/CZ
MQA(SBFPFS?IL=;XVKV/HI6O]!"V-C>>8_K`BZXS)VU)6C:R7EC6;_D#RZ[*A
M"56"X!L0:"/@6-97Z.*`E*>\%C4@>W??H^T_4H0!89L#K#RY6Q)/ABT=,?@&
MTB[QP;PY)XO#(MSZ6)(R>L%@8HIH0)-G:8/4'A@8?VCD,^EURV&:1;)_A8^7
MH8:ZBA"DOZ`.54HZ9"#O4/ABGF4F4O=Q5^*_RI[DL,:84;-\BBJ%&G%1>C=F
M;]W*Q8@[$[J<8;_ZWN-,9[8J(-"-I!R"S[]9V0;OJOD>APXSLB*IQ8P71);(
M*8'&43"?3H3`:QRL;#L$Z,A@V.*`^ZDF^2R$>R\\W'L>PSUK4.C'&_DM0B2I
M-8O9MJ%=TQ70D+S..4IP,9K!J!34")2A?W(8HC_)-/WSO$;HWY"&(W^S4"N;
M+(@+%LD&1X5A8IXI4?!"H4K1W"IRN#1OU=C>N"G4]0EL%7Q&6VXUNB!KBY75
M@`H/4Q#I"L$63;1]OJL%P;24CVWKDS0N-B2D`*TY?L"4EUA$((TH)H/?I_YI
M(0>FUQ9;D>U2/`4IE5C>Y@/,`K94$?'TPBJTM^#-L?,R15$C0UX#-LRLB&6,
M2:6[BG0-"@ECP$E1=\"?(?8:S\!^7M=A!N!HW(IYL_<SP\SM)P_O/]S]XK/[
MLJ6;E$22,M22`2&?"@K]T=I$X<'3E#%^EIUVE[A+CD'HN,5OVP5EQ=_?09B,
M6'<>B>CFD`+JL>93DWFQ-ENK$@^48ME]*H?,T?.%9SU=V?&F;+7CIR/)4:+L
M+25@[!6>+*^E/V%Y'T2^70L0D2(?BUSZ<K4G>(Q8&8X9E+_B4DQZ4(&0`Q5W
MYK3>YT^R*Z>RIG;8T`6&I&J,LDXA0F5.'24[06<^XR)S;?6U0?2=IT<G7]\M
MTR/YB6-.UBA]8NJW<W1R?+?ZXI"S*,YMN*S_O.!_IO<XS?(7D8M3.??O\!<Z
M@2JPBBOX?Z!/ED^!]/[(Z?0*N_0]?N5E`X[0M^<C4D/7801]<,\&7CTJA.^[
M<L\FNRG+$%J(BB7],LO9+-65:"/24'$(_P(N(LWL,O-L5]$%`&H*P)';R=_@
M@;`>@%85W6,3OYF+(D<268ZU\+J!2Z>\M5KE0V8([\K?F+R<@6$NRQ@7\Y72
MXV8[+CNOA,@+R"HY^C,1<8#?Y"/".0%SEQ;,`1A\T3'^WJT(X5+B,D98+D48
MD+R.WMH]>S'8M[11]>W.MB.V+\PD9`B;]LDM^>X^XQP+W;SQ:$KQ@U+6''5!
M$T/[$8)3',GZ^:?_U35HJT??JF.P.GCW]N>?_GOU-,>&EH(N@U]EK*T,;*4?
M5O+G-7B1$JA'U^8Y!(5S8MZTUQLHK.#L11\O["OQL9DL`ROM*SR\[0J==0&[
M6:@?MKAMP1[(HZ,PFPC4:O#ZZTRF77&!DGC$]OA#\&,TQ-W=2[I;JLHSSAUL
MWA8O8LLZU."=X2CO(X_&P5%U1MHGSI&CEFBFA9*@2B5*I%U)MRB]LOY!:DDX
MH0E+XZ+X>]5,ZAF";Z57''2,P"H58U`X9/%Z6A-P8\S5)V)L%UW.%/0LEXUU
MP[(2TB69@C&&))`=;>'O@_?S-VPN2=IZ7LR@E<W5J=%;1/#'-G/U"B(XVN(?
M83A"WF:FK:A9(B;5-5J1YLA)9X^\+1_+#D?8IX7B5RA'#(`M\5W4^Q?[N,N0
M/-*WBNODCM$6"%G43Z7O(]-OA4[8$(459BU54<#X@:68J&T;=41"6,\B*&=+
M4-=Z2\'U@*BGF+<8#.2P+>.0+4(:]JQ%96L6#;0G.Q0^L.WHS"T)K.?C;D.[
M1['9F9D8K%S(W5"L<>MF]8ZKJAZIS)\(J6QH8V"^L$$NKLD;R'K'[3&WU0DV
M\@L1YGL]GMD[-B$([(\Z$9<O9A5;ER`0/F/73"/"2S1)&1_010T]\#$#=F3$
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M%'UN<`P&7P;Z>IKMB[7SQ#F"O05?R6,RA+"]DGTD,.19>O$LR8U^(E8&9;@I
MQZK1HD5;9/YU2^Y>B$,$VK`R1VH!6NS0ZA,0VUWS\@QJ[R8%#!:)\2($UO8&
M<.4F&F7C[\":>,"2M)UJ0W?%A]%W:3)?L4QI!K2T6%XVD_:WD5_&*%][%VG=
MNW'9*O$9)G*<8X"PB[H2GBC0A-:JY1AMT@2<9'#/WD5%NUU(!)S`6_F)8X&`
M\Q'M3XZ?B)16X_V[!J/"LM+L$]R>F@_8I[KO2-$1-.F0$4OI@QK?2['>$N7T
M%4^RG,FJ0,WZ<'4Z0]':DA""[5(;M02<=AWDT"1_T:NR;JBANEM7_E(O-W,M
M/.52<L(CPHA^P+,14+A$9)^](KU=[#<0;\>E_P$45:U.@:F%9\$A#PSMUR$3
M#Q89&J(!W>R8^WI.==5+F);<JW9T$JGFT%F9ON$$EHJ7@P,_.Y\??K[[X.&7
M_;&+A6S(7_6??D:.D+0P(MFD0I[1N@`J#FN1GIC^).G-*>Y4,@I\`]J+2:G_
M"-0:VZ\L)V2-^#F<!\?G>F!L7X'&9M;4-><!0[4#,51'-XP+G"-?(+&+!BU5
M@96`MPJMF2)A+5=S[<SGU^I",<]E@,;^W&4!<)S2KTYY?79MS0<N>TP+)),T
M$[/I'U`#;$&2.Y2#Z2O.B!\26>%&4VT^I>B!#O-2++`6LK.:YM\IFAC(G'JY
M'<KZC$I5J$OBR'J`-+I_$G867MU$>NE.,OH39]'*Q*\S`GB835E?FJ5S-45,
MRH8'L[H1T*A]EI%[,D%P9Z(1:2./U'MD*#;[NL0#G)WZ&J*)5PY7L6>$V1A^
MS(M!>'U4TE<3;:$I/5HCPBC."A!`6W0@2MLZPS%S%ZA-Q'.Y"=H(A8I^B:++
MA-C+3E"8A/**>FS4!<]::?<*_2Z^0M4K6'KHP#-]"6_31U4$B=1B[:@`S\()
MY*N<^HTU6(`'9/PM9M=A``S'O4D=_A5)-M3BLC83%7>C_W4AV6ZC0CZ]S]XX
MYD8;ICI<LFV(CQ0P-&V**>Y[@K[OJ.A%;[>LH1%*6"@5/E,:V]Y#*"R*B\HU
M/.4YV.(Q9PRQ4($[3'[LM867TW9PS.N$TP*D@-64B`,RY?<<6>G-S&X9EP>X
M#*@8RR,QRKX:_0F5[_JR6-B.&^[TP>_C5JR8SG$#)4DL5O<2N<Z=U#^JI=#H
MY`U:H@L:NR8E25"*D/F12;AFNALJ\^U^]8T?WLV][O$KUJPS*2CAI"8E'0I,
M$VZ`0MGXK]D2#!XMC+L\AW:IS8;S`A4MMS\,")[CU-*0&$99D.V+U$UI`@Q0
MM/%H`<S/['(C[/S27/K68'()<-C_5I9X$C75$$@YA/MJW!18J1G?);LATP__
MHBT$+I&5<6&CE:R#11+_1*`+58/G5C"F5Q[8Y89<S1RQC"69FN"HAJ0*$-$;
M-S3:A_6-LSTYJ*&,6D,3#+5>1//'A1F#B*C#&`NE&55^4GJ=1F8DW^K'WL%J
MP/'5_LG^IBW2DZ'"GI];ARDNIM^R]V_]P\9Z,4_L,*$?77L66CHPBN0:QX3C
M_+>E]J;SALMJ1Y5"[Q"2B(:/[^Y2BJDOU1;,,\_XWQE5J*OJFZNS?ZYV\E<\
M]PUG)#B0<0('$"%`RC,[*.@?\_V+<PJ\]'#[Q_Z7P^@GLVGU+:DR,F__<72U
M^!U[XX1A^I2'O$1D08]1'%N]C.3%6?=*X5G,7*;4%&G4]+7DI>3U[U9I.I?9
MK83O`[M3]*</S4F$B:UBI_P[5E,ZI1.-R(HV4(+B*"7"GRA_,,+N?F7%K?V_
MG@R`\*FZC<C0($V7[;NW3U19>?>V"T7[B_T>=/V!KP1!Z(_T'X89ATS-_L-.
M]_ZG+@+]3[_)^GP4]+G_2&)5_XN_FA<;+-6`[ET*OWN[\1ZWLKW#'AG<3O&B
M/)?]!-BYD`WK[ZCSE/"A/666TCRS!6)J8MBO7BWP.1RS0/'-&F+;6OKR'8GJ
M$1,^/^=.&("/0]HDCQ@A26FT4-"@N$$(08['^&6>U6&D"-?426\EBFD8G<QU
MN*2P0+&6(E\%6P(DWE2@2<&']/I=\$\\3CYBH1H(C1U+-XSFR6N=*%=9PAI0
M6$``*\QE"(=RM)I&<-G%.K42;TGSE+,6+ORS5NX]YREH6QCI#H@].Z$;@AA)
MGY$CZW2$R7JW5AO7C"!_F+N5$V4&>HDBF_K,?%!=H^2#`/.D.5^!Y@9W>#Q=
M$Y#JN$]_G(/[FP>*IC]T7]*,HC,36Y?SV991!'&%V.,!8JL9]-=PHM8!'7!K
MSM^]M1Z2=V_Y^XH/^-`)Q1?3\\'JGW$>=;IT$3VOOJ43?>];RYH<;<@B4_N\
MH5LCXA:E>/2?(,=VCJ3H:5..C:/?%S!:LJNG^03AE/#V&Q,,P2E@-/"C+,2#
MSW_EMH*H]#@J[AQ<F8;V+,0OWDSPR+L%V#L:C4"CUE"7I,N0D&<R"^K$@[:6
M(,P,5M<B("CUU[GF6\0%^3OM[<G3^32R+:G5)2-MU>#$/L/,<VJ%-GE@N,J\
M(!NI<,%]C=1?M,Q1Z#.P,J?'1Z2"6VQHP',;9C>#9]-CM\)1/%IJPY$@MJ]3
M1RFOTFTG9*&X,\5//$?=,8\%47Q/=I2-2K4`==GD$X(.%V].$FB%G6GSE&[M
MHUXPAX[%22^MWT-S#B-5AJHYZ"F3W5G'$=:<,^=16=ER(#8U5C7[]FAH&[(.
M,6TO]WBGO60NYKW;ECO[R]9VN-+N\ER-?5D=A[:40!(]B-)(K&8CS844;N,L
M`6+JF@A-O.YQ&+SEK#ZZ8-:@Z_JML\^4<YB([/(AL4">UE?$&JT8.*?`;S36
M6GU'\J27(&F^"I\H$-U#M?;DT$,4T^T*>>FAQL"WA,]-+<+!G*XEOYV!!9F0
M14-%(8CBA!1XV/8Y/*@$`JV3(%+S%AZ.Y"<Y7V"F0:PH[K<20RBDW.9B#B:V
M.SE0#0"!1S2>QI!GGW%#+2)@R1D/+27SQC.F["Y-X9>0";<DKG1"G@7)+V`R
MZ-X.<JN(/.1/R(M270M;)*I!6V/6C34U9S96_EKK9)-!`RW]OB+8LNLZ[*A0
MNK&C:-#`&ST=<_*6Q-OT+P&S(`2/Z6W:.\*+`P.N8>'>J=TA(47=>7ST\O1N
MO@F$J'>7E6JIG$RX5."1+%1W_G"+A+')7K%WH)$%H9*]DD'6I,)Y+EE_TW_B
M$@1160HLI5*J,]))'@"7[!:9E+8DLA]^C7/U(&MG^IH%BU[D.M;JFP#MZ'G0
M7#[$):<1[H7A.1A+>BB+4SGK?O7">\=MM04?\IFJKBR4?*:=D20+QM"J*U&F
MU:4,TSWA[7^D0TG^9VA7]Q6E:'X[(>F&CHN4M_RHW>O0H^M<B9+CN,4,1=54
M$Y'6U]TP$7RA2*X*A.XD:M42J'4OF^L1NL%?\!@\9$E7F1ZR6,\9AD,`>+)S
MP:JNN`=6=VD<]4CSFVSJ)5G5.+2U$$L9D>L45V2VHIM5?0ZIF"Y(6DP8H<7I
MWI>+NB&#LN`6'+2"ICP=S>O?Y>*8GE6SE"[.TR=J-K4^D%.N9!A7G]__;(]K
M9W_5AM(-YMJZD;X+MFKOR<R9=Z2+??UJB&#S?W%$N+F]U!59,+F@VA=_=ZK1
M"?E=%.KJ.RM#N]_[Q<GT2-7J&!:;2+N2=Y3"SA2G>F"(H:.'[#S9!1)7:\)X
M;R\\=PC9<5Y!U3QIS2HDU<DIFVK'/K+@YSIOIZP5VHF&J2#$[PBXUH4E:C^I
MFFBC;S8H8QUIPDZ+%O$"`&(!WG"#%^;%B]1!H'7:Q?*T'/U7<VRH)+HWS<:@
M6<;,<7G&V1-^C`8D);T6JFO@39:K5=ZT'Q=@VXLJD&.S_L0S=KLW`\?SS*0O
M?$^6?/%JI>4OK/4M&*;N1!N1VM-@\V."#U>G3*&NL=8B(G07`-3?.0VQ>@,Q
M^(T#LX*)JR'SJT>35;2VD'.U)9]QD^B;WU8'=P6Q.94G6]IQ[UA[\%,X"1BQ
M1T0S,M1$\N6ZNH"&&LU\<D_^.3B26%A:8=[))>NT,G:6K8)?&"R6XP39:)6<
MP*UPVB:8<98<[LFJ=E(5G!>1&^[L$J+(^XBKO/L[D^S#NP:@FOF][(,S'C67
M0[^C>AN*5G>F$TY4BT>Z=-5&NYDH*E$-<"@LB/?(1<\FL!KO>F,%I1C+`X:C
M9GXQ6%R"N.:J'45ALK9;.0A]`PQQT=E&(?.Q>ZN&&]QL3]D"M'<'%9!34=8D
MFF@C8#L!;'4]\7\Z.V1H362B!N-GG91Z%U`J?:BX0[P8](#P-;DGQ(>0)Z'N
M`."*D@Y?M:08K&K0`Q2#]7+A5A#C;QT`#2(>=@0I"T1OX2V+&XI.IDQQ258)
M5P;"UEN>:8.0>`;B1+XZ(HP,ZB2AGJ>AP>^F@[,2'+(`0<C=]`B#=AJ].ZN/
M65D&^B!@GY7`^%3`Z8ZHJ\WS(^"]^:]6W2*D'A0;%)9+^[%KUK+`LG@S3NJ)
MPJL$SS1.(AKQ:,2:I=I(>-B,2O`&#KTC(FGV0$*^R676(?L*LQD%L@O[S1R8
M(XY@6N9`]H$:N6J(LA_:K3\8Q3TN!^3M!6`7^I(L;RAP>2P94A*E-3!!4IX-
M&)['N!T/6Q7P*+@IU3'GY$BXFY`2K3X,S34HN6>?5%B7PNFT)JE%$]8WHK&;
M;JYSHX<L>A)O@/!<?0PO5:;*$<QZ$>CQWL@BQ9HV@(<8W%\90J$R'D0\"M'R
M4FI)R??)54?`-SHXV!9$3:+['@'C')C"(2H;R*[N<=%),%+LJ5(0]R*1&`I*
ML.+&8?4<#AUCT&M%7B5&BN8_AIN*S<2[:-=-:?02'XT'/MP'=;`41]+2DWPJ
M*6$)"7),"(.5632:-6[95"EO8&E`725J20.7&>'"4H)I?G(W%94CNH+\D,[)
M9@4<*.YI84,F#916>C<=Y9&ZTN8H"KFGR>."/TRY@@CJ'J<8S?+5&1`..Z4&
M4W(]BK@COZ+L#5;R+"=-I?':T08@W+GA)^)J*5R&N4,#M!GFIJA7OLI<%[XB
M(&,D=`B"NR#<]'FBU+)('&P2CH-%A>,HDAT$I7/%DDAAV+5PUOL<'QOK-A"W
M$8S)0LQ<@ZQC%M.G*?UDQU"5ZL?);L_$6S+!TT0R+N3!;44B;3ALIFY;QP\Q
M799OM[5G@\;*&7BN2J5`&D<`J,&A!`N'BJHKC$3;6.>^?-:H`]!*`0GB%3.Q
M*96RF3<B',OT_AL7M#,E4KQWQ2L>X%*U+;*S&#2)"SEFZD)[1LL"9@LAP9&Z
MK949D=0%^QVX&<"N$2)W0&R0RBP9H3>.#?O="J#<U'1=PC/+[1J;$32#GH4+
M<+O,(S`GW['K)YQR=Z+8V'&(@=IF]!8$4W874M;8KB70I5WJCV#+!4PQ@8UI
M/PROI8<<",0\T(UP6V;]/<%+D8K5#KJ+UJ6ZXH(RH.9=D0/QQ#!`O#P'FNK-
MXDX.EZHHPF9@RXQK$B`=/_O@E^W,FMDZ1)#-]4,%HW<FL_0XB&^XM#(;AZ!#
M"3R(]]:I@ED89'>'QE[#!@%SMRAK$L4K#MHSK-M+#:\66$`)0$R,8L8&MI.]
M@&+2U1#<."(QW&39Z)C1!<9##4]NQ?#I(-U`^IAC:]:B+:Z.)B'>0@>/-AU2
M?[6P6WTX8/WJ+A>![*O1X_Z7>P</_C[IKS(GZ$XZI@WIC\@!T:^7!X.+_XF\
M/F")>W#M-DK^M]"TY%$09-,;R5D,ZRO,]P]\,>"2/+H=$N*""H)K@PG&3U(V
M$]7(/-H:4YN)5UQA@,B)C*VTT+&OU<X?3YX_H3E-\FSU.,#"F1U!,&3LH#AY
MXF","X?I!AE<YL5-I+%WRM/-@^?J;8(DP)J2M_!@*J8:FJ0,'1(I'N+'FR-*
MFEE:Q$`!7J?XPFTM23>_&(CV3E'.[O<,QV.%WBQPXZAEQ#5=GQZ=#=>G$\.&
MOT*VP188JKK*Y)SCPF.:3,IO`,T4LN-0,)E;-.KD54]GRJ:X>%K7Z!N<H[P&
M,&2#W;.G"!I3W*F2*M$W+XA"N?`<%QSR>E;%!DZ&D[B^T_WJG\'#?K%?:-;M
MN(:"FJYEFJ($/=!-_02Q2MHL@QOL7?]O5U.=Z3+S<N-X+8T'PB%0@X.ZQYX!
MB_%=6(&XI`TE;QPAPS%1_/`6&*_1)L=IQ3+JU];I`M=[.RJBP@A!)%60.;*=
M%O[-HB1<:C^%$6OL($*N%R\@:*9!Q^$[MP(.BR^CNU'@2C^\96XUIW3%!R8S
MA&M$RM2:4W)8)H$WC?/TL/[LPF8PY"C7A(/*XW)2(DO8B*/UTW/KE!"3<M,`
MFF`],AX@:=J>I!E9-#^&V!-I+$!C"*($18.!TXE2II[[]H8TC^`Z1BL(1+;H
MH;J)_)?+5;2'2P?#6]=3['L#W.T!5,':R2KNG+Z0#635(]Z@PA!%02OK3$W+
M[Y.3%SR+]Y7EE#XJ3$L71OARL^5E`+VAYQ"7:&T\I6P(5_S/O2*!]94G'NC/
ML[O_69:JCYK4=".4#&2A`_)/\#@F8JSGNE43&S:`U]4![H4%RA?3=E]WX1(0
M<MV)),&7&"\1R"=D3'$[IBC*#'F`V#X0P'!9ZAA`[R#R6*7Y$$:7;_HE#Q%?
MRZ9RT21)6#P$6XWI':U9E,C1-$:!T)/0P0R"NC4X7H4%"7:#U_U6"%Z#X#%V
MPUG%>U$06)\&-H7E-POUT"C&N"8!EIN<RFZC*"G=K@%KGK$\UEG1B$7F#B#M
M@$VKMV-&<TY3L#IFQ?.F.@1;DTWK_EY*Y\I]#1"X;CX-G;%?J@N4$4<[`7IF
M7`S0X]$?Z/H#YZ)*6IB+&<BK28FA;T]O=NPV%6KE>Z/'"5:&/X-REYH9U^*!
M-+_^\49>0#M*0E7F@-7>.E!V8W]AG(2-.Q&H68D<@DIYK)-%+^8D`R6M*W-$
MW7K;&@<(,S8KCPFS]YH$C2PW%V0+-D??4EDN2H2@.YF>5A<UE:(@\7`Y2K;:
M=LD&<*E)]X=K]'B9)+'U8UPB21$EY`:IPUS(W!;^`VTH+$;I9*1FY);<=I5[
MB:,ZHUQUZ/.8_L@TK"V:,Y_-'??`"9;CL=!<G@R;OY%I9:V5N[],1T6XCE'&
MFIU"%CL5ATU5Y+/)^Y@!L`JIG;0TG;/\3_)UT"N^J)5FR,#'5@<57L+.=-[B
MR21.G:MR<]ZRQ#?)FJ)VD7XR9U$KN4<E"[NMMBO6$J,LU2'")+(L;DAZUAU9
M(G,3D;LA24SD=7.Q@V`4G0FAR7O*U3D?TQ6F8!9^I2P=S(8*``S/G$DS"D1)
M$6>8ILO@3;B`%S1"/U>7EI^&'B3EW)G$9!S.N+B`.N5<2OV-DL"T@A;):'46
MY'=?"SQI6=']"W@IAE2>W2X:X^BTSCF8XNN'*9P*'$);8*H=37"B@6Y`B6`A
M>.1UW,#I!3>-X?$XE1_W55%(F:M@]ON6R7T=(ZG'3D-U]L!B/;[TP%5&3!=Z
M8[\4KMI:!P/V4BJK1Z>,&E&3#J>V(0J`"H[@S0\49A#BO-9E28*J'G4.X5<,
M2Q5;$'"%[$S<NEW<*8G0E3ULL?@=&8Q#88;,,6O;ZJ8`)':WC]E1^D9N5MB"
M4%6_IUZ*I50]%D_'&_"`J"/,JEO-L/?>.1"%@:.2,!R/`W=]'^Z&F"^*3>D#
MBF*'5A1+Y\CKS,"4W?HUA"31B!-]Q/FE+O'?1G<=5PRYOLBI4%A3OVK,`:3D
MO:H\62@%P8J0*O("'N`'N:)"8H+KQPJ7/%YT,JE>Y,6=LAM4BA<V$%,,%;>+
MJ=^73%"/@$*,!`)[##>'N84]GFV!?+P/@2TFZO?`Q//7P??(]43_)"+=0!J;
MV7NH%1Q[`AH`8.&VG%F\H3>,Y\(BG>[>;9J2->FY$)];X@_YM&IT7+_Q20U.
M?K&^)#]3LV1/J8+X03W(!8#89'XT+=JEA.T'*G_+;&F(_PK7;<7:#*[<_D6M
M!LI]<#YU<\7DQFI63&GE:G0,1D(9%)$()RN22@ZRZ*H8]!/8T47=U$FL9X:M
MQ`,"GW9L:I"^+'M%I)26H9&1L]RT7-JQF`^'T8C/+=OLD$7D@K@$[0X@6/K!
MQSK,HO_G:]=\ON87[*RY*\7TLIVH>XX0'.;(;F`K-D)83RS)16&8"YL3]XLD
MA=/;&B+";`>?T;`E:=M(+@GZ![`YE]B3A3%;D50D-^P%*;Z1E33/29(P`X&>
M6F-$1&XC5::\%2O+F-U%V>I3>I?D*0ED;"=<&C@,@`56./?-%QEOIBY*Z)X`
M#&C4TF=]"8LUL2))R$]&1M=E[MT=I.88`-@0-)1\T[V[,8WMO`;N>RXK4"EW
MW_O&/`Q*XIW$M+349@TR[E'T$JE^$[<L]1)M4[*%X2<@4X4_5XP<Q/AJS3&(
M^H[^V!5Z,HJ_:J],BKEM#JO@P=)EJXXT2[U-TR0X&'X1LJ']H_Q2;`\HS]KD
MBR\5O.?6POR2K:F0R-&U19&`7[1V*#>LF38M%@N<`U],J.RK*&D[*2^RX3%$
MG*,RG)&H%MAGM<"_]-^Q[*YZRP+,1^"KXJ]9BJ(.X27/\>:5G/BV<_)/]6L$
M(L)C2>!1\<OT"/O.T\='=[5J1QY6-U=K/AQ&$NP7-K4R?NZ,(Z7>BZ:'E29(
M0)UDOA*CPX64YT"\IU0S:=$QSN"U<(8>+8(8)SK'4#!H"QV<$7.J5YS6MU=`
MU]S2$`LT-%=PR>I`@H\\QNAD`;S)(F4F/8T0NQ"21"11WAR/YL82&RZ_5B(_
M=$M<D)/1;1U"5Q"=D?U^#6@J"VP9T&A#'7ACPF@>L]\UC%^D&63@F:0P13G%
M@ZQ:Q.'!!+_('II?=D8IX"G[M!EFK"R?79="FL)J;#5I7!#ISD%XA:60<?2:
M29'\83.QP4>;2,NSO/7.87J9"WW&Z8"+GNR$;RE5`=:MKW:X`@Q'JKM0K<&P
M&W`0,+):,U?]TRD?O$9^&31&@"5!W+6"W?DA8?P2>UR,R+\'0YIZLG;&&]^&
MG`KYPL]&V5@AJV8M(H[ORJC6?9L7V4/#1I$2*\!"UZG'G`C*AB*JJ\";,`V"
M5*TN_%CIUEW!LJC/^DV(F,^U:5W[)9=Z#1&ULPR@?Q46C<X]#L,3M=!J1P6S
MQ5'3/<FI'PNRX8'4@`23PU"+(6/1%9E-`]J[46H[<L7Z2T[=3.OW$#E@_(+`
MV"2%S[*I5FW+:C0P*=_;-?OI8%KIH*3LF>293('"<GO*Q\1?-('8084LC5>*
MO;9^3%<^<95I7CQP52`2A/+FVK)9TD@UH$&*>*)98CD)']H*8C2WK8NTPQ!A
M7\H5YH:H<P1Y4FJ!M$$8UV!K*O]I_U31R$KFCD`3/7VAW-*6Q9X5MY`&HA":
MX37".WA7<@O0UDZE2<RTT$#::`I-19+@.@;)04_F0[IH[A;TE6V_F8B]10P(
MJ)4R@A.@DTE/30XY9)5X<2P`*BDW8WBV,,@-Y;,+RUJT'\^:K^ZM'I6YVY=V
M(0>'%P)JJHZBW]S8Z%^*K`46F\\]"$]93BWC4%DQ<S]$21D<AX8?.-H[V"LF
M!\TSDX'!*HI5*'/N\=]\$'$(Z90W-V2(JEC;7=+`6,_5UL-M8!$RV^2+;8%F
M##?X?]JFKP+&CY\67?7N[\11@^<&*<)+)AOR']YZRP)D1N/^QBFS9>F[O/22
MLMQ%8YDY9$WYK<1![O'2;_[$PC1J&U0G*IGE>G$-$ML.A-('I?7L'`["@__\
MT[^&S-C//_V;SP($C.UDU*MS-I?220YO4Z+.$*-X)+JE5O5DEV(M0TX'@<EB
M,AI;W1\"]>UR*2&>VXO13'_Q:7"C3K%N=8%P)=1=Q[-Y=3SB)Z=;.X%A'4LY
M?2C;:*X?VFO$@4,Y-6-E.-PD@.%NTAT\GY]^$$8,$+(+%9T<_-(\]7I5J@-7
MNR+QW%I#W`YNL;O3<PS)!N[CJ*)92#H8A:J+EEEK!+]*D#0)D$J`RO6@^]!I
MS,^H026>2SS0@W$_?&Z717>STK**6YF+RCT-&"EYFF*W&(J(H]&]B#OB?++*
MI=.,F3%;DVXH$&M34YLSN50+IT4XFVU*U-GRE8@8#5M*TB7U-'.H(DF@A62C
MH(8/;O=(;:-7B4#U9KC9,I0/(AE,4CW7I(>*."W?\B?Z3N,O,Q+7A=^SU/.=
M+?7`^^:5#Q3@Z7LD'K[`B6+ODI`/E@2]E"/YTKI&2J`J!;N[DESB#?LU7UO/
MK8V,"?\9U$5W4^_`1N4R'D1M0GJAC3>A;-<Y@D%UF+!\RS\L;MOB)X'_6Q!6
M>G(;&BH]G3+XVF>LGD3'(-CHERTZDDZI7L/D$9U:YZ->#P@M8.)<-NN(I!?Q
MS,ET#$M4<GF:V[/1`C%,E$_MUC,UN$H/`7R%2EBB,#/SF0IHG=6Y]V.<Z,>3
MX[->F^0`55\I9#-ZO)`^3D3MD&V2\[6Z]RLF$GSC_$)U/)A7'1SJUA=N+20;
M0V^AG?W$[`<8779=>Y,?%^V$MFIQX;@,4Q3<)]<7[:F>\ED[=3'"$/R#"4YQ
M^$U@JM/IW6LLI!V4*[*+B>&>%WR`,OJXTXO1W;3FL\7H/O68IAN3@0DM/\SM
M@$ZW\]V\B!?O>\3-1V<Q?TVC("V!EFFTWCBRW?]G]?MMMTW_:/S[_Z#Q;SO[
M_]$+J$8+S,I-'4__Z`7$'!>)S]*CX![^T0N("%EFT7-K"JK^[^D%S#^F-40_
M,<IC0RF(UTY#%"]8=&MHMA'>=S'\:!4RA8X"XNR*RB/:N?5TW8S\!T"0D'7@
M=R\7!.]Q#5JH=ZGTNMW/R**GAIZRG]/2PG'>!+DZ>$,Y&S];:\G/6"P`A5N-
M6MBHV&_^]89X*[U)7>HNCQWK=&O1&;.V>KK`5&J"9SN6P=.')<@U4F$"K4O;
M.GY(8@8\&',PD0X6)UDSCP%A=15YFAMHYM?RA(N5XPO:1!8>A7@?G@'J2HEW
M.=D-($E@F*)L`DMX.^SB8P3(B*MKB_QRF=AIOA?ROH1"-V32`S8ON.>\*K*@
M+A*1OJ95[,&S]$4,Z@2/"-K0<=$QN&D5L6,HGGOM`WBQO[3@N3N8#C'6X[];
M.PC]3!GB93)AV:IR*LMU4\+I_]'&M8Y],5W?#K)"%X:I5K0(GO:3]]3=FL/0
M<9B&5*;AICG^1LD"1)>HMHQN,?-8A^WUGZYZFKA-=/NI!.W6&F!R?O;!"9BD
MI>I$TH0?K*>)(;?1K0[7<XWK0V[=2(91;49NG[PIX_:D&B3H7J:V+)SS8Z^2
M6%WM6/?`#VI&Y=/EK'97/)<?K+'EQG/[0.X$EX2O"I?'=V8KW_<[@$EOT7?2
M^Y%`G<IJKO'CL3DN#$TIS)V@LJ?TC?"BYF8;\<I,?C_.?V\G+Z&L]VB;H3)E
M4%3'6.6*[';69GDQXNYE,[4VDVK>5H0CM]'2T>!3263I6"`9+QDB(<X'I@!]
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M4_3;*.-F!D^M<]1!DA!V+V;*"B#0'4:[92CE'#NG\J/]EB)M5"B+/`"?$6>8
M$</(+CKW/Q<_*Y9+/80&=&+I!?VFT?8)+'7+U]SW0Z+9>YMTW?YP&6Y_BN.=
MVI8NH)0IE.NW>K].G5H1;##(S>M@,!FZP5MFST2EC_TQJ2P:Q5FVD\*NB3K1
MKMW6KI3OIZJ':!!0LH@`#D,0/,2WEK,450&<7D_+W\)X]_8W![_RY;[EKOV7
MV6U/)BM=:OSB2L5O8DB!BF/_R&'I>1*%$=;4LDZ#HO==QC,C5B8G'M>Q)?.X
M7^NJD[T3JM'6FMH0+OE,Z&#L/$R_3Z":0M%%Q>T[-`X3:%$?ML%,B84%2`':
MQ8`AHHUA%*_G2HSDU3`$*\G]1_K4D=Q&F11P5RE:Y[?WXMLC?L%FDEH`$LC1
M:N-ILNV_O1/C7I6OXK4'-HL/&C&,A1:45(LF)"$;>H9UH7SP]-MF1+X)=759
M$?`O)&;*^5X65_WVV"J;%D6MG*8\G=MM,UWD4UNE?`0BV7X@C'@KZ`3[M/C8
MIB>2E@D/9\P`)$L4I1Q*%80?9_6088,XF9('B934=458=MN6F?![Z.3@NG>_
MT".7V?P:@1+E2EHV3*EFT.Q.[,=^9;;UNWSLEP`Q7LYC77W>'!)06OA-3HR2
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M5_PI+"6.LA*-X(M9;Y5:S``M.28L@D&JWZ#FI3JR98]][@%H&QMJ<5*([`8S
MZ749`/1,NX8NL%UQ]7IY=JRR/2?[&B9@[G-$YXF<.L&Q$)XY3SA,8^=(ZWL\
MC9NO#[FGZ-0SE+F9@ARV"<O6E/,8<C*LT@+N,J@18>8&`\H.2JH'H7^#@:_6
MREM<K3.FQ53+9;I]'C?<)L/D%>[0A$OY]M?H>+6_AA'_N-\[Z/<.G<,/US;E
MDR&R;R_\*N_ZC<]\B<F?P#[*A;]D+Z%THH867'4TRK216`PV8"..<O?L5W91
ML)'*D4:&332(E4(BV@Q1`#!_>\(@O,Y=RQ345@M&SFA??2Q+^G#>L=VWQ_16
M\Z.>"B$Z:BVQ8%W7=JP\$.R.J(IU:D&G!K&,`44K;>$B3FK)Q<=4PIUVV&>B
M3]HX'2HIB@R66`JFT3(IY;:!YWRO_6(WTDBB;MK\R.)\/U&BU>1L;:R<+2Y]
MK.B:WM+WX:3Y+=:OMQ4N`&XF2J(U^IK"".5C03C+`,I.5QK%=E9"%O'L!O3A
MQ26)R63MM@SCBCLD)%`;]APS_GJ+;DZWMGZXP02F+]Y8Q"[\X6)=]<'2/>AN
M&6C;YO(!V(2\??;JF18O%YJ\;*1`.HL'KB,-T_2!`D4W;1%@`F?JXC5M=.U,
M,O@O\*V?)P,6L+5DJJV3.=8]GR[VSON,*Q9WG[2NLY3:J8W4U$L_T%'@7^MZ
MH-(7-5VPZ(@V1US=[F\-M_H[H^W67S;[VQL;_=%@J^,O>UM;_<'67NLO@XW^
MUO9V?[3;NF.SM;;078TS;*>Q.:R+D726Z7SA9SF=O=8)[GZ_1ED3T>4`S7=^
M/JE-9`8`=W8&(':J<IMI6R`T/ZT]V1CV=[>&S;\X-*73E`]8I<>;#R<!]/ET
M2R,\C')HE.!PR>]$XY;$,;'O04J='Q,;R6*2,Y`6>;<(;9VA2H$U=6"3/OG)
MS26??+SD<P=+/G>X['.HW88^;Z[E+Y:1C^\`?U%J>ZIJTUXL4%K[GM?=F'`'
MHP/3!_.]Q;I_1LT/N[%/`L)<92CG&"$(07,V]Y4J.#EKS@L;\?GX@]VZ&_U&
MG^IFIXL8J<KO$WZZE?SB-F"XN[FAI45)36*JPG6*&R0=2W/)/#OEMEOB#;UP
M?C+.9G6RW^WO']D)?2:OPJ_3&%_VGN;;S;G_5IYC;96KSYZ^?/7(-6(;NXNV
ML[84/FIEC#)MW6#KGJQ-04U7EILKGQ<D%I=TL"EN\A9S8>NYC,I.TWM::VC^
ME8J>48^%^4<``=/:<;O%Q)$9X&35(,7T15[],::MOUY<\0L<01U<+B3$4BJ>
M+_=&M,-JR!.6">$V@JP%C?H:8K`1=CTOMBH%_-81:&S%68<D"<LPIHDM:+O`
MTMB,(E/5B_C8[3/M.+-4Y=2MIR#05A)_S"JRZWU)#PK+1$8>T6KYKBPT,T2!
MCG:P^1_GNLY;,_(MN8//F?D=P#B<<\Z1$E6O82*64!J;_"H%-UPJ+\&,(X9,
M[K]@5_P9XBST-Y$57CGX9I"%_8R%9I<5XX+!+S$/J!$%PG!U[B4#M3@E\^G<
M4DL</Q9SP?:MR2J-5:*>ZY-R4IQ:`XGBDU.W&`LR)Q=3/G/^=<^"/T@"I_-K
M[JB^Q2IELVR[9]CIUKG)2(?0N(69"AM<S-L`Q]T<8W7%-!!W&.0L$BB*-ZKQ
MS7OK_$A@W1W+]IF*(`''0YZ[GM8<Y5KZY!?0\I_S),EXB+/(B542B&65LSEB
M6R(DPM6JGCZ&+XE4VKKVF54?3O,N37&)K">48(!8:!2.@MXL<[WY-WK3LEN^
MM,@X2A#'D=TKO<_<GG!(KXV)_^<^':/5[OY_-27-4(W1`QS1>O([S0=K3^GX
M^\BB$R"202=:O?,^PJ9E2'&#^>+[RE_<<Y]Y]]>;<Y2-K6#'@CON65[@U28!
MFV^OH@(&._@A@Y:SL3K8Z@^'>_VMO9WF6W=?3Y^`:RDBD<<#2%XA`0)T!A^^
MHK%RZ*`A44PD_M"4.#]L6L;[RG"PW=\=`96P@)7-X:@_VAI:FZ2HH9?6MK_M
MXGEM#T;^CYW-3>:[;3I0GT;KH:FM-F.)+]?';WFL9N"%;/^OQC1(]M5#+@X]
MO;AM1,9OOQ53\??%7+A%M8@,^D);Q#L+QSR<6]8@Y2-.&'Z`*%IH.NYA%%(.
M8S(;L0=Y-MG%X<Y6@7]ELWU@=,O_O!O&6TW/29F]YE)2=M(4GE=TK@S6-S8*
MV,ZM-[=L3'M<WTQ/J0"V<V,*Z&\I7+#"+#=PE/EOB^POKGHO3F^G;K"`/+)H
MC-QRT:AW))0<()FWBA,I286UIX;+6%0$F<:$_C`(5N"XS>U!?WN'P:34>#!E
MO4Q!6HS$GEG!7QKSW!SNVD0]U*I)D!1CI4$[`QS.`;3>*>@L)1E$>RSQBM/=
MC9`FTCYND=8P8EZ]`@*299B#F7G<QF:P'E]$O\?-#=L0:V.P7<P)%5IAVB;:
M:Z!'`O]8NW_!4-_FM)1QI"`$9LN:N]%,+6S4:%2H-I1L"OV6W5%!570<^TA'
ME5Z_G*0L#-'UV=$+F3FQ]28B;-<5[<B`O4&UH:""O(D/XD\LHUQP%W>9<X6X
M$6?QOR5GB6<8<`6D9G=O%X0'SKN7958&XH,MALI%J8E)!F`[>Z/-_N9@`9<<
M+,4E!\WMP)UZ)B=I(9>TWBBY1.=NV!]R>+N)Y@9`175.68M+>BW._6=BD3_.
M+W'`@T=(&"AY)-A[@.8!M=L8[A54+,[_X5([>]C:61T"$CS<(Y5*E0T'5VL*
M)>!.S]L+F>DFD$VJE_+FBIQTI:]XK(C77P(`7O4>7_#[=)N[\LZ>79VN]U;M
MC_!45<TH=<M$GEO:GAPTD[.WQ'+,UE*G2>LGQ6')`DK>+-Z1?\FFE;CF1#)6
MLEB+<$T5TJRU_@1S\/$N]O;!+;6/'`')1Y@3PV6+X[>YF0Y9UZDO9-%@S\Y^
M8U_3V=_D[&-[;,HI7>+LC[;[.[L,U3K[:([A<`>UL[N`0=:6T[Z'/-<0^8&F
M)"/`;]]TJ=MX$N-*+1112\DZRT@73+'9W]T9]8>9;N*SM#'MK[K7O/`#PB8C
MF=8"E/*:@4RL2WXNL2YV`:Z";/)D,2")>WJ!!TH&3>"V7FI3+S\5-_IO]%E"
M/$,,$BHUU96-]>V1&2"Q2N+]@9WYT47ZUHYN&@(;&<2/@"&733(4+/0#[12X
M)A`-9Y5"]32BQ22I<,/<AL",RLAZ83QQO"2&C<B<M_M[S`V]4##%'>/+Y!VG
M3=1$\_:-H-[.QF[9?Z"2YHM'[#H:5<HF+*_#7J=:'(SS&Q)"(7[8=.*G%80@
MQD9_A"II\3_SV]K<Z0]W[^#_!C.AU1*INE-=14W3K6;'L'T9FFJMZ]#;LYRF
M"XFJ5+#8E8)&I>1L3"G3OMA@9@$;YI,EQ@^PR*)Z)WC62BB@I1AL*\.)GLYQ
MCT19D=3A5]=O./1!)3<MTC^;9/D+(XD4EHAAT66:'B'9_806"UNTF#P?08D$
MYJ.?<(E`)KQ-P*-UR-9:W/O'I]/QL^`YW6`#\?7(9Y$6YM#XVE%<.O?<;K'W
ML'`)H0FL$`'3)*P;S@N6)]@+6XX4S?`P'ZDY3NR>SJGE#AEY2B`CPT[F$LCM
M-T^XG?;\/=>KJ"XBB!EDLRA^_AF7(7XF`2)^.L@_'9K>C5]WR&G;&KR5G`/Q
MCDWB<$W/_8[-K#I+DS4I31A'%\D;*UD.G@P!D%A\'[;$HA:.B':^+&'<^+#9
MC!+)5MWF4ZDG0*1EYP46BZXMM:F0),R877S1>-.7(9$E3JU2"/1=Q`B[:^**
MO\)58"U*2JT_68FS<H4P`&.6Z1MSTJ5]+':RR?&P+Z.:,9&<,6\2,IOF1L1,
MX)(^A'#_=`Y*3D+_I2R+ZOM&I0:;5#0J*=.VN[T=66FZN71-VYP.TN<-3_:6
M.FA`5)T#DS6S=(]G<`[+T-;H,213R131Y`-@^:V!,_DH=.0CQ?0._-"YH"F6
MH!C!7]7^-,=(RCWK+S%!4_9B`,N?$M_X]'0&?'KIH/[2L[/]TY?+]226V-[N
M;?YN^$WZ=H.]ZN1/E%=2GZ1^]/6W?>BM2I7#5?*B9VNU9`URR<2F]:0<MZO!
M5`2`I6/4^/PC"D>Z4JV<<MKVJAG>O5O<UJ`I;<W$&-&/P!P5=#*[Y/3T!LDM
M&QSB)=FA)*C\\_+B\]/'3OEY"QE3*B/FW@86H_YON,57[(?-+9N+?AYM8B@C
M5\9TO:4'6I".V2;L4(HZN414YVDOT&G*HF*+!"A%`E2;P>B"G(F1^G[FMY`D
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M>>JA5]WC(KE?RA0!IO<`2BEL,T^ON92"`/:FS4GLQ'\I9:^#B#@4MPYU5CYJ
M9I&6YVN;I3'RI2U)-.9W!BT;H#D?T=JN(J8KD/I+%?AH=M5X!*Z'".9L5N8*
MS:D4#*_HT!J\=B![+8.@Q2/^A2S'\:G6P>_QK7;7=W;X_^WU/8+?*SOK.S"O
M_DI:AU@V?I0?UFW%Y734($TAB9)XZAW:4/&`3I8OIQ.TKA\,7T<<;`L[*O!^
M\P[F&NST!YM[P"*;A0U5([,F+2:Z9N^Q4H&Q"C+6"7BO/?[IX_(&>4LX/9%9
M9.=>I[3BH4P@2WY^"`&;AX&^\%,E>9"?48FFZ'SO`B>)\*"E"<D:M:SSA9)=
M9.,QS3$)%C=OC7&]R:#GP[_'_(*<0`1TMCWEP8AM\$9M.'(EB&9:!(7L>.-E
MJ6^$AW>OW_?<T\'><!AVMA?<R&X7()8A`--!6;C;S)+9M+*UD0UIYY3"N%)J
M`@DGJK>I[77DFSNU]8]L/M34:-Z;%O,V:)_-SNQPM<PR!Z`*PRW#&"7)8N[)
MVEIDJIH%9S$?!VV+].AJI]L\]@NLU)VBZB/EY!L\O[B&]YGL#J*8Y`>@NUI>
M2DQ\D?HM'8N4ZA\BJI*>R#J=?.D`96Y'J4;`N!((!9?HD?CF04U*->5[B[\Z
MWL(P:KYFZJASUA*UI8C-\Z]+0'?*>QXL+XKW+G[W[1]F?U=!U7_[E\'&O_`O
MNKNXP'L[X5?ZS<U3@M3^R#%E:+/>CY/WO9<(BBO]]?48'_1#C*!?_.[F2/OV
M[37U^)B#@&2MKWZ9+RZH43:/11>D?M9VMD)'BW:P]>#B/9.6+%"%A\ZL.CKI
M?#;99=$<]YL/+IZC:?:N238XO^/TLOM%52TG%7U9BQ`C^L0<*`CI5L6A.@*J
MO=49I6$_HG1[`GFK<$_OB?K&$`_2RT5'VR)%$5]3TSQP`,"45-M/LE-3"_U8
M/%U&P;@W6&/T-3-K")JI7\\-AJK'KV88DYT5#WPO5^[X%G2]>$+'>X#"*BD2
MV[L,-5BP=S#DVFU\8MMKFVD^V%&0)+5LJX2Z'9E1548;QJ'Y25*)4(5;^@B1
M$F'#J$8!\\^;J35B4&ED1D^-MGR?KU(?(RC=TNW<&C\O"C],KV*`=JRT+%Q$
MRCK,;!=Z"U=XJQQC=Q&368Q;._=$`I8&AU1UGB67F4B.BRTQQJ['%V=K/!\Q
M1@<.\[V7_"'3MHK3_PS.T,Q3YFD8!"6;G2J)@J0;[&[9"P*%N17345TF3JP(
M#L$PTD:P&YP!&/G4'2BQ+-VGS#>$)WA=+=)TH:O%E)JF$I07DLY&ZL6*/=Q&
M+])^&TKU]MM7*J@X6Z/J@OT\\BM*6EGAAU7.\HO71K!<EOLRKJ\^4(<8KYI$
MR!9CW9%9-%KW%^[[_"NK)W!8OJ<4.E<B5<>YX\8!)T%B(XKFXBVQ/3%CJ4V(
MI#%ZJR*5/:E_4F))ML9[)BYVUY^L3,DH3\0$MH=]$JJE[6#ST\U6>FA`ML[.
MYB@<AQ2$4+R9?==M,7Y<!B.2>O92O!=-[`&1&MO4_#H_U\SIK9YEK%B"BQ]W
MYF$;]5(1PN*QF\8?_9^2:)-3[K(R!U^E<KS'BB@[M0KH>`I"M7ZIN\A==#BS
MPF":D=^38]1I\957KXC83R<G-_/QC14&M-+`E$VCR+RHX]LQ3!EK"[9K:+N'
M5->6(GM%8CN&#*%?9<$=H%A)6EMB,M783W8?'A3W\),/##AT0<C?G)Z?QQ&$
M&$=D;VV5^6Q:8SFATV*OP>KP9!`(>D@9\9$)V(2J4N[/VS%I:?.W18BB,@;*
M<=,-7[I$&CD!?!*9('4"N2]6[8*=D3K_\L+6-FR^E=.T&&^3JK'-_G!O8^GY
M1_["KS+_G:U1?Z=*,V/^9$R,=ON#C>UEYY^"\[_*_$=#*O5&F:5L_CM[[,GV
MTO1GMVR7?YWY0_\]O)1@5>:OY%U24884=^R;7YUU]*>/*>>6PP[K*FL(&<AF
M[0S2`)X7^&Y\<6F(GF1WAL(JD""?[I:8>F6J)<1HODBCXTV`-RN/R$41G8+8
M47G4-F<MCE>4'%WV7@K1).YP0)^1WNJSEP?(,*9[A^1NS5:2*B=QNP7:U7O+
M[:E(-T3F3\]I7L:,DF9+AES<SS<Y:^6#'QNQ35QV?2#BVDTU_"0U9W.JNNIM
M&1.VB%J7"(,!?0\B-0`C,KIF,.T(U%CZ/_OO>GE1%Q<?9DV&CV2IM<TH8OOU
M!A1V#BJ"JJ/+I$6+)ZE%2(H_>/^)UN+38^]R-XKF(Z/A-Y\^KGWZ.-K]IOFG
ME[D!!L`_=CE!786/FH\-UC>W?(Q-XD:M4?)44]5LZGX1#-X<;N?31RN]:O[^
MJ;;'+WU<8'>/;UMT(JUZ!'C&^L!\1X/FF'EN<.%K3M$<4+V]1$,+[/-_MO0*
M]AM]F3TI:T3TZ:./74`77Q-$>&P=%`B,2T'?WBC["C$FI1U6>1`.MJWRP:-X
M8"E?-%?7NTWTNG96])U2N[OYTN'16J`@#65&GTG78C2STRU=$O_J-AH5XT%2
M\2`WY6JB,B\OR<%DM$!O&@\QE&=E7I:F->9*">Q3R6CB#P[F.BW<6#,0,S7\
M4XT7I8LLY5J`F664$!^1AV,^$_Z@W$@$)E:J1H<-[,EZ40\&H"(>F+93CKP\
M+?9"7C"=8D`$X#`52#*CU!29/U>+T+BVD":O-ZFLF(I)*1<^$D5.^#0LAKDZ
M,/]K=9TF`+V*CRSME.^G=9N-FI-[T&BY#>,L:8Q8Z>][^79-I0:Q%PRC2B%N
MS@4FMU(`[<N;BVM$/3TK6/<E:E`>)K>L\?HP;J^L$=4N@D0,UEHQ%@0VA,0W
MA^\5;3D9<(L!4_YND`Q:>R,HCX*9P+&;*6$$WUQJ'$#<+!1,@YP;D(79!8N.
MG[A?%N/?(+EW_,1?WTPN^3?V[^6'8)+N09G/*!88%+.IC]\E8T#)9R!#N:8S
M3]7V`!E+MJ,1-6^'B+8=8[[5Q1\H3\YX7$0+.9ITNJ[7E]C`JSLQ@O]1_AK;
M'-UU8HPR(;HQAO/5'<?03)[PP-".N#'-W$^.0PIQ>C\-8-QSVP8[*'`F\(_Y
M2@"R;[T%E)A+JR.F^<;O,KY631IIIFN`*@V789]\:7"-*USJ&4EBM#31ZP>.
M=S"G(S_\^UX\;FF\1S%:;Y_11!-KK],2Y%\0@Y9"<>>7N1[=T+Q%[+;V/>R6
MA4L4-A5!)25VLB)DEY@LP1ZM>7\9!?1M6(`EBFH:,BO3/S>,C2^N$[_U7H#5
M=TW^YI*:X*)`]#"!H_BY.(;O@'O-6$^7V9)P)!`*7%%)S2H$?7T)]F>"H;=*
M!3GB3&%(DK$NV4#U^7HDRUE&8C*Z$.OY)<^[-$RC?./,O6M4D^&8?LY"<E0M
MF%4-Y/WNKJ38U2T@W7]M]K.`D'!>'("H_FE9`K<JYE+IH"O`RP_U[VAUAK4:
M!9BU.IJ!$B(4A2OSK5"<=D2B/"SD)7+S[V1A2JI>3OZFE#7-H%M4NTC``E8.
M42<)C=`V%4B;6Y=9J%9RH*)<2`8@;WV9/LCY:L/%;)FRCGK_=L'Q^EJGQ5GS
MN#`61.XK$19%%KE2,(Y@XB*;2%2T!\E2!PET0P=31$V0329BL8)X3]S#G,MR
M770NS8Q_JCYVSY(9_Q(Q\[4)P,G@/]I&:W]Q+/Q1_9QD.V0O\/UD\I/VMO2^
MPKRIXU`PT/B=G"F<\`DXI"6-F7I4;%\J6^1YB^_DW\R',GD?FHA[((OHEN79
M,1_X]:CEDL$8GN"F+[2:?.ZRV9.TRJOD$$>N+%TAHM:#7FLO0J\:29$'%F91
MNJFC=D9)24OB+N:#U>5$\G[OI6ALB>%Z$B&=H\UG4OBRNS`,++L_^FPQ]WSZ
MC5^2XUBMC@VY=]>>5B[=K\'NQM.E3YFX/U$1:4P-#B)5+@=$#W<XXSW&T0UU
M<I)'9?,0&I@[:F2:<V%)UD1:XT/QWHF[A"=`+79/]NNY<F;43S2Z[F4#(\W(
M][7A"FLT_P`RYLHZR^)I4$8CX_[U_`969![AW+@IH_`;0LK]3T_8#16<.N7S
M):6=3W5NTS$,:"A8<\'V=H?0PT*ZP/"[F<NYD:@Q$XG/",NJOJM3(CTT1Q0Z
M^%3A:OAKS0['HXW1&M&1KYJ7$*MY7(]8L9(?6<F3@+,"P?KRIA4(J%5QA=K6
M?B5^@7[9X0Z%;`T;,`*JK1#;"^Z[D?T1J)G\J`O8)K@B_`:+W,"L<=EKS[$U
MCWO9S_KVS/L8:TRR:Y1GK!UU\T.,G>5T$>$_YKW7N*'3]U(8!JB1'OH69Q';
M!5.I@%OA#8)Q,F,JMK"@0QAJFD((9'ZDN%0=&5JHTX]S;Q$T?>W3J8*"(8";
MO_Y+ZA+9_,.^[*]S^OH\"2'>?`"?X;2%R,5;S6</@%'D\2`C/GVLE%HUNU5L
MBW]C<YI7%=Q^^Z)*OZ)Q:2M/N?FE[_SRY^:OTR):7;I6!_V-34#XX;#Y2DAQ
M\0[0EM4VMM\>#OM[[5Z`M3EW`/C-3W4\TMK96(&LKN;K?S;):N9OMAPXM/IU
M\U$Q9!6HQ:(GQ*8^I<*U:KJ@=,EE$28=$2K=C#^L2<Y1Q^1U\LRWKCI%#';6
MMP3N6$F.!K2DLO2;>D96'*6*.S3KU,HOMS,U<=W593E--9D:J!43]LMU%5&,
M;P4XF0"2P_Y6M"?D`]U2!0W21X(>_,5>W"7&.=@=9JMRJ6^ZK>,1G;I<"]?*
M56>ROY<:TZ>SM4'8=9>6)?N+MLK11/_V_$KB,J(C$FS)OS?KCC95B+Y+;&8+
MG$JYQ;P6!D:L:/G<0+_*6JS$6\XV,-;-4:E6O79A%R0%,".E0!L%R%[QD#O7
M$I0'YIJE?N:F\_/2O$<]9D22?,G(J\S=.N^JG"R,TN9Q^D&9#+TG>)^4'D=M
M:/.9E\SY1@Z\1;/W8?V4)++O$E]N[>)^,P1B[_^*4)!N`^7%5>^N+@AQ;1QS
M@@KW-!90V!%00D!1[Q7RX4WO%9C74P0N]=RGTR(R)@C[]?04.SLKW@(YE=`@
MA#'%71*:H#J"D^F9W0=W,[Z>T`KM-&H(E*0OQ6G&)C41/DEM?#+[^$#MLL2`
M2#'$)C?,E<WA8<L<XDETS/ZK@T\?]]1`S[>IL&*^(-9VB"=R.;TV\/N56=U/
M!/FQ\:U9?"GD#`]<1*LE&^JD%#T8ZH&%,&,)C_^,_AA0_$LUP5AH;Z6S;W+F
M=CK]":E5GL"PLW3J"G'6H(5XU+C-9+-)O@5C1*A#:4*1HF>Y4>!0]`F#=R^U
M]XXOZQL"T:R7EB`K?44EJ_`FD1-!>4*3/+M1,(WLTK4T24K>W,$PQ#O;G4DK
MW)4BL]?2J-W<<,<Z.?RD.A*VT)RU$%7VZ^>"@1#*^DO:`*B.F7`Q>V.'M+X)
M5>5ZN@2#A[!9$"@0!A0=RD4<PF@(C4)+XH";+M.7&D_PJHC+)+Q+GEI3M%9^
M8!F%MD<:PLBO;U+RD"2X&?8LURWW6<L4PRTAA4O>+OC8*6?HMFV8M@*^F,O(
MR6M>2QO95!2K(ZS)T?9&\_?+?*[=!DZG=KC1FD;'8!T&7',*3PWFD_1OK$%[
M!C1@T=5*L3M1<ZN%RAIB@X"^R8(SC,?4/IN`F+<.IY`<ANJ8SGT;<OQ^<LF@
MS[UCW!-O95\?I[FBX_S9CK^`.D<?X6H-YJ*3<VJ+`3RBGM>Q([>=F+@27('+
M)6;%O^B@,IIIH(H\Q@K5@/V:8=$8@H_937DSNI1)?Z%U)2-N`K9H:&T+4BFH
M!;J^?SE3*BW^+FVY`.V"V438E=%Z5<T#BD(.<]HZ=E&'P?6KF7,I+="*EO0W
MK\NT;$G&ND8Q:X%G7LW$JO6,-R0]`CTFA;"*\=JU?B8KL`O2TEJ+\H__W__]
M?PYTJ&Y(6)V\)8C&+(]NIMCR;]?5-X+"U[0DC.-B"10!:@KIX_Y-)!`2RUQX
MA[0162JOE/<.(H!C$%A5V$C8!28T>MZX(ED9#BZ%I!=T6,?/(C*O0(O"WF:Q
MU&`I>2`"A:T-DYR?TAK2OX4H*(R3W0Q"1<_'IS?3[R9$'YWGXOY!H^//H**(
MJ$^V643)`9J[L=G*;LDL\(?\M8)]SB9X!PK61+^?XD"8QM,TG7O%+<[.'9R\
MU*9WG=#BD-5W*?'UN`:U(5J*>HA\O!%HDM^00^Z!`44\R48#8;,VA#47/S+[
M4]7,+MQ!H</RCJP8W5,PSB8,`,YZ,STQ5]E.O_@SS_M4!DB>[*TDA]!1^+N8
M:$I=*XL28IX%++2<0ZA5PMSMRNZ#G">A5&@]]@-4T8+V*9-U[ZVU!9+DC[E:
M\Z<[7)<=]>M..1C+CTUKU-X/D;@!SF:M&-\!VC7G@`WS(ZBP71;3;G?$]J%8
M9/3+K.A9PL':[70MCAX;49M96JFCRZ^$]2&#$G30/*]87\3\R1Z_C&M0Q>[/
MO]O?)!4362BY9$"O=[1DWX5`8-N(`_Y$]CCSP@^@[(3K>,97X[-QO_<<&^04
MT?W'\?7XBJ(><[#^.Z&VL6W),Y3:N&7,_.F:'0."4/]HR3.7@5EI68FE+<04
M]%B(-"D:*&ICRB1(>6V%:N2$SH0R"#/.S:YDTRDJ<$E&>%Q=$?(*&2!#@!:=
M>1"HD`26X3"Z;9[5KFSME(_D-*"<]I.DNYX=;-7&*RY!;3]N1&(5N^7P+H`Z
M'D99I"U.`(Z'(!S6(1/U1`=29_Y<UUA-B18:*`!.Y@8`IX2`O>2"1S=*CH!E
MG1?JM./H6U:4#%1,1O%"FT1FZES1$8O;]U#Z-]HH9)<_CF"B`V^YT^H*YP!+
M_5O2=CFQ*SYHD<VJ5/NUVW1I"_HMI52LO2(A#$!_`_0J-LX[;/+]2]T.=$[U
MM9DJ^4'FC*VCA23Q#,\7;YJK`%%Y"&N?\Y+Q&7J/BJL;EI&HE0>G"XM2=:2L
M=-2\"B-IX1C(R$3/?Z3`Q=C#C1;>)]3W"*U_.@:=T!XP`9^IX>Y&<V9*:,N=
M+=LJO['JFI&5U<94+1,O3=F^9#ND_\'HRBF`>DX]-UR85)RFK`GG-!T;5PG`
MKZ64R?*D.,-S/"[.+-*LQ3?T8XT:<$&O29A5[^8[MZ9X9.<)P]-@(FPZW:;Y
M"59@UI&RI.X3YZ@SIOB60K);JXF;?AAS72`LR1:%6H^MY\1K7=`;HI.BDO,B
MZCAN^I8XM.IPKEED_;J4:):>ZN)RU[\(_-BD`H-TV9ZN,J^=,,L]+Z-!02?.
M&@[Y<4&CCE,<6UD_&B:06@<]7SEM-S54+^J@",C*9WZ9(R^7W#F83Z=C9I)]
M+@M:$HQP4IY#?"VS0N)';$%HJ1TH+`\F&KZ=I8?8D4PO)#T3`U*RJJVSV"<,
M@-MO_:$Y[ACO.J-N9:U>K',RE-2:Y`>R5/=H6+6C0#V+WM:;8GKZ97H!'V_!
M'N6@&918P$=AOK-8-"8'F5NR%6TC2FR2@/06X]YHJTJ>4,[]HV$`UAH"C^I%
MHY5`G,M+VIT(!>`4,"E&FLVOKVFB)[+5V%E9-.5%FNXE&5[35-@V^K4EA]IE
MA=+I,LF2CH<`4C1J$.%FJ_A\@5^1'ZSS;U,K,%4$X2*RYKV%.Z,/EJK?Q`%A
M8+/!T$>:R5:=)-/9%!DAKC;35?J"B^@`?$FELE`31$IR4?%\K!U[/:2#;7NF
M/ZL7A0W-A5/SPA"&_-:O=9Q>H8NDF]+E&-%'"&6"5$,*)V-'C`8@[&W0Q?AP
MS,E$;%IH(#*#.$<T04,#V[S2:)L[:T#70-],R&_'LVN^,YG<BM!\+>'.GQ*U
M2MF>CENYV-I2M.DU%M(;Y0B9!/6]+9(B2DOC2RC^/_SN]MNREOW0PQN:]4,O
M#M`[08K:'H0`AWCR/8?9L"-6K-69]N=/M`S+?ZHLA-CN1W:BB.?EUQNAQK+*
M\&%^5,FO"^>]N[Z7)_<9\]Y>S_9L?=Z4)W3H^Y9_L-_9\0O3>K@^R/."P$E9
MU@Y'UQ>`EF1PZ6I.76^OYT.N6GC%H!4.6X)2'<[N@$<INJOOW,,FL;)7G__2
MLW%VV"AVI;D$9-0YM@Z)?>4BFNR.[YGQ1?.J&]!WW?F,FW0^SP?5V4^A;$G>
M2*1#@+J3$N=MEOI%)N66O0MDDJH\+`1EZY?T2-[KI'>X__(X8G=ON6Z5W%<Y
M:F9.!`XOKU(]ZHJ*>_"I\MC"!L^_.Z0/OXUO/]+SBM\"S%[J_\F55*<@^QC!
M/_^,%=O\<_G*\$4RHNH<D9">.[QGFF`CORQ!8I'WO)?%@6"&Y+KI-:PN*=<0
M>VQ@)217JG'-C'OVXZ&4-YZD12^$<7C2JR`,;2)@A/Y_QS9SP<[AZU=BE[ET
M.HMI-G[JMNOP0,-AS%/G!M1L&B2+$P9RL2.F2R=`!Z/F@P>/L_A[W'=8DW=K
MQT`LFOP9%WQ&DS!G:JTSPL#C0&2Z\\G:<6#TRKIAYI;'D;%I?=QQZF$ZEQ8:
MMF;9=8W>Y>%\"77^FQ^/56L0I>S0[,?_$D[UR>26W/(KNW)^+6QH=ZS%!]V>
M=?1G*V)`'+'_#[UKETL.>3W(O2Y?3$!4X5USVMW?D-^R"%$S(9$[U$<^A"4?
MXPLEEW1<^;"UD_N;X_H5'->%;JOM$IYQH^GR6M:8I3.5G;?_Q#ZN@G9F=WO@
MYA=R=O<>Y.R6-'7'MW8BRI3]7]T[E>A=SMTK]7J)$!3>*;U<L^6F@>GUFDVN
MNMMF\;W2V2I&['*W2M@(<P60P`,W!CY8#HM%]!0UK&R1`NQ^P/#NM2]-E^5=
M3>ZIW<[D>:";MUM_]8%NWK!`!A:ZK-W^7@_/N9UL+J>5N/BOLYJ](H'Z@:MI
M>J_?X2^,,5&%:A+"\ONCF@\](W-T3%4/H2^8;%BW<.O159R>%')PC#T^@-_I
MP3_\U@)V)5(^O;D\>T^Q9XYD\&A",G,DJFVE1Z#1,G*[_-;U7GS9H@N!\I:?
MB[ISC^NJ,!%*ZH1C^BO%9.:72I@GY;^I+YN6@!86+$6=CDSI2GBR2"IPIWI!
MR^0S/X(-O^E%K;@/^V0N[!C*$!.>7O7UR/LQR/,S2JL8MM\[GM_\-.$7^X1^
MJ(8ED*6OJ<GH_Y@H^2Q5G72'6#C]GK3.%Q*`J68DF7\36)LCM#G@[1AU!XGK
M(CUU`>H("2<W&`.I]1G+\UK9W*RFPLDB_SM/+.4\PA77-Y-*;1NMB2E8_7,E
M\01HC:IE%6]WN:48?Q+2NNV((<S?+MYHN*4(V=>)J>K>J#%AL,_7=$DCZJ(U
M9._TN(!0NUQ&L;A'2>,5:$#@$Y#'NU7(BJUB3P@$E[06G4V6+K&'M$P/BBIT
M>@7"G\"I94WCSK#=;TZM?,2O$IP.$6G7S2'W=(L$&6:8'T+44\;+@5=0F!NC
M<)<5_HOGE&-K_TCB&BY2K\MDOA"72KJ`B$QN1JK"^_AP#D#>&8M^0TO&%'+*
M<>AF;-K[?@-^*>Z"E/L'B5$G"D.NKM/XA4/47\+U3*)&V%<]3FK"-/.".*14
MCK,HFJRKC8X8>BE^2#]HA`Z!_ZK0H;Z!0".1B>PHV=>H"(6?<=_0PR?6;6YA
MK%)M#2VR+9%X.29_#1%NX<GR$^D4),VE3]Z[1M?I>0KM.*GW6&T&)&,Y%N2T
MH.'"#]U,+MZ>S.FV;*DIC^Z/7*;F'EKC)@$?12ZS<,]T:\0LR^T+-ZYI&I;J
M1M//1A<ZPL2*B0!VB=N?H*T5`;`[?YTB22HZRFCR2#;/1?V#:HNT,^>*O%YY
M=CT?T+]HV_3&`L_ZNX5+)S-8'2C;ZF:5D](A@[#HGI-AYSE24GCIZA22-1E(
MW2^*&'(*O/I,JPF&G=/(T&!BS6@Z1UL!):G%VL/KO>\QN&D1VS&3I69@,93B
MD`#P\ZGIG&X]^IA%V=_P";540$"KQQ+M#:!-6E(5KL\RODB-:;ES+\UVE+?I
MQAK7[61KB;G`4#G^536F9&\O;0?)N+0FUH3:J]-V$$5YEF44+*.#5F-KN08_
M)5R'1*QJ2VM90:WYEBQ9>+WA:]N$ZU5]Q(0;7ONHB`JFSP(Z9G66Z?9`5[D#
M`JA,UYJSKE94U9++;[?6NS"RNU5W$TNP(:<]=*WN,R*[3;'P>#IYHR)'3M4S
M_O?R#?**G\Q>$+@.3W[W]N3[YFLXFL5UX1MV_A.OU/U,SF\M:9<#F"5T,CK<
M`2VF@G"Q+"-$R/V>I?J/='@]!#(MWCV[QLC("622'U&P*'-ZC*SY4T3ED6)E
MH5+FH;H[F2SG8K:,GP.XF.')3X:'+//NP]H)5030N)]7[ILII=R=EL3ZDT;)
MZ_<`6/2LTWI)OII<L1IE)B?N*"PY2X^3W"UF&I2W)'<%*E`L47B5DGEL]BW.
MO3=G6=])^U^ZL$W%B0Q:&62OKVYA")^GJ`+V(8LG#\*--9@KUJG$&EM-7,/4
MPI1*;+64(@2?ORBS.$5!%[^M@*QF+K<0/Y_NXS>P@&E>T!.?G7O5FD7GYRW6
M,",XSISK97$:^)J<5S5L\0S3QY'!6FR(3$T]&`XB^VYULY?VRP`X>EYII<<B
M*8$5*<]X)IP'BNHO#6[UR'W'C#EJQ#9/E+F9R\9SQE1U96&52AE94Z@DLL72
MKM0W+BVBRE-F';`\QZX5Y-9\&T)]J])2A4]_O1!#*(P=0(3=*EFG>/L.#(%*
M_V4@!&DYCT@Y@77B,N24SULI[Q,WT7S`P",EF<NZC;R-%/<6!;(X2J/:86Q3
MM6FJ_.9Q?S6/NSBDO[#7+>L;OLDM:3@L2#,[Q4F$*L)<"SN[)NG*X0;]3"6&
MQFL<4TM,"+E0U[XA[+OLP+J6TY%.AQV@;J\`T).J*5F_3%T)D2]UU9+:6GJ'
M3.!C*>DHJ;T$;M2R./JE+DL%86I+4J&"L>P@I+G59'6(<(=KFU0EIBS25];&
M!_E?X.6#EMX[1K*F/6F>14G=PK@O/9F2=[*-$SEWML^AAYWF><FB3B'<JNY%
M<`@2&\<.H:02M7HFEQL&F@X-'=`97$>.X?8[')>Y>OMZDN?23GTY!L9?X:F9
MJG-%I3\P65=^\Y._DCDKQS'ELEY-SIF#@^J6OH2A12]AR]=MU>8T<H`;WX]L
M7)A-+E.9MZ@%YZ3=MK[2J7*"93K>N;T=^(8XO5%<(N%]_W[)J:N:PM3%>L=W
MDCU<S[_VG&M%Y$NLP[NUK4[6S]>]6[7G1!@F:/>>Q@&X=Y*>90L1'9.IVH=F
MC$$?3@F*;6#DSE6=5+4ZO;.;N74#.=/M=MX<55OY@>L,K;@G.%X=E+6EB1CL
M.$NA]"#GGA>GJDP_I^IQ[JRU(*F^8.&JY;XIWJH(.Z'G?!524OQ`T`CC"B;2
MG$($T-6%RX'?D]->$T040X1'K^*)VB)X?\QB$V;QH;=:SCQ)%K/=M`3QK(.[
M-LK"/2Q6)#-%4RP^\JB+SQ/RIF>349Y(K;H1'>>%WTO"PP_\+:=9/@=2NT#O
M&AP2`[9MS#N.;%=+[_OGU-)I"GU2%.[>7^;F0,QRH4L(%GBL$+E=E$N[;RLJ
M>-"[85*Z[[;W;\A9%8P".>,>*G/>)0K_<2$T\;!.1,4,=6#/_$-DPFF&/4'J
M#/"Q,W=S3B_AO[N>BR'2>;R7;[M8C>!<536.Z,NP('>`V)4"4NS,6%*)666?
MKZCE&9^%*PEC[[_Z$V=A8V]M,!2B&);.IX]^77C;VGG9P`\WMVA'LC,RQE>P
MED8GNY\^0C+&[D(2)4.Z$C"@A9*Z<%D545H>;RP.F\CZJV&.E<.H%0)"9@"C
MVP\LROP==G00W]L_+J2<LH+JL*,;=KJ%.GNL-H&]JC*F3#9:+C=*([0_1;-?
M,M%;IKEV6HWU\O<%E.,7I(9S7;X`O.FM?!(KV.<LBRJ//ROX_+[A6M34"I9:
M*Y9EL21-7:!$@9;5SU"&GW3`.OB;J_Y0E#]^UA6>K=.^$`NF-JKB-\C_`#!8
MS6+R3O'J`U.O1O4/=[_]T-2KK?J4OMYJ2I=U(2VZ5_.'1IW<T6LZOP)$/[LZ
M;>UC`PBO>]$-)-R%@1615J+;,C#\"^*[!\#>0)*R8IMU0'7#/,'5\05K)[&6
MT>H[P.ILB.NX<49S5E*R'E.^JD1$)1#U=`T\R&=>((?7Y^N9+Y*[T-RXX\IV
M%^+25<?3,3T6U$`H!U4#C`)CO%X&H73E.>"&9+[4S%N269&*NMR*$&E:V4Q2
M?H;\);2037W;J7KJ>Z]]:*(6W0BB.4*6H*4)%`9Q(3\A8,Z@_ZV+A*G`CNJ3
M.&<02U:/0M=JRJ`=5#74<BSCR3G)DL0CU'XW@+#R.]':6M[C?3@BSY"/<U]?
MB"HFQCIJ"")!)>R$&A_J$77GLK"-5V4#S?F5,S"3#.7DZ%KL`:;G\@^0`(6_
MLIE<`3@5D,;(L7A!ZP50M]42P^5)%]M_3I>*)"*9=-?)^4^8`53$);,XAP/J
MR4!F<V(841K<//S9[]<?/A-/['[-D80O#B8N^'BJ+OJ"<&)3[L(]=510IK7.
MQ@*047_*AV/1OA1^=GG,_GD@QJ<@7?+0J?PRK+G(!<I[IY67&BOH2APU$$<`
M.`/7-,K)EP`F0W"4T-ZO`TK&1'X#)-W)X\S)EO.F@F(!G:/"W<QQ[R^&298Z
MZQ=$)`M[NVF-9TN]'B.2^:ON[\#`"!REB/U>TJ=`A<&>[!GONB?"43C!'2XY
M@RK0XKJ)R2N)H([!>Y>M-I+;^CXH]%J]`,[:%P5V4!+N3F6O+0VV_PV0M?Q"
MK!\D'M!\$9S,<B\9,07,J:B<I6F*E/8F#8R\XQAH8U)38<(5&N<?&]EM,<W+
M!K@YVACT=_:VW#_;W=ON;^Z"='XU;#-X]E?$-<N&*MIZ[F6HDBL[@;T6$O?S
M<,UA\3V;0(D5%=]:"NNS?>S"-0%MU`#06MW(5-`SR"R34UY1TP$!6']H"315
M'/4W=+$(Y9I%>51^YR%(9@)&N[#%)G31C0_:*A.N2@ZO(_EJS#/:U32=FP=U
M(.\!F-N#&P4UI_T=]7E7O8.;*=4=!],;>JL9KM%\#-3LCUPU]^DCN\%]6:7Q
MVL#,:MYG$?$PV*S\6G*7.TS!D%V6#*)4P;7OG[S<A%1QA\5/5]/W1-FM`>CW
MFQ`39YTTRW/4G^[".9'&0WT5F==>/C7KE=\ODT!+9PN3U5M"Y.;C1WB7D][`
M]LI_;O;=YF,<2!SEC`Z!S1<SDCM<-)MMR;I[TS7+B=_;9G90]I#&?2QVJV4,
M=$%LG07\]046,%-&";%`HD7M5A5PJ7^PRTUO`%P/^SC;7,.XCA$8P3VRCBP1
M#`;UFW\A15A;O5IZEAJ!.(;'$N[:MEJ/2A&DW!:S9F!JY?ND,@PNXR.7";$D
MULAE&*=3NF!S1320B@:QN@M%]*L:"]2XH_G:.MZ]MBM0"V3'W5#/),C0=(NM
M2FJT09:E3ZHFV;5SR39)\JH\<';<<]9D8=F@L*D'\40?*SVI3!=2NXL9?TZ%
M529%2CR"P%6J=WG*:Y"*LLVTR,+(8@<XLXOWL395-B8I+>]KPZZE7(WE<X0T
M`_;[L]-[JER7DBT?X%MV\L]*E>S[,UP7A'7N&OD@QZ5P>!:FP=2WC9W3J?'J
MHHX#:+C$4BDQR0.]*P-;%0C)Y*ZX+QD.TID8,)L;G:1-@BHY9`B.;.?(#[X&
M3*TN=^,"/1D,=QEZ)DIY4^OWV%791Q.0U<M/.\P98W^WQL2&*SO^L3#JRG$K
MXRZ2,)8:]E>))C>-F&X3#5ML.Y8+Z9(L4_#YGE(>LEC-U-3V=\=>.SHU&J%7
M1M4'N]_LCG,N;)BQPR6F8HZOMH#MZH,/64!S1YY<7I"BQ\6UGS[^E_';Z]^C
MNULG!=,S*I=D?6[0\E#LG<Y.W?KL$O;BYT6J;O5VBM6(S/5!]\^QAJ/NTQ18
MGI\BO291J!H)@]5V4GH]!015CG3-705S3%`R07IO^(%L(YD#LF$/#DD3:-_(
M9MFTDF!)BE23Z/>J[^?;:+3X*AP<'3#"R$L]'ULT[+8ON[]TKWFY=:=]R78]
M'[.?;-5NN0#K<%WNW+AM0XH$.'"E^:K=0Q''D/(]H,FGC\8TZ&LN54?#=_EY
M/E8Q5(LH+TK&8J[NVOC(5T#0=FEU.6-F)[/AC$N)+'-75$?\NR6G!RL%X!5`
M"),+VHCPGH)PJ1EU9>'JHF4KU-3+1R]?'/_'OW_W'__>\VMU6/7QAVOY'5Q*
M07\[;)1K?#,8'H`],CJ-22NN(^&%ULRZBH=QQY3R6(YC;IG-1TB4Q<#ESD;N
M33L=G_(#]+VVDF&^IVG,;N=G7'%TZ%GH^HW-F^<8K<N3+?9CQOQF1C;1J3+L
MD*J7EH$:?)JN->,X6!=[#.2\M*3?2H*("9[\>/#BY1.G38>A6'W,NK030)AK
M]8%.9HVG3<9A=)F54TWMR72)L)R8(C=P<G5#/21/Y!EJ-J)+B""S4[F%CA1[
M!J3_C,P&MER/V$[:`X2&YI>W/O%L`!5\FYG"-S]\@?*>XDH65.=63C!6N)/7
M\@QE964B<1:?3DZX1HT=9^&`#\6\>:LF5"I1YO!BI"WBR$8G66?5/(W6>6H"
M=IM;6_W1EOQV#(H1>,=HL/T5`;L\40/$E\Q%Y$8<RNNE`H!2V?3ZMLQ::RZ.
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M?EO,K_W9#`3M:![7.6;UY%T"CE$?=LFJP)U4RC_SY,S>:O[K(TP1K"FD)A7V
MI%6Z_1$.]`;E(:6XC%8A946FM8[E-O'TL5*W1D,2Y^""QKW5BT>?/N+']??"
MGZ$/V:E?ZE)9I^P86T/7J+)H4K/Q=F]V+.`^1X:'H7Q-9+_FMEDW!M[13V`Z
M5^PUE]/AW-MF)*`(=Y\?;8ZSWS,S36VXW1\,1][9VB)=4M(`''9[Y._M&SRH
M)Z-S`59*Y&RFCLB#]9W1-_8DT9IO=,IK<&?,@C6>1E::&:3"Z+#8V!$K7JS(
MRA^B<BFF;Y?M1)IV/82-9\-5E`OWH=R\$U7>8\LG9<"M>(MYJBJ'3W<)+LR[
M49Y`=6E@R`W32)E.#=-TX70-WLWW6@9[B@OJ"JHM8A;8`1!29@!$JK7O2MR7
MU;AXQG:F=@`X(:R@EV%LE$Y*Z:N?%"P"?)EDBS.7YIMXJGHD=C49'\8$B4,=
M&V<D3Q:LFE@T]KLI*Y^0-SC]`++]F+87K[%3CR['5\V'4);:(S^;TKDON5/5
M;X9<3N&2?]];ZDOX>X5!!IS&!FR@:4K!DCLIB5)L;GD_Z-;&8/6G1[8(;S*E
MY3PRZU+NSB16F](A7TE[3:\^?8SW0K\^>WE0R];4(.P!3%T-@(:08KE5/REY
M7W;TU99"@FA2]($4;A"--.0E:\8^'@VAPA&)AAD7-PQW!LLP#5.+A@Q6E)L1
M^.">)HRCFXN3.9$)#^4`<9G,8.2+&P5)<"6XB:BJ(/8>4E;`_G8,6#FGO6=S
MB]/NN""U(=]!:$CL<V;D_.&J7LJ74E/]YDF5CXJ;JT7#R$467S#GX^F8*S%8
M]2%<=<J=::@>6%EI^^3+\#E6=/='LB,DTO)%;BQEZG@T_>'`@X(K6[O]W;U!
MSKQYH!E4-W:BB&BPM]7?XBH*6;XK@YV]_M[V=O[`4J:PO>JN1LV8:F[/JZJ.
MYHGNTFN9H*T'[C!_:40,")'ZPO2Z!RR1EP$W83#)8?T<HN<LYQ@6X6@].WHA
MW1MNNT'3!G?:C0]V.,0$DB3CJP_!))6>C*KW*36_'"S=0"'K&8Y8P1_%5';U
MVA3$&M'4T7N[WK#S*\P+&UOXGVZ7UQO60L3;<ND+_`KFEDW.O5R7TUL[)U'O
MYXB`[(,XN1*S>@DF*[10@G:77.N=*SRNJ(16B0J1N`;A=#(YLT6N[`ZK"Y$J
M>,KV0,\RPTP7S=X*8.9"I<2J,E`PQ>P8Z]]N+'#:X[HZ?!>/B(9JGB$,R;J7
M`."R2>HG>3,HY]MN&0XT^-7E9OI<18=K8D-^PYB90[WQ_':J`?!50&D9$+)+
MR"`C-"O&C>=N;:O"WE*VOS]KF)ZE/W#BWY`5P;Z`DR$T:BP=(L?HH2T/MB-"
MBF,/;VYND)FTBXS)&?6T:NJ8?GU.D$I*N//)QD);\O79%<DNU1V]'*6B$/-J
MZ@`ES-\[N5B+*]5/V:S(IF`-R2I7+Z/(P5VDY.UT63F!E:#8A>@FEIADU4*X
MR.F0;$7>*C`^YHX6[OPTM6B,GJ!T.Q;5MU%!Y^?F"HP1LT4]6D[B269NDO]I
M#RK[L=;L+!M3?!"Q?W'BJN='50823SAH-3S[H74W<Z.:HR"P10=EC!77!';U
M<9+`*1.F@H_2U$,(+.ALU9;9G!6<?@9]=7%^9;7&..K[5>KLT11O0H'MU?33
MH^8@A^G\T#Y.O0R/N(^4RQ=?I"-ZH)ZSS9=>Z90N^>5C:VW8^FXQQ-,Q\O'/
M=EGA<RP>H!7CA:?`J0`TS,G]`$F2'T#!\:=T+^H=<SK*0N&5-8SYBR4EW.:W
M/S3??9)%TY]FY-I>\B3&2?.I0_4_94(FGC0;9#P&UO]C[<IVVSJ2Z*_<AP"T
M`3%#2?8X,P\!J"6&`FL9+3,/01XD:R,BD0*OZ&2`^9A\2[YLSJFN7EC=?7E)
M^\F&>+N[>JOEU-*:2DZU#-?Y!7H3;!C6`1(.PW+B#-0<P@H4`_)Q!H8(KB2_
MWN/4S7[GMY$[+AP)K&'2_M/2<,$\=CP<QDT_F#SA-6I`E=`R82G+8[&'+,5^
M"PI$>>>Y6N#Y:^6GT@"_G8"#(\)N]@SU"H1</(+VKH'&.!JWZPYVB*Q=3*RM
M#T%)%!<`Y$3V3&L')42HB/SU)U?6)P[\]:?>$3!X/*`6IB;D86H43OB64WL#
MF*Y]&X5[OI;E4WSNP@R;7X[EQ?-?LY6)S;!Z>`;DE5HY]F-_`=D"3R!X">HY
M08D6ZCJ:%VYMVYR'D-<:`6?^'52>P4.LU(O<ES>UFY8<F7+3C$0>B-OA'J!(
MQ&E[,*%/_W+?M"$/7S#J#IT1;D>Z?.33`,=2+K<YI'O)?I%8:[LC^^,)[U1G
MZV3N"9LY=2\1C7^G61`O/[0#"O,#!F5A/S\"L7IMKL)5WF,5XR%N(/"EMG%]
M#,^@2/+^'L\0WV3I2V^K8T5^9,@_/HIK&PC\VQS^`3O9LSJ4GZEL[#X*<3^`
M$MR(4CO;-^0"O$`H(\CW#`@=QX<W&A^3:MLHTHE)@A._4#SXTW`E]3?=N`'L
ML\UQ!.JX>W5>Z:H=*\:JA+CQ`A'XCT@7.^YI6N.#M^3D^I6(/395H796Y!@F
ML`OXH6@GPBK?'/#UB:>WS9NKBX/FNTQV0=<">LJ\X':+?G@\;.68J'A=^6*H
M%$H7M9>%AP#+0V[0)VH)W>X^O7</O-FVD36MJIR*IDF-B4`W^K[Q=I<=86G]
MQG']3N^;/8HVEH'_Y1,OW]'KW7.;L<@4,2$W=B'%8"8L)F4'.UD\WX!I8F\B
M2MZZF6<B^(B/Q^$8OC@M)1@2T]"'F`9-"T//CE-KZTS!8`/:9F"9SBP2B8KC
M6"3@1FJD8Q+&LK&])6I/@?N3D7A-;?/C.:9.(5<<L@11IOFQ&VO-:#AR8*:)
MLQZX"8Q1:-U2&1W5,!^_BO1DG@G?74.]:U9=PG\MH+E#/-&0%QXX)D\E6H>7
M7&"(TAUU=(OK(QGRHD*VX),H9X-HBMJM2/?DE$91<PH88_Y%G#A'4RA3OH^=
M7GU<36>5]KOU]E&_2,DIJ?5#P"Q!$U^I]29+ZC5BOPY;39G3V>_LF8A[NQ4$
M%NT-W6AHNE,J-("E>;2A4$S`,?-%X3?0F:#9.X6NB[?LJ?BZN7N8H*(NN@7G
M($!J:?,?WH%_53Y)5F^]I5[2^]*F7GF,I_<":BRXI2J3F2RYX+L-.&?^`SN+
M)5VR.9^TOW5RWF6-E+A)FYB&'MEWKAH[5&+/UJCYZ-ZSJOVL^5&UGS_2[IF*
MLCI6YWMUWC%RH];;IIN7;I=>JE3K3FY)Z5=/3;:12%#JU$23;2CT:_=BK<E%
M#38U7\-$;-]4S&&ESA/;P<_*?KID\D)J1'/W"#CK!'D.T)"[;NM@USDO;,<7
ML_M7:-\(HJA863\ABW4B2EOMBP$*R(ICQ/;]*<9#4/<#E$&L-QI*U0[?5_JC
M?Q]*_VV#2:/2HXL.K5(^N'C$.CF-YDE"`Q@@R(R'8-G?9TK06ON=*LC?%`0(
M1Z:F^7H$04UL*DVPM<5N+X((43H5;IW1=M)9?2/$(<S''I%OU7_7T3?RV)(`
MQD])>4"T@""UE)PQ;:IG+#4FHW"Q0Y2M?2B6Z5)7/HH"K*P9^&9;XFR$2P4W
M+;EB'<8!KF?Z9>7^][ZUGA!#P<;&W1++XZRN4[:G'@N[TK(?9!&H[S^0V;W"
M;@>V"G#@]>WFJOS.NTZA(D:<L]U'[RQ-B-/]7@W[T:[]44_?."NN76..X;CV
M/:+0P_WPV]MV^/-K.!F;O0E4^,^/4SH0>!>.II^K)_[GQ9/O;O2#[0X1;?['
M?*Q`^25JK_6E'K`3>I3XN'PXOWA#J;_8OTNY\.-ALQXATFIO#<JEP7[_!L3(
M]>SZH]O%UZ*]KFXX]7)!P)7,;MS/U'Z&1\QE_"'(*F%\+P&R;TF.W>`N'@F5
MMPQAGVO`>3#*I427[5K0;W%Z>DDF/@.HSC,$8L'"1"0$$!TWR4IC70%X<S2"
MBG%L!7C/A\>A7!S%909O'*H?V;FG[6"GJ6.PM$K+RK]9TL9OL>0+?''E=?SC
MJ??-C81(/`ODG=$%A77.4'H&-2Z0T`DK#9;V+2!,&-CT&$]!L7<DK=Q`\RDK
MO1?\.6[+Q1_K$!K8<*:E7:#S.W3U!72F.VD_HO/C9>E,+@AETL//-XDLLK00
MQS1<"6IIXF699]NENCJBJZ&9>\>Z!J#(=NL&V-8T&><$">7<M0@`S!"_P?80
M<,80D;H?/NS^PW8@)SB#Z[]"``:YL9TA[JE0R=AP^N/?+97!T4CS(_@%QG.`
M[/IFG!S,(SB?<:P`5&^Y6ZV5,@/FV\6:Q@\(?']0^+Y\Q2!CD/.`Y09J?KWZ
M<Q!+[5;DNYV1K#LB'KX`*Q:`B)`360$9G/V8#A"!UIXF]P)$:P0(;0/[[>!#
MV1")TT-X+!"5%HY:>,D627^XBY%+V'Y[M==8%D[(MJ=^![T&2TCV!@X@P5`(
MH*N#6?^YH_,3SB0(_#G]9%+:=$@<.'ELP8&_Q-[Q/!:]+CED><F0*\0FM(_Q
M<G&]Z;!Q2\E0=PW#L80+3!56RAV,QH6?V4^OIKB[OE(R^$@\JJKZ<7C^+IX"
M&$"3688T#]Z5]Z_'^C7_\R+8K#)UALM'A`]3):TI:77B)=LJ"7-E62F-OQ.^
MH[=L:<))*G\F$?I-Y=A%`U;I==ZPL.=;B#^4\$%)J;,[(W=0W6[AY(VJ?=>X
M8FK[2)<=[LI@/];L81_5"!<\8#R@##*J+F;*Z/"RN%,HU!5/P!.'B(FAD-HX
M0S`#$6C1B:4X:O&6B)-PV<FT"T9Q&"I$'A#YGCE/L3ICJTOW45ZH>Q*+:GS+
M-`=&,<B-7]6TSZI'T-COYC=WQ*[<N-H^-:E`@O!.OU,1U#AJN^20]UK6[NFJ
M>]%G%9>N@_@^R)M7F>U1>=>[M]4D:B6"Q@*JKO"Y/52%#L1/GG/LPI=>O\TX
M9N';GV;S^[L)%7!P>?!>1.[V:;8TFT,7+MA_*DI@2?@52/PW'&:@CQR9PD'$
M.VP`\E6[;$$.-F,5A'XM8*>!<:R[#:O[J^S*ZH:>L&RU5S?MLV>K>UEC"U=W
MUK&CJQMOL,%A?V&_@&GB)2^H+9=0\O`J>UFS\61TM$Q6Q!XLKRLV4E@`KTXW
M<$0@QC^3V(4/?RA^6(HEV1S!$MS&Q1GD0`HDU.M\X5\[HP24RZ1V7*<P-"F3
MV;(PK]'^$:]E\$U/V'B:I?;BHEE<+'/\<P@5M1W$-)WP[#*UP9*+/8RE0R2I
M38BOE(0D,6@E_\N.TP5W*/AT4)7>(CS@$7>QQS!S/MML/69YM:+`VH$K>[_?
M'6F42!U_ZN7(LR@"]1TO!FM>YL1NS.&[SAXM_0)4X,+=.">Q_;DRO7J4DT`#
M&ET5HIR2Z9:Q\7U4;F'-AM/[1KOV"H$0@)#(0A05@G0C:)YY%_N$)V]^23\!
M?/5>,\C9UJFSP-7\SMF%1,0I*N3!'<V7XB'R5+LT4=2UUL=:3,#V"J@0UE]F
M#OO5LI\GZ'<.5*3EKY*:AM4926<[6@'$CA1"P3'GY9T(AZ);=5]N%/A+,1YJ
MD,;Q9\CY(`1$2NJ@I720U.#=S7[$)&>,M0)SS)"=@:;9%GZ)S48?;)\G2_6)
M0WDNY:SV:[^0V&8XCIDV:K_81YRT1.QD<?[9I^<QCW;UQRX,8_5W-'!$D7.F
M/9&)))'!4CM`[0/@0Q"[^2]X_ZGR"ZJI%7])C$(?J>$84#@P=A2$(4*$DMM4
M%CR@;K[#B2]21\'@TD51IJX:5=_9OEB@RI+8L:$J=ZNS(_A&1.<:!96<),%N
M^$HDV8I[KB+%78G6Q@I)X77WQ@'>EL:HVP,9)@MB'51))`/:@U!0P%+)(1`=
M!4B)H<UCZ<#?`(O;(1+5P<O_^B7`0<#+/;1"LEE&4@LO]>HAD/+>\O2/I<)U
M#)O%'0.NDA;T8\9AOY=_;9]G`?EW)JG7KC+[(>`1L4X/D7KF^%%+*,6&#L"I
MW@]'&>3-O[\;CC+NJ%@*CDGU4*7/H-BI4$_GC2>H6.T`8^^,AJ,,X`:.KX6>
M0L$83.G:CC%PZ;SVSSSK$\D-=#ET5'NP/:Y$R>:2/:W088=TVI"8UNYVE79@
M%5TIG.:UG'*P=CS4*Q4H*`+KU:C8?($@]8*C][U=H:R@1J=)DEQQ:$=D`BX#
MA"<*<;;T.WG#HWJXN-RX"^#IGW^K.`F].@36!$<<[K(FD27YHDO#9RS$HT]9
MN0B(/$UGL0L1<,XTBW_S14^]ZSMV+(0&VC\QD(*5F'@I)#6=_.(,1A3_'4,I
M<[&Z9S`@F<^M"63T3B#`ID_!'D0;/DPDL\PEQ_NB!3&WGB.]H$-+&CB.KAFW
MV:?OT^:*E&*#6A@D\__V;*S`?-J';8ES\H(\YX$KTA/6!".12!P)>$ML&YLW
M\!49$+:KOO>B%;>WQ`FH\&=(:,R+]FDU/-/!+7N7A?:"/Z0Q!968?.:"<4]<
MZE%V#:+<DMN&B@:.N%G=@1;5K7`)+R'V)4_5KG:0=L?0'^!9EJ@';<9X9Q7P
ML=G?VO;UQ_\#``#__P,`4$L#!!0`!@`(````(0`E/7G\G04``.8=```8````
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG)E=;Z,X%(;O5]K_@+B?@,U7$B49
M3:BZ.]*.M%KMQS4E)$$-$`%M.O]^CSENR['!I<Q%IRF/3UX?^_6;P.;K2W&Q
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MPG(',",QL?7AYUW6I-!1*+/@@:B45A<0`#^M(A=;`SJ2O'3_W_)#>][:7K@(
M(M=C@%L/6=/>YZ*D;:5/35L5_R'$9"DLPF41#]3+ZWS!EP$+PH^K.*BHF^!=
MTB:[35W=+-@U\)[--1%[D*VALIB9!_T9GAE,28SY)@9U0X%N8#F>=Z&[<9ZA
M@ZE$]CK"*1$/$,$;XH"\-XTP\[Y&LS8!;VWX^:Z-O97MY.\1677"W86K7(Y'
M+Q-1T*SIH@2LB%+:L4<D[$3Y/'"[?U1X;&:(//\S\@2LR//H6^\107F<<3_D
M/B7B/L'<U7+%W@DB#;;\],X)6)'V7A:7$Q&3M#YAE!9^1IJ`%6GO&QBE(8+2
MF.\MU:TV?IUT+**RIIE4#*+R`G51$8&%>_.*,H'81!")(NIZYXC9HP*FTL*0
M[J8](J,>';U,1*VHJ&E]$X,4<9$B#A&YX\)EY$<KQ<ZQ$2$B&1RW_=9-4]F-
M4F0N%9F2,>HT,U3HO*S`<YX<R"M5*#)FH4:&"A4G^.3-R/"\[PN,M#1#9MF=
MSCP:/)QEG1&&"E3"8^*2ZRD2*'[=,V1,EC8B5*8XTJ?W$0.@WT?-U0R945N/
M7Z?"E`B9V+^!+%&=+3[5@?MQ)T9>Z`=+U=E&A,I4XF2BS(%<T9S=#XX1F2:$
MRIP5+TS/EU#S-3+&;IH0*O-3$</TC-%=C8R4-VQJ$T+ES0H;IJ=-H$:A9(R>
MQC+#")')E;0Q!W5'*RFCRI/,J*?'KU-AL]*%#Z2+ZFG)R&5FOLNXIS"QF:%"
M11;T3L5IKN:8(.1T5%TM&;-0K#/"4*&S4H;K*:/Y6C(C(KJ/OK&9H4)%*O0Z
M^L&>Q`SI=U)S-D<&!7ILT-IFA@J<E3?B6[GR23)0]MU>,L/&E8W$,L,(E:GD
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M&,2RS#!"Y<W*'D_/GD#]=B,9H[.QS#!"92JY8\YN;R!OU.R6S+BSL<;`=2IL
M5LIX`RFCF&$O&5S#:.0([X>,QA"AOI(QTYS=C?K`V9)!H:$7+AF+E&['9H8*
MG94UOIXUFK,E8Q:*=488*O13:0,/X-0S4G.V9/`>F<]PS15KFQD4B$_J\$'6
M-3EE/Y+ZE)>-=<F.<"O;741P?-7XG`Y?M-6U>V#U4+7P?*W[]0S/4S-XFN4N
M`#Y65?OZ0CP)?'M"N_L?``#__P,`4$L#!!0`!@`(````(0#$KZ2`Q08``.<?
M```8````>&PO=V]R:W-H965T<R]S:&5E=#(N>&ULG)G;;J-($(;O5]IW0-S'
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M8O<?1N%/U;:IVWK?K2#<&H6.UYRNTS5$>GS85;`"E7:O*?<;_R.[SV7DKQ\?
M^@3]4Y6O[>#_7GNH7W]IJMUOU;F$;$.=5`6>ZOJK0K_LU*_@XO7HZL]]!?YH
MO%VY+UZ.W9_UZZ]E]7SHH-PAK$@M['[WXU/9;B&C$&;%0Q5I6Q]!`/ST3I5J
M#<A(\;W_][7:=8>-+Z)5&`>"`>X]E6WWN5(A?6_[TG;UZ5^$F`Z%0;@.(D"]
M_CM?\21D870[RAH5]0O\5'3%XT-3OWK0-7#/]E*H'F3W$'EZ1;`4Q7Y4<'\)
MB&VA#-\>N7Q8?X/,;36232`VD4\0X159@ZRK-ECQ?&T*AKSZGM$67</V\C-$
MY``Q-^Z)W$58TN`^\Z4I>.-#;",M)M(02?J<"A%&*4L3&\F'B(QC*5AHY%OB
M8(7SQ2F8B"-WSA")L.`\83SA1)M%!#+B++T2EC1H]_G2%$RDF;!84D10&F.!
MD)(0N46(.!*F8RUET1)E"K:5B>"Z8%2&""H341J*E%-I0T2F*8^#P*3>$A<O
M$:=@(HX1<8B@.!G()"3J<P=@"5,.-WM\*)@((XV4(:*%R2A-1JTV)`2/XC@U
MV]R2EBZ1IF`B39"<(:);3<9<FOOB\'``EC`&_C,_:3U-I)D6QE[3C$X;2^,P
M#<B$R2TF%#$D-S!5MP4N,P4<Z#">KN--F,&D!2(#8^+*$"1G+L26IZ;T[*9C
M.-.'TU>0RF6:T;6-TX1SLQ&QN!8B8I&"=5\;Q):G!O5\>3C6+7FD=!E#!N6E
M(DT8V<^Y13`NXN!==6I4SU>'@]U21S*3L>'P9YRG,B3]F5M(Q),X,D'LW"WR
M!W4$H[N6S-A,,Y@[SGB:"&9NKFL[]`@N(7\L-BUB"UQD$VSL$]+L.;TUAB[`
M0QZ%$^6UF#3F29":'-L"%UD%&WN%)+V5:08SF(@X88FYMT[@T"Y2*4,6FRBV
MO$6&P<:.(:EC:$87.$F2*!G5=^@9D#L6A6:XV_(6F08;NX8T@75YAZX0Q7`(
M,)VEDS<D0M@^9OM;VCBQ#?40(N!W[B-[?Y5M'Y*4+].,KC"<[P3-<FXA+$U#
M.$>9I=HZ%[D'Q[$_G##2#%;,H690GXP"+@4W_859M)@(3L^2OW>8XG"S^2.P
MI^T'"^K\F69<]N9$[/P1_U!UCF%"W:CSV$<&C:3S./01F(5T'3D?`BQ($S--
M;8G$1)1$>5OBV$PDV:H9'YK)70B/.62_YR["%JFF^FRG4X_0Q$OHHT2F&>Q#
M&"+J,6WP.*$;$0.]05((&0T2;4M<Y"9\[";TW)YI!N]^QV(PE(2/_)A2H3K.
M!N_MYT6.PL>.$I*]FFE&BU3/'Y*1F93;3`)'&O'N?B:>,G,PCKTE)+V6\:%Q
MR.ESM<6XS]6<N,M,H6.7&=B7WMG(.`>0"[&Z4IG*_(W3TS?FHV9<\IR(+6^1
MOXBQO]#MD&D&^Y%'24S'4NXB;''$6^:56*BK;),>?+>#)=:,,X<89AJQ91*/
M<7N+0%N`G]>GM\%$T_*0F;XW3D8=9AJQY0&SH`,53;)'QDDFD,$2QV(XD;6X
M]P%;&G&5F04>NTM(SH&90`9T7+-,#D*Y$[%E+G(6@<[B+C`R3GDNQ):WR%/$
MA*>,"HR,+C"3`2/#/-=1)@E;W/_R$S'A)^8DKS<),LX<NA!;)G&3&WL8Q[^[
MQ"Z+T-O$A5CRY"(7Z>D;>U@S6$#XLC<-.:VQ$['E$1>9MX_EA)O0(ZQF7$5V
M(K9,XB?N(DLT`&>1->.4-]M'I)KZL\_8/7VKR"KBQM=%EA+>)5R_9L,6U%$F
M"3MWL,:AN)DE5E<1D>8Q"/>Q1,:90Q=BRR2.<J/$Z!+N$M]V$O6T!JN<7H$M
M;Y&3P%O84?;HJ-8,ONR*1`1?.-`28Y1)`L7AJUI\DWDIGLO?B^:Y.K?>L=R#
M>P8K]<#<X(M:_-#5E_[-Y5/=P0O6_K\'>*%>PFO-8`7POJZ[MP_J5?#U%?WC
M?P```/__`P!02P,$%``&``@````A`/MBI6V4!@``IQL``!,```!X;"]T:&5M
M92]T:&5M93$N>&UL[%E/;]LV%+\/V'<@=&]M)[8;!W6*V+&;K4T;Q&Z''FF9
MEEA3HD#227T;VN.``<.Z89<!N^TP;"O0`KMTGR9;AZT#^A7V2$JR&,M+T@8;
MUM6'1")_?/_?XR-U]=J#B*%#(B3E<=NK7:YZB,0^'],X:'MWAOU+&QZ2"L=C
MS'A,VMZ<2._:UOOO7<6;*B010;`^EINX[85*)9N5BO1A&,O+/"$QS$VXB+""
M5Q%4Q@(?`=V(5=:JU68EPC3V4(PC('M[,J$^04--TMO*B/<8O,9*Z@&?B8$F
M39P5!CN>UC1"SF67"72(6=L#/F-^-"0/E(<8E@HFVE[5_+S*UM4*WDP7,;5B
M;6%=W_S2=>F"\73-\!3!*&=:Z]=;5W9R^@;`U#*NU^MU>[6<G@%@WP=-K2Q%
MFO7^1JV3T2R`[.,R[6ZU4:V[^`+]]2696YU.I]%*9;%$#<@^UI?P&]5F?7O-
MP1N0Q3>6\/7.=K?;=/`&9/'-)7S_2JM9=_$&%#(:3Y?0VJ']?DH]ATPXVRV%
M;P!\HYK"%RB(ACRZ-(L)C]6J6(OP?2[Z`-!`AA6-D9HG9()]B.(NCD:"8LT`
M;Q)<F+%#OEP:TKR0]`5-5-O[,,&0$0MZKYY__^KY4_3J^9/CA\^.'_YT_.C1
M\<,?+2UGX2Z.@^+"E]]^]N?7'Z,_GG[S\O$7Y7A9Q/_ZPR>__/QY.1`R:"'1
MBR^?_/;LR8NO/OW]N\<E\&V!1T7XD$9$HEOD"!WP"'0SAG$E)R-QOA7#$%-G
M!0Z!=@GIG@H=X*TY9F6X#G&-=U=`\2@#7I_==V0=A&*F:`GG&V'D`/<X9QTN
M2@UP0_,J6'@XBX-RYF)6Q!U@?%C&NXMCQ[6]60)5,PM*Q_;=D#AB[C,<*QR0
MF"BDY_B4D!+M[E'JV'6/^H)+/E'H'D4=3$M-,J0C)Y`6BW9I!'Z9E^D,KG9L
MLW<7=3@KTWJ''+I(2`C,2H0?$N:8\3J>*1R5D1SBB!4-?A.KL$S(P5SX15Q/
M*O!T0!A'O3&1LFS-;0'Z%IQ^`T.]*G7['IM'+E(H.BVC>1-S7D3N\&DWQ%%2
MAAW0."QB/Y!3"%&,]KDJ@^]Q-T/T._@!QRO=?9<2Q]VG%X([-'!$6@2(GIF)
M$E]>)]R)W\&<33`Q509*NE.I(QK_7=EF%.JVY?"N;+>];=C$RI)G]T2Q7H7[
M#Y;H'3R+]PEDQ?(6]:Y"OZO0WEM?H5?E\L77Y44IABJM&Q+;:YO..UK9>$\H
M8P,U9^2F-+VWA`UHW(=!O<X<.DE^$$M">-29#`P<7""P68,$5Q]1%0Y"G$#?
M7O,TD4"FI`.)$B[AO&B&2VEK//3^RIXV&_H<8BN'Q&J/C^WPNA[.CALY&2-5
M8,ZT&:-U3>"LS-:OI$1!M]=A5M-"G9E;S8AFBJ+#+5=9F]B<R\'DN6HPF%L3
M.AL$_1!8N0G'?LT:SCN8D;&VN_51YA;CA8MTD0SQF*0^TGHO^ZAFG)3%RI(B
M6@\;#/KL>(K5"MQ:FNP;<#N+DXKLZBO89=Y[$R]E$;SP$E`[F8XL+B8GB]%1
MVVLUUAH>\G'2]B9P5(;'*`&O2]U,8A;`?9.OA`W[4Y/99/G"FZU,,3<):G#[
M8>V^I+!3!Q(AU0Z6H0T-,Y6&`(LU)RO_6@/,>E$*E%2CLTFQO@'!\*])`79T
M74LF$^*KHK,+(]IV]C4MI7RFB!B$XR,T8C-Q@,'].E1!GS&5<.-A*H)^@>LY
M;6TSY1;G-.F*EV(&9\<Q2T*<EEN=HEDF6[@I2+D,YJT@'NA6*KM1[ORJF)2_
M(%6*8?P_4T7O)W`%L3[6'O#A=EA@I#.E[7&A0@Y5*`FIWQ?0.)C:`=$"5[PP
M#4$%=]3FOR"'^K_-.4O#I#6<)-4!#9"@L!^I4!"R#V7)1-\IQ&KIWF5)LI20
MB:B"N#*Q8H_((6%#70.;>F_W4`BA;JI)6@8,[F3\N>]I!HT"W>04\\VI9/G>
M:W/@G^Y\;#*#4FX=-@U-9O]<Q+P]6.RJ=KU9GNV]147TQ*+-JF=9`<P*6T$K
M3?O7%.&<6ZVM6$L:KS4RX<"+RQK#8-X0)7"1A/0?V/^H\)G]X*$WU"$_@-J*
MX/N%)@9A`U%]R38>2!=(.SB"QLD.VF#2I*QIT]9)6RW;K"^XT\WYGC"VENPL
M_CZGL?/FS&7GY.)%&CNUL&-K.[;2U.#9DRD*0Y/L(&,<8[Z4%3]F\=%]</0.
M?#:8,25-,,&G*H&AAQZ8/(#DMQS-TJV_````__\#`%!+`P04``8`"````"$`
MJ)4`\B<$``"R$```&0```'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R4F-N.
MFSH4AN\K[7=`W)=3"(0H255.>U=JI6IK'ZX).`D:P`B3R<S;=]EF*'8RALE%
M$LSG/VO]7C9V=E]>ZDI[1ATI<;/7;</2-=3DN"B;\U[_]Y_T\T;72)\U15;A
M!NWU5T3T+X<_/NUNN'LB%X1Z#10:LM<O?=]N39/D%U1GQ,`M:N#."7=UUL-E
M=S9)VZ&L8)WJRG0LRS/KK&QTKK#MEFC@TZG,48SS:XV:GHMTJ,IZB)]<RI:\
MJ=7Y$KDZZYZN[><<URU(',NJ[%^9J*[5^?;;N<%==JP@[Q?;S?(W;79Q)U^7
M>8<)/O4&R)D\T/N<`S,P0>FP*TK(@-JN=>BTU[_:V]1>Z>9AQPSZKT0W,OFN
MD0N^_=F5Q?>R0>`VC!,=@2/&3Q3]5M`FZ&S>]4[9"/SLM`*=LFO5_XUO?Z'R
M?.EAN->0$4UL6[S&B.3@*,@8SIHJY;B"`.!=JTM:&N!(]L(^;V717_;ZRC/6
MOK6R`=>.B/1I225U+;^2'M?_<\@>I+B(,XBL(/KAOF,XF[6]]CZ@X@XJWJCB
M^(;M6@LT3)X5,RG.^NRPZ_!-@\J#N$F;T3JVMZ!+W5F!QX_=`5MHGZ^T$^L*
M-($A?3YX@;LSGV$8\H$).>/KVL@X(A$](-8B$M__D.L%(I/<,RN12.^)J8H)
M3HQVP$!]W`[:2;3#]60[...SJJ`>1G)#_$C%%S-)%C"IFA&RA7*<9JL>=`K3
M+.D4H1F$O&&2DMP0RUV2MX;?1>%Z&S''5,T(\<.$6!X_A:&X)P7I!5*]A9R!
M][%H)2*:)>)9(IDE4A4A.`!+T-2!9=.7=MKK4"=CEJXOS9F0,Q#'R,A.S!+Q
M+)%PPF-+R-IB+ZD:5!J"$[!X39U0US*%90?D&<L9E0.S1#Q+)+-$RHD-\\CV
M1GN$Y&&9G2:_K`QH)]$$+_BMS^<X9U0FS!+Q+)%P@I>!S^I@3).%D:HD!"/H
MKNW#CS/:239"6GE#SJB,F"7B62+A1,#&>K,RY*51)2#8$(@VJ"<#A:7TY=6`
M(WR`'-MQ/4>:+=&4L*U@$]@2$4\)9VTYEK.1\DLXHC`Y51&"`S9L8J:5H+:`
MT9('4OSAP*A,$)#'+@C(.S8,C,H')2(:07<_DRDQ8P3?*TV?#5X@#5-H<T@1
M7S2/Q"-"]X^6..&3\>:[SY]4B8@6T"W1<@OX!DJT0-ITAC:'7/[D$H./QIOO
M!A_/(\D\DBH1T0*ZJYI8L.P)`><R>6GP+6FHP@'B#RAITD3#346IQ/-(,H_0
M(R0-]?$/<2OX$9&??FK4G5&$JHIH.;[2XY\#0SFV\J-I:&]ADPO[7:D]LK<1
M:S?'&W!B;+,S^I%UY[(A6H5.(&D9/FQ?.G[FY!<];ME)X8A[."NRKQ?X;P#!
M?MHR`#YAW+]=T%/M^&_#X1<```#__P,`4$L#!!0`!@`(````(0`V)8$EE0,`
M`.H+```9````>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;)16VXZC.!!]7VG_
M`?'>$`AW)6EUN,R,-"NM1C.SSPXXB=6`$78ZW7^_91Q(,#VA^X6$\O&ASJG"
MU.KQM2JU%]PR0NNU;AD+7<-U3@M2'];ZKY_90Z!KC*.Z0"6M\5I_PTQ_W/S]
MU^I,VV=VQ)AKP%"SM7[DO(E,D^5'7"%FT`;7L+*G;84XW+8'DS4M1D6WJ2I-
M>['PS`J16I<,4?L1#KK?DQPG-#]5N.:2I,4EXI`_.Y*&]6Q5_A&Z"K7/I^8A
MIU4#%#M2$O[6D>I:E4??#C5MT:X$W:^6@_*>N[N9T%<D;RFC>VX`G2D3G6H.
MS=`$ILVJ(*!`V*ZU>+_6GZPH"W1SL^K\^4WPF=W\U]B1GK^TI/A.:@QF0YE$
M`7:4/@OHMT*$8+,YV9UU!?BWU0J\1Z>2_Z#GKY@<CARJ[8(@H2LJWA+,<C`4
M:`S;%4PY+2$!N&H5$9T!AJ#7[O=,"GY<ZTO/</W%T@*XML.,9T10ZEI^8IQ6
M_TF0=:&2)/:%!'XO))9K.+;K!Y]A65Y8O"N+;=B!:[G>?"ZFU-79E"".-JN6
MGC5H/<B<-4@TLA4!<^^/5#,X]B?#P"E!\B18UKJO:^`%@R*_;+S`6YDO4)G\
M@ME*#%P'C..Y8TP\Y?'M,23I(:)6XMEI'[CR6N,M68\0C0*R!^U0CUOM[_=$
M+U&`A<3^N5L9`.Y!CQ?XXR?'_:8K1I4S1?C+,4DZA2@DV11Q0S*2#$WT<<D"
M/)(L`V/)P3C;6-V4J(%4#60W@5&RSCA9T9O.']_=ODYB$[REH[*$XQRW$@/7
MH71J(\XBDEE$.HO([B%&3H#JV[())Y9P%M[O6+%IK4-O#"J]<*$X(3%.]\K:
MRGL3]XM7`L6F9!:1SB*R>XB1"7`\?=X$L4DU0=&YE1C/[EQ0%F.Y")4:7%1-
MF$6DLXCL'F)D`IRQGS=!;%)-4,Z0K<3<T1G/(I)91"H1[UN=W=L^,D$,9S<?
MK?NO@0"KXI4C=BLQ]\1+1-"UB.LN+:5-DMMU)PA"93V]7;="QPF5<Q.&()&F
M?(#EAZ%W_7Y*[7+&D1_O"K<''..R9%I.3V)^\2&S(3J,5D]+\;U2XK$5P5=T
M&D]A%'LO'ML1G.I3?&)'<+A/XZD=P1D_C6=V!$<]Q,TA(1BU&G3`_Z#V0&JF
ME7@/4A:&#V="*X<U><-ITXTJ.\IAR.K^'F&FQO#]7Q@`WE/*^QOQ@&%*W_P/
M``#__P,`4$L#!!0`!@`(````(0"$MRGS^`,```80```9````>&PO=V]R:W-H
M965T<R]S:&5E=#0U+GAM;)27VXZC.!"&[U?:=T#<-Z<$<E"248?#S$BSTFJU
M,W--P$E0`T;8Z72__98Q,-CTV-E<)`$^_[C^*HQK]^FM*HU7U)("UWO3M1S3
M0'6&\Z*^[,WO_R9/:],@-*WSM,0UVIOOB)B?#G_^L;OC]H5<$:(&*-1D;UXI
M;;:V3;(KJE)BX0;5<.6,VRJE<-A>;-*T*,V[055I>XX3V%5:U"97V+:/:.#S
MN<A0A+-;A6K*15I4IA3F3ZY%0P:U*GM$KDK;EUOSE.&J`8E341;TO1,UC2K;
M?KW4N$U/)<3]YB[3;-#N#F;R59&UF.`SM4#.YA.=Q[RQ-S8H'79Y`1$PVXT6
MG??FL[M-7,^T#[O.H!\%NI/)?X-<\?US6^3?BAJ!VY`GEH$3QB\,_9JS4S#8
MGHU.N@S\W1HY.J>WDOZ#[U]0<;E22+</$;'`MOE[A$@&CH*,Y?E,*<,E3`"^
MC:I@I0&.I&_=[[W(Z75O+@++7SD+%W#CA`A-"B9I&MF-4%S]Y)#;2W$1KQ>!
MWU[$]:VEYZ_6_T=ET:L$OU0\RUO[KA_HYV+SN#J;HI2FAUV+[P;4'LR<-"FK
M9'<+RLR?!;C,HQD=^YUAX!03>68J>W-E&C"<0)9?#\%JL[-?(3-9SQPY`]\C
MLPQ\D0GG.BM/1*(!8;EB]XZ'$[]T77%(,A"L4"#L,7;(QS3VCVMB")'!+,3A
MOD=^`K3'>(*U(]XYG#-R.'-BM1!%XCDBB21S8B(BA`Q%]'C(#(9R$"*4O#UR
M9CEAY)QJB4A+Q%HB41&"`S#5J0-#P:N3SP;M3;!YDFLI"4?.K+OJ=YV-[\!'
MS&3($?@>922S(BT1:XE$10A6P`HVM4)M`8-E"Z1*/7(FZ"Q8!.Y"BB[DUU7Q
M:XE82R0J0H@?UKMI_(^5`ALD^[`4\WSDC"+.D!.\6*0JB1378L6UY.-K0L2P
M0D\C5F><P6*D_D::ZY$SJDBU1*0E8BV1J`C!`;:QF[SOU`XP6+<`<D;E@):(
MM$2L)1(5(3BP$1UXK.K9(+$6@K7T=!\Y$WA\!;16W0K(5L'NX\5/THH9\@$*
MZR(M$6N)1$4(QKBP[WF\-CI:M,3?R&_''E*$&.J12(_$>B11(J(1;,/T\$/B
M\NT5O(#'MUJPGAG!(:416B3J;Z50B?5(HD1$(]C&:F+$8\\*]#/ZAZ6'^J?%
ML1SI'1+V@"+62(_$>H2U7VRZ']^(V\';*]XW5*B]H!"5)3$R?&.MTP(>^/'L
MV-8]=UV==#YTM["!ARVT=#YF;2`[;X\7H`MKT@OZ*VTO14V,$IWA5@ZL*J;1
M\CZ.'U#<=%W,"5/HO[J_5^BW$;0&C@7P&6,Z'+`;C!W\X3\```#__P,`4$L#
M!!0`!@`(````(0`NLH$/P`(``&D'```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0T+GAM;)156V^;,!1^G[3_8/F]@+D%HI"J5=6MTB9-TR[/#IA@%3"RG:;]
M]SNV$T*2MDM?`L[YSO>=FP^+Z^>N14],*B[Z`A,OP(CUI:AXOR[P[U_W5QE&
M2M.^HJWH68%?F,+7R\^?%ELA'U7#F$;`T*L"-UH/<]]79<,ZJCPQL!XLM9`=
MU7"4:U\-DM'*.G6M'P9!ZG>4]]@QS.4E'**N><GN1+GI6*\=B60MU1"_:OB@
M]FQ=>0E=1^7C9K@J13<`Q8JW7+]84HRZ<OZP[H6DJQ;R?B8Q+??<]G!&W_%2
M"B5J[0&=[P(]SSGW<Q^8EHN*0P:F[$BRNL`W9'Z;8W^YL/7YP]E63=Z1:L3V
MB^35-]XS*#:TR31@)<2C@3Y4YB]P]L^\[VT#?DA4L9IN6OU3;+\ROFXT=#N!
MA$Q>\^KECJD2"@HT7I@8IE*T$`#\HHZ;R8""T&?[W/)*-P6.4B^9!1$!.%HQ
MI>^YH<2HW"@MNK\.1'94CB3<D<!S1T)"+\P2DJ3_9_%=1#;!.ZKI<B'%%L'0
M@*8:J!E!,@=FDUG\9F:0DO&Y,4[6%=`*NO&T3&?9PG^"$I8[S.TY)AP1/HB/
M$8#J:001=.CUVNXC,$Y018S&"&(R&_EME+<.$T\PR8@XB@!HIA&\KVS`!0YM
MUF%`XI'2B3IS9LU1G`9ID(^((U&(ZW)1`YZ('O)PHLZ<.M$HAV8$KXM"9R\7
M->"):#I2.E%GWHMF2122$7&4:?H140.>B)[VU)EWHG&69MD;HK./B!KP1/1T
ME)UY)QI$24"BUS,UZWYRF=X?)`,VHH<1CI+3&CN,4X9;GL1O]#7_B+`!'PN3
M^%!%UUR'<6-,9E$.@WZ8=-==MRW=,AGHFGVG<LU[A5I6PZ4,O!D,B'2[TAVT
M&.S26`D-.\Z^-O!)8[!1`@_`M1!Z?S#;>/Q(+O\!``#__P,`4$L#!!0`!@`(
M````(0!9$7.$U@(``-X'```9````>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM
M;(Q5VXZ;,!1\K]1_L/R^7!/(1B&K3<BV*[525?7R[(`)U@)&MK/9_?L>XT"Y
MM$GRD,#)>#QSQAQ6#V]E@5ZID(Q7$78M!R-:)3QEU2'"/W\\W2TPDHI4*2EX
M12/\3B5^6'_\L#IQ\2)S2A4"ADI&.%>J7MJV3'):$FGQFE;P3\9%213<BH,M
M:T%)VBPJ"]MSG,`N":NP85B*6SAXEK&$QCPYEK12AD30@BC0+W-6RY:M3&ZA
M*XEX.=9W"2]KH-BS@JGWAA2C,ED^'RHNR+X`WV_NC"0M=W,SH2]9(KCDF;*`
MSC9"IY[O[7L;F-:KE($#W78D:!;A1W>YFV-[O6KZ\XO1D^Q=(YGSTR?!TB^L
MHM!LB$D'L.?\14.?4UV"Q?9D]5,3P#>!4IJ18Z&^\]-GR@ZY@K3G8$C[6J;O
M,94)-!1H+*^1D?`"!,`W*ID^&=`0\M;\GEBJ\@C[@34/'=\%.-I3J9Z8IL0H
M.4K%R]\&Y&I1'8EW)H$59Q+7L[S%W)T'UUELHZ@Q&!-%UBO!3P@.#>PI:Z*/
MH+L$YM:9T=%Y_9]5D*=)'C5+A$.,P(6$>%[703A?V:_0T^2,V4PQH3>$;%N(
MMJUYX[;PE]<=+MFU"!T?6.I\0;?ZOOZ=5"M?@[7\=M^-*0!WYV<L=8H(_:&T
M>`H9D>RFB![)P(X_M*-C\N$87[:E%P&NYV+FAD.1&X.9]3"CW+97$?%5Q.X2
M8N`3A-P>FP9'&)K8I12$P<B?P2R:,[EP`F]\++=]0+CP9\$HI+@/\&:._@SW
MV%U"#-S!`W:[.PT>NQNG9S"P?]>!<7I7$;%!S)L.S7S7'[N[Q&#<F;EIQDI)
MQ8%N:5%(E/"CGHD^,'?5;EP_>OII&]4W[A)FP+0>PWAOZG:W`,9K30[T*Q$'
M5DE4T`RV<JP0U`HSH,V-XG4SY/9<P6!M+G-XCU*8+HX%X(QSU=[H&=*]F==_
M````__\#`%!+`P04``8`"````"$`(`G3>(`#``"S"P``&````'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;)26VXZ;,!"&[ROU'9#O-QP2<E+(:L-JVTJM5/5X
M[8"36`N8VLYF]^T[@PD!YR#V)@GAYY_/XQDSB_O7/'->F%1<%!'Q!QYQ6)&(
ME!?;B/S^]70W)8[2M$AI)@H6D3>FR/WRXX?%0<AGM6-,.^!0J(CLM"[GKJN2
M'<NI&HB2%7!G(V1.-5S*K:M*R6A:/91G;N!Y8S>GO"#&82[[>(C-AB?L423[
MG!7:F$B640W\:L=+=73+DSYV.97/^_(N$7D)%FN><?U6F1(G3^9?MH60=)W!
MNE_]$4V.WM7%F7W.$RF4V.@!V+D&]'S-,W?F@M-RD7)8`:;=D6P3D0=_'OM#
MXBX758+^<'90K=^.VHG#)\G3K[Q@D&W8)TW7/UG&$LU2V#GBX(ZLA7C&1[_`
M7QX$494`@ZA_QS`/`49QFS#MW\>03]6V?9=.RC9TG^D?XO"9\>U.0Z00TH#9
MF*=OCTPEL`T0:Q"$Z)J(#"S@T\DYUA.DD;X:.I[J742&XT$X\88^R)TU4_J)
MHR5QDKW2(O]K1'YM94R"V@2^#^9^X`VF83@:3R?]78:U"WS7+CX8WD9PS7*J
M3#U239<+*0X.U"D`JY)BU?MS,+R<#L@#:A]0')$);%A$%.S)R]);N"^0]:16
MK(P"/AN%WU7$1P5N'#`T(+"$_B`H1A#<)R1;F3_:<0,K[KEBV"@Z()"%-@@6
MRA!J]'9F\"'0M=8]:MP-H5&,6HJPJXAO*3J$8-(FO$V&XHC`ZIL=&7?CKHRB
M33;I*N)SQ8F]0P9%W)\,Q5VR:3?NRBC:9+.N(CY77"$;OX<,Q5TRWRYT(PFK
M)ACYX<A.F;G?1K\"!MW4/V4HML"L_EH923NP;[?"N>0*&[XQ>Q\.*+;83AUF
M>L!(.FQ6F\3GDBMLL_>PH=AB.]D:-B/IL%F-$I]+3B:=-O#AO.B?N$IMT5GE
MM*HU'3RK6^(+FFM\>`CWWEC?'-GM(\2W^G!5:]I\@=4R\07--3X\K/OSF:.]
MS1?878%O2*B`#I_=%A<TU_CPJ&[Q]7M'P$QD5V%@=TBM:7.>&*I"Q=$*;<;5
MT1.$7N`%TU,IF#HT(Y%YT>=,;EG,LDPYB=CCB./#H\V_S<Q6#U/-#9A^2KIE
MWZC<\D(Y&=O`H]X`!Q5IYB=SH459C1%KH6'NJ7[N8#AF\%KV!B#>"*&/%_C2
M;\;MY7\```#__P,`4$L#!!0`!@`(````(0#I(S^O5@,``-4+```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;)16VV[B,!!]7VG_(<I[B0T$"@*J=JON
M5MJ55JN]/)O$(5:3.+)-:?]^QQDP,;>&%R#A^)R9,Y/)S.[>RB)XY4H+6<U#
MVB-AP*M$IJ):S<,_OY]N;L-`&U:EK)`5GX?O7(=WB\^?9ANI7G3.N0F`H=+S
M,#>FGD:13G)>,MV3-:_@GTRJDAFX5*M(UXJSM#E4%E&?D%%4,E&%R#!573AD
MEHF$/\ID7?+*((GB!3,0O\Y%K7=L9=*%KF3J95W?)+*L@6(I"F'>&](P*)/I
M\ZJ2BBT+R/N-#EFRXVXNCNA+D2BI969Z0!=AH,<Y3Z))!$R+62H@`VM[H'@V
M#^_I](&.PV@Q:PSZ*_A&MWX'.I>;KTJDWT7%P6VHDZW`4LH7"WU.[2TX'!V=
M?FHJ\%,%*<_8NC"_Y.8;%ZO<0+ECR,@F-DW?'[E.P%&@Z?5CRY3(`@*`SZ`4
MMC7`$?;6?&]$:O)Y.!CUXC$94(`'2Z[-D["489"LM9'E/P31+162]+<D\+TC
MZ7<EB3"@)K]'9MABIN0F@*8!25TSVX)T"L2[Q#`,E^JY3"%%2W)O6>;A.`P@
M"0WE>5W$A,RB5[`TV6(>$`.?#D,=(H)H7$@01CNDTQ[OE"W8*EO/;2@/>*,M
MTS\M,[A&QH+G(7"[X&.R#Q^5$3-L8TXK`Z2=H/5\`"UY.5%["'!M=K+/#"-`
M3(<(H.G:$5Q6MF`_]^'PL+B(\93)X'3VHVNT+=C7CLG0\6+6B/&T'<)K+.C/
M=M;=?+>'/O(=,1TBL.^#UM-VV7<+]G,_]ATQGO(YWR?7:%NPKQV3V+F*OB/&
MTW8(SW<*S=U.NYOQS:F/G-^"N@1AYT]G[RE.J_8#?VS^%N2)D]$9#^Q<:LEW
M]`"G63N,F(R=`M:!(L@+PT'\0AS,O(Y!X&"[/'HH@KH$`9BV$Y<?`FK1?B>>
M*`2"/'%R>\:#JV:??<D?R,=DXIBW!3@Q_1S$+\#!\.M8`)QP'Q2@\QB$1>F:
M`N!P:[<@G>R]W3IP8@+2_3L"/<#M"K>/DJL5_\*+0@>)7-O-B<+:X.ZZK>Z^
MW^QE[@]8JFJVXC^86HE*!P7/X"CIC:$""M<RO#"R;G:;I32P3C4_<UB?.6P(
MI`?@3$JSN["+GUO(%_\!``#__P,`4$L#!!0`!@`(````(0!85;5QZP0``#$6
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;)287X^R.!3&[S?9[T"X
M'[`H*D9],]C.[IOL)IO-_KE&K$H&J`%FG/GV>TH1.66G]?5B5.9W#GU.GY9C
MU]\^BMQYYU6=B7+C$F_B.KQ,Q2$K3QOW[[]>GI:N4S=)>4AR4?*-^\EK]]OV
MYY_65U&]UF?.&P<RE/7&/3?-9>7[=7KF15)[XL)+^,]15$72P-?JY->7BB>'
M-JC(_6`RF?M%DI6NRK"J'LDACL<LY52D;P4O&Y6DXGG2P/CK<W:I;]F*])%T
M15*]OEV>4E%<(,4^R[/FLTWJ.D6Z^GXJ197L<]#]069)>LO=?AFE+[*T$K4X
M-AZD\]5`QYHC/_(ATW9]R$"!++M3\>/&?28K%DQ<?[MN"_1/QJ_UX+-3G\7U
MERH[_):5'*H-\R1G8"_$JT2_'^0E"/9'T2_M#/Q1.0=^3-[RYD]Q_95GIW,#
MTQV"(BEL=?BDO$ZAHI#&"T*9*14Y#`#^.D4FK0$523[:]VMV:,X;=SKWPL5D
M2@!W]KQN7C*9TG72M[H1Q;\*(ETJE23HDD!$EX0$7K`,23BW9_'5B%J!-&F2
M[;H25P=<`_>L+XGT(%E!9JEL!N]J'+W6KZ2"1IGD66;9N`O7@?`:YN=].ULN
MU_X[U#3MF'C,+`*,[&Z(K*#,2V\7[GD)#F$W0DX?2.IU0;6&NOY_IF[#E[`<
M_NV^L;H`N7L]^E#'Q&**AT;'B):$C8E!$B1G^B-R)+QQ(7D_^MDRPH.+%3,;
M,"$F=E:"6@EF(I`^&,CCTR5A6$*#L<^B"1Y]K!B3/BM!K00S$4@?+*FA/KG,
MIK`-F6TI@[1YC#3_QXJ9!^VBFW@+$D3#UP*79:?A9$:&=*2YA&IXN%P@7,O.
M-)P$\_[VJ!IS7`US%22L5T%;2+%B3+-M):B58"8"Z8.-<#C;9GT2MKE9,29]
M5H):"68BD#[9UV@/#;N;99`^C[J;%=.[F1!]4]*!\.XP]<08`9JEF0XLOEH!
M2'&$%9MG5,*Z4NWA$"O&-*-6@EH)9B*0/@*;T7!*S0);VN;9#C))M"/4CC`C
M@E7*;N&'C4M4CX&>IZ-]N(/NUIUHQMMI1+\S=IV.NLD]?KJ8#%_:2F%?9<-Z
M98,QT&N95=6.8)TS/,Z8*,@XJU:$VK,P(X)5RB[C<96J)S%W#T1!1I56A-JS
M,"."5<)@ABH?:R&(C-+W(LU+<0=UWIMY,_20CY;L27O>[G#$PIOCB&@40?4(
MW*9$X2B"Z1%3?(_Y,`)72K8AC_M!-2W8]=IC)Y8_]J",1C]8$6K/PHP(5BF[
MD<=5JM[%XGI3@]-N4SMB1:@=848$JY0]R4#E@ZY7G0R>TY'K%=2Y?NX-=UOX
M3-B3]LS>$10Q]4(<,ATZLMO5443@A=C#XW7"\#WF7H3O87"];&P&E;+L]:H-
MPA72>JF8*,CH>BM"[5F8$<%^D!W-XRI5_V-QO:E)ZEQO12BQ(LR(()5PEH54
M/N;Z-LJVUW=0Y_JEIQD2/*R['D=,P,.X):`8(![R:%M`>3@G]\^^NPGA\&OX
MNN^WJ@[J)$X=5!6\.O$=S_/:2<6;/&6;PH_=_FI_`O@<R/,;[7I,5G"J-+Y.
MX<2PO>[W`7!@=TE._/>D.F5E[>3\"+>"7]2PKU?JR$]]:<2E/3;;BP:.ZMJ/
M9SB:Y7!>!<5QG:,0S>V+/)6ZW@Y[M_\!``#__P,`4$L#!!0`!@`(````(0#K
M4H_YWP<``.4B```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*Q:;8_B
M1@S^7JG_`>7[0=Z`!2V<%LBTE5JIJJ[MYRR$)5H@*,G>WOW[VO',,)[)D;#J
ME^/VB>WQ8WO&SLOCYV^GX^!K5E9Y<5YXP=#W!MEY6^SR\\O"^_N+^/3@#:HZ
M/>_28W'.%M[WK/(^+W_^Z?&]*%^K0Y;5`[!PKA;>H:XO\]&HVAZR4UH-BTMV
MABO[HCRE-?Q9OHRJ2YFENT;I=!R%OC\9G=+\[)&%>=G'1K'?Y]ML4VS?3MFY
M)B-E=DQK\+\ZY)=*63MM^Y@[I>7KV^73MCA=P,1S?LSK[XU1;W#:SG][.1=E
M^GP$WM^".-TJV\T?COE3OBV+JMC70S`W(D==SK/1;`26EH^['!A@V`=EME]X
M3\%<1&-OM'QL`O1/GKU7QO\'U:%X_Z7,=[_GYPRB#7G"##P7Q2N*_K9#")1'
MCK9H,O!G.=AE^_3M6/]5O/^:Y2^'&M(]!D9(;+[[OLFJ+404S`S#QHUM<00'
MX-_!*<?2@(BDWYK?]WQ7'Q9>-!F.IWX4@/C@.:MJD:-);[!]J^KB]"\)!>B4
M-A)*(_#;8N2&8B058ZTX'0:Q/\&U;ZC!U<9I^%7K1<-IX,^BZ6W%B52$7ZDX
MO:4WHF`UL=^D=;I\+(OW`10TA*.ZI+@]@CG84D$GEW4:?I0%B!P:>4(K"V_J
M#2#`%93.UV44!X^CKY#NK919N3*6Q%I)8$+0[,8&$AL0!C`"1IH6Y.]_H(56
MD)9R:*6`*\^0LUPK":6RL8'$!H0!,`Y04C:'"'95^WY0F4`EJ'R6"<O'%<G$
M<'#J=(TM&EI$\W"0Q$&$B3`JL"ML*KBU[ZPRM`)U"O'2?KME1D(WR6D13<Y!
M$@<1)L+(`1&3W.W\H'##0:V](B2>,5:1E0\MI-0V#I(XB#`1YC+L=--EW/43
M.'=`_LZ4H"%.AY`8"M5(4FS1T4*:CH,D#B),A-&!@\>F$SU@E[B7#AKB=`BQ
MZ-B[10MI.@Z2.(@P$48')QKK3`['P_O9H!W.AA"+S<1*CA;2;!PD<1!A(HP-
M%+;)YO;V0&'N,B&6RU/+92VD77:0Q$&$B3"7`ZA>TV?JBLW^N.U^H\C]E]`X
MTEUD[4(;%TI<2#"(>XR-T*B9#C>I;<))JN*U"B1$XQ!VW[4+;5PH<2'!(.XF
M]KK^;E)G9&X2%/+CY<$J!VP14$81<-*'4!#-N-1&2H5,:FP=58F2FC1C3>!/
M_&D\LTP))01;NG5!'@1LDT80C.JJ#_GV=56`#7"J)8<1."$G+NJUL/`UA01%
M\*.=B&++U74@%6&_:JF6V$BI:SDD4C&$/J@5H['/@RJ4>3BMM%0POCK!(X$]
MU8A$"V,XQ#5EZL",,D'A3$=A'6C(<,#-/4G!/*7"ETA%`Q)76R#%/0=^=WB.
MTM:Q0!`OY+$S$9-45R%+6V:R)*2JUI]&,SL(`D<P<"OL5[78?8U<?:QJJ86S
M%!+45;52L:-JI909"(*LJK4F8A%(10A(CZK%QFU$HJ-JJ<TSR@2QJM60X8"=
ML$U`4D:))BXD)$3F>=5BDS8\_U@.J=,S0@19Q6S/L`%)=16SM-5Q*DLIJN\9
M',J3R.H"0J[7L[QQ&+@1FB_%Y4>'LGE$T4C!8D,02[:&;B:;I*+K"9\$#B0D
MU))LS(;)Z':9-M+\B)+0^+J;UBZT<:'$A02#6$UB^S7=Q)K\T+3;&+(8H.V%
MQX='N\.OI2)(J5ZP<:'$A02#."EKSC$V6D<:W)$G),@<(%UHXT*)"PD&<8^Q
MX1OUW^&F'`^NM;D*G8EA[4(;%TI<2#"(NXE]N[^;U.7-[8B-`'L>&R#']@V=
ME.HXJI2MZP9)7$@PB)/!_MN?#'5K1D8V\+"934,_L(;7-=X"X^`!I^6UKSEM
M14G=/G*E%.0&G^\%83B+[:TDE"58MG4]3A^;;G_ZLD6;)2=[.XZ(7Y=`WTDC
M"72E49HQTR@A.3Z-'V9Q8$^ZH92!GMR#*W;N_ERIS[-4$P0;6'*U[]JQS?5(
MM90RN4K+,J\/_D,07.?UYFY#*./]\HJ]N3]7ZN2,JVSN.J_V[7Y(`EUYE69,
MKA*BO(9^/`NGUI@BI/%^8P/TW7NX4O]F7`FZYM6:8M;-"MU;6%HVN4K+E-<P
M"L9^:!6-4,9[Y14?/IMY-9I:__O6Q@COTA*RCF3+U;64ZLBYLF7$04&4\TDP
MB<:6;:%$8"=T;V7TP`S#[4[92%M\:2JAD:W97VLIA>EH=8!>AT@I\%8-*HD+
MB:LM^Z851DGF^<<2Z$XHC5W@>'U1LE80[+=;A*2MVXU'VI*-IWW65^OU*^2[
M9AV\,\6#U6@\$F(9)*FN#)(4RZ`#"6:>M<S(&G^:#/H0Q3L?VS=V+$XT&%FS
MLGWR2D5S5G:AQ(4$@S@GR)FYGY#3QY[>P]MI)U,$6:SL,U8J,E9:\;K7'`C?
MA^.*I$BLZ/TVO6,]9>5+MLZ.QVJP+=[PW37LD>6CANG%^BH:JS?K]I79'!Y2
M@P,V'OAS?!C<<B6$*W"2MEV!]_=PQ])V)80K37G;ZT0Q>!:WZ,#'`$^M&K!(
M^QJP1(N=500+M.!/\?R)/C:P70*/VAQ:00R;KP)L^<D<WANUD)[.X05,"_XP
MAU<9@(^T(?C(X)*^9'^DY4M^K@;';`^)])NW`25]ID!_U/(1P7-1P^<%D&MX
MG0Z?DV3P+-W'MS?[HJC5'[B`_D!E^1\```#__P,`4$L#!!0`!@`(````(0#]
M7(=_C08``*,A```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;)R:6V_K
M-@S'WP?L.QA^/['E6^R@Z4&[HML!-F`8=GEV'24Q&L>![5[.MQ]%*ZE%2;%Z
M7MJ&)?DW*>H7->K-U_?FX+WRKJ_;X]IGB]#W^+%J-_5QM_;_^?OQ2^Y[_5`>
M-^6A/?*U_YWW_M?;GW^Z>6N[YW[/^>!!AF._]O?#<%H%05_M>5/VB_;$C_";
M;=LUY0`ONUW0GSI>;C"H.011&&9!4]9'?\RPZEQRM-MM7?&'MGII^'$8DW3\
M4`[P_/V^/O7G;$WEDJXIN^>7TY>J;4Z0XJD^U,-W3.I[3;7ZMCNV7?ET@+K?
M65)6Y]SX0DO?U%77]NUV6$"Z8'Q0O>8B*`+(='NSJ:$"T7:OX]NU?\=6]UGF
M![<WV*!_:_[63W[V^GW[]FM7;WZOCQRZ#>LD5N"I;9^%Z[>-,$%PH$4_X@K\
MV7D;OBU?#L-?[=MOO-[M!UCN%"H2A:TVWQ]X7T%'(<TB2D6FJCW``\!7KZG%
M:$!'RG?\_E9OAOW:C]-%GJ9)EB\AS1/OA\=:Y/2]ZJ4?VN:_T8O)7&.62&:!
M[^<LV2)=AC$#T9DDP?A$6.!#.92W-UW[YL'4@&1_*L4,LA4D-E<$I0C?.^&\
M]I>^!\_:PS*\WL9I<1.\0NLJZ7,_^L#7BP^[>`0@>E$&-7=EX2R416_%H]R/
MAJE,9):)/R,CG&%Q)@\?9^$E[Z@\^B03G_3BH10(+NX%"F=8`RCKTC>]MZ.3
M@S3,@[NT<$;I2W.E!?;)Q\-DEF7,/B,EG%4I:5%;;EE*&+QI56(7+I=BQ\V,
MK8A35:5E.CYQ%IN744!\LD.$:KP,%[.J(DY5E195-3&K%KIJ$A8+:-?U+2KB
M5%5I454M(\M@R6FQC*7SQ6*@JGLVJ<*9N5P&7IIP&"T$'J\7C)%$620#DZJ\
MM"@3#B';$PB=D94`BCZ0)#:O+IM;9`5&Z%CEL<,TLQ%`H';9KV>36O`'F14L
M,<(E'.AB=K`PC/190DN177[P4I454"$%NXV6""3"TJ0*6P#%!&(FPC/K*H$T
M[:XT):+A:DT&(K$H=UE$G4G,!*6E!86,4&FF*)U%F`"ZJH!W:4$@,]#(L4Z=
M1YB,[LZE!8.1`4A)F#MP`2/5L3F;U+&QH#`"K^G8B&T2)="NZZW&,"(K,FD%
M6T`8F7"4QBX%ZT3"9)JR!821@4@I<Q'6@82Y-&$+"B,#D)S>US&0]-J()`L)
MQ<F!+G$,`SNSPCJ/,!$M-[>`,/H4C]";U"AYI&S=W$*_R(0HMWG2$87)M#HM
MB(H^A2CT)G5*:NG<C0P\<CH=82!1D812H)!;0!@;<,2<NHF1JO+9I"I;0!C_
M&(XPC,B:<)1;*!B;<.1T+L-(HFPZ(.46$,8&'+$",ES?G1A&9"6?U#Y;*!@;
M8#3/!(PBJB82Y18$Q@829<G\L1OCB*[I;)1;"!@3%N'AUZ')DD"30Q)F@B=1
MFEQ8$!@3*,TLJ0XB3`!J.AIB0AVLR.E(AI&DEY)`:E$6THHIF;Z;S!0EL3-M
MH30I7"\L=$U,)'*J$R/5.L\FM4X+`\7?1M,Z\>^',',X*&`D41;)P*0J6QB8
MF&`T/ZT81F1-)"HL#!2'/EIPE*8N!4OR3!89DVD%6QB8&&#$G.B+D:1F$Y`*
M"P83`Y"<SF082(1-1"HL)$Q,1%H6#G]28211EIQ2I\O"PH1`"><:MN3U?8Q1
M1%7R2E&UD3\AO)I1DT":#I0TZ2A,")!$02YO*AA'2I)HFI:4A!:ZIR8TS7^B
M@F&J[-FDREKXFX(7W:9.?[]@(!$6N<"D"EM0G!(L75]"]"9JDD93\">A!;^I
M@49.GZ-@(!&6?%++M-`W-<'(:6=B)%$VP"@)+0!.#3!B;LH2/9/]@LFTI;4`
M.#71R`G`&$EJ-M`H"2T`3G^(1AA%5#]#HY30"$]/+I__8B`1EF!2A\N"_=3`
M*K>IEF2:KK`15A;J9P16US<O>JMEGDW*YF46-&:"*Y//(K&_3O.$D419)`.3
MTF!FH6/V*4BA-U&3D-+?9S(#D0IHZTPK)7LF"X>)M((LU,T,.'([E6$D*<Z$
M(V8A<&;`D=/9"`.)L.%LE#`+@>&*6Y\>IS,_1A)E$XT8)?!X)3[>&#>\V_%?
M^.'0>U7[(JZ[([@#OE@O5_%WN*34GJSNQBOZX/(;N"(_E3O^1]GMZF/O'?@6
M<H9XKN[&2_;QQ=">X-GABKL=X&X<?]S#/T-PN`?&>[AMVP[G%^(C^LN_5]S^
M#P``__\#`%!+`P04``8`"````"$`ONXR=9`%``".%0``&0```'AL+W=O<FMS
M:&5E=',O<VAE970Q,RYX;6RL6%V/JS80?:_4_X!XO^&;)"C)U2:!]DJM5%6W
M[3-+G`1MP!&PF]U_WQELB#^XA*WZ<KDY.Q[/F3/VV%Y]?2\NQANIZIR6:].9
MV:9!RHP>\O*T-O_ZGGQ9F$;=I.4AO="2K,T/4IM?-S__M+K1ZJ4^$](8X*&L
MU^:Y::Z19=79F11I/:-74L)?CK0JT@9^5B>KOE8D/;2#BHOEVG9H%6E>FLQ#
M5$WQ08_'/"-[FKT6I&R8DXI<T@;BK\_YM>Z\%=D4=T5:O;Q>OV2TN(*+Y_R2
M-Q^M4],HLNC;J:15^GP!WN^.GV:=[_:'YK[(LXK6]-C,P)W%`M4Y+ZVE!9XV
MJT,.###M1D6.:_/)B1+7-JW-JDW0WSFYU<+_C?I,;[]4^>&WO"20;=`)%7BF
M]`5-OQT0@L&6-CII%?BC,@[DF+Y>FC_I[5>2G\X-R!T`(R06'3[VI,X@H^!F
MY@;H*:,7"`#^-8H<2P,RDKZWWUM^:,YKTPMGP=SV'#`WGDG=)#FZ-(WLM6YH
M\0\S<K@KYL3E3N`[X&1DH,<'^OW`8+8(`C]<S&'VD8'PUS9L^/(9W?D][)&!
M(1\(7SYP?$:+Y:M-_SYMTLVJHC<#:AHR4E]37"%.!,ZZO+.I>R5^)`0H@$Z>
MT,O:G)L&Y+B&ZGG;^$ZXLMY`\8S;;'4;1[;8=18H+[K=JT"L`HD`6,"HIP42
M_@^TT`O2Z@+:=L"=IZMPZ"RZ(7L5B%4@$0")`U25RL&#A36\)#HE<!`4OZ3$
M7(YQRVQ\V#M[N0+99->;]#PT)-:01$0D*K`P5"JXNC]99>@%ZA3RU<>MEQDS
M&B77F_3D-"36D$1$)')`1"0WK@\:MQRZN;<,\9<2JX6B1V_4#=MK2*PAB8A(
M(<-*GQXR&LLA,R2`8A2$6"HA]T9]R!H2:T@B(E+(L+F((>-&%<#J_V0)H1>9
M"T-\B8MK*UQZHYZ+AL0:DHB(Q`5/+<JFZP8S4.N3;-"/S(8A"AMUG^V->C8:
M$FM((B(2&ZA<E8T3S+#SC2\%'"='SY#`ZS?<G8;L-236D$1$I%`=D%F,=3S`
MUEJ.L(/8P0&;U$Z']CH4ZU`B07*8V-:$`GD0)FN"L"]V>FX=!L&)[;Y"O4#=
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MJ^T%MN/)^T/2.0?*$VH8N[;`E=V(VG;6G//L94O!!^PA`WLRQL#O0ZSU2RE@
MD+(E:_7-K!YISGV)>>`0TSQTX?:I+65N`I\):<!V+Z1A@&Y;N9PO6BOES2!W
MV7>E'6[08`70<`#\TL>LX*K3M;.8#Q2@Y.X+K.0-%[N_$/E_$Y`=(20!.72_
M#NX<#D'$@QGEA+C5@\;#K'CC<>;>$AJ=TIV2;L))E8RE-I:([_3ZHTH6I&V]
MR-)R2)3V#HUE@EMY]Y-*+$%,1_9(Q%XI"E*=R(Y<+K61T5=\`(*#QF;5P^QU
M:KN,X,P'A:#@\&KUU,ZEX%MXS6K7CHJ[\,HUX&?K17"W'?#O@_^V3E5'?@3W
M17W`-HC@4C:`AQ'<?`;P>02WB`%\$<%Y''"KGQA>PZ[IB?R>5J>\K(T+.4*R
M[';?JMA[&OO1<-6?:0/O8&T!G.'=D\!1UL8KR)'2ION!$_0OJ9M_`0``__\#
M`%!+`P04``8`"````"$`O?@3H'\"```1!@``&0```'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6R45,MNVS`0O!?H/Q"\1]3#=AK!<F`W2!N@`8JBCS--K23"
MHBB0=)S\?9=BK"IQ`K@70:2&,[/#72VO'U5+'L!8J;N")E%,"71"E[*K"_KK
MY^W%)TJLXUW)6]U!09_`TNO5QP_+@S8[VP`X@@R=+6CC7)\S9D4#BMM(]]#A
METH;Q1TN3<UL;X"7PR'5LC2.%TQQV='`D)MS.'1520$W6NP5="Z0&&BY0_^V
MD;T]LBEQ#IWB9K?O+X16/5)L92O=TT!*B1+Y7=UIP[<MUOV8S+@X<@^+$WHE
MA=%65RY".A:,GM9\Q:X8,JV6I<0*?.S$0%70=9)O%I2MED,^OR4<[.2=V$8?
MOAA9?I,=8-AX3?X"MEKO//2N]%MXF)V<OATNX+LA)51\W[H?^O`59-TXO.TY
M%N3KRLNG&[`"`T6:*)U[)J%;-(!/HJ3O#`R$/Q8T16%9NJ:@V2*:7\99@G"R
M!>MNI:>D1.RMT^I/`"6#J<`U6+OACJ^61A\(7C>B;<]]\R0Y$A\]!8;1Y7LF
MT9TG67N6@EY2@OH6@WU8S=)TR1XP#?&,V00,/D=,,B(8NADMH8VII;?C.2I[
ML%?V<7DKF[`QE?EGY(5,]C\R'HQY3\QGBWBT'Y0#9C;!S$?$"V6$G%^@!^/E
M8%EC;J?9!M`9TM@H4VE_W>G"M]L[77B,V9\;7(PY/^_@%$Q\96\7O#A5S;+T
M#%E_\*7L\\[T?F?I[)5L&,'0YPI,#9^A;2T1>N_'*\4&'7?'R5^GOH=>[\_R
M]?!'8.,'G,B>UW#/32T[2UJHD#*.+C$/$V8Z+)SNT3G.I78XB\-K@[]>P!Z-
M(P176KOC`H79^#-?_04``/__`P!02P,$%``&``@````A`(J!'0(4$P``L6@`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&ULK)W9<MLX%H;OIVK>P>7[
MMD51LI9*,A6+^R9*-<NU8RN)JVW+92F=[K>?`P*'(,Y/TU9F^J*3?#@X6'[L
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M\'W_,WZYORONGW94VZ234N#+?O^[,DWO%*+(EQ`[:A2H7\[N=E]O?CP<M_N?
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M^:S<?#RGDE`'.%#7_N/3>#'^</D'=<=;8W.--IYKL6(+U?>4VT""4()(@EB"
M1()4@DR"7()"@E*"2H*U!+4$&PFV'7!)\K0:49/^?VBDW"B-N':O&71$$X*P
M!4<))`@EB"2()4@D2"7(),@E*"0H):@D6$M02["18-L!CB`T4(`@/HU`_3,)
M]Q$5B^8,IX_X;H5?:YL)=<2V(TU=DU5KTHH")`02`8F!)$!2(!F0'$@!I`12
M`5D#J8%L@&R[Q-&(1F;02,WV)PYLR@V-C=026D%P9--&@ZJU)JUJ0$(@$9`8
M2`(D!9(!R8$40$H@%9`UD!K(!LBV2QS52"!'M>$>I:P;<;A2KS69T`*B(]=$
M]*#6B*,%0$(@$9`82`(D!9(!R8$40$H@%9`UD!K(!LBV2QPM:$ES@A;*VM5"
MDRF-BQTMY&C6&K5:``F!1$!B(`F0%$@&)`=2`"F!5$#60&H@&R#;+G&TH)75
M"5HH:U<+32:N%E>B7[1&K19`0B`1D!A(`B0%D@')@11`2B`5D#60&L@&R+9+
M'"UH<G:T4$MF?Z[VC*=.+LJ3JY,F0J>9T*DU:G4"$@*)@,1`$B`ID`Q(#J0`
M4@*I@*R!U$`V0+9=XNA$DX"CT_!<HJQ=+3016LR%%JU1JP60$$@$)`:2`$F!
M9$!R(`60$D@%9`VD!K(!LNT21PNU/S]!C,;<5<,@(<="R&&M6CT0A8@B1#&B
M!%&**$.4(RH0E8@J1&M$-:(-HJV#7'G4UA./`2YF-*8-=QM/;UII@<P5?FW0
MU&_1"E&`*$04(8H1)8A21!FB'%&!J$14(5HCJA%M$&T=Y,JB-J!=6=[00N]7
M'2T,TH>0ZDQEI?8R:J2S*$`4(HH0Q8@21"FB#%&.J$!4(JH0K1'5B#:(M@YR
MM5`[S:X6^J2LZ2+'[_>WOU_O:1U`O:%'(Y].Q,PYF=ZO4C*VNQ@T;]%*G40J
MB6AJ:Y?.GB_&NL!8^;29LE8SL5@(K16G&"&*$26(4D290915=I];U,F7S'UA
M?76L9F)Z+:T5NZ\0K1'5B#:(M@;IW+MRJRWJ_RZWWN@Z<AMD*VSEM:A3%;+"
M`F/E+_3QZL@39T>A->"ZBJQG1K%%`XDEUE=SECORQ&%N:@W8<V8],\HM&DBL
ML+Y,8J)DI35@SY7US&AMT4!BM?757[*--6#/6^N9D-M,U.ZYVTQZ>C]M#-KN
MKS?;3GO0:-S=FLU$5U^I@RL:$,8TO-BNCBVDSVHJ3C]"]G75M"//\^9ST>LB
M-J$MT.O)Q6PUF*FDUTIF*F4KSM1L,14M+F.3P4SE;#68J:+72F:J9"N=J?%\
M,IZ+&XN*308SM6:KP4S5O58R4QNVTIGRI_Y\*O;Q6S9Y+5-N"U9G#MT6_&OS
MFCZY<!JV1C[-96TCFH_D>MW$&ZR90-VNN4N6T*"QFEKILFDRFD`C-I&H4[3I
MPR0:6]<#5HFUXC$A=3.P\*XF8N;-.-)@!G*V&JR!PEIQ!DHW`]YH,9:U6W&L
MP1RLV6HP![6UXAQLW!R,9Y/%1.B[Y5BOY<!MBM1@G:;XQF"JS,4F4:-Q\Q1!
ML^):J>M5-732UO3U9A`8*[K$X=*%B"+KBZUBBP;<)^@K19197^P^MVC`?8&^
M2D25]<7NUQ8-N*_1UP;1UOHB]ZZNZHCF?Q]B]$&/,\1HY,R=_DBTP95:1E,+
M\`?;=V"LW"E6CKXA6YEYRI\N?#'Z1FQ"[>[U!A>_*U,)^W*R+C.5LI69IT:+
MZ4(L(#(V&<Q4_JY,%>QK,%,E6YEY:N%/KV#R-/(-9FK]KDS5G-Q@IC9LI3-U
M-9[/%D*^+9N\EBFW9:L#KZ&6_<_]\VN;PNZR4)^;.4U;(V<D:]%`PPH\;>7;
M'6:(*#*HXSZV:,!]@KY21)GUQ4--;M&`^P)]E8@JZXO=KRT:<%^CKPVBK?4E
M1S(UTCAZ#\]0C;D[0QDTM:<O*T0!HA!1A"A&E"!*$66(<D0%HA)1A6B-J$:T
M0;1UD-/WU$A]BA;*7&BAT92VW^U([8_$*+5JTOEX3E;<V`)$(:((48PH090B
MRA#EB`I$):(*T1I1C6B#:.L@5Y[3SB['>'9ID'/B[X_$MG!EK:P\VA=%9!2B
M580H1I0@2A%EB')$!:(2485HC:A&M$&T=9`KCSIB?&7F>F-0,X>3=H*YIEV8
MZEO=$W]$`:(0480H1I0@2A%EB')$!:(2485HC:A&M$&T=9`KBSH*[,KRAA;F
MY+"KA4'="090,`84(HH<Y.:3-G1./G_IU$!=F<LQV:#.\2A;T6JQ':9A(Q\8
M*W$:+@X%0FO%0T/D(+>0Z@2A*\:O%=*<0W0U,JA;R!8-%M)8O7H&/&[=V/+)
M.'8$=4M+*UZGM&\T/64NYE.-U)3="N6/Q&'N:FRLG)4ZG&4:JZDZ._WCD]C2
MA=:'+:9V"Q'<,JH=1U?1-\JH-RC==?E8(^=4RQ^),]:5L5(W>VU-]#19[6M*
M`K56_D@\(15:7[:L)N),5\[%U*Y9W.*JO<`)Q=5;!Z>X9L_A2BKV3"MUN$)M
M02T&VH+T%%=;32GSK94_$J=FH?5EBVLBZE;O77CS\+=7&K%Z"O>$$C?F;B,V
M2`@LQI$51QPNL;$2`HN]>6A]M25^*Z*CLCK8.*7,RER462.WXWJBTZV:=-Y4
MV5BY*GNV@3:G<J'U9<NL,W$UTO<2%[8?N*4];5U)^V`HK4:NPO*":\41*5=M
M:\4V;:RNO";3TXL1';UT_^LV5%-RDR$[/T?2R736C>:6OF_91IO)4Y\\4X67
MC4`CY]E97UXRKDQ$LF+A`D0AH@A1C"A!E"+*$.6("D0EH@K1&E&-:(-HZR!7
M-[7>ZH[$:BDQGE[0:N?$!]+5`D<JIY%03LY))J*C7!N1Q0S1*D(4(TH0I8@R
M1#FB`E&)J$*T1E0CVB#:.LA53JYTAY<,/BYI#1+RV.%-WU-8*]8B0!0BBA#%
MB!)$*:(,48ZH0%0BJA"M$=6(-HBV#G+E4:O;;L=Z0QZS&.XLQGV-A#QRB6.M
MK#QM1$8A6D6(8D0)HA11ABA'5"`J$56(UHAJ1!M$6P>Y\JA5^0GRZ$5\=P7J
M:R3D$:O&E;5B+0)$(:((48PH090BRA#EB`I$):(*T1I1C6B#:.L@5QZUD3A!
M'KWO<.312,@#R^76RLH#*/0!18AB1`FB%%&&*$=4("H158C6B&I$&T1;![GR
MJ(W/"?+H?9(CCT;N&:HG=B`K>J9,K2DZ!Z8!HA!1A"A&E"!*$66(<D0%HA)1
MA6B-J$:T0;1UD"./JM43Y&G,W8V70=W;($0!HA!1A"A&E"!*$66(<D0%HA)1
MA6B-J$:T0;1UD*N%VCV^OZM,]&:SVU4,4DFT&SY_+#?!UJH=R1"%B")$,:($
M48HH0Y0C*A"5B"I$:T0UH@VBK8-<>>2NO7.4.KQBF^`&WJ#N=0.B`%&(*$(4
M(TH0I8@R1#FB`E&)J$*T1E0CVB#:.LB511XGO*$%GAI,#++'&2M$`:(0480H
M1I0@2A%EB')$!:(24>4@M_[DMOZ-^L.]^T0CVN#P>+*RR`Y$>/+$5K0)Z0Q7
M\IS-6K'[B)%-,4:4,'+=B[/\U%JQ^XR1=9];9+,*!2K8:C#%TEIQBA6C)D57
MGM/V[A/<NQODR*.M.BA@*S?K]HA:G_Q9*\YZQ,A65HPH8>2Z%^<[J;5B]QDC
MZSY'5#!RW8L-<&FMV'W%J*?BR=<IL[$R%RLCC3JUO)H`"AA=M;TG1!0QLM40
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MF3<7!8XX%DU.;0YZQ&USP#69<$2;7,K)39KD_`MY7I!QG,'$<K8:+&YAK3A+
MI9N^&"(KCO!:XHZTZNTC)W3<QMR=B`Q23XFT%>O[8IVU8JO!L@;6BLL:,J*.
MWW$OE@X16SG->2I&CYBMK)0)HI01=]V9F.(R-G`2DP]HY&PU6.+"6G&)2T25
M@US]R+VCWR]-<>J"5/18@T2/%;UJQ1$'"QE8*RYDR.Z=.<@7@V3$$;MMRT-9
M3>Z[L@)*;8IJC*"'),;=>VCX04!OTBARFXYMG3"J%.S+9K!$5#G(%5D>#@SO
MHJ9X(F!0YW'VE44#60^,%3UO8:73[CLHLK[8*D:4H*\44881<XL&LEJ@KQ)1
M97U15MU:EGO]7^M*>`1`YS#-HL4Y.//%J+(R5NK!CW:@@Z84L"_;E$)&YM<M
M\]EL))\IB]AF<,B*;198QH0CVO121GI\]#K/H33;N(S#!]/*;5H#Q2W8ETV^
M9,0K&S$55!S^6O*NYNITH;MNE9J_[_<IZ@EY.7YJY/2X%@T4.3"^Z)D7%B%$
M%!G4<1\C2C!BBBC#B+E%`UDMT%>)J+*^H,?1N.[4_AOCFC(7BP^-U',E;:?Q
MY2_.5O3,8Q.QNX;HZ5K&RK:UD"-:%"&*&=FG51-&-F***$.4,QK,:L%6UGV)
MJ'*0V^S524&WV;]1\?I@H;M=4X_LD19BU2>6HBMC]=:89GS9TH3L7H]IWGPZ
M]>2K+R*V>:VC-Z-1;+/`W2GAB#:]E!&O^6"[Q@:#B>4V,=L<H:$5[,NF7R*J
M'.2J1YDX13UE+KJ-1F)Q)TX`5E,3<;`M!FQE2Q,:9+9C"V]^)7]S&G$LZG-M
MQX6:BMFJV[-,IFQR*2>GMV/CBXE81F;L9C"QG*T&BUNPE4V_1%0YR!6/W)\B
MGC(7XFGDWL/)E>E*/5]*$<F*VWV`*$04(8H1)8A21!FB'%&!J$14(5HCJA%M
M$&T=Y,JC#@"Z(Z-:$/S2<XCTIGY03B-7.?E*@)6)Z"C71F0Q0[2*$,6($D0I
MH@Q1CJA`5"*J$*T1U8@VB-3W#VRSULKI[QGHE[8_[EZ^[5:[AX?#V>W^A_I6
M`4V"GSZT6'](X7HR6JJK<JI,"*%O+-`M;5_(F$*:19F,,YW3=QF:(0I"%OS%
M!ADR]I?J5TX]Z?@40NN9OI`)A30'P-*;/Z60YM`70JXHI#G]AY`9A30O.Y<A
ME.GFZ67)/:HU>D5>3\X\JC7]OC099TQQZ$RW)\Z8XM`Y;E\(U31-31A"'\#X
MW,>O5?(]]M?*41]75=S#/T^6GZF!8<+75/.]%4_UWEOM5.N]E4YUWEOEU(+Z
M&A#=#"[5"3[FB&X#E^JNKR]D2B%]N:(K%@KIRQ=="5!(7SIT>;BL>D/H4G2I
M;BHP!W0WNE0WGWTA4PKIRQO=+E%(7][HZH-"^M*AJ]2ENO+`=.C';DOUNS4,
MN:8XU[UQZ%IYN>H-"2@D["T/76Q22%\Z=/-&(7WEH6LA"NG+-=T\+]5U4$^N
M?6H@]!A<7PCU5GH""T/H]7=+]4(Z#*%7RRW5R]XPA-ZAME2O2<.0A$+4.\TP
MA-Y.ME0O(,,0>I48I=.$7+;C`GTPYOGFVZZ\>?EV_W0X>]A]I4%ZU+PE\$5_
M<D;_XVA>#/%E?Z1/Q=`*B#Z]09\&VM$;&D?J5P%?]_LC_X.2OE2?NFF^WO'I
MOP(```#__P,`4$L#!!0`!@`(````(0"$G@X8=0,``-H+```8````>&PO=V]R
M:W-H965T<R]S:&5E=#DN>&ULE%9=;YLP%'V?M/^`_-Z`(0E)%%*UJ[I-VJ1I
MVL>S`R:Q"AC93M/^^UW;A,9`&O9"PLV]Y_A^^.2N;U_*PGNF0C)>)0A/`N31
M*N49JW8)^OWK\6:!/*E(E9&"5S1!KU2BV\W'#^LC%T]R3ZGR`*&2"=HK5:]\
M7Z9[6A(YX36MX)><BY(H>!4[7]:"DLP$E84?!L'<+PFKD$58B3$8/,]92A]X
M>BAII2R(H`51<'ZY9[4\H97I&+B2B*=#?9/RL@:(+2N8>C6@R"O3U===Q079
M%I#W"YZ2](1M7GKP)4L%ESQ7$X#S[4'[.2_]I0](FW7&(`-==D_0/$%W>'6/
M%\C?K$V!_C!ZE&??/;GGQ\^"9=]81:':T"?=@2WG3]KU:Z9-$.SWHA]-!WX(
M+Z,Y.13J)S]^H6RW5]#N&62D$UMEKP]4IE!1@)F$,XV4\@(.`$^O9'HTH"+D
MQ7P>6:;V"0KC2;B8X=D<_+TME>J1:4SDI0>I>/G7>N$&RZ*$#0I\-BC1?#*+
M@PA?!_'MB4R"#T21S5KPHP=3`Y2R)GH&\0J`AS."5+3OG79.4(P\.*N$-CQO
MPGB^]I^A=&GC<V]]X-GZX-;#!]*6&=C&,VMGS:QKJX]R;PWG-.$P3?0_--HY
M0?!L#Q_&<8MKF:W/],QGUGHX"8++^`2U,_0`TCJC[M;6.HV@AJ$:3ZV=#75;
MW,8"]^3L,(OA+.<NE;X:,0PW0+P_2SK.96TL3D_CY3`KS.!Y@N9"QLL1M#K0
MI6TL#NTB&*;5@GYV6PSM'"[AM61UG,O:6%S6"S=E.<`ZA<CW"ZRC7,[&XG)>
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M<\`,3"&%W<WLB^(U'!36*ZY@I3)?][!#4U@?`MWOG'-U>H$Q]MNM?/,/``#_
M_P,`4$L#!!0`!@`(````(0`X;U<-H0<``&@@```8````>&PO=V]R:W-H965T
M<R]S:&5E=#@N>&ULK%IMC^(V$/Y>J?\!Y?L!>2$A:-GJ@+RJE:KJVG[.0EBB
M`X*2[.W=O^\X]CBQA\!RZI=E>?:9&?OQC#UQ]NFW[Z?CZ%M>U45Y7AKF>&J,
M\O.VW!7GUZ7Q]Y?PT]P8U4UVWF7'\IPOC1]Y;?SV_.LO3^]E];4^Y'DS`@_G
M>FD<FN:RF$SJ[2$_9?6XO.1G^,N^K$Y9`U^KUTE]J?)LUQJ=CA-K.G4GIZPX
M&]S#HOJ(CW*_+[;YIMR^G?)SPYU4^3%K8/SUH;C4Z.VT_8B[4U9]?;M\VI:G
M"[AX*8Y%\Z-U:HQ.VT7R>BZK[.4(\_YN.MD6?;=?B/M3L:W*NMPW8W`WX0.E
M<_8G_@0\/3_M"I@!DWU4Y?NE\=E<I)9E3)Z?6H'^*?+WNO?[J#Z4[U%5['XO
MSCFH#>O$5N"E++\R:K)C$!A/B'78KL"?U6B7[[.W8_-7^1[GQ>NA@>6>P8S8
MQ!:['YN\WH*BX&9LS9BG;7F$`<#/T:E@J0&*9-^7A@6!BUUS6!JV.YYY4]L$
M^N@EKYNP8"Z-T?:M;LK3OYQD"E?<B2V<.-*)T_FX80<1VN#P*8);X.J&@2L,
MX%,8../Y;.:X<P]\W##TA"%\8B3K0T.$.FF'")\RHI3G1D!?V,$G!KP]-1.6
MOHW$?I&A;DUNPI>RS8Q-UF3/3U7Y/H)R@\6J+QDK7G/!O&%.\.'*+!E*$L@.
MYN4S<[,T0#%8_QHR^]NS.?>?)M\@&[>"L[K"41EK9+#48VXW.A#H0*@#D0[$
M.I#H0-H#)B"+U`;R_/_0AKEAVN"L5@AT8EF:$,A`DXT.!#H0ZD"D`[$.)#J0
M]@!%",A&(H0-R7)]X\"<8%:P1?1RPG)==:(KSG&@8F3BS%3*6E*D&`0)"!(2
M)")(3)"$(&D?432!_8MHPC;3!PN'N8':`^6E`+1R..FF2I(B52)(0)"0(!%!
M8H(D!$G[B*(2"**H=#MC&+L5`R>QXH@#.Z.4QW(]+4,D"<TV!`D($A(D(DA,
MD(0@:1]1Y@X'SP-S9VQU[AQQH,YZ<Y]K<Y<D.7>"!`0)"1(1)"9(0I"TCRAS
MAY-`F3L_5L;LY+V=`LQ0E8$C,UONGVN";`@2$"0D2$20F"`)0=(^HLR9M<G]
MH_3V1!E;G:A`>+O$CK\U038$"0@2$B0B2$R0A"!I'U$F"M6H3+2WN,VAV'Y=
ME9"P<*A>$<"&WH!W#,R).G^!S+N%EDA7`::MM14;3K)A"Y)E8LZU+2*0)"R3
M4/I&)")(+*WZKK4*3"0)':5]1XIPK,%2E+NB$+32*%%+5S42D-7?%$S?U#8%
M9,$:=)H0X:ZR9H[J*T"6VW9UENE9,UL[HD/D0&D,QXN0U25XW$$]0WT(";+$
M$*93VYMJC42*G*$AJ.O`.KZ/EZK)&T0XI'&)5P*RH3WH9NS;JG9K-+RS#L)]
MITL@#.$)IVVE;<N>SK5%#M$Y;*G=$/1%CI#5.8\IE'P@7HIF0_%4A5DK^8#"
MO/-4%.:0ENE:=JY9XP3;B'5'8<G"!0S0D.?4S/?=V51=O1`I0RG5[F,1LOH"
MDW`)LH;#I4@9"J?JR_K2!_3E;2R$0`%6)H>4#+9<;7-="Q9;^^$DVW0L=!\(
M"#-XZD[MF:]MG2':#:644%@,OJ\P@1(UX-QS/,_75C2]%T^5F#6U#TC,>V!%
M8@XI*6QYVJ#6IF#=D5BR.HD%)'+*M%W-=8BNAU)*Z$M<QVC829X@-!@M1<90
M-%5=6'-%W9]J(M@#E]9%"$C):U//O#4:WA%=N.]D"(2AR&MG[MN>OJ(A.K^3
MUL1YC(9=O$2/-S>OG'W"TU`\57C6LS^0UKS%5]*:0Y8O-Y.U*:&;VP1GP<U!
ME\,$"CM?R(HH%`NHYRNA4*H8JC)`ECXB`Z-KK1B'V-6GW!HM3SNEUR9GV7<2
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M`1K>'$*"+#X$&V[B/%]_$$/.T!#4U8%X-U?G2WD!V:]>)?0>E%G[K^W.`NIE
MU[J#;B6O8-E=(004"CM?*&%$H9@:)A1*%4-5'O8@T:_A=@.=C6$#>/":&5XK
M$H4XI-XO>MJC_5H8`@LGNJ%00*&00A&%8@HE%&(O1=GH^2"X0OPE)W^5=<JK
MUWR='X_U:%N^L1>8T*X\/TF8OUU=>0NXNX-9Z+AEX6M7[2\;?P$71]0B]A=P
MZT-Q>'_[N4T;S<\*WNNVF[V.L\!7_*SL!;QWN.+?`?]7#9P%7,%3@]5L`=?3
M5W!W`5>W@$_DB.`][R5[S?_(JM?B7(^.^1YDG+87MA5_4\R_-*(@7\H&WO"V
MM7F`-_HY7%=.65[NR[+!+RR`_!^!Y_\```#__P,`4$L#!!0`!@`(````(0`8
M+#:0\3L``,!I`0`8````>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK)U;DQM'
MDF;?UVS_`XWO0Q90J)M,TM@(0.)^M=[=9S;%;M%:%&4D^_;O]PM$>$:$GZP$
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M'?J_'S_\\VOQ[Z^^_O+YG[,O'W]>?_SM@VZW1`4%?_[\^6\A=/%S0&K\%JV;
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MEC3A7RZ\-DN70<Z72XV%9R).,*?,A4DZL#P)_Y)F>N;:+#\&.4'*QZI'^$`]
MQWGJ7R[S]S8^TJ<58O+NV[L?O__R^9^OM.[*XM??WX55?/!=Z-?6ACA\NUH\
MMUAHE0B]_$_HYH?7NA*M`U^UQ/WCQ\'@X?NW_]"J]#[%_-014T>,+2(L0:';
MB0=3#QH/9A[,/5AXL/1@Y<':@XT'6P]V'NP].'AP+,!;Z6D=Z7'Y(QR%;H(C
MN[L_&<C2ADZ(15B3B0=3#QH/9A[,/5AXL/1@Y<':@XT'6P]V'NP].'AP+$`E
M1*O1'R$D=*-W:?70#&H#/\68D9[,]LFZJT/&;4AK"60*TH#,0.8@"Y`ER`ID
M#;(!V8+L0/8@!Y!C22II>A_\$=)"-UHLE1JM$"YU,:C76AO26@.9@C0@,Y`Y
MR`)D";("68-L0+8@.Y`]R`'D6)+*FM[$E;7N/:N]AD+T28[=U)\B&6EO5.AZ
M=$]0&V3-)B!3D`9D!C('68`L058@:Y`-R!9D![('.8`<2U*YT-;F"A<ANG81
MR9TVG86+)^>B#6I=@$Q!&I`9R!QD`;($68&L038@6Y`=R![D`'(L2>5"6ZW*
M1=BWW3Z&\ULZ*ER\=0L]U9XB&56>AC?.4QO4>@*9@C0@,Y`YR`)D";("68-L
M0+8@.Y`]R`'D6)+*DU[<E:?^]2M$URXBN8MGZ;`G'H-,0*8@#<@,9`ZR`%F"
MK$#6(!N0+<@.9`]R`#F6I+KQ6O&K&Q\>D.'=F^N?C]!1[202]WRXC=NX#6J?
M#Y`I2`,R`YF#+$"6("N0-<@&9`NR`]F#'$".):DTA1)$Y:G_`3F%US82JE\K
M0W^2R5&M#Z(I44,T(YH3+8B61"NB-=&&:$NT(]H3'8B.%:KUA#.IKP^\Z#$*
M]2+W'"7D'J1;]Z+)4=E<[$L-#4T9U1#-B.9$"Z(ET8IH3;0AVA+MB/9$!Z)C
MA6ISX?!:FCOS8,6SKLXU=DM_"F<<&7,/ULCK::.LX20W-#0E:HAF1'.B!=&2
M:$6T)MH0;8EV1'NB`]&Q0K6><$Z]0D\\UJH_NZ4_A9JH]+BGQQ<'<I0UG!!-
MB1JB&=&<:$&T)%H1K8DV1%NB'=&>Z$!TK%"M)QQ(2STOWCZ$.K1?]])IM]Y@
MW_L'JXW*YH"FJ?MB*6R(9D1SH@71DFA%M";:$&V)=D1[H@/1L4*UN7!\+<V=
M6??B:;=ZL")RZYZK9H_#AP5Q=<QZ@*:,:HAF1'.B!=&2:$6T)MH0;8EV1'NB
M`]&Q0K6><**]0D\\`%=Z(G+KGB_IA,]AXNJ8]0!-&=40S8CF1`NB)=&*:$VT
M(=H2[8CV1`>B8X5J/>$@>X6>>.ZM]$3DGAY?Y0D?>OFG!VC*J(9H1C0G6A`M
MB59$:Z(-T99H1[0G.A`=*U3K"<?=*_3$TW&E)Z+ZZ;GUQ9WP2:!_>H"FC&J(
M9D1SH@71DFA%M";:$&V)=D1[H@/1L4*UGG#,O4)//!57>B*JGYY;7UL8M%%Y
M<0.:,JHAFA'-B19$2Z(5T9IH0[0EVA'MB0Y$^BI-L;14>H:^UO#RHNFIJ[H.
MD9![LGP=(D>UZHBF1`W1C&A.M"!:$JV(UD0;HBW1CFA/="`Z5JA6Y^L0_;NZ
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MT!5ZXNFITM,>J,HT\G6,81N5]0!-&=40S8CF1`NB)=&*:$VT(=H2[8CV1`>B
M8X5J/>$04.HYK0!W;\)WML\\2/'X4)E*)XK;MO@^'@)-B*9$#=&,:$ZT(%H2
MK8C61!NB+=&.:$]T(#I6J-)RZT]@_2Y.X?5Z;*A8CXDF1%.BAFA&-"=:$"V)
M5D1KH@W1EFA'M"<Z$!TK5+OP1ZKB$?GVR\?W?_OI<]B(=3XOM_J*=_SB]RU/
M6H8>\^.24;G6N:+@)$7=:MN57ZPC5YN:YBA;$1NB&=&<:$&T)%H1K8DV1%NB
M'=&>Z$!T3$C%)UUV+=*?Q\X\5#R'W49T&W_XY_0MHXP*%[<PEAIJPU`8<^6J
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MZC5^C=<0[KQ&%,K9K;&AVPZ,;U.[,UJ[HN[<NCM-?:E`&WYL\^%N.+P9N@6O
ML?'TZ+63&O@TFEE4/IO-,RH:^BDL+IC"TGKJG<+*HGIOS+HSRL]J8[.JW@5W
M;B^XM;[R,KDSU#N)?6>4G\3AHDD<K:^.MT\H%EVQT,3:4O6:B2A46[/[.[=U
M&M^FJ-YKGN0H>[RFANY/Z3>\OQD]#.Z1?ZEW)72>`_.OG8/U/K?><THN#/4-
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M1>5)["Z:Q-X:]D[B8%'U))R.HT4]IZ/.5>WL>W/UPA=,Z,8E:T3%&V`\:E&/
MD$F*JEXPL6&!FMR7I=.,:,Z^%D1+-EQEU#/5-?O:$&US7S;5748]W>_9UX'H
MF/O""^:ZNNV(=5M#>2D<)Z3=M5W-A&A*U!#-B.9$"Z(ET8IH3;0AVA+MB/9$
M!Z)CA>H'38]C[X-VV4LA].*>LX3RZW<\:E%/=DU25/@L*"_N]^[#D&F.,MT-
MT8QH3K0@6A*MB-9$&Z(MT8YH3W0@.B;4\06&\'NR*I%G*@`AW!F+2)^WV"T=
MGSH]?<Q9N/"OJHE%26\V-G(?)DUSE'7?&,HY,B.:&ZJ[=Y\<+7*4=;\TE+M?
M951,U5_0VJ+J$=VK?9.C;,2MH3SB+J.>$?<658_H=LR''&4C'@UUE(1"+:H\
MHYU)B%2ZRN>GG\(O_%*.5`D!-+&HXD-NHL903JX9T=R05OPBD]SG<8L<9;=A
M:2AWOR):&ZJ[=U7X38ZR[K>&<O<[HKVANGNW#SKD*.O^:(@2P\^P51)?5!(Z
M]5(_[`F5;HDFA@JW1(VA?'=F1'-#U;H^<E6H18ZRN[,TE+M?$:T-Y<_C-T1;
M0[FO'='>4#U5=W(XY"B;ZM%0ATAMH?\`D:$7)S*AO.2,PX\1A:AJ/^X7N4F*
M*K_`0-08RC=LEKNWZYY;E%:'_-SZ#PD6.<H:+MG7*J.B+S_[=>ZKB+IS[YQ-
MCK(1M[E[0[N,BK[\B/O<5Q&%+S#D*.O^F+L7JC9?^BFG.BGZE^A3N+.?:F-E
M97=PYQ;,<6I8%VW]!4YRE$U]2M00S8CF1`NB)=$JH^(N^ZFN<Y1-=4.T)=IE
MU-/]/D=9]P>B8X5JK]=5T.Y804NH^D`/7V"P=GK<\U/G[]6D,PH5>QLP?N@V
M>+Q_NAL\N?U'8UWIV/O\@#.+RH>S>49%0S^'Q25S6%I7O7-8653OK5EW1OEI
M;6Q:U=L`GS-;7WFAW!GJG<2^,\I/XG#1)([65\?[1[.OWC]GEIH0[I::B*HJ
MWP!?8;A+4;W7/,E1]H!-#:5O%#SI*PQ/=V[OU%A0M4WV&3^SJ#(!VVG9@`N+
MZAMP:4&]`ZXLJO>BUSG*YK`Q5+VIF5II\D7YSAKVCKC/43;BP5#OB$>+XB<_
M=Z'D59XJ7K8AC86S\BL,IX[U&:5>:.W:@J\PI*`S7V'(47;94^O]^>\4--:J
M=V&965296^EB,EJ<'VYI'?4.M[*H7L_K'&47O+$9*'7:VSE@9J6IEXM6>S5%
M0_^([3GBX:(1C]:P8X4*9;XRL\ZL4"'<K5`1E:7=NQ;U7,TD195?82!J<E]V
MEV=$<S9<$"W9<)51SU37[&M#M,U]V51W&?5TOV=?!Z)C[DO=USL?+925Q)<M
M#Z$7YS:B_J\PW,6@,Y\QI:AZ-^Q?N%.+BJ^'T>-@]'ASXTI`C05IW/R4^8=E
MEJ=E-N;6L'JN_1P6%M4WAZ4%]<YAE>?0,].U]=4[K8U%];Y#MA95OK4N\;.W
MAKV3.%A4[R2.%M7Q(E/#WDR][!.FN]"-2]6(JF6H13UW?Y+Z*CY.FA(U"17=
MSXCF;+@@6K+A*J.>J:[9UX9HF_NRQ-]EU-/]GGT=B(ZY+RQ#H4QYQ;LD5C6K
M[4@J=/9_A>$N-93>YY__B47E#<*4J"&:&<JUG;FAW->":$FT,M0[U;5%Y>XW
M1%NBG:'>[O<6E;L_$!TK5+U>[O^0<NBIE_J93:@ZW.`K#"GHS.O%NNI=OJ86
M5=VO>U>_:BRJ6MOQ%88\+WO,YM:P=Q(+BZHFX3>)2XO*"_DJC]B3]VMKV#N)
MC47U3F)K47D2NXLFL;>&O9,X6%0U":_C:%'/Z:AS52-6:Y#?"EWV@KD/W;AD
MC:AX`XQ3E%"/D$F**E\P1$WNR])I1C1GPP71D@U7&?5,=<V^-D3;W)=-=9=1
M3_=[]G4@.N:^_`OF_KK*[2G<28R5V_!MX/SJN'>?:HY3P_);#413HH9H1C0G
M6A`MB59$:Z(-T99H1[0G.A`=*U0_>]<58.]9@$W(Z?&%]1QE^3<AFA(U1#.B
M.=&":$FT(EH3;8BV1#NB/=&!Z%BA6D\H:%V^/;N/]:]R>Y:0T^,^3!SGJ*PG
M]E4\4%-&-40SHCG1@FA)M"):$VV(MD0[HCW1@>A8H5I/*`%=H2=5C(IO#MQ'
MI$^^[,:/B29$4Z*&:$8T)UH0+8E61&NB#=&6:$>T)SH0'2M4N[BN*G;/JEA"
M[E%QE8QQCC)C$Z(I44,T(YH3+8B61"NB-=&&:$NT(]H3'8B.%:KUA(I&^:@4
MF[S^^N5]K(54BUI$^A#''(Q35($F1%.BAFA&-"=:$"V)5D1KH@W1EFA'M"<Z
M$!TK5&O1/K[2<L9%"'?;LX3*%0QH<@\T)6HJ5,\SU`_*]#DSSU1N*%?:B*JZ
MZ.#>?:5I?)^BJD.0KU-..J-\47)J4;KT8N.*DVL:\:*CTD/7L7YX?_I#?)?_
MFI93+[7%A.H?1+EW'VN/K6'_W<E1]G1.$ZI_3O3>?VAI#?5.S#>L.,17&?$0
MSG:79\0IW%TS3X<IZLSI,$65GX(0-;DOW89ZZOY,5*R%5UB,YZ)R77R(R.6X
M^SK6.$6=J<Y87Y5KY+A%53F.3Z,MZK(<]T<2?W<N*P<\\*B24%D.R*A(.3SO
M*:HL!Q`UN2\(]]OX<$DO_/N9W.(_M#OUXAH>W/?`QSG*GLH)T92H(9H1S8D6
M1$NB%=&::$.T)=H1[8D.1,<*U<_J=5O\\!L_W0LRH7I;^>!>`^,<E?7$OLH3
M&*,:HAG1G&A!M"1:$:V)-D1;HAW1GNA`=*Q0K>>Z7?\#=_T)A2^DYI?.@R\O
MY:BL)_:EAH:FC&J(9D1SH@71DFA%M";:$&V)=D1[H@/1L4*UGK!1O^(E'??U
MU2LM(O?T^/+20QME+B9$4Z*&:$8T)UH0+8E61&NB#=&6:$>T)SH0'2M4ZPF[
M\BOTI$U\L:M^B,CI\>6E')7UM`T-31G5$,V(YD0+HB71BFA-M"':$NV(]D0'
MHF.%:CWA:%#J"=N&%_TYU(=XR*@>K(B<.5_M2`V+=]"$:$K4$,V(YD0+HB71
MBFA-M"':$NV(]D0'HF.%*G./_IS6?UP]A=>'DX2<'G]<S5'V%$V(ID0-T8QH
M3K0@6A*MB-9$&Z(MT8YH3W0@.E:HUN//CL41XXRI>&8L'Z3'B(K*TYAH0C0E
M:HAF1'.B!=&2:$6T)MH0;8EV1'NB`]&Q0K46?RX^XX('X,>$BF(4T81H2M00
MS8CF1`NB)=&*:$VT(=H2[8CV1`>B8X5J%^=.X1?]N/,C#^&&\E=UQAD56W`<
MPE-4_>/.#ZY$-<U1MB(V1#.B.=&":)E0_+'BTV\27A&M<\/B@AY<N6N3HVRJ
M6Z(=T9[H0'1,J.,GH!^[RA&#^.<J+J\_G7IQ+ZU4G"C=MJBX%70;H_1KV\)O
M!1W>#-P&?YH&4X#=J\;&SX/-B.:Y8>K9G>P6.<!Z7K*;%=$Z-^R>\R8'6,];
M=K,CVN>&W7,^Y`#K^5AU4S_)UU4P'EG!2*@N*S[XLJ)%505#FH[=ZSO%-O6I
M-7R,OQ)V\,;);RQ`A[Q\1']T!:Z91>6>YT0+0W&PP>B-RX>E!?0.MK*H/-B:
M:&,H#G;W^,8M`5L+Z!UL9U%YL#W1P5"ZLN$;MUD\6L!S@]59<UUAY9&%E83J
MCQ0>?=W+&I[)FM1]O@/3U%`?*82'9#!XXXXNC?6LA.O+&O0\MX9YL(4;[,[?
MVZ6UZ1UL95&YYS71!H.Y)VUK;7H'VUE4'FQ/='"#/?CGX6AMGANLSAKE5G5B
M/;.#"^'N%1)1O=8\NH=T_)BBSF1-&Y77FH320W+SQMW;QGI67%_6H.>Y-<RW
M>V$H#N;6JZ7]U]Z15A:5NUT3;0RER[I]X[9%6POH'6QG47FP/='!4.=E'>V_
M/C=2G2_7%:`>68!*R*TR[@TRMH9G\B5UGR]_FAJF56;$128U>>[I.&T19WEX
M2\0YT:(>Z\$[7%J3WK%6%I4O8DVT\6.Y&[:U)KUC[2PJC[4G.OBQ7'7P:$V>
M&ZO.&%\3.[/"L/#U&)%;8=RDQA9U)F-27_D&3*UA>CK\FZ*Q__[<\Y$R!AW/
MK6$>:V$HCG7KLW-I_[UWK)5%Y8[71!M#<2SL+K;VWWO'VEE4'FM/=#`4Q[KW
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MH@71LD+U-6MMKU;MXD.=RZN:3Z$7MY@GE`N-8XO2[C^?$E'K2E%UQ?K1O9JF
M.<I6GB9W;VA&-,\-BTD\NA+3(D=97\NJK_H>7E?U>6+5)R&WN_;G=XLZLU>*
MW9>U0FL8=X9W`U^N:"S@N:UAVBRAY[DUS`F_,%19QD]]6E0U8I$+]0U65)6D
M9Q[,$.ZR,2*W&77GM_%3:GCF!K=1EAO3U#!M1H?8YS?6\W,[J72#T?/<&I8W
M.$;9Z?KNC3N%+:W-<X/5]S:<Q<NO2YRYM^GH7BYZ$;GD]27+IQ1UYMZV4?G>
M)A235R5+UW-C/>NVY&4%A6Z+RC=R3K0PE`9SR\+2_O-S0]5W-IQ&K[BS\?!:
M?DC^%)'+6ARA4L,S=[:-RG<VHI1(`]S7U.*Y-$HYBW[G:=KZ-4HVU"(A>T`>
M_0JTM#;/#5;=V<'-=:?3&%^O",9<VKIG:=R&]=_=(LRN>=JRF$RNYZ;]S\\E
M4[R_;5B^F_,.MFA9'.T1JT(;\-QX[A;K@J_(WL%-B/>W.++Z6Z*/KGBL6]R&
MV;V;=##=3\3I)H+-.ICN&.)TQ\"6'6S5P=8=;-/!MAULU\'V'>S0P8XU<\:N
M._0-;GCJ,U8?^YY<$5[&8M/R"VX=3,80)V-@,@8F8V`R!B9C8#(&)F-@,@8F
M8V`R!B9C8#(&)F,E<\9>?`X<W/`@:*P\"78P/5NQ;1$G4V`R!2938#(%)E-@
M,@4F4V`R!2938#(%)E-@,@4F4V`R53)GZKJCX>"&9\.6Y85<#Q(.C-)3,C<-
MO1ZO6I1#O%^4(ZLW%4_NY:^9I:9:(_.NJMB@G]Y.FFQ7V%,^N;CY7W=2&MSP
MJ&3,S=]OY2WLS.]R[`Y[?OYZ=UYU_T.\O_^1N?F[W8'N?VIZ[OYWA3WE+:*[
M_V$O??F6='`3]][EGM28F[^O#%K8V?N?1J@NL_C-P&[^8;-YS?S3YK0XK0QN
M(G/S=SM]W?]V7]N?_UUA3WF+4\]_<.6^]13O\B>Q:E,UO,$K.H?E3179=$#6
M=+!9!YMWL$4'6W:P50=;=[!-!]MVL%T'VW>P0P<[ULP9"WO$,N->_D.(@_`L
M^-4@L6K#I6_RU1_$C*UIM>'*3<VP;,8ABCC9!)--,-D$DTTPV02333#9!)--
M,-D$DTTPV00[=##9+..<S;`7*VWV%SL&6OAH+#+W_.4WWNG%*&-MF-F9=#`9
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MR9RQ<+PK'[]S&Y9T'*R>L<C"'UTH7G_N`U5M6-JPPAB8C(')&)B,@<D8F(R!
MR1B8C(')&)B,@<D8F(R!R1B8C(')6,F<,7_$#F^Z%RZ8':?O\%>W=(9PCQ].
MKSFLD-DV-2:98)())IE@D@DFF6"2"2:98)())IE@D@DFF6"2"2:98))9,B<S
MG.[+Q^\_.?VE2D'U:$;F;.;J@;W^VC`SI]<?F&R"R2:8;(+))IAL@LDFF&R"
MR2:8;(+))IAL@LDFF&R"R6;):IOAH[[*YIG%]!3OJB^)U<8&J+[DL&R,;#H@
M:SK8K(/-.]BB@RT[V*J#K3O8IH-M.]BN@^T[V*&#'6OFC(6CO'_^PA^\N_8@
M$?X:AR^]).94HO22PPJ598GA])!*)9A4@DDEF%2"22685()))9A4@DDEF%2"
M22685()))9A4ELRI#&=\KU(GCQ>="\.?<8+.R)Q.U&524X45.MNFQJ033#K!
MI!-,.L&D$TPZP:033#K!I!-,.L&D$TPZP:033#I+YG2&`H#7^;)MSC#6$JJ2
M36).)DHV.<S$309DDAF'**1+)IAD@DDFF&2"22:89()))IAD@DDFF&2"22:8
M9())9LF<S'#^]S)?]IOV!OJ*#Q_-MKY0G$`&*-FDIH4EV6R;FF'9!)--,-D$
MDTTPV02333#9!)--,-D$DTTPV02333#9!)/-DCF;H0!0VCRWS8D%@_KY:XL(
MI3'49<(?-(FG$;,C8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R
M!B9C)7/&0@&@-/;R,^,PUA)JF6U]H92)DDUJ6C]^;5,3+)E@D@DFF6"2"2:9
M8)())IE@D@DFF6"2"2:98)())IE@DEDR)S/4!DJ9YQZ_6$NHC47F7G\HV0S;
M,+.CQP],QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!DK&3.6"@`
M7&,L%@QJ8Y$5/Z@V'@S!I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'K`
MI`=,>L"DIV1.3SC1EWK^@]4Q%@=J<VW!H%P=45$+O]T:KSHPR0233##)!)-,
M,,D$DTPPR0233##)!)-,,,D$DTPPR023S)+5,O7KORGSA5O-4U^N/I.86SE1
M4<MA>>4DFP[(F@XVZV#S#K;H8,L.MNI@ZPZVZ6#;#K;K8/L.=NA@QYHYF^&\
M_\<\FN$7J_LC?6*US"&*;3FLD%E6(E*%AG&2B3C)!)-,,,D$DTPPR0233##)
M!)-,,,D$DTPPR023S)(YF>&T7\H\LW'1+W:GL<CJSYJ&J*FEI@HKC+5-C>GQ
M`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.QDCECX4A?&GOYFS%\
M'1*/7ULQ*-Z,0U344M/JW$`FF6UW)E@RP2033#+!)!-,,L$D$TPRP2033#+!
M)!-,,L$D$TPR2^9DAA/]'R0S%@>J;4[X>=JX?REEHJ*6PTS29$`FF6UW%B>9
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M3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QDKFC(6Z0&GL/]BOQA)#+;,M.Y0R4<G1
MKT-..Z%")IAD@DDFF&2"22:89()))IAD@DDFF&2"22:89()))IAD@DEFR6J9
M6KYJF6<>OU.\J]8D5O\LQ1#5FAR6C9%-!V1-!YMUL'D'6W2P90=;=;!U!]MT
ML&T'VW6P?0<[=+!CS9RQ</;_8QZ_42PC5(]?8D%"7DMO4:W)887,LBJ1JC6,
MDTS$22:89()))IAD@DDFF&2"22:89()))IAD@DDFF&26S,D,98%2YKG'+Y81
M:F.IM%#^1/((;#(@T[.&..D!DQXPZ0&3'C#I`9,>,.D!DQXPZ0&3'C#I`9,>
M,.DIF=,3#OK7Z(F%@5I/9/7J>(MBVJ@-*QXH,!D#DS$P&0.3,3`9`Y,Q,!D#
MDS$P&0.3,3`9`Y,Q,!D#D[&2.6/A-'^-L7CZKXVU%8%R"43%;-2&%<;`9`Q,
MQL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QDKFC(4S^S7&XAF_-M:>
M^TMC*(N-VK#"&)B,@<D8F(R!R1B8C(')&)B,@<D8F(R!R1B8C(')&)B,@<E8
MR9RQ<#0OC;W\`#"*I_Q:9GOR+V6B+I:::J-2R&R;&I-,,,D$DTPPR0233##)
M!)-,,,D$DTPPR0233##)!)-,,,DLF9,9CN:ES'\-1N_>?_?SOR<?OK[_\)OV
M@#?A3VS_^/UI0_<_@U$\RM?&(G.O.)2_4E.%F1UM2MJFQF0,3,;`9`Q,QL!D
M#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,9*YHR%HWEI[#]X_.(IOY89F3L`H/PU
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M<#0OC8577?IK?>?DQ5-]+2^=]&_;#<AX<`>F9PM,IL!D"DRFP&0*3*;`9`I,
MIL!D"DRFP&0*3*;`9`I,IL!DJF3.5#B2EZ;.Z8E'^%I/8F4A2[_>\/2-ELRD
M!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZP*2G9$Y/.'^7>HH'
MZ?)?$#\(WPCSWR\R5OR*^#9.^YZVB*Q/(>K?AR61L;OP#8P<AC]K6H05BV3;
MU)C<@LDMF-R"R6UD^BERZT]NP>2V;5M.V:W_TMV&67?2#2;=8-(-)MU@TAU9
MG++3'0[O?X#N6`.H']+$\HW2&MJRXJ9TZ(YA^C2J^Z^&ZBEN(^RVZ2EN.S<F
MTV`RW;;M_LNA\MY&6$_RCI[D'4S>V[;=<Y?R-L)ZEW+T).5@4MZV[9Z[$J"-
ML-Z5`&5/+@'"@;],@'/+<2P0U*8C"S_<WCZ=0V]5\E.8WN)M6->SWA5VYZHZ
MRH`4=G_*D?O[F]LG_Q<0E1(I2&?DYX=4EK1#VCU3EK2L:.JGH52IIC&\O[FY
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M3=N=Q2E'P)0C:*L<`5-"H*WL@\D^VLH^F%2CK;R"R2O:RBN8))9MG;%0;"F-
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M>.O'5`Y<,J;2`F,J+3"FTJ(><W1_^_#DSN+*DTO&5.I@3*4.QE3JU&/>/#SJ
ML_)Z3ZY<.C.F2Z]05RO?<N>2*M;AJM?9?63ANV;MFCX<.>E*JAAV[G5FO2FZ
M[4T%A_HRE6=IT)AG-V_TO<7J_[`CM@;EQAF'1>5<.TM;HI1S::S>*2D-VRF5
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M+!_TO@730A99T58Y`J8W*=K*/ICLHZWL@^F%B+;R"B:O:"NO8))8MG7&0L6R
M?(F]K+IP'PN?]78LLOK=YO>)<IN:EH\Z]D-RF\+.O=MB6'JWZ<\)H2OI3UWI
MKN1-@\\F940[,<L29<0ELU"2I%GHX<DC^(V/\N:2B2B5,!&ETB43479=,A$E
MW"4340YB(LK!2R:BM+QD(LK4,Q-QR:M5"<F;OAMQ>L5=6ET(_?AE*+)Z&6I9
MH=4GCE(UAA6G;;W0P)2';7>68$HZ,"4=VBK#P)1.:*O<`5/NH*T2!4Q9@;9*
M`3"E`-K*-YCDEFV=23W],!E_GOG<*R2T].XB<_L35A=BV-G]2>JMVI\DEHJ8
MSU074I`N.Z\"/EVDO)V&I8&48TPIK\=\IKIPR9A*"XRIM,"82HMZS&>J"Y>,
MJ=3!F$H=C*G4J<=\IKIP9DR77J%HZ=]RY4+QTV<9TJNE(]G"P3Y]\?L^UC[K
MMUQD]5ON#I^T65--^_E<T-*11JAR+;+\2KM['#VPK)!:GGNII;"JE(5!E6QN
MT)'^8._`E5*TXEPRJ+(-@RK;,*BRS0^JFMV]NU(M2Y<,JG3#H$HW#*IT<X/>
MWHX>_-_4TMIU9M`ZWQY\V;LCK\J?*#C%NT4LL>H%E%EO%J6P8M\Z'9`UQHHA
M9AUL;JSH;]'!EL:*_E8=;&VLZ&_3P;;&BOYV'6QOK.COT,&.QF)_SI@>?JP0
MPZL_BW\(W7B1D=5OHSN7UN-!:GKN;93"]`OJ[6TAMVF$^#8:ZG<J#Y\>W'%<
MME/4F==1GH<-H`1(3?.@2@`WZ-V-AG7G1Z7$)8,J2V)8=5:VIGE098D;].GF
M\=&?]Y4WEPRJ5,*@2J74-`^J5'*#CO1+/D?N]BJYS@SJ\BV4&OO>2!=N71]B
MR;)Z)256/#;*KA@GUK]RQ+!JZYJ:%DRYU'9G2:*5`TR)@_Z4.&!*$[153H!I
MY4!;Y028,@!MI1M,NM%6NL$DMVSK3(;"76GRW%J?ZH'YL\>?!@^1A1\X;'<'
MPSM7>)+$U/3,)L+"RF^M=92!;="X:MR\\7^L59;3M,ZM&.VT+!DD/K'>.2@7
MT@@Z]K47_O]9._NEQG$LBK]*USS`-LX'^:B9KFH(D$`""6_`S*1[IK9GV0*F
M]O7W=RU+L74/EMG:/SGWZOK(YTBQ9=FX)P388P@1'..(X)@A1##1$"+X:@@1
MK.:(8+4A1'#?$"(8LD`D\ZBMXGW$HV'5KSNK!*S[4MPT6Z;$HRDMFF$E,'ZS
M7!Y^<QBSBL,PE\-PDL.PC</PB,/PB,,PA,-0WV%([3"D=ABZ.@P1VUBFF"W9
MM15K;9PH33#6-+\&"1C;XZ,J*.4PE'(82CD,I1R&4@Y#*8>AE,-0RF$HY3"4
M<AA*.0RE'(92#D,IAZ&4PU"JC65*V9)56ZF2/,T25V?^;[#350?R.`QY'(8\
M#D,>AR&/PY#'8<CC,.1Q&/(X#'D<ACP.0QZ'(8_#D,=AR.,PY&ECF3RVZ-26
MIS60/O`8;&9E\D'58*=[:51+6.L'+5_S0<B05GKMXY06ARW:IJ810UN'H:W#
MT-9A:!NPSFL?)ZRG%\B=RK72\AL/')#2(F,<X#`<X#`<X#`<X#`<$##U)LC,
MEHK^#PX(*T[=W\0&ZS@@8:V3(AP0TGK>!*EYU\]KXVE#_%0\8HB?L)X#XH?\
M@-GE)>Y(&;$X[DC%(\;(3UC/`7%'*O?>^R*GC%@<8Z3B$<,8">LY(%[)#YCU
M$.>DC%@<YZ3B8-G<88L^;>>4IO9FD:@SM0<LN_O/[I.9-YHT;B)/%\+"-2DM
M=H`?@`:+=__3\RI_40/C-$D,D_?KXZ54OR<-+Z6T2`/WE&E@IR$T<%BJWT,#
MAZ6T2(/)IDP#DPVA@>]2_1X:^"ZE11HXK4P#ZQ5H=-TX_^"B8IV?_60U6+9:
MG>W(NJQBTX(;3VFQXU>Q:;-:/69W]RPS^W7,L7_PW6?&4_F>M'6J=KIXVD2L
MA\5MS.EG<9?2>L_%MI46S\4N8CTL[F-./XN'E-;+8M]*BRP.$>MA\1ASWF61
M.1$6'YD7YY:?.S%@V;SHGM$U3>W_<;YOE55U2HO]QHG-$<*\.!F/>9,N>X*!
M%9NDPKP8TWII8,6F6L>*91IX<0@-O)CJ]YP-O)C2XMG`BV4:F'$(#<R8ZO?0
MP(PI+=+`C&4:N+%`(W.CK<U]X%=Z'M;R.A=R#9;-BYE;F!>;IO#K=6-*BQW'
MC0%K1N%T<;98G&5NQXU-P]+$F.KWT,"-*2W28&(LT\"-0VC@QE2_AP9N3&F1
M!FXLT\"-0VC@QE2_AP9N3&F1!FXLT\"-!1J9&VUA[B-N;)8%V]>,\X!E<V/V
MQ`$W-FDE-Z:TV''<V&!A;IR=+R;G67G,V.24IL94ON?T8\:4%EE@QB(+O#B$
M!5Y,Y7M8X,64%EG@Q2(+K#B$!59,Y7M88,64%EE@Q2(+G%A@D3G15A<_XL2P
M&MF=%P.6S8O9^]<XL6E:<F)*B_W&B0&+5R?C1;589,]&L6+3L#0OIOH]IQ\K
MIK1(`RN6:>#%(33P8JK?0P,OIK1(`R^6:6#&(30P8ZK?0P,SIK1(`S.6:>#&
M`HW,C;:"VG9CO=%TR/MC<VN97ST&K#M#GKM=-TW3XM5C4^UTV88O&RS,D%P@
MS^;^/J;)*<V0J7R/$-@RI44AL&61!:X<P@)7IO(]+'!E2HLL<&61!:8<P@)3
MIO(]+#!E2HLL,&61!9XLL,@\:<O&;4\6UG?FS3)SY[<Z8-T9,M^TQ`R95JA[
M^LU]3$J+_<:)`6MFR-&B.EODCX:9(9N&]/_]*].;E-8[46-%1P,K=FB,1[/S
M:95=P.+%(33P8JK?PQ8OIK1X-O!BAX8\&YAQ"`W,F.KWT,",*2W2P(P=&O)L
MX,8"C<R-3",?<J/EY_-BP.S+B,D&H_-L'10WIK38(ZSG,*SG,)SF,&SE,#SD
M,#SD,"SC,/SA,,S@,,S@,+1W&$([#%4=AJH.0\0VEBEF2\?M^>/TF_;;WZ]O
MSW^MCW]^KY\WR9VE[1V`\V85NC.U!*S[Q/W</7%OFG:^`NTQQ$SEHNB(Z3#$
M=!AB.@PQ'8:8#D-,AR&FPQ#388CI,,1T&&(Z##$=AIAM+!/3%F-S,?_'?^@[
M#PN[W4OI@&5J9M<4#,V4%E5B:#H,-1V&F@Y#38>AIL-0TV&HZ3#4=!AJ.@PU
M'8::#D--AZ&FPU#38:C9QKIJ+CZX6%[G9Y-I@V6*N<7R4]I),8]=51Z[%MB-
MP-8"VPCL5F!W`ML*;">P>X$]"&POL(/`'KM84.SSZQ_'X]OJZ>WIR\]_'5^^
M'R^//WZ\?OKM^6_[\KJ]@-C"/[T<O_WRTP5UEG4QSGAJ$V/3$3&^TZEBLPDQ
MMMW(V-1B4QF;SXCQ2Z#:S><6JQ\!.R[SA<7J#R6YV.2<&)^E5S4G=CP^@"YC
M=CR^IRUC=CP^SZQB4SMG7!G(6&6Q^O['\[1VX=?%QZP='UQ0-2>F`_]91L;&
M%JMW(_F:IA'_+4.V,XW8)JEB8VO'C@H9LW;\:TP9,QWX7XLR9CKPK_MDS'3@
MG\3)F.G`LWT5&UF[D6XWLG9AXZX[+V/3(>QQ]S'3(>R>]C'3(>S>]3'3@7L7
MR=/:C;1^(VO''8EL9SKP73@9,QVX[I$QTV&D=1B9#B.M0V7M*MVNLG;5.^U,
MA[!AQ)V7RG2HWM'/=&#E0?;!=`A[\WU-:U?I=I6UJ_0XJDR'<"GA:YH.E=:A
M,ATJK4-E.O"T3_1A#DV>O*H()'DT(R(+(@L=@?Q">F@!]85F?F9GXTS6LPE<
MS]\SNJ1G[QD&88>8X#W#'NP<4A',P<X0%<$:/+@7D7/ZRB=$5(2^\ND&%:$_
M_,2I"/WAQ6T5H3^\**LB](>W+$5DQ"G5OK2AK$?R"`9ZK-IPU*/1)C<]M]G4
M]L[,9F:4/:V'MNQI/;!E3RL;UE*Y>E!+Y49X7H]H2,L6E0UF.4K"4%8:U`-9
M^J.R82S]40]BY8^OU?*KKD4I=73,*?,YM#KRU\GRJUVN"2]A6<7H`AFEBF97
M5<<&G\(14.EGNR:7]1Y&S\GV(B[KG8$^1KOYDFU2JJ9MB[.:*F8[V)9L*%(Q
MVVQFQU.QU6*ZO%JH,[$FLI$1^Q`X//B>M>?/IP0G'$O&:,?![#/(OAW?0N1P
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M.QG9$SG(R!W'N9/'V1+9R?YLZ<].]F=+?W:RVCW5[F7D@<B#C*S&C`5]]T.;
M"]GFDLBEC*R(7,ES<$WD6D9NB-S(:FLB&WEVUIR=C3P[:\[.1E:[I=IMB'Q.
M-P.O7W[^]]/WX^[IY?N?_WK]]./XC863LW_8.RLO8?TY_/'6?&OUU^<WUJ99
M6_GITQ_'I]^/+Y9-\K?GY[?X!Y/NY_\\O_RS7ISY\E\```#__P,`4$L#!!0`
M!@`(````(0!`G.@BNP(``(L'```8````>&PO=V]R:W-H965T<R]S:&5E=#8N
M>&ULC%7;;IPP$'VOU'^P_!X,["59M&RT:90V4BM552_/7F/`"L;(]F:3O^\8
MLP2RFX07+L.9<V:.[6%]_20K],BU$:I.<12$&/&:J4S418K__+Z[N,+(6%IG
MM%(U3_$S-_AZ\_G3^J#T@RDYMP@8:I/BTMHF(<2PDDMJ`M7P&K[D2DMJX547
MQ#2:TZQ-DA6)PW!))!4U]@R)GL*A\EPP?JO87O+:>A+-*VJA?E.*QAS9))M"
M)ZE^V#<73,D&*':B$O:Y)<5(LN2^J)6FNPKZ?HKFE!VYVY<3>BF85D;E-@`Z
MX@L][7E%5@28-NM,0`?.=J1YGN)ME-RL,-FL6W_^"GXP@V=D2G7XJD7V7=0<
MS(9E<@NP4^K!0>\S%X)D<I)]UR[`3XTRGM-]97^IPS<NBM+":B^@(==7DCW?
M<L/`4*`)XH5C8JJ"`N"*I'`[`PRA3^W](#);IG@VPVC'C;T3C@HCMC=6R7_^
M8]11^.2X2X;[,7D9+"[#601:'Y`07TC;URVU=+/6ZH!@KX"D::C;>5$"Q.<;
M@0X<=NO`*;[$"&HU8/[C)HK"-7D$QUB'N?$8N+Y@>@0!T5X9U*8K.[!3=I:Z
M4FY\8"@3GY<!?Z?+.#"LR;#X*.IYO;+'S`>818\8-0B0Z<H.#&L`;;WX=N*M
M!TV0AOTP7=J!6^G>W"X"QV-0S!O^+L=2[D3$*RCQ_9WDLL::762XHE$T.^\L
M[,!A>TYS'JX"H'A?U>6-5;O(6'5^7M7-\,%1\6=_%ER"6^_+NL2Q;!<9R[ZQ
MC59G9.,K-U\^D'6)8]DN,I9=ONK6#S\_)"37!?_"J\H@IO9NL,5P[/MH/W.W
ML3N9K^/S9-O.8M)_@%G8T(+_H+H0M4$5SX$R;"W4?IKZ%ZL:J!R&FK(P#=O'
M$GYZ'$Y^&$#CN5+V^`+"I/^-;OX#``#__P,`4$L#!!0`!@`(````(0`W9$'\
M/P4``,43```8````>&PO=V]R:W-H965T<R]S:&5E=#4N>&ULG)A=;ZLX$(;O
M5]K_@+AOP,9\14F.&JKN'FE76JWVXYH2)T$-.`+:M/]^QPP?MCDER=Z<TR0O
MP^-WQC/@U;>/XF2]\ZK.1;FVR<*U+5YF8I>7A[7]]U_/#Y%MU4U:[M*3*/G:
M_N2U_6WS\T^KBZA>ZR/GC041RGIM'YOFO'2<.COR(JT7XLQ+^&4OJB)MX&-U
M<.ISQ=-=>U%Q<JCK!DZ1YJ6-$9;5+3'$?I]G_$ED;P4O&PQ2\5/:`']]S,]U
M'ZW(;@E7I-7KV_DA$\490KSDI[SY;(/:5I$MOQ]*4:4O)UCW!V%IUL=N/TS"
M%WE6B5KLFP6$<Q!TNN;8B1V(M%GM<EB!M-VJ^'YM/Y)E0@/;V:Q:@_[)^:56
M_K;JH[C\4N6[W_*2@]N0)YF!%R%>I?3[3GX%%SN3JY_;#/Q163N^3]].S9_B
M\BO/#\<&TNW#BN3"EKO/)UYGX"B$65!?1LK$"0#@7ZO(96F`(^E'^_\EWS7'
MM>T%"S]T/0)RZX77S7,N0]I6]E8WHO@71:0+A4%H%\0#^NYWNJ"13_S@>A0'
MB=H%/J5-NEE5XF)!U<`]ZW,J:Y`L(7*_,N08UOK54F&-,LBCC+*V0]N"5=20
MG_=-%*^<=[`TZR3;J83HBJ17R$P`W8`("U<1?VQZ3R+%DD0F0:)M\0N(/:!1
MX[Y31>@-$HT$#+J=1(HAT<J-8W<(BVPH88K$UQ7)G$)#@R"WHTGQVH9U#Y[$
M1C*V*(G:7-*8,<*,A":J@K@L"/QH=%9C@QI7V62-L2]W3Y](>9%AWQ@>[4,)
M<`S+,.V;4VB(@8XX7V-2;-@W%@RBH23`K>"Q@)ADJB"DE,7!D'D-#/:4ZMT\
MF!0;8&P(BV`H03`O]OS`2'RB"@(:A5^!R=EF-`X/&NL\H+S(`#2,V:($`0,:
M>).Z0X&:]:\0X_^#*"\RZBXT/$2)2F`L(IE3:.DE8)EJX[Q]K5KWCT8&7*=!
M`Q^HY[N!49R)(0F)Q^BXNW4^V925-%_APQ:N-A8E,!8@04W'%T/7F.P-71+$
MU!N+5*>3K?MV.FST*ITW[KJ.#C4='8F9&\5&^A.B:7S&&(W&+.B`LG_?#HC=
M7@,T;KXEJ.G3&X>4&%L\T22^%P7CV-'A9`>_'4ZJ]=IC8UHZ]U#3P<%(\%Q#
MDA!-XL5^$(_\.IYLWK?C8:M7O8O'I'1XJ.F3Z\5!%/ECX;>B1#[7P3I[@T/H
MD308(^F(=XT-\H.Y8=Q]VVGP[A$\(9J=11,PEX5TK!"=[:[)0::C@[ACW73^
MJ;/A@=`XBA@S1$D7J?</]@9A2@_7&8TA<J6[8.>'#3#,>V+6UY9,Q\/$PCF)
MSF=,D"M\V/75$B2N^<Q"4-3;XWI!:/J<Z!H?-I'2IS1`>M?X:-7Z%B:N,1RV
MG6@64-?,`MXU/RC.!CW#8WO`*NQ$T$>&,C`S/"O1#92]7&DR\MGT^F,,E5>9
M1AH0VT[4;66?D,BP.M$4C'GNV`UT2-GS[X?$2:&7HSGO*(KF(%7%'*1L[/=#
MXCC0(<>.UF5<FQF$D1#FAB%*J":B+`R@-8[+U0TU1LN-69^.&.*.DZ%C5<<'
M"T/F$=^HC$2^K@\CQO<I5(;R&*Z3&A/F1M+II"%*<76D*,)7/`_>!&)B3DQY
MJ")).XW+?%CPN!HDQ5,3/%0H>'7@"3^=:BL3;_)$A,(KT/#M<%KS2.4+NO']
M%DYQVB,/9_@!#E'.Z8'_GE:'O*RM$]]#2'<1@H$5'L/@AT:<VZ.,%]'`\4G[
MYQ&.RS@<`+@+$.^%:/H/\GAA.(#;_`<``/__`P!02P,$%``&``@````A`#4G
M:X?'`P``;`X``!D```!X;"]W;W)K<VAE971S+W-H965T,C@N>&ULE)?1;J,X
M%(;O1]IW0+XO8`I)B)*,VG2[.]*N-!K-[%X3<!*K@!%VFO;MYQ@3%YO6);D(
M@7S\_#[''!^OOKY4I?=,6DY9O4;8#Y%'ZIP5M#ZLT:^?CS<+Y'&1U456LIJL
MT2OAZ.OFCR^K,VN?^)$0X8%"S=?H*$2S#`*>'TF5<9\UI(9_]JRM,@&G[2'@
M34NRHKNI*H,H#&=!E=$:*85E.T6#[?<T)P\L/U6D%DJD)64FP#\_TH9?U*I\
MBER5M4^GYB9G50,2.UI2\=J)(J_*E]\.-6NS70GC?L%QEE^TNY.1?$7SEG&V
M%S[(!<KH>,QID`:@M%D5%$8@P^ZU9+]&=WBYQ7,4;%9=@/ZCY,P'OSU^9.>_
M6EK\0VL"T88\R0SL&'N2Z+="7H*;@]'=CUT&OK=>0?;9J10_V/EO0@]'`>E.
M8$1R8,OB]8'P'"(*,GZ42*6<E6``OKV*RJD!$<E>NN.9%N*X1K<S/YF'MQAP
M;T>X>*12$GGYB0M6_:\@W$LID:@7@6,O@A,_CI+YXAJ5VUX%CA>5V6250(VK
M"]-#)K+-JF5G#^8>..=-)F<R7H*RC$\,(U.CT1'[*&`0*2ER)U76:(X\N)U#
MEI\W<3I?!<^0F;QG[A4#WYK!)K$=$W&ZT$P`CK5M".70]OOIO+B3L'0GTROM
MWJL+0RN1?DQ';-\A$HT83B!HTYU(>(U`7,<@3F^UKC*GF'C`O#U9F7,1AC<0
MF>Y-PC"]!\^-T]#RIAB7-Q=A>(-)-MV;A.VXI98WQ<RB;OJ%?H*AU`X^]F13
M^'`HZ4PK&DYGUSB5L.TTUKHJPXH9/MK.L(LPO,$K-SV*$OXLPXIQ>7,1AC>Y
MA@Y*B_L=E;`=-SO#BM$9CJ+9(+]A:&?8PN,D_@`W7*?7N):P[=HJ)?>*<474
M11C>,*Q_TT/:T9_ENX=<]IR(Z4]6\,DIQZK>F]70SGD/Z:1C;*=Y1'RP9&!9
MTZ>;4RN`:>ZM0*@7N9.$!7-0,^TWV8F8P9-E?;H_M0BXRS56D-.?"S']@<P5
M_B1MOQJCY"IHD%RS4FZQ!40+G`X_;SV&:?6JQ47V@R.K5A[O>PC\Z*7;0K9.
MQ/1WU9*"U6KP2:I=2X9J&WJ=]X=@^KMJ68'^?1R_4:H5I%,=6HNBW`5(E1Y8
M^&:Q#I,_;]X*JS*KFG[5S5:D/9`M*4ONY>PD&WH,?8"^JC<;=U&W7=!_0*_?
M9`?R;]8>:,V]DNSAUM"?PY1HU6Y!G0C6=+WRC@GH\KN?1]C5$>@FH=5`WIXQ
M<3F1^Q&]3]S\!@``__\#`%!+`P04``8`"````"$`[VKV^8P"``!K!@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R,5<MNVS`0O!?H/Q"\1[3D5R)8
M#NP&:0.T0%'T<:8I2B(LB@))Q\G?=U=T5"D.4E\,<36<V9W=E5>W3[HFC](Z
M99J,QM&$$MD(DZNFS.BOG_=7UY0XSYN<UZ:1&7V6CMZN/WY8'8W=NTI*3X"A
M<1FMO&]3QIRHI.8N,JULX$UAK.8>CK9DKK62Y]TE7;-D,EDPS55#`T-J+^$P
M1:&$O#/BH&7C`XF5-?>0OZM4ZU[8M+B$3G.[/[17PN@6*':J5OZY(Z5$B_2A
M;(SENQKJ?HIG7+QP=X<S>JV$-<X4/@(Z%A(]K_F&W3!@6J]R!16@[<3*(J.;
M.-TN*5NO.G]^*WET@V?B*G/\;%7^5342S(8V80-VQNP1^I!C""ZSL]OW70.^
M6Y++@A]J_\,<OTA55AZZ/8>"L*XT?[Z33H"A0!,E<V02IH8$X)=HA9,!AO"G
MC"8@K')?972ZB.;+R30&.-E)Y^\54E(B#LX;_2>`XBZIP-6E=L<]7Z^L.1)H
M-Z!=RW%XXA2(W\X%DD#L!L$975(",@[\>US/DOF*/4+1XH39!@S\]IBX1S`0
M[95![7)E!*,RNH*I;$-@*).\+3,=RZ#I4VC=^X7B)<`-BI@EBYX_9!`PLP'F
MGQ6C0@%R>:$(AEY`>;U_YQX'T`72,!>72R.XD^Y-/D7`KD$RR]Z'496+L50W
MW/$\`HKWK<9[8]539-C;67+]MBK,XK#`3C6YQOWYCRQ>',N>(F/9FU>R8;G#
M!FEI2_E)UK4CPAQP<1/8B3[:?U,V"8[MZ_@LW73CS/H7L.LM+^4W;DO5.%++
M`B@GT1)JL>%K$0[>M)`Y;+SQL.7=8P4?=0EK,4&_"V/\RP&$6?\WL?X+``#_
M_P,`4$L#!!0`!@`(````(0"V'74.0$```+N$`0`9````>&PO=V]R:W-H965T
M<R]S:&5E=#$W+GAM;*R=6Y/<-K9FWR=B_H-"[T>JS+H[;)\XRBOSGHR>F6>U
MK&XKVI(<DOKV[^=#`IL`]J*8E=6>AU&?Y8T+N0`0V&15_?C?__KXVXM_O/_R
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M"@K^_/GSWT)H\TM`*OP:I><G!8<O+WYY_Y>W?__M6_OYG\OW'_[ZZS?YOM4E
MA2O[X9=_3]]_?:=;JFI>C6]#3>\^_Z8.Z/]_\?%#&!NZ)6__]=/+L1K^\,NW
M7W]Z>7WWZO;^ZGJD\!=_?O_UV_Q#J/+EBW=___KM\\?_%X-&J:I8R76J1/^F
M2NY?W8QO[Q].E0P4O$D%]6]/ZP,%U;=3M_5O3\$G=OLN5:)_4R6CT:N'V]N;
MNX=[53S0_'TJJ7\ONV#-NU._]6\JJ/\UT-!CBM>_=IW#/1MI!)U:"/_CPJL:
MV6`(_^.RZQII_,1F\T`:OK*1#9KP/YYX;39<1GF\/-58F!.Q@WG(/'&0CFR<
MA/^1>GKFVFQ\C/(`*:?5@/"1:H[]U/]XFK_7<4J?5HCIVV]O?_[QR^=_OM"Z
M*XM??W\;5O'1#Z%>6QMB\]UJ\;W%0JM$J.5_0C4_O=25:!WXJB7N'S_?7-_^
M^/H?6I7>I9@WC!G5$1.+"$M0J';JP<R#N0<+#Y8>-!ZL/%A[L/%@Z\'.@[T'
M!P^.'K0%>"T]G2--ES_"4:@F.+*[^\9`EC9V0BS"BDP]F'DP]V#AP=*#QH.5
M!VL/-AYL/=AYL/?@X,'1@[8`E1"M1G^$D%"-GJ7%I!F-W)1X$V-N-#.[F>7F
MU:0+Z2R!S$#F(`N0)4@#L@)9@VQ`MB`[D#W(`>0(TI:DDJ;GP1\A+52CQ5)#
MHQ,R&CW6\^9-#!JTUH5TUD!F('.0!<@2I`%9@:Q!-B!;D!W('N0`<@1I2U)9
MTY.XLM:_9[7'4(@^R;&;^B:26VUTOJ]KT@59L2G(#&0.L@!9@C0@*Y`UR`9D
M"[(#V8,<0(X@;4DJ%]K:5"["7N'Z(9P9TO;TR=N%4%/M*9*;RM/XJIY6DRZH
M\P0R`YF#+$"6(`W("F0-L@'9@NQ`]B`'D"-(6Y+*D[9AE:?A.1.B:Q>1W,;S
M6]B'34"F(#.0.<@"9`G2@*Q`UB`;D"W(#F0/<@`Y@K0EJ6Z\GM+5C0\39'S[
MZO+Y$2JJG43BYH?;+$RZH&Y^@,Q`YB`+D"5(`[("68-L0+8@.Y`]R`'D"-*6
MI-*D@S(TA;/?A6>>4,U)4O%H&;L=])L8-+@3Z$(Z:R`SD#G(`F0)TH"L0-8@
M&Y`MR`YD#W(`.8*T):FLA61%I6UX63N%UW,HH7HSX(U-<E3G@VA&-"=:$"V)
M&J(5T9IH0[0EVA'MB0Y$1Z*V0K6><'KUF81G+7XAL^16OX3<\G?MM@<Y*IN+
M=:F@H1FCYD0+HB510[0B6A-MB+9$.Z(]T8'H2-16J#87CKG>W#/6PW`FXH)X
M4TMZDZ(&5\0<8]:F1#.B.=&":$G4$*V(UD0;HBW1CFA/="`Z$K45JD6&LV\I
M\LP*&8_*JL_N\IN09Y5"MT(ZA9,<906G1#.B.=&":$G4$*V(UD0;HBW1CFA/
M="`Z$K45JO6$0^X%>N*9N-*3CLGU*<GG@T+F6Q*+-6]*-".:$RV(ED0-T8IH
M3;0AVA+MB/9$!Z(C45NA6D\X]Y9ZGKU[#VNG?X!%Y!Y@=_7:.$D%*W-=09MK
M,T;-B19$2Z*&:$6T)MH0;8EV1'NB`]&1J*U0;2Z<A+VY$'[AACZ\N_$/L)MK
M)^E-BAI^@*6S^4.WM$YSL2P247-&+8B61`W1BFA-M"':$NV(]D0'HB-16Z%:
M9#A9ER+//,#B0;Q:(=/9O%XA[_T\ZZ+,Q32\A8M//D,SHCG1@FA)U!"MB-9$
M&Z(MT8YH3W0@.A*U%:KUA!/U!7KB`;S2TYW)RS/S@]?319F+:7@U63_39D1S
MH@71DJ@A6A&MB39$6Z(=T9[H0'0D:BM4ZPE'YU+/<]_EQB.XO)62_"N.47=0
MSU'8B70Q6230+-=D47.B!=&2J"%:$:V)-D1;HAW1GNA`="1J*U2)'%^6Z3B%
MUYF.A-P^WBF<Y"B[\5.B&=&<:$&T)&J(5D1KH@W1EFA'M"<Z$!V)]$56\4"H
M]?A,Q_!3:LQT1D+U;O#:O^W(45D/TQF,FA,MB)9$#=&*:$VT(=H2[8CV1`>B
M(U%;H5K/'Y3.&/>E,ZY=ROU-BAK<#>:8+#)6KF*&9HR:$RV(ED0-T8IH3;0A
MVA+MB/9$!Z(C45NA6N1EZ8PQTQD)U<N@5SC)4>9B2C0CFA,MB)9$#=&*:$VT
M(=H2[8CV1`>B(U%;H5J/3V<\_W7PF*F.A-P2Z=ZN3')45H?LQXQ1<Z(%T9*H
M(5H1K8DV1%NB'=&>Z$!T)&HK5*L+285RIWCF"19S$.5&/KSS#\>EG#N<$$V)
M9D1SH@71DJ@A6A&MB39$6Z(=T9[H0'0D:BM4N^A+7NC=^W>^SK8O7<9=KL)&
M_AM#Q7M[0PK.G[]<N_<F4XO*GP;.#-4%<R*XOH1P=KY@.,6C=C6<TNF['$Y`
MTS'0C&A.M"!:$C5$*Z(UT89H2[0CVA,=B(Y$;85J%^&@7+HX'0)O3E_VGQM2
M\8Q=>4FH'%()U2,#0RI%E4.JMV`^,M:7$8Z)Y66<6:'BJ;+J>D3E5RQCH"G1
MC&A.M"!:$C5$*Z(UT89H2[0CVA,=B(Y$;84J%]?^.'H:4E?:P0Y+.96KSZ6&
MBO%D:'@\650QG@S5!7.VMKZ&R\YLUSRS)>0V)#ZSF*-L69X2S8CF1`NB)5%#
MM"):$VV(MD0[HCW1@>A(U%:HUN//;&=&5G<TL[O\YCH=J*K$[[7/+.8H*S@E
MFA'-B19$2Z*&:$6T)MH0;8EV1'NB`]&1J*U0K<>?Q&)F\57X":@SIG@HNX[H
M]O0#;Z<?\Y@038EF1'.B!=&2J"%:$:V)-D1;HAW1GNA`="1J*U1K\2>P,RYX
MRKI.J%R/@::,FA'-B19$2Z*&:$6T)MH0;8EV1'NB`]&1J*U0[<(?J8HI\NW7
M#^_^]N:S=N#]V_IK_<!4_#&J:YZT#.5,T22C<E?OLKO3%!6ZG/?^-R[).,M1
MMB+.B19$2Z*&:$6T)MH0;8EV1'NB`]&1J$U(+U-TV;5([2<NV'E>AW"WR8E(
M3=@MG:2HT&IV<0UCJ:"..3GJQF4<9U97W@K-#>4QLB!:&JJK=RF5)D=9[U>&
M<O7KC(JN^@O:6%3=8M[RGP;]-D=9BSM#N<5]1@,M'BRJ;M'MTHXYREIL#9VD
MU0-"=5TR($*X&Q`150,":'J=T%TW;&9$<T-Y<"V(EH8TH(J1Y`YI38ZRV[`R
ME*M?$VT,U=7GK7?RB@O:6<%<_9[H8*BNWNWECCG*>M\:ZI$8#I_E>?)YRW,Z
MPN8TQ9OKB"JW0%.+*MVFJ(SF%I7OSH)H::A>UW-JYG3SFQQE=V=E*%>_)MH8
MNNF&X99H9RC7M2<Z&*J[ZI:]8XZRKK:&>D3ZQ,#S1#)?<)U07G(F&16SR"]R
MTQ2EYZQU?T8T-Y1OV")7;P67%J6^Y'E[ZY[938ZR@BO6M<ZHJ,OW?I/K*J)N
MW3-GFZ.LQ5VNWM`^HZ(NW^(AUU5$W;K'T#%'6?5MKEZH6J+#H;R:W<,;X5-X
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M!0=;/.0H*W@T--AB:U&GDUJ]L`TDU)Z>+;AA<BVA:KW#!P]6;O"RISG*+GMF
MM<?%[>;JYL'O3>96JAK??N0N+"H/I"51<[ZYE94:;&YM48,7O,E1=L%;Z\&9
M12MY*!>MA`9;/+#%XY-:;*U@SPJEKEZR%0KA;H6*2.^#[#9,;CI43#`O=9JB
M]%[&"LZ(YKDNBUH0+5FP(5JQX#JC@:YN6->6:)?KLJ[N,QJH_L"ZCD1MKDO5
MU\N#AG,E\5F'G)M0BW,;4;7-O79;F$DJ%][6Y.64ME-5591_X,Y27?J<(&R'
MKJ\?[\.J47_O/;>@P<?#(G?+;"RMX&`?&HL:ZL/*@@;[L,Y]&+@U&ZMKL%M;
MBQI\ANPL*F?[]D_JQ,$*#G;B:%&#G6@MJN=!%E*60WF5/WW^74/PW&NBFU"-
M&ZH15<M0AP;N_C35I;=9-DYF1/.$BNH71$L6;(A6++C.:*"K&]:U)=KENNR"
M]AD-5']@74>B-M>%94B3H9)[YE@=PIW$B,(KK+R4W.+\E0I6@Y`+3HK*>X;9
M#="<:&$H9W:6AG)=#=&*:&UHL*L;B\K5;XEV1'M#@]4?+"I7?R1J*U0_7E1]
MY?5YCY=0B],=476XN4$2)0:=>[RDJ@:7KUGX[%I]&.N?8GSA^9*B-%J**'<J
M6J2ZU"^;9DNK?K`3C475G7`GVY5%Y85\G5LL^N7'_<8*#G9B:U&#G=A95.[$
M_DF=.%C!P4X<+:KNA-/16M3W=-1C]5R^]XD/&"9\;R(JG@"3C`:$3%-4]8")
M=15HGNNRX;0@6K*NAFC%@NN,!KJZ85U;HEVNR[JZSVB@^@/K.A*UN2[_@`D?
MYE<+T?`#YA1>KSB&\J2=)*2LHEW-E&A&-"=:$"V)&J(5T9IH0[0EVA'MB0Y$
M1Z*V0M5$"Y\<5RZ>]5`XU>(4A8J%\N-W8E'5.N$7OFF*JC]@N',O0V8YRG3/
MB19$2Z*&:$6T)MH0;8EV1'NB`]&1J$VHYP,&?9-?BSPSJ6):K/QT]E2#?K5?
MSF=,,AI8#Z865:WL^(`A1V5CL1-Z[6=H85$9+0W5U;LW1TV.LKI6AG)=ZXP&
M+FAC476+[M&^S5'6XLY0;G&?T4"+!XNJ6W0[YF..LA9;0TP)Z4N[BP9$2EWE
M\].;4PUN0,2H8HQ,+2J_T9X1S0WEP;4@6AK2B2]OV?Q6LLE1=AM6AG+U:Z*-
MH;IZEX7?YBBK?F<H5[\G.ABJJW?[H&..LNI;0ST2?5[O><LSTWVW$14B)T13
M0Z7;5#"CN47EN[,@6AI2^<*MRT(U.<KNSLI0KGY-M#&4W\=OB7:&<EU[HH.A
MNJONY'#,4=;5UE"/R#\DMW?+W)ZAO.1,,BKN-)^SL:[R`X94L$!S0_F&+7+U
M=MU+B])^.+OU+PF:'&4%5ZQKG5%1E^_])M=51.$#AAQE+>YR]8;V&15U^18/
MN:XB"A\PY"BKOLW5"]6;KY#9*M-H9Y[9(=SMLB*J,KNC6W_VODU1U3'.7^`T
M1UG79T1SH@71DJ@A6A&M,RKNLN_J)D=95[=$.Z)]1@/5'W*457\D:BM4>]5C
M_!*O(=QYC:AZH8</&&Y3N3-:^Z*0L4]UZ>=^0\9^]'#W>#MZ=/N/N36HE2-/
M<R]G85'Y<+;,J"CH^]`\I0\KJVJP#VN+&KPUF]XHWZVM=:MZ&N`]L]65%\J]
MH<%.''JC?">.3^I$:W7U/']TZ+ID2(9P-R0CJK)\_(3A-D4-7O,T1]D$FQE*
M7Q0\ZA.&QUNW=YI;D(;TT`#L^F"U+ZU@'I.-H:$&5Q8TV.#:H@8O>I.CK%M;
M0^IPOAX.K70]1?K."@ZV>,A1UN+1T&"+K47QS<]M2'F5CZSG;4ACXJPZ?494
MK7CXA.'4NH;EX&5/<Y1=]BRAM+SU?L)@I087EH5%Y8&T)&K.-[>R4H/-K2UJ
M\((W.<HN>&L].+-H)0_EHI708(L'MGA\4HNM%>0*=7=95O`47J]0"96IW8R*
M">:?6-,457["0#3/==E=7A`M6;`A6K'@.J.!KFY8UY9HE^NRKNXS&JC^P+J.
M1&VN2]57.Y\[#9O_?'DXU>+<AHKURJ?\4A>?,*1R9]XQI:CZ*SO_P)U95'P\
MW#R,;AZNKEP*:&Y!@X^'1>Z6V5A:P6J6^3XT%C74AY4%#?9AG?LPH']C=0UV
M:VM1@\^0G4453ZTG=>)@!0<[<;2HP4ZT%L4'V9W/E_H'V=/>,)VJ<4,U9C6K
M9:A#`W=_FNHJ7B?-B.8)%=4OB)8LV!"M6'"=T4!7-ZQK2[3+==G`WV<T4/V!
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MP75&`UW=L*XMT2[795W=9S10_8%U'8G:7!<>,)=E;N^8N4TH_!14/OK?N;>:
MDQQE%S@EFA'-B19$2Z*&:$6T)MH0;8EV1'NB`]&1J*U0/?<T0ZNY-YQ8OPOA
M;HY%Y/3XQ'HJ6'YT0C0CFA,MB)9$#=&*:$VT(=H2[8CV1`>B(U%;H5J/EME+
M](1PIR<BI\>]3)S<=5%Y]@#-&#4G6A`MB1JB%=&::$.T)=H1[8D.1$>BMD*U
MGI`"*G-\9V9/RA@57P[<1:2O5>S&3XBF1#.B.=&":$G4$*V(UD0;HBW1CFA/
M="`Z$K45JES<7Y85.X774R4A-U5<)F.2H\S8E&A&-"=:$"V)&J(5T9IH0[0E
MVA'MB0Y$1Z*V0K4>;2NKJ5)D$89GS7THZ4Q%I*]!S,$D115H2C0CFA,MB)9$
M#=&*:$VT(=H2[8CV1`>B(U%;H5J+3^Z<<1'3,^7KB/N$BA6,:$HT(YI7J.[G
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M="`Z$K45JM5=ML6_YQ8_(:?'/08F.<H6S2G1C&A.M"!:$C5$*Z(UT89H2[0C
MVA,=B(Y$;84J/0]^UQ\7BXO_M-VIGM,CL5@'[EV2Z4V*"C^@U3V@_/D@QW0B
MB69$<Z(%T9*H(5H1K8DV1%NB'=&>Z$!T)&HK5(L,6_IRB1Q^G#^$\'H+DU#X
M"9Y.SL@KG.2HK"?6I8*&9HR:$RV(ED0-T8IH3;0AVA+MB/9$!Z(C45NA6L]E
MYX0'GA,2<LN@SQ/F*',Q)9H1S8D61$NBAFA%M";:$&V)=D1[H@/1D:BM4*WG
MLN/1`X]'"3D]/D^8H[*>6%>QKY@Q:DZT(%H2-40KHC71AFA+M"/:$QV(CD1M
MA6H]O<>VVU<Z1USX)U@?TMFJ2"$FY,SAL10+%IJFN:#)G!'-B19$2Z*&:$6T
M)MH0;8EV1'NB`]&1J*U0;2X<]2YX+,638;D[?XC(Z?%YAQQE+J9$,Z(YT8)H
M2=00K8C61!NB+=&.:$]T(#H2M16J]0R<I,]L('AZ?HBH2"%.B*9$,Z(YT8)H
M2=00K8C61!NB+=&.:$]T(#H2M16JM83S\@6S)AZOJUF34,XA31Z`ID0SHCG1
M@FA)U!"MB-9$&Z(MT8YH3W0@.A*U%:I=].4>1K>GOTWQ]&33`],.AO(W5Y.,
MBBTXTF<IJOZY]7N7:YSE*%L1YT0+HB510[1*J/BI^S71)A<L+NC>Y2VW.<JZ
MNB/:$QV(CD1M0CT_RO[@DQ,^5?:D/ZIPJL6=I5(:HW3;H>)6T&V,TJ\B#C\=
M-;X:N0W^+#6F`+M7<VL_-[8@6N:"J69W.&]R@-6\8C5KHDTNV-_G;0ZPFG>L
M9D]TR`7[^WS,`59S6U53S>1'G^L8?L*=PFNM"=7YX7N?'[:H*O,+TSG*NCXS
M]'"2?S]ZY>3/+4`K>3ZB/[A,Y<*B\MJ_)&H,Q<9&-Z_<>%A9P&!C:XO*C6V(
MMH9B8[</K]P2L+.`P<;V%I4;.Q`=#:4K&[]RF\76`K[76#UJ+DNL/#*QDE#]
MA>^#3V!:P3.C)E6?[\`L%=2[H3!)1J-7[N@RMYJUD1X:-:AY:05S8XUK[-;?
MVY65&6QL;5&YY@W1%HVYF;:S,H.-[2TJ-W8@.KK&[OU\:*W,]QJK1\UE^9Y'
MYGL2JM>:!S=))Q9U9M3$ZO6#*'FM22A-DJM7[M[.K>;O39+3GX%86%2N>4G4
M&(J-N?5J9?]UL*6U1>66-D1;0^FRKE^Y;='.`@8;VUM4;NQ`=#34>UFM_=?O
MM52/E\L24(],0"7D5AGW!)E8P3/C)56?+W^6"J95YH:+3"KRO=F1A@LJ7N8>
MV=ALZK;NO<.5%1EL:VU1^2(V1%O?EKMA.RLRV-;>HG);!Z*C;\ME!ULK\KVV
MZA'C<V)G=C-,?#U&Y%88UZF)19T9,:FN?`-F5C#-#O^DF-M__][\2",&%2^M
M8&ZK,13;NO:C<V7_?;"MM47EBC=$6T.Q+>PN=O;?!]O:6U1NZT!T-!3;NO.+
M=&O__7MMU2-&X^J"K,)C"'?[WXC<&N/V&Q,K>&;$I.KS#9BE@FF-Z7DDI2+Z
M9V@C@XJ7N4=YC8E1J:WB(YG3L%M9B<&FUA:5KV%#M$W(-FA^(NRLR&!;>XO*
M;1V(CG5;MTI3U+\+N[4RWVNL'C$^/7AFC6%.\#'E!'.O)T13HAG1G&A!M"1J
MB%9$:Z(-T99H1[0G.A`=B=H*U2XTQR^9O2'<S=Z(ZDSZ@SL<31Z[*)LK4Z(9
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MC*.K=&XOUD5C[OCHTYI=V+G;'%LH4U1=T3BDE=ETE>LVIU+5X$)"O`NK;C,:
MU&U.+#7H%@[=Y#/-N9L<CJZ7W.1XU"U?XXZN(G-CV9^X+.S,KZLJPFQH:2RG
M`[:EC^OS@FYQZM6YD9S"JEL,IEM<-3=^\,N4;O*9!MU-5K\NNLDAWB_.D;F1
M[*:8%HP4=FXD=V'%34XL#BQ7L^YQ^L_GAC%JULH,IGM<M?;0LUB<:<_=8G\*
M?.8WPJ.K[GQ8K+@/+O'\QL(&OQ(N@NPN:ZF.]:N@,0UO,-UN,&TGP'1OP71O
MP31BP=8];-/#MCULU\/V/>S0PXX]K*V9<ZLA=]'T"?%^^D16?SCLM6KZ=&%F
M1\;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QDKFC/F#YO")
M9G3%XZ6Q.A/PZ-[+R%@L6G[SV,-D#'$R!B9C8#(&)F-@,@8F8V`R!B9C8#(&
M)F-@,@8F8V`R5C)GS)]!B^/8.7D\CXZN(BN3`SU,<PMQ,@4F4V`R!2938#(%
M)E-@,@4F4V`R!2938#(%)E-@,@4F4R6K38W\P?F,GE.\6PV-Y8W09$0VK9GK
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M#]OUL'T/._2P8P]K:^;<AIU9Z?;<(R+NY.JQV>WN!K1J;'9A9D)/#3`9`Y,Q
M,!D#DS$P&0.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y.QDCEC86=6&@NS\7D_/#X*
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MC(')&)B,@<D8F(R!R1B8C(')&)B,@<E8R9PQ?S8+3\,[?2?[C"4T_`D-V(S,
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M,-D$DTTPV02333#9!)/-DCF;X=!?VCSW^(M)@MI8ES@H%M.12YAJP]*%%<;`
M9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QDKFC(6C?&DLS+_P
MA^,OS<6$WQ>*@T3*$Y0)_/$(:;545'.T4-D5-2:58%())I5@4@DFE6!2"2:5
M8%())I5@4@DFE6!2"2:58%)9LEJE?O$J5>KMSK/.A:?*W"D_L7HM'2$OD\-,
MW71$-NMA\QZVZ&'+'M;TL%4/6_>P30_;]K!=#]OWL$,/._:PMF9.9T@`^)GY
MO&U.>#7FYV9B3B92-CFLD!FK*^:K9()))IAD@DDFF&2"22:89()))IAD@DDF
MF&2"22:89())9LF<S'#^]S*?^0)#OV^7-KO\0OG01,HF%2W,:6IV1<VP;(+)
M)IAL@LDFF&R"R2:8;(+))IAL@LDFF&R"R2:8;(+)9LF<S9``*&V>V>:$-_"8
M?UT2H32&O$PJ6AOKBA;&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&
MP&2L9,Y82`"4QL(VYYF+:<PE5'O6\-,J$NP64Z1L<IB)T_3KBAK3]`.33##)
M!)-,,,D$DTPPR0233##)!)-,,,D$DTPPR023S)(YF2$W4,H\-_UB+J$V%IDS
MAI3-=1=F=F0,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9*QD
MSEA(`%QB+"8,:F.1E7\F:'0-)CU@T@,F/6#2`R8]8-(#)CU@T@,F/6#2`R8]
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M8%())I5@4@DFE6!2"2:58%())I5@4EDRIS(D`;S*Y^U7;V(^H9;9Y1A*F4BT
MI:*US*YH(1-,,L$D$TPRP2033#+!)!-,,L$D$TPRP2033#+!)!-,,DOF9(:4
M@9?YG`_U;V+N02I+;2[;]F:4PH8_U,]!YG%:%#2F-3>V6?PF`;D%DULPN063
M6S"Y!9-;,+D%DULPN0636S"Y!9-;,+DMF7,;,@BEVW^-;MZ^^^&7?T_??WWW
M_I.VHU?A3ZK^_.-I;_D_HYN8<:AG8V3UA_ICIW5B18L_+B9C7='"&)B,@<D8
MF(R!R1B8C(')&)B,@<D8F(R!R1B8C(')&)B,E<P9"UF"TMCSLW1AAOD74HFY
MLPBR=#G,Q$EFF;^PLPB89()))IAD@DDFF&2"22:89()))IAD@DDFF&2"22:8
M9);,R0Q9`B_S64MK3#>XI=6EX[2TIJR$>M2=-+D'ZH(*MV!:6L'D%DQNP>06
M3&[!Y!9,;L'D%DQNP>063&[!Y!9,;L'DMF2UV[`>5F[/+*VG>)?F22S\T_D:
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MR1B8C(')&)B,@<D8F(R!R1B8C(')6,F<L9`KN,18S"W4QKI\0YYAXVNDR<,[
MD?@53F$,3,;`9`Q,QL!D#$S&P&0,3,;`9`Q,QL!D#$S&P&0,3,;`9*QDSEA(
M"%QB+"80:F-=4J$TAESX;1=6&`.3,3`9`Y,Q,!D#DS$P&0.3,3`9`Y,Q,!D#
MDS$P&0.3,3`9*YDS%H[YEQB+:8':6&1ZKIH*+8%@TQXF/8B3'C#I`9,>,.D!
MDQXPZ0&3'C#I`9,>,.D!DQXPZ0&3GI(Y/>%,7^IY_L']-J8':G.1N=TEWE6D
MHE5.E$PRN^IL($@FF&2"22:89()))IAD@DDFF&2"22:89()))IAD@DEFR9S,
M<*;W,I^UNXS)`:DLETBW<7PSNHUA9W:779`YTT0%DULPN0636S"Y!9-;,+D%
MDULPN0636S"Y!9-;,+D%DULPN2V9<QO.]*7;<[O+F`.H9V-D;G?IM&II[<(*
M8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@,@8F8V`R!B9C):N-W?E4R_.7
MUE-5+@N3F%M:\;HIAV699+,1V;R'+7K8LH<U/6S5P]8];-/#MCULU\/V/>S0
MPXX]K*V9DQG.].7T^P]DQO1`-3/ONI1!N>#B;44.*V1V18U))IAD@DDFF&2"
M22:89()))IAD@DDFF&2"22:89()))IADELS)#(?X4N:9M?0N'OIK8Y%5>](4
M5[#IB$QZ4%9ZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZ2N;TA!/[
M)7KB";_6$YE;'?'&Z*X+L\DC8V`R!B9C8#(&)F-@,@8F8V`R!B9C8#(&)F-@
M,@8F8V`R!B9C)7/&PHF]-!96Q_1'[,_-K7C8K^5%ILR-69F,[L!D"DRFP&0*
M3*;`9`I,IL!D"DRFP&0*3*;`9`I,IL!D"DRFP&2J9,Y4.*F7IL[IB2?[6D]B
MY7'\#DQZP*0'3'K`I`=,>L"D!TQZP*0'3'K`I`=,>L"D!TQZP*0'3'I*YO2$
MDWJIIYA(WW[]\.YO;SZ'F?7R18^VZ_Q!Q%T\\-?6$LL9?4VJCN5MASX2KW^W
MJ$3&L/!C;]U;A-&]VYW(;1=FTU9NP>063&[!Y!9,;B/3;_"T-N063&Z[LF67
MW?HOW5V852?=8-(-)MU@T@TFW9'%+CO=X2S_!^B.*8%:=V+Y1DEWQXJ;TJ,[
MANF'!<)??-?OFG6Y49GN(NRVR717N3&9!I/IKFRJW>7*Y;V+L)KD'37).YB\
M=V7[^R[E7835+N6H2<K!I+PKV]]W#8`NPFK7`"AK<@,@'/C+`=`SK\LOG>YB
M@J`V'5GX]:+=[!Q[JY*?PK1X=&%]<[TO[-9E[#0"4MC=:8S<W5U=/_H_-Z<A
MD8)T_=]O4J.D:]+NF49)QXJBOAL:*E4WQG=75[<CUU>-G:=T0\.I:]*ZH>'4
ML8%N:$S5W7B\N=$W&/4JJD'VE&YHW'5-6C<T[CHVT`T-OJH;^DM7=W>WWHJ&
MXYE^N!$:$ASE"#T=?._"]W<O+GDBQ3Q)/7`C"S\:WPV/\0T^/;A+1<\-W"[,
M[IM&:63A5^P5+;BWY!JGJ6BXI)]>?CT-:65V:H$:IVA!XQ1,@[*W5;?,:5@^
MI54-2[2@80FF,=C;JENZ-0J?TJI&(5K0*`33D.MMU4U!C;DSK=9C[MYGSLZL
MBJ=XEQY+3+^3R(;#9)19X=FOE%,+T^\%LJ*S'C8W5C2QZ&%+8T5]30];&2OJ
M6_>PC;&BOFT/VQDKZMOWL(.QHKYC#VN-Q?J<L9!L^<]7B?M0C1<96?UXNT'2
M.A4-O^<FS^$>MZFV*LP_5Z0[A<7'FX;O>.PRJ]*?8LX\W7+';#1I1#RE%QHD
M*4P+=KXF_@E4"QOLB(92K$UWR#JBH?24CFAT/:4C&G`I;+`C&H/HB,;@4SJB
M8?F4CFBDGNF(&[PA%>4';\I>G!YQ?_K\^_<.7>7F[#ZFM*IG7&+%'-0R%./$
M"JT]0S6&Z7?]F"^-2S"-PZXZB],R!*9!A[(:86!:AE!68P=,8P=E-5#`-"I0
M5D,`3$,`9>4;3'++LLYD2%%YD_%;R7./D)C<JMU%YO8G;AV0SE2TFJ4].E-8
MGG[2&9E^:7,X3^CO4MS<7KECM?RF@M7NQ-<OY5TW;!A(.=J4\KK-J\?QM6]3
M8^`I;6I8H$T-"[2I85&W>7-W??_HSN(:)T]I4T,';6KHH$T-G;K-J_L'_3A1
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M(<FQK[]?H0\V.HL`1G\TH:SJ[NK.1*%1Q(&ONQ;M3>FDQAQ9(=,Q82#33AAG
M"@RI_]XP$*F$0;8<$P8B[8;A%QA27[UA(%$)`XF."0.)=L(X5V!(G9V+HU*H
ME4=+A5J!P5Y4\H[JPC*66$];I6T3L>JZH3KKH-I8L>W(L18WUX3!C2^?)`F1
M52-6"GY:UWTX?T>WSJY8JPNG0-((G+]E5!3ICBK5A>36.RJ:#+T5^0I-RJ@(
MT!U5J@O)K7=4)"BC(D$9%;VYHU:G-U)B=#LW:B4XW#J"&SJ+FW^=$@/6W=9G
MK"<9H:3@5EQMHR3!D$WN+NF!1"88&I&V:$0PMG32%O8%@WUI"_N"<4*4MO`J
M&+Q*6W@5#!++MA5C'&$=QKZO!KFT;FHB`]8]M]7[1+)$;,J?\R<:N(UNG63B
M;,>"6SRW\<5-J<-#?^SJ7!)-I[;H=OJ9!T6,B0*1Q"@Z&XEZXX-NQ@2"E"00
MI#0F$-0U)A`$-R80-"B!H,$Q@2#+,8&@U(%`*O%:Z;,^OWU/=2&64#OGN(!U
MTU#&^J4:W+K5!<'08>ZN2$."(3IIB\($0T[2%NT(AG:D+4(1#%5(6R0@&!*0
MMO`M&.26;;M,KNJR=)N&VJ]A#9Q"VI95YHE8M3^1ZD)T&[H03+V5^Y.$Q2*F
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MY3AL1Z_>-(T`@EN1ICD=R:`(H!IT,6'8ZOH128P9%)7(H*A$!D4EU:#KR6I5
M7^^CFS&#(B49%"G)H$BI&G3.EY7FU?(BKH%!*[U9J;'6VW=L75>A9-FI@T>L
M.*Q15_`#Z\\<P:VS=8U-"PPMY>Y2ED`X@B$<Z0_A"(9,I"V:$`Q-2%LT(1@*
MD+;0+1AT2UOH%@QRR[85DYS\.DP.Y7KSKW-]P.R=;/D\.EU4A2=(C$V'-A'1
MK;QKS2D#Q]YX69CM[28_UA^^A^48UE#&R&$E,4#\F!C00AR!*E.>.(\\=W]D
M01YC`D$Q$@B*&1,((AH3"+H:$PA2DT"0VIA`4-^80!#D0""51JV*5V:;(8V&
MJE\WJP2L^]C'HMHHH='LEL3`?D0PSEF"H3?!R"J"(2[!4))@R$8P-"(8&A$,
M00@&^X)!M6!0+1B\"@:))58QQC'78<SV(^,>^UA9TSK!!*SSV$?T*S"8$C^8
M$@RF!(,IP6!*,)@2#*8$@RG!8$HPF!(,I@2#*<%@2C"8$@RF2JQBRDI6[SFV
M8HFKLT6,V.FZA`-),.@1#'H$@Q[!H$<PZ!$,>@2#'L&@1S#H$0QZ!(,>P:!'
M,.@1#'H$@YX2J^BQHE-)3W$@O>-GL%6H774S8L1.E[6PEK'BA*:_>46WH<<^
M3FXIF<)M&(&F"8-;P>!6,+@5#&X#UGGLXX3US`*Z<W>%6WWA@0*R6XH8!0B&
M`@1#`8*A`,%00,"\)T'67FVQW&J/*_ZTW51I-6&E`DY8L2BJ@.C6\R3(R2,M
MVVUSZCQA=P76,^`NN9T&K+:7^\(C=7Z?L(XZ3D'T#'A(34\#5GN%8^&1!GQ,
M6#'@4X'U#/B<W$X#5C-\*3S2@*\)<Y5CI:$R=PQLF]:QO%2F]HA55__5=?)5
MD]SHX;01=E03BU6G$\5-;IJN_A<73?V@!L*)#3F/G>\?+>7^>]S04G9+ZXAZ
M(M83!G(:$\9#=L/[?+0H3,)`4\-A(+(Q8:"[W']/&.@NNZ750&G#82"]@3"Z
M9[*U5:_>H\90[>J<LMH^N`>$6D5>V&E]O84:8U/BRV[R0^IUX98FCAICC2W<
M#S?C[NYE)7;$&+OG&N9\]XAQ3!2(,;NE*!#C8!1H<4P4:#%WWQ,L6LQN*0JT
M.!@%4AP3!5+,W?=$@12S6XH"*0Y&@1('HJB4:*6N]R@QE,:Z2HSELK)(,5W(
M;W3KZ#:DQ.R6YHT2(Q82TGPVXTFZZA<,I!B=AO)B[K]G^9%B=DMA(,7A,-#B
MF##08NZ_)PRTF-U2&&AQ.`S$."8,Q)C[[PD#,6:W%`9B'`X#-0Z$4:G1:G/O
M46.HY775&&M^#)PSTG11J86\&)L.J3&[I8FCQH#%']06Z\EZ/:G4CAICPZ'$
MF/L_12OI&35FMQ0&:AP.`S6."0,UYOY[PD"-V2V%@1J'PT"-8\)`C;G_GC!0
M8W9+8:#&X3!0XT`8E1JM,/<>-89"7E>-`:OVC-4O#J@QN@VI,;NEB:/&B(7<
MN+Q8SR^J[A%C]!E*C;G[GN5'C-DM18$8!Z-`BV.B0(NY^YXHT&)V2U&@Q<$H
MD.*8*)!B[KXG"J28W5(42'$P"I0X$$6E1*LNOD>)H1K956+`JOUB]?@N2HQ-
MAY28W=*\46+`8EZ<S=;->EW]-HH48T/FG].S)#PVC+G_'C>DF-U2&$AQ.`RT
M."8,M)C[[PD#+6:W%`9:'`X#,8X)`S'F_GO"0(S9+86!&(?#0(T#851JM`IJ
MJ<;1=WBMK65=>`E8-T->R%TWL2D_EO<L`=<QL;?.577$0H;DIJ3E2J]CH@]_
M>F69N^]Q0Y;9+1&!+"-V/@I4&7WX<SX*5)F[[W%#E=DM18$J(W8^"D09??AS
M/@I$F;OO<4.4V2U%@2@C=CX*-!E]^.-&46G2RL:E)H?J.[',W*GO!*R;(>N;
MELB0N4+M!];><XP2LUN:-QDR8.E6K'4S6=<_#9,A8\.A#)G[[PD#*6:W%`92
M[(0QFRXO%DVU@46+8\)`B[G_GC#08G9+8:#%3AA3;S40XY@P$&/NOR<,Q)C=
M4AB(L1.&NQJH,8=!PTIZ5J\NI1=^EOCAPZ]_?_WV^:_=VQ^?6L1]'57Y9/0Z
M%KZY@,^*GUY4E<\M)]4VB?:_3_CDE":*(G/#A*%(P1"@8)R/!4-:@B$MP5"2
M8,A&,#0B&!H1#$D(!O^"0;9@D"T8W)98AUL>.JBX[4\KP;][@DM8]WW"-:U7
MA5MBY]K!;ASLUL'N'&SG8'L'NW>P!P<[.-C1P1X=[,G!GAWLQ<%>NUC%&!L$
M.1J_ZT-`O-*K/=#*773"NK=.7%0_AT!F:(I;0:9@D"D89`H&F8)!IF"0*1AD
M"@:9@D&F8)`I&&0*!IF"0:9@D"D89)981:;5,NO4.ENUKU5Z9W:=3F)=M#CC
M)ZQBL]H<PF9HVF53,-@4##8%@TW!8%,PV!0,-@6#3<%@4S#8%`PV!8--P6!3
M,-@4##9+K&+3:H$EFT/)--0.N\=?P"K&JKO,8"R[%<>?8#`F&(P)!F."P9A@
M,"88C`D&8X+!F&`P)AB,"09C@L&88#`F&(R56&#LIZ^_O[U]N_[X[>,O/__U
M]N73V]7;GW]^_?#KY[_MLZ+V8U>!?_CR]ML_?MAR8\UE>W<-*Y[;!-N&4^SE
MQ@92F^UG:,<YV+&1Z"_;;._:&K.U%WK5>%M4:+;V4%?;S&Q^+`N;`]^.T/$V
M?';@DHFT]P?4?9J-=F=L-C_>@*]];GF7.C9>*N_:F)^]G]NU,3][.;1K8W[V
M&F+7-C=;>[^)S&%U@8W[V+3=AO?T,??PQFYIAZW]F**VV_+%/FSL?%R;S<_M
MDZ&F-I['`WW:W/G"F-NGS3W<!B=Q+FSN?#7);;<PV\*WV;KP<1BOW=SZY&/:
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M$TB;N.%C>N7Y3&VT7<$*S]MY%CCA\2S/`B,\6^-9.'YY,,.S</1RA[QG867=
MT]7V`@OODW;:7+#BO&C8L[!PO//5L[!PO)G3L2Q9'=Z6Z5E8'5ZOIY8-BMVX
M-&Q-R[Z43<F^D*>L&^]MU7&V4]:-XI)G80W\]&09R$]`,^;CIIBM96P_85N^
M=M/UILU*[EJW.<EEKLU(+G-M/O)Z8[?&KM-C@4TG1Y#+J64B/Q%-60.WMXTE
M/7<81G$':2S=N<)I&,3M:].T6R*/4"PD.M=B*=`]X)IVX^*VL=.E)YQ-PVJZ
M+6C@X:9G#S==./AF?KGQ:-P2JBMQ`O7BW-K1[_2_1?>N@#CRO7&Y1W]]V=YH
MK0>1W3!]V=Z^K#8*K9-+*JL>OQ1-)_3IVBB`3BZI>'KM*&9.&,^U73=<)=WP
MCS/GG=GVOLV^6(#-393V:0#&<VVT6S*>FT;MQ?76I[?.]MIYYN?:[*7Q-I[7
M;LM#L"9P5P.-Y3G^<>9^O5I=[GF<0!DZ8'EQ+=?0>L,-Z-IF9V)P+0<L1]?R
M;")Q+4]<Q#RYUR+/6%[<JYOGQ0R+=^0\<VGSXO;V:A=+KF6W6%SNW2N>`Y:C
M:WG&\N):[AGGWAWG`<N#:SE@.;HS/3#3HSO3`S,]NKT]TMNC:[FRBU#W&O1Z
MT3`?-W?1V_9,;]/+*]=R39L;=W5NL=RZECLL=VYO.RQ[=W5VK,[>79T=J[-W
M>WOF0N?%O<YYYC+GQ;W*>>:B\<6]9GRURR;7LN-B<N]>2QZP'%W+,Y87U_+`
M.`_N.`<L1W<^!^9S=.=S8#Y'M[='>GMT+4]8GES+]8QCP;^JI,W6;7.%Y<JU
M7&.Y<=?@%LNM:[G#<N?VML.R=U=GQ^KLW=79L3I[M[=[>KL/EI_R!=C77W[^
M[\=/;\>/7S[]\9^O'_Y\^XW"X.1'>ZGAE_![9_C/M_A2Z']^_L9OH=0.?_CP
M^]O'?[U],6^<?_O\^5OZ#TGWI_]]_O+OMOCXR_\!``#__P,`4$L#!!0`!@`(
M````(0`#-FJ$L@(``,X&```9````>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM
M;)1576^;,!1]G[3_8/D].!"^$H54Z:INE39IFO;Q[!@#5C%&MM.T_W[7.*&D
M[:KL!3"<>^XY]]J7]=6C;-$#UT:HKL!A,,>(=TR5HJL+_.OG[2S'R%C:E;15
M'2_P$S?X:O/QP_J@]+UI.+<(&#I3X,;:?D6(80V7U`2JYQU\J926U,)2U\3T
MFM-R")(MB>;SE$@J.NP95OH2#E55@O$;Q?:2=]:3:-Y2"_I-(WIS8I/L$CI)
M]?V^GS$E>Z#8B5;8IX$4(\E6=W6G--VUX/LQC"D[<0^+5_12,*V,JFP`=,0+
M?>UY298$F#;K4H`#5W:D>57@;;BZSC#9K(?Z_!;\8";/R#3J\%F+\JOH.!0;
MVN0:L%/JWD'O2O<*@LFKZ-NA`=\U*GE%]ZW]H0Y?N*@;"]U.P)#SM2J?;KAA
M4%"@":+$,3'5@@"X(BG<SH""T,?A?A"E;0J\2(,DFR]"@*,=-_96.$J,V-Y8
M)?]X4'BD\B31D03N1Y(P">(HR?(+6(A7-!B\H99NUEH=$&P:R&EZZK9@N`)F
MYRP&35['Z/5?5L&C(]DZE@)G&$&X@?8\;.)\L28/4%-VQ%Q[#%Q'3#@B"*@9
M)8&,J:2WBWS*[,`NLRNZDW+M7TS31&^G6?Q/&@<N,'"/XN,\'GE]9H^))YAD
M1)P9!,C4X*GF[QMU0;!O)NQQ_LSO%7C,!0J@PU,%[V=VX)?>T]&9S^PQ^=#Z
M61(MXVP$G%E/SQ,[ZPLXCN\+<$'G`L+TF=\+\)C4"TBC=!$OWU8`F_1RZPY\
MGCG.7V;VF*/U-%M&R^?B>.]^KOAC)[FN^2?>M@8QM7<S(P3-X]MQG&VC82*-
M'V"<]+3FWZBN16=0RRL(G0<9%%[[@>075O7#H=XI"X-D>&S@O\'A:,P#`%=*
MV=/"C;SQ3[3Y"P``__\#`%!+`P04``8`"````"$`Q#",6MH$```N%P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6R4F%]OZC@0Q=]7VN\0Y;TD=@@0
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M/_)20+=AGM0,/$OYHM`?6_4ON#BPKGYJ9^#/RMN*7?IZ;/Z2Y]]%OC\T,-TQ
MC$@-;+[]>!1U!AV%,B,>JTJ9/((`^.D5N5H:T)'TO?U]SK?-8>E'DU$\#2,&
MN/<LZN8I5R5]+WNM&UG\AQ#3I;`(UT4B4*^_YR,^BUD\^;I*@(K:`3ZF3;I:
M5/+LP:J!>]:G5*U!-H?*:F03Z,_MD<&0U#7?U47MI4#7,!UOJ_$T601OT,),
M,VN;X938W"#B"Q*`OHM(&'I7I%N<@J'!OG<1Q^+H4K<=P!J9<8>YWKDE-BZ"
M:(,;]=>FX*4/M2_:^-20ALBL[>HTYCSD1F<W78+-)DG,DFL1H@T&V%^;@JDV
M6%F&.&0FK3@^"<=3-C'5$20!)(EGERI$'2S]_NH43-5%[%(6)Q41%#<.Q[,X
MI,#&`1!ADR'"%&P(&]/[KA%!85&43)4XBFRZR'C&QK,PO*Y((FXZ1)R"S;UP
M72O8-F1@VBYK\GIGW`LN@FA3>=<Q$_<^53!MW-C<IHA@XQXFTX0GQH+<$"+F
MR?@Z.J(LH<J4S45?VIRZR%`X,];4&AE7]UP$T<A`4/_VM;0YMV8#->22YT2H
M/B,KW-/+T-Z=7J<9G.#;9D<0M]LQY=F]EU]+T]FU_4Y#*/".X5'&Z7AL4%BT
M-%5H>9YF4.!-TW,1='J5<_=OGZ(-<:;O,610W!WC(XS;^=03UP"!Z/;0\8NO
ML?CJ#NA];<FE[]P?6.<V0ALX*#>8'1R6_VFF>V_+`=T,%6AD1S\79&C_W8T,
M\T3S:ZVAKE(S19P(U3DH1QAF`)UHRP@1<NIS(52?D29?&*$=(]9#'[-#PIYH
M)T,$\D%)TM)T*]M.J*%N`RV%;H8J')0EW,X2RPDUXQ:(=>XP5."@,.&*IBV,
M3#?4S)V;XY.6FZ$"!V4)5[3YM&"ZH8:Z"LU-[$2H/BC3WZVYHFD#+3?43%>>
MO02QSAV&"C3BI)\;JE=M4^C,>+-=:ZBKPFID[UCA@V*EI<V)-MU00TY]&$^W
M$=I'(U7<;LCM-+'<4#/=>]L3C77N,%3@H#CA&`/=N+OAAG96V`J=#%4X*%"X
M'2BV&SK#0IN-DR$"U;M2_\W<TG0S6VZHF3OSAP+=#!4X*$\BS`'ZR&"ZH8:Z
M"LU-[$2HOD%Q`F>9ELF8>U@S>%!T^^68(K?>CO'$$P\$3^E>_$RK?5[6WE'L
MX*DY'$W!I2H\[\0/C3RU!W_/LH%SRO;/`YQ+"S@5#$<`[Z1L/C^H$]7+2??J
M?P```/__`P!02P,$%``&``@````A`.MV/191`@``DP4``!D```!X;"]W;W)K
M<VAE971S+W-H965T,C0N>&ULC)1+C]HP%(7WE?H?+.\G3B`!!A%&`XAVI%:J
MJC[6QG&(11Q'MGG]^U[;0'EUR@;B^/CS.=?7&;WL9(TV7!NAFAPG48P1;Y@J
M1+/,\<\?\Z<!1L;2IJ"U:GB.]]S@E_''#Z.MTBM3<6X1$!J3X\K:=DB(8167
MU$2JY0W,E$I+:F&HE\2TFM/"+Y(UZ<1QCT@J&AP(0_T(0Y6E8'RFV%KRQ@:(
MYC6UX-]4HC5'FF2/X"35JW7[Q)1L`;$0M;![#\5(LN';LE&:+FK(O4M2RHYL
M/[C!2\&T,JJT$>!(,'J;^9D\$R"-1X6`!*[L2/,RQZ_)<)IB,A[Y^OP2?&O.
MGI&IU/:3%L47T7`H-AR3.X"%4BLG?2O<*UA,;E;/_0%\TZC@)5W7]KO:?N9B
M65DX[0P"N5S#8C_CAD%!`1-U,D=BJ@8#\(ND<)T!!:$[_[\5A:URW.U%63_N
M)B!'"V[L7#@D1FQMK)*_@R@YH`*D<X!TP?UAOA-U!EF2]?Y/(<&1#SBCEHY'
M6FT1-`WL:5KJ6C`9`MDE2_^9#"*Y-:]ND5\*:@.GL1FG_=Z(;*"$[*"9W&HZ
MEXKI'45VDA#P=S()T<]-WB_[T9P30X$Q.IE+DN3$]0$F09.>:?[N[!73]Q07
MWF"CQ[TY<8Z!??*6]OM7WH)FX,L:7\Y-[\]=^(%0C_MQXFL_@\L])T$3_*1Q
M.LBN3;TC",["O0IMU](E_TKU4C0&U;R$.L11'QI.AUL5!E:UOKT6RL)M\(\5
M?/PX]%X<@;A4RAX'[MZ>/J?C/P```/__`P!02P,$%``&``@````A`,%62E&,
M`@``J08``!D```!X;"]W;W)K<VAE971S+W-H965T,38N>&ULE%5;;YLP&'V?
MM/]@^;V86YH5A53)JFZ55FF:=GEVC`$K&"/;:=I_O\^8,-)F$WLQ^./XG.]J
M5K?/LD%/7!NAVAQ'08@1;YDJ1%OE^,?W^ZL/&!E+VX(VJN4Y?N$&WZ[?OUL=
ME=Z;FG.+@*$U.:ZM[3)"#*NYI"90'6_A2ZFTI!:VNB*FTYP6_2'9D#@,KXFD
MHL6>(=-S.%19"L;O%#M(WEI/HGE#+?AO:M&9$YMD<^@DU?M#=\64[(!B)QIA
M7WI2C"3+'JI6:;IK(.[G**7LQ-UOWM!+P;0RJK0!T!'OZ-N8;\@-`:;UJA`0
M@4L[TKS,\2;*MDM,UJL^/S\%/YK).S*U.G[2HO@B6@[)AC*Y`NR4VCOH0^%,
M<)B\.7W?%^"K1@4OZ:&QW]3Q,Q=5;:':"PC(Q945+W?<,$@HT`3QPC$QU8`#
ML"(I7&=`0NAS_SR*PM8YCI?!8ADF$<#1CAM[+QPE1NQ@K)*_/"@:J#Q)/)#`
M<R!)KN>2$.]0']\=M72]TNJ(H&=`TG34=6"4`?'E@"`2A]TX<(Z7&(&O!HKP
MM$Z3<$6>('-LP&P]!M81$XT(`J*C,JC-5W9@I^Q2ZUS9>L-4)KXLD_R/C`/G
M&-;1^33YX[Y7]IAT@EE<5@;(_``=&&H`84VD7^?6@V9(0U/-EW;@7GI,[F"!
M,9DX\Y?\7I]+N<F(%XM@"1S_;B9W\%QVL$R+FB;)Y>1"$TXC]`.9S)!U!\]E
M!\NY;/I*UE\-?G0DUQ7_R)O&(*8.;NQC&(;1.MY(F]CUZVM[FFWZ/B;C![@I
M.EKQ1ZHKT1K4\!(HPSX6[>\:O[&J`\_AOE`6[HC^M89?`H=Y"`/(=ZF4/6U`
MF(P_F?5O````__\#`%!+`P04``8`"````"$`(9Z'52T#``"\"@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6R<EEMOVC`8AN\G[3]$N6\.D`,@H&J(
MNE7:I&G:X=HD#K&:Q)'MEO;?[[,-%#M5"NM%(<GSO;S?P8Z7MR]MXSQCQ@GM
M5F[H!:Z#NX*6I-NMW-^_[F]FKL,%ZDK4T`ZOW%?,W=OUYT_+/66/O,98.*#0
M\95;"]$O?)\7-6X1]VB/.WA24=8B`9=LY_.>852JH+;Q)T&0^"TBG:L5%NP2
M#5I5I,`Y+9Y:W`DMPG"#!/CG->GY4:TM+I%K$7M\ZF\*VO8@L24-$:]*U'7:
M8O&PZRA#VP;R?@DC5!RUU<5`OB4%HYQ6P@,Y7QL=YCSWYSXHK9<E@0QDV1V&
MJY5[%R[R,'#]]5(5Z`_!>W[VW>$UW7]AI/Q&.@S5AC[)#FPI?93H0REO0;`_
MB+Y7'?C!G!)7Z*D1/^G^*R:[6D"[8\A()K8H7W/,"Z@HR'B36"H5M`$#\-]I
MB1P-J`AZ49][4HIZY4X3+TZ#:0BXL\5<W!,IZ3K%$Q>T_:NA\""E128'$?@\
MB(2Q%TWB=':-RO2@$IU4)JD71D'RL1-?9Z6*E".!UDM&]PY,'OCF/9)S'"Y`
M5U9G"C5^OSI0%AES)X-4*-`<6OJ\CI+ITG^&-A0')ALRH4ELAD24Q":3'QG9
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M:F;,_8=$KHF9[N#;]F08AQ/`?]1?1=DI6".0':"Q'`[(7%F<Q=Z;2;6'RO.)
M+-7[$CH/??[0K]8>[?!WQ':DXTZ#*UB8@9?"ZF?Z]*$O!.W5NVA+!9P:U-<:
M3HD8]O7``[BB5!POY-OO=.Y<_P,``/__`P!02P,$%``&``@````A`)%"S\`4
M!P``Q!T``!D```!X;"]W;W)K<VAE971S+W-H965T,C$N>&ULK%G;CJ-&$'V/
ME']`O*^Y^R;;JS&FDY42*8HVR3.#L8W&&`N8F=V_3Q5]H2\$,ZN\[*P/58<Z
M7=75!6P^?RNOUEM>-T5UV]K>S+6M_)95Q^)VWMI_?26?EK;5M.GMF%ZK6[ZU
MO^>-_7GW\T^;]ZI^:2YYWEK`<&NV]J5M[VO':;)+7J;-K+KG-[ARJNHR;>%G
M?7::>YVGQ\ZIO#J^Z\Z=,BUN-F58UU,XJM.IR/)#E;V6^:VE)'5^35N(O[D4
M]X:SE=D4NC*M7U[OG[*JO`/%<W$MVN\=J6V5V?K+^5;5Z?,5='_SPC3CW-T/
M@[XLLKIJJE,[`SJ'!FIJ7CDK!YAVFV,!"G#9K3H_;>TG;TW\E>WL-MT"_5WD
M[XWT?ZNY5.^_U,7QM^*6PVI#GC`#SU7U@J9?C@B!LV-XDRX#?]36,3^EK]?V
MS^K]U[PX7UI(=P2*4-CZ^/V0-QFL*-#,_`B9LNH*`<"_5EE@:<"*I-^ZO^_%
ML;UL[6`^BQ9NX(&Y]9PW+2F0TK:RUZ:MRG^HD<>H*(G/2.#O`,F(8\`<0^$8
MSD(_6BR[NX\X0FQ=V/"7W=%W9\LH"N?+!6`CGG/F"7^99SA;>.XJ&/9SZ'IU
MRW](VW2WJ:MW"VH:5J2YI[A#O#5P\76G=Q:9^*]$0`:0Y`E9MO;"MF"-&ZB>
MMUT8+3;.&V0\8S9[T\93+6)N@>E%VH,.)#I`),`!14(6I/!_D(4L*(L'M.=`
MK]/7-'`+[G+0@40'B`0H&J"J=`T!;*SA+<$S@4Y0_%(F@E"+<4]M0NB=(EV1
M)D.8"!T&DA@(D1%%"FP,70KN[@]6&;)`G<)ZB;C#:*E&OJ=&H^*$B1!G((F!
M$!E1Q($06=QX?M"XT\#OO:=(")D5JH)0VSRQ,.)N!P-)#(3(B!(R['0Y9+KK
M9]@ZQJ-'/S5ZBD2!V".Q@1P,)#$0(B-*J-!4Y%#'XT-C-3Z&T$:/324VD(.!
M)`9"9$2)#R<0J8&.QX?&:GP4\=7L:S4=4Z,`FITH$2]8J85_8$R*412J1@DS
MFG<]VG/G[B)<:42$V8#BP;LIZE>J>JF0VDN1O>PKH("(!E8E@!#HX8$<ZJ)0
M)(!V(B((0BW,F+E!M,+(7!1FU*<_H8@/NUFX!9&K+A-A;K`?A)$7]0$H2^!!
M[J970&>MJF40':^Z)8E[2`K`R#BS@D.!=X7$A$C/!59JY'AZ3JY=#ZVUR"FD
M5&\HK1,30ZT>E"^C]Z54<8A7J[L(5OHB$&XTJ5SQ[)`5_U"]=B3:0M`S_$'%
M<L?QDN56\D)0>JUHM6.=<,=I58MG]?3<TY,=[L`K;>]12*E:`8U6+;52JM:`
MB$*O5BT>Q%+D/Y9#>IHK@BBD%',0!6IGB#UJ]:B8&1=4OM1`]&;,N'Q:WRMH
MQO-`:_V$VTPK;SSP1Y;F:W6'NAULQ_"8Q/LQ3F;Z1J>0DFP!21+UW7E@7$%?
M.(D)$091>C79.!<8BCX\.7ITO,`=(O(1SK6NOV=6H[-C;\-WPL&$$A,B"J1J
MQ-E"T^A',UC?#\[''A)IC8E"ZG2I3P4Q<P2K7I1PY%!B6A$%4D7A%*&)\J()
M(Z9'QP]E9U)('C*9E00=3"@Q(:)`:L1XZ$L1#\PL\B9A(T)?V'N/07WCCDWH
M8$*)"1$%4L+$_C0]S,Y:+0D&:7U.?P!D5@_Z'.?J)2<F1!1(%8.CP>0UA]E`
MKV\&^7XWT/JNI_78F/N,G[G<:KQ?\YOAZ/JV\WQ_%>I;B7`FV+VBT\ACJ2I?
M&T?&2PY$&O+98(#-^VT'\HTT4H-':60T<AH9Q&:O:+D*/:U?$A:0#ZUB@E8\
MXZ>GFDX$<A?P*=2G>JX=S<P`=_A@./2=$K>2M3)FEM>EN_2\?MCOW`AWFY97
M//ZG:Z7#@J*5S0\BK_K[`!P%H=4_RBNCD;4RB.;5=\.5O]!F',+()^85YX#I
M6M%:ZT<4ZO.JC4`QOL%%GP=Y95:R5L9,\^H'7N3Z6M$03@ZF@T6C[M?!::0[
MU*8_[L*X9RP!A;!/BB""2`LU9HZ/<LZXY'5@$,WYW)L;W(1Q3TPYS@;34TXG
M":6\*22/DWAG2#)`_1+(?9-M7FHE/SLP1PDB/1?,+FH"<9*0(O^A9P<?2;0:
M9E#_JCCF5@^JECD^.'BH%?0@;//##PK\?M,*^4.S#B9%%TPA)8,"&LT@M9+2
ME3!Z"<)/3:P:1`;IIR/Z[:+,ZW,>Y]=K8V75*WX6@NK:;03,OUG-UT\T0NT*
M3/IK',B!W+BR@"M=&HTK2[BR'/"!;V-/W1AH>(##@/W>AV]I0WBPAC?H9DQ/
MX?H)GI#,"_MP#6^E!_!H#:]^!W!0W8EV1*3P#>V>GO/?T_I<W!KKFI]@,=VN
MH]7T*QS]T;(GQ^>JA:]GL-[PJ0B^EN;P0M7%)Y535;7\!]S8$=]?=_\"``#_
M_P,`4$L#!!0`!@`(````(0";J][:H2@``-+I```9````>&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;*R=VY+;QK*F[R=BWD&A^]WBN4F&[1UJ$B#.I]@S<]V6
MVI;"DMJA;B^O]?:3150BJ_('"Z3"^V++Z^.?68G*1)T`LG_Z[W]__?+F7T_?
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MZ</S%PJ`_O^;KY]-;5"7//[[Y[<+:OCSQ]=//[]=;N[6][/EG.1O?GUZ>8T_
M&Y=OWWSXZ^7U^>O_ZT5SZZIWLK1.Z%_K9'&W7:]7F^T].0D8KJPA_3O2>L"0
MW)[#IG^MX7PI80<,-]:0_K6&JZOL[JT=_7O;)=*==HZ4_N5+#';)SNKIW]NN
M;$ZU<V[)_,=-US;G(C#_<=O5S:EN^D:=`@I>WYR+Q?S'C5?(Y3*7>KDN>^:.
MZ,.4@KFR1.=<,>8_;+P4>:#$YEPKYC_X"E=WJ\7Z?GN^JT*V7"XT9K!M\!+?
M]??S>7@X/KX^_O+3]^>_W]"@2ZE\^?/1#.'SO7'&`T/?^#!47!HI:(@P7MX;
M-S^_I0NA0>"%QK=__;):WO_T[E\T)'VPF@?4S'W%@15F_#%NCQI$&L0:G#1(
M-$@UR#3(-2@T*#6H-*@U:#1H->@<\([2,^2([IE_(D?&C<D1]^X#`TG:0B6$
M%6QRU"#2(-;@I$&B0:I!ID&N0:%!J4&E0:U!HT&K0><`+R%T8_\3"3%NZ+ZC
M5IR[9NNGX*$7K>C6'$1K7W(8)$.:@$1`8B`G(`F0%$@&)`=2`"F!5$!J(`V0
M%DCG$B]K-!MX61M?^_"(9M3GY'"G/O1D1=/FD(GY4J7K,(C8[`@D`A(#.0%)
M@*1`,B`YD`)(":0"4@-I@+1`.I=XN:#YU<M%/^W<F75@."W&T$]+3];+85P[
M`#D"B8#$0$Y`$B`ID`Q(#J0`4@*I@-1`&B`MD,XE7@YHH>+E(-SQ1NUWO"7]
M&M],UP<@1R`1D!C("4@")`62`<F!%$!*(!60&D@#I`72N<3K>%HF>1WO%/_K
MI\\?_GAXI@&&%@,C"5G2VJI?<1DG?CXL.>\BSYK#0-P1:^?/'L=>M*1;58:U
MU<P718.(A[48R`E(`B0%D@')@11`2B`5D!I(`Z0%TO6DWXM[6:,9V,O:2'9H
M+\SI,6H_/3U9]KOK\^TR$*?GESH]5D1A.>E1"^=H$`WIL42*X00D&:Q<UVH)
MF`XB=IV!HWP@CB-](<7@R!&MU%*F'$3<6C7X9E(/Q'&D6VL&1XYHI78D[2!B
MWYTEYR1YV:=]]@W9-VH_^SUQLP_D:,EFF,DB(#%8G8`D@Y5[[4O_CDX'$5][
M!HYR(,5@Y;K>^*[+0<2N*W!4`VD&*]>U6EZU@XA==ZXC+V/F?,-+V0\-LV<O
M?BHM<G.)Z,C(R2:BF)&,"B=$"2-_C%[YW9Z*BCLG8R3N<T0%H]50>"6BBI'X
MJA$UC/Q0U:#6BHI#[1CAK6>.F_Z!1/:[:]IM<9,/9\>46QDD#X*<*M2#R]&J
M:,YD7Q&BF)%TV$G<LV'"*JIC&>#7:OY-1<6&&?K*!3F^=/2%^')4:S6EE*+B
M%BMQSZ@6Y/C2+3;BRU&MU4S3BHK=TYEX/Y">,^3?W69O[AY<A:=CL\E6([)%
M"V\_MU;#Y(%5%(BD1U_@450<>H0H1G1"E"!*$66(<D&!4`M1<:@EH@I1+2C@
MOA$5NV\1=1[R\VJV[S?DM=_MDS]N[L$<&%.J%^ZQRD+-_`<K,O452JOU[JG6
M:MR-N$&S-O_7+_?KQ6*V4`->S.W19NQR>R=6R98J$>08ZA#2*T+(V%,PA)Q5
MWB7K>B]&53JJDJ/RYH*U6O)5[$N&R9I1,(AF5*6#:*\*HF-?([,/17]+01JY
M6B_TR#PHD]ROU:+I8!Y6F+(-7O-15%SO$:/-N?P6F]GJ?KZ!^K/>O6V$3NN)
M7;GU-X3%#::L"C68L2C88,ZJX$47HN(82D:T7G?Z%$IKN&HVK-DPV&(C*C9L
M&05;[%AU/F7W!S9S#N,.;#^V'#5>5'GUR!OOEFHV/Y@G6\8N>-E'4?%E1Q8M
M^L%M-5MM]=HD9BMJ0G*!M35$P+X3-I1R2Z>;R]@JV%S.JN`%%Z+BH$J.@$I'
MK@8'+7LU[J`U7*!CJ+NAP1;;JUKLV'!DA#('36YE32R%[+F4.V7V:+$;9M&#
M>8QIAB-O6:JOYFA5R_/+!^<SIPA1++ZXET^($C1,$65HF`L*='R!ODI$E?CB
M4&M!`?<-^FH1=>*+W/O#@SEW<I/X8\.#\:*&AQYYR]RE6L(<S"-HLEL&[Y:C
M5?E3E)YP(U;UT\-RN;LWHX:_5XU91.W*7:;+ZR1A<382-O0BU3&DK`K%D+$H
M&$,N,00B+=A7,*R25<$YI&*5/*FMKPJB8<-@$"VK@D%TK!J9R,@P6*G_\_PG
ME>#H\;5S0&I>-M"EVB-O&!I0H/>/UM=2AK0(46R1X_Z$*$'#%%&&AKF@0*@%
M^BH15>*+"[\6%'#?H*\642>^8!@RQVGN,#0QE_2G;][VJT=+VCK)G;V&_9<U
MI/2*2M__Q[E5R0(A0A0C.C&2DYV$D?A*$66(<D;!4`M6B?L2486H9A1TW[!*
MW+>(.@]YTXL9_KV\_M#T<O;B3R\6>9N;E3Y$L:*)Z85=!8>OB%5>?ZWU_,(J
M;VQ?JUW12>+BVRQAPV`0*:O\(-3V(V.5#.2YM!BH^X(-@T&4K`H&4;%*@JBO
M"J)APV`0+:O\(%0Z.E9=2H=?J]1BL%:OFV#,,D5-,!8Y,\!!4"`A1ZMR)QA$
ML?CB<CHA2M`P192A82XH$&J!ODI$E?CB4&M!`?<-^FH1=>)+3S!FF^HE-SS!
MG.5JQ+%'N3(4'JR*7LWAJSDBBA#%B$Z($D0IH@Q1CJA`5"*J$-6(&D0MHLY#
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M^QI1P\AWK]9!K:C8?<=H)(GF",Z]JW]L>#9>U`S:(R^W@(X+B]S<`HI9);US
M0I0PHL'"R:TZA4I%Q;V3,1+W.:*"D3R/+Q%5C,17C:AAY(>J=@ZMJ#C4CM%(
M(NG._@<2:;RH1%HD0\YA,2"GIV%C;57N"PR(8D;282=QS]>=L(KVZI);_9`@
M%14;9N@K%^3XTM$7XLM1P0L,HN(6*W'/J!;D^-(M-N++4<$+#*)B]YVX)^0O
MOFC'Y!7%Q)QMY"K[/3)[*Z?C8>]M5=XV3E_@<3&H./0(48SHA"A!E"+*$.6"
MG`O2H1:BXE!+1!6B6E#`?2,J=M\BZCSDY]6<6;FC]D1>[1&7._7VR*S;A[S"
M"PSFP8RIAXFTCJGT:7ED?='ZTKS`,-]N=NOY3JT_8FZ0%@%#5'.=G!.K9'.6
M"'(,=0SI-3%D["H80\ZJ8-<4HRH=5LEA>;,!/`UD7S)0UHR"032C*AU$>U40
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M8<-@#"FK0C%D+`K&D$L,SD7KKBG85S"LDE7!.:1BE3MK]3T?SD_#AL$@6E8%
M@^A8-3*1T<@8G,BN>\)DCJEUJ?;(&X8&%.C]H_5%=Q?7280HMLAQ?T*4H&&*
M*$/#7%`@U`)]E8@J\<475`L*N&_05XNH$U\P#-&LZB4WO`&C4S!(8H],_3B#
MA-H0'=C0*T)]5QU9)0N$"%&,Z,1(SG821N(K190ARAD%0RU8)>Y+1!6BFE'0
M?<,J<=\BZCSD3R_F\-'=6/_8ZK,_PG2??=#IM:D`;W.CSYT/5A0>OH[L*CA\
M1:SR^FNCGIG$K/+&=GB%0>+BVRQAPV`0*:N\(/3V(V.5#.2YM.C<';KN"S8,
M!E&R*AA$Q2H)HKXJB(8-@T&TK/*"T.GH6'4I'7ZMDBI8JU=.,,:-VBKUR)D!
M#LL!!1)RM"IO@ND-'12++RZG$Z($?:6(,C3,!05"+=!7B:@27QQJ+2C@OD%?
M+:).?,$$0X4RDES^L:>K?S-I:?R<LRO1KO2-]&!5X1^`Z3V1AKOB*&:,(D0Q
MHA.B!%&**$.4(RH0E8@J1#6B!E&+J/.0?Y>:TU$]HRS6=S3]W_CS5TM[SBJK
MMP>+_)^+V:A-Q$%4G*8CH@A1C.B$*$&4(LH0Y8@*1"6B"E&-J$'4(NH\Y&7.
M]"ID;KZ^XO=CSI;^D&J1^PLRB(Z((D0QHA.B!%&**$.4(RH0E8@J1#6B!E&+
MJ/.0GQ:::+VTA)?>*R-7N;!(%HD'5@DZ(HH0Q1[RX[SMN&F%QTT6>4<2\XUZ
MF^#`*F_]H4?XXZ@*SB18%5REQ*RBF=W9NLC3:[\;S)8<QK^-^070-]?_$,VJ
MW]B[*VJ+_`W41F^@V'"B=ZQ[27]D#<WK+W*1&_6N1<SNS<7PCQ+.G?6SWQ5F
MD^YVQ43E]GMZ[YJ';3Z/Y(?5@)P(,/V]RCV`M(8.BL47N?=#-[M5-_0?VA>M
MC!=U+_9(U;C44O\;0]9P8F-D51/G;JSR:AP>!+'JNAJ?VC5>MQ)?X;;1(G<E
M+BB8\-Z7L^R.K*&#8O$%"3?+=DSXS8N65;_\IR*6:%?ZEY\>K"JX_A0-U_X1
M480H1G1"E"!*$66(<D0%HA)1A:A&U"!J$74>\N]<LVQW$SDQZ/2K?&_0Z9&9
MD8<Q;J7?OCR8W-&]32I)#Z`(53&B$Z($48HH0Y0C*A"5B"I$-:(&48NH\Y"?
MGK'MP76+3-P.K'KD+3(!'5$5(8H1G1`EB%)$&:(<48&H1%0AJA$UB%I$G8>\
MM*SUVC]\UYSE_L3&2)84!T1'#_D1F$7J]??MVJYIG<VA1?[4NE,G@`>KFIA:
MV9>WC-K)*])^Z+>M?->X\K7(7]OM]%MG;$C#S#`PP=M"1U9=%[I>K4[D'9>E
M=/.9<5#UNGH+]6!54[UN??FAR_;>[W6SQ+NA8/H5H3O0K^TBD5J5_MSI_895
MF:]WB@H6G*SR0Y?5N1^Z7EU.]#HN(]=CR\B=6JT?K&JJUZTO/W19DOJACR_]
M;EXGK8>UG_3J:B4WV'D=_&!59CH9^E[*H5\KBV:8B!%%B&)$)T0)HA11ABA'
M5"`J$56(:D0-HA91YR$_D7K!.U&#P[J6>_EAW2-OG;2`WVX6%1L>$46(8D0G
M1`FB%%&&*$=4("H158AJ1`VB%E'G(3\]9BWICF[.!G0B4\92S<T]<M=):T!'
M1!&B&-$)48(H190ARA$5B$I$%:(:48.H1=1YR$^+7KY.Y`+7K&N+W'42H".J
M(D0QHA.B!%&**$.4(RH0E8@J1#6B!E&+J/.0EXN-7K,ZM\CU)VUG+_[MPDB>
M_!P$R42$2R^K,J]1#-/5_%X6`?V/^8B*1\08T0E1@BA%E%G4?Z/QW&*.J!!#
M-U2U@"A%Q:%6B&I$#:(646?1R)<O-[08N33\W9!;XT7EUB(WMP-RN@(6>.>(
MZ%MYN_X7X69SM3J/1,!]%5ODI.*$*!%#\TV!Q6RN5D&I"-ASAFYR1(486L\J
MYE($[+E"-S6B1@S'8VY%P)X[SXU_)]^V@=K@!LHB;Q>RT#D\L(H2+O>G5AU'
M5?#H@%7]JX2;S6RYVZK$Q:RAA=+E]DZLDADA$>08ZA!25MD7[C?T.N5<;;PR
MU@1#R%DE(12"`B&4K+(A[.B<;"4[A_/H4[$F&$+-*@FA$10(H655'\)\MMIL
MUCH3'8LNQ>"7H]F&ZK77XM9'.)M^,^MN."WRMOD+?3A\8,.)*K7NI;\B:^@]
MPEGH@\N8W=.N3XK2>81S3MJ)5>(^092.MZAN@XP-@RWFK)(6"T3E>(MJ7*O8
M,-ABS2IIL4'4CK>H[K..#2^UZ!?8;4<7&SRZL,A]3B+(R2L.;O;,0XZM(VOH
M/A@37SQZGQ`E:)@BRM`P1U2@88FH0L,:48.&+:+.,_330TG\!^Y_XT4M/GKD
MSU+ZSS4<-KUJXM3&JB8>_K'*#HZ;W6*ASK=BEEP:&NUX,`3%%9&PH3=.X21E
MKYGVF\YPHPYQ,O85#"*W*NH9#J)@PV`0):N"052L"@918Q`-&P:#:%D5#*)C
MU:4@_$H=/XT[O[)S7B9?]R!V,QS&<;\^6.0-,+V*D)-)'&!ZE?/4-;*^'!2C
M^Q.B!`U31!D:YH@*-"P156A8(VK0L$74>89^VBBY.,"<WY$+GR=LC*$:4WJD
MUA3J)C^PH5=[F#OK7NZOR!KRUYCGV]5ZIC:T,3NG.UUN<>W\Q"K9>26,I+U4
MM3?;+9:ZO8S-@NWEK)+V"D;27JG:6VV6]_H8O6*S8'LUJZ2]AI&TUZKV9O1G
M2?4$T+'9I?;\6J*4>K4T44%&KBJH1^;-KB%]"_UG?0Z;7C4U*UE?M$,;?,WU
MG!!97_0RD=D]SN[FJYGW?^J97<QZ[UP%"VR(D$>QA`V#X:2L\IX#P5O[K`H&
MD5N5-T5=TR<ENP\&4;$J&$2-031L&.R)EE7!(#I670K"KT]SN.ENIB;JTYZ%
M.L]U-SWR1SB=_8-533RF8Y5;ZR/UV;=H![T+>WL;Z*6;U"Z;K$H&A>2J$%*K
MLB'0'R`8V]M?$T+.[4D(!:-@+Y0JA/&]_34AU-R>A-`P"H;0^B%<VMM/Q."5
MX_W8H;%Y)_KZ4\6S"W\(M4@M[-5IZL&J)H90]B631L2(!I)A5%WH<Y:8532)
M#RKWW<R^(B6(891D0VDQ9>2WJ#?VK`JVF&.+!1M*BR4COT6]L6=5L,4:6VS8
M4%IL&?DMZHT]JRZUZ%<7E?,-@]V]D:M*ZI&[[K:JB76W53F[^`A1++XX^R=$
M"1JFB#(TS!$5:%@BJM"P1M2@88NH\PS]])B#8W<N,D^,;C[8NS=>5-9ZY$]1
M>EUW8$.WX/`A$JN"(V-D53P_S.AYA#IWC=E1>(9BE8S-":-@!"E'X*T"8-7$
MOH)!Y*R2(`I&P2#*JX*HV%<PB)I5$D3#*!A$>U40'?NZ%(1?J>9T5U>J?4WR
MAHW]O7&C2K5'W@`S(&?BT.5TM+Z<77R$*+;(<7]"E*!ABBA#PQQ1@88EH@H-
M:T0-&K:(.L_03QO=#)"V_LMOX67OO3%4B>J16E/HC;TUG%I36%\R^T76D'Y@
MT>S!YJ,;>]9X<Y\NC).$P'-*PH;27LJ('].,;>Q9$VPOQ_8*-I3V2D:VO=&-
M/6N"[=787L.&TE[+B*]O;&//FDOM^;5$`P74DCL$7/<7K8T755@]\B<K_=N2
M!_-7XXWAQ&1E5=(1D364F6F]I3^>IOY4#7LG<UFK8F4-,4AE08.I;G`UG\WG
MZHPJNZK!G%4R!12,Y`I+:)#.Q/17VRNV"UYAS2IIL&$D#;:ZP>5R=3]32^..
M[2XUZ!>7/CB>&)[P@/A^.`WFW!P$!9)ZM"IOH6K/C.6A5"R^V/T)48*^4D09
M&N:("C0L$55H6"-JT+!%U'F&?GIHA(![__:%JO&B[OT>^9.*_I77PWVOFII4
MK"\IU,@:VDEE,5^L%KM[M0V.643FH7M_B($+(&%#:3!EU(^ZB_EZ1DVJ+5S&
MHF"#N56Y)W=L*`V6C+C!W6R[U0_/*Q8%&ZRQP88-I<&6$3>XFB^V^B]_=2RZ
MU*!?7#2D0W&Y$\MU#XWNC1M573UR%G\'JYK:O/:&WMH24"R^N"1.B!*+'%\I
MH@P-<T0%&I:(*C2L$35HV"+J/$,_;>:8R]T23`S9]E3,.4B][Y'YJN=PXRWT
M#RX?K&IJXK?NW2_)X4$JM]@7[^QN!NL`&]*EPK5G5K8QF243CC+8?BKMRQ7/
M<8]Z31`YMRA!%(R"0917!5&Q*M@3-;<H032,@D&T[)YFVB'WT!,=JRX%X17D
MEEKT"K)___;FKX*<_9P'$@EMI7\KZL&J@E\%$0T/$$=$$:(8T0E1@BA%E"'*
M$16(2D05HAI1@ZA%U'G(3R0=;WB)#(\L6R/W!WZ+O*^"K%9J'CZ(2M+3^W*^
M11NA*D9T0I0@2A%EB')$!:(2486H1M0@:A%U'O+3,W9J>=579K=X4FF1^U40
M1$=$$:(8T0E1@BA%E"'*$16(2D05HAI1@ZA%U'G(3XL^HINX:_`H;FN1K/8.
MB(Z((D0QHA.B!%&**$.4(RH0E8@J1#6B!E&+J/.0GXNQ<S=W27O56<D6#^$8
MR7Q[$"33%1R^'ZUJXJL@HN(1,49T0I0@2A%E%CG?/\@%!:(OQ)>CTANY4E0<
M?86H1M0@:A%U%O71^^DVAT#N4OB'OOFS-5[4/&:1F^X!.5VA3ZJ.UM?E;X>(
M@/LJYO:EL9.@0&.)^!K_\D4J`FXL$\^,<D&!Q@KQ91M3YTZE"-AS)9X9U8("
MC37B:_S*6A&PYTX\$_++Q!PKN64R,4+WIU#N"_O;'JGC$EC76)7WE`A+9%!Q
MZ!&[Y[W]>C/77^"(67-I2=[OD%@5#"$1%8>0,@J$D+$F&$+.JF`(A:@XA))1
M((2*-<$0:E8%0VA$Q2&TC`(A=*RY%()?>J2ZI?2,7`U%/5*G].J]Z</6&@:O
M^"@JON+((GM*OZ3WPN]56<=L10.@;!EU69]8%8P@$15'D$Y'D+%5,(*<5<$(
M"E%Q!.5T!!5;!2.H616,H!$51]!.1]"QU:4(_+(SAV8WC'C]&9LWXO5(C7CZ
MJ>/6JH(7?!057W#$J+_15LLE?6]./:J)64.E':J[:T)(V)<LL5-&@1`RU@1#
MR%D5[(5"5-P+):-`"!5K@B'4K`J&T(B*0V@9!4+H6',I!+_TS"':#:5GC_2<
MX\EMC]2(IZKC8%43?Z-+5'S%D45VQ%OO9KO=3-5US&:7;C8[V=K8@YV>L"^W
M]'K#4`@9FP5#R%D5#*$0%?=":5$HA(K-@B'4K`J&T(B*0VBO"*%CLTLA>*6W
MTP>1X77>6>Y/MA:I44\]N#JP*GC%1U'Q%4>,^IOM?K-;P0]KLN32O=97'JN"
M$22BX@A21I<CR%@2C"!G53""0E0<0<GH<@052X(1U*P*1M"(BB-H&5V.H&/)
MI0C\LJ,(;ACQ=D:NRJY':L13[_$=V#!XP4=1\05'%O$:;[F;[_3/H<5L=NE&
MLW5G8P^&D+`O9\2[(H2,S8(AY*P*AE"(BGNAO"*$BLV"(=2L"H;0B(I#:*\(
MH6.S2R'XI3=V)'S->V8[/!&VR!_[])^'/[`J>.U'4?&U1XSZNVZ^I6\\Z8T&
M2R[==;8&^]#]+[SJ[4C"OMP:M(:7(\C8*AA!SJI@'Q2BXCXH&5V.H&)),(*:
M5<$(&E%Q!"VCRQ%T++D4@5^`MQU^[_#PVR)_[--O41W8,'C!1U'Q!4<6V;%O
ML9O/=OI)=\QFEVXY6W?#*7U@.Y*P+[?N>D,>?A?WF_5<+3@S-@N&D+,JV`N%
MJ+@72HM"O5"Q63"$FE7!$!I1<0BM'\)RK!<Z-KL4@E]Z8V?]]#;9FXE5GWT%
MUME4KO0;^@^[7A1\R"P:OL8CH@A1C.B$*$&4(LH0Y8@*1"6B"E&-J$'4(NH\
MY*>-DNNMEG[P;8&=\7->1LGMN%JI^^K!JL*)[#V11A()*!)/K(H1G1`EB%)$
M&:(<48&H1%0AJA$UB%I$G8?\1)IS[.LW^KO^V-L]8[+(>UM@?J]2>!`5=_P1
M480H1G1"E"!*$66(<D0%HA)1A:A&U"!J$74>\M-#\[>7'N?9V,0(:2S5!J5'
M[ML".T!'1!&B&-$)48(H190ARA$5B$I$%:(:48.H1=1YR$^+.:Z\X:[I3S>]
MN\8B66$<=H".B")$,:(3H@11BBA#E",J$)6(*D0UH@91BZCSD)\+<PSGYL*Y
M1:[_&O#.G@(Z)YB,9$8Y")+I"M\6L*J)MP5$Q2-BC.B$*$&4(LHL<M\60%2(
MH7-!\&J`J#C4"E&-J$'4(NHL&GDU8#[3AX$_E-S>C3\8#LQ)K\.<[M"[TB/+
M+K\?X"BXQV)F3D9.(RQA)M[5%[531\'>,V:.]WR$%<S$NWX#P%&P]XJ9X[T>
M80TS\:YB;QT%>^^8C18`;5&\NSL\Z]&7A6#:8^:=B<SO]<'<(`MNBBCY?0MT
M<L$7$`UL>_[ZW?W\3G4J)=]:T7PKC\&V,_^+5%0/X)SJ`1A5@&5]@_/5G>IG
MJH=K&J02`>=4(L#*@?4-KK=WZCB=2N2:!JEJP#E5#3"J$\OL%2[NU(J2JF:B
M06^6F,_T(=M4(>'96N^#?C66C@*<)*JWX`\LFWBHY<B<0K*G6RO[/<X[]8H`
M%9*-B_8V3@Q82%8F54J%!(P*R6]PK;N9"NF:!JF0P#D5$C`J)-V@N@^ID*YI
MD`H)G%,A`:-"\AN\U[<*%=)$@ZJ0S$&0N]Z8*B1[XN2L+.8S>YA$LYN31'4/
M4R%9&16ZR$:FHT'F%))E]O:9W:ENID*RBJD1"9Q3(0&C0O(:5/5(571-:U1%
MX)FJ"!A5D=?:?'FG'BQ3%5W3(%41.*<J`D95Y#6H+H]*:*(U54+ZT&NJA/J#
M+'?_0+^><Y[HU%BDYATJ(6LZ54*#S"FAGM$/T)K7]U8C0Y$UFAJ*P#=5$#"J
M(*^]>YU2JJ%KVJ,:`M]40\"HAE1[JN^HA*YICTH(?%,)`:,24NVI!R=41!/M
MJ2(RIUNWC$/]:9A?1#WS5T;ZB0X5D95-%=$@<XK(LGX<FNGIA88A*Y@:AL`W
M%1$P*B*OO:4N6BJB:]JC(@+?5$3`J(B\]F"50D5T37M41.";B@@8%9'7WD8/
MZU1$$^VI(KKM^&\^P_,_9FHD4@L7*B)K.E5$@\PIHI[9D6AL+K-&=.TR48ZL
MKL$W%1$P*B*O/?V%8*JA:YJC&@+75$/`J(:\YN;Z'J$:NJ8]JB'P334$C&K(
M:V]-?Q/:WX90$4TTJ(K('"+>,A(9O=Z-]XS^4ANGG2H&&.V^@-'N"Q@-*\!H
M<P6,T@^,T@^,4@Z,\@N,\@N,\@N,4@J,\@>,\@>,\@>,,N8RE1Y]6&G.4*8?
ML<UG_7DD+8Z'>VJE?TCT@57!9S..B+-+F>S=.P]L*)/`*)/`*)/`*)/`*)/`
M*)/`*)/`*)/`*)/`*)/`*)/`*)/`*)/`*),N4YD</^J\^3NZ]/B<[T`WMVJ'
M3;GM91.Y'41.;H%1;H%1;H%1;H%1;H%1;H%1;H%1;H%1;H%1;H%1;H%1;H%1
M;H%1;H%1;EWFYW:N3SHG]@1GO1I$+?,?Q6U56@]SD4G&D$4CNGB$G498,L+2
M$9:-L'R$%2.L'&'5"*M'6#/"VA'6^4QEC%8RWK3GG$U/)<^8ZN3US'TZ-S='
M2*1SV'&$4:9`1YD"1ID"1ID"1ID"1ID"1ID"1ID"1ID"1ID"1ID"1ID"UHXP
MRI2K4YDR!SPW+%!HCX3IL<Q=H+!.&*4'=)0>8)0>8)0>8)0>8)0>8)0>EZG+
M-X<3P^73..,4ZO5/R.;S_HR#&N)AXV%@[D,4UM$\-BP<\"$9F_I/R;9J*4I]
MU[=*,FZ5^LY&(JU2WP&COAMLG4BVZN2:NG.0<1/4G:X[U9UFF^YVY]3-;K?U
M7K_9LX")`\"YE5%I![MRD/$%4+]99@_LY_K8DWK1*FCE*,YQT\0R*7+J6&B0
M>G%HT'$'O\XRR+Q6G3--U==F-WM+7_>[7[]&>Z;VI^JTAV9%:SK5UX/,Z>N>
MV?WI`DX!J*^M%?T3[&MP3GT-C/JZ9WPTM[Y39TE4O]:*_AEM4'6SV>_=TLUV
M?^B5M-U5^B4-#T?F5C;5S8/,Z6;+[)GV_$XYIVZV"J^X1DH:G%,W`Z-N]AM4
M`P=U\D1SJI/-%NV63C9ZO4CHF:IE.&N96].I3AYD3B?WS);6'+O8VEPJK/XU
M6_K)QCYX;]0`1EWL-;?8ZF&*.GFB0=7)9O=T2R?WNRU_P.C9U*DH/:XV^0F_
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M3Q;TR7D:T-V]I`B68Q$\+"FW](;(B+<51=#_>I3R]GYUOW^_'LT#?=*M1OM@
M11'TQTO*V\.*(EB-14"WZW)_7G1B='1S+?=T-XWUW?OY_OUH+YAR'+M2ZK8Q
M_?OE_OUR]&*6U&=CCJBHQVKZ@>IVK+O>4UK>K\:*Z;C;[<V+9'CA]);8WKRW
MA9^85Z&HN^@M+?R,3FUFU%VCG]$)S&Q/1RYC=G2:,MNWXY_1#_'LS4_C8&OT
M(S=[\[,S^`G]FLL^HI\5P4_HIU?(V]@G]#LI>_-3*&A#/VI"[8Q]<MS0Y=+?
M0$8;^O/,>_,'D_&3XV:^-W]J&#^AOR-,WL8^H;\#O#=_ZA=MZ._X4CMCG]2+
MU;ZFWW$=L:%/6IKLQSZA*UV,76FSV-`G8]XZ\M:-?I(L[O?I8JRR"_JD'/VD
MH4_:T4\R:B<;;2>G3_+13PKZI!R]TF)!V1Z]TH*NM!SU5I&W:O23P\+<VV,W
M]W&QI.L9O8O)V\,%;ZO]8?23(]E$H[T3TR?QZ"<G^N0TZBVA3]+1WDFH=]+1
MWDFH=])1;\V6;I*QFC(#R1BG*9UN^9%/NO/Z8>0#&HW-8#SR"1U!T=@R]@D=
M)E$S8Y_DVSV=%(\YV])`,,9W^W+L2FAD,P/;B$6UW=.!\L@']79/I\HC'QRI
M_,?NF(?MGA9((P:'[9Z>FHU\<-R:26WD@WB[I^7FR`>G[9Z.XD<^2+8T9HYQ
M,WN,<>H0F@5&/LFV>SJQ-Q^\&^;GEU]^^O/Q]Z?R\?OOG[^]O/GR]!LM+6?G
MOX#Y_?/OYMRJ_Q^OSW_2DO/MFU^?7U^?OY[_\]/3X\>G[T9`6Y/?GI]?^7^8
M!OY^_O['>?GZR_\7````__\#`%!+`P04``8`"````"$`.@N*R%4'```R'@``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6RL6=MNXS80?2_0?S#TOK9U
MEXS8B[6M*UJ@*+;MLV(KL1#;,B0EV?W[#D6.)'(L.RGZ4F].SYPA#V=(2GKX
M^N-TG+SE55V4YZ6F3^?:)#_ORGUQ?EYJ?WT/OWC:I&ZR\SX[EN=\J?W,:^WK
MZM=?'M[+ZJ4^Y'DS`85SO=0.37-9S&;U[I"?LGI:7O(S_)^GLCIE#?Q9/<_J
M2Y5G^S;H=)P9\[DS.V7%6>,*B^HC&N734['+M^7N]92?&RY2Y<>L@?'7A^)2
MH]II]Q&Y4U:]O%Z^[,K3!20>BV/1_&Q%M<EIMTB>SV65/1YAWC]T*]NA=OL'
MD3\5NZJLRZ=F"G(S/E`Z9W_FST!I];`O8`;,]DF5/RVU;_HB->;:;/70&O1W
MD;_7@W]/ZD/Y'E7%_K?BG(/;L$YL!1[+\H51DSV#('A&HL-V!?ZH)OO\*7L]
M-G^6[W%>/!\:6&X;9L0FMMC_W.;U#AP%F:EA,Z5=>80!P'\GIX*5!CB2_5AJ
M!B0N]LUAJ9G.U';GI@[TR6->-V'!)+7)[K5NRM,_G*0+*2YB"A'X%2+ZU+-M
MR_'<CXM80@1^A8C1#^1&<LC0S@!^,;DQR'XCTA&1\(L9/SQEZ)\V*_QB[-0R
M;-=K?;N1U!>!\-L/U_!LW7:8XS<B=2B.-B?[!R:]-^`97^^V?+99DZT>JO)]
M`CT)*UI?,M;A^H()8N'P`72E-%9)4$),Y1N366JN-H$BJ:'\WU:6Y3W,WJ!D
M=X*SIAQ=9FR0P>J3R6Y5(%"!4`4B%8A5(%&!=`#,P);.&VB&_\,;)L.\P5FM
M$>C-,A0CD($A6Q4(5"!4@4@%8A5(5"`=`)(1T-#$"!.*Y?KN@C7!HF`?&=2$
MX3CR1-><8T'[=(5CRY1-1^G,($A`D)`@$4%B@B0$28>(Y`GL3\03MN-^LG&8
M#/0>.-\98%F^;,&:DVZZU%$ZEP@2$"0D2$20F"`)0=(A(KD$AD@NW:X8QF[-
MP$FL.6)!K77V&(ZRL6PZ$H9M"1(0)"1(1)"8(`E!TB$BS1W.$VGN?&N=LK/P
MM@TL4+:!([;9[2$;@FP)$A`D)$A$D)@@"4'2(2+-&4X`:<ZW)\K8\D0%PN\5
M[`C8$&1+D(`@(4$B@L0$20B2#A%IHNSB3,_-=G&;0[%[69=0L'"P7#'`A/.1
MGYI,1)Z_0+Q^H3ND[P#=5#:(+2>9T(9=F^B>*^\B04?"-@D[;40B@L1=U%!:
MZ<"D(Z%0.A22C(,+CV3<%8/@`H0.,;;L$$?@+CT8CZ]>)`0)_._](*9=(]F6
M8IH@.>V=QM!=PS:5`RH4%"B5\611EPP=BCMD$*:F3^3T\[GISI4C-+V37C*?
MW?`^X7Y+E^T7D`GG8C];WY1=VV#@[07H66A*(""#]<C;2C<-<^XIBQMB&.RC
M_1#4U8V0U6\E,862#^1+,6PLG^PPNTP.-X;;]:TSNN(PAY0*5^IR(P*-.PX+
MK=Z$``-Y1=N^[]AS>?5"I-RN:&3UVC&%$H3&TZ5(&4LG^\ONJ)_PEU]IX7Z%
M);9F=RVP7*I@PU%VU(U@L;&-%]FV9Z%\(""LX+DS-VU?V2]#C!LKJ?9XB)`U
M=%C,IX<2.:'G6J[K*RN:HM)8/MEB=N?]A,7\B@PIT(.USB&IA`U7&=0&67<L
M%EK]C`,,%#6EFXXB'2)CK*2$OT0ZQL`^6X+0:+84&6/99'?977GH[N!:^/&;
M@\YOW)+I')+J6E<K;X.!=TP7\KT-@0@4=6UYONFJ*QJB^%B9"=N)>(R!?;Y$
MS>?I].C#L+%\LO'`DHR_LS,SNK(S<\CPNTK?L"<^8`%T<YO@+'ADQA8)1.``
M"GLM9$44BFE@0J%4"I1M8'?W8?W=L8%?]:5"XQ![3=5MC8:KG-(;G;/,.X4F
MM/J%#T2@P?M-]QW+]'WE^`N1--9RHM*Z,:"C,0;V"1.$1$+7F;N&>J-)D326
M4/886)+'K,<-A[UZG7RBQYF*4H$<DGK<<-6W1[H(A#MXMT#TF0%9O1.!@`QH
MT"[0<)7+78B!P_77;>4`C9#5/\K$"/49D^L9E=5.,7`LHVP^>_3X1(&+)Y7A
M\<4AJ<\[J'?FBJ6<-6CJ0"=0**"!?$2AF`8F%$JE0-D&]EPPM.&_G3/\Z4)J
M?_'`,5P,DY0@)]WK?B$E[1'J,U"@"Q;O3\MR?,]3\H7(@<KO*I>L3R18,*I^
M/_C($!*4YT,P#0?N6.IS&'+&AB"M#KL:W5R=[^4%6O_J^X/!XW$K(V\1`AI4
MUZ:';IBS%2RS;X2`0F&OA19&%(II8$(A]D%,')Z@Q>WA'[CX%XI37CWGF_QX
MK">[\I5]O((GL=5#!_,O:UMO`6\V0$#!8V\!KR4H#E_BOK535/AK^$+7UH6*
M&_#E[HK.VES`R^$K^A;HMP>]*F0MX#TI#5C;"WB'>`5W%O">#?!9)P1?["[9
M<_Y[5CT7YWIRS)_`E'G[TJGBW_SX'XTHGL>R@6]U;1T=X-ML#N_3YE/HVZ>R
M;/`/EJ#[VKOZ%P``__\#`%!+`P04``8`"````"$`J\7/%RD%```2$P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RL6%V/JS80?:_4_X!XO^&;$)3D
M:D-">Z56JJK;]IDE3H(6<`3L9O??=P8;L$TN8=6^;#8GX\.<.?;8>/WUO<BU
M-U+5&2TWNK4P=8V4*3UFY7FC__4]_A+H6MTDY3'):4DV^@>I]:_;GW]:WVCU
M4E\(:31@*.N-?FF::V@8=7HA15(OZ)64\,N)5D72P-?J;-37BB3'=E"1&[9I
M^D:19*7.&,)J#@<]G;*4[&GZ6I"R8205R9,&\J\OV;7NV(IT#EV15"^OUR\I
M+:Y`\9SE6?/1DNI:D8;?SB6MDN<<=+];;I)VW.V7$7V1I16MZ:E9`)W!$AUK
M7ADK`YBVZV,&"K#L6D5.&_W)"F-KJ1O;=5N@OS-RJX7_M?I";[]4V?&WK"10
M;?`)'7BF]`5#OQT1@L'&:'3<.O!'I1W)*7G-FS_I[5>2G2\-V.V!(A06'C_V
MI$ZAHD"SL#UD2FD."<!?K<AP:D!%DO?V\Y8=F\M&=_R%MS0="\*U9U(W<8:4
MNI:^U@TM_F%!%J=B)#8G@<\[)!,#'3[0'08N[,"S/!^?/C$0?FW3AD_^1,M;
M!)[G^L%R>J3/1\)GE^OD(PU6L+;^^Z1)MNN*WC28U%"2^IK@$K%"(.L*SY+N
MK?B1$V`!DCPART9?ZAH4N8;I\[9U?6MMO('E*8_9C6.4B*B+0'^1=J\"!Q6(
M!<``1;TL\/!_D(4L**M+:-<!@TY;5AEU$=V0O0H<5"`6`$D#3"M5@P,KZ_Z:
MZ)S`03#[12>LI9SCCL6XT#Q[NSPY).I#>ATCY#!"8A&1I,#*4*7@\O[D+$,6
MF*=0KSYOUU<,V+&@27%]2"]NA!Q&2"PBDC@0HHJSO<7GY2%/*Z]+:\<0%TP?
M!-OJJNF#NF'[$7(8(;&(2&J@":AJH"EA.YJ>>#A.SIXAGM,OGVB$[$?(883$
M(B*E"OU&3'4Z/PR6\^,(VP2PWT0C9#]"#B,D%A$I/SR="+UU.C\,EO-CB"VZ
M[WCJ0F5!#O3!?HI8SDI>S7O.-"@]C)!81"05J\^HP&!9!4-LN]T5;--RY=PB
M/@(>/R&`!TDJ/87IP)_DM$]R7-_T3:40,>>!R7SW89)N"PH_W[XV6E;.(3@#
MX(8(TE7O>,`#\SH:P;T.\IE49^4O`U.N:]S%P.R<H17WT=E3U6*[+C3BKN7L
M.#38[,OI1-V8:9^[*%$K>YC-;74"SU%;8-P-F^<K[K?SM;+=6=+*H,%797^-
M<(>"5?#(5TXC:N40]]4-_"!0VGW,R>UYON*./%\KV[\EK0P:?`U47_F8![[R
M*%$K9^:^FHYG6HY,'EM\V#Q?<8,6M+*C;+MS-9<L?=E16`<PF>ZT8<R!'V39
M+B^5@$%*'Q[-;Q;UR'/.)=:!0\QS>&/PW-%2YB'S+(=BB66X([>=N5PO1BMM
MBT'VJE_=$9[5(`J@^[V$G]99%)Q1N[9PX`,%*!ZX($INN+C1_V<#V6E!,I!#
MPSD^LCCT8-;R*)@T0PL=;3N<BS<H:^FL8)-3]J:X>R"4:*`2]FFY$'BBF"C$
M=WK]T4P6K446Q5H&2=;VT/W$N+4LRADZ_@&N`]HF-T!X0\"G26\M>^-G;YP%
MJ<XD(GE>:RE]Q;?Y`-9=C_8W#4\MI8+O\`8")Y:*VR&\0-W!G1!>1\;XDQL^
ML9L,E<@-X8@_'K#S0C@LW\']$$ZF@!L]$=Q(7),S^3VISEE9:SDY@4:S[4`5
MN]-@7QKNWS-MX"ZBM?("=T\$CJ`FOC><*&VZ+_B`_C9K^R\```#__P,`4$L#
M!!0`!@`(````(0#)?]!E0A```!=2```9````>&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;*R<VW+;.!*&[[=JW\'E^[%%4;(E59*M2#R?=*@]7"NVDJC&MER6
M,IEY^VT0:#:!GZ;L[,[%R/GXH]%``R#0I/3A'W\^/ES\L7LY[@]/'R^]J\'E
MQ>[I[G"_?_KV\?)?_XQ^FUQ>'$_;I_OMP^%I]_'RK]WQ\A^?_OZW#S\/+[\?
MO^]VIPNR\'3\>/G]='J>75\?[[[O'K?'J\/S[HFN?#V\/&Y/],^7;]?'YY?=
M]KXN]/AP/1P,;JX?M_NG2VUA]O(6&X>O7_=WN^!P]^-Q]W321EYV#]L3^7_\
MOG\^LK7'N[>8>]R^_/[C^;>[P^,SF?BR?]B?_JJ-7EX\WLW2;T^'E^V7!VKW
MG]YH>\>VZW^`^<?]W<OA>/AZNB)SU]I1;//T>GI-ECY]N-]3"U2W7[SLOGZ\
M_.S--J/QY?6G#W4'_7N_^WEL_7UQ_'[X&;_L[XO]TXYZF^*D(O#E</A=2=-[
MA:CP-92.Z@BL7B[N=U^W/QY.F\//9+?_]OU$X1Y3BU3#9O=_!;OC'?4HF;D:
MUF[<'1[(`?K_Q>->#0WJD>V?]>?/_?WI^\=+_^9J?#OP/9)??-D=3]%>F;R\
MN/MQ/!T>_Z-%GG*J,3(T1NBSPTA/0=\4I$]3<'@UG(R]\8VJO:?@R!2D3U/0
M&XG;/07);-U>^N2"@S<5O#$%Z=,4G%QYH\$Y1V]-,?I\7PMI@M:.TF=3<#(>
MCVXFM_U=,S4%Z?-]+?1H\.FQ0-%NZGQ3.#P>`>H/4Y1BVA,'CT.O_F`_O;?T
MJ,>Q]R04;QPU'D=#_6$JG;QMP'D<#_7'FSKG6L^T>N(&V]/VTX>7P\\+6@VI
M=X_/6[6V>C-EC:>L[JUF$K\VAVG>*2N?E9F/E]00FIY'6GC^^#0:#SY<_T&+
MQ9W1S%'CV8H%*]1T5F8#%X0NB%P0NR!Q0>J"S`6Y"PH7E"ZH7+!TP<H%:Q=L
M6N":PM/$B(;Q_R-&RHR*$??NG($$;>@$A!5<)'!!Z(+(!;$+$A>D+LA<D+N@
M<$'I@LH%2Q>L7+!VP:8%K(#0*@$!\6G!ZK[/\1Q1I>B.UIHCPZEO=_A<:T8T
M$9N)-+8EBT;2!`5(""0"$@-)@*1`,B`YD`)(":0"L@2R`K(&LFD3*T:T,$.,
MU%[DG0N;,D-K(XV$)B"CL;-NS;6H-VJ-I(D:D!!(!"0&D@!)@61`<B`%D!)(
M!60)9`5D#633)E;4*$!6U/IGE%+7P>%.G6LRHKG8A&LXG3HSJ!%QL0!(""0"
M$@-)@*1`,B`YD`)(":0"L@2R`K(&LFD3*Q:TH[%BH;<&5VK'UQ\65=`.BR9C
MO[GW+(`$0$(@$9`82`(D!9(!R8$40$H@%9`ED!60-9!-FU@QH!V5%8/^CE=J
MN^,-T2<DM:5:``F`A$`B(#&0!$@*)`.2`RF`E$`J($L@*R!K()LVL3J>[L#O
MZ'BEMCM>$U^?<NN.;X@L39[O+$V!$=%X:-:OT=C9E86-B->O"$@,)`&2`LD,
M$:_SAHA#X'71&!+1:#RR5]VR$;'7%9`ED!60-9"-(;775A#IU&D%L;6"G;[O
M[WZ?'ZB7:=?=,:M\.L3HHXTR8L=6DW9L@02&T(VN%4AGMQ<V(NZ2"$@,)`&2
M`LD,:0422-&4ZG&Q;$3L8@5D"60%9`UD8PA&31W]__>PU5;LN#&:R&U(D'0"
MC._`J/QI?;(=#CPWD"+@;HK$,J-84$]EB=A2QVBJS)G^J0C8<B:6&>6">BHK
MQ):IS&E9*0*V7(EE1DM!/96MQ%9WR]8B8,L;L4S(FMR>.BZW4Q<=LY@2=SR-
M:[DS'O2!>]C>+=XZ*_+"E!N2MIG)'2/$F+)4[A(8LJV;>AQYGC>93.Q5,F()
MW9A>KRYFE56=>S-).E6N4RFKV*G;J7O#R5C2ZU3.JEZGBDZ5ZU3)*NW4<#(:
M3IQ#5\627J>6K.IU:M6I<IU:LTH[Y8_]R?C&#M^&):\Y98]@E5]HC^!?NC^I
MLZES@S+(I\-Q,X@F3CINP>5Z>R80%4_)T*"AND72`C4:C&`0&Y?HI-#4#W,F
M%M,]JD14[$!J.S#U;D:W=A@R+M3K0,ZJWAXH1,4.E+8#WF`Z='NWXE*]'BQ9
MU>O!2E3LP=KV8'@[FHZ<^&ZXU&L>V$-1Y5':0_',8JK3+E0%>S17J7,:AL-I
M@Q:">@(<&!7ES]A6B"@26ZR*!?683]!6BB@36VP^%]1COD!;):)*;+'YI:`>
M\RNTM4:T$5MDWHZKRK2TX_IK2XS.UUCAULBZ=_H#9PPNU.,1&A1^[_@.C,J^
MQ;JK;\@J<Y_RQU/?67TCEKRV^M8;^OA-3B5LRW+==2IEE;E/#:9C-]N4L:37
MJ?Q-3A5LJ]>IDE7F/C7UQS=P\S3AZW5J^2:G5EQ=KU-K5FFG;H:3VZD3O@U+
M7G/*'MFTKO6.['\>GE\[W+6WA<J,LRW4R%K)&M0S60.57E:C75;%$%%D4,M\
M+*C'?(*V4D29V.*E)A?48[Y`6R6B2FRQ^:6@'O,KM+5&M!%;L)*I'!FN9.].
MZ*L'M3K@XNUH[#QDF1M5;TI?--P5`:(0480H1I0@2A%EB')$!:(2485HB6B%
M:(UH8R%[XM+TM@)Y9JNAY,X$U<C*\OL#YYB\4(_5J2"I)#R`0E1%B&)$":(4
M488H1U0@*A%5B):(5HC6B#86LL.CLFDXS]Z0]E>O#[B1TJB=^#>J%@H0A8@B
M1#&B!%&**$.4(RH0E8@J1$M$*T1K1!L+V6%1Z;)V6,[,&IU=LW9L!K6>!7B`
M`D0AHLA"EI]J0VCY^4L;SMJ*/>D9M9)W@F0IAV-F8%0^[7CD,'KK'%E#4?%J
M$5G(;B1M=?X/C516G$8:U&YD@UKNNZF>0.V=E:U7,Y0L$,L1HZ:,K*!V:]TT
M1?_0&V(^PB#5H4T(_(&3:ERPBIK2J#K"J<V/56;OCT_.@2,4&Q+&5PK8;7S?
M^9=R'Q`ZC:R<BS]P'H(LN."9-FI;X_9C('_@[%%"L25M-05O=>=<M=Y4L)NK
MMO]O7TV&^K307DT,<D+J[.@7K#K37&U^3#>+)O#^P,GIA&)+FFL*ZA%,+^Q-
MPM]>&\1J;_Z.%NNMO-5BL[NG+FYYZ:PC"SI:U"/C3(NUR@FPDWH.Q9:T^$Q!
M.\KNEOG,Q&UVQES=?*B1'67/F70+5IUIL[9E1]ES#J:AV&(G(H-N!CIK?B7S
MP&ZMVMR](\)Z+VA%6"-["KN/7Q9#4_!,:[7JQJN='E\-*#'0_J\]4.NT1"AV
MI>6.D?%MNYC=^NYMV[N/1\-F$R>C?.2FN>=&U7L\$@VW)T`4(HH0Q8@21"FB
M#%&.J$!4(JH0+1&M$*T1;2QD!_)]&SU*(\"=2"/[>#2$2=NH)#R`0F.^=8B*
M$,6($D0IH@Q1CJA`5"*J$"T1K1"M$6TL9(5'O>9IK3*M_6W_\EJ7M+=[!K7.
M0@M$`:(0480H1I0@2A%EB')$!:(2485HB6B%:(UH8R$[++0:6V$Y$PLE=V)A
M4.MXI-+62B4H0!0BBA#%B!)$*:(,48ZH0%0BJBQD]]_[]OB4XH3^TZC]5HQ1
M$9)["6[H647;`]E7#=U]@:AXN8H8R4LN,:*$D6W>.7NDHF+S&2,QGPL25Z%!
M!:MZ:RQ%Q356C/"5&+4ED>%-N]XSPUL?`]I[F]H"Y::E-0M$`2/;==E2ZYV*
MJ-CUB)&8CQ$EC&SSSADI%16;SQB)^1Q1P<@V[YQ)2E&Q^8I11\>K$T:SJ3S?
M\?I`8G6\1E;'`PI4=H*6&O^F25:&B")&T@TQHH21W0VR:ZZ#F(J*NR%C).9S
M1`4CV[QS6BM%Q>8K1AV]K$XU[5YNW53?_J*>6F?<15TCJ_,!!:8@^<>^AH@B
M1M([,:*$D=A*$66,Q%:.J&!$8Z.U,CHGSE)4['W%J*.G*6I63Y]92)3<N4]J
M9!\)A\[1=4$#616T'^E"UDI4['K(R#R['(ZFMVYF/V(-G8Z:?H%E.&:5W+T3
M1"FCB<F83)W5*&-!;V4YJVC'\+I+A:BXO24C7?_ME7-CJOCZ:]7;=W%U7FS/
MHS/157(GNAJI-%K3#M]WSPZ^*=C;VD!4W-K0(//J$'U[U)LX#8ZX%$W3QH..
MX#8>L.V$"TJ\4ZYN5`?7O_*<89IQF=[*<E;U-K<0%;M4VO4[2V3%!5ZKW`ZM
M=;ZG%>%,:)MC/#LS]S522:6F8WW?V6<M6-7;UD!4;#YD1+6TS#M;AXA5%+Y&
MY8V=L,2LDE`FB%)&/'5OG5M<Q@*K,G<1REG5V^)"5-SB$E%E(3M^ZFS=GIJ_
M=HO3)W1K?Z&1,V.=6;6@5Y?KJ=[;R$!4W,C0()5\;0+F^\XB&7'!]MCJ"&OC
M!)M/N*!$.I4:58*?DKKT!:[V?\ZK?FS!JAJ#W%0MS8!5I6!;XDV)J+*0%625
M<K&"W#]):[F]_AI$^0?NHH6@'M<#HZ(3,A<,$45BBU4QH@0+IH@R+)@+ZG&U
M0%LEHDILD:MV+],@MGKYEZ;22%EQ.E\C>VOC.ZO*PA149^EF1L!0"HR*-D#<
MTR$C\Z[8Y/9VX#X#BUC3NV3%X@(;3[B@U)<RTNNCU\J;UR>`C*_WUI5+73W-
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M])3<B9Y&SN;.R0`LZ">=ZH*]8S%@E;0F-,@<QZ;>Y,9]@SOB4E1%,W&AIV)6
MM6>6<4JJ2[DZ?1P;7HV<;63&9GHKRUG5V]R"55)_B:BRD`Z>_G4K_2,YC[N7
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M@JXL.J\$="7L;`\]9Z`K7>VA1#A=Z6H/96GI2I?7]"!HIK*SZ'4QF:V[)D4Q
MG:V[IL2&9E$7IR\`ST+Z)BK60-_6G:DOY.(5^FKM3'U[%J_0]V!GZJNN>&4^
MF<V[ZE],9HLN'DQF]"5^M!-,9_2=<.399$;?#$>>3V9YS:^;F4T_R_>\_;8K
MMR_?]D_'BX?=5UK\!O5;P"_ZA_WT/T[F6Q9?#B?Z03ZZ>]'6G'Z`<4<_-4$_
M97=Y\?5P./$_J.)K]8."]:^0??JO`````/__`P!02P,$%``&``@````A`)AQ
MGW,Q`0``0`(``!$`"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````````````````)R104O#,!B&[X+_H>3>IFEA2F@S
M4-G)@>!$\1:3;VVP24,2[?;OS;JN3O3D,;QOGCS?EVJYTUWR"<ZKWM2(9#E*
MP(A>*M/4Z&FS2J]1X@,WDG>]@1KMP:,EN[RHA*6B=_#@>@LN*/!))!E/A:U1
M&X*E&'O1@N8^BPT3PVWO-`_QZ!ILN7CG#>`BSQ=80^"2!XX/P-3.1#0AI9B1
M]L-U(T`*#!UH,,%CDA'\W0W@M/_SPIB<-;4*>QMGFG3/V5(<P[F]\VHN#L.0
M#>6H$?T)?EG?/XZCILH<=B4`L<-^.N[#.JYRJT#>[-GNS76)]VV%?V>5%*,=
M%0YX`)G$]^C1[I0\E[=WFQ5B14[*E)"4%)N"4+*@Y.JUPJ?6=)_-0#T)_)MX
M`K#1^^>?LR\```#__P,`4$L#!!0`!@`(````(0`[+NUU70,```,,```0``@!
M9&]C4')O<',O87!P+GAM;""B!`$HH``!````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````)Q6WV_:,!!^G[3_`>5]#6U9UU4A%:54K=2N:&';HV6<`ZPZ
M=FH[#/K7[Y+0%-8CFWA!P;[O[KN?ONARE:G.$JR31O>#XZ-NT`$M3"KUO!_\
MF-Q\.@\ZSG.=<F4T](,UN.`R_O@A&EN3@_427`=5:-</%M[G%V'HQ`(R[H[P
M6N/-S-B,>_QKYZ&9S:2`:R.*#+0/3[K=LQ!6'G0*Z:>\41C4&B^6_E"EJ1$E
M/_=SLLZ1<!P-\EQ)P3UZ&3](88TS,]\9K02H*-R^C)!=`J*PTJ_C;A1N_XT2
MP14,47$\X\I!%+X=1+?`RZ"-N;0NCI;^8@G"&]MQ\@7#=A)TIMQ!2:<?++F5
M7'ND58K5?ZIOE3MOXU_&/KD%@'=1B`+U8?6Y+;O]+7MQ[TLE@5^[DJ6&F@E>
M['*<2*_`/<[&W'J"<N_+-N>*1<VX)O2:18:UP4;:8[S8G:ZS+<TV\\:'H='.
M*)ER#RF[XHIK`2QYY^G_R+,Q_[>)Q*.ELM(<,S/VF&/"&MUEZ&M'=ECM0H9\
M)P4-Y!$;9BGA=^7[%7>R,C"VX-`832PILHS;=4DDD7,ML1&P!-A`"%-H3Q+;
M=-BZCO!S(?/2%U(T\48\+8Q*L9'9"$4Q&=>`-N0>^06WD")S3,28KZL8D8KO
M`678:"4]NY=\*A5J)@6'1BD^-;9JL8KQ/;:Z1O!@;O<%/LNDK_-3%A$FPF,'
MX?C!H4(:P8BDA?#L06+A>IQ'#?G2(@D99;DR:P!V!1H#XMD8RXZ43(JI@^<"
M0\Q&2_RE*;3G\7B/YK;<GY`8.OELPJ?H.HE(B)RVR5.I;9,?FI9T,9+2HYUS
M+5_>:N(;]X6%MFYLC^\I::8=TSL`\_D`S-D!F'IH;R9\,U[:_3D_P,Y7$O,=
MA,%)AC.@&L)T\>XIQ`1?^;3`Q[-A_391]T`&:2KQ`28A+0.,#>C.)NM]8T/O
M&<)4BVP\`;J$22L-A`Y9.X;N=[(;V[TA(<,%QQ'JF"3#3$)NBJHIQY:$M`]V
M.@#MH^(0#!VT]O>`MD,^"%AC56W^Y\O0B'/%[K:CMK-M_;5?W4O]Y'[D$W.-
M6\GK`KE[&-65@ZO5Z_W;072+NZ-5I9(ZQ^FKS/N+<MW]6>_T\7'OJ'O:Q4UV
MZRP*-RV*#VW\!P``__\#`%!+`0(M`!0`!@`(````(0";/64!!P(``"8=```3
M``````````````````````!;0V]N=&5N=%]4>7!E<UTN>&UL4$L!`BT`%``&
M``@````A`+55,"/U````3`(```L`````````````````0`0``%]R96QS+RYR
M96QS4$L!`BT`%``&``@````A`%4]->@L`@``7QP``!H`````````````````
M9@<``'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!`BT`%``&``@````A
M`(_F.N`U!```S@X```\`````````````````T@H``'AL+W=O<FMB;V]K+GAM
M;%!+`0(M`!0`!@`(````(0!SGU)R,`4``(X2```8`````````````````#0/
M``!X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"+0`4``8`"````"$`2"TI
MW90#``!;#```&0````````````````":%```>&PO=V]R:W-H965T<R]S:&5E
M=#,V+GAM;%!+`0(M`!0`!@`(````(0#8QTG5#P0``%\/```9````````````
M`````&48``!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L!`BT`%``&``@`
M```A`*S^D8(=!```D@\``!D`````````````````JQP``'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"+0`4``8`"````"$`/?S0+>,#```\#P``&0``
M``````````````#_(```>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M
M`!0`!@`(````(0"C/G#3J08``+@F```9`````````````````!DE``!X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L!`BT`%``&``@````A`-?>.UO*"0``
M0T$``!D`````````````````^2L``'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"+0`4``8`"````"$`QEKY<,`"```&!P``&0````````````````#Z
M-0``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+`0(M`!0`!@`(````(0"0
MNXXP100``*X1```9`````````````````/$X``!X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L!`BT`%``&``@````A`+\/@=LU!0```!L``!D`````````
M````````;3T``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"+0`4``8`
M"````"$`WET7$X@$``#T$```&0````````````````#90@``>&PO=V]R:W-H
M965T<R]S:&5E=#,P+GAM;%!+`0(M`!0`!@`(````(0"L1`L8XP(``.('```9
M`````````````````)A'``!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL4$L!
M`BT`%``&``@````A`+TB+6)P`P``O0L``!D`````````````````LDH``'AL
M+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4``8`"````"$`<CNKT)P7
M``!RP0``&0````````````````!93@``>&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;%!+`0(M`!0`!@`(````(0";%'J1R@L``)]J```-````````````````
M`"QF``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`&+$;>2%AP``5M@!
M`!0`````````````````(7(``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A`"4]>?R=!0``YAT``!@`````````````````V/D``'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0#$KZ2`Q08``.<?
M```8`````````````````*O_``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"+0`4``8`"````"$`^V*E;90&``"G&P``$P````````````````"F!@$`
M>&PO=&AE;64O=&AE;64Q+GAM;%!+`0(M`!0`!@`(````(0"HE0#R)P0``+(0
M```9`````````````````&L-`0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL
M4$L!`BT`%``&``@````A`#8E@265`P``Z@L``!D`````````````````R1$!
M`'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"+0`4``8`"````"$`A+<I
M\_@#```&$```&0````````````````"5%0$`>&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+`0(M`!0`!@`(````(0`NLH$/P`(``&D'```9````````````
M`````,09`0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L!`BT`%``&``@`
M```A`%D1<X36`@``W@<``!D`````````````````NQP!`'AL+W=O<FMS:&5E
M=',O<VAE970T,RYX;6Q02P$"+0`4``8`"````"$`(`G3>(`#``"S"P``&```
M``````````````#('P$`>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`
M%``&``@````A`.DC/Z]6`P``U0L``!D`````````````````?B,!`'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"+0`4``8`"````"$`6%6U<>L$```Q
M%@``&0`````````````````+)P$`>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM
M;%!+`0(M`!0`!@`(````(0#K4H_YWP<``.4B```9`````````````````"TL
M`0!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`%``&``@````A`/U<
MAW^-!@``HR$``!D`````````````````0S0!`'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"+0`4``8`"````"$`ONXR=9`%``".%0``&0``````````
M```````'.P$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+`0(M`!0`!@`(
M````(0"]^!.@?P(``!$&```9`````````````````,Y``0!X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`(J!'0(4$P``L6@``!D`
M````````````````A$,!`'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"
M+0`4``8`"````"$`A)X.&'4#``#:"P``&`````````````````#/5@$`>&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@````A`#AO5PVA!P``
M:"```!@`````````````````>EH!`'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;%!+`0(M`!0`!@`(````(0`8+#:0\3L``,!I`0`8`````````````````%%B
M`0!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4``8`"````"$`0)SH
M(KL"``"+!P``&`````````````````!XG@$`>&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L!`BT`%``&``@````A`#=D0?P_!0``Q1,``!@`````````````
M````::$!`'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+`0(M`!0`!@`(````
M(0`U)VN'QP,``&P.```9`````````````````-ZF`0!X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L!`BT`%``&``@````A`.]J]OF,`@``:P8``!D`````
M````````````W*H!`'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"+0`4
M``8`"````"$`MAUU#D!```"[A`$`&0````````````````"?K0$`>&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````(0`#-FJ$L@(``,X&
M```9`````````````````!;N`0!X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L!`BT`%``&``@````A`,0PC%K:!```+A<``!D`````````````````__`!
M`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4``8`"````"$`ZW8]
M%E$"``"3!0``&0`````````````````0]@$`>&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+`0(M`!0`!@`(````(0#!5DI1C`(``*D&```9````````````
M`````)CX`0!X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!`BT`%``&``@`
M```A`"&>AU4M`P``O`H``!D`````````````````6_L!`'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`D4+/P!0'``#$'0``&0``
M``````````````"__@$`>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+`0(M
M`!0`!@`(````(0";J][:H2@``-+I```9``````````````````H&`@!X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L!`BT`%``&``@````A`#H+BLA5!P``
M,AX``!D`````````````````XBX"`'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"+0`4``8`"````"$`J\7/%RD%```2$P``&0````````````````!N
M-@(`>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+`0(M`!0`!@`(````(0#)
M?]!E0A```!=2```9`````````````````,X[`@!X;"]W;W)K<VAE971S+W-H
M965T,C`N>&UL4$L!`BT`%``&``@````A`)AQGW,Q`0``0`(``!$`````````
M````````1TP"`&1O8U!R;W!S+V-O<F4N>&UL4$L!`BT`%``&``@````A`#LN
M[75=`P```PP``!``````````````````KTX"`&1O8U!R;W!S+V%P<"YX;6Q0
52P4&`````#@`.``Z#P``0E,"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJ6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue from collaborative research</a></td>
        <td class="nump">$ 20,111,173<span></span></td>
        <td class="nump">$ 15,532,680<span></span></td>
        <td class="nump">$ 42,015,994<span></span></td>
        <td class="nump">$ 50,283,510<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
        <td class="nump">120,895<span></span></td>
        <td class="nump">548,864<span></span></td>
        <td class="nump">1,112,238<span></span></td>
        <td class="nump">3,744,047<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
        <td class="nump">20,232,068<span></span></td>
        <td class="nump">16,081,544<span></span></td>
        <td class="nump">43,128,232<span></span></td>
        <td class="nump">54,027,557<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump">11,087,919<span></span></td>
        <td class="nump">11,968,253<span></span></td>
        <td class="nump">32,233,828<span></span></td>
        <td class="nump">36,924,987<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump">1,986,555<span></span></td>
        <td class="nump">1,514,334<span></span></td>
        <td class="nump">7,322,974<span></span></td>
        <td class="nump">6,640,740<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
        <td class="nump">13,074,474<span></span></td>
        <td class="nump">13,482,587<span></span></td>
        <td class="nump">39,556,802<span></span></td>
        <td class="nump">43,565,727<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
        <td class="nump">7,157,594<span></span></td>
        <td class="nump">2,598,957<span></span></td>
        <td class="nump">3,571,430<span></span></td>
        <td class="nump">10,461,830<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
        <td class="num">(553,612)<span></span></td>
        <td class="nump">1,557<span></span></td>
        <td class="num">(627,281)<span></span></td>
        <td class="nump">4,752<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net comprehensive income (loss)</a></td>
        <td class="nump">$ 6,603,982<span></span></td>
        <td class="nump">$ 2,600,514<span></span></td>
        <td class="nump">$ 2,944,149<span></span></td>
        <td class="nump">$ 10,466,582<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per common share</a></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per common share</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average number of common shares</a></td>
        <td class="nump">1,184,507<span></span></td>
        <td class="nump">1,092,307<span></span></td>
        <td class="nump">1,463,798<span></span></td>
        <td class="nump">1,078,145<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average number of common shares</a></td>
        <td class="nump">21,242,978<span></span></td>
        <td class="nump">21,502,424<span></span></td>
        <td class="nump">21,908,859<span></span></td>
        <td class="nump">21,412,848<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs of sales and operating expenses for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CostsAndExpensesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_GeneralAndAdministrativeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherNonoperatingIncomeExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueFromGrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Revenues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenuesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Shared-Based Payments</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>5. Shared-Based Payments</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Stock Option Plan</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s 2000 Stock Option and Incentive Plan (the 2000
 Plan) allowed for the grant of awards in respect of an aggregate of
 130,725 shares, which was increased to 150,297 shares, of the
 Company&#x2019;s common stock in the form of incentive stock
 options, non-qualified stock options, stock appreciation rights,
 restricted stock and restricted stock units and other performance
 awards.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Effective February&#xA0;2003, the Company implemented the 2003
 Equity Incentive Plan (the 2003 Plan), and it was amended and
 approved by the Company&#x2019;s stockholders in 2005. The 2003 Plan
 originally allowed for the grant of awards in respect of an
 aggregate of 2,051,644 shares of the Company&#x2019;s common stock.
 During the year ended December&#xA0;31, 2006, the maximum number of
 shares of common stock authorized to be issued by the Company under
 the 2003 Plan was increased by 460,746 shares to 2,512,390. During
 the year ended December&#xA0;31, 2008, the maximum number of shares
 of common stock authorized to be issued by the Company under the
 2003 Plan was increased by 745,716 shares to 3,258,106. During the
 year ended December&#xA0;31, 2010, the maximum number of shares of
 common stock authorized to be issued by the Company under the 2003
 Plan was increased by 532,654 shares to 3,790,760. During the year
 ended December&#xA0;31, 2012, the maximum number of shares of
 common stock authorized to be issued by the Company under the 2003
 Plan was increased by 545,970 shares to 4,336,731. As of
 September&#xA0;30, 2013, a total of 8,171 shares were available for
 issuance under the 2003 Plan.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Stock options granted under the 2003 Plan may be either incentive
 stock options as defined by the Internal Revenue Code (IRC), or
 non-qualified stock options.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following stock-based compensation amounts were recognized for
 the periods indicated:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">111,888</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">117,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">284,281</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">353,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,647</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">109,280</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">274,940</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">135,936</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">209,599</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">393,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">628,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <i>Employee Stock Options</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2012</b></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">53%&#xA0;-&#xA0;58%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">51%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.24%&#xA0;-&#xA0;2.05%</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">1.18%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected average life of options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Fair market value of common stock at:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">$1.50&#xA0;-&#xA0;$7.51</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">$1.50</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected forfeiture rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.06%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">5.57%</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Fair Value of Common Stock&#xA0;&#x2013;&#xA0;</b>Before our
 entry into the public market on October&#xA0;10, 2013, the
 Company&#x2019;s Board of Directors determined the fair value of the
 common stock. The Board of Directors made determinations of fair
 value based, in part, upon contemporaneous valuations to determine
 fair value. In the absence of a public market, and as a
 clinical-stage company with no significant revenues, the Company
 believes that it is appropriate to consider a range of factors to
 determine the fair market value of the common stock at each grant
 date. The factors include: (1)&#xA0;the achievement of clinical and
 operational milestones by the Company; (2)&#xA0;the status of
 strategic relationships with collaborators; (3)&#xA0;the
 significant risks associated with the Company&#x2019;s stage of
 development; (4)&#xA0;capital market conditions for life science
 companies, particularly similarly situated, privately held,
 early-stage life science companies; (5)&#xA0;the Company&#x2019;s
 available cash, financial condition and results of operations;
 (6)&#xA0;the most recent sales of the Company&#x2019;s preferred
 stock and (7)&#xA0;the preferential rights of the outstanding
 preferred stock. The contemporaneous valuations were performed in
 accordance with applicable methodologies, approaches and
 assumptions of the technical practice-aid issued by the American
 Institute of Certified Public Accountants Practice Aid entitled
 <i>Valuation of Privately-Held Company Equity Securities Issued as
 Compensation</i>.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Expected Volatility</b>&#xA0;&#x2013; Volatility is a measure of
 the amount by which a financial variable such as a share price has
 fluctuated (historical volatility) or is expected to fluctuate
 (expected volatility) during a period. The Company does not
 maintain an internal market for its shares and its shares are not
 traded publicly. The Company has been able to identify several
 public entities of similar size, complexity and stage of
 development; accordingly, historical volatility has been calculated
 using the volatility of these companies.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Expected Dividend Yield</b>&#xA0;&#x2013; The Company has never
 declared or paid dividends and has no plans to do so in the
 foreseeable future.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Risk-Free Interest Rate</b>&#xA0;&#x2013; This is the U.S.
 Treasury rate for the week of each option grant during the year,
 having a term that most closely resembles the expected life of the
 option.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Expected Term</b>&#xA0;&#x2013; This is the period of time that
 the options granted are expected to remain unexercised. Options
 granted have a maximum term of ten years. The Company estimates the
 expected life of the option term to be seven years. The Company
 uses a simplified method to calculate the average expected
 term.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>Expected Forfeiture Rate</b>&#xA0;&#x2013; The forfeiture rate is
 the estimated percentage of options granted that is expected to be
 forfeited or canceled on an annual basis before becoming fully
 vested. The Company estimates the forfeiture rate based on turnover
 data with further consideration given to the class of the employees
 to whom the options were granted.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Equity instruments issued to non-employees are accounted for under
 the provisions of ASC&#xA0;505-50, <i>Equity Based Payments to
 Non-Employees</i>. Accordingly, the estimated fair value of the
 equity instrument is recorded on the earlier of the performance
 commitment date or the date the services required are
 completed.</p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table summarizes stock option activity under the Plan
 during the period then ended:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>Options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average&#xA0;Exercise</b><br />
 <b>Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average</b><br />
 <b>Contractual&#xA0;Term</b><br />
 <b>(in Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Outstanding, December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">687,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.19</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,025,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.75</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Forfeited or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,949</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.13</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Outstanding, September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,877,003</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 September&#xA0;30, 2013:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercisable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,855,178</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Vested and Expected to Vest</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">918,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.44</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The aggregate intrinsic value of options outstanding and options
 exercisable as of September&#xA0;30, 2013 is approximately $17.4
 million and $12.2 million, respectively.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The weighted-average grant-date fair value of options granted for
 the nine months ended September&#xA0;30, 2013 was $2.00. Total cash
 received for the options exercised was $851,183 for the nine months
 ended September&#xA0;30, 2013. The total fair value of shares
 vested in the nine months ended September&#xA0;30, 2013 was
 $402,084. As of September&#xA0;30, 2013, the total unrecognized
 compensation expense related to non-vested stock-based compensation
 arrangements granted under the 2000 Plan and 2003 Plan, net of
 related forfeiture estimates, was $1.5 million, which the Company
 expects to recognize over a weighted-average period of
 approximately four years.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 50<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6406099&amp;loc=d3e25284-112666<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 40<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6418621&amp;loc=d3e17540-113929<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5444-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6AAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedFinancingReceivableRelatedAllowance', window );">Allowance Recorded</a></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Amounts classified as restricted cash</a></td>
        <td class="nump">$ 404,850<span></span></td>
        <td class="nump">$ 404,850<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedFinancingReceivableRelatedAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of allowance for credit losses related to recorded investment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28368275&amp;loc=d3e5212-111524<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ImpairedFinancingReceivableRelatedAllowance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EXJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Asset and Liabilities</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Financial assets and liabilities subject to fair value measurements
 were as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active&#xA0;Markets&#xA0;for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable&#xA0;Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,522,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,522,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,974,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,974,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active&#xA0;Markets&#xA0;for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable&#xA0;Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Preferred Stock Warrant Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table provides a rollforward of the Company&#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total unrealized gains (losses) included in earnings</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(626,349</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance at September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Depreciation and amortization are computed using the straight-line
 method over the following estimated useful lives:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Computer equipment</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Software</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">
 Shorter&#xA0;of&#xA0;lease&#xA0;term&#xA0;or&#xA0;useful&#xA0;life</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Dilutive Securities Excluded from Computation of Diluted Net Income Per Share</a></td>
        <td class="text"><div>
 <div>
 <div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic and diluted income (loss) per common share is computed as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,603,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,600,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,944,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,466,582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,434,756</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,600,514</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,944,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,466,582</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">169,226</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,184,507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,092,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,463,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,078,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>Basic income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>0.14</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,603,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,600,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,944,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,466,582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,403,843</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,600,514</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,944,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,466,582</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,184,507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,092,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,463,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,078,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,058,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,410,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,445,061</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,334,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,242,978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,502,424</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,908,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,412,848</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>Diluted income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>0.01</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <!-- End Table Body --></table>
 </div>
 </div>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
        <td class="text"><div>
 <div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following common stock equivalents&#xA0;are included&#xA0;in
 the calculation of diluted net income (loss) per share:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,910,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,276,516</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,910,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,276,516</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 </div>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Summary of Significant Revenue [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
        <td class="text"><div>
 <div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 </div>
 </div><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Summary of Significant Accounts Receivable[Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table represents the percentage of all significant
 accounts receivable:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.1</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Property plant and equipment estimated useful life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a,b,bb)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=SL7498348-110258<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19190-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6327-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6442-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-13-438247-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-13-438247-xbrl.zip
M4$L#!!0````(`"2!;$/W*/^]3$(!`-DK#0`1`!P`;6=N>"TR,#$S,#DS,"YX
M;6Q55`D``_.8@E+SF()2=7@+``$$)0X```0Y`0``W%U;;]M(EGY?8/^#U@^+
M76#+KOO%Z&3`ZTR`I).UTS,]^R(H$F,3+9,>DG+L^?5[BI0472B+DD6:'@1(
M'+,HU??Q7*M.'?[RI\>[Z>`ARO(X3=Z=D7-\-HB2<3J)DYMW9[,<C?)Q')\-
M\F*43$;3-(G>G3U%^=F?WO_[O_WR'P@-KJX&?IHDT70:/0U^'T?3*!L5T>!#
M8N\81W!Q/+N+DN)_!M]&>309I,G@=_?JXX">D\'@MBCN+R\N?OSX<9YED\7'
MG(_3NXL!0HNO^&LUN\O!0)Y3F.'*I:MTEDPN!VKE5UX6C0H8/IC`/"X'%!.&
M"$&$?J7X$K-+KO]O=71Z_Y3%-[?%X+_&_PV#L4#VCL'5^=7Y"K#_'%RG20ZC
M[^Y'R=/`F4X'5_:N?'`5Y5'V$$W.YQ_Z^"V;#H#3)']WM@+/_OH\S6XNX"O8
M13QGYZP:>6FO3I\9/XV3/RQ]R_'V%VOC?[!R-#'&7)17%T/C/.64J.<F4XU8
M?G8>UWTR#"47OW_Z>#V^C>Y&:!,!2,K-:'2_O//[*/]6WC>_<%$^!TP0(XM;
M)M'/+RIGE$?C\YOTX0(NU`R_NTD>UR9V-QIGZ4V4Q..\E!A["S8,KTRI>+J/
M\MHYE5=JOL5.9%*LSVL.7UQ4%]>&QK5#934T7@S-B_NL'JN]8J=!UJ<Q!KDN
MLJ?Z>^87:V8_GF49:.^N^^97[8UT_<;H<7Q;?Y.]4O--<?(0Y47]+=6UFIN2
MV5V]'$Z*[,(^D0L8$67Q>'D#*.#^>]($;=PW*[*=`F\NX.H9J.I@4"KK]#(O
M1?HJ^CXH->?2?NJ[LSR^NY]:^2Y_-\I`V*91,QTM[[C-HN_OSJS4HH5DGC_F
MDR-4N+EUN*A@S77N$LS579I<%^GXC^O;41;EU[-O^3B+OT43=U;\EL1Y/@.3
M/$Z3(GHLKNQ\HW0Z_!(09:CA"!%&,/I?#%\RO/[J#_$0OH\3S,@0M&R6Q-4]
M>?G99X-)-([O1E-0N`^_AF>#>/+N+)X,J=+P1PZ9U*$7!#Y2FCF(2\J1PP5'
M1`FFL.,IG_CV\\F0G;TG3&*.B?SEXC`L&_BGHSS__/UOHRP;)<7GK#39O\[N
MOD79Y^_7$>A#7,11[HW`QD_<I_FX?#XP/XP8`A:"8?C1,&HT?B1$"FSXP3P1
M5W$W#%P44,X1IXHA(X,0A9AZ8*=-&`3:\L2&\NR](%IAO<+2RQ!7](']O0R2
M(BZ>MDC_/"O*2`"B@P/984>*#27,DUI0)#`&L7$#A=P0!,@7(#2!%[B2NT,Z
MA*O`_]E[*C#%5`,ES5!4B*V67CJ326P#A]'TR^C)ABR_W:>),[Z-HX?(_O?S
M]T_Q%`P;Q$`'JHS`TDK&"O:YSQW^=NVO$H"WX(-2>(HY$+\0ER$N3(A<3TBD
M#%-4@W1P!JIEM0:#UF!3\O#+Q:&`.K`;$M3C&`'`//!<3@3R*(#G(0F1T9Z#
ML"L)5U0Y(0Y^V@W[G<PR<(S=*%G[G$1%?!<MJ9ES]S5UX<=X\ELRB3+G)HM*
M"@_D0&-%9!-!0&+;?M(0#`()D)"2(@[RCUPN0^0X.,`LX,QUPF$I!J4,+*7@
M(#S'\F`EZ_H>IO\]CB8?0;ZF8&Y&<.?G[U^R=#(;'VI-%U0-#96<J4=#&>%M
M$F<%B((`T>/):T!"?_D%IR58>_R6"DK.WNL.Z'T5]P^$FB[=?VGNJ(;@B:H3
M^__EAXWR6R>9V'^"?\SB!^`:QCJ%!W<]@>_\ZV@Z.]`5@GJ98UVA"+G/K!?4
M/I.(8X\@[6GXRS<.]9F1W&%6C^F00F3$,!<$:['"31,X*PI:N@O7+EK8M#]*
M\G)9P;&,W90"Z3[]'#*77.?'*)M\OK<#\W`49Y]&V1]147XR\&^=T"GY&MY'
MV7!;K&B-#S4A.$MN0R<%L7?@(>-HCGP6T(`9WX>_+'5\R,$$GHN%?K9#P9Y@
MXP4QYA99#76."(]Y/D.^81[$F*Z/M`,&#8A2+C-"Z1`&#:75.$)MZO),?+$5
M7"Y&OI3,X#'*QG$^^C:-*HWNB!TWP!YW0@]):]4Y#S#2(5#$!$1DVG69C\,J
M!`6U(UH(HE8RDI.CWB,]'XZ(35L7'-I$<#[49;`_!WFC^[@83:NQBU7',,W"
M63'+(GMSN=[:#7"/^1YWM8L\XD-6YF.--"8<,>4H[M$@X$XP5`N94(0:I6DM
M]F:P3JM)*RKZM\@ZOFCB/$39Z"::2UOT)8M/P.51III(4#&/(\^AX/_!<B,7
MNQJY@:9:,(BQF*BT32Q,=<>TM/8L>FK51!EG@3"S5JBNLVI'?_PRU"LY<!Y&
M\=1:3M"G/]M`KR-N0^YP8KA"6G*,N`>!K.$48@[7X<QH3D->9EQR:"`C`/-P
M`F+W(#^MT/X5TA50CF02/$)"`C]^3>VO_C7LB@)Y/^?\=,+^,K:Z?G(]M4+P
M5`S1$I_0WC?E8OT)?,VB43[+GDKOO:YU?XFF?8N\K)/D3*]8F#WS;RUF?\,6
M`6(X?&Y.:!$:TK(GU'=FQ6V:Q?_L7;A/SMYSNER%;3#_G4"_C++/V74Q`H+*
M#/I+E)7W=B`P+R$`6X'!I!;[+DCK'$`F4&2S,>0`8(;F:8%7[E^_/(AIO.+4
M$"ZQBR84)B!65.09`.M(G?$X@[SO8SSZ%D^KU;F^XF3@@R!^(RL/=N?LUT%^
MOK=E0<#$1S"^45XE=Y_B)+Z;W<WM0^[/H@_)UQ_IWZ-1=NC>ZPO`"Q6$*K3+
MK$2#"Y8<4EG.'<0\@4,CN3+8J[8'0*T9,U+I%:4^&-C6PY_=S:96&?SH/H-I
MEI84?IY&I4E-)LY=FA7Q/\O??\E2^+[BZ<L40EKKN/\QB^\/WX=Z"5VAICY$
M*!@%`6:0^6L)#L,A2%)'!J'G`YET6(8K1!#%":%KPG(2M!L<KFQSQI,/R7Q%
MH7?J(^U2B!1"&L)6#,6.Z1^E/WW4FG(!B!E,5E.*AGBVE,56/N4PP$8.O363
M=AM1&4VI7A/]FKD?:23#=);UUDJ"DV!<2[T:<Q^.;)V9M^`<I2T^H5*LN<<3
M^<6OMQ%D+=^+$^2E+3QQR+$D%8(?[A9_XMI(NVR@>)M.)U&66ZM?//7N>4M]
M]MXF39J3U<1H:^+'JGC\$/56Q;G=7F4"ONT8%5\@6V=FL14-?K[:BS[E-N#)
ME=V`R-L9K!0H/@=@'>J'N_M1G$63,$Y&R;A,#\91_&#]PE541D?.=)K^.,EV
M3F/D3N`KWR<:,1TZB(>^CQPW")"`,,YS/>-@EU7E12MJ?@"2S?2N&,5)-`E&
M60*WY6N1X?=X'/?/P$L(:1%18.,U74_T]D%9APZ_C,`33*ZBARB9]3>*$>6>
MI=&,K(0Q]9/?!3`I//@W+GY-DW%?86J[NZ-MO%*'<AO!SJ6:8ZIAVL<GS'SK
MN78M9J7DI29B`4OV%APQ(.3$*&&PJ@V\:F'L7VWJL]""*=),::+W+#CM$ML5
M=GH'CMK54XDI9[0^D#YV9>DVB_H;4E&[MJ3%&N8CH-7'5+^FQ754%-/(.F:[
MPI#?VLJL4OO].!]/TWQVVC7EYVGQB/8Y]0URI%"(!Y@@HR1#`CN:^<9U_$7%
MJ-H=9S4#]:SO[;&*4PBT((6FC-.=WG>7=C>4F\XCC^;:@.T:@L02FX.UH7Z-
M/<^CHK=+!Q!I,6D$@SFL+!BM3GGC^1:0-E?7>RS!VNZ\JK7(HW;BZ]B^9!&D
M%.6.=)+W-CBV&SX$,\Y7'ECMS&O"C-CNM-?7(O<.IP17C+E>+3+;AZ%)"?D;
M<3[@DY6@%*^J96-`=0:H=\^W-G2NYEHW_S?RW$2Y3Z>LY&ZBVON@VCCST$&T
M8!';C26C]XEJ[7F'S5V*G\LXOT9%7XVPK<:G$")INKW-4@=@T]'LV%S\<Y;F
M'6IJP_U4NXL&(1(SJV4XSV.HJ63ZMK]DY]O^DIT/"7B`)(_'I021MKBJ.6JF
M,2-AH`G"O@<1I*M"Y#J.1#[5O@I`%%S)EGOUA-*-"ISV.&BM)GK]>WI)M3UX
M#,:VANHV*'BF&+&?MEE"L"B46LWCMF?=T#:!,>L=/DC1.9=&KYKAYP"LG+!;
MCR7?2'3!?\;$S4"L`/Z4)M%3=2`NG"63MQ)064\K,5=$FCGH!D!68$-J5"U<
M5`*?VBR^VB-S\FO(FFS'J/+DZE_2J=7X+V!F05A&-Y%=V<KMPFT+%9Y(;E%B
M')_X),"(.&#Y`+`+1L\81#A3(0>'K%VR-'I\[2CS"3"N:4:YP@-A3'J3E.5!
MRS/2GZ+B-IW\'#"/<SIT#48[6.B0(-=@:0]_4>0H19"6(?RLL.^K<,BL85CO
M1'`XJ'5;$8VRL8UH/XUB@&IW'"/GSH9[?69!;PI*,R!].X?,%J?;][=C./FI
M9&IMKCH7I(-3R?UE_)D&#2=GG+S".?".2H0MGX80D&!CA#PJ+J)`E#`.DAQ#
M7*2%@QS&./(\K1T/AQISYV<2(K3AY'0%PZT6@G;)#22T1F*(-_3!W.S?NWTM
M^"(`O5*A0H$'6L5]KA$D[!A15RGI"(6E5$,Y7Z/:@E^'Y'4J1+L4!!M<@EVB
MZJABLOIZT8[**KNDR199$LF$/)BE74667=4B=LD2N"V(3`2FA].TLS*QLPJ#
M+HFR->H::T(.WV'=76_0Q<9SER3AFG-=+]F&7F;)G\KUGS)R^EM<W/Z6I-^L
MM:\6%N]GY?IUFHSC:75`QOX7/@^^%`*L.%_4PCR]8,$+:%3"4$NC)/P8&AEE
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M2*ZSM!O>NB$*[NZGZ5,478,S@UOJ%U!`?1^J'AQVK23_FA9`_LIU+\V+7]/B
M[U$Q7S,]NM4!L&@PTX]V3U08`RS:?I45B[Q!%%5CR)1OB`<?@$)&',2Y*Y`V
M0*4O`BU]%D)TYB\S/"(V#%EK_'1?`6NY509#*"44V\GE8QY?)O'TW1FD^-'1
M>S%TJ+:[O+=;8]4,WBDVFNCI*Z[>)`O'U"^UN9_:)?9>[JYV2<`+]EI?R>AI
M0=HU>NQ5C5X'\.@6O/:L5P=PQ!).1U:I`TQ\'5,7IJ8#5&Q+\+JU'?9T:9OF
ME)_Z`%%G9N<Y9D[S]'F79J<+.%V;G2XP=6]VND"U;7;:J,:VF+049:V*H>W5
M9L]7HX1]9]5QM=DMHV=4M(9^<>"":\.4ZB5^K7%[3Y\M7SPD,1.KQR_Z0X#M
M-]8:`7Q1Z,(HPZL]GWJ#GQ$EVSN:(>8;A=2V!F&BC_@II4<EK8WPR_ENLC!&
MBB/U_U1-OU_8#W:Y*DI`D,6JS6C6'54Z'A-$>LAU;0N=@(`K]#!'3B@<EX:>
M"!Q>&4R[L\<P",SI&Y_OZ"F[7IY\HA>M+-]UA)D]1=A2/]W2OXKRQ*T1%"1W
M[<SM<ZCV4W`"D>F*`=:8@68R<-K6PKN):+/3<$D,W6PVW`SG?N%XR:MD.A0,
MWE@PZMXPLW%NX245)0TDX!0GCDK09`EZ%^3:<U6K`S[&X)(F\TZS]D*4C*,W
M0X`]FK_58KPIP"Y]@VT^15I2@&HGVYR]5X1C0EDO74/[!*BF!+RJ9]CBH47/
M4/$B>^T9VI<+W50NNG$,SPG`">QBA5DL,/?/+W2!G]O62:0-OU![UTL9V7Q'
MZC&'F@353$,VBD+L0)IJI$)&&XPH#;2PISEU55$WK^<]IX<1L]GP,7F`M#;^
M-HUV*Y)]4VTU,(>/.C5'S<R$"$)*N:.0(SP#(D,)<JA2R+5'$S65-&!Z>;*`
MG*^_J.1@C`U>O+OV9I?EQ2/?MGNX),V_[WE1:OKRW;).`9_+U;?+'H&YTS!,
M2JI;>N5-N0A*[7O#I%8<)M7+,*QU`D13`EXW#-ODH<4PK.*%]SL,:UTN9%.Y
MZ"@,>T8`3A"&5)C9'+/N81C6!7[;5EJ]B?1<2DYD.^)?[@TQ$`7%)!>ZKVZA
M9?RD(?[7]@KK-+3H%2I:MMX1US>OT+)8T(9BT9E3V/G\3V`42\C45)!E+WU"
MZ_"9[6)R&I?P"EFHYD21=K+0Y9;HN<#RE&EHYRQ1HA4Y?..X$4ML46AQVER]
MW>BB)$2W8T;+R@MA"SR9U(2HG6;E-<.+]@FP"YY[-H)Z$%]L\=!B?%'QTN^L
MLWVYD$T5HYL`XSD!.(&'K3"S.>8>+OYW@M\VF]LZ:MG'K)-2P51+BRY5?R7K
M*3GGDM)>;@JW3@`W/P_(]]DO;/+0HE^H>-']]@NM*P9NJA@=^85G!.`$=K%Z
MYFJ!N8=^H0/\@IZ]-YL=NGNZ)VS+U97J8DMX\8Z/-[<EO$71";-,OFS^V6*6
MV8;8,`Q3[T)L%GFX.E=O2VHV&3JAU(C%*9@W*#7LL)*T(Z5FJ5?TG)D7B$T'
ME,#3[:0D9R$T\MR(MZ5(&PR=4)$6IVG(^>I;Q5^L2"?JA3=OO80E6)(&)\IJ
MF@;A,)#4!!IIPCCBV!Z6\:E"`2?24]+U&*$_F]]A]GS[LS:;WW6)E:STXGH>
M3<O=[KH$;<^,[7F^NUX2>/K75!T,?3L<I\8)L-0$A89!$*Y\T'1"'>1[Q@\]
M0D@HPV49(N62J16KM_^]55VW]CM4%+;;K(&Q#`.A%<(!\4$4?(J,9\KW)3A2
MA!R((<N>-^`=5MNL'=W*KVUC(,UQ;XO@X#F,PARYC(#U9[Y`+I$A"HEP,65<
M,""C>JW(9J+6Q!*TJQ''@E;"#3`K3XQZ$`8$@0N@*4/2#^'A!X[@!%>@"=D`
M?;!"S(6BE(FJ25^<W-A6'>ET.OJ69M5QRM-IQ=&"@"%O)]0#3D*,N!_8]VH%
M8"884]QX7D`]=_GV`$I%O58<AO:U+4@SKK8M2'.NP((PL:N?Y5OI!MHE8=1V
MW<<[".M9`]`NE0XO=U,/;/AYZA";"WS4;I$-0CSI4L2TPO:]?1H9:32B/O,@
MG@Z)*\DRPI8EUM>-K]L':K>">A5=MP_9!M?//]L]K:-?P>HU8Z6NI;8(7465
MBP3E$%L))RQC3-!S3QOE2TC8?[I4OL.C'FOS6M4.L%I*[WCIT[[W=S+&'$<0
M9'!(D>W)CPP+`Q2H_V?OVIH<-9;T^T:<_\"VCQWC"-&FH+C-K$\$0LCN6,_E
MS/2QU_OBH*7J;L)(:`'U=)]?OYE5@$!7I`;$>/K!GI8$5?EE965F955EFN/A
M6*.JK9`B!*Y;RLH8],3OK(M]<YI04]<\53-DS:"P\#`,(EO@=L.$471"ALY(
MT<U"V^L*$$6?X7AV/E-J"\6F?Z#0D:43"Z1@/(+5^9@8\E#WP"'W/&*IIJN-
M/*54U+5A]Z`#H>&G+$ZZ8CE4%)@6!JQ0/-W%I.`Z",V(R*9EC6#E;BF.EEVQ
M%'4)<`U/=7I2[>EF?85G%",8N=0C1!O*#G'!H#B.(UOVD,KJV##'INI:JJ+_
MP3T%[8`%/>L2XQFYX(?JF-+1T)6'AH-5'!T+;(?F``>(9P\-P[!'JR4&H;L\
MYE.6&*TYRIVP@Y2/EQSE*?.@-;\1>2Q.HA"#XP35A#4H#6J9&)77%8IIOG3[
MN'WC3250JZ9GX5.6SM6M,&VW$=%L%LUYR)X'Z_F3IYZ@:9T+=&R9%/J1O1$&
M[DS/EH?:&/X:&4/-<\>*Z52Y<`S:]<V;XM%G'S$K^+*=$_5V:6I)`$_1#KVH
MBFI9Y6V:W6`.P#[M[%"7B&DMQ(?/#'U1PXP)1$X\/7CFG':*1E2-'*B`O8TS
M8^I08E,36$'!)7`IE6VJNK(]=*AF6Q0,Q%C$;,$W(`:E:TJPO11VI]J-G!6-
M;OK3,34-AUBRZ;F@&2D%#FE#7(_#S[9I.6Z>ZT]=/Q:Q;BN*R;0UM[23NGX<
M/X%\G7+:C&Q(0?U:IF,ZTLA0DZT1+*6HXL+L<"WXW\AVU)%F&]31,H2@#74=
MO`[-*!VKK`6G\5*N)!_K3DJYYIX0QB9-:I<.=ARNY=J@Z5-/G.OUTLK\8?#\
MMK9E5\\D=&OLVL:HUL&XS;R=K/6RVM@EOOW&,"T(FSH/+/;O6"5[R+/9=5*]
M<%3PGDMEUU%Q-Y^")ZB`EAMZEFKIFFX8FEY,`N72;L(8',>6UL9"V*2.A'3H
M*2YUQJYL4&,,UL139&L,DJKI+IBLX5`;*>/5LDNEMJFHK;!:H*XR]3KF-3J?
M^#RHFNJ?6=BW>8S9C*A63D1]@/X#RNKD&Q]M`\58MKIQ;&@/_3N!-G2UXQ25
M\QP&;"00J`'IL+]Q6AQR+_8F<KO]06`!9JCPPH&"\;O"]#$8KKQ<;L"2WL)$
M7T/50+]53T=M)W\#Y7*&83@V';%%#,1P10A_AXQKQ/G4F45Q&OP[.U"Z(T-Y
M=TRI5V+A#WY]1=-LT/L5IC2"=HV'I2,FP12KXBR"U`][)R>&@:$G8`JMY)/8
M0?[V_0<PA1B=[.U4P`+`IF83=<M!P2KM57Q?PC3'G%BVJ5I*V6<\-,&Y:K^/
MPBF+$Y3?]*EWP`SKXA^R!0I,4TJ*>I/P[56W8%Z*S(!-K@4;'SL;EOO0?TD7
M[:._BO1JMO"#F$W'P=R?3[C9RG<)/C*NS)PPC#[[Q]]C>`9PQQN9HQ&Q9,W"
MP@WCT4AVAIXGZT0G[M"U'66HB6VPDJ=U!))UKR/U@SF;>GX\A]>2BB*_#29!
M_Z:K`19()J9.394J6MD!.02EA4,2'4@XAO<I=E/.G7#<F:%YZL*_07KRL:$.
M8&*2.@O6^+JV#>4F@ITKB%-"D^WCT^TLIK-UB;`E_EBR/Z#)O@1K@ZI8,ZEA
ME]>`AV`<7@3U66A-O,M,=6*2_0NA76);XD[OP*E8<)[@+DO9>RA1W&&QSF>@
MK54)4(2SZ$Y?XI3RG$T=V>Q@I/&`%>Y-:'2K\MU__XF7Z>RK]<1J@+:-V4\W
MRI=OM9GOTWL6B]][/&`6KL'!_2DY!%L)W]C[!B]QZCUB6+:W_@[>2]9@@M+*
M7O<FX5L,1U%@=7.KKW<PC55M^;H8NJG^VXFJ16?(,FR=E(-(M1%M4T"]&^"M
MWI"@M9TZQ]W82!7+JQ)J*8J^#NO$@M7/.U30@74$Q*9)-:+KAV1U[X&"!D\:
MMP\:4Z8KU%")O1GN.WRFN-$2HNV'M#%\:QJ*J=I:V>C4KQE:V=7KIQ0;Z-R"
M&*L[]B*WIE?:P0$8]M[A,W$OVC!-VZ@QA`"@Q>+LW2ABLG(@ZJ%HM71[-YCQ
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MZ'3!70]?$X94;6'Y_46RX:3%;)LN8Z?@>^E`=LJ!!MS)CC6?I9-V-9]V7LW7
M`3Y[`UY[&JR+X5(+/!UIIBY`D2JH+M1-%["4#=GK5G_8EK839!,ZE3:]A]J9
MYMG'F6:&GW:I>;J`T[GFZ014]YJG$UB;FJ>-&#V"L@P=0&G$5EN+V).LZ+5.
M-$,Y+6+?,GI-/2GO2[W]"D2/YQHLBYA*G7!WY_@M2VEO]+4\2ZM)39A!?<1O
M$^VD$&<M_#1/=J&IFF*1'N+'HZKM[=?I6;Y`O$S?3_G75%4]:>U:"[^1Y]2S
M;4,_6?R;3(-1X,_*R"B@_<VR`FSPKIW0_3K/TFOK*K"U#Q6UNN>`5IL#G9;4
M.LB(%J]A"L:HO2JIU;U@T-J"T4Y-K6,DH(&=?P&:%*#/7U3K+`PPBF2B/2NV
MN,X-HE*#M#0!1/Y^+.Q-J((7=_MH&MIG@%F7`6>U#!M\:/."/N>+T6O+T+Y<
M6'7EHAO#L$\`FC@2QC'K.>;^V84N\--5MM2^VP7#4*V6$I3PB($*:E$U,&A@
M[Q2&L]J%UAF@UV7`>>W".A]:M`N"+_TJSMZ]7!AUY:(CN[!'`!K0BP*SEF&V
M>F@7NL"/MZW-+\0N4&*T(_X\DJJ!*)B:076KKV:A9?RD)OYS6X4J&UJT"H(M
M&QF]^F856A8+M:98=&84=HY_`TJ10U9M`=GHI4UH';X&?M`781)X70VK'=GG
MFTLZ+!4,S;!()>5*?VQ"^PS0B\IC!U*.G]4H;/"A1:,@^-+OI4+[<F'4G1C=
M6(5]`M"`6A28M0QS#T-(G>"'I0(E^I=@%U1=,UM:*?--=QVWF2BEAJKV<FNA
M=090NUQHI[]V89T/+=H%P1>KWW:A]8FAU)T8'=F%/0+0@%X48V[FF'MH%SK`
MKV^[+WB:66CHZNRQ5>(W+TLJ8\]0;<^2+:)AB0'#E8<CU90]6'RYIC%T-:*N
M[LK2,]Z5[1(KP<*4?;@<VR5HE.X#H'=F1&L\T<O1T#<GMFICP5Z+R&-;@^EL
MCDS9(:HCCUQ[-'8)(6-C7)1BUG1=+^=V[ZJ:Y";<MJL3EXILGW<>MP_TS)6G
MSP$9)K&Q?VQWS>%61KF#"LHZ+_&EG3#.+6JM]JLG<ZUEV89J;4E/?UAKM8B]
M_2+`^A\B:0?6/;/T<B'0<ZGMMHL`"_=K8QW:O=IN'R@H;;M/6KM]Q(7C55MG
M3UGPVING0?KTD=T%28JW3=_YLR.D6#6Q>F!>NWC3=R*::UBZ*H,M<4#W>*8,
M,Q-\)]U4',_UA@8=`N5\/0`#]M9Q/[[_R7MWY7Z2KMZY__7#+@)7Y#LS-I_B
M78UQZ!\1!CM`-]9-]D`CR(H.>H-JGB[C&D[V=,L8.H[A@$\H9.P6!HT)0BND
MK#-X'(0L=OV4W47Q$1G(&^0OO?@'C+_L3R8,2,&(BL2)*G.Y0N4*PBB:+#FP
M()GXX>_,C\?PS1&7?9IA-T^M2#1!\`Z:-HF^?EHT)]`U*>5:5OYGE5(D9).\
M#RP.HJDWGXZ`[5W3J0J.RHHM:TJ5V@I=Z])\-9]$\2**1:TB>.#];>6KQG"`
MI39L1\&L2WBORP0_;FC!VG,,2TXZ-H:6/=+S.K:*(BN6C)4?ZQ.Z#LP%Y+$?
M7LVG[/&_V7DF*M[#`75(5%VC>AG,&G$KVC-#MIH*38O3,>3#+(7F53F?J+N(
MVZ5>A."=1<&`BOSG5O52HFG-6R@NL[^_+9=MS&K'N%&2)AM5&Y-KP#0,H\F?
MC0'4AB-XTE%DVQK!`%%P%BQGI,I#Q?14UP0?Q*5BGGP7IF^FP<-W=^D;0(*?
M%E*2/H7LQXNWSL>?KM[)U^\_O):(M4C?2./W[Z[EL?/VZI??7TO7P8PETCOV
M6?H8S?SY&RE[?OC^^OK]V]>24KSQZ>I_/6@"OK@H]7.#?^N7$N?'5.8<D7*6
MX`,_\"?X7XM#]!GMD(=_!/@'#\-*HK2FA!=#.5E!0>"QI%Y[_W,M7[T;>>^N
M7TOTVP9IO[YG$HJ>/W_ZSI\MWGSS"')BOTDDU(A2!8<_GTJ@_H#?P0/CJ*17
M*;R.3T)+^,7WDH_UCF!D;J-8PA_OT.F2HEO)QV*CB13,I9@E"S817T*K=W<Q
MNT-U$]U"*R"C`U/5);%5,I`^WP>3>^FSCV].,'$NM)U&$M&5@6J;Q6/0%O0&
M[V_%,N$57X"[B`8H0,*`P!F^%A2(^,_01"0JH@ZD.3@\_[?TP^`V@%[%V\6/
MXJ._6%7=DV)>]FH`3<1%3H[\.>#=QI?HS"?\IPBK"$@+%B-56"T*VA`,NZPG
M)41M5TR\VUL8,N32F-W$2S_..>PH;_!"^(#S-&.^%,P6(<_UB8,E)$3#1D0!
MG1TRI`D)&G"&!"D?<Q^=8F@$OD*.`+.C!_AX\U3NKCK62:G4#8XUKM0ON9@7
M?>`8PU@%<Q#6IZ,E%@DIR:RD#A2=#`Q*,V',9/&P)%Y"2R.>1)8__P3&31)P
M1VS"L$3MBL<:&2#]AN#SS'\,9LN9-!?UB?G$675>D79_M<D-T^:&28'8V:RR
M$$01^`6M5,9B;=K!*]2`V4F-O#-H41WH1!UHMG*98<D:J8/&VH$F:QZ'Z1EH
M,H6P!XU)]8%)RFBT@:I;`Z(8EZ61@49JH"'*?C1BE)Z%)I]'V]'HFCHP=%I!
M8]HP7H9RN2YGT,@!-.JYT<#8V*920D,'FF8,3(U<2D[6_R>V2-?)5SCYH)!\
M>`FKE@+-,*0FR9OZS&(F^0]^$&)D#J<]M(2T\GJ#5?(X<3U1P9_*]D=H*6#5
M%GIAT)Z0_RS@5J4P<*@D*FT`SZ?L%FOWY8-T!6W&H!:E/"#I1E,FO;KZZ()>
MYHS:8Q-[PJ=K;MQ1J:/$<PKE&RY6DY*+#::%QVB%.(`-C^[F7':%/"`S%MQM
M1[F<!A/TQU_7`\B).T2P6G(?"^'=:#_E(IKU,7S_<>1]E-WWO_SB?/@$C4P`
MI;](V"'FK3-*NHEBD!H>_)ZP,$P6/M:N+#XO_.DT__PYF*;W/U[8ZK<78"F#
MN_F/%RA.++[(7=C_E&5IR,":2M><VI^9/Y5DN8PB+G^8YFT:]-NBD1_2:?69
MAZRSFRA-HUE!A[;[E::^?^FZTZY_J$I'G$M[;9&VJ@NQ32B\W^H<.P!^[8W]
M[U9G9S[AOQ&[)!)9I%(2A<'T8H/#,'UAYL$7QK:I55Y77M_'C*W(>`O+_OMD
M]=E#4[[ZN-TJKJT[C^/`%\BS=V#7>L6R%T&_4'?9$,YD=-O^8E)Z$+#ZM0%^
M&>$FM0CZ7J#*-CVO;8[9,)H^K3MF1RNAS(&\`P9$X$%^X[J>-Q[OT$MIM"C_
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MOG*UM8%NG&>=WG_N&*HU,.USKNN_0+=7`RLVC98W(>O*;I[>8S\=CQ<.OG#P
MA8-MN;_5?:321I%X%+_=1O+:D?_'+<>>'JL.:DEI[\:R^U15HT?V^7%\;[8(
MHR?&*D?=Q7V"U7']/AS2O_6#&,5HR0\=,W]RGYV[$^>4I2"16)(&,WXU+Q)G
MW*?%L7IQJ'F9Y(=`AZ$/ZX)/D_LHQ,.<O"%Y$0=X#DR:15,6KAZ&U_TD6<ZR
M4X/%^?G\B!T7CZ_X;)QI-'\VSM2//QMG'W]4J[&F7@ZW7&AG/I'T]0Y!UR=.
M6B)T[TF1EW,?>Z-=WB->T`'+-PT>@BD#UCP%+)R>Y)B=ZD9N&5[EVX9$[K2N
M_EK;X\48/T2AGP9AD#Z=>WQU[=M5&_+J3]WJ;N!UTMK(]W>^?PR2/^7;&/SV
M`!D!GJ^$22G.+0_X8#E^]]O/5]>>_.F#XP+]I2@8N53I=LE1+Q5=C.>Q\;QG
M$T\NR3:Q_8LJ$?^!Q?X=D\+@EJ^HHM+*[XP29*Y:P(MZ26>C?[CCO[I.&>,*
M>^;'?[)TM="N7G%,-Y>Y/=4P?R>7NK)5P_S=O-3)>32,(.IKT3"W47S+@G2)
M]PM[8)OT2\7HT"NYU,V#QJ2)L&/+MTF+!1K7#K_F:L$5:H$'#3?&"!>=ZQSD
M;0P9R`2\OQ07L-/X"=V72-PV7=Z$P237/]#V^TD:5=;_I+C:O"?5Q3#"8"!0
M.`IB$,,HQCN^,"@S?LTWW0@DBJ8J:0EXN'%+.S-_RHK&?!$,A`>P/6A"M,A/
M&@PP1KCPXW0@+1=Y.J<9)DV:LVB9\$>S]P%\01XTLJ+M4KH2<4;_)L'TU3SW
M0I5)(E,$9HE`!&$P#R9^*"<I6O5)=MO\<Y#>@UJ4$I#/X!8>`,T9B[O-225G
M!31QP\(`?@*B[OT4,U`$B4@YL8@##*0"K8`D"?#"M0]3>G['!'[!GC2"-@HP
M*U:O6Q3\8<VJB'`NC]%B&]#991;S%4T'\TFXG++7TBOR_4H>.'<F]T@S7G'@
MUBKC0I8P(UHPD:@*OID%(7C)T1SP56_DOY%>J6NM`@_397;'GA]!9G?`]1BS
M$N&HW0>+1'"61UEO,!L6D`D-:=6&\/4RX\%IQUOG28094]A4M+$GDX=_EX6O
M2S<YH!=:ZF7B+P(\Z))Q&09H&@C1PGP>W+E+)@$3*56$5`0X]"B>P609^G'X
M!$0"=[*_TB62!@_$P0/\!=_=LW"*25T8/I')5[GA5;-`F[[&RFW(,*!>Y!^8
M^,G]0+J%&34'KH0K!'G.F&68)L)!S08S0;WTRECK:!;A&HBA"I82/SR0AV21
M)XS_6YX4`'M[9:XUNLC2QZ=(F4AODS<;K4IM0!M%>V4=LF?>\UOW6;X;>"G@
M654FDRB>\BP,7#!@[L%DYTR:L?0^FH+;>,<'C\]*$'V6Y)EA2OL3&7TIF]R+
MN;"(81H%$R;[P70M*84S8S'*)C1Q-4]2&'R1T\5E(!T\P\$'H7&RE*X^9@SX
MD+4G.=`>\B8-.1]1S_,]HU]SG-C4AUR.Y)]!CHHT&%DNG$]LLHQAN`%)5G+"
M3S+5GA_5XN:#M]N3!`N%22P\G5^K`9F;K9X+MXJE1[EZA9'U,?^9F.9<H_&\
M##A`(O637YH;#SYH8K[KL\1?\'V>U`,G*XS'/>?=;;B<B$DLO;H/0!QC+@6K
MH-'W$F@&W"[+R0?%7KR$4XMM!IJ^EZ8B@XJ?I86X+&?.DJ81<',>H?:>^6#2
MX3_,;17DZ30R[80J"5,^99E(1**CU4<`(MH`E8O)682U"Y^J?0%*,%4,.D!.
M`.T8[P1I!>7%<$T;XG044LN%,Q"J(--Q\.^_V8"KK)`]XC`@%;M4K9B2@#M\
M&DA;F;DB![Y'?9KRN;#::2P]*F9F4E*8O97H41Y&_KT((^^3ZO7QF>-(<&9.
M0DQ7AQ*W0/63AZ?%X/-'(VD1^IDK!(Y*E&VPHB2#LY@P)M+4+'$AT3=^\3#<
M&,-P5WD8[F.^U-G/+YA_0<(%Y%^7GS`3UG7,-<$37RL5R;@^,_;G^GZWV,N>
M5C,:H8&^]Q_$%$4?3'AQW"IBCD4TY,C-V4W(1+_%+,\C0(+IHI.^,;H0S&N`
M=A1[A;KB^(`0SI5,TZZG$D+]4]:),4-=)BWG[)'%DP`<^\O\?,3?_J-X"YC.
M4(]GB:(XZ[$ST`@\CE157OD1A23C]K9!R,=9C")/)86:;5M[7-,P;@<PYYPP
MV<)9X.YZKI*$9<DB?O_/WILV-VYDB:+?*T+_`:^>'5$5`=($"&[ML2-(47+7
MW+)+4RKWQ'U?*D`R*<$&`386J=B__IUS<D$"!!>I)!&D,-.V)8I(9)X\^RK?
MB6"`5U3VJB\S_\&>1,6*/@=``G'966X((`0JB9SAKR$!MWWRPG$BF!&NS'G9
M%+4TGR>:8`_'($A!*H#QYZ$P("-WPH#+(SG.4]_'BP++*F&S+>BPMGF>MHZ8
MD$9!*#BJF[A</9RG$?6WDC89U[AN/,0485,#\XV50LA$I@]!)`3M(ESDR(!4
M4@&&BN"$4!(]4$TCZB<;2_T5#H"=N-29B'A=KJ2*7H9Z2S_LF^C%4CT>7I]K
MH:I6I]%IF5I&%']IOL$JMVZQ`[A,F-)RI)JD'BL](8]N9>X&5CP78ASVX(IF
M6?(2FEL>[SDG^)C6'!,-:"^A1WF24Y0E/)$%RZ([4`EQ57A7Q+F;L`!]]H`;
M?HFLMI?JA28RIM(%J*.@!<:Y]FT&&C5W>"U92SG1+%,3M4*:P(\![R#XBO.^
M^L[3YWUUMF1>/6'>UT,_?XVO?KWY5'LVM_DCS>>GA7--1<$O1<9/1>5&SZ]]
MRI2L%TSBVA,Z_\O07<9FC0(HAEP+U1+_A':]&WA7Z.5X8=!5&X@[078>XM`#
M=.WXV5$*-M2&1]\!]\:!`_'[IP5YG<FW-7RJC7`VM[0G?M%HZN,CHEI5H6D[
M`[/7.G2WHQ<Z;JLY<`Y\TA<_<Z_9?MXC'U^B1'M;NR-N:Q\=)7?[/=/J/_-5
M5X6.VTWK,'7B!Z7C0W;U.1(9OHVRI4I[?+3]SC);-K:.>#1YOS\&JFXU>YVC
MH^IG_]YIB==+W6'/OBW1"WI\]-ANFP/GT1+H*(C1:EJ'5B:.C1B/L`7(Z73.
M>BJZJ:%68]W^\#L%G7EOO]>6P5:/$^'^R_65^EYQ:)O]7L]LM0XC$Q\$J$.`
MI[R$IFJ0.2R,>LUG]K*>FG)R2IV-7E(]>55PJR'X(BI*5122+3K((ZM@7U*"
M'/![SZP_',7)JG[&4[`F]O#`4P5MY6GU>S5BL]_IF%;O,.-&*F\P'"P27S.,
MRL8&_D6Y^%2#=*$E^N/')\\N!E;?[+:.P(8^!'#LIE,SBR=F%D?0Y0+K!-R;
MFXC=4-%0D$1>$'M3/&V:*Q/2JKZ)>X2J'HQE&@=6YL(S6PP(U5KA&U6)^"OC
M!ZO7=&"9A>?[LOC]!\MNVO(3$\OWD%5Y=_#]BA3H?*$219&C*NO+J(:H0:4H
M^>*78JU5-FH^P(X1"^H(RLLJM@+O'N#[@]ULM9IBR@?V$("5L/H?H#-3U9/R
MA:J`CS_:[UB8P*2^IKT=+W+7^WD)5T)OSA^0%S*?R5HOV2KXP:>#%7YP6K;9
MZCM-8[@+F7C%$=]/&F`9T4W@_8?J^\I&GO`^%ED-E=CKIDDIL(H;4;,/7@@E
M+R^KDK'1JX"E,H2T\%N;?C.-`!NYS.EB^!NU`C=5^6;R.[&:G0S3>>5[OCL)
M+\B+>6&F.**!17&&NXZ"JN@3=Y^CLWF81J*0<EW2S[P[_/6_?DKCQHWK+O\Q
M]F(LGH4-?YKK/0D^\P.=AW$27^.E4[68+!;[PKXE(Q_`^2LL;/R77`Q(3+11
M`.YQ%84!_#CE4+T*?6^ZXO]63_/^$=^2SVS^RUL6^E^O+JS>P!XXC8;5MEJ-
M_P&XM[]>?QE_M7OMKX@)K4&[];7UUO!FO[SU9O!Q'_Z_^W78ZMKGK7&KT6M?
M7#:<L35H]%O=4</J7?;:W<M>I]T:?;7@P5\1"@((V]C*T_<BGTAY0`5UGZF-
M!]R6Z`F1@<VX1N[K1K/8&,Z`O$5*1]:J7"UT\*;E'P+C=W>5D2M<D,5)]7)X
M/9*%C,/K/XT_PF;^:XV6(X@`\7?!><;P^AS8W1*D4M]N(1F(WC>RF8[&BD13
M"4ZPO$/(3&&R+`D4]90!%:`;OPV'5T2_'WC/!M$UYU+VGCC#V<++,"I<PKL/
MEY^OWW..2!M5JVXZ&+$#;.J"7]JZ=3[#N'S?L,KZSF$K3>`8P./^G1+^F**C
MAMK7]):Z%O$JS'M>LHD5U#/>B"F>1MX$]H"EN:+L<C.PN/3B^Z4ZW^P0N!L4
M+F+S^%<OH.I-7FDX`34BWS=*O[$FKU]7VZ9RY/F<BWY:=P[KPN40&SO#QDTW
M7A"02C*'RRNI&K`Z)"HL<5$S4?)(9Z02Z>QE,V^&73BRNG98$7N/>,"(IXDL
M3MW0U@=KD3'XS;F]ZEN"_93$V:JAMP!M_G>J=R-_$'%VMA&G#<2)>B3'K27V
M7`@2U0T')6O$;D&.P%T2$L,G[`'TTY$8R2O571\I$\1X>!]@+3CA-SU/\OPV
M]$%*Q_HUR>+C"9.;@^V#4+ZE8FGLVV(@POJ\?9$7I-BY2%W@VAG$":BE#*#&
M/99)QVSI\@+VE#I2Q6R:$NYJ>"#;F\$3C6QUV=C(%'KAW(OB1'M[?!NF_DQN
M7.@\J&:(78B.,D+S"0,")B\`)K5&;05DRV2%1V78;TI[`T&5O^;L3>%%H:BW
M7S^^*;N:R7>BMBM`6OY]W&FFMFV`*N<$.?+<R@N*G`">?"@OV,`)<`\/X04;
M.`$B1]5X0;%W#;NC]E7H'O)])$-LSA"%Z<UMKL1^([<3G10$"\%[SC?62S2H
MPR*J*=`]:+\ORGG7U=V':J@%_9;J83_-/_%&;<'--;L18O>QBFP:>/PIL=1;
M["@$JKP?__+VPQ^7:YIN>SQTNO:@W;BP^E;#@9<T1H/>>:/?=KJ#8>O2LKLM
MKNE:VJDW[3M_O'/5<B$>!K-S8HXW#,#,XLQ,>'KE_<)V+L:CP66CU^H-&\ZH
M>]X8]3N7C4%O:)U?#D;]\^'@0<J[U7\>[;W?-#00$>+G@/0H]?P9C0QUW<9'
M4+Y8<>91=0P)G4'YM%5@&G-L^(8P5OTG5P;V;!`V,3>`N5\J8=Q?);G8?[M!
MZD:K-4<"7.`U[Z`FE5_^-LY=J*<;MD($TQT$#M=HIKZ+_8>:8!O@'X2#0?I5
MX(7L(8X5X3^P;.&F:75-N]?AKK!>OVT":9O<?,C\8#GH@-1,J0GC#W;34:XT
M.$Q4V![NACIJS96#ID'[E(`S!,QV[!;6P?U61))=4H\T.'=`K:CH]HRE[&##
M'3:@*O+F1>2H#!4-J*L&";7UT!&Y-[E.%;_B[B?=_M-W/^FW'][]I/NR?4#J
M>OTB=[YG/NAK?)P5@F8SVZA^:+$.(S\HC`P<T:G\I3YV"C2(VY;9;3US]?.I
M)R(!BG0JCR+?&S5OF^U!U^SUCZ)LO$*8T7T-F-'OF&W[F:?)OP(NTGL%N.+T
MNV:_?Q2X4B',Z+\"S&BU.V;KN<O$3X&+;#55;EG$*#!P\AC3M3MFQSFD/G*$
M57!UL?1#>'P5R>:1MI[5`P6^95K/G?MZ:@1S/,5[><BO)=VNAP(?%NW*1\H^
M\P%CGWF:'@8*GBNSK6T/NN/S=J]QV;>LAG-IGS?Z5M=N=$8]D+RC3F_<N:Q$
M<`Q_$*EM?/@:0?WQT::'[S"G)=@_;MVROE-#N\;"IJL4&",/?,S'"693V60F
M-6`?A7[<FXB)7"Z<H4"1+6V"FXI<:4.`,$:T"(,04#Z@P7*)-PEG*YXI>T9I
M*L`$69IX4TI.34#%2OB`B(BGB*NL$9]]PY0PBK2()&(6+3#HHI(`M`W*F-LB
M]1,/GH5-^1Z&YVB""T^17;@K.1P/5GGG:?V>Q)%C$U-S9"(T["^<T*K9G_FL
MB+,-\Q1IC!@-'J-18KZ;8!X;/"9'4.$`I\LI/(ZMK1?>?S*@CU/7;PSG<R_`
M?*//K/'%C6X819O>C8>?O[S7%H>-T`'T$XAY:SB=B@>V\GOQ%CC5@0-+/)Q[
M&L#I1KA'S"+4[E/T^<>Q4'RX2C:&C1(R)NS6]>?9I,(,/Q"2<&(<G;?^9TI<
MYB'!=]Y=<3B=&Z0XS)!/^L*THH8:58CC1.3/,N<CUG+C]1TT]8$4>CI(EHZ=
M0Z*S-SJ*8/`O8G/X*D5G)%',&6$)3P/BO\B$>?XKK**BB$@A>X#6S#_!$>S!
M4##E'L_$7#$6T'@\N;;V%IZX3N,VU^="(IVSB%-3-@:2Y@N&*]?G(\("G!(R
M2Z=B?&#3^$2$.V$!F_.<L@+(RXA60II21Q%_\:&849:>6#X6^:^4,QJ)(2P:
M'MTQS/`*HVS4(,UJI*P^6`5CWSA0TKAAX0UP'N`#R$8B#V>3L<*X(1&F+<Q`
M40R')SMFN8O=5J<!AM.:##A[DY,"1:V*QN_\+MA4X\+G8!]J50.9X."9;_!*
MY-_92_OK+RUY)7^1O$'C=QITI*^MYBB*;'&!>[D[HM1#"O?R)&KZ<O9-7$!]
M-S<B%3AQG&33YKB<T%BRN'OD`"A<1/&'6HP.+I/+!/_./1\QD6YXIJ508@84
M(8)VJFPN4,D$5([GB/&`$DA&IM@8/GE_RPBIM;UC]J>X,<Q^H^JFA@O"#B'!
MDY/E-*$<(Q(#+K710ZK\!K,(`>^F8A:>"^+S1DREV7RJ+"52FWL9*?R+,F10
M)^/)"/AMGL"MIW3D7U65!`VA7L@D$Y6`F\>S6U=,*LXFU]S#%:R63)!N08W)
M,PF.GPB2"3#F>]C!>^#G@`$BY3C'L`,J]ED@MP>#1`AOJ1L@3-.8[:4>T!S%
MGY"+"T;+U1[DV;[/:``!9X%P=M`&*-V>]L&S9E,:"7CCXD@DR>+P4DECB(UW
MVKA6>!3]6)BI'&<'4YM^_S-/(WHO9K7]E$DK72P26YZ2)`JP&`G0S8MO\96,
MU)N=4((U=#BA7KBF]&FZH1(N4ZP>G/&97V%!`45)(8J1Q<'%-K*)K6KBIAC'
M22FD7'2+HB<%JSRD2!HUDK`AELSQN?<5(1#R4(I!H/K$*U-,7/.%GJ7-X#9(
M(4&EAN.7G/-%$TA5&4>NA(W2<)5Z+90->#HWA)@7D4Q94=/:?W#6RYAI%XH"
M/@ITK*"5EI-S7%5U@W7BU83E#:A=D<LGY^E*U?HS^>O)LR<T,Y#8,RY%_%)D
M$!+=:MP&:?@&I^<1\7&!A.HS:**AMHV"T%;%E-OM%5Q`MUCR6G1.%]YHK9!U
MDK-7ME@KI.?$6!4QI9S1'!>G<_%$\T#-FPS%5'!OR:N@Q9*-O#6<:;(Y7H8T
M)0J[2*OE]F&F=56#P?PFT<K<AGV9\9VWF*2Y/J=QMBN5Z(SB8BDR1H5:1E]5
MW$<N;'(.1=:Z*@:05T(%`#D;7GQ!O]4\?F,M$`@O4[*^&=L3K=1\0)J&&K";
M,.$CZ6F2M'0O("-6A,BUO3C!QXF*[O$`LLH%]-UHII20>RK3F=XB(9D%LQYV
M%VA9J<)B([V]3)/5+#:S:./34MR$6VE&*J?<O!7NY6B!C]#5@:_(@.L&)82P
M6V\BFY;;>/)^MU$$H"_MG(9]QD21=VZTX@G<'"3B;'P4[!J.E;(\7>-2^A8N
MQ;D3[ERW`I3_3%C\,4G-`M%SMP9\N'YFOFS>ZL232'148^C/:$J]A_:%R%SG
MH\OQ`8T_ZSR2HYFLY]+]=-I$1C5PM^B-J1[ST6$D)Z8;,P],FX235Q*%/MY.
M("Y!TPR1.60THKLQPHC/FD4^QD=EHT8D$$>21$4@`!)IQKCR)N^OU!2$=5VN
MK2F+&9%`1]QU]ETP7X7Q*ETL\#@J'@6;-RXS;O,&=L[(S5PG(/AA:^@Y<*>"
MKJ9>-$T7',.YWXLL4DWWQ$'?E_!]Q&&YKNP3X<4*-AQ_<[XDC:L7;+BINW0G
M.&!>#+J7QF`@3!$20'>NY_-OK;@(UTA..G6%Q."B7;T0JR:`%\:*#PJ!0"ZY
MZ&^6P.-3!LK&/,=/X'2T>ZWH3;NGLS<E-R4V&_'YR20-)\6AOB[-NA:V/5VI
MEQ211]\&#6J58)6#S^5L7O*S^#ZOTR6Q)^M>I$(0\")`;LV58"HJ9!)7.#3P
MX#-R4Z"/W`,Z=:.\]4&1"KIT=#^OBK*3"R^TX9-50SG[Y@)II->]J&)LLL]!
M`;CSL()W$VLTR6U#/J><LD#X+'])$&0`)2[-Y#N+IBURZ8)"*+P'.WT'6EQA
MZV&\*;\LU(JGPH4K/PTG?_&J(+6([_T-]'X;AF*L]^;X@<*VA3MCCW@<'U-K
M4#\!;JYO.DE>FDDJ!;H7KG&=Y`E+A;:V'K#0#``O*5N8HR4J`'0M2$02+>6R
M%1$.?RZ!5P-#4[IA6&(B\DG?,^GB\.89_T7\RW'@F3=->+5N@0,IX4L64(G+
MLVE<15X82>&@%TF7]B+Y<TEEP>^&UW^^/WM3K-MO#1K8I6?-P:U[R+FN(YWH
M9UBXG5F9NHL;=K%6P,=G0EIYUJ>XWDPJHX@@"HS`M?^FMC]%-@S*!!;UP;>+
M%>"PZUD894Q)41P(:70[3GD3))VE&N_^=?WIXKV,C%%E-.@J$]P6/S+GK4H<
MK_MK.!>F'D#N`D$?HR(93KF]HOR?\F[I%0H_Z-D%MBWA#9%$PR!I6W"764G#
M(8.<:-RS%V_E2;+3$+#F"0(SH9+MX"[T.7,@,WSA_BWT'1+>.?>5++4,;A+E
MO9:KXF[%WD)^*'*%<_1!4IZ*^:X%L;+<B+W7?V[$S]B["?!>4:GY*YW=9$$+
M+C!))XDE>Q/1R<Q^FB'W5SZ%?-$ZOSA>B5GPZ/^'ZS^N<0.()&^D:?P3+(4P
M0DXKV[AL*'S70)TA0R%^[VXQH4N$%VF2$P:[T4$B>`CP9%#6X:9ON+Z@O0K-
M<,HV8'$,N,BCX_@"D+9QS&1V@I*J%.-L$D>A;B'BI)J7)C.^5;\LKBGN1#MN
MQE(_"+EST"?94L>Y#3J!,O>$_BD/'LSD@Z64L`G_8:F27B:$<[S9!-=F5%"'
M)!37\$27/00KCR?A!_F@$Z&.2I&0D2R=?1"J+L*9-U])FT-KU9/K[\.#VYRZ
M](`3WP,P9$ZUTG*)=5GMS=#@EMU\,##)C6+!#DF_DCIFN3M4WS2:T!/$XX@B
M:FG,ER!-L8&:XBKCN>^^7"&'1>T8GHD3A2MKW!AS$T87UU?P;1"<R)F1H)'#
M"P/!%ZUH,LX.2^`3^#WR/RJI(F+*5(:>E#!0[@("YA3$R`A<BJK#:P7?D#>E
M14K7G<!8!AZ'/NDY+A=54DR#VNT![5S(R`V>D6^4HUZLV9!Y/-59&T=S0J<X
MPR*A;.N!TS7E7CU-IUU3U/5G`1=BM2A/?5LLN=>8`K72^R;Q2E?.7>PF`FJE
MRQT[44#,((L*`5XS7WF;I,4(\C%=B)0?S4$M#A$NL8\76C/`;[!%%;>OB`/&
MM\8<,P;,S$K*&YO8\8Z\F)/,G$2K!#!;PH1L$]`#X6!LQM^L^XVPM\F:`]E8
MIE&<DE,N%$L(="#YB=F2LPQ">-$Y)T%VB<)%@(?)>B']S58YF&0=OW1D)O0A
M)9X+,52\-?[/V^XHB2884L9--?+5T(I_9<*2>Y0G^+W2?*YF3M_C/$'`(:<*
M1=N#Z$C6.0^RU#BDVP-X[(+$6SZRGX*PA0LJTAFG,I75I"_LK>MIGK3X72FW
M1`H,B7TP;8(ST0H2&8MX=7YKIOQ]A>Q,"P!F9J[NQ*'3>#E7"L=,7W@8,Y'D
MKP2KR>LM:TV+T`4G.B-I1\O?)J<U"@1XW_A\2:73T:LWR-L<L.),JG%DW)4@
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M(B+330IFJT&Y05(-1[6-VC.6&+M*&5U7LX2Q0:H--7GDN0YRLR:U;`1AC8E8
M=!J5Q+I_(IB6VX56C2_ZR=ZQ4EM;2CXP!>5FR)(1/]-E>$F:L")[%#%F:G(D
M;D!Q,W[!@FX,:EN;L3EQ02B^&4(D\7P>=T#)HE]^WB'.$S%6I",%D@;6(2Q:
M4.JO+[/5"YX+=)U,M-!$`1-XK\_\G9V]R?N\N&]8\MIB3B&'5M8YFZ2V%.[X
MA7(@$8CH[2AED/')B`)VT`255CARHAEI`G)%CD?(>*8^1GUY>DV<^>74][BN
MA!@M#5:,<!3RN_3^BQE<-T-3</E[#\5*>)\I8-*RJ@@_VM/C+9P!FLZ%61.9
M.%@5.;[N%=_A$]>P:'O\M#1ZFC7"S3Q5T@A]8/F&T@6RU!0AX;>5#>AA*HI(
MBLJ!BEQP7N"(ZXLU?3Q+'MN4ME.(]F:A()Y>(CO4;K4<7.XA0"LXTL)'Y%[P
M0_I"Q@'ASV")QT6WOEN8!,#9"[('>*;4#C)%F@QEHW#6(E0/>6Z>,2Z5>FFZ
M-7>`[>R-#CA:;W]4T[-K,A>'GD2BI9]+%T3UD"E9+;EO7-YFK&%0EC*X)S+I
MWBI.R-+U:K#@Q@L8B[AYN1[G-==CD`)J+)>FP]WFPJ018R6*"6HRS*PYUZ/T
M)K=CKK_PE*!U3KF..1B<DU$C?3R(SG"RHBM^0([)BM"R:&LFWX@KYHPKW(9<
M<7]\^5:"`-_R"*#50V\N]MW<=?%%T#&O"I:D4Y)#3>4L*7FGM&GN>)?C!811
MQ$.]:BR/"&WQIJ+H-;FA@J=_G!4*'W5T*>0.YLH#;U*?MTW5OB2PLF`$43V8
M]C5TUI6]`_>+'"ZC37=%?(2G=)4HBU@:Z5%4!W7>V1W):%)F4(GVYJ`MD7:8
M"QD9RUM7-%TM.</&35"F)>A,"R^.J=(/7LGM8*)UM$*`.E4,#=43G'5PB?D/
M5,Z)M#B<H3,C3H3CX-WE>/A>V80&"1R\%!TAB-341MT4#-U(&/;D<-3,79=G
M+:[O2B;=<G.4UXO@XY02)&QWLM9`O:&=`72N"[=&XHMMO)T@P%?SJX[(Q2&#
MQ#Y>=E4TBF&);Y$[9%341`\%:``XTQ-D==-`9=@I'P<MF)$KN7&4MGTG\J)`
M^_#BO\GL"+%QKDC]%?YQ[CE67MNI;""0%+)<U%O$U(M,0FC^9)(69*U+(U?N
M])V[YJS(10=C'GH(XE0DC!%Z\W$'QCNK\##/NEH+\"LGM#9TA1]+[9[";^_L
MM?5N7=%`79Y7]]"L>>;?Q>]YAIM(&\Y;\V&:4)IGOGQ4QM,>M'5MX\@^)UN!
MR)4MBL3AW`3*CHZ3W.HB0C#==1GH=`D#4=J7!0(HQZX`$AX((1V!8ZW(=]-+
M*W4?I":.--]I7)HY%T\]7B0W-37>9&IA*B$(.%M#/!<*-Y6`3GB3;;J,`ERS
MWM1Y[.`I'L!'B%ZIO)=["@(<OT7'$Y'HF;:D4I?EHAI1%A.YL[\4H4X,>"/<
M=X#;4]GYN4A/EM'BQ1II5H1)_A$&#:ULHYBY7RK[A8^%A"?39H).5(GMK$B;
M&^-(HGX;D3G3@'>F;)!XROF<UWANE/,":/KHYL+W/+7S,"B)5I776A8=TDML
M$9,94-COZ[`BCY#F]=<W+//(<D[#+/6.8FW>)$UDN;M*5\J7@2#=ZK04%ZI2
MLLNAV4<;(5UP$>T!SL)&UCB^,II%O6)I>GGFKL(W!J&2A:EP#681SHGOW;@B
M<WCS-9UMJ87&:ZI8>>)G678J5&9CJ*R""M8IEE)SL7)6-VRR<JY\YBVI&;D2
MQZS(KM"!1>;52(_YK)`M@95+JD2QO.E#F2-Z2^VP"`+@*90K<;^R,?D6RFES
M%\+@+LW_+C2Y()52/,;M.I0]5/LB1-Z9UMM".O]E.;0X0+Z\\<^LY<E9OFD#
MA5QD"E66YB#/7U)C1]QA2[@^5U0-A)]AR/G/PE6>?33^F<<6R,*1.O?[LG@=
M/Z`,6LACDU7#[Q3!M5;VIIB]:M-"_CD-Q=PIGQ'FGCV@WG_MD'+YDM.@/R=@
ML_=\K]E.40O.U=UAT1U1!^;\9O$9I?")`%E%%`=*G,BW#]E&_5X^L"H0*6_@
M%(?>EC;3^"2^Q*7M!H'JS<W2U!)W:VU_WM9#;4T8;BXY3'454M\3F4IP2]/;
M,.1%U@K9]%-E;13*Z@4W-9;(,@:4(I%+'<@4>#T+),R`E(>+5B<5TOP:%/:Y
M%,8".7.8B,X^ZZD%"P0G+4&,6D5`M,1$$:X7,)$JGMBAG`87BRS<4L@5$Z'$
M_%X5F\QI\5ISE,S;H;<KR.8N>0OTG<VR.'\^:R*OP9;OOR+$>+F#^NY)^2K%
MQH>P/9[D7Q1M6TFQ4&BAJ;3T967(/F0':&?DTIRH,GN-V/-A3-%1!BET:W^/
M[ZX.V`;L!Y%^D=@W0146N=4#QGI,6@DAY='G5IT*%(G,(ZG-RY"/-`R$498E
M<I3D[I!@+I"O/#F-=MW[<IM<KL19VQ]B8$K5$4EW&Y+QJ;#2/2OM$Q,75(8B
M#INB;$9GEEF;-RZ]M#H9S112$/.].<OL2/ZPJ5E?EBWF>S6-:W@+'[R[%;4,
M56^RV7S.?(":JR_;P-F;7*;&'5,YH%IW`M1A]\/MIO'/\#Y/T?F"T7Q%4P$:
ME!F/OP68F"U<]E.F4GZ7$;?=@2LG.D3.-I=%-(VKPI<W?E46C*S7L3ZTQ@`6
MH2H#X\O5!<_`X5G6^Q<*P`I9J<!C"P60;<E2`:[CKA<*;!8*F'*"T"BI&=A=
M,4#Y`[MK!K95#)R],7;4#.Q3,4#XM:5F8)^*`?*8;ZL9,/:H&#A[LZ-F8'?%
M`'&N'34#7/_94C%`2+&U9F`'7F`ZU=F;AY<1%(H(>!CB@64$A5SG!Y01E!<1
M2)_>OF4$:ZMRS>:A900E101GQ0:!.\L(2HL(UIS+N\H(BKKS6AQE5QE!61%!
M7MG;64:P47H)!]_^900J>>;LC?&(,H)<$8'`C0>4$:P5$9S)0K4'E!'DBPC.
MWCRNC"#W%)?Q#R@CT(L(-$B>0AE!L8`UUZQ'JB'DT.9NGYA.JK/@[7Z?,ONG
MJ(R[B?#6QWG/$^6'RE*>O<V`?*+.-G7K[$W>D9)E*I,73.X#M\MS1#>(\+,W
M^=I(':'RLGZM/+NX'\6@**0H931/GKQAQ9I@*4&7(>JF'L]9/--J[:0\)FFB
MQ8N4D(==J,+FG-OH3#9,)$%#!<M!6("3ABLHJ1#5R58(5L(<.5-3[I'*_M2!
MNMFM^)"[+LM#QHYZ&4H),R4+E2BS1+-6'HYDG"2`+:UR`K,A^=*.@$KY"[<U
M`I6="D3`)J>!KZD)&F/53%5M)[(K@6PK4C1PDLW)^!JW7]+D!;KS-?-9SS8^
MT]J9RNJ#;7IV:<;YV9N2N]9SSO?(..?.9F-;SOG6C'/$B+URSC=FG#<?&PQ2
M9*C)'ZG-\G:"ZY;X:W2V%:-(0B/='$LN+\N*B_2Y2]!M\K/EU:Q,XN1;=W,%
M)WXL+]E(_>7/-A_8+:[H(2*NH1@Y:8&;O5?;G?7KHV76IL7LG/B2'Q!SX4;(
MY^,K%EUC$\"QYZ=D33YV+`QJ;_24%X>.;?6^_GD]_@KR[2OU&(S?PH&G(/;]
M^)>W]MH0F5%KW.Y:';OAM"^<AC/H7S3Z@]Y%X]+JC%N7[?[YQ<7P:_NK9;_]
MM=5LM;)3;SA&_JS_RY"JV&R(^';#_DAQ+/2GN?@N/1=_2A.RED1[B^^$P?J9
MUP?G['MFY^VOMC5H]?N=07;N!QXI#X_KZ2V;I3[[-*<OCM`:030'7".\NTX`
M740\;"AJKFB:^--/#QKU!L-1]_*R<6Z=#QM."R`Q&';[L$KO?'0^<+JM[OF#
MI@>]0,:UUA.>N%><+D#!)*]WC)!3YH`L5\M\`%<^)5*NIR0ER$.H'O4?#\@L
MW[5Q6\L&V9RY+DZ1FWAU_NGCQ^'5-2Q"+&T9LUU`7)_!2`,>"/.Q;7B\=+%'
MG/I]B6$T\?N]-TMN?WG;=WY4D]&F%"Y1H\:*8^VUJ??R%+FY9C.Y9F?PX][S
MRN0S6QYYJL]?XZN_>R)@?^-`P$>/K7S0B+H\B4BJRR8I)F*2XAJ$@88`_0.2
M?.7X3</'.!?/-A'.\X/))I'Q4W&JF6#3A0EF3S[><X\GGALZ4N0U"J`0(C#;
MW850N78#[PK="2\,NFH#<2?(SD6WN]3ULZ-\`;5Z]Z/O@'O_7^9&\?NG!7F>
MKZ"DN`!;84U.E(F143A;%<7(J8T<UM1`TQBS*<LSF3;O7&FOFQC//-WS^R=2
MV\[`[+7LO1Y_],#4%^*>.X_;:@Z>>31L]:ZXUSR*<>,O2>G;!M'_QO,;CXZ2
MN_V>:?6?^:JK0L?MIC5X?71\R#'P1R+#MU&V5&F/C[;?66;+[IB#]J/)^_TQ
M4'6KV>L<'54_^_=.2[Q>AM&<>0GO3<&^+;%2]/CHL=TV!\ZC)=!1$*/5M`ZM
M3!P;,:YW.OG^'7P'-(I$+?PAY/G.G"'?A#.D!&<>2I+/^L*7H((::C76/0Q^
MIZ`S[^WWNF;+I.CX:I'CJ_TX$0Y_F6,FSSH3E5&*C9B(SSV2D3Y*'-IFO]<S
M6ZW#R,0'`>H0X+&:G6>V3H\?A7K-9_:RGIIRT@:N/0O3B<]>2DX\_HU54D]>
M%=QJ"+Z(BE(5A62+#K*>]%,Y"7+`[SVS_G`4)ZOZ&4_!FMC#`X]9`]6GU>_5
MB,U^IV-:O7[UU>)#@.=@D?B:850V-O`O%B>BA\.%UKD0/SYY=C&P^F:W=00V
M]"&`8S>=FED\,;/(I_AI.7S\JR2C^;?Y_^CCM8*9[Z^"R%=5X+,1NX7'O3OV
M(<#6M+P"IU"'\V2U$\YP/+:LWF7#:8V=AC.V.HV^-6PW.FVK/QQ?],[[W=&#
M:B<>VY%R"U.>R&NA)I,Y$!D<1L:[CV$L4D*S3I3JN8/WI+R@9A&XWPTSO^U\
M:1RUC`'N/[S^$P>"-UH=4^R>3G?%"WU597,92,P,&*(`E8;TTJ+GL-B7<.E-
M#=MN:0/-R]9I:NM0(P%<1;0H"T0W'K%'V?I8=(K)[S$1+=^S]3UQ=3Y>W=D;
M-7&)&L,'<JP6]B//G@\HBD%=$E3;-'@TQEDXM*EF`1BYEX@^XLO(H]8)<U&?
M34T*<M_+>D9KC4/P<,DJ:W5'-;<(4-&^&Q;*+[-]+[`<SJK(GH(EQ)]DBWP^
M(X$:SF+!(>_0Q"M\MCD"!"P1K?8I^MN7Y^Q1#[>I=&RH1J6]4%V</;P87HS'
M76!K@W[#<4;`UIS116/0'8PO.A9:A6VLB[/>_FJW'*?3ZEH[ZN)V'ZW`R=WX
M=AC,\#\7@#@@H1`]/X,N%WFHV97_G8/\Z;A[9W!QV>GW&I;='C2<WKG=&'9@
MF4[OHFM=GE_VNDZ[6MP]`Y"!H*DL1]>K>JDA?M;T';L?4)4X#IZ@KB:);.6U
M#&./#W9`IL6B.RJFI^JXA#KD(.7?N1$6R1OA4@[P\7$XGFP[%2U#,0-A"B_T
ML)%2-).M`G`,O1B3DZ^>CS*X4L<*U>4TQU,GKD_M=>);QA+>X.X'I^6`*=_"
M^NK=/&=S:<!>G.@[:*90G8IZUVWH8WGY!?%M+&V.8D9_N%[ZWG=PH@*168/6
M9<]QNHT+JV\W'*OO-(:#RVZC>]'K7ISW1Z-QO\N)S&K`_3:L?K/7:VMUN'ML
MMG"Z4EUSF/43BD>K[#M7O$_$\![P1*BB(@LM!:SX$%Q1]6B!Z<ED4:IN.E!!
M=\OJ.L[%N=,X']J@F[:<06/4&O4;HXN^W>^T.]UNN_.UTVI97QV`;=-J:R!]
M80CE[^<J0MI-5EBIFP#"XJ52D?[3Z^_M]KAW?GYI-UK.!4B[<1<X?-MN-\87
MUO!RV#YWSML/JWU^9KXI0<.'DDFXR*8H<M),5A[]BBN9>]W22F;E[,J;P.*A
MKO/P4F6K=;B"X>=_=UTQO*.<LURJ9[^H_*;)OI?[W0`Y!!A*59<<%.RGA<(I
M1+NVA:I1\J8XRT6Q^<=YL;_#@?G#(_VMIM6S3=`P#N)T?;E3@HYA]EK=YSWE
M\<5HMN9?A/,$U,1'QF\/6+-AF:`6FJV^=1PX?23'/74>?IE&`5E!1X?OG<'`
M[!XH*?<T#WM:C/RC.SF@8O+=[*UE=D%X=P:'2:]Y\?/VS9[3,WN#HT#QZK+S
M3_,YNO..%^\[(->[KX6IO\!93XRG8YP$'>DX/2L*[[3YE,>$Y([9'X!AUGLE
M>`['[5L'MD./L#KH=(I(7[(VZ'2@=@JZRK9LV/)(T>.8N7\\B;`66').VQP<
M0WKX0>#3`\NG9]J#NJO;@S2CF,9)I(O4%Z.]EA&;BK$DU!9_@6,<>,_XDR>R
M=Q:6ICBF93VZ)/DQ36PJ3USO+,=LMP>F,^@]"UQJ':RJVD2M@]4ZV+XZF(E)
MRY67$8^,BCJFTQV`17J8CL#/+B$>"96V:7?1_UK;Z`]B/*?41^$E)<0IP2V/
MT[G*,OI@+0MZ=_;H]BE,(S?VIA6?P63MFL%$A]@T<6@8)-X,ZS&\.W:-L\N\
MQ&/QA:C'N8S"!<\](F/FT[RX]M-GX8Y'X_-VI]UMV,[Y><-IM2X:@TMGW!BW
M'&MPT>T-+@?VIBS<?:HNGGEH7'X@$8X0`Z.0CR%B69Y]AN18%R"F9\ZR3STY
MTGCJ^E,T,T7EUTQ,!5NKC\*Y109AU2O.\AW83S^OJ+LEJ793(JY]N!S@^M7/
M\NHZ\?EM=TL"_01__H(5EMDV?J<*R^SWBR#'X39D2N/>)X]4.X\09G]X0;5`
M5B/ZCM3V`V3P'_S`3YRL7_T#US?\E%RDG@"VUG@PPJG)PX9E7$5R%#<5J#[*
M)C]D?HUM6IVN:5FO;A16??#ZX"_OMSVZ8+EB=?;1L[KVP#;MWJM#^_K8];$K
MR>(JK]^-CI[E809+UVRU'YW!<JQD4!^\/GB%65_%&-WYT3.ZCCEH#>"?9\[)
MJ`]>'_R5'/R5Z'CCHV=]O>[`=+J'KGVNCUT?^]B/?9*ZW?@4/'=F>V"9@\&A
M^_74!Z\/?AH'/W7M[G]=;&^;Q-B#>IE&TULW9J?$$:U^R^SU7YUWNSYV?>Q*
M<L*J\#WB9H;HVWUT7,TV!U;+''0.4V]V4*EO][IFQWIUSJSZQE^2N^T_YXL^
MR%?C;!OX]51%2'N.#AA[\=0/X_0YRI<ZPU'KLG?9;9QW.QT^+6?8.V\USAUK
M?-GIMGO=3K<28V+:S7Q)\D6N+<Q$7>NAI\/44PZ^=\J!)-W'U3_50Q">6N,[
M]1*)>@@"'>S`0Q#JK/MZAD(]0^'D#?9ZAL*+X/21'/?4_?+U#(6CP/9ZAD(]
M0^&D$;R>H5#/4"!&5\]0J"#"5P6]ZQD*QXCG]0R%M6>+)'/:G6B?"A%?%]1.
M05>I9RBL:_;U#(7M\*EG*-0S%+X7B>H9"IO@4L]0>)W:1*V#U3I8/4/AIIZA
ML#']L9ZA\'#&<TJS`%Y20IP2W+XGI?<@'?7'VTP#@WU;LB#&_,^(\D`3[$)M
M+*B3LL&P@?(9UK*69:09F(A&*V(NEG'OQL8/;:MK]CLV??J#W>Z8'3!^886(
MQ4LVQ?QD?V7RO_;;CMFU.OR7GFV#EMI5VPB\X%&[,'-O:N9NF_^//MI_T$5)
MKG-A%`1F4$_<F,TP00I@27`=8OW;#3FL1ZOL*U?N"C\:WKO13%2)?$J3.('M
M>\'-_S)DT&PVO&.1>\,^LX7K8:+V.<`A<J=)ZOI?6+2PGRS9VNY8UG#8=AK#
MT;C3<,8CJS'L#T>-=J?=']J7_>Y%?_2UW6I97]MO?[WJ_=_V[Y8]UA+07_[H
MF\9P7*:8U?`[/+-(%Y_A/:XO7AA?AM$GN%O86W!#$868B/7I4]?M0:?;&MG#
M1ML:`C3[5KLQ[%K=QN7XLCULVQ>#87_CY(V#<`8.-&,9><'46[J^L10@P[+-
M"="?.V-&"M3':=)'X!GN#3`(2B$'6CWC4S8"`)\Q!Y(S5LR-8J)&^#QB[AP3
M!EW*,M]"OK`,SO&`[_$T]/@5)Z%W^Z5)Z$J'RHM'\5"_\_`L\RV//,WGIV!-
M;7/"?;EG/J`\GSJ`6@!.K-DR9*#*UM7S?^_X'+#;+&G@6D[E+_61QJ%EVO;`
M=#I'4?E;76<+H$BG\BCR_7FYG3[@BE7GM3P,,[JO`#/ZK;YI68-CP(Q*<Y'>
MR>.*;;:<@0GFU3'@2H4PH_\*,*-M=<R6?11%314V590Q?O(8T[6Z9KM3!S;J
M$.ZS\?@JDLTC;;T!95]UVX=L[5G32V7H98^1X$_B<R\)H8QVQQ%&&^((OU&O
MP0_!%8N\</8$X\;7QXM_^.-R?<#X1>O<&5Z>-[I.][+A.!>M1O]R-&ZT.^?V
MH#\:M<>MRZ\=C)[8;W_M]GM6OUV(G3S9F9\H)'7I>M&_7#]EPSA.%_Q%%]\P
MG,9F&'ZQGBQ6`OK^I>7TG,;HLMUK.-V+\\9@V'<:X_:%?=$>C,?PKZ]M$79Z
M@HC3SI/E(:A_G27Q,)A]]-R)YU-?I=\!H0'Q9Y^"S]AK*0(<AR_\$0:1_!4G
MQC]7E,EQ;'A@;#?&5F?8<,X!<L.!;3?LR]&@9SN7;;OE5"O*Y`5N,/5<WW`)
MF!0=\C-P&G$Z^0LN`H-.<X`[LLB4&0L.96(GL,H]JP-$SS>EW1D\/'[4/5R3
MHOK5U0S8'7]G)LO9VI,(Y8)!@L'X7>-/AIN<;<U/H=U.GLH,?KWW%`'KEZVC
M]FPC]24$O?1A\-=?\]V0>!X\W7[F_TG#1)]\?Q5Y4Q9GOWM!'B"3R/A)VR%]
M/J0<JNR9W]WH;Y#>V0?S,-J]RH<9;,^;@O#GFM33$L+!V<6.1F[P%V\.IP=3
M7NWD$R;&[`;<ITG,HCNRQM2C'X)E^HI!N!-F?P9A!K7=J/D,T#QZSEP]7O:1
MW3'?L%X5UO,S/W%[PZ,X\[-J2G5+QX)ISF7RNBW]["SE4-\[QIW6>Z[S#]>;
ML;KQ+3G2IO@#EO+!7@[2'>>1@:>>V;%MLV4_<WK04_&!(S_E2YU7O`BS8Q_]
M^AU@J`]_:HDKV_C<[V'`5L:"?`_&/`UFQ]?^R^Z:+:=G6MU#,X'7=MX7/_EI
M<+]CA,)I*7>?69Q$'H:F2;T[.H[GM!RS_UIZ-5?CL*^"RFLH[.1U=2[=,[[P
M)1A,#;4:ZVKX'5_&>'6=_)0`(7+O'J=*^I5/8V^WS4'/`;OS,/,3'@2@&BS5
MP9L*:;$UL%Z#LGM*G=!>4MU]57"K(5A#\$6[&!Z#PW1K._2LFN21R2PO*'T/
M^;UG;E=^%">KSWCX,YZ"S;V]T3:;LRABF#:)Q7_W+I8H)JKL;55Y+O5(&^%=
MMS<P[<?WE:[D&(8CLI>.%G%J8%6%RFJ3N[IJ>VURUP9C#<'CA&"1K^:W>TL-
MT']Y:W4W,T_M.UK%\J8'CKX6[;#5W&,V+19S6U3,_<1E6:_WFNIB[KJ8NP)H
M6!=S'P*$.V%6%W,_A])U8`RHB[E?TYFKUO:F`D[CNAK[N_#[\#NM]URA`-!+
M4NY)5V-;?;,[Z)C6X^=$/Z-2<H+'?*D#5RBJ\CH.?PHZRJG78P^H/GG0.4Q2
M].L][XN?_#2XWS%"X;34N[H>^XC8734.^RJHO(;"3EYWA/DRIU/9^9+9,J\(
M:C7\:OC5]=AU/?8V):QO6O!/J]4YB![V(`#58*D.WE1(BZV!]1J4W5-*,'U)
M=?=5P:V&8`W!NAZ[KL=^^N_5]=CU&:MPQE.PN>MZ[+)*T8YM#IQ'I[O4Y=BU
M;5D#ZY!$5AO<U57::X.[-A=K"!XG!+=-!M1&__&O4@V:]NS,N\-?_^NG-&[<
MN.[R'UA)_"\L).8U',-@IIG`HK9X]BGXS*9I%'G!#7SACS"(Y*\C-_9B>O<7
M]BT9^:"B_@KO,OY+KG\]O66SU&>?YI2+E$Z3%)^#7UATQT:K+ZLE_.T\C!.U
M@#$%X0>_?&;S7]ZRT/]Z=6'U!O;`:32LMM5J_`_`M_WU^LOXJ]UK?\4AU:U!
MN_6U]=;P9K^\]6;P<1_^O_OU\K(W/!]8G<:Y/>HUG$O+;@RL4:MA]ZUNZ^+<
MN1C;[:\6//@KPD:`IGBY0E.GRP6]_&<CI^L[/^ZIZ<M*)5IB4S+^K1O<P-->
M8"2WS/`!^LQ@WSQ-VS?<B!EN;,Q#WP_O2WP4F_>]:R.VYH;9C*V$407$/__T
M\>/PZAH6`2/*=Y<QVP64=?LKC&8,S"^XQ"GSL5)K"EBB?E^ZLYG\7<R4[W5_
M+"OD4NI&GHK%0_W.YDGT:PJ/>&;+(T_S^2F8L%NKPZ;3*'5]8^+Z;C`%]$TV
MMRBP3M6<M5IFM]4SG<$SSY8Z+7?L%<B*J;<$Y%FZJ\7CZY)>$#^^-Q'P7:?=
M-CO=1Z>!OBJ;K,X=.@$A8.3:TYPR;8,0:/7:YJ!="X%:"&P5`DZW:[9;5BT$
M:B%PVD+@FBV3HBG0(G'0KCR5/](4&)`ET&T_<U7CJ9'YZ?KP]G#3/<*-MLD/
M=^%&`3P:7['H^M:-&+KPIL-@-O;\-&&SO#/OR7QQ%W9KT+^P.XW.<&@U'&L\
M;@Q&YZ-&ZZ(_M+N]5KL]&FWRQ6W[[1!^.H(8=<V8<9@9H*"$"V:\\\,X?F\L
M0:>%WQ=A8,0(8<.+\?<E?=6-887:?3>P2]UWN$=T:8_8C1<(I_8_F3L33NWM
MWKV.54'O7OWJ8W.G'KKYW?>W..MN\8Q/\.<OMQ'3FVH"D[_5>FI>!#.];V>Y
MCD9[GSR?5;3'$R\`J3^\H%J`JM%[1P<_93H<.V[N/.9+=V:L;_.(;G-;FH"F
M494I7%H6P<FZ(OY@25YK?Y05^3TV[R.]!UVSVVJ;@[Z]U^,';XKRR%/:<,J6
MV;&<$S_EP'%,RWGF<,"!3VFU3'1G=YX;94\KZO&1Q?$_C#28>=C":4*^`R9<
M-P!C/YRZ^%$2&DLW2CP,D"3P-W@RQN0LRM]Z<9[VW7&/KNFT';/7>=$Q;"]_
MS.]F;\=RS._D;\=QS.]G<'6\[BCC=2^91E]#K89:#;4ZHK[#C!6J(9KQH!KJ
M4:CJ9\T\UK[H#DS;?K3&^%WZ[H.@\X(P$6]]SBK(&E@UL%X<6*>F"Y]24LM+
M:B@UW&JXU7`[I$Y<%0V8)V/=TX!A3*^Z8Y%[P_*:KQ&F29RX`28A55X+_EYW
ME&5:?<?LM`XS*>C9U9;O!T]K8)OM&CR;P.-TVV9O<)B1*T<`GE8/6^$^<QO<
M4W=;X&LF^#/GWMO39PD@$W7+E>;=\EP_%#;]<#-+KM1JBBC1_HN5H9U<;N-1
M]U[^A0CUZ2&YE^5:0[F&<@WE[X'R:9D73Y0G]H(RZ"CSRIZ=!H\R#ZVZ4#ED
MWEI5H7)<>6[5-0X>F?FFY;W!(EB=%R:W8$JXLUECXD[_CO&)X.C8^5.DU`%C
M[SOMQV)E)5OI'F<*WC&`Y0`I>]4'2YWB]TH3B.JTJQIJ-=2J#+43]S>\PH0^
M&Q0SZ[E[I!V9<5GGJ-7`.D5@G9KF>TJ)0G6"50VW&FZ'?^/+:,#5=0C7*7YK
M64AUBE^=XE>G^-4I?E5AT1?S.9LF1CCG+3&]._;=;2B.B!_;+;/5Z9M.[]$-
MNT^;I``^CM4R+:OFR!OAXW3,5K?&GTWP:6-;F-:C8]BOTQEQ.D[^.C120ZV&
M6I6A=NI."-$>OW9#:&+9,FW'-@>]VI+<!)].RS8=^T2SAY\`/H-6W^QW3C34
M^P3P<2S;[#OUI)A7Z]NO8R(UW&JX'?Z-+Z/^5D79Q==,\.?Q7@.."``3)0(J
MK?/ZSU"A+08U[K]87=5Z;%6M-91K*)\*E+>-!M%F?_"O;AA-N/W7LL&%#YH[
M6!A>F,!'MZ$_8U%\\>_42U9_A`D;>_$4Y%$:/<.XPGZO?=X?CGN-[D6GWW#Z
M%Y>-H=T9-9R+_J@U''?&E]9XT[C"TAE^5E\-['N*$83J[IVFH4,GP[K!SP8'
ME?%NS.;>U$O>;Q'3I7ON/N\8Q3&-L#3L5LNF<DWXH6T:R2TSSL/%T@U6AA?'
M*7K:C"1,7!^CRVW'M-L#L]US8`'I<IL;URSRX*=APZ*5U*\V(L0=BQ(/<7L9
ML3F+(H;C?`!DL,([^<WBW]X;\S`R?K":H#2BML/G.,+;4I]J3;T`2TEAA644
M3AF;T2[<)?SVS5NX"?-7Q@^P5T`W_*>Y'[QQAN-S`OQ38'R:)F%N/IEEX[#=
MEI,'/$TH(K4O"0'\,8=2.(=%DL@-8G>:>&$0&Y'KQ0B.']HMT^Y:9K<'RV&-
M+4`C8C[5Z89S`"Q^:1K&B5BD`"F[W2=0&?,H7-!&8A?N"Q;I6:;3LN#.>]IM
M>PE6^(JK&VV[8G7!H[4+;AH?`E@%'@X8G<:X]Y);>OFF9]113,-JFUT`6LOJ
MYO!0*L7T[7L`8;Y>61!IAK'9/0#J$C;E7^C&@,_PO\1K\+P*6'S!7.1YQB1-
M`,8+UPO@ZVG`:05ANW6H<M/X<PF+X#A2G]%ZL!D\](>K3XC5`D%@'?PV846L
MGT*<E<XF`"_QI`@&A`R>HCK8_[N[TC"_2YC?S6,^8C0<Z`?',?N#OMGK.!*A
M88F-*`V<`K'4Z9:@L&6US$''-FVKE\,5P&*):>=[X?#Y.H(0%F_#X?,2IJ=A
M,7*GMMD&)K<O#L/S:UA<0BD[$)=@64#=1R`NLJ,UU'TPXFZDX.H@[G^G_CKF
M]DN%)3!TK%1NM0>;..9X+VP;KXM$#TF:?9O>NL$-(P$)X)7\0PM\&5-WZ:'`
M%K@`$EE[(ZP1@/86&TMW12HG+/#9O6.!,?+@\^EM$/KA#6S!!-R>-HUW]$?`
M].MT$K-_IR";_)4)JWA(T-'T%B_<(BF5)#Y;P-^->\"_B+FH>V8D`1M>`'K0
M<I(W25R>($'@UO&+7-O8!`<):&^3^."'<:>@?<4>_0F8H^68#K`'VY:"K#K(
M54)TUJ`,PR1OM!UL)P$,S=J3-W:Z9J_?+^&-(/?;[1ZH#?U-K'&\78?+T+5A
ME[+'+]K^73\.Y>T5U[EW(U!L$CZ<.Z)-+E-`+C>FC=IFO]<QVW9O7>G$'196
M:\(J^.)-+S%0F63?6#3U8B(!8'VXP00N$A[R<`,A$>S:S0"N`R!1]K-O2P^6
M29$K`J\%)F@2J=T"^B$U)'@=1+#T'EIX2H?YH=7L=DBM%1MJ;A".(!\0$K"(
M4@S%8JB4+V$30,FX*"#X1\\'5<Y#Q)^&T<P-X&-)$AKO60=6!F?W)F)$OV9>
MT^8KX,71JG""KCF`'8)DW>LZ""PN+"&.2ZUCY$L[`,]>JX]M8HA8D6V5K+F.
M7-4AX/]V@]2-]-NSZ/:L4O*]B<(XSNP6P'98Y0<0&Z#,FAU0!=8UF+[IV#VS
MW>]OI-$2\!@?Y(5Q3N#&<3CUB$<H5DEO()$,B`1KH$$0>:Y?$=B.4UYT#<P'
M=!6$V1VP=#1\.%;N9%)2S"C,TU"<*R@YEA"!>/,B;BM,$.>G/D#-FWM(;_`5
MP_?<B>>#4=\$<@W<&R[M)LSWV!WL([D%1L*I9>I%TW2!$GG*8K$P%\WQK2XI
MA?1V81\SL8<%2&')P;80E3R2VA-0*#R-Q$_*'')2UXO0DY4RT[B_]4!4PU?<
MV5]IG'!]#U_-L%/3W$!I#8\OPXC('KB3%R+\TEB*Y4]+I,_&%;`Q_.AWEMR&
M,Y,C$]=)Z%[H?=I&D*5G;I'SGS]15R@9T``NRH*8O<^^,?Y9WBYR,B(=/E<1
M;I@RI[@ZB>P5(4C$$,)V73*)*X*Y_\QT=`U/P<@T->>(^GFD?CI7/XW/WNB^
ME%*VBE(,5'S`)4+9.T`<P.OPAA&(\6*$AJYKU5+E`H0.`\91W#10B($R"0P@
M$7^$!0EG"/(ECY>\G*PA9'5Q"LC$MX-X)94+W554=OC<@4LL)U@$]BC>2@?C
MN\'WXV]!BL(:WW+'-5SE.4+*1%G\[Q24D,)W-YA>9%-SJB':P#/I!UE72W'=
M0&=$3>,25`E0>OP0"`8Y"&["!SLL`;Z?:FK%`J2WIV6Q"7HLH$\&LSQRK%F9
MPKK3C0)3@Y?P`FU_Q=87J'L%0'OB;,#6EBZ0H<(I<5WXEDD>69B/U2K)/2I9
M"]*P%*F,0N2$\,L8.#%8E-E?A!SE.J5F!+LDN/X*(^2!XKOZ39J[-XE6-:IM
M^"C%$K)-(HWP+>[<8::GK>]QZPX)U'P!_9E$H$JW:]@_M7^43Y9>A3@C(J@X
M(&B#_,#PL2^.:[RCOGRDL+IQPYLW,E-\XL:(PF&!WCE_!Z1<TI6%95MX+^^:
MA.;Z1>.?.$;B-6RX<)3W$J`5X>)C[\Z;@7SDW"X(`Q#I*9A96%Y%.NUT&H&L
M"X,-3!Z6V,GF-3++V$&.VRLE!JT4@W"7&Q%H'^)_VHXE?K`=6@Y_[M@V\3\W
M`$YGDH%(5PA[!_.=;Q\.)9T`]\BZZ,/8F#%`%KS<R6KS#6G`68`^@12NGHM#
MI0IEC$49(=DQ]V7]8J>>,/I][V_6^-O#S<(_61-*QOD[(#ZA:<A-QVP3.?CF
M-&;N(M$\3\8?H3%3!R3>,&$`(75$>((<*<`=<',<$W;YT`R0!F,V+?[5,KF[
MUZX(VFLVNQ[/BA^BQNCNKCW4&.`,B4=7E_=4D1"VFAUT$V,P"/]M.=G/8"[A
MZO0#EYUF'M')WUI@MAPQPZ7N?N=\E_-MO@4T-`S2*L4:P@I1P9@R#2!.)W\)
M/BG<=,I^!@L!0^BP-6Y0J$+-7$0GG$Y3O@W`7O45>I;:JG+O:0R(J>R4G*U8
M/*FK*4'D@"`%)"9;16C9RZ7O\097Q0-I@*!G:5\1$_L(PH*#&>RSA(ES2">.
M%@I<U^?PZG`5LDC('!+R18LG;MX343!Z/P#N"W<&_T4YF]?AI`F,=@\!@QY0
M(($EP"!$HS>#1_'0!0UI3162IMK:<U(DHG'?;`^`15O]9J\'_^TV!QWX3Z_9
M:YGT5[LEH,%_(>AQI;.H-B/I/8+FMKCP\@33S-,_L#XT*@'G[]"WW3,M>V#V
M^O8FI5E<.UX-X$*`-*T#9E]SJ$16E(O,4N]?-;CHQ<;[>T(+,$U@7R#^=-89
MZ^%`SKN231P]=WGDRL24#M322&F=>]%"Z(,>)]`T`,YS#XHLW*ZQ3"?`.C*7
M<Q$;(G;CQ13)1D="0)8:7;^L3#>&O&C=&K3;PM:Z80':\O`W=&TK-QGII;HW
M35>0?W!::Z;4F@H.UD8CN?6BF0:3DBBP6?*AO?[AXV2=,D64D8XJ.BIXFI+.
MW<N:&J\<@B5V^&X#AKH6$F+P<)$6)RHZ6DE??0P$RLZ/VF()RI:&JBM%N!\"
MT##_G:*C"?"H:#?OT&0*]@]HRPP%N.#K.5E,409REZA.ZSQ8)3!=-P7A2WMI
MRH3UI3'B\W)#8ZM3"3>BG0'EE2ZEU&D*.A<9F'1_'H(4\-A#@0"HG=(-TZ?<
MWC2W`J($#'KB2=G9]XF."_VE])Y0-.]S31PT)=>TGA2U_QVM?77S/DFE0*BN
M;[6PJ6I26#%P"P='/`&FA"H$!C=*L@J,=S%C!N8>PB(87LE"TL8%J<@F#XMG
ML20OP+`S4?+[0C`M+PE+O#J(ZGF?)Z9-H2*$+-MJP,H-4NG:`[@8U'&8N+88
M5.IDJ^`]ERDZUQGJEJTQ85-W`3A`_5WPYOE#)8')KLS3&/HBA,;-8X4@[B),
M@R3.+)*<0WWN!:`I>Y0UH%SK7$%/*+0!8AQ3J*0I3!Z%)`I=0?597$$F)O`0
M`H:Z0'\,1`K6#9DSO%N-X'04ME@[N8DA`C\E.14Q$8A9D1LO$$?AYGY&B4`V
M*4<I#!:Y(O2QII4@-6<(@FZ%!L\EX%D3W(DMOH"[R*"=I;9LP2&N7>R%17@0
M%LRT0-`F[$3C$\S&J7#^8/0D6H8\Y@$',A$BJ(#A-7&@!C=`#,(&Q0W/V)R,
M;*Z%N_![[-T$=/5%-8[N!>-00J$H6)`R3(;;SC,4_K\-B<C[YA`74H]%JC*;
M(5P8&,IXA"&&OGCT+1ZMLN]<N2O\;(C1-!ZNBG^C\-Z'X(JP\7]%]?B0%X]?
MB'#Z%9WKT<G+*0"6GO+BT+&MWM<_K\=?`6I?N3!XBVXC;^'Z\2]O[;54YY;5
M=9R+<Z=Q/K2=AM-R!HU1:]1OC"[Z=K_3[G2[[<[73JME?;7?_MIN6@,-IB\'
MG`?>RJ;W7KI>]"^DRB$H`PN^"<0!).?+,+H*X^2.Q:@B?V8H;(4WX?MO9@DH
MIM^#LWX/SN#2<GI.8W39[C6<[L5Y8S#L.XUQ^\*^:`_&8_C7U_;7SMM?T;O:
MZC[@&IX6&OFK4&M\%'%@4"1^YYE^LT_!9S2UD*@QVS_^,P@G:,JCL^=#L$P!
M-`#9*3Q%.W[Z-/Z+\47OHM5V&H/>\++A##JMQF@X=!J7HUZGU;='G99U_J`T
M_M;S>S[GH>^']\0'A5,L1#\PAE(B^!-(MWNA*6R2`^O)&.O!>AF0QTPY\D8&
M:.A)&4R>3[CQE$2#2-PD[W(6TN=:=B0O6,1O*%Q/!N5-0`*#;/;LVF%=N/?8
M>/<11*YOM-]SA_^<4D%!U@VO,<VU;[?^L9^J2-#<!6%;*YS87/+)P9VO'CW_
M]/'C\.H:%ID"[-UES';=]GI'$\Q#B'YY"]@Y9;X?+UU,7U"_+U'4B]_OO5ER
M^\O;;O]'55DTI51\5>^#Q3HC=@.`XN4Z_V3N3)3KR%/DZE!G<LU^]\>]:_35
M/C8_\C2?;RM$TDY6=G"M3DD=_-1:SHQ<GYS'0':E41N*V:RA\7-W8'ADF_EW
M'1PM]>@&@(\?GW1TQ==?*/TX#2(&6_@/9NRYP(QY[36+WPN[A+-+.1?OQ;'@
M>WN;O.N"P=A^IC%CI];0I.X2=H0L>TL<_G'4^J`JZ.^KAWXLC^_V!J8]Z-9$
M_:J[GSRNHCRS9Y_#I,P;K6-A'9V#67S#XBM@==/5,U21#R_[K4[;:IRWAZV&
MTQX-&_UA%RS\0;M[.3@?]2_&W4I4D:M8B02,\8$GQ!A7W#?W2?KFSC&7/XNB
MT$\5*BE7V[_ZI,H.>(!C(S,V>4)+S(N7SC`]Y<;U3<K^3H.$4E>7<':>PAF@
MI]JG.`%3Y83<<8NZFHRMS.1&Q"8HQ2A3VRC:X,T,D7T>RQ0^W2,.JTR$-(EO
M&4MB[J17*Q<*K6@G\%G,L,H`-499"H"P4'%L$<"9\6"[".H62H'5RN26U@,@
MZ_&;=>K=3EMY.B2W4CI-J!/`,)A]YD5D0_3I$]D_9X^']J5]T1V<CQNM\^$(
M'6[#QN!B;#<N1L/V^7AD#R\N>Y6@SF[3^,BP5NGBFY<8DBFN*D9[>Y:I4ETD
MXF]YS2=%Y[*J3Y/G3-UAW.$Z3)-;X]H-C,L(W53Q-&Q,T*5IB#(-8QY.TY@H
M1^#V#)U,X5(&.!9A$`(Z8=@%,\<F*)DP8N$N69IX4Y$UA@E9HN(#J2]JBJVB
MJTS+?7/UU1MQ@KU@R5D#^\5BMIBS`<VQE8%F8'5,0V.ZV2ZO:9T+#+G*R0GT
MG2WM"K1*TQT5P6>;BBRWEEBBF:D5_6+T^A%EO_FB7QZD(KA6)":L)YU1JE`2
MAIA!I#$HPU5\296[\M`?PD2K]U5'$WF4&U>1,H'B72)X2`%2@.E\CE_V$3=B
MF:"/V2LL0"'"OO$`+R8@T?-S=RI4)1&!Q9`FXF]#;G7)/?^J!I[8/D=.?H05
M<R.#+[_)W]0:5.2ZRML>;(&UB9H`YFIGD4X4G!2,S*XN+O1!B5%;]>);HO?<
MTJ@HJ,HW-^&)&1PA7"08C^(FLC*,;A)NBLMP8!(+V4Z%,H%SWX&'\9+A3U&8
MWE!Y>[\B4#_/RNQPXW*[GEX%2*'^6(0QXMJ-_[1N_/;#W?B]VHU_4)_0$&LS
M0"Q.]G#G6Z?J&K):9K?5,YW!,_?Z/JU0P!5(&BPM\I7PKCQ^?'=@H--NFYUN
MJ_8AUH&!5RH$'AG3/2(BQ\9CO;8Y:-?2H)8&6Z4!>B[:K4?/Q:NE02T-CD,:
MO,)P\8!,@FZ['F]3!XX?$3C>Y`'[5N))^I8G1>VZ-Y_E$`G`EVF2\CJ'@J07
MI?949YY5LG('G&HJ)MSSU%Z(?8-?L=@%O;K*@1PQ=Y[PLL_M4=&S-[4C[UD=
M>9V'._*V//(TG]>.O.V)F??,!X+Z':3C;8R@09=].0U57F0___>.S_9J;[E[
MG.-1^4M]K&_6M.V!Z72>>4SE*2CU.U"D4WD4^6[/C=GI`ZY8C_;/GJKC9@=F
M=%\!9O1;?=.RCL*E5VDNTCMY7+'-EC,P[5[[&'"E0IC1?P68T;8Z9LM^=`W!
MZ^$B6TT59>J?/,9TK:[9[AP27X[0AUB'"A["XZM(-K7/O::7[Z>7I_&X/WMB
M]OJ(F*PM!K5[TOK:JEF1HF'N&67-8WHM];+P?!8G8<#$M`QT<O,B@E`.?;C%
M81JR9"!;!%Z(&=K4Z19;5D141J-Z(Q;J&E11PPK3L6/LD'2&90F,S_CA7GWJ
MH]UIKC>/-.X]WKJ5_/VBO53IX"I5QL,[&,OT\R7\A"^8\6::(E]W[D4Q3@"X
M(EC:QM2'IZ8`K02'KL@.<O*@:T>4&\B:C9S_?$XE$L9UPA;&.8--7T7A3>0N
MFMF7QC]C-VMY9-655K3,%?$*N26^DSC!1&TL@Z(&L$&8\,;$$;\GN/$)@WO'
M).Y"S4G'Y/G2!A_S(>LU7-&6B]+M8]Z5&%WY6&PAQE?!V5(:""*[?N6?133#
M1F(T<0RC*7IM">_&S:BMU/NLQFJR,GYWIU'X&PMD=8GO3;'BB_?`*D`:ELC#
M>B](YP!-'=0EFB'2"JAC*R`J6L/U?^B7H1Q@&7;U6__+&=:Q++$N`'NYT+@I
MC=RH0('&6!!=4%MJ.E6>1L0U[W^L'`*M<;V#<2*-E>3Q0U*L*!N4?>ABK=<;
MWH=D9+R3&5Z7-JD&$93W-:/.@0VJVHOC'-[1;628)RH(>?]\+\%&TS/DD#CA
M+)P05]>G`LG=3['Z1&TY26@4(W6=UUK3R89]^9Y[8K<S7F!!L48/9U3PJ`@O
M']G6@YZ?H;S=_'HUX6,J!/,UAH!/0.S)ZLIW@P16P.9O!+OGJOIMM<_M[OFH
MW>A>.NV&<V%?-/K=BU%C;'><RU[OTK$'@X<WG7K&HE\)(4)'!1ZZCRH6^>:V
MR^1V29+SH7>83H.U/6)D:`3,,!("/2(V99[)L42B`"B.&?(K+UZ&I`K,5<&5
M+)X"LN:S-QBGP"40@A"W<FI601V8<N(ACHS3U]1$NQNN3Z`PP$EL0+%`]$!T
M^.((6R9&-[R.2)LJ97S&@F$>QS_#<3-4"*9/5Z.)@L0+)"<A<=DTQKF]TN-`
MV%'B_2?;/A:#4?52-FT+R,Y%JZ'A$W73L"T#SBC[JV=MRK!#W,+E3[-YZH.,
MNV-UOL!:OH`RAO(&@GRH]?"$`.>A"0&G[O8ZYW@<96RA\NZO-D_0.07G];:;
MN0[GR3VPFM=^']6EG<LT`A,R/8(KLEJO@V8^NA-LL1Q&7-4)YW.T&8Z'M75>
M*RE1MP[TT!C>@GIM'T>Q!K+I6]`,=;,MG&<_4[9I]BM6L6M?U![B>J#VH#=G
MN[!@C[Y0^UIRS]@K^N(;CIE@,SE\[C--<GSR[M`E7;KWZP[=HN[0K6?J#5UV
M^CRPS]WX%FX&_X.W`TB&F/]<EO;`[G0O+B\&``4'@'+>:S=&%ZUAHS_J]`:#
MBW%O:-N5Z."C3&T$##%S^D$#466M;;TOBO1XQ=0!Q@NP.3C/3O<"XQ:L17\E
M1M=L:"4=\TX=+KIPO1L/G4Q@.:;97-*(*4\2VL?H_**9M=3,1PP?4#XTGA)/
M$ZU9!LFFH8",?Q)^6?%'V>M+NO;%3`/R6X)1'\8>.7.UL_$F6+`GMH*]1G^S
MQ)BG.)21SYT.%POL4D^U/,'?L6@0EC\[:%7"BC\O[+7@M!!VN6@;9AI+/Z6A
M>V*X(]K\V(-$]NZF00[?R/:.M<;<^[C5]J+3/&G_P1+\^A6/N\Q&JS^!8WP(
M/LGF)9E+[FD'&>A\<9T%="Z=<=L:M1O]<;O;<%KG5J-_WH=_C0=#>]P>=)UA
M&UB`U7W[:\.R!_V^XVC<<?\S/?%4"#G;X#0&0[11ZO0Z3S@8XD'P*=R-FLG#
M1_(\O=@Y/[?/NW9[#$@V[#0<0+7&T+%'C7ZW;5\.NJ/><-3>)'8.*(0LJ[D^
ML*ABTN:3&KA4["-7&'RC]Z_BPYIH5(Z<&-\QX3+Q'ZWAV7Y#"*DY5HRZ.S+D
M,SGC$R.U5C<;1=,TABI0@B/'<'$UFY"5C.3.OQ)[,C*!P]S1#`JSC+B(9SVL
MY4*/:P->$7)A)(;&9LYD$=F5XU?=(!]OZG4>!P5M6"F%1PMGUY4"%>W,S4M$
M>/7;S;Z1!1&5;YPN"[\-7U(PP\/,Q.R16`U$]N*86J)QOS6-%]+\S:I1I>RC
M*3S^*.33Q<+5FUKB2\_>;!E!N-=L2SF3KFR@KS;(MCC!EV9LT%@H/GH*IYQJ
MI"@"_`07'<=OW9EA8S9DR[3[?=G/3\"B]!!K4]V#L/R;9VLS0BK28NQ#8/R!
M%G,V[FH4LEN\9?@@"!<>GQGE&A.O(:+04]7-D6N*LI\C]F^<43-5-=53S10O
M)8'Q\/,77$+E;E`,%^#44)D26NP5R<"CJ/X"4Q9HVJ4<;U6(TF8;24#OO1']
M(S'U0])'EIBB8O9K(T>SND^M)VM+RXF9L7@:>1/>T^^/$%[7,XD#^3YW)8D0
MD/%19"$,Y:-Q8>J8!G.,$O-,`MX"CT>B]0B4GLWB:$<2:"VV3\HP9W5A&H'N
M_._415\#/K:]M^Q&+7:CJ,]K!.2.`=O5XQ`8PSU83Z8,#.W!"'Z^;(Q'':OA
M7':=1M^Z=!J#<6_0:?>[J'&"86Z__17S4AHMJ]'6%-"RK>4W7U!\_DB1,C[-
M27N*/V6DC=VPIT^@*:YKANMG'K5`V;8Z=L-I7X!F..A?-/J#WD7CTNJ,6Y?M
M_OG%Q1#.;(%>:#G==F_0ST[\H/.L=0LFY`/#16N9>L%Y/[==GNQ:>^V6,[QL
MM1O61>>BX5B==F-HVU:C>S&TAL[XHM7O5ZQU]V<].4EO*5OMEMV?-^54D4R?
M441B2WA[VPH\,@Y:#-CMGK_2;7\&RF.X8HPR6GB$7^H0^N!'4*M<ZI"+2T]`
MALP]G/$IOTHL3:2E<>:L>+'R#P1)Y$Z3C'&&T8T;B-@[M3OFK@;OQJ7QFK&7
M,*G^!*CDN53\?TLI#0%EBVT;TYA+Z!/-3'-M3B/1Q9R2"()T[LI.J85<0%2P
M:`T>>N"SHD$-G8H,B`Q:,J.-^J%3SA,\L";-](ZY=.B&>&Z6Y8M1SH7>#)HK
M)EJ39VE)9ALP!:QXJ_<XQ$0'-N/`#\(@$]Q:UUU^_(C=8#X'15=H(B8<=L^,
MI%U<*,^VE#>!F'W\:?Z1Q3$K&SWY=(,'+ASKL@ORZ-RQ1@UGW,76YM:XT7/&
M@W&KU;\8]CH/XU[/K/6)OA>@W7F+="'Z6BC4X;0%UTD-N7U2L0M-<\E/MK6+
M3MW/HFJ-:>OY<G4_B[J?1=W/8N.['EGCU#:=+K8;KBO1ZWX6NW&E/>B:O7[=
MSZ+N9[&&&?V.V;8?W7NTYB("5TZ_GP5(G'[7[/>/`E<JA!FGW\^B;;;:'5,V
M<:TX9E385'E%_2SLCMEQ#JF/U/7YS_C"72A2][-X$+58/5#@6Z;E'+)YX1$2
M3-U$^HW!_T<?KWGY]W?:%ZJ-68!I'\-@1@T(KL(XR>I/1R*"])RN_]YE;]1O
MG=N-KMUU&DY[C%E[PV'#Z0T<VQGTVZ-.JPK5QU:K:5R(*)PA`&-@9C_=1W7B
MDY^",I>H37TF6O;F<8'XN=;\`59R6M:[O]_3&8UWU/,"?GI/(3-,89,A21GN
MN.;I)-D[^?-G;U1&T^?SIO&GR`GQ8EK.I`2G;"DWH?!(8MB6:`2.@<`;&EB)
M(56@9!K.F80T&]'#IN,)DXD:?$5JQD&S#+4N(L;,7?&M,!?30="'G%UH;"Q<
M'HOG8Q&-=(FOL%JM'U5R&P^NKC`$&J>3O]B4\J!N,.$MH/#MPOV&P:"2H-Q!
M0E39V1!R=!0,W*H!FEZ4'9ARUD3Z"P)1CH7>D'B7/:4_1!,K9PS+;&B(+,]<
M@E5&H1M1D?H8^,HT"2.,65/Y^C2B0<X`UER.7NY]9V\V[Y,WSX%W_=#IF&W+
MHN#J#T[?[`\L/AP7IU=BEO[9FP=U?*!^#R9&P;&"Q+MCF#/)X[`_6`/'!,;$
MWP5,SQQTN^IE^_:6X/;DIG?E46@;WW\L_R[D(&/<^@.EZXTIO,Z3F'F2"_VQ
MD.<\>Y;,G0]_7*[G[ERTSIWAY7FCZW0O&XYST6KT+T?C1KMS;@_ZHU%[W+I4
M6=U6R^X,VFTMX^K!!RO4!X4!1AQYMM-G+_[[G%H?X$]/-]=[/+AH=T=PN',X
MG#,>=1K#B\Z@X71;Y^U!MSWLMRZJE;J3@PH2-H>*@6`A-*UBX@XFWV%VBD?Y
ML=I(Z'(FI]?DZ"4P0A)1/B%UH>&Y&POW+^``JI(F5T<CQ=.?@<>34:ZQ@B:F
M5A=8P1,;M\P7Z_"J')1&[!MF)O-,795F#<NF-"7Y[(WL*$8=IN(4A)HH"(*%
M?Z/T49GH'3/U)UIYPM.(1-\=ZI`T8PO>^&-F\K$;V*W*A&^Z$4]R@"-%<+L5
MD6V7.3C+6BW*.EJ&"9.7K.2TIO-0.L]41V">B,PQ.!*$37E7:JJ)3]5>T\UE
M6CRK1_50X2GFJ+DW11.FE`:MHU["Y3$\?N<")TI1G$9+D>L*ZVS`(%P^4S40
M!V53)-@85K+)`\ATQ*I<E"Z#>8+W(YLOF3M)]@8((U&-T>[=0@J73&V+11<K
MD=]&3\5950!E_?_9O&Z6P[N9STX6:7-@;*GJ=P_S_ZY9=.<QGEOV05SD&>98
M&Y_9%.@+_LF^]`YS:3(U0WS\/I?5_`'^[8/2AHW)?EM,_FF\R_X(W_S-\S$_
MY!JV")@->/0AF#:-=_QC^/O5W/L/B_C'L,([_OM[WD')]XR/GJ^WI:.?\!\X
M+2RCOO%>XCA/G*-$:YYK)\#.9[GK&?P9+7!%=`9W0S#F>T-%2&XN.Y&9;8J3
M5N%"LNNH!II_H2QQV6"()TY%V,<H%HR)Y1OX$2['WDU`]9R$8!)O`2L#I:/C
M4Z"NH`294>'G[!6G@0WLIT\#Z]@/3P.SMG0^>JK/ZW>_]+N_VX_=W^C&?G2P
MY4&.U3R%2J+/_/^)\/^O@1A(&*@//NANZ0)&>OP7E.+9-G@B7O;[!8KS[-<M
MF7F3?>__NV%V($C]`5I.I0!5HS=6C)=+#P*R&EQZ[+BY\YCVZSAF?9O?SR?J
M%/2B$XG;9FM*\G.'2+\W2:-G-1^=T?/C<V_W*0YH.4W[I`_8Z3<?/0/C*`YH
MV<U'#\79>L#CRT+<QH$R)\G1,2'+:G9.&X4[SX3"%3K@HXM4CN.`O6<2(Z>>
M\,J]N<?'DEHGCM"MYJ,S<X_B?%:[V3OI`S[7!9Z65L1#2$?'?IP35XAZ)TZ<
MO1.WJGO-1Z>IOVYM*(M4#T6D^NAX4^O$;9GVB?/>YW*G5.5\W6?2W$]+,<J2
M>XZ/_YRV9=89G+II=N(,J--Y)NWVZ4<>]Y??2M+!ON6YAE8.N#D;;'.V6:6S
MZTI2<U]Q)EVO^_29=-TMP_TV9G4]>T>U0[Z[3KG9D;VP(>\I*UI\'4D<8V!)
M!2A8>2C4.1YU*&.W.F*=>`9$5NWA/!K0A^Y84Q4</U)_N7WJ3@VG4WM<7V%:
MS*/[L!T%4EO].H9YTJXZP.#3=F79_3HMZ-4&PIP31^[^BZ@<#W-CEDP`W=R)
MH]BR(YN[\9D7@--$F><:ZGLY;`T[E\ZH<7E^>=YP>N>7C<%%OPN_.G;;:=GC
M4>N!LRN>NWW'M3:E1(<6`;Z2K3NT#:LA&S0>@[MUL6P?NU(%]$$THRE?5)C/
M&Q!1IXQ8MGH87I]G:-NS^J:A().#1I'E(`[\S/=R]F8#X'B_AVRV+;XO+MN]
MAXU$U&1`4_:JDC.#J2N!::0Q>;SA#R/?A46NI[<A%M(OPAGS99.F;+BB]EZ/
M7-WA34#C>8%J@,!6-)V1EHNP>07.[H'G8ZQIF<I:<SFL%Q:XD5U$Z!&:^@,O
MX5_+YD7R$8\5*<2_Y&T)#(`K:\@=NSBH5?2'0%B+43QXQ&R"L0(U0@38#++'
MAH_-*MPD:W>U8,EM.&OR]_!EY:PC[`;#!W"RB&;L!7P2KAQ1M_VMB+G,YS/_
M,%Y1\L[/_#YESYU-LX;DBV`5>!7_N\`NA9(4,L$]K"^EGXJ0%'$+D=1?T<I3
MWE"#T,&8\5E,6:>"_='@V`-2:LAAXOEPE?$F*B7.)`A=TNC9F^PJL"D/'W_)
M"4GA:=/@K:GHJ_QF:4$QA$N._-KP6I.3>,3H"UZP3!/9*L;'1GBB-0Z.\'+C
M.%TL1?\9ZF]SBV./5=LB[>^`KXAM+HT8%Q.WL)D2#0FE+]/F&\3&\EP0)[TB
M:A'7(NS4U^7GX9O%'CR-.?:+B00WS`:)2PR$QT&2>C,&VUUYS)]E?S+N0A#Z
M<"G)BD_HNF79WWQOSC+6Q3>TKI"6*!][Z12%IFI9!'+(Y13V'\,G0`M^>CWD
MPFYW+R]&%PV[U^DWG,ZYW>CW>^W&R!Z>6[V>8_4JTD;,QK'.BX4;45<E#4I&
M!B9#PNE1FL@SZDY_QH0_%T)R5W=.(?*H9<26;M:EC3?#E/VE8FQ")I21=<7I
MM^'PBG0+8B)QH846$/_?3*DOO*/27^GL1BTW91'*0UAAZD73=('M@*9,B!6-
M7<`&PXCFXRYX?!XY11RSA+B<[[D3)&2:K2<:Y/"79>/\>#,GWN=IIOH<\HG!
M2%KH$\2&0;0H?5M;E:;(<B@)7AJ3S*:`GA#%91`S<1BART?#&[<NME4#YH6L
M?()B,0<86"(##;81XZ!1)Q:L3[7\*7T?+'(#_`YG3J=\A\#[Q,W2=7!>##RO
MB1U@@=F&P4V(WP>I[O'!BF=OLL:O7*8@C\=.KG*[9DZNA#'3.FA)^!-2*$7$
MU+B\?GER_C0U:UV;5$U`T4<_FVO?`<Y,[;SD9:UH;^$"1(3[C1%`<G..XR2=
M<7Y?&`P)B!VEN;F0.F+PEEZ_9Y>)2E`!*J@]W7JPK0B7/>.C'"-JM&6`;"<)
MS5NYB;&3FESC:A0LRWP/X$?-2T7[/3<.`[*%LS').5II`CM,4NR[1_H]-HI+
M?<1Q'")^EHTGCS5"?!WJ5V[R<W(;A>G-[;8N<OFFQT)AFVGV%T>.O#ZB.ME*
M)2NOSGA)7,#A_)1YH<055#L7Q\3R1J-\6CTN$H38]#@F9`G*7U68DUYHLWO&
MQVY/9)O=6=9FEW@YU_X(7S*VE</ZE`^D)%5D@=T(`X;XK#1/`HBFQ.X/C_5-
M$;_4]D_ZF32$$:]SZ_*!L-KAE4'C&@'-8L9OA9DR2[Q%TVYQ8BSO.*Q8&VA;
M+`IH:&ST-TOR[)0:?)*`D@>=>*$V8=T+9BG8AYEN*5F#N%"X8UB!V]`ZVH%(
MF6F#[SV:]/NH@?;/WMU5]KFD'RZR+I>5UG4DG.5EQN0'X,.*E5K"S1\0*G"H
M629IR:#*^H@2T:`(C;P;C^,)#AU.5APAT3(1#2R!_1/ETIWK_IME&H$5%3/.
M[]>:R#:-\\W-1/6YSZ@LD':<<+01?5SIR>QL!FE:L">VDC@]!ZFB9CHO%LAS
MX""\NRP^7#R[[#0J=J9O!QUMI(K,D']EO@L<8@R"VT^)9%#,DA(C335.`C2J
M^)O@LAEI5P77AS(O]+/*"ZTLE@_7<UBY?E'01;G!GY#6BV*-ZT^R"2IU&J4[
M5;JW4#QUO1<PQ2=C(+YEI#<C@NMM/87V:@K\#VC8]CT]@@X/')R1S%-?)=X6
M.LH;]Y''47H.^H_L?\H3>[-^H?>WC&_-]_X&!>HV)+]C=@S4?LG1N0`.71$/
MI,Z+,C6;PY<V+>^#)IROWR@-"W?%M.^(J^]<E"H(@RQ#?\K*S!Q\U,19J*$D
M0[FHS;N),LM"N24)0X136DBRE0`Q2#E0MR,RL<AQC/P4C``/P(*<25U!G%.(
M`Z5DJ].1P0:O#!<@)>76T"MV1_Q%]RH*TW!.X[5S%ZV_I6G\$6H(QUO]HOV*
M+"KF^]_651C>79IT*1L-Y\Q=6`NIRM7`H[;%ATRXA9:W"N<KPN3&4LWX@$8;
M7/]5.O'A*CZA)8$;)E]69?E>MOVK3R1T8G[)VU5^(429X!@^NW%]4UX-'-JD
M]MX\/D#RT"?O+,[+N`<)!G)YZ24N60J2=\WD1L0F(I8SWLF/X&6^">EU+_@3
M\IR5D[9:.917PE]!.X'/P*8VW!L7!;6PY!$6(%FQ1;S6O)K8@%"9ES[3'3]J
M9=(5/@$1HNZ,L*H*FGX&M0%4:+PRU$$JBX\ZAR?I0RZR&??#\*D`&_4VE-<B
MY(:.=5[TD2!O);&I'`ERFA--PQ'VJ6P43WR1=WN?HG&5B=BA<"E-?;!EX?6<
M'4897$D/Y2C"S;W-`A\0[P>GY9C]3@O5OBVTAJP>MK>9HU8%P2Y1_?R7M"RS
M&0(?,MV_TDA'ZK/0[S./6UZRZW9,P;.XT9<I`KXB!%.T5>ARR;:@H`^]7:*<
MJ>OW<JB0&T4K1%VQ14+X7>-VMHEC]'CRF3\4.8MO06MMH/M`VF7DP].I4FD>
M2%/`'-,H$GR>W"U!(_M,\S8L@-32:+-+G(,P0QLM6G&-HI_BIGS6T;O+X?7H
M?>DW2`>><=Z`[/G=\/K\O=&W6UH:@H:HO^N;X@?(IOEHZ$KKX#+OFX;X":6*
M%^3,+E,;^456FW[^6P^8#IBM*][<O]1A+H%$IJ`>RI2.>!$N`!GHTG"'S"4/
M:TW"--'>B/BD'8_?H=Q\MIN(C%9$\W^GKE"=R8.J?,,\1KA,$2'#*!_0I(BE
ML'"DUTE&1'+>IL()-IP?L=M;/[ZT\S7&&ZC#\PT`!2ERS8H9Q6PJ%!0W(:P<
M/V%98O>XJA)Q1%DN<7%#R_X?'Y+UABF/\DEM?H#/YH6B$MO>?R'KX5LHOO<C
M&#^^86U(,KK4$WE(\]2GJO&DD31P9W^EI.'^.PWQ/\(!R6-LF!UUYWH^W2[I
M?"YWB'(6SGDC!M`3"I9LB(_MRNK;K_ZX1M930%;[.Y"5<V<1(*,XAR"`$MP]
MXQ.V>,``D]8B&G\B?YN@\LQG*WW@JTYA.:F]\.4H.D@+(I;'WL)#7\H&EDZB
M/D<:(?+U_,;VH19<"80+K:5TI1@3MW@0U<NVZ_IQJ"6]8*A5"JHLW8>VP4&&
MNT`XB@P@/N_+C96[E5)E^(8H'<8`_>8N@R>^$L53&$4A32GB=Y/!4BIV8`NX
M3T3T3QADK*G^<%3??A35"U17HB@--%RC,6!A4D3'S+P@+#1$J@T/<8L%O>`N
M]!&QM?8.ZS&_+-^"JV64G0&[<H7/FX*`0,I)<>25.!S&8YHW33,7`T:J16,'
M2!&-'2Y\R6^*?DO2]?AD+')PHFJ)+,/GL29*1HOC<.K187F$"5,Z6&#$:(Q@
MYL:3T=T!'-R99;F!-V8S<_,QWIS516'=S#@CYS>"5R&73-S3+L(G-`4\$S'7
M4&KAE+:\X/-^LWL7>:IT$"\NF`1;TYTR!#O34WI<-9$VP\DIRTP2Q=AU9,K9
M#@BJ>QRZR-FZ>,SWN-TI;)<UNZ@B\8[+_2]^T[5CO!Q/[\;",GI*(^C8>K,\
MQY0S9_#PWBP';,U2O[KN1U/V[/<W8K&<K9U8-OK==K@P"[[B)VW/\IKN*0+6
M+QOF[-D\YPL.@'\8_/77?#<DG@=/MY_Y?\@RS39Q129J]KL7Y`$RB8R?BD&1
M(2DRV3._<V,U^P"TU]VK?%`6\9"$_],2PL'9Q8[V59D)DNWD$YKKNP'W25E#
MV:/<F_%J0;@39G]J-N0>J/D,T#QZSEP]7B;]X*\)ZZ4[]?6=^5DUI;J173%A
ME&3RNBW]["SE4-\[QIW6>WZ2[QU?*ZCV%LK-50?HR3@O3LL_[&51K?64Z9D=
MVS9;]J-;N+]<PY\3..5+G?<%.G#6AS^U]F#;^-SO:R5++Z^L?&]KN*[9<GJF
MU3TT$WAMYWWQDY\&]SM&*)R6<O<YGX]_=!Q/5`6\#G97C<.^"BJOH;"3UZTG
MS1W4K"_R3.$]I-R,S'7X3;@.2T[^4+;WK"]\"0930ZW&NAI^+PF_4S"AMSGY
M*0%"Y-X]3I6$O\S#("D1-#)<N1';\+F'")M'NE[:;7/0<\#N[!]$#WL0@&JP
M5`=O*J3%UL!Z#<IN&Z08MK[QV4O)S<>_L4KJ[JN"6PW!&H+/#,'C<YAN4W$_
M9M4DCTQF>4'I>\CO/:^6>APGJ\]X^#.>@LV]+8)SM:M9=>6YU"-MA'?=WL"T
M!X^>P?G^A*SOVKBL@76$5%:;W-55VVN3NS88:P@>)P2+?#6_W5N&W/V7MU9W
M,_/4OJ-5+&]ZX.AKT0Y;S;VYX21M=O)($5=?D[JFNIB[+N:N`!K6Q=R'`.%.
MF-7%W,^A=!T8`^IB[M=TYJJUO:F`T[BNQOXN_#[\3NL]5R@`])*4>]+5V%;?
M[`XZIC7H[?7\P8MVCOV8+W7@"D557L?A3T%'.?5Z[`'5)P\ZATF*?KWG??&3
MGP;W.T8HG)9Z5]=C'Q&[J\9A7P65UU#8R>N.,%_F="H[7S);YA5!K89?#;^Z
M'KNNQ]ZFA/5-"_YIM3H'T<,>!*`:+-7!FPIIL36P7H.R>TH)IB^I[KXJN-40
MK"%8UV/7]=A/_[VZ'KL^8Q7.>`HV=UV/758IVK'-@?/H=)>Z'+NV+6M@'9+(
M:H.[NDI[;7#7YF(-P>.$X+;)@-KH/_Y5JD$KV;(^:A['R/]LY%18Y\<]%=B-
MH^ESU2%&.-]2E6P:R2TSSL/%T@U61@+J;2Q47B^)C07F;<(J>N:F,8_"A2'*
MDXPD%#]:QH1-W31FM*!'A76&&S$47;#"Q(UAS709!H9K_)MJ4^6J2ZQ,;:Y=
MS4'`]24#1J;+#'Z.U2%C-DTC<E'@ON$$GK\RIF$0>W$"D(8EHGS:E[F6W4\I
M_XNUC-@FOAR>EW<Q8PF+%EX`;T*(PJKP.EQUCO7G=U1_/@\CNB>Q.WA:VU\:
M>\&-A/6[-'!G?Z4Q_/R>0SSF3ZOB7!Y:-,((5O$S3PQ<I>%2';#8;5R]JWH$
MK.PR6.&S\]#WPWO\;<&2VW`6_T."4(-:["T\WT5(<:C]M!5@IB2'$.M^X2UN
M(-:$!<2J\&%"Y)*5K]*;<$OT#O6*E?&.-6^:N"@<&HZ*.`>'A=>L/.8#UJ71
M':QX%_IN(O9D`H3F;NHG\ILLF3;?$R+RK<$::@<S%L'FZ;S!U%NZ/F`XT3QL
M9QI&43@)(P+N9,5/!`]KNQ8X/7,3=W],^59R]=_R5Z^IJYOY>>GZK>='Q`QK
MB.L#[,([("V@=2."/\%-WKO1#%EQLH'#$"KL<#>8QOVM-[V%/W`\#P.\&B]P
MX9Y<'U;P`N`]*;:C`.REUA0S`VY5HP+BOQ$B?H2[!;;L">Q'@O!4I;61:H74
M$G_?B0)-P)P8,0H(#A'(&%Z?P]-]N[7NMMU\(;L@;&N>Z<T7SL&=UP7./WW\
M.+RZAD6F`'MW&;-=M[WND@HC((-?WK;>&E/F8_'J%$"D?E^ZLYG\_=Z;);>_
MO.WV?]Q4VUJ<$:R-$%8&6E[O$6OVNS_N;86I?6Q^Y&D^KX<C;PUBC%P?R)$A
MV>WH!7,$!7X'<U$<7>R*IV>E0<1@"_\!MGCC`C,VWODA"._X/7#)J9_..+MD
M;A0`]SB^&JAW7;MKMIU'3VA\52ZK.K7R"%GV-5LF19[=(I[=?ARU^M5W0]==
M06M?UE'XLCX$!JGEZ'22)CZWV37[AEM815-JF4;36S=&_XJPJF+N^9J@[</B
MV""5'4S>F(F5T,B"M\#!O?@6K5WR8*']!(O,O'@:IH%T\AASL/Z,13@#Z^@=
MB/IP`=QD"4:@.[U]W\RY*E*TR?]#IK\+YUDF'BR)3H#,Y8#GXWO`'<:W8)1+
M#X6+OJ8$?H+MP@I3W_46Z%!R_148<M(^A%?['AF?8,'A#P"5*=CQXG4Q?"TD
M6`B[#H#ELVE"K_.]?Z<>&.]\6PA%%J"#@OI4A,$=BV+\TX3=NG<>.8L$R&?>
MG+Z<X*Y0Z<$_H-LK636-X3QAW)G!/\G=%KH'2Z[AGHQ,X=B9\>M*2,W*K>&A
MZ0R'"Z?DE`#8X1?OW,@+TUA^-3.,8R-.$41QAB-H^2*6F`)9))3PR)L02:%1
MT_@_PD4:N#?4"5+A)@+6)QSE>X)/`3/A1O@5ZY"&5^%UKL,70>0:2S=*O&GJ
MNQ$'+GY*^[D-?2`(Y3O<C,U"_XS1F90NQ`'Y]F@S@*NS=(HX17@+#YG*/\L"
MED1JG[#+&*`(S\S0&Q`N!<'1\TU80.O79@"L`%=C`8&8Y5Y_'Z;^#/VEZ)CR
M`L+'*2C0@#L_S9CX20)OG<9#0-T$-L1]%^H^JN.=3';8!`#/,EXE3\+AL68U
M`,)GG[LQL83%,@P0\P`RW,?(>1"L\(Y]@_N+&5H@]#;T5:.22!</\$LXSN*3
M@)JNPGQ"QP7L[18>1V<F7W)?\/85;)X"FOB>B11&'OYP'@;H91%H";L_!P!Z
MB?'9B_^F+7I*=JD'=V^[^[Q(<9U.$&,3CWRJQ)`W.P2Y8"EK#X1$&J&CU0L2
MEWQP]UYR"[__!?Q"N0.)YWE)RF]4W/Z?@<?=SM=X\\`WQFP9QN@6OT77,:TS
M<8._8UAM9;!O4X;L`7W0"Q1WN%]8-HU07R:/);DY22P26YV)Y9K&;\`U(CRG
M*2A?_HE6GC"*E,P88)\("\W8`@\+_]`30!1AQ$SX)C`]D`#`47T#&-K?%2'P
MRQR<I6PA)_HR3)B\Y#B=_"5%JXJRA9S79PC,)33'8#RCBBCI/G@2XAI*P"(:
M4ICTN3LEM019^Y1YY+SEZ@?75B(2)(P"<_"X%)+3,%J&8B?F)@S"Y6]"D$_!
M@BL?(.[@:US.WX(Y(0\@F7)5+DI$49+;B#$Z!;!1A@&XY!8%):+O%K-/\$(>
M*]U%LC?DKX]`+@9"@\Q$++]SN/"I"`&"X`/<!J*AI^258=`*@RU_-J^;Y?!N
MPKM]WYW(&^-4^Q$`])%_&'JH,%ZSZ,X#48"O^B`N$C579GQF4Z`O^"?[TCOT
ME#.*6B'%BH_?FV`(L%N,%,!W/L"__5OF+6"5WQ:3?QKOLC_"-W_S?/3^7L,6
M46$TX?O3IO&.?PQ_OYJ##(SXQRB8^.\\"'7A>\9'#Y"\8+_A/W!:6$9]X[W$
M<0J/P86@!DHR3X`=E$V\I4PYT&B!1Z1G&`U$&/.]F;""W%QV(C/;%">MPH5D
MUU$--"^+0D5LB4C&&1.IGLAR8..D50*4M(`/\6..MZAI<)U#/`4**TJ0F4<J
M]BL.\@SLIP_R=.R'!WFLUG-'>>IWO_R[C[YS]/?W!^Z6D9=N`'Q!*9YMXW>2
MXMGO%RC.LU_+Y7K!*GB6Y,S#0^H/T'(J!:@:O7>TOU91AF/'S9W'?.FVYO5M
M'M%MU@DF6Z.5PC;;&?ZI6O)`SVJV]WJR),;XXTO44WSO`2VG:9_T`3O]YJ.;
MP1[%`2V[^>@P^-8#GE:N4^8D.3HF9%G-1S=1.@X4[CP3"E?H@(_./SN.`_:>
M28R<>AH7]^8>'TMJG3A"MYJ/;JM\%.>SVLU'9T@?Q0&?ZP)/2ROB(:2C8S_.
MB2M$O1,GSMZ)6]6]IE-AYE-A;2B+5`]%I/KH>%/KQ&V9]HGSWN=RIU3E?-UG
MTMQ/2S'*DGN.C_^<MF76&9RZ:7;B#*C3>2;M]NEK@_HGU^/A@=EU):FYKSB3
MKM=]^DRZKO.(3+IG[Y=PR'?7*3<[LA<VY#VI7UY)$D=IIXH<%.H<CSJ4L5L=
ML4X\`R*K]G">J[_MJS$+C]1?;I^Z4\/IU![75Y@68YTT4EO].H9YTJXZP.#3
M=F79_3HMZ-4&PIP31^[^BZ@<3^/&?-Z^%E<1MN%(5KPL^M^IMT3,I0U6L:-%
M;KM,;I>JK*FW"+6?Q88Q3>-/;/(0L<2+1,<1X#2NS[#ZFO<EH0;:L@WUS(N7
M(35<FM/:^!592^].I^DBI9_/L*!]&;&I)_K31/BU1:C*Z*EWA?2\\OX2*]%R
M!CVYV)$%UH"]8%,6;*W"FQC@BR/L7A/=\/XX67.4IO&9+5TODEU2J`T'"ZB#
M'&^-@YL0;5>H0XL78+M=-J-N&]I>Z7%W$4:)]Y]L^]AU)<4-9#VIXR1RD58:
M/G4NX$VBD*V)[DF99SKK?)W&;)[ZAN_=E4U3>S5^YN=HR]O=4@F\R=>[Q35=
M_GDE/&15D>'GG":BC,6\N`AO&ROF1O&I6P#7X3RY!S94P_=YX'N91H&7I`<`
ML-5Z'1"637`BKI2$\[DW90=D')U7`G;LUH?M"`UO@6W!2,E[>4L+6=@M:%1Z
M+"N<9S_[N,WL5^PNJ7U1>XCK3]J#WIR=@H'Q88'*J^SY]S$,;AH?J>O4D!3O
MREH:>@]5:B\:BV$OH%"C*BR'HV"'.M#!?3R83P<3%@4I^F@*1#/2U:EKEFA=
M>>?%L@O;\/K<:'=;IK%FDIG&E8_MO;C>7F*;->7#L"?X:R3'NJSO98+;OO/8
M/5DP-)DFNY;[6Q8P5.ZQ'1--Y%%M-$'%FWH16#_8VVK*LJ9,9V)^"UE2;A2M
MJ%FLZMGG!OS-U'LO"!.^`0$WGV$_KL]K8*1NL(6MHX6D)HM,5J+YI!MY<4AV
MU'S3#M0<&S2FYBE*0",-M#:Z`?Q)=+7#9KHQ65!3T9T4MGM#_03%V)EL->P!
M1C_<1&&Z;!H?<`23>O\=]0OE;0PYML3I`K>3>[7JX,M[`I]E,YC@MZ`X7&B]
M$2DLQB*?'QCW`@N(W0QA#>UF^4D0\#<!-00M0%-KM#C!GK*\F^].B-++<J=4
M9B!"<VV_.8!QLA=;RUG=$>_1N$1N2G8\1XA[%FV\YTA[FVGX0*1X&[)?;`PF
M6E-,)-O1<:]\=L:9[,.G=U/,6@0K$@#<NF<T>DQ`/Z,\3KRW8#_!'\5GV/JR
M`4380']$51J<?N;-V+Z7(3]\ASF);_^X=<OZ3HF#`%ZC(Z.PZ2K)#O(!(.,$
MA)SJ?10)[7S0%0-L4WP3,:[!D)P@+);?#:-8C>82+9"E.%V$03@%GHGCU(+$
MFX`&T*"^X=S)%;E+EB;>E#<UCACZQI"/\R:-O(LA\E.??4-2I/['O'TGHGBL
M&&Q^@]A5T@7)L$"?%CP+FT*.'?&&AYR'(-\738-AE7?>>UVQH2,#[\-NTZ(U
M,WJ\)K1J]F?>B#GCCEDR!+:^3-CT-@C]\(:&R2U]-P$8+>`QV6X;I?+E%![_
M!.]8*(\7TGKJ^HTAZ.D!2I[/K/$%W6[DGWLW'G[^\EY;'#9"!]!/0'[D6!,L
M^;WH^JAX./>T;,.)6]'ODX:X\9%NG#N"%H!GHG:WL`ZVZ/;GBA=J^,&E$G7M
M7O\SG-H4;.B==Z=M!+\&F)W.X<5X"GAR&;'&U`>XX#E0#Y`_(W.//-<G3%0>
MU&P'3>/*78F6M&&.79*P6D,B\F,J%`'>&$0,IQ*2(BN)8LX(2WC+>OX+^\:B
MJ2?_!JLLY6N10O8`K9E_@B/8@Z%@RCT6_+%R;>TMVB!*[AN^]=B=[(&-=`ZJ
M'E&3!]23A(%H?1^%*]<G7*"^^-3LG/S70*"?B'`GH*#,/3Y*+P_R,J*5D"8-
M%O%7"LBS-W+Y6/-3*U^VAD=W(.?G`+0D5E,/1'=?4G5C4)\P^Q@TI_`&.`_P
M`60CD0?HX4F^(K?(/<AQ01_.-+K+X?6(M-LOX1+6Z;8Z#;MCKLD`H4=**5"T
MXU"Z__R[8%.-"Y^#?8CMSF\T>Y%6Y$U7^60Y[:7]]9>6O)*_2-Z@\3MYS/6U
ME3&0!AR^X3I--',#)_2NL_1-7$!]-Z^2+-(X$9,UYRLA)S26++NWHX8'PD7T
M656+\5@*ZE`X.X#S[]SS*O$<;YG!I>/WTL#CB*"=2HVL6,=TB>>(\8`22$:F
MV!@^"3:(F%6I]@XK,7%CM\#<J+MNPP5AQSM)T[B*L(01?1%-YP$>0M"J1L>@
M_JK!#3P4(@,>6TYEJG@0C;F8BEQ\B7]1A@SJ9!17X4,QR)Q@``N)V?E75:29
MK^Q9+7OOBON64S`DGJ$:FY]9FMS#%:R63)!N08W),PF.GPB2"3#F>]C!>S0B
M_!3;_5-@36/8-/=AL4!N[_I2>$O=`&$J)O_N5`_(*_<3<G'!:.7`@H11!^K4
M%2R0QQ6U,1,TYH`F$+LT2"&1+`XOE32&V'BGS?2`1]$4P'&L<78PM>GW/].I
M[/>DD(3!3YFTTL4BL>4I2:(@-P^&5#)S-Y3.WN3@Y-*XW8+2I^F&2KA,L7OU
MC,:(B.;AFH(!DD(8Q^+@8AN9':G,HY0&?;IDGHMI,WP$B8)5'E(DC1I)V!!+
MYOC<^XH0R!<R\OAX::F7(5!-KE#[OM"SN&DHAD2@0H)*S=D;W>>#IU9"VG`U
M8<3M2:5>"V4#36K5(1\9&_MWRD?DY,7^,QN2#S;3+A0%?!3H6$$K+2?GN*KJ
M!NO$JPG+&SEGXNQ-3JE:?R9_/7GVA&8&$GO&I8A?`DM8TO2&$&<I*6Z#-`SO
M%<3'!1*JSZ")AMHV"D);S=K9;J_@`KK%DM>B<[KP1FN%K).<O;+%6B$])\:1
M55-7.%4U%QB>Z]:]8]JT*AP71`.)O"4*3C58II&WAC---L?+D*;$S!_2:KE]
MF&E=U6`PVOB2+=B7&=]YBTF:ZZ@L*LN#)IO,V)+QJ01"+:.O*NXC%S;E:!7=
ML2NOY-[S_;P-+SV_VJWF\1L=TB"\S#,ULV5/M,(1T#2@W$5M,V`W8>*YVC1T
M,7`L8ADARN$EY,M&*KK'`\A)X:#O1C.EA/`14#S/QBR8]3B&((.>M-A(;R_3
M9#6+S2S:^+04-^%6FI'**3=OA7LY6N`#/73@*S+@ND$)(>S6F\BFY3:>O-]M
M%`'H2SOGP]N)(N_<:*5G`(FS$3:MXU@IR],U+J5OX5*<.^'.=2M`^<^$Q1^3
MU"P0O9P;U5@_,U\V;W7B220Z$@\4_,^-$7_X3$[8!DW`H]=I_%GGD1S-N.V=
M]],)[4<26JDWIGK,1X?1+(1E,&0S\\"T23AY)5'H4YQ(7(*F&2)SR&A$=V.$
MZ*.@T80X4-YGW$4C$$>21$4@\"$+N\C[*S4%]:E[PF*.*7"2(>XZ^RZ8K\)X
ME2X6>!P5CX+-&Y<9MWD#.V?D9JX3$/RP-?0<J,D_^1@>7@-9I)KNB1&Y2_@^
MXK!<5XYD\;*QB!Q_<[XDC:L7;+BIN^31/3&S21J#@3!%2`#=N9Z?Q0#S*I%T
MZ@J)P46[>B'&ZX`7QHH/"H%`+CD<)`B/3QE&Z'+\!.=@\<F$2LYI]X0>CK6;
M$IOE$\*X-)RH+$],_.3N5U?9]G2E7E)$GMQ,KI)(GQY%0]<<8J(0>S(\*A4"
M3"S%J4.$=268B@J9Q!4Q5A$./O/$R*W8`SIUH[SU09$*NG1T/Z^*LI,++[3A
MDU5#.?OF`FFDU[VH8FRRSY<8C^:SP,I9HTEN&_(YY90%PF?Y2X(@HXE+*,WD
M.XNF+45H\PJA\![L]!UH<86MA^'C5)<X;,N3TTOEIR%-9,.\6+F([_T-]'X;
MAC*$N#%^H+!MX<[8(Q['Q]0:::S,]4TGR4LS2:5`]\(UKI,\8:G0UM8#%IH!
MX"5E"W.T1`6`K@6)2**E7+8BPN'/)?!J8&A*-PQ+3$0QZDNZ.+QYQG\1_W(<
M>.9-$SY+N,"!E/`E"ZC$Y=DTKB*<TBJ$@SL3)A(FDF1^V&M\T(UF,6P=D=YX
M-[S^\SVL\4?8U*OL6X.&U2YQ<.L><J[K2"<ZK#'6K$S=Q0V[^&\W2$%1S%YA
M483=VA1`E\HH)=!(,`+7_IN/"BVP85`F7*1;#W63F0(3@@;43PRG2Z:D*`Z$
M-+H=IX2[.99JO/O7]:>+]S(R1N%[T%4FV7A+SEN5.%[WU\CT?NY)Y@G_<1Q.
MN;VB_)_R;ND5"C_H69Z*3W`@W=I5M@5WF9E:1H:$'CG1N&<OWLJ3N-,-SYU-
M`07>?A?ZG#F0&;YP_Q;Z#@GOG/M*B!P6W"3*>RU7Q=V*O87\4&?9/#<DY6ST
M8$ZL+#=B[_6?&_%3ZVMC_)7.;K*@!1>8I)/$DKV)Z&1F/V'"3:!\"IB@`6J$
M#%*H])8UC_Y_N/[C&C>`2/)&FL8_P5(((^2T8M1H*?C)*Z-`G2%#(7[O;C&A
M2X07:9(3!KO102)X"/!DG/^)#8$(6[57H1E.V0:8Q8:C-3$ZCB\`:4MY;3P[
M04E5BG$VB:-$:->)DVI>FLSXSH9/DZ:X$^VX&3NA\@&Q<]`GV5+'N0TZ03:U
MFNN?\N"4=;M9G&_"?U@*L*X4YP`O6"!RFU10AR04U_"XAYMB2#R>A!_D@TZ$
M.BI%0D:R=/9!J+H(9]Y\)6T.+7=*I/3IP6U.77K`B>\!&#*G6FFYQ+JL]F9H
M</-%>2D/-XH%.R3]2NJ8Y>Y0?=-\F"Y\,:*(&M4,24VQ@9KB*N.Y[[Y<(8=%
M[1B>B;-!Y6O<&',31A?75_!M$)S(F9&@D<,+`T&.E<TX.RR!3^#WR/^HI(J(
M*2./=Y,2!LI=0,"<@A@9@4M1=7BMX!ORIK1(Z;H3&">MQIA[C'?`1944TZ!V
M>T`[%S)R@V?D&^6H%VLV9!Y/==;&T9S0*<ZP2"C;>N!T3;G79FG#:=<4=?U9
MP(58+4H<FRV6W&M,@5KI?9-XI2OG`(![N$%>;@:0#X@99%$AP&OF*V^3M!@W
M#(,7APB7F/N'U@SPFRQ?DCA@EC&9E9SEC$U,^B,OYD1+*06K9(KCZ3E,R#8!
M/1`.QF;\S;K?B.'@^Z(#V5BF49R24RX42PAT(/F)&>&S#$)XT3DG07:)PD6`
MA\F2:_]FJQQ,2(211-61F="'E'@NQ%#QUO@_F\^9)M$$0\JXJ4:^&EKQKTQ8
M<H_R!+]7FL_5S.E[G"<(..14H6A[$!W).N=!EAJ'='L`CUV0>,M']E,0M@M,
M`,W3&:<RE=6D+^RMZVF>M/A=*;=$"@R)?3!M`I+Z/L]Q$:_.;\V4OZ^0G6D!
MP,S,U9TX=!HOYTKAF.D+#V-N,#MG-7F]I6B6D0N.\T#]:/G;Y+1&@0#O&R\I
M53H=O7J#O,T!*\ZD&D?&70D2.:^4%^FPS'LQQ/:7Z/R-4$LNE6G$.5!_BM=2
M*)04I6G6_%'\6J:GZ,H;>7-RSY$G2]Q1T_A=\^4I)W.^AZ)BR5[>/RC]?:Y.
M*[25/*2X2RL#544,VA)OY_8,&`TQ$:;"\SG;Z?><Z32K4W8QOT"A4!ZA-[HT
MUTSJ4J?F%I?FFKDCDZ36O)K;?)IGZYF0FUR;V2$T_\F:#S/ON02F-^-B/6]!
M9\?1?,_P:E28BEPVO[DI*3_2^Z42+2FGTTNX+*<)]2#V,#.?>%.8)@(J4^8M
MD^Q6,/61ZW^ZR"C&U?"[N7H`91&[L8@=D3DD.6"1D<8B:K:V:#$%5H;\N#L@
M%H=5`9^RI2M"D'H`)F*JW`AO1*9D;;:HR!H_>U.BZDH'`U\I%6XL/;U6>.+^
MIBB&._L+Y*T('L<ZHR9<)"*_(_Z;!SWE!DDU'-4VY!IIB;&KE-%U-4L8&Z3:
M`"-G(M=!;M8T)BE2#CI'^&E4$NO^B6!:;A=:-3ZIK22GRFQM*?G`%)2;(4M&
M_$R7X25IPHKL4<28,9L^WVV!"J-6&=T8J.YJ;$Y<$(IOAA!)/)_''5"RZ)>?
M=XCS1(P5Z4B!I(%U".--$^"RUY?9Z@7/!;I.)EIHHH`)I'&X^3L[>Y/W>7'?
ML.2UQ9Q"#BTEMKG4EL(=OU`.)`(1O9W7UB0JHN"OR$4B'#G1C/?$$"MR/$+&
M,_4QZLO3:^+,+Z>^QW4EQ&AIL&*$HY#?E=Q&87ISFV>'6Z`IN/R]AV(EO,\4
M,&E9580?[>GQ%LX`3>?"K(E,'*R*'%_WBN_PB6M8M#U^6AH]%9Y36"3S5$DC
M]('E&TH7R%)3A(3?5C:@AZDH(BDJ!RIRP7F!(ZXOUO3Q+'EL4]I.(=J;A8)X
M>HE((=YN.;C<0X!6<*2%C\B]@*6@PL?-.2#\&2SQN.C6ITQ33>OC[`79`SQ3
M:@>9(DV&LE$X:Q&JASQWUC*=7BQ,M^8.L$G+)S.;'H!J>G9-YN+0DTBT]'/I
M@J@>,B6K)?>-R]N,-0S*4@;W1";=6R4*<H7KU6#!C1<P%G'S<CW.:Z['(`74
M6"Y-A[O-A4G#$RG6$M1DF%ESKD?I36['7'_A*4'KG'(=<S`X)Z-&JCZ!Z^$*
M7EG1%3\@QV1%:%FT-9-OQ!5SQA5N0ZZX/[X<^^R$4E6P))V2'&HJ9TG).Z5-
M<\<[J2"(9]PHXJ%>]P:6N1'>4J)W6-5`K\D-%3S]XZQ0^*BC2R%W,%<>>(.M
MQK"=B/8E@94%(XCJP;2OH;.N[!VBMEJC37=%?(2G=)4HBU@:Z5%4!W7>V1W)
M:%)F4(GVYJ`MD7:8"QD9RUM>0?JY[`P;-T&9EJ`S+;PXIDH_>"6W@XG6T0H!
MZE0Q-%1/FM=@VV/^`Y5S(BT.9^C,P,9EQ-'?78Z'[Y5-:)#`P4O1$8)(36W4
M3<'0C81A3PY'S=QU>=;B^JYDTBTW1WF]")6E$]BX[4[6&K5-X.W<K@NW1N*+
M;;R=(,!7\ZN.R,4A@\0^7G95-(IAB6^1.V14U$0/!6@`.-,39'730&78*1\'
M+9B1*[EQE+9])_*B0/OPXK_)[(#;5ZF_PC_./<?*:\N-U1O<7C[+1;T%>3<\
MD4D(S9],TH*L=6GDRIV^<]><%;GH8,Q##T&<BH0Q0F_F\8>MPL,\ZVHMP*^<
MT%0OR!,P^;'4[BG\]LY>6^\6GY.;+GIHUCSS[^+W/,--I`WGK?DP32C-,U\^
M*N-I#]JZMG%DGY.M0.3*%D7BF+_BV=%QDEM=1`BFNRX#G2YA($K[LD``Y=@5
M0,(#(:0C<*P5^6YZ::7N@]3$D>8[C4LSY^*IQXODIJ;&FTPM3"4$`6=KB.="
MX:824+#%4(NDRRC`5526\$H[#3MXB@?P$:)7*N_EGH+@CG%?D(Q$S[0EE;HL
M%]6(LIC(G?VE"'5BP!OAO@/<GLK.ST5ZLHP6+]9(LR),\H\P:&AE&\7,_5+9
M+WPL)#P+/6K$;<R*M+DQCB3JMQ&9,PUX9\J&:!.J^9S7>&Z4\P)H^NCFPO<\
MM?,P*(E6E==:%AW22VP1DQE0V._KL"*/D.;UUS<L\\AR3L,L]8YB;=XD362Y
MNTI7RI>!(-WJM!07JE*RRYDG+-H,Z8*+:`]P%C:RQO&5T2SJ%4O3RS-W%;XQ
M")4L3(5K,(MP3GSOQA69PYNOZ6Q++31>4\7*$S_+LE.A,AM#9154L$ZQE)J+
ME;.Z89.5<^4S;TG-R)4X9D5VA0XL,J]&>LQGA6P)K%Q2)8KE31_*'-%;:H=%
M$`!/H5R)^Y6-R;=03IN[$`9W:?YWH<D%J93B,6[7H>RAVA<A\LZTWA;2^2_+
MH<4!\N6-?V8M3\[R31LHY")3J+(T!WG^DAH[X@Y;PO6YHFH@_`Q#SG\6KO+L
MH_'//+9`%H[4N=^7Q>OX`6700AZ;K!I^IPBNM;(WQ>Q5FQ;>"RY#,7=*N@2M
MLG>]_]HAY?(EIT%_3L!F[_E>LYVB%IRKN\.B.Z(.S/G-XC-*X1,!LHHH#I0X
MD6\?LHWZO7Q@52!2WL"1K9>HY#!S6>91^9/X$I>V&P2J-S=+4TO<K;7]>5L/
MM35AN+GD,-552'U/9"K!+4UOPY`762MDTT^5M5$HJQ?<U%@BRQA0BD0N=2!3
MX/4LD#`#4AXN6IT4]3JD2KE<"F.!G#E,1&>?]=2"!8*3EB!&G36<SQ(31;A>
MP$2J>&*'IE@R%EFXI9`K)D(E80+,-HM-YK1XK3E*YNW0VQ4L%IZ(*'L+T>I/
MQOGS61-Y#;9\_Q4AQLL=U'=/RE<I-CZ$[?$D_Z)HVTJ*A4(+3:6E+RM#]B$[
M0#LCE^9$E=EKQ)X/8XJ.,DBA6_M[?'=UP#9@/XCTB\2^":IG;R@>J0+&>DQ:
M"2'ET>=6G0H4B<PCJ<W+D(\T#(11IK7A7,_=(<%<(%]Y\CD%NO:]W":7*W'6
M]H<8F%)U1-+=AF1\*JQTSTK[Q,0%E:&(PZ8HF]&99=;FC4LOK4Y&,X44Q+`]
M<F9'\H=-S?JR;&R.F-RBOQ7>0CU3DJVH9:AZD\WF<^8#U%Q]V0;.WN0R->Z8
MR@'5NA.@#KL?;C>-?X;W>8K.%XSF*YH*T*#,>/PMP,1LX;*?,I7RNXRX[;[$
M02C:ALXVET4TC:O"ES=^51:,K->Q/K3&`!;ADTF^7%WP#!R>9;U_H0"LD)4*
M/+90`-F6+!7@.NYZH<!FH8`I)PB-DIJ!W14#E#^PNV9@6\7`V1MC1\W`/A4#
MA%];:@;VJ1@@C_FVF@%CCXJ!LS<[:@9V5PR<O=E=,\#UGRT5`X046VL&=N`%
MIE.=O7EX&4&AB("'(1Y81E#(=7Y`&4%Y$8'TZ>U;1K"V*M=L'EI&4%)$<%9L
M$+BSC*"TB&#-N;RKC*"H.Z_%47:5$905$>25O9UE!!NEEW#P[5]&H))GSMX8
MCR@CR!41"-QX0!G!6A'!F2Q4>T`90;Z(X.S-X\H(<D]Q&?^`,@*]B$"#Y"F4
M$10+6'/->J0:0@[MJ9A/X!98\':_3YG]4U3&W41XZ^.\YXGR0V4IS]YF0#Y1
M9YNZ=?8F[TC),I7)"R;W@=OE.:(;1/C9FWQMI(Y0>5F_5IY=W(]B4!12E#*:
M)T_>L&)-L)2@RQ!U4X_G+)YIM792'I,TT>)%2LC#+E1A<\YM="8;)I*@H8+E
M("S`2<,5E%2(ZF0K!"MACA"]BS:D8IK?;K?B0^ZZ+`\9.^IE*"7,E"Q4HLP2
MS5IY.))QD@"VM,H)S(;D2SL"*N4OW-8(5'8J$`&;G`:^IB9HC%4S5;6=R*X$
MLJU(T<!)-B?C:]Q^&<+F5G3G:^:SGFU\IK4SE=4'V_3LTHSSLS<E=ZWGG.^1
M<<Z=S<:VG/.M&>>($7OEG&_,.&\^-ABDR%"3/U*;Y>T$URWQU^AL*T:1A$:Z
M.99<7I85%^ESEZ#;Y&?+JUF9Q,FW[N8*3OQ87K*1^LN?;3ZP6US10T1<0S%R
MT@(W>Z^V.^LK,SE%BU#J"9CG:%]6=L#5YTTUCC1*=D9#`[?,EMVV`I_``U@$
M*H:7->@DQ_YBZ8<KIN?*B^5SR=ZQZ[N13!27DPY,]56N[-!&]*"QX`@HA&3_
MF2Q^'$8W;B!P2#A$,,6)4AO0RO`2%BLW"I"1JW=D)K:P1;`5>J=D@19NXZ!V
MDO4,R>I&J&U(/H<V2_K.\KSTIO49M')U?'-1>;J>RYQWFWA!0SRG6NH)5X<^
M\@30,9S^S4?)D&,('I`ZA=B`+**(2]H>!6&P5I\F+O,LGW0KTVBK0LMXN1$#
MUD6I$1\"2J5[]S&,X_>5)>0+<MS@?C?TWRH,L"+W+<-9%W]B<ZY&JV.>:8DQ
M5USI5E9&&4C,#!BR(^^"UPWK`S1L6Q]K5[9.4UN'C'I<180+`^$9%WN4:8C"
M:YO?8R+2K[/U/7%U.&;[O9"_O`_=`BP)6>*:GY@3Q"&YX;`20X8PS][PP>*T
MJ68!&+F7B)Q>X'IBH!FWE1+.J[3O972M.?'P<-A/5X:=2?]%@(I46AQ7EUMF
M^UY@.60AV5.PA/B33%?G]0J4_$53OBE:8O!;W#(M3<`2T6I_HGW^<I)GY`G7
M&B\\UWAA91F"ON&L&WA4;%F*':K6QU.>Y8854(3G/+N1GM4OD+2"1NGP';X7
M(377`<>5R?S$P+AL]^0&57Y\4WJII:5$.2RF-L%^A%T$&]?3VY!J+="10>\B
M\:/RO[+W4@JX<OF!I@H:>-;PFO,>U!#.5,_+0HL^6"`+/N(C=Z)F+,OYY,#E
MVFZ%C"M,><(81T/NV+VGUI$B+T@I7>27E!T+,U`3@XQ<LM!\9"32>T).6-%O
MC-[#E\W-N*!D,LT+KD)2N]Z*F`LF3B0G^92\4YO25$0K7:.1+^)^W5R#Y5S3
M"LTIH"^EGXJ0%'$+D12+"K5L;03N>M)U1=!`M^@`B+[(52@E(]YI131>%$2D
MXBVBT)(`5$PPD\ED1A9$YP[&?'!RPVO-G/SW@F5*@OL6\,X7J00RX*M%PH22
MFHE90IUBI&Q*=3Q2\<;4;1X*PR_3YAO</9EC4QBSQKMO\AR*0@0N/VXM_KLQ
M1V$;"79%T4\<CZ!0!%T5'A4USXR5Q_Q9]B?C+L1`"(4G94Q2_4VD0<AH%6VH
M(JKT'Z![Y!1HXPJXZ37VUJ^LY/R04Z*`1L4L`%3M7'^:<D,JBUXF]V&#G'J"
MZYR]$7\42C&Z.MP(7<>Q\6Z&Y8GD5^9I+3036'[R7OB:<IVW>/X-K8]S)\+%
M`BLEB;AX08R<!<'#8^3UXI;66BQ-%>ID)>DB24DA'B4$K7?W(((,`;%P#V-R
M\U#9TBTOTH'M<<>[6.7LC:I?Q.G1&$Q099AJRI:<10+*:R-,$XK(DMF/T!:-
ME?3C<@,&I[VC=TUPY&NF572"WC%L@+DS;("U,S*-<],8R^:^XX:-DN4.6RWA
MOI8JG9C#DA]E(FK5?-GW@$-'4);J$ZN@I:$'?'REUB2-AX..^YDG3(.).+F/
MV5$@$8(4M6R>303,+@,`\F,\/E\-L^/.9$TR8<7&%_,L,82L\,WCL;F_YHOL
M86]J\#/6P,;]6``SZLFP$<<J(KM&;@RFYIIY1+<C44C2L.;[GJSX3<JL%E:R
M!*=%FJ\3YM!1(J+JI7[/D*K8K.&B\_:&:?>J[R$V=&3/M`&N!7%M4B3PKO5!
MRU$_BD*01-PF'7M^RD5(.10R%@8B/DWRAR\</3,3]SS\VM%Q&VN'+VXZ!P=I
MD,H.RUQ-QW'%<1JMQ,.<OZHVSVM^ZQD"08PHI306F0Q7WA)84U"XB,_R?;QY
M0U%-QM8?\.)M&1C[\:S-'(NT;=C[Z^CDP&F;O,L<Q_>@<87D+J_-ISFS_WC`
M<7;MS]:4GLW@2HATQ#M&GSZ/+SXWSC]]_#B\NH9%*"*RC-DN6!7A8DQH/NPO
M;UMO#9PZ&"]='#&A?E]B%K[X_=Z;);>_O!W8/[X%8O9N@E_>3BG;^JU4M_Z?
M1L,842/N+[3;?S)W9C0:^BDB_9>97+-C_:@6^2F9Y;]S)UXV"9,D7*A]=#8_
M\E2?UZ]^T5?_E,>.2&+[WBC=SYL/ZT>A]^9I;,?A"T]L?S9/G9+@_]\6_1^P
MQ<0@A_#;-0@#^0+EP0?=,M+2K:$OZ&3-MO$[.5FSWR_0VYK]6NYV+=A(#X/`
MTSSQ`I#Z`P1JI0!5H_=;>Y/D(""C@_<D<'/G,>W7<<SZ-K^?3Z!.!<QJ7:,J
M4[A&X6Q55+@>S&:$8G@#``A!,_Q_S\\O+BXO-W">)%SJ?U%:<$Z';UALL:<6
MS_LM9-\O:7E2M$G75.4G97HES_ZPE]8D?B7W&#W6-;NMMCGHVWL]'H3WD;O\
MY2W_[W?O^<5.:<,I6V;'<D[\E`/',2UG<-*GM%JFT^V:G>=&V>_6C(J!@X,R
MJ(\LCO^1=\9G3ON<.WZS+_3%>=K#GEA'E7==TVD[9J_3?2RJO'\)0OCN8WXW
M>SN68WXG?SN.8WX_@]MZSJU\;=U7NOF<+\``BOQ1*,SDQLRTY6]"6RZ!_D.Y
MU;.^\"7PJ89:#;4::L\%M:?1"8_(C"T/D%*4]W':(/QECE5PZT)'.A(WR@M\
M[B&"Y['V17=@VO:C-<;OTG<?!)T7A$D6X'4>?<`:6#6PJ@:L4].%VR#X9F$*
M[/JE1.WCWU@E#:6&6PVW&FZ'U(FKH@'S9"R9[F?(3,>-^8V5UX*_UQUEF5;?
M,3NMWFFJ+=\/GM;`-MLU>#:!Q^FVS=Z@7X-G`_;T^J;E=`ZHYIZ`VP)?,\&?
M.??>GCY+`)FH6ZXT[Y;G^J&PZ8>;67*E5E-$B?9?K`SMY'(;C[KW\B]$J$\/
MR;TLUQK*-91K*'\/E$_+O'BB/+$7E$%'F5?V[#1XE'EHU87*(?/6J@J5X\IS
MJZYQ\,C,-RWO[4R?1NG.9HV)._V;BLO72E$KS\Z?(J4.&'O?:3\6*Q^3A/7\
M.M51IN`=`U@.D+)7?;#4*7ZO-(&H3KNJH59#K<I0.W%_PRM,Z+-!,;/:M7%9
MG;2K&E@UL)X'6*>F^9Y2HE"=8%7#K8;;X=_X,AIP=1W"=8K?6A92G>)7I_C5
M*7YUBE]56/2%ZC*J&H]^;QN*(^+'=LML=?JFT[-JDMH`'\=JF995<^2-\'$Z
M9JM;X\\F^+2Q+4SKT3'LU^F,.!TG?QT:J:%60ZW*4#MU)X089U"[(32Q;)FV
M8YN#7FU);H)/IV6;CGVBV<-/`)]!JV_V.R<:ZGT"^#B6;?:=9Z:O4U-[3\FW
M7\=$:KC5<#O\&U]&_:V*LHNOF>#/X[T&'!$`)DH$5%KG]9^A0KME/7"QNJKU
MV*I::RC74#X5*&\;#:+-_N!?Q4_+A,]+#X+F(_.PSF_C]$8:M<<G',_$5&5X
M6$[(%0,KY<B^+4,IZ[%\A'I/-9:OVWKX6#[[<`/JZE<_RZOKN64G.9;OX#"K
M!_15[](J-]+MX`=^Z5%]!S]P?<-/R47J\7T%BX`/+#>&#<NXDD/(C6NT"-9T
MZ^>.2'QWE,>T.EW3.OBHN_K@]<%/X^"GY8M7K,X^>E;7'MBFW7MU:%\?NSYV
M)5E<Y?6[T=&S/,=LM[MFJWV8RH?ZX/7!3^W@)ZG=G1\]H^N8@]8`_CG,'+[Z
MX/7!3^W@KT3'&Q\]Z^MU!Z;3/4P11'WL^MBG<^R3U.W&I^"Y,]L#RQP,#E.@
M7A^\/OBI'?S4M;O_=:/(Q:Q,G-.01M-;-V:GQ!&M?LOL]5^==[L^=GWL2G+"
MJO`]XF;&IR7FFS^R\]5!(_0#JV4..H>9`G90J6_WNF;'>G7.K/K&7Y*[/46Q
M35_5F#Q%;0V^9R)WX.$/GQFF./HKXT,<IZ"?#:?3,`UHQ-8UMC9QHUEL#&?A
M,F$SVK:G#J`6VET]TWW>DJ$/@?&[N\HNQFY9EHD50<;E\'ID>.)HUW\:?X3-
M_-<:+<<T[F^]Z2VLXRX8II##-\^-+^'2FQI]NX4ZK3N]]=B=:O\R=[T(D29E
MQH*Y<1JQ!:])"F:PRLR+IWZ(GQH15BS)OWJ!\6?SNFG\-AQ>T<BR#YA;&E"Q
MDNL;EU[@!E//]6&)SVP91H5+>/?A\O/U^R;51]%&U:J;#@8+12Q.?:Q]VKYU
MVLZ&?<,JZSN'K32-<Q!Z\$7"'PYN;5]@`P0W3)1EW8<1%A\9:<QGN<U8/(V\
M">S!#598J(4/;P;6/(Q@$;Y?7$8[!.X&_BPWCW_U`OA@P6O`W$F8)O1]6&#]
MQA":7IQM&U#%8-3=$IM:XKIS6!<N9\7<""$QP=1;'$YGN'.X/&,,Y),O,;`Z
MIH'P%Q>%E".*T1)XE40R>MG,FP&K28Q;%U[F`BQ@1;A_PULL7>RO245M`&7X
M-9#8#4L/?L9EI@!\3&.F\7ASB3M`?/`!/]M^I/G<Y7Q`F_^=ZE4;#R+.SC;B
MM($X(W;C<MQ:`J[#N57M'R`\?'3+@ACNDI`8Z_\>0#\=B9&P63?!T2RP2A""
M4`BP))[PFYZGXL3;T)^Q*-:OB>H5DQ4@C=P<#C?T<%`A)RK70(3UD:\@RTW#
M-,XN<.T,LH(1L!+K'>]#6"1F2S>"!XP)H#FB!)N*AJP9'N`5(+CAB4:VNKM<
M1B'P-1-6P;_.O2A.M+?'MV'JS^3&@6@3P"ZMCA()STLX)BZ684#`Y'6;<$IM
M*R!;)BL\*H,/9]H;"*K\-;!*_D5\FF/9\3GJ:.\$,(4"I.7?QYW2^?G*Y5#E
MG"!'GEMY09$3P),/Y04;.`'NX2&\8`,G0.2H&B_XDAT!C@K@18Y,VP;B0C*,
MX911F-[<TFGQ1+*NM_2,L7'/L`R8LQ"\YPGS45#''+D2#>JP")<S,3/N/7C=
M2W+>GV;>'?[Z7S^E<>/&=9?_N`:%TYM[4S=(,I7K"I:=>BS^PKXE(Q^8RJ_P
MO/%?\IDOD3MCPV#V"=%=/!6C`N?=H2Y)3Z^(E\#SG]G\E[<L]+]>75B]@3UP
M&@VK;;4:_]-JM=I?K[^,O]J]]E<LWFD-VJVOK;>&-_OEK3>#C_OP_]VOUN"\
M8Y];W<;E9>>\X5QT+QM#>]!KM-N=UGC<'8U:`^NK!0_^BB<4!SRH+BM!8F0P
MJ:S*JO8:J;URG(6%W!O.()%$$`\]N%"AH[D3ST>1DH2$B+Z/C;A=TMA08U2E
M\'DDG;@^("D(A5O&4$U-D!BRWH7`B&@OIN&S&+58&D-V3X^0;A6FDV2>^J`&
M\TT3/X,U)"W?1UZ"[1#G<R,-Q*X\/%%V."!58+BT-=_[&ZCT-@QG\$1V#.2,
M'L)C$2:L@@Q+,JM8P)<V+>\#6(M;<J/$=EQ44E+?C>`>8B\6PD!"V#0\>#8`
M!1H.#U^`ZTI!M(&R&GF@#\#S<V!)812+;@=X7UQ>2\:#8M7CVBY@R-)=<>3Q
M0"V)5@+$*?RR`/4$I:$18C-+X(`1N_,`+"01Y14`4_ZV1,<]7C[**B%:U>GP
M'2C)PP5H8')K@"3`=?'/^/143&QV>9_X>9J`OIV[:/TM3="]-(2[=PF"V,P`
MT#WF^R\OY479VL9WKTO>MD5_M4U#T)"X15@+J<K5P*.V!8`-"?7SM"%Q?@^F
MOA>#SO/T:^Q!,<)KQQV"2D+ZZQ##*9P+C%;95Z[XW0[O0>453L?+,)J#2@D`
MCC\$5P#2</9X"9`&'G^*]S=]"W;:U%N`G/WE[8<_+M<DQ.BB=>X,+\\;70>$
M@^-<M!K]R]&XT>Z<VX/^:-0>MRZ_=EHMZZOS]M=V>^`,-/GW].?.`_8#W+<7
MX6.?HK$7+\/8]3_-/X;!S4?0YV;#.`96R&]$B=NGDYWG7;O=&O<:-D&FW[,;
M@\OS06,TZ`[@$:O;Z76J)3LS<"%)()@:!">#`ZJR<E3GT"YL%?\GO`E3XG,9
M@P9KQ?#Q8#X=S*6#`5<5W"V:<?X#]ADM`.;1G1<3LX*'T>IL=X'G*(A=12&P
ML`08]Q5(UT0X?R[`Y%LB&#.(->7#TIX4VNGZ7B9,\&2&2Z'H];)K0?D)3%9Q
MVC!G@TZ]:)HND&M-Z8,9J)8)(]M.*,)3-XI6F;0GD17P-X/2L2)]>*+!S6=-
M\D05P4@BO+!UE%W"KS+CUA[:6"#!8DWQ+ML!:>BT`L@++BB`"Z$S![\A.O=,
MW1@=`',0$7D!`]N]`:!$7,E9::L!</@/-V!.+,$$)BDHW\\=0>S;E+$9QY8X
M7>!V<J_&U_*7FL(*D8B6H"HS8V`T++Q`X)OFDQ+G@L58Y/,#XUY@`;&;(:RA
MW2P_"0(>;(+_H`Z7AR;WK!'()BC!R".R&Z+TLMPI69QX:.L0=JWM-P<P3O9B
M:S/BGVQ&.$.B7*F;`KG0ZH\VWG.DO8TKF:0-Q/P%,?-]?"$^ODW0H^91*NEA
M,2[K-4&?7<],D0#@%MF+02B@GU$>)]Y;%\UP^=DM\V<-(,(&2(X2A71=_#]&
MY!2T@>DMFZ4^^S2_6"S]<,78-8ONO"G;("YI6C#^]&G^6:$/EX;G"-ZGEVP]
MJSOJ=T'F6Q?#;L/IC7J-00O^U;7L\\ON>7]\,6@_2+*U7K*;&'GJ&ES+GFJ`
ME!80QP^-$KGGF<0!035CK;.Z<1C%S-8[]6SJ#.8\O#-8^W`]LNI7/\NKZX9)
MY5VNE$9.;<$,WMK*X!VM\$^1\9/,.2D3D06M_,DCZI4"$78!.S"$:C2NNT*M
M';CN^W7J!W[6OE^GEQ;^F<7,C<!6I?02=L?\,/.-O&2FY`][Z4#K&;&69?;[
M1U?]]>C3]HXQ-?"1I[7[CFGWCZ[@Y9&G;7?:9K]S%#7,56%>OY%GT>=AU]G"
M"[PXB5Q,!GEQ]O7=:;^.V7KNN5+5._7`,KO.JVO,8K4&P-=:K^W8=L\Q!\XS
M'_O49J>=SD#2&GXU_&KX'2_\3MT2_D*YQQO#3QC4#N)'*I;^RPU4>ZQEV>Z8
M@_9AJNVJ#QT;-+;.X`C&XAX$.NU!V^QT#V.G5Q\Z7;MO]@:'M.N/4.T]I5&D
M-01K"-80/'8(YCGL6FEX2?G0<R6*Y?/1_HSQ#2)K,'ZR)+++06LTZ)RW&]WQ
M>;_A6+U^HW\QLAKG%[T+9^0,G6[O84EDW6?.C@8X8':B@@1=2E73H9<1+PI5
MI8:LM$J-"E`+><]8;7WV1L]3SA(JD]!8N']G2:2\%.2O=':CEINR*'$IH3J?
MCLSK9WDU",_-EMFC(NT.\THI.Q)S.7V/9QM[+#8Q'YH%J7B9,)-B7M,9,9\2
M?[6Z=5%/1,5T5#*ELCOU5:DBED-)5-/$^8(I6*0,8F:Q.&OASABEE4\`*'G`
MP!(9:+#(A(-&G;@PNK3\?;#(C7>'>YRE?(?>C(F;I>O@98M>LFH:GP(J[0EN
M0OP^51H5TY:S"B;<L]JNF:LL"F.F(`OO$/`GI""^@2\WM7Q>_?)PBW=P4*K]
M6JJ>7WQX*P>*/L_57/O./>\CIBYK9<IRX\3]Q@@@\$ACZGN!-R58I;,57:_Z
M**%"3D#L*,4"4?Q;5AXL$&-*2/![=IEHDA>@@K5`O$@(EX6G];JHR,@JM$2M
M,H`@7?#:%([O7J)5HV(:-<'0C<.`TC@I.YRG2^NTTC2&TP1V+CHW(,_%,NR9
M!]2#9YA'X4)@K-KJ_L5RWTJ8R;<\,]$4^<WR[1"9O$"SF(G*\4^6"6_)%\^G
M@Z<)X--_B+3S#$R_-R_+ZE=E=KDT>57PKG"XF:M`N4'L5=@<BF4!&=@W%DV]
M&*D"A#0N@N465&X)R!*4ORH__!CXC9;33H4`^-0D=*,9GW4,%(K5>";GY5ZP
MQ-87B"\9V\IA?1HS4<\,,`2.[`8,\9ES"0D0`:V'P6-]4\0O<SGYN\H1<H?G
M/C-,U#:"%.^;ROXG?XGJ?,Y;XE1](`H3==8&B@MV6_$!&M'?+,FS4ZK\Y\7^
MXJ`3+TS8]#8(_?!FA5G?:9Q$*]5,0+(&<:&\IC8KS)`(`2)EQN=,Q_)2"SQO
MG\*"O!J65]$^13<N:'-TBG,EPU#G"V976DN,3W/58.9:29BQ$IU/7RE@CYWQ
M>?=RU&B->NV&<^'T&X-^>]`X'YZW+&L\:`^'EP^K@;.?1\NS0'C>H?8,R^#U
MCE!VXFWIX*N8GO>[.XW"WQB(/,#Q#\&T:;Q#M,M:%9S_O-:]8/SS>ZJN18D:
M(;GS<O$S[%SAN_=810X$-DQO`-.U'A8.LM-6*\_HL'N%DKG85>0&Q1O0S!)P
M?>%.&?#;*=4F\^_/PVDJ*)@JK`#>5""4Y87!KV?8%"4([RC)P@#B#P$Y`TK!
M`)4BG*V$ZQSEK;ND5\14)4?=/4"V)HC49U1O-D5I&G$.GR:AMUBD`14R,13U
M!:XM:LABP<^6WA($=T"<:!F%LW2*-6C!C)3#F+-43LDA4#]+7.`+<>HE0O\,
M@'H:8DU>E<UW;VC\9`D*%G8IB@7/T)0%A,("BP^9K#NA=D:D=\Q+H.(IA5.!
M";@:U>8M0I]-P4KDYR7I4SR-F3$M35-$9@V\$=:;>P1P+FWQT*2WJ.IH8O$$
M4[Q\/!KM`_"*`-Y8L)E'>+9@6*SHQ0O2HE<HRB.4?N+I1KQD4^R'@>+DUO5]
M1H6-?&\NU6S!KE-@F]2L;,+PY0N&!7'`V($7"[8->(&ZW5F^,'2*N`'+@;U_
M*U0I/!O?F(21L%(B)H06B250W``AF2_Q">[ZAC1=%VN%?!__JQ,=`*$Q84F2
MZP0T_CEK8H3+1^D-RL+8NPFXDBWOFPK_N7@BD,V\*=875J@9`AJ,!%/JYA6X
M(%HY%T%+9+%/*QII^?"20]E5`/!HG:6)%D,`O-#W$;&P\](,Q3P(;@^HSM0?
M,OX7]`GQY!!NAO8D^8]\D<#.!'2=V!6M"*@)S(0QT'5\#[03P1>UP\#7!`5M
ML`RU-;A="2LLTRA.75[>248O(1FG5-X0(I'%Q?CG:\#"B,Q3VN'%-]%`#7!X
MX<58AVR\N[XX?X^X?2Z,R5RG,VJ$%B9`*$PSB6/`7_@*P$\W.3<=0VV^Q#?@
MJC8U9(7!:MX23\0Y';X`OH'JN+)I_PP(.4C=X$74"X;6%#S_#CT-[S6P81,+
MM.UG9%PMO(0PB!L[U!4$/09$=M2E:8EZ9"+*?N,4F(0"KP[<)O59H?Y@HD5=
MO+F;D`X(T?V*RG)=B0U_I<%4M!)25>*E3^,N\!YB7G6*%)XW]S-6FV_E=!6%
MR`@3T,+GGL]FV7O@ZG,8]1F."ZLXMO-N\OZ=\QXEZR?0>?/]IRQ1.DO*0;;X
M>]43#.6NWARI?%N9_2"[;VGP4UR`Q/<V/J"#")1@WKL&>>CL+U`Y9+/!@($^
M':-,Q6;BHBL8F@?^2CB/N&&,!L!2JN^9&H#E4X+*`Y3A"UXGQ'O'[2HO5F7$
MFRXH.\LRC$73E5V%RZ9D.E0:+6O*U8[WW>79F_P^I4S7H$?B!=TQ@NC19P,R
M$WDU<#7@!E(P[@'#<@B>;>_%(B6UO$./V`X5S*)*!Z]3S6`R2(K-5$C**;U!
M*1P<2KS50HB:(8<:EA2S&VY8?Y(?H;AC-]F%S-B<3%XW+K2M`[N?RDR`F>(]
M4JM*J2BHQG[(RH&%L!RS1_7[SO5\\B3):\,>I?-L9[`(MF\AR8&.V\A$UJI_
MA-NG<G^3>SZF'NETM^$][R_E\J@!H4N81M/,8P*72RT7,]TTKU&C+26U:0W!
M\&G.2[BS;9+&J-\HJ`JP29V4.'UF'CS$(N#J&E%>IOV3/A&0D8]^#F4,5`/Q
M/I4Q\&Z9+PNQR"<5T44=`-@0\J-TXI/Z'*)ZB^!Z]^'JT_LR5Y*$+R>\3%YC
MGP-NPG3,7J=E8LR+^RYT/PKGV-P1ASR=.S<R=!2MR;!3"?ZK@5B4"/\Y*MC<
M8X+[^L'J-N$5@!]\E1P.<8\S(SL&FX"`ALP;64P87#!3L0#E$37@N+1JO]/L
M&@O/][E@XXU:@7>EW+E#!@QV+"._NFCWP7%SJG0M4(5<3S;?R(1!'E7X_\I=
M-D_MELD[?2[<"#V4\16+*.#W7'V,+L_'W5ZG<]GH=UH8J!M<-H:#<Z?A#/K=
MWOG(.>\/[6KU,?H#4.4##QF\^QC&\7L#8&00D"H;M)/[]6F_BAR0RT]=?YKZ
M0L^2`0-LY#KU@0VC!7P;HE#F?Q3F,A`H$PABO)MAV8HW21/1(9-:W,A/WHMV
M+I+3DS7*7%B$K\^;I6H^:&HP%P&;]9:9K%.&B_+2PBZ]"/G+4OAC*6,IY@$E
M(FJ@O#OT,,S(6!?:*'4VRCH6C:07>:R\R#'Z!E!4^0@@5ZV")H&[(OZ#NCIJ
M66A'4&1F*1HUR;:>V+VGH;=X4_[9M?@4>7IY8]_,3L.I-AF+'C9`R1XV0&T<
MF<:Y:8Q-8>/AW)MM\3!^%+`PT!61^#+<QJ'#N4[6U4=!2T,/[J'4Y^IPT-T+
MTT6#B3BYC]Z+.-%<Z&A:,\U!?<Z/SU<#;3Y47FW"BHTOYE$JZHLT8?+8;";T
MS8A8MJG!SU@#&V_O`S##-VS&L8H(:_013_5VR!KQ2A22-)R+VO";Y*<B[7]M
M"4Z+7)+FT%$BHA)*]PRIBLT:+G;HNF':O>I[B'/]#&>I#'IS,]H+9SQ@%*:%
MF,@:]6-6P!WH"-0!=.SY*3?ZRJ&0L3`0G6F2/WSAZ.@0>-#AUXZ.VU@[?''3
M.3A(K9F#0'8T12\RR-V5>)CS5SQ%UKE>7";O4(Q`0'KEC:(Y"]EH1NM101XJ
MC)5AZ,T;BFHRMOZ`%V_K6+P?S]K,L<B!5QJK.L5`,Z=M/A&!<'P/&E=([E+'
M5FHX%=<=HLIZ*>!4E!$V3Q=S4?Z)#C8^%T6>HKR!5,=Z>`.ISN%:*=6O?I97
MUYUWRKLCZ=80]9#*ML%;)66_\YY)ZM=RAU[!1GKR$MX]GG@!2&$KJ4H!JD;O
MZK4=.M`Q7[J=5'V;1W2;VR;-:1I5F<*E#:)[/)NI>+WM'T6;=$U5KFBCGJ[9
M;;7-0?_0;9B>]Y0VG+)E=JQ#S]A][E,.',>TG,.4]K[4*:V6Z72[9N>Y4?:T
MNDM]9''\C[PS/G/:Y]SQFWVA+\[3OK=)S[NNZ;0=L_?X1F3O7X(0OON8W\W>
MCN68W\G?CN.8W\_@MI[SU*KK3Z<IS5-A8`VU&FHUU.JV44]@QI8'2"G*^SAM
MT*]\BQNK.S!M^PB:1[T@3+(`K_/H`];`JH%5-6"=FBY\2CUJ7E)#J>%6PZV&
MVR%UXJIHP#P92Z;[&3+3<6-^8^6UX.]U1UFFU7?,3NLPC>V?76WY?O"T!K;9
MKL&S"3Q.MVWV!H<9!G$$X&GU^J;E=`ZHYIZ`VP)?,\&?.??>GCY+`)FH6ZXT
M[Y;G^J&PZ8>;67*E5E-$B?9?K`SMY'(;C[KW\B]$J$\/R;TLUQK*-91K*'\/
ME$_+O'BB/+$7E$%'F5?V[#1XE'EHU87*(?/6J@J5X\ISJZYQ\,C,-RWO[>Q-
MUM876U$T)N[T;RHN7RM%K3P[?XJ4.F#L?:?]6*Q\3!+6\^M41YF"=PQ@.4#*
M7O7!4J?XO=($HCKMJH9:#;4J0^W$_0VO,*'/!L7,:M?&9772KFI@U<!Z'F"=
MFN9[2HE"=8)5#;<:;H=_X\MHP-5U"-<I?FM92'6*7YWB5Z?XU2E^56'1%ZK+
MJ&H\^KUM*(Z(']LML]7IFT[/JDEJ`WP<JV5:5LV1-\+'Z9BM;HT_F^#3QK8P
MK4?'L%^G,^)TG/QU:*2&6@VU*D/MU)T08IQ![8;0Q+)EVHYM#GJU);D)/IV6
M;3KVB68//P%\!JV^V>^<:*CW">#C6+;9=YZ9ODY-[3TEWWX=$ZGA5L/M\&]\
M&?6W*LHNOF:"/X_W&G!$`)@H$5!IG==_A@KMEO7`Q>JJUF.K:JVA7$/Y5*"\
M;32(-ON#?Q4_+1,^+SURG8_,PSJ_C=,;:=0>C:%6(ZOA83DA5PRLE"/[M@RE
MK,?R$>H]U5B^;NOA8_GLPPVHJU_]+*^NYY:=Y%B^@\.L'M!7O4NKW$BW@Q_X
MI4?U'?S`]0T_)1>IQ_<5+`(^L-P8-BSC2@XA-Z[1(EC3K9\[(O'=41[3ZG1-
MZ^"C[NJ#UP<_C8.?EB]>L3K[Z%E=>V";=N_5H7U][/K8E61QE=?O1D?/\ARS
MW>Z:K?9A*A_J@]<'/[6#GZ1V=W[TC*YC#EH#^.<P<_CJ@]<'/[6#OQ(=;WST
MK*_7'9A.]S!%$/6QZV.?SK%/4K<;GX+GSFP/+',P.$R!>GWP^N"G=O!3U^[^
MUXTB%[,R<4Y#&DUOW9B=$D>T^BVSUW]UWNWZV/6Q*\D)J\+WB)L9GY:8;_[(
MSE<'C=`/K)8YZ!QF"MA!I;[=ZYH=Z]4YL^H;?X*#[^!I:U4T/\V\._SUOWY*
MX\:-ZR[_<2$&7%VQZ!IK4*Y"WYNNOK!OR<@'AO(K/&C\E_SR]?26S5*??9K3
M=T>@6LVNW-6"!<GPWHUFQ(,$"_J7ZZ=4_#*,XW3!/Z,\0;6V,0V#!'[YS.:_
MO&6A__7JPNH-[('3:%AMJ]7XGU:KU?YZ_67\U>ZUOV)N9VO0;GUMO36\V2]O
MO1E\W(?_[W[M#;H`TDZ[85N7[8;3&EN-T47?;K3'K8MQI]NWQN/.5PL>_!5A
M($!0Y,QZA4WW!<J*7"_"RTX9%@<Q=WIKA`0DPT5(&EYLL#CQ%C1R+*2:(F,&
MO\"W884;5'&--,:R)/S+R'>G?S?@>D(?>\'00HUEY&'9C;$(9\S/O@R/N]F5
MB'HEK<R)<.85ER+UND]?BM3K/+P4:?#PRI@G6ZJN)7C;/G`!R.N]@G+:(S`]
M2X+_,VUT:V)^G6:_O:WOMR6;HN0#8>W-&(!FY3%_]J)F3<GUMGY\7B5QQZM.
MRV!5=WP78I6T[R6K0]]OI_UCMD8C^['3?[F+[UC/=O/5I??/7OQW8QXQK*,'
M0(#F:T2@[!X:'_"+>@.(__WGAR\7C>NKX3GL7[/(K*;ME&..W6QU^'V^3!,W
M;?-6TRI#VQ-E(K(KIN_-R:(*#^`(*[F$7K;"BKE1_&*WO_O%I\Y3+M'"7KC1
MWRS)#.U<#P\W63=S*\IA?K":G58IA_FAU^Q8A^$P?%.OA</,PVC.O"2-6"5D
M4Z?9ZKZ@5M+L]'8*D_T[^O#_T<=K'LFG=3+F'9C($_`96/S2"]Q@ZKG^AR!.
MHA27C[GS\\G\DA?]4;O5&K4;UF6_WW#ZHU&CWQ]T&J.V,[`[K<ZPW[(>Y)>T
M^LJW]A1^2&6MX@\>_D`\\U^262H0&1J,Z-(\=:N9?;O36?A27E6=Y\=X#O)O
MJK-XV5E*NC9EWXL3H'+ZFFG<WWK36_EM8^K&M_D&4(#T(%;8"A80;W>GTS"E
M9]WE,@J_D2<7WP$;G+I1M$)7J]BBFV#\KM1#9"!ZT?IC-BW^V:(_VZ8Q2VE(
M+ZT.2\6W890T@'07L)M$#,-I$H#.P\72#59J>\C5C`@GYD2X(7@1/!^$02/[
M3/-4+Y@;`_^3L*-5HAG`BQGW7G(K0)BAS9"_!5>YQN;D0+TQ\`7T;[^['%Z/
MWI=^`Y8X#V?>W)ORYEGOAM?G[XV^#=`H0]3?]4WQ`XR]>.J'^*F&KK0.+O.^
M:8B?C!F#^X8;R,YHHML=.(@7WS+<B:N?_]8#)3.:WJX(;&X<,W'YON=.T(+%
M)!,!)%!)$WH6%A$KXS<CQ!MLV,Z^P47,R,6A-FNXDS!-M#<B/FG'XW<H-Y_M
M)G*#OV-"\W^G+AK2/$H0,;DO_``N;)DB0O*M2W9I&FFL"```@F@#%RC:EB%%
M:+#)G6##^1&[O?7C(X).@'9\>`SN%K\0J,/S#0`%*7+-PA'8F^@,VZDE[";$
M-)XGC$UTCRLT8;5$2[/MT089;-A/Z*-*I77CDL+?9_/"G%[;WG\AZ^%;*+[W
M([MCOF&MJ4S($7_FVCU'+`_I5"(N8-)D)8)=:>#._DIC5-[^G8;X'PR),:04
M0$[LVN?>N9Y/M^L%2.Q3FB#&63CGC>A]3(`3^1O0O;E+*=JODV&-K*>`K/9W
M("OGSD8(W"]"!`T,00`EN(NH"M@[`S8\3?P5<G0OR'Z;Q"RZ0S1H@N)&JTYA
M.:F]\.5@";$@8GGL+8`.-HHT$O4YT@B1K^<WM@^UX$H@7&@MI2N!6/O,?)>W
M>U;;=?TX5'M.;D%&*$%U)[5^O@T.LERT&Z1:G(+&YL9YAR+?$,42#-!O[C)X
MXBM1/(51%`*NTVXF.BRE8C=S$_>)B-ZRE]]*J/Y;GORT"0@UU5>1ZMN/HGJ!
MZDH4I8&&:XBE09@4T3$S+P@+C3]CJ3#%3"[H!7>ACX@=PUY)B0X2H1;'Z>0O
MQNGXKW1VPS5FKI8M7*`RV)4+ZMT2K`>D)"3E9%5^.%B--6^:ICH4MQZXL0.D
MB,8.%[[X%GR)2[H>*ON@%DX3HEQB&;[O@4(Y0R45F$8X]>BP9$^XQ@UL-I`C
M/5=/1W?/;HE*0XMQ9H7\49E%&WBCN!X`5D[KSEM=F""D&6P3-_;H#A5RR10?
M[2)\0E/`,V[&PK>%%K["+R]X]E%V[TL6>>&L20>!Q?,F@=+^$^V0L.+"_9MI
M"`8/9RCFQL(ZU7!RRC*31#%V'9ERM@."ZAZX/.-L73SF>]SN%+;+FEW4W,]0
M>&YTN-S_XC==.ZQRCZ=W8V$9/:41=&P)6L_1*]K9DB*U*:NJ>[BNR?6KG^75
MKS?G2J6]6<[6O*:-?K<=+LR"K_@[0Q:O]YXB8/VR+^R>/6*_A(GK/PS^^FN^
M&Q+/@Z?;S_P_9)EFF[@B$S7[W0OR`)E$QD_%H,B0%!DMPY,;J]D'H+WN7N6#
MLHB')/R?EA`.SBZV7\-U9H)D._F$YOINP'U2UE#V*/=FO%H0[H39GYH-N0=J
M/@,TCYXS5X^723_X:\)ZZ4Y]?6=^5DVISC,OF.9<)K]L%MB#KO:IOW>,.ZWW
M_"3?.[ZTO/86RCW''!QTI!63<5Z<EG_8RZ(2OVI]K<R.;9LM^S`SR%_;*5_J
MO%F,Q'E\LN<#:[Y?]>%/(8M]&Y_['=,*9=1OG@:S(^SMT35;3L^TNH=F`J_M
MO"]^\M/@?L<(A=-2[CZS.(D\JKI`]>[H.)[3<LQ^66G,*;*[:ASV55!Y#86=
MO&X]:>Z@9GV19PKO(>5F9*[#;\)U6'+RA[*]9WWA2S"8&FHUUM7P>TGXG8()
MO<W)3PD0(O?N<:JDGR_2+@E7;L2VAQ9E/]+UTFZ;@YX#=N=AY@,\"$`U6*J#
M-Q728FM@O09EMPU2;!:F$Y^]E-Q\_!NKI.Z^*KC5$*PA^,P0/#Z'Z385]V-6
M3?+(9)87E+Z'_-[S:JG'<;+ZC(<_XRG8W-LB.-F4'=YJ[9Y/Y5%E;X]L]5E]
M&^%=MS<P[<&CF_N_/R'KNS8N:V`=(975)G=UU?;:Y*X-QAJ"QPG!(E_-;_>6
M(7?_Y:W5W<P\M>]H%<N;'CCZ6K3#5G-O;CA)FYT\4L35UZ2NJ2[FKHNY*X"&
M=3'W(4"X$V9U,?=S*%T'QH"ZF/LUG;EJ;6\JX#2NJ[&_"[\/O]-ZSQ4*`+TD
MY9YT-;;5-[N#CFD->GL]?_"BG6,_YDL=N$)1E==Q^%/044Z]'GM`]<F#SF&2
MHE_O>5_\Y*?!_8X1"J>EWM7UV$?$[JIQV%=!Y344=O*Z(\R7.9W*SI?,EGE%
M4*OA5\.OKL>NZ[&W*6%]TX)_6JW.0?2P!P&H!DMU\*9"6FP-K->@[)Y2@NE+
MJKNO"FXU!&L(UO78=3WVTW^OKL>NSUB%,YZ"S5W78Y=5BG9L<^`\.MVE+L>N
M;<L:6(<DLMK@KJ[27AO<M;E80_`X(;AM,J`V^H]_E6K02K:LCYK',?(_&SD5
MUOEQ3P5VXVCZ7'6($<ZW5"6;1G++C/-PL72#E9&`>AL+E==+8F.!>9NPBIZY
M:<RC<&&(\B0C"<6/EC%A4S>-&2WH46&=X48,11>L,'%C6#-=AH'A&O^FVE2Y
MZA(K4YMK5W,0<'W)@)'I,H.?8W7(F$W3B%P4N&\X@>>OC&D8Q%Z<`*1AB2B?
M]F6N9?=3RO]B+2.VB2^'Y^5=S%C"HH47P)L0HK`JO`Y7G6/]^1W5G\_#B.Y)
M[`Z>UO:7QEYP(V']+@W<V5]I##^_YQ"/^=.J.)>'%HTP@E7\S!,#5VFX5`<L
M=AM7[ZH>`2N[#%;X[#ST_?`>?UNPY#:<Q?^0(-2@%GL+SW<14AQJ/VT%F"G)
M(<2Z7WB+&X@U80&Q*GR8$+EDY:OT)MP2O4.]8F6\8\V;)BX*AX:C(L[!8>$U
M*X_Y@'5I=`<KWH6^FX@]F0"AN9OZB?PF2Z;-]X2(?&NPAMK!C$6P>3IO,/66
MK@\83C0/VYF&411.PHB`.UGQ$\'#VJX%3L_<Q-T?4[Z57/VW_-5KZNIF?EZZ
M?NOY$3'#&N+Z`+OP#D@+:-V(X$]PD_=N-$-6G&S@,(0*.]P-IG%_ZTUOX0\<
MS\,`K\8+7+@GUX<5O`!X3XKM*`![J37%S(!;U:B`^&^$B!_A;H$M>P+[D2`\
M56EMI%HAM<3?=Z)`$S`G1HP"@D,$,H;7Y_!TWVZMNVTW7\@N"-N:9WKSA7-P
MYW6!\T\?/PZOKF&1*<#>7<9LUVVONZ3"",C@E[>MM\:4^5B\.@40J=^7[FPF
M?[_W9LGM+V^[_1\WU;869P1K(X25@9;7>\2:_>Z/>UMA:A^;'WF:S^OAR%N#
M&"/7!W)D2'8[>L$<08'?P5P41Q>[XNE9:1`QV,)_@"W>N,",C7=^",([?@]<
M<NJG,\XNF1L%P#V.KP;J7=?NFFWGT1,:7Y7+JDZM/$*6?<V629%GMXAGMQ]'
MK7[UW=!U5]#:EW44OJP/@4%J.3J=I(G/;7;-ON$65M&46J;1]-:-T;\BK*J8
M>[XF:/NP.#9(90>3-V9B)32RX"UP<"^^16N7/%AH/\$B,R^>AFD@G3S&'*P_
M8Q'.P#IZ!Z(^7``W68(1Z$YOWS=SKHH4;?+_D.GOPGF6B0=+HA,@<SG@^?@>
M<(?Q+1CETD/AHJ\I@9]@N[#"U'>]!3J47'\%AIRT#^'5OD?&)UAP^`-`90IV
MO'A=#%\+"1;"K@-@^6R:T.M\[]^I!\8[WQ9"D07HH*`^%6%PQZ(8_S1AM^Z=
M1\XB`?*9-Z<O)[@K5'KP#^CV2E9-8SA/&'=F\$]RMX7NP9)KN"<C4SAV9ORZ
M$E*S<FMX:#K#X<(I.24`=OC%.S?RPC267\T,X]B(4P11G.$(6KZ():9`%@DE
M//(F1%)HU#3^CW"1!NX-=8)4N(F`]0E'^9[@4\!,N!%^Q3JDX55XG>OP11"Y
MQM*-$F^:^F[$@8N?TGYN0Q\(0OD.-V.ST#]C=":E"W%`OCW:#.#J+)TB3A'>
MPD.F\L^R@"61VB?L,@8HPC,S]`:$2T%P]'P3%M#ZM1D`*\#56$`@9KG7WX>I
M/T-_*3JFO(#P<0H*-.#.3S,F?I+`6Z?Q$%`W@0UQWX6ZC^IX)Y,=-@'`LXQ7
MR9-P>*Q9#8#PV>=N3"QAL0P#Q#R`#/<Q<AX$*[QCW^#^8H86"+T-?=6H)-+%
M`_P2CK/X)*"FJS"?T'$!>[N%Q]&9R9=<!^]/,^\.?_VOG]*X<>.ZRW]@@]1_
MX4U]FE]*Y]2'C`"OX/73U:_PN/%?\I'/@$I!"M!&]L:^)9_9_)>W+/2_7EU8
MO8$]<!H-JVVU&O\#(K']]?K+^*O=:W]%M:PU:+>^MMX"F#W^E!>'CFWUOOYY
M/7X+*#H%4O1C\M1X,_CK#)[LP_]WOXY:XW;7ZM@-IWWA-)Q!_Z+1'_0N&I=6
M9]RZ;/=!21U^;7]MO_W5:5MVWV[;V1'E?O.G^(,E'PA*'^&&AW>NYZ/8_!("
M[U^$P;5&L",W]J9/?=AOL?>/P/-!A8Y2MG9<>W@QO!B/NPVG->@W'&?4:?2=
MT45CT!V,+SH6:N1M.J[Q4_Y4U*WRCS`0^!'<\#-><,2JX(T-WO[:Z-H]NV]E
M%[;]$/D#?_2F^&$L+KF")[0`)^%%G<'`R8Y8V/9C47/L^2GI-15$SL$:<HK#
M7D;AXC?BFA6\+?OMKY9EV7:[O\9`LGT7:"Z/IGAI%3Q8_^VO[4[/<MHMC=#6
M=YX_V@<AX\="PG\(KB*V=+W9`1A*Y](9MZU1N]&'\P+NG5N-_GD?_C4>#.UQ
M>]!UAD!L>,Y!M].W.MDQ=YUBUYF'4[(?@%BGS.-!ENJ=N_?V5[O=:77;V\Z]
M?I(MG*>"2&RUX)0#Q[&<07;,W*;SY[ER5Z3&?`F'4U#@(W85H5!)5E<^T/$P
MF%W`ITM2JJIWHQ:@LMUJ=WLMC63W/U$>$DK/&U)F`7[AT_Q_A?9:P<-WWO[:
MM;MM_9ZW'B%_VG,T>Q`8G,"KB,I`K^U!I]/MMS15M;CO_*E^`^,N<GWX^W`&
M=K87DZ5W5V'MKOOVUU[;M@<]3?79<8HUAH2=-Z]XB'XV6OT9L]F'0)@JP0UU
MO>>I'-7#81O,D7['LOKM'+/:\T"[I-)86*('T'SW96`.*/<6_-KO=P;;Q%+A
M*/F37Z-/;80./73+`8IP[T;UCNL@1;<[7<V2*=][@5<!.@`QX'\NLL2S*W(]
M%4%5P5/;=,F.U0-NUM,XV0-.M4&=_D@^I<_PG&`-0#O/!X!&9PT"0WLP@I\O
M&^-1QVHXEUVGT;<NG<9@W!MTVGU`:\?A!I[M4`"@1+,N.T3^O&.>FW,.!XN\
M28H(@K+\8K'TPQ6+QEX,4,)/W6BE?VFX0%7N)3&BU^\.X?R``J,^,/U^YQ(P
M8M!JV)<7E^<7SOABV&MS>%B@HPTT"^K[SKB'?@YVZDPK2:T@G5A@639`$MJ6
MLT-#+YQE7^L$-,.*FB:6A2QBX+1`1=C'.A$G*:CR43AE;!:C%?XACE.,`G^:
M:RZ1"A[<MM<5@)WGV$L!^A#<8>2BX@J0A=Z]-1-F_R,5W4<Q<Z,IBI4QCV8L
M,K9:0>473!C0?=OMOIWS)6TY1/Z\?P8S5(Z1%;+9A8@H#&7P[$MX18$F;TER
MYCK+CWXV2'SXX_*QSD"[Q&Y_Y/F*TG,9P09)KX*??9(B:%LL0GCZ/R^N*[9[
MH_/A""AC-+R\!`3IM!J#WOFX<3X>=5L7[:%EM2R`1PL80]OIZEZJ?4ZR2Q90
M&]MTFJ28,(RH%MU54B"`8=1PNMUVR]HF#\I.4_3OE*+(.,,K`&`IGE622OHE
M5/+X(VXFE`JB1'L[0>3/HIA$N7UU`)$POK#/VP.XX(X]&C2<X:#7&%FVT^AU
M;'OH#%L7`UB%V&#11-SO+/S\BYO@VU;SN9I^3!"$_5ZK#5>[QP&TDVYT;5[(
MFB'0'.:I_]&;,TJ%^@(''_G?I0L6[[4S[K8NAW9C-+X8-9S.N-\8=?HM8.>#
MX3D(_E''/H<C`CO'\+J(KF_+9>@^;RI#CLHQ`<35Y2!6#&&B`,4,LS(J],!A
MBF'#!R,-TV-X9E-X)]*`LH*9K%@K)<@;OG=7U@#HM5>2;"\5Z;8>7BKB/+14
MY-03@<\Y'D>4-49<H?))OVUC!;I_?.KE%=?A/+D'5O/:[Z.ZM'.9@H8(:G7U
MK\AJO0Z:^>A2H6X8K4AJA_.Y-V5'Q-HZKY64R+^/V5B&M\!<7#Y?OO+WA6SZ
M%C1#O7@FG&<_^WBL[%=,[-:^J#W$]4#M0=#%=V'!6H5"EI;ZG7J_9CR4FU-#
MS!;@J=^C5?85D54QQ,+O3SSCF3*]V.Q_&6K&8&2#,NS>L,]LX7IH75.4PITF
MJ>M_`>`\F<%A=RQK.&P[C>%HW&DXXY'5&/:'HT:[T^X/[<M^]Z(_^MINM2RT
M):]Z_U>`[&5/JX'Y<[AR_60UO(D8O0=#.7Z(U>Q/;XQUG4Y_Z+3&#0N,RX8S
M:+4:@WZ[WV@-K,'EV+DXOQSU'V2,67UE?CR%\87OF>#/@Z9QQ7/LC=\]'XRF
M,&"&S-PA!B_`9BBX%0>;[[2FGMF0_$!.HH!-R7"\]Q*<?LKG%QM7LJY"[9Y_
MX4OH`]H$4\9SZB-WR=+$F\8FK#9M&N_4W]_SF@?*E<?:!'+P&?^=`I3L5JMC
MBD(368:S<%?&A!D1HX0G*H'PXCAEV0L-M,PH?NCS!B\SD1Z/-1*Q,&#C?QCO
M/*T"[@>K90XZ+1,KM[PY6'A1`MAN+.2-\98X8`R;*KM?6LQ`%(DPLL.Y<47`
M:!M)Y+D^O]^YY^-WX8^BN.4,F\W<I#Z7\:("`\QG2@/F14!3GM#_,^Q2WV:[
M:UKMCBPMHK8U4XH6\1*$G^E]\(C^3"30:REQ;L*2>\8"PVKV.C^*D@&GV?H1
M=QC`E<:NSXN`Q,[@%%,!;=E.9`F,-^"M1/!^%>BQ[H7J&.2AY@R6P@H(WG9$
M:Z+1-(8!/KSIMG)7##>..9I&&LR$'X*P#QXOQ3_?YS@R11N>BBTB$6HA`,VR
M8`NL(`HMC/M;@`E<;8K>IZ;Q1YA!3*NWH;XN:LN\]D?;]*U[!U"8\D4D,E,-
MT2ULC]X./)0UX,J`2'A-$>(#"W"C6ZI8$;38@0#`IM[NKTR)J0A(Q3XDZ/(M
MHN@\!L<&C\5-XQPW&22X2I[&O-@(PL0()Z`JJ#HC_5D301J$XJXCD72$R''V
M1ET]1R,/\0V!<$.I7LDZ'N18'/]?B1ZPAVS1)-&Y*K8[UZ_GL\"(84Q^1UP'
M*UPH#!O'E8DIMD9]NW?I]#&9`G,K[$YCU.N#!M#M#$=VJSOJ=BTNVUH".D]_
MWAPP?9^;)#P()>H5,G'UG'+>&8.:`^*]80WA8<=JVXWAA7/>Z-CC=J?G@'K4
MNJR$G.\!0>F`(EH7H/I>T?[TN\4?//SA(ZPE#4X/A<HUB^X\X$"X.T_MLU+*
MR!]H6@&71(9HY1OAY70)UZ!J^482-@3+)WZ=NZ2\UB(.KSIX:9(BJZU;L`@K
MXZ0C'03E[[\-[9Y%#<1\%&,I9BVQ7-\P7.U/X`14M7J=\&Y>YV[@SES3^)U]
M\Z:A:?RW"X<PC>LPA;W\GS!B+F'1AV#F/:`GU[."_T_L!,B^L6DJ#T\248+1
M5"!<N#/X'*1$$#'LDX>V&4H'+E/QP1_L%BI8/JXC)*O2#?3*:Q`A#"21AV[^
M)"3E"2L6F)$N\;D?VMDR<`-2C;JA%ERH?YC&#TY/^PK>(FADU#Q/*7A*V,.W
M+2>WHJ:KJ:]G)^$Z'IREKS_#A=_ZZJA<"@B1ZH&H%(ON=[Q\V02YFU"]J?9>
M6=M+B,D1,4ZGR,3!]*5&AAE6PFH<'_-0!(8L:D^I81R7^.O`$JT?$T!]C.=$
M>&VQP1]`[8@MM7M'K2,S*_/ON\U5@?.7,A<TL&6(NJ.'ATG1[ZA=AUDDN%+8
M(T+$Z01KB#%7'$N7AWYR&Z8WMT6X9\>1:AH6SV;/$O-8X9<0H@DJCJ@UW@14
M]LN[7DYO/7:GBFT1#-E.WE%9-!7X^Z@,YA4BL12/LD=`^V`3<`UQ@OHW6!/O
M]>:;L%.^$="L4-$E^,,VF"_4.H(A+[[&R![>9NF[7%1K^2T#I3>195(%_QV>
M0=)GAGO87%'T,P!RXGT*4MR'?AF*RVD4GL8)Z87N.AXU@=G-",>36[BN$O[`
MSS%AZVJFSL^%3HE=&G@S#6,&G"#!KRZ\62-!."JUU*#6!SGM,\#3X2Y8!!<0
M(E>N"",MT@K#&GD.AEN6V2O;Q!5*$@%-I)4RB@-0>=3,4*")1JYRB44*P%LB
M9#6*-\G*8Q'PFP6W[/@MH5&:HW-N`14XBT2G/*'2)M57),H@TX%%N,3U8NU1
M)%M7W]5^;,C@318CXA/*.L/'TT!82\FJN%580B&DI(R9V'#.HP#;S1FD0AS2
M`V>JIX8X1(01^)CS_236(N8Q\\DG0$U$P6!O`L$$(7%U`2YXE>Q50@TU;@`(
M0;XE2;[1K09H%$[E5Z<,:"_>A&*B1<$9M3EAW^"7&#,P5]C`@AA52&=)V/0V
M"/WP!JU'_)GS[WCJ(7.?>U,AIK#9J8]-2E(XT5(X<V&SRV48)5+LJZTL?7BI
M9C7/O8CZI&)`84W7X'T^LI0HQ(>`[YK4$TIW6RR\!+@$'6=&A%#N",B^VBSO
M4#M3/)7Z86P"L+IR;.("QR"T\T2+89<G-</')OYQRG*4,`L91WH2$=0BH^'Z
M*&9$4YE0(W@D7E`3-[8ES2Z%'!P`I)AI*BR=-`^\)O:<QAXKIN;6\@'#@0<'
MB5+<`!E)-(C6%]2*5MKXFNP$;`*:6V6)(W(]N\>='QQ)O7`FF]]HQ$+2"G9-
MS9A%XQ6X_:)RD/-:Y$^_AA8Y-%MW`FVX_7D:D40OL+CGT6.J(9?&19\5W5:\
MAX<*SXDNJH(W24<*(850^;?L9EMIS.\REZH+?VHU6RB8Q!_7M.CW0N7.%C#Q
M;A%?`(X^F`_\$$2QC!QNCSN%)N0VG:+?'&PYA?P3/TWI*;K-?ODI3(U9Z^Z]
MBN#)<&O3/;"BVDU+009`):'&NT.I!DZ:0-*41.IY-=>Z)NL-=:;<;WF6:W?>
MQ`UM:Y>?NP]M0RCYM2UMV-`/@_QIU,[.WI3M+=>(G:ZYI>%)X4"DWP8W#10T
MN2-5XZ+!>E`773)ZH.!QB8%.2,H472_[.5X05C<\_HB0351/+UB<V\6"*\4,
M6#SVZ)(JBI*C>HLK(?9SYK$Q'G[^TN!=X18AJ"8IZ;MB%H"(U"2BT=J,86_M
M$K<U:IF__S9NM;KT!OJQ1W[Q>]!W>'\G0*((CX$O5*\R]W0322<1<M+:3;3!
M302X*75SL\"P911(<QT5'4?=SD;'$5HDW'4TR/EUMCJ.,O;_0T>37V0C`)11
M_0-"(I41S1W2(LBN1C0R!0X)/74#[OS0;NWT3>4\4[#$#]V\AVP/WY3F'1".
M#=VNX2PMYX`2]!:7>:_.WN3\5^8Z22*Q2,.=\U^"C;@1O&8M4)CUI,O</'F6
MA.MG>C*@`<5+,5A(D4*;OB`#M7D;($[B;6XL:0.4*H![J7\Y3:"@`.YV8VGQ
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M/0AO#-:<N=P?+]*?4)3RU*8_0EWGR12,[`4;/`:;,ZUR<"*IMA%2KV/JU4Z_
MC64UNX]VW/S0SS_\``\.Q[MVWDE3_KQRESS8!]3_'A_0IK/MZP,:-)U]GO\N
M9]`S93>I?*'?@#Y=8#BH-4R92.>M<K+0?[M!Z@*KY]B]V7.UYI+B)^4J#X]K
MDX6@.9SNP\B?W8,QIH0G^1BXPJ+D3DGBD/1`S,,T*G5'-<7;N?HN7TA!2OE*
M\J_%(FZ*'$]-4`AAMPM8XA*S<0/U23'+,V+<4"^*Q_4,)_$J[-N.;Z90UA^@
M#MX:0_@F"%D.UXL4U46`T)\!^6/^P.%YH&Q^F#)0$D$#^))&?[,5BI-ABG7&
M@-[T1KS;_X_A,)=91<2NKG<(IQ$J04JY^:&7B<?UY`>\%"'MN#I<<L5YW49D
MM9>G.6G1YY)\'9+>MB:MT6&FAT]RPP(TQ9;N>LV=A2ZO=J=3_GR9YB1X6T?S
M2XDG..FLN3*\N43NG).)$\.ZG^GLS?Z>IG4_4Y'P-GB:I&$()U%.I[PE6F8!
MTTY))U6N9UY5'VCYX7G35\SY0#>-9OTI)S=Y1J1YF?G!=UF8.Y.NGD-!?E#2
M5?[9AWBK,CO\\=XJ:72]I+=*X+CKQZ&:*HK&5DJ#+U2&::EY1Q-B`T&C[)OX
M14H6PFD<Y9%50V3!P4)Y@-C%NFN,$V?1.89.,6G7JD2K8O*5:4S`-H6[$--G
M`V._-*R3]93)JWYI1]F+.99T_2:?_"-X[,:L&NS3A'.2]\A%S7GC9F$A$\;0
M724B^2-B<#1F%MPRP.\G!/R-_AG,#U##?7P7)P?-^5OH);!*-GE:]^%PWKCC
MI%+-4MM8?[_Q#E<M)M;(9#/-);+Q91'S%I,TBCF/>E_FFSE[D\_!<;5$&ML2
M9O&CO#+5(UT$CU*846-"IDMD.A,SQ_@T,`#"7Z%'>**AO'28H4+N3M'>DO/)
M;A!R`2\J#'@3G!AU8:X"D[:-3C86Z_3'AXB+\>3K'!I(X7<U<BH?S[F_923*
M2I.7:./:;H7*Z.8I1V#*&@.Z=TOR*9O&/\G`T49@:;O9:Q<8Y\[OP*37D;Q1
M%'R+W-'`U$>LBL3J>("16/),3XO+1J=K:>75P+=L3`+7N2TM(<2EC[8YX=1`
M,3PN-;(%'I<Q(3W=66(R@B)'YVC\_7VF<CN97@Z98]P5@5C!B"JX'0EDI*]_
MHZ18X%-%+R3&KCM:WDRIYT]B3*G;[VR/RLIB[MBZ$U)JCA&JTAO<0Q6!^4[O
MGI/W03UW5E9%O%:CD-VB@Q@.]0'^[=\"7<%/I%@+T_JWQ>2?5?9C?9HFH<C`
M:FU+P)H6BQ#/LC*?@H=+@PJF3*%%"4Q\'\<5F)*E?BN!&S%L3.FT7%+*!@!H
M:[EQ%LQG:!4LXI(,H7PZCS"&]3WKOC@S\XR9PA)9-28@X3$<IT&`(S;JL.6!
MSC('GG0DB+&*>.Y8*V<ND?&DN>,GV6ZS/<Q473V>,4(+6L;ZZ`RO(PRQ,T$L
MN2UWP0FU^2R?(V8I_U?>TD!3B/T[I3+W;)GDGN1P$.#=8UL3P&?2\G(U?6A!
MD?Y#`T'Q49[9*U.S-C\O9S:B2POH[-^IB]UU2//&.!/M4)8VP%[*MT!^H!@H
M"W;N)K*AJXI1NW$,2ALN0.Z&D7!H:/1QZ^IUA53;A6_P=3>QX>*`5Z',\MQ-
M/!<J<S%ZS<OOA2"@[UJ[#;W[@I#X*C8<R1XRFBDJK`H,(>/QY1VM^[5HU\J)
MA6J]&VG)X6=:1>:Z9N%8^_A#S[3*4,WPP=#/8&]_Z!G/.?VAWRY[9,U7IF<"
MXA&1O9"GB;OQRY4>.1,44]C@.?2,:GPZ<YGB'Y5O@5())>_9Z3=$U:G.<GOY
M+#==P#VC[U!D=.A-5HK.0,R$R_D"E8>/B#7OXVL:.,1`1O@7&!S42V9S6@FQ
M&Q)\VY75I("ABG__T![D*D3*U=4L'5?(#+.$90MJ+4N>S5*YE;-`W$`^\1B6
MT"Y-#IJ>8<6!KFIOO+%K/NM[W+!AI2LU5)@/LO!R$4RK(F;&KGRKG"\O4Y!R
MZI#.S3AQ:+XV,^^`72_8DNXV68RI;.)\FKZI%8I-PP:@["+$2_L)3IS.7=%/
M_B%N2GT5I++,V4,"FPM;07Y<A*>3OT1RF4AA@E4"=A/*KE'$N<BVY!Z\M6A6
M/GEK?0_"L2=*9G6C3'?F:3+W[(TVSER`+H-!]5"LI,*XA.=R>W9CNJ#"&/1&
M95/)']`E(5^@*6::!QB84[YC`PPBN(=WK`E,PIU0(2A?A/AXK/&"G9[D]WD_
M-QY';B!792HK8<H<W5O3:35A9LRB]`;UPQE-&"=VBR]:L82D7P9+-C-S3G&/
ME`R0@BJ+46.&6B(CN6+BE*/XAI/KGE/5D5PH1'KZ*K<RX<UHMP'S3)`]%FM#
M/GI_LWL/6$F>/T^5:Q*+L'-'H3204+E@5\:[_/Z5NQDY%VU/B>?M-YJ=Z^R-
MDM[:B]Y7A^9D3$6/4&CIU%MC(#I;)M:7`%=+M&GWI0$1L:06MU#V0@GKDHP+
M-+D0>]O+_&L=_D*FEQ+_FN*!8K6S'@<1)E%6LE]:AER=>\O%0G)&8!T/>4`\
M)+QGZ`(CQ7]6\<"((8UBA9GYG7E<T:8N&!F4$G)A$P.*;MQ`YGB)1>1K]I"C
MU<']B&EF6A!F\%R$,RQL<%4):<&,IC1]@;GN+%1U'\/K/['YZ*"!?1>5`IZ9
M*#RAM"K*>#$R93M=L]WKB'S:3L?L=/O9WK?%JF`Q50._+8\V7Z:N8ELRLH4(
MLR&VI7&F\OA6ILEK88C3B6^UB_$M+7-OS\SV_1/:52^#XHV)#'_ETY(NJX&V
M/^V]^]8;Z.BS_MJF\2E@ZX:V*#_06R7L4U,@Y;A$4U5!H+N>RFL(=L&9NR<>
M4VL!AEK.(8D'$<UO2]^9>:=Y]<\6H#;ASPR.!X2&/0^OLR<O[GCU,;6&TSO3
M_O_L75EO(T>2?F]`_T&K\0"[@%+.LRK38QNHT_:@NZ55M[V8)X$MEM3$4*26
MI.SN_?4;F95ULD@6CY)(ML8S8XEB'?%E9&3<,1B9S)_U=LPAQQ16ES;@$H.O
M7=H@VI0F+"EM$-6'[[JT@6]3VK"(MI/6I0VMKM_KTH:K.Y`.D_VO:"A'@I?V
MXDBEF*G%S-?ZQ&83I\0NC/LV1WU-V*RY7J%\&&:Q6OL,T]T!-58QS,5J:[EV
M<V&_[-1(O?O?B?)Q6O41-[=#*/O0K>*W@1>]GG][LG_M><KK46V@FM<5-""4
M=BFK*BW$;1,ZR\-"-6O!2`>B1-,]YBM-3%\)'4ZHGN)YC"P+89G096,:3HNT
M_>:P5M$O;=ZK\1K+VBR6905`VFSP4<.0=G<QJLIPN*0>9:XK1V:9%J'16O>7
M\K,6QK3,6M:B6FF&^ZI6HN7V$R>U+M+GILRJPIO:Z,[:Z]O4W$>P<YZ*II(E
M?Z()F>NZV"%PJDE.R07-@MZ-]C'F="W'A_@>2I_-\^JS\^-H\^I'\]VKFOLU
MK(P5I$',<DRKY(Q=%>(X;0Z&Z8.Z;4AK<4#KI#+LI#FDM>`%2C*T15#KL$):
M#<Q<C4ME$K\DD'4(95@)J[>HN\A<FC69T\`%J\)<)V]6![J6A[D6>!)K@:[E
M82YCG\T'NN+>[:Q<0%<Z=`<%I0U=K=,\FBSN!4]-O0!+PV-6L2@'R-J'QU*I
M9O7P+/-OH]"85<:W"XU9(?L:%MNSL)C1[&QQU7PFW7J1L9,6%5JY1ZVL3EA^
M,M=7*X0.)BY6LA'K%5>YK5AK[6C.;FVS%BT)_U&(IW.K,)MTB[0V/O6WP.DU
M*JFI387$J7J:+F>ZW:WJ,K=F#>\`[X_F.:]IV?8(_G)8THJ:UY!D^Y!D?@@-
MC!9DRM>+1VL.,L0:3_78M*<H"81JTIF>DY$K`YM$-T_>U.*;&T4W3]YD-SV(
MLJ^#""\>LM.^'KT4F)R[BML<:N6<4RE6%]C9"-8604L;LJPZ!=.@I95;JP*6
M%7_@<00LRUVK;<"2E&KTGC=@R8HG9P'+<LRC@X#E;S6KT_2%S^%*>\HV>%%G
MXUEOF+8!QF:DJ"DJ++5Q65A?V"[FN3Q0N!^\MCP6MW*S?B>DF<6:,]W*N-W2
MFD5M;2T+U^UC..J7B>:)8#*>3F'73AZM+-GGR)2>VENLYLKX5+THH-Z`JP1`
MTT"^O#%,H[-.^^G0K]$U-3]]&O>_GOY[-/YKE#9N]WZE5/L!3TQ9WSWH[EKH
M?=+*NN:?DB?1!+.FE9<I^^T*1=\.STI=QB!$0#5(LC;3Y+1H.4T++W<Z)/BD
MJ4E]^:TTHY::O>_)#E]9P5>&K$6;=W*!"]YI-Q?0.,3F`UN-480JQ`OKQFQK
M>'ZQH*"P5:746B_0T%FI9C$:6TG?>C;,ZLY20LOA"FTNEH<W+V.@^>89DS3'
M.UTLH^U:G<::8\!@26+.UXHQ=CL>3_H#/1_!2FIC?VGSH#"P],`+(WO3/"[]
M4/UQL?F3@PFDSH<RE@ZUJ**ZZS#&LT4QY@MUE@0N"F>DS0TYJ7=\UN,O%C+5
M@E#%23%[:X-JC/0M6OJ7F[S+<'7N,JV(M59>4XO`USUBZ._(;IQBO5(09TV7
M6!N/:MT788VSA1)IM7?UY$W-O[JT7MED*M4/MI.B>E'K.Z"P4KP_2[O_SHH]
M,W&I,(;&`HEGC<IR@7;)J,T[6"<FJ:BU<6ML5S=]\/P3]#[+#=C:(UH]X,73
M8/>#%U:F@SIV"99:E"?S(VR_(ZE9OUD6:/'0'6>`N@(WD'/R9F7RYRIRM#MK
M4>*G(U9`L8B</;&RH^$`SO;AL"31S$_Z?R!)#B$1M&QQZQEDBRWN!K4M-SZ;
M]=C_G(WO3<0CO:V7ATC^*U5Q`3ZC'.G.O/`$<S(737H;[-I9\@C_?@*C!,3@
MZ6?X(:OZ,P9[$#(M9L:W0YMQDIKN)EU$:P.9$"Y>Y/PT7T)SN&>Y7Y_+H^%L
M!VMK3>8]F+\)!WNSG=X(8!LSG;>RTX$[W_6^5CA3GE>XQ8Q/+K-J;T%MB,`-
M#[1L.YA[C'8YP6.*CTI/ZXT:G;`G-I>XX3%[<I)=-NUU>6XSP%,*=>:*\3B5
M,06ZTF2R?G*;9N68YEW:_,P"J*7Q/+H5D#XZ!O"2<*5>"#O(YZ3<&*<WZZ5Q
M$7WYU?7E1_M2@?K'+\6/J7-+K]#'KX_:`]8'X0^F[]3PTVR0>LJMKIX&O7/1
M<''Z`:P*^Z3>P'H]\J'1-@L45+@)2+@[K=7>:E$'!H.Q#*RW?CI[ZN>S8,TG
MAIHL#K'L+&W@H"F\\]0`K*W<2B^%4DISZA.8&LX%.6:Z'>O<SXS@LJ=C,72:
MM:/WP>5U9%V$B^=^GU3'&8'%#);-DV&#AD)G.E?HG*=%W<$),/Y+^[]*I:#)
M:`(?FZBP)2#K4KO@7>X&:9Z\7JA\E&:24E%U0\#CGX:V#U%F.IZ\*6_0JILT
M<RE]+47L"\%5B#-]#SUNW:[*-.4<[7ZR2()HBI-/D[RE2KW3G$Y<+!TB)9==
M\RF2[H62:-L3H3%?%LK/!:=6"Q7R7!#GA0.KQ?JUBZUFYNFGL2Y?T![1L;;M
M:_[T/<%_^T':\Q,[FF=0*WPN&<L*L1;.;3I?4#$1+@F<MC9I9TL-[_0(`8.+
MG2OJVG`N+CKH+N_!JMTZ)V_6,%V;#=>3%LU@J[R3_M=\U!_\J3_\\?N'^]&7
M'X*RNNR-^F]39;J00N%@"BKL]&F2?$R^S/SA^/;?/\.M3G\TEWMF9US>%;WZ
M`YN`8VYX!<J*J3;([V?D.MSH.KG[Z2P9#V^N(N(JJCA"A!&,_AM,,';SX6-X
M0UUVHPG!BN$;?&;\7N:JP73,*7%O?O\0GAEUX`&VRD]G\)5!'_[:ARLE_./<
MA"0,7.811(C/$!<J1GX@'.0JYE+)J<N9<\-O^-G/V**Q-CDE*,+D3OOGX(*T
MPZ'^_K`WBAX>A^.O23(M_\$SW;O^2,R4YBL0RG"KWGVR`W`>8:'*J/SV/I[#
MQ96.1V).D/0E1UR*&,E`843C*`XB'D8>W)W!;7\&#3F#9@?DE<#*FX.9WF#O
M0.H]/#W\.A[V*Q?$XTFD&YO"+2_O0CC(0'6<3)\))>4!_Y`((^))@KA+?.1[
M2B'"F1MSSXFD3V[@'^">"\=Q7(O3-I25`'J?S*XFX]LDZ4]U.[JK)U"-;B_O
M[HRC^/(.!!2(@K2Q6F<["CESH$01Q5'@A\CCGD0\<"/D*9\@00+AQ1Y6V.<`
M"K`.Q^E_+"SMZ4E!>)JB^U[O\8</>N"QKVLTM4P&T90*JB*RY'\MOG*5&EO>
M7[U)/^X-)G_H4(JGJ\O2L337@^F_8]BYIE\R<.>U/M\WA.]&40<XX8NBC/!E
MO,7G0,1<Q82['/DQ<Q%WH@`I#W9BR"(:,16&\'\W](9JSL(4BQ^_?S8T.@0_
MLHG>?XQ!K=*^LZ_/`C_=%'ZSL87L"/QF-!K@_[3Z@9_J#X2;#^R)E5I`.P'Y
M!CZ36'TAE$C)YV6#\!P:"AH@2HB'.*,*^3("V2!51)DB(:7JAF!LQ,,5P?^J
M0;L+2@]->`!(@NU>>!`K/`CEK\)C"_@W%!Y6*Q#L!86'-P1573MSFI^L;Z$#
MU)LCZ&(B0#((R>A&RGE$`\#+08+Z"G%/N<@'=D6NH!24"QPIN`O13P<L"594
MX@+-=L2]#"!2.:PS0*A^.HA/;;Y(LAT@@6Y3#DJ[^8;>SX5Z2K:!@2CQA6`'
M<\SAR(`EU`>((^BRC<;FX"!,X(A(@1S8I:!^"XRDPR/DAX3)('9"S[>GB1%U
MA)306$;9BV*@W+4P<`)MC!'0MJF*$(]$B*0`(*@;2QG&6A+A?(\`!D+M(P:.
MPEWS`;5:!<A<0@\`@R[XP(B&="\P=_\P<#DFJFL^8)H/N%%].#X`#+K@`Z;?
M(L6`.GN'`2'"E:QK/N":#XQ,I`>!01=\P/5;,,,'+ML[#,"&=(GHF@^$Y@.6
MZ@?[)P_F,>B"#X1^"Y&:@_NW%PP&;M<8.%9MU@X=N0D&N17VMDC\>I?T=%BD
M?SFZ3G16V6!T[^LL[>"SMNE^&_T^FB0F5:C_2V\P>IMF66^,EE`4X%$.X9L8
M%XPRZ3)!$"`"NT4$VH/K!LCG)%9$R5!Z.-TM<'(@ASJ,EW3)W5!?1=0&FJ;7
M-JZV.302OI4ZI:16LABF*5])5[7P<8OY\(CKJQCL*Z1<8"L>$8$\$C@HCFE$
MXPCXC9!4ZP:.<H3U<B^@J^S2!Q[+<Y'B)-F&';:C>=YW!X\+A",Q$G!L((YC
M'WE*N`@^Q,J%XTHXA>^.UES[=;I*-/^>YL-;A\9UT5]M:\?D4@3J40L2!*'G
M@5!@8%!SZCG(%Z%`*O(CZ0H143\N/)-4O;.4K7C[$IVKPJA1FKT8;N>T6H=F
M)PQ#*3P?^7`[Q#G\Y,781<RA/O.(HE@5*UI-K6D9&B[15$+B@R[;>I>%O*^R
M@K1#9'4X-!U6Y?5FZLJ,8#,XPJ)>;N[KUUEARB&"`A:FDA5,UB&YYI(;S0;]
MP?!))TM\T*>(.5FB+VG.M8X3:B?6TZR7QDFCWD2/W)O"[C-NKC1:OPV*#&NS
MC!$@L03;5-]\NBH^[%'L^L)3*)#21SQ4#$G)&(K<R/$E'!:AYZ3'!"B@0L%V
MPR7U:R>D[R.:A'*'=(1FYN+@C#FX[.0X7C0=ATK<#9HL\R43X1#"OPTT.7&Z
M09-;-RQ3E+K?`IC&<I/=@)G9K(R!<:+(\:.I*)>J(S"-\>O"/E<$*T&_!3!K
M9O(.P73UHYVSGXG$KOP&MKD"(QB[W6`IK:?:=11W9*=87MFQZ#IE<0:V3/2_
M3P.CJ?X^!=-U^'9PMXU=IJ2C!2)FV)EW)_A4*M\/(\1HI,`04Q'RN'(0F&',
MC:A#<&9\@IYX)4I9,2U>NB654=;D,KORSZV\#X9>11FC&Y)+K:?IP^=Q-D]\
MF.B6,FF=^N3TR;SGZ1!(;(%'$WG/OOZ*@7HQ;UFUPH/9>,45ZV3Y=TJDZ\R[
M%UL1R3,'R_X322G=<"6%M9&K^6UK4_E!S[;3\TAT:FS)27UYI]W4_E>3?M73
M2<-Y5O[F5(.<IX[VO6-'SE%-XT@R#V.$)0%)[G@,^<`"R%78$S[U72]0:<:O
MKBZPQ06VUJ#ZVXNU44@+PDQ%A>E$6NL`_%CDW^NF"L/AZ71P/S(M)FSWUM1#
M;>=?V9J\K)O!8-0?F,R;']:HD5U%`"T5>B^NP4VIL<_P+Z_#Z!H%EV_?>E<?
MX":F$/IQFJP"LP[<Z:?QI)],3!3A-AD.IX^]6\`N__U1%[;9W_\:]&>??SI3
M].]G`!R@]M/9K2G4/LNJR_\#H5,_N=?%D^9M?TUZ_5.$RE1,RK_TLWL*N&=>
MHC[K5[_SIWW8I_%L-G[(WX/@Q=?LZO/79S_WL[^O<L@DX_C6;"VK;1/F:3'/
MK>ZS%=37KEA^;76'9IO^;ZD3]90\SDZGX^&@?S8',6QAV'WP@=.TO<I=(#[J
M,K'B-=Z9,K'B]TA7BQ6_-I>-U=I"K(?`;JYX!J3>#T;[!=0K>^LTZ^;3PX"L
M596CX,V59-)O@\S7U=Q>3FB]"H35O%;5I'3YNF=L3>E:6\Q8Y?`>`!B#=OBW
M((BB.%X@>6;CQ_)?<DVXHN@CDCRT5/7?1C%<4'Q_7M'_H*=_@*"N*\D[%75;
M<V;&,J8!@[G>)1>LU96C\5^3WN-/9^F_S;5_[_IU=T$@X1?TJ`D4\D(>-8&$
M7CB=$+BUZE/OB/:B$JB8"']P0HB0"W'<+"PZ8N$](E`=-X%N1\?(;H30_BI&
MOPR&H!T>GDC"1\[0NAG@,=-'V(5[U`1VM8#'I16E(Z<.3OSP(U>(W"/?G.Z1
M6]7N!=]CX;/'VI"9LFDZT7GWR>A6S],\--F$C]R684<N>[MRI^P+?4Y'FOMQ
M*49%O_[#DS_';9D)=>RFV9$+("$ZTFZ7Q>!*0;;TJ_K3)I%2FPJRJXD,WU>S
M[8H^OUOD%+Y\4B*C@LT7_0>Z(Z'K2$1"#R,><Q?YPO>0P[R`^S'%(>>+DA)?
M8G+%#K(0[;"OJ1UKIF_Q#6<<NL[N,PX=OD'&H?."F7>=/_LU-6E%EL>"_+#R
M%)=O(=FE<:9"!8777)C7D,]JM8T<>:9(,3>&;PQT$_'M[G5<YO.!QA7HL3M_
MN'CU3'^#Z4/DJ)F:R-=8[U&[-`DY<I<?E:_I4]]LP)`?.7/+9U$YUG/W[M#_
MFG:>VW2`Q/LG;9I?WIF_3KVGV>?Q1+?E]/20U-]&MQ/3>&$+/ZV9"4.P)(*N
MW2?$\0(FB!,@WX\]W6M3(2_`''FQ\'P:!R+R>-H<0T^!$)BJ;,Y6MWCL:!#/
MLN$='Y/)PQ;]<W<QB\>TG'!W,8=G):$[F@USF=[Z%_CB;/J;[</Y/XF6!+""
M(*E[]XGYH^Y*F;_4SE!NZJQX\YA,;N:Y?7YTC!LJ$L"M4,STFG!?(*EB'X4B
MDD[(8B6<,`U:T(MR1]EG!JNZ4ME\/U->=9LTO\O[\>C/9*IOJA\[_3B>Z<&)
MQ=^#\73V?CS[5Y+U4(7MEKY-/)Z4VJIVMAU:0L]A._#2=GA>XG<D<^RJ_V'>
M*5OU?'5W!_'Z3:A;KH)N\(@IEO7151V`,==:)A]0:$817F:"3(]-GF[3L/6Y
ML`.!+@4ADE5ZSRRGJ@Y">7YE./AST$]&?3U?"L`+=81OLFUG,3B-)-;=&`56
M"[J9+Q"J32H$BT(<D!BC.-0-:N"L0UX4*A0Q11TO8C160=[/%U]@06D9G);4
M5GH]PX:?S`:@[U4O3_^@A]-?34!<O`1`\Z=.P,*`^])'`0F!<4(LD<2$(^9Z
M+@]H%'$ORN$A](+F;7U;DOEB[",Y<<GSL$\Q7PC+0V&>]>'9D'DR<(!YF#H0
MYC'-2Q?,K=LU\[!\&,W!,,\&\&S(/!DX1%ZX[F$P#WR5N.[S\`XO!EH=S+FU
M`3X;,D^&S@$=6_`+O/7S,$\Q_0BS\B#8O6:>]?'9D'DR=-P+]V!XA[KN,RG,
M3CY9$S-.#H5WUL9G0][)T'$NE-B*=W8V!<F.`$E'CFXT]LC'H0Z]"*284(AC
M%2%?B!"Y%![BJ,"CGE>,/5)MQAYE?[0?EIP=^8"0=\GL\[A?_<+_;65IKPG$
MO+,(>"F.A'01CO3\)QQ2I`)%D*^PYXB8A_#+#35N"H)K,*Q/:3<#HIX-!6S<
M\FW'03W+F*0:[?6Y@5)%(0D8$KZ+$7?C4(_R]I$;^I3$2BK/IZD7]O)V-K8C
MD?!6(Y&*^5%F!L[EJ'J;[.*7W/PM5UN/9%"5U6Y)6X<#HIZ-U4'1E&R]:5!9
MK.G=>)C<ZM#?Q[&?V#E)21\8*!@_/&@W7,],RO-T#_L*@!W@DKW+*C6AY48Q
MT]FSK;\UN0W8>:/14V_XKC<`'$:]T6U28[G=(Y0MY"J$6O(-($1K`*VBJ03#
M=3)->I/;SY>?AH-[&U!X>!PF^J<NY:1/G9@I`MI/H("X0$KDB5@@ZD@?)+XC
M(VG[?L,]!<*9YV?5^W:N_X!JLI$(]!CW:<09DCZG:4V1%U$'.9QRSU%"8>ZE
M!YYHI?QT._^P1F]][PKN8QQ(Q*0/M%`@R)=>K#NW>]S!H0@9N['3#LF>3CM<
M3F$4^*X(0$-W8=T0CP*,)*,!(MR1'L&Q&\D@I?"?/=AKDZ_Z&&=[-=EP79:=
M/[@X)D00H-JA8,[Q,((5]B(/P>JZ7($V3P,_#6M:%6W]D\M"T[^:C.\GO8?I
MQZ^/R>^C?DUNY\AU`$?;\ZHE1X#:SFK2>%T:]^Z`[Q0P.+YXE^=[AKI!/!Y/
MDL']J#1*LG97.ZKY_G,7K&9?94?`,=",:L!M3&O7IR876&X2EB8,SA:JYX8J
M*A&7!+0?BC&*%8L)=7T5J3!W&KBBY:G9A2'<CL(FO4#$O@ND($&Y0ESH8Q04
M/!"W@51NJ,?/^^E)0RHB=G_LX)3T^MD!"Q?RF")@5A^8.`Z0U!75?L!B&E`G
M\/UB/O`_GT;)]G:P53``"[CDJC>9#6X'CRF3%\I&ES03ZG-"0&%WN,F*XQ%2
M*HJ0%#SBA`<^HVZFTU*,]+S6]5Z\VVT*A[TKV49,+!ECGB<(4AB67`]]1[!#
M(Q2Y;@Q6':<*%S/-&6VMW^Y^I[8F<EX=\D+FB=#G*`S!;.4NZ+]>K)5@[%/F
M"B=D5.0LW=YI51?>NR>QY;F#>2@%D;!J<0CG3DST&/.((2>*B*1NP,((IQK.
MHG.G>VUVB^5K29YV."BQGC;;N1&=D;T92<P8T1QALA=&M(G^B]5K2!IB"!BD
MB>,C/Q*!'B,NP)H."?I_]JZU26UDR?Z5"7^77>_'C;D3(2'IAF,]XP[/W-V8
M3PZF6[;9Q>`%VN/>7[^9)4&+=P&2*!J^V&U#"_)45E56ULD\VI@T5[DA,:\T
ML14.'PRETMPR_?I,BXVOI1M6U"P5"5=I$C$J,S"5PXK*2!Y9D\+*HU6:TG3!
M7!=AA@9S\X\V;2E+3O2QT4&+CFRT/6IX<Z6$%C*-J,;<7D^+*(XMS-PT(8GI
MI5SF;+%A4A/Z=5@G2-!%"!SNC9@W$)OT'W,ATJ07)2I6$/['$"Q;'D<LIYE-
ME%(V3>;1H_=T;SM!.+=W-1*FEK*82-B.,+O+C8QLVNM%3,22Y22!S2Q>3/$[
MIL/.$6XQDA,*I[64E)?90O`LBF&@\%(_-G!L%10>-S?RM_%WU\,$CSDTQ#QA
M^YXKT'/-89%5;S@8#>[[PUH68^WMC=W4M`\!7NKK)00.,;"A(J=-Q52N.!#<
M[JUSN>GLPX'S1B">K,2S!N"WQ\E2GG#]'H@(FU/8`/#R3T="9;W(PNR)4IZQ
MC-LTA3\^BHHJ!(?K!NJ6?.U?J51:D0%/44'\,*?;`M(Q-**$I%Q1"6=MGD'D
M;^$,8*S.HIS*E.3<]+(L!MAHB5MMO]QBQK*M*T5<\V->]=ZRLO']XVPZZX^P
M<UH#&*S;O$$%VM-F7&>HH,R(FK<<:%*+4VU>M_B?XR$\9CB8/;4TV=:]QG.R
M.3*YI"U-M<WV>SC@MK&*'_[[<3H[E.)R@B.R.(NS-%6X\9NJ6$HD661AE<\D
MQ?X"'&'$FWG".:SX?(\C[C=M]V($P`_N`U^*Z+ZER!D18F7T,EC'S2E^::70
MFSXG'4Q=E]!\/+D;3V=8EPH#^`'^F@SN#[YN;#MFJ.KQI&YI(=N/1@>[2)TB
M'=(>0E9G>^O6+X/]6S'K]:=?[B9C?,=#\O3O*5;HOH=5K8_#%,,(?8>CY6%G
M_OW+YNZ=`UE;G"8\,K!FPO;1HY'I&?@CM3%+N54BYDCI4J]^@;,R,U0(^PRA
MOTU>X=S:;M/4+M)D,(>WW$0#$')O++?9GHVYL4X'W=-4L%0*PO32@C7_OFO.
M_79T/_Y:O!M/I_'W_F"(J9\_QGB[/QZYLH`OX^%#,9FV$!B\^NG'=/"/T6#X
MSU>SR6-Q;'3$7_WT9MFJ][,OQ>2W\6@\]^?21ISKH\-:R'0T8A9/\[)6-K?;
M@L:2T1V91_$6DQDNJ6_FV=\O6SD]-^29=LTS*V.QQ4'9[23`T4+BF1:"B/75
MX_E[KTRX93?%00O0,(,[@%#4\)H;;OCJR[;-.RVE1?GWV]'=I/C6'SR<83GQ
MW/4-UCTQ7CMW[S-BG\EQU=3_PZ*G?X!F:S@E:XH<D5V&KYNR8^D)T(LI*=U8
M2<.6(KIM#CQ/_OXQCN__]W$P*2#L`Z>?/=T-^X[*E\'_?FLHZ]%X``N^+#FA
M7-5*.[T-6@;B.?Y?)$/>?_JO_J25A7CW!N)IO5S;0+!)TQ1-+.=MB`X*TU!P
MJ:1FM0UD]7LO6_6O8@2K\!!>CQ^^#D:#J>LX^#W@B`W.54H)HD5M*]ECA=>Q
M,A]@F4WHQTH&1PPA.-E_I-Q@S[Z])JV*DL\0S_HN2@)/U=IRR939M=>LF.*3
MQ0G07+!6,:.MVI>#65FJP!V0*`Y_X8+\O3_$1;N\?U^%*D"KF1MDH16L8S7+
M#[%J2Y#\#E^#^&,TJU8&F#OM`;")*<YL`C_G49I(&HE<B<C07$0VU59RHXP1
MHCRV,;'"DMEIQ+*]X/R#$3K(:#89_/7HR!>P05>]"B>8])PXHF!_\E1_T^$]
M*$[U"&U4#/:#"R0&UGPC<RPF)!'+L[R7B32+-2_Q@*]@5<T;3K/1(^J&X.'A
MW:#_%UYOA;D7X,TP.@W9$W2O6.)[XH!@+]#C!MY#15((P<S.36#%DNVM'-].
MIX]88XMMEQ=IC@`-9VQM]]]KAE?P\W9477T$'?Q0B^.^<B;QMV@U(502J&%+
MJ1%WPHU[L;&"L@Q>7\H.[3!BV=Y_CQXP+L9EL'B8W]O&P^'XOH_7CN-:T<KH
M\^_%_>.D93?86"_OE]YCFP[B1QJXNG5^F\`W=$$5_%SRZ?%<\74,O_U_G0>*
M7">].(&9D<1Y#AXB261U+XUZ::)(QF-*L;^9*YUCX!M+&^1^2_9M!>XB]/%^
M]C@I;T6+R?<@]P,X%$7<2F7%KNU@DS6K"9N-+I(^^Q4`N-'/@IPF9M,T.=[&
M[3,E0)_@NV?$LBV+56+SZ>H,FT*:L1ZW,,*2)382L=510IF(M&0L%C')+#S%
M+82K!T0_6VK\W%V'YS`SDQ+;?PN7Y?*P8+G-''H]_"?\-(5P8;(HT9P\8#6Z
M>Q)NH?TA)NHAM)I.@PD42&*8SH7!TQ$>EIB,$FUD)!0J81"5*%7UVZIU*VS8
MWAJ8Y4GJ_:?XX<'Q^[&G?>U#[OJ#!U?$?E3WJI/G#TU[&K;'B*(_"6GS*.E)
M%6G+-3,"/H"#O[F^J156!YO3Y1+RT3)-J/QAF31\2]?=!A842DB9?-#"UO.K
MAZPI70-BK/(H)CT2$(:`8+TSG+/ED8OL<R*^INB#9/6[A9[WT51&A(':18NF
MCQ;>3#2@HJ2M]]==Y82MUZ&J'F9;:!K%#"MA,IE&1D*T"2L.5F8B88PL_(.\
MIIK5KQBV6]8M!LJ2MC%P+E%Q\DEX&&A!J&T;`XX8E#VGE0T.@[+2NFT,!&)0
MMD[6(C@,RKK=MC&0B('CZ"XQWD+"0+>-@:JV"%@3F3H&@X989&"V@7>5)7"F
MD;I>K1.;0[`465?7FU$9Q;2GHCQG&<2@@`ZEY9Y0QIQ>!+,80M('I(X-OA?/
MQ\_LQ_WP$4)23&/B3OHXJX3O5BL,3KNC0)`XP7624ZOK9?U^C;%C1G0B8QOU
MC$DBD5HXJQC.HTQG*C&`2QJK$A'NF@!:2^I10Q.FAX@FQ$V*MH3F?+\5G"O"
M]36@J>!,OYN,?32:O)JMC$I%J;@.-`55[:`IJGB86\;T-8#IME33#ICS8()S
M2ZVE+Q]-RX2Q+8'IHA*-C;JTDO0*]B!XJZ*B'3`U@JFPB0O1Y@JFN85XC^AV
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M)Y6NB(RG$[&",$`)CADS3L6NRO+C<7N6G1/S^[<3[`P#+9B.DK>!%GL66J-:
M-@J7XQ)G/[X-2H_\L^A/#H4!8F*J-C35B(52.4TE6)4CK0U6V%AG,82$DF:]
M)(\37(0J=1!36;7A^QRPI+JBI.G@P"X62V8L5E589P4Y/&U@>,X)?$ZD$EQ5
M.0RH3=,\4J@[QU/7-'O14`[39HIPZ[FLULWS(GS_VO\Q^/KXM922J;^(WC)7
MKJ\<YU"\]O>=V`2/@A#)&"$C*C&P@!@#N1X\BDV:,ILSS12M&O@N=9YHP,":
MU\]?R8:#SZC&%W\NZO3`XNTH*4;PB3/\C-.!@<<WA(M+W%53Y2`C.HA+4+Z^
MR[BDU.F`>%PK;8X+3/9QJ+?(-38.C/\)RQL;]!1A!&=T29GS(#OK#2OGJ.*O
MN(K"2P`!EQ$)WC'?7=:MV-2FLC_K0S0_*/XN/2<?/U-^L#G38'0@Y;&*VBEA
M9G]CY5SHQ,B$1#R/X0S=4RJ*.6PG,C=2\\3V=.]YA._HGZLM*/V^?,O+`767
M-GC'MD-YU5.)5IF\EV5IA.UF(Z$8G,Z$%'!8DUR3N*<7C:9A-=`0KE)6OR,*
M:S7PPL6?&NX-#1*8".P@2K.S+P;GP@!9;=S4VM9N60OF\"2/$#,7TWK0A56'
MLZ=Y>]'J=/=^XAX">&TZ^QT*#$2A)3`,IKLJ\QI,;)5-]YM#C&0L$X9$J<1V
M7Y9H;-:>1DE"5)80@D)@.V+29I!HIF6W0PG7TLI]3E:4`/_A"I.48#2+1&*3
M*$G!E2QC-LU8S+)$EO(+1TG8?G\^TI<KCYMALTG__I"`>Z?1QQD$T^&._[G>
MQ'K'%VZ[<W<;9C:IT=NED)NGG_OJN'FBQ=9E2$_5<6LUQL#BI_H^<NR1([>&
MV5YJ(B8LEN'!$2PF!'5L>XG(<TU4FCU'E)B6X2;8(X<?,-X[K#\V;O,@^$GD
MQ"AC#["NDTQC/E-2&CH3B790J4TR&%[6=C&K^&+9H;HD3@J#-$HFB8!8C2[3
M*/VFF#4QD29W8#AY!1;%6M/(J!Q^UB1-=;XNO-7T#'N+2A3]X=WC7\/!_?M/
MX'@'M3X_!A[_BRA_B#C*C*_>1'G;NRF2WX3K'V.7/_Y[,H#=<`HGR>P'+OA3
MF+_O8?9B"439R>G;@>?A`)R,51?0:Z>!TX'PA7?AMF]'R'&`5^N?LO3@$+`5
MN=$"GAQE*2YN.K-1PG/X*54)SWHYT7%M`ON#>P`,-62]G3TI/HTGQ?Q?A_?N
M:G?*^X,*#FNDJI]`3H0@@-,N;,7\?*==YH(Y(81B]79I39YVVTVP*2*7DR@0
MN!Q^STU$!H$<E5&/V1SU!U'$K1=')%$42VSCG&0+%X01LY*!;X<<_.X%QK_@
MUAL;)/L@F5-+$4:&[0P8.&TW3!]Y9MC:U+B;9]/DTOFY`RU'AM-$KL7VQTK<
M[>[ZYM%Y?[XX/5-0JKOD1_C4R8&@*NE<BS)$]?!3MH@%M4)#."9()'I"1%:P
M7F236'`+I^I<Y!_=JBP4K-)[>]XU8GU]TIWZ*:O/CC_!CC'O31`:S)CKD?`1
M=A&EM6I^L.Z,2U9[.+N"!LF9JN\+U^C.;<.LL'4ZQ'KJ'.X\;XL,1\.E'D,'
M@T1+D)!29BG%"-A*=<RN+;.<:YWK*.MA7\54F,A:P(\E6JM8:J*47O#*).>R
MWD1PFSE!SF%'CS-M.A=WO82$U/2*MZ0N8!98KB0-)>IZMR3EV.UMXBRQ+$P*
M:743RDZ^[KST0<=HII7)M;HTT(J$T(?B:W^`-4'S^\K'_A`I+^QX^%<S"Y+2
M..8BBA.DM:8)C6(3)Q$VAXE9;E1FDL51Z$[_R7^E)FU`+NYXTX-=2MIV<5/6
MBVM.+S0<J(/443@@T',%GKX4)_30<*"93AYKAF_K;L1V,>W7Z0*42Y)1(R-E
M.8N$E@0=*(N2E'+3RU4:)W9Q?">OJ3EC9Y_M&*QT-]J`P6[M"R\4D,*,$W--
M_J)-V]:Z%K4QOAPM*[L6F3-V[-F"P7K7HC8P$%7BF[P6,CP,UKL6M8&!1`Q<
M]1$S1W4Q:S5SN8),=[7'TG$DF\Y<G@$K7SK@^C[I6]TK2V&]AG.\#=\2Z9)X
MSQ?H+&X"^.&M>D0N(%*@)M)9+XV$$!!R\03""`4O6VWB7BR>R<:"<<OK#5&"
MNB7R!,;;:_RQP6K1M:+PDRA2JWT0#A9EM*QC&?%2MV*WC'AEA9<$[C;=]=,A
M6#?YR.;]I6X1HY(PP6JSXD"+/.#8+T+?#2Q>#<I+(0^&U0"T?J5\I&6[)\:!
M*KKGF!9TW[38((;<DBYT%U/"R4);"$+V#7U;LM`>8]R(I6BH(H9*(=:BA:Y4
MH;UL;4!ZE[4H"MW5>%DL&ZSW,^U$$[HKZUQ1)%Y)&M\V)BU*0G?GEHTJ0G<U
M5G@Y)PR<8+O1@^[*+(/<`VOLTAS;IP9]I#IP9],**ZX5'`WK335W:`,?+R?;
ME44:%@J.*A.F>S79KFS$0@P8,<YK@W:0F&Q#TI(GV^LE+.FT0;3A0K$-$R\<
M7<F3T?"2E2RI9L;46XTVJ2K9D&Y,5U-!(KW7*ICO/$Q]N0.!.%HWJ^3&K2[E
M`:K+G>P97N)R;M%@7$K!Z_/D4'&Y+J35NO,0L\%#FA)6:UHXYV0W\5/*<;.&
M6&EKK0,.UB)K45/J=!A\>K7Q@"6EEA#H3E'*[;.6*J&/<XR.X6A;3\JMIQ2^
MDV2GX=',3>P:"MW*2567T50>)9W2,@3=J$FQ`-2DMD#0E9C4G):!?53#@J`S
M+2DVUY(ZHX[29@@ZDY)BE924#6XB=*8DQ2HE*7$4+Z69W/,9A:3FXJ5>:>F.
MI1+6,.I"1XJ]4!VIS6"V+"/%7JB,U!8PVU618B]416HKF&V*2+&7*2*U&<N6
M-:38"]60V@AFRQ)2[(5*2&W!LE4%*?8R%:0V0]FN@!0+74!J!93N.-SEKKS*
M3&Y'BF>;D6W+1SW;>!X+.U"/8E4SQ?,-8P?B4>RC\U-,#I_383N0CJJNT`XQ
MLB%>-^^.P$KGO.Y:U!4"KWL=@L9(K+3B=<.Z9>L:%)?`ZSX.%J_K45KQNHDT
M0M,]L)R%U]WMM"AO.,3V:=$UK[O=*8%T9VH@"C@OKWOG&#=B*4<G9YR1>AAZ
M%E[W";9ZSFC'8;>,U8Z!!]K4)B>\_;&VKWZ)I(1WUIESW='"VS?0K=@0VU+-
M/4.4UFGA[7NU==L4K:M='&Q5PZ3R]D>:N:.%L7)MT6J15-Z^60;U?Z26MK;1
MMDLJ[V!2HN0LJK'4Z]1;))6W;Y$CE1,MA%[J/M`AJ;Q]&S'/9XV2LC;#SD<J
M/\%>+U*YJ_@V1#$M-TR\T$CE)Z#A12IW&RD$"O022.7M3P5'*B=&6VKKNTUH
MI')O((ZF#+MM5PDN=)WI%BRI_`3/\"*5EVTBJ#)U$F3(I/(N/,2@AQ!NZD3[
ML$GE)[B)'WO8!:M<6EZ_?@R.5'X*#%X"X,&3RGG7I/+RP"J(,,<Y1L=PM$TJ
M+]6W*!+VPB&5UU#HEE1.*U(Y/3N=>`,$W9#*:=7(D-C@(.B*5$XK4CDY>VG!
M*@2=D<II12H7P4V$SDCEM"25D_`F0F>D<EJ2RC7EQT#03.;ZC*1R9SX[B$QQ
M%@Y5#:DNJ.7T15/+5\%LF5I.7S2U?`W,=JGE]$53RS>`V2:UG+YD:ODJEBU3
MR^F+II:O@-DRM=Q=!3'K!`6O`,M6J>7T)5/+5Z%LEUI.+X-:O@"E.VHY/9S$
MVKR1RGID63<8&7.1L$S`H"=P8,"&S5&<,14IP42L+(3!(OYXQ$&A<0O;)L_3
MCLGSJQ9V0)YW)MHSCJ(O=YX>39VG'T5%G:>6`"ZOSV=IV]SY,K-]V+K3IN;`
M&8%P`KMD!8AC50<J@]VW.=Y@]RQX6@$[Y.RI^A?\>_"`__-I4$Q^FMY_*;X6
M_WSU93;[]H\W;_[^^^_7T^+^]>?Q]S>]M__QZA?T8\HDQQSE\Z\]/VI:?':W
M6#__^&LR?!C\H_CQ;3BX'\Q^+9!#_-/#`%Z=@MG_?/6<VWI$K>YO_<GLZ;?^
MUR+^,9B^^L5=GKTKIN_Z?XTG_=EX`%'#[\7D.WQ8^:B?WVS\A%]^?C/_"I6Q
M;Y:L_?F;DS*H?>$9?'#:GQ5(J.01T1&61#S_[^*-Q>BA]C8;<8*/?JB]Z><W
MM8?__*8:LZ8&$!>I2QO`;#AX-Q@.GZYQR*J]\]*&[.X3K#HHE7:-8U9%=)<V
M9O^:%,6H-QE/I[WQY-NXO":XSO%S9XZ+&S^(`?H/O]\/BM%],;W:N><.Q9<V
M=LFX^((22;AF?BZ&7XK!UZL:O:4\3Y"#=V(^*'G:_(":#T!@BBR_WC81J&MT
MB#*'>GT.L:BA[*-:[>PJA]Y=15SOT%>E`H6;^Z4<]!6ZP?QZ[_K\H+XGL-NF
ML'Y[?M4N$=]<8@,[Y;I=@MY<8IW]==4ND=P\8IU<>=4>T;MYQ%YB<I`.TO0%
ME_<'__'TK7C_*<9SZ&=76[;D4S``#Q^PS\\?XZJNMS<>#LMO<W4GEAT<_T!]
M:J4@('E*BM']EZ_]R?\L'T9_[P^+:5,>]6O_O\>3WN-T-OY:3%:6J*N[FMU5
M&W-S&@^GN<K;X5U%93>O\?":Z[R@WE6.>7,;#[?Y]^__&D/X/')QT&?X)H.]
M'_HR/6A33?/-@SP\Z+IOZ7=U!;BYCX?[7#U1H-Y<(TB/*?OT_3X#'/`WWV$[
M#NQIM.0L.]MA7>6`NN8QESN@>WK]7=&0MCZ(EXG.%@F"(#T^)#(]\QM`=HX!
MO)'I+VO(;F3ZRQNS&YG^TL?O1LB^P-&[$;+/2L@.UB%NA.RV"=GA#OV-D-TA
M(3M4-[@1LL]&R`[6)6Z$[',1LD-VB1LA^RR$['!=XD;(/@\A.UB/N!&RST3(
M#M$C;H3L"R=D!^A4-T)VZ(3LL)WF1L@.DY`=K-?<"-DA$[*#=9L;(?M""-GA
M>M"-D'T!A.R0W>=&R+X`0G:(#G0C9+_(`;T1LE_(D(9%R`X`'<V=7":GC%/'
M5&/6D!^`E>"!)J,7OMX;]J?3]Y]<?GAEMRNOG+I*(1,8(+I_'`F/8"@Y;64<
MN5+.S1?C>&/Y[I]\'H,&;^M\T&XTT<L<OJW94A;L#/0]/\3W]SCPTP_%?3'X
MWO]KN"]HN)34::`^M)X[O?E0N(G40)UH/9-Z<Z*+2*N&ZD]K>=6;/X6?9`W7
MF5:RK#=GNH24:W#NI"RE6(MC9:"LZP_%=#9YO)\]XCCUQM-9/'K`%.OD>['L
M/N!HX&7WLS^*R=?!J`.*TO^W=_Z];>)@'']%U6P#!DZGD])6TU7:KE7;NW\G
MEK(6J8$50K:^^[.!I$V3;$X:VX_-(YU.72$T^//EP;^>[P.+);BY.1C-0Q*`
MS4,2M2FO1&OS1%(]%"/!.R,!59,ZU<^2`)2Z^)Y*S4.T-P_A`)N'<+5(P'4V
M#^WB)(G6IE'1E.07P3M2"M[B-*W(^`K9:MF)`$V44EYV.C.V[,35,'+=&"DE
MP?`*3J*8]ZD*+%Q192F-@>Z@.6V;HLR;9C)]:HNF>%DZ[Q[%ZVR1EZ=%-<^G
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MJA9!M>T9[SE"W%%/F%KKZ-Q1OU1Y3/DKE8LG*R1`EZ5^I_*=X[Y!_GK5SD]H
MK-1?H%P_3UAJ!],Z$>%#PA0/@UCVIM((Z)CJ6CK%K/>>/A=E,6LU[IN1T_1<
M(2QUIVD-2V]!L8"&0!=<MH'*?HX,%*QX`Z5UJ/@;V(=\UUA`8>&P/TT31Q:'
M6`G&P.8]??W<W01Q!.X8,YP#=Q`:%H-Q'N!(%J(]PX?E8&R7@P&J"*P'8Z`>
M#%3V6!#&;$$8F#K`BC`V*\(`U026A+%8$@:N)K`FC*V:,%`U@45AK!6%`2H)
MK`ICKRH,/$E@61CWR\*`4Q76A7&@+@QDU6!AF`-4,\[U1JP,XY.AH7'=8&D8
MWSP,S4L(:\/X9%MH0S]8',8GIT*3"L+J,'X2Q?(POC`%M=\>1O,$G1T/[M,^
MT!1'B6!@A2#NTW:,&>[3=A`:[M-V'J"<,G`/H,'Q.FAXN,G>17QHR^,51S3V
M]8(C8*LU>&YG<#GVHS^@<U9J"?,3DPGS<$'2)*0Q=1KD96EN6Q]@D&AAX3I(
M:6W73XV&0+,]KAZS\NV$VE,KOM]%MU98+')YAN!X^U"U35;>W3[4N<X%`+@8
M*4EH!/0-N07CJ[P[>92)/SHV;!'C<L`8!6!G2#<6Y#>K`YR)V%G,-TX=)4O&
M"0<[<:K"<M@%,7*:HG_#(_ED,@;UM5A7XK[GSS)RRIIL\IW8[6K81O5C6Y?%
MO*US<>+'XJ?\2>=6.L!`:<R!SNGL!;3/4LKKU4DCI<FY#X_GDN9-]6W^(ZOS
MBW*>E?<R=VS2-/DXV;)`=(L\8/LISYK\H7J\NYA]KZM%-R0=9>REC`2$NXRT
MWXXS[,6IG\5IE]^^%=-\K$$8/:5L>DK!501Z2NGVE`+,'CVE#'I*@=4!>DI9
M\Y2"JPGTE++E*05:$^@I9<53"K`FT%/*CJ<47$F@IY0E3RF0DD!/*<<]I2"J
M*HY2!GKN8K6CJ=_^(H-*5<K99)Q]0$<P^(Y@P%6#CF`'J&:<F:T[9</<V<6U
M0S:3Z53V59KK?)H7BTST-%%#.C6$KG*07>5<T@W&'A31GB)":T)'K`E=DA#&
M(=33._2$5I<.6%VZI!^,1RBFP\6$OJD.^*:ZI"`,1RBG0^2$-KQ^$D4;7H^8
M\C"(9=)H&@%]2J_E/H!U@I\%M5D[MGC:DV(!#4=L@O$NV60_QRT;F#I!4O`<
MT0$T#^GLXJD0+OJAJ_`K2L%*G"U;[43\%PAZR]\9P((FYQ!`H',Y%!)H1PZ3
M"MI4PV$R>*2*5HR!]DT5'1E-)4-9Q00X.U81DZD\1IN8(">L*AK5C@03V!Q2
M14QC"'J0TSK5,)E*RK1)"7*FI1HE4WF25BBA,:5+E-!M$CHBEM(`Z!AV+T1+
MZTAQWO+'5TOL9U5S;--!J]"2A`!=-=\+FH_/$]IVNH&)ICX\05H-."T!BM.N
M:%42`"V1\S$KZO^RQS8_?5[]^+>XIMS9]?Q)OG3>]/&6)UV4HA?1=&<$'I&*
MDLAC4LPG4G$`=-!T#%+4!U+H[>.@MX\=J:!A#S@D/*54(DDCH''V.F_F=3N=
MMW(%6(Z*10=3[DJO%QM3'C(98CJ_S>M94?KQS%C?%F?RGBF*\EVBI(8`01*E
M[GLFP?IBBRPQ'0"=+?G%6LMZ:>*)F346$AB"`TB0VN]9_HKR7I`1">6*!=@<
MUYOV:Y,_M;([M1#_VS(%OGZ"ML@HH)`3RDU`H7&?-AHF\0@1[?5WB[LBJY]E
M>O/66'5Q=>FP(%9%)L<W'GX/EB&APB`6W+D/`03NW(="`G?NPZ0B77+<HZ+7
ME<8R$<RE`,-D&)RS.`:*1'EP?FIH`Z1Y.#AS`AH.`?IZ489SYBL<EM(8ZOR!
M*IQS3^%@_IXCF#!_SQE,0+<Y*B:&W?ZH?*5#DY#&0'?.*=*Y++U]=C#WU15,
MF/OJ`J:(I.Y-)KSN,/C\)L+,9`<H868R;$J]BR8E"8V`]KFWN&AVK7_Y7:[O
MR*-,_%$/6&"6N$N4,$L<.B+,$G<1&F:)@T6#6>)N8,(L<:B`,$O<+5*8)>X,
M*<P2!T^*!(E<+"=1FCI1OV,BNMIW+R\FA0(>Q\J-T%(YQ`F1H)6`VU8"!J6"
M5@+@D&#6-G1`6.S,?O-C*2H;S0\H15S_/3-X]\PTW[,<3^#VC4.-&A+]=.(^
M/Q[?0=N;/]:9C;[1_/@.LM'\@.*Q_GOF)()FS<)/2*35CB8B'-A[5]RPN&VM
M_2NYR0O4/??F'CHM>$2S8E_CT!X_Z9Y"C7V-$)PB2;B_(MNRZ&^X><CJO%G=
MS2S/FK;._^I__>>'Y;_[2\A/O?E\T50AH_&7?V_.-RXR'/M#'-OO2E_$%__R
MYIO=%0O11B_W+S_W3SO+Y0SHBX15_GK?-ML_WUWV/"^K;F)F^X6WM<W+-3<_
M_.>'5]]=Z=:'63N`]]X]U,/7.V8+W/3/^X:$AB#2'530T'=Q=.,:\I<*G_U<
M/>;3]G'S\]UW6!Y5N-!5]MQM^]A^H>51E0O5U7V=S79<IS^H<)G)_8Y[$@=V
M?+P/S.*'_P%02P,$%`````@`)(%L0]AX:=&'#@``5,<``!4`'`!M9VYX+3(P
M,3,P.3,P7V-A;"YX;6Q55`D``_.8@E+SF()2=7@+``$$)0X```0Y`0``[5U9
M;^,X$GX?8/Z#U@,L9H%UG*3GZJ`S`^?H08`<AI/,SN[+0)'*#K=ETD-*2;R_
M?HO4;>NR)5EB,"_=B<+C^TI%LEA%EC[]\K9PC!?@@C!Z.C@Z.!P80"UF$SH_
M'3S>#\?WYU=7@U]^_OJK3W\;#HWIU+A@E(+CP,KXW0('N.F"\6"^,<H6*^/<
M="S/,5ULS;@F],N3*>"?AOS7-O#1[V?3:^/XX,@PGEUW>3(:O;Z^'G!NATT>
M6&PQ,H;#L+O??&`GQ@\'QX@M\9<I\ZA]8OR8>'3.P>_81D@GQO'AT8?AT='P
MZ/CA^/#D\,/)=S_])UF:+5><S)]=XUOK'UCX\/NAK&%,#Z8'"8Y_-^X9%5AZ
ML33IRA@[CC&5M80Q!0'\!>R#H%$GH&N@1*DX'208OCUQYX#Q^0B[^3`*"PZ^
M_LKP"Y^\"9*J\/HA+'XT^OWF^MYZAH4Y)%2X)K52%65C656//G[\.%)_]4L+
M<B)4*]?,4E*J`-#(+2%_&X;%AO(1BGGXX>C@3=B#GV6'GSAS8`HS0V$X<5=+
M.!T(LE@Z,`B>/7.8G0X6<_JF)'_X\<.AK/_-!;.\!5"D:E]2E[BK*SIC?*%0
M#PS9[N/T*@5_85J<S8$22R@-<@-U',G"H\+V1G713K'F'_<NJISLXV[VF5!\
M1\1T)DP0V<6Y8PI!9@3L7<!7;'F?-"8FAYU>Q!;-N\_@$LMTFB=VA;/;`L:.
M"YRB"KQ`32:;[34.^=P4SY\=]BJNJ$TX6&Y-R)OMU89\083E,.%QN.-SDY+_
MJ=$UIO:MZ<J'L[NE7"GPF1C;MGKCIE-W7-?MLT'6]]YB8?+5W>R>S"FJL652
M=VQ9N$BYN)).F$,L`FU0K]/QWOE'I3Z;A/]F.A[<@"FK2[V,IH2Q$.#B:[PF
MYA-Q$#>(?<AH=W#=R7&"#0+G8-^[S/KR+Y-S+!]"6^U5:B50.I01<$NN_G-(
MU9C""U!OI]F_+2C=R6BSE)B"!>3%?'+V*Z)B)'N7T*5P"<Z68#\*F'G.-:[O
M>YF,,OO=OW[@CL'V'-36"^)XTKBY!\OC:M:[?+,<SP;[,V<+N3OR7+6H!$7!
MO@77-XU0Z>^?T:;;BQHU"KA#>8_QN5V=PJ7)*;8CNI%U7;`-RGG"&1I][@I7
MZ,L_/;*4:W<,-.NO]42U0W\MLVW!QJS>39,C1IH1S\RQ@0O9J[NZ`%1%T@;!
M+?MJDJ4<`/:9](]-S)44;"N;A*J]M,LL'AA*X.IO<F8`*E3WEV_RQ[J3U^[]
M[HM]M,&X6ZH=ZZO)[6C!OZ,/SW"!/]W-?I4F]*/`N1(?G3FF]07;0'#"KS?A
MJ*)T?L-L<%J461MH]ZIG`6X+EZ?ZFZ)M>VN0Z35N1^'RC<2[JA:FBJJ=M,KK
M_-FD<Q!7=/-/3;,KZJI5CI\]5RVMA%ID:3JA-CU27(14Z?&<`]2W4&KUW*`$
MSIGCF$^,ATZZ:V+)23?JJXUU;\<^&V6]6!#7[XOBHJ,L:*`M.0.W[FT_3.,9
M\H90LO`6O@8J70NUKREW0W,PFK73;<]R;PBNABZC46^(<,I6IH.3;)O#H'[W
M#<KB$HNS%<`94+2QW8ECTA8H5^ZET3W^DX`_/93BY4M;AGRE+IH)0-TR%\0#
MBSS?40!)),,M.,($<X@=3K$3#D*Z./VM?D;EF,P#O+EG#II,N\ADC^C:%F>A
MEZ4E(57LLQ_4PP==B"#JNQ^B>)!+4R>""'IN6PRAKTG.V&[2X=3ZO+%5SWT2
M0QLZL4/_K0^0#2>=+-NZ6E3OMFT!),X[S)+NJRDXTA5SS@2BE?Z)E'NB);'4
M!=-S8;4QIIJ!U+;@IKA'X+A;\#BN`G*'X*,+'%JX(K0^XG9"T$>QM*%$-7"T
M+:)2;TOKFK,3@O;%DNN1V(-`MNJ[7Z)H8_CLA*#UN67-"=/^#%NAP]8M7!R9
M_BB]<Y^!3W#UX^`2_[A=X+9I?X#LC*)U:W?-T].6=9O;34#0BB]TR/L<*:)8
M%J@MS[7[3V5?39W+]WL?K77?.J:*Q^T5#D2"DDKU[LC+%8RGWWW0N;I!,3/%
MD[I&X8GAW#27(ZD3(W!<$3Y16C(\/`IN4WP3//XC/`V'=J&<E<X]SE5LR.\)
MESUP3@<EA4<=XHX]Z[?@5D.?6:4C#MR#Y)G?4@(YY3M!+X\LBSRH_A^[PU4B
MR529+E#*RQ+25,#_Y/;_Q724\>">FYROT'A01R-RT%>KVP6KB^"P]A0!G>/_
MQ+UEU"I\%855NN6@CD\7*U).X1[@WD+PZ^6[0)^ZE9&)=_-J1&<(<?!M^N_*
M86=7ZYA+L7[W9*U15K0_:9?J=7;9+E!/."Q-8@?G`(L%G5VV&]0Y/GJTEG+!
M%U3I@H-R9Q%+NC\SU\H<'J75.N,2NN:"V^'%NE14HR\,2H=Q2:4N>%2>\WLR
MRP>WY=2!')5<X,YSY55_F84A!WEAE8A#8J<\YFDZ)K?"IO''C6UR^KY_4&(D
MY,T0V=J0X#8YK#_C;+&QHP@[8WG&O,$XBEWEG/CN\'!@O(+DH7['WY:<,([O
MXW1P/#`\@>#8TC_ITE=VY5-93/C[]T"X>/V)R?[P'LCF&#8QRQ]U8[FV-"7)
M5MSSQN2/WA'Y8H=5S/GX'7'.,8!CLA_T(9NQ04U2S=I113R/-'JI)3S+;+F8
M\_MYM\5>K9BQ1O9&">-BRS%FK)'!4?D=;WC/8KH:F1Q5O54Y<UB2M48FR"ZL
MLTI%Y(_UG+DKV"'K`;]X4?[I'5+.B[/%K#^^-]:%?J-X=!^^-]YY\9N8\B[;
MBKZ>&4BGM>L>ZF;>NBZ"J_+,JW0=^!N//'?O1K$NG'2_`@5N.@AC;"\()3AH
ME=RBK`69T,MJ=1-44L<B190"*R>BE"[5!=(H)\\U$WG*D2[32=#+SS-(YZ58
MLTIV%J9#TYFE\12K<DFEC@(6@`N3=%9=H)HZ3/D?BVD4U^F&A1IA,E&22J*1
M'_5:+]<AVA*0HEL+)&]A6;.[BI1'R_!$%=ZE"YF6<8K,I2+EP<^:I;7TWY=3
M+9G>M=Q"%JRRZ5$=3D]:>J\KLMP<YSGQMF&_Z:XO)FDOUYJ9JF6\J8AAQL)?
M+[[4Z8YR,ZUX;X[K3@`E9^.0XC+9RP7X_^?M-K=IHIL#I$L4+PGRB61R2!7I
M`F.4-6YL_]<3KJ\A8;0B!W1QG2Y8K+_N*[KFE<UA4EZO7VR2V9>V)+21,:D'
MG-:<R-MP6J^Z':?-:U[R249/R4CE&KPJ-?HAZ34';F4QK]?K!YOT&8C*9-:J
M]8-+5DBA,J/,RAUY_^0B/.'LA:"%<K9Z%(`K<.!DI_/XTGN^:[!J`SWB=T5?
M\`W4X)?50(_X15N<7?EE-?"7=SKWFD"82(2-+31GXW3>&^<V<RALT4!'UR`L
M`%O(7=25$)[\0II*L+)@5!T9R*-56J^3H^M1`IADBI@<"CF%N_5`[K`!2^Z)
MMYDTM#RWUY*`,E<-+8^\M22@3+-!RR-CV]M%:\?VR^9++<\-;F]-I:2RQ2J9
M<W2VYZ[6[:VQM4&5'3?1R!5;3P)IKYN6]P#J"2#/--$RSE)/%"7>32U#Q_4D
M4LVWF!-9?M<S9[FG2<_075OZ$GG6=8W--RV5#6^VEN'[I@63[>+4\IAXTZ+9
M\,MK>8A\-ZE4BK?H=L*\]I>N.\==YS/5FH#?_?O1G>5>BY#&7',\C?GE^Y.3
MK3J;ZO4;"?_>,`JK&Y-_`?>S1^T*0"M7:P1?.G-%173EE7IPY;V`2WF^@\S*
M6CH^*@FCNJIJZ?NH+H,*PZ&>RT.CM0RWJK[AI#S#@8<C_D*B=G2`6S+C\!Q2
M-4)#63<ZFZ62WA9-V&1^ZEX3[,U^;_ZO(PQ54(Y?3.)(!7]@B:!5D!?@S!3$
MJL*C0BO]9AIH46VN83O='$WA+I$?H95C*AXY%_)*$GF2L-`J>Z1V_/NER2F6
MS5/5&@UVP3\3R=A1/8+]P'+HY)#?M;5.,AXJBPE?QPMP7(UOO<43\$`5U628
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MUYMP(F]^W#`;.DLNN<W;"MCZ1[AZ$$>\EL?$+M]('-OLZ4#8!'K^;-(YB"NZ
M^:<^POWLN6I2)U1NTIU0/W!'#ER5CKY*W#WZTN^)]U1)"KYRK1_B>.:X(90L
MO(6O04I70NU9CWIWE/]381(^O@!LB/`B-S]&U=J=9C8MQE;\E;,M&^DQ3WG'
M\@7^#28O3?!:O:%^\V4>;X9OU%"O^3Y@K\V\X$1+_6;\RIKA&[;38[9H.G,P
M9R[P>FP3[?0C662UA2<S&VK%F5W+6&3[\DF.'RU=4GL146)2U3(PN0\A)59:
M+:\/[T5&L?6E90BR?1DE5SA]@XX3SFS/<F^(`\)E--KFR:^<L97IN*O>;\$O
M%TN'K0#.@,*,N-(EWU.D]]Z3@#\]F?K^I7<"O64NB`<679^+T@V+Y$W(<T8%
M<X@=^FDF'(0\YN_'F#,JQ^P?$."9([/>](YA8<1=>]SA`UWQ/TAO4P_1YP8!
MM=#Y;=#W]0UL1@%E62W$G[AH/DO&TJ:@@M#JJP-Q&J`H9]:[)=17%4LEOY!6
MD4\G3HF@A;;MPJ*O;Z0T5*3%&RD(P[Q#_'W5I?4]CA:BGZ"Z^ZJOOCXTP9F5
M@TO\]!?!+D@/)5K?$%6`^FDD(3SA&H*__!]02P,$%`````@`)(%L0\!>T9)8
M*P``4=$"`!4`'`!M9VYX+3(P,3,P.3,P7V1E9BYX;6Q55`D``_.8@E+SF()2
M=7@+``$$)0X```0Y`0``[7U;<^,XEN;[1,Q_\'HB-G8C-M-IY_3,5$;G3,BW
M:D?8EL-V5O?L2P5-0A(V*5(-D+;5OWX/0$HD)0($*5`'5/FERFD#Q/D.;N>.
M/__7^SP\>B6,TSCZ?GSZ^<OQ$8G\.*#1]/OQCZ=/HZ>+FYOC__K/?_ZG/_^/
M3Y^.'A^/+N,H(F%(ED=_\TE(F)>0HV?O/8[B^?+HDDQH1!/XV-$MC7Z^>)S\
MGR/QW^`(?O6W\\?;H[//IT='LR19?#LY>7M[^\Q8L/KB9S^>GQQ]^K0:[;>,
MKF]'__;Y#$@K_>4Q3J/@V]&_EWYUP8@G!PZ`HF]'9U].OWXZ/?UT>O9\]N7;
MEZ_?_O4__F^Y=;Q8,CJ=)4?_R__?T/C+GSZ)'D>/GQ\_ER#^SZ.G..+0>K[P
MHN71*`R/'D4O?O1(.&&O)/B<?S3,X1X!0R/^_;B$\/V%A9]C-CV!8;Z>K!H>
M__,_'66-O[US6NGP]G75_/3D;W>W3_Z,S+U/-.*)%_F5CN)C=5U/?_GEEQ/Y
MUW)KH"-(ULW+9/WI)/MCUIK3;UR.>1O[DJ<&<(Z4+<2_/JV:?1*_@DGY]/7T
M\SL/CO]3#/AG%H?DD4R.),7?DN6"?#_F=+X(R7'^NQDCD^_'\VGT+N?IRR]?
MOXC^_W(9^^F<1,"8X"I*:+*\B28QFTNJCX_$=W\\WE3(GWL^BZ<DHCZ7ZRW)
MU^Z):'RB_=[)KM0^0L_?GQ)8H&*,\>2:1C"CU`L?8BYWS47H<4XGE`1=B#?\
M\CYA/'B,=)J(%I]/9B2AOA?:!W8#1^&<C,*$L`B6P"O9$<GV]ZR3?.'QV748
MO_&;**",^,F.)&]_;V>2+RGWPYBGC(S9U(OH/^3N&D7!O9>(7T[&"W&MP._X
M*`CDC'OAKOMZUS$MHGY*YW./+<>3)SJ-8!G[7I2,?!^NM`2NW8<XI#XE?4#?
M9>"]XU^WNO8H^\T+4W)'/-%=K,OUD3#BG"0PC;?4>Z$AT$WX/GC4G3@\/C[`
M!PEC)'A*8O_G7SW&H/V*M.5>N=9`"B*/"//%[3\EE1Z/Y)5$::?3OR]2\'BT
MW8H_$I_05^\EW"^+])3LG4-7/*%P6I+@!R>3-+R%^WTOAU'MN/M?'Z`Q!&D(
MJ_62AJD0;IZ(GS)YZEV]^V$:D.":Q7.A2Z6)O%3RIB2X)TDF&L&B?YJ!3+>7
M96258$1^C^#W@3F$*X]%\!V.P^M=B;7(YP<6@]"7+.&&OOI[2A?B[BX(K?OK
M;JSJ,%[/:'N0,<V'L;ECA!@QB\.`,"Y&39;"$.73/@"V',LF2K$!@G-A37OP
MEH*QO2@)IJ/TBZS8&)+A\F_B9"`1E\-?O8L?=SV\NH^[+_1K!6.\D!KKF\>"
M]84_CIYGY!)^&D]^%2+T#PYG)?SJ//3\G_`-((YG_1X8+-%H>A<').R19WU0
MN]=UEM/MP_6TNU+4=C2+2&]!'257[[30JGHX*DP'Z177Q<R+IH3?1-M_LHU.
M-U2O&*_31%ZM-/+IP@M7J^E'!)>0;#V:,D)VEU!V&MDB!R[B,/1>8K8RTMU2
M7QRZZ['ZN/<ZCFD5]7Q.DVRL""X=*4&3J"=C8.O1]H.T."'O:$3GZ3Q;@7*M
MK5:?+7.#/3+LRNE!ZB=W%&[#)([6HP&%C_'2"^&0[7,;[#Z\15Y<0?-X2<@Y
MB4#&3AY"+^H!LO$H5G7\%T[^G@(7KU[[$N2-AK#C@+J/$\*?X[7E>^U`XF5W
M"^PP'H<T6!VQ#XQP8>+,5/V:S@689_*>G(<@,G7AR1ZIZYN=6BM+3TPR'-,-
MZ*M?8+!@/;8;K'@65Q,*(_*1^V;#RM8D3NRD;'#J_=QH-;)+;.AC3708O_<-
MLF6D$VU[7Q;FP_;-@%*\PZ1LOGHDH3#%7,0<J!7VB8IYHB>V[$J,X\SJ8T_9
M(:EOQCV"CL!`6T@9W`)"0\BHRPU:<"/TON,Z4>`B6_I81#O0T3>+&JTMO:^<
M3A3TSQ:E16(/#&DUMENLZ&/[=**@][-EPPC3_PEK,&#O$B[LS&R7CI,980]P
M^S&2T"S<+C?;]+]!.E/1N[2[8>GI2[I5#I,#])AOBE&1+;#*0Q!I`G^2T+TP
M/#[*/UP&LNY%H^0DH/.3O,V)Z-`C/3!4M@P^!63BI6'2CKKM[ONA-9Y[-.I,
M:M:[3TKE")_F9/Y"6$LR*UU[I'$&GV!^^D(^K3G3CM*Z#^3T!NN\*9$V5:$9
M-AF)`I$0DOU6?,I60DLV^$EU]+XI,LQ2D60`(7#`5$8/14Y2S&HG4;)^XO$7
MR?^4?YIZWN)$'*4G)$SXZC?R</WTY31/0OJ7_->_KX)(09T2E_E%RIATJ68C
M@;1(PN_'#8U/$.DN'%+W)#&COK8+$@:6DG*H?",`17L4ZM>^E0>/!C?1A;>@
MB1>J:%>T1J%<Y"AP%:'9'_'H&KV`C.7YRD50;81'9\-:K;1!I]*(J9MM,:@6
MN6="\X+_"6OJJQ=*72RY\!A;@BXF(\T4*,SZHJ`2=UP>`':9RV7U$+8;HM`+
M:G`<22JT#-]LAD'K99Y7]`B3?0'_I\E]'/G:S:GM@HM!9OKHCQ9%8P?H;L'X
MS?88U%<2"&OIW<[B0Z,0#K9M5U,SV?7=7,32<$49=T?&IM^[CLBNVV28<]\%
M*4$:XS*AI?',J6^+074U!59WL=:U1*)X`>I*G@"A7]KU;7&H5@0G@+ZK)%[3
M!0.#].-17_A]:Z5:!8[&;FA85C[)O(B.?BWI>KB"H/'@:>B$@R,!E8($JQ3+
MD>^G\U1ZB/.,-B66QH[M\&P[/,1O?G\B3%SPIQ=Q]`K[D;Z$I'H6WN7FX@J5
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M'$>C,`&601FZY=:83UU?G@:8]2$6!537%ZL!5(6=K\!X`$MXPVM?8/MW9[&I
MW<8"6#N#R1KOF;MS:8ZW6;DM\![`_#8;<`JX_S%\N,V6H`+N+\.':V!2*H2)
M+P>`M\7N_7KJ+-ZV#NWR9:1SP!8WD[M;>1?L3<Z4`K^[>WL7_/J`I>)D<W>G
M[X)>;Y`IT!_FOM<$3!70W3736#KRRF#=M=7L`E;7NL#NKI)L::(506L%!]S5
MG9M#I.IL!9MI)&ND7P9QGIDA525M%&`'<8(9@-5&KA1P!W&&&<!5A2$72`=Q
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M86=\7(;;OJ&3*SBTFU_3P17ZFX^`IEX?F6(?F6([4?F1*?:1*:;-L?G(%/O(
M%--F+MVG8G7"5,O+Z2\D5%W(3;T&$&[7)CC88=-5+\'!#ANM^@@.-K1>.0VW
M17"PPUDHO00'.YR*TDMP,%I:RG9!:*VG;[">^KU$)/Q^Y@#2CY@$NYY[4\O4
M$`+DNB#>MED-(3JN.]*556L(07'=4=;'JCL<%=<%JLY$CA\C9PNSD:/L<"*I
MM%XT]."I_F!NGTLN1Q1U@J@XE%R.*C+!V6BO00\M<C/D#S'TY":"/Y-1F!`6
MP?WQ2M!?&Q$%*Z[#^(W?P/Y@Q$]P*"H][5AZ?7H4!?=>(M][',-*DK]3/-EM
MP]I??+ETA,CS\8%17^4M;M6UNUV7$__S-'Z%>:&921=^V+3DPJ]^7SUHX\=L
MD3_D=PFSG:V]]:\V,+3HB&&9OGD8USI:MO^.0=WJZ,V7:#1]RM13E5M"W=Z*
MSTJQ@<Y3#I<)YRJG2;N^^Z"TSEUBWL\*A0\L]@D)^#7<5F(W>R#HWX@3T`L?
MTI>0^N,)B/\PA><$CB*R^E=>)J:6Q;M^$L6#Y84DOW+OO3G\^,R\B'N^/"-T
M47\&'0\,3^NH1I7G>7V!!)<RN0ZN$!H'F7AW3][DG^#2]L-4R+4_X.YE;R#V
M$,;'KX2-PC!.YMNEE^U^&V7NJ@\N:N^%^K8.4/T,X^G\[8K6CE"NWR+*]H.F
M'BE:6=!#`^J!EE<</0TKI[[]OMP"G620M8O+3"0X0.=!9[:UD?E=]B5T9H"!
M&.ZR9V&W_6)/3'#9+[$;CXS5>I?]%;NQ8&<]!MVMT6A*;*U15JR+*O$,W>W>
M/VZ%>)$C/W,ZD=I8CRN#+EF3\-U7AH$R>O6A82D/+5K&`E@G0F9,5G"3?J)!
MN[V(L9R3YHM8J\M4L!IL;?P)-E[/%G%W6=IX[IRG=#X'Y`")3B,ZH;XHVI_5
M`A/2:@RRAXA(5OMT7"=]W>K:HTQ&1]Q)MZS4-M>IYK("#=S,Y1I_".:$K!#.
MFM("J\*<H&Z/80Q14F/T>+>N'TKJ<.V+`>9S8]X?`]V:CKSV4F7IYSLD&$>/
M1)3WA.TDI-8X8JM_GGN<*EU5_8PQ5"[ILHKL?1^5.^?+]8]_H83!]3M;WI)7
M$FHLH8:=47'=1(LTX9*84ZTC0]?#%01GK1&<.8;@:VL$7UU`4)(W^/92U[H[
MVGWC#X$2R=%3.I?;"SB&G:TXIN_BB"SO//:3)-=I%!@(+,;=K-!7?0;-D+KF
M3IA/\]W'R1-)DI"(FUC44S/!U?$CV.\4&2S^YF>W:KGCLG6_$P_,MR.Z];X7
MZ`8['=^^V].ZURCRZ.9`9:9@+SIAF2L6U:D###'8VS08K.@A9)OTSB=3F0\]
M9<4XC\.Z/:-V=S>8`UQR"^C\(>W,&[6<,%.*7&*(QD^R)WX,Q3782?.MY4J=
MF<GE4+!>.7"VS0'W@L)ZY<#7;0ZX%_+5S2Y2]XZ:J?;<-EMR,([):O)ZSI85
M7Y<8;LBL:/A%/%^`]AHE6N-=?5L,<\S.5".9%M>K72^+2>'K8N9%4]@E/T`H
M\T*1_/XK$'X;\T8WRVX?=YTO/Z+X13QNE9TA<)3"G^/(AUY>OM?-/)4VAQHX
MSXS\EK:&<<5U\5>:S+8(YE6*^>.&"IF?U+HBW/V,A5HM<^,(Y2;U26O[()KN
MM0[%:AL\$4M[K]5(5,ZH$,V&QAY.]EKIVMII^$<P.^YK4NP>NX-2%QU:]SJ)
M$ET!;6_8M"SWU):XJ;_Y\&U6+8MZZB[P,F[%_>,27I/:GCO!/<2@[L(``7L,
MD'I34NF1/Z)KI73/>4QF8@,2=@/_"6>$SM6E^=6-<9X0B@1WLAS=1\I_GI/(
MGP'G&A[4:NIV0%C0G@K;)&NY)DRCC31V<P)+D\E"T\$)^HM#Y=040;F+$QAT
M)A!%8RLQ<E<AO:5AN%0?D1LMK(SZ*PV)%SS!U0#(1$ZZ>GA54XQ9N_/^7\PN
M4I[$<\)T5HB:ABCER&3:6(48[>&K;C]HZFT58GJ8@,["M*MULPE622NN+X94
M:F'K<:172ICV":12`RMC_GCZ-7XE+!("]P@D59\J4#>U1GSHP5!&VLP*Y=MV
M-ZS8*3-%T%1\JM;N;6+.0-3"/L`[$;FB-+HV2YA:K(=O`-V1016!%SW(U]AR
MIA=Z]<M_<\N@+_X>4->)E_BU5\Q.>+5H7"G,I1;IT"?4[##?$:<3Y[;!`=4H
M>Y=?HBJ+?NB>0*O@-+;$(3B!S($J%7)TOXQ5F%L:W!`RP<SAZ52B(21^F2/=
M-%NUS>X:C,-DNY5P3A,J78HH=6.VJ-":&I3-K=@`/GP]COIZ/KPC']Z1#^_(
MAW?DPSOBCG?APXY>R4Q6RC'H!C4\L[(#QHD/H[);1F6D:AG[-:\>E!G9V'CN
MA%&Y/UNK`[.[;QO=(=A<-3:Z0["T&IF4#\'6JC;1?9A:AV6,O.()G8L7OW]P
M,DG#6_J*4[):!,JG"6$B;'XQ)PTY=:K6.`:-C):G>)*\>8S<@)P532E<X+(Z
MCA$.?5\KJN`E63#B9[DIHWG,DOP=D9OYPJ.L]A7JLF[8ICM*%F[*8$.)6A%1
M<$W?Q4_Z.#E-!RO\OO5>Q(-<,5O"`.,)[#^B7]NFO5#*EA*/DUD<!C#=#,Y&
M6:!$RUY=#PP$#RP&83Q9/H3B&(R"-5?/EYLOCVP@,>GI%*+:([TEMMIO.(5R
M^PT54VREGDXA6K%ZHK*&F_1$"4KV9R1(Q8,F:IYKC/S&W??ZMF6'^[(2RFO,
MDP.T6ME@H-$V03=E83&A_HP?B'6[Q5ULQ(SR53`$LU"+.ZUJ^U.H2$.P$>V(
MN4&Y&H(9J2,'=(K-$(Q*+6$;ZTY#,#EUG'*MMH4>ZV?LU6@K%AJ=]>4KXN`J
M*:P9=DG#-($[_4E4')%52*[>Q=O.)!!/^V:'HI0C\J8DN">)>`5\7KQS/##(
M(_A]8`[[RH-C,9KR*MP]ATON1C+(@VFD?,S.RK=1GN_;C?+S9?T'-!::/D<<
M(`=5=ESKGW>'-\*WHS4&-78[("Q(952NYHLP7A(BRP^/Y<VKM1"KV^/:L';<
M'F:6+BN#V$KO%V?=Z44<O8+$)52K:B5I;>*_45>;=)YUI[.QJT4ZSSN3V=C3
M(I47G:EL[&F1RLON<][<U2:=W<FT2^6AU;8URU+>@]Q9B3%NO+SQ39%&UEC'
M^.9$%K4R4-FV:%[O,K(C@AR@8VD?TV!)JT=_S:LS&[<5D')!`#-A<0@NB:[H
MF\61(;@C.J)O%FR'X)3H"+Y97AZ"5Z(C^&;Q%MTUT2/X-IO>O5B$+N@5>@!^
MC$$_,#7F*_1*?!U<;C:M6!:E([VV,!R'WLH_679-;OL[RW]%JN>1SM-0Q`F5
M`Y'@YY#(M1D%Y:`DI=-598BV]7G,L/WA)1R84>P"I7A!^1]A[QD])HD'^K9.
MA4@?7K#^KTS]Z&)#)Z=P-#F=#3HZA>>>J&X];1>G,!Q>BH0-1$CN\;TG2>P3
M6QZ="]2L?KP43U#'DJZ+F#?<FN;]<5U,AQVXCAR[[[;CQ_SB^\@"LL*Z)HEI
M"':H;LCM:>WHAJO]KPXIMPW!]_:1!&2,N85X,03/VT<B4!O8?Z3$G\94)W?]
M:OVF.KE>J.XCU4GK&1D%`<W(NXDF,9M+N04]04DX^L32(XQGC_5>PJ@^U5&[
M7[7Z/.4@`W$^\H$\GJUJ\2,C>B-(<S\,(T%O:)`,.G5TJ0W3JM:.4)YM@!M0
M*T&J2/@-YRD)QDS\7YQ;]ZDXD<<3Z</-_VH.M,O'45R"H<<YT"$.!GVA_NV&
MB/3F`1IC]DBGL^3J':XLRN$<!E%B_4>>_U59Z+[+IYS!O%Y!ZWB""R\,27"^
MW`5^BZ\B.;#G<237X(6WH(D79AOHD7#"7DEP';/K5&@)<I]%OKK&?MOO(*/-
MR'M*7[C/Z`O,1YK\B*CN3#+L;"471!DGEOV!2XL-W9J-=GV1'FZH)ZY\;O]8
MQ%%!K'(ZVG_)RMS<DP3$4Y^0@(M(I8?T):0^*%U$%&T=3TK+I&YV6O3&<9J5
M67E)7VD`@O*CEXB2`)=Q&'I,FW%NWA\?W2T%D2+(S9_B#T1]OIGTM//(0S4L
M%!28>3K_"R@8HM[!N@`['*=7(?%7Q1L8_!BSVI*;.WVO!T2_Q:)R0W;CC?@3
M67@,%H>\.K>H>H;O<J%<-0/K]EDDM_1Z]Z\N0['O%:>9VD7=ZBM69O+1>R71
M.8T3XL^B.(RGM.'Q&7T'FQF]XZAM(J^J!XKK.R/)`(%)#YM\?7Z+6_)5U0./
MK^>M^5K?`P_!16L$]3WP$%RV1E#?PV:F=>NUK>R!PE<AYM8I`34-4.A+X`*6
MKK62G4-CVU*WMS/G6X;:+==P9<(US7&XN4G/(Q%:36:`?EJ$5"61F_3LB<-U
MH6C:IO;H6,E$TJ^K)*':"FU>,UWU,F69F$KC(--A[\F;_)-ZRQAUQO/G&5OK
MUXER#2+FVH-UBA6381;CUV#6+WON#'B$'M!F%M5G$[03<7PF3ZHIK?V5V!.=
M?%^L:7?CJ]K`5(AZ:YAG0YU-(]FQ@.EN!)4Q3+5:7<!T-T3*'*;!;+H;$M5F
M;RI4X0*FN]%0;6`J].4")E8(E-$]VJ@Y54(Y:]B"?G'6/X9AH((5&U.E3!Q@
MB'L;YK35&UP.Z.V"N[7UW.58WDX37S+[N!RPVVW';ZCM+D?I=ID\T_@#EV-U
MN^"V%2N&'LMK>SWL&H?D<OZ2-88T!J.YG*'4^ARTXBYW.7=I1XZT#8DHS"ON
MV1VZ24#&$3H%],,0_CH%CQ5,&+8`V#(NL(`];-EPAT#5@@7#EAY;1QT6P`]#
M?#0*VRM`'X9L:.3Q+4`CR7^-R6TFKN$J;*7Q"]VL91VLTF.60SUS/U-/GL+!
MN<=)\.`M9>:E,ZEOHS>/!0VUOJIM,$(`+O/#323EPZ+*7GD5*LY4[H._TF1V
M$P5"SDOS2Z_"[:U#9`.@M<^C/@<$=SR(-05Y933W0O;A"0GD7/+G&(2#\M^%
M,>D^3OZ;)(_$CZ<1_8<RQZ._\0Z*>YFQ&42N_%>BW>F^65I/A)40HI5Q2JB6
M])6(I.KGM_AY%J?<BP)UF*!1OSU0*"P!I"N9Y<X8J_;.>Q<*OC9$M-H&)8P?
MF"9J0>O*2):;8-*H+W97;300.I'2M<LJ6*G&-U^9*%7W2G,_##2/0@C0+.#B
M[VC4:4^!<@O<:HSUMUI)S.+GRRW9*A,]C<HU[OI]M`#U%PW-.<DOFR1?O2\H
MR_1[><6KN&/M^X/BSK5'V6]>F(JWZ]/YZAA9$!^DIV?"YBHYK,<!T?BGVQ&J
M#;%RKQ5::F9('*7)#)1LM6[0YXB#Y."^^+8CMU1I`K;)&DT2PD"H9J(:59W8
MW?.(0UY#KQX-Q44%VMROPKG;\U+:&FY0-T!5=A0X;J*$T8A37Y[3UF^`Y@$'
MM?9R.'+F^4TN!/R5"!\[[*E7PKPID7^\]!*ROOUL+\F.5`R1T^,TX8D7"7]]
M=>'TQ%/U>$/<Y[])P]AJA:Q70E^[7#F<DRM/J?<4=OTH,+(O]#+4!\]:#]7:
MLJ-+`\W6M!A`9!UI\KN5C7'S"&L]6%OAP-8G&]W3:OCH-`9WG,A,5+XP8-N9
M6/\.P<[FK@/,XMC+#-A7V5U.$.F3I7NQ`;B<?#*(]:HSTKF<_3((YBIM+RZG
MW>R-LW8\%RYG\CC-2@,WA\O90$X?`,UF&9?SBIQ>M@:V69>SE8:P;%O;;5U.
MAMH'PPV"5EQ.DAK"?E?;:%W.P=H'9WN,X'4YLVO0K%6$]^*GE!D^L%H3FEDY
M#X=I[6P'RPDSI<F37[5^AK6%ID6<L\M9;X9H-3X+]$POLT6Z%5):7J&5B,XA
M+,Z:$-0RGHU(=?1\TPXOS5D*7*T[AX:2M+<7II3V1=O<O@/ER(;S+N?*5Y>/
M@SX]ZX8WWO998V;[<BI!M+2NQ(6WQ5%AYXLX04D9#>7'25`_URO*ZL,A##L[
MFPJ8TT]%!95-;4!6Y-I21[KD^K48!8-3OY*(,"\4[Z,'<]@=/!$6_5>2SYXV
M(<6L+P8J.$_B.5DGU]_F,Z!)_M'U<`B!-CY)W^<@4"`EPHFR*W!SSF"IEUY1
M-]DC)CUQD[GLG&)FB5TVQ]IWK%%/=TI]R)'523G@\*,]3(JIC(0?6F1F+S2X
M&\OP&XYP=(77S%!C$_10;(U&EV]%:S>YY880Y-4:N:$4C!Z#U<&6T</U;K!3
MNEG#'%7;UP[.S%:=Q3[QA,[%K3".GF=$N.#'$^F-_\%I-(5?G8>>_Q.^`>/P
MW,;-J`]_NXL#$F(H^\.H-)(7/-5366GS44OBHY;$`=:2Z!(S5!=&*`XY42#W
M.F8/<)0+][BHL0S_@_-(ME#Q<,]4#)[3JX#-<I7B??"V=MQ!Y7Y^5/GH;U7\
M%H?PF5!45-WS>MP8>?`<?:3\YS4C9/6,P[[X63ONH+C9Y$FQ\&'<*BEY8*28
MO3N/_21)IB],ZAZU[W.DCVB8O47#5/44?.M?;_$]6(8>-P(WMD-9',R#MG<P
M?V1`6P^3Z<;[_A43=&OF83%W4\X>0EKI`-A;+W0/(=&T1^;^@5-,[7*U5ZE_
M"&FE`S@!3`R8;;-,'?4TE3(B1@#M%2`<(]-[*VI[7+W3Y)9Z+_)Z<^;!$_4;
MV1OFA9J&5LP%%R"HPE*$.82?.(A6634$X4&%]1B,N*R-(N98\$HFIG*N];+7
MF0IZ&,46>L7[=/)5\DMU_3'#GE:HS-?OJE+%?P-7ZDBJ:_;Q'`26DU8QE^.(
M)'1.[F@(AW\<D?P`?8[/X4<:_(`#CXVF("QFZN+V++?[P/YI%J\Y/H%(1B>4
M!+=BW\*IY8D(@@GLZR#UDTT+:C]C?+C4A^=2;T4A7AQUPF"%I>(91Q%8!-=3
M_J1EDXO`J"MN*$.%1$E>*"*$6L1'-W\!!:'ZD<)Z/,KV.-3#Z-ECN9>2KUE8
M6UX.K'B*4(W&M#^>%J>6A)O?TMV0UERV`?1ZH98Y95VJQ[=7F06'#\F%9]4G
M.92@[JY>27<M4%V]DDCEQ)0^N#:R3;V7S4!^.&`_6F?^F=_O@W#2MV2#VLB!
M[L#O"VU+,\`0_)S]\\%($D+W67:(^3#6N@[FW75+/'"I2(N9,->HB);AU>E$
MPTE(VG:[7,S$?('RL?TG%.<+"!?,\Q/A.J:1O':TQB=U>Y27;7/7FZSZ5]H[
M"N*5S1TSHNG,IPV]'$,R6'-@A;"<(A,,JZ8?)LP^$(IB5!NT:3W&ZO:#IKYL
M]L>Q+YF=7>5[7`,>750SM$%9!.V$G>K#!N*(&JB_=`[1W-$LP*&;/?:FOS4=
M*^CGA,'\-UYM%95.K7.T-?*XI-E=IP"</`!VGRZ\<+6TI?U&MBZ,65;BML(X
M$E4MY*BYPT`.P[='5M9`W.5+&"(4EKJJF`,SEM5)W*V[8W![O)!.TVB:$5(A
M=T7HI?)!9-/>#B.[2!G;CD'K^!&'<=Y$U_25"'^#2E'O\"&W\<8ILX-W_2&G
M\<I'!ZP`+GW);<1OL1V\J^\XC/9Y1ACQQ#.>NZ$M?0?=Z#9HDV@/AJJ>=7\+
M,N7:H]E*+#I`.X`E7G855M!59^=84[X-7(XC0.-.23I`#QYPD#\E:1$_!-1!
M]A3*@_-QQWMG3UDV<SF0$X<[#H2"-AIZNYIZ!F;EW;L3S`70&*9M,S<.GFG[
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M7FIO9>==A?26AN%2?8EMM+`RZJ]P_'G!DT])Y(L$"U\]O*JI'3K@O(@N6,SY
M1<P6^8&GH473W%+I)'Z;G68Q983+%X0(4Q.D;6^'HOSH5\GZ^G"E%KWW0ZTR
MOL>PITTJY>-%UX24]%L-976M,<ZOG!RNOR$V6UGAV[TH"3%)HT"`%ZRH8]=V
M(SMCIV)/C2>C*$J]\`YDXH1$'AQ)N0"GD_^,^UJE-)^"X('%4^;-N3".23U7
ML<!UE+?^EE4D=W%(_!0$9I%GFPO1))!;=3XGS*=>*!Y/&_&'#8*TF';XJE5T
M*Y[J:%VWZ65D.9.@01$ZC4HZR@8KLI(L=#K3+Y7N'[6";6-+C2-S<Y=I5SMT
M3F!Q,:WDL]D$)\QGD3)_5HZ(WM15M*8$\_X'C<Z6]6E5\VC\$M*I7):BVF](
MQ$\J9;ZQ#P[GI5R0OWPIQ>B51>2.)+,XJ#;XQ];%NL.'[+Q;(PHY;%EQZOBO
M:&F'"D`5!?+\?([S4[9R:JE/%].NENB4%<_.E"71='2:=?THT]>>^MHR/K(8
M^#UYDW]I6:)OHR]>.&?).Z"9C_JV5E;\C\6$Q5)A`XGG`6X#*C*-5E7M\J-*
M=62;=[9):R'_K(;()E5#H;(+7@Q`1^]2\32!Z9&Z#A(X0PJ&L5.ETOAH+O#^
M@A[UHDMXUYG=JV$^QL(??NR+4<"/=>1NIKYWM$L6I=L,C82'&NV^`^M:^15=
M3H;?E1$UIDCG0_EWWS*U%FOG@_1W6>]A&\^_\^'X.W"B4S26\P'X.S!$90!P
M/JI^!\R-BH+S0?/=P"M]7^@!\?WB[6*E*UB"I2;TRI*M`)DUWE/WXN+MX]U.
M7#P]*.'.($JG0'YX<MYN\?`%9PY/$K3ABR[X<WCR8?>H@X(KAR<D6O"T%^PY
M/'FR>[)*P96#%#3UR5(%^(.2.EO&615<."A!LUT42V&4/TCIT]!%67#AH(11
MPY"/`OWA":2FB2$%#PY7]"P"!0NTAR=(MG"<%VPX/,FQ=:Y<P0PD.=&L-D.[
M"/UJOGZ==Q/=/=DW;$4\"_K[,7WC;GXOZ*O+I2A:AY:67A;3Y0`5V]P]Q6=W
M[,J\L#7LKX<XY9JD\@*X>Z+M[L"WHN`+N.[)LA:6MR[=L(#NG@B[._3-/-,"
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MBJAZ.Z('X=8GK30>/H77K_YH.-24%'/&M))0G<]`,<=M3\)Q/D^E]2[I=GDY
MG[?28E.T5X/0<U7,_$=:$6GKBN[F$L13^J_FBS!>$G).(A@M>0B]R$DKRU/Z
MPLG?4Y'@]VK)`&&KQ.9\'D?2X%H^&!7*A*HU3G'0#5K&:<(3+PKDB[IFY)>[
M8&"X>1AKE;?B[QC45;/839G<U`L'2>P3$O!K.!?%DA7AD#=BSX,0E+Z$U!]/
M@&8=)M/^5HL4C:*@%+^9W5'Z4H>&/2U1:9S;I*6X]5=02KUXP@XNE[3PT8TG
M)3^%ML*504<4/&)?/C"0ZE1T%PT<*JV3'2<=:^ML=K93F$DWUG,LI<8WD)X(
M$^^^7[V+%`4.RV#\"M)D&,;2]3)>)+2^7+O-SZ/,8U7P41D+&YL[0+OVIJYO
MZP#5=291;5,7:(;Q=$7`%*T=H5Q_'2C;8U%/`^JQ9>F::N!\?7L\NZ;YS5S6
M=DN2-WK^\9:IT_3PK$1[UF[[`S1W=F*.H33ALKFS$^Z2E.>RU;(--OM2E\MV
MS"ZSWD+;13=B6H:N-&<-P4.W$]"*80;=>V=]13=8HEPNF]/Z<.MB6'&YCDX'
M!IC9O]`KY32Z8$R4,IT4MU:$T&,F>H&JT#W04[,,0]OU6FO#O+H3W]YZYVYK
MN1JLVVH6EFQM/*E:E;@"U4#W=-V9>A\G0F2^IN*0!1%QG;#!QVSJ17DQ%>$.
MCT,:K.J6PHW,1:"`^.=X4M.Y\'T^`X'G(;`(QPFKQO=$X7J=4-^+DKQ<B%`D
M`*4(?A\XU:M?#)-Z>6EP'']X)`)@6%Y!B/\\7S98(W4]</SB&_0TVB1U/0:/
MH/7#,98P@+)"DRVZM#X$?1\4%"EH'7-1>JP5CH9>&$BN/<IDT1L9U,=EY6WO
MA89P_!%^1SQQ405C42$C92RKG'4?1VSUSW./TRS3OK@7ZL'W,!`JO_342W)_
M1#%(?$PJ93?1(I5U;>'<#ZF<>6..V1S*SA-C+`:E)UF*L#)18N[J[RF5Y>:N
M>$+G<*4%/SB9I.$MG1#MXMCU:RB^H77VWP@NZ8"&J:@@]"2F0T[1U;L?IB`B
M""NC**B4KH3!*X]%,%\BEE1::IKFOX>!</FU29=8N3Y,^*6`1@*C8Z3KUS"1
M<UE/JCCRQY-,'!+_O0:E*&:FJ-M\"?79JBT;ENJ]JEO<2(85&=IH@&HC[#=H
M&N7PJCE<(S+B6U@,'Y^Q!=F)5V=,'E=J%O0KB)NDT2%X`=IBUNL1Z&9_=>R"
M\HBLK5'U!XA7,&)('WK*(*(:VG''JE8RB,@(L^W411(;1/B#%O[.RMH@PB!:
MK8#66L@@`B1:LL">XHH>4&'N?JT5];6"8UG.'*ZW2KG_!^"):D-[V3?B#@+I
M`YW%(:P>+JA/EJ+M`%A?D"CNS/D"]E9>*SD4=\9%S`%<?GZ28%54ZE#AN+FX
M'@D'P=]/TESBS<&,?#C8Y9$^@'76!8.;L]'TA.D09D-3]>[@J'=S%6W6)1@`
MVQ\RN0M8/DYFA#W`6<I(0IG\:UZ!8`C+9[,803.A?SX1%+S`E0'_^/]02P,$
M%`````@`)(%L0QKD>8Q3;```EOX%`!4`'`!M9VYX+3(P,3,P.3,P7VQA8BYX
M;6Q55`D``_.8@E+SF()2=7@+``$$)0X```0Y`0``Y;U[<^0XDB?X_YKM=\#5
MGNUTFRFK@HQW[?2LZ9%9(SME2B<INV>N[*R-(A$2IQAD-,F(3/6G/SSX#@($
M&2"`R+.=[5)*I,/=Z3^'P^%P_.O__KX-P`'&B1^%?_G)^GGR$X"A&WE^^/J7
MG[X^?;A\NKZ]_>E__]M__V__^G]\^``>'\%-%(8P".`[^`\7!C!V4@B>G>]1
M&&W?P9WS`H,$W/GA'R].`B\`_E\/1"'XCZO'.V#_;`'PEJ:[7W_YY=NW;S_'
ML9=3^]F-MK^`#Q_RD?Y*>?H5+'ZV$5N5OSQ&^]#[%2PKO[J.H9.BIX&'N/D5
MV!-K^L&R/ECVLSWY=3+]=;;Z?ZI/1[OWV']]2\&?W#^CAR?S#_@-\/CSX\\5
M\?XG>(K"!#V]W3GA.[@,`O"(WTK`(TQ@?(#>SQG1(!,7(&6&R5]^JDCX_24.
M?H[BUU_0,--?\@=_^N__#="'?_V>^+47ODWSQZU?_N/SW9/[!K?.!S],4B=T
M:R]B8FVO6NOU^A?R5_ITXO^:$"IWD4NT),`@8#Z!__4A?^P#_A52\X>I]?/W
MQ/OIW_"`_QI'`7R$&T!X^#5]W\&__)3XVUT`?\I^]Q;#33L701S_@M__)82O
MZ%MZ>(0U'L%:X!'^1_9K8F<_`?SDU\=;ID#K&BWZTB_*F'R`L1]Y'\-AW#;>
M5LWV4^K$Z0F,5][/6`_P/[!GJ#$/OZ<P]*"7LX\I<0R4#$1LFQ#%9".W1C#`
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M>0TQ"<@(@8R25JR<(I5=DVI'"1F`#(9AM:"B37J=B'B$+O0/F*//</L"XXYO
M=_2X!E0T>1#UM(NY/6W@HB0%?J?$],XCI\EF#Y%--5)8!M>&E59MF(&6+S`5
MFT5:7]&*FI(/4=^[6DXF;.0@>F9,+">+6`=07)`;1:P#C%\B18)91+*23&*6
M)S@&$]\;-+2@R2/$>[2N]YT7/_!3%.1VN@/&\VI]03L3PD&89953*"8%*K2T
M.P$)LME5V>#W'0P3[6#AVUD#*1P=:(+)?KL/<&[F!NZ01_5)&A#]'$#\PV7H
M76ZC./7_27[_$$<[&*?O#^A3I>AO'_^Q]W=;+JKDD%<+0BD\"]OU;+DN,)N/
M#*I#@V)L@`8`U=%!/CP@XY._%QS(!7I;PM0D#<ZP"N]@D@"GHD>OJD<':<>I
MC*S9<4A%7L//R/L`_=S2]C7\3IS-9#V=$%>#?_/W2\_S\5!.<(T>]ETGN($'
M&$1DF,\^BGC2*(1H[8W_G7P-/1A?OL80MOB6T^E)=B9>A+2-Z!)=RF96#`.6
MM9S/YO._3XD;>44O8Y""790B$KX3H%AYZZ"APU?@9BR`;3XPSM.0D8%S</R`
MK!G2"+Q``)TX1!C:8XZ`&P7H;U&<02EG\.=1PHDV!ZU8E]0E%\.!?#Q0&1`4
M(X)\2$#&!,6@:J,MQ3HBX=@UQZ*HZ3@\98SM<*7Y'^QAY>A7MDN-MMLH?$HC
M]X_;)-G#A]AWX0.,G]Z<&'88"/=5C8Z2QY>@C4[6B^5ZG?G$$L<N(0T23!OX
MF#C88>H`S8$@P?3UN31Y4A]Y+RHUH0T(<4"H`T0>$/IZ'94\R8E/N@U],N_M
M]B^![X)HLX$QGOT:7]H$?R0"WC;7TZDQ+>O)@K\'Q_=NPVMGYZ<.<Z'`>%KE
M:J^=!?%=KV+/HL0:I@1N0Y#1TI1OD2"8W1!LARA]\$/@L@53MGSB&UIM-<31
MA.29.)OSR91_A_`8)LCIH!75=35V%ES8]*2E;Z[NQZBP,U]-UO;1Y)T%EEE<
M&>2CD96]:0N4,?5R['*H7NCBHQB-Y(-JXQFR,!E3-TVO1:T$@M<89\@V4$_"
M6(JG:(D#!FAR)*>W0^.X;SY:"N%_WF^*E9"8*;!?U^_:F+P)3J?SM;5<L9W9
M#ONKDCX*5\NUM';W)4=VIL/"LE?H@_M-F50QPD7)D;_IE)"G2'P/9DX9?7`G
M26"*UBNQ^X:+K$U*F0@#G..>^%J4[)$>X2O.?D?Q^TFI97$R^CR4,(^BB;WY
M?+J>B"22XV+DWJEDIQFKQ6AJ?M4;K8VDR*;?*X<Q/7<\DD*R2A>.[1C@\7H[
MD!;/UT]_>I(U_[5/4L+1<_0(L7I\4KQS&[K1%MY%"?K]M9.\/<31`4U6WM7[
MUP2B%?3]CDQ<*,YT4_]`"AFZ3CN,,932-)%\_D5K1]?VK(B?"B[`<P0*/DB)
M'^4$8%;P'S$S(.<&7+T#S`_.2A4<@9(E_><T=.O7;NH735MQH=\0Z=>G^D6_
MQ_]RL7IWN7I?WL&?]EB_?OAG$!4*=@J>?M6;*QL/Y_5$VT@?48MS#`AQZ)&$
M^A4^JXJ/>Z+U-8E9/M+:,Y8YB[VLTH$)<20(F=G$7N6A34Z7;B(!0AE428.,
MMB;'(E]NXBK(QLL'>H39K4H+V=(JPWLOTZTA6%Q;PS&90/?GU^CPBP=]"D?T
M0Q.%Z%=_OT2>Q,/>Y%/@O#8^[_'?%6#I:%#1&<9:SY897/+7`7Y?+21.8]\6
M8W]L&V<:!C;C=@GE)!>VN,;]?E/=@*UD</#.DD!JH3<1Y8F%OAP*+OYL:X7_
M2],*9`R2\V+EP_!&8[-V2'5F8%Q-6!5-W&]`K5*CJ@FREVQ`6F!<;1#G4F1!
M8DAK=U&HG;Y!II5H3!0,=09EFF"0/K7$P6'J>WZP1X$Y?(+N/B;A^<?O;K!'
M$?PGI!0<(>RI2[G??'1BG!U,\DH4*B@K.)-"6V44+8-AT1(,:['(U_V584$Y
M+L@'!GAD4!D:NY1\\++""]#Q-07BRE5'G0J"`HQCO#[!$;O6L%PFDFI1NS35
MGJ&#N7IO)W#YW4_&,47NB.?CC'AB"#='F4[F<EW4U3M@D?H=<Z8K/VF(KFV>
MKMD*.A,7)X)EB8ZO\ZN<H3N\\T-XF\+M2+ZO)'\^CJ[@611IT]G*ENO5?L<\
M`,+$>3JP83KD>JM"AYNF#J-!.CP3'W<$4(D.K?Z5S/%>7YPMO(EPX4@OZZR\
MIMW;E+R((F`Y6\WX7@33!+]3JD:YA8'"\N!^T2VM7@`?VV@W,!MZT@*XLG0J
MN0R]+U%8*:9Z1C\E>!,Z"A-^^[">5%3"L1]KHAF"R6*9[V!6!B#U\O4A0'4,
MW5W(1M2%?:0+A^KB`UL9)H!YF/W7L#U`JUJ@CBN$F7$]_:-*8)(1A=M<6:M\
MTX.\-PZ`HM0)N`#JS_,"\_R,"=,2;;W=AFHF4#/B4C)]MME5!%A_2+FM]F[]
M.YM/JC:KOTINN!@V'WIJ#9A;1'8LHSZ#[N@95WM&N3GW[)^VM!K6/&H[.#%/
M/$2$BD-VZ>O&.&9>Z[<C>;5;M9"W;CZKR\K[.KV%-9NW6;LA/OP4J6C3G9KI
MZRTOYAD5$P.&>/A/CA__U0GV\,9/W"!*]D<=<[J?5XZ)%B;$8]KUK(8+3`L0
M8J"DIG-..%4X`P-VCI$=XX,EOU$8$9H[>.^9@)G>WM<NNNMRL&/(#"-+WLK"
MP8!91L`4A1"E?_;YYL3>,QJ%5Z=2>T8E8JH#"Q^CFDSS<C7\.L#OZZW9&"R%
M+2R%,NMO,Y>:I1\)*Z7L_2J";[AQ&HQOT?\$;]#?MFXD=#RLNHR=R8EH)YG%
M9#:9T7+UDA8HB*&?D/F%3E:6_-OVY=\5EZ=+DM!B2JAGIT.F;'9#-IVWK(B!
MJ2@/YVM`QWQUM4_\$";)I?N/O9^0FG7R8PSY._O=[RF<USJ9$8Z,IGG/]IPD
MJ-`$.5'-F_MRQ;59XEZ(R:MJJA2VU.KT*:8J4X#'#AE93VL&69\RUWE^.JH5
M6CH#2AF2,5%D0)#986I=>-%9-=O"#[[%('TG@1I,TH0TR?7N8_Q?<D?1'L^G
M]QM2.)?]5?R[#R&N%X,#.!;?8)RL.)"E(X-B:-I^V@/W,<A'!W1X7#U+&<B>
M,0;G8VN/]A2@HOM4/6D$'#H%`=Q[*WTWS#6<@*\.3S)4V3H<#VYG@KMMHO]@
MM@].0,J(TFLGCM]1!$_R3@P[$WM7H=L08D@X&6^OLFPI:45$.M'B'RJ4P64*
M<MHTCSH*X'>-R]85R3XK9"?=B?$/L"*[DR)<>[C8G?(WHNC5"]L5"3_O%/X%
MOOHAZ20XK@HZW;U\X6VN\#K]>"]W5773XDHRQPN+[^V*OZ_=&Y^T/9K7/+,]
MLL+MX&&X/%7^<\.FX-YQ/V69@]$'XOAO0S>&3@)O(/UO+XM@D-".U':^A(UU
M,>D$*QT!Y$.`?`P]Y1NC:8%4=.`6E^X;+LL'Y`:2LP$PW\*[,<Q1H$$PC@+?
M?7^&W],K-/8?_2RD\:Y^X-89$E[(+_)-`0YB"6GP.R8."'5-N4SYDM<GUJ;D
M!N*RW60%`-FB)'.0^`B3-/;=%'H\[GM9A2!)[;@5XU/4J.?6O#-_48X(NC!O
M$LQ'4%36UKVF#O,PWP\<W:Z@AR*U>(C`29+[#>E\Q=VE;WE0)9J/1A<-#^UY
M?L:>T"#[!^2&2[T;[R<*9)<"12("*<,4TYQJ2&D77J/]_XV<YTWOXT?_]2W]
M^!W&KI_0"S.+/R;97UD;ZX-(J<=0+_Z$C7(];Z(L(X7W\`@MD`^5W2I;/I(4
MSXQTYE<0C.-IAL"UD)_<,&L`2@<9?0N.^^O-&*07&X5%PXYK)PCPM0.G@+X'
M5=WX%V=5.-:;K)9=KJ"REU_VNJ$#X_9^1ON%D31&6Y%F=[MY].YIO4MB.7CI
M]!<]]2FE9OT:/>*[3G#CI,XC//CP&TVA?8K*=LK/,-[Z(;-^O"\)U?7M/?D3
M;\:]7BYIU7L^`O#0$"`F8V2[M&`35=JR@[0<1W$-_*A:L&I:P$,`.D:>=4>C
ME"W9064<#17SHVHB6]H3V=%ZQ*U:AK9:^H$@+RKLAVA,KG>"!QA$.SS.T?UP
MC]"%_N&H'K'_^]K\D@!SHM<&+N>SA=5T2B7]MLLGXVP(7?Y(NO0-9U21ON42
MR7P(G7Y(N@;LF@8,NC1R")Z/O9"HOB2Y($3^?O-IG^YC^!EQL-UO[_"F8E*[
MH)+^ZH[14/@42NK=TA`V14^;+6>S61$U89NT\-J'#@:RT0"EW;SI-?OMG^Z*
MUK9_5NVRQM>,56JFIU[TM4U6IAQ[1+-1Y/].<2853SA8UW)\8O5"ZLO0N_-=
M?-5=$0M^)-7H'@H7F\5)O5]7[OW$>1.UW?7<GF7'HZ_K-WF''@@H_<H2$=(1
M\(H!JH[)QA+>.A8>[_YF]"LKPVP$O(147$@YK@+LEJ]?".TQA%7CDOICN?1#
M/=6EQ/DD9?DFJ\1J.!W3W%$;DWUNDYL+^Z4$>,50AKFETY4@ZI^26NLB;75I
MBK32YK1:M6*L\^+Y`F$OQE2D;'=V*,>D^;7[S744MK4.Z_.F1I?%84MT^IS/
MUHOUD9,Z5`.F+-&.LZT9<7W^29K$38]TJ$9)65(=K8!RXGK]CS2IZ=9?\3V+
M;VR"@Q%`9YM+Z=*-E@*`:+OUT[R'/V8'M\\)71\FPET+^]%0N;G?AS'A6Q\F
MLSRQ7)*G%:S5`4SJ;#B>'NRF'ISA>E"VAS_$Y&L[]KW5:2RR.T^>]"-B&K9[
MG\B8KM>3ON#6?R9E/%5TX]MX)/-/JO17G2XL1R$I#;YV=G[J!+2)QR-,8'R`
M>/>=9H!)KX_0;>9:A]-1C.A>S`F7DJV*`V9DB*PT/!LD[YR3#T,*5++MA'PD
M?;@>3R'YR1,JM$LUD^B^['NPI3=1W5]QFH']X,3W\1-:3$./'#W/+Z?L-@[F
MFWK`RV)'^!+Z937`+N"*R.+25THX:[50W'*J':!2A+8K0A,D7H`=DOK`ZO"C
M`91=5LJ`(5<]FH%'?</E/GV+8O^?S&YVO#?T`*W)1H]["Q<M`,OFP9*>=E"=
M)&`+F&C].'"X$FH`%<L"&6!J58L1(.*V@V0]K1,\_5H.SI>+*1LX.ELORA",
M#1B?*9DVL+`;(_)4801([O=IDJ)U-%IIBG[-ZBLZX5+A0SB-,%^MV)BI$#0$
M.$-%9*,GXLNH#4(M=LC%45,S1H#I:?^2N+'_`KVK??HU]'M-0.TOZP18*T?"
MIVI7Z[:%4P:UDC1`M$%.W!#8G2YXM14PV0`NH0B<@-@D$OT%B;[GB*X-C5Q#
MYN*2K3K-".7V\&T^I@=UO7J4SA>K>0N^QFO`VP=&_25IF;'^S\G/$ZO,.8`/
M8&;/+R:3"?[_Q\NG"V!?6/;L8F'/R,:`=3%9KR[6UJP>.)*_569!W,7V">&#
MW,P"IA-$!MD2>>H&NMEO+?);^P(@.COHXMWS0&LK;Y9A,["IN;%KM-W!,,GK
MF!YAZL>D\*#/IKXP!;78%65+^.JRA57N^17$R:9?2=ZP[?Q1=&`?Z<`9J`.%
MF.QKY@VX]E*D;B0_P@`',==1(MPY4O!M30CFL"2<ZUO-UBWHS2@#0MJ@]I$C
M"$\#7SSG?'@A;3*J@YB"3@'392&S2T^Z4!G#-\0BBDMN0[38@)0U<5@*O:X8
MER(\B3=PF<Y*8!:4`26=0](H9$H7WV:*_Z>[*-%S^G"H"3?A*:PL7?C<HV^.
M>TK2X^%MMZ]V/:T8?2TLB&\?+RHQ+"8$"DJ:KB25*9D]0#*5..*86A,V+%7H
M1,E3M$F_H07[;8A6Z*_^2P#)!>!"F.&_JP%!7(:$K6ZQ6#3PE-,%)6%`*!N"
M+WERTX`R%]<DC`D9:AOBNI6C!W](<GP`A(2Y?O+'%0S=MZT3=W0=[GI-*>KX
MO(@W\+6*95R%(L`D04%3=W]BF<+:)PFK#GEB)EH'G8":S,#;>\$:YW+@SM>T
MXJW.B["CGTR6;+R]5ZU0X\W!4J45`)SVJX1%+90/MQ8E&0*W9S1F/Z05;^@%
M6<Z&<&9N;B]X^,+T3(/6(!E9J.H04".@FC;8@:6:5HR`T74,/3_%/XE^V\H;
M.F%4LB%L8LLI.RRDY,C/AF!HH(`M&(HV7>)I0]"Q^7$1U-")$0BZ8S1G%'A!
M)W[N^O7*0PN-67F<]0@^^KH$2A:0-05U":@-04?FQP70W0E=^T;"SP.,\2^<
M5VB)?MKJ*SHQ5.%#>/4PG;'72B4]8!F"HJ$BYBU7<GEPVY4@`(G_&OH;W\67
M5<3P`,,]!-")PY%J1P\P?HD426S15&=%P$O7C?9E-VCG)=!\\JX;>5SGT=2,
M$>[C&:M5]-O2AW6Z#,*!<"759+YB3[F$E"FS;7^YF#,M6RYM2*D9&1<CI1[,
M0`<:L5_^O_*&5IP4;(@:U7)M64RPT`R"60G_@2+RDR0FIOF/C9`/H;I>)+5#
MS+JQI.BGQ/=@-AQTH]B#WF5"[O8F#0B#V_`ACER8D!8/2&Y\IVCE<H"/WW$U
M&:,#M?11U+=9E"U"C^:@BZ)O;,X$[KU8<H$O%2%L`"<!?LD(OHU^1UG!)?Z$
M%U)O7+VC!%)VE#=QU*M/JZ'/&A<@9P-<)J#""/H99*R`G!=2PUZ]]21C1TN+
M2+TZ)1[XTO-\/"K2EK.E87YNG1K;2H[EY2HM*$?1O:9@B93C5ZZ8ZJA28CVO
M-E!J9T(X]E[/R\TD0JIZ;YKV^B,9TMF#I%,8'O'-KA$<<10B*S0ZP#C%=4P/
MZ#D8Q]"C[:[('Q(T)+EIEN&)Q=[5$,8(,2;:1WA&+@7/@Y.<-`HZ,MK9V6"W
MH$[O(%8?;(P@M=64NJ"=-[\KI7Y@W;P\?D@P@N1V*7GY37$JL_'==4[XO;!;
MG<;%]36NFWF",>Z0V3KU]GG3&!=38TO4X)#)31;=#B8AM,&-*8[E!%D[W<I3
M)JNFF&0TP6TI@NOU+ZV@[?8NQUK3%/@SV*OT>/JZB\+2&;+CU=Z4U"X6^K(G
MO.5ES^<"$*YV,P-XI$JPH&V),:I.CM#=[L(UKT"&VG]C;3)(DWH@GY"NW%G.
M@5VKTWA,*5CK8XM:W=):%65M2=9@/J<Q#L2BU`GX$#M!D@66Y!D/@5932=8E
M'G+D48>:=A.J0Z)%<A/LO;-!"^-QC?;?M^W(TBH[T39Q8$";%0G"V:5P55#\
M:A(J^"U2.$K0@Y(]ODIRY\3I^Q=GRS]-T/*H4G0<CR_J5Z<3NXC52BH`D]%\
M;.!$F>R^,JE#!=NPZHA@:$`+&DAQ]=%V/']/A/N.2GSP&!$_2SG->S+3>OFV
M\B2]&R32Q*35BOOMUHG?<4JSHW#1B)T3$0.MP:M36\-QED#WY]?H\(L'?0HQ
M]$,36>A7?[_>HW51F'[R$]<)_A,Z\<>P[09S[J,*<,0;7S1(02/DNP64$J"D
M`*8%/H8Z[M^6)I<]1*ZQD2%B8!@0G5K0,M_LDS3:PKCGC-/QELHYA\^*J'DM
M)HN\RC<C:."\(U%4WLSSF)T),&*Z$;//VH0CH"8=4+O)TG/7;T[\"@7[/7:\
MI!!H?$Y$C6]E33.<Y?1`1M"<SG$2);5KDMZ&J8]FK(?]"Z(([C?HU[A[,EF2
MZP29F&56,2:@(JT0J_:!C6/TG4@UW-_\].TV]/R#[^VS*^2N<(/-!^>=W!AY
MUW&*5!IY';`]D6?Q'@*321/@M2[,Y=@`#P[*T>E.%2#C@YP!`TZU:E&A+:;"
M;W457E`=9GUCA76HW-%(PF>K2Y+QE70ZKT=<UTL6S5^01NF"H<,R6U_1X&3:
M^!"_PF"Q;#B.1U(L3[-`)4&]3N!D$>O`)BO9P'=>_,!/M5Z'(&)^;7AC*D0O
MAL@2IO-;TJ>T((4,+6PY]J(YJV84=*.AOQA-`##%4&_Y-:-I-_927@/L^UIP
M=J@]K,_:KWNZRQG+Z,&U&5/!8*E:,0`^@#&G.($^##*^5[MH?N@&>WS(S0]S
M(8MI3W,E%A]3'"]P;=9DUR-:;#ZOSR7T#Z(6R,X87L&<&/$4V;H!%$3AZP?$
MS;8+0AI\QM`/VBKU!0AA2B[_RUS&+HIU7X+2B3J.QS`C0D8K78^<:?-?]EB;
M#_C:!W)ATGWZ!N.'*$GCXN:D!_3Q$N%+QF115^N09+`L7$1FYWVQLX%!=620
M#4T*Y\C@H#XZ(,.;='F9#OW9G?IS).E/H5>1"<N&#Y+V@:2<0FMC"(WY<;L+
MHG<(D^H?+L-P[P1_A0D^\%[VOFK8HC2RJL^O2>"Y1]N$Y8H>;LN1XU:1LT.O
M7P"8CUS[XP7"$QX<'.CH8%<,K_@0G'*%<5PU>AT4`]?_1H<&V=B5GH(:CL\I
M5UE+V\'<K(@!-2Q/V\$ZB7ZH.'4G2]FFA(8E[S&>$O`L$85._%Z3@[1>Z1$>
M]""J.1`4YU1TM;,J.J1U.I48U,9L>!@RJCDAWTB:*BX*<\+W?ZE/2B"-R*0%
MR%DHTX*W_L#IBMEZ:M@@#_+9^>YO]UOJ[ZI_3)#7RUUCY@#[F5POROI]21]V
MA<OYK.6RRZ%DX^9A26UD')P484P>J1CE5T;3&B]0:7J:Q`D0U@ST,D/`)>!J
M>BM=C[_9Q=#UVY97K8\H]0#EN()&.9O8BVD.Y?)M75@<R+_=Y#\_(ZD7.\>&
M4@=!0UI)B8Z2*IJ9X]3_)_GY%H4S?HP3`W>,BL/>KZM/7`CS)MJ89;)8S!=Y
M@J)B/E7RH*0_?F$@)PDQDO!'V-<G?%=.820-''N/H1I0E$+HC?!*JJ"?#G5/
ML.CG`-*\A5?E5V`"8;ZJ:4)F\2.Z-%TOUU8+6`NR9/NF2EC_'"Y%Y&-TXGT6
MIXI0PR;[+J-E!0%<=6E!8K$A<[^IEC@_PL!)<?B>I`FI:GZI5C5W;=>>1E0E
M>D_B5+CR'BT+,UR7&X3WFWKY?38D/;8#RD$KY?:ZMV35*<MN*"OB*8MU.L&,
M'5@I`*OYD],_@]&>IG9^HO,@XXE43?0U[:R*IJ"FUF(QQ-D<'9#2?V!2H<+H
MP65,S/M05\19.`\^9@9Y#XY2Y60QLEP`;AH5IG[Z?AMNHGA+URWM\87X>\KS
M%@),"=KCW+(GRRQ?D5&E_<X(75`A/'9`P$Y4R);6,D#:CLR$;)'MTT56DXKH
M`=,R!R&JK?%[].2LT-XH#S#V(^\3^ETS-<I_5E&7'B8#XNULBC+0W+2R?C:4
M&"#4U+?ID2.8/40P%7UZ.HTL;]3#UX-J-.!.06)8*)_4@H1B>%%SL=;+63L.
M2%\G(U`P3*A6#/"%4H^`(\-JM_^Z!M19/\4=NUE;^W.*+;\VN+B)K)K^/_./
M^EJTG2Z0W5<@E1;?:DQ->S^679VU/R.RG,]"_JS8MO&8/2R@Z<KQZ_KLN#?S
MMA#S*FVV:A)-4RW$TY$D_.C$H1^^XF*@/`GANXUOP7]684*OE0%1RY@O[&RO
M+R=#*N:*5)SOZDFZG2X4,7?R&CY=&FTA^%,0)<F?\>D.@/Z]10O;!)/6=;14
MPG>KR(B/DO:74U4&D0NH:EZ0K103_,"-'^Q3Z`E^T/QIC;X@8T'4JF;3]9+I
M#3):9OB#(8)ENWGDQ1PKICJ#01^N)N!Y.80&LG@NH:H:$YR"6*O3KK<T.HEA
M+4"GUHKC+(QI=RI36(*O+PA7MQFN[@BN"JE-`I1`FU,1U4C98_L8^'=^$+RS
M+^!L/*%ZWZP^O/AYT*4UIUMDB``@%,#_=+:[_P6N(\4GAT^1P*I+H/$NS%.D
ML,6E4+)CU6[TQ=Y4BZARL)8=7D'T7_&]>9>O\#EZ<.+4=_V=D\+;\`J&<..3
M1@BMWZ`7`>5([<.=:''V?+Y<YT#.3TC!;`"`CT[ALYCE&+A)T0L=A1S15`WU
M\51@U520#P#0".`Y`I4QT`P(LE'(&3P=OF(\->2N!-$EC4MK1^=*0_"SOA+Z
M7,P0K)<>J+<"M43;&9=/,#[X+BQK@FJ=D`/"`?KI?O,(W>@U]/\)/9KM)J5$
M=QV]SV6/HC*:E\NZ\`U/Z_PNQ,)?9!S4ZOCJK;T++G`E8,E'OI="RP#UMT37
MJ5*;K=*LLKC*Q$55I]%PG2I;I8R#YMJJ9H2/9ZSC^X+O/<8]9RZ_.;&7D$MM
MJW_'LGR)TO^$:2GE*48_:#S3G.$0(80/"5MY5U]QMUCP`RA#@-Y-7'L&\X0>
M3`'BJH)R@_WCZ%HFGO)K&)<NSZUJ#%_M#.*LP!P%\&$4?LC43&Y)S[QI[1VG
MO%%!:\'UZ-CO[3`'?\T?RG7FE7)Q]BO\G*4:).U,_`A.ME4RT2V0]3R_84.)
MYRT+/F-081=8/YA+/OV;=/CI[$@MB"M*W)%!?T@/S'4A2MPR^XMJ]=5X3K[?
M86:XEW.RG]?A`9M,"._7KM:KIK/"M``EIODJ3CGBT;-L%:D2(^[<[#2X5A"V
M:F+\XDEZ;.4:XHL^@]O0@]__+_C>4A38_IRB<LK6P<5+$XM=9'KP**,#""&`
M**DOL3Q=(+NO0"K*+KG&E-=?LF579NVD1(4@CDQZR?T^35(G]/SPE?VQ>"^I
MQ0&'$_%C1C.[#@I:MD.]*24+*G2U0426K#9#U@M!817"1\`Z&UCJ4I(J8'WR
M`QA?.RE\C6+V)%)_2BET:D.+^]OYO(850@7D9'1!8[@L=B]9U%E^J_G43?U8
M:%6VC2NRXEU$KT/'IUON-[5?,;]3YXM*$=#%38\@9%$#18T*.;"$M^!JO]6%
M%*DR$_!\=I!9_P9#WTU("2PE!3W@:3RHU<].Z[@24I$JJ#W"5Q^?G0_3+\ZV
M[4A7ZV-*850?6]R`IO6E2$D&8#JZ`'*"-'8_:=3AH-V(ZE;?(K>6#-4_]OX.
M;PGQ\U*-IU1FH^I#BQK(:C7)%QDY`=UYIQ,$(9:.B`,Q891EF]J-IY9C:I%:
MEYVG[QT]%1L/*;;R<F3AFIIIL2M$WM?>O?`$,6QA,51:][')-(V[(:X^V\8[
M(U&(D'83;1V?U=JW_5GEEMY@0/@&P:D]KQE\00?\3BEI-?Q3I+)[2Z46!PSS
M.H9#FQ+D%/\3\FAI@&C[!X@+=Y^_1<]OT3YQ0H]S_$;D/>6E_@),B1X1L2?S
M]3JK\*<&Y.=TLUN6OD4@S4BKKN>7+F<5_@5=>E<.H@QRTEI/^D@7VI8@M)JJ
M_1X@+8OU1?6EP(\\HW?A4&=2?=DLCU+AK,>-D+.%J%M!/Z`!C'(N@T46]3!D
M`'/]S&#Y.<X&<V:ZDVE!L*"G:6I,1S#_R?'COSK!'EYZ_[5/4@SY^\W?2.UN
MRCK@PW]'87#/941T.;B<Y$43F!P@]$!)$*?V<Y)Z@GUY4MJ%E`<BI5-*&6W`
M-TH2!+Y#C^KI7`4(V65U-="M);WP2A*8)I>A=Y=IUX?)9^C@IMW>??@(W7T<
M^^$K>N!+A,L[Z3]QQY[.\W9RQ]`"7PF,"R<XK85U#'?"`&G97&$!Y#R`>]Q>
M/QN6/%7E@[3V,N&HG3Y]VG5]7N0*=5@*C:H*=88I5+TKDHCA=M<EZ[N=JZM[
M=EZ"YBZH?/IGYN((T\+);6LZ'<>]$3;.V+/U5V/#J^7Z(B?:+GC^BZ.K<W):
M-33*=ECEYSAK9]75JFR$@<[1??6^P6>QR+N]2_9CA!T#>JEI5BT]4++?;IV8
MM&1I=W/@DQ\ZH>L[`=5],Z#[(3P<MZ_;2)])J\^[>B]^_'<?QDCG;^]W\(`^
MW7>_<Y')?UF';^)R)'RZ<KF>'/F;J_<J+@KB@%`'OV/ZNKV'/.&/UG"EO&Q)
ME8-=R'9;`=RM*:V@O`UW^S0A#%G<XCC>&SK@=\R&<-_MY71QA#E*+H.8I;F(
M3I:0!%O_]S["==,/L>]"7$L-+EVRT_'9B?_`8<TFBL&MAW<*W'R^%=.#<A"R
M;;45>0SEF0(WNS?<;#/@9O>TQ-7\./-9@YMM(-R&"$F#6_\U]#<(2W@/)WV#
M,;A_26!\(/%_#[%UHLONAR[;0'1->Z-K:@:ZIOT,;[V:=J"+OY.M!UU#A#Q"
MU]<P8B!+[^9]#[/L0M;4%&3Q5Y]DN7G]AOMNW8:X38P3X"XEOSE^B-NK=QG&
M:<1UX/4DCD63P;/5_#BGWIV`HODF.CSN\5LR`#`'`+.@V1.H4Q]Q&K0CU+[4
MPRLBE=`K-6#R9USP%>P]<J$(@%E#?2,<AQ34M?J8T[^`Z>ZH.CL0CXI;)84N
M>HO4%@I7-\@<RE!7)<J_<#!LY7W(!SBNXUD=U-DQJ>)!EW*/DF;=U0Z$F0L)
MZC71"_8%^U"?V.MCGKF'%"J*D#7,>7K&/GO[]A*M8\;TBD842NC0Z:C.T*"2
M"LF0'LD'&E)@(4$0T1(+F4.=J1_L6PNP7*_M47VA,646NI3;++1X0""#,=8H
M;4"7E:@72C>CZGX$U([EYLRIJZC6!Q[O-7//R?>CH<,YB3`FFA&:3/..O8SJ
MRO:R"[UG[L?31+/.5$QBY3ZACWFW@EU8<::@^&]^^G;D?I*Z_TGJWJIPXX16
M#U,Z?2S-7N%D`83SR?.6$SS5HD7,2>NF5(.9HX"FX(<2E>MGUE2M(7S%[?-H
MX_B/H=?7Y2A6\P+K^<I!C[H0P-##(<P[=.+Q=?.4.G%JN':65>V\P%<_Q'L6
M/!WI]-K2W%F7=Y?S%;3.`O>;HO3Y-DS2F#1#2.BMSEWVR'U7AY?F,21\:?=Z
M>ARSW6\J%>(5TMF5Y9H#-6EB-P.TB"&V$8`7L=Q6`'>J2PL@]W'HI\BO7(;>
M)_\[_BGA5Q2Q7U`)/287PB?0;#LOCLUID2,M.37=Q41R!+3K`AI1+=1I<37T
M\/4@I8/0ISTF^]D/_>U^>X>F69@\..\$G5]##\;T5VW;1+U?5]U%J`=OHM=.
M+]?SI4W["%'J(",/*#&0#P#("/EOQ]RV:?,4XXIOF20^OZO0:#JP)>I`29^A
M`3@O.@WUU:*.N?PW&,+8"9"GO/2VB%/<QQ2?@/A(;ZUCS#1=;RF<U3M8$>[%
M,YMDH71&D$SL=9(@HZEG=I<IJ%T5%)\?=6HD=4[U@@99G>]%-&,@MK@AL]B[
MYN"L[XF0J2V*-LU!M7RYC\`W0&Y#T,B.P<75)B4<_\T/H.,]N3Y$(B6WH<MN
MW\EZ5'68S>!#-)Y:3!;K"0VI*260D[K`'1L5M^&4(HS5(@R616=_32F"V17!
MM'?.[(!*$;WR))>#V1C"\#J.DN2ZO.F'@UO.X\JQR^9%V#)F<Q2(4?QB:H"0
M`Q5ZJB$L2R:+(Y-6*,L2T!XJH!I\=\.JQ'B'2G1$S;?;G>/'T,L2W^'K(W2A
M3_:L'F&`]R(O@R#ZAK?W&"%;'PH*(^@>;(DNYN:S_(JCG#@HJ(.2/,CH@V(`
M/;'T6!H@@"Q>)24%L0<]G8'S`"NNAL]]-:4/J*2I;WSC)[LH<8+[S5T4OMZA
M0-^CS3+H5E57N?`@4LJAVX\_X=W,Y;R&8=K@.@;Y.'A#%X\$R%!Y#Q(ZF`'%
MO*.KQFZH)J+J^%!5AWZD#X/!,>0'*%(+]D,WVL(G%"&3XI*.2]583ZM$<#L+
MPF7CJWFV/J6$0$%)^X5K,B2S!TBF#%]\4ZM!B*,*`U!RAT="`3:GI1_O#7UH
MJ;(A;%<3:\Y`3$Y.:[<^62*V0T=`1$WX:3-"#H:.]&(0CKBG-_COZ,=2OS,)
MUGIB=:))ZU$,>6)V(<J`\Q="!BF`*LWG*Q!7,:Y!N('TO[?AI>M&>UQAZ+QS
M3KAWOZ<67WQF1(UOM5XM"XP14B"GB5L%Y51!1E8;S"1*2Q,GN6`[MF`*@25F
MD0UP">C$+("5^9S>'[KRJA$P*_D13]K-9R)(*RF/>;1E&-R&2CVK02[F2J@?
M=<=F*@:\AG:,P5Z\A]5F\7V^>O-5W=AK\"/N]ZT%'WN8<->%`IHFNE-DSN<Z
M(AZD92AZ$X<]#+03=6V:D;)+?SS:3=8LX1$%LFW[K!UOJ-ZKY[,C:$*SI;7,
M[M<N8./EL/%#]'/60")&-!5OW$L4D.T7<I(`T]2P>2]12.((;JH?3-M>O1BX
MBNUZ`268,=.6;!U@R#QRW_V>UCFVP8SP9&-9O&5D!4B$K"FSZRG2-A'%%$S?
MU,JP2/Z\VJ83,P!VOX.X6"=\O79V?NH$W1MPH@2T0H[%E6A&'JVPIASL%>1!
M1M^$S;LQ5$``27L4DUM-HD)PI[P$-BC#Q5_-`FN7=?-1R]6@&?!]B.'.\3W^
M(:O.U[1"M<Z+<(N.]8H'T(SH.`>M3LGZG"(MR?CDDIFY\&RW1S[,6E1B!K@>
M(6Z4X*;[F-3-X88GXA!K?5DKT-HX$C7`]<J><.!6(PTRVJ9,A"?+329!<L86
MH<Y/B_E.:S?'?N;*1R!30UIP^'#//=!8_ETEFO)!A>]AG15[@.`!W&L^>SB,
M?;I__L!G7IF]-\VB9M(U^:2D*Y$Z\3&&*'Z_#+W[S<9WX<=_[/T=3A&RSQ8)
MO*4Z;=G-DN"A%7LRG2SF-'=9$B4K@(B0!3"GJSAQ*5M$JR$B/E-,R8*"KLX#
M2++EM5L^:2]YE>0XQ1%9Y#D%%:5CFB/Q!(IY?7I6Z@8M)2R&]VY]5.'DUS:^
M^.W#!9Y(`%62`9@.L/1,B">+5(L)"Y$\1$?G),DSJNI\R11?SM19I_Z?T&F?
M*UL>4SXY'O,@>H1SM;*M938;-NT`-PA5/0>>*DD[2/]3>CM8L1GN5&D(/LLT
M+:&G;^9B`Z*<JA@2:YN;WJ+`N]WNXNA`FWIS%V6\-U3/5.ULB'KWZ=2N3EB8
M&*A2T[R2DR6A/5!"I3,9WP2/)C2.6B3-:TD>4/KHXS[!^.##F+,8Y#VO?J9C
M,R.Z6K!6J[QX!9$#57H@(ZA\UI,EE<632NMB3YJ(]F`1%<V2W?"J3)<=6M$R
M;W86A&JJ^QQ0ZKBP\HOT1J_@Q!<'<^>\@=PORFN)`[X,RF8U?D'F:767TFWX
M,O3(-59X7D4N"F=.4E9__,[7]%A[*R_"=?;+Y>H(`B096*4)*%'MT#A=U':\
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M\T-XF\)M,RW7]VWE27MAUD1W1R?+Z6R1I?`I<;)VJI$')7WP.QX!D"$47Y\T
MENR6.;)W)/Y'4H`M30%JM@5Z@[O<).BG036^B'F5F^";QOF@7K=WS:W)S.KC
M?W3<W#:&R#W<CK;;VL:0NX>WT7Q#6S_DBCN9H?>R\1W,;[$3II\@9#>`ZGI:
MDR-I8:7/-G96<G?YBO2+S]^!792B4?%EO3'$3?!PN5>0V=LK'@ML(,0MR:B5
M.0?'#T@O^S0"+Q!`)PZA!_;DKD"W9IM._@E5%S5(4E3-Y1!J`),;K1M6'Q]S
MLG`UOU)\9RWI.T%8-CT&2P5ZDA*$I83?9Z/YE-(T0VUHX83OM#'U)GK;99PB
M!K%X?"7%:^C_LVR/D;FNPEF-(M@!QB_1>*)9F6Q4((RJJBL^0"1K@ARU^Z8W
M']**D7KBXU@'.N#\V?FO*+[>)VFT11;):1/>\J!"4!^/+MPQV\KSA(0&*(AH
M;05^HCQ9OIV^;D##;[8556V>(;0>L_^.;TCF5JK7GU%J[)6!A6NUK=DDMW/R
MNN;R\^%"V*)"J+/N%F.I&W935BTV36_]YMMT[1F5-ET=6'3&M]?SK'5+?G&[
M9IL>+(0M*H0RFVXSEII-'\DJ)2?Q.0KA^V<G_@.FGU`XVK;KT[86%'E-=99"
M@"?!A:HU7<U6V7$)0A5L"5FPP73!!F]J'LBFIE>05IQID"ZL50I+R0)"MWT'
M5T/V0;K`=OO7U9:&Z('$(A\AJA0=T]\79POO-[48DWM;"_MYA=,BDPGAZ]UG
M>?H.D\(7]]67.9JO:)$C7V.Y8\!M+)W&5IU*^4K0@A687CO)VT,<'7P/>E?O
M7Q/HW8;%U9^7;NH?>*>3>A!0B29AKD2#M^4LCT`1;8")@YPZN'H'F#[N:E;>
M@%L.H:?B=205+'(5N%@%NUP%+^]@4XCN<$57ALS>IEV#:C_UF8W=C@K!`82,
MQ'+ODQ&+R60@IK57$HZL%3K18HUL@NA;0O/KYXMP7N7A0$T:A/C;\`"3](39
MNHV`?H2W<"7<@]->VP+(+D8P=;8^507UV7J/Q?9#]'^YV$;CF&/6`OAEJ<YL
MW`Z;J7F$C,1Q[SEIEG?8Z8UG4V=J65IIG:G/%^$#9NHN31J$^**[V-"9NHV`
M?H2W<"5JPZO55&2F+MNR&3I3GZJ"]IFZ<G>&R3CFF+4`?EFJ,QNWPV9J'B$C
M<=QS3II.UI/U0#R;.E/+TDJCO^2Y(7K`S-RE.4T(IQ>BWT4)9_*M/*,6E^7`
MPHUX%M-%";GL\GI,8!04[:+$Q_65'4`:*,;4SN7PJ1Q_"A")UEXD2OS!0#$:
M4FB+5`:R7P8CT787PS<8)KBB=OQ/(E`S?`)$Q&U+H?<]=D8-Q]J05KO/O,Q/
MPSQ'U]%V&X75%CM73N*[(E].@(HNO]O-FJC939?VLM4S@V(,\!P!.DJ]&149
MQP"_(5D9BU8(`B?`UIN=L'*I.I(W)]8>&PTQ>R9^!75I-L)O_&"?0N]DV\GI
M&(GRC#GA`RG+Y7H@SK.13$?Z$(7\H%AO`&`8VJOZE%).BX9&JR\70B_YA`1[
MV+\$OGN_V4!\/]O]IL)!6XUCC[=5%]>*LR9Z&-2>3JVLGP"VSEU&G6;.=X0^
MOIV*#(!^*&P4CZ&XV'8LX0M?E5,'F#R@]$$^`"XBK/HL#<6W8RG`;O_ZY%SD
MM]A/4Q@>F<)^AQ2!BULSN]CX\59;T6Y_O!>UNSUUJB<<^7;INM$^Q,DCQ&R(
M?G1I:X2'"''[3O_W&7Y/KX)CGS:8C-)@I!]OPB>GYG:QH?(-E$.`^AB`DL__
M\SL>!Y"!M"5?1]1'?@X:40O>P6V2[*%7U<U3ZH2>$R,W<.E%.T8\IBX4&6;\
M]4AD@#;E!")1^`CQ@08<^N!6!:UN_>@AY6%%DP-!>UI-)M:$!@^WH4]ZB.!>
M(3'IQX",JGD0'4T945PT%]'5'N0T::DWB?"=S3D-TA5$1SQPDB!V)LB'N!1D
MOT.?+$SS;B_Z)G06;LIYNU5V.:#=X\-]]YO+,-P[P6?'#U$`Y""&'ZA6'C/S
M;OTDHN\JA[@@8SV:R.1G\RAI'`0ZA#C8EM1S2RI\@FJLCR*V51$;+0LH<5"A
M#C+R(*>OPSN,(KHM^L63XI/K\R(]@5PZESZJD^ISL@8H'HI27F-GFSPC2E_Q
M.HS1&XWWX7O3TN63^C(J?#GSQ,Y[M986N\L&`1L4BGQ[\]VW2H2"?O7F).!;
M%`?>-]]#H8S_^I8FFIS6N'II.+%\,)"/!O!P@(S'[#FHT:V-JYSL6'(`W7T`
M$V04![PR@M_=8$]V?YL6HMW'#74<1SYOD%ZE^L!"[<_1%;R!!QA$.^B1_I#;
M+8Q=M,S`_;LNDX<&4UQO>`)577YQ.,M]YG2KZ2&WA=G3#H]>/C*Y)\>MC0V0
MM]PU&S_J\I>J]-7PG*6;>([`%03%R%F[UIJ^+A/PT'2H.MVH*IW1ROP*S2P=
M4#$W[3[T=,=SY$U/5*^6='/&>E&O^`1?VV+-[N=5)I!93`AG1A?+HW5=69Z:
M4].4#98B7&/E5E;3)QSAE*5YNXRNEL_EZD-J+))'03P76CRC*T[(&1`TA_5L
M8D]9RR)-4_<@$1IPS6EHG$T'B4&`>7/Y^)Q_!.T38=/JCZ:UFIRC`(XL.3Y%
M,?1?PVS>Q%AHS)P$&H]D!2;R6?H3U0WIWASWB<J60KF1[<X)WT$,4\</DWPQ
M0)*;S>4`#>GH@A@?V')AC%\"9.LM]J%NYS*R,AGN*$NA9.."RL!'ZP.JP$=F
M1D&Q%QM97S;#^*Z'FERT3Q/?:SU@H,5]#O9A3'\[[(M(==!/I#J15@U<)I>>
MY^/1G.`:K5F0\NGJA?!YF20P?4`F^N8DL$@8\0SO9-JZW/6IC/>YNF'6]-JT
M7K3PU_O`PUD;G]9U.`EP"G;07RO\Y(WO,4=@E[&D;U=>BRH;/IL.7M3$X`J8
M0G<U!C*G3E@`.0]E8ERC\U:KOR*MD]>$:JQ>'L5-';EB*?K5D=>YWVQ\%^)K
MO\F<P6V(W?ZLPGQ.*P/B_=+SAD>4#"CH:.Z4?;I4=F^I5&5PN.95S=ZPE2`E
M3KD/8>IOX6<_@,@AA?F6/<Z_/CB^1Y')"T;Z$5`=<?3B3O2FN=5JMLHVRA']
M#W@`L,U'*$IXZ&[0#HW2O#)'<:@PH@ZL3`=$!<4`13D/W>#!@^0!@,89?T0U
MV%4U%*%A;@CTZQ]'C-HF_4&8+V;V_GI4[ZB^[J+P:0==?^-#[PZO_%`DXJ`W
MR=K0V[OM"3#I8QCM[@0$Z!'=+J8G>$1Z/B;)F0$!YH8LUC`_6;J#<&2R[Y2N
MT,'N%6!60,$+(,R0%1O1)TVW$89,=\32=5KWU9DF*S:9E]N7-G<>?KJ'RQOF
MRD6_A);%6KZUV=F>I^U)E0NUX^&%ST6OYGG`5>Q%C]VPI_,4^*GR+.AAF.H9
M;W(*)MMN9Q3[*%NDL<VJMD1C*$$K$NX@"C:33_MT'\/L&J8,WLD-\\95T;=U
M((;/DG@GD;QG9(DB2AE0TB"_8"LG#FYTW=XZANAD^GO&L-;L,"3*M.#*I-Q9
MB"&OU8$(*,5@IW*]C^/C+-%`(N:YF(PS4=-<+/*C3WT\#<A&,=KC#-$$<3S(
MOF9G@-&&(0^`:E5#!B,67U5Q@/\)G;@S7A8G9!YR*]P)=_V;+*P!Z"57OAP@
M(&,9C>&A.LEQO#H#'+>8]P`L-S5E-IZ10<G!<T'(2#SGW`FO-B?Y%8>]\8R&
M.@\\#]))CN?E>>"Y:=[#\%S3E-%X?D:CRIF@*Y1,1'3)GG!8:0V=HLE89X'I
M@5K)0;TX"U`?V_@@5#=T93:LOT5R0)W3,1+2&7/"R1Q[/AD(Z&_1><!YB$9R
M,,_/`\P-RQX&Y:J>#`;R\QN,H;-)V96!O>F8!^22.>'`TI[.!P"Y',AH&`_4
M!\V\<T4T#,S'UCT`S`UM&0#F^\T=3!((;_P$=V1%7'?U`NU!0!]\.5P)7S6$
M],?`+6YY0\B#DKX!G3]'T@'!ZI/[!KU]0$I!<G^5N2\R6NF\T`^XKYX9>]7"
M1LX!<Y<>#4#Q(]+\Q^\[7*OS!0KN.37>T8?5.B.BIKE:SED[2I@@R"@"1-((
M-)X@9=9T%PD%*0&#H-5N>1PTM>A!3DEL_.J$V?G%R]#[XF#?=+^YVB=^B.![
MA_[W-H7MW1B$WU5>PBK(F*`Y+2UKG=?J5RB3L\24-I[:<NK@=TP?D`'&F='8
ME:9CR&T9(W='2>@8PMNRA%=3[-D3S&419Q_=J?`[SS@6&O"5Z7N&^1O"E&BC
MZ,7"7O7P-82V66ZFO[CB+F9$<4_R+OUE%O<L;)E-<"HUI(HZE%)=6E8!%>;P
M&>(H\+V<TP=D.CG4[S>??-R#V'>")_0;VGRSX]YE.;15KBID,"QZH':YLN<M
M:*^-2W!0'1FCH1@;E(-KOZ]9O>J.G,9%0W=.4W?1(-TI6Q7)1&)M]23MTYR=
M@^J1DI0]S+FXK1-2>]9JWA:O#/1@9N5!=:J4>K8#C`\^_$;<&+Z0E!S;K(Y]
MMLY*-(<ZQC?0XL+2MZP=2_(%J99?U=_ZK$IGTL:`J/DNY^NLJ1$A0QL4):`D
MI`G-)\MDES*1AE5ZMR9X]E1#$%-N;3!`?!2M?^GQOBR3R_MT[)=4`X/)B7B-
M:-ZJD5I3E6!^_/0C.T6O""MRQ*R`)K]V.-M]^+-V^'3:X1&.^#K1`:@')TY]
MU]\YM`DUPK>?^A!/?6GLO^`[C=%,^37TRG]_=.(0/<LJDSN!H$(@#N=2T'IG
M$RL_:E8;"Y2#@<IH),2MC0?R`>5">$UU$\)7%.5X/!"K4M$,ZPAO;?^*NSU4
M%``S<MD-X_A7:01V-6TFI39QC!O1V=7S/KPX[A_D]H^P>6&Y3K=Q.MJJ+N7$
M+R1EWZ%QG=A]V'['3EL*6/15U;L/@GR)MJ-:S]>K;`>"G(<&:/A]@&@=6BZ:
MPQ:+%B@P:WQ2OWA45[.R4122N<;Z'8/@/F1=U*5ACV(4N8NKBXF\R#,%>X_>
M1D[N+;UHNX\0N[:CUDW:-C!Z0K[8P^BC3CVA$`7CIRA^1*J.]VZZQU>H,^='
MQN-*PYAV'H0/ILRL10V)"6[R#FJT],4?,F0CT<4#>@_/DT'A</4&`7P[JT_Q
M'"7H!,ES=.G^8^_'\"'&*YKT_0%]#=S%O>B*VO%9!0AH`%(W5\+F-[=F#6@]
M1R"C#G+R@-`GT7\Q@F[`R=8!A6#6:C-O'$BEQQ,;Y,FM&I/B9MV&4D'-:<$M
M#!.:]B:)B(<(.1.8(E8Q5U<PA!N_SU;78'(J,3V01^&J],4DVWS/1B(PIKFJ
M^F`@'\VL#2HE"B+Q[L?M+HC>(<P50=R>5KR?"(<:^D]1HYQ%^,;_)XQO0[>U
M(W[K(\H7U?7Q!==,EC5?KK(FMI0"SF^K7OZ>PKI59UU3]_[3Y;`K<NCLU<^S
M]W*EV2*IEDD7:?:+LX67WWUFNKSZB,K)L3*NL#]?3?*4-GH0X-?![YB`KOEK
MJ`RVJ`S*IJ,60ZE-,4U)=5KS381S4QW?)'M(@T73D86+9:;YE0D5>Z`D-%OU
M`#F:=LV10[5EUXVFS;8K\FJQ;D0+QC'TGO`=4#?^P?=@Z#VB1?,#C&]PIC*^
MW.);(%F?3?A]E9@094JT:G8VR[L(%*0!H0URX@!3)Q?$4_J`#J`)2Z/(3V!V
MZ;HQOF$MQ$4QQ8:.EPV1`+0<W!4J(O>*:85A7^NN(;27%O6#]\[_QSXK\Z-_
M@*'+J@T2>5,;8%O9$375^6JQ;(=JA2PHZ9J`T-,%IND&NLT-=L@+D<O\ROW5
MEW>`%NGTMV]1X,'V_D1Z<,DU7#8BV5HS%(M_=0)FNWOAU\U")>%)_)J%_.IW
M,6@"0MU8@/:7G<Z@KZ\QV94`047J'=<A&83+FA'W!&>I,3GYO]J(65^4?T?>
M#3E!-$6[.#'W"C]%\<<`NK3<_<9'+A'1;VU$<!(]Y9G%$Y@5OJ9H/9EE'0M*
MQ-++8K=9%YHW.B*><[(AR17T$`^*JWJ0T1U@G.)B-G++=^J$Y/GLZF.R*U:G
M[(?DM?)B6M5Y3V6*;76%>7N?;$10#DEJ%/)!\5F@8E@=655E6J*K^U(++2:3
M133@FY^^@4-$2B3SF^4WX"5R8@]L24Y4W_7&,IQ5F>D]5?OZ(Z0')[Z/R:$C
MCTP+B&UR0;/0?,Q\65MTQ.)(-#ZPYVN&0T"4P7U,C_MY-"0B>09"WH3@2(KH
MV77D9++P7P+8Q/@%KH`&!U9`J"=`ZK)A=GC$U9E^<-*KTB_WZ5L4^_^$GI`=
M'+VD#8Q-3D27TNOY;-(.0DH1E"1-`-Y)8G8#+@O1'*[,>H#'LD\VX%IU90K0
M;I-DWPMDV0N:`4:Y$';S:!',!1<E9PZP!H@G#"J?*:M.0-7ML`M,%?V8`J3[
M<H79XT-7W](,J0HKHMY\8<UL+JXJ-,T!UU!!A1$6C2PU8N`E4B>W9;=D842%
MU>E36B#9Y5B:.M+O7<0S]YJ3]+URTM/)G+&K;4SBO;\\70["''P(9M)'39K_
ME23+'DFN[#)Y@FB1C=:DUX&3)$?I)'RI38)3;=WYP&%D]:;0!_'<)Y4Y;\^D
MU_.53@*2;&C@XK';,NQI/KS6U+@"A;4[)ZHP.C"X3$`^-"!CMV7.B^&U9\H5
M*(WV#JGNM>CR>[(=#B/_/5RGFB*+G>-[60<4_D75[<^JC2Z.&1!N_[2<E*4X
MF$QQ+8#6FZ5/E\FNRI3UY=%=3\.VJ49HP9!=#Q0B%T(O^82$P=D$?.K_-O13
MWPD>]B^![]YO$,QYBWG1]Y5"1I`I49-#1E=DI2EI@&F#G#C(J`-*'N3T=:%K
M#/'MFOC8^(&?2;VC4D<96=+Y)MH8`LN>]EV':A]%2EH;"`YY!3<1;L1-_Y5Y
M$T9-S6DDU:\)3N)7T*@7UFJ:G^^K&W6.:99UOY!ARW_G9JY\):!.30-<'Z##
MEO_^R/$&H\?_ZE35PTVR#$GC.D&*\ZFL$4[7NRE!T?WFFA3$D>5.CXFW_I[F
M(*C&C/`57.OUC.L![C>`DJ79`7."GN'BMJ$X%Q=%-M7:2-.BFU9#[8IJCC5E
M$NZ*3'(]Z=#3$EA4#,`D@S7A=I:+J=V-T#(?WTCGF058&;KHA*^A>Q.#S%\$
MVSREZD8ZX>1^AY<#R<?O,';]A%.)T_6>)C2W,B.\OEZL5VWXI<GVC"HHR.K'
MZ^G2VI6NI$[R5AZ3PT<7\#FY*),:\J36@4RNN;*PR%:8)O2U-PGKN!*K^SVU
MZ.,S(UK<L5HMROB6V1M/^QU5<N6UJ_)>9`([/016"#TQ6VU`3T!71D'OZOT9
MC<WKUR/PI@GP*]D1+H9>+>8"`+QZ!YBRWL8_DJ7NAN%%E]#:@7ALN4)0;&C,
M*##V:$?9AX0)\!S>5=&>+VT1G)K5:7(L/=206X>LD2@5;2G95U^R=KW:1_V8
MI/X6']'ZFL#-/KCS-Y#<.,N"Y:G4-.QU#615M/?_=+E<E_M<U%IWQ313M$`&
M,!\0[,F(($!#JM_24J*-;A]6#`CHB``/"<B8&IV:4B71?C;'>CCHW:`ZT4]4
M]Z9.4:-1X<H1RX>C2H!A-$P(6-H8$[YJ>;F:#$,[P\HU!BPGZ\&FUUTY"6D_
M!?SM+HX.4/^E%$.L6BAD86K,*/#^%D=);[32ETR`)^%$>&]U-1=901":AL&O
MOYS'*P0S+IP0,D0A@)4Z,0I1=WX(;U.X[8VJ\D43D%5P([PNG2[7(HEL3!@0
MRJ8MRH>)+)++[I!9._B.;%8(@'5]&07"+[#W+A)^Q03@(3Z$JPU6"TL`<HBB
M84CK*R-G,KO`]=[CB(?WAY6(MQ@@GG:?48&8D+?(E6*4GWB(`M]]'YQF;[YN
M@O]H\"2\+[NP5@*^A%(W.;5^BOSGEE9GF*\0'MOT9!0V!Z/2+#SVW^"9E0W,
M>8&TN1`<)C(!WY/[!KU]0`HESPB(PR!H,OC0R/P+;P3>-`)^!3O"5R7-9B)I
M(EH8H??*',E"B]>#F'##CKCIBH&QKC.CT%AN!O6UA,J;)J"Q9$<X+IL)U4=6
M-DH-P^)`D0W;`!U@HD*H:VAGW'J.<C#T6])6*6'4'`^G8TP-!X=)T:WX)5X5
M-:HWVO*;U2H%#$LZVM@UR_T+.:2II)<_4JB2@;4;TO1BCV,J>JL[!+Q&=UU'
MEXIUA!N/Z(OR:K[+ORL,'8I!A;MCSJ;9<IF\JK5`>QCSM@CSJB;X(Z.H3N-U
M^;39;.MUWVU/J+;;/C=,XSMY\Y1K]O&UW)%]J@!5ZS5@6=AB($<6//AZ;$;`
M^>@<8'CE1RETW\(HB%Y]F'!OI>>_H#J$Y'(CW'IPM;)G-%8D]$"#X(6&&^PE
M"F8Q!=-]O;U$(>WA0BH)T81P5L1BW8K1,H'!'?K^;TX"+U]C2`H@K_$=LC#>
M.2AP[+QH7/Q]E9.?*%/"]PU/9EDQ44D:%+1!E;@)=Y>/(W_6R;J/J,IFV;Y6
M7)N#>VE+#T@3B+3QAM9J-_``@XA6]-+.4$P;X+VC%(P<1H3;),SRUJTY.;)<
MKQ#,6ZKI0IPL(>V:D#A;X94$]6),P`CKN.K2B7%8XJ_D!-XT!5>]%D[V:KV8
MBJ%+]Z)0LLS'8.LKLQ'HXZPO!15F'!)I.=`0,\C>-`6)E!WQ/@C+A2`2*6$#
M<3A`8CX.KZ-$[ZFL'I8J#+Z*EN0D?<K!/J-8-84A;G=VN<61["/I)X7/;;:N
MV,7>5)X&$F)+-*-@+VPKVSNL(:M"&E#:H"2N.#TT@L#'KD2]P!WYHA&DKKN3
MJL0/SCMQ*7R1U62/>@&V3".)ZTNJ7[E_"?Q7`M;K:+L+(/[IQDFY'H7YCBY?
MPF)(_$(;?):Q[D6B@B;NA)L1!1ZBJCJ]+%7(NN<H:8*2*,!4-;H,.8+:@E]3
MNZ/H0N"1B^#J1U/$G\:^FT+OVDFP!\/_P34)!R?`)^_9T2;_-;6Q/I<7X4/1
MDTJ@GU$$F!:9I,D/%:K:HGQYLA*8T6DJH3?)^1L?R>PD("XU@-N?ZKH>5>ZG
MM1O?EB69PC6,$/8:"YANC<B*,BHC?7+\F!0EE7VV&/-`QTL:X@P^1Z+U:ZOU
M>KHH`HVJ#8$-H@H.F"SP"KKJ0PV9<K;Z04R5UN-5FNCIB39DRFJ*7^@'NVIL
M(:`-;<'%WDWW^-84Y*L>88!+U2_=U#_XJ<^LK>[_ONIP0X0IT<G)7DU6%;SE
MI$G4D1$')77M?9['D=\^EM\9(K_2N;N/:1]-XL(J-!*YXAUH!Y$R"<\G=&)=
MS5;K'M`VJC/MZ'HI^[V!C]_]%-SYSHL?^&GK!HHQN!;L4SM8>]K1CK=V",,)
MC`_<XO^.MW1A^)@5X5K[=24_7X$KIIAAEM#4>X)`HJPMLZXAW=P%39().89B
M#$/774<G.*%7S<#97=_6:`MK,A,#VYWN?G#2Q6[!'1';Z2&V`4@\,E]!.-YI
M;PM78R[C2N3CYX_JPEPVONC2:C99MDYH&1D#T#1$()JW=MUX[P3@Q0GP;JLQ
M"&D8$Q,15<%-0<#U/HYA*)2-:;RA&0\9&Z)6A(^E<6`!,G+FP&.(?)7E%<3+
MJR!?7H$/P&4+J!,T#?OKPDY5*Z9`Z`N2O#>**B]I!E+)B:BMS5?<*0:4%,V!
MTT`IF8@R#4?'1M@%I89&]*`I=5!<Z'UTXA`QEJ`)?K_=DZS)#=SXKL]&5.>+
M2E'5Q8VPS<WF!;(H39`3!16J(".K"UY2Q<U#NT(XCRV<.H2)&F8=94**T8.T
M`PSW$-_[^EOL\(I\FL\IQ5%C<.$EPFI:;*<1$O2N8DI$%TA.D85@@KP'8DI(
M+QH8QE,W_C:!)96E$-*/T(U>0Q]7?7SV`S2C12'\#-.WR"L?X!;8]Z:BOG"E
M+XL]*K(GJ[R2A4*D,LH%*,8!=*`+4'E,4QW^N+JP&+HX4H4J3735OXRK#N)Q
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M>$1Q^B%X@$PL]+)ET@+<Y_:]"J;\,@&;!3.7R0-$7P\AYA7>;[[`],E!X<[7
MT(/QG8]^G^"33#DGG*\UB)PF\`_A5=#^K,5LN;;K+B)+M>,.&[MB0'R190A3
MD.`QP1X/"H)\U'(9H6?M,+Z":DXG;P9VF8!R0'"_P3>4`S(F((."8M02T_K\
MT_A*HELVSG=_N]^"N&Y-55O2[<].<25-KS=8JSHR>9BI^\U3BA9+N#OY_>8Y
M=L+$<4F#)UZW?H$7%6;[NKD1S05;\_6$8AO3Q!`F5&F#>O2O"F'-K?DERVP7
M,D>9S!=4Z$A<:%6I1'&KK287!16F"X8)MV5X]0G%P$KZM<-&B\]EB:!$<Y_O
MH0+88@*HM/B$W9R[*:64,)L2S7.'>>JP+9Y@/*DZ.&YG0S1BL:;3O"/GY2N:
MF%^=%()=E"(:/MD4Q!X"1VXTX-TV"U$2X!P</\!+'9!&X`4"Z,2X^IV&QFX4
MH+]%,>T(J2L\EJ&B"K:/,\L:HED9,E7@?OQAM46G?`06@2='`5HF,_<->GL\
MUUXBZ'A^L$_]`WR"[CXF+40^?G>#O0<]7&:-VXGN*:+O-_F9`Q0X/[TY,6Q+
MQ(TTB,HI52KGPJUK;#N/:[/Q<31;Y0"4+("<!WH&H<(%?JDXS8,8`803/:DV
M`Q1JUQ0:"2ATTU1HU%>ARD*.46!<BUKD?[CS]G<=590C#'26?J]OW>)\.;'&
M]'VZ"SPU:W8L)_AC.#]>->I('TZO$VSR=N4DOHLOKL'B08_X:G%/UX^:%G?6
MBT519"VM_&[>JL]J<3]D-'JU$QT/D`&-<DOC:>C(]]ST]3NYUO!.S6WH1EMH
MF@<:!*AV-]/_0VCV)=M=$+U#Y!+C@^_"G&?HX8\(PX1\Q<N`\$(<8WE&!HGH
M1QZY\$ML'2ES+#U^2)X`PO/_8F*W>*F,$9!Q4GHJW)&]P@PHN<'OE?P`RA"]
MK\V4U:4N_1[YN';]?G@YTN]%5<'1(`5K<'?R,<]PAI*_YP_A*L4#,\GCG;/+
M[!FZ3*V5M5#A-@V*`#4J^LA_DBW@#RUZY5S\?;9^4#`P'.'[Z/6'G_;I/H:?
M_1#7'CWB;<,@WQGY%,7W.XAWXL)7TA<MZ;DH/86V%C]W`L,]&@2WA()T8)"-
M#.C0Y3$4-#@H1@=T>`/7KZK41SQ5IK*'V`]=?U?55E9"2#KY<<L'U3LK"6AK
M=TRGJEZO$WJ((\1A^OZ`/CYN)(UO/-NQSACT?EV+*^'S)#PQ6[.6[<B<-B#$
M25*K(&_**E"B_/DA/4+O(A/:$15:/<C%K+D=QP)JTPO56GO1\N:3'@FD;@I:
M`-O)EG#[C_6\!;/U]KG5&X*,2M[(U<+1DJ*N!:>/%M3C6-C4VZ$LIDJ#T)PU
M"[YZQY?$W&\PH^*QOC@E_>CFL2<<B"[G+;F)]B;95^_TWAWT`+D'Q*28?1S%
M$.!?OZ$'T4+%#X%I]X"=@``!L'>J42_H&5F+.,:?BRP9KM[+9_)S.M^<V!.;
MX$^EK\5!G,BT:$`[F2]7QVZ#G<&LC(_=2/7!XC`=9L*4^$&E&H\3EHS]G;H:
M7]YK#PJK4;UOD@34=H\EXTN9Z,=(UOI^AW],LOL8WWOF+0<3-LAS=7,K',FO
M\E9?0BZ+G@/,1LZO/WTW,%NI1&_MFRJ9>@KMF.QNQ/'4Q\\(JMD4!U-U?U76
M\57LU&\FR7Y+?S?8V9PPB&;',YQS\1W*=4?<5)_'ZUZHX`-4&#':)2G2Z)%[
M^N3X,5$7+'P4T>?')/6W)%&#?I6^07"#C_VA%^C-%5])KP;\^ZO`<?_X@$A&
M^)`8I?'A(?9=_,#GR(.!:<[N=&QW.;X3/Z9.)YC@Y6N(^S/$^8ZVG_QQ]8[_
M]Y/CHM%%/5T?2AK<60_VA`.`V7I=]UD)30%5AB%)(S0$7MR1_]*Q#/)*8RF&
MNI[]=NO$[]B1/-0ZYESODS3:PKBN+1-<QP!$M/F'OFJ5<U0=(D&]1__U+7V.
M;N`!!M'NNGK@NK6W0J]7E1]F%^-+M"VHM5JM)O1T.Z4,8DP:GU3W*/'Z"775
MY]+'D-:J2$M(@^<(9,1!C;JF)A7CB6X?B9X.$5W-*?=^X"V/O?=0G"0O$_LP
MN;20?SO`./510/.`GH=Q#&GXP_,R8J^J]S)"?`EW_5K8I9?!E,&EA?Q*01OL
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M'X!(&N('I`O:F%?[2JIR7NV`77->Y:E'HC>X&KR4[WQ3CW?H8DLT;K-G"VM>
M\Q)7QJWCY<IJU60U>A$O5W!;BN`*?8DH:!L^14AK^F+VJ]XQ>_L;RF/V5C9$
MXUE[N9PUH&<&W&3+:`^646W,SC7#XYB=K1B)L_3UX%FZ\TT]LW076Z)7DDVM
M];(^2U\;-TO+E=6JR6KT+"U7<%N*X`IG:5'0-F9I(:WIFZ6O>\_2[6\HGZ5;
MV1#/.DTF#>B9`3?9,MJ#950[2W/-\'B69BM&XBQ],[S^IOM5/?-T)U^BZ1I[
M/EW6ZV]NS*N_D2QMU5_<F%Y_(UGVJA^Y.8_Z&V'X-B9L,<W)]#/#ZV^Z7]7D
M9R1599"T\*KN9\RKOY$L;=W/&%Y_(UGVNI\YB_H;8?@V_8SJ^IN;X6[&4"\C
MQ?36ZZ4U6=9]C'DN1J:H=0=CMGN1*;<M16Z5KF6@9S$[Y7#3.^70_H;RE$,K
M&Z)']M;6LHD\,]`F6T9[L(QJ4PY<,SQ..;`5(W.*[EW,PWQ#TY1\6AF(M9A/
MUK/Z7(RB0"-F8"F2U1V`D94\<@2U3Q)4Y1S;KY"'JQU9GN#@PY@+_,H#&G!>
MCMYG<5>&V/A]]1@>RK55X5HS.H>*8(N*H`IWQP9>A5E#3"V1:FO/)5;DU/ZP
MROBTE0/1G:+5K#B[P>A)IBDB/5TJNY`J:U;H=DBE+`;E&E@M_&1K01LR7CA=
M#[.FAR_-OCT?O^]\>ER>7N3"^^A2Z*O&GPRFA7L$SXL6Z05=9L?.HN]I6[_.
MDH/L4B>-6%>N0>(>\AYGK[@1%_0NP-;Y3BZ104QOM?L(F5`[<BO2%&[.''TL
MP5$',=RBC71HJW0-N_$3-]J'Z:<H?HB2]`"3E/:A3F/?)4_TFJ3&XT)[5#&:
M:,+W\2YG$WZXTNK\6KL<5KKU51L;YLR2>Z,J[((JOR8%169\%.).\=UV+NYS
MN(GB#?3)'5/(7^B][$Z/J^@.X\;];F?OE7-;NO$/O@=#[Q'9D0I<M(Y[KIZW
M31A16*\6L]7(OK;P%SE_X)'A+<[,N9ZL][H[]7+UO/LP:(W2S]*;\B`^FO]D
M?IJS6E'S)'M&:Q=+]EJK>\!S6'-W2B&\A)PN5W(6X5VN$;,%K#-;F<O5<]T9
M.@<8XT:W@;\AW6ZCW7@A.1KJ)3H+'5EU)=65<[[I#&$_)R6_(?9)?IC0^J]1
M@,C@Z\14!]>-D<\]O*Z+(XK;^631L?<B+\`N.?S10NP3=%]WF8>"D'9/J0;H
MHX?8+9_F['TG:3$?0W@;(G.'2:K*<[:.>ZY^LTT8X?L/RF+*L;PFO4L"\0=R
M!G\4IWFRXHG+Q%0^;+!^_%P_/U26EX?QT9PF\].<E<N\\T-XF\*M]"VSDO`Y
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MQ&N%U&L5\`1.P1MP,'/`S[A3?>S+'%6//T$`PAS(N=-Q1,T<=9.9(W\3F1]P
MS)A%%+K0\DC=^)_EG*/B@^,'^,[P3U%,[F(?.1(Z&NX,8^2F#,)EC=926H;S
MV!/F7)&J?<+7><?,)VFYS(>BZ;C0S`9IQD^2O8,<U(\01+.P.T8LW?HYSJI@
M]#[?FH>QZR=8EMLPC?TP\5VR$R6]8+1[P',H&.V40O1(\GHRG\HI&+TO:GL*
MGD#!5+:;?6[UHG+5W$@=^(5R#D0Y9<TH@.6`VEWBJ*B64AXI]I7.*AX\%HEZ
M?MG3.W.<<X@`6<P+5XY,I])*=MJ\'^7FS`(^*4HEGNY+D8+):%Y4M:/=KXT!
M2RDQ'O<+G+D7^QOT7]]2M%RGAR6RO\"'V'>EEROV'/T\/1Y/).%K&>SY?$P_
MF/,(,B;S/^(FIW[[HN^L'*2T;T#<9D[M`T-=/Z(7%7$+(_G6SH^G=X<J8QA7
M9GYVXC]@2B+:^PVIH9":\.:/=#8[4EPQ1!M&3E`0,Y>U%94OZC:XJGM+>"I7
M?%JZAQJ@6\G3#:F8ISQEJ0:<A&75&9FZYR11OV0J^=1F<2XMPB*&!YSTU_/;
M<A+RB:=O-75_C7,,QC\5+7"26X&V=Y)'.J,@NX5]T6#.FA<WI,OS<"4[X':<
MQGAKJM20I">],8/GDW4[8R08,L)(BU$,(&X+UUZE=BXQ,@>M,N-AUO<P(O;]
MC39!;`3JCW#K^*$?OEY'81H[;KIW`GP6?HP)N2<'YQ8K]Q-/-`Z9KJ9%WWQI
M,736$!-\RU,*>=>-..<6WY.3LTOZ2YQ9<#WFQY`\)66L'N=W"FY!A5W2,>8,
MH_$Q/T@MX5.HKZFTBUS39QNJ#W/ATD+X`9_P'$-[(N;847UCD#,*Z.N<"Y_D
MM!;C.,[1PGA5&?`3],G:']3HY\8%H<Q@O47OY^^M&KZ9_/$&+4.+E@1*C+B;
MB[/U=YVB"9=R3N?2JR::#O$XI"1/`,QPI3O*C^`WY7Z7^@YBOC@BJZ8/'E8>
MV80XJC=[_='\KK`[&<\QBWW8<_3<]_LT29W00Z%SO=!N),"PQSLC;\P40KB$
M=#F1[G<K3#5K=<_3M\K1LGBA;E2.=\[.LQ/1,MTD_QN=N4,<M4SW>)SS=(#]
M*DI7ECVJXQNQ3'='(H&/X:B;::<IEK635J%Z`3Y235TY`>N4EB15/:5.G)JK
MK+F(LJ[@JQ^&'?HZPYEAO%+G]H]RYC.!AE)GT='/<]:04&9K+Y>6]&QN=2[1
M4>JL>I*1]AUF8N7./_Y,)$VC\P$:_5&G*]4UY7V^YSD>T6;+Q]I(M4<ZCCN$
MDS,ZU#U`/.'K!5;3A=S3WMS)CUT'`NSS/`D^]K<1+0BY-RCOI,>GR#PY/O2K
MGN,*Y:\PP>*%7G&!4(1_I2J%)3S\&:U11&42[C.Y6DEK293[:<HC0$Q6KG"+
MR*]5)<-&3_Z/\AU8I2J90A%=7&=.%9I&`-][J]TC*W0/,B/H7M_OQ_2]&I)&
M)S+U0_EI&0OQE2T_Q23JO7_(D_8*/YO@`?S_W_I^U3D5"9_^'%,M5.R\D*@H
M&!JK%QYSN#-*FK!D$*W[F,Z6MMS,2.8DRIK&RJUN9]H'3XJ2RY/I91,$/&A"
M_*<!18@C`E=FTH+[,8R,CA.6MR?_\XSX0Y[^`9G0%V<+;R*<>1D:4@P9RJ1(
M=@#_PH'.?-6C_4;"#U#I_V)^2'"*.0*8)?`[9<K4B][&UB^]PO<?>WRQ,=41
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M&DP_]9T`[/8O@>^":(-DPP4,.TP/[)!L"4LVI?Z&[PXTH]5_#?V-[R*W<NFZ
MT3Y,D08?(J1/'R;/\'MZ%1SWB._YLDJ4"W$DW"9VLEIG'J"D"TK"(*<,?L>T
M`2&N:[="ON3TJL7]=NO$[WB'M4,)6G'6RXQK&!37FQ9\1IL4S?]X*R/_\08>
M8!#M<&AP'25I\AGR2JV%WU>)4E&FA+.ZUC0OE\OHD9W$XA\5ZH"0![_3`72!
M=10%V#4%\"14!LN^UEM#9B\E:0%GZJ0D;+\.G"3)FOI??O<3UF=G/J\2?"PF
M1.<&>[W*LZ4Y*4!H%==E@-\Q/5W8DB(?#9V)5%&W5,KPU&5P-?QP%:$5+[2H
M`:^!HQ"O>D4PT_J.#MRT,2*<+IFO[29VL@J/DJ`9\#E9S&KYBI!PRE'$,\-6
M)#%UHA5-=WX(;]&/G1`J']2!FV)TX2Z_\^711/,[I@((&=T`&2:/W4\>Y9@X
M,J96(-1EUVK]]YMK)WG[%$3?DLN7A)RO[?IR;:_H0$0+'\)!RK*H+2IL"85?
MF!X@!)&?S4CJQLFI4C80$_604CEZ.,;8BB.6;C0CZI,?.J'K.\%#E/ADBT(8
M6>Q7]2",R8_P7=2+];0%:05=D!,V"7%RI#Y&7F^I-2"PTW@92.3K3"LBG_$E
MLUU?G3ZD`V5D9.$H:+FTCJ(Z0D$W;/J+T0SFV&(HQT'-9%HMOA17CVU'[A]O
M4>"AST.75<S/<_2@4AMOCBX:N\P6JV*I7]+(5ONZ+/TD88BU/T<I\OY)A=*_
M`$@7^7_RX,9W_?3/>@'`LJLZ"%HU8080.H,MY@M:@=$WQ)A;JP43(`8$4U+D
MLYOR':-%R^7)XM;'A\T),1+KIL^C,5CYK<['E=^AR>9%\$J_R6JQ6MK9A9=M
MJ!@[_=4&>;FRL1&O+;4G5\`CR(L*J.86QFYXE5<F=JC$C.GR2Y3"&S]Q@RC9
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M0;$N`)\@2S8ITV]5?!B7)8TZW+;"I0[98[&U1;B8%>C=[+'VZ+$\<JPGN721
M/Z$;B>S"+-'W54>[(DP)UZ9/[6D3.,CB*/'\O"TE#ZKT-8:^TL6WBV.$"?&'
M2'X_1%@+0^B27?1O?OH&G)*\]LBXCUD?Q<?"^C,.M5_@-_*G09`M7S8%KP5'
MPA57JZ4P6!%Q^G<3H3I,<NZYTK!HX$_.E8($Q8W:#LZ.\-4;MQ0D-7>%@C>6
MO$;XI2/@"CNENK;D1OW<\6Y#-]CC_M-?0[3^^!;[V.+OT<>_#((HQ=$Z-^P[
ME;:V%<:)C`L:]7PZ7593"8*N#!0,@"H'`+,`"AXTK5I4:J[W)*!1<X(+)97J
MDS*3J%US27)6QRLU&7HW+E(D?VQT./2&S-;MA$R)(%NY$XTK)HO%4<Z$Y4CH
M$\TVIY(#K#751@A?<=9C<(`E02FL*]/-:#HZV/"%HRZV"L>/P)ZCJJ_Y%,4Y
M`_>;FN.A[/6>4GJ2-RH.Z\>[Z(QH3V?S:BB6K2D\Z@?H7<D7^8(CC<"^&C]L
M2$/'K)48@DJ$XPDG9P1$A!-=>63%.A3TI<]1/01#/)3=V.XWC9`L<SZF168C
MJI$$9Y>>1S)1N)R9J@V'8=3VB)%]*(PLR534L$TS0[9AWDTL:AOP30P*W,C=
M)@,S?(UW]8=G=89$@X_%W+([O0B]7\C0]-X)<A/8-WO@[1#C;XZ9`5>[P0K$
M6"U*DA=647#CFS60F)/6]E,=#VL)>=HX$=PQM28K:UXMR\ZB#K##=]5@<CKB
MC],%JCB";()[R`72U"%+IG3V0.G43>$\)-4G9*8VM$RO^Y<$_F./&Z(<1/J/
ML!Y7.8DR>!`^#SU9YIF,@A(@I$QH22)#.'N0<,HFR`Z3J\V)/'48@!=^P\;6
M9_4AI5<?PJDU7R]9,-';<?%DJ1CX,*'+(L^\.,`P:Q;I[-[#>EP?-OKVL['G
MRZ*C5<.0#.C7(T.V5I`8TZ6GP^`X4#&@.T^#H<YS;LSG->*E]S&N]=Q:,P&C
M_]2:%/':,6,24/@'T;A*,``JW.8Y;8_J`TB?$QC3R=*:LF(MK?UT3I6)$6D9
MT%R'8U@<2&ANM--@!HW':[?+>%HC)C(6A&L9YY,9`Q:8E-[FNA)$:T='AVBZ
M$-(P-AY(JKHP!"?\Z^.9S^O%2K^+QM=EO7>[2>F]@EV*>#S$F'"A>I?A=:!&
M]]7FB"/?\YWX_<D)H,`E",SG%>.FE0GAE-!R4DET45(`TS+D$@0I\MEU^2ZH
M@";=A]!E>TWHL'6B`SK%4JDC]77\G$*H'`TN;$+V)-MA+!?JVK-<ITEC]Y)&
M%0J89E2U_G;!M5A]['CX4I_[]`W&V9U;R2-TH7_`"R5R]Q:K&:C8NRK1(<*0
MN(WE+4,)67*'%2&<7[>6@)(TO7=-4R=1^6+3DKQC,;4"JX^EUL`FK!X]`(1.
MLD?3()X`:0DZF@U)?=^_PX!UAJ'K+:6@X[(BG&R:S"<YW"C!++#)RO)Q)$<+
M0S%574"3)ZI=$Y6TW\B+KO6B3,@<Z_CJUHIV9)$:/)'/2A_4A1\RNJ`=S2;+
MR;P5,H2*KK,ZI\HS:P.&DY)>*/\+6+.+Z<K*:\31KY^009.M<S"=7`!L"L!!
M,_4-\N_TMQ;YK6T,J&J6R,11J3@MT$$#W&\J5Z%S4@CMSZH$4!L#PC=8V^LL
M04U24&B6J1#2FC4X72R[$"NJBX4!\B4*/SB5WZ$H*4P<EQ[XTY],X%I@#35,
M->D#SB-$J[J]FY(:<&[>FOV\<@"U,"%J;=/9<EX'48V8YKRU'/%J8!(73RU>
M.(9WC!F61G3@YFOH^8@;_V6/HHN/3APBEA)\@,G%X<9S].#$J>_Z.P=?"/X$
M7<1SZC-/#0VEIA!S`UD476*LE_E.4FT@D(\$BJ'P\<3:8*`<35<(J40Y),Z\
M@TGR*SY%6-$1S'7D%#I*(["KZ2CAZD@5Z$]$3=4EG*)R*8>9ONZ0;&'Z">)4
M366T*'R$;O0:DM.A-XB9ALWT?%GU82=AS@1/T]C6:HVLEQQ^RFB##80DI-M5
MR8.XI`\\-(#B0U$C"6Y5!4?$25JV1AY4Z`,\@(8S4R,)G^UXQ%L<@^!NKLYK
M#"&KD8^2DU.]85N<I.JG(YD^YL%YQSJK#$//:7*^)/,53?Z$Q8]HTUFDFNFD
M[D5VE&3-;]!F$'H\AQP1:_XB(UGS$)2H/A\A1TQZO?OW'71QN$(_&W82'CS`
M(-J9X"*Z4-=T#%S%:%FCX,8*'Y/4WR*GQ%QZU!]2N:*HC2R\W;>:9TOWK[0;
M24%!SV+]!"GL7(JH0PIEX7FKP=2B[F-IY4QT3[_AGBDAR8>]PM!%H3J[-0#G
M:>73&Y,547^XG$VLK-/D5_`$7@MR*%BB]%1/9Y)$LG*12G(@IZ>S/X`L^0A\
M^\JF9@+K1%,Y=_&5H6/:^AO)\O//.=>?43AIU086KB->6-F>3?:ZYN/,PX6P
M1850-66U&DMUQCJ65:--)VCE^.B_OJ7)_3Y-4B?$G4OY'ZG]%?46W\J':+@S
MM_-,2$Z-I$$H/5`AJ!4/IXO8:!%%[RK[EL$E\)T7/V!<WZT8+UQ#;($/6S4Z
MT?0E2I]@F@80E\7=AM=.\O;)\6-2BE#>9=CQT06):$"<&&?"/<RF,ZN!030`
M*$<`MR'`8P`\2-;%K1Q&U];*F,J8G0U<^UEZ&X![Z$\+I"'V+M"[1,$H6O?0
MJKP;/\"[.[0TK^)X+KW_VB=M5QR<2DTER(>Q*'Y]O)T5@^<#@6RDO#XU&RLO
M4JV,!LKA-,W'"G1#$Y";#713DG?$U/T#-&2C]$0XU!S`"<HTQA/<;U@<]S$A
M#A7=R&>S)MR&;947U[(0?[_A@-X@I$O2!4%X+O"W7"=.II/R$@TWVFZCD%/*
M?KH:HM0)=*EAP55#37@0\>U!J_?K=@&=7J]#HP9YNR,&KYS$=_M9#X.&?D_7
MSIAP'FJ9WPK"\7,M00T99!1X[R)\*>%AB*.3H(HI\7/DO1/AK<W=2]"".4H0
MN'YO1%SP]-!CRM/LZ?GN3\#/<U1)_5\F]!VBA_Z-_H5^>'$2B/[Q_P%02P,$
M%`````@`)(%L0U\W`>?#.```GTX$`!4`'`!M9VYX+3(P,3,P.3,P7W!R92YX
M;6Q55`D``_.8@E+SF()2=7@+``$$)0X```0Y`0``[7U;<^,XEN;[1,Q_\.9$
M;.Q&;&96.N=6%5TS(=^J'>NT%+:SNGM?*F@2DM%%D6J"5*;JU^\!2(FD1(``
M"`H4Q)<JIPV`YWRXG3O^]-_?E^'%&B4$Q]'/[SY]^.'=!8K\.,#1XN=W7Y_?
M3YZO[^_?_?=__?,__>E_O']_\?1T<1-'$0I#M+GXJX]"E'@INGCQOL=1O-Q<
MS!)$4)1Z*0QW\8"CWU\]@O[/!?UO<`&_^NO5T\/%Y8=/%Q=O:;KZZ>/';]^^
M?4B28#OF!S]>?KQX_W[[O5]SRGZZ^/</ET!<Y2]/<18%/UW\1^57UPG*/QP`
M33]=7/[PZ?/[3Y_>?[I\N?SAIQ\^__2O__G_JJWCU2;!B[?TXG_Y_QL:__!O
M[VF/BZ</3Q\J3/[/B^<X(M!ZN?*BS<4D#"^>:"]R\02L)FL4?"@&#0MV+P#2
MB/S\KL+A]]<D_!`GBX_PF<\?MPW?_?,_7>2-?_I.<*W#M\_;YI\^_O7+P[/_
MAI;>>QR1U(O\6D<Z6%/73S_^^.-']M>\-<$_$3;*0^PSE"0(O."VH/]ZOVWV
MGOX*8'[_^=.'[R1X]U_T@W]*XA`]H?D%H^&G=+-"/[\C>+D*T;OB=V\)FO_\
M;KF(OC/D?_CQ\P^T_[_<Q'ZVI*LH"FZC%*>;^V@>)TM&];L+.N[7I_L:^4O/
M3^(%BK!/V`I*B_7XD3;^*!SO8U=JGZ#G;\^PY!']QG1^AR.8(^R%LYA@^HGK
MT",$SS$*=(B7'/F8;,R\!&E-A,+PZ1M*L>^%YAF[A^-MB29ABI((EL`:=>3D
M<#SC)%][Y.TNC+^1^RC`"?+3CB0?CM>9Y!M,_#`F68*FR<*+\!]L=TVBX-%+
MZ2_GTQ6]*N!W9!($;,:]L.N^[OI-@UP_9\NEEVRF\V>\B&`9^UZ43GP?+JD4
MKM)9'&(?HSY8[_+AH_._:W7GX>17+\S0%^31[G1=[HZ$"2$HA6E\P-XK#H%N
M1(Z!D3YQ]G`$>6N.D@0%SVGL__X7+TF@_9:TS5%1:R'%(D8H\>GMOT"U'D]H
MC:),Z_3OBQ1[&!VV(D_(1WCMO8;'A4A,R=$1NB4IAM,2!5\)FF?A`]SO1SF,
M&K][_/4!&D.0A;!:;W"84>'F&?E9PDZ]V^]^F`4HN$OB)=6.LESK*YJBX!&E
MN6@$B_[Y#62ZHRPCHP1;Q'L"OP_D6;CUD@C&(7:P[DJL09QG20Q"7[J!&_KV
M'QE>T;N[)+3IK]V@TOA>S]SV(&/*?\;DCJ%BQ%L<!B@A]*OIY@;!4L1],*CX
M+9-<T@T07%'[V,S;4&![41)DO](O9^7&8("SO]&3`46$??[V._VQZ^&E_]UC
M<;]3,*8KIK%^\Y)@=^%/HY<W=`,_3>>_4!'Z*X&S$GYU%7K^[S`&$$?R?K,$
MEFBT^!('*.P1LSZH/>HZ*^CVX7KJKA2I?LT@IP^@CJ+;[[C4JGHX*F0_TBM?
MUV]>M$#D/CK\DVGN1)_JE<>[+&57*XY\O/+"[6KZ&L$EQ%I/%@E"W2643E\V
MB,!U'(;>:YQLC70/V*>'[NY;?=Q[FM\TRO5RB=/\6Q%<.DR"1E%/QD#EKQV'
MT_*$_((CO,R6^0ID:VV[^DR9&\R1859.#S(__8+A-DSC:/<UH/`IWG@A'+)]
M;H/NGS>(Q2TTCS<(7:$(9.QT%GI1#RQ+?\6HCO]*T#\R0/%VW9<@+_4),PZH
MQSA%Y"7>6;YW#B12=;?`#B-QB(/M$5N-`*BX^<K.)3,OZ'MZ%8+(I(/)$:GK
M&TZAE:4GD"2_.0S6M[^P`<'NV\.`XH5>35:`*+[<-PQ;6Q,]L=.JP:GW<T/I
MRT."H8\UH?']WC?(@9&.MNU]6<A_MF\`*O$.\ZKYZ@F%U!1S'1.@EMHG:N:)
MGF#I2LS`P>IC3YDAJ6_@GD!'2$!;R!*X!:B&D%-7&+3@1NA]QVE1,$18^EA$
M'>CH&Z)6:TOO*T>+@OYAX5HDC@"(TK>'!44?VT>+@M[/ECTC3/\GK,0'>Y=P
M86?FNW2:OJ%D!K=?@E*<A]L59IO^-X@V%;U+NWN6GKZD6^YG"@97%8L)3>BH
M<0J-4130P/;\M_1CI@+SV>>!`""F]LV0YB_$21W>XI,L28$@_\,B7G\,$/Y(
M$:<_,.C?__"I2%'X%_C5;Q/X=,!B.T-OL1T.K@\4_OSN\.\?>Z?G.DL2%FE*
M?"_\&_*2VRB@GM4&TKA-U:@\7)3T-[]MIV72,"V35]@@'HU`KQ$EWZ]_'+=D
MY.C,4(+CX`Y^1QJ`Y+<]-IUT%N6H+%L>C\8<&?Z";&YW//I>8%@!6>S/_5.3
MK_IK^&!"#?(!^OY_T::!K.9V1Z,/1*`X8F8-IFV2:9;2O#*:\\<G5M3I6)3?
MX1`EU["R%G'"Q[7>ZEBT/:$%ID=<E#YZRZ:UV-AL1UWUFITD=4J]Q-^.!S\>
MW+'US+RBQ<<5RZ)Z[[_A<'<]SY-XJ7)6;ZF(&W;319P$*&$IHY]^^.'=Q6H;
M_O^0L\PED%&7HH0@UI+VQ'$"%/S\[O+=14:`N7B5^[1."YX]>:+$YW+$1W"7
ME#A]'G$2R@4E4O\Z(M4BZ958_=N(%?^6*F'Z]Q$F@0A7XO0?(TYB9;6$ZC]'
MJ+BR:XG2CR-*LKK)#C20./L%[4\?]^U>_5O#)"L]:.LS<X^\,DPR\G[A>:M<
MJ4%A2K:_V==NBE__MDW$G'D;:A`O]OZ>CM/26%\/ZTYW&=3YB%(YZAN[6.(A
MR5`UW;R5`4Y[*]3OXA-G'@[NHVMOA5/891S:.:VM4$[S_/>-<7M_M$<7QPS+
M:62/SI:U6FMCG4HI4/?;VJ":UF^AWDOX'XU(6GLA\V>FUUZ2;."F9-E:'"[D
M^EKABMYQ11+53;ST<,1CX;"A%7I+644(^'XS&[3>%)+2$TSV-?P?IX]QY`LW
MI["+71Y8M0SQT<)I/`"Z%8#?;V^#^EH1GD9Z#ROA6*,0#K;#<,UVLIN[#9&7
MEBM*NKMEWL1[=R"RZR$9\N@/04I@`2VYT-)ZYC2WM4%UO8R4Z&)M:FF)XA6H
M*T41`?'2;FYKAVI.@#_HNUSB!5UL\,!B8;%/8Z<;I5H.'ZW=K/&RC>LM2LN*
MUY*HQU`X:#UX6CK9X2,%E0(%VS)%$]_/EAF+LBZJPG!Y:>UH)#[K&27T@O]T
M'4=KV(_X-43UL_`+6KZB9(]*I:XFZ;S4I[.UJT$ZK[3);.UID,IK;2I;>QJD
M\D9_;;9W-4FG_MIL[VKC[-KY$*HVDLEWS+L*^>VM4O\`Q^@]_-A*=MG0*KT-
M'IL674&JJU6>7O):'&+J7RJ5,HY-IZ2>/Q#-7EF7'YCV_I*P8LB;5K6LH:$-
M>HL"Q*S&"7NO@1_E*M7%AC-=[/.AGO,6/\;.8?[9K1A$>6#:5<02(XWX0Q``
M7N/31TEL#"@1<BON4!X?CBFM!,:M($/5<Z>*A$X<89QZX2D@P3$#5P&1=,V6
MD4PN;RD)O,0A.B5,+F\P"9@X-N82'[?"=]6743W:I,1%)UQW^,<1/U2"@J)F
M)-QA=>GF&I+'JMT85&+E5ABX,E;MQM(2*K?"P)6A:K?8EE"Y%0NN#)6$V;@4
M-/L.`1\Z5@JGU6>W,C1U@V6J`H,HN*.4'MP\NKK@UN;D+;%S\RSK@ITX"+.\
M!=P\V;H@)S;FELB-YQQ_S1T$GY:P:1B'3\+P:>B"J$*EDZ,^?'VR"U"BUB5N
M;IJY#"TP3MARB9Z.]>ND5IV"I7`_"='5.B3:*/'2!5TM2*('E##>TM6:)'I0
M\1)O7*U'HH>2>,NY>8*WAIO57&,-IHT2(#>5'GY$VZ'WHD%L<JPJBQHJ\L*5
MJ]59=.(,ZZ)Y/9;O;'9;+7:Q$9'#`VL+S@\C.M5]N8/%85Q4U+;&_#17:Q[I
M0728&.]JM2,]?)I":?5*&_V8(Q2A!4TR<@DC;N&8$B@WU7U5=TQ[KEJ)F)MZ
M?U=S916AOM7]X=85FS&<WU"*?:!V+/^B4OX%L)LF#.:`'><SE+#J=3P&)'I:
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M.<:HMKI,SR8L50VBPS/<U:`Y+7@X![BK@7,R&+4:WX[W,.`8`'X2.'4)`!_!
ML17_;3DZ[CZ"/Z-)"#1'\*TULA(&%Q-6YZ`H]<9S21TTLQ.T5">BQ0G%;6Z#
M]FW$[%:BO?((]CF$-[<=`M4W.,Q2;HP+K[4-RG]!$4J\$*9_$BQQQ%XAIWNL
M6`P<#MIZV>`D/R9VYT;+HN>UMO.BE<\V7I'(RZ%XOY4-2A]1F@/W$!/>$5AO
M8^6%K16BRS%:M-+:U-+:FV"/</W5Z1%OPI9.EMX:0B#YT%*[-[!,PYA5JQ:S
M(>YCAPNVP^Y`3/N%U3?B4K[?SB*U+43:I:WE,#YH9N5E`D1+6*%@LH;MM$!;
M?;:XG&5#/U5'&1"G!\2)9"^U,:RZ75NDX;WJ(Z+SRW6[O0I4K8*CZT9[%;`.
MM<=N=OKAER!ID<;KFV[_DG#=0J\`#G^5N6ZG5P"I4>#O9J-W:H>UJ1>NV^D5
MH-K3<+M%T#JUB#B6N4YQLR=1KK0#1CL[8*>06==04M0_.L70G@EV?"W5]:A:
MGHFA7K)LS\#:*=[Q)):4#"P-=B[70QP58"%=PQE5;G_++E;Z+MI=&'\C]W!J
M)`APL6"6F@1_STA*"2(O\1/RX\C'[-VQ4B![B2FELR1>8^#[:O.5H.`^VHG_
M$S_%Z[PRH=C@V,NGK+AZY=ZU:_;[2O5UDJO?+@?$%PB+.(:UY=-P*G2#\O\K
ML<<9P@:/-PC.+!^S$XO#0ZV)#1KO/)RP=5">`]/Y]C$+#M'B/I8<WK7IOH_V
M:K'S7=\M_8;%3?D&I3)#E:Z#X6FO#KP*3_M=C=1`./Q2]4&</?)D>@P#Z;WJ
MZ-(P[_<;!C<[N:,HN-@>W2([P##XF]4>4I7F:J_;,'AI>L)`FJ/&SI9"?9H$
MX"+.N2H`\^.`9`<8-G\M>TUCH`'Q>Q^M8<5UF,^F`8;-G]Y\B@8:$+\-"JH:
MGTT##)L_O?D<FB9_&J&5H"$45I.)#^IG@@!6`#+=S$+0@ZB?&G[+@F8X+"@,
M8*?>7^PC%!!J$Z4)<7"$H^F\D@S&8ZNUGY4J3H6?#@5`"1611%HYI['EBEH[
MRZ1\):W#+C8MSGU:->NO057M+JY'JAT+5=X.<CVX[5CXMECB7,]F/Q;,*@:%
M,PB^4S2NB)%L,E.Z_VR(:13W#4!Z@5?GC."!\=_UBH8]`'A@FW>]U*%I#)MM
MGZY7032-XH'OPO4@+CT`I=Q7KE=*U+=CUVMQM=H]2B#=E`O-`*GB-BD1U<G@
M&'YPN;Y)OK8T%4R.>CDQIR0UFL%4Q1GD>AZ-OJ-!)F_$T8*J9D#KQ_SA>@RS
ML04K[3\\7ART]3IN7'^#'G8-J_*3XR4#NV$HO,AV&%ZZF:=H"$.AR%IBZ.;-
MI(JA6DQVB9[.W>+>22@9J5_"IG&!K-A<`&5)>H;@_799A4_#?I;#=QM)*S8V
M<I%N,/'#F&0)FB8++\)_Y/,6!8]>2G\Y+^[6."+E$^3WT3Q.EKE'UD0D=#ER
MQ?#!RB+/$NSS7A-5ZJH?34&0_V$1KS\&".>!%/##?OP$_.JWVRB%R:4"=+**
M<\AN8%GF931WO]KC0:&CE1C;V;3Q(;[#OUN)W"IR<'?BWS-:,)V&%\7%;6\D
MGI^S@:XR@B-$R`/G43VUOL>@M.GI.?E^5LKX50B[AJ,J#HL7#8#*6>7TK)2+
MWMT9;0%.9L8V,F]-QN+[",X_+YQEKR'VIW.XGV@"/X(#&FW_Q2F=:V1(*U%J
M<%\7E:H?O27\^))X$0&4Z<E9>]]I/U:MO:.9UTUWEU!PPQQRN52;%PEX1-_8
MGP@<[V%&:P5\A?L[^0:B`0CYTS5*)F$8IPVAG&;'MC)SV2M!_\C@\[=K^(_P
M;FEN.P"J7^![HC==.:T'0KEX@W#;VZ(>!]A+-I6-VX)\<WL;RHF63$"U%!5A
MTE5SMS9X$K*AJV9J;<P,WUFNOD76#5]I'=?5"/)N\'46?5T-'%=6Z&I1]CS)
M9O?*B6N/OW2&BR.0;`%S[K4<+<`4]_HQW]2Q8Z$V:J"01?A<'KF2-@?4@C]+
MTZ;KR2XM^FO+A7`V#SNWZ<H"G`Y7DINAFJT:>0TCB7UYO$5EU[GVG"V7@!K`
M@1<1GF.?1E#F>2-4U8+KP*?!`MT];(8J`AZ2UE+7C]_!BM]JN?(P+*-=0$:9
M(_:$0AIL2O75;U2)X'FV%$:P].!/"GHCT-'LS.:PU=K-:E)FZZJK7>`J<^RJ
MG4P/NO;%<SP;V2F<R[M6NZSI+^P!7B:>[P3V"2&(AL57\]C&LUN=?@HCV2%=
MSA6/?&[[05'?-@FM_893-U5^;N3[VZU&RL"O;]UBAP?3".Z5+*'&1*IBQU&R
M_2>MDL^-ZNCG&Z>*4E-$B?GQK:)SM=G]^&>,$KBZWS8/]"DS@<-2LK-5ONZC
M59821LPGH;]>U&,H'%PJ<W`Y,`X^*W/P>0@<5.0E<KC4A3$):F/8>49X=UZI
M7_R2G8W$)7V)([3YXB6_H_0NBP*)BURZFQ'ZZGJ))'7MG:P\]5F44GJ,TV>4
MIB&B-]1]),>7YB"GHX`:E"E<-TM+*Q3M"0Z-"\_5<`,M_.1/25?#"?1ADSB\
M77>T:>U5@;VCFSMI^$EOO2C@4MB>SVNNO6,L*_UV*V=Q'D!S(X]DS0S.QFT=
M%V4S>\7]L"8UZU<CU'*6`=>E?"U#22.>3?8ZU[V?O:!W>8B>6_D"O:+W^1`]
MM[(!](Q_M1>%%4U$QZQM?%)>^=D6"19K5L"ZG9?-Z(-7IY\:C=(-K;P?1S#=
M0OM\<UNKW@:QU,;$M.LW+UK`;OL*XIL7XC]0\`N0+7@"QM#@0\?E:Q2_TN+!
M^5D$Q_FV.AS>[GDY=[?)3YTX9E+.;U.?&8J7[R\X?3L@F-0I)D][FE-Q8HM>
M&>[G6R-J&M^R]);S+B]F[^(AHLQP81^+_D&A-[_>Y@2]>\;.3M?5?Z&\U:`S
MG)UBWX/DTF:-,G`6ZUD.ZAK;[%2*\!U]KCI*^:X;)DYZ[]2*+RI%)C3M'H4:
MC"<_5_SD=;'<=#Z>HQXQ[F?/N>]'DI+IJT!S!*8QG;390(H2GQ*U0+4>VU>.
MSLI`R@D]O8K1&]V:*+F'_X1O""\;=;.6QE:2=.#4@-G-2X(]8?+[%8K\-YCY
MWX5VV]9NP^!ELR-+H-^W=AL$+VW&4T&'0=!?'B.?9#FH=AD$#R)C+*>QD?/E
M-L0/.`PW_$-EKX61K_Z"0^0%SW!<`F>T>!O_\[RF-F;MB_?W.+G.2!HOX4X6
M[/N&AE8*4;/R%C5BA$<OO[V9,L%ST'03X6SO-[%5QI>(2\!66I@IS`OR-D8)
M'Y=Z`R/?_/K\2[Q&243%VPG(=C[F<-W6^G0,P+Q3UW4SKJPDME\EAQS:<]T,
M1I85[X2+Z0#4LUM60GN<6&QSO4*56.`3KZO]M>B\24P>K":)S-F2EP;6TEE9
M[_CB>JTB-U](=OT`;]4/RBK<=0'5=?^N/#`"^YSK\=GR(''5?==]G?(0'>C&
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MD$?06QP&,-T)W`RL?J`07E$/&QS,DGB%DG0S"^DQ'@4[5*\V^X_E[G$BTW-0
M'#5>28J\-8XQ*"X/'^^5Y:W2<U`<;:&>\]QQ,CVM9/GX;RC(Z$O`?,P%7D;I
M[J?C!9%'Q%6#AZ[,4451:J>X^N!$KP`V7Q&N>YT49``I%*M7D*O[6.,>KIO#
M.6J=ZU;,CGBU*).N&SHUT1,I@:Z;/14AD]9173>*:BXUH4;L>BB]JL`O=9M6
M+V'GO>\Z"*I+A,=T.)^"L;Y$_0:'60I2[S.MU\9JN-U^]\,,2+F#><IO849R
MT10%CRB]CX`$-(/;^0TF>+3R:SPZX,$%'2W(%D-:)<_GD-[<=@A4%RM"DNYM
M:RMQN-M%*WCUH-[F)*BT5):\1L-D[>&0'M$O,1P7RSAB+Y-0B0!.3=&Z5AUE
MV)R*]X+Z.%8LLAY<HSY>>?2<+&\$N%W2!+]2LN!>_AH%Y;^W>YQGJ-4?T`;_
MC91,0O9%%+S$''8XS.N.9J5$/\*+-SH=:Y1X"_284?F]6(KL\";3+"6@@@?T
M*<#@[QE)J8C%X5QWM,%POA-V#JA5X5@PRH`X/2!.=&:KC7$67%;OX,'[8_8D
MC$[&QY,(?E>#1_L",/'Z@4M`*DN(W:R2PW_^6PT^Q4/,==.D&G@<W=IU6V2'
M#5I_@4+#?;R*":96))<0ZJ(,Z3F0Q^N@HD9W*P]ZUA="?3O_.&[G3AJNWE/$
MKMX;RNIR"9].?(-K^YAK02]AZCN0X;3\4Q/X?2#OH]K'=_1-:=#?#?+)DC+#
M8]7(V">(RM6F>0!!O'V?7SQ!!!]::F09&WXXV-`\16%H?VLW*U[BY2J,-P@Q
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MM5=C@]_^ZH49-_)+?YRS*&MX3-Z*^E)`S?;'&[1&8<SHNHY)RQTIWW^0M7W&
M@F_ZV`E]:VUWI.N&*SW4S.EX>I:N4\K`,;PNF8S0S94[_&#]L7CC4?!2N%1=
M=^2.!1R/!=E8L%$.I];REFZZ:?LM;^F6@[:SFCN6@!=[O\9JH0-"</3Y%4!,
M@@#G)-Y'\SA9,A)LN/ID=#^./4:JZZ`,FRW)H>W]!GFKBFX$N>D]GFYE.2.Z
M4OV"PI=N;A!(:'@XV_$J(W!$$C+Q@3S":&(_)DALD6_O9V,C-E'%]\'Q6@^$
M\GS!W$>PWA%HU?>$9"B8)O3_]!ZLUPG)_RK/J,[@5J(?0H\0H(-N).&";&AH
MD=XBE'&:/-&2&K??4>)C`A<S:&>[/Y+BK[SEJ3748'C>K:!=H-:U%X8HN-IT
M85]A5$NQ.MN:1]?>"J=>F&^@)[ALDC4*[N+D+J,&'[;/(I_G5E,?QS*W.7G/
MV2OQ$_P*\Y&E7R,L.I,D.QOQZG*CL?,_$.9NP`>SH=;7S@QPB*N>VU]7<502
MRYT.]9%LQ92!9B.6J_<:&5E#CR@%@=A'*"`TTG26O8;8G\X!*1PMIO/*<FY:
M10J][2@PU2F_P6L<@`#\Y*7T(8B;.`R]1%CZ1;Z_?>X>,*R.H/`QTC\@_CDL
MT]-0W$DM201'>)DM_PR*`\UUAAN?JBH+!,?^;8C\/+SY!F1M'\9O?,FXTW@]
M</1K3+.V\YMY0IX1:)^P.-@5?T#5"XQ+J-+4SIC>L)9,!+O=O[VTZ;[GG+I\
M@X'2*$9F\LE;H^@*QRGRWZ(XC!<@==U'/K_>@;B#R4(ATTBU/@BOAY7XI)PD
M"0YD>IC$]>5;K(@KKX<]7*^4<6WN88^#:V4.FGO8X^!&F8/F'B8+N"BO;6X/
M*[A2<;Q)66EH8(6^%"Y@%@E2L<<(;'#\]F;F_,``^\")_VYM;@?-?7J>$-6^
M<L/R\RK$/(E<IF=/"#?%"PN;FJ-C*Q.Q,"0N"?56UN8UUZEOLB074W%<E-A]
M1-_8G_A;1JJS3=>1M%=AESC?(F26)73=K$/3XKBH>M@DL'4]V(+O%*@%IXC$
MZW)!N9DMKP(11TK;071YCJM(2F0L(7(S1E@:(KXF7D+D9A"P/$02J\C-H%^5
MLXBCM9<0N1GOJP(1QRQ00N1FD&^SYZ?<9#P]Q'5AJ%7CKF6[-*PS5P&2-0#4
M=IBD8N;NXXHZJ"D[-US-#-):<A6+GJOI/RJX<*TYKN;\Z"P:V=`;5S-_=#`S
M%6+I=&:0ZCKL&OKG:JZ\,3!;8T==K?NH?&<8B3AQM>!Y1S15(Y)<?5A13SJ6
M#J[K]J"B6[!IQ;8>[ZG%X0*H&/)<0G:^.D>'^/T2OO/52I0#I$O01K5$*CJY
M!&S4.:2"8DK`SD*OX&;&"ZS#SE844,6(&WRQ1>A<3.,'"+5OS_.IJL`D@>#*
M(RB8>1M6*V8P6=R3;UX2M%0<KK>Q$?5V4ZP,6G(-1:18Z(D7+=@)]1><OMU'
M`=6/LD+PJJ%]<"D<E(<P-+P5;';KC(E*.P:>$*N8R$S@C.;7V@(4Y\%U'-3J
M`\,@;X-Z4DY3E?Y'JL,0X("M:?)"BQ-6_TX9>XS3OZ'T"?GQ(L)_<--0^_N>
M4^CE;E!0?XI?T7:?C@UI,Q%&HH>WC@!JUL)K1$N>O'R+7][BC'A1P,\0D.IW
M!`JI!1/IDEGM;&/5?O&^4^.B,#NDWL9*!A^`1A]G$A7UKS:Q2:.XF'J]D>UL
MR,I35F3K[."=UNW];'#S1$4,P;(H_VZ-.N'>JK:P6X.^^:ZH"''D:G,@N>6"
MK521^J[C6\OX>A707)#\ND_R[?<53G)+$KLX>>@8&_^DT+GS<,(*7$X(R9;;
M8V2%?)!)7E"RY$DW/7[0&GZB'<';$%LG?ZD#YZ;R29:^@1K/E[C[_.))(G@L
MW#JBQ<N[,TW69)ZB!$35A%;G;1)F>_[B*:^AM8=#>E&!CO0+#1/I>2D=?.ZD
M;H"Z[$CYN(_2!$<$^^R<-GX#M'_PI-9>P0Z;>7)?"`%_033B!O;4&B7>`K$_
MWG@IVMU^II>D)A6GB/0T2TD*^CJ.%O6%TQ.F_.^=XC[_E9F;MBMDMQ+ZVN7<
MSPURY7'UGM)K$`52UH5>/F6N0D`^.W1XFM4J*/W!;6SUR?`F/\]!,H'QB78U
M0Z@OQY32C*BK!ZZ_3-3'=!Q%5W$UK>DD]HG($.%J7M5)3`Q7-W4UH>MHLV+&
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M1WQ)=AZSJ@>>55W,(Z:EW/;-,(RI`SN03N*OPE=L(/4+BE#BA7#<38(ECC"=
M-'J<%:M8F$<GU]<&5W`JQTNTJP7S4,R`(&=1U&-`'`A#4<5]K.1BPM4#U_8;
M+)$;M$9AO**$R:PMF9YV<S?-['ZY/$Z3WW+5V&MT/EPWS?1T0=:T/TD9R_7H
M7HF[J`I;R\'O^L*4NO=JUAJ9*\;U0&5EU"3%/M?CB'N]S25V]=F9:WN&V?BU
M=M;E_LIIV\7TY"Z]/+":I'A)[_=I]/*&:+3;=,X"W[X2'"W@5U>AY_\.8\!W
M2.$*3+`/?_L2!P#(:!ZQ9AXYC0)410U^,96U-F,QI+$8DH/%D'3"E)OR+>A)
M1=]=N(N3&9Q*-$*-/AD"_X-SF;7@87AD*DX>Z6UF2_7QBV-@V_C=DRI>,):I
MZF]5_!J#1()#6D#^R.MQ[\LGC^@3)K_?)0AM7U([%IZ-WSTI--M\:@8&MEOF
MJ\B)H+/WQ4M^1VFN-\V+ET!J3/?Y)5?-_&-,]QA_:BC^M*Y?NNZ'T(S&==1B
M?NP(TC.P[?8`I`DQ8PQWE!?&C&`OKQ`[[UXZG8G9UPU=KU5S`E/3K&2Z7KVF
MQXD98MV:LYN17K5KURO5G,"I)>-D.%[AF@'[U"LILA,`9@ULC#YQ>S[QKD=2
MI5!37@C0M(&3^YT31VNO=M*VID_Q6G??&`J_?HK(PKD[1YB^V;VK3M43BDU?
M&H3MG44AH?VB7$^(!D/"770=1^R8R;R02G!]V.05*3C%=58O@-;3$MO[R"GB
M5*FKV.N]</B=$2V%[_QV>>IX6;A'9;\^(MO3UVVN6AUK2BMWO"ORTG383P=*
M3G$UYR4:)U&PLUW%]%?'.FZE/^\FMA8.D(Y$#7(>N/[#O7*PO+*\1G`W2\1)
MXMR@^-E`6I6,D\1:6&?Z*#`K4&`%86I&O2<D0\%-EL"YEM/)6"(J;VUK#.18
MC)UYW:U33-4JQS_UDG387IGA3<6^<<;U:*X>9D#C6-$+9_DQ1SE""TKJV>'<
MA[E;+WAEG`C3%K5NP2KY^7\;C5/1W17I>HS*\"9!WN+B>M#*\.9&VC33*5!E
ME%^/H_8Z_[+2\*9'T=+F_.-,PYLA91N=\T\UG>HM5).C=1YL&N7HOH/4QC>:
MAB==R\Z8F^DMYF;,2D2>ZZ\G];2ACAV2<2Z/&SP@0.WV.TX?L/?*DN0F08!S
M`N^C>9PL&0$VPO>O0X^0(IE`6!R\H:&18%VZ*F!QP"3`3P3#@BA6LD]71S`!
M\=-/V`JD6+&77`D1%FUM"LCMX2NFN(==DF(0$6;;U<\@?@:A"Y&;QM)K*CV-
M4%FLWQ7.4?L;H-)$4E.SL3RAK?*$G+F<1BC%2_0%AR#OQ!$JSO*7^`I^Q,%7
M./"2R2)!;#,TS;+:`,>G^>LJCIY!J,-S##<)W;=P:GFTAN@<]G60^>E^[:!^
MOC$6DSR]8I(LS1!FCWELX=@OY*DBOPZ.U9:\-?G^UKFC,B*CD*!DC1Y:RFI)
M=;5;_I.#O<(K&>TCV`E0*HI^5R4PP1[GMQ]<>-7$_T>&"1.$^=S(]K>IC_&E
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MW`Y-";_+:&[7#)#S\<H+MX<:,\NRUJ5]VTB<:QA']!UP]M7"C\H^0PZ_3`Z.
MWUK<J]Y(-J196Y8%SAS(0=:D/BAWMX'V=,6"/:)%3DB-W"VA-QE/,Y+M/6#.
MKK,D.8S9U1QDP'S>1W=XC:C[DF=UT!AHV/S&66*&W]U`@^;W!;YJ9H(K(PV;
MXV^Q&7ZWXPR8VY<WE"!OGG+O0?5QK%L01^OU8*W7IVU3-"`]5W4A55'"U?`@
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M$U^5MQ'<^R@`%#G5W.2[FZ9W77XFGUI:@3%J<O2H]+03GI)1G$`03#>/WE+D
MUVEL:H/FFT)VA+V%(FXPQWZK`5`JEJXXC0=`-]Q:O@KIE?9&=MYMB!]P&&[X
ME]A>"R-?_06./R]X]C&*?)JIYO,_SVMJA@XX+Z+K)";D.DY6Q8$GH$70W%`A
M2/*0GV8Q!IWJ&31GC!(^0<+V9B@JCGZ>_"L.)E3H?1QJN=%WDCU-4LF*+M\A
M5-'Y!)0UM;9Q?A7D$/$-L=_*"&Z/M-#4/(L"RCR%H@FNPT9FOLT>`YK.)U&4
M>>$7D(E3%'EP)!4"G$C^D^YKE-)B"H)9$B\2;TFHN8GI?IP%+J)<>2RCG'R)
M0^1G(##3XA:%$,V*RU_'RR4M&^^%^`]:?&RV1Y"0IPZC&N5NBZF(UEV;7K[,
M9A(T*(07445'V8,B+_1&2X]+D:H^J)60NF3A1049M*)='.)@J_7,*E;-Z?P.
MTRT+1.\J$[0%H)D9V\B,[QTTTTC>,";;U0R=<]ARB5`>W&]B)WAOE27^6S6+
M8U^#$QI8Y/L;075;?W'Z&N)%L1R7JQ#1GW@F@-8^=G!GT@2M-KF(F*5S9T?Y
M@M*W.*@W^(/[EK3&0$9F@M5<.K#]-.'/:6F&"N`J"MBI^Q(79W-M5_-WGVQ7
M0W2RRJV7W-*N(CKENHX%A]6I;ZP2^*L79N@1?6-_42PVO-?77A!SQ:,@F(_F
MMD96_-?5/(F9FD=E!+@+,,T>W%;8+8XJWI$MW]DDK:5\L/W$]I5G+H7<+C:]
M\9H^J?())ME#=>>NOW0KN*O=S53!2O)@+[%R\^E0D8N@'O0F+7"Z&C6C:8VL
M5"Y7<(FY6INC*X@-%CBG,U@Z0"4R\CJ=F])ECX8JCG:GLU`ZH*@53.1TWDD'
M,'D:N]/))!WP:M4*G,X5T0..ZUIS.@^D&U8ZIL`23K>T"0-P'L3]E$_'CFJ$
M&*O#7.Y/&DH#Z,&O\?F`5@U[*G$;-8AF.4XG8-_5-^\[J[`&@@I<?9W>%+;J
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MZ?G2R5+#>0?<9A5)3N92S36CFN!R+B^H4\\I3K>X4&,CO?9`J$7#J2@IH+%D
MI"4?76T,*[5%\F?T5CB_#:@9[A.'F<:F`WB4YPG@!;*HGO.()-\*V^MC-R%)
M8YT):ISOP^%J8HTQ_)JWP/&2;`9[%)<ONQ;%MO/*VPRO>FX(,R*,9_3X#&0_
MG(W/0'88:-C\CL]`:C(\/@,Y/&[[?`;R%"4K_:?Y1E&U"Z#-C_*Y:0X](J:-
MS_&Y:2T]'JJ-#_&Y:5@](JA-3_"Y%5)U;%";']]S*[KJV)AV34V/4R\\#2O+
M+(F#S#],(:2O=<4;+TPW1M]4XM0/.\R_6<&:@H6`UNS3U-!3$+@GP"IW-_-&
MSY)ZZ*;S2EIF'!$<H-Q2-_-P(/%"C_(@-C2,+]YWNCF$K^_4VUBA,M_"8BIK
M;8Q63WY^@Z.+Y-D2$\*9T'PR"4'I;-_AV[0\C(T]UE+N7DO94,U:ZF(55),L
M_VZ-.N$.JK8P4XUX[XIY$#T@P6_<"RW<YR&:&YJDH;C%6+ZY3Y?S`DWGCRAE
M!8CV4E-%1TB7X=P+.>5,L.M!(0>'3JUT3G7/GP42AR5;.3*$Z_II&QIUN<]5
MS5+N&A(4"A`H*JY:C14Q,R<DNVHR5@2TDY3@JH%8=2.K:_"N6H';I=\#B>$<
MTA-;$6E;<<=,#;-K1+Q=KL)X@]`5BM`<I[/0BP83+7L#%$6(V8H3_)JQS4T/
M1:9,3-,WE,QB4!A0BI.\T``0+Q^C96IT(]IC$S'PO>WLD.H?\N(ROX*HDI?V
M*"Z0)BW2Q+"67E<5T)W064A8/0XOV=1X8%>#PH0K##H@'`H!/Y^QZA^I/+&=
MW&(*U<!0&MG,R[7%H+<A7M`7)"8+]!*7%1W0?50YFIK6N-H`-M4VP^=9F4RD
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MR)O`,IBN43()PYB%/TZ9K-*T/4P.;V4>ZX(/+R*DM?D`:!?>U,UM!T!U6_@5
MM_D`:&^*V1$V'0+-\#W1B\^<U@.A7'R5<=O;HAX'&!3+RA7;@GQS>ZM%<*3E
MBJK:7=$;7'W-2?8"D2AR?B`TN&[M5,*L(@AVLD(.^A$'%63,BW6N&QA5UIN"
M*NYJA(8.;%P[G>MQC9U`JEFK7(UYU-N%+::]3@ES;ET%.G8N5Y]WU0!/SI3I
MZ@.NLEIY321KU()=#^<7Z?XB=';ZMK/QBSH(<31C9]]4Z+B*'NS$>0X#HSV+
M5<MF.Y?JNZW6,0%.A\89=PT-0AM<#2,)4Y?;A8D?XY0:#QJR'#NE2)9A)B]`
MX%4(`-L()2D>"*6V$B"?U5@6NQX$'4XNR;UI#IJY-OX9FP=`^YS7RK481_AX
MEMQAG1?/&%31.?:]*#V<@O$4Z.)6DD.6XV.2ZWPZ.U86C7$?BO#9_F+<CQIA
MGAZAQB/ZO]M_9'@-0B3@SDC;M&U'N;[#X>H)`=#83U$@HER)6<DA+07PTM<#
MV(Y]0J%':8R)]-Q*]K;%68+>:(S]&MU'<*"@G"QYUJ2ZV^$MHHD3>5[U$R:_
M7\,QCU/Z$Y<=?@]+"73L;KI^\Y(%DEQN+9UL\''K)1&<TC2?*'?B2S'2ULL&
M)W<>3MA+]!7!_SZ"@RM;MAY[<GVM!/<O5T`;BP.@B3"KF'CA=/X01XL'V-<!
MJXHAN?JTAK+!\R/Z5I$?$I"A,MC\E9F0XU=Y&$M)!2N4I!N:\)3"S4IOU17+
MGY+B4;J[E>)QI=ON!JU1&#/*BN=^A/M1IJ<=CO:]N'+3U-[/!C<OB1>@;?9>
ML54J;^0(9TBNKPVNOM((JEN2XB6(<[PXSKU&IZ-+[W/G>A2B&CJ2>I[KB=)J
MH$D>`Z[''ZJ!UB;_NQYV:&)?REHJ7(].5,-24L]Q/5!1<0&*#`[=ZOJ[!I6\
M1N)Z?*(:;GJ:NNLABVH82NA7KJ<JJ0(FH6*['D"D>A7(VM5+W$8U0<'34L(V
M*@H2!O82KE%3T+']EOCUK1V<8M0`BUT>8P9,^"BO-BUI^:(>@^"@-3E?U,,*
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M57J%):7JC4Y'\]KGSO74/`GY7NA!.*<T1@E-HH95F\#KNL=%%2^QFN.ZGX5_
M#S3Z/0WJ'JY'SR@B:U1+<3W(1@Y;+:G.]5`;,72=E4;78V_45IZR)N5ZN(TJ
M?.84=]=C<IH5)*$4716Z79>BV^%I6IJN/QG(]W!Q[X"!U*K@TM?BZ&KO-ZA,
M%/FJ%$I#V-R)TC,G%1@W%I70W+3VG--GLG6U-ZR+VW3<G(35S7J+0^">4%S2
M#6T[D.LT)ZAE`^XULO:JC!2(/`^!;'^;>Z]Y-@X*Y<OA<*[[K02#FG^:XR>W
M*CD*9MZ&];*Z"Z5)?JV2W/8D=K=!K11XZ#AU'8'@C&KU!5`C*Z.61-<5X_%<
MT0+.GMP]GBX'QMGBE>%GE*RQC\I9JW)"'P/QMWZ#/#GF#^"$O2;"V%,(A#'\
M/;OH-9//))/\W10R\5.\AIVM&"^D/?!0\"B6^>2;EP15LJFC+Y]C0K)E_CMM
M;#I\Q*V;K,?][+J/NL_),+,=7/=D'V<&5`_HXSG!AR7;L:H(F9]F11!+,0L%
M3!@-I5)W*YTM4IM\?TNUJ]1G09/1H9E^E&=V+R-9`[AS5>1TT+*GO;F]Y<M+
MZRX#$M$7'.%EMGRBJR+<WGIW<3)=(1J_$"T>$-QKJL)SE['MHE*;/5IX(%FC
M/'R#B@VDU=FD,]+)'H-:L+DNZAM"M-/V/)XP/ZR;YCH.83_&R?:IC`=03B."
M)HL$&7H`AI/^I_7A^@FB/XZ5LIK;K[?<AH?M;.Y-+M6[D%R]B3Q7R8X^(XO3
M7%..0/EE>5@H\H>CP$E1V+*&U<:P5$9?91XZL#D,J45K5O??/U8!;-S@,CC9
M4]K.8YOO27W3^0,B!"E$Y2@,<-+;6P6H<]W:3_'&"]/-3K+I2S26^4Z#)"S3
M;11\S0F^4M-TKGME1@LI,GV`U0^?Q0`B2G'"_GJ%(C3'@WE<M.:"I>:'+9TJ
M%Z'T"%8BP75GHYE=[>$L7Y&JLUR+']>&\%R/@+UWJ^W&K^X3T[*AN<VMV-JY
M0,H1/XS]US8#@B?/!Q3;^:>/E%@:\0#_^/]02P,$%`````@`)(%L0])>N7?G
M$@``A,8``!$`'`!M9VYX+3(P,3,P.3,P+GAS9%54"0`#\YB"4O.8@E)U>`L`
M`00E#@``!#D!``#M7=UOX[@1?R_0_X'-0[L%ZCA.;J_=8/<*YVL;((D#)WN]
M]N6@2+1-G$3Z2"J)^]=WAOJP+,FT)#L;&=#+KB/.#&<X/_%C."(___,U\,DS
ME8H)_N5@<'AT0"AWA<?X],O!MX?>\.'\^OK@GS_]\0^?_]3KD?&87`C.J>_3
M!?G%I3Z5CJ;DT7D57`0+\N#.:.#\C3PYBGI$</++V?B&'!\.")EI/3_M]U]>
M7@ZE]!(AAZX(^J372RKX.5+EE/QX>`S:9$K&(N3>*?E[YM&YI(X&:N*!$J?D
M^&APTAL,>H/CQ^.CTZ.3TQ_^\=\LM9@O))O.-/G@_A6(CS[VD(.,#\>'&:O^
M3!X$5T`=S!V^($/?)V/D4F1,%97/U#N,A2IC+($6Y.K+0<:^EY-#(:=]J&+0
M_^7V)FJ4@S_^@42TIZ]/TF<K'/@DX3GI,ZZTPUV:8?$9_\W"@<78YME*"BRQ
M6H-/GS[U36F&.E2]J>/,4_J)HYX,=5S0-XU[-.B=#%:Y]&).52F;*2GG"Z;\
M=46UP'&EF%+.7&40@5Q'GTZ.,CP</!0&Y6W@:=G'ZOI`U`,J*IF;9=W,5^!!
M&D^G;-GF_MB/"C/4+H!3R\4JN:+NX50\]^/"\J9P0RGAC5O'&I<B[W&!UZ.L
MG`T*RFNCK^ZLG`5+RGD8?Z9*EW-%9>5\2L]E.1>6(,\@PZ,=.:7ZS@FHFCLN
MK8X.Z(,"RO65D,$%G3BA#ZK^'CH^FS#J'1!':\F>0DU7"$*^)/D)I7QV.!?:
M]";F;WPRGS,^$?&?\`!?F5,I?/H(D"'XX]OXVJJHCOO%/A+W+X0;HJH.]RZY
M9GIQ#>)E8"H](,S[<F"E2!5)5/'HA'%F5!X<#4B/).S9GR"*1+)(1MCG?EY"
M7G@('?B(_V1^NX[OAKYAO(&_8^:8PL8XE]!E<MV`<ZG9>K[X:>*1W3GJ`30V
MH!I-KAB'GI@Y_KU01IUSWU$JQA:Z;`P,OU9DL'OP!-R6"B(X7G$E?(9CFT?.
M'!]'!/(PHU2KSGW;N^_>@9Y5SZAFT#ZU?6FX-SCTA^H.)1]6U/EKY^"*#KZ&
MR6I`A[ZFDH,9S[3<DT4RN^L^VER7%B@B)F0TQSDPPSDC]K4X;Y1T1KF"6DA4
M+_EP(Y3JG%K5J>>.FEWYXD5=<X])ZNIRIQ;)[$[]L;I3430QLCNGV9QV)S15
MCR+M*)>M.))3A[/_&8.6#0U_#+EWGS$VT\LNF2^8<GVA0DD?Z:L^\X7[6P8"
MW[%2.Z#^CA.ME`O^&,%*^IG1%],3G#F*&3!E:^[@U`Q.#VS*8>!U':Z'KEE0
M,3Z]!_^Z##AJ@:2B*+OK_Y%W_4,8!(Y<H+\S%9!E#22IHH-`,PC<2P%#K5[<
M^^@Y6"']'K(YEC3M+6H)M,/A4QX.B>QH_94([ES?\.W7X(*9\#TJ%3:F7B!M
M4[]7EV9U^N"HT`=D!/^%1*+)APO@<9GNIG\-G;]L8ICRP>P:IM;&N#'U<>9V
M+A2X=`;+IS,,.M\["\-5#Q+;UF$'RJ``%!3E]8PPDDCK\-$,'V.JM`Q='4H8
M9:$;CWTV=&&=!]K2QK/)1H+M2#C.(^&&`@;(Y2O3Y(8Y3\R'+J,#0C,@G`O?
M=YZ$3&;\-\R%]Y@.IY)NMZQH)-@.A),\$%;J,+.&N!:RK*8#1E-@!`'3YB=X
M#Q:&.!^GW-VB;Z@IT@Z&'XI@2*7'0:6,_`X%#<<)L7!\O4A?I\;#0@4Y=G]_
M+%DM>##0D%OFPY@C.$TG!<;]<8U=3[#]&A+CLJ8/'^D9E?<PKY-4,VE*SR@'
MK9L/$XV%V]'R8QXME\'<%PM*22R3X`*V0T3#I67XI.CO(?R\?*Z_;EC/;?=I
M(7*X%$0B29T_WS)0F#S88<`P%6GW_!:!0_(A^=7%$MX4'8_.D[]3;,0"[<@H
MQ!#K(".JH</%=X@MUT!'`[%6C!P70H[E<>8.#^\;<ZP!D=W49$=-M?AC!YIW
M"$360,H6XNWPJ!24[-#Q78-0-7#12+`=$27124M`JH-&M?3?94^?25,!E]TY
MVG3_RTRRH><9+1V_F"*\K12[YPNAR&PMQO51/;G,MQY95I;-,\;=3^VP+J&Q
M*C3B.?]H8EU85,+'-J+L("G$+VNL5#JD?%>DI%17#I,_.WY(;V%P#Z.89#J8
M#)6BVFQL1:-]&AGY?M79$5>(@=9"7(88]2)&,9+1C*2J$:-;O/^6:M>!\VW!
M>2_IA$I8DI@,FG\[4@)].O7<$HH;A-N!5Q*H;0:\5(LH2XC$>F0GV!W&WA1C
M5+IH[Y2N<(SI,^4AW19C=N%VC&T3$E[%6*I%GC56I,/8VV*L2`6K=I>R9UP?
M;0DQNVP[PK8)+6\BQN^B$S4Z?+T)OBZ59@'&>KXI.@G]&_;<='Y6*LF*G9-B
MEFL=[*05DJA&8JKL</(V_9`[HU[HPQATP?P0/W-[H&XHS13V\M7U0X]Z5U($
M&&<.DR]A#"GU[JB./E:#0<2$AQMV5SM5P8[,8EB[5J\6:XK4B:YDJ2Q)M"43
M4)=D]$T9H`Q43K[Q`Z6CN'H'[C<&]Q">>]71=>E(#G+4KH"];?5V4!>"\8U!
MG=6S,K`3;3LX-X9SLB6;W>]=HJ>L-(_(!A+LH"K$\]=L&Z\":-W><H>'K?%0
M*8!;G='N_4),?ZWWN]#L;@:TP@=F\3=@U>+V];CMOB^&ZJW?J'48V!D&3(K%
M2M)&->]7Y;/[O1@P+TWYZ-S]=NY>CMCFG3-EV0R?RU?\69R.-I=DAT0QE+T&
M$MDY@*DP)LE62>(Z.Z#L$BCIKMEH;G;U7QSII1&4$7^<T0OX-9I\Q:V#;PHF
MZO#HS'?<WT`&U*,BOGL)G3F?W@J/^K7@]1;UVT%9C'U7`&5F$R^JD!A-,\$F
M>*1GE*"VR&#T)49A\]RHW(MUCF7T8JV)4;O#]<X[P!A34;I:<5.O+K\=5\6(
M=]7.+H547%&'A)I(,-F#F#R8;FU6FOA49;/Z_8="M+HTE[&;]KR9K\]G#I]2
M=<V+19L];F.V^[T0"U[C][@&POB:+-<.`%L"X"K4)G;!N,OFCI]TM=\XK#@-
M=?H5ZV8\U)!EAT>U%.<>B2HD:8W+D2+$.F.VM-8.+C7ALO$DA4I#14,I=H@T
M.I&A&TEVAXRU6>P5,5&3WXZ&>D<R=##X#C!8+@=N0=,@#*+.VG3)23>]/MMF
M=X+MP"D$7#<!)[L`B>M/AJ%HM$F'H"[/9IL]&#Q@(SU?(PVM<B]_G$>U[F9[
M@788%>*WM8\(Z?JD78$G.6\C/FX#/^:MA)'*?'8H%.*VI>=_=.[>620K=Z9'
MQ8]MJC#9'5V2!YP[%*1S,CS&?_"NFS&=$'.-S2E>X?+E0#%X+V#<CYXYTD5^
M^P4X_7FT$PXC<3\1FP@H<*_>N&-`DVN_6*M$PDS2R9<#O.NFE]Q8\BMP'+X&
M?D*BF<9:SI=R"`I2?R..[Q_TVVOYJALK&`X,)89?I&+VQ&Y8$5*_HLE`6V+R
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MG@9`IQVYN-8TP!GV`7&>E):.J[\<3!S?3!(,(4P>F/`>#6LT0.JDZ"FZP.K+
M@4>?&#SE#,/E.-AKB=]3*EB\P.@?HL9?I0CG2>4,*MW83B(`'<U^_+52(6X!
MN;DO4_)-8N>(K(<.&4TRSYK9OE,K8U=%VUEF;R$ZV6=U?\.*A+HB]@H%B7%S
M3/N8,0`[_HEAVACKUB:Q<+U9*[B2>CMOAC&=XN)0R$63OJ(&]SZ`(\!IP&B2
M??$!\UY\$LV]P[SU;5*?=^L6\4(9QXO>K$G.!)WAD6!47L,__HRRX)8&3U1F
M3+?0Q#VCN5WWU!.!PWB9A9%Z-@-W8$HZKCG:&5.\2>O>5'4EEDYYI#)@/!.$
M,P;6YLQZ-K&AH6=W:;AE0(^V?Y)[1U>MKL3V=F#>8;=W[H-FHTFT`Q;OAYE]
M,%7,_E`WC)MQ7*VT23,!V=:!EH"7Y?U>@PWY#9=<4VAQS&[-&EZ'*[(V676?
MXAV(#VN-_D[O0./K.RJ97\Z^TOOIY'DK&N%YJ7O4E^$!H=QH4VZVE:%E_5VR
M":Y7AF#HJX3TJ#=4U]R-CF;"#91[*5RJ\`!,ZDAW!L[-='@KGU'$3;)[X?LP
M$0!KGS'8"U)6SSR*"O!N`K,J6FVJBBQ;+J!VC9YRK1^@1JHN"M.?J@QMF@N9
MK1%J,E7,!?;H"H!,LOFKL@5#4-CQ?X:!'[]83T\!RK3`3J2M8`"?OA\$+NA<
M4I=%G7T@P+?1$977P=QA$@G+Y@:UN%HT(;@0;FB^_N4>C.),+S);O\-8E:R9
ME<A;9-^ESVY`RJ+PXN8+VO2")N\.Z#C%GF4XI8_BW@%08>JPIM<\D_B1M:D>
M7]9-#*9PN(9[M]<N^EX8QD]X!/,-U/#Q13S.1*@<[A7=5XF\54ZU:OPX@_E5
M32M7>-ID:K45TN,RF=(86XOK.W<QGCZ=+7!H"I],)UYN]U=8(3O>@\LH>`SG
M@@6'KJ5HD_N^`JSXN10*QFXYC]<]15-L5&TRQ\S)`3H7-/K_FE_$$[7Q:A1O
M$^$^S-1OHA6;D'BVQV@R@1EV>@Q'P855B-ODR?@SGCF+9/X'EE59:\I*LSZ;
MXJ/W&^%NJ$H:G$FJ8('PS*@L.L5*UBIWQ'&0=7M"I4&T.DPMFD=N5#L_FE5E
M:.5`%BMO/FZ_@C5<_N.'K(6E1'NPWW,+:BUN'?D;U5<A]U1Z0L$RFI<QMA+U
M'EA]1[4)2U$P08K@/GSRF0M=/T7DF7N"DKWNC/%UF/9AD+S#D-T$W(AR$+I9
M6XME>[&[<1?B`(%G"&*(Y=;!!1V>/)_LUI3L\51G:=5*,5$[[G\\@.94.H'"
MJLQ"84V'6V)Y?1&M;(E;X5,W]/$6GS,:QYBI9X:>(("^GCD^^Q^&I^]SEI6U
MR3;"6MDZB7-+;%T6M5IS`\DK(2F;\LP60LXGT58$F\Y*H;Z%K%:VC=DH4"8A
M"["X)O$B2KK`>S?N0^G.BD<$K#31]B)7)G.1M'=KJ!$,5"R@^5U[?*NMN2PU
M^?8AX:F629C=]3"G+ILPZMW@&P+(</`$JDG\I:1JVEJ51.]%@Y9?$'86*EB\
MJ=)U7W66%JWZ-BB=7_-5(V_EBB\WY1OQC9FBE3GV8OI\/X%)C2P+V19*VA2"
M6=USCF/G_Q*^M[*_"L/])4SJ4"X>B2_AIY#9EW,[,2W:O%TUY&>!^\S1-&:H
M'NC<@:KHN>\H53`.-U,4GEZ[MED:2MMR3K#+_/#L(AZG.?@67>-'DHZ_NJ8_
MHQ.!/5?T5YRJL@J8+27M0YA@[1W;A;M.)M3T[67)8]L(:5L*V5I;EB;`4Q,6
M4R7)`\W86S0=&#O/E)\QH:D[X\(74U:^R[>!KDT#2"8Y+1,`BO+92Z.^51GV
M(!::F#*"#FMJFA3/(?8I_LIEP&XF+6PTW0JN9^_WKIH[O9F+%[T[:F8/;E>@
MW0MWFIOH,!ES&GWYGZ[*;JF>"6])4`;K^LS[T":Y$X/LB<Z5J-LV*.65+EM\
M6FC:-+SDM,PO+]>4MW(]&>L:+Q)-L#B]QO*.:A/UR'U:6++&W$I*BY8E1M'"
M]S,90]<1[,7:^0$Z3>Z9A=&CB&/**\&`P@2I,D>;IDI11O=PL#;EN\3,BAPM
M-/.XMIF;.5IHYHA7M&XM80N->GP1U8Q:2]@^H\[JXG$S0_N,/*]KY&:&]AEY
M4;L'K<#10C-K]Z`5.%IH9FTK]]'(JCWJ>L*6&56:>MKB7%.S-U^XGFHH)5ZZ
M@'1GBR5)LE[`JWM6-_>'(:SEI<E?F6BSJV,RO;-M\,85M2E%H+&MT44V)@DR
MRHF,KG::Y!,'WZJ"E:7=^YZYLZV))GV6>O^FN!@"M$#7",O;,<6W#=:SR6?6
MH>/C(1,[;-NZ%6>!^_Z?>1>OLBR+^UBI6A3Y*>J9C_VLI6AE]"<]+`MC#>="
MZ8)3<H7[L!VX/`',NPAEM-T+]4?]_1U],46XS^.'N!ELXE(O$N1)-8*7:^C[
M0N?B6[L3V:IAQ6;5H\A:@2D%KYATJ*!S7S$IZJ6JME5=J:UKKOAZ0P#M\='1
M47%FMIZF3;.T;_.)%.9KD"'WEA\>L^B(C'AC);>U5H.G;7MLL>K+3*A$W0B:
M12/74[9K=/WV\%7`:\/-G"&^4*2`21O1.X+R<S\Z:Q-^_A]02P$"'@,4````
M"``D@6Q#]RC_O4Q"`0#9*PT`$0`8```````!````I($`````;6=N>"TR,#$S
M,#DS,"YX;6Q55`4``_.8@E)U>`L``00E#@``!#D!``!02P$"'@,4````"``D
M@6Q#V'AIT8<.``!4QP``%0`8```````!````I(&70@$`;6=N>"TR,#$S,#DS
M,%]C86PN>&UL550%``/SF()2=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`
M)(%L0\!>T9)8*P``4=$"`!4`&````````0```*2!;5$!`&UG;G@M,C`Q,S`Y
M,S!?9&5F+GAM;%54!0`#\YB"4G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(
M`"2!;$,:Y'F,4VP``);^!0`5`!@```````$```"D@11]`0!M9VYX+3(P,3,P
M.3,P7VQA8BYX;6Q55`4``_.8@E)U>`L``00E#@``!#D!``!02P$"'@,4````
M"``D@6Q#7S<!Y\,X``"?3@0`%0`8```````!````I(&VZ0$`;6=N>"TR,#$S
M,#DS,%]P<F4N>&UL550%``/SF()2=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`)(%L0])>N7?G$@``A,8``!$`&````````0```*2!R"("`&UG;G@M,C`Q
M,S`Y,S`N>'-D550%``/SF()2=7@+``$$)0X```0Y`0``4$L%!@`````&``8`
*&@(``/HU`@``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EIOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Schedule of Stock Option Activity (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning Balance</a></td>
        <td class="nump">3,249,702<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
        <td class="nump">687,183<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
        <td class="num">(1,025,933)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited or expired</a></td>
        <td class="num">(33,949)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending Balance</a></td>
        <td class="nump">2,877,003<span></span></td>
        <td class="nump">3,249,702<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable</a></td>
        <td class="nump">1,855,178<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options, Vested and expected to vest</a></td>
        <td class="nump">918,600<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Beginning Balance</a></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Granted</a></td>
        <td class="nump">$ 3.19<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercised</a></td>
        <td class="nump">$ 0.75<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Forfeited or expired</a></td>
        <td class="nump">$ 1.13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Outstanding, Ending Balance</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="nump">$ 0.94<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Exercisable</a></td>
        <td class="nump">$ 0.94<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted- Average Exercise Price, Vested and expected to vest</a></td>
        <td class="nump">$ 2.44<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted Average Contractual Term, Granted</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Contractual Term, Outstanding</a></td>
        <td class="text">7 years 3 months 12 days<span></span></td>
        <td class="text">7 years 3 months 18 days<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options granted weighted average remaining contractual term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)-(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E5ZAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail) (Sales [Member])<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Servier [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">71.30%<span></span></td>
        <td class="nump">14.20%<span></span></td>
        <td class="nump">58.80%<span></span></td>
        <td class="nump">12.60%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Boehringer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">11.50%<span></span></td>
        <td class="nump">15.60%<span></span></td>
        <td class="nump">15.90%<span></span></td>
        <td class="nump">17.20%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Gilead [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">10.90%<span></span></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">13.70%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pfizer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">4.50%<span></span></td>
        <td class="nump">7.70%<span></span></td>
        <td class="nump">7.30%<span></span></td>
        <td class="nump">7.40%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Government Agencies [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">0.60%<span></span></td>
        <td class="nump">3.50%<span></span></td>
        <td class="nump">2.60%<span></span></td>
        <td class="nump">6.90%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Eli Lilly [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
        <td class="nump">0.90%<span></span></td>
        <td class="nump">59.00%<span></span></td>
        <td class="nump">1.60%<span></span></td>
        <td class="nump">55.70%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail) (Warrant [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance beginning of year</a></td>
        <td class="num">$ (52,947)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss', window );">Total unrealized gains (losses) included in earnings</a></td>
        <td class="num">(626,349)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance end of year</a></td>
        <td class="num">$ (679,296)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of unrealized (holding) gain (loss) which is included in the statement of income (or changes in net assets) related to those liabilities still held at the reporting date for which fair value is measured on a recurring basis using significant unobservable inputs (Level 3).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2002

</div>
          <div>Age</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract', window );"><strong>Defined Contribution Pension And Other Postretirement Plans Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan', window );">Eligibility of employee participation plan</a></td>
        <td class="nump">21<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage', window );">Percentage of employee vested contribution</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company's contribution to plan total</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 55,311<span></span></td>
        <td class="nump">$ 48,891<span></span></td>
        <td class="nump">$ 194,498<span></span></td>
        <td class="nump">$ 179,966<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Defined contribution plan, employees contribution, annual vesting percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_DefinedContributionPlanEmployeesContributionAnnualVestingPercentage</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Employee eligible age to participate in benefit plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_EmployeeEligibleAgeToParticipateInBenefitPlan</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPensionAndOtherPostretirementPlansDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EMODI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">24 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="5">1 Months Ended</th>
        <th class="th" colspan="3">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>May 31, 2006</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2004</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2003

</div>
          <div>Series A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series A Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series D Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2011

</div>
          <div>Series D Preferred Stock [Member]

</div>
          <div>Raven Biotechnologies Inc [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2008

</div>
          <div>Series D Preferred Stock [Member]

</div>
          <div>Raven Biotechnologies Inc [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>May 30, 2010

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2008

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series D Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series A- One Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series A- Two Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2004

</div>
          <div>Series B Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series B Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2006

</div>
          <div>Series C Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Series C Preferred Stock [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">34,239,374<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,427,388<span></span></td>
        <td class="nump">6,916,110<span></span></td>
        <td class="nump">38,337,678<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 34,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12,016,500<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 24,843,211<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 30,261,672<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 44,898,754<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Convertible Preferred Stock Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuanceCosts', window );">Related offering costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">156,788<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">238,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">101,246<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Shares of common stock allocated but unissued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,003,300<span></span></td>
        <td class="nump">13,604,016<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued to acquire entity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="nump">12,466,039<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchased shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">518,708<span></span></td>
        <td class="nump">2,875,327<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0.65<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold', window );">Outstanding stock</a></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors', window );">Percentage of preferred stock holders with voting rights of board members</a></td>
        <td class="nump">66.67%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePerDollarAmount', window );">Accrued noncumulative dividends on preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0522<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0522<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="nump">$ 0.08<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0341<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0.0324<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock series</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="nump">1.506<span></span></td>
        <td class="nump">1.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.14<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.00<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ConvertiblePreferredStockConversionPrice', window );">Conversion price of preferred stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.20<span></span></td>
        <td class="nump">$ 12.39<span></span></td>
        <td class="nump">$ 18.77<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.70<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Reserved common stock</a></td>
        <td class="nump">17,129,782<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NetProceedsFromPublicOfferingOfCommonStock', window );">Net proceeds from underwritten public offering upon closing of firm</a></td>
        <td class="nump">$ 40,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Earning per share received by the shareholders</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.39<span></span></td>
        <td class="nump">$ 12.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 12.20<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 6.95<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 7.70<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
        <td class="text">1-for-18.7739<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ConvertiblePreferredStockConversionPrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible preferred stock conversion price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ConvertiblePreferredStockConversionPrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NetProceedsFromPublicOfferingOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net proceeds from public offering of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NetProceedsFromPublicOfferingOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock minimum holding percentage for elect to convert all outstanding shares of preferred stock into common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PreferredStockMinimumHoldingPercentageForElectionOfDirectors</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Preferred stock voting rights as separate class holding percentage threshold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PreferredStockVotingRightsAsSeparateClassHoldingPercentageThreshold</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockholdersEquityLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockholdersEquityLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Costs related to the issuance or offering of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuanceCosts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of equity interests issued or issuable to acquire entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 805<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7488404&amp;loc=d3e6927-128479<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 4<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:perUnitItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesSubscribedButUnissued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued for each share of convertible preferred stock that is converted.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePerDollarAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount per share used to calculated dividend payments on preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockDividendRatePerDollarAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockLiquidationPreference</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityReverseStockSplit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability - Changes in Lease Exit Liability (Detail) (Contract Termination [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Contract Termination [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual balance</a></td>
        <td class="nump">$ 10,073,939<span></span></td>
        <td class="nump">$ 10,607,499<span></span></td>
        <td class="nump">$ 9,607,638<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Principal payments</a></td>
        <td class="num">$ (466,301)<span></span></td>
        <td class="num">$ (533,560)<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsForRestructuring</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCostAndReserveLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringReserve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3OBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">2,156,114<span></span></td>
        <td class="nump">2,156,114<span></span></td>
        <td class="nump">2,156,114<span></span></td>
        <td class="nump">2,156,114<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">392,274<span></span></td>
        <td class="nump">392,274<span></span></td>
        <td class="nump">392,274<span></span></td>
        <td class="nump">392,274<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">4,336,037<span></span></td>
        <td class="nump">4,336,037<span></span></td>
        <td class="nump">4,336,037<span></span></td>
        <td class="nump">4,336,037<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">5,909,906<span></span></td>
        <td class="nump">5,909,906<span></span></td>
        <td class="nump">5,909,906<span></span></td>
        <td class="nump">5,909,906<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">769,468<span></span></td>
        <td class="nump">769,468<span></span></td>
        <td class="nump">769,468<span></span></td>
        <td class="nump">769,468<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">3,391,991<span></span></td>
        <td class="nump">3,391,991<span></span></td>
        <td class="nump">3,391,991<span></span></td>
        <td class="nump">3,391,991<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Warrant [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">180,784<span></span></td>
        <td class="nump">180,784<span></span></td>
        <td class="nump">180,784<span></span></td>
        <td class="nump">180,784<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Options [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Preferred Stock</a></td>
        <td class="nump">2,910,952<span></span></td>
        <td class="nump">3,276,516<span></span></td>
        <td class="nump">2,910,952<span></span></td>
        <td class="nump">3,276,516<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EJHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
        <td class="nump">$ 806,275<span></span></td>
        <td class="nump">$ 783,462<span></span></td>
        <td class="nump">$ 2,400,000<span></span></td>
        <td class="nump">$ 2,400,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Jan. 30,
				 2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LeaseExpirationDate1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesRentExpenseNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3RAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 7,522,029<span></span></td>
        <td class="nump">$ 18,695,197<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump">26,047,169<span></span></td>
        <td class="nump">29,047,958<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="nump">404,850<span></span></td>
        <td class="nump">404,850<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
        <td class="nump">33,974,048<span></span></td>
        <td class="nump">48,148,005<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="num">(679,296)<span></span></td>
        <td class="num">(52,947)<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Quoted Prices in Active Markets for Identical Assets Level 1 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="nump">7,522,029<span></span></td>
        <td class="nump">18,695,197<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="nump">26,047,169<span></span></td>
        <td class="nump">29,047,958<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="nump">404,850<span></span></td>
        <td class="nump">404,850<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
        <td class="nump">33,974,048<span></span></td>
        <td class="nump">48,148,005<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Other Observable Inputs Level 2 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Significant Unobservable Inputs Level 3 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_MoneyMarketFundsFairValueDisclosure', window );">Money market funds</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RestrictedCashFairValueDisclosure', window );">Restricted cash</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Preferred stock warrant liability</a></td>
        <td class="num">$ (679,296)<span></span></td>
        <td class="num">$ (52,947)<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_MoneyMarketFundsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Money market funds fair value disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_MoneyMarketFundsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RestrictedCashFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restricted cash fair value disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RestrictedCashFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesFairValueDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value portion of warrants not settleable in cash classified as equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Overview and Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Overview and Basis of Presentation</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>1. Overview and Basis of Presentation</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 MacroGenics, Inc. (the &#x201C;Company&#x201D;) was incorporated in
 Delaware on August&#xA0;14, 2000. The Company is a clinical-stage
 biopharmaceutical company focused on discovering and developing
 innovative monoclonal antibody-based therapeutics for the treatment
 of cancer and autoimmune diseases. The Company generates its
 pipeline of product candidates from its proprietary suite of
 next-generation antibody technology platforms which it believes
 improve the performance of monoclonal antibodies and
 antibody-derived molecules. These product candidates, which the
 Company has identified through its understanding of disease biology
 and immune-mediated mechanisms, may address disease-specific
 challenges which are not currently being met by existing therapies.
 The Company creates both differentiated molecules that are directed
 to novel cancer targets, as well as &#x201C;bio-betters&#x201D; which
 are drugs designed to improve upon marketed medicines.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The accompanying unaudited interim consolidated financial
 statements include the accounts of MacroGenics, Inc. and its wholly
 owned subsidiary, MacroGenics West, Inc. All intercompany accounts
 and transactions have been eliminated in consolidation. These
 financial statements have been prepared pursuant to the rules and
 regulations of the Securities and Exchange Commission (SEC).
 Certain information and footnote disclosures normally included in
 financial statements prepared in accordance with accounting
 principles generally accepted in the United States of America
 (GAAP) have been condensed or omitted from this report, as is
 permitted by such rules and regulations. Accordingly, these
 consolidated financial statements should be read in conjunction
 with the financial statements and notes thereto included in the
 Company&#x2019;s Prospectus filed with the SEC pursuant to Rule
 424(b)(4) on October&#xA0;11, 2013 (the Prospectus). In the opinion
 of the Company&#x2019;s management, the consolidated unaudited
 interim consolidated financial statements reflect all adjustments
 necessary to present fairly the results of operations for the three
 and nine months ended September&#xA0;30, 2013 and 2012, the
 Company&#x2019;s financial position as of September&#xA0;30, 2013,
 and the cash flows for the nine months ended September&#xA0;30,
 2013 and 2012. These adjustments are of a normal recurring nature.
 The results of operations for the three and nine months ended
 September&#xA0;30, 2013 are not necessarily indicative of future
 financial results.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company currently operates in one operating segment. Operating
 segments are defined as components of an enterprise about which
 separate discrete information is available for the chief operating
 decision maker, or decision making group, in deciding how to
 allocate resources and assessing performance. The Company views its
 operations and manages its business in one segment, which is
 developing monoclonal antibody-based therapeutics for cancer,
 autoimmune and infectious diseases.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On October&#xA0;16, 2013, the Company completed an initial public
 offering (IPO) of its common stock, which resulted in the sale of
 5,750,000 shares, including all additional shares available to
 cover over-allotments, at a price of $16.00 per share. The Company
 received net proceeds before expenses from the IPO of $85.6 million
 after deducting underwriting discounts and commissions paid by the
 Company.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28200181&amp;loc=SL6228881-111685<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 720<br><br> -SubTopic 15<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122524<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7668296&amp;loc=d3e288-107754<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2197480<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 915<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6472506&amp;loc=d3e38932-110933<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 852<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2209116<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 272<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2134480<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2122150<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>3. Property and Equipment</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Property and equipment consists of the following:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,172,535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,003,706</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,323,081</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,323,081</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,603,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,747,790</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,893,770</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,881,706</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Property and equipment</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,643,994</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,607,293</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(15,174,112</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,339,497</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,469,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,267,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Depreciation and amortization expense for the three months ended
 September&#xA0;30, 2013 and 2012 was $316,852 and $235,543,
 respectively, and $834,615 and $722,496 for the nine months ended
 September&#xA0;30, 2013 and 2012, respectively.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Lease Exit Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>6. Lease Exit Liability</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On July&#xA0;16, 2008, the Company acquired Raven Biotechnologies,
 Inc. (Raven), a private South San Francisco-based company focused
 on the development of monoclonal antibody therapeutics for treating
 cancer. Raven was considered a development-stage enterprise as
 defined in ASC&#xA0;915, <i>Development Stage Entities</i>. In
 connection with the acquisition, the Company issued 12,466,039
 shares of its Series D convertible preferred stock in exchange for
 all of the outstanding capital stock and convertible notes payable
 of Raven.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company undertook restructuring activities related to the
 acquisition of Raven. These restructuring activities included
 reductions in staffing levels and the intended exit of leased
 facilities. All severance-related payments were completed in the
 year ended December&#xA0;31, 2009.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In connection with these restructuring activities, as part of the
 cost of acquisitions, the Company established a restructuring
 liability attributed to an existing operating lease. The terms of
 the operating lease extend through 2018.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Changes in the lease exit liability are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="7%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrual balance at December&#xA0;31, 2011</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,607,499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(533,560</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrual balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,073,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(466,301</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrual balance at September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,607,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of September&#xA0;30, 2013
 are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Twelve Months Ending September&#xA0;30,</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,229,454</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2015</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,589,410</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2016</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,808,119</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2017</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,049,273</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2018</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,315,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">616,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,607,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The purchase agreement provides for a specified total of certain
 contingent milestones that are based on the achievement of certain
 product sales derived from the acquired Raven technology. Also, a
 onetime payment of $5.0&#xA0;million will be made to the Raven
 stockholders upon the initiation of patient dosing in the first
 Phase 2 clinical trial of any product derived from the Raven
 &#x201C;Cancer Stem Cell Program.&#x201D; No payment shall be made if
 the Phase 2 trial start date has not occurred on or before
 July&#xA0;15, 2018. Other consideration includes a percentage of
 revenue (excluding consideration for research and development and
 equity) received by MacroGenics for license of a product derived
 from the Raven &#x201C;Cancer Stem Cell Program&#x201D; and a onetime
 payment ranging from $8.0&#xA0;million to $12.0&#xA0;million
 dependent upon a specified level of sales of products derived from
 the Raven &#x201C;Cancer Stem Cell Program.&#x201D;</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The contingent consideration will be accounted for as additional
 purchase price and recorded as incremental in-process research and
 development expense when it is deemed probable that the
 contingencies will be attained. No additional amounts have been
 recorded during the nine months ended September&#xA0;30, 2013 and
 2012.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section P<br><br> -Subsection 3, 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 5.P.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>4. Stockholders&#x2019; Equity (Deficit)</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During 2002 and 2003, the Company issued a total of 34,239,374
 shares of Series A-1 and Series A-2 convertible preferred stock
 (Series A preferred stock) for $1.00 per share resulting in net
 proceeds of approximately $34,000,000.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On October&#xA0;12, 2004, the Company entered into a series of
 transactions raising $30,261,672, net of related offering costs of
 approximately $238,000, from the sale of 71,401,237 shares of its
 Series B convertible preferred stock (Series B preferred stock). In
 connection with the Series B preferred stock offering, 13,604,016
 shares of common stock were allocated to holders of Series&#xA0;A-1
 preferred stock as an anti-dilution measure but remained unissued
 at September&#xA0;30, 2013. Upon completion of the IPO in October
 2013, these allocated shares were converted into shares of common
 stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On May&#xA0;16, 2006, the Company raised $44,898,754, net of
 related offering costs of $101,246, from the sale of 110,952,217
 shares of its Series C convertible preferred stock (Series C
 preferred stock). In connection with the Series C preferred stock
 offering, 10,003,300 shares of common stock were allocated to
 holders of Series B preferred stock as an anti-dilution measure but
 remained unissued at September&#xA0;30, 2013. Upon completion of
 the IPO in October 2013, these allocated shares were converted into
 shares of common stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On July&#xA0;16, 2008, the Company issued 12,466,039 shares of its
 Series D convertible preferred stock (Series D preferred stock) in
 exchange for all of the outstanding capital stock and convertible
 notes payable of Raven Biotechnologies, Inc. (Raven). Subsequently,
 in March 2011 a settlement was reached with the former Raven
 stockholders bringing the total Series D preferred stock issued in
 connection with the Raven acquisition to 14,446,227 shares.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On September&#xA0;19, 2008, the Company raised $24,843,211, net of
 related offering costs of $156,788, from the sale of 38,337,678
 shares of its Series D-2 convertible preferred stock (Series D-2
 preferred stock). The Company also issued preferred stock warrants
 for the purchase of 2,875,327 shares of Series D-2 preferred stock.
 The preferred stock warrants are exercisable at any time prior to
 September&#xA0;2018, but expire upon an IPO, and have a stated
 exercise price of $0.65 per warrant. On May&#xA0;16, 2010, the
 Company exercised a put notice to Lilly in accordance with the
 Series D-2 preferred stock purchase agreement, resulting in the
 issuance of 6,916,110 shares of Series D-2 preferred stock and a
 warrant to purchase 518,708 additional shares of Series D-2
 preferred stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On January&#xA0;11, 2011, the Company raised gross proceeds for
 $12,016,500 from the sale of 18,427,388 shares of its Series D-2
 preferred stock. Issuance costs associated with the sale were not
 material.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Due to certain provisions in the Series D-2 convertible preferred
 stock warrant agreement, these warrants are required to be
 classified as a liability. Management believes that the
 circumstances requiring cash settlement of the award are remote.
 The Series D-2 preferred stock warrant liability is recorded at
 fair value, which is adjusted at the end of each reporting period
 using the Option-Pricing Method, with changes in value recorded as
 &#x201C;Other income (expense)&#x201D; in the accompanying
 consolidated statements of operations.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Holders of the Series A-1, Series A-2, Series B, Series C, Series D
 and Series D-2 preferred stock are entitled to vote, together with
 the common stockholders as one class, on all matters as to which
 common stockholders are entitled to vote. In any such vote, each
 share of Series A, Series B, Series C and Series D preferred stock
 shall entitle the holder to the number of votes per share that
 equals the number of shares of common stock into which each such
 share of preferred stock is then convertible. For so long as at
 least four&#xA0;million shares of each of the Series A, Series B
 and Series C preferred stock remain outstanding, the holders of
 each of the Series A, Series B and Series C preferred stock, each
 voting as a separate class, shall each be entitled to elect two
 members of the Board of Directors of the Company. The holders of a
 majority of the common stock, voting as a separate class, shall
 have the right to elect one member of the Board of Directors of the
 Company. The holders of a majority of the common stock and the
 holders of at least 66 2/3% of the preferred stock, each voting
 separately as a single class (and on an as-if-converted basis to
 common stock with respect to the preferred stock), shall be
 entitled to elect all remaining members of the Board of
 Directors.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Dividends are noncumulative and accrue on the Series A-1, Series
 A-2, Series B, Series C, Series D and Series&#xA0;D-2 preferred
 stock at a rate of $0.08, $0.0341, $0.0324 and $0.0522 per annum,
 respectively, and are payable when and as declared by the Board of
 Directors. Dividends must be declared so that the Series A,
 Series&#xA0;B, Series C and Series D preferred stock are paid in
 like-kind and participate equally to those of the Series&#xA0;D-2
 preferred and common stock. No dividends have been declared and
 none are accrued at September&#xA0;30, 2013 or December&#xA0;31,
 2012.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s Series A-1, Series A-2, Series B, Series C,
 Series D and Series D-2 preferred stock are initially convertible
 into 1.506, 1.00, 1.14, 1.00, 1.00 and 1.00 shares, respectively,
 of common stock at the option of the holder. The conversion ratio
 of certain series of preferred stock is subject to change in the
 event specified dilutive transactions occur. These dilutive events
 are considered to be the sale of common stock at a per share price
 less than the applicable preferred stock conversion price. There
 are no anti-dilution protections for the Series A-2 preferred stock
 and no adjustment to the Series A-1 preferred stock conversion
 price is made if a common stock issuance is at a price per share
 greater than the conversion price of the Series C preferred stock.
 The conversion price shall be $12.39, $18.77, $6.95, $7.70, $12.20
 and $12.20 for each share of Series A-1, A-2, Series B, Series C,
 Series D and Series D-2 convertible preferred stock, respectively.
 The Company has reserved 17,129,782 shares of common stock for the
 potential conversion of the Series A-1, Series A-2, Series B,
 Series&#xA0;C, Series D and Series D-2 preferred stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Each share of Series A-1, Series A-2, Series B, Series C, Series D
 and Series D-2 preferred stock automatically converts into shares
 of the Company&#x2019;s common stock upon closing of a firm
 commitment underwritten public offering of common stock registered
 under the Securities Act of 1933 which generates net proceeds to
 the Company of at least $40&#xA0;million. The holders of two-thirds
 of the Series&#xA0;A-1, Series&#xA0;A-2, Series&#xA0;B, Series C,
 Series D and Series D-2 preferred stock, voting together as a
 single class, but separately from the common stockholders, shall
 have the right to elect to convert all outstanding shares of Series
 A-1, Series&#xA0;A-2, Series&#xA0;B, Series C, Series D and Series
 D-2 preferred stock into shares of common stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In liquidation, the holders of Series D-2 preferred stock are
 entitled to receive $12.20 per share prior to any distribution to
 the holders of any Series C and Series D preferred stock. The
 holders of Series C and Series&#xA0;D preferred stock are entitled
 to receive $7.70 and $12.20 per share, respectively, on a <i>pari
 passu</i> basis, prior to any distribution to the holders of any
 Series B preferred stock. The holders of Series B preferred stock
 are entitled to receive $6.95 per share prior to any distribution
 to the holders of any shares of Series A preferred stock. The
 holders of Series A preferred stock are entitled to receive $12.39
 per share prior to the holders of common stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In connection with preparing for its IPO in October 2013 (see Note
 11, Subsequent Events, for additional information), the
 Company&#x2019;s Board of Directors and stockholders approved a
 1-for-18.7739 reverse stock split of the Company&#x2019;s Common
 Stock. The reverse stock split became effective on
 September&#xA0;26, 2013. All share and per share amounts in the
 consolidated financial statements and notes thereto have been
 retroactively adjusted for all periods presented to give effect to
 this reverse stock split, including reclassifying an amount equal
 to the reduction in par value of common stock to additional paid-in
 capital. In addition, in September 2013, the Company&#x2019;s Board
 of Directors and stockholders approved an amendment of the
 Company&#x2019;s certificate of incorporation to, among other
 things, change the definition of a designated public offering to
 remove the per share price requirement.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityNoteDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E6FAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems', window );"><strong>Clone 1 Of Future Minimum Leases Payments Under Leases (Line Items)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 3,460,609<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">3,396,780<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">3,385,321<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">3,486,881<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">3,035,013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="nump">625,540<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">17,390,144<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Contract Termination [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems', window );"><strong>Clone 1 Of Future Minimum Leases Payments Under Leases (Line Items)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">1,229,454<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">1,589,410<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">1,808,119<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">2,049,273<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">2,315,026<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="nump">616,356<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 9,607,638<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CloneOfFutureMinimumLeasesPaymentsUnderLeasesLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EOZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail) (Accounts Receivable [Member])<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Gilead [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">51.20%<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Pfizer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">22.60%<span></span></td>
        <td class="nump">45.40%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Boehringer [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">11.10%<span></span></td>
        <td class="nump">18.00%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Eli Lilly [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">11.00%<span></span></td>
        <td class="nump">28.20%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Government Agencies [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Significant Accounts Receivable</a></td>
        <td class="nump">4.00%<span></span></td>
        <td class="nump">8.40%<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 21<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13537-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6404-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 20<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28364263&amp;loc=d3e13531-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 18<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6351-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ConcentrationRiskPercentage1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EUHAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">$ 19,643,994<span></span></td>
        <td class="nump">$ 17,607,293<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
        <td class="num">(15,174,112)<span></span></td>
        <td class="num">(14,339,497)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">4,469,882<span></span></td>
        <td class="nump">3,267,796<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">2,172,535<span></span></td>
        <td class="nump">2,003,706<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Software [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">1,323,081<span></span></td>
        <td class="nump">1,323,081<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">599,650<span></span></td>
        <td class="nump">599,650<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Lab Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">10,603,598<span></span></td>
        <td class="nump">8,747,790<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Office Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">51,360<span></span></td>
        <td class="nump">51,360<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
        <td class="nump">$ 4,893,770<span></span></td>
        <td class="nump">$ 4,881,706<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentGross</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EEXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
        <td class="nump">0.00%<span></span></td>
        <td class="nump">0.00%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">51.00%<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1.18%<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected average life of options</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock', window );">Fair market value of common stock at:</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1.50<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions', window );">Expected forfeiture rate</a></td>
        <td class="nump">5.06%<span></span></td>
        <td class="nump">5.57%<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">53.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">1.24%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock', window );">Fair market value of common stock at:</a></td>
        <td class="nump">$ 1.50<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
        <td class="nump">58.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump">2.05%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock', window );">Fair market value of common stock at:</a></td>
        <td class="nump">$ 7.51<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award options fair market value of stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsFairMarketValueOfStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(v)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>37
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y
M/2(M+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V
M-C5B.#4P8F$B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7
M96(@4&%G92P@86QS;R!K;F]W;B!A<R!A(%=E8B!!<F-H:79E(&9I;&4N("!)
M9B!Y;W4@87)E('-E96EN9R!T:&ES(&UE<W-A9V4L('EO=7(@8G)O=W-E<B!O
M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
M4&QE87-E(&1O=VYL;V%D(&$@8G)O=W-E<B!T:&%T('-U<'!O<G1S(%=E8B!!
M<F-H:79E+"!S=6-H(&%S($UI8W)O<V]F="!);G1E<FYE="!%>'!L;W)E<BX-
M"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE971S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^0V]N<V]L:61A=&5D7T)A;&%N8V5?4VAE971S7U!A/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7U-T871E;65N='-?;V9?3W!E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`T+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N<V]L:61A=&5D7U-T871E;65N='-?;V9?0V%S/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`U+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3W9E<G9I97=?
M86YD7T)A<VES7V]F7U!R97-E;G1A/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`V+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O<&5R
M='E?86YD7T5Q=6EP;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='E?1&5F:6-I=#PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970P.2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-H87)E9$)A<V5D7U!A
M>6UE;G1S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968]
M,T0B5V]R:W-H965T<R]3:&5E=#$P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^
M3&5A<V5?17AI=%],:6%B:6QI='D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3$N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y#;VQL86)O<F%T:6]N7V%N9%],:6-E;G-E7T%G<F4\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,3(N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M
M96YT<U]A;F1?0V]N=&EN9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/E!R;V1U8W1?36EL97-T;VYE7U!A>6UE;G1S7V%N
M9#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D5M<&QO
M>65E7T)E;F5F:71?4&QA;CPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#$V+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!
M8V-O=6YT,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#(\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y0<F]P97)T>5]A;F1?17%U:7!M
M96YT7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S7U1A8FQE<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DQE87-E7T5X:71?3&EA8FEL:71Y
M7U1A8FQE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970R,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S7SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R
M,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D]R9V%N:7IA=&EO;E]A;F1?3F%T
M=7)E7V]F7T]P93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970R,RYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C;W5N=#,\+W@Z3F%M93X-
M"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H
M965T,C0N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z
M17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI
M9FEC86YT7T%C8V]U;G0T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(U+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT-3PO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970R-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?
M4VEG;FEF:6-A;G1?06-C;W5N=#8\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C<N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y3=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0W
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#(X+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4W5M;6%R
M>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT.#PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R.2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/E-U;6UA<GE?;V9?4VEG;FEF:6-A;G1?06-C
M;W5N=#D\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,S`N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3
M=6UM87)Y7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0Q,#PO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S
M,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE
M;G1?4V-H961U;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(
M4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,BYH=&UL(B\^#0H@("`\+W@Z17AC
M96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.
M86UE/E!R;W!E<G1Y7V%N9%]%<75I<&UE;G1?061D:71I;SPO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970S,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I
M='E?1&5F:6-I=%]!9#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-"YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S7T%D9&ET:6]N83PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-H87)E9$)A<V5D7U!A
M>6UE;G1S7U-C:&5D=6QE7SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/E-H87)E9$)A<V5D7U!A>6UE;G1S7U-C:&5D=6QE7S$\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,S<N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3:&%R961"87-E
M9%]087EM96YT<U]38VAE9'5L95\R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3&5A<V5?17AI=%],:6%B:6QI='E?061D:71I;VYA
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#,Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3&5A<V5?
M17AI=%],:6%B:6QI='E?0VAA;F=E<U]I/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^3&5A<V5?17AI=%],:6%B:6QI='E?1G5T=7)E
M7U!R/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#0Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]L
M;&%B;W)A=&EO;E]A;F1?3&EC96YS95]!9W)E,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T,BYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG
M96YC:65S7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T-#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y#;VUM:71M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\R/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#0T+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O9'5C=%]-:6QE<W1O;F5?
M4&%Y;65N='-?86YD,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C
M92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-2YH=&UL(B\^#0H@("`\+W@Z
M17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\
M>#I.86UE/D5M<&QO>65E7T)E;F5F:71?4&QA;E]!9&1I=&EO;CPO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970T-BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-U8G-E<75E;G1?179E
M;G1S7T%D9&ET:6]N86Q?23PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970T-RYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@(#PO>#I%>&-E;%=O<FMS:&5E=',^#0H@
M(#QX.E-T>6QE<VAE970@2%)E9CTS1")7;W)K<VAE971S+W)E<&]R="YC<W,B
M+SX-"B`@/'@Z06-T:79E4VAE970^,#PO>#I!8W1I=F53:&5E=#X-"B`@/'@Z
M4')O=&5C=%-T<G5C='5R93Y&86QS93PO>#I0<F]T96-T4W1R=6-T=7)E/@T*
M("`\>#I0<F]T96-T5VEN9&]W<SY&86QS93PO>#I0<F]T96-T5VEN9&]W<SX-
M"B`\+W@Z17AC96Q7;W)K8F]O:SX-"CPO>&UL/CPA6V5N9&EF72TM/@T*/"]H
M96%D/@T*("`\8F]D>3X-"B`@(#QP/E1H:7,@<&%G92!S:&]U;&0@8F4@;W!E
M;F5D('=I=&@@36EC<F]S;V9T($5X8V5L(%A0(&]R(&YE=V5R+CPO<#X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X
M7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B
M.#4P8F$O5V]R:W-H965T<R]3:&5E=#`Q+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,4%!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$;V-U;65N="!A;F0@16YT:71Y($EN
M9F]R;6%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$;V-U;65N="!!;F0@16YT:71Y($EN9F]R;6%T:6]N(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG,3`M43QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%M96YD;65N="!&;&%G/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG9F%L<V4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!097)I;V0@16YD
M($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E-E<"`S,"P-
M"@D),C`Q,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A;"!996%R($9O8W5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`Q,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M96YT($9I<V-A
M;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B=1,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!296=I<W1R86YT($YA;64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B=-04-23T=%3DE#4R!)3D,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V5N
M=')A;"!);F1E>"!+97D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<P,#`Q,3(U,S0U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0W5R<F5N="!&:7-C86P@665A<B!%;F0@1&%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)RTM,3(M,3,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B=.;VXM86-C96QE<F%T960@1FEL97(\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0V]M;6]N(%-T
M;V-K+"!3:&%R97,@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-2PP,C`L,C@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
M+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V
M-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W
M,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE
M970P,BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M
M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB
M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P15%60D<^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^0V]N<V]L:61A=&5D($)A;&%N8V4@4VAE971S("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D-U<G)E;G0@87-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S,L-38Y+#$Y
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#<L-S0S+#$U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C;W5N=',@<F5C96EV86)L93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR.#$L,C@R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP-#8L,C$Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&5X<&5N<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#$P,RPT-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,S<L-C,T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@8W5R<F5N="!A<W-E=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,V+#DU,RPY,CD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT.2PY,C<L,#`X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y297-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0P-"PX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XT,#0L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N
M970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#8Y+#@X,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L
M,C8W+#<Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3W1H97(@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-#<L,C0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,30W+#(T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L.3<U+#DP-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S+#<T-BPY,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^0W5R<F5N="!L:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#<Y."PR,C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#<S
M.2PQ,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/CDS.2PX,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#(S-RPP,C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E(&5X:70@;&EA8FEL
M:71Y("T@8W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PR,CDL-#4T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-C(X+#<V.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU92`M(&-U<G)E;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#(Y."PS,3@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-"PQ
M,C,L,3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@8W5R<F5N="!L:6%B:6QI=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C4L,C8U+#@Q,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#<R."PP.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE
M87-E(&5X:70@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XX+#,W."PQ.#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XY+#0T-2PQ-S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9F5R<F5D(')E;G0@;&EA8FEL
M:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@X."PV.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#@P,2PV-3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C<Y+#(Y-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4R+#DT-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5F97)R960@<F5V96YU92P@;F5T(&]F(&-U<G)E;G0@<&]R=&EO;CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PX,3(L,S0R/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DL.34V+#,T
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E1O=&%L(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT-BPP,C0L,S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-C$L.3@T+#(P.#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO
M;&1E<G,G(&5Q=6ET>2`H9&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"`D,"XP,2!P
M87(@=F%L=64@+2`T,C4L,#`P+#`P,"!S:&%R97,@875T:&]R:7IE9"P@,BPQ
M,C0L-C(T(&%N9"`Q+#`Y."PY,30@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A
M;F1I;F<@870@4V5P=&5M8F5R(#,P+"`R,#$S(&%N9"!$96-E;6)E<B`S,2P@
M,C`Q,BP@<F5S<&5C=&EV96QY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR,2PR-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,"PY.#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1R96%S=7)Y('-T;V-K+"!A="!C;W-T.R`Q
M-"PS.#$@<VAA<F5S(&%T(%-E<'1E;6)E<B`S,"P@,C`Q,R!A;F0@1&5C96UB
M97(@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4W
M+#<T,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@U-RPW-#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L('!A:60M:6X@8V%P:71A;#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38U+#4V.2PQ,S0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-C0L,S,T
M+#8T-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,3<R+#4R."PR-30I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3<U+#0W,BPT,#,I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!S
M=&]C:VAO;&1E<G,G(&5Q=6ET>2`H9&5F:6-I="D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#0L,#0X+#0Q-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@X+#(S-RPS,#@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@
M;&EA8FEL:71I97,@86YD('-T;V-K:&]L9&5R<R<@97%U:71Y("AD969I8VET
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#$L.3<U+#DP-SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4S
M+#<T-BPY,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-E<FEE<R!!+3$@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T
M;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>2`H9&5F:6-I="DZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-C@L-S0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8X+#<T.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$M,B!#;VYV97)T
M:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-T;V-K:&]L9&5R<R<@97%U
M:71Y("AD969I8VET*3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S+#8T-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<S+#8T-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R
M:65S($(@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C
M:VAO;&1E<G,G(&5Q=6ET>2`H9&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R
M<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,30L
M,#$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S$T+#`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5R:65S($,@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T
M;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G(&5Q=6ET>2`H9&5F:6-I="DZ/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N
M=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#$P.2PU,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$P.2PU,C(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!$+3$@0V]N
M=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G
M(&5Q=6ET>2`H9&5F:6-I="DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#0L-#8R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T+#0V
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V5R:65S($0M,B!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E-T;V-K:&]L9&5R<R<@97%U:71Y("AD969I8VET*3H\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L
M92!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@-C,V+#@Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-C,V+#@Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X
M-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T
M-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H
M965T,#,N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5--$)'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/D-O;G-O;&ED871E9"!"86QA;F-E(%-H965T<R`H4&%R96YT:&5T:6-A
M;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO
M;B!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0R-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#(U+#`P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S
M=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPQ,C0L-C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP.3@L.3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPQ,C0L-C(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PP.3@L.3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y4<F5A<W5R>2!S=&]C:RP@<VAA<F5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS.#$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E
M<FEE<R!!+3$@0V]N=F5R=&EB;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB
M;&4@<')E9F5R<F5D('-T;V-K+"!P87(@=F%L=64\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E
M9F5R<F5D('-T;V-K+"!S:&%R97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8L.#<T+#<Y,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#@W-"PW.3(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E
M<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8L.#<T+#<Y,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#@W-"PW.3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&]U='-T86YD
M:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-BPX-S0L-SDR
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C8L.#<T+#<Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06=G<F5G871E(&QI<75I9&%T:6]N('!R969E<F5N8V4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C<L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C<L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5R:65S($$M,B!#;VYV97)T:6)L92!0<F5F97)R960@
M4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,V-"PU.#(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#,V
M-"PU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&ES
M<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPS-C0L-3@R
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPS-C0L-3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E
M<R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-RPS-C0L-3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-RPS-C0L-3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@;&EQ=6ED871I;VX@<')E
M9F5R96YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y397)I97,@0B!#;VYV97)T:6)L92!0<F5F97)R960@
M4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('!A<B!V86QU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!A=71H;W)I>F5D
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PT,#$L,C,W/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S$L
M-#`Q+#(S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!S:&%R97,@
M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PT,#$L
M,C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-S$L-#`Q+#(S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K+"!S
M:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<Q+#0P,2PR,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW,2PT,#$L,C,W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@;&EQ=6ED871I
M;VX@<')E9F5R96YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,S$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,Q+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<FEE<R!#($-O;G9E<G1I8FQE(%!R
M969E<G)E9"!3=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<&%R
M('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U
M=&AO<FEZ960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q,"PY
M-3(L,C$W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3$P+#DU,BPR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C
M:RP@<VAA<F5S(&ES<W5E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$P+#DU,BPR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,3`L.34R+#(Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E9F5R
M<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q,"PY-3(L,C$W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#DU,BPR,3<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%G9W)E
M9V%T92!L:7%U:61A=&EO;B!P<F5F97)E;F-E/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4L,#`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($0M
M,2!#;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F
M97)R960@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!P<F5F97)R960@
M<W1O8VLL('-H87)E<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@
M<')E9F5R<F5D('-T;V-K+"!S:&%R97,@:7-S=65D/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-"PT-#8L,C(W/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L-#0V+#(R-SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@<')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0T-BPR,C<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PT-#8L
M,C(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y!9V=R96=A=&4@;&EQ=6ED871I;VX@<')E9F5R96YC93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PT,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M97)I97,@1"TR($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE('!R969E<G)E9"!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE('!R
M969E<G)E9"!S=&]C:RP@<VAA<F5S(&%U=&AO<FEZ960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-2PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV
M97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8S+#8X,2PQ-S8\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,RPV.#$L,3<V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYV97)T:6)L92!P<F5F97)R960@<W1O8VLL('-H87)E<R!O=71S=&%N
M9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,L-C@Q+#$W
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8S+#8X,2PQ-S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%G9W)E9V%T92!L:7%U:61A=&EO;B!P<F5F97)E;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#0Q+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T
M,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3:&5E=#`T+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%2C9!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VYS;VQI
M9&%T960@4W1A=&5M96YT<R!O9B!/<&5R871I;VYS(&%N9"!#;VUP<F5H96YS
M:79E($EN8V]M92`H3&]S<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R
M/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M4F5V96YU97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y2979E;G5E(&9R;VT@8V]L;&%B;W)A=&EV92!R97-E87)C
M:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,"PQ,3$L,3<S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q-2PU,S(L-C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`T,BPP,34L.3DT/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,"PR.#,L-3$P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F%N="!R
M979E;G5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,C`L.#DU
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-30X+#@V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,3$R+#(S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,L-S0T+#`T-SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(')E=F5N=65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PR,S(L,#8X/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38L,#@Q
M+#4T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0S+#$R."PR,S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-"PP,C<L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O<W1S(&%N9"!E
M>'!E;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!D979E;&]P;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3$L,#@W+#DQ.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#DV."PR-3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,BPR
M,S,L.#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,S8L.3(T+#DX-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L.3@V+#4U-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3$T
M+#,S-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C<L,S(R+#DW-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C8L-C0P+#<T,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L(&-O<W1S(&%N9"!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,L,#<T+#0W
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$S+#0X,BPU.#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS.2PU-38L.#`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-#,L-38U+#<R-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8V]M92`H;&]S
M<RD@9G)O;2!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XW+#$U-RPU.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#4Y."PY-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4W,2PT,S`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PT-C$L.#,P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!I;F-O;64@*&5X<&5N<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@U-3,L-C$R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH-C(W+#(X,2D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#<U,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C;VUP
M<F5H96YS:79E(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@-BPV,#,L.3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#8P,"PU,30\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(L.30T+#$T.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3`L-#8V+#4X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F%S:6,@;F5T(&EN8V]M92`H;&]S<RD@<&5R(&-O;6UO
M;B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$:6QU=&5D(&YE="!I;F-O;64@*&QO<W,I('!E<B!C;VUM
M;VX@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F%S:6,@=V5I9VAT960@879E<F%G92!N=6UB97(@;V8@
M8V]M;6]N('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PQ.#0L-3`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PP.3(L,S`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2PT-C,L-SDX/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PP-S@L,30U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$:6QU=&5D
M('=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#(T,BPY-S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,2PU,#(L
M-#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,C$L.3`X+#@U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C(Q+#0Q,BPX-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E
M.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F
M-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3
M:&5E=#`U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%0C)!13X-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT<R!O9B!#87-H($9L;W=S("A5
M4T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/D]P97)A=&EN9R!A8W1I=FET:65S/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&EN8V]M93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#DT-"PQ-#D\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#0V
M-BPU.#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="!I
M;F-O;64@=&\@;F5T(&-A<V@@<')O=FED960@8GD@*'5S960@:6XI(&]P97)A
M=&EN9R!A8W1I=FET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!E>'!E;G-E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,S0L-C$U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(R+#0Y-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M
M8F%S960@8V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS.3,L-38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C(X+#<Y-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!V86QU92!A9&IU<W1M96YT(&]F
M('=A<G)A;G0@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV,C8L,S0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN
M(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8V]U;G1S(')E
M8V5I=F%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S-2PP
M-C,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BPW,3,L-#(Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')E<&%I9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH.38U+#@Q-2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@V.2PR,S$I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#DT,"PX
M.3<I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH-2PT-#0L,C@X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,CDW+#(Q-"D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU,RPX-C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E(&5X:70@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T-C8L
M,S`Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,Y-2PV.30I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R979E;G5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@Q,RPY-C@L.#4Y*3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(W+#DS-2PR-C@I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E
M<G)E9"!R96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-RPP
M,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT,#0L-S(W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!O<&5R871I;F<@86-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3(L.3@X+#0T
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@R-"PR.#$L-#0Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H(&9L;W=S(&9R;VT@:6YV97-T
M:6YG(&%C=&EV:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0=7)C:&%S97,@;V8@<')O<&5R='D@86YD(&5Q=6EP
M;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP,S8L-S`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#4S,"PQ,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&-A<V@@=7-E9"!I;B!I;G9E<W1I;F<@86-T:79I
M=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPP,S8L-S`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#4S,"PQ,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-A<V@@9FQO=W,@9G)O;2!F:6YA;F-I;F<@
M86-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@:7-S=6%N8V4@;V8@8V]M;6]N('-T
M;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-3$L,3@S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#0L
M,S`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3F5T(&-A<V@@<')O=FED960@8GD@9FEN86YC:6YG(&%C=&EV:71I
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U,2PQ.#,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-"PS
M,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.970@8VAA;F=E(&EN(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$T+#$W,RPY-3<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C0L
M-S8W+#(W-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@8F5G:6YN
M:6YG(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-#<L-S0S+#$U-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4U+#(Q."PS-C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N
M=',@870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S,RPU-CDL,3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`S,"PT-3$L,#@U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO
M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?
M86,R85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O
M0SHO83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS
M:&5E=',O4VAE970P-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG
M.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@
M8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\
M345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X
M="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA
M=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@
M0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A
M8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/D]V97)V:65W(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY!8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]V97)V:65W(&%N9"!"
M87-I<R!O9B!0<F5S96YT871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CXQ+B!/=F5R=FEE=R!A;F0@
M0F%S:7,@;V8@4')E<V5N=&%T:6]N/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($UA8W)O1V5N:6-S+"!);F,N("AT:&4@)B-X,C`Q0SM#
M;VUP86YY)B-X,C`Q1#LI('=A<R!I;F-O<G!O<F%T960@:6X-"B!$96QA=V%R
M92!O;B!!=6=U<W0F(WA!,#LQ-"P@,C`P,"X@5&AE($-O;7!A;GD@:7,@82!C
M;&EN:6-A;"US=&%G90T*(&)I;W!H87)M86-E=71I8V%L(&-O;7!A;GD@9F]C
M=7-E9"!O;B!D:7-C;W9E<FEN9R!A;F0@9&5V96QO<&EN9PT*(&EN;F]V871I
M=F4@;6]N;V-L;VYA;"!A;G1I8F]D>2UB87-E9"!T:&5R87!E=71I8W,@9F]R
M('1H92!T<F5A=&UE;G0-"B!O9B!C86YC97(@86YD(&%U=&]I;6UU;F4@9&ES
M96%S97,N(%1H92!#;VUP86YY(&=E;F5R871E<R!I=',-"B!P:7!E;&EN92!O
M9B!P<F]D=6-T(&-A;F1I9&%T97,@9G)O;2!I=',@<')O<')I971A<GD@<W5I
M=&4@;V8-"B!N97AT+6=E;F5R871I;VX@86YT:6)O9'D@=&5C:&YO;&]G>2!P
M;&%T9F]R;7,@=VAI8V@@:70@8F5L:65V97,-"B!I;7!R;W9E('1H92!P97)F
M;W)M86YC92!O9B!M;VYO8VQO;F%L(&%N=&EB;V1I97,@86YD#0H@86YT:6)O
M9'DM9&5R:79E9"!M;VQE8W5L97,N(%1H97-E('!R;V1U8W0@8V%N9&ED871E
M<RP@=VAI8V@@=&AE#0H@0V]M<&%N>2!H87,@:61E;G1I9FEE9"!T:')O=6=H
M(&ET<R!U;F1E<G-T86YD:6YG(&]F(&1I<V5A<V4@8FEO;&]G>0T*(&%N9"!I
M;6UU;F4M;65D:6%T960@;65C:&%N:7-M<RP@;6%Y(&%D9')E<W,@9&ES96%S
M92US<&5C:69I8PT*(&-H86QL96YG97,@=VAI8V@@87)E(&YO="!C=7)R96YT
M;'D@8F5I;F<@;65T(&)Y(&5X:7-T:6YG('1H97)A<&EE<RX-"B!4:&4@0V]M
M<&%N>2!C<F5A=&5S(&)O=&@@9&EF9F5R96YT:6%T960@;6]L96-U;&5S('1H
M870@87)E(&1I<F5C=&5D#0H@=&\@;F]V96P@8V%N8V5R('1A<F=E=',L(&%S
M('=E;&P@87,@)B-X,C`Q0SMB:6\M8F5T=&5R<R8C>#(P,40[('=H:6-H#0H@
M87)E(&1R=6=S(&1E<VEG;F5D('1O(&EM<')O=F4@=7!O;B!M87)K971E9"!M
M961I8VEN97,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H
M92!A8V-O;7!A;GEI;F<@=6YA=61I=&5D(&EN=&5R:6T@8V]N<V]L:61A=&5D
M(&9I;F%N8VEA;`T*('-T871E;65N=',@:6YC;'5D92!T:&4@86-C;W5N=',@
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M;F0@17AC:&%N9V4@0V]M;6ES<VEO;B`H4T5#*2X-"B!#97)T86EN(&EN9F]R
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M=&\@4G5L90T*(#0R-"AB*2@T*2!O;B!/8W1O8F5R)B-X03`[,3$L(#(P,3,@
M*'1H92!0<F]S<&5C='5S*2X@26X@=&AE(&]P:6YI;VX-"B!O9B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!M86YA9V5M96YT+"!T:&4@8V]N<V]L:61A=&5D('5N
M875D:71E9`T*(&EN=&5R:6T@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T
M96UE;G1S(')E9FQE8W0@86QL(&%D:G5S=&UE;G1S#0H@;F5C97-S87)Y('1O
M('!R97-E;G0@9F%I<FQY('1H92!R97-U;'1S(&]F(&]P97)A=&EO;G,@9F]R
M('1H92!T:')E90T*(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F
M(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BP@=&AE#0H@0V]M<&%N>28C>#(P,3D[
M<R!F:6YA;F-I86P@<&]S:71I;VX@87,@;V8@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,L#0H@86YD('1H92!C87-H(&9L;W=S(&9O<B!T:&4@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L#0H@,C`Q,R!A;F0@,C`Q,BX@
M5&AE<V4@861J=7-T;65N=',@87)E(&]F(&$@;F]R;6%L(')E8W5R<FEN9R!N
M871U<F4N#0H@5&AE(')E<W5L=',@;V8@;W!E<F%T:6]N<R!F;W(@=&AE('1H
M<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P
M+"`R,#$S(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV92!O9B!F=71U
M<F4-"B!F:6YA;F-I86P@<F5S=6QT<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M8W1I;W5S(&1I<V5A<V5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B!/;B!/8W1O8F5R)B-X03`[,38L(#(P,3,L('1H92!#;VUP86YY(&-O
M;7!L971E9"!A;B!I;FET:6%L('!U8FQI8PT*(&]F9F5R:6YG("A)4$\I(&]F
M(&ET<R!C;VUM;VX@<W1O8VLL('=H:6-H(')E<W5L=&5D(&EN('1H92!S86QE
M(&]F#0H@-2PW-3`L,#`P('-H87)E<RP@:6YC;'5D:6YG(&%L;"!A9&1I=&EO
M;F%L('-H87)E<R!A=F%I;&%B;&4@=&\-"B!C;W9E<B!O=F5R+6%L;&]T;65N
M=',L(&%T(&$@<')I8V4@;V8@)#$V+C`P('!E<B!S:&%R92X@5&AE($-O;7!A
M;GD-"B!R96-E:79E9"!N970@<')O8V5E9',@8F5F;W)E(&5X<&5N<V5S(&9R
M;VT@=&AE($E03R!O9B`D.#4N-B!M:6QL:6]N#0H@869T97(@9&5D=6-T:6YG
M('5N9&5R=W)I=&EN9R!D:7-C;W5N=',@86YD(&-O;6UI<W-I;VYS('!A:60@
M8GD@=&AE#0H@0V]M<&%N>2X\+W`^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S
M7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A
M+U=O<FMS:&5E=',O4VAE970P-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N
M=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@/&(^,BX@4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y5<V4@;V8@17-T:6UA
M=&5S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4
M:&4@<')E<&%R871I;VX@;V8@=&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S(&EN
M(&%C8V]R9&%N8V4@=VET:"!'04%0#0H@<F5Q=6ER97,@=&AE($-O;7!A;GD@
M=&\@;6%K92!E<W1I;6%T97,@86YD(&IU9&=M96YT<R!I;B!C97)T86EN#0H@
M8VER8W5M<W1A;F-E<R!T:&%T(&%F9F5C="!T:&4@<F5P;W)T960@86UO=6YT
M<R!O9B!A<W-E=',L#0H@;&EA8FEL:71I97,L(')E=F5N=65S(&%N9"!E>'!E
M;G-E<RP@86YD(')E;&%T960@9&ES8VQO<W5R92!O9@T*(&-O;G1I;F=E;G0@
M87-S971S(&%N9"!L:6%B:6QI=&EE<RX@26X@<')E<&%R:6YG('1H97-E(&-O
M;G-O;&ED871E9`T*(&9I;F%N8VEA;"!S=&%T96UE;G1S+"!M86YA9V5M96YT
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M"B!F<F]M('1H97-E(&5S=&EM871E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z
M(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@26X@861D:71I;VXL('1H<F]U9V@@4V5P=&5M8F5R)B-X03`[,S`L(#(P
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M('-T;V-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^0V%S:"!A;F0@0V%S:"!%
M<75I=F%L96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!I;G9E<W1M96YT<R!I
M;B!H:6=H;'D@;&EQ=6ED(&9I;F%N8VEA;`T*(&EN<W1R=6UE;G1S('=I=&@@
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M;F%N8VEA;`T*(&EN<W1I='5T:6]N<RX@0V%S:"!E<75I=F%L96YT<R!A<F4@
M<W1A=&5D(&%T(&%M;W)T:7IE9"!C;W-T+"!P;'5S#0H@86-C<G5E9"!I;G1E
M<F5S="P@=VAI8V@@87!P<F]X:6UA=&5S(&9A:7(@=F%L=64N/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B`\8CX\:3Y!8V-O=6YT<R!296-E:79A8FQE/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!8V-O=6YT<R!R96-E:79A
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M92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A
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M92!W87,@<F5C;W)D960@87,@;V8-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q
M,R!O<B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R+"!A<R!T:&4@0V]M<&%N>0T*
M(&AA<R!A(&AI<W1O<GD@;V8@8V]L;&5C=&EN9R!O;B!A;&P@;W5T<W1A;F1I
M;F<@86-C;W5N=',N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y$969E<G)E9"!)
M;FET:6%L(%!U8FQI8R!/9F9E<FEN9R!#;W-T<SPO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1&5F97)R960@25!/(&-O<W1S(&%S
M(&]F(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!C;VYS:7-T960@;V8-"B!L
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M3V-T;V)E<B`R,#$S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^4F5S=')I8W1E
M9"!#87-H/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
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M:&5E=',@87)E("0T,#0L.#4P(&%T(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S
M#0H@86YD($1E8V5M8F5R)B-X03`[,S$L(#(P,3(N/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B`\8CX\:3Y&86ER(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO
M:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE(&9A
M:7(@;6%R:V5T('9A;'5E<R!O9B!T:&4@9FEN86YC:6%L(&EN<W1R=6UE;G1S
M(&EN8VQU9&5D(&EN('1H90T*(&9I;F%N8VEA;"!S=&%T96UE;G1S+"!W:&EC
M:"!I;F-L=61E(&-A<V@@97%U:79A;&5N=',@86YD(&UO;F5Y#0H@;6%R:V5T
M(&%C8V]U;G1S+"!A<'!R;WAI;6%T92!T:&5I<B!C87)R>6EN9R!V86QU97,@
M870-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@1&5C96UB97(F(WA!
M,#LS,2P@,C`Q,BP@9'5E('1O('1H96ER#0H@<VAO<G0M=&5R;2!M871U<FET
M:65S+B!4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@<F5C=7)R:6YG(&%N9`T*
M(&YO;BUR96-U<G)I;F<@9F%I<B!V86QU92!M96%S=7)E;65N=',@:6X@86-C
M;W)D86YC92!W:71H('1H90T*($9I;F%N8VEA;"!!8V-O=6YT:6YG(%-T86YD
M87)D<R!";V%R9"`H1D%30BD@06-C;W5N=&EN9R!3=&%N9&%R9',-"B!#;V1I
M9FEC871I;VX@*$%30RD@.#(P+"`\:3Y&86ER(%9A;'5E($UE87-U<F5M96YT
M<R!A;F0-"B!$:7-C;&]S=7)E<SPO:3X@*$%30R`X,C`I+B!!4T,@.#(P(&1E
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M92!F;VQL;W=I;F<@=&AR964-"B!C871E9V]R:65S.CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`V<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G
M0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS
M<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E/@T*(#QT
M<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\+W1D/@T*
M(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/DQE=F5L(#$F(WA!,#LF(W@R
M,#$S.R!&86ER('9A;'5E(&ES#0H@9&5T97)M:6YE9"!B>2!U<VEN9R!U;F%D
M:G5S=&5D('%U;W1E9"!P<FEC97,@=&AA="!A<F4@879A:6QA8FQE(&EN#0H@
M86-T:79E(&UA<FME=',@9F]R(&ED96YT:6-A;"!A<W-E=',@86YD(&QI86)I
M;&ET:65S+CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#9P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I
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M;F-L=61E('%U;W1E9`T*('!R:6-E<R!F;W(@<VEM:6QA<B!A<W-E=',@86YD
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M8FQE(&UA<FME="!D871A+CPO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y
M;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P
M(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0Q,#`E
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U)3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1T;W`@=VED=&@],T0R)2!A;&EG;CTS1&QE9G0^)B-X,C`R,CL\
M+W1D/@T*(#QT9"!V86QI9VX],T1T;W`@=VED=&@],T0Q)3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1T;W`@86QI9VX],T1L969T/DQE=F5L(#,F(WA!
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M871E9"!W:71H(&$@9VEV96X@<V5C=7)I='DN/"]T9#X-"B`\+W1R/@T*(#PO
M=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A
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M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($9I;F%N8VEA;"!A<W-E=',@86YD(&QI86)I;&ET:65S
M('-U8FIE8W0@=&\@9F%I<B!V86QU92!M96%S=7)E;65N=',-"B!W97)E(&%S
M(&9O;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P
M.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL
M87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!4
M86)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0T.24^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^
M1F%I<B!686QU92!-96%S=7)E;65N=',@870-"B!397!T96UB97(F(WA!,#LS
M,"P@,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$
M,B!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A;#PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@<F]W<W!A;CTS1#(^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^475O
M=&5D)B-X03`[4')I8V5S)B-X03`[:6X\+V(^/&)R("\^#0H@/&(^06-T:79E
M)B-X03`[36%R:V5T<R8C>$$P.V9O<CPO8CX\8G(@+SX-"B`\8CY)9&5N=&EC
M86P@07-S971S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY3:6=N:69I8V%N="8C>$$P.T]T:&5R/"]B/CQB<B`O/@T*(#QB
M/D]B<V5R=F%B;&4F(WA!,#M);G!U=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I9VYI9FEC86YT/"]B/CQB<B`O/@T*
M(#QB/E5N;V)S97)V86)L93PO8CX\8G(@+SX-"B`\8CY);G!U=',\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DQE=F5L
M(#$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB
M/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N
M=&5R/CQB/DQE=F5L(#,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM
M/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*($%S<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-A<V@@86YD(&-A<V@@
M97%U:79A;&5N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RPU,C(L
M,#(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#4R,BPP,CD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@36]N
M97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,C8L,#0W+#$V.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M-BPP-#<L,38Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B!297-T<FEC=&5D(&-A<V@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XT,#0L.#4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C0P-"PX-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1O=&%L(&%S<V5T<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C,S+#DW-"PP-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S,L.3<T
M+#`T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P
M>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B
M;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!,:6%B:6QI=&EE<SH\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@4')E9F5R<F5D('-T;V-K('=A<G)A;G0@;&EA8FEL:71Y/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#8W.2PR.38\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V-SDL,CDV/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R/@T*(#QT9#X\+W1D/@T*(#QT9"!C;VQS
M<&%N/3-$,38^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,30@86QI9VX],T1C96YT97(^/&(^1F%I<B!686QU92!-96%S
M=7)E;65N=',@870-"B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!R;W=S<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1=6]T960F(WA!,#M0<FEC97,F
M(WA!,#MI;CPO8CX\8G(@+SX-"B`\8CY!8W1I=F4F(WA!,#M-87)K971S)B-X
M03`[9F]R/"]B/CQB<B`O/@T*(#QB/DED96YT:6-A;"!!<W-E=',\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS
M1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$
M8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I9VYI9FEC
M86YT)B-X03`[3W1H97(\+V(^/&)R("\^#0H@/&(^3V)S97)V86)L928C>$$P
M.TEN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^4VEG;FEF:6-A;G0\+V(^/&)R("\^#0H@/&(^56YO8G-E<G9A8FQE
M/"]B/CQB<B`O/@T*(#QB/DEN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,3PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,CPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@07-S971S.CPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ."PV.34L,3DW/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ."PV.34L,3DW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Y+#`T-RPY-3@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,CDL,#0W+#DU.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@4F5S=')I8W1E9"!C87-H
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`T+#@U,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0L.#4P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!4;W1A;"!A<W-E=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT."PQ-#@L,#`U
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C0X+#$T."PP,#4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@3&EA8FEL:71I97,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%!R969E<G)E9"!S=&]C
M:R!W87)R86YT(&QI86)I;&ET>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@U,BPY
M-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/BDF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/B@U,BPY-#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM
M($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@07,@;V8@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@=&AE
M($-O;7!A;GD@=')A;G-F97)R960@:71S(&UO;F5Y#0H@;6%R:V5T(&9U;F1S
M(&9R;VT@3&5V96P@,B!T;R!,979E;"`Q(&)E8V%U<V4@=&AE(&EN<'5T<R!A
M<F4@;F]W#0H@8F%S960@=7!O;B!A('%U;W1E9"!M87)K970@<')I8V4N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!#;VUP86YY)B-X
M,C`Q.3MS($QE=F5L(#$@<V5C=7)I=&EE<R!P<FEM87)I;'D@8V]N<VES="!O
M9@T*(')E<W1R:6-T960@8V%S:"P@8V%S:"!E<75I=F%L96YT<R!A;F0@;6]N
M97D@;6%R:V5T(&9U;F1S+B!4:&4-"B!#;VUP86YY(&1E=&5R;6EN97,@=&AE
M(&5S=&EM871E9"!F86ER('9A;'5E(&9O<B!I=',@3&5V96P@,0T*('-E8W5R
M:71I97,@=7-I;F<@<75O=&5D("AU;F%D:G5S=&5D*2!P<FEC97,@9F]R(&ED
M96YT:6-A;"!A<W-E=',@;W(-"B!L:6%B:6QI=&EE<R!I;B!A8W1I=F4@;6%R
M:V5T<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O
M;7!A;GD@9&5T97)M:6YE<R!T:&4@97-T:6UA=&5D(&9A:7(@=F%L=64@9F]R
M(&ET<R!,979E;"`R#0H@<V5C=7)I=&EE<R!U<VEN9R!T:&4@9F]L;&]W:6YG
M(&UE=&AO9',Z('%U;W1E9"!P<FEC97,@9F]R('-I;6EL87(-"B!A<W-E=',O
M;&EA8FEL:71I97,@:6X@86-T:79E(&UA<FME=',L(&EN<'5T<R!O=&AE<B!T
M:&%N('%U;W1E9`T*('!R:6-E<R!T:&%T(&%R92!O8G-E<G9A8FQE(&9O<B!T
M:&4@87-S970O;&EA8FEL:71Y("AE+F<N+"!I;G1E<F5S=`T*(')A=&5S+"!Y
M:65L9"!C=7)V97,@=F]L871I;&ET:65S+"!D969A=6QT(')A=&5S+"!E=&,N
M*2!A;F0@:6YP=71S#0H@=&AA="!A<F4@9&5R:79E9"!P<FEN8VEP86QL>2!F
M<F]M(&]R(&-O<G)O8F]R871E9"!B>2!O=&AE<@T*(&]B<V5R=F%B;&4@;6%R
M:V5T(&1A=&$N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[
M($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I
M;F<@=&%B;&4@<')O=FED97,@82!R;VQL9F]R=V%R9"!O9B!T:&4@0V]M<&%N
M>28C>#(P,3D[<PT*('!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET
M>2P@=VAI8V@@=V%S('1H92!O;FQY(&9I;F%N8VEA;`T*(&EN<W1R=6UE;G0@
M;65A<W5R960@870@9F%I<B!V86QU92!O;B!A(')E8W5R<FEN9R!B87-I<R!U
M<VEN9PT*('-I9VYI9FEC86YT('5N;V)S97)V86)L92!I;G!U=',@*$QE=F5L
M(#,I(&%S(&1E9FEN960@:6X@05-##0H@.#(P.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$
M8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$.#8E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A;&%N
M8V4@870@1&5C96UB97(F(WA!,#LS,2P@,C`Q,CPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XH-3(L.30W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T
M86P@=6YR96%L:7IE9"!G86EN<R`H;&]S<V5S*2!I;F-L=61E9"!I;B!E87)N
M:6YG<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V,C8L,S0Y
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%L86YC92!A="!397!T96UB
M97(F(WA!,#LS,"P@,C`Q,SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V-SDL,CDV
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z
M(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@
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M9FQO=R!M;V1E;"`H:6YC;VUE(&%P<')O86-H*2X@5&AE($-O;7!A;GD@=71I
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M;W5S(&5Q=6ET>2!I;G-T<G5M96YT<R!S=6-H(&%S('!R969E<G)E9`T*('-T
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M8VQU9&5S(&%S<W5M<'1I;VYS(')E;&%T960@=&\@<')O9'5C=`T*(&%P<')O
M=F%L+"!M87)K970@<&5N971R871I;VX@86YD(&-O<W1S('1O(&1E=F5L;W`@
M=&AE('!R;V1U8W0N#0H@4VEG;FEF:6-A;G0@8VAA;F=E<R!T;R!T:&5S92!A
M<W-U;7!T:6]N<R!W;W5L9"!R97-U;'0@:6X-"B!I;F-R96%S97,O9&5C<F5A
M<V5S('1O('1H92!F86ER('9A;'5E(&]F('1H92!O=71S=&%N9&EN9PT*('=A
M<G)A;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@
M=&]T86P@=6YR96%L:7IE9"!G86EN<R`H;&]S<V5S*2!O;B!T:&4@<')E9F5R
M<F5D('-T;V-K('=A<G)A;G1S#0H@:6YC;'5D960@:6X@96%R;FEN9W,@:7,@
M:6YC;'5D960@87,@82!C;VUP;VYE;G0@;V8@;W1H97(@:6YC;VUE#0H@*&5X
M<&5N<V4I(&EN('1H92!C;VYS;VQI9&%T960@<W1A=&5M96YT(&]F(&]P97)A
M=&EO;G,@86YD#0H@8V]M<')E:&5N<VEV92!I;F-O;64N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B`\8CX\:3Y#;VYC96YT<F%T:6]N(&]F($-R961I="!2:7-K/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!3=6)S=&%N=&EA
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M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
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M<R!A;F0@9V]V97)N;65N=`T*(&%G96YC:65S(&]F(&AI9V@@8W)E9&ET('-T
M86YD:6YG+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!&;W(@
M=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F(WA!
M,#LS,"P@,C`Q,R!A;F0-"B`R,#$R+"!A;&P@;V8@=&AE($-O;7!A;GDF(W@R
M,#$Y.W,@9W)A;G0@<F5V96YU92!W87,@<F5L871E9"!T;PT*(&-O;G1R86-T
M<R!A;F0@<F5S96%R8V@@9W)A;G1S(')E8V5I=F5D(&9R;VT@52Y3+B!G;W9E
M<FYM96YT#0H@86=E;F-I97,N($-O;&QA8F]R871I;VYS('=I=&@@3&5S($QA
M8F]R871O:7)E<R!397)V:65R(&%N9"!);G-T:71U=`T*(&1E(%)E8VAE<F-H
M97,@4V5R=FEE<B`H8V]L;&5C=&EV96QY+"!397)V:65R*2P@0F]E:')I;F=E
M<B!);F=E;&AE:6T-"B!';6)(("A";V5H<FEN9V5R*2P@1VEL96%D(%-C:65N
M8V5S+"!);F,N("A':6QE860I+"!09FEZ97(L($EN8RX-"B`H4&9I>F5R*2!A
M;F0@16QI($QI;&QY)B-X03`[)F%M<#L@0V\N("A%;&D@3&EL;'DI(&%C8V]U
M;G0@9F]R(&%L;`T*(&]T:&5R(')E=F5N=64N($%L;"!O=71S=&%N9&EN9R!R
M96-E:79A8FQE<R!A<F4@9'5E(&9R;VT@1VEL96%D+`T*(%!F:7IE<BP@0F]E
M:')I;F=E<BP@16QI($QI;&QY+"!A;F0@52Y3+B!G;W9E<FYM96YT(&%G96YC
M:65S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F]L
M;&]W:6YG('1A8FQE(')E<')E<V5N=',@=&AE('!E<F-E;G1A9V4@;V8@86QL
M('-I9VYI9FEC86YT#0H@<F5V96YU92!E87)N960@:6X@=&AE('!E<FEO9',@
M:6YD:6-A=&5D.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3(E/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R
M/@T*(#QB/E1H<F5E)B-X03`[36]N=&AS)B-X03`[16YD960F(WA!,#M397!T
M96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S
M;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N
M=&5R/@T*(#QB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E
M<'1E;6)E<B8C>$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B
M;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!397)V:65R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-S$N,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,30N,CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3@N.#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,3(N-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)O96AR:6YG
M97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,2XU/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ-2XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ-2XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-RXR/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1VEL96%D/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`N.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,RXW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+C`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!09FEZ97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XT+C4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-RXS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XW+C0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!';W9E<FYM96YT($%G96YC:65S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,"XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+C4\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(N-CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-BXY/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@16QI($QI;&QY/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XY/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU.2XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4U+C<\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'@[($U!4D=)3BU"3U143TTZ(#!P
M>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@<F5P<F5S96YT
M<R!T:&4@<&5R8V5N=&%G92!O9B!A;&P@<VEG;FEF:6-A;G0-"B!A8V-O=6YT
M<R!R96-E:79A8FQE.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C0E/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY397!T96UB97(F
M(WA!,#LS,"PF(WA!,#LR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($=I;&5A9#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q+C(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!09FEZ97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR,BXV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-2XT/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F]E:')I;F=E
M<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C$\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$X+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!%;&D@3&EL;'D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,2XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."XR/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1V]V97)N;65N="!!9V5N
M8VEE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^."XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M/&(^/&D^4')O<&5R='D@86YD($5Q=6EP;65N=#PO:3X\+V(^/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@4')O<&5R='D@86YD(&5Q=6EP;65N
M="!A<F4@<W1A=&5D(&%T(&-O<W0N(%5P;VX@<F5T:7)E;65N="!O<B!S86QE
M+`T*('1H92!C;W-T(&]F(&%S<V5T<R!D:7-P;W-E9"!O9B!A;F0@=&AE(')E
M;&%T960@86-C=6UU;&%T960-"B!D97!R96-I871I;VX@87)E(')E;6]V960@
M9G)O;2!T:&4@86-C;W5N=',@86YD(&%N>2!R97-U;'1I;F<@9V%I;@T*(&]R
M(&QO<W,@:7,@8W)E9&ET960@;W(@8VAA<F=E9"!T;R!O<&5R871I;VYS+B!2
M97!A:7)S(&%N9`T*(&UA:6YT96YA;F-E(&-O<W1S(&%R92!E>'!E;G-E9"!A
M<R!I;F-U<G)E9"X@1&5P<F5C:6%T:6]N(&%N9`T*(&%M;W)T:7IA=&EO;B!A
M<F4@8V]M<'5T960@=7-I;F<@=&AE('-T<F%I9VAT+6QI;F4@;65T:&]D(&]V
M97(@=&AE#0H@9F]L;&]W:6YG(&5S=&EM871E9"!U<V5F=6P@;&EV97,Z/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B
M;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D
M97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@]
M,T0V."4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L92!(96%D("TM
M/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,"4^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M('=I9'1H/3-$-"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@0V]M<'5T97(@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^,R!Y96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-O9G1W
M87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^,R!Y96%R<SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($9U<FYI='5R93PO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/C$P('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@3&%B;W)A=&]R>2!A
M;F0@;V9F:6-E(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/C4@>65A<G,\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!,96%S96AO;&0@:6UP<F]V
M96UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@4VAO<G1E
M<B8C>$$P.V]F)B-X03`[;&5A<V4F(WA!,#MT97)M)B-X03`[;W(F(WA!,#MU
M<V5F=6PF(WA!,#ML:69E/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^26UP86ER;65N
M="!O9B!,;VYG+4QI=F5D($%S<V5T<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@87-S97-S97,@=&AE(')E
M8V]V97)A8FEL:71Y(&]F(&ET<R!L;VYG+6QI=F5D(&%S<V5T<R!I;@T*(&%C
M8V]R9&%N8V4@=VET:"!T:&4@<')O=FES:6]N<R!O9B!!4T,@,S8P+"`\:3Y0
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M8V@@=&AE(&-A<G)Y:6YG(&%M;W5N="!O9B!T:&4@87-S970@9W)O=7`@97AC
M965D<R!T:&4@97-T:6UA=&5D#0H@9F%I<B!V86QU92!O9B!T:&4@87-S970@
M9W)O=7`N($%S<V5T<R!T;R!B92!D:7-P;W-E9"!O9B!A<F4-"B!R97!O<G1E
M9"!A="!T:&4@;&]W97(@;V8@=&AE(&-A<G)Y:6YG(&%M;W5N="!O<B!F86ER
M('9A;'5E+"!L97-S#0H@8V]S=',@=&\@<V5L;"X@07,@;V8@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,@86YD($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q,BP@
M=&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H97)E('=E<F4@;F\@:6UP
M86ER960@87-S971S(&%N9`T*(&AA9"!N;R!A<W-E=',@:&5L9"UF;W(M<V%L
M92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/E)E=F5N=65S/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($U!4D=)3BU,
M1494.B`R)3L@1D].5"U325I%.B`Q,'!T)SX-"B`\:3Y2979E;G5E(%)E8V]G
M;FET:6]N/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
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M*&DI)B-X03`[;&EC96YS97,L(&]R(&]P=&EO;G,@=&\@;V)T86EN(&QI8V5N
M<V5S+"!T;R!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('1E8VAN;VQO9VEC86P@
M<&QA=&9O<FUS+"!S=6-H(&%S(&ET<R!&8PT*($]P=&EM:7IA=&EO;B!A;F0@
M1'5A;"U!9F9I;FET>2!292U487)G971I;F<@*$1!4E0I('1E8VAN;VQO9VEE
M<RP-"B`H:6DI)B-X03`[<FEG:'1S('1O(&9U='5R92!T96-H;F]L;V=I8V%L
M(&EM<')O=F5M96YT<RP-"B`H:6EI*28C>$$P.W)E<V5A<F-H(&%N9"!D979E
M;&]P;65N="!A8W1I=FET:65S('1O(&)E('!E<F9O<FUE9"!O;@T*(&)E:&%L
M9B!O9B!T:&4@8V]L;&%B;W)A=&]R(&]R(&%S('!A<G0@;V8@=&AE(&-O;&QA
M8F]R871I;VXL(&%N9`T*("AI=BDF(WA!,#MT:&4@;6%N=69A8W1U<F4@;V8@
M<')E+6-L:6YI8V%L(&]R(&-L:6YI8V%L(&UA=&5R:6%L<R!F;W(-"B!T:&4@
M8V]L;&%B;W)A=&]R+B!087EM96YT<R!T;R!T:&4@0V]M<&%N>2!U;F1E<B!T
M:&5S92!A9W)E96UE;G1S#0H@;6%Y(&EN8VQU9&4@;F]N<F5F=6YD86)L92!L
M:6-E;G-E(&9E97,L(&]P=&EO;B!F965S+"!E>&5R8VES92!F965S+`T*('!A
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M<V5L;`T*('!R;V1U8W1S(')E<W5L=&EN9R!F<F]M('1H92!C;VQL86)O<F%T
M:79E(&5F9F]R=',@;V8@=&AE('!A<G1I97,@:6X-"B!S<&5C:69I8R!G96]G
M<F%P:&EC('1E<G)I=&]R:65S+B!4:&4@0V]M<&%N>2!F;VQL;W=S('1H92!P
M<F]V:7-I;VYS#0H@;V8@=&AE($9!4T(@05-#(%1O<&EC(#8P-2TR-2P@/&D^
M4F5V96YU90T*(%)E8V]G;FET:6]N)B-X03`[)B-X,C`Q,SM-=6QT:7!L92U%
M;&5M96YT($%R<F%N9V5M96YT<SPO:3XL(&%N9"!!4T,-"B!4;W!I8R`V,#4M
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M92!U;FET<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1F]R
M('1H92!P97)I;V1S('!R97-E;G1E9"P@=&AE($-O;7!A;GD@:&%D('1H92!F
M;VQL;W=I;F<@='=O('1Y<&5S#0H@;V8@86=R965M96YT<R!W:71H('1H92!P
M87)T:65S(&ED96YT:69I960@8F5L;W<Z(#$I(&5X8VQU<VEV90T*(&1E=F5L
M;W!M96YT(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!L:6-E;G-E<R!T;R!U<V4@
M=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!T96-H;F]L;V=Y(&%N9"]O<B!C97)T
M86EN(&]T:&5R(&EN=&5L;&5C='5A;`T*('!R;W!E<G1Y('1O(&1E=F5L;W`@
M8V]M<&]U;F1S(&%G86EN<W0@<W!E8VEF:65D('1A<F=E=',@*')E9F5R<F5D
M#0H@=&\@:&5R96EN(&%S(&5X8VQU<VEV92!L:6-E;G-E<RD[(&%N9"`R*2!/
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M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%1H97)E(&%R92!N;R!P97)F;W)M86YC92P@
M8V%N8V5L;&%T:6]N+"!T97)M:6YA=&EO;B!O<B!R969U;F0-"B!P<F]V:7-I
M;VYS(&EN(&%N>2!O9B!T:&4@87)R86YG96UE;G1S('1H870@8V]N=&%I;B!M
M871E<FEA;`T*(&9I;F%N8VEA;"!C;VYS97%U96YC97,@=&\@=&AE($-O;7!A
M;GDN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M34%21TE.+4Q%1E0Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QI/D5X8VQU
M<VEV92!,:6-E;G-E<SPO:3X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
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M=6QT(&9R;VT@<W5C:"!A9W)E96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!'96YE<F%L;'DL(&5X8VQU<VEV92!L:6-E;G-E(&%G
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M;VX@=&AE#0H@86-H:65V96UE;G0@;V8@8V5R=&%I;B!M:6QE<W1O;F5S+"`H
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M86YY(&UA>2!P<F]V:61E('1E8VAN:6-A;`T*(&%S<VES=&%N8V4@86YD('-H
M87)E(&%N>2!T96-H;F]L;V=Y(&EM<')O=F5M96YT<R!W:71H(&ET<PT*(&-O
M;&QA8F]R871O<G,@9'5R:6YG('1H92!T97)M(&]F('1H92!C;VQL86)O<F%T
M:6]N(&%G<F5E;65N=',N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1H92!#;VUP86YY(&1O97,@;F]T(&1I<F5C=&QY(&-O;G1R;VP@=VAE
M;B!A;GD@8V]L;&%B;W)A=&]R('=I;&P-"B!A8VAI979E(&UI;&5S=&]N97,@
M;W(@8F5C;VUE(&QI86)L92!F;W(@<F]Y86QT>2!P87EM96YT<RX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@26X@9&5T97)M:6YI;F<@=&AE
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M971E<FUI;F%T:6]N(&EN8VQU9&4@=&AE(')E<V5A<F-H(&%N9`T*(&1E=F5L
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M=&]R<R!S=6-H(&%S('1H92!T97)M<R!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q
M.3MS('!R979I;W5S(&-O;&QA8F]R871I;VX@86=R965M96YT<RP@<F5C96YT
M#0H@<')E+6-L:6YI8V%L(&%N9"!C;&EN:6-A;"!T97-T:6YG(')E<W5L=',@
M;V8@=&AE<F%P975T:6,@<')O9'5C=`T*(&-A;F1I9&%T97,@=&AA="!U<V4@
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M<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@57!F<F]N="!P
M87EM96YT<R!O;B!E>&-L=7-I=F4@;&EC96YS97,@87)E(&1E9F5R<F5D(&EF
M(&9A8W1S(&%N9`T*(&-I<F-U;7-T86YC97,@9&EC=&%T92!T:&%T('1H92!L
M:6-E;G-E(&1O97,@;F]T(&AA=F4@<W1A;F0M86QO;F4-"B!V86QU92X@4')I
M;W(@=&\@=&AE(&%D;W!T:6]N(&]F($%C8V]U;G1I;F<@4W1A;F1A<F1S(%5P
M9&%T92`H05-5*0T*($YO+B8C>$$P.S(P,#DM,3,L(#QI/E)E=F5N=64@07)R
M86YG96UE;G1S('=I=&@@375L=&EP;&4-"B!$96QI=F5R86)L97,\+VD^+"!O
M;B!*86YU87)Y)B-X03`[,2P@,C`Q,2P@=&AE($-O;7!A;GD@9&5T97)M:6YE
M9`T*('1H870@:71S(&QI8V5N<V5S(&QA8VME9"!S=&%N9"UA;&]N92!V86QU
M92!B96-A=7-E(&ET(&1I9"!N;W0@:&%V90T*('9E;F1O<BUS<&5C:69I8R!O
M8FIE8W1I=F4@979I9&5N8V4@;V8@<V5L;&EN9R!P<FEC92`H5E-/12DL(&%N
M9`T*('=E<F4@8V]M8FEN960@=VET:"!O=&AE<B!E;&5M96YT<R!O9B!T:&4@
M87)R86YG96UE;G0@86YD(&%N>0T*(&%M;W5N=',@87-S;V-I871E9"!W:71H
M('1H92!L:6-E;G-E('=E<F4@9&5F97)R960@86YD(&%M;W)T:7IE9`T*(&]V
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M;'9E;65N=`T*('1O(&)E9VEN(&%T('1H92!I;F-E<'1I;VX@;V8@=&AE(&-O
M;&QA8F]R871I;VX@86=R965M96YT(&%N9`T*(&-O;F-L=61E(&%T('1H92!E
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M($)%4U`@:7,@=&\-"B!D971E<FUI;F4@=&AE('!R:6-E(&%T('=H:6-H('1H
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M('1O(&UA<FME="!O<'!O<G1U;FET>2P@9&ES8V]U;G1E9`T*(&-A<V@@9FQO
M=W,L(&5S=&EM871E9"!D979E;&]P;65N="!C;W-T<RP@<')O8F%B:6QI='D@
M;V8@<W5C8V5S<R!A;F0-"B!T:&4@=&EM92!N965D960@=&\@8V]M;65R8VEA
M;&EZ92!A('!R;V1U8W0@8V%N9&ED871E('!U<G-U86YT('1O#0H@=&AE(&QI
M8V5N<V4N($EN('9A;&ED871I;F<@=&AE($)%4U`L(&UA;F%G96UE;G0@8V]N
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M=&]M97(@;VX@82!S=&%N9&%L;VYE(&)A<VES(&%N9`T*("AI:2DF(WA!,#MI
M9B!T:&4@87)R86YG96UE;G0@:6YC;'5D97,@82!G96YE<F%L(')I9VAT(&]F
M(')E='5R;@T*(')E;&%T:79E('1O('1H92!D96QI=F5R960@:71E;2P@9&5L
M:79E<GD@;W(@<&5R9F]R;6%N8V4@;V8@=&AE#0H@=6YD96QI=F5R960@:71E
M;2!I<R!C;VYS:61E<F5D('!R;V)A8FQE(&%N9"!S=6)S=&%N=&EA;&QY('=I
M=&AI;@T*('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G1R;VPN(%1H92!A<G)A
M;F=E;65N="!C;VYS:61E<F%T:6]N('1H870@:7,-"B!F:7AE9"!O<B!D971E
M<FUI;F%B;&4@870@=&AE(&EN8V5P=&EO;B!O9B!T:&4@87)R86YG96UE;G0@
M:7,-"B!A;&QO8V%T960@=&\@=&AE('-E<&%R871E('5N:71S(&]F(&%C8V]U
M;G1I;F<@8F%S960@;VX@=&AE:7(-"B!R96QA=&EV92!S96QL:6YG('!R:6-E
M<RX@5&AE(&%P<')O<')I871E(')E=F5N=64@<F5C;V=N:71I;VX@;6]D96P-
M"B!I<R!A<'!L:65D('1O(&5A8V@@96QE;65N="!A;F0@<F5V96YU92!I<R!A
M8V-O<F1I;F=L>2!R96-O9VYI>F5D(&%S#0H@96%C:"!E;&5M96YT(&ES(&1E
M;&EV97)E9"X@36%N86=E;65N="!E>&5R8VES97,@<VEG;FEF:6-A;G0-"B!J
M=61G;65N="!I;B!D971E<FUI;FEN9R!W:&5T:&5R(&$@9&5L:79E<F%B;&4@
M:7,@82!S97!A<F%T92!U;FET(&]F#0H@86-C;W5N=&EN9RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
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M(&YO="`H:2DF(WA!,#MT:&4@8V]L;&%B;W)A=&]R(&-O=6QD('5S92!T:&4@
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M:61E('1H92!U;F1E;&EV97)E9"!I=&5M<RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
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M;G,@:71S(')I9VAT('1O('5S92!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('1E
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M86=R965M96YT+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5
M<&9R;VYT('!A>6UE;G1S(&]N(&5X8VQU<VEV92!L:6-E;G-E<R!M87D@8F4@
M<F5C;V=N:7IE9"!U<&]N#0H@9&5L:79E<GD@;V8@=&AE(&QI8V5N<V4@:68@
M9F%C=',@86YD(&-I<F-U;7-T86YC97,@9&EC=&%T92!T:&%T('1H90T*(&QI
M8V5N<V4@:&%S('-T86YD+6%L;VYE('9A;'5E(&9R;VT@=&AE('5N9&5L:79E
M<F5D(&5L96UE;G1S+"!W:&EC:`T*(&=E;F5R86QL>2!I;F-L=61E(')I9VAT
M<R!T;R!F=71U<F4@=&5C:&YO;&]G:6-A;"!I;7!R;W9E;65N=',L#0H@<F5S
M96%R8V@@<V5R=FEC97,@86YD('1H92!M86YU9F%C='5R92!O9B!P<F4M8VQI
M;FEC86P@86YD(&-L:6YI8V%L#0H@;6%T97)I86QS+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5S(')E
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M9B!T:&4@87!P;&EC86)L92!L:6-E;G-E+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!T>7!I8V%L;'D@<&5R9F]R;7,@
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M96YU92!F<F]M#0H@8V]L;&%B;W)A=&EV92!R97-E87)C:"X\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X
M.R!&3TY4+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@;&EC96YS92!A
M9W)E96UE;G1S(&AA=F4@;6EL97-T;VYE('!A>6UE;G1S#0H@=VAI8V@@9F]R
M(')E<&]R=&EN9R!P=7)P;W-E<R!A<F4@86=G<F5G871E9"!I;G1O('1H<F5E
M(&-A=&5G;W)I97,Z#0H@*&DI)B-X03`[9&5V96QO<&UE;G0@;6EL97-T;VYE
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M1')U9R!!9&UI;FES=')A=&EO;B`H1D1!*2!O<B!O=&AE<B!C;W5N=')I97,F
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M)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)
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M<VUE;G0@;V8@=VAE=&AE<B`H82DF(WA!,#MT:&4@8V]N<VED97)A=&EO;B!I
M<R!C;VUM96YS=7)A=&4-"B!W:71H(&5I=&AE<B`H,2DF(WA!,#MT:&4@96YT
M:71Y)B-X,C`Q.3MS('!E<F9O<FUA;F-E('1O(&%C:&EE=F4@=&AE#0H@;6EL
M97-T;VYE+"!O<B`H,BDF(WA!,#MT:&4@96YH86YC96UE;G0@;V8@=&AE('9A
M;'5E(&]F('1H90T*(&1E;&EV97)E9"!I=&5M*',I(&%S(&$@<F5S=6QT(&]F
M(&$@<W!E8VEF:6,@;W5T8V]M92!R97-U;'1I;F<@9G)O;0T*('1H92!E;G1I
M='DF(W@R,#$Y.W,@<&5R9F]R;6%N8V4@=&\@86-H:65V92!T:&4@;6EL97-T
M;VYE+`T*("AB*28C>$$P.W1H92!C;VYS:61E<F%T:6]N(')E;&%T97,@<V]L
M96QY('1O('!A<W0@<&5R9F]R;6%N8V4@86YD#0H@*&,I)B-X03`[=&AE(&-O
M;G-I9&5R871I;VX@:7,@<F5A<V]N86)L92!R96QA=&EV92!T;R!A;&P@;V8@
M=&AE#0H@9&5L:79E<F%B;&5S(&%N9"!P87EM96YT('1E<FUS('=I=&AI;B!T
M:&4@87)R86YG96UE;G0N(%1H92!#;VUP86YY#0H@979A;'5A=&5S(&9A8W1O
M<G,@<W5C:"!A<R!T:&4@<V-I96YT:69I8RP@<F5G=6QA=&]R>2P@8V]M;65R
M8VEA;`T*(&%N9"!O=&AE<B!R:7-K<R!T:&%T(&UU<W0@8F4@;W9E<F-O;64@
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M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!.;VXM<F5F=6YD
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M/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@34%21TE.+4Q%1E0Z(#(E.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(#QI/E)I9VAT+71O+41E=F5L;W`@06=R965M
M96YT<SPO:3X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@
M0V]M<&%N>28C>#(P,3D[<R!R:6=H="UT;RUD979E;&]P(&%G<F5E;65N=',@
M<')O=FED90T*(&-O;&QA8F]R871O<G,@=VET:"!A;B!E>&-L=7-I=F4@;W!T
M:6]N('1O(&]B=&%I;B!L:6-E;G-E<R!T;PT*(&1E=F5L;W`@86YD(&-O;6UE
M<F-I86QI>F4@:6X@<W!E8VEF:65D(&=E;V=R87!H:6,@=&5R<FET;W)I97,-
M"B!P<F]D=6-T(&-A;F1I9&%T97,@9&5V96QO<&5D(&)Y('1H92!#;VUP86YY
M('5N9&5R(&%G<F5E9"!U<&]N#0H@<F5S96%R8V@@86YD('!R92UC;&EN:6-A
M;"!D979E;&]P;65N="!P<F]D=6-T('!R;V=R86US+B!4:&4@<')O9'5C=`T*
M(&-A;F1I9&%T97,@<F5S=6QT:6YG(&9R;VT@96%C:"!P<F]G<F%M(&%R92!A
M;&P@9&ER96-T960@=&\@80T*('-P96-I9FEC('1A<F=E="!S96QE8W1E9"!B
M>2!T:&4@8V]L;&%B;W)A=&]R+B!5;F1E<B!T:&5S90T*(&%G<F5E;65N=',L
M(&9E97,@;6%Y(&)E(&1U92!T;R!T:&4@0V]M<&%N>2`H:2DF(WA!,#MA="!T
M:&4-"B!I;F-E<'1I;VX@;V8@=&AE(&%R<F%N9V5M96YT("AR969E<G)E9"!T
M;R!A<R`F(W@R,#%#.W5P9G)O;G0F(W@R,#%$.PT*(&9E97,@;W(@<&%Y;65N
M=',I+"`H:6DI)B-X03`[=&AE('-E;&5C=&EO;B!O9B!A('1A<F=E="!F;W(@
M80T*('!R;V=R86TL("AI:6DI)B-X03`[=7!O;B!T:&4@97AE<F-I<V4@;V8@
M86X@;W!T:6]N('1O(&%C<75I<F4@80T*(&1E=F5L;W!M96YT(&%N9"!C;VUM
M97)C:6%L:7IA=&EO;B!L:6-E;G-E("AR969E<G)E9"!T;R!A<R!E>&5R8VES
M90T*(&9E97,@;W(@<&%Y;65N=',@96%R;F5D*2!F;W(@82!P<F]G<F%M+"!O
M<B`H:78I)B-X03`[<V]M90T*(&-O;6)I;F%T:6]N(&]F(&%L;"!O9B!T:&5S
M92!F965S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@
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M=&EO;G,N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
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M9B!T:&4@86=R965M96YT+B!&;W(@=&AO<V4@<FEG:'0M=&\M9&5V96QO<`T*
M(&%G<F5E;65N=',@96YT97)E9"!I;G1O('!R:6]R('1O('1H92!A9&]P=&EO
M;B!O9B!!4U4-"B!.;RXF(WA!,#LR,#`Y+3$S('=H97)E('1H92!O<'1I;VYS
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M('1H92!O<'1I;VXL(&=E;F5R86QL>2`Q,B!M;VYT:',N(%-U8G-E<75E;G0@
M=&\@=&AE(&%D;W!T:6]N(&]F($%350T*($YO+B`R,#`Y+3$S+"!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!E=F%L=6%T:6]N(&]F('=H971H97(@=&AE(&]P=&EO
M;@T*(&ES('-U8G-T86YT:79E(&ES(&-O;G-I<W1E;G0@=VET:"!P<F4M861O
M<'1I;VX@;V8@05-5#0H@3F\N)B-X03`[,C`P.2TQ,RX@2&]W('1H92!#;VUP
M86YY(&1E=&5R;6EN97,@=&AE('-E;&QI;F<@<')I8V4@;V8-"B!T:&4@;W!T
M:6]N(&ES('1H92!O;FQY(&1I9F9E<F5N8V4@8F5T=V5E;B!P<F4@86YD('!O
M<W0@861O<'1I;VX@;V8-"B!!4U4@3F\N)B-X03`[,C`P.2TQ,RX@4&]S="!A
M9&]P=&EO;B!O9B!!4U4@3F\N)B-X03`[,C`P.2TQ,RP@=&AE#0H@<V5L;&EN
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M=W,L(&5S=&EM871E9"!D979E;&]P;65N=`T*(&-O<W1S+"!P<F]B86)I;&ET
M>2!O9B!S=6-C97-S(&%N9"!T:&4@=&EM92!N965D960@=&\@8V]M;65R8VEA
M;&EZ90T*(&$@<')O9'5C="!C86YD:61A=&4@<'5R<W5A;G0@=&\@=&AE(')I
M9VAT+71O+61E=F5L;W`@86=R965M96YT+B!);@T*('9A;&ED871I;F<@=&AE
M($)%4U`L(&UA;F%G96UE;G0@8V]N<VED97)S('=H971H97(@8VAA;F=E<R!I
M;B!K97D-"B!A<W-U;7!T:6]N<R!U<V5D('1O(&1E=&5R;6EN92!T:&4@0D53
M4"!W:6QL(&AA=F4@82!S:6=N:69I8V%N=`T*(&5F9F5C="!O;B!T:&4@86QL
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M<VES(&%N9"`H:6DI)B-X03`[:68@=&AE#0H@87)R86YG96UE;G0@:6YC;'5D
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M(&5A8V@@96QE;65N=`T*(&ES(&1E;&EV97)E9"X@36%N86=E;65N="!E>&5R
M8VES97,@<VEG;FEF:6-A;G0@:G5D9VUE;G0@:6X-"B!D971E<FUI;FEN9R!W
M:&5T:&5R(&$@9&5L:79E<F%B;&4@:7,@82!S97!A<F%T92!U;FET(&]F#0H@
M86-C;W5N=&EN9RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M268@82!C;VQL86)O<F%T;W(@97AE<F-I<V5S(&%N(&]P=&EO;B!A;F0@86-Q
M=6ER97,@82!D979E;&]P;65N=`T*(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!L
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M,C`Q.3MS#0H@8F5S="!E<W1I;6%T92X@36%N86=E;65N="8C>#(P,3D[<R!D
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M;W(@86YY('!E<FEO9`T*('!R97-E;G1E9"X@57!O;B!E>&5R8VES92!O9B!A
M;B!O<'1I;VX@=&\@86-Q=6ER92!A(&1E=F5L;W!M96YT(&%N9`T*(&-O;6UE
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M)B-X,C`Q.3MS(')I9VAT+71O+61E=F5L;W`@86=R965M96YT<R!H879E(&)E
M96X-"B!D971E<FUI;F5D('1O(&-O;G1A:6X@<W5B<W1A;G1I=F4@;W!T:6]N
M<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1F]R(')I9VAT
M+71O+61E=F5L;W`@86=R965M96YT<R!W:&5R92!T:&4@;W!T:6]N<R!T;R!S
M96-U<F4-"B!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;&EZ871I;VX@;&EC
M96YS97,@=&\@<')O9'5C="!P<F]G<F%M<R!A<F4-"B!N;W0@8V]N<VED97)E
M9"!S=6)S=&%N=&EV92P@=&AE($-O;7!A;GD@8V]N<VED97)S('1H92!D979E
M;&]P;65N=`T*(&%N9"!C;VUM97)C:6%L:7IA=&EO;B!L:6-E;G-E<R!T;R!B
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M="!A;F0-"B!C;VUM97)C:6%L:7IA=&EO;B!L:6-E;G-E<RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QB/CQI/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;W-T<SPO
M:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@4F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT(&5X<&5N9&ET=7)E<R!A<F4@97AP96YS960@
M87,@:6YC=7)R960N#0H@4F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O<W1S
M('!R:6UA<FEL>2!C;VYS:7-T(&]F(&5M<&QO>65E#0H@<F5L871E9"!E>'!E
M;G-E<RP@:6YC;'5D:6YG('-A;&%R:65S(&%N9"!B96YE9FET<RP@97AP96YS
M97,-"B!I;F-U<G)E9"!U;F1E<B!A9W)E96UE;G1S('=I=&@@8V]N=')A8W0@
M<F5S96%R8V@@;W)G86YI>F%T:6]N<RP-"B!I;G9E<W1I9V%T:79E('-I=&5S
M(&%N9"!C;VYS=6QT86YT<R!T:&%T(&-O;F1U8W0@=&AE#0H@0V]M<&%N>28C
M>#(P,3D[<R!C;&EN:6-A;"!T<FEA;',L('1H92!C;W-T(&]F(&%C<75I<FEN
M9R!A;F0-"B!M86YU9F%C='5R:6YG(&-L:6YI8V%L('1R:6%L(&UA=&5R:6%L
M<R!A;F0@;W1H97(@86QL;V-A=&5D#0H@97AP96YS97,L(&QI8V5N<V4@9F5E
M<R!F;W(@86YD(&UI;&5S=&]N92!P87EM96YT<R!R96QA=&5D('1O#0H@:6XM
M;&EC96YS960@<')O9'5C=',@86YD('1E8VAN;VQO9VEE<RP@<W1O8VLM8F%S
M960@8V]M<&5N<V%T:6]N#0H@97AP96YS92P@86YD(&-O<W1S(&%S<V]C:6%T
M960@=VET:"!N;VXM8VQI;FEC86P@86-T:79I=&EE<R!A;F0-"B!R96=U;&%T
M;W)Y(&%P<')O=F%L<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/D-O;7!R96AE
M;G-I=F4@26YC;VUE("A,;W-S*3PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@169F96-T:79E($IA;G5A<GDF(WA!,#LQ+"`R,#$R
M+"!T:&4@0V]M<&%N>2!A9&]P=&5D($%353(P,3$M,#4L#0H@/&D^4')E<V5N
M=&%T:6]N(&]F($-O;7!R96AE;G-I=F4@26YC;VUE+#PO:3X@=VAI8V@@86UE
M;F1E9"!!4T,-"B!4;W!I8R`R,C`L(#QI/D-O;7!R96AE;G-I=F4@26YC;VUE
M+CPO:3X@5&AE(&%M96YD;65N=',@:6X@05-5#0H@,C`Q,2TP-2!R97%U:7)E
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M<F5H96YS:79E(&EN8V]M92`H;&]S<RD@97%U86QS(&YE="!I;F-O;64-"B`H
M;&]S<RD@9F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT:',@96YD960@4V5P
M=&5M8F5R)B-X03`[,S`L(#(P,3,-"B!A;F0@,C`Q,BX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!&
M3TY4+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI
M/E-T;V-K+6)A<V5D($-O;7!E;G-A=&EO;CPO:3X\+V(^/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@4W1O8VLM8F%S960@<&%Y;65N=',@87)E
M(&%C8V]U;G1E9"!F;W(@:6X@86-C;W)D86YC92!W:71H('1H90T*('!R;W9I
M<VEO;G,@;V8@05-#)B-X03`[-S$X+"`\:3Y#;VUP96YS871I;VXF(WA!,#LF
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M:&4-"B!O<'1I;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
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M=&\@=F5S="!D=7)I;F<@=&AE('!E<FEO9"X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@=71I;&EZ97,@=&AE($)L86-K
M+5-C:&]L97,@;6]D96P@9F]R(&5S=&EM871I;F<@9F%I<@T*('9A;'5E(&]F
M(&ET<R!S=&]C:R!O<'1I;VYS(&=R86YT960N($]P=&EO;B!V86QU871I;VX@
M;6]D96QS+`T*(&EN8VQU9&EN9R!T:&4@0FQA8VLM4V-H;VQE<R!M;V1E;"P@
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M)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\
M8CX\:3Y.970@26YC;VUE("A,;W-S*2!097(@4VAA<F4\+VD^/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN8V]M92`H;&]S<RD@<&5R
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M)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)
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M8V]M<'5T960@8GD@9&EV:61I;F<@=&AE(&YE="!I;F-O;64-"B`H;&]S<RD@
M86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@8GD@=&AE('=E:6=H
M=&5D+6%V97)A9V4-"B!N=6UB97(@;V8@8V]M;6]N('-T;V-K(&5Q=6EV86QE
M;G1S(&]U='-T86YD:6YG(&9O<B!T:&4@<&5R:6]D+B!4:&4-"B!T<F5A<W5R
M>2!S=&]C:R!M971H;V0@:7,@=7-E9"!T;R!D971E<FUI;F4@=&AE(&1I;'5T
M:79E(&5F9F5C="!O9@T*('1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K(&]P
M=&EO;B!G<F%N=',@86YD('1H92!I9BUC;VYV97)T960@;65T:&]D#0H@:7,@
M=7-E9"!T;R!D971E<FUI;F4@=&AE(&1I;'5T:79E(&5F9F5C="!O9B!T:&4@
M0V]M<&%N>28C>#(P,3D[<PT*(%-E<FEE<R8C>$$P.T$M,2P@02TR+"!"+"!#
M+"!$+"!A;F0@1"TR(&-O;G9E<G1I8FQE('!R969E<G)E9`T*('-T;V-K+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!"87-I8R!A;F0@9&EL=71E9"!I;F-O
M;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4@:7,@8V]M<'5T960@87,-"B!F
M;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\
M+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P
M<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B
M;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3$E/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@/&(^
M5&AR964F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E<B8C
M>$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@
M/&(^3FEN928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[4V5P=&5M8F5R
M)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D
M("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*($YE="!I;F-O;64@*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8L-C`S+#DX,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPV
M,#`L-3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT
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M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R;FEN9W,@
M86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<-"B!S96-U<FET:65S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L-#,T+#<U-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#(L-C`P+#4Q-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^*#(L.30T+#$T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#$P+#0V-BPU.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!.970@
M:6YC;VUE("AL;W-S*2!A;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$V.2PR,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%S:6,@=V5I9VAT960@
M879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XQ+#$X-"PU,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ+#`Y,BPS,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0V,RPW.3@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`W."PQ-#4\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&
M1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D)A<VEC(&EN
M8V]M92`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R93PO8CX\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^/&(^,"XQ-#PO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQB/B8C>$$P.R8C>$$P.SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&(^)#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#X\8CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQB/B8C
M>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&(^)#PO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\8CXF(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/CQB/B8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
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M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!.970@:6YC;VUE("AL;W-S*3PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C8L-C`S+#DX,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#8P,"PU
M,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY-#0L,30Y/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C$P+#0V-BPU.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R;FEN9W,@
M86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<@<V5C=7)I=&EE<PT*(&%N9"!O
M=&AE<B!A9&0M8F%C:W,@=&\@;F5T(&EN8V]M92`H;&]S<RD\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@V+#0P,RPX-#,\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M*#(L-C`P+#4Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPY-#0L,30Y/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B@Q,"PT-C8L-3@R/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@3F5T(&EN8V]M
M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR,#`L,3,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($)A
M<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N9&EN
M9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PQ.#0L-3`W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,2PP.3(L,S`W/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,2PT-C,L-SDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO
M9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP-S@L,30U
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%9F9E8W0@;V8@9&EL=71I
M=F4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`L,#4X
M+#0W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P+#0Q,"PQ,3<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XR,"PT-#4L,#8Q/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,C`L,S,T+#<P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@1&EL=71E9"!W96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@
M;W5T<W1A;F1I;F<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#(T,BPY
M-S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,2PU,#(L-#(T/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,C$L.3`X+#@U.3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(Q+#0Q,BPX-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^1&EL
M=71E9"!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+V(^/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\8CXD/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/CQB/C`N,#$\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF(WA!
M,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#X\8CXF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&(^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF(WA!
M,#L\+V(^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^
M/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F]L
M;&]W:6YG(&-O;6UO;B!S=&]C:R!E<75I=F%L96YT<R!A<F4@:6YC;'5D960@
M:6X@=&AE#0H@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@:6YC;VUE("AL
M;W-S*2!P97(@<VAA<F4Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*
M("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%
M.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL
M<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^/"$M+2!"
M96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,"4^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I
M9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E
M<CX-"B`\8CY4:')E928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[4V5P
M=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG
M;CTS1&-E;G1E<CX-"B`\8CY.:6YE)B-X03`[36]N=&AS)B-X03`[16YD960F
M(WA!,#M397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5R:65S
M($$M,2!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
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M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,BPQ-38L,3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C(L,34V+#$Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR+#$U-BPQ,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%-E<FEE<R!!+3(@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XS.3(L,C<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,Y,BPR-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5R:65S($(@4')E9F5R<F5D(%-T
M;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS,S8L,#,W
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,S,V+#`S
M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,S-BPP
M,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS,S8L
M,#,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!397)I97,@0R!0<F5F
M97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M-2PY,#DL.3`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4L.3`Y+#DP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XU+#DP.2PY,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%-E<FEE<R!$(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S8Y+#0V.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-CDL-#8X/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%-E<FEE<R!$+3(@4')E9F5R<F5D(%-T;V-K/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS.3$L.3DQ/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,SDQ+#DY,3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Y,2PY.3$\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS.3$L.3DQ/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!787)R
M86YT<R!T;R!P=7)C:&%S92!397)I97,@1"TR(%!R969E<G)E9"!3=&]C:SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@P+#<X-#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-S@T/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%-T;V-K($]P=&EO;G,\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR+#DQ,"PY-3(\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-S8L-3$V/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3$P+#DU,CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#(W-BPU,38\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QB/CQI/E)E8V5N=&QY($ES<W5E9"!!8V-O=6YT:6YG
M(%-T86YD87)D<R!!9&]P=&5D/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!);B!-87DF(WA!,#LR,#$Q+"!T:&4@1D%30B!I<W-U
M960@05-5($YO+B8C>$$P.S(P,3$M,#0L('=H:6-H#0H@86UE;F1E9"!!4T,@
M5&]P:6,@.#(P('1O(&%C:&EE=F4@8V]M;6]N(&9A:7(@=F%L=64@;65A<W5R
M96UE;G1S(&%N9`T*(&1I<V-L;W-U<F4@<F5Q=6ER96UE;G1S(&EN(%4N4RX@
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M869T97(@1&5C96UB97(F(WA!,#LQ-2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F
M('1H:7,-"B!A;65N9&UE;G0@9&ED(&YO="!H879E(&$@;6%T97)I86P@:6UP
M86-T(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@8V]N<V]L:61A=&5D(&9I
M;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!);B!*=6YE)B-X03`[,C`Q,2P@=&AE($9!4T(@:7-S=65D($%3
M52!.;RXF(WA!,#LR,#$Q+3`U+"!W:&EC:`T*(&%M96YD960@05-#(%1O<&EC
M(#(R,"!R96=A<F1I;F<@<')E<V5N=&%T:6]N(&]F(&-O;7!R96AE;G-I=F4-
M"B!I;F-O;64N(%1H92!A;65N9&UE;G1S(&EN($%352!.;RXF(WA!,#LR,#$Q
M+3`U(')E<75I<F4@=&AA="!A;&P-"B!N;VYO=VYE<B!C:&%N9V5S(&EN('-T
M;V-K:&]L9&5R<R8C>#(P,3D[(&5Q=6ET>2!B92!P<F5S96YT960@96ET:&5R
M#0H@:6X@82!S:6YG;&4@8V]N=&EN=6]U<R!S=&%T96UE;G0@;V8@8V]M<')E
M:&5N<VEV92!I;F-O;64@;W(@:6X@='=O#0H@<V5P87)A=&4@8G5T(&-O;G-E
M8W5T:79E('-T871E;65N=',N($EN('1H92!T=V\M<W1A=&5M96YT(&%P<')O
M86-H+`T*('1H92!F:7)S="!S=&%T96UE;G0@<VAO=6QD('!R97-E;G0@=&]T
M86P@;F5T(&EN8V]M92!A;F0@:71S#0H@8V]M<&]N96YT<R!F;VQL;W=E9"!C
M;VYS96-U=&EV96QY(&)Y(&$@<V5C;VYD('-T871E;65N="!T:&%T('-H;W5L
M9`T*('!R97-E;G0@=&]T86P@;W1H97(@8V]M<')E:&5N<VEV92!I;F-O;64L
M('1H92!C;VUP;VYE;G1S(&]F(&]T:&5R#0H@8V]M<')E:&5N<VEV92!I;F-O
M;64L(&%N9"!T:&4@=&]T86P@;V8@8V]M<')E:&5N<VEV92!I;F-O;64N(%1H
M:7,-"B!A;65N9&UE;G0@:7,@969F96-T:79E(&9O<B!F:7-C86P@>65A<G,@
M8F5G:6YN:6YG(&%F=&5R#0H@1&5C96UB97(F(WA!,#LQ-2P@,C`Q,2X@5&AE
M(&%D;W!T:6]N(&]F('1H:7,@86UE;F1M96YT(&1I9"!N;W0@:&%V90T*(&$@
M;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)B-X,C`Q.3MS(&-O;G-O
M;&ED871E9"!F:6YA;F-I86P-"B!S=&%T96UE;G1S+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!H87,@979A;'5A=&5D
M(&%L;"!!4U5S('1H<F]U9V@@=&AE(&1A=&4@=&AE#0H@8V]N<V]L:61A=&5D
M(&9I;F%N8VEA;',@=V5R92!I<W-U960@86YD(&)E;&EE=F5S('1H870@=&AE
M(&%D;W!T:6]N#0H@;V8@=&AE<V4@=VEL;"!N;W0@:&%V92!A(&UA=&5R:6%L
M(&EM<&%C="!O;B!T:&4@0V]M<&%N>28C>#(P,3D[<PT*(&-O;G-O;&ED871E
M9"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S
M7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A
M+U=O<FMS:&5E=',O4VAE970P."YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2!0;&%N="!!;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;W!E<G1Y(&%N
M9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T)SX-"B`\8CXS+B!0<F]P97)T>2!A;F0@17%U:7!M96YT
M/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M
M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%!R;W!E<G1Y
M(&%N9"!E<75I<&UE;G0@8V]N<VES=',@;V8@=&AE(&9O;&QO=VEN9SH\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L
M92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E
M<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS
M1#<V)2!A;&EG;CTS1&-E;G1E<CX\(2TM($)E9VEN(%1A8FQE($AE860@+2T^
M#0H@/'1R/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H
M/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@
M86QI9VX],T1C96YT97(^/&(^4V5P=&5M8F5R)B-X03`[,S`L)B-X03`[,C`Q
M,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^1&5C96UB
M97(F(WA!,#LS,2PF(WA!,#LR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@
M2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!#;VUP=71E<B!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,BPQ-S(L-3,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XR+#`P,RPW,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-O9G1W
M87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PS,C,L,#@Q
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,S(S+#`X,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1G5R
M;FET=7)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3DY+#8U
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU.3DL-C4P/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!,86(@97%U:7!M96YT/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3`L-C`S+#4Y.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XX+#<T-RPW.3`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]F9FEC92!E<75I<&UE
M;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,2PS-C`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3$L,S8P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!,96%S96AO;&0@:6UP<F]V96UE;G1S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PX.3,L-S<P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L.#@Q+#<P-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Y+#8T,RPY.30\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ-RPV,#<L,CDS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B!,97-S(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I
M>F%T:6]N/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,34L,3<T+#$Q,CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XH,30L,S,Y+#0Y-SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT+#0V.2PX.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR
M-C<L-SDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM
M/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1&5P<F5C
M:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX@97AP96YS92!F;W(@=&AE('1H<F5E
M(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R
M,#$R('=A<R`D,S$V+#@U,B!A;F0@)#(S-2PU-#,L#0H@<F5S<&5C=&EV96QY
M+"!A;F0@)#@S-"PV,34@86YD("0W,C(L-#DV(&9O<B!T:&4@;FEN92!M;VYT
M:',@96YD960-"B!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,BP@
M<F5S<&5C=&EV96QY+CPO<#X-"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q
M-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R
M:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@*$1E9FEC:70I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-T;V-K:&]L9&5R<R<@17%U:71Y("A$969I8VET
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QB/C0N(%-T;V-K:&]L9&5R<R8C>#(P,3D[($5Q=6ET>2`H1&5F
M:6-I="D\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1'5R
M:6YG(#(P,#(@86YD(#(P,#,L('1H92!#;VUP86YY(&ES<W5E9"!A('1O=&%L
M(&]F(#,T+#(S.2PS-S0-"B!S:&%R97,@;V8@4V5R:65S($$M,2!A;F0@4V5R
M:65S($$M,B!C;VYV97)T:6)L92!P<F5F97)R960@<W1O8VL-"B`H4V5R:65S
M($$@<')E9F5R<F5D('-T;V-K*2!F;W(@)#$N,#`@<&5R('-H87)E(')E<W5L
M=&EN9R!I;B!N970-"B!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0S-"PP
M,#`L,#`P+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!/;B!/
M8W1O8F5R)B-X03`[,3(L(#(P,#0L('1H92!#;VUP86YY(&5N=&5R960@:6YT
M;R!A('-E<FEE<R!O9@T*('1R86YS86-T:6]N<R!R86ES:6YG("0S,"PR-C$L
M-C<R+"!N970@;V8@<F5L871E9"!O9F9E<FEN9R!C;W-T<R!O9@T*(&%P<')O
M>&EM871E;'D@)#(S."PP,#`L(&9R;VT@=&AE('-A;&4@;V8@-S$L-#`Q+#(S
M-R!S:&%R97,@;V8@:71S#0H@4V5R:65S($(@8V]N=F5R=&EB;&4@<')E9F5R
M<F5D('-T;V-K("A397)I97,@0B!P<F5F97)R960@<W1O8VLI+B!);@T*(&-O
M;FYE8W1I;VX@=VET:"!T:&4@4V5R:65S($(@<')E9F5R<F5D('-T;V-K(&]F
M9F5R:6YG+"`Q,RPV,#0L,#$V#0H@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!W
M97)E(&%L;&]C871E9"!T;R!H;VQD97)S(&]F(%-E<FEE<R8C>$$P.T$M,0T*
M('!R969E<G)E9"!S=&]C:R!A<R!A;B!A;G1I+61I;'5T:6]N(&UE87-U<F4@
M8G5T(')E;6%I;F5D('5N:7-S=65D#0H@870@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,N(%5P;VX@8V]M<&QE=&EO;B!O9B!T:&4@25!/(&EN($]C=&]B97(-
M"B`R,#$S+"!T:&5S92!A;&QO8V%T960@<VAA<F5S('=E<F4@8V]N=F5R=&5D
M(&EN=&\@<VAA<F5S(&]F(&-O;6UO;@T*('-T;V-K+CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B!/;B!-87DF(WA!,#LQ-BP@,C`P-BP@=&AE
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M960@<W1O8VL-"B!O9F9E<FEN9RP@,3`L,#`S+#,P,"!S:&%R97,@;V8@8V]M
M;6]N('-T;V-K('=E<F4@86QL;V-A=&5D('1O#0H@:&]L9&5R<R!O9B!397)I
M97,@0B!P<F5F97)R960@<W1O8VL@87,@86X@86YT:2UD:6QU=&EO;B!M96%S
M=7)E(&)U=`T*(')E;6%I;F5D('5N:7-S=65D(&%T(%-E<'1E;6)E<B8C>$$P
M.S,P+"`R,#$S+B!5<&]N(&-O;7!L971I;VX@;V8-"B!T:&4@25!/(&EN($]C
M=&]B97(@,C`Q,RP@=&AE<V4@86QL;V-A=&5D('-H87)E<R!W97)E(&-O;G9E
M<G1E9"!I;G1O#0H@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@3VX@2G5L>28C>$$P.S$V+"`R,#`X
M+"!T:&4@0V]M<&%N>2!I<W-U960@,3(L-#8V+#`S.2!S:&%R97,@;V8@:71S
M#0H@4V5R:65S($0@8V]N=F5R=&EB;&4@<')E9F5R<F5D('-T;V-K("A397)I
M97,@1"!P<F5F97)R960@<W1O8VLI(&EN#0H@97AC:&%N9V4@9F]R(&%L;"!O
M9B!T:&4@;W5T<W1A;F1I;F<@8V%P:71A;"!S=&]C:R!A;F0@8V]N=F5R=&EB
M;&4-"B!N;W1E<R!P87EA8FQE(&]F(%)A=F5N($)I;W1E8VAN;VQO9VEE<RP@
M26YC+B`H4F%V96XI+B!3=6)S97%U96YT;'DL#0H@:6X@36%R8V@@,C`Q,2!A
M('-E='1L96UE;G0@=V%S(')E86-H960@=VET:"!T:&4@9F]R;65R(%)A=F5N
M#0H@<W1O8VMH;VQD97)S(&)R:6YG:6YG('1H92!T;W1A;"!397)I97,@1"!P
M<F5F97)R960@<W1O8VL@:7-S=65D(&EN#0H@8V]N;F5C=&EO;B!W:71H('1H
M92!2879E;B!A8W%U:7-I=&EO;B!T;R`Q-"PT-#8L,C(W('-H87)E<RX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@3VX@4V5P=&5M8F5R)B-X
M03`[,3DL(#(P,#@L('1H92!#;VUP86YY(')A:7-E9"`D,C0L.#0S+#(Q,2P@
M;F5T(&]F#0H@<F5L871E9"!O9F9E<FEN9R!C;W-T<R!O9B`D,34V+#<X."P@
M9G)O;2!T:&4@<V%L92!O9B`S."PS,S<L-C<X#0H@<VAA<F5S(&]F(&ET<R!3
M97)I97,@1"TR(&-O;G9E<G1I8FQE('!R969E<G)E9"!S=&]C:R`H4V5R:65S
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M<W1A=&5D#0H@97AE<F-I<V4@<')I8V4@;V8@)#`N-C4@<&5R('=A<G)A;G0N
M($]N($UA>28C>$$P.S$V+"`R,#$P+"!T:&4-"B!#;VUP86YY(&5X97)C:7-E
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M97,@;V8@4V5R:65S($0M,@T*('!R969E<G)E9"!S=&]C:RX\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@3VX@2F%N=6%R>28C>$$P.S$Q+"`R
M,#$Q+"!T:&4@0V]M<&%N>2!R86ES960@9W)O<W,@<')O8V5E9',@9F]R#0H@
M)#$R+#`Q-BPU,#`@9G)O;2!T:&4@<V%L92!O9B`Q."PT,C<L,S@X('-H87)E
M<R!O9B!I=',@4V5R:65S($0M,@T*('!R969E<G)E9"!S=&]C:RX@27-S=6%N
M8V4@8V]S=',@87-S;V-I871E9"!W:71H('1H92!S86QE('=E<F4@;F]T#0H@
M;6%T97)I86PN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[
M(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
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M87,-"B`F(W@R,#%#.T]T:&5R(&EN8V]M92`H97AP96YS92DF(W@R,#%$.R!I
M;B!T:&4@86-C;VUP86YY:6YG#0H@8V]N<V]L:61A=&5D('-T871E;65N=',@
M;V8@;W!E<F%T:6]N<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@2&]L9&5R<R!O9B!T:&4@4V5R:65S($$M,2P@4V5R:65S($$M,BP@4V5R
M:65S($(L(%-E<FEE<R!#+"!397)I97,@1`T*(&%N9"!397)I97,@1"TR('!R
M969E<G)E9"!S=&]C:R!A<F4@96YT:71L960@=&\@=F]T92P@=&]G971H97(@
M=VET:`T*('1H92!C;VUM;VX@<W1O8VMH;VQD97)S(&%S(&]N92!C;&%S<RP@
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M:&]L9&5R<R!O9B!A="!L96%S="`V-B`R+S,E(&]F('1H92!P<F5F97)R960@
M<W1O8VLL(&5A8V@@=F]T:6YG#0H@<V5P87)A=&5L>2!A<R!A('-I;F=L92!C
M;&%S<R`H86YD(&]N(&%N(&%S+6EF+6-O;G9E<G1E9"!B87-I<R!T;PT*(&-O
M;6UO;B!S=&]C:R!W:71H(')E<W!E8W0@=&\@=&AE('!R969E<G)E9"!S=&]C
M:RDL('-H86QL(&)E#0H@96YT:71L960@=&\@96QE8W0@86QL(')E;6%I;FEN
M9R!M96UB97)S(&]F('1H92!";V%R9"!O9@T*($1I<F5C=&]R<RX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1&EV:61E;F1S(&%R92!N;VYC
M=6UU;&%T:79E(&%N9"!A8V-R=64@;VX@=&AE(%-E<FEE<R!!+3$L(%-E<FEE
M<PT*($$M,BP@4V5R:65S($(L(%-E<FEE<R!#+"!397)I97,@1"!A;F0@4V5R
M:65S)B-X03`[1"TR('!R969E<G)E9`T*('-T;V-K(&%T(&$@<F%T92!O9B`D
M,"XP."P@)#`N,#,T,2P@)#`N,#,R-"!A;F0@)#`N,#4R,B!P97(@86YN=6TL
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M;6)E<B8C>$$P.S,P+"`R,#$S(&]R($1E8V5M8F5R)B-X03`[,S$L#0H@,C`Q
M,BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A
M;GDF(W@R,#$Y.W,@4V5R:65S($$M,2P@4V5R:65S($$M,BP@4V5R:65S($(L
M(%-E<FEE<R!#+`T*(%-E<FEE<R!$(&%N9"!397)I97,@1"TR('!R969E<G)E
M9"!S=&]C:R!A<F4@:6YI=&EA;&QY(&-O;G9E<G1I8FQE#0H@:6YT;R`Q+C4P
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M;VYV97)S:6]N('!R:6-E('-H86QL(&)E("0Q,BXS.2P@)#$X+C<W+"`D-BXY
M-2P@)#<N-S`L("0Q,BXR,`T*(&%N9"`D,3(N,C`@9F]R(&5A8V@@<VAA<F4@
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M<R!!+3(L(%-E<FEE<R!"+`T*(%-E<FEE<R8C>$$P.T,L(%-E<FEE<R!$(&%N
M9"!397)I97,@1"TR('!R969E<G)E9"!S=&]C:RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
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M8VL@<F5G:7-T97)E9`T*('5N9&5R('1H92!396-U<FET:65S($%C="!O9B`Q
M.3,S('=H:6-H(&=E;F5R871E<R!N970@<')O8V5E9',@=&\-"B!T:&4@0V]M
M<&%N>2!O9B!A="!L96%S="`D-#`F(WA!,#MM:6QL:6]N+B!4:&4@:&]L9&5R
M<R!O9B!T=V\M=&AI<F1S#0H@;V8@=&AE(%-E<FEE<R8C>$$P.T$M,2P@4V5R
M:65S)B-X03`[02TR+"!397)I97,F(WA!,#M"+"!397)I97,@0RP-"B!397)I
M97,@1"!A;F0@4V5R:65S($0M,B!P<F5F97)R960@<W1O8VLL('9O=&EN9R!T
M;V=E=&AE<B!A<R!A#0H@<VEN9VQE(&-L87-S+"!B=70@<V5P87)A=&5L>2!F
M<F]M('1H92!C;VUM;VX@<W1O8VMH;VQD97)S+"!S:&%L;`T*(&AA=F4@=&AE
M(')I9VAT('1O(&5L96-T('1O(&-O;G9E<G0@86QL(&]U='-T86YD:6YG('-H
M87)E<R!O9B!397)I97,-"B!!+3$L(%-E<FEE<R8C>$$P.T$M,BP@4V5R:65S
M)B-X03`[0BP@4V5R:65S($,L(%-E<FEE<R!$(&%N9"!397)I97,-"B!$+3(@
M<')E9F5R<F5D('-T;V-K(&EN=&\@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:RX\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@26X@;&EQ=6ED871I
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M9F5R<F5D('-T;V-K(&%R92!E;G1I=&QE9`T*('1O(')E8V5I=F4@)#<N-S`@
M86YD("0Q,BXR,"!P97(@<VAA<F4L(')E<W!E8W1I=F5L>2P@;VX@82`\:3YP
M87)I#0H@<&%S<W4\+VD^(&)A<VES+"!P<FEO<B!T;R!A;GD@9&ES=')I8G5T
M:6]N('1O('1H92!H;VQD97)S(&]F(&%N>0T*(%-E<FEE<R!"('!R969E<G)E
M9"!S=&]C:RX@5&AE(&AO;&1E<G,@;V8@4V5R:65S($(@<')E9F5R<F5D('-T
M;V-K#0H@87)E(&5N=&ET;&5D('1O(')E8V5I=F4@)#8N.34@<&5R('-H87)E
M('!R:6]R('1O(&%N>2!D:7-T<FEB=71I;VX-"B!T;R!T:&4@:&]L9&5R<R!O
M9B!A;GD@<VAA<F5S(&]F(%-E<FEE<R!!('!R969E<G)E9"!S=&]C:RX@5&AE
M#0H@:&]L9&5R<R!O9B!397)I97,@02!P<F5F97)R960@<W1O8VL@87)E(&5N
M=&ET;&5D('1O(')E8V5I=F4@)#$R+C,Y#0H@<&5R('-H87)E('!R:6]R('1O
M('1H92!H;VQD97)S(&]F(&-O;6UO;B!S=&]C:RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
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M(&5F9F5C=&EV92!O;@T*(%-E<'1E;6)E<B8C>$$P.S(V+"`R,#$S+B!!;&P@
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M;W5N="!E<75A;`T*('1O('1H92!R961U8W1I;VX@:6X@<&%R('9A;'5E(&]F
M(&-O;6UO;B!S=&]C:R!T;R!A9&1I=&EO;F%L('!A:60M:6X-"B!C87!I=&%L
M+B!);B!A9&1I=&EO;BP@:6X@4V5P=&5M8F5R(#(P,3,L('1H92!#;VUP86YY
M)B-X,C`Q.3MS($)O87)D#0H@;V8@1&ER96-T;W)S(&%N9"!S=&]C:VAO;&1E
M<G,@87!P<F]V960@86X@86UE;F1M96YT(&]F('1H90T*($-O;7!A;GDF(W@R
M,#$Y.W,@8V5R=&EF:6-A=&4@;V8@:6YC;W)P;W)A=&EO;B!T;RP@86UO;F<@
M;W1H97(-"B!T:&EN9W,L(&-H86YG92!T:&4@9&5F:6YI=&EO;B!O9B!A(&1E
M<VEG;F%T960@<'5B;&EC(&]F9F5R:6YG('1O#0H@<F5M;W9E('1H92!P97(@
M<VAA<F4@<')I8V4@<F5Q=6ER96UE;G0N/"]P/@T*(`T*(`T*(#PO9&EV/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W
M,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V
M-6(X-3!B82]7;W)K<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R960M0F%S960@4&%Y;65N=',\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY$:7-C;&]S=7)E($]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S(%-H
M87)E8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5D+4)A<V5D(%!A>6UE
M;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@/&(^-2X@4VAA<F5D+4)A<V5D(%!A>6UE;G1S/"]B/CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B`\8CX\:3Y3=&]C:R!/<'1I;VX@4&QA;CPO:3X\+V(^/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GDF(W@R
M,#$Y.W,@,C`P,"!3=&]C:R!/<'1I;VX@86YD($EN8V5N=&EV92!0;&%N("AT
M:&4@,C`P,`T*(%!L86XI(&%L;&]W960@9F]R('1H92!G<F%N="!O9B!A=V%R
M9',@:6X@<F5S<&5C="!O9B!A;B!A9V=R96=A=&4@;V8-"B`Q,S`L-S(U('-H
M87)E<RP@=VAI8V@@=V%S(&EN8W)E87-E9"!T;R`Q-3`L,CDW('-H87)E<RP@
M;V8@=&AE#0H@0V]M<&%N>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@:6X@=&AE
M(&9O<FT@;V8@:6YC96YT:79E('-T;V-K#0H@;W!T:6]N<RP@;F]N+7%U86QI
M9FEE9"!S=&]C:R!O<'1I;VYS+"!S=&]C:R!A<'!R96-I871I;VX@<FEG:'1S
M+`T*(')E<W1R:6-T960@<W1O8VL@86YD(')E<W1R:6-T960@<W1O8VL@=6YI
M=',@86YD(&]T:&5R('!E<F9O<FUA;F-E#0H@87=A<F1S+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!%9F9E8W1I=F4@1F5B<G5A<GDF(WA!
M,#LR,#`S+"!T:&4@0V]M<&%N>2!I;7!L96UE;G1E9"!T:&4@,C`P,PT*($5Q
M=6ET>2!);F-E;G1I=F4@4&QA;B`H=&AE(#(P,#,@4&QA;BDL(&%N9"!I="!W
M87,@86UE;F1E9"!A;F0-"B!A<'!R;W9E9"!B>2!T:&4@0V]M<&%N>28C>#(P
M,3D[<R!S=&]C:VAO;&1E<G,@:6X@,C`P-2X@5&AE(#(P,#,@4&QA;@T*(&]R
M:6=I;F%L;'D@86QL;W=E9"!F;W(@=&AE(&=R86YT(&]F(&%W87)D<R!I;B!R
M97-P96-T(&]F(&%N#0H@86=G<F5G871E(&]F(#(L,#4Q+#8T-"!S:&%R97,@
M;V8@=&AE($-O;7!A;GDF(W@R,#$Y.W,@8V]M;6]N('-T;V-K+@T*($1U<FEN
M9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#`V+"!T:&4@
M;6%X:6UU;2!N=6UB97(@;V8-"B!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&%U
M=&AO<FEZ960@=&\@8F4@:7-S=65D(&)Y('1H92!#;VUP86YY('5N9&5R#0H@
M=&AE(#(P,#,@4&QA;B!W87,@:6YC<F5A<V5D(&)Y(#0V,"PW-#8@<VAA<F5S
M('1O(#(L-3$R+#,Y,"X@1'5R:6YG#0H@=&AE('EE87(@96YD960@1&5C96UB
M97(F(WA!,#LS,2P@,C`P."P@=&AE(&UA>&EM=6T@;G5M8F5R(&]F('-H87)E
M<PT*(&]F(&-O;6UO;B!S=&]C:R!A=71H;W)I>F5D('1O(&)E(&ES<W5E9"!B
M>2!T:&4@0V]M<&%N>2!U;F1E<B!T:&4-"B`R,#`S(%!L86X@=V%S(&EN8W)E
M87-E9"!B>2`W-#4L-S$V('-H87)E<R!T;R`S+#(U."PQ,#8N($1U<FEN9R!T
M:&4-"B!Y96%R(&5N9&5D($1E8V5M8F5R)B-X03`[,S$L(#(P,3`L('1H92!M
M87AI;75M(&YU;6)E<B!O9B!S:&%R97,@;V8-"B!C;VUM;VX@<W1O8VL@875T
M:&]R:7IE9"!T;R!B92!I<W-U960@8GD@=&AE($-O;7!A;GD@=6YD97(@=&AE
M(#(P,#,-"B!0;&%N('=A<R!I;F-R96%S960@8GD@-3,R+#8U-"!S:&%R97,@
M=&\@,RPW.3`L-S8P+B!$=7)I;F<@=&AE('EE87(-"B!E;F1E9"!$96-E;6)E
M<B8C>$$P.S,Q+"`R,#$R+"!T:&4@;6%X:6UU;2!N=6UB97(@;V8@<VAA<F5S
M(&]F#0H@8V]M;6]N('-T;V-K(&%U=&AO<FEZ960@=&\@8F4@:7-S=65D(&)Y
M('1H92!#;VUP86YY('5N9&5R('1H92`R,#`S#0H@4&QA;B!W87,@:6YC<F5A
M<V5D(&)Y(#4T-2PY-S`@<VAA<F5S('1O(#0L,S,V+#<S,2X@07,@;V8-"B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,RP@82!T;W1A;"!O9B`X+#$W,2!S:&%R
M97,@=V5R92!A=F%I;&%B;&4@9F]R#0H@:7-S=6%N8V4@=6YD97(@=&AE(#(P
M,#,@4&QA;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@4W1O
M8VL@;W!T:6]N<R!G<F%N=&5D('5N9&5R('1H92`R,#`S(%!L86X@;6%Y(&)E
M(&5I=&AE<B!I;F-E;G1I=F4-"B!S=&]C:R!O<'1I;VYS(&%S(&1E9FEN960@
M8GD@=&AE($EN=&5R;F%L(%)E=F5N=64@0V]D92`H25)#*2P@;W(-"B!N;VXM
M<75A;&EF:65D('-T;V-K(&]P=&EO;G,N/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I;F<@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&%M;W5N=',@=V5R92!R96-O9VYI>F5D(&9O<@T*('1H92!P97)I
M;V1S(&EN9&EC871E9#H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@
M)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z
M(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP
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M3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N/3-$8V5N=&5R
M/@T*(#QB/E1H<F5E)B-X03`[36]N=&AS)B-X03`[16YD960F(WA!,#M397!T
M96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0V(&%L:6=N
M/3-$8V5N=&5R/@T*(#QB/DYI;F4F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C
M>$$P.U-E<'1E;6)E<B8C>$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4]
M,T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS
M1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S
M/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A
M;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR
M,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN
M(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!297-E87)C
M:"!A;F0@9&5V96QO<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,3$Q+#@X.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$W+#DU
M,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C@T+#(X,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,S4S+#@U-CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/
M3E0M4TE:13H@,3!P="<^#0H@1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-"PP-#@\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.3$L-C0W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$P.2PR.#`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C<T+#DT,#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S
M;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T
M86P@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,S4L.3,V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C
M>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P
M.2PU.3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,SDS+#4V,3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XV,C@L-SDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO
M=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.
M+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QI/D5M<&QO>65E(%-T;V-K($]P=&EO;G,\+VD^/"]P/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE(&9A:7(@=F%L=64@;V8@
M96%C:"!O<'1I;VX@87=A<F0@:7,@97-T:6UA=&5D(&]N('1H92!D871E(&]F
M#0H@9W)A;G0@=7-I;F<@=&AE($)L86-K+5-C:&]L97,@;W!T:6]N+7!R:6-I
M;F<@;6]D96P@=7-I;F<@=&AE#0H@87-S=6UP=&EO;G,@:6X@=&AE(&9O;&QO
M=VEN9R!T86)L93H\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@)B-X
M03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O
M;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D
M:6YG/3-$,"!W:61T:#TS1#<V)2!A;&EG;CTS1&-E;G1E<CX\(2TM($)E9VEN
M(%1A8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T:#TS1#<U)3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Y)3X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M
M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O
M;'-P86X],T0S(&%L:6=N/3-$8V5N=&5R/@T*(#QB/DYI;F4F(WA!,#M-;VYT
M:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E<B8C>$$P.S,P+#PO8CX\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R
M/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^/&(^
M,C`Q,CPO8CX\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B!%>'!E8W1E9"!D:79I9&5N9"!Y:65L9#PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C`E/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1&-E;G1E<CXP)3PO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X<&5C=&5D
M('9O;&%T:6QI='D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1&-E;G1E<CXU,R4F(WA!,#LM)B-X03`[-3@E/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1&-E;G1E<CXU,24\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!2:7-K+69R964@:6YT97)E<W0@<F%T93PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE
M/3-$)U=(251%+5-004-%.B!N;W=R87`G/C$N,C0E)B-X03`[+28C>$$P.S(N
M,#4E/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^,2XQ
M."4\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!%>'!E8W1E9"!A=F5R86=E(&QI9F4@;V8@
M;W!T:6]N<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M8V5N=&5R/C<F(WA!,#MY96%R<SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C
M96YT97(^-R8C>$$P.WEE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@1F%I<B!M87)K970@=F%L=64@;V8@8V]M;6]N('-T;V-K(&%T
M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R
M/CQF;VYT('-T>6QE/3-$)U=(251%+5-004-%.B!N;W=R87`G/B0Q+C4P)B-X
M03`[+28C>$$P.R0W+C4Q/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1C96YT97(^)#$N-3`\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>'!E8W1E9"!F;W)F
M96ET=7)E(')A=&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1&-E;G1E<CXU+C`V)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT
M97(^-2XU-R4\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M
M+3X\+W1A8FQE/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%
M6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D9A
M:7(@5F%L=64@;V8@0V]M;6]N(%-T;V-K)B-X03`[)B-X,C`Q,SLF(WA!,#L\
M+V(^0F5F;W)E(&]U<@T*(&5N=')Y(&EN=&\@=&AE('!U8FQI8R!M87)K970@
M;VX@3V-T;V)E<B8C>$$P.S$P+"`R,#$S+"!T:&4-"B!#;VUP86YY)B-X,C`Q
M.3MS($)O87)D(&]F($1I<F5C=&]R<R!D971E<FUI;F5D('1H92!F86ER('9A
M;'5E(&]F('1H90T*(&-O;6UO;B!S=&]C:RX@5&AE($)O87)D(&]F($1I<F5C
M=&]R<R!M861E(&1E=&5R;6EN871I;VYS(&]F(&9A:7(-"B!V86QU92!B87-E
M9"P@:6X@<&%R="P@=7!O;B!C;VYT96UP;W)A;F5O=7,@=F%L=6%T:6]N<R!T
M;R!D971E<FUI;F4-"B!F86ER('9A;'5E+B!);B!T:&4@86)S96YC92!O9B!A
M('!U8FQI8R!M87)K970L(&%N9"!A<R!A#0H@8VQI;FEC86PM<W1A9V4@8V]M
M<&%N>2!W:71H(&YO('-I9VYI9FEC86YT(')E=F5N=65S+"!T:&4@0V]M<&%N
M>0T*(&)E;&EE=F5S('1H870@:70@:7,@87!P<F]P<FEA=&4@=&\@8V]N<VED
M97(@82!R86YG92!O9B!F86-T;W)S('1O#0H@9&5T97)M:6YE('1H92!F86ER
M(&UA<FME="!V86QU92!O9B!T:&4@8V]M;6]N('-T;V-K(&%T(&5A8V@@9W)A
M;G0-"B!D871E+B!4:&4@9F%C=&]R<R!I;F-L=61E.B`H,2DF(WA!,#MT:&4@
M86-H:65V96UE;G0@;V8@8VQI;FEC86P@86YD#0H@;W!E<F%T:6]N86P@;6EL
M97-T;VYE<R!B>2!T:&4@0V]M<&%N>3L@*#(I)B-X03`[=&AE('-T871U<R!O
M9@T*('-T<F%T96=I8R!R96QA=&EO;G-H:7!S('=I=&@@8V]L;&%B;W)A=&]R
M<SL@*#,I)B-X03`[=&AE#0H@<VEG;FEF:6-A;G0@<FES:W,@87-S;V-I871E
M9"!W:71H('1H92!#;VUP86YY)B-X,C`Q.3MS('-T86=E(&]F#0H@9&5V96QO
M<&UE;G0[("@T*28C>$$P.V-A<&ET86P@;6%R:V5T(&-O;F1I=&EO;G,@9F]R
M(&QI9F4@<V-I96YC90T*(&-O;7!A;FEE<RP@<&%R=&EC=6QA<FQY('-I;6EL
M87)L>2!S:71U871E9"P@<')I=F%T96QY(&AE;&0L#0H@96%R;'DM<W1A9V4@
M;&EF92!S8VEE;F-E(&-O;7!A;FEE<SL@*#4I)B-X03`[=&AE($-O;7!A;GDF
M(W@R,#$Y.W,-"B!A=F%I;&%B;&4@8V%S:"P@9FEN86YC:6%L(&-O;F1I=&EO
M;B!A;F0@<F5S=6QT<R!O9B!O<&5R871I;VYS.PT*("@V*28C>$$P.W1H92!M
M;W-T(')E8V5N="!S86QE<R!O9B!T:&4@0V]M<&%N>28C>#(P,3D[<R!P<F5F
M97)R960-"B!S=&]C:R!A;F0@*#<I)B-X03`[=&AE('!R969E<F5N=&EA;"!R
M:6=H=',@;V8@=&AE(&]U='-T86YD:6YG#0H@<')E9F5R<F5D('-T;V-K+B!4
M:&4@8V]N=&5M<&]R86YE;W5S('9A;'5A=&EO;G,@=V5R92!P97)F;W)M960@
M:6X-"B!A8V-O<F1A;F-E('=I=&@@87!P;&EC86)L92!M971H;V1O;&]G:65S
M+"!A<'!R;V%C:&5S(&%N9`T*(&%S<W5M<'1I;VYS(&]F('1H92!T96-H;FEC
M86P@<')A8W1I8V4M86ED(&ES<W5E9"!B>2!T:&4@06UE<FEC86X-"B!);G-T
M:71U=&4@;V8@0V5R=&EF:65D(%!U8FQI8R!!8V-O=6YT86YT<R!0<F%C=&EC
M92!!:60@96YT:71L960-"B`\:3Y686QU871I;VX@;V8@4')I=F%T96QY+4AE
M;&0@0V]M<&%N>2!%<75I='D@4V5C=7)I=&EE<R!)<W-U960@87,-"B!#;VUP
M96YS871I;VX\+VD^+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B`\8CY%>'!E8W1E9"!6;VQA=&EL:71Y/"]B/B8C>$$P.R8C>#(P,3,[(%9O
M;&%T:6QI='D@:7,@82!M96%S=7)E(&]F#0H@=&AE(&%M;W5N="!B>2!W:&EC
M:"!A(&9I;F%N8VEA;"!V87)I86)L92!S=6-H(&%S(&$@<VAA<F4@<')I8V4@
M:&%S#0H@9FQU8W1U871E9"`H:&ES=&]R:6-A;"!V;VQA=&EL:71Y*2!O<B!I
M<R!E>'!E8W1E9"!T;R!F;'5C='5A=&4-"B`H97AP96-T960@=F]L871I;&ET
M>2D@9'5R:6YG(&$@<&5R:6]D+B!4:&4@0V]M<&%N>2!D;V5S(&YO=`T*(&UA
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M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D5X<&5C=&5D($1I=FED96YD(%EI96QD
M/"]B/B8C>$$P.R8C>#(P,3,[(%1H92!#;VUP86YY(&AA<R!N979E<@T*(&1E
M8VQA<F5D(&]R('!A:60@9&EV:61E;F1S(&%N9"!H87,@;F\@<&QA;G,@=&\@
M9&\@<V\@:6X@=&AE#0H@9F]R97-E96%B;&4@9G5T=7)E+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CY2:7-K+49R964@26YT97)E<W0@
M4F%T93PO8CXF(WA!,#LF(W@R,#$S.R!4:&ES(&ES('1H92!5+E,N#0H@5')E
M87-U<GD@<F%T92!F;W(@=&AE('=E96L@;V8@96%C:"!O<'1I;VX@9W)A;G0@
M9'5R:6YG('1H92!Y96%R+`T*(&AA=FEN9R!A('1E<FT@=&AA="!M;W-T(&-L
M;W-E;'D@<F5S96UB;&5S('1H92!E>'!E8W1E9"!L:69E(&]F('1H90T*(&]P
M=&EO;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^17AP
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M97AP96-T960-"B!T97)M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B`\8CY%>'!E8W1E9"!&;W)F96ET=7)E(%)A=&4\+V(^)B-X03`[)B-X
M,C`Q,SL@5&AE(&9O<F9E:71U<F4@<F%T92!I<PT*('1H92!E<W1I;6%T960@
M<&5R8V5N=&%G92!O9B!O<'1I;VYS(&=R86YT960@=&AA="!I<R!E>'!E8W1E
M9"!T;R!B90T*(&9O<F9E:71E9"!O<B!C86YC96QE9"!O;B!A;B!A;FYU86P@
M8F%S:7,@8F5F;W)E(&)E8V]M:6YG(&9U;&QY#0H@=F5S=&5D+B!4:&4@0V]M
M<&%N>2!E<W1I;6%T97,@=&AE(&9O<F9E:71U<F4@<F%T92!B87-E9"!O;B!T
M=7)N;W9E<@T*(&1A=&$@=VET:"!F=7)T:&5R(&-O;G-I9&5R871I;VX@9VEV
M96X@=&\@=&AE(&-L87-S(&]F('1H92!E;7!L;WEE97,-"B!T;R!W:&]M('1H
M92!O<'1I;VYS('=E<F4@9W)A;G1E9"X\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@17%U:71Y(&EN<W1R=6UE;G1S(&ES<W5E9"!T;R!N;VXM
M96UP;&]Y965S(&%R92!A8V-O=6YT960@9F]R('5N9&5R#0H@=&AE('!R;W9I
M<VEO;G,@;V8@05-#)B-X03`[-3`U+34P+"`\:3Y%<75I='D@0F%S960@4&%Y
M;65N=',@=&\-"B!.;VXM16UP;&]Y965S/"]I/BX@06-C;W)D:6YG;'DL('1H
M92!E<W1I;6%T960@9F%I<B!V86QU92!O9B!T:&4-"B!E<75I='D@:6YS=')U
M;65N="!I<R!R96-O<F1E9"!O;B!T:&4@96%R;&EE<B!O9B!T:&4@<&5R9F]R
M;6%N8V4-"B!C;VUM:71M96YT(&1A=&4@;W(@=&AE(&1A=&4@=&AE('-E<G9I
M8V5S(')E<75I<F5D(&%R90T*(&-O;7!L971E9"X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4
M+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!S=6UM87)I>F5S('-T;V-K
M(&]P=&EO;B!A8W1I=FET>2!U;F1E<B!T:&4@4&QA;@T*(&1U<FEN9R!T:&4@
M<&5R:6]D('1H96X@96YD960Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0X-"4@86QI9VX],T1C96YT97(^/"$M
M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U
M.24^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY.=6UB97(F(WA!,#MO9CPO8CX\8G(@
M+SX-"B`\8CY/<'1I;VYS/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E
M;G1E<CX\8CY796EG:'1E9"T\8G(@+SX-"B!!=F5R86=E)B-X03`[17AE<F-I
M<V4\+V(^/&)R("\^#0H@/&(^4')I8V4\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D+3QB<B`O/@T*($%V97)A
M9V4\+V(^/&)R("\^#0H@/&(^0V]N=')A8W1U86PF(WA!,#M497)M/"]B/CQB
M<B`O/@T*(#QB/BAI;B!996%R<RD\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(
M96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($]U='-T86YD:6YG+"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-#DL-S`R/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N.30\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXS/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!'<F%N=&5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-C@W+#$X,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M+C$Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@
M17AE<F-I<V5D/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#$L
M,#(U+#DS,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,"XW-3PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($9O<F9E:71E9"!O<B!E>'!I<F5D/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^*#,S+#DT.3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2XQ,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P
M>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X
M03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@3W5T<W1A
M;F1I;F<L(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XR+#@W-RPP,#,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M+C4P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXR/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S.CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>&5R8VES86)L93PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PX-34L,3<X/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,"XY-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@5F5S=&5D(&%N9"!%>'!E8W1E9"!T;R!6
M97-T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XY,3@L-C`P/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,BXT-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O
M9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4
M:&4@86=G<F5G871E(&EN=')I;G-I8R!V86QU92!O9B!O<'1I;VYS(&]U='-T
M86YD:6YG(&%N9"!O<'1I;VYS#0H@97AE<F-I<V%B;&4@87,@;V8@4V5P=&5M
M8F5R)B-X03`[,S`L(#(P,3,@:7,@87!P<F]X:6UA=&5L>2`D,3<N-`T*(&UI
M;&QI;VX@86YD("0Q,BXR(&UI;&QI;VXL(')E<W!E8W1I=F5L>2X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE('=E:6=H=&5D+6%V97)A
M9V4@9W)A;G0M9&%T92!F86ER('9A;'5E(&]F(&]P=&EO;G,@9W)A;G1E9"!F
M;W(-"B!T:&4@;FEN92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L
M(#(P,3,@=V%S("0R+C`P+B!4;W1A;"!C87-H#0H@<F5C96EV960@9F]R('1H
M92!O<'1I;VYS(&5X97)C:7-E9"!W87,@)#@U,2PQ.#,@9F]R('1H92!N:6YE
M(&UO;G1H<PT*(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+B!4:&4@
M=&]T86P@9F%I<B!V86QU92!O9B!S:&%R97,-"B!V97-T960@:6X@=&AE(&YI
M;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S('=A<PT*
M("0T,#(L,#@T+B!!<R!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q,RP@=&AE
M('1O=&%L('5N<F5C;V=N:7IE9`T*(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E
M;&%T960@=&\@;F]N+79E<W1E9"!S=&]C:RUB87-E9"!C;VUP96YS871I;VX-
M"B!A<G)A;F=E;65N=',@9W)A;G1E9"!U;F1E<B!T:&4@,C`P,"!0;&%N(&%N
M9"`R,#`S(%!L86XL(&YE="!O9@T*(')E;&%T960@9F]R9F5I='5R92!E<W1I
M;6%T97,L('=A<R`D,2XU(&UI;&QI;VXL('=H:6-H('1H92!#;VUP86YY#0H@
M97AP96-T<R!T;R!R96-O9VYI>F4@;W9E<B!A('=E:6=H=&5D+6%V97)A9V4@
M<&5R:6]D(&]F#0H@87!P<F]X:6UA=&5L>2!F;W5R('EE87)S+CPO<#X-"B`\
M+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
M7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N
M="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R
M85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3:&5E=#$Q+FAT;6P-"D-O;G1E
M;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E
M;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT
M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O
M;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&5A<V4@17AI="!,:6%B
M:6QI='D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY297-T<G5C='5R:6YG($%N9"!296QA=&5D($%C=&EV:71I97,@
M6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5A<V4@17AI="!,:6%B:6QI='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CXV+B!,96%S
M92!%>&ET($QI86)I;&ET>3PO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!/;B!*=6QY)B-X03`[,38L(#(P,#@L('1H92!#;VUP86YY(&%C
M<75I<F5D(%)A=F5N($)I;W1E8VAN;VQO9VEE<RP-"B!);F,N("A2879E;BDL
M(&$@<')I=F%T92!3;W5T:"!386X@1G)A;F-I<V-O+6)A<V5D(&-O;7!A;GD@
M9F]C=7-E9`T*(&]N('1H92!D979E;&]P;65N="!O9B!M;VYO8VQO;F%L(&%N
M=&EB;V1Y('1H97)A<&5U=&EC<R!F;W(@=')E871I;F<-"B!C86YC97(N(%)A
M=F5N('=A<R!C;VYS:61E<F5D(&$@9&5V96QO<&UE;G0M<W1A9V4@96YT97)P
M<FES92!A<PT*(&1E9FEN960@:6X@05-#)B-X03`[.3$U+"`\:3Y$979E;&]P
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M>6%B;&4-"B!O9B!2879E;BX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
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M96YD960@1&5C96UB97(F(WA!,#LS,2P@,C`P.2X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
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M>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-H86YG97,@:6X@=&AE(&QE87-E(&5X
M:70@;&EA8FEL:71Y(&%R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$
M8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D
M('=I9'1H/3-$.#,E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T
M:#TS1#<E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G
M:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%C8W)U
M86P@8F%L86YC92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$Q/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3`L-C`W+#0Y.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@4')I;F-I<&%L('!A>6UE;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH-3,S+#4V,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%C8W)U
M86P@8F%L86YC92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ,"PP-S,L.3,Y/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!0<FEN8VEP86P@<&%Y;65N=',\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/B@T-C8L,S`Q/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@
M06-C<G5A;"!B86QA;F-E(&%T(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^.2PV,#<L-C,X/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM
M($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)6D4Z
M(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#!P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@1G5T=7)E('!R:6YC:7!A;"!P87EM96YT<R!T;R!B92!M861E('5N9&5R
M('1H92!L96%S92!A9W)E96UE;G0@9F]R#0H@=&AE(&YE>'0@9FEV92!Y96%R
M<R!A;F0@=&AE<F5A9G1E<B!A<R!O9B!397!T96UB97(F(WA!,#LS,"P@,C`Q
M,PT*(&%R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T
M)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,
M05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-C@E(&%L:6=N/3-$8V5N=&5R/CPA
M+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$
M.#4E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T
M<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@
M0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1W96QV92!-;VYT:',@
M16YD:6YG(%-E<'1E;6)E<B8C>$$P.S,P+#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B`R,#$T/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,2PR,CDL-#4T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B`R,#$U/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XQ+#4X.2PT,3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#(P,38\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L.#`X+#$Q.3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@,C`Q
M-SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPP-#DL,C<S/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B`R,#$X/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR+#,Q-2PP,C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%1H97)E869T97(\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C8Q-BPS-38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2PV,#<L-C,X/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@
M,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@
M<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
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M(&]N971I;64@<&%Y;65N="!O9B`D-2XP)B-X03`[;6EL;&EO;B!W:6QL(&)E
M(&UA9&4@=&\@=&AE(%)A=F5N#0H@<W1O8VMH;VQD97)S('5P;VX@=&AE(&EN
M:71I871I;VX@;V8@<&%T:65N="!D;W-I;F<@:6X@=&AE(&9I<G-T#0H@4&AA
M<V4@,B!C;&EN:6-A;"!T<FEA;"!O9B!A;GD@<')O9'5C="!D97)I=F5D(&9R
M;VT@=&AE(%)A=F5N#0H@)B-X,C`Q0SM#86YC97(@4W1E;2!#96QL(%!R;V=R
M86TN)B-X,C`Q1#L@3F\@<&%Y;65N="!S:&%L;"!B92!M861E(&EF#0H@=&AE
M(%!H87-E(#(@=')I86P@<W1A<G0@9&%T92!H87,@;F]T(&]C8W5R<F5D(&]N
M(&]R(&)E9F]R90T*($IU;'DF(WA!,#LQ-2P@,C`Q."X@3W1H97(@8V]N<VED
M97)A=&EO;B!I;F-L=61E<R!A('!E<F-E;G1A9V4@;V8-"B!R979E;G5E("AE
M>&-L=61I;F<@8V]N<VED97)A=&EO;B!F;W(@<F5S96%R8V@@86YD(&1E=F5L
M;W!M96YT(&%N9`T*(&5Q=6ET>2D@<F5C96EV960@8GD@36%C<F]'96YI8W,@
M9F]R(&QI8V5N<V4@;V8@82!P<F]D=6-T(&1E<FEV960-"B!F<F]M('1H92!2
M879E;B`F(W@R,#%#.T-A;F-E<B!3=&5M($-E;&P@4')O9W)A;28C>#(P,40[
M(&%N9"!A(&]N971I;64-"B!P87EM96YT(')A;F=I;F<@9G)O;2`D."XP)B-X
M03`[;6EL;&EO;B!T;R`D,3(N,"8C>$$P.VUI;&QI;VX-"B!D97!E;F1E;G0@
M=7!O;B!A('-P96-I9FEE9"!L979E;"!O9B!S86QE<R!O9B!P<F]D=6-T<R!D
M97)I=F5D(&9R;VT-"B!T:&4@4F%V96X@)B-X,C`Q0SM#86YC97(@4W1E;2!#
M96QL(%!R;V=R86TN)B-X,C`Q1#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@5&AE(&-O;G1I;F=E;G0@8V]N<VED97)A=&EO;B!W:6QL(&)E
M(&%C8V]U;G1E9"!F;W(@87,@861D:71I;VYA;`T*('!U<F-H87-E('!R:6-E
M(&%N9"!R96-O<F1E9"!A<R!I;F-R96UE;G1A;"!I;BUP<F]C97-S(')E<V5A
M<F-H(&%N9`T*(&1E=F5L;W!M96YT(&5X<&5N<V4@=VAE;B!I="!I<R!D965M
M960@<')O8F%B;&4@=&AA="!T:&4-"B!C;VYT:6YG96YC:65S('=I;&P@8F4@
M871T86EN960N($YO(&%D9&ET:6]N86P@86UO=6YT<R!H879E(&)E96X-"B!R
M96-O<F1E9"!D=7)I;F<@=&AE(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E
M<B8C>$$P.S,P+"`R,#$S(&%N9`T*(#(P,3(N/"]P/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?
M.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X
M-3!B82]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VQL86)O<F%T:6]N(&%N9"!,:6-E;G-E
M($%G<F5E;65N=',\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY497AT($)L;V-K(%M!8G-T<F%C=%T\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;&QA8F]R871I
M;VX@86YD($QI8V5N<V4@06=R965M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/C<N($-O;&QA8F]R
M871I;VX@86YD($QI8V5N<V4@06=R965M96YT<SPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@/&(^/&D^3&5S($QA8F]R871O:7)E<R!397)V:65R/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!.;W9E;6)E<B`R,#$Q
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M9"!);F1I82X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@57!O
M;B!E>&5C=71I;VX@;V8@=&AE(&%G<F5E;65N="P@4V5R=FEE<B!M861E(&$@
M;F]N<F5F=6YD86)L90T*('!A>6UE;G0@;V8@)#(P(&UI;&QI;VX@=&\@=&AE
M($-O;7!A;GDN(%1H92!#;VUP86YY(&ES(&5L:6=I8FQE('1O#0H@<F5C96EV
M92!U<"!T;R`D,S`@;6EL;&EO;B!I;B!L:6-E;G-E(&=R86YT(&9E97,L("0T
M-R!M:6QL:6]N(&EN#0H@8VQI;FEC86P@;6EL97-T;VYE('!A>6UE;G1S+"`D
M,30P(&UI;&QI;VX@:6X@<F5G=6QA=&]R>2!M:6QE<W1O;F4-"B!P87EM96YT
M<R!A;F0@)#(P."!M:6QL:6]N(&EN('-A;&5S(&UI;&5S=&]N92!P87EM96YT
M<R!I9B!397)V:65R#0H@97AE<F-I<V5S('1H92!O<'1I;VXL(&]B=&%I;G,@
M<F5G=6QA=&]R>2!A<'!R;W9A;"!F;W(@86YD#0H@<W5C8V5S<V9U;&QY(&-O
M;6UE<F-I86QI>F5S($U'03(W,2X@5&AE($-O;7!A;GD@8V]N8VQU9&5D('1H
M870@=&AE#0H@;&EC96YS92!G<F%N="!F965S(&%R92!N;W0@9&5L:79E<F%B
M;&5S(&%T('1H92!I;F-E<'1I;VX@;V8@=&AE#0H@87)R86YG96UE;G0N(%1H
M92!#;VUP86YY(&AA<R!D971E<FUI;F5D('1H870@96%C:"!P;W1E;G1I86P@
M9G5T=7)E#0H@8VQI;FEC86PL(&1E=F5L;W!M96YT(&%N9"!R96=U;&%T;W)Y
M(&UI;&5S=&]N92!I<R!S=6)S=&%N=&EV92X-"B!!;'1H;W5G:"!S86QE<R!M
M:6QE<W1O;F5S(&%R92!N;W0@8V]N<VED97)E9"!S=6)S=&%N=&EV92P@=&AE
M>2!A<F4-"B!S=&EL;"!R96-O9VYI>F5D('5P;VX@86-H:65V96UE;G0@;V8@
M=&AE(&UI;&5S=&]N92`H87-S=6UI;F<@86QL#0H@;W1H97(@<F5V96YU92!R
M96-O9VYI=&EO;B!C<FET97)I82!H879E(&)E96X@;65T*2!B96-A=7-E('1H
M97)E(&%R90T*(&YO('5N9&5L:79E<F5D(&5L96UE;G1S('1H870@=V]U;&0@
M<')E8VQU9&4@<F5V96YU92!R96-O9VYI=&EO;B!A=`T*('1H870@=&EM92X@
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M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N
M>2!H87,@979A;'5A=&5D('1H92!R97-E87)C:"!C;VQL86)O<F%T:6]N(&%G
M<F5E;65N="!W:71H#0H@4V5R=FEE<B!A;F0@:&%S(&1E=&5R;6EN960@=&AA
M="!I="!I<R!A(')E=F5N=64@87)R86YG96UE;G0@=VET:`T*(&UU;'1I<&QE
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M(')E<V5A<F-H('!L86X@9'5R:6YG('1H92!F:7)S=`T*('EE87(@;V8@=&AE
M(&%G<F5E;65N="!A;F0@<&%R=&EC:7!A=&EO;B!O;B!A;B!E>&5C=71I=F4@
M8V]M;6ET=&5E#0H@86YD(&$@<F5S96%R8V@@86YD(&1E=F5L;W!M96YT(&-O
M;6UI='1E92X@5&AE($-O;7!A;GD@9&5T97)M:6YE9`T*('1H870@=&AE<V4@
M<&5R9F]R;6%N8V4@;V)L:6=A=&EO;G,@<F5P<F5S96YT(&$@<VEN9VQE('5N
M:70@;V8-"B!A8V-O=6YT:6YG+"!S:6YC92!T:&4@;&EC96YS92!D;V5S(&YO
M="!H879E('-T86YD+6%L;VYE('9A;'5E('1O#0H@4V5R=FEE<B!W:71H;W5T
M('1H92!#;VUP86YY)B-X,C`Q.3MS('1E8VAN:6-A;"!E>'!E<G1I<V4@86YD
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M92X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1'5R:6YG('1H
M92!T:')E92!M;VYT:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@
M86YD(#(P,3(@=&AE#0H@0V]M<&%N>2!R96-O9VYI>F5D(')E=F5N=64@;V8@
M)#$R+C,@;6EL;&EO;B`H:6YC;'5D:6YG(&$@)#$P+C`-"B!M:6QL:6]N(&UI
M;&5S=&]N92!P87EM96YT*2!A;F0@)#(N,R!M:6QL:6]N+"!R97-P96-T:79E
M;'DN($1U<FEN9PT*('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB97(F
M(WA!,#LS,"P@,C`Q,R!A;F0@,C`Q,B!T:&4@0V]M<&%N>0T*(')E8V]G;FEZ
M960@<F5V96YU92!O9B`D,3@N.2!M:6QL:6]N("AI;F-L=61I;F<@82`D,3`N
M,"!M:6QL:6]N#0H@;6EL97-T;VYE('!A>6UE;G0I(&%N9"`D-BXX(&UI;&QI
M;VXL(')E<W!E8W1I=F5L>2P@=6YD97(@=&AI<PT*(&%G<F5E;65N="X\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@070@4V5P=&5M8F5R)B-X
M03`[,S`L(#(P,3,L("0S+C$@;6EL;&EO;B!O9B!R979E;G5E('=A<R!D969E
M<G)E9`T*('5N9&5R('1H:7,@86=R965M96YT+"!A;&P@;V8@=VAI8V@@=V%S
M(&EN8VQU9&5D(&EN(&-U<G)E;G0-"B!L:6%B:6QI=&EE<RX@070@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,BP@)#$P+C`@;6EL;&EO;B!O9B!R979E;G5E#0H@
M=V%S(&1E9F5R<F5D('5N9&5R('1H:7,@86=R965M96YT+"`D.2XQ(&UI;&QI
M;VX@;V8@=VAI8V@@=V%S#0H@:6YC;'5D960@:6X@8W5R<F5N="!L:6%B:6QI
M=&EE<R!A;F0@)#`N.2!M:6QL:6]N('=A<R!I;F-L=61E9"!I;@T*(&QO;F<M
M=&5R;2!L:6%B:6QI=&EE<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@26X@4V5P=&5M8F5R(#(P,3(L('1H92!#;VUP86YY(&5N=&5R960@
M:6YT;R!A('-E8V]N9`T*(')I9VAT+71O+61E=F5L;W`@8V]L;&%B;W)A=&EO
M;B!A9W)E96UE;G0@=VET:"!397)V:65R(&%N9"!G<F%N=&5D#0H@:70@;W!T
M:6]N<R!T;R!O8G1A:6X@=&AR964@<V5P87)A=&4@97AC;'5S:79E(&QI8V5N
M<V5S('1O(&1E=F5L;W`-"B!A;F0@8V]M;65R8VEA;&EZ92!$05)4+6)A<V5D
M(&UO;&5C=6QE<RP@8V]N<VES=&EN9R!O9B!T:&]S90T*(&1E<VEG;F%T960@
M8GD@=&AE($-O;7!A;GD@87,@34=$,#`V(&%N9"!-1T0P,#<L(&%S('=E;&P@
M87,@82!T:&ER9`T*($1!4E0@;6]L96-U;&4L(&EN(&%L;"!C;W5N=')I97,@
M;W1H97(@=&AA;B!T:&4@56YI=&5D(%-T871E<RP-"B!#86YA9&$L($UE>&EC
M;RP@2F%P86XL(%-O=71H($MO<F5A(&%N9"!);F1I82X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@57!O;B!E>&5C=71I;VX@;V8@=&AE(&%G
M<F5E;65N="P@4V5R=FEE<B!M861E(&$@;F]N<F5F=6YD86)L90T*('!A>6UE
M;G0@;V8@)#(P(&UI;&QI;VX@=&\@=&AE($-O;7!A;GDN($EN(&%D9&ET:6]N
M+"!T:&4@0V]M<&%N>0T*('=I;&P@8F4@96QI9VEB;&4@=&\@<F5C96EV92!U
M<"!T;R`D-C4@;6EL;&EO;B!I;B!L:6-E;G-E(&=R86YT#0H@9F5E<RP@)#DX
M(&UI;&QI;VX@:6X@8VQI;FEC86P@;6EL97-T;VYE('!A>6UE;G1S+"!I;F-L
M=61I;F<@)#4-"B!M:6QL:6]N('5P;VX@24Y$(&%C8V5P=&%N8V4@9F]R(&5A
M8V@@;V8@34=$,#`V+"!-1T0P,#<@86YD(&$@=&AI<F0-"B!$05)4(&UO;&5C
M=6QE+"`D,S`P(&UI;&QI;VX@:6X@<F5G=6QA=&]R>2!M:6QE<W1O;F4@<&%Y
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M<VAA<F4-"B!0:&%S92`R(&%N9"!0:&%S92`S(&1E=F5L;W!M96YT(&-O<W1S
M+B!4:&4@0V]M<&%N>2!H87,@9&5T97)M:6YE9`T*('1H870@96%C:"!P;W1E
M;G1I86P@9G5T=7)E(&-L:6YI8V%L+"!D979E;&]P;65N="!A;F0@<F5G=6QA
M=&]R>0T*(&UI;&5S=&]N92!I<R!S=6)S=&%N=&EV92X@06QT:&]U9V@@<V%L
M97,@;6EL97-T;VYE<R!A<F4@;F]T#0H@8V]N<VED97)E9"!S=6)S=&%N=&EV
M92P@=&AE>2!A<F4@<W1I;&P@<F5C;V=N:7IE9"!U<&]N(&%C:&EE=F5M96YT
M#0H@;V8@=&AE(&UI;&5S=&]N92`H87-S=6UI;F<@86QL(&]T:&5R(')E=F5N
M=64@<F5C;V=N:71I;VX@8W)I=&5R:6$-"B!H879E(&)E96X@;65T*2!B96-A
M=7-E('1H97)E(&%R92!N;R!U;F1E;&EV97)E9"!E;&5M96YT<R!T:&%T('=O
M=6QD#0H@<')E8VQU9&4@<F5V96YU92!R96-O9VYI=&EO;B!A="!T:&%T('1I
M;64N(%5N9&5R('1H:7,@86=R965M96YT+`T*(%-E<G9I97(@=V]U;&0@8F4@
M;V)L:6=A=&5D('1O('!A>2!T:&4@0V]M<&%N>2!B971W965N(&AI9V@M<VEN
M9VQE#0H@9&EG:70@86YD(&UI9"UT965N(')O>6%L=&EE<R!O;B!N970@<')O
M9'5C="!S86QE<R!I;B!I=',-"B!T97)R:71O<FEE<RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E
M9"!T:&4@<F5S96%R8V@@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:`T*
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M;6ET=&5E(&%N9"!A(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT(&-O;6UI
M='1E92X@5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H92!P97)F;W)M
M86YC90T*(&]B;&EG871I;VYS('=I=&@@<F5S<&5C="!T;R!T:&4@<')E+6-L
M:6YI8V%L(&1E=F5L;W!M96YT(')E<')E<V5N=`T*(&$@<VEN9VQE('5N:70@
M;V8@86-C;W5N=&EN9RP@<VEN8V4@=&AE(&QI8V5N<V4@9&]E<R!N;W0@:&%V
M90T*('-T86YD+6%L;VYE('9A;'5E('1O(%-E<G9I97(@=VET:&]U="!T:&4@
M0V]M<&%N>28C>#(P,3D[<R!T96-H;FEC86P-"B!E>'!E<G1I<V4@86YD(&-O
M;6UI='1E92!P87)T:6-I<&%T:6]N+B!!<R!S=6-H+"!T:&4@:6YI=&EA;"!U
M<`T*(&9R;VYT(&QI8V5N<V4@<&%Y;65N="!W87,@9&5F97)R960@86YD(&ES
M(&)E:6YG(')E8V]G;FEZ960@<F%T86)L>0T*(&]V97(@=&AE(&EN:71I86P@
M,CDM;6]N=&@@<&5R:6]D+"!W:&EC:"!R97!R97-E;G1S('1H92!E>'!E8W1E
M9`T*(&1E=F5L;W!M96YT('!E<FEO9"X@5&AE($-O;7!A;GD@9G5R=&AE<B!C
M;VYC;'5D960@=&AA="!E86-H#0H@<&]T96YT:6%L(&9U='5R92!C;&EN:6-A
M;"P@9&5V96QO<&UE;G0@86YD(')E9W5L871O<GD@;6EL97-T;VYE(&ES#0H@
M<W5B<W1A;G1I=F4N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($1U<FEN9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E
M;6)E<B8C>$$P.S,P+"`R,#$S('1H90T*($-O;7!A;GD@<F5C;V=N:7IE9"!R
M979E;G5E(&]F("0R+C(@;6EL;&EO;B!A;F0@)#8N-2!M:6QL:6]N+`T*(')E
M<W!E8W1I=F5L>2X@3F\@<F5V96YU92!W87,@<F5C;V=N:7IE9"!U;F1E<B!T
M:&ES(&%G<F5E;65N="!D=7)I;F<-"B!T:&4@8V]M<&%R86)L92!P97)I;V1S
M(&EN(#(P,3(N($YO(&UI;&5S=&]N97,@:&%V92!B965N(')E8V]G;FEZ960-
M"B!U;F1E<B!T:&ES(&%G<F5E;65N="!D=7)I;F<@=&AE('1H<F5E(&%N9"!N
M:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!="!397!T96UB97(F(WA!,#LS,"P@
M,C`Q,RP@)#$Q+C8@;6EL;&EO;B!O9B!R979E;G5E('=A<R!D969E<G)E9`T*
M('5N9&5R('1H:7,@86=R965M96YT+"`D."XV(&UI;&QI;VX@;V8@=VAI8V@@
M=V%S(&EN8VQU9&5D(&EN(&-U<G)E;G0-"B!L:6%B:6QI=&EE<R!A;F0@)#,N
M,"!M:6QL:6]N(&]F('=H:6-H('=A<R!I;F-L=61E9"!I;B!L;VYG+71E<FT-
M"B!L:6%B:6QI=&EE<RX@070@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BP@)#$X
M+C`@;6EL;&EO;B!O9B!R979E;G5E#0H@=V%S(&1E9F5R<F5D('5N9&5R('1H
M:7,@86=R965M96YT+"`D."XV(&UI;&QI;VX@;V8@=VAI8V@@=V%S#0H@:6YC
M;'5D960@:6X@8W5R<F5N="!L:6%B:6QI=&EE<R!A;F0@)#DN-"!M:6QL:6]N
M(&]F('=H:6-H('=A<PT*(&EN8VQU9&5D(&EN(&QO;F<M=&5R;2!L:6%B:6QI
M=&EE<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/D=I;&5A9"!38VEE;F-E<RP@
M26YC+CPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M26X@2F%N=6%R>2`R,#$S+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@86X@
M86=R965M96YT('=I=&@@1VEL96%D#0H@=&\@9W)A;G0@:70@86X@97AC;'5S
M:79E('=O<FQD=VED92!L:6-E;G-E('1O(')E<V5A<F-H+"!D979E;&]P(&%N
M9`T*(&-O;6UE<F-I86QI>F4@=7`@=&\@9F]U<B!$05)4+6)A<V5D(&UO;&5C
M=6QE<RX@1VEL96%D(&AA<R!E>&-L=7-I=F4-"B!W;W)L9'=I9&4@<FEG:'1S
M(&9O<B!T:')E92!O9B!T:&4@<')O9W)A;7,N($9O<B!O;F4@<')O9W)A;2P@
M=&AE#0H@0V]M<&%N>2!R971A:6YS(&1E=F5L;W!M96YT(&%N9"!C;VUM97)C
M:6%L:7IA=&EO;B!R:6=H=',@;W5T<VED92!O9@T*($YO<G1H($%M97)I8V$L
M('1H92!%=7)O<&5A;B!5;FEO;BP@3F]R=V%Y+"!)8V5L86YD+"!4=7)K97DL
M#0H@075S=')A;&EA(&%N9"!.97<@6F5A;&%N9"X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@<F5C96EV960@86X@:6YI
M=&EA;"`D-RXU(&UI;&QI;VX@;&EC96YS92!G<F%N="!F964@9F]R#0H@=&AE
M(&9I<G-T($1!4E0M8F%S960@;6]L96-U;&4N(%1H92!#;VUP86YY(&UA>2!B
M92!E;&EG:6)L92!T;PT*(')E8V5I=F4@861D:71I;VYA;"!L:6-E;G-E(&=R
M86YT(&9E97,@;V8@)#(R+C4@;6EL;&EO;BP@)#(P,`T*(&UI;&QI;VX@<F5L
M871E9"!T;R!P<F4M8VQI;FEC86P@86YD(&-L:6YI8V%L(&UI;&5S=&]N97,L
M("0S-34-"B!M:6QL:6]N(')E;&%T960@=&\@<F5G=6QA=&]R>2!M:6QE<W1O
M;F5S(&%N9"`D-3`P(&UI;&QI;VX@<F5L871E9`T*('1O('-A;&5S(&UI;&5S
M=&]N97,@:68@1VEL96%D(&5X97)C:7-E<R!A;&P@9F]U<B!O9B!T:&4@;W!T
M:6]N<R!A;F0-"B!S=6-C97-S9G5L;'D@9&5V96QO<',L(&]B=&%I;G,@<F5G
M=6QA=&]R>2!A<'!R;W9A;"!F;W(L(&%N9`T*(&-O;6UE<F-I86QI>F5S(&$@
M<')O9'5C="!U;F1E<B!E86-H(&]P=&EO;B!A;F0@;&EC96YS92X@5&AE($-O
M;7!A;GD-"B!H87,@9&5T97)M:6YE9"!T:&%T('1H92!O=&AE<B!L:6-E;G-E
M<R!A<F4@8V]N9&ET:6]N86P-"B!D96QI=F5R86)L97,L('=H:6-H(&%R92!S
M=6)S=&%N=&EV92!O<'1I;VYS('1H870@=V5R92!N;W0@9W)A;G1E9`T*('=I
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M96QI=F5R960@96QE;65N=',@=&AA="!W;W5L9`T*('!R96-L=61E(')E=F5N
M=64@<F5C;V=N:71I;VX@870@=&AA="!T:6UE+B!':6QE860@86QS;R!P<F]V
M:61E<PT*(&9U;F1I;F<@9F]R('1H92!#;VUP86YY)B-X,C`Q.3MS(&EN=&5R
M;F%L(&%N9"!E>'1E<FYA;"!R97-E87)C:`T*(&-O<W1S('5N9&5R('1H92!A
M9W)E96UE;G0N($%D9&ET:6]N86QL>2P@1VEL96%D('=O=6QD(&)E(&]B;&EG
M871E9`T*('1O('!A>2!T:&4@0V]M<&%N>2!H:6=H('-I;F=L92!D:6=I="!T
M;R!L;W<@9&]U8FQE(&1I9VET+"!B=70@;&5S<PT*('1H86X@=&5E;B!R;WEA
M;'1I97,@;VX@<')O9'5C="!S86QE<R!I;B!I=',@=&5R<FET;W)I97,N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
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M;VUP86YY)B-X,C`Q.3MS('-U8G-T86YT:79E('!E<F9O<FUA;F-E(&]B;&EG
M871I;VYS('5N9&5R('1H:7,-"B!R97-E87)C:"!C;VQL86)O<F%T:6]N(&EN
M8VQU9&4@82!L:6-E;G-E('1O(&ET<R!T96-H;F]L;V=Y(&%N9`T*(')E<V5A
M<F-H(&%N9"!D979E;&]P;65N="!S97)V:6-E<RX@5&AE($-O;7!A;GD@8V]N
M8VQU9&5D('1H870@=&AE#0H@9&5L:79E<F%B;&5S(&1O(&YO="!H879E('-T
M86YD(&%L;VYE('9A;'5E(&%N9"!T:&5R969O<F4L(')E<')E<V5N=`T*(&$@
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M;G1S('1H92!E>'!E8W1E9`T*(&1E=F5L;W!M96YT('!E<FEO9"X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@86YD($=I
M;&5A9"!H879E(&%L<V\@86=R965D('1O(&5S=&%B;&ES:"!A(&IO:6YT#0H@
M<F5S96%R8V@@8V]M;6ET=&5E('1O(&9A8VEL:71A=&4@=&AE(&=O=F5R;F%N
M8V4@86YD(&]V97)S:6=H="!O9@T*('1H92!P87)T:65S)B-X,C`Q.3L@86-T
M:79I=&EE<R!U;F1E<B!T:&4@86=R965M96YT<RX@36%N86=E;65N=`T*(&-O
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M3U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(%)E8V5I=F%B;&5S(&]F("0Q+C$@;6EL;&EO;B!A<R!O9B!397!T
M96UB97(F(WA!,#LS,"P@,C`Q,R!R96QA=&4@=&\-"B!A;6]U;G1S(&1U92!T
M;R!T:&4@0V]M<&%N>2!F<F]M($=I;&5A9"!F;W(@<F5I;6)U<G-E;65N="!W
M;W)K#0H@<&5R9F]R;65D('5N9&5R('1H92!C;VQL86)O<F%T:6]N+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!R96-O
M9VYI>F5D(')E=F5N=65S(&]F(&%P<')O>&EM871E;'D@)#(N,B!M:6QL:6]N
M(&%N9`T*("0U+CD@;6EL;&EO;B!U;F1E<B!T:&ES(&%G<F5E;65N="!F;W(@
M=&AE('1H<F5E(&%N9"!N:6YE(&UO;G1H<PT*(&5N9&5D(%-E<'1E;6)E<B8C
M>$$P.S,P+"`R,#$S+"!R97-P96-T:79E;'DN($YO(&UI;&5S=&]N97,@:&%V
M90T*(&)E96X@<F5A8VAE9"!U;F1E<B!T:&ES(&%G<F5E;65N="X\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@070@4V5P=&5M8F5R)B-X03`[
M,S`L(#(P,3,L("0T+C0@;6EL;&EO;B!O9B!R979E;G5E('=A<R!D969E<G)E
M9`T*('5N9&5R('1H:7,@86=R965M96YT+"!A;&P@;V8@=VAI8V@@=V%S(&EN
M8VQU9&5D(&EN(&-U<G)E;G0-"B!L:6%B:6QI=&EE<RX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QB/CQI/D)O96AR:6YG97(@26YG96QH96EM($EN=&5R;F%T:6]N86P@
M1VUB2#PO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M26X@3V-T;V)E<B`R,#$P('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-O
M;&QA8F]R871I;VX@86YD#0H@;&EC96YS92!A9W)E96UE;G0@=VET:"!";V5H
M<FEN9V5R('1O(&1I<V-O=F5R+"!D979E;&]P(&%N9`T*(&-O;6UE<F-I86QI
M>F4@=7`@=&\@=&5N($1!4E0M8F%S960@;6]L96-U;&5S('=H:6-H('-P86X@
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM0D]4
M5$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5<&]N(&5X96-U=&EO;B!O9B!T:&4@
M86=R965M96YT+"!T:&4@0V]M<&%N>2!R96-E:79E9"!A;B!U<&9R;VYT#0H@
M<&%Y;65N="!O9B`D,34@;6EL;&EO;BX@5&AE($-O;7!A;GD@<W5B<V5Q=65N
M=&QY(')E8V5I=F5D('1W;PT*(&%N;G5A;"!M86EN=&5N86YC92!P87EM96YT
M<R!A;F0@86YT:6-I<&%T97,@<F5C96EV:6YG(&$@=&AI<F0-"B!A;FYU86P@
M;6%I;G1E;F%N8V4@<&%Y;65N="!I;B!T:&4@9F]U<G1H('%U87)T97(@;V8@
M,C`Q,RX@5&AE(&9I<G-T#0H@='=O(&UA:6YT96YA;F-E('!A>6UE;G1S('=E
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M9B!T:&4@1$%25`T*('!R;V=R86US('5N9&5R('1H:7,@86=R965M96YT(&EN
M('1H92!C87-E(&]F(&9U;&P@8V]M;65R8VEA;`T*('-U8V-E<W,@;V8@;75L
M=&EP;&4@1$%25"!P<F]D=6-T<RX@5&AE($-O;7!A;GD@:&%S(&1E=&5R;6EN
M960@=&AA=`T*(&5A8V@@<&]T96YT:6%L(&9U='5R92!C;&EN:6-A;"P@9&5V
M96QO<&UE;G0@86YD(')E9W5L871O<GD-"B!M:6QE<W1O;F4@:7,@<W5B<W1A
M;G1I=F4N($%L=&AO=6=H('-A;&5S(&UI;&5S=&]N97,@87)E(&YO=`T*(&-O
M;G-I9&5R960@<W5B<W1A;G1I=F4L('1H97D@87)E('-T:6QL(')E8V]G;FEZ
M960@=7!O;B!A8VAI979E;65N=`T*(&]F('1H92!M:6QE<W1O;F4@*&%S<W5M
M:6YG(&%L;"!O=&AE<B!R979E;G5E(')E8V]G;FET:6]N(&-R:71E<FEA#0H@
M:&%V92!B965N(&UE="D@8F5C875S92!T:&5R92!A<F4@;F\@=6YD96QI=F5R
M960@96QE;65N=',@=&AA="!W;W5L9`T*('!R96-L=61E(')E=F5N=64@<F5C
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M,#LS,"P@,C`Q,RP@=&AE($-O;7!A;GD@:&%S(')E8V5I=F5D("0S.2XP#0H@
M;6EL;&EO;B!U;F1E<B!T:&ES(&%G<F5E;65N="P@:6YC;'5D:6YG('5P9G)O
M;G0L(&%N;G5A;"!M86EN=&5N86YC90T*(&%N9"!M:6QE<W1O;F4@<&%Y;65N
M=',@87,@=V5L;"!A<R!R97-E87)C:"!F=6YD:6YG+B!);B!A9&1I=&EO;BP-
M"B!";V5H<FEN9V5R('!U<F-H87-E9"`D,3`@;6EL;&EO;B!O9B!T:&4@0V]M
M<&%N>28C>#(P,3D[<R!397)I97,@1"TR#0H@4')E9F5R<F5D(%-T;V-K(&EN
M($IA;G5A<GD@,C`Q,2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@5&AE($-O;7!A;GD@9&5T97)M:6YE9"!T:&%T('1H92!D96QI=F5R86)L
M97,@=6YD97(@=&AE($)O96AR:6YG97(-"B!A9W)E96UE;G0@:6YC;'5D92!T
M:&4@;&EC96YS92P@=&AE(')E<V5A<F-H(&%N9"!D979E;&]P;65N=`T*('-E
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M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!#;VUP86YY(&-O;F-L=61E9"!T:&%T
M('1H92!U;F1E;&EV97)E9"!E;&5M96YT(&]F(')E<V5A<F-H(&%N9`T*(&1E
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M1$%25`T*('1E8VAN;VQO9WDL('=H:6-H(&ES('!R;W!R:65T87)Y('1O('1H
M92!#;VUP86YY+B!,:6ME=VES92P-"B!";V5H<FEN9V5R(&-O=6QD(&YO="!S
M96QL('1H92!L:6-E;G-E('1O(&%N;W1H97(@<&%R='D@*'=I=&AO=70@=&AE
M#0H@0V]M<&%N>2!A9W)E96EN9R!T;R!P<F]V:61E('1H92!R97-E87)C:"!A
M;F0@9&5V96QO<&UE;G0@86-T:79I=&EE<PT*(&9O<B!T:&4@;W1H97(@<&%R
M='DI+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&5R969O
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M:6UA=&5D('!E<FEO9"!O9B!D979E;&]P;65N="X\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@86YD($)O96AR:6YG97(@
M:&%V92!A;'-O(&%G<F5E9"!T;R!E<W1A8FQI<V@@82!J;VEN=`T*(')E<V5A
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M;65N="!S97)V:6-E<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@5&AE<F4@:&%V92!B965N(&YO(&UA=&5R:6%L(&UO9&EF:6-A=&EO;G,@
M=&\@=&AI<R!A9W)E96UE;G0@<VEN8V4-"B!T:&4@861O<'1I;VX@;V8@05-5
M(#(P,#DM,3,@;VX@2F%N=6%R>28C>$$P.S$L(#(P,3$N/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)E8V5I=F%B;&5S(&]F("0R-#8L,S<U
M(&%N9"`D,S4U+#4V."8C>$$P.V%S(&]F(%-E<'1E;6)E<B8C>$$P.S,P+`T*
M(#(P,3,@86YD($1E8V5M8F5R)B-X03`[,S$L(#(P,3(L(')E<W!E8W1I=F5L
M>2P@<F5L871E('1O(&%M;W5N=',-"B!D=64@=&\@=&AE($-O;7!A;GD@9G)O
M;2!";V5H<FEN9V5R(&9O<B!R96EM8G5R<V5M96YT('=O<FL@<&5R9F]R;65D
M#0H@=6YD97(@=&AE(&-O;&QA8F]R871I;VXN/"]P/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%1H92!#;VUP86YY(')E8V]G;FEZ960@<F5V96YU
M97,@;V8@87!P<F]X:6UA=&5L>2`D,BXS(&UI;&QI;VX@86YD#0H@)#(N-2!M
M:6QL:6]N('5N9&5R('1H:7,@86=R965M96YT(&1U<FEN9R!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD(#(P
M,3(L(')E<W!E8W1I=F5L>2P@86YD("0V+CD@;6EL;&EO;@T*(&%N9"`D.2XS
M(&UI;&QI;VX@9'5R:6YG('1H92!N:6YE(&UO;G1H<R!E;F1E9"!397!T96UB
M97(F(WA!,#LS,"P-"B`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DN($]N
M92!M:6QE<W1O;F4@<&%Y;65N="!O9B`D,BXP(&UI;&QI;VX-"B!W87,@<F5C
M;V=N:7IE9"!U;F1E<B!T:&ES(&%G<F5E;65N="!T:')O=6=H($1E8V5M8F5R
M(#(P,3(N($YO#0H@;6EL97-T;VYE<R!H879E(&)E96X@<F5C;V=N:7IE9"!U
M;F1E<B!T:&ES(&%G<F5E;65N="!D=7)I;F<@=&AE#0H@=&AR964@86YD(&YI
M;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S+B!!(&UI
M;&5S=&]N90T*('=A<R!E87)N960@=6YD97(@=&AI<R!A9W)E96UE;G0@<W5B
M<V5Q=65N="!T;R!397!T96UB97(F(WA!,#LS,"P-"B`R,#$S+B!3964@3F]T
M92`Q,2P@4W5B<V5Q=65N="!%=F5N=',L(&9O<B!A9&1I=&EO;F%L#0H@:6YF
M;W)M871I;VXN/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[
M($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P
M.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($%T(%-E<'1E;6)E
M<B8C>$$P.S,P+"`R,#$S+"`D,3`N,R!M:6QL:6]N(&]F(')E=F5N=64@=V%S
M(&1E9F5R<F5D#0H@=6YD97(@=&AI<R!A9W)E96UE;G0L("0U+C`@;6EL;&EO
M;B!O9B!W:&EC:"!W87,@:6YC;'5D960@:6X@8W5R<F5N=`T*(&QI86)I;&ET
M:65S(&%N9"`D-2XS(&UI;&QI;VX@;V8@=VAI8V@@=V%S(&EN8VQU9&5D(&EN
M(&QO;F<M=&5R;0T*(&QI86)I;&ET:65S+B!!="!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$R+"`D,30N,"!M:6QL:6]N(&]F(')E=F5N=64-"B!W87,@9&5F97)R
M960@=6YD97(@=&AI<R!A9W)E96UE;G0L("0U+C`@;6EL;&EO;B!O9B!W:&EC
M:"!W87,-"B!I;F-L=61E9"!I;B!C=7)R96YT(&QI86)I;&ET:65S(&%N9"`D
M.2XP(&UI;&QI;VX@;V8@=VAI8V@@=V%S#0H@:6YC;'5D960@:6X@;&]N9RUT
M97)M(&QI86)I;&ET:65S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^4&9I>F5R
M+"!);F,N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!);B!/8W1O8F5R(#(P,3`L('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A
M('1H<F5E('EE87(@86=R965M96YT#0H@=VET:"!09FEZ97(@=&\@9&ES8V]V
M97(L(&1E=F5L;W`@86YD(&-O;6UE<F-I86QI>F4@=7`@=&\@='=O#0H@1$%2
M5"UB87-E9"!M;VQE8W5L97,N(%1H92!#;VUP86YY(&=R86YT960@4&9I>F5R
M(&$@;F]N+65X8VQU<VEV90T*('=O<FQD=VED92P@<F]Y86QT>2UB96%R:6YG
M(&QI8V5N<V4@86YD(')E8V5I=F5D(&%N('5P9G)O;G0@<&%Y;65N=`T*(&]F
M("0U(&UI;&QI;VX@86YD(&AA<R!R96-E:79E9"!M:6QE<W1O;F4@<&%Y;65N
M=',@86YD(&9U;F1I;F<@9F]R#0H@=&AE($-O;7!A;GDF(W@R,#$Y.W,@:6YT
M97)N86P@86YD(&5X=&5R;F%L(')E<V5A<F-H(&-O<W1S('5N9&5R('1H90T*
M(&%G<F5E;65N="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M5&AE($-O;7!A;GD@:7,@96QI9VEB;&4@=&\@<F5C96EV92!M:6QE<W1O;F4@
M<&%Y;65N=',@;V8-"B!A<'!R;WAI;6%T96QY("0Q-R!M:6QL:6]N(')E;&%T
M960@=&\@<')E+6-L:6YI8V%L(&%N9"!C;&EN:6-A;`T*(&1E=F5L;W!M96YT
M(&%N9"`D,3DU(&UI;&QI;VX@<F5L871E9"!T;R!C;VUM97)C:6%L:7IA=&EO
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M<')O9W)A;0T*(&EN($IA;G5A<GD@,C`Q-"X\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@:&%S(&5V86QU871E9"!T:&4@
M<F5S96%R8V@@8V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@=VET:`T*(%!F:7IE
M<B!A;F0@:&%S(&1E=&5R;6EN960@=&AA="!I="!I<R!A(')E=F5N=64@87)R
M86YG96UE;G0@=VET:`T*(&UU;'1I<&QE(&1E;&EV97)A8FQE<RP@;W(@<&5R
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M<V5R=FEC97,@87)E(&YO=`T*(&EN8VQU9&5D(&EN('1H92!E>'!E8W1E9"!O
M8FQI9V%T:6]N('!E<FEO9"!T;R!P97)F;W)M('-E<G9I8V5S+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!D971E<FUI
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M(')E<V5A<F-H(&%N9`T*(&1E=F5L;W!M96YT('-E<G9I8V5S*2!A;F0@=&AE
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M86-T:79I=&EE<PT*(&9O<B!T:&4@;W1H97(@<&%R='DI+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&5R969O<F4L('1H92!U<&9R;VYT
M(&QI8V5N<V4@9F5E(&%N9"!R97-E87)C:"!A;F0@9&5V96QO<&UE;G0-"B!S
M97)V:6-E<R!W97)E('1R96%T960@87,@82!C;VUB:6YE9"!U;FET(&]F(&%C
M8V]U;G1I;F<@86YD#0H@<F5C;V=N:7IE9"!O=F5R('1H92!E>'!E8W1E9"!O
M8FQI9V%T:6]N('!E<FEO9"!A<W-O8VEA=&5D('=I=&@@=&AE#0H@<F5S96%R
M8V@@86YD(&1E=F5L;W!M96YT('-E<G9I8V5S('1H<F]U9V@@2F%N=6%R>2`R
M,#$T+"!W:&EC:`T*(')E<')E<V5N=',@=&AE(&5S=&EM871E9"!P97)I;V0@
M;V8@9&5V96QO<&UE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%1H92`D-2!M:6QL:6]N('5P9G)O;G0@<&%Y;65N="!R96-E:79E9"!B
M>2!T:&4@0V]M<&%N>2!I<PT*(&YO;BUR969U;F1A8FQE.R!T:&5R969O<F4L
M('1H97)E(&ES(&YO(')I9VAT(&]F(')E='5R;B!F;W(@=&AE#0H@;&EC96YS
M92X@5&AE($-O;7!A;GD@:7,@<F5C;V=N:7II;F<@<F5V96YU92!A<W-O8VEA
M=&5D('=I=&@@=&AI<PT*(&YO;BUR969U;F1A8FQE('5P+69R;VYT(&QI8V5N
M<V4@9F5E('1H<F]U9V@@2F%N=6%R>2`R,#$T+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!A;F0@4&9I>F5R(&AA=F4@
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M="X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)
M3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE<F4@:&%V
M92!B965N(&YO(&UA=&5R:6%L(&UO9&EF:6-A=&EO;G,@=&\@=&AI<R!A9W)E
M96UE;G0@<VEN8V4-"B!T:&4@861O<'1I;VX@;V8@05-5(#(P,#DM,3,@;VX@
M2F%N=6%R>28C>$$P.S$L(#(P,3$N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#$R<'@[($U!4D=)3BU"3U143TTZ(#!P>#L@1D].5"U325I%.B`Q
M<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%)E8V5I=F%B;&5S(&]F("0U,#$L-SDT(&%N9"`D.#DV+#(X-2!A<R!O9B!3
M97!T96UB97(F(WA!,#LS,"P@,C`Q,PT*(&%N9"!$96-E;6)E<B8C>$$P.S,Q
M+"`R,#$R+"!R97-P96-T:79E;'DL(')E;&%T92!T;R!A;6]U;G1S(&1U92!T
M;PT*('1H92!#;VUP86YY(&9R;VT@4&9I>F5R(&9O<B!R96EM8G5R<V5M96YT
M('=O<FL@<&5R9F]R;65D('5N9&5R('1H90T*(&-O;&QA8F]R871I;VXN/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!#;VUP86YY(')E
M8V]G;FEZ960@<F5V96YU97,@;V8@87!P<F]X:6UA=&5L>2`D,"XY(&UI;&QI
M;VX@86YD#0H@)#$N,B!M:6QL:6]N('5N9&5R('1H:7,@86=R965M96YT(&1U
M<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D#0H@4V5P=&5M8F5R)B-X03`[
M,S`L(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I=F5L>2P@86YD("0S+C(@;6EL
M;&EO;@T*(&%N9"`D-"XP(&UI;&QI;VX@9'5R:6YG('1H92!N:6YE(&UO;G1H
M<R!E;F1E9"!397!T96UB97(F(WA!,#LS,"P-"B`R,#$S(&%N9"`R,#$R+"!R
M97-P96-T:79E;'DN($EN8VQU9&5D(&EN('1H92`R,#$R(')E=F5N=65S(&%R
M90T*(&UI;&5S=&]N92!P87EM96YT<R!T;W1A;&EN9R`D-3`P+#`P,"X@3F\@
M861D:71I;VYA;"!M:6QE<W1O;F5S(&AA=F4-"B!B965N(')E8V]G;FEZ960@
M=6YD97(@=&AI<R!A9W)E96UE;G0@=&AR;W5G:"!397!T96UB97(F(WA!,#LS
M,"P-"B`R,#$S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!!
M="!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!A;F0@1&5C96UB97(F(WA!,#LS
M,2P@,C`Q,BP@)#4X+#`P,"!A;F0-"B`D,2XS(&UI;&QI;VX@;V8@<F5V96YU
M92!W87,@9&5F97)R960@=6YD97(@=&AI<R!A9W)E96UE;G0L(&%L;"!O9@T*
M('=H:6-H('=A<R!I;F-L=61E9"!I;B!C=7)R96YT(&QI86)I;&ET:65S+CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@/&(^/&D^1W)E96X@0W)O<W,@0V]R<&]R871I;VX\
M+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%
M6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN($IU
M;F4F(WA!,#LR,#$P+"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@82!C;VQL
M86)O<F%T:6]N#0H@86=R965M96YT('=I=&@@1W)E96X@0W)O<W,@9F]R('1H
M92!D979E;&]P;65N="!O9B!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS(&%N=&DM
M2$52,B!A;G1I8F]D>2!K;F]W;B!A<R!-1T%(,C(L(&]R#0H@;6%R9V5T=7AI
M;6%B+B!4:&ES(&%R<F%N9V5M96YT(&=R86YT<R!'<F5E;B!#<F]S<R!A;B!E
M>&-L=7-I=F4-"B!L:6-E;G-E('1O(&-O;F1U8W0@<W!E8VEF:65D(%!H87-E
M(#$@86YD(%!H87-E(#(@8VQI;FEC86P@=')I86QS#0H@86YD(&-O;6UE<F-I
M86QI>F4@;6%R9V5T=7AI;6%B(&EN(%-O=71H($MO<F5A+CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P
M=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5<&]N(&5X96-U=&EO;B!O9B!T:&4@
M86=R965M96YT+"!'<F5E;B!#<F]S<R!M861E(&$@;F]N<F5F=6YD86)L90T*
M('!A>6UE;G0@;V8@)#$N,"8C>$$P.VUI;&QI;VX@=&\@=&AE($-O;7!A;GDN
M(%1H92!#;VUP86YY(&ES#0H@96QI9VEB;&4@=&\@<F5C96EV92!C;&EN:6-A
M;"!D979E;&]P;65N="!A;F0@8V]M;65R8VEA;"!M:6QE<W1O;F4-"B!P87EM
M96YT<R!O9B!U<"!T;R`D-"XU(&UI;&QI;VXN(%1H92!#;VUP86YY(&AA<R!D
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M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.
M5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!H
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M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92`D,2!M:6QL:6]N('5P9G)O;G0@<&%Y
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M:&4@=&5R;2!O9B!T:&4@86=R965M96YT#0H@=&AR;W5G:"!*=6YE(#(P,C`N
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H97)E(&AA=F4@
M8F5E;B!N;R!M871E<FEA;"!M;V1I9FEC871I;VYS('1O('1H:7,@86=R965M
M96YT('-I;F-E#0H@=&AE(&%D;W!T:6]N(&]F($%352`R,#`Y+3$S(&]N($IA
M;G5A<GDF(WA!,#LQ+"`R,#$Q+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!4:&4@0V]M<&%N>2!R96-O9VYI>F5D(')E=F5N=65S(&]F(&%P
M<')O>&EM871E;'D@)#(U+#`P,"!U;F1E<B!T:&ES#0H@86=R965M96YT(&1U
M<FEN9R!E86-H(&]F('1H92!T:')E92!M;VYT:"!P97)I;V1S(&5N9&EN9PT*
M(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R,#$R+"!A;F0@)#<U+#`P
M,"!D=7)I;F<@96%C:"!O9B!T:&4-"B!N:6YE(&UO;G1H('!E<FEO9',@96YD
M:6YG(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R,#$R+B!.;PT*(&UI
M;&5S=&]N97,@:&%V92!B965N(')E8V]G;FEZ960@=6YD97(@=&AI<R!A9W)E
M96UE;G0@9'5R:6YG('1H90T*('1H<F5E(&%N9"!N:6YE(&UO;G1H<R!E;F1E
M9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@070@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,L("0V
M-S4L,#`P(&]F(')E=F5N=64@=V%S(&1E9F5R<F5D('5N9&5R#0H@=&AI<R!A
M9W)E96UE;G0L("0Q,#`L,#`P(&]F('=H:6-H('=A<R!I;F-L=61E9"!I;B!C
M=7)R96YT#0H@;&EA8FEL:71I97,@86YD("0U-S4L,#`P(&]F('=H:6-H('=A
M<R!I;F-L=61E9"!I;B!L;VYG+71E<FT-"B!L:6%B:6QI=&EE<RX@070@1&5C
M96UB97(F(WA!,#LS,2P@,C`Q,BP@)#<U,"PP,#`@;V8@<F5V96YU92!W87,-
M"B!D969E<G)E9"!U;F1E<B!T:&ES(&%G<F5E;65N="P@)#$P,"PP,#`@;V8@
M=VAI8V@@=V%S(&EN8VQU9&5D(&EN#0H@8W5R<F5N="!L:6%B:6QI=&EE<R!A
M;F0@)#8U,"PP,#`@;V8@=VAI8V@@=V%S(&EN8VQU9&5D(&EN(&QO;F<M=&5R
M;0T*(&QI86)I;&ET:65S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^16QI($QI
M;&QY)B-X03`[)F%M<#L@0V\N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!);B!/8W1O8F5R)B-X03`[,C`P-RP@=&AE($-O;7!A
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M=',@=&\@=&AE(&UO;&5C=6QE+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q,G!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X
M)SX-"B`F(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T
M.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!5
M<&]N(&5X96-U=&EO;B!O9B!T:&4@06=R965M96YT<RP@16QI($QI;&QY(&UA
M9&4@82!N;VYR969U;F1A8FQE#0H@<&%Y;65N="!O9B`D-#$N,"8C>$$P.VUI
M;&QI;VX@=&\@=&AE($-O;7!A;GDN($EN($UA>28C>$$P.S(P,#@L($5L:0T*
M($QI;&QY('!A:60@=&AE($-O;7!A;GD@82!M:6QE<W1O;F4@<&%Y;65N="!O
M9B`D-3`N,"8C>$$P.VUI;&QI;VX-"B!A;F0@:6X@36%Y)B-X03`[,C`Q,"P@
M16QI)B-X03`[3&EL;'D@<&%I9"!A;B!A9&1I=&EO;F%L(&UI;&5S=&]N90T*
M(&]F("0U+C`F(WA!,#MM:6QL:6]N+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B!/;B!/8W1O8F5R)B-X03`[,C@L(#(P,3`L($QI;&QY(&YO
M=&EF:65D('1H92!#;VUP86YY(&]F(&ET<PT*(&1E8VES:6]N('1O('1E<FUI
M;F%T92!T:&4@86=R965M96YT(&%F=&5R(')E=FEE=R!O9B!O;F4@>65A<B!O
M9@T*(&-L:6YI8V%L(&1A=&$@9G)O;2!T:&4@4%)/5"8C>$,Y.T<F(WA#.3L@
M=')I86P@:6X@5'EP92`Q(&1I86)E=&5S#0H@<&%T:65N=',@=')E871E9"!W
M:71H('1E<&QI>G5M86(N(%-U8V@@9&%T82!F86EL960@=&\@<W5P<&]R="!T
M:&4-"B!P<FEM87)Y(&5F9FEC86-Y(&5N9"!P;VEN="!I;B!T:&4@<W1U9'DN
M($1U<FEN9R!T:&4@>65A<B!E;F1E9`T*($1E8V5M8F5R)B-X03`[,S$L(#(P
M,3(L($5L:28C>$$P.TQI;&QY('-A=&ES9FEE9"!I=',@;V)L:6=A=&EO;@T*
M(')E;&%T960@=&\@=&AE(&-O<W0@;V8@;6]N:71O<FEN9R!P871I96YT<R!U
M;F1E<B!T:&4-"B!04D]4)B-X0SD[1R8C>$,Y.R!A;F0@14Y#3U)%('1R:6%L
M<RX@5&AE($-O;7!A;GDF(W@R,#$Y.W,-"B!O8FQI9V%T:6]N<R!C;VYT:6YU
M960@=&AR;W5G:"!397!T96UB97(@,C`Q,BP@=VAI8V@@<F5P<F5S96YT960@
M=&AE#0H@9F]L;&]W('5P('!E<FEO9"!F;W(@96YR;VQL960@<&%T:65N=',@
M86YD('1H92!#;VUP86YY)B-X,C`Q.3MS#0H@9FEN86P@<F5P;W)T:6YG(&]F
M('1H92!T<FEA;"8C>#(P,3D[<R!R97-U;'1S+B!4:&5R92!I<R!N;PT*(&%D
M9&ET:6]N86P@8VQI;FEC86P@=')I86P@86-T:79I='D@=6YD97(@=&AE($5L
M:2!,:6QL>2!!9W)E96UE;G1S#0H@87,@:70@<F5L871E<R!T;R!S=6-H('1R
M:6%L<RX@26X@1F5B<G5A<GD@,C`Q,2P@=&AE($-O;7!A;GD-"B!R96%C<75I
M<F5D('1H92!C;VUM97)C:6%L(')I9VAT<R!T;R!T:&4@;6]L96-U;&4@9G)O
M;2!%;&D-"B!,:6QL>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@4F5C96EV86)L97,@;V8@)#(T-"PU-#(@86YD("0U-3@L-3$V(&%S(&]F
M(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S#0H@86YD($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3(L(')E<W!E8W1I=F5L>2P@<F5L871E('1O(&%M;W5N=',@9'5E
M('1O#0H@=&AE($-O;7!A;GD@9G)O;2!%;&D@3&EL;'D@9F]R(')E:6UB=7)S
M96UE;G0@=V]R:R!P97)F;W)M960@=6YD97(-"B!T:&4@86)O=F4@;65N=&EO
M;F5D(&-L:6YI8V%L('1R:6%L<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@1'5R:6YG('1H92!T:')E92!M;VYT:',@96YD960@4V5P=&5M
M8F5R)B-X03`[,S`L(#(P,3,@86YD(#(P,3(L('1H90T*($-O;7!A;GD@<F5C
M;V=N:7IE9"!R979E;G5E(&]F("0Q.3`L.#,S(&%N9"`D.2XU(&UI;&QI;VXL
M#0H@<F5S<&5C=&EV96QY+"!U;F1E<B!T:&ES(&%G<F5E;65N="X@1'5R:6YG
M('1H92!N:6YE(&UO;G1H<R!E;F1E9`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R
M,#$S(&%N9"`R,#$R+"!T:&4@0V]M<&%N>2!R96-O9VYI>F5D(')E=F5N=64@
M;V8-"B`D-C<S+#DR-R!A;F0@)#,P+C$@;6EL;&EO;BP@<F5S<&5C=&EV96QY
M+B!.;R!M:6QE<W1O;F5S('=E<F4-"B!R96-O9VYI>F5D('5N9&5R('1H:7,@
M86=R965M96YT(&1U<FEN9R!T:&4@=&AR964@86YD(&YI;F4@;6]N=&AS#0H@
M96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,N/"]P/@T*(`T*(`T*(#PO
M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A
M7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H965T,3,N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE;G1S($%N9"!#;VYT:6YG96YC:65S
M($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6ET;65N=',@86YD($-O;G1I;F=E
M;F-I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B`\8CXX+B!#;VUM:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE
M<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^3W!E<F%T:6YG($QE87-E<SPO
M:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O
M;7!A;GD@;&5A<V5S(&]F9FEC92!A;F0@;&%B;W)A=&]R>2!S<&%C92!O=F5R
M('!E<FEO9',-"B!E>'1E;F1I;F<@=&AR;W5G:"!*86YU87)Y)B-X03`[,S`L
M(#(P,3@N(%-E=F5R86P@;V8@=&AE(&QE87-E<PT*(&-O;G1A:6X@<F5N="!E
M<V-A;&%T:6]N(&-L875S97,N(%)E;G0@97AP96YS92!F;W(@=&AE('1H<F5E
M(&UO;G1H<PT*(&5N9&5D(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"`R
M,#$R('=A<R`D.#`V+#(W-2!A;F0@)#<X,RPT-C(L#0H@<F5S<&5C=&EV96QY
M+B!4:&4@0V]M<&%N>2!I;F-U<G)E9"`D,BXT(&UI;&QI;VX@;V8@<F5N="!E
M>'!E;G-E(&9O<@T*(&5A8V@@;V8@=&AE(&YI;F4M;6]N=&@@<&5R:6]D<R!E
M;F1I;F<@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD#0H@,C`Q,BX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1G5T=7)E(&UI;FEM=6T@
M;&5A<V4@<&%Y;65N=',@=6YD97(@;F]N8V%N8V5L86)L92!O<&5R871I;F<@
M;&5A<V5S#0H@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@87)E(&%S(&9O
M;&QO=W,Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L
M92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X,R4^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD
M(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT
M<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4
M+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX]
M,T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/
M3E0M4TE:13H@,3!P="<^#0H@5'=E;'9E($UO;G1H<R!%;F1I;F<@4V5P=&5M
M8F5R)B-X03`[,S`L/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(#(P,30\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS
M+#0V,"PV,#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#(P,34\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,SDV
M+#<X,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@,C`Q-CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,RPS.#4L,S(Q/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B`R,#$W/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#0X-BPX.#$\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#(P,3@\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,#,U+#`Q
M,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G
M8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y
M;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^
M#0H@5&AE<F5A9G1E<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-C(U+#4T
M,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T
M;W`^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ-RPS.3`L,30T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?
M.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X
M-3!B82]7;W)K<VAE971S+U-H965T,30N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]D=6-T($UI;&5S=&]N92!087EM96YT
M<R!A;F0@4F]Y86QT>2!!9W)E96UE;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^5&5X="!";&]C:R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y0<F]D=6-T($UI;&5S=&]N92!087EM96YT<R!A;F0@4F]Y86QT>2!!9W)E
M96UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@/&(^.2X@4')O9'5C="!-:6QE<W1O;F4@4&%Y;65N=',@
M86YD(%)O>6%L='D@06=R965M96YT<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!);B!C;VYN96-T:6]N('=I=&@@86X@07-S970@4'5R
M8VAA<V4@06=R965M96YT('=I=&@@5&]L97)A;F-E#0H@5&AE<F%P975T:6-S
M+"!);F,N("A4;VQE<F%N8V4I(&5N=&5R960@:6YT;R!D=7)I;F<@2G5N92`R
M,#`U+"!T:&4-"B!#;VUP86YY(&UA>2!B92!R97%U:7)E9"!T;R!I<W-U92!4
M;VQE<F%N8V4@861D:71I;VYA;"!C;VYS:61E<F%T:6]N#0H@87,@9F]L;&]W
M<SH@*&DI)B-X03`[)#$P+#DU,"PP,#`@:68@8V5R=&%I;B!M:6QE<W1O;F5S
M(&%R92!M970L#0H@:6YC;'5D:6YG('1H92!I;FET:6%T:6]N(&]F(%!H87-E
M(#,@=')I86QS(&%N9"!F:6QI;F<@;V8@=F%R:6]U<PT*(')E9W5L871O<GD@
M<')O9'5C="!L:6-E;G-E(&%P<&QI8V%T:6]N<SL@*&EI*28C>$$P.S,V+#$S
M-2!S:&%R97,@;V8-"B!C;VUM;VX@<W1O8VL[(&%N9"`H:6EI*28C>$$P.W)O
M>6%L='D@<&%Y;65N=',@8F5T=V5E;B`Q+C<U)2!A;F0-"B`T+C`E(&]F(&YE
M="!S86QE<R!O9B!P<F]D=6-T<R!A8W%U:7)E9"!F<F]M(&]R('!A=&5N=&5D
M(&)Y#0H@5&]L97)A;F-E(&]R(&]T:&5R('!R;V1U8W0@9F5E<R!E87)N960@
M8GD@=&AE($-O;7!A;GDN($%N>0T*(&%D9&ET:6]N86P@8V]N<VED97)A=&EO
M;B!R97%U:7)E9"!T;R!B92!P86ED('5N9&5R('1H92!!<W-E=`T*(%!U<F-H
M87-E($%G<F5E;65N="!W:6QL(&)E(')E8V]R9&5D(&%S(')E<V5A<F-H(&%N
M9"!D979E;&]P;65N=`T*(&5X<&5N<V4@=VAE;B!I;F-U<G)E9"X@3F\@<&%Y
M;65N=',@<F5L871E9"!T;R!T:&4@861D:71I;VYA;`T*(&-O;G-I9&5R871I
M;VX@:&%V92!O8V-U<G)E9"!D=7)I;F<@=&AE('1H<F5E(&%N9"!N:6YE+6UO
M;G1H('!E<FEO9',-"B!E;F1E9"!397!T96UB97(F(WA!,#LS,"P@,C`Q,R!O
M<B`R,#$R+B!!9&1I=&EO;F%L;'DL(&-E<G1A:6X-"B!A9W)E96UE;G1S(')E
M<75I<F4@=&AE($-O;7!A;GD@=&\@<&%Y(')O>6%L=&EE<RX@0W5R<F5N=&QY
M+"!T:&4-"B!#;VUP86YY(&ES(&YO="!O8FQI9V%T960@=&\@<&%Y(')O>6%L
M=&EE<RP@87,@;F\@;W1H97(@<F5V96YU92!F<F]M#0H@<')O9'5C="!S86QE
M<R!I<R!B96EN9R!G96YE<F%T960@8GD@=&AE($-O;7!A;GDN/"]P/@T*(`T*
M(`T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q
M-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H965T,34N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY%;7!L;WEE92!"
M96YE9FET(%!L86X\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUP96YS871I;VX@06YD(%)E=&ER96UE;G0@1&ES
M8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!"96YE9FET(%!L86X\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$
M)TU!4D=)3BU43U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB
M/C$P+B!%;7!L;WEE92!"96YE9FET(%!L86X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@3VX@4V5P=&5M8F5R)B-X03`[,C4L(#(P,#(L
M('1H92!#;VUP86YY(&5S=&%B;&ES:&5D('1H92!-86-R;T=E;FEC<PT*(#0P
M,2AK*2!0;&%N("AT:&4@4&QA;BD@9F]R(&ET<R!E;7!L;WEE97,@=6YD97(@
M4V5C=&EO;B8C>$$P.S0P,2AK*0T*(&]F('1H92!)4D,N(%5N9&5R('1H:7,@
M4&QA;BP@86QL(&5M<&QO>65E<R!A="!L96%S="`R,2!Y96%R<R!O9B!A9V4-
M"B!A<F4@96QI9VEB;&4@=&\@<&%R=&EC:7!A=&4@:6X@=&AE(%!L86XL('-T
M87)T:6YG(&]N('1H92!F:7)S="!D87D-"B!O9B!E86-H(&UO;G1H+B!%;7!L
M;WEE97,@;6%Y(&-O;G1R:6)U=&4@=7`@=&\@,3`P)2!O9B!T:&5I<B!S86QA
M<GDL#0H@<W5B:F5C="!T;R!G;W9E<FYM96YT(&UA>&EM=6US+CPO<#X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!%;7!L;WEE97,@87)E(#$P,"4@
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M>$$P.S,P+"`R,#$S(&%N9"`R,#$R+"!R97-P96-T:79E;'DL(&%N9`T*("0Q
M.30L-#DX(&%N9"`D,3<Y+#DV-B!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N9&5D
M(%-E<'1E;6)E<B8C>$$P.S,P+`T*(#(P,3,@86YD(#(P,3(L(')E<W!E8W1I
M=F5L>2X\+W`^#0H@#0H@#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-
M"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T
M93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V
M9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O
M4VAE970Q-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T
M960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E
M=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H
M='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL
M.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I
M<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N
M="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L
M87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U8G-E<75E;G0@179E;G1S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4W5B<V5Q=65N="!%=F5N=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*(#QD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/C$Q+B!3
M=6)S97%U96YT($5V96YT<SPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
M,'!T)SX-"B!/;B!/8W1O8F5R)B-X03`[,38L(#(P,3,L('1H92!#;VUP86YY
M(&-O;7!L971E9"!I=',@25!/+"!I;B!W:&EC:`T*(#4L,#`P+#`P,"!S:&%R
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M(&%N(&%D9&ET:6]N86P-"B`W-3`L,#`P('-H87)E<R!O9B!T:&4@0V]M<&%N
M>28C>#(P,3D[<R!C;VUM;VX@<W1O8VL@870@82!P<FEC92!O9@T*("0Q-B!P
M97(@<VAA<F4N(%1H92!#;VUP86YY(')E8V5I=F5D(&YE="!P<F]C965D<R!O
M9B`D.#,N."!M:6QL:6]N#0H@9G)O;2!T:&4@25!/+"!N970@;V8@=6YD97)W
M<FET:6YG(&1I<V-O=6YT<R!A;F0@8V]M;6ES<VEO;G,@86YD#0H@;W1H97(@
M97-T:6UA=&5D(&]F9F5R:6YG(&5X<&5N<V5S+B!5<&]N(&-O;G-U;6UA=&EO
M;B!O9B!T:&4@25!/+`T*(&%L;"!O=71S=&%N9&EN9R!S:&%R97,@;V8@<')E
M9F5R<F5D('-T;V-K(&%U=&]M871I8V%L;'D@8V]N=F5R=&5D#0H@=&\@8V]M
M;6]N('-T;V-K(&%T('1H92!A<'!L:6-A8FQE(&-O;G9E<G-I;VX@<F%T:6]S
M('1H96X@:6X@969F96-T+@T*(%-U8G-E<75E;G0@=&\@=&AE($E03RP@=&AE
M($-O;7!A;GD@:&%D(#(U+#`R,"PR.#@@:7-S=65D(&%N9`T*(&]U='-T86YD
M:6YG('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@86YD(&YO(&]U='-T86YD:6YG
M('-H87)E<R!O9@T*('!R969E<G)E9"!S=&]C:RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@26X@3F]V96UB97(@,C`Q,RP@0F]E:')I;F=E
M<B!N;VUI;F%T960@82!B:2US<&5C:69I8R!A;G1I8F]D>0T*('1H97)A<&5U
M=&EC(&-A;F1I9&%T92!G96YE<F%T960@8GD@=&AE($-O;7!A;GDF(W@R,#$Y
M.W,@1$%25`T*('1E8VAN;VQO9WD@9F]R('!R92UC;&EN:6-A;"!D979E;&]P
M;65N="X@5&AI<R!F;W)M86P@<V5L96-T:6]N(&]F(&$-"B!D979E;&]P;65N
M="!C86YD:61A=&4@=')I9V=E<F5D(&$@)#4N,"!M:6QL:6]N(&UI;&5S=&]N
M92!P87EM96YT('1O#0H@=&AE($-O;7!A;GD@=6YD97(@=&AE($]C=&]B97(@
M,C`Q,"!A9W)E96UE;G0@9&5S8W)I8F5D(&EN($YO=&4@-RP-"B!#;VQL86)O
M<F%T:6]N(&%N9"!,:6-E;G-E($%G<F5E;65N=',N($EN(&%D9&ET:6]N+"!"
M;V5H<FEN9V5R('=I;&P-"B!P87D@82!R97-E87)C:"!M86EN=&5N86YC92!P
M87EM96YT(&]F("0T+C`@;6EL;&EO;B!T;R!T:&4@0V]M<&%N>0T*(&EN('1H
M92!F;W5R=&@@<75A<G1E<B!O9B`R,#$S+CPO<#X-"B`\+V1I=CX-"B`\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W
M-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,
M;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T
M93@V-C5B.#4P8F$O5V]R:W-H965T<R]3:&5E=#$W+FAT;6P-"D-O;G1E;G0M
M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M
M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^
M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M04)!13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI
M9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U
M;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^57-E(&]F($5S=&EM871E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@-G!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M/&(^/&D^57-E(&]F($5S=&EM871E<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@5&AE('!R97!A<F%T:6]N(&]F('1H92!F:6YA
M;F-I86P@<W1A=&5M96YT<R!I;B!A8V-O<F1A;F-E('=I=&@@1T%!4`T*(')E
M<75I<F5S('1H92!#;VUP86YY('1O(&UA:V4@97-T:6UA=&5S(&%N9"!J=61G
M;65N=',@:6X@8V5R=&%I;@T*(&-I<F-U;7-T86YC97,@=&AA="!A9F9E8W0@
M=&AE(')E<&]R=&5D(&%M;W5N=',@;V8@87-S971S+`T*(&QI86)I;&ET:65S
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M<F5D('-T;V-K(&%N9`T*(&-O;6UO;B!S=&]C:RP@<')E9F5R<F5D('-T;V-K
M('=A<G)A;G0@;&EA8FEL:71Y+"!I;F-O;64@=&%X97,L#0H@<')E+6-L:6YI
M8V%L('-T=61Y(&%N9"!C;&EN:6-A;"!T<FEA;"!A8V-R=6%L<R!A;F0@;W1H
M97(-"B!C;VYT:6YG96YC:65S+B!-86YA9V5M96YT(&)A<V5S(&ET<R!E<W1I
M;6%T97,@;VX@:&ES=&]R:6-A;`T*(&5X<&5R:65N8V4@;W(@;VX@=F%R:6]U
M<R!O=&AE<B!A<W-U;7!T:6]N<R!T:&%T(&ET(&)E;&EE=F5S('1O(&)E#0H@
M<F5A<V]N86)L92!U;F1E<B!T:&4@8VER8W5M<W1A;F-E<RX@06-T=6%L(')E
M<W5L=',@8V]U;&0@9&EF9F5R#0H@9G)O;2!T:&5S92!E<W1I;6%T97,N/"]P
M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'@[($U!4D=)3BU"3U14
M3TTZ(#!P>#L@1D].5"U325I%.B`Q<'@G/@T*("8C>$$P.SPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN(&%D9&ET:6]N+"!T:')O=6=H(%-E
M<'1E;6)E<B8C>$$P.S,P+"`R,#$S+"!T:&4@0V]M<&%N>2!U=&EL:7IE9`T*
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M9"!O9B!D:7)E8W1O<G,@:&%S(&1E=&5R;6EN960@=&AE(&5S=&EM871E9`T*
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M97,@;V8@:71S('!R969E<G)E9"!S=&]C:RX\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H
M(&%N9"!#87-H($5Q=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^0V%S:"!A;F0@0V%S
M:"!%<75I=F%L96YT<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)
M3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@5&AE($-O;7!A;GD@8V]N<VED97)S(&%L;"!I;G9E<W1M96YT
M<R!I;B!H:6=H;'D@;&EQ=6ED(&9I;F%N8VEA;`T*(&EN<W1R=6UE;G1S('=I
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M(&9I;F%N8VEA;`T*(&EN<W1I='5T:6]N<RX@0V%S:"!E<75I=F%L96YT<R!A
M<F4@<W1A=&5D(&%T(&%M;W)T:7IE9"!C;W-T+"!P;'5S#0H@86-C<G5E9"!I
M;G1E<F5S="P@=VAI8V@@87!P<F]X:6UA=&5S(&9A:7(@=F%L=64N/"]P/@T*
M(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^06-C;W5N=',@4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/D%C8V]U
M;G1S(%)E8V5I=F%B;&4\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($%C8V]U;G1S(')E8V5I=F%B;&4@=&AA="!M86YA9V5M96YT
M(&AA<R!T:&4@:6YT96YT(&%N9"!A8FEL:71Y('1O#0H@8V]L;&5C="!A<F4@
M<F5P;W)T960@:6X@=&AE(&-O;G-O;&ED871E9"!B86QA;F-E('-H965T<R!A
M=`T*(&]U='-T86YD:6YG(&%M;W5N=',L(&QE<W,@86X@86QL;W=A;F-E(&9O
M<B!D;W5B=&9U;"!A8V-O=6YT<RX@5&AE#0H@0V]M<&%N>2!W<FET97,@;V9F
M('5N8V]L;&5C=&EB;&4@<F5C96EV86)L97,@=VAE;B!T:&4@;&EK96QI:&]O
M9"!O9@T*(&-O;&QE8W1I;VX@:7,@<F5M;W1E+CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].
M5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!E=F%L=6%T97,@=&AE(&-O
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M9@T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S(&]R($1E8V5M8F5R)B-X03`[
M,S$L(#(P,3(L(&%S('1H92!#;VUP86YY#0H@:&%S(&$@:&ES=&]R>2!O9B!C
M;VQL96-T:6YG(&]N(&%L;"!O=71S=&%N9&EN9R!A8V-O=6YT<RX\+W`^#0H@
M/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y$969E<G)E9"!);G1I86P@4'5B;&EC($]F9F5R:6YG($-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P
M="<^#0H@/&(^/&D^1&5F97)R960@26YI=&EA;"!0=6)L:6,@3V9F97)I;F<@
M0V]S=',\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V
M<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($1E9F5R<F5D($E03R!C;W-T<R!A<R!O9B!397!T96UB97(F(WA!,#LS,"P@
M,C`Q,RP@8V]N<VES=&5D(&]F#0H@;&5G86PL(&%C8V]U;G1I;F<L('!R:6YT
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M(&]F('1H92!O9F9E<FEN9R!I;@T*($]C=&]B97(@,C`Q,RX\+W`^#0H@/"]D
M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y297-T<FEC=&5D($-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y297-T<FEC=&5D($-A
M<V@\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[
M(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
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M<R!A<F4@)#0P-"PX-3`@870@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,-"B!A
M;F0@1&5C96UB97(F(WA!,#LS,2P@,C`Q,BX\+W`^#0H@/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER
M(%9A;'5E(&]F($9I;F%N8VEA;"!);G-T<G5M96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/D9A
M:7(@5F%L=64@;V8@1FEN86YC:6%L($EN<W1R=6UE;G1S/"]I/CPO8CX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F%I<B!M87)K970@
M=F%L=65S(&]F('1H92!F:6YA;F-I86P@:6YS=')U;65N=',@:6YC;'5D960@
M:6X@=&AE#0H@9FEN86YC:6%L('-T871E;65N=',L('=H:6-H(&EN8VQU9&4@
M8V%S:"!E<75I=F%L96YT<R!A;F0@;6]N97D-"B!M87)K970@86-C;W5N=',L
M(&%P<')O>&EM871E('1H96ER(&-A<G)Y:6YG('9A;'5E<R!A=`T*(%-E<'1E
M;6)E<B8C>$$P.S,P+"`R,#$S(&%N9"!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R
M+"!D=64@=&\@=&AE:7(-"B!S:&]R="UT97)M(&UA='5R:71I97,N(%1H92!#
M;VUP86YY(&%C8V]U;G1S(&9O<B!R96-U<G)I;F<@86YD#0H@;F]N+7)E8W5R
M<FEN9R!F86ER('9A;'5E(&UE87-U<F5M96YT<R!I;B!A8V-O<F1A;F-E('=I
M=&@@=&AE#0H@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D
M("A&05-"*2!!8V-O=6YT:6YG(%-T86YD87)D<PT*($-O9&EF:6-A=&EO;B`H
M05-#*2`X,C`L(#QI/D9A:7(@5F%L=64@365A<W5R96UE;G1S(&%N9`T*($1I
M<V-L;W-U<F5S/"]I/B`H05-#(#@R,"DN($%30R`X,C`@9&5F:6YE<R!F86ER
M('9A;'5E+"!E<W1A8FQI<VAE<PT*(&$@9F%I<B!V86QU92!H:65R87)C:'D@
M9F]R(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@;65A<W5R960@870@9F%I<@T*
M('9A;'5E+"!A;F0@<F5Q=6ER97,@97AP86YD960@9&ES8VQO<W5R97,@86)O
M=70@9F%I<B!V86QU90T*(&UE87-U<F5M96YT<RX@5&AE($%30R`X,C`@:&EE
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M3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#9P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
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M9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@-G!T)SX-
M"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!3
M13H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P('=I9'1H/3-$,3`P)3X-"B`\='(^#0H@/'1D('=I9'1H
M/3-$-24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P('=I9'1H/3-$
M,B4@86QI9VX],T1L969T/B8C>#(P,C([/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M=&]P('=I9'1H/3-$,24^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$=&]P
M(&%L:6=N/3-$;&5F=#Y,979E;"`R)B-X03`[)B-X,C`Q,SL@1F%I<B!V86QU
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M(&1A=&$N/"]T9#X-"B`\+W1R/@T*(#PO=&%B;&4^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$
M15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I
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M82!G:79E;B!S96-U<FET>2X\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\
M<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!E=F%L=6%T
M97,@9FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@<W5B:F5C="!T
M;PT*(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&]N(&$@<F5C=7)R:6YG(&)A
M<VES('1O(&1E=&5R;6EN92!T:&4-"B!A<'!R;W!R:6%T92!L979E;"!A="!W
M:&EC:"!T;R!C;&%S<VEF>2!T:&5M(&5A8V@@<F5P;W)T:6YG('!E<FEO9"X-
M"B!4:&ES(&1E=&5R;6EN871I;VX@<F5Q=6ER97,@=&AE($-O;7!A;GD@=&\@
M;6%K92!S=6)J96-T:79E#0H@:G5D9VUE;G1S(&%S('1O('1H92!S:6=N:69I
M8V%N8V4@;V8@:6YP=71S('5S960@:6X@9&5T97)M:6YI;F<@9F%I<@T*('9A
M;'5E(&%N9"!W:&5R92!S=6-H(&EN<'5T<R!L:64@=VET:&EN('1H92!!4T,@
M.#(P(&AI97)A<F-H>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^
M#0H@1FEN86YC:6%L(&%S<V5T<R!A;F0@;&EA8FEL:71I97,@<W5B:F5C="!T
M;R!F86ER('9A;'5E(&UE87-U<F5M96YT<PT*('=E<F4@87,@9F]L;&]W<SH\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
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M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T
M=&]M(&-O;'-P86X],T0Q-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A;'5E
M($UE87-U<F5M96YT<R!A=`T*(%-E<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(')O=W-P86X],T0R(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/E1O=&%L/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!R;W=S<&%N/3-$,CXF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY1=6]T960F(WA!,#M0
M<FEC97,F(WA!,#MI;CPO8CX\8G(@+SX-"B`\8CY!8W1I=F4F(WA!,#M-87)K
M971S)B-X03`[9F]R/"]B/CQB<B`O/@T*(#QB/DED96YT:6-A;"!!<W-E=',\
M+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S
M='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L
M:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I
M9VYI9FEC86YT)B-X03`[3W1H97(\+V(^/&)R("\^#0H@/&(^3V)S97)V86)L
M928C>$$P.TEN<'5T<SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^4VEG;FEF:6-A;G0\+V(^/&)R("\^#0H@/&(^56YO8G-E
M<G9A8FQE/"]B/CQB<B`O/@T*(#QB/DEN<'5T<SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,3PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V96P@,CPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^3&5V
M96P@,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@07-S971S
M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT
M<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+#4R,BPP,CD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C<L-3(R+#`R.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!-;VYE>2!M87)K970@
M9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR-BPP-#<L
M,38Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(V+#`T-RPQ-CD\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%)E<W1R
M:6-T960@8V%S:#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0P
M-"PX-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`T+#@U,#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@5&]T86P@87-S971S/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,S,L.3<T+#`T.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,RPY-S0L,#0X/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QI86)I;&ET:65S.CPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS
M1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!0<F5F
M97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='D\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH-C<Y+#(Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^*#8W.2PR.38\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O
M=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(^#0H@/'1D/CPO=&0^#0H@/'1D(&-O;'-P86X],T0Q-CX\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0Q
M-"!A;&EG;CTS1&-E;G1E<CX\8CY&86ER(%9A;'5E($UE87-U<F5M96YT<R!A
M=`T*($1E8V5M8F5R)B-X03`[,S$L(#(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@<F]W<W!A;CTS1#(@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^5&]T86P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(')O
M=W-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/E%U;W1E9"8C>$$P.U!R:6-E<R8C>$$P.VEN/"]B
M/CQB<B`O/@T*(#QB/D%C=&EV928C>$$P.TUA<FME=',F(WA!,#MF;W(\+V(^
M/&)R("\^#0H@/&(^261E;G1I8V%L($%S<V5T<SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^4VEG;FEF:6-A;G0F(WA!,#M/
M=&AE<CPO8CX\8G(@+SX-"B`\8CY/8G-E<G9A8FQE)B-X03`[26YP=71S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY3:6=N
M:69I8V%N=#PO8CX\8G(@+SX-"B`\8CY5;F]B<V5R=F%B;&4\+V(^/&)R("\^
M#0H@/&(^26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P
M,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG
M;CTS1&-E;G1E<CX\8CY,979E;"`Q/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`S/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!!<W-E=',Z/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!#
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M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@36]N97D@;6%R:V5T(&9U;F1S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,CDL,#0W+#DU.#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR.2PP-#<L.34X/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!297-T<FEC=&5D(&-A<V@\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0L.#4P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C0P-"PX-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI
M9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L
M:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P
M,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1O=&%L(&%S
M<V5T<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0X+#$T."PP,#4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-#@L,30X+#`P-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF
M(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF
M(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF
M(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T
M.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!,
M:6%B:6QI=&EE<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@4')E9F5R<F5D('-T;V-K('=A<G)A;G0@
M;&EA8FEL:71Y/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4R+#DT-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#4R+#DT
M-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%
M.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@
M9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!!<R!O9B!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R+"!T:&4@0V]M<&%N>2!T
M<F%N<V9E<G)E9"!I=',@;6]N97D-"B!M87)K970@9G5N9',@9G)O;2!,979E
M;"`R('1O($QE=F5L(#$@8F5C875S92!T:&4@:6YP=71S(&%R92!N;W<-"B!B
M87-E9"!U<&]N(&$@<75O=&5D(&UA<FME="!P<FEC92X\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@3&5V
M96P@,2!S96-U<FET:65S('!R:6UA<FEL>2!C;VYS:7-T(&]F#0H@<F5S=')I
M8W1E9"!C87-H+"!C87-H(&5Q=6EV86QE;G1S(&%N9"!M;VYE>2!M87)K970@
M9G5N9',N(%1H90T*($-O;7!A;GD@9&5T97)M:6YE<R!T:&4@97-T:6UA=&5D
M(&9A:7(@=F%L=64@9F]R(&ET<R!,979E;"`Q#0H@<V5C=7)I=&EE<R!U<VEN
M9R!Q=6]T960@*'5N861J=7-T960I('!R:6-E<R!F;W(@:61E;G1I8V%L(&%S
M<V5T<R!O<@T*(&QI86)I;&ET:65S(&EN(&%C=&EV92!M87)K971S+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!D971E
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P>#L@34%21TE.+4)/
M5%1/33H@,'!X.R!&3TY4+5-)6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#QP
M('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5$585"U)3D1%3E0Z(#0E.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!P
M<F]V:61E<R!A(')O;&QF;W)W87)D(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS
M#0H@<')E9F5R<F5D('-T;V-K('=A<G)A;G0@;&EA8FEL:71Y+"!W:&EC:"!W
M87,@=&AE(&]N;'D@9FEN86YC:6%L#0H@:6YS=')U;65N="!M96%S=7)E9"!A
M="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A<VES('5S:6YG#0H@<VEG
M;FEF:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<R`H3&5V96P@,RD@87,@9&5F
M:6YE9"!I;B!!4T,-"B`X,C`Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI9VX],T1C96YT97(^/"$M
M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X
M-B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-B4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%L86YC92!A="!$96-E
M;6)E<B8C>$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
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M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4;W1A;"!U;G)E86QI
M>F5D(&=A:6YS("AL;W-S97,I(&EN8VQU9&5D(&EN(&5A<FYI;F=S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8R-BPS-#D\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!"86QA;F-E(&%T(%-E<'1E;6)E<B8C>$$P.S,P
M+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8W.2PR.38\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@26X@;W)D97(@=&\@97-T:6UA=&4@=&AE(&9A:7(@
M=F%L=64@;V8@=&AE('!R969E<G)E9"!S=&]C:R!P=7)C:&%S90T*('=A<G)A
M;G1S+"!T:&4@8G5S:6YE<W,@96YT97)P<FES92!V86QU92!W87,@97-T86)L
M:7-H960@8F%S960@;VX@80T*(&1I<V-O=6YT960@8V%S:"!F;&]W(&UO9&5L
M("AI;F-O;64@87!P<F]A8V@I+B!4:&4@0V]M<&%N>2!U=&EL:7IE9`T*(&%N
M(&]P=&EO;B!P<FEC:6YG(&UE=&AO9"!T;R!V86QU92!T:&4@<VAA<F5S('5S
M:6YG(&$@8V]N=&EN9V5N=`T*(&-L86EM<R!A;F%L>7-I<RP@=VAI8V@@87!P
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M/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!T;W1A;"!U;G)E
M86QI>F5D(&=A:6YS("AL;W-S97,I(&]N('1H92!P<F5F97)R960@<W1O8VL@
M=V%R<F%N=',-"B!I;F-L=61E9"!I;B!E87)N:6YG<R!I<R!I;F-L=61E9"!A
M<R!A(&-O;7!O;F5N="!O9B!O=&AE<B!I;F-O;64-"B`H97AP96YS92D@:6X@
M=&AE(&-O;G-O;&ED871E9"!S=&%T96UE;G0@;V8@;W!E<F%T:6]N<R!A;F0-
M"B!C;VUP<F5H96YS:79E(&EN8V]M92X\+W`^#0H@/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYC96YT
M<F%T:6]N(&]F($-R961I="!2:7-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^0V]N8V5N=')A=&EO
M;B!O9B!#<F5D:70@4FES:SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
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M(&)E87(@;6EN:6UA;"!R:7-K+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM
M5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q
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M8VEE<R!O9B!H:6=H(&-R961I="!S=&%N9&EN9RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@1F]R('1H92!T:')E92!A;F0@;FEN92!M;VYT
M:',@96YD960@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,@86YD#0H@,C`Q,BP@
M86QL(&]F('1H92!#;VUP86YY)B-X,C`Q.3MS(&=R86YT(')E=F5N=64@=V%S
M(')E;&%T960@=&\-"B!C;VYT<F%C=',@86YD(')E<V5A<F-H(&=R86YT<R!R
M96-E:79E9"!F<F]M(%4N4RX@9V]V97)N;65N=`T*(&%G96YC:65S+B!#;VQL
M86)O<F%T:6]N<R!W:71H($QE<R!,86)O<F%T;VER97,@4V5R=FEE<B!A;F0@
M26YS=&ET=70-"B!D92!296-H97)C:&5S(%-E<G9I97(@*&-O;&QE8W1I=F5L
M>2P@4V5R=FEE<BDL($)O96AR:6YG97(@26YG96QH96EM#0H@1VUB2"`H0F]E
M:')I;F=E<BDL($=I;&5A9"!38VEE;F-E<RP@26YC+B`H1VEL96%D*2P@4&9I
M>F5R+"!);F,N#0H@*%!F:7IE<BD@86YD($5L:2!,:6QL>28C>$$P.R9A;7`[
M($-O+B`H16QI($QI;&QY*2!A8V-O=6YT(&9O<B!A;&P-"B!O=&AE<B!R979E
M;G5E+B!!;&P@;W5T<W1A;F1I;F<@<F5C96EV86)L97,@87)E(&1U92!F<F]M
M($=I;&5A9"P-"B!09FEZ97(L($)O96AR:6YG97(L($5L:2!,:6QL>2P@86YD
M(%4N4RX@9V]V97)N;65N="!A9V5N8VEE<RX\+W`^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M
M4TE:13H@,3!P="<^#0H@5&AE(&9O;&QO=VEN9R!T86)L92!R97!R97-E;G1S
M('1H92!P97)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N=`T*(')E=F5N=64@
M96%R;F5D(&EN('1H92!P97)I;V1S(&EN9&EC871E9#H\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS
M1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L
M;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#DR)2!A;&EG
M;CTS1&-E;G1E<CX\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R/@T*
M(#QT9"!W:61T:#TS1#4R)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$P)3X\+W1D/@T*(#QT9#X\+W1D
M/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CY4:')E928C>$$P.TUO;G1H
M<R8C>$$P.T5N9&5D)B-X03`[4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CY.:6YE)B-X03`[36]N
M=&AS)B-X03`[16YD960F(WA!,#M397!T96UB97(F(WA!,#LS,"P\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!4
M86)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5R=FEE<CPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<Q+C,\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$T+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C4X+C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$R+C8\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!";V5H<FEN9V5R/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3$N-3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34N
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,34N.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,3<N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($=I;&5A9#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$P+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3,N-SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,"XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4&9I>F5R/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"XU/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XW+C<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N,SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXT/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@1V]V97)N;65N="!!9V5N8VEE<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C`N-CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,RXU/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR
M+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C8N.3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($5L:2!,:6QL>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C`N.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3DN,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2XV/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XU-2XW/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE
M($)O9'D@+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M.'!X.R!-05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F
M(WA!,#L\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F]L
M;&]W:6YG('1A8FQE(')E<')E<V5N=',@=&AE('!E<F-E;G1A9V4@;V8@86QL
M('-I9VYI9FEC86YT#0H@86-C;W5N=',@<F5C96EV86)L93H\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@
M8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#<V)2!A
M;&EG;CTS1&-E;G1E<CX\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R
M/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@=VED=&@],T0Q-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,38E
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@
M,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^4V5P=&5M8F5R)B-X03`[,S`L)B-X03`[,C`Q,SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F(WA!
M,#LS,2PF(WA!,#LR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M
M+3X\(2TM($)E9VEN(%1A8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B!':6QE860\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU
M,2XR/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4&9I>F5R/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C(N-CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-#4N-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($)O96AR:6YG97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XQ,2XQ/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ."XP
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@16QI($QI;&QY/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$N,#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,C@N,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*($=O=F5R;FUE;G0@06=E;F-I97,\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XT+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C@N
M-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM
M/CPO=&%B;&4^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B`\8CX\:3Y0<F]P97)T>2!A;F0@17%U:7!M96YT/"]I/CPO8CX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M
M96YT(&%R92!S=&%T960@870@8V]S="X@57!O;B!R971I<F5M96YT(&]R('-A
M;&4L#0H@=&AE(&-O<W0@;V8@87-S971S(&1I<W!O<V5D(&]F(&%N9"!T:&4@
M<F5L871E9"!A8V-U;75L871E9`T*(&1E<')E8VEA=&EO;B!A<F4@<F5M;W9E
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT
M86)L92!S='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O
M<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T
M:#TS1#8X)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$
M-C`E/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($-O;7!U=&5R(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^,R!Y
M96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-O9G1W87)E/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XS('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@
M<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P
M="<^#0H@1G5R;FET=7)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XQ,"!Y96%R
M<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QA8F]R871O<GD@86YD(&]F9FEC92!E<75I
M<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C4@>65A<G,\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!,96%S96AO;&0@:6UP<F]V96UE
M;G1S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B!3:&]R=&5R)B-X03`[;V8F
M(WA!,#ML96%S928C>$$P.W1E<FTF(WA!,#MO<B8C>$$P.W5S969U;"8C>$$P
M.VQI9F4\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEM<&%I
M<FUE;G0@;V8@3&]N9RU,:79E9"!!<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y);7!A:7)M
M96YT(&]F($QO;F<M3&EV960@07-S971S/"]I/CPO8CX\+W`^#0H@/'`@<W1Y
M;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!A<W-E<W-E<R!T:&4@
M<F5C;W9E<F%B:6QI='D@;V8@:71S(&QO;F<M;&EV960@87-S971S(&EN#0H@
M86-C;W)D86YC92!W:71H('1H92!P<F]V:7-I;VYS(&]F($%30R`S-C`L(#QI
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M:`T*(&9L;W=S(&5X<&5C=&5D('1O(&)E(&=E;F5R871E9"!B>2!T:&4@87-S
M970@;W(@87-S970@9W)O=7`N($EF#0H@8V%R<GEI;F<@=F%L=64@97AC965D
M<R!T:&4@<W5M(&]F('5N9&ES8V]U;G1E9"!C87-H(&9L;W=S+"!T:&4-"B!#
M;VUP86YY('1H96X@9&5T97)M:6YE<R!T:&4@9F%I<B!V86QU92!O9B!T:&4@
M=6YD97)L>6EN9R!A<W-E=`T*(&=R;W5P+B!!;GD@:6UP86ER;65N="!T;R!B
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M97(F(WA!,#LS,"P@,C`Q,R!A;F0@1&5C96UB97(F(WA!,#LS,2P-"B`R,#$R
M+"!T:&4@0V]M<&%N>2!D971E<FUI;F5D('1H870@=&AE<F4@=V5R92!N;R!I
M;7!A:7)E9"!A<W-E=',@86YD#0H@:&%D(&YO(&%S<V5T<R!H96QD+69O<BUS
M86QE+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E=F5N=65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q.'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^4F5V96YU
M97,\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@34%21TE.+4Q%1E0Z(#(E.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QI
M/E)E=F5N=64@4F5C;V=N:71I;VX\+VD^/"]P/@T*(#QP('-T>6QE/3-$)TU!
M4D=)3BU43U`Z(#9P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:
M13H@,3!P="<^#0H@5&AE($-O;7!A;GD@96YT97)S(&EN=&\@8V]L;&%B;W)A
M=&EO;B!A;F0@;&EC96YS92!A9W)E96UE;G1S('=I=&@-"B!C;VQL86)O<F%T
M;W)S(&9O<B!T:&4@9&5V96QO<&UE;G0@;V8@;6]N;V-L;VYA;"!A;G1I8F]D
M>2UB87-E9`T*('1H97)A<&5U=&EC<R!T;R!T<F5A="!C86YC97(@86YD(&]T
M:&5R(&-O;7!L97@@9&ES96%S97,N(%1H92!T97)M<PT*(&]F('1H97-E(&%G
M<F5E;65N=',@8V]N=&%I;B!M=6QT:7!L92!D96QI=F5R86)L97,@=VAI8V@@
M;6%Y(&EN8VQU9&4-"B`H:2DF(WA!,#ML:6-E;G-E<RP@;W(@;W!T:6]N<R!T
M;R!O8G1A:6X@;&EC96YS97,L('1O('1H90T*($-O;7!A;GDF(W@R,#$Y.W,@
M=&5C:&YO;&]G:6-A;"!P;&%T9F]R;7,L('-U8V@@87,@:71S($9C#0H@3W!T
M:6UI>F%T:6]N(&%N9"!$=6%L+4%F9FEN:71Y(%)E+51A<F=E=&EN9R`H1$%2
M5"D@=&5C:&YO;&]G:65S+`T*("AI:2DF(WA!,#MR:6=H=',@=&\@9G5T=7)E
M('1E8VAN;VQO9VEC86P@:6UP<F]V96UE;G1S+`T*("AI:6DI)B-X03`[<F5S
M96%R8V@@86YD(&1E=F5L;W!M96YT(&%C=&EV:71I97,@=&\@8F4@<&5R9F]R
M;65D(&]N#0H@8F5H86QF(&]F('1H92!C;VQL86)O<F%T;W(@;W(@87,@<&%R
M="!O9B!T:&4@8V]L;&%B;W)A=&EO;BP@86YD#0H@*&EV*28C>$$P.W1H92!M
M86YU9F%C='5R92!O9B!P<F4M8VQI;FEC86P@;W(@8VQI;FEC86P@;6%T97)I
M86QS(&9O<@T*('1H92!C;VQL86)O<F%T;W(N(%!A>6UE;G1S('1O('1H92!#
M;VUP86YY('5N9&5R('1H97-E(&%G<F5E;65N=',-"B!M87D@:6YC;'5D92!N
M;VYR969U;F1A8FQE(&QI8V5N<V4@9F5E<RP@;W!T:6]N(&9E97,L(&5X97)C
M:7-E(&9E97,L#0H@<&%Y;65N=',@9F]R(')E<V5A<F-H(&%N9"!D979E;&]P
M;65N="!A8W1I=FET:65S+"!P87EM96YT<R!F;W(@=&AE#0H@;6%N=69A8W1U
M<F4@;V8@<')E+6-L:6YI8V%L(&]R(&-L:6YI8V%L(&UA=&5R:6%L<RP@;&EC
M96YS90T*(&UA:6YT96YA;F-E('!A>6UE;G1S+"!P87EM96YT<R!B87-E9"!U
M<&]N('1H92!A8VAI979E;65N="!O9@T*(&-E<G1A:6X@;6EL97-T;VYE<R!A
M;F0@<F]Y86QT:65S(&]N('!R;V1U8W0@<V%L97,N($]T:&5R(&)E;F5F:71S
M#0H@=&\@=&AE($-O;7!A;GD@;V8@=&AE<V4@86=R965M96YT<R!I;F-L=61E
M('1H92!R:6=H="!T;R!S96QL#0H@<')O9'5C=',@<F5S=6QT:6YG(&9R;VT@
M=&AE(&-O;&QA8F]R871I=F4@969F;W)T<R!O9B!T:&4@<&%R=&EE<R!I;@T*
M('-P96-I9FEC(&=E;V=R87!H:6,@=&5R<FET;W)I97,N(%1H92!#;VUP86YY
M(&9O;&QO=W,@=&AE('!R;W9I<VEO;G,-"B!O9B!T:&4@1D%30B!!4T,@5&]P
M:6,@-C`U+3(U+"`\:3Y2979E;G5E#0H@4F5C;V=N:71I;VXF(WA!,#LF(W@R
M,#$S.TUU;'1I<&QE+45L96UE;G0@07)R86YG96UE;G1S/"]I/BP@86YD($%3
M0PT*(%1O<&EC(#8P-2TR."P@/&D^4F5V96YU92!296-O9VYI=&EO;B8C>#(P
M,3,[36EL97-T;VYE($UE=&AO9#PO:3XL(&EN#0H@86-C;W5N=&EN9R!F;W(@
M=&AE<V4@86=R965M96YT<RX@26X@;W)D97(@=&\@86-C;W5N="!F;W(@=&AE
M<V4-"B!A9W)E96UE;G1S+"!T:&4@0V]M<&%N>2!M=7-T(&ED96YT:69Y('1H
M92!D96QI=F5R86)L97,@:6YC;'5D960-"B!W:71H:6X@=&AE(&%G<F5E;65N
M="!A;F0@979A;'5A=&4@=VAI8V@@9&5L:79E<F%B;&5S(')E<')E<V5N=`T*
M('-E<&%R871E('5N:71S(&]F(&%C8V]U;G1I;F<@8F%S960@;VX@=&AE(&%C
M:&EE=F5M96YT(&]F(&-E<G1A:6X-"B!C<FET97)I82P@:6YC;'5D:6YG('=H
M971H97(@=&AE(&1E;&EV97)E9"!E;&5M96YT(&AA<R!S=&%N9"UA;&]N90T*
M('9A;'5E('1O('1H92!C;VQL86)O<F%T;W(N(%1H92!C;VYS:61E<F%T:6]N
M(')E8V5I=F5D(&ES(&%L;&]C871E9`T*(&%M;VYG('1H92!S97!A<F%T92!U
M;FET<R!O9B!A8V-O=6YT:6YG+"!A;F0@=&AE(&%P<&QI8V%B;&4@<F5V96YU
M90T*(')E8V]G;FET:6]N(&-R:71E<FEA(&%R92!A<'!L:65D('1O(&5A8V@@
M;V8@=&AE('-E<&%R871E('5N:71S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%
M.B`Q,'!T)SX-"B!&;W(@=&AE('!E<FEO9',@<')E<V5N=&5D+"!T:&4@0V]M
M<&%N>2!H860@=&AE(&9O;&QO=VEN9R!T=V\@='EP97,-"B!O9B!A9W)E96UE
M;G1S('=I=&@@=&AE('!A<G1I97,@:61E;G1I9FEE9"!B96QO=SH@,2D@97AC
M;'5S:79E#0H@9&5V96QO<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&QI
M8V5N<V5S('1O('5S92!T:&4-"B!#;VUP86YY)B-X,C`Q.3MS('1E8VAN;VQO
M9WD@86YD+V]R(&-E<G1A:6X@;W1H97(@:6YT96QL96-T=6%L#0H@<')O<&5R
M='D@=&\@9&5V96QO<"!C;VUP;W5N9',@86=A:6YS="!S<&5C:69I960@=&%R
M9V5T<R`H<F5F97)R960-"B!T;R!H97)E:6X@87,@97AC;'5S:79E(&QI8V5N
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M($-O;7!A;GD@9'5R:6YG(&%N#0H@;W!T:6]N('!E<FEO9"`H<F5F97)R960@
M=&\@:&5R96EN(&%S(')I9VAT+71O+61E=F5L;W`-"B!A9W)E96UE;G1S*2X\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%
M3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE<F4@87)E(&YO
M('!E<F9O<FUA;F-E+"!C86YC96QL871I;VXL('1E<FUI;F%T:6]N(&]R(')E
M9G5N9`T*('!R;W9I<VEO;G,@:6X@86YY(&]F('1H92!A<G)A;F=E;65N=',@
M=&AA="!C;VYT86EN(&UA=&5R:6%L#0H@9FEN86YC:6%L(&-O;G-E<75E;F-E
M<R!T;R!T:&4@0V]M<&%N>2X\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/
M4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!-05)'24XM3$5&5#H@,B4[($9/3E0M4TE:13H@,3!P
M="<^#0H@/&D^17AC;'5S:79E($QI8V5N<V5S/"]I/CPO<#X-"B`\<"!S='EL
M93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!D96QI=F5R86)L97,@=6YD97(@86X@
M97AC;'5S:79E(&QI8V5N<V4@86=R965M96YT(&=E;F5R86QL>0T*(&EN8VQU
M9&4@=&AE(&5X8VQU<VEV92!L:6-E;G-E('1O('1H92!#;VUP86YY)B-X,C`Q
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M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($=E;F5R86QL>2P@97AC;'5S
M:79E(&QI8V5N<V4@86=R965M96YT<R!C;VYT86EN(&YO;G)E9G5N9&%B;&4@
M=&5R;7,-"B!F;W(@<&%Y;65N=',@86YD+"!D97!E;F1I;F<@;VX@=&AE('1E
M<FUS(&]F('1H92!A9W)E96UE;G0L('!R;W9I9&4-"B!T:&%T('1H92!#;VUP
M86YY('=I;&P@*&DI)B-X03`[870@=&AE(&-O;&QA8F]R871O<B8C>#(P,3D[
M<R!R97%U97-T+`T*('!R;W9I9&4@<F5S96%R8V@@86YD('!R92UC;&EN:6-A
M;"!D979E;&]P;65N="!S97)V:6-E<R!A=`T*(&YE9V]T:6%T960@<')I8V5S
M('=H:6-H(&%R92!G96YE<F%L;'D@8V]N<VES=&5N="!W:71H('=H870@;W1H
M97(-"B!T:&ER9"!P87)T:65S('=O=6QD(&-H87)G92P@*&EI*28C>$$P.V5A
M<FX@<&%Y;65N=',@=7!O;B!T:&4-"B!A8VAI979E;65N="!O9B!C97)T86EN
M(&UI;&5S=&]N97,L("AI:6DI)B-X03`[96%R;B!R;WEA;'1Y#0H@<&%Y;65N
M=',L(&%N9"`H:78I)B-X03`[:6X@<V]M92!C87-E<R!G<F%N="!T:&4@0V]M
M<&%N>2!A;B!O<'1I;VX-"B!T;R!P87)T:6-I<&%T92!I;B!T:&4@9&5V96QO
M<&UE;G0@86YD(&-O;6UE<F-I86QI>F%T:6]N(&]F('!R;V1U8W1S#0H@=&AA
M="!R97-U;'0@9G)O;2!S=6-H(&%G<F5E;65N=',N(%)O>6%L='D@<F%T97,@
M;6%Y('9A<GD@;W9E<B!T:&4-"B!R;WEA;'1Y('1E<FT@9&5P96YD:6YG(&]N
M('1H92!#;VUP86YY)B-X,C`Q.3MS(&EN=&5L;&5C='5A;"!P<F]P97)T>0T*
M(')I9VAT<R!A;F0@=VAE=&AE<B!T:&4@0V]M<&%N>2!E>&5R8VES97,@86YY
M(&-O+61E=F5L;W!M96YT(&%N9`T*(&-O+6-O;6UE<F-I86QI>F%T:6]N(')I
M9VAT<RX@5&AE($-O;7!A;GD@;6%Y('!R;W9I9&4@=&5C:&YI8V%L#0H@87-S
M:7-T86YC92!A;F0@<VAA<F4@86YY('1E8VAN;VQO9WD@:6UP<F]V96UE;G1S
M('=I=&@@:71S#0H@8V]L;&%B;W)A=&]R<R!D=7)I;F<@=&AE('1E<FT@;V8@
M=&AE(&-O;&QA8F]R871I;VX@86=R965M96YT<RX\+W`^#0H@/'`@<W1Y;&4]
M,T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/
M3E0M4TE:13H@,3!P="<^#0H@5&AE($-O;7!A;GD@9&]E<R!N;W0@9&ER96-T
M;'D@8V]N=')O;"!W:&5N(&%N>2!C;VQL86)O<F%T;W(@=VEL;`T*(&%C:&EE
M=F4@;6EL97-T;VYE<R!O<B!B96-O;64@;&EA8FQE(&9O<B!R;WEA;'1Y('!A
M>6UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!D
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M97-E87)C:`T*('-E<G9I8V5S('1O(&)E('!E<F9O<FUE9"!O;B!B96AA;&8@
M;V8@:71S(&-O;&QA8F]R871O<G,@86YD(&UA<FME=`T*(')A=&5S(&9O<B!S
M:6UI;&%R('-E<G9I8V5S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
M)SX-"B!5<&9R;VYT('!A>6UE;G1S(&]N(&5X8VQU<VEV92!L:6-E;G-E<R!A
M<F4@9&5F97)R960@:68@9F%C=',@86YD#0H@8VER8W5M<W1A;F-E<R!D:6-T
M871E('1H870@=&AE(&QI8V5N<V4@9&]E<R!N;W0@:&%V92!S=&%N9"UA;&]N
M90T*('9A;'5E+B!0<FEO<B!T;R!T:&4@861O<'1I;VX@;V8@06-C;W5N=&EN
M9R!3=&%N9&%R9',@57!D871E("A!4U4I#0H@3F\N)B-X03`[,C`P.2TQ,RP@
M/&D^4F5V96YU92!!<G)A;F=E;65N=',@=VET:"!-=6QT:7!L90T*($1E;&EV
M97)A8FQE<SPO:3XL(&]N($IA;G5A<GDF(WA!,#LQ+"`R,#$Q+"!T:&4@0V]M
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M3F\N)B-X03`[,C`P.2TQ,RP@<VEG;FEF:6-A;G0@:G5D9VUE;G0@86YD(&5S
M=&EM871I;VX@:7,@=7-E9"!B>0T*('1H92!#;VUP86YY(&%N9"!C86X@:&%V
M92!A;B!I;7!A8W0@;VX@=&AE(&%M;W5N="!O9B!R979E;G5E#0H@<F5C;V=N
M:7IE9"!I;B!A(&=I=F5N('!E<FEO9"X@2&ES=&]R:6-A;&QY+"!T:&4@0V]M
M<&%N>28C>#(P,3D[<PT*(&EN=F]L=F5M96YT('=I=&@@=&AE(&1E=F5L;W!M
M96YT(&]F(&$@8V]L;&%B;W)A=&]R)B-X,C`Q.3MS('!R;V1U8W0-"B!C86YD
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M=&%N=&EA;"!I;G9O;'9E;65N="X-"B!!4U4@3F\N)B-X03`[,C`P.2TQ,R!A
M;65N9',@=&AE(&-R:71E<FEA(&9O<B!S97!A<F%T:6YG(&%N9`T*(&%L;&]C
M871I;F<@8V]N<VED97)A=&EO;B!I;B!A(&UU;'1I<&QE(&5L96UE;G0@87)R
M86YG96UE;G0@8GD-"B!M;V1I9GEI;F<@=&AE(&9A:7(@=F%L=64@<F5Q=6ER
M96UE;G1S(&9O<B!R979E;G5E(')E8V]G;FET:6]N(&%N9`T*(&5L:6UI;F%T
M:6YG('1H92!U<V4@;V8@=&AE(')E<VED=6%L('9A;'5E(&UE=&AO9"X@5&AE
M('-E;&QI;F<-"B!P<FEC97,@;V8@9&5L:79E<F%B;&5S('5N9&5R(&%N(&%R
M<F%N9V5M96YT(&UA>2!B92!D97)I=F5D('5S:6YG#0H@=&AI<F0M<&%R='D@
M979I9&5N8V4@*%1012DL(&]R(&$@8F5S="!E<W1I;6%T92!O9B!S96QL:6YG
M('!R:6-E#0H@*$)%4U`I+"!I9B!64T]%(&ES(&YO="!A=F%I;&%B;&4N(%1H
M92!O8FIE8W1I=F4@;V8@0D534"!I<R!T;PT*(&1E=&5R;6EN92!T:&4@<')I
M8V4@870@=VAI8V@@=&AE($-O;7!A;GD@=V]U;&0@=')A;G-A8W0@82!S86QE
M(&EF#0H@=&AE(&5L96UE;G0@=VET:&EN('1H92!L:6-E;G-E(&%G<F5E;65N
M="!W87,@<V]L9"!O;B!A('-T86YD86QO;F4-"B!B87-I<RX@17-T86)L:7-H
M:6YG($)%4U`@:6YV;VQV97,@;6%N86=E;65N="8C>#(P,3D[<R!J=61G;65N
M="!A;F0-"B!C;VYS:61E<G,@;75L=&EP;&4@9F%C=&]R<RP@:6YC;'5D:6YG
M(&UA<FME="!C;VYD:71I;VYS(&%N9`T*(&-O;7!A;GDM<W!E8VEF:6,@9F%C
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M+"!P<F]B86)I;&ET>2!O9B!S=6-C97-S(&%N9`T*('1H92!T:6UE(&YE961E
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M(&]F('1H92!A<G)A;F=E;65N=`T*(&-O;G-I9&5R871I;VX@8F5T=V5E;B!T
M:&4@;75L=&EP;&4@9&5L:79E<F%B;&5S+B!$96QI=F5R86)L97,@=6YD97(-
M"B!T:&4@87)R86YG96UE;G0@87)E('-E<&%R871E('5N:71S(&]F(&%C8V]U
M;G1I;F<@:68@*&DI)B-X03`[=&AE#0H@9&5L:79E<F5D(&ET96T@:&%S('9A
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M9VYI=&EO;B!M;V1E;`T*(&ES(&%P<&QI960@=&\@96%C:"!E;&5M96YT(&%N
M9"!R979E;G5E(&ES(&%C8V]R9&EN9VQY(')E8V]G;FEZ960@87,-"B!E86-H
M(&5L96UE;G0@:7,@9&5L:79E<F5D+B!-86YA9V5M96YT(&5X97)C:7-E<R!S
M:6=N:69I8V%N=`T*(&IU9&=M96YT(&EN(&1E=&5R;6EN:6YG('=H971H97(@
M82!D96QI=F5R86)L92!I<R!A('-E<&%R871E('5N:70@;V8-"B!A8V-O=6YT
M:6YG+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!D971E
M<FUI;FEN9R!T:&4@<V5P87)A=&4@=6YI=',@;V8@86-C;W5N=&EN9RP@=&AE
M($-O;7!A;GD-"B!E=F%L=6%T960@=VAE=&AE<B!T:&4@97AC;'5S:79E(&QI
M8V5N<V4@:&%D('-T86YD86QO;F4@=F%L=64@=&\@=&AE#0H@8V]L;&%B;W)A
M=&]R(&)A<V5D(&]N(&-O;G-I9&5R871I;VX@;V8@=&AE(')E;&5V86YT(&9A
M8W1S(&%N9`T*(&-I<F-U;7-T86YC97,@9F]R(&5A8V@@87)R86YG96UE;G0N
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M9`T*('=H971H97(@;W(@;F]T("AI*28C>$$P.W1H92!C;VQL86)O<F%T;W(@
M8V]U;&0@=7-E('1H92!L:6-E;G-E(&9O<@T*(&ET<R!I;G1E;F1E9"!P=7)P
M;W-E('=I=&AO=70@=&AE(')E8V5I<'0@;V8@=&AE(')E;6%I;FEN9PT*(&1E
M;&EV97)A8FQE<RP@*&EI*28C>$$P.W1H92!V86QU92!O9B!T:&4@;&EC96YS
M92!W87,@9&5P96YD96YT(&]N#0H@=&AE('5N9&5L:79E<F5D(&ET96US(&%N
M9"`H:6EI*28C>$$P.W1H92!C;VQL86)O<F%T;W(@;W(@;W1H97(-"B!V96YD
M;W)S(&-O=6QD('!R;W9I9&4@=&AE('5N9&5L:79E<F5D(&ET96US+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!R96%S
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M:&4@=7!F<F]N=`T*(&9E92!U;G1I;"!T:&5R92!I<R!S=6)S=&%N=&EA;"!P
M<F4M8VQI;FEC86P@86-T:79I='D@;VX@86YO=&AE<@T*('!R;V1U8W0@8V%N
M9&ED871E(&%N9"!I=',@<F5M86EN:6YG('!E<FEO9"!O9B!S=6)S=&%N=&EA
M;`T*(&EN=F]L=F5M96YT(&-A;B!B92!E<W1I;6%T960N($EN('1H92!E=F5N
M="!T:&%T(&$@<VEN9VQE('1A<F=E=`T*(&QI8V5N<V4@=V5R92!T;R!B92!T
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M4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ
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M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$
M14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
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M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
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M<F-H+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'
M24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>28C>#(P
M,3D[<R!L:6-E;G-E(&%G<F5E;65N=',@:&%V92!M:6QE<W1O;F4@<&%Y;65N
M=',-"B!W:&EC:"!F;W(@<F5P;W)T:6YG('!U<G!O<V5S(&%R92!A9V=R96=A
M=&5D(&EN=&\@=&AR964@8V%T96=O<FEE<SH-"B`H:2DF(WA!,#MD979E;&]P
M;65N="!M:6QE<W1O;F5S+"`H:6DI)B-X03`[<F5G=6QA=&]R>2!M:6QE<W1O
M;F5S+`T*(&%N9"`H:6EI*28C>$$P.W-A;&5S(&UI;&5S=&]N97,N($1E=F5L
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M92!W:&5N(&%N;G5A;"!S86QE<R!R96%C:"!C97)T86EN(&QE=F5L<RX\+W`^
M#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z
M(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]4
M5$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@070@=&AE(&EN8V5P=&EO
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M979E('1H92!M:6QE<W1O;F4L#0H@*&(I)B-X03`[=&AE(&-O;G-I9&5R871I
M;VX@<F5L871E<R!S;VQE;'D@=&\@<&%S="!P97)F;W)M86YC92!A;F0-"B`H
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M:&ES(&%S<V5S<VUE;G0N/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
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M:65V960@869T97(@=&AE('!E<FEO9"!O9B!S=6)S=&%N=&EA;`T*(&EN=F]L
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M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!-05)'
M24XM3$5&5#H@,B4[($9/3E0M4TE:13H@,3!P="<^#0H@/&D^4FEG:'0M=&\M
M1&5V96QO<"!!9W)E96UE;G1S/"]I/CPO<#X-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(%1H92!#;VUP86YY)B-X,C`Q.3MS(')I9VAT+71O+61E=F5L
M;W`@86=R965M96YT<R!P<F]V:61E#0H@8V]L;&%B;W)A=&]R<R!W:71H(&%N
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M3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I
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M8V5P=&EO;B!O9B!A(')I9VAT+71O+61E=F5L;W`-"B!A9W)E96UE;G0L('1H
M92!#;VUP86YY(&ES(&%T(')I<VL@87,@=&\@=VAE=&AE<B!T:&4@8V]L;&%B
M;W)A=&]R#0H@=VEL;"!C:&]O<V4@=&\@97AE<F-I<V4@=&AE(&]P=&EO;G,@
M=&\@<V5C=7)E(&1E=F5L;W!M96YT(&%N9`T*(&-O;6UE<F-I86QI>F%T:6]N
M(&QI8V5N<V5S+B!&86-T;W)S('1H870@87)E(&-O;G-I9&5R960@:6X-"B!E
M=F%L=6%T:6YG('=H971H97(@;W!T:6]N<R!A<F4@<W5B<W1A;G1I=F4@:6YC
M;'5D92!T:&4@;W9E<F%L;`T*(&]B:F5C=&EV92!O9B!T:&4@87)R86YG96UE
M;G0L('1H92!B96YE9FET('1H92!C;VQL86)O<F%T;W(@;6EG:'0-"B!O8G1A
M:6X@9G)O;2!T:&4@86=R965M96YT('=I=&AO=70@97AE<F-I<VEN9R!T:&4@
M;W!T:6]N<RP@=&AE(&-O<W0-"B!T;R!E>&5R8VES92!T:&4@;W!T:6]N<R!R
M96QA=&EV92!T;R!T:&4@=&]T86P@=7!F<F]N=`T*(&-O;G-I9&5R871I;VXL
M(&%N9"!T:&4@861D:71I;VYA;"!F:6YA;F-I86P@8V]M;6ET;65N=',@:6UP
M;W-E9"!O;@T*('1H92!C;VQL86)O<F%T;W(@87,@82!R97-U;'0@;V8@97AE
M<F-I<VEN9R!T:&4@;W!T:6]N<RX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3!P="<^#0H@1F]R(')I9VAT+71O+61E=F5L;W`@86=R965M96YT<R!W:&5R
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M<F4@=&AE(&]P=&EO;G,@=&\@<V5C=7)E(&1E=F5L;W!M96YT(&%N9`T*(&-O
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M,#DM,3,L('1H92!#;VUP86YY)B-X,C`Q.3MS(&5V86QU871I;VX@;V8@=VAE
M=&AE<B!T:&4@;W!T:6]N#0H@:7,@<W5B<W1A;G1I=F4@:7,@8V]N<VES=&5N
M="!W:71H('!R92UA9&]P=&EO;B!O9B!!4U4-"B!.;RXF(WA!,#LR,#`Y+3$S
M+B!(;W<@=&AE($-O;7!A;GD@9&5T97)M:6YE<R!T:&4@<V5L;&EN9R!P<FEC
M92!O9@T*('1H92!O<'1I;VX@:7,@=&AE(&]N;'D@9&EF9F5R96YC92!B971W
M965N('!R92!A;F0@<&]S="!A9&]P=&EO;B!O9@T*($%352!.;RXF(WA!,#LR
M,#`Y+3$S+B!0;W-T(&%D;W!T:6]N(&]F($%352!.;RXF(WA!,#LR,#`Y+3$S
M+"!T:&4-"B!S96QL:6YG('!R:6-E<R!O9B!D96QI=F5R86)L97,@=6YD97(@
M86X@87)R86YG96UE;G0@;6%Y(&)E(&1E<FEV960-"B!U<VEN9R!44$4@;W(@
M82!"15-0+"!I9B!64T]%(&ES(&YO="!A=F%I;&%B;&4N(%1H92!O8FIE8W1I
M=F4@;V8-"B!"15-0(&ES('1O(&1E=&5R;6EN92!T:&4@<')I8V4@870@=VAI
M8V@@=&AE($-O;7!A;GD@=V]U;&0@=')A;G-A8W0-"B!A('-A;&4@:68@=&AE
M(&5L96UE;G0@=VET:&EN('1H92!R:6=H="UT;RUD979E;&]P(&%G<F5E;65N
M="!W87,-"B!S;VQD(&]N(&$@<W1A;F1A;&]N92!B87-I<RX@17-T86)L:7-H
M:6YG($)%4U`@:6YV;VQV97,-"B!M86YA9V5M96YT)B-X,C`Q.3MS(&IU9&=M
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M<&%R871E('5N:71S(&]F(&%C8V]U;G1I;F<@:68@*&DI)B-X03`[=&AE(&1E
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M;VUP86YY)B-X,C`Q.3MS#0H@8V]N=')O;"X@5&AE(&%R<F%N9V5M96YT(&-O
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M871E('5N:70@;V8-"B!A8V-O=6YT:6YG+CPO<#X-"B`\<"!S='EL93TS1"=-
M05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!)9B!A(&-O;&QA8F]R871O<B!E>&5R8VES97,@86X@
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M96YT)B-X,C`Q.3MS(&1E=&5R;6EN871I;VX@;V8@<V5L;&EN9R!P<FEC90T*
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M<F5D(&]P=&EO;B!F964@=&\@=&AE(&1E=F5L;W!M96YT(&%N9`T*(&-O;6UE
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M=F4-"B!L:6-E;G-E<R!E=F5N="!A(')I9VAT+71O+61E=F5L;W`@86=R965M
M96YT('=E<F4@=&\@8F4@=&5R;6EN871E9"P-"B!T:&4@0V]M<&%N>2!W;W5L
M9"!R96-O9VYI>F4@87,@<F5V96YU92!A;GD@<&]R=&EO;B!O9B!T:&4@=7!F
M<F]N=`T*(&9E92!T:&%T(&AA9"!N;W0@<')E=FEO=7-L>2!B965N(')E8V]R
M9&5D(&%S(')E=F5N=64L(&)U="!W87,-"B!C;&%S<VEF:65D(&%S(&1E9F5R
M<F5D(')E=F5N=64L(&%T('1H92!D871E(&]F('-U8V@@=&5R;6EN871I;VXN
M#0H@5&AE($-O;7!A;GDF(W@R,#$Y.W,@<FEG:'0M=&\M9&5V96QO<"!A9W)E
M96UE;G1S(&AA=F4@8F5E;@T*(&1E=&5R;6EN960@=&\@8V]N=&%I;B!S=6)S
M=&%N=&EV92!O<'1I;VYS+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`Q,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T
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M9F]R(&1E=F5L;W!M96YT(&%N9`T*(&-O;6UE<F-I86QI>F%T:6]N(&QI8V5N
M<V5S+CPO<#X-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#
M;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3AP=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QB/CQI/E)E<V5A<F-H(&%N9"!$979E;&]P;65N="!#;W-T
M<SPO:3X\+V(^/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#9P=#L@
M5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@4F5S
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M;&%T;W)Y(&%P<')O=F%L<RX\+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP<F5H96YS:79E
M($EN8V]M92`H3&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,'!T)SX-"B`\8CX\:3Y#;VUP<F5H96YS:79E($EN8V]M
M92`H3&]S<RD\+VD^/"]B/CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0
M.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*($5F9F5C=&EV92!*86YU87)Y)B-X03`[,2P@,C`Q,BP@=&AE($-O;7!A
M;GD@861O<'1E9"!!4U4R,#$Q+3`U+`T*(#QI/E!R97-E;G1A=&EO;B!O9B!#
M;VUP<F5H96YS:79E($EN8V]M92P\+VD^('=H:6-H(&%M96YD960@05-##0H@
M5&]P:6,@,C(P+"`\:3Y#;VUP<F5H96YS:79E($EN8V]M92X\+VD^(%1H92!A
M;65N9&UE;G1S(&EN($%350T*(#(P,3$M,#4@<F5Q=6ER92!T:&4@<')E<V5N
M=&%T:6]N(&]F('1H92!C;VUP<F5H96YS:79E(&EN8V]M92`H;&]S<RD-"B!A
M;F0@:71S(&-O;7!O;F5N=',@87,@<&%R="!O9B!T:&4@8V]N<V]L:61A=&5D
M(&9I;F%N8VEA;`T*('-T871E;65N=',N($-O;7!R96AE;G-I=F4@:6YC;VUE
M("AL;W-S*2!I<R!C;VUP<FES960@;V8@=&AE(&YE=`T*(&EN8V]M92`H;&]S
M<RD@86YD(&]T:&5R(&-H86YG97,@:6X@97%U:71Y('1H870@87)E(&5X8VQU
M9&5D(&9R;VT-"B!N970@:6YC;VUE("AL;W-S*2X@0V]M<')E:&5N<VEV92!I
M;F-O;64@*&QO<W,I(&5Q=6%L<R!N970@:6YC;VUE#0H@*&QO<W,I(&9O<B!T
M:&4@=&AR964@86YD(&YI;F4@;6]N=&AS(&5N9&5D(%-E<'1E;6)E<B8C>$$P
M.S,P+"`R,#$S#0H@86YD(#(P,3(N/"]P/@T*(#PO9&EV/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S
M960@0V]M<&5N<V%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q.'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3!P="<^#0H@/&(^/&D^4W1O8VLM8F%S960@0V]M<&5N
M<V%T:6]N/"]I/CPO8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@
M-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
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M;'D@=&AE('9E<W1I;F<@<&5R:6]D(&]F('1H90T*(&]P=&EO;BX\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,3)P=#L@5$585"U)3D1%3E0Z(#0E
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM0D]45$]-
M.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@1F]R(&%L;"!T:6UE+79E<W1I
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M<&5R:6]D+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-
M05)'24XM0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\
M+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.
M5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@0V]M<&%N>2!U
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M97-T+"!E>'!E8W1E9`T*(&1I=FED96YD('EI96QD+"!E>'!E8W1E9"!V;VQA
M=&EL:71Y(&%N9"!T:&4@97AP96-T960@;&EF92!O9B!T:&4-"B!A=V%R9"X\
M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y.970@26YC;VUE("A,;W-S*2!097(@4VAA<F4\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#$X<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B`\8CX\:3Y.970@26YC;VUE("A,;W-S*2!097(@4VAA<F4\+VD^/"]B/CPO
M<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4
M.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($EN8V]M92`H;&]S<RD@
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M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
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M:7,@8V]M<'5T960@8GD@9&EV:61I;F<@=&AE(&YE="!I;F-O;64-"B`H;&]S
M<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S=&]C:VAO;&1E<G,@8GD@=&AE('=E
M:6=H=&5D+6%V97)A9V4-"B!N=6UB97(@;V8@8V]M;6]N('-T;V-K(&5Q=6EV
M86QE;G1S(&]U='-T86YD:6YG(&9O<B!T:&4@<&5R:6]D+B!4:&4-"B!T<F5A
M<W5R>2!S=&]C:R!M971H;V0@:7,@=7-E9"!T;R!D971E<FUI;F4@=&AE(&1I
M;'5T:79E(&5F9F5C="!O9@T*('1H92!#;VUP86YY)B-X,C`Q.3MS('-T;V-K
M(&]P=&EO;B!G<F%N=',@86YD('1H92!I9BUC;VYV97)T960@;65T:&]D#0H@
M:7,@=7-E9"!T;R!D971E<FUI;F4@=&AE(&1I;'5T:79E(&5F9F5C="!O9B!T
M:&4@0V]M<&%N>28C>#(P,3D[<PT*(%-E<FEE<R8C>$$P.T$M,2P@02TR+"!"
M+"!#+"!$+"!A;F0@1"TR(&-O;G9E<G1I8FQE('!R969E<G)E9`T*('-T;V-K
M+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!X.R!-05)'24XM
M0D]45$]-.B`P<'@[($9/3E0M4TE:13H@,7!X)SX-"B`F(WA!,#L\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!"87-I8R!A;F0@9&EL=71E9"!I
M;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4@:7,@8V]M<'5T960@87,-
M"B!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3$E/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@
M/&(^5&AR964F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E
M<B8C>$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^
M#0H@/&(^3FEN928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[4V5P=&5M
M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(
M96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($YE="!I;F-O;64@*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C8L-C`S+#DX,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,BPV,#`L-3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R;FEN
M9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<-"B!S96-U<FET:65S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L-#,T+#<U-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(L-C`P+#4Q-#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#(L.30T+#$T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#$P+#0V-BPU.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!.
M970@:6YC;VUE("AL;W-S*2!A;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$V.2PR,C8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%S:6,@=V5I9VAT
M960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#$X-"PU,#<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ+#`Y,BPS,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0V,RPW
M.3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`W."PQ-#4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D)A<VEC
M(&EN8V]M92`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R93PO8CX\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&(^,"XQ-#PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQB/B8C>$$P.R8C>$$P.SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&(^)#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\8CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQB
M/B8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&(^)#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\8CXF(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQB/B8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
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M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!.970@:6YC;VUE("AL;W-S*3PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C8L-C`S+#DX,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#8P
M,"PU,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY-#0L,30Y/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$P+#0V-BPU.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R;FEN
M9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<@<V5C=7)I=&EE<PT*(&%N
M9"!O=&AE<B!A9&0M8F%C:W,@=&\@;F5T(&EN8V]M92`H;&]S<RD\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@V+#0P,RPX-#,\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#(L-C`P+#4Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPY-#0L,30Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@Q,"PT-C8L-3@R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@3F5T(&EN
M8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR,#`L,3,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($)A<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PQ.#0L-3`W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PP.3(L,S`W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PT-C,L-SDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP-S@L
M,30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%9F9E8W0@;V8@9&EL
M=71I=F4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`L
M,#4X+#0W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P+#0Q,"PQ,3<\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR,"PT-#4L,#8Q/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,C`L,S,T+#<P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@1&EL=71E9"!W96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R
M97,@;W5T<W1A;F1I;F<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#(T
M,BPY-S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,2PU,#(L-#(T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,C$L.3`X+#@U.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(Q+#0Q,BPX-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^
M1&EL=71E9"!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+V(^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\8CXD/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQB/C`N,#$\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF
M(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\8CXF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&(^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF(WA!,#L\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF
M(WA!,#L\+V(^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^/"]T86)L93X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@
M9F]L;&]W:6YG(&-O;6UO;B!S=&]C:R!E<75I=F%L96YT<R!A<F4@:6YC;'5D
M960@:6X@=&AE#0H@8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@:6YC;VUE
M("AL;W-S*2!P97(@<VAA<F4Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^/"$M
M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V
M,"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@
M<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E
M;G1E<CX-"B`\8CY4:')E928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[
M4V5P=&5M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A
M;&EG;CTS1&-E;G1E<CX-"B`\8CY.:6YE)B-X03`[36]N=&AS)B-X03`[16YD
M960F(WA!,#M397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q
M,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^
M,C`Q,SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^
M/&(^,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"
M96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(]
M,T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5R
M:65S($$M,2!0<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,BPQ-38L,3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(L,34V+#$Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR+#$U-BPQ,30\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(%-E<FEE<R!!+3(@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XS.3(L,C<T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,Y,BPR-S0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5R:65S($(@4')E9F5R<F5D
M(%-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS,S8L
M,#,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,S,V
M+#`S-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,S
M-BPP,S<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS
M,S8L,#,W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!397)I97,@0R!0
M<F5F97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^-2PY,#DL.3`V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4L.3`Y+#DP-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XU+#DP.2PY,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%-E<FEE<R!$(%!R969E<G)E9"!3=&]C:SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-S8Y+#0V.#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW-CDL-#8X/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%-E<FEE<R!$+3(@4')E9F5R<F5D(%-T;V-K/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS.3$L.3DQ/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L,SDQ+#DY,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Y,2PY.3$\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS.3$L.3DQ/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!7
M87)R86YT<R!T;R!P=7)C:&%S92!397)I97,@1"TR(%!R969E<G)E9"!3=&]C
M:SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@P+#<X-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-S@T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-T;V-K($]P=&EO;G,\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#DQ,"PY-3(\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-S8L-3$V/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.3$P+#DU,CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#(W-BPU,38\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96YT;'D@27-S=65D
M($%C8V]U;G1I;F<@4W1A;F1A<F1S($%D;W!T960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/CQI/E)E8V5N
M=&QY($ES<W5E9"!!8V-O=6YT:6YG(%-T86YD87)D<R!!9&]P=&5D/"]I/CPO
M8CX\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.+51/4#H@-G!T.R!415A4+4E.
M1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!-87DF(WA!
M,#LR,#$Q+"!T:&4@1D%30B!I<W-U960@05-5($YO+B8C>$$P.S(P,3$M,#0L
M('=H:6-H#0H@86UE;F1E9"!!4T,@5&]P:6,@.#(P('1O(&%C:&EE=F4@8V]M
M;6]N(&9A:7(@=F%L=64@;65A<W5R96UE;G1S(&%N9`T*(&1I<V-L;W-U<F4@
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M,C`Q,2X@5&AE(&%D;W!T:6]N(&]F('1H:7,-"B!A;65N9&UE;G0@9&ED(&YO
M="!H879E(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#;VUP86YY)B-X,C`Q
M.3MS#0H@8V]N<V]L:61A=&5D(&9I;F%N8VEA;"!S=&%T96UE;G1S+CPO<#X-
M"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4+4E.1$5.5#H@
M-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U14
M3TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!);B!*=6YE)B-X03`[,C`Q
M,2P@=&AE($9!4T(@:7-S=65D($%352!.;RXF(WA!,#LR,#$Q+3`U+"!W:&EC
M:`T*(&%M96YD960@05-#(%1O<&EC(#(R,"!R96=A<F1I;F<@<')E<V5N=&%T
M:6]N(&]F(&-O;7!R96AE;G-I=F4-"B!I;F-O;64N(%1H92!A;65N9&UE;G1S
M(&EN($%352!.;RXF(WA!,#LR,#$Q+3`U(')E<75I<F4@=&AA="!A;&P-"B!N
M;VYO=VYE<B!C:&%N9V5S(&EN('-T;V-K:&]L9&5R<R8C>#(P,3D[(&5Q=6ET
M>2!B92!P<F5S96YT960@96ET:&5R#0H@:6X@82!S:6YG;&4@8V]N=&EN=6]U
M<R!S=&%T96UE;G0@;V8@8V]M<')E:&5N<VEV92!I;F-O;64@;W(@:6X@='=O
M#0H@<V5P87)A=&4@8G5T(&-O;G-E8W5T:79E('-T871E;65N=',N($EN('1H
M92!T=V\M<W1A=&5M96YT(&%P<')O86-H+`T*('1H92!F:7)S="!S=&%T96UE
M;G0@<VAO=6QD('!R97-E;G0@=&]T86P@;F5T(&EN8V]M92!A;F0@:71S#0H@
M8V]M<&]N96YT<R!F;VQL;W=E9"!C;VYS96-U=&EV96QY(&)Y(&$@<V5C;VYD
M('-T871E;65N="!T:&%T('-H;W5L9`T*('!R97-E;G0@=&]T86P@;W1H97(@
M8V]M<')E:&5N<VEV92!I;F-O;64L('1H92!C;VUP;VYE;G1S(&]F(&]T:&5R
M#0H@8V]M<')E:&5N<VEV92!I;F-O;64L(&%N9"!T:&4@=&]T86P@;V8@8V]M
M<')E:&5N<VEV92!I;F-O;64N(%1H:7,-"B!A;65N9&UE;G0@:7,@969F96-T
M:79E(&9O<B!F:7-C86P@>65A<G,@8F5G:6YN:6YG(&%F=&5R#0H@1&5C96UB
M97(F(WA!,#LQ-2P@,C`Q,2X@5&AE(&%D;W!T:6]N(&]F('1H:7,@86UE;F1M
M96YT(&1I9"!N;W0@:&%V90T*(&$@;6%T97)I86P@:6UP86-T(&]N('1H92!#
M;VUP86YY)B-X,C`Q.3MS(&-O;G-O;&ED871E9"!F:6YA;F-I86P-"B!S=&%T
M96UE;G1S+CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!4
M15A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@
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M+W`^#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T
M-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE970Q."YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15A*04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R
M>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("A486)L97,I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O
M;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@1F%I<B!686QU92!-96%S=7)E;65N="!&:6YA;F-I86P@07-S970@
M86YD($QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q,G!T.R!415A4
M+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!&:6YA;F-I
M86P@87-S971S(&%N9"!L:6%B:6QI=&EE<R!S=6)J96-T('1O(&9A:7(@=F%L
M=64@;65A<W5R96UE;G1S#0H@=V5R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@
M1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE
M/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C
M96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$.3(E(&%L
M:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^
M#0H@/'1D('=I9'1H/3-$-#DE/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!W:61T:#TS1#8E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A
M;CTS1#$T(&%L:6=N/3-$8V5N=&5R/CQB/D9A:7(@5F%L=64@365A<W5R96UE
M;G1S(&%T#0H@4V5P=&5M8F5R)B-X03`[,S`L(#(P,3,\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@<F]W<W!A;CTS1#(@8V]L<W!A;CTS1#(@86QI9VX]
M,T1C96YT97(^/&(^5&]T86P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(')O=W-P86X],T0R/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/E%U;W1E9"8C>$$P.U!R:6-E<R8C>$$P
M.VEN/"]B/CQB<B`O/@T*(#QB/D%C=&EV928C>$$P.TUA<FME=',F(WA!,#MF
M;W(\+V(^/&)R("\^#0H@/&(^261E;G1I8V%L($%S<V5T<SPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^4VEG;FEF:6-A;G0F
M(WA!,#M/=&AE<CPO8CX\8G(@+SX-"B`\8CY/8G-E<G9A8FQE)B-X03`[26YP
M=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G
M('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\
M8CY3:6=N:69I8V%N=#PO8CX\8G(@+SX-"B`\8CY5;F]B<V5R=F%B;&4\+V(^
M/&)R("\^#0H@/&(^26YP=71S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`Q/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`R/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O
M;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY,979E;"`S/"]B/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A8FQE($)O
M9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@
M/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@
M+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%
M1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!!<W-E=',Z/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!#87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C<L-3(R+#`R.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^-RPU,C(L,#(Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($UO;F5Y(&UA<FME="!F=6YD<SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(V+#`T-RPQ-CD\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C8L,#0W+#$V.3PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@4F5S=')I8W1E9"!C87-H
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-#`T+#@U,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT,#0L.#4P/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!4;W1A;"!A<W-E=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS,RPY-S0L,#0X
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,S+#DW-"PP-#@\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D
M;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@3&EA8FEL:71I97,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%!R969E<G)E9"!S=&]C
M:R!W87)R86YT(&QI86)I;&ET>3PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B@V-SDL
M,CDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XH-C<Y+#(Y-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!
M,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT
M<CX-"B`\=&0^/"]T9#X-"B`\=&0@8V]L<W!A;CTS1#$V/CPO=&0^#0H@/"]T
M<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#$T(&%L:6=N/3-$
M8V5N=&5R/CQB/D9A:7(@5F%L=64@365A<W5R96UE;G1S(&%T#0H@1&5C96UB
M97(F(WA!,#LS,2P@,C`Q,CPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!R
M;W=S<&%N/3-$,B!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY4;W1A
M;#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@<F]W<W!A;CTS1#(^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O
M;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT
M97(^/&(^475O=&5D)B-X03`[4')I8V5S)B-X03`[:6X\+V(^/&)R("\^#0H@
M/&(^06-T:79E)B-X03`[36%R:V5T<R8C>$$P.V9O<CPO8CX\8G(@+SX-"B`\
M8CY)9&5N=&EC86P@07-S971S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A
M;&EG;CTS1&-E;G1E<CX\8CY3:6=N:69I8V%N="8C>$$P.T]T:&5R/"]B/CQB
M<B`O/@T*(#QB/D]B<V5R=F%B;&4F(WA!,#M);G!U=',\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M
M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E-I9VYI9FEC86YT/"]B
M/CQB<B`O/@T*(#QB/E5N;V)S97)V86)L93PO8CX\8G(@+SX-"B`\8CY);G!U
M=',\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI
M9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R
M/CQB/DQE=F5L(#$\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/DQE=F5L(#(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/DQE=F5L(#,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP
M('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*($%S<V5T<SH\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-A<V@@86YD(&-A
M<V@@97%U:79A;&5N=',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@L
M-CDU+#$Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@L-CDU+#$Y-SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!-;VYE>2!M87)K970@9G5N9',\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XR.2PP-#<L.34X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C(Y+#`T-RPY-3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(%)E<W1R:6-T960@8V%S:#PO<#X-"B`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C0P-"PX-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^-#`T+#@U,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XF(W@R,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X
M('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O
M;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@5&]T86P@87-S971S/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-#@L,30X+#`P-3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT
M."PQ-#@L,#`U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O
M;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T
M)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$
M14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'
M24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($QI86)I;&ET:65S
M.CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!0<F5F97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI='D\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XH-3(L.30W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R
M,#$T.R8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XF(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF
M;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O
M;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH-3(L.30W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^
M)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C
M>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-
M"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G
M/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P
M>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C
M,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4W5M;6%R>2!O9B!0<F5F97)R960@4W1O8VL@
M5V%R<F%N="!,:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@5$58
M5"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@5&AE(&9O
M;&QO=VEN9R!T86)L92!P<F]V:61E<R!A(')O;&QF;W)W87)D(&]F('1H92!#
M;VUP86YY)B-X,C`Q.3MS#0H@<')E9F5R<F5D('-T;V-K('=A<G)A;G0@;&EA
M8FEL:71Y+"!W:&EC:"!W87,@=&AE(&]N;'D@9FEN86YC:6%L#0H@:6YS=')U
M;65N="!M96%S=7)E9"!A="!F86ER('9A;'5E(&]N(&$@<F5C=7)R:6YG(&)A
M<VES('5S:6YG#0H@<VEG;FEF:6-A;G0@=6YO8G-E<G9A8FQE(&EN<'5T<R`H
M3&5V96P@,RD@87,@9&5F:6YE9"!I;B!!4T,-"B`X,C`Z/"]P/@T*(#QP('-T
M>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4]
M,T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E
M;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED=&@],T0V."4@86QI
M9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L92!(96%D("TM/@T*(#QT<CX-
M"B`\=&0@=VED=&@],T0X-B4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M('=I9'1H/3-$-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M
M+2!"96=I;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@
M0F%L86YC92!A="!$96-E;6)E<B8C>$$P.S,Q+"`R,#$R/"]P/@T*(#PO=&0^
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M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!4;W1A;"!U;G)E86QI>F5D(&=A:6YS("AL;W-S97,I(&EN8VQU9&5D(&EN
M(&5A<FYI;F=S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8R
M-BPS-#D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q
M<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!"86QA;F-E(&%T(%-E
M<'1E;6)E<B8C>$$P.S,P+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X
M03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8W
M.2PR.38\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%<W1I;6%T960@57-E9G5L($QI=F5S/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'
M24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N(&%R92!C
M;VUP=71E9"!U<VEN9R!T:&4@<W1R86EG:'0M;&EN90T*(&UE=&AO9"!O=F5R
M('1H92!F;VQL;W=I;F<@97-T:6UA=&5D('5S969U;"!L:79E<SH\+W`^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P
M<'0[($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S
M='EL93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS
M1#`@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X
M)2!A;&EG;CTS1&-E;G1E<CX-"B`\='(^#0H@/'1D('=I9'1H/3-$-C`E/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#0E/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$
M(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-O;7!U
M=&5R(&5Q=6EP;65N=#PO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^,R!Y96%R<SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%-O9G1W87)E/"]P/@T*(#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XS('EE87)S/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@
M1G5R;FET=7)E/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XQ,"!Y96%R<SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P
M/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*($QA8F]R871O<GD@86YD(&]F9FEC92!E<75I<&UE;G0\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE
M/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/C4@>65A<G,\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!,96%S96AO;&0@:6UP<F]V96UE;G1S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B!3:&]R=&5R)B-X03`[;V8F(WA!,#ML
M96%S928C>$$P.W1E<FTF(WA!,#MO<B8C>$$P.W5S969U;"8C>$$P.VQI9F4\
M+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F
M($1I;'5T:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO
M;B!O9B!$:6QU=&5D($YE="!);F-O;64@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\9&EV/@T*(#QD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!"87-I8R!A;F0@9&EL=71E9"!I
M;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4@:7,@8V]M<'5T960@87,-
M"B!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[
M($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!
M,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L
M;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P('=I9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G:6X@
M5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-3$E/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS
M1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D
M/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V
M86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@
M/&(^5&AR964F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E
M<B8C>$$P.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED
M)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^
M#0H@/&(^3FEN928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[4V5P=&5M
M8F5R)B-X03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X]
M,T0R(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(
M96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*($YE="!I;F-O;64@*&QO<W,I/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C8L-C`S+#DX,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,BPV,#`L-3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
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M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R;FEN
M9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<-"B!S96-U<FET:65S/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#8L-#,T+#<U-CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^*#(L-C`P+#4Q-#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^*#(L.30T+#$T.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#$P+#0V-BPU.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO
M<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS
M1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!.
M970@:6YC;VUE("AL;W-S*2!A;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$V.2PR,C8\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q
M-#LF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^)B-X,C`Q-#LF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F%S:6,@=V5I9VAT
M960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4
M+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#XQ+#$X-"PU,#<\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XQ+#`Y,BPS,#<\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#0V,RPW
M.3@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#`W."PQ-#4\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QB/D)A<VEC
M(&EN8V]M92`H;&]S<RD@<&5R(&-O;6UO;B!S:&%R93PO8CX\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M
M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^/&(^,"XQ-#PO8CX\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQB/B8C>$$P.R8C>$$P.SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^/&(^)#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@86QI9VX],T1R:6=H=#X\8CXF(W@R,#$T.R8C>$$P.R8C>$$P.SPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/CQB
M/B8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&(^)#PO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#X\8CXF(W@R,#$T.R8C
M>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/CQB/B8C>$$P.R8C>$$P.SPO8CX\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
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M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!.970@:6YC;VUE("AL;W-S*3PO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C8L-C`S+#DX,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T
M)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#8P
M,"PU,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPY-#0L,30Y/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].
M5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$P+#0V-BPU.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N
M/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*($QE<W,Z('5N9&ES=')I8G5T960@96%R;FEN
M9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I;F<@<V5C=7)I=&EE<PT*(&%N
M9"!O=&AE<B!A9&0M8F%C:W,@=&\@;F5T(&EN8V]M92`H;&]S<RD\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@V+#0P,RPX-#,\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/BDF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^*#(L-C`P+#4Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,BPY-#0L,30Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/B@Q,"PT-C8L-3@R/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T
M>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@3F5T(&EN
M8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O;6UO;B!S:&%R97,\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XR,#`L,3,Y/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G
M/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P
M,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N
M=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/B8C>#(P,30[)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P
M,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z
M(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M($)A<VEC('=E:6=H=&5D(&%V97)A9V4@8V]M;6]N('-H87)E<R!O=71S=&%N
M9&EN9SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@
M<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PQ.#0L-3`W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,2PP.3(L,S`W/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,2PT-C,L-SDX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PP-S@L
M,30U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%9F9E8W0@;V8@9&EL
M=71I=F4@<V5C=7)I=&EE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,C`L
M,#4X+#0W,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N
M;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P+#0Q,"PQ,3<\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR,"PT-#4L,#8Q/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U3
M25I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,C`L,S,T+#<P,SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@1&EL=71E9"!W96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R
M97,@;W5T<W1A;F1I;F<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(Q+#(T
M,BPY-S@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W
M<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR,2PU,#(L-#(T/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4]
M,T0G1D].5"U325I%.B`X<'0G/B8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,C$L.3`X+#@U.3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C(Q+#0Q,BPX-#@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\
M+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@/&(^
M1&EL=71E9"!I;F-O;64@*&QO<W,I('!E<B!C;VUM;VX@<VAA<F4\+V(^/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\8CXD/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/CQB/C`N,#$\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF
M(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!
M,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#X\8CXF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\
M+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQB/B0\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^/&(^)B-X
M,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF(WA!,#L\+V(^/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQB/B0\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^/&(^)B-X,C`Q-#LF(WA!,#LF(WA!,#L\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#X\8CXF(WA!,#LF
M(WA!,#L\+V(^/"]T9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@
M+2T^/"]T86)L93X-"B`\+V1I=CX-"B`\+V1I=CX-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F($%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R;VT@
M0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\9&EV/@T*(#QP('-T>6QE
M/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&
M3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I;F<@8V]M;6]N('-T;V-K
M(&5Q=6EV86QE;G1S)B-X03`[87)E(&EN8VQU9&5D)B-X03`[:6X-"B!T:&4@
M8V%L8W5L871I;VX@;V8@9&EL=71E9"!N970@:6YC;VUE("AL;W-S*2!P97(@
M<VAA<F4Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%2
M1TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO
M<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S
M93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS
M1#`@=VED=&@],T0Y,B4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L
M92!(96%D("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0V,"4^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,B4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y
M;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG
M;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E<CX-"B`\8CY4
M:')E928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[4V5P=&5M8F5R)B-X
M03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS1&-E;G1E
M<CX-"B`\8CY.:6YE)B-X03`[36]N=&AS)B-X03`[16YD960F(WA!,#M397!T
M96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L
M<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@
M8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T
M;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,SPO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^,C`Q,CPO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!"
M;V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5R:65S($$M,2!0<F5F
M97)R960@4W1O8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,BPQ-38L,3$T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C(L,34V+#$Q-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XR+#$U-BPQ,30\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y
M;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%
M.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%
M6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-E<FEE
M<R!!+3(@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XS.3(L,C<T/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C,Y,BPR-S0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,SDR+#(W-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T
M;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M
M4TE:13H@,3!P="<^#0H@4V5R:65S($(@4')E9F5R<F5D(%-T;V-K/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS,S8L,#,W/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0L,S,V+#`S-SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT+#,S-BPP,S<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-"PS,S8L,#,W/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A
M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!397)I97,@0R!0<F5F97)R960@4W1O
M8VL\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#DP.2PY,#8\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-2PY,#DL.3`V
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C4L.3`Y+#DP
M-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU+#DP.2PY
M,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%-E<FEE<R!$(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^-S8Y+#0V.#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XW-CDL-#8X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C<V.2PT-C@\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%-E<FEE<R!$+3(@4')E9F5R<F5D(%-T;V-K/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,RPS.3$L.3DQ/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C,L,SDQ+#DY,3PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XS+#,Y,2PY.3$\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPS.3$L.3DQ/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^
M#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.
M5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.
M+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!787)R86YT<R!T;R!P
M=7)C:&%S92!397)I97,@1"TR(%!R969E<G)E9"!3=&]C:SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3@P+#<X-#PO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ.#`L-S@T/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$X,"PW.#0\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(%-T;V-K($]P=&EO;G,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,RPR-S8L-3$V/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C(L.3$P+#DU,CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XS+#(W-BPU,38\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/"]D:78^
M#0H@/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y3=6UM87)Y(&]F(%-I9VYI9FEC86YT(%)E=F5N=64@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA
M<GD@;V8@4&5R8V5N=&%G92!O9B!#=7-T;VUE<B!#;VYC96YT<F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\9&EV/@T*
M(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#$R<'0[(%1%6%0M24Y$14Y4.B`T
M)3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/
M33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I;F<@=&%B
M;&4@<F5P<F5S96YT<R!T:&4@<&5R8V5N=&%G92!O9B!A;&P@<VEG;FEF:6-A
M;G0-"B!R979E;G5E(&5A<FYE9"!I;B!T:&4@<&5R:6]D<R!I;F1I8V%T960Z
M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0Y,B4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L92!(96%D
M("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0U,B4^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@
M/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W
M:61T:#TS1#$P)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT
M9#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0Q,"4^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,3`E/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`X
M<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@/&(^5&AR
M964F(WA!,#M-;VYT:',F(WA!,#M%;F1E9"8C>$$P.U-E<'1E;6)E<B8C>$$P
M.S,P+#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T
M>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI
M9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C96YT97(^#0H@/&(^
M3FEN928C>$$P.TUO;G1H<R8C>$$P.T5N9&5D)B-X03`[4V5P=&5M8F5R)B-X
M03`[,S`L/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@.'!T)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R
M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P
M,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L
M:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N
M/3-$8V5N=&5R/CQB/C(P,3,\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P
M="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$
M8V5N=&5R/CQB/C(P,3(\+V(^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\(2TM($5N9"!486)L92!(96%D("TM
M/CPA+2T@0F5G:6X@5&%B;&4@0F]D>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T
M>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*(%-E<G9I97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW
M,2XS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ-"XR/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XU."XX/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,BXV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F]E:')I;F=E<CPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C4\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG
M;CTS1')I9VAT/C$U+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$U+CD\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+C(\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D
M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!':6QE860\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XQ,"XY/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XP+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$S+C<\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C`N,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].
M5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%!F:7IE<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N-3PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-RXW/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XW+C,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P
M/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C<N-#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#
M145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M
M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-
M05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($=O=F5R;FUE
M;G0@06=E;F-I97,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XP
M+C8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,N-3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,BXV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
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M;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E
M;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%;&D@3&EL;'D\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XP+CD\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I
M9VAT/C4Y+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$N-CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-34N-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M(2TM($5N9"!486)L92!";V1Y("TM/CPO=&%B;&4^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@,3AP>#L@34%21TE.+4)/5%1/33H@,'!X.R!&3TY4+5-)
M6D4Z(#%P>"<^#0H@)B-X03`[/"]P/@T*(#PO9&EV/@T*(#PO9&EV/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W5M
M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@
M;V8@4&5R8V5N=&%G92!O9B!#=7-T;VUE<B!#;VYC96YT<F%T:6]N/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(%1H92!F;VQL;W=I;F<@=&%B;&4@<F5P<F5S96YT
M<R!T:&4@<&5R8V5N=&%G92!O9B!A;&P@<VEG;FEF:6-A;G0-"B!A8V-O=6YT
M<R!R96-E:79A8FQE.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P
M<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F
M(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@
M8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A
M9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$8V5N=&5R/CPA+2T@0F5G
M:6X@5&%B;&4@2&5A9"`M+3X-"B`\='(^#0H@/'1D('=I9'1H/3-$-C0E/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!W:61T:#TS1#$V)3X\+W1D/@T*
M(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@=VED=&@],T0Q-B4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G
M0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O
M='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CY397!T96UB97(F
M(WA!,#LS,"PF(WA!,#LR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,B!A;&EG;CTS
M1&-E;G1E<CX\8CY$96-E;6)E<B8C>$$P.S,Q+"8C>$$P.S(P,3(\+V(^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\(2TM($5N9"!486)L92!(96%D("TM/CPA+2T@0F5G:6X@5&%B;&4@0F]D
M>2`M+3X-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($=I;&5A9#PO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C4Q+C(\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/B8C>#(P,30[)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!09FEZ97(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XR,BXV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XT-2XT/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%
M149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@0F]E:')I;F=E
M<CPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$Q+C$\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/C$X+C`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B4F(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!%;&D@3&EL;'D\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ
M,2XP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XE)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR."XR/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-
M"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*
M(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z
M("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,
M1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1V]V97)N;65N="!!9V5N
M8VEE<SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C0N,#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)28C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&%L:6=N/3-$<FEG:'0^."XT/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XE)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-"B`\+V1I=CX\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X
M7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B
M.#4P8F$O5V]R:W-H965T<R]3:&5E=#$Y+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N="`H
M5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I<&UE;G0@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V-H961U;&4@;V8@4')O<&5R='D@86YD($5Q=6EP;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@/'`@<W1Y;&4],T0G
M34%21TE.+51/4#H@-G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!0<F]P97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W1S
M(&]F('1H92!F;VQL;W=I;F<Z/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU4
M3U`Z(#!P=#L@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G
M/@T*("8C>$$P.SPO<#X-"B`\=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!
M4%-%.B!C;VQL87!S93L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`@=VED=&@],T0W-B4@86QI9VX],T1C96YT97(^#0H@
M/'1R/@T*(#QT9"!W:61T:#TS1#8T)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@=VED=&@],T0Q,"4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$
M,3`E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`X<'0G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P
M,#`@,7!T('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI
M9VX],T1C96YT97(^/&(^4V5P=&5M8F5R)B-X03`[,S`L)B-X03`[,C`Q,SPO
M8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('-T>6QE/3-$
M)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX],T1B
M;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^1&5C96UB97(F
M(WA!,#LS,2PF(WA!,#LR,#$R/"]B/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!#;VUP=71E<B!E<75I<&UE;G0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG
M:'0^,BPQ-S(L-3,U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+#`P,RPW
M,#8\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%-O9G1W87)E/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PS,C,L,#@Q/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C$L,S(S+#`X,3PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&
M/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%
M3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)
M3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1G5R;FET=7)E/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^-3DY+#8U,#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XU.3DL-C4P/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O
M<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U3
M25I%.B`Q,'!T)SX-"B!,86(@97%U:7!M96YT/"]P/@T*(#PO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&%L:6=N/3-$<FEG:'0^,3`L-C`S+#4Y.#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XX+#<T-RPW.3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-
M"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L
M:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,65M
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($]F9FEC92!E<75I<&UE;G0\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XU,2PS-C`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-3$L,S8P/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO
M='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\
M<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q
M,'!T)SX-"B!,96%S96AO;&0@:6UP<F]V96UE;G1S/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^-"PX.3,L-S<P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C0L.#@Q+#<P-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL
M93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q
M,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*
M(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z
M(#$P<'0G/@T*(%!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:
M13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A
M;&EG;CTS1')I9VAT/C$Y+#8T,RPY.30\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP
M="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H
M=#XQ-RPV,#<L,CDS/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A
M<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T
M>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:
M13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=4
M15A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!,97-S
M(&%C8W5M=6QA=&5D(&1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,34L,3<T+#$Q,CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX]
M,T1R:6=H=#XH,30L,S,Y+#0Y-SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^*28C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C
M;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B!0<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XT+#0V.2PX.#(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,RPR-C<L-SDV/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:
M13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X
M(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P
M,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@
M,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V
M7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K
M<VAE971S+U-H965T,C`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+2#X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY3:&%R960M0F%S960@4&%Y;65N=',@*%1A8FQE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$
M:7-C;&]S=7)E($]F($-O;7!E;G-A=&EO;B!296QA=&5D($-O<W1S(%-H87)E
M8F%S960@4&%Y;65N=',@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@4W1O8VLM0F%S
M960@0V]M<&5N<V%T:6]N($5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P
M=#L@5$585"U)3D1%3E0Z(#0E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3!P="<^#0H@
M5&AE(&9O;&QO=VEN9R!S=&]C:RUB87-E9"!C;VUP96YS871I;VX@86UO=6YT
M<R!W97)E(')E8V]G;FEZ960@9F]R#0H@=&AE('!E<FEO9',@:6YD:6-A=&5D
M.CPO<#X-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"
M3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@
M/'1A8FQE('-T>6QE/3-$)T)/4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@
M8F]R9&5R/3-$,"!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I
M9'1H/3-$.3(E(&%L:6=N/3-$8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@]
M,T0V-"4^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M('=I9'1H/3-$,R4^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$,R4^
M/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$-B!A;&EG;CTS
M1&-E;G1E<CX\8CY4:')E92!-;VYT:',@16YD960\8G(@+SX-"B!397!T96UB
M97(F(WA!,#LS,#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('-T>6QE/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T
M('-O;&ED)R!V86QI9VX],T1B;W1T;VT@8V]L<W!A;CTS1#8@86QI9VX],T1C
M96YT97(^/&(^3FEN92!-;VYT:',@16YD960\8G(@+SX-"B!397!T96UB97(F
M(WA!,#LS,#PO8CX\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X
M03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$
M,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^
M)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N
M/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS
M<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C
M;VQS<&%N/3-$,B!A;&EG;CTS1&-E;G1E<CX\8CXR,#$R/"]B/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,3$Q+#@X.#PO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&%L:6=N/3-$<FEG:'0^,3$W+#DU,CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,C@T+#(X,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,S4S+#@U-CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)
M6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G
M5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@1V5N
M97)A;"!A;F0@861M:6YI<W1R871I=F4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
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M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^.3$L-C0W/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS
M1')I9VAT/C$P.2PR.#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W
M<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$
M<FEG:'0^,C<T+#DT,#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R
M87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S
M='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF
M(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@
M<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P
M.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED
M)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*
M(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@5&]T86P@<W1O8VLM8F%S960@8V]M<&5N
M<V%T:6]N(&5X<&5N<V4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!
M,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,S4L.3,V/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y
M;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C(P.2PU.3D\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)
M6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,SDS+#4V,3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N
M;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XV,C@L
M-SDV/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A
M<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P
M,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P
M,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52
M+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU4
M3U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@
M/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF
M(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X03`[/"]P/@T*
M(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@
M/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF
M(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP
M('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L92<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\
M+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@1F%I<B!686QU92!/<'1I
M;VX@07=A<F0@17-T:6UA=&5D(&]N('1H92!$871E(&]F($=R86YT(%5S:6YG
M('1H92!";&%C:RU38VAO;&5S($]P=&EO;BU0<FEC:6YG($UO9&5L/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`V<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)
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M/"]P/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z(#!P=#L@34%21TE.+4)/
M5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$R<'0G/@T*("8C>$$P.SPO<#X-"B`\
M=&%B;&4@<W1Y;&4],T0G0D]21$52+4-/3$Q!4%-%.B!C;VQL87!S93L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B
M;W)D97(],T0P(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`@=VED
M=&@],T0W-B4@86QI9VX],T1C96YT97(^/"$M+2!"96=I;B!486)L92!(96%D
M("TM/@T*(#QT<CX-"B`\=&0@=VED=&@],T0W-24^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$.24^/"]T9#X-"B`\=&0^/"]T
M9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'0@<V]L:60G('9A;&EG;CTS1&)O='1O;2!C;VQS<&%N/3-$,R!A
M;&EG;CTS1&-E;G1E<CX-"B`\8CY.:6YE)B-X03`[36]N=&AS)B-X03`[16YD
M960F(WA!,#M397!T96UB97(F(WA!,#LS,"P\+V(^/"]T9#X-"B`\+W1R/@T*
M(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&
M3TY4+5-)6D4Z(#AP="<^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-
M"B`\=&0@<W1Y;&4],T0G0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'0@<V]L
M:60G('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\8CXR,#$S/"]B
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!S='EL93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/CQB/C(P,3(\+V(^/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I
M;B!486)L92!";V1Y("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C
M0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$58
M5"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@17AP96-T
M960@9&EV:61E;F0@>6EE;&0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E
M;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z
M(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!%>'!E8W1E9"!V;VQA=&EL:71Y
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^
M-3,E)B-X03`[+28C>$$P.S4X)3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C
M96YT97(^-3$E/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L
M;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4]
M,T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@
M4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W`^#0H@/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL93TS1"=72$E412U3
M4$%#13H@;F]W<F%P)SXQ+C(T)28C>$$P.RTF(WA!,#LR+C`U)3PO9F]N=#X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C$N,3@E/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@17AP96-T960@879E<F%G92!L:69E(&]F(&]P=&EO;G,\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CXW)B-X
M03`[>65A<G,\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C<F(WA!
M,#MY96%R<SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($9A
M:7(@;6%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!A=#H\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1&-E;G1E<CX\9F]N="!S='EL
M93TS1"=72$E412U34$%#13H@;F]W<F%P)SXD,2XU,"8C>$$P.RTF(WA!,#LD
M-RXU,3PO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/B0Q
M+C4P/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V86QI
M9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[
M($9/3E0M4TE:13H@,3!P="<^#0H@17AP96-T960@9F]R9F5I='5R92!R871E
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1C96YT97(^
M-2XP-B4\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-
M"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$8V5N=&5R/C4N-3<E/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-
M"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%-T;V-K($]P=&EO;B!!8W1I
M=FET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQD:78^#0H@
M/'`@<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!415A4+4E.1$5.5#H@-"4[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU"3U143TTZ
M(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-"B!4:&4@9F]L;&]W:6YG('1A8FQE
M('-U;6UA<FEZ97,@<W1O8VL@;W!T:6]N(&%C=&EV:71Y('5N9&5R('1H92!0
M;&%N#0H@9'5R:6YG('1H92!P97)I;V0@=&AE;B!E;F1E9#H\+W`^#0H@/'`@
M<W1Y;&4],T0G34%21TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[
M($9/3E0M4TE:13H@,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL
M93TS1"="3U)$15(M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@
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M.'!T)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!S='EL
M93TS1"="3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N
M/3-$8F]T=&]M(&-O;'-P86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/DYU;6)E
M<B8C>$$P.V]F/"]B/CQB<B`O/@T*(#QB/D]P=&EO;G,\+V(^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!S='EL93TS1"="3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P="!S;VQI9"<@=F%L:6=N/3-$8F]T=&]M(&-O;'-P
M86X],T0R(&%L:6=N/3-$8V5N=&5R/CQB/E=E:6=H=&5D+3QB<B`O/@T*($%V
M97)A9V4F(WA!,#M%>&5R8VES93PO8CX\8G(@+SX-"B`\8CY0<FEC93PO8CX\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('-T>6QE
M/3-$)T)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!T('-O;&ED)R!V86QI9VX]
M,T1B;W1T;VT@8V]L<W!A;CTS1#(@86QI9VX],T1C96YT97(^/&(^5V5I9VAT
M960M/&)R("\^#0H@079E<F%G93PO8CX\8G(@+SX-"B`\8CY#;VYT<F%C='5A
M;"8C>$$P.U1E<FT\+V(^/&)R("\^#0H@/&(^*&EN(%EE87)S*3PO8CX\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\+W1R/@T*
M(#PA+2T@16YD(%1A8FQE($AE860@+2T^/"$M+2!"96=I;B!486)L92!";V1Y
M("TM/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@3W5T<W1A;F1I;F<L($1E8V5M
M8F5R)B-X03`[,S$L(#(P,3(\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$
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M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M,"XY-#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R
M87`^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XW+C,\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\
M=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M
M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&
M5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($=R86YT960\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XV.#<L,3@S/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,N,3D\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^-RXP/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO
M=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R
M('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M
M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS
M1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].
M5"U325I%.B`Q,'!T)SX-"B!%>&5R8VES960\+W`^#0H@/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@
M86QI9VX],T1R:6=H=#XH,2PP,C4L.3,S/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XP+C<U/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@1F]R9F5I=&5D(&]R(&5X<&ER
M960\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XH,S,L.30Y/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+C$S/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT
M<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/
M4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$)T)/4D1%
M4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@/"]T9#X-
M"B`\=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P
M.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="
M3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$
M15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[/"]P/@T*(#PO=&0^
M#0H@/'1D/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!
M,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y
M;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO
M<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4]
M,T0G0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-
M"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%
M.B`Q,'!T)SX-"B!/=71S=&%N9&EN9RP@4V5P=&5M8F5R)B-X03`[,S`L(#(P
M,3,\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T
M>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C(L.#<W+#`P,SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X
M03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C$N-3`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R
M:6=H=#XW+C(\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0
M.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M
M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\
M=&0^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S='EL93TS
M1"="3U)$15(M5$]0.B`C,#`P,#`P(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@,3!P="<^#0H@4V5P=&5M8F5R
M)B-X03`[,S`L(#(P,3,Z/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X
M03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T
M9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[
M)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D
M/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R
M/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$
M)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($5X
M97)C:7-A8FQE/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#@U-2PQ-S@\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S
M='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XP+CDT/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@
M,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!697-T960@
M86YD($5X<&5C=&5D('1O(%9E<W0\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/CDQ."PV,#`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$
M;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XR+C0T/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/"$M+2!%;F0@5&%B;&4@0F]D>2`M+3X\+W1A8FQE/@T*(`T*(`T*(#PO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V
M9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E
M.#8V-6(X-3!B82]7;W)K<VAE971S+U-H965T,C$N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4R
M1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY,96%S92!%>&ET($QI86)I;&ET
M>2`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y3
M97`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E)E<W1R=6-T=7)I;F<@06YD(%)E;&%T960@06-T:79I
M=&EE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#:&%N9V5S(&EN($QE87-E($5X:70@3&EA8FEL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S
M='EL93TS1"=-05)'24XM5$]0.B`P<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T
M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*($-H86YG97,@:6X@=&AE(&QE87-E(&5X
M:70@;&EA8FEL:71Y(&%R92!A<R!F;VQL;W=S.CPO<#X-"B`\<"!S='EL93TS
M1"=-05)'24XM5$]0.B`P<'0[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U3
M25I%.B`Q,G!T)SX-"B`F(WA!,#L\+W`^#0H@/'1A8FQE('-T>6QE/3-$)T)/
M4D1%4BU#3TQ,05!313H@8V]L;&%P<V4[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F]R9&5R/3-$,"!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P('=I9'1H/3-$-S8E(&%L:6=N/3-$
M8V5N=&5R/@T*(#QT<CX-"B`\=&0@=VED=&@],T0X-24^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M('=I9'1H/3-$-24^/"]T9#X-"B`\=&0^/"]T9#X-
M"B`\=&0^/"]T9#X-"B`\=&0^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@06-C<G5A;"!B86QA;F-E(&%T($1E8V5M8F5R)B-X03`[,S$L
M(#(P,3$\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B0\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PV,#<L-#DY/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!0<FEN8VEP86P@<&%Y;65N=',\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@U,S,L-38P/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@06-C<G5A;"!B86QA;F-E(&%T($1E8V5M8F5R(#,Q+"`R,#$R
M/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL
M93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ,"PP-S,L.3,Y/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!0<FEN8VEP86P@<&%Y;65N=',\+W`^#0H@
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/
M3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O
M='1O;2!A;&EG;CTS1')I9VAT/B@T-C8L,S`Q/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XI)B-X03`[/"]T9#X-"B`\+W1R
M/@T*(#QT<B!S='EL93TS1"=&3TY4+5-)6D4Z(#%P>"<^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE
M/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/@T*(#QP('-T>6QE/3-$
M)T)/4D1%4BU43U`Z(",P,#`P,#`@,7!X('-O;&ED)SXF(WA!,#L\+W`^#0H@
M/"]T9#X-"B`\=&0^)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@
M/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`Q96T[($9/3E0M4TE:13H@
M,3!P="<^#0H@06-C<G5A;"!B86QA;F-E(&%T(%-E<'1E;6)E<B8C>$$P.S,P
M+"`R,#$S/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^.2PV,#<L-C,X/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X
M)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S<'@@9&]U
M8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/@T*(#QP('-T>6QE/3-$)T)/4D1%4BU43U`Z(",P,#`P,#`@,W!X(&1O=6)L
M92<^)B-X03`[/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T
M<CX-"B`\+W1A8FQE/@T*(#PO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1G5T=7)E(%!R:6YC:7!A;"!087EM
M96YT<R!5;F1E<B!,96%S92!!9W)E96UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\9&EV/@T*(#QP('-T>6QE/3-$)TU!4D=)3BU43U`Z
M(#$R<'0[(%1%6%0M24Y$14Y4.B`T)3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4)/5%1/33H@,'!T.R!&3TY4+5-)6D4Z(#$P<'0G
M/@T*($9U='5R92!P<FEN8VEP86P@<&%Y;65N=',@=&\@8F4@;6%D92!U;F1E
M<B!T:&4@;&5A<V4@86=R965M96YT(&9O<@T*('1H92!N97AT(&9I=F4@>65A
M<G,@86YD('1H97)E869T97(@87,@;V8@4V5P=&5M8F5R)B-X03`[,S`L(#(P
M,3,-"B!A<F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%21TE.
M+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@,3)P
M="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M0T],
M3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E<CX-
M"B`\='(^#0H@/'1D('=I9'1H/3-$.#4E/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!W:61T:#TS1#4E/CPO=&0^#0H@/'1D/CPO=&0^#0H@/'1D/CPO
M=&0^#0H@/'1D/CPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(%1W96QV92!-;VYT:',@16YD:6YG(%-E<'1E;6)E<B8C>$$P.S,P+#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL
M93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-
M"B`R,#$T/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N
M="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT
M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XD/"]T9#X-"B`\=&0@=F%L
M:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,2PR,CDL-#4T/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#
M0T5%1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4
M+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@
M34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B`R,#$U/"]P
M/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS
M1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT@86QI9VX],T1R:6=H=#XQ+#4X.2PT,3`\+W1D/@T*(#QT9"!V
M86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO
M=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$
M=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4
M+5-)6D4Z(#$P<'0G/@T*(#(P,38\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N
M/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!
M,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C
M>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT
M/C$L.#`X+#$Q.3PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`]
M,T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL
M93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z
M(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT9"!V86QI9VX],T1T;W`^
M#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S96T[($9/3E0M4TE:
M13H@,3!P="<^#0H@,C`Q-SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C
M>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)B-X03`[
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^,BPP
M-#DL,C<S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS1&YO
M=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$
M)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P
M="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T)SX-"B`R,#$X/"]P/@T*
M(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&
M3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT@86QI9VX],T1R:6=H=#XR+#,Q-2PP,C8\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O;&]R/3-$(T-#145&1CX-
M"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4
M.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!-05)'24XM
M3$5&5#H@,65M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(%1H97)E869T97(\+W`^
M#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$
M)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!A;&EG;CTS1')I9VAT/C8Q-BPS-38\+W1D/@T*(#QT9"!V86QI
M9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C>$$P.R8C>$$P.SPO=&0^
M#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U325I%.B`Q<'@G/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\
M<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X
M03`[/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X-"B`\<"!S
M='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P(#%P>"!S;VQI9"<^)B-X03`[
M/"]P/@T*(#PO=&0^#0H@/'1D/B8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@
M<W1Y;&4],T0G1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U3
M25I%.B`Q,'!T)SX-"B`\=&0@=F%L:6=N/3-$=&]P/CPO=&0^#0H@/'1D('9A
M;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^
M)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;3XD/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N/3-$<FEG:'0^
M.2PV,#<L-C,X/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&YO=W)A<#TS
M1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE
M/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CPO
M=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/
M4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@
M(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9#XF
M(WA!,#L\+W1D/@T*(#PO='(^#0H@/"]T86)L93X-"B`\+V1I=CX\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R
M,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P
M8F$O5V]R:W-H965T<R]3:&5E=#(R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@86YD($-O;G1I;F=E;F-I
M97,@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!!;F0@0V]N=&EN9V5N8VEE<R!$
M:7-C;&]S=7)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F($UI;FEM=6T@1G5T=7)E
M($QE87-E(%!A>6UE;G1S(%!A>6%B;&5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/&1I=CX-"B`\<"!S='EL93TS1"=-05)'24XM5$]0.B`Q
M,G!T.R!415A4+4E.1$5.5#H@-"4[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86X[($U!4D=)3BU"3U143TTZ(#!P=#L@1D].5"U325I%.B`Q,'!T)SX-
M"B!&=71U<F4@;6EN:6UU;2!L96%S92!P87EM96YT<R!U;F1E<B!N;VYC86YC
M96QA8FQE(&]P97)A=&EN9R!L96%S97,-"B!A="!397!T96UB97(F(WA!,#LS
M,"P@,C`Q,R!A<F4@87,@9F]L;&]W<SH\+W`^#0H@/'`@<W1Y;&4],T0G34%2
M1TE.+51/4#H@,'!T.R!-05)'24XM0D]45$]-.B`P<'0[($9/3E0M4TE:13H@
M,3)P="<^#0H@)B-X03`[/"]P/@T*(#QT86)L92!S='EL93TS1"="3U)$15(M
M0T],3$%04T4Z(&-O;&QA<'-E.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)O<F1E<CTS1#`@8V5L;'-P86-I;F<]
M,T0P(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#8X)2!A;&EG;CTS1&-E;G1E
M<CX\(2TM($)E9VEN(%1A8FQE($AE860@+2T^#0H@/'1R/@T*(#QT9"!W:61T
M:#TS1#@S)3X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@=VED=&@],T0V
M)3X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*(#QT9#X\+W1D/@T*
M(#PO='(^#0H@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X\(2TM($)E9VEN(%1A
M8FQE($)O9'D@+2T^#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%
M1D8^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.
M1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%2
M1TE.+4Q%1E0Z(#%E;3L@1D].5"U325I%.B`Q,'!T)SX-"B!4=V5L=F4@36]N
M=&AS($5N9&EN9R!397!T96UB97(F(WA!,#LS,"P\+W`^#0H@/"]T9#X-"B`\
M=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT('-T>6QE/3-$)T9/3E0M4TE:13H@
M.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^/"]T9#X-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS
M1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P
M<'0G/@T*(#QT9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)
M3D1%3E0Z("TQ96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!
M4D=)3BU,1494.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@,C`Q-#PO<#X-
M"B`\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G
M1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O
M;2!A;&EG;CTS1')I9VAT/C,L-#8P+#8P.3PO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[)B-X03`[/"]T9#X-"B`\
M+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N.R!&3TY4+5-)6D4Z(#$P<'0G(&)G8V]L;W(],T0C0T-%149&/@T*(#QT
M9"!V86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ
M96T[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494
M.B`S96T[($9/3E0M4TE:13H@,3!P="<^#0H@,C`Q-3PO<#X-"B`\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%
M.B`X<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L
M:6=N/3-$<FEG:'0^,RPS.38L-S@P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T
M=&]M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^
M#0H@/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[
M($9/3E0M4TE:13H@,3!P="<^#0H@/'1D('9A;&EG;CTS1'1O<#X-"B`\<"!S
M='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#-E;3L@1D].5"U325I%.B`Q,'!T
M)SX-"B`R,#$V/"]P/@T*(#PO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3X\
M9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z(#AP="<^)B-X03`[)B-X03`[/"]F
M;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#L\+W1D/@T*
M(#QT9"!V86QI9VX],T1B;W1T;VT@86QI9VX],T1R:6=H=#XS+#,X-2PS,C$\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@1D].5"U325I%.B`Q,'!T)R!B9V-O
M;&]R/3-$(T-#145&1CX-"B`\=&0@=F%L:6=N/3-$=&]P/@T*(#QP('-T>6QE
M/3-$)U1%6%0M24Y$14Y4.B`M,65M.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N.R!-05)'24XM3$5&5#H@,V5M.R!&3TY4+5-)6D4Z(#$P<'0G/@T*
M(#(P,3<\+W`^#0H@/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/CQF;VYT
M('-T>6QE/3-$)T9/3E0M4TE:13H@.'!T)SXF(WA!,#LF(WA!,#L\+V9O;G0^
M/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M/B8C>$$P.SPO=&0^#0H@/'1D
M('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C,L-#@V+#@X,3PO=&0^
M#0H@/'1D('9A;&EG;CTS1&)O='1O;2!N;W=R87`],T1N;W=R87`^)B-X03`[
M)B-X03`[/"]T9#X-"B`\+W1R/@T*(#QT<B!S='EL93TS1"=&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N.R!&3TY4+5-)6D4Z(#$P<'0G/@T*(#QT9"!V
M86QI9VX],T1T;W`^#0H@/'`@<W1Y;&4],T0G5$585"U)3D1%3E0Z("TQ96T[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($U!4D=)3BU,1494.B`S
M96T[($9/3E0M4TE:13H@,3!P="<^#0H@,C`Q.#PO<#X-"B`\+W1D/@T*(#QT
M9"!V86QI9VX],T1B;W1T;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X
M<'0G/B8C>$$P.R8C>$$P.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B
M;W1T;VT^)B-X03`[/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M(&%L:6=N
M/3-$<FEG:'0^,RPP,S4L,#$S/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/
M3E0M4TE:13H@,3!P="<@8F=C;VQO<CTS1"-#0T5%1D8^#0H@/'1D('9A;&EG
M;CTS1'1O<#X-"B`\<"!S='EL93TS1"=415A4+4E.1$5.5#H@+3%E;3L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;CL@34%21TE.+4Q%1E0Z(#%E;3L@
M1D].5"U325I%.B`Q,'!T)SX-"B!4:&5R96%F=&5R/"]P/@T*(#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;3X\9F]N="!S='EL93TS1"=&3TY4+5-)6D4Z
M(#AP="<^)B-X03`[)B-X03`[/"]F;VYT/CPO=&0^#0H@/'1D('9A;&EG;CTS
M1&)O='1O;3XF(WA!,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@86QI
M9VX],T1R:6=H=#XV,C4L-30P/"]T9#X-"B`\=&0@=F%L:6=N/3-$8F]T=&]M
M(&YO=W)A<#TS1&YO=W)A<#XF(WA!,#LF(WA!,#L\+W1D/@T*(#PO='(^#0H@
M/'1R('-T>6QE/3-$)T9/3E0M4TE:13H@,7!X)SX-"B`\=&0@=F%L:6=N/3-$
M8F]T=&]M/CPO=&0^#0H@/'1D('9A;&EG;CTS1&)O='1O;3XF(WA!,#LF(WA!
M,#L\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G
M0D]21$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]2
M1$52+51/4#H@(S`P,#`P,"`Q<'@@<V]L:60G/B8C>$$P.SPO<#X-"B`\+W1D
M/@T*(#QT9#XF(WA!,#L\+W1D/@T*(#PO='(^#0H@/'1R('-T>6QE/3-$)T9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86X[($9/3E0M4TE:13H@,3!P="<^
M#0H@/'1D('9A;&EG;CTS1'1O<#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T
M;VT^/&9O;G0@<W1Y;&4],T0G1D].5"U325I%.B`X<'0G/B8C>$$P.R8C>$$P
M.SPO9F]N=#X\+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^)#PO=&0^#0H@
M/'1D('9A;&EG;CTS1&)O='1O;2!A;&EG;CTS1')I9VAT/C$W+#,Y,"PQ-#0\
M+W1D/@T*(#QT9"!V86QI9VX],T1B;W1T;VT@;F]W<F%P/3-$;F]W<F%P/B8C
M>$$P.R8C>$$P.SPO=&0^#0H@/"]T<CX-"B`\='(@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q<'@G/@T*(#QT9"!V86QI9VX],T1B;W1T;VT^/"]T9#X-"B`\=&0@
M=F%L:6=N/3-$8F]T=&]M/B8C>$$P.R8C>$$P.SPO=&0^#0H@/'1D('9A;&EG
M;CTS1&)O='1O;3X-"B`\<"!S='EL93TS1"="3U)$15(M5$]0.B`C,#`P,#`P
M(#-P>"!D;W5B;&4G/B8C>$$P.SPO<#X-"B`\+W1D/@T*(#QT9"!V86QI9VX]
M,T1B;W1T;VT^#0H@/'`@<W1Y;&4],T0G0D]21$52+51/4#H@(S`P,#`P,"`S
M<'@@9&]U8FQE)SXF(WA!,#L\+W`^#0H@/"]T9#X-"B`\=&0^)B-X03`[/"]T
M9#X-"B`\+W1R/@T*(#PA+2T@16YD(%1A8FQE($)O9'D@+2T^/"]T86)L93X-
M"B`-"B`-"B`\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B
M80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S
M7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3:&5E=#(S+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%44]!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY/<F=A
M;FEZ871I;VX@86YD($YA='5R92!O9B!/<&5R871I;VYS("T@061D:71I;VYA
M;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/DEN($UI;&QI;VYS
M+"!E>&-E<'0@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I
M960\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^4V5G;65N=#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y/8W0N(#,Q+"`R,#$S/&)R/E-U8G-E<75E;G0@179E;G0@6TUE
M;6)E<ET\8G(^25!/(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D]C="X@,38L(#(P,3,\8G(^4W5B<V5Q=65N="!%=F5N="!;
M365M8F5R73QB<CY)4$\@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W)G86YI>F%T:6]N($%N9"!.871U
M<F4@3V8@0G5S:6YE<W,@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA8W)O1V5N:6-S(&EN8V]R
M<&]R871E9"!D871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y!
M=6<@,30L#0H)"3(P,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F(&]P97)A=&EN9R!S96=M96YT
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);FET:6%L
M('!U8FQI8R!O9F9E<FEN9R!N=6UB97(@;V8@<VAA<F4@<V]L9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L-S4P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@
M<'5B;&EC(&]F9F5R:6YG('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M(&EN:71I
M86P@<'5B;&EC(&]F9F5R:6YG(&)E9F]R92!O9F9E<FEN9R!E>'!E;G-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#4N-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R
M,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P
M8F$O5V]R:W-H965T<R]3:&5E=#(T+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-D%!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#$^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C
M8V]U;G1I;F<@4&]L:6-I97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$
M971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C8V]U;G1I;F<@4&]L:6-I
M97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D%L;&]W86YC92!296-O<F1E9#PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;6]U;G1S(&-L87-S:69I960@
M87,@<F5S=')I8W1E9"!C87-H/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0P-"PX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#0P-"PX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E
M.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F
M-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3
M:&5E=#(U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%,U)!1SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T
M<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@+2!3=6UM87)Y(&]F($9A:7(@5F%L=64@365A<W5R96UE;G0@1FEN86YC
M:6%L($%S<V5T(&%N9"!,:6%B:6QI=&EE<R`H1&5T86EL*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@
M,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY!<W-E=',Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W+#4R,BPP,CD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X
M+#8Y-2PQ.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DUO;F5Y(&UA<FME="!F=6YD<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,C8L,#0W+#$V.3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y+#`T-RPY-3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<W1R:6-T
M960@8V%S:#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`T+#@U
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0P-"PX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C,S+#DW-"PP-#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT."PQ-#@L,#`U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I
M;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET>3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH-C<Y+#(Y-BD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,BPY-#<I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y1
M=6]T960@4')I8V5S(&EN($%C=&EV92!-87)K971S(&9O<B!)9&5N=&EC86P@
M07-S971S($QE=F5L(#$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!C87-H(&5Q
M=6EV86QE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4R
M,BPP,CD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ."PV.34L,3DW/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y-;VYE>2!M87)K970@9G5N9',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(V+#`T-RPQ-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP-#<L.34X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2
M97-T<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0P-"PX-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT,#0L.#4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS,RPY-S0L,#0X/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#@L,30X+#`P-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@=V%R<F%N="!L:6%B:6QI
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y3:6=N:69I8V%N="!/=&AE<B!/8G-E<G9A8FQE
M($EN<'5T<R!,979E;"`R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!<W-E=',Z/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E
M<75I=F%L96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUO;F5Y(&UA<FME="!F=6YD<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E<W1R:6-T960@8V%S:#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQI86)I;&ET:65S
M.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R969E<G)E9"!S=&]C:R!W87)R86YT(&QI86)I;&ET>3PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-I9VYI9FEC86YT(%5N;V)S97)V86)L92!);G!U=',@3&5V96P@,R!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^07-S971S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[
M)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y-;VYE>2!M87)K970@9G5N9',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-T
M<FEC=&5D(&-A<V@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@87-S971S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY,:6%B:6QI=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@<W1O8VL@
M=V%R<F%N="!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^)"`H-C<Y+#(Y-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B0@*#4R+#DT-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E
M.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F
M-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3
M:&5E=#(V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%345!0SX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T
M<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@+2!3=6UM87)Y(&]F(%!R969E<G)E9"!3=&]C:R!787)R86YT($QI86)I
M;&ET>2`H1&5T86EL*2`H5V%R<F%N="!;365M8F5R72P@55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=A<G)A;G0@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^1F%I<B!686QU92P@3&EA8FEL:71I97,@365A<W5R960@;VX@4F5C=7)R
M:6YG($)A<VES+"!5;F]B<V5R=F%B;&4@26YP=70@4F5C;VYC:6QI871I;VX@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y"86QA;F-E(&)E9VEN;FEN9R!O9B!Y96%R/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4R+#DT-RD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('5N<F5A
M;&EZ960@9V%I;G,@*&QO<W-E<RD@:6YC;'5D960@:6X@96%R;FEN9W,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#8R-BPS-#DI/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"86QA;F-E
M(&5N9"!O9B!Y96%R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#8W.2PR.38I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V
M7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE970R-RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P135:04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4W5M;6%R>2!O
M9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O;&EC:65S("T@4W5M;6%R>2!O
M9B!097)C96YT86=E(&]F(%-I9VYI9FEC86YT(%)E=F5N=64@*$1E=&%I;"D@
M*%-A;&5S(%M-96UB97)=*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E<G9I97(@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O
M9B!A;&P@<VEG;FEF:6-A;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<Q+C,P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+C(P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+C@P)3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+C8P)3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0F]E:')I;F=E<B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y097)C96YT86=E(&]F(&%L;"!S:6=N:69I8V%N="!R979E;G5E
M(&5A<FYE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$N-3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,34N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3<N,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y':6QE860@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A
M=&EO;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!A;&P@<VEG
M;FEF:6-A;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+CDP)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3,N-S`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!F:7IE<B!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y097)C96YT
M86=E(&]F(&%L;"!S:6=N:69I8V%N="!R979E;G5E(&5A<FYE9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XU,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C<P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N,S`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RXT,"4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D=O=F5R;FUE;G0@06=E;F-I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N8V5N=')A=&EO;B!2
M:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!A;&P@<VEG;FEF:6-A
M;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RXU,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+C8P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;&D@3&EL;'D@6TUE;6)E<ET\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M0V]N8V5N=')A=&EO;B!2:7-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O
M9B!A;&P@<VEG;FEF:6-A;G0@<F5V96YU92!E87)N960\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N.3`E/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3DN,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XV,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-2XW,"4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@
M/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X
M7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO
M;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B
M.#4P8F$O5V]R:W-H965T<R]3:&5E=#(X+FAT;6P-"D-O;G1E;G0M5')A;G-F
M97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@
M=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH
M96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N
M=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP
M93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!2
M96UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D
M>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3UI!13X-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS
M1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT
M($%C8V]U;G1I;F<@4&]L:6-I97,@+2!3=6UM87)Y(&]F(%-I9VYI9FEC86YT
M($%C8V]U;G1S(%)E8V5I=F%B;&4@*$1E=&%I;"D@*$%C8V]U;G1S(%)E8V5I
M=F%B;&4@6TUE;6)E<ETI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1VEL96%D(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT
M<F%T:6]N(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=',@
M4F5C96EV86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$N
M,C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&9I>F5R(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N
M(%)I<VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=',@4F5C96EV
M86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C(N-C`E/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#4N
M-#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y";V5H<FEN9V5R(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VYC96YT<F%T:6]N(%)I<VL@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4VEG;FEF:6-A;G0@06-C;W5N=',@4F5C96EV86)L93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$N,3`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;&D@
M3&EL;'D@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR."XR,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=O=F5R;FUE;G0@06=E
M;F-I97,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-O;F-E;G1R871I;VX@4FES:R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M:6=N:69I8V%N="!!8V-O=6YT<R!296-E:79A8FQE/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C@N-#`E/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R
M85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E
M=',O4VAE970R.2YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P159'044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG(%!O
M;&EC:65S("T@17-T:6UA=&5D(%5S969U;"!,:79E<R`H1&5T86EL*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUP=71E<B!%
M<75I<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^1&5P<F5C:6%T:6]N($%M;W)T:7IA=&EO;B!);7!A
M:7)M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17-T:6UA=&5D(%5S969U;"!,:79E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S,@>65A<G,\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-O9G1W87)E
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1E<')E8VEA=&EO;B!!;6]R=&EZ871I;VX@26UP86ER;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5S=&EM871E9"!5<V5F=6P@3&EV97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<S('EE87)S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&=7)N:71U<F4@6TUE;6)E
M<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5P<F5C:6%T:6]N($%M;W)T:7IA=&EO;B!);7!A:7)M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17-T:6UA=&5D(%5S969U;"!,:79E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)S$P('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,86)O<F%T;W)Y(&%N9"!/9F9I8V4@
M17%U:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D1E<')E8VEA=&EO;B!!;6]R=&EZ871I;VX@26UP
M86ER;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5S=&EM871E9"!5<V5F=6P@3&EV97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<U('EE87)S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S96AO
M;&0@26UP<F]V96UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<')E8VEA=&EO;B!!;6]R=&EZ871I
M;VX@26UP86ER;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE87-E:&]L9"!I;7!R;W9E;65N
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=3:&]R=&5R(&]F
M(&QE87-E('1E<FT@;W(@=7-E9G5L(&QI9F4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL
M/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A
M7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A
M-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T
M<R]3:&5E=#,P+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U
M;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R
M<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!
M(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT
M;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C
M<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM
M96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@
M8VQA<W,],T1R97!O<G0@:60],T1)1#!%1UI!13X-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^
M/'-T<F]N9SY3=6UM87)Y(&]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L
M:6-I97,@+2!38VAE9'5L92!O9B!$:6QU=&EV92!396-U<FET:65S($5X8VQU
M9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@1&EL=71E9"!.970@26YC;VUE(%!E
M<B!3:&%R92`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M8V-O=6YT:6YG(%!O;&EC:65S(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!I;F-O;64@*&QO
M<W,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8L-C`S+#DX
M,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,BPV,#`L-3$T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`R+#DT-"PQ-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+#0V-BPU.#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,Z('5N
M9&ES=')I8G5T960@96%R;FEN9W,@86QL;V-A=&5D('1O('!A<G1I8VEP871I
M;F<@<V5C=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-BPT,S0L-S4V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#(L-C`P+#4Q-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M/B@R+#DT-"PQ-#DI/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,3`L-#8V+#4X,BD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.
M970@:6YC;VUE("AL;W-S*2!A;&QO8V%B;&4@=&\@8V]M;6]N('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,38Y+#(R-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<F;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%S:6,@=V5I9VAT
M960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T86YD:6YG/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$X-"PU,#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`Y,BPS,#<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#0V
M,RPW.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#`W."PQ-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D)A<VEC(&EN8V]M92`H;&]S<RD@<&5R(&-O;6UO
M;B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P+C$T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y.970@:6YC;VUE("AL;W-S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPV,#,L.3@R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPV,#`L-3$T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY-#0L,30Y/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L
M-#8V+#4X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3&5S<SH@=6YD:7-T<FEB=71E9"!E87)N:6YG<R!A;&QO8V%T
M960@=&\@<&%R=&EC:7!A=&EN9R!S96-U<FET:65S(&%N9"!O=&AE<B!A9&0M
M8F%C:W,@=&\@;F5T(&EN8V]M92`H;&]S<RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6T^*#8L-#`S+#@T,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#8P,"PU,30I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,BPY-#0L,30Y*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$P
M+#0V-BPU.#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T(&EN8V]M92`H;&]S<RD@86QL;V-A8FQE('1O(&-O
M;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,C`P+#$S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<F;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)R9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%S:6,@=V5I9VAT960@879E<F%G92!C;VUM;VX@<VAA<F5S(&]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#$X-"PU
M,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+#`Y,BPS,#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ+#0V,RPW.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`W."PQ-#4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5F9F5C="!O9B!D:6QU
M=&EV92!S96-U<FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,"PP-3@L-#<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C`L-#$P+#$Q-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#0T-2PP-C$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PS,S0L-S`S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&EL=71E9"!W96EG:'1E9"!A=F5R86=E(&-O;6UO;B!S:&%R97,@;W5T<W1A
M;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#(T,BPY
M-S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR,2PU,#(L-#(T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C$L.3`X+#@U.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#0Q,BPX-#@\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I;'5T960@:6YC
M;VUE('!E<B!C;VUM;VX@<VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,"XP,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X
M-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T
M-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H
M965T,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$4S3T)'/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R
M;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE
M<R`M(%-C:&5D=6QE(&]F($%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU
M9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E("A$
M971A:6PI/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^.2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4V5R:65S($$M,2!#;VYV97)T:6)L92!0<F5F
M97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@
M17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA
M<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,34V+#$Q-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34V+#$Q-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,34V+#$Q
M-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,34V+#$Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4V5R:65S($$M,B!#;VYV97)T:6)L92!0<F5F97)R960@
M4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^06YT:61I;'5T:79E(%-E8W5R:71I97,@17AC;'5D
M960@9G)O;2!#;VUP=71A=&EO;B!O9B!%87)N:6YG<R!097(@4VAA<F4@6TQI
M;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O8VL\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,Y,BPR-S0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XS.3(L,C<T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,SDR+#(W-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y,BPR-S0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-E
M<FEE<R!"($-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!
M;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E9"!F<F]M($-O;7!U=&%T
M:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R969E
M<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS
M,S8L,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PS,S8L,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PS,S8L,#,W/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PS,S8L,#,W/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y397)I97,@0R!#
M;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^06YT:61I;'5T
M:79E(%-E8W5R:71I97,@17AC;'5D960@9G)O;2!#;VUP=71A=&EO;B!O9B!%
M87)N:6YG<R!097(@4VAA<F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O
M8VL\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L.3`Y+#DP-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L
M.3`Y+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L.3`Y+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L.3`Y+#DP-CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V5R:65S($0@0V]N=F5R=&EB
M;&4@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U
M<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@
M4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-CDL-#8X/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S8Y+#0V.#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<V.2PT
M-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-CDL-#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y397)I97,@1"TR($-O;G9E<G1I8FQE(%!R969E<G)E9"!3
M=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY!;G1I9&EL=71I=F4@4V5C=7)I=&EE<R!%>&-L=61E
M9"!F<F]M($-O;7!U=&%T:6]N(&]F($5A<FYI;F=S(%!E<B!3:&%R92!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R969E<G)E9"!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,RPS.3$L.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS.3$L.3DQ/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS.3$L.3DQ/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS.3$L
M.3DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U<FET:65S
M($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H
M87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L-S@T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@P+#<X-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X,"PW.#0\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.#`L
M-S@T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y3=&]C:R!/<'1I;VYS(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%N=&ED:6QU=&EV92!396-U
M<FET:65S($5X8VQU9&5D(&9R;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@
M4&5R(%-H87)E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E9F5R<F5D(%-T;V-K/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DQ,"PY-3(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#(W-BPU,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M+#DQ,"PY-3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XS+#(W-BPU,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
M+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X
M-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]A-S9F-#<Q.%\X
M,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$O5V]R:W-H965T<R]3:&5E=#,R
M+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN
M=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA
M<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U
M:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S
M970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,]
M,T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S
M8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R
M97!O<G0@:60],T1)1#!%54A!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY0
M<F]P97)T>2!A;F0@17%U:7!M96YT("T@4V-H961U;&4@;V8@4')O<&5R='D@
M86YD($5Q=6EP;65N="`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0
M<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN92!)=&5M<UT\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]P
M97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$Y+#8T,RPY.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#$W+#8P-RPR.3,\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE<W,@86-C=6UU;&%T
M960@9&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$U+#$W-"PQ,3(I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L,S,Y+#0Y-RD\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<F]P97)T>2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0L-#8Y+#@X,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C8W+#<Y-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@17%U
M:7!M96YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR+#$W,BPU,S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`P,RPW,#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-O9G1W
M87)E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP;65N="!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]P97)T>2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#,R,RPP.#$\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#,R,RPP.#$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D9U<FYI='5R
M92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-3DY+#8U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y.2PV-3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQA8B!%<75I<&UE;G0@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET
M96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P+#8P,RPU.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#<T-RPW.3`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9FEC92!%<75I
M<&UE;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E!R;W!E<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4Q+#,V,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Q+#,V,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&5A<V5H;VQD($EM
M<')O=F5M96YT<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE
M;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#@Y,RPW-S`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L.#@Q+#<P
M-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V
M9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E
M.#8V-6(X-3!B82]7;W)K<VAE971S+U-H965T,S,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(
M14%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y(%!L86YT($%N9"!%<75I
M<&UE;G0@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1&5P<F5C:6%T:6]N(&%N9"!A;6]R=&EZ871I
M;VX@97AP96YS93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S
M,38L.#4R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`R,S4L-30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`X,S0L-C$U/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,C(L-#DV/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
M"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T
M,39?86,R85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z
M+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O
M<FMS:&5E=',O4VAE970S-"YH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D
M:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M
M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U/1$D^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4W1O8VMH;VQD97)S)R!%<75I='D@*$1E9FEC:70I
M("T@061D:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^,C0@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-3XQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0S/CD@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^.2!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87D@,S$L(#(P,#8\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`P-#QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#`S/&)R/E-E
M<FEE<R!!(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-E<FEE<R!!
M(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-E<FEE<R!$(%!R969E
M<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$Q/&)R/E-E<FEE<R!$(%!R969E<G)E9"!3
M=&]C:R!;365M8F5R73QB<CY2879E;B!":6]T96-H;F]L;V=I97,@26YC(%M-
M96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@
M,S$L(#(P,#@\8G(^4V5R:65S($0@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=
M/&)R/E)A=F5N($)I;W1E8VAN;VQO9VEE<R!);F,@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^2F%N+B`S,2P@,C`Q,3QB<CY3
M97)I97,@1"!4=V\@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA>2`S,"P@,C`Q,#QB<CY397)I
M97,@1"!4=V\@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,#@\8G(^4V5R:65S
M($0@5'=O(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-E<FEE<R!$
M(%1W;R!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY397)I97,@02T@
M3VYE(%!R969E<G)E9"!3=&]C:R!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/E-E<FEE<R!!+2!4
M=V\@4')E9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D]C="X@,S$L(#(P,#0\8G(^4V5R:65S($(@4')E
M9F5R<F5D(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^4V5R:65S($(@4')E9F5R<F5D
M(%-T;V-K(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DUA>2`S,2P@,C`P-CQB<CY397)I97,@0R!0<F5F97)R960@4W1O8VL@
M6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P
M+B`S,"P@,C`Q,SQB<CY397)I97,@0R!0<F5F97)R960@4W1O8VL@6TUE;6)E
M<ET\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4W1O8VMH;VQD97)S($5Q=6ET>2!;3&EN92!)=&5M<UT\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3G5M8F5R(&]F('-H87)E<R!I<W-U960@;W(@<V]L9#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S0L,C,Y+#,W-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PT
M,C<L,S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-BPY,38L,3$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,S@L,S,W+#8W.#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<Q+#0P,2PR,S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$P+#DU
M,BPR,3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0<F]C965D<R!F<F]M(&ES<W5A;F-E(&]F(&-O;G9E<G1I8FQE
M('!R969E<G)E9"!S=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^)"`S-"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(L,#$V+#4P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T+#@T,RPR
M,3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#,P+#(V,2PV-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`T-"PX.3@L-S4T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@
M4')E9F5R<F5D(%-T;V-K(%!E<B!3:&%R93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E;&%T960@;V9F
M97)I;F<@8V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ-38L-S@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#$L,C0V/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&]F
M(&-O;6UO;B!S=&]C:R!A;&QO8V%T960@8G5T('5N:7-S=65D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`S+#,P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S+#8P-"PP,38\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!I<W-U960@=&\@86-Q=6ER92!E;G1I
M='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0T
M-BPR,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,BPT-C8L,#,Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5D('-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3$X+#<P
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L.#<U+#,R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X97)C:7-E('!R:6-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N-C4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]U
M='-T86YD:6YG('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5R8V5N=&%G92!O9B!P
M<F5F97)R960@<W1O8VL@:&]L9&5R<R!W:71H('9O=&EN9R!R:6=H=',@;V8@
M8F]A<F0@;65M8F5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C8N-C<E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@;F]N8W5M=6QA=&EV
M92!D:79I9&5N9',@;VX@<')E9F5R<F5D('-T;V-K/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP-3(R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#4R,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,"XP.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#`N,#,T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#,R-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@<')E
M9F5R<F5D('-T;V-K('-E<FEE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,2XU,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!P
M<FEC92!O9B!P<F5F97)R960@<W1O8VL\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,BXR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+C(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+C,Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q."XW
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#8N.34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`W+C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E)E<V5R=F5D(&-O;6UO;B!S=&]C:SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,3(Y+#<X,CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.970@<')O8V5E9',@9G)O;2!U;F1E<G=R:71T96X@<'5B;&EC
M(&]F9F5R:6YG('5P;VX@8VQO<VEN9R!O9B!F:7)M/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#0P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^16%R;FEN9R!P97(@<VAA<F4@<F5C96EV960@8GD@=&AE('-H87)E:&]L
M9&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3(N
M,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#$R+C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,3(N,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXY-3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<N-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V97)S92!S
M=&]C:R!S<&QI=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S$M
M9F]R+3$X+C<W,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT
M;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C
M,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z
M+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K<VAE
M971S+U-H965T,S4N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@
M<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H
M87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%
M5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O
M:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A
M<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O
M;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L
M92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5,6$%)/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$
M,CX\<W1R;VYG/E-H87)E9"U"87-E9"!087EM96YT<R`M($%D9&ET:6]N86P@
M26YF;W)M871I;VX@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0T/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$P
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,#@\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`P-CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#`S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/D1E9F5R<F5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!W:71H
M($EN9&EV:61U86PL(%-H87)E+6)A<V5D(%!A>6UE;G1S(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^06=G<F5G871E(&]F('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPP-3$L-C0T/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!A9V=R
M96=A=&4@;V8@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C0L,S,V+#<S,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C,L-SDP+#<V,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C4X+#$P-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-3$R+#,Y,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!3=&]C:SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-#4L.3<P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3,R+#8U-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<T-2PW,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XT-C`L-S0V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&%V86EL86)L
M92!F;W(@:7-S=6%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@L,3<Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%>'!E8W1E9"!L:69E(&]F(&]P=&EO;B!T97)M/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%G9W)E9V%T92!I;G1R:6YS:6,@=F%L=64@;V8@;W!T:6]N<R!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-RPT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!9V=R96=A=&4@:6YT<FEN<VEC('9A;'5E(&]F
M(&]P=&EO;G,@97AE<F-I<V%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$R+#(P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!);F-E;G1I=F4@4&QA
M;B`R,#`S(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D1E9F5R<F5D($-O;7!E;G-A=&EO;B!!<G)A
M;F=E;65N="!W:71H($EN9&EV:61U86PL(%-H87)E+6)A<V5D(%!A>6UE;G1S
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^17AP96-T960@;&EF92!O9B!O<'1I;VX@=&5R
M;3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S<@>65A<G,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D+6%V97)A9V4@9W)A;G0M9&%T92!F86ER('9A;'5E(&]F
M(&]P=&EO;G,@9W)A;G1E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y4;W1A;"!C87-H(')E8V5I=F5D(&9O<B!T:&4@;W!T
M:6]N<R!E>&5R8VES960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C@U,2PQ.#,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D9A:7(@=F%L=64@;V8@<VAA<F5S('9E<W1E9#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`R+#`X-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M56YR96-O9VYI>F5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(')E8V]G;FET:6]N
M('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S0@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5Q=6ET>2!);F-E;G1I=F4@4&QA;B`R,#`S(%M-96UB97)=
M('P@17%U:71Y($EN8V5N=&EV92!0;&%N(%1W;R!4:&]U<V%N9"!;365M8F5R
M73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$969E<G)E9"!#;VUP96YS871I;VX@07)R86YG96UE;G0@=VET:"!)
M;F1I=FED=6%L+"!3:&%R92UB87-E9"!087EM96YT<R!;3&EN92!)=&5M<UT\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5N<F5C;V=N:7IE9"!C;VUP96YS871I;VX@8V]S="!R96QA=&5D('1O
M(&YO;BUV97-T960@<W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&%R<F%N9V5M
M96YT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#4P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D5Q=6ET>2!);F-E;G1I=F4@4&QA;B`R,#`S(%M-96UB97)=
M('P@36%X:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$969E<G)E9"!#;VUP96YS871I;VX@
M07)R86YG96UE;G0@=VET:"!);F1I=FED=6%L+"!3:&%R92UB87-E9"!087EM
M96YT<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P=&EO;G,@9W)A;G1E9"P@;6%X:6UU
M;2!T97)M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,3`@>65A
M<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-T;V-K($]P=&EO;B!0;&%N(#(P,#`@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5F97)R960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT('=I=&@@26YD:79I
M9'5A;"P@4VAA<F4M8F%S960@4&%Y;65N=',@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!
M9V=R96=A=&4@;V8@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,S`L-S(U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92!I;B!A9V=R96=A=&4@;V8@
M<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3`L,CDW
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V7V%C
M,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE970S-BYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15I/044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^4VAA<F5D+4)A<V5D
M(%!A>6UE;G1S("T@4V-H961U;&4@;V8@4W1O8VLM0F%S960@0V]M<&5N<V%T
M:6]N($5X<&5N<V4@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3(\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I;VXL
M($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S=',@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y3=&]C:RUB87-E9"!C;VUP96YS871I;VX@97AP96YS93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,S4L.3,V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R,#DL-3DY
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`S.3,L-38Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`V,C@L-SDV/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@1&5V96QO<&UE;G0@
M17AP96YS92!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY%;7!L;WEE92!397)V:6-E(%-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;BP@06QL;V-A=&EO;B!O9B!296-O9VYI>F5D(%!E<FEO
M9"!#;W-T<R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO
M;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,3$L
M.#@X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,3$W+#DU,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(X-"PR.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS-3,L.#4V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES
M=')A=&EV92!%>'!E;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D5M<&QO>65E(%-E<G9I8V4@4VAA
M<F4M8F%S960@0V]M<&5N<V%T:6]N+"!!;&QO8V%T:6]N(&]F(%)E8V]G;FEZ
M960@4&5R:6]D($-O<W1S(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VLM8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,C0L,#0X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Y,2PV-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P.2PR.#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W-"PY-#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
M;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V$W-F8T-S$X7S@R
M,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B80T*0V]N=&5N="U,;V-A=&EO;CH@
M9FEL93HO+R]#.B]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P
M8F$O5V]R:W-H965T<R]3:&5E=#,W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M
M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X
M="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D
M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%15A!13X-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY3:&%R960M0F%S960@4&%Y;65N=',@+2!3
M8VAE9'5L92!O9B!&86ER(%9A;'5E($]P=&EO;B!!=V%R9"!%<W1I;6%T960@
M;VX@=&AE($1A=&4@;V8@1W)A;G0@57-I;F<@=&AE($)L86-K+5-C:&]L97,@
M3W!T:6]N+5!R:6-I;F<@36]D96P@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4VAA
M<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M96YT(&)Y(%-H87)E+6)A
M<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^17AP96-T960@9&EV:61E
M;F0@>6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU,2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E92!I;G1E<F5S="!R871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XQ."4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C
M=&5D(&%V97)A9V4@;&EF92!O9B!O<'1I;VYS/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<W('EE87)S/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&86ER(&UA<FME="!V
M86QU92!O9B!C;VUM;VX@<W1O8VL@870Z/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D(&9O<F9E:71U<F4@<F%T93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XP-B4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C4W)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^36EN
M:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R<F%N9V5M
M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M17AP96-T960@=F]L871I;&ET>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3,N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$N,C0E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!M87)K970@
M=F%L=64@;V8@8V]M;6]N('-T;V-K(&%T.CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^(#$N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-H87)E+6)A<V5D
M($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB87-E9"!087EM
M96YT($%W87)D(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+C`P)3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)I<VLM9G)E
M92!I;G1E<F5S="!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR+C`U)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9A:7(@;6%R:V5T('9A;'5E(&]F(&-O;6UO;B!S=&]C:R!A
M=#H\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`W+C4Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?
M.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X
M-3!B82]7;W)K<VAE971S+U-H965T,S@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5)3T%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-H87)E9"U"87-E9"!087EM96YT<R`M
M(%-C:&5D=6QE(&]F(%-T;V-K($]P=&EO;B!!8W1I=FET>2`H1&5T86EL*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$:7-C;&]S=7)E($]F($-O;7!E;G-A
M=&EO;B!296QA=&5D($-O<W1S(%-H87)E8F%S960@4&%Y;65N=',@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!/<'1I;VYS+"!/=71S=&%N9&EN9RP@0F5G:6YN:6YG
M($)A;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C0Y
M+#<P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS+"!'<F%N=&5D/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV.#<L,3@S/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO
M;G,L($5X97)C:7-E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PP,C4L.3,S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYU;6)E<B!O9B!/<'1I;VYS+"!&;W)F96ET960@;W(@
M97AP:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S,L.30Y
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYU;6)E<B!O9B!/<'1I;VYS+"!/=71S=&%N9&EN9RP@16YD:6YG($)A
M;&%N8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#<W+#`P
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L,C0Y+#<P,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3G5M8F5R(&]F($]P=&EO;G,L($5X97)C:7-A8FQE/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#@U-2PQ-S@\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.=6UB
M97(@;V8@3W!T:6]N<RP@5F5S=&5D(&%N9"!E>'!E8W1E9"!T;R!V97-T/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,3@L-C`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT
M960M($%V97)A9V4@17AE<F-I<V4@4')I8V4L($]U='-T86YD:6YG+"!"96=I
M;FYI;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5V5I9VAT960M($%V97)A9V4@17AE<F-I<V4@4')I8V4L($=R
M86YT960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RXQ.3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E=E:6=H=&5D+2!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!%>&5R8VES960\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XW-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H
M=&5D+2!!=F5R86=E($5X97)C:7-E(%!R:6-E+"!&;W)F96ET960@;W(@97AP
M:7)E9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+C$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5V5I9VAT960M($%V97)A9V4@17AE<F-I<V4@4')I8V4L($]U='-T86YD:6YG
M+"!%;F1I;F<@0F%L86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`Q+C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D+2!!=F5R86=E($5X97)C:7-E(%!R
M:6-E+"!%>&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^5V5I9VAT960M($%V97)A9V4@17AE<F-I<V4@4')I8V4L
M(%9E<W1E9"!A;F0@97AP96-T960@=&\@=F5S=#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`R+C0T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@079E<F%G92!#;VYT
M<F%C='5A;"!497)M+"!'<F%N=&5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG-R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E=E:6=H=&5D($%V97)A9V4@0V]N=')A8W1U
M86P@5&5R;2P@3W5T<W1A;F1I;F<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<W('EE87)S(#,@;6]N=&AS(#$R(&1A>7,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG-R!Y96%R<R`S(&UO
M;G1H<R`Q."!D87ES/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T
M-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE970S.2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15!8044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&5A<V4@
M17AI="!,:6%B:6QI='D@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A
M:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y*=6PN(#$V+"`R,#`X/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R:6YG($-O
M<W0@86YD(%)E<V5R=F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]P97)A=&EN9R!,96%S93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P,3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3VYE=&EM
M92!P=7)C:&%S92!P87EM96YT('5N9&5R('!U<F-H87-E(&%G<F5E;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M061D:71I;VYA;"!A;6]U;G1S(')E8V]R9&5D/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DUI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY297-T<G5C='5R
M:6YG($-O<W0@86YD(%)E<V5R=F4@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]N971I;64@<&%Y
M;65N="!P86ED('5N9&5R(&QI8V5N<V4@;V8@<')O9'5C=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^."PP,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DUA>&EM=6T@6TUE
M;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY297-T<G5C='5R:6YG($-O<W0@86YD(%)E<V5R=F4@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D]N971I;64@<&%Y;65N="!P86ED('5N9&5R(&QI8V5N<V4@;V8@<')O
M9'5C=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,BPP,#`L
M,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE(%!R969E<G)E9"!3=&]C:R!397)I97,@1"!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\
M<W1R;VYG/E)E<W1R=6-T=7)I;F<@0V]S="!A;F0@4F5S97)V92!;3&EN92!)
M=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4VAA<F5S(&ES<W5E9"!I;B!C;VYN96-T:6]N('=I=&@@86-Q=6ES
M:71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R+#0V-BPP
M,SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A
M7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H965T-#`N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$503$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQE87-E($5X:70@3&EA
M8FEL:71Y("T@0VAA;F=E<R!I;B!,96%S92!%>&ET($QI86)I;&ET>2`H1&5T
M86EL*2`H0V]N=')A8W0@5&5R;6EN871I;VX@6TUE;6)E<ETL(%531"`D*3QB
M<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G1R
M86-T(%1E<FUI;F%T:6]N(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5S=')U8W1U<FEN9R!#;W-T(&%N
M9"!297-E<G9E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=6%L(&)A;&%N8V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L,#<S+#DS.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3`L-C`W
M+#0Y.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@.2PV,#<L-C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<FEN8VEP86P@<&%Y;65N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H-#8V+#,P,2D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#4S,RPU-C`I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W
M,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V
M-6(X-3!B82]7;W)K<VAE971S+U-H965T-#$N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4V1D%%
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/DQE87-E($5X:70@3&EA8FEL:71Y
M("T@1G5T=7)E(%!R:6YC:7!A;"!087EM96YT<R!U;F1E<B!,96%S92!!9W)E
M96UE;G0@*$1E=&%I;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L;VYE(#$@3V8@
M1G5T=7)E($UI;FEM=6T@3&5A<V5S(%!A>6UE;G1S(%5N9&5R($QE87-E<R`H
M3&EN92!)=&5M<RD\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/C(P,30\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,RPT-C`L-C`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XR,#$U/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XS+#,Y-BPW.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,L,S@U+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,RPT.#8L.#@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XS+#`S-2PP,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1H97)E869T97(\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8R-2PU-#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPS.3`L,30T/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYT<F%C="!497)M
M:6YA=&EO;B!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#;&]N92`Q($]F($9U='5R92!-:6YI;75M($QE87-E
M<R!087EM96YT<R!5;F1E<B!,96%S97,@*$QI;F4@271E;7,I/"]S=')O;F<^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(R.2PT-30\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,34\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3@Y+#0Q,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PX,#@L,3$Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$W
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T.2PR-S,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P
M,3@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S$U+#`R-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M5&AE<F5A9G1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C$V
M+#,U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M.2PV,#<L-C,X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V
M7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE970T,BYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P13-!1TT^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]L;&%B;W)A
M=&EO;B!A;F0@3&EC96YS92!!9W)E96UE;G1S("T@061D:71I;VYA;"!);F9O
M<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C,@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#$^.2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R
M,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S
M,"P@,C`Q,SQB<CY,97,@3&%B;W)A=&]I<F5S(%-E<G9I97(@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY,97,@3&%B;W)A=&]I<F5S(%-E<G9I97(@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY,
M97,@3&%B;W)A=&]I<F5S(%-E<G9I97(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY,97,@3&%B
M;W)A=&]I<F5S(%-E<G9I97(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,CQB<CY,97,@3&%B;W)A=&]I
M<F5S(%-E<G9I97(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY,97,@3&%B;W)A=&]I<F5S(%-E
M<G9I97(@6TUE;6)E<ET\8G(^4V5C;VYD(%)I9VAT('1O($1E=F5L;W`@0V]L
M;&%B;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/DQE<R!,86)O<F%T;VER97,@4V5R
M=FEE<B!;365M8F5R73QB<CY396-O;F0@4FEG:'0@=&\@1&5V96QO<"!#;VQL
M86)O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^3&5S($QA8F]R871O:7)E<R!397)V
M:65R(%M-96UB97)=/&)R/E-E8V]N9"!2:6=H="!T;R!$979E;&]P($-O;&QA
M8F]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CY,97,@3&%B;W)A=&]I<F5S(%-E<G9I
M97(@6TUE;6)E<ET\8G(^4V5C;VYD(%)I9VAT('1O($1E=F5L;W`@0V]L;&%B
M;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/DQE<R!,86)O<F%T;VER97,@4V5R=FEE
M<B!;365M8F5R73QB<CY396-O;F0@4FEG:'0@=&\@1&5V96QO<"!#;VQL86)O
M<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3,\8G(^1VEL96%D(%M-96UB97)=/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^1VEL
M96%D(%M-96UB97)=/&)R/DUO;&5C=6QE/&)R/E!R;V=R86T\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY";V5H
M<FEN9V5R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/E-E<"X@,S`L(#(P,3(\8G(^0F]E:')I;F=E<B!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R
M/D)O96AR:6YG97(@6TUE;6)E<ET\8G(^36]L96-U;&4\8G(^4&%Y;65N=',\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY";V5H<FEN9V5R(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^0F]E:')I;F=E<B!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*86XN(#,Q
M+"`R,#$Q/&)R/D)O96AR:6YG97(@6TUE;6)E<ET\8G(^4V5R:65S($0M,B!#
M;VYV97)T:6)L92!0<F5F97)R960@4W1O8VL@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,#QB<CY09FEZ
M97(@6TUE;6)E<ET\8G(^36]L96-U;&4\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY09FEZ97(@6TUE;6)E<ET\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q
M,CQB<CY09FEZ97(@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY09FEZ97(@6TUE;6)E<ET\8G(^
M4')O9W)A;3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N
M(#,P+"`R,#$R/&)R/E!F:7IE<B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/E!F:7IE<B!;365M
M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P
M+"`R,#$S/&)R/D=R965N($-R;W-S($-O<G!O<F%T:6]N(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\
M8G(^1W)E96X@0W)O<W,@0V]R<&]R871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CY'<F5E
M;B!#<F]S<R!#;W)P;W)A=&EO;B!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/D=R965N($-R;W-S
M($-O<G!O<F%T:6]N(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^1W)E96X@0W)O<W,@0V]R<&]R
M871I;VX@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^3V-T+B`R."P@,C`Q,#QB<CY%;&D@3&EL;'D@6TUE;6)E<ET\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%Y(#,Q+"`R,#`X/&)R/D5L
M:2!,:6QL>2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y397`N(#,P+"`R,#$S/&)R/D5L:2!,:6QL>2!;365M8F5R73QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R
M/D5L:2!,:6QL>2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/D5L:2!,:6QL>2!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R
M/&)R/D5L:2!,:6QL>2!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/D5L:2!,:6QL>2!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY,:6-E;G-E($%N9"!#;VQL86)O<F%T:6]N($%G<F5E;65N=',@6TQI;F4@
M271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]L;&%B;W)A=&EO;B!A9W)E96UE;G0@9&%T93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B=.;W9E;6)E<B`R,#$Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=397!T
M96UB97(@,C`Q,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B=*86YU87)Y(#(P,3,\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B=/8W1O8F5R(#(P,3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M3V-T;V)E<B`R,#$P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B=*=6YE(#(P,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG3V-T;V)E<B`R
M,#`W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DYO;BUR969U;F1A8FQE('5P9G)O;G0@<&%Y;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C`L,#`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#(P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$U+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0Q+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^3&EC96YS92!G<F%N="!F965S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`L,#`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-2PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4P,"PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-L:6YI8V%L(&UI;&5S=&]N92!P87EM96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0W+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.3@L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E)E9W5L871O<GD@;6EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,"PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XS,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S4U+#`P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-34L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@Y+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.#DL,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V%L97,@;6EL97-T;VYE('!A>6UE;G1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,C`X+#`P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C,P+#`P,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^.#,L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y-2PP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('!E<FEO9"!O9B!D979E;&]P;65N
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R-R!M
M;VYT:',\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)S(Y(&UO;G1H<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<R,2!M;VYT:',\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E)E8V]G;FEZ960@<F5V96YU92!U;F1E<B!A9W)E96UE
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(P+#$Q,2PQ-S,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M-2PU,S(L-C@P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#(L,#$U+#DY-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C4P+#(X,RPU,3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3(L,S`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,S`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$X+#DP,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XV+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPR,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,BPR,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-2PY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPU,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPY,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.2PS,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,C`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XW-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ.3`L.#,S/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PU,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-C<S+#DR-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C,P+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O;F4@<&%Y;65N=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0Q+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R960@<F5V96YU93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#$P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,RPQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,2PV,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Q+#8P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@L
M,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3`L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#`P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C<U,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!R
M979E;G5E(&EN8VQU9&5D(&EN(&-U<G)E;G0@;&EA8FEL:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Q+#(Y."PS,3@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$L,CDX+#,Q
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR-"PQ,C,L,3<V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/CDL,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L-C`P+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#8P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M."PV,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-"PT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-"PT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XU+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4X+#`P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4X+#`P,"PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5F97)R
M960@<F5V96YU92!I;F-L=61E9"!I;B!L;VYG+71E<FT@;&EA8FEL:71I97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@L.#$R+#,T,CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#@Q
M,BPS-#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,3DL.34V+#,T,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,#`L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XY+#0P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#,P,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.2PP,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-3<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV-3`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0VQI;FEC86P@
M;6EL97-T;VYE('!A>6UE;G1S('5N9&5R(&%G<F5E;65N=#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3<L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-RPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"PU,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM97)C:6%L:7IA=&EO;B!O9B!M;VQE8W5L97,\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^36]L96-U;&5S(&AA=FEN9R!E>&-L=7-I=F4@=V]R
M;&1W:61E(')I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYU
M;6)E<B!O9B!P<F]G<F%M<R!#;VUP86YY(')E=&%I;G,@9&5V96QO<&UE;G0@
M86YD(&-O;6UE<F-I86QI>F%T:6]N(')I9VAT<R!O=71S:61E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^061D:71I;VYA;"!L:6-E;G-E(&=R86YT
M(&9E97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C(R+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XR,BPU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-E:79A8FQE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPR.#$L,C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,C@Q+#(X,CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T-BPR,3D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PQ,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C0V+#,W-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-#8L,S<U/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,U-2PU-C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P
M,2PW.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`Q+#<Y-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XX.38L,C@U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(T-"PU-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C0T+#4T,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU
M-3@L-3$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y.=6UB97(@;V8@86YN=6%L(&UA:6YT96YA;F-E('!A>6UE;G1S
M(')E8V5I=F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5C96EV
M960@:6YC;'5D:6YG('5P9G)O;G0L(&%N;G5A;"!M86EN=&5N86YC92!A;F0@
M;6EL97-T;VYE('!A>6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.2PP,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0<F5F97)R960@4W1O8VL@<'5R8VAA<V5D/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`Q,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y297-E87)C:"!O8FQI
M9V%T:6]N(&-O;7!L971I;VX@9&%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<R,#$U+3`Y/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)S(P
M,30M,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4&5R:6]D(&]F(&%G<F5E;65N=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG,R!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$05)4('!R;V=R86T\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y497)M(&]F('1H92!A9W)E
M96UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,C`R,"TP-CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5V
M:65W(&]F(&-L:6YI8V%L(&1A=&$\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG,2!Y
M96%R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V
M7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E=',O4VAE970T,RYH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14I(04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N
M=',@86YD($-O;G1I;F=E;F-I97,@+2!!9&1I=&EO;F%L($EN9F]R;6%T:6]N
M("A$971A:6PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-O;6UI=&UE
M;G1S($%N9"!#;VYT:6YG96YC:65S($1I<V-L;W-U<F4@6T%B<W1R86-T73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5N="!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#@P-BPR-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#<X,RPT-C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPT,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,96%S
M92!E>'!I<F%T:6]N(&1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^2F%N(#,P+`T*"0DR,#$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X
M-C8U8C@U,&)A#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T
M-S$X7S@R,#-?-#0Q-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H
M965T-#0N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T
M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@
M8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T
M('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@
M*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S
M<STS1')E<&]R="!I9#TS1$E$,$5.1D%#/@T*("`@("`@/'1R/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R
M;VYG/D-O;6UI=&UE;G1S(&%N9"!#;VYT:6YG96YC:65S("T@4V-H961U;&4@
M;V8@36EN:6UU;2!&=71U<F4@3&5A<V4@4&%Y;65N=',@4F5C96EV86)L92`H
M1&5T86EL*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]M;6ET;65N=',@06YD($-O
M;G1I;F=E;F-I97,@1&ES8VQO<W5R92!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L-#8P+#8P.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q-3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPS.38L-S@P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#XR,#$V/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#,X-2PS,C$\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/C(P,3<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L-#@V+#@X,3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q
M.#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPP,S4L,#$S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4
M:&5R96%F=&5R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,C4L
M-30P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3<L,SDP+#$T-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V$W-F8T-S$X7S@R,#-?-#0Q
M-E]A8S)A7S1E.#8V-6(X-3!B82]7;W)K<VAE971S+U-H965T-#4N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$52-$%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;V1U8W0@
M36EL97-T;VYE(%!A>6UE;G1S(&%N9"!2;WEA;'1Y($%G<F5E;65N=',@+2!!
M9&1I=&EO;F%L($EN9F]R;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/CD@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/DIU;BX@,S`L(#(P,#4\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,CQB<CX\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2;WEA;'1Y($%G<F5E;65N="!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y!9&1I=&EO;F%L(&-O;G-I9&5R871I;VX@;V8@87-S
M970@<'5R8VAA<V4@86=R965M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#$P+#DU,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VL@<VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-BPQ,S4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M87EM96YT<R!R96QA=&5D('1O('1H92!A9&1I=&EO;F%L(&-O;G-I9&5R871I
M;VYS/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-:6YI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY2;WEA;'1Y($%G<F5E;65N="!;3&EN
M92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y-87AI;75M(')O>6%L='D@<&%Y;65N=',@<&5R8V5N=&%G
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2XW-24\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-
M87AI;75M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY2;WEA;'1Y($%G<F5E;65N="!;3&EN92!)=&5M
M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y-87AI;75M(')O>6%L='D@<&%Y;65N=',@<&5R8V5N=&%G93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
M>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S
M7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I
M;&4Z+R\O0SHO83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A
M+U=O<FMS:&5E=',O4VAE970T-BYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N
M8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O
M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14I#044^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^16UP;&]Y964@0F5N969I="!0;&%N("T@061D
M:71I;VYA;"!);F9O<FUA=&EO;B`H1&5T86EL*2`H55-$("0I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXY($UO;G1H<R!%;F1E9#PO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y397`N(#,P+"`R,#`R/&)R/D%G93QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y397`N(#,P+"`R,#$S/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3(\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y397`N(#,P+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E9FEN960@0V]N=')I
M8G5T:6]N(%!E;G-I;VX@06YD($]T:&5R(%!O<W1R971I<F5M96YT(%!L86YS
M($1I<V-L;W-U<F4@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5L:6=I8FEL:71Y(&]F(&5M<&QO
M>65E('!A<G1I8VEP871I;VX@<&QA;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&5M<&QO>65E(&-O;G1R
M:6)U=&EO;B!T;R!S86QA<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y097)C96YT86=E(&]F(&5M<&QO>65E('9E<W1E
M9"!C;VYT<FEB=71I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#;VUP86YY)W,@8V]N=')I8G5T:6]N('1O('!L86X@
M=&]T86P\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U+#,Q
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#@L.#DQ/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`Q.30L-#DX/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q-SDL.38V/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A-S9F-#<Q.%\X,C`S7S0T,39?86,R
M85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO
M83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A+U=O<FMS:&5E
M=',O4VAE970T-RYH=&UL#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q
M=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA
M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P15%7044^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q
M/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@+2!!9&1I=&EO;F%L($EN9F]R
M;6%T:6]N("A$971A:6PI("A54T0@)"D\8G(^26X@36EL;&EO;G,L(&5X8V5P
M="!3:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P
M,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$V
M+"`R,#$S/&)R/E-U8G-E<75E;G0@179E;G0@6TUE;6)E<ET\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3V-T+B`S,2P@,C`Q,SQB<CY3=6)S
M97%U96YT($5V96YT(%M-96UB97)=/&)R/DE03R!;365M8F5R73QB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y/8W0N(#$V+"`R,#$S/&)R/E-U
M8G-E<75E;G0@179E;G0@6TUE;6)E<ET\8G(^25!/(%M-96UB97)=/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U8G-E
M<75E;G0@179E;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YI=&EA;"!P=6)L:6,@;V9F
M97)I;F<@;G5M8F5R(&]F('-H87)E('-O;&0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@<'5B;&EC(&]F
M9F5R:6YG('!R:6-E('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<VAA<F5S('-O;&0@=6YD
M97(@;W9E<BUA;&QO=&UE;G1S($]P=&EO;B!T;R!U;F1E<G=R:71E<CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S4P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E
M961S(&9R;VT@:6YI=&EA;"!P=6)L:6,@;V9F97)I;F<@;F5T(&]F(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#@S+C@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I<W-U960\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(L,3(T+#8R-#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#DX+#DQ-#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`R,"PR.#@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(L,3(T+#8R-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#DX+#DQ-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#`R
M,"PR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4')E9F5R<F5D('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y-:6QE<W1O
M;F4@4&%Y;65N=',@5')I9V=E<F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^4F5S96%R8V@@36%I;G1E;F%N8V4@4&%Y;65N="!2
M96-E:79A8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XG
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XG/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B
M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]A
M-S9F-#<Q.%\X,C`S7S0T,39?86,R85\T93@V-C5B.#4P8F$-"D-O;G1E;G0M
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M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`Q+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970P,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,#,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`T+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,#8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#`W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P."YH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#DN:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#$P+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970Q,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3(N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$S+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970Q-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,34N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$V
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q-RYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,3@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#$Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R
M,"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C$N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(R+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970R,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,C0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(U+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970R-BYH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,C<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#(X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R.2YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S`N:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#,Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970S,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S,N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,T+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970S-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,S8N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,W+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S."YH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,SDN:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#0P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,2YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#(N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#0S+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970T-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#4N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0V+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970T-RYH=&UL(B\^#0H\+WAM;#X-"BTM+2TM+3U?
M3F5X=%!A<G1?83<V9C0W,3A?.#(P,U\T-#$V7V%C,F%?-&4X-C8U8C@U,&)A
$+2T-"@``
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.0.8</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>226</ContextCount>
  <ElementCount>238</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>101 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>103 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassified</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>104 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfIncomeAlternative</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Income (Loss)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>106 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/StatementOfCashFlowsIndirect</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>107 - Disclosure - Overview and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</Role>
      <ShortName>Overview and Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>108 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>109 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlock</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>110 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>111 - Disclosure - Shared-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</Role>
      <ShortName>Shared-Based Payments</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>112 - Disclosure - Lease Exit Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlock</Role>
      <ShortName>Lease Exit Liability</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>113 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCollaborationAndLicenseAgreementsDisclosureTextBlock</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>114 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>115 - Disclosure - Product Milestone Payments and Royalty Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRoyaltyAgreementDisclosureTextBlock</Role>
      <ShortName>Product Milestone Payments and Royalty Agreements</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>116 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPensionAndOtherPostretirementBenefitsDisclosureTextBlock</Role>
      <ShortName>Employee Benefit Plan</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSubsequentEventsTextBlock</Role>
      <ShortName>Subsequent Events</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>118 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>119 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlockTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>120 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsPropertyPlantAndEquipmentDisclosureTextBlockTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>121 - Disclosure - Shared-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables</Role>
      <ShortName>Shared-Based Payments (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>122 - Disclosure - Lease Exit Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsRestructuringAndRelatedActivitiesDisclosureTextBlockTables</Role>
      <ShortName>Lease Exit Liability (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>123 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlockTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>124 - Disclosure - Organization and Nature of Operations - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureOrganizationAndNatureOfOperationsAdditionalInformation</Role>
      <ShortName>Organization and Nature of Operations - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>125 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformation</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>126 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilities</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>127 - Disclosure - Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPreferredStockWarrantLiability</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Preferred Stock Warrant Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>128 - Disclosure - Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfPercentageOfSignificantRevenue</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Percentage of Significant Revenue (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>129 - Disclosure - Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfSignificantAccountsReceivable</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Significant Accounts Receivable (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>130 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesEstimatedUsefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>131 - Disclosure - Summary of Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Income Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfDilutiveSecuritiesExcludedFromComputationOfDilutedNetIncomePerShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Income Per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>132 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShare</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>133 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentScheduleOfPropertyAndEquipment</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>134 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformation</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>135 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformation</Role>
      <ShortName>Stockholders' Equity (Deficit) - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>136 - Disclosure - Shared-Based Payments - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsAdditionalInformation</Role>
      <ShortName>Shared-Based Payments - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>137 - Disclosure - Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockBasedCompensationExpense</Role>
      <ShortName>Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>138 - Disclosure - Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfFairValueOptionAwardEstimatedOnTheDateOfGrantUsingTheBlackScholesOptionPricingModel</Role>
      <ShortName>Shared-Based Payments - Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>139 - Disclosure - Shared-Based Payments - Schedule of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSharedBasedPaymentsScheduleOfStockOptionActivity</Role>
      <ShortName>Shared-Based Payments - Schedule of Stock Option Activity (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>140 - Disclosure - Lease Exit Liability - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityAdditionalInformation</Role>
      <ShortName>Lease Exit Liability - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>141 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityChangesInLeaseExitLiability</Role>
      <ShortName>Lease Exit Liability - Changes in Lease Exit Liability (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>142 - Disclosure - Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureLeaseExitLiabilityFuturePrincipalPaymentsUnderLeaseAgreement</Role>
      <ShortName>Lease Exit Liability - Future Principal Payments under Lease Agreement (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>143 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformation</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>144 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>145 - Disclosure - Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfMinimumFutureLeasePaymentsReceivable</Role>
      <ShortName>Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>146 - Disclosure - Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureProductMilestonePaymentsAndRoyaltyAgreementsAdditionalInformation</Role>
      <ShortName>Product Milestone Payments and Royalty Agreements - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>147 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformation</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>148 - Disclosure - Subsequent Events - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.macrogenics.com/taxonomy/role/DisclosureSubsequentEventsAdditionalInformation</Role>
      <ShortName>Subsequent Events - Additional Information (Detail)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement had a mix of decimals attribute values: -6 -5.</Log>
    <Log type="Info">Element mgnx_NonRefundableFees had a mix of decimals attribute values: -6 -5.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenue had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueCurrent had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_DeferredRevenueNoncurrent had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_LicensesRevenue had a mix of decimals attribute values: -5 0 1.</Log>
    <Log type="Info">Element us-gaap_OperatingLeasesRentExpenseNet had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">Element us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized had a mix of decimals attribute values: -5 0.</Log>
    <Log type="Info">'Monetary' elements on report '136 - Disclosure - Shared-Based Payments - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '140 - Disclosure - Lease Exit Liability - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '143 - Disclosure - Collaboration and License Agreements - Additional Information (Detail)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 103 - Statement - Consolidated Balance Sheets</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Sep. 30, 2012'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2011'</Log>
    <Log type="Info">Process Flow-Through: 104 - Statement - Consolidated Balance Sheets (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 105 - Statement - Consolidated Statements of Operations and Comprehensive Income (Loss)</Log>
    <Log type="Info">Process Flow-Through: 106 - Statement - Consolidated Statements of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>mgnx-20130930.xml</File>
    <File>mgnx-20130930.xsd</File>
    <File>mgnx-20130930_cal.xml</File>
    <File>mgnx-20130930_def.xml</File>
    <File>mgnx-20130930_lab.xml</File>
    <File>mgnx-20130930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ER4AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Milestone Payments and Royalty Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jun. 30, 2005</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPaymentUponAchievementOfMilestone', window );">Additional consideration of asset purchase agreement</a></td>
        <td class="nump">$ 10,950,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement', window );">Common stock shares</a></td>
        <td class="nump">36,135<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement', window );">Payments related to the additional considerations</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
        <td class="nump">$ 0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement', window );">Maximum royalty payments percentage</a></td>
        <td class="nump">1.75%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementLineItems', window );"><strong>Royalty Agreement [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement', window );">Maximum royalty payments percentage</a></td>
        <td class="nump">4.00%<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPaymentUponAchievementOfMilestone">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional payment upon achievement of milestone.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalPaymentUponAchievementOfMilestone</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of additional consideration paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AmountOfAdditionalConsiderationPaidUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares which could be issued as additional consideration under asset purchase agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfSharesIssuedAsAdditionalConsiderationUnderAssetPurchaseAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyAgreementLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RoyaltyAgreementLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty payment as percentage of net sales under licensing agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RoyaltyPaymentAsPercentageOfNetSalesUnderLicensingAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EM4BG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump">425,000,000<span></span></td>
        <td class="nump">425,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">2,124,624<span></span></td>
        <td class="nump">1,098,914<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">2,124,624<span></span></td>
        <td class="nump">1,098,914<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockNumberOfSharesHeld', window );">Treasury stock, shares</a></td>
        <td class="nump">14,381<span></span></td>
        <td class="nump">14,381<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">26,874,792<span></span></td>
        <td class="nump">26,874,792<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">26,874,792<span></span></td>
        <td class="nump">26,874,792<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">26,874,792<span></span></td>
        <td class="nump">26,874,792<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="nump">$ 27,000,000<span></span></td>
        <td class="nump">$ 27,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">7,364,582<span></span></td>
        <td class="nump">7,364,582<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">7,364,582<span></span></td>
        <td class="nump">7,364,582<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">7,364,582<span></span></td>
        <td class="nump">7,364,582<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="nump">7,000,000<span></span></td>
        <td class="nump">7,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="nump">71,401,237<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="nump">71,401,237<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">71,401,237<span></span></td>
        <td class="nump">71,401,237<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="nump">31,000,000<span></span></td>
        <td class="nump">31,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="nump">110,952,217<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="nump">110,952,217<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">110,952,217<span></span></td>
        <td class="nump">110,952,217<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="nump">45,000,000<span></span></td>
        <td class="nump">45,000,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">30,000,000<span></span></td>
        <td class="nump">30,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="nump">14,446,227<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">14,446,227<span></span></td>
        <td class="nump">14,446,227<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="nump">9,400,000<span></span></td>
        <td class="nump">9,400,000<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.01<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
        <td class="nump">75,000,000<span></span></td>
        <td class="nump">75,000,000<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible preferred stock, shares issued</a></td>
        <td class="nump">63,681,176<span></span></td>
        <td class="nump">63,681,176<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
        <td class="nump">63,681,176<span></span></td>
        <td class="nump">63,681,176<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Aggregate liquidation preference</a></td>
        <td class="nump">$ 41,500,000<span></span></td>
        <td class="nump">$ 41,500,000<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockLiquidationPreferenceValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockParOrStatedValuePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockNumberOfSharesHeld">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares held for each class of treasury stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockNumberOfSharesHeld</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Product Milestone Payments and Royalty Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RoyaltyAgreementDisclosureTextBlock', window );">Product Milestone Payments and Royalty Agreements</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>9. Product Milestone Payments and Royalty Agreements</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In connection with an Asset Purchase Agreement with Tolerance
 Therapeutics, Inc. (Tolerance) entered into during June 2005, the
 Company may be required to issue Tolerance additional consideration
 as follows: (i)&#xA0;$10,950,000 if certain milestones are met,
 including the initiation of Phase 3 trials and filing of various
 regulatory product license applications; (ii)&#xA0;36,135 shares of
 common stock; and (iii)&#xA0;royalty payments between 1.75% and
 4.0% of net sales of products acquired from or patented by
 Tolerance or other product fees earned by the Company. Any
 additional consideration required to be paid under the Asset
 Purchase Agreement will be recorded as research and development
 expense when incurred. No payments related to the additional
 consideration have occurred during the three and nine-month periods
 ended September&#xA0;30, 2013 or 2012. Additionally, certain
 agreements require the Company to pay royalties. Currently, the
 Company is not obligated to pay royalties, as no other revenue from
 product sales is being generated by the Company.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RoyaltyAgreementDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Royalty agreement disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RoyaltyAgreementDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EB2AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
        <td class="nump">$ 2,944,149<span></span></td>
        <td class="nump">$ 10,466,582<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump">834,615<span></span></td>
        <td class="nump">722,496<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
        <td class="nump">393,561<span></span></td>
        <td class="nump">628,796<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrant liability</a></td>
        <td class="nump">626,349<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
        <td class="num">(235,063)<span></span></td>
        <td class="num">(2,713,429)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
        <td class="num">(965,815)<span></span></td>
        <td class="num">(69,231)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num">(1,940,897)<span></span></td>
        <td class="num">(5,444,288)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
        <td class="num">(297,214)<span></span></td>
        <td class="nump">53,860<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
        <td class="num">(466,301)<span></span></td>
        <td class="num">(395,694)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
        <td class="num">(13,968,859)<span></span></td>
        <td class="num">(27,935,268)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
        <td class="nump">87,035<span></span></td>
        <td class="nump">404,727<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
        <td class="num">(12,988,440)<span></span></td>
        <td class="num">(24,281,449)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num">(2,036,700)<span></span></td>
        <td class="num">(530,136)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
        <td class="num">(2,036,700)<span></span></td>
        <td class="num">(530,136)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
        <td class="nump">851,183<span></span></td>
        <td class="nump">44,309<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump">851,183<span></span></td>
        <td class="nump">44,309<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
        <td class="num">(14,173,957)<span></span></td>
        <td class="num">(24,767,276)<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump">47,743,155<span></span></td>
        <td class="nump">55,218,361<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump">$ 33,569,198<span></span></td>
        <td class="nump">$ 30,451,085<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase decrease in deferred rent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_IncreaseDecreaseInDeferredRent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Depreciation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 480<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_FairValueAdjustmentOfWarrants</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsPayable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccountsReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInAccruedLiabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInDeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInPrepaidExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_IncreaseDecreaseInRestructuringReserve</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceOfCommonStock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQVBG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheets (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump">$ 33,569,198<span></span></td>
        <td class="nump">$ 47,743,155<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
        <td class="nump">2,281,282<span></span></td>
        <td class="nump">2,046,219<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="nump">1,103,449<span></span></td>
        <td class="nump">137,634<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump">36,953,929<span></span></td>
        <td class="nump">49,927,008<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
        <td class="nump">404,850<span></span></td>
        <td class="nump">404,850<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump">4,469,882<span></span></td>
        <td class="nump">3,267,796<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
        <td class="nump">147,246<span></span></td>
        <td class="nump">147,246<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump">41,975,907<span></span></td>
        <td class="nump">53,746,900<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump">1,798,228<span></span></td>
        <td class="nump">3,739,125<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump">939,811<span></span></td>
        <td class="nump">1,237,025<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Lease exit liability - current</a></td>
        <td class="nump">1,229,454<span></span></td>
        <td class="nump">628,768<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue - current</a></td>
        <td class="nump">21,298,318<span></span></td>
        <td class="nump">24,123,176<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump">25,265,811<span></span></td>
        <td class="nump">29,728,094<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Lease exit liability</a></td>
        <td class="nump">8,378,184<span></span></td>
        <td class="nump">9,445,171<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent liability</a></td>
        <td class="nump">2,888,688<span></span></td>
        <td class="nump">2,801,653<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Preferred stock warrant liability</a></td>
        <td class="nump">679,296<span></span></td>
        <td class="nump">52,947<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
        <td class="nump">8,812,342<span></span></td>
        <td class="nump">19,956,343<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
        <td class="nump">46,024,321<span></span></td>
        <td class="nump">61,984,208<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value - 425,000,000 shares authorized, 2,124,624 and 1,098,914 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively</a></td>
        <td class="nump">21,246<span></span></td>
        <td class="nump">10,989<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost; 14,381 shares at September 30, 2013 and December 31, 2012</a></td>
        <td class="num">(57,742)<span></span></td>
        <td class="num">(57,742)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump">165,569,134<span></span></td>
        <td class="nump">164,334,646<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num">(172,528,254)<span></span></td>
        <td class="num">(175,472,403)<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
        <td class="num">(4,048,414)<span></span></td>
        <td class="num">(8,237,308)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td>
        <td class="nump">41,975,907<span></span></td>
        <td class="nump">53,746,900<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="nump">268,748<span></span></td>
        <td class="nump">268,748<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series A-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="nump">73,646<span></span></td>
        <td class="nump">73,646<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series B Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="nump">714,012<span></span></td>
        <td class="nump">714,012<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series C Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="nump">1,109,522<span></span></td>
        <td class="nump">1,109,522<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-1 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="nump">144,462<span></span></td>
        <td class="nump">144,462<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Series D-2 Convertible Preferred Stock [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock</a></td>
        <td class="nump">$ 636,812<span></span></td>
        <td class="nump">$ 636,812<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsPayableCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccruedLiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AdditionalPaidInCapital</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Assets</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AssetsCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CashAndCashEquivalentsAtCarryingValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7501430&amp;loc=d3e39927-112707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.26(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRentCreditNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_Liabilities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesAndStockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LiabilitiesCurrentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OtherAssetsNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Assets<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 340<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6386993&amp;loc=d3e5879-108316<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PrepaidExpenseCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentNet</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amounts of cash and cash equivalent items which are restricted as to withdrawal or usage. Restrictions may include legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or entity statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits. Excludes compensating balance arrangements that are not agreements which legally restrict the use of cash amounts shown on the balance sheet. This element is for unclassified presentations; for classified presentations there is a separate and distinct element.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestrictedCashAndCashEquivalents</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 4<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringReserveCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Paragraph Question 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringReserveNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RetainedEarningsAccumulatedDeficit</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquity</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockholdersEquityAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TreasuryStockValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 08<br><br><br><br> -Paragraph i<br><br><br><br> -Article 4<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WarrantsAndRightsOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EVGAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Detail)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Computer Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DepreciationAmortizationImpairmentLineItems', window );"><strong>Depreciation Amortization Impairment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Software [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DepreciationAmortizationImpairmentLineItems', window );"><strong>Depreciation Amortization Impairment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">3 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Furniture [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DepreciationAmortizationImpairmentLineItems', window );"><strong>Depreciation Amortization Impairment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">10 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Laboratory and Office Equipment [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DepreciationAmortizationImpairmentLineItems', window );"><strong>Depreciation Amortization Impairment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Lives</a></td>
        <td class="text">5 years<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Leasehold Improvements [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DepreciationAmortizationImpairmentLineItems', window );"><strong>Depreciation Amortization Impairment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
        <td class="text">Shorter of lease term or useful life<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DepreciationAmortizationImpairmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_DepreciationAmortizationImpairmentLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -URI http://asc.fasb.org/subtopic&amp;trid=2155824<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentUsefulLife</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Organization and Nature of Operations - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Segment</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013

</div>
          <div>Subsequent Event [Member]

</div>
          <div>IPO [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2013

</div>
          <div>Subsequent Event [Member]

</div>
          <div>IPO [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OrganizationAndNatureOfBusinessLineItems', window );"><strong>Organization And Nature Of Business [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">MacroGenics incorporated date</a></td>
        <td class="text">Aug. 14,
				 2000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment', window );">Initial public offering number of share sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalCommonStockIssuePricePerShare', window );">Initial public offering price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 16<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses', window );">Proceeds from initial public offering before offering expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 85.6<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when an entity was incorporated</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityIncorporationDateOfIncorporation</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalCommonStockIssuePricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional common stock issue price per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalCommonStockIssuePricePerShare</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OrganizationAndNatureOfBusinessLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OrganizationAndNatureOfBusinessLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from issuance initial public offering before offering expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ProceedsFromIssuanceInitialPublicOfferingBeforeOfferingExpenses</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock Issued During Period Shares New Issues Including Underwriters Over Allotment</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuedDuringPeriodSharesNewIssuesIncludingUnderwritersOverAllotment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NumberOfOperatingSegments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ENFAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Minimum Future Lease Payments Receivable (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2014</a></td>
        <td class="nump">$ 3,460,609<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2015</a></td>
        <td class="nump">3,396,780<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2016</a></td>
        <td class="nump">3,385,321<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2017</a></td>
        <td class="nump">3,486,881<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2018</a></td>
        <td class="nump">3,035,013<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
        <td class="nump">625,540<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
        <td class="nump">$ 17,390,144<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the next fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the forth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the third fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing in the second fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of required minimum rental payments maturing after the fifth fiscal year following the latest fiscal year for operating leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EPXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 16, 2008</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LeaseExpirationYear', window );">Operating Lease</a></td>
        <td class="text">2018<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement', window );">Onetime purchase payment under purchase agreement</a></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense', window );">Additional amounts recorded</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">0<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Minimum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts', window );">Onetime payment paid under license of product</a></td>
        <td class="nump">8,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts', window );">Onetime payment paid under license of product</a></td>
        <td class="nump">$ 12,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Convertible Preferred Stock Series D [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Shares issued in connection with acquisition</a></td>
        <td class="nump">12,466,039<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contingent consideration recorded as incremental in process research and development expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ContingentConsiderationRecordedAsIncrementalInProcessResearchAndDevelopmentExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LeaseExpirationYear">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Lease expiration year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_LeaseExpirationYear</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time milestone payment to be paid under agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OnetimeMilestonePaymentToBePaidUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>One-time milestone payment to be paid under agreement upon specified level of sales of products.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_OnetimeMilestonePaymentToBePaidUnderAgreementUponSpecifiedLevelOfSalesOfProducts</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringCostAndReserveLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of stock issued during the period pursuant to acquisitions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesAcquisitions</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0ELXAI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2010</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2008</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2006</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2003</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,051,644<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increase in aggregate of shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,336,731<span></span></td>
        <td class="nump">3,790,760<span></span></td>
        <td class="nump">3,258,106<span></span></td>
        <td class="nump">2,512,390<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">545,970<span></span></td>
        <td class="nump">532,654<span></span></td>
        <td class="nump">745,716<span></span></td>
        <td class="nump">460,746<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance</a></td>
        <td class="nump">8,171<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option term</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
        <td class="nump">$ 17,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value of options exercisable</a></td>
        <td class="nump">12,200,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equity Incentive Plan 2003 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option term</a></td>
        <td class="text">7 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
        <td class="nump">$ 2.00<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Total cash received for the options exercised</a></td>
        <td class="nump">851,183<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
        <td class="nump">402,084<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equity Incentive Plan 2003 [Member] | Equity Incentive Plan Two Thousand [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
        <td class="nump">$ 1,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Equity Incentive Plan 2003 [Member] | Maximum [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
        <td class="text">10 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Stock Option Plan 2000 [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Aggregate of shares</a></td>
        <td class="nump">130,725<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increase in aggregate of shares</a></td>
        <td class="nump">150,297<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromStockOptionsExercised</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (d)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EZOAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments - Schedule of Stock-Based Compensation Expense (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 135,936<span></span></td>
        <td class="nump">$ 209,599<span></span></td>
        <td class="nump">$ 393,561<span></span></td>
        <td class="nump">$ 628,796<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">Research and Development Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">111,888<span></span></td>
        <td class="nump">117,952<span></span></td>
        <td class="nump">284,281<span></span></td>
        <td class="nump">353,856<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl" style="border-bottom: 0px;" valign="top">
          <div class="a">General and Administrative Expense [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
        <td class="nump">$ 24,048<span></span></td>
        <td class="nump">$ 91,647<span></span></td>
        <td class="nump">$ 109,280<span></span></td>
        <td class="nump">$ 274,940<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AllocatedShareBasedCompensationExpense</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>8. Commitments and Contingencies</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Operating Leases</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company leases office and laboratory space over periods
 extending through January&#xA0;30, 2018. Several of the leases
 contain rent escalation clauses. Rent expense for the three months
 ended September&#xA0;30, 2013 and 2012 was $806,275 and $783,462,
 respectively. The Company incurred $2.4 million of rent expense for
 each of the nine-month periods ending September&#xA0;30, 2013 and
 2012.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Future minimum lease payments under noncancelable operating leases
 at September&#xA0;30, 2013 are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Twelve Months Ending September&#xA0;30,</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,460,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2015</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,396,780</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2016</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,385,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2017</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,486,881</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2018</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,035,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">625,540</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,390,144</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EGZAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Dilutive Securities Excluded from Computation of Diluted Net Income Per Share (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="nump">$ 6,603,982<span></span></td>
        <td class="nump">$ 2,600,514<span></span></td>
        <td class="nump">$ 2,944,149<span></span></td>
        <td class="nump">$ 10,466,582<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities', window );">Less: undistributed earnings allocated to participating securities</a></td>
        <td class="num">(6,434,756)<span></span></td>
        <td class="num">(2,600,514)<span></span></td>
        <td class="num">(2,944,149)<span></span></td>
        <td class="num">(10,466,582)<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) allocable to common shares</a></td>
        <td class="nump">169,226<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
        <td class="nump">1,184,507<span></span></td>
        <td class="nump">1,092,307<span></span></td>
        <td class="nump">1,463,798<span></span></td>
        <td class="nump">1,078,145<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic income (loss) per common share</a></td>
        <td class="nump">$ 0.14<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
        <td class="nump">6,603,982<span></span></td>
        <td class="nump">2,600,514<span></span></td>
        <td class="nump">2,944,149<span></span></td>
        <td class="nump">10,466,582<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings', window );">Less: undistributed earnings allocated to participating securities and other add-backs to net income (loss)</a></td>
        <td class="num">(6,403,843)<span></span></td>
        <td class="num">(2,600,514)<span></span></td>
        <td class="num">(2,944,149)<span></span></td>
        <td class="num">(10,466,582)<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) allocable to common shares</a></td>
        <td class="nump">$ 200,139<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average common shares outstanding</a></td>
        <td class="nump">1,184,507<span></span></td>
        <td class="nump">1,092,307<span></span></td>
        <td class="nump">1,463,798<span></span></td>
        <td class="nump">1,078,145<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities</a></td>
        <td class="nump">20,058,471<span></span></td>
        <td class="nump">20,410,117<span></span></td>
        <td class="nump">20,445,061<span></span></td>
        <td class="nump">20,334,703<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted weighted average common shares outstanding</a></td>
        <td class="nump">21,242,978<span></span></td>
        <td class="nump">21,502,424<span></span></td>
        <td class="nump">21,908,859<span></span></td>
        <td class="nump">21,412,848<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted income per common share</a></td>
        <td class="nump">$ 0.01<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
        <td class="nump">$ 0.00<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 18<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 21<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_EarningsPerShareDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358780&amp;loc=d3e565-108580<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLoss</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1377-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate of earnings distributed and earnings allocated to participating securities under the two-class method to the extent that participating securities may share in earnings as if all of the earnings for the period had been distributed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ParticipatingSecuritiesDistributedAndUndistributedEarnings</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Earnings allocated (not distributed) to participating securities under the two-class method to the extent that participating securities may share in earnings as if all of the earnings for the period had been distributed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_UndistributedEarningsAllocatedToParticipatingSecurities</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 16<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E3AGM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Les Laboratoires Servier [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Les Laboratoires Servier [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Les Laboratoires Servier [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Les Laboratoires Servier [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Les Laboratoires Servier [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Les Laboratoires Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Les Laboratoires Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Les Laboratoires Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Les Laboratoires Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Les Laboratoires Servier [Member]

</div>
          <div>Second Right to Develop Collaboration [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Gilead [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Gilead [Member]

</div>
          <div>Molecule

</div>
          <div>Program</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Boehringer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Boehringer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Boehringer [Member]

</div>
          <div>Molecule

</div>
          <div>Payments</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Boehringer [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Boehringer [Member]</div>
        </th>
        <th class="th">
          <div>Jan. 31, 2011

</div>
          <div>Boehringer [Member]

</div>
          <div>Series D-2 Convertible Preferred Stock [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2010

</div>
          <div>Pfizer [Member]

</div>
          <div>Molecule</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Pfizer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Pfizer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Pfizer [Member]

</div>
          <div>Program</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Pfizer [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Pfizer [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Green Cross Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Green Cross Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Green Cross Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Green Cross Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Green Cross Corporation [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 28, 2010

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>May 31, 2008

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012

</div>
          <div>Eli Lilly [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Eli Lilly [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseAndCollaborationAgreementsLineItems', window );"><strong>License And Collaboration Agreements [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementEnteredDate', window );">Collaboration agreement date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">November 2011<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">September 2012<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">January 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">June 2010<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">October 2007<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableFees', window );">Non-refundable upfront payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 20,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 15,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 1,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 41,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_LicenseGrantFeesReceivable', window );">License grant fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">30,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">65,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">7,500,000<span></span></td>
        <td class="nump">7,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ClinicalDevelopmentMilestonePaymentsReceived', window );">Clinical milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">47,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">98,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement', window );">Regulatory milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">140,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">300,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">355,000,000<span></span></td>
        <td class="nump">355,000,000<span></span></td>
        <td class="nump">89,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">89,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_SalesMilestonePayments', window );">Sales milestone payments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">208,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">630,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">83,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">195,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">27 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">29 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">21 months<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
        <td class="nump">20,111,173<span></span></td>
        <td class="nump">15,532,680<span></span></td>
        <td class="nump">42,015,994<span></span></td>
        <td class="nump">50,283,510<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">12,300,000<span></span></td>
        <td class="nump">2,300,000<span></span></td>
        <td class="nump">18,900,000<span></span></td>
        <td class="nump">6,800,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="nump">6,500,000<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,200,000<span></span></td>
        <td class="nump">5,900,000<span></span></td>
        <td class="nump">2,300,000<span></span></td>
        <td class="nump">2,500,000<span></span></td>
        <td class="nump">6,900,000<span></span></td>
        <td class="nump">9,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">1,200,000<span></span></td>
        <td class="nump">3,200,000<span></span></td>
        <td class="nump">4,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">25,000<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="nump">75,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">190,833.0<span></span></td>
        <td class="nump">9,500,000<span></span></td>
        <td class="nump">673,927.0<span></span></td>
        <td class="nump">30,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">41,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">50,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,000,000<span></span></td>
        <td class="nump">11,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">11,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">18,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">14,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">675,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">675,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
        <td class="nump">21,298,318<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">21,298,318<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">24,123,176<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,100,000<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,600,000<span></span></td>
        <td class="nump">4,400,000<span></span></td>
        <td class="nump">4,400,000<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,000,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">58,000,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,300,000<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">100,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
        <td class="nump">8,812,342<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">8,812,342<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">19,956,343<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">900,000<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,400,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,300,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">9,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">575,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">650,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement', window );">Clinical milestone payments under agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="nump">200,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">17,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations', window );">Commercialization of molecules</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">4<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">10<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements', window );">Molecules having exclusive worldwide rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights', window );">Number of programs Company retains development and commercialization rights outside</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement', window );">Additional license grant fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">22,500,000<span></span></td>
        <td class="nump">22,500,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables</a></td>
        <td class="nump">2,281,282<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,281,282<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2,046,219<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="nump">1,100,000<span></span></td>
        <td class="nump">246,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">246,375<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">355,568<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">501,794<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">501,794<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">896,285<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">244,542<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">244,542<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">558,516<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfAnnualMaintenancePaymentReceived', window );">Number of annual maintenance payments received</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">2<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PaymentReceivedOnCollaborationAgreement', window );">Received including upfront, annual maintenance and milestone payment</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">39,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Preferred Stock purchased</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 10,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ResearchObligationCompletionDate', window );">Research obligation completion date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2015-09<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2014-01<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborativeAgreementPeriodOfContract', window );">Period of agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">3 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfPrograms', window );">DART program</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAndParticipationRecognitionDate', window );">Term of the agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2020-06<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ClinicalDataReviewPeriodForAgreementTermination', window );">Review of clinical data</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">1 year<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining clinical milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalClinicalDevelopmentMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Additional payment under licensing and collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalPaymentUnderLicensingAndCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining regulatory milestone payments available to be earned under a collaboration arrangement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_AdditionalRegulatoryMilestonePaymentsUnderAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ClinicalDataReviewPeriodForAgreementTermination">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical data review period for agreement termination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ClinicalDataReviewPeriodForAgreementTermination</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ClinicalDevelopmentMilestonePaymentsReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Clinical development milestone payments received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ClinicalDevelopmentMilestonePaymentsReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementEnteredDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreement entered date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CollaborationAndLicenseAgreementEnteredDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>us-types:dateStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborativeAgreementPeriodOfContract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaborative agreement period of contract.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CollaborativeAgreementPeriodOfContract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseAndCollaborationAgreementsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_LicenseAndCollaborationAgreementsLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_LicenseGrantFeesReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining license grant fee payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_LicenseGrantFeesReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Initial fee received from collaboration or license agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NonRefundableFees</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfAnnualMaintenancePaymentReceived">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of annual maintenance payment received.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfAnnualMaintenancePaymentReceived</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of programs for which collaborator has worldwide rights.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfLicensedProgramsTypeUnderCollaborationAgreements</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of molecules to be developed and commercialized as per collaborations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfPrograms">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of programs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfPrograms</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of programs for which company retains development and commercialization rights in certain countries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_NumberOfProgramsUnderForeignDevelopmentAndCommercializationRights</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PaymentReceivedOnCollaborationAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total cumulative payments received to date under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_PaymentReceivedOnCollaborationAgreement</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ResearchObligationCompletionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research obligation completion date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ResearchObligationCompletionDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_SalesMilestonePayments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate potential remaining sales milestone payments available to be earned under collaboration agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_SalesMilestonePayments</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAndParticipationRecognitionDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront fee and participation recognition date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_UpfrontFeeAndParticipationRecognitionDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearMonthItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Upfront payment recognition period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_UpfrontPaymentRecognitionPeriod</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.3-4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 3<br><br> -Subparagraph a(1)<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 4<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountsReceivableNetCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueCurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 8<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DeferredRevenueNoncurrent</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_LicensesRevenue</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of consideration recognized during the period for the milestone or milestones.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 28<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=19771982&amp;loc=SL6892177-166501<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodValueNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
        <td class="text"><div>
 <div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>11. Subsequent Events</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On October&#xA0;16, 2013, the Company completed its IPO, in which
 5,000,000 shares of the Company&#x2019;s common stock were sold at a
 price of $16 per share. Additionally, the underwriters of the
 Company&#x2019;s IPO exercised the full amount of their
 over-allotment option resulting in the sale of an additional
 750,000 shares of the Company&#x2019;s common stock at a price of
 $16 per share. The Company received net proceeds of $83.8 million
 from the IPO, net of underwriting discounts and commissions and
 other estimated offering expenses. Upon consummation of the IPO,
 all outstanding shares of preferred stock automatically converted
 to common stock at the applicable conversion ratios then in effect.
 Subsequent to the IPO, the Company had 25,020,288 issued and
 outstanding shares of common stock and no outstanding shares of
 preferred stock.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In November 2013, Boehringer nominated a bi-specific antibody
 therapeutic candidate generated by the Company&#x2019;s DART
 technology for pre-clinical development. This formal selection of a
 development candidate triggered a $5.0 million milestone payment to
 the Company under the October 2010 agreement described in Note 7,
 Collaboration and License Agreements. In addition, Boehringer will
 pay a research maintenance payment of $4.0 million to the Company
 in the fourth quarter of 2013.</p>
 </div>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TextBlockAbstract', window );"><strong>Text Block [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>7. Collaboration and License Agreements</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Les Laboratoires Servier</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In November 2011, the Company entered into a right-to-develop
 collaboration agreement with Servier for the development and
 commercialization of MGA271 in all countries other than the United
 States, Canada, Mexico, Japan, South Korea and India.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20 million to the Company. The Company is eligible to
 receive up to $30 million in license grant fees, $47 million in
 clinical milestone payments, $140 million in regulatory milestone
 payments and $208 million in sales milestone payments if Servier
 exercises the option, obtains regulatory approval for and
 successfully commercializes MGA271. The Company concluded that the
 license grant fees are not deliverables at the inception of the
 arrangement. The Company has determined that each potential future
 clinical, development and regulatory milestone is substantive.
 Although sales milestones are not considered substantive, they are
 still recognized upon achievement of the milestone (assuming all
 other revenue recognition criteria have been met) because there are
 no undelivered elements that would preclude revenue recognition at
 that time. In the event Servier exercises its option to continue
 development of MGA271, Servier must pay a license grant fee. Under
 this agreement, Servier would be obligated to pay the Company from
 low double digit to mid-teen royalties on product sales in its
 territories.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that the option is substantive and that the license fees
 for this option is not a deliverable at the inception of the
 arrangement as there is considerable uncertainty that the option
 would be exercised and the additional fee to be paid upon exercise
 of the option represents its estimated selling price (i.e. no
 substantial discount was given). The Company&#x2019;s substantive
 performance obligations under this research collaboration include
 an exclusivity clause to its technology, technical, scientific and
 intellectual property support to the research plan during the first
 year of the agreement and participation on an executive committee
 and a research and development committee. The Company determined
 that these performance obligations represent a single unit of
 accounting, since the license does not have stand-alone value to
 Servier without the Company&#x2019;s technical expertise and
 committee participation. As such, the initial upfront payment was
 deferred and is being recognized ratably over the initial 27-month
 period, which represents the expected period of development and the
 Company&#x2019;s participation on the research and development
 committee. The Company further concluded that each potential future
 clinical, development and regulatory milestone is substantive.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During the three months ended September&#xA0;30, 2013 and 2012 the
 Company recognized revenue of $12.3 million (including a $10.0
 million milestone payment) and $2.3 million, respectively. During
 the nine months ended September&#xA0;30, 2013 and 2012 the Company
 recognized revenue of $18.9 million (including a $10.0 million
 milestone payment) and $6.8 million, respectively, under this
 agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At September&#xA0;30, 2013, $3.1 million of revenue was deferred
 under this agreement, all of which was included in current
 liabilities. At December&#xA0;31, 2012, $10.0 million of revenue
 was deferred under this agreement, $9.1 million of which was
 included in current liabilities and $0.9 million was included in
 long-term liabilities.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In September 2012, the Company entered into a second
 right-to-develop collaboration agreement with Servier and granted
 it options to obtain three separate exclusive licenses to develop
 and commercialize DART-based molecules, consisting of those
 designated by the Company as MGD006 and MGD007, as well as a third
 DART molecule, in all countries other than the United States,
 Canada, Mexico, Japan, South Korea and India.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon execution of the agreement, Servier made a nonrefundable
 payment of $20 million to the Company. In addition, the Company
 will be eligible to receive up to $65 million in license grant
 fees, $98 million in clinical milestone payments, including $5
 million upon IND acceptance for each of MGD006, MGD007 and a third
 DART molecule, $300 million in regulatory milestone payments and
 $630 million in sales milestone payments if Servier exercises all
 of the options and successfully develops, obtains regulatory
 approval for, and commercializes a product under each license. In
 addition to these milestones, the Company and Servier will share
 Phase 2 and Phase 3 development costs. The Company has determined
 that each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Under this agreement,
 Servier would be obligated to pay the Company between high-single
 digit and mid-teen royalties on net product sales in its
 territories.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated the research collaboration agreement with
 Servier and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The Company
 concluded that each option is substantive and that the license fees
 for each option are not deliverables at the inception of the
 arrangement and were not issued with a substantial discount. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusivity clause to its
 technology, technical, scientific and intellectual property support
 to the research plan during the first year of the agreement and
 participation on an executive committee and a research and
 development committee. The Company determined that the performance
 obligations with respect to the pre-clinical development represent
 a single unit of accounting, since the license does not have
 stand-alone value to Servier without the Company&#x2019;s technical
 expertise and committee participation. As such, the initial up
 front license payment was deferred and is being recognized ratably
 over the initial 29-month period, which represents the expected
 development period. The Company further concluded that each
 potential future clinical, development and regulatory milestone is
 substantive.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During the three and nine months ended September&#xA0;30, 2013 the
 Company recognized revenue of $2.2 million and $6.5 million,
 respectively. No revenue was recognized under this agreement during
 the comparable periods in 2012. No milestones have been recognized
 under this agreement during the three and nine months ended
 September&#xA0;30, 2013.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At September&#xA0;30, 2013, $11.6 million of revenue was deferred
 under this agreement, $8.6 million of which was included in current
 liabilities and $3.0 million of which was included in long-term
 liabilities. At December&#xA0;31, 2012, $18.0 million of revenue
 was deferred under this agreement, $8.6 million of which was
 included in current liabilities and $9.4 million of which was
 included in long-term liabilities.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Gilead Sciences, Inc.</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In January 2013, the Company entered into an agreement with Gilead
 to grant it an exclusive worldwide license to research, develop and
 commercialize up to four DART-based molecules. Gilead has exclusive
 worldwide rights for three of the programs. For one program, the
 Company retains development and commercialization rights outside of
 North America, the European Union, Norway, Iceland, Turkey,
 Australia and New Zealand.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company received an initial $7.5 million license grant fee for
 the first DART-based molecule. The Company may be eligible to
 receive additional license grant fees of $22.5 million, $200
 million related to pre-clinical and clinical milestones, $355
 million related to regulatory milestones and $500 million related
 to sales milestones if Gilead exercises all four of the options and
 successfully develops, obtains regulatory approval for, and
 commercializes a product under each option and license. The Company
 has determined that the other licenses are conditional
 deliverables, which are substantive options that were not granted
 with a substantial discount. The Company has determined that each
 potential future clinical, development and regulatory milestone is
 substantive. Although sales milestones are not considered
 substantive, they are still recognized upon achievement of the
 milestone (assuming all other revenue recognition criteria have
 been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Gilead also provides
 funding for the Company&#x2019;s internal and external research
 costs under the agreement. Additionally, Gilead would be obligated
 to pay the Company high single digit to low double digit, but less
 than teen royalties on product sales in its territories.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated the research collaboration agreement with
 Gilead and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include a license to its technology and
 research and development services. The Company concluded that the
 deliverables do not have stand alone value and therefore, represent
 a combined single unit of accounting. Due to the lack of standalone
 value for the license and research and development services, the
 combined unit of accounting (the upfront payment and the expected
 research and development reimbursements) is being recognized
 ratably over a period of 21 months, which represents the expected
 development period.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company and Gilead have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. Had
 management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Receivables of $1.1 million as of September&#xA0;30, 2013 relate to
 amounts due to the Company from Gilead for reimbursement work
 performed under the collaboration.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognized revenues of approximately $2.2 million and
 $5.9 million under this agreement for the three and nine months
 ended September&#xA0;30, 2013, respectively. No milestones have
 been reached under this agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At September&#xA0;30, 2013, $4.4 million of revenue was deferred
 under this agreement, all of which was included in current
 liabilities.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Boehringer Ingelheim International GmbH</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2010 the Company entered into a collaboration and
 license agreement with Boehringer to discover, develop and
 commercialize up to ten DART-based molecules which span multiple
 therapeutic areas. Under the terms of the agreement, the Company
 granted Boehringer an exclusive, worldwide, royalty-bearing,
 license under its intellectual property to research, develop, and
 market DARTs generated under the agreement, or the Boehringer
 licensed products, throughout the world.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon execution of the agreement, the Company received an upfront
 payment of $15 million. The Company subsequently received two
 annual maintenance payments and anticipates receiving a third
 annual maintenance payment in the fourth quarter of 2013. The first
 two maintenance payments were solely attributed to the passage
 time. Because Boehringer has the option to cancel the program after
 the second anniversary of the agreement, the third maintenance
 payment will be recognized over the remaining obligation period
 once received. The Company has the potential to earn milestone
 payments of approximately $41 million related to pre-clinical and
 clinical development, $89 million related to regulatory milestones
 and $83 million related to sales milestones for each of the DART
 programs under this agreement in the case of full commercial
 success of multiple DART products. The Company has determined that
 each potential future clinical, development and regulatory
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Boehringer also provides
 funding for the Company&#x2019;s internal and external research
 costs and is required to pay the Company mid-single digit royalties
 on product sales. From the commencement of the collaboration
 through September&#xA0;30, 2013, the Company has received $39.0
 million under this agreement, including upfront, annual maintenance
 and milestone payments as well as research funding. In addition,
 Boehringer purchased $10 million of the Company&#x2019;s Series D-2
 Preferred Stock in January 2011.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company determined that the deliverables under the Boehringer
 agreement include the license, the research and development
 services to be performed by the Company, and the
 co-promotion/manufacturing services. The Company concluded that the
 co-promotional activities were optional and were subject to further
 negotiation upon reaching regulatory approval. As such, the
 co-promotional period is not included in the expected obligation
 period to perform services.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company concluded that the undelivered element of research and
 development services had fair value. The Company concluded that the
 license does not have value on a standalone basis (e.g. absent the
 provision of the research and development services) and therefore
 does not represent a separate unit of accounting. The Company
 concluded that because the drug candidate has not yet been
 developed, the license is of no value to Boehringer without the
 ensuing research and development activities using the DART
 technology, which is proprietary to the Company. Likewise,
 Boehringer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of account and recognized
 over the expected obligation period associated with the research
 and development services through September 2015, which represents
 the estimated period of development.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company and Boehringer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable. However,
 had management considered participation on the joint committee as a
 deliverable, it would not have had a material impact on the
 accounting for the arrangement as the period of participation in
 this committee matched the organization period for the research and
 development services.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&#xA0;1, 2011.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Receivables of $246,375 and $355,568&#xA0;as of September&#xA0;30,
 2013 and December&#xA0;31, 2012, respectively, relate to amounts
 due to the Company from Boehringer for reimbursement work performed
 under the collaboration.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognized revenues of approximately $2.3 million and
 $2.5 million under this agreement during the three months ended
 September&#xA0;30, 2013 and 2012, respectively, and $6.9 million
 and $9.3 million during the nine months ended September&#xA0;30,
 2013 and 2012, respectively. One milestone payment of $2.0 million
 was recognized under this agreement through December 2012. No
 milestones have been recognized under this agreement during the
 three and nine months ended September&#xA0;30, 2013. A milestone
 was earned under this agreement subsequent to September&#xA0;30,
 2013. See Note 11, Subsequent Events, for additional
 information.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At September&#xA0;30, 2013, $10.3 million of revenue was deferred
 under this agreement, $5.0 million of which was included in current
 liabilities and $5.3 million of which was included in long-term
 liabilities. At December&#xA0;31, 2012, $14.0 million of revenue
 was deferred under this agreement, $5.0 million of which was
 included in current liabilities and $9.0 million of which was
 included in long-term liabilities.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Pfizer, Inc.</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October 2010, the Company entered into a three year agreement
 with Pfizer to discover, develop and commercialize up to two
 DART-based molecules. The Company granted Pfizer a non-exclusive
 worldwide, royalty-bearing license and received an upfront payment
 of $5 million and has received milestone payments and funding for
 the Company&#x2019;s internal and external research costs under the
 agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company is eligible to receive milestone payments of
 approximately $17 million related to pre-clinical and clinical
 development and $195 million related to commercialization and sales
 milestones for each DART program under this agreement. The Company
 has determined that each potential future technical and development
 milestone is substantive. Although sales milestones are not
 considered substantive, they are still recognized upon achievement
 of the milestone (assuming all other revenue recognition criteria
 have been met) because there are no undelivered elements that would
 preclude revenue recognition at that time. Pfizer is responsible
 for all pre-clinical and clinical development costs for the
 program. In addition, Pfizer is required to pay the Company
 mid-single digit to low-teen royalties on product sales. Under this
 collaboration, one DART program is currently being pursued and the
 Company will complete its research obligations under this program
 in January 2014.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated the research collaboration agreement with
 Pfizer and has determined that it is a revenue arrangement with
 multiple deliverables, or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 research collaboration include an exclusive license to its
 technology, research and development services and manufacturing
 services. The Company concluded that the manufacturing services
 were optional and were subject to further negotiation upon reaching
 regulatory approval. As such, the manufacturing services are not
 included in the expected obligation period to perform services.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company determined that it had fair value of the undelivered
 element of the research and development services. However, the
 Company concluded that the license does not have value on a
 standalone basis (e.g. absent the provision of the research and
 development services) and therefore does not represent a separate
 unit of accounting. Facts that were considered included the
 development of the candidate noting that because the drug candidate
 has not yet been developed, the license is of no value to Pfizer
 without the ensuing research and development activities using the
 DART technology, which is proprietary to the Company. Likewise,
 Pfizer could not sell the license to another party (without the
 Company agreeing to provide the research and development activities
 for the other party).</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Therefore, the upfront license fee and research and development
 services were treated as a combined unit of accounting and
 recognized over the expected obligation period associated with the
 research and development services through January 2014, which
 represents the estimated period of development.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The $5 million upfront payment received by the Company is
 non-refundable; therefore, there is no right of return for the
 license. The Company is recognizing revenue associated with this
 non-refundable up-front license fee through January 2014.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company and Pfizer have also agreed to establish a joint
 research committee to facilitate the governance and oversight of
 the parties&#x2019; activities under the agreements. Management
 considered whether participation on the joint committee may be a
 deliverable and determined that it was not a deliverable because it
 is a participating right and not an obligation of the Company.
 However, had management considered participation on the joint
 committee as a deliverable, it would not have had a material impact
 on the accounting for the arrangement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&#xA0;1, 2011.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Receivables of $501,794 and $896,285 as of September&#xA0;30, 2013
 and December&#xA0;31, 2012, respectively, relate to amounts due to
 the Company from Pfizer for reimbursement work performed under the
 collaboration.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognized revenues of approximately $0.9 million and
 $1.2 million under this agreement during the three months ended
 September&#xA0;30, 2013 and 2012, respectively, and $3.2 million
 and $4.0 million during the nine months ended September&#xA0;30,
 2013 and 2012, respectively. Included in the 2012 revenues are
 milestone payments totaling $500,000. No additional milestones have
 been recognized under this agreement through September&#xA0;30,
 2013.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At September&#xA0;30, 2013 and December&#xA0;31, 2012, $58,000 and
 $1.3 million of revenue was deferred under this agreement, all of
 which was included in current liabilities.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Green Cross Corporation</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In June&#xA0;2010, the Company entered into a collaboration
 agreement with Green Cross for the development of the
 Company&#x2019;s anti-HER2 antibody known as MGAH22, or
 margetuximab. This arrangement grants Green Cross an exclusive
 license to conduct specified Phase 1 and Phase 2 clinical trials
 and commercialize margetuximab in South Korea.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon execution of the agreement, Green Cross made a nonrefundable
 payment of $1.0&#xA0;million to the Company. The Company is
 eligible to receive clinical development and commercial milestone
 payments of up to $4.5 million. The Company has determined that
 each potential clinical development and commercial milestone is
 substantive. The Company is also entitled to receive royalties on
 net sales of margetuximab in South Korea. The Company and Green
 Cross have formed a joint steering committee to coordinate and
 oversee activities on which the companies collaborate under the
 agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated the collaboration agreement with Green
 Cross and has determined that it is a revenue arrangement with
 multiple deliverables or performance obligations. The
 Company&#x2019;s substantive performance obligations under this
 agreement include an exclusive license to its technologies and
 participation in a joint steering committee. The Company concluded
 that the license does not have value on a standalone basis and
 therefore does not represent a separate unit of accounting.
 Likewise, Green Cross could not sell the license to another
 party.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The $1 million upfront payment received by the Company is
 non-refundable; as such, there is no right of return for the
 license. Therefore, the upfront license fee and participation on
 the joint steering committee were treated as a combined unit of
 accounting and will be recognized over the term of the agreement
 through June 2020.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There have been no material modifications to this agreement since
 the adoption of ASU 2009-13 on January&#xA0;1, 2011.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognized revenues of approximately $25,000 under this
 agreement during each of the three month periods ending
 September&#xA0;30, 2013 and 2012, and $75,000 during each of the
 nine month periods ending September&#xA0;30, 2013 and 2012. No
 milestones have been recognized under this agreement during the
 three and nine months ended September&#xA0;30, 2013.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At September&#xA0;30, 2013, $675,000 of revenue was deferred under
 this agreement, $100,000 of which was included in current
 liabilities and $575,000 of which was included in long-term
 liabilities. At December&#xA0;31, 2012, $750,000 of revenue was
 deferred under this agreement, $100,000 of which was included in
 current liabilities and $650,000 of which was included in long-term
 liabilities.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Eli Lilly&#xA0;&amp; Co.</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In October&#xA0;2007, the Company entered into an exclusive license
 and collaboration agreement (together, the Agreements) with Eli
 Lilly to jointly develop and commercialize teplizumab, a humanized
 anti-CD3 monoclonal antibody. As part of the Agreements, Eli Lilly
 acquired the exclusive rights to the molecule.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upon execution of the Agreements, Eli Lilly made a nonrefundable
 payment of $41.0&#xA0;million to the Company. In May&#xA0;2008, Eli
 Lilly paid the Company a milestone payment of $50.0&#xA0;million
 and in May&#xA0;2010, Eli&#xA0;Lilly paid an additional milestone
 of $5.0&#xA0;million.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On October&#xA0;28, 2010, Lilly notified the Company of its
 decision to terminate the agreement after review of one year of
 clinical data from the PROT&#xC9;G&#xC9; trial in Type 1 diabetes
 patients treated with teplizumab. Such data failed to support the
 primary efficacy end point in the study. During the year ended
 December&#xA0;31, 2012, Eli&#xA0;Lilly satisfied its obligation
 related to the cost of monitoring patients under the
 PROT&#xC9;G&#xC9; and ENCORE trials. The Company&#x2019;s
 obligations continued through September 2012, which represented the
 follow up period for enrolled patients and the Company&#x2019;s
 final reporting of the trial&#x2019;s results. There is no
 additional clinical trial activity under the Eli Lilly Agreements
 as it relates to such trials. In February 2011, the Company
 reacquired the commercial rights to the molecule from Eli
 Lilly.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Receivables of $244,542 and $558,516 as of September&#xA0;30, 2013
 and December&#xA0;31, 2012, respectively, relate to amounts due to
 the Company from Eli Lilly for reimbursement work performed under
 the above mentioned clinical trials.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 During the three months ended September&#xA0;30, 2013 and 2012, the
 Company recognized revenue of $190,833 and $9.5 million,
 respectively, under this agreement. During the nine months ended
 September&#xA0;30, 2013 and 2012, the Company recognized revenue of
 $673,927 and $30.1 million, respectively. No milestones were
 recognized under this agreement during the three and nine months
 ended September&#xA0;30, 2013.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Collaboration and license agreements disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_TextBlockAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>2. Summary of Significant Accounting Policies</b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Use of Estimates</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The preparation of the financial statements in accordance with GAAP
 requires the Company to make estimates and judgments in certain
 circumstances that affect the reported amounts of assets,
 liabilities, revenues and expenses, and related disclosure of
 contingent assets and liabilities. In preparing these consolidated
 financial statements, management has made its best estimates and
 judgments of certain amounts included in the financial statements,
 giving due consideration to materiality. On an ongoing basis, the
 Company evaluates its estimates, including those related to revenue
 recognition, fair values of assets, convertible preferred stock and
 common stock, preferred stock warrant liability, income taxes,
 pre-clinical study and clinical trial accruals and other
 contingencies. Management bases its estimates on historical
 experience or on various other assumptions that it believes to be
 reasonable under the circumstances. Actual results could differ
 from these estimates.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In addition, through September&#xA0;30, 2013, the Company utilized
 estimates and assumptions in determining the fair value of its
 common stock. The Company granted stock options at exercise prices
 not less than the fair value of its common stock as determined by
 the board of directors, with input from management. Management uses
 contemporaneous valuations in estimating the fair value of its
 common stock. The board of directors has determined the estimated
 fair value of the common stock based on a number of objective and
 subjective factors, including external market considerations
 affecting the biotechnology industry and the historic prices at
 which the Company sold shares of its preferred stock.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Cash and Cash Equivalents</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company considers all investments in highly liquid financial
 instruments with an original maturity of three months or less at
 the date of purchase to be cash equivalents. Cash and cash
 equivalents consist of certificates of deposit and investment in
 money market funds with commercial banks and financial
 institutions. Cash equivalents are stated at amortized cost, plus
 accrued interest, which approximates fair value.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Accounts Receivable</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Accounts receivable that management has the intent and ability to
 collect are reported in the consolidated balance sheets at
 outstanding amounts, less an allowance for doubtful accounts. The
 Company writes off uncollectible receivables when the likelihood of
 collection is remote.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company evaluates the collectability of accounts receivable on
 a regular basis. The allowance, if any, is based upon various
 factors including the financial condition and payment history of
 customers, an overall review of collections experience on other
 accounts and economic factors or events expected to affect future
 collections experience. No allowance was recorded as of
 September&#xA0;30, 2013 or December&#xA0;31, 2012, as the Company
 has a history of collecting on all outstanding accounts.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Deferred Initial Public Offering Costs</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Deferred IPO costs as of September&#xA0;30, 2013, consisted of
 legal, accounting, printing and filing fees were capitalized. The
 deferred costs are included in prepaid expenses on the consolidated
 balance sheets. The deferred offering costs were offset against the
 IPO proceeds received upon the completion of the offering in
 October 2013.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Restricted Cash</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company is required to maintain certificates of deposit that
 serve as collateral for various operating leases and corporate
 credit card accounts. Amounts classified as restricted cash on the
 consolidated balance sheets are $404,850 at September&#xA0;30, 2013
 and December&#xA0;31, 2012.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Fair Value of Financial Instruments</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The fair market values of the financial instruments included in the
 financial statements, which include cash equivalents and money
 market accounts, approximate their carrying values at
 September&#xA0;30, 2013 and December&#xA0;31, 2012, due to their
 short-term maturities. The Company accounts for recurring and
 non-recurring fair value measurements in accordance with the
 Financial Accounting Standards Board (FASB) Accounting Standards
 Codification (ASC) 820, <i>Fair Value Measurements and
 Disclosures</i> (ASC 820). ASC 820 defines fair value, establishes
 a fair value hierarchy for assets and liabilities measured at fair
 value, and requires expanded disclosures about fair value
 measurements. The ASC 820 hierarchy ranks the quality of
 reliability of inputs, or assumptions, used in the determination of
 fair value, and requires assets and liabilities carried at fair
 value to be classified and disclosed in one of the following three
 categories:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 1&#xA0;&#x2013; Fair value is
 determined by using unadjusted quoted prices that are available in
 active markets for identical assets and liabilities.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 2&#xA0;&#x2013; Fair value is
 determined by using inputs other than Level 1 quoted prices that
 are directly or indirectly observable. Inputs can include quoted
 prices for similar assets and liabilities in active markets or
 quoted prices for identical assets and liabilities in inactive
 markets. Related inputs can also include those used in valuation or
 other pricing models, such as interest rates and yield curves that
 can be corroborated by observable market data.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="100%">
 <tr>
 <td width="5%">&#xA0;</td>
 <td valign="top" width="2%" align="left">&#x2022;</td>
 <td valign="top" width="1%">&#xA0;</td>
 <td valign="top" align="left">Level 3&#xA0;&#x2013; Fair value is
 determined by inputs that are unobservable and not corroborated by
 market data. Use of these inputs involves significant and
 subjective judgments to be made by a reporting entity&#xA0;&#x2013;
 e.g., determining an appropriate adjustment to a discount factor
 for illiquidity associated with a given security.</td>
 </tr>
 </table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company evaluates financial assets and liabilities subject to
 fair value measurements on a recurring basis to determine the
 appropriate level at which to classify them each reporting period.
 This determination requires the Company to make subjective
 judgments as to the significance of inputs used in determining fair
 value and where such inputs lie within the ASC 820 hierarchy.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Financial assets and liabilities subject to fair value measurements
 were as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="49%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 September&#xA0;30, 2013</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active&#xA0;Markets&#xA0;for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable&#xA0;Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,522,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">7,522,029</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">26,047,169</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,974,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">33,974,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr>
 <td height="16"></td>
 <td height="16" colspan="16"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="14" align="center"><b>Fair Value Measurements at
 December&#xA0;31, 2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" rowspan="2" colspan="2" align="center"><b>Total</b></td>
 <td valign="bottom" rowspan="2">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Quoted&#xA0;Prices&#xA0;in</b><br />
 <b>Active&#xA0;Markets&#xA0;for</b><br />
 <b>Identical Assets</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant&#xA0;Other</b><br />
 <b>Observable&#xA0;Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Significant</b><br />
 <b>Unobservable</b><br />
 <b>Inputs</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 1</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 2</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Level 3</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Assets:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Cash and cash equivalents</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">18,695,197</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Money market funds</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">29,047,958</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Restricted cash</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">404,850</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total assets</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">48,148,005</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Liabilities:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Preferred stock warrant liability</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 As of December&#xA0;31, 2012, the Company transferred its money
 market funds from Level 2 to Level 1 because the inputs are now
 based upon a quoted market price.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s Level 1 securities primarily consist of
 restricted cash, cash equivalents and money market funds. The
 Company determines the estimated fair value for its Level 1
 securities using quoted (unadjusted) prices for identical assets or
 liabilities in active markets.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company determines the estimated fair value for its Level 2
 securities using the following methods: quoted prices for similar
 assets/liabilities in active markets, inputs other than quoted
 prices that are observable for the asset/liability (e.g., interest
 rates, yield curves volatilities, default rates, etc.) and inputs
 that are derived principally from or corroborated by other
 observable market data.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table provides a rollforward of the Company&#x2019;s
 preferred stock warrant liability, which was the only financial
 instrument measured at fair value on a recurring basis using
 significant unobservable inputs (Level 3) as defined in ASC
 820:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="86%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance at December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(52,947</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total unrealized gains (losses) included in earnings</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(626,349</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Balance at September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">(679,296</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In order to estimate the fair value of the preferred stock purchase
 warrants, the business enterprise value was established based on a
 discounted cash flow model (income approach). The Company utilized
 an option pricing method to value the shares using a contingent
 claims analysis, which applies a series of call options whose
 inputs reflect the liquidation preferences and conversion behavior
 of the different classes of equity. After the equity value of the
 business enterprise was determined, the total equity value is
 allocated to the various equity instruments such as preferred
 stock, stock options and preferred stock purchase warrants. Key
 management estimates relate to the time period to liquidation and
 conversion behavior of a particular class of stockholders. The
 business enterprise value includes assumptions related to product
 approval, market penetration and costs to develop the product.
 Significant changes to these assumptions would result in
 increases/decreases to the fair value of the outstanding
 warrants.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The total unrealized gains (losses) on the preferred stock warrants
 included in earnings is included as a component of other income
 (expense) in the consolidated statement of operations and
 comprehensive income.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Concentration of Credit Risk</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Substantially all of the Company&#x2019;s cash and cash equivalents
 are maintained with major financial institutions in the United
 States. Deposits held with banks may exceed the amount of insurance
 provided on such deposits. Generally, these deposits may be
 redeemed upon demand and, therefore, bear minimal risk.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Financial instruments that potentially subject the Company to
 concentrations of credit risk consist principally of cash and cash
 equivalents, and accounts receivable. The counterparties are
 various corporations, financial institutions and government
 agencies of high credit standing.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For the three and nine months ended September&#xA0;30, 2013 and
 2012, all of the Company&#x2019;s grant revenue was related to
 contracts and research grants received from U.S. government
 agencies. Collaborations with Les Laboratoires Servier and Institut
 de Recherches Servier (collectively, Servier), Boehringer Ingelheim
 GmbH (Boehringer), Gilead Sciences, Inc. (Gilead), Pfizer, Inc.
 (Pfizer) and Eli Lilly&#xA0;&amp; Co. (Eli Lilly) account for all
 other revenue. All outstanding receivables are due from Gilead,
 Pfizer, Boehringer, Eli Lilly, and U.S. government agencies.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table represents the percentage of all significant
 revenue earned in the periods indicated:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="52%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Servier</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">71.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">14.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">58.8</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">12.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">15.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">13.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.5</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">6.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.9</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">59.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">55.7</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table represents the percentage of all significant
 accounts receivable:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="16%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Gilead</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Pfizer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">22.6</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">45.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Boehringer</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.1</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">18.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Eli Lilly</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">11.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">28.2</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Government Agencies</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4.0</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8.4</td>
 <td valign="bottom" nowrap="nowrap">%&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Property and Equipment</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Property and equipment are stated at cost. Upon retirement or sale,
 the cost of assets disposed of and the related accumulated
 depreciation are removed from the accounts and any resulting gain
 or loss is credited or charged to operations. Repairs and
 maintenance costs are expensed as incurred. Depreciation and
 amortization are computed using the straight-line method over the
 following estimated useful lives:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="4%"></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">3 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">10 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Laboratory and office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">5 years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 Shorter&#xA0;of&#xA0;lease&#xA0;term&#xA0;or&#xA0;useful&#xA0;life</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Impairment of Long-Lived Assets</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company assesses the recoverability of its long-lived assets in
 accordance with the provisions of ASC 360, <i>Property, Plant and
 Equipment</i>. ASC 360 requires that long-lived assets be reviewed
 for impairment whenever events or changes in circumstances indicate
 that the carrying amount of an asset may not be recoverable.
 Recoverability of the long-lived asset is measured by a comparison
 of the carrying amount of the asset to future undiscounted net cash
 flows expected to be generated by the asset or asset group. If
 carrying value exceeds the sum of undiscounted cash flows, the
 Company then determines the fair value of the underlying asset
 group. Any impairment to be recognized is measured by the amount by
 which the carrying amount of the asset group exceeds the estimated
 fair value of the asset group. Assets to be disposed of are
 reported at the lower of the carrying amount or fair value, less
 costs to sell. As of September&#xA0;30, 2013 and December&#xA0;31,
 2012, the Company determined that there were no impaired assets and
 had no assets held-for-sale.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Revenues</i></b></p>
 <p style="MARGIN-TOP: 6pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <i>Revenue Recognition</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company enters into collaboration and license agreements with
 collaborators for the development of monoclonal antibody-based
 therapeutics to treat cancer and other complex diseases. The terms
 of these agreements contain multiple deliverables which may include
 (i)&#xA0;licenses, or options to obtain licenses, to the
 Company&#x2019;s technological platforms, such as its Fc
 Optimization and Dual-Affinity Re-Targeting (DART) technologies,
 (ii)&#xA0;rights to future technological improvements,
 (iii)&#xA0;research and development activities to be performed on
 behalf of the collaborator or as part of the collaboration, and
 (iv)&#xA0;the manufacture of pre-clinical or clinical materials for
 the collaborator. Payments to the Company under these agreements
 may include nonrefundable license fees, option fees, exercise fees,
 payments for research and development activities, payments for the
 manufacture of pre-clinical or clinical materials, license
 maintenance payments, payments based upon the achievement of
 certain milestones and royalties on product sales. Other benefits
 to the Company of these agreements include the right to sell
 products resulting from the collaborative efforts of the parties in
 specific geographic territories. The Company follows the provisions
 of the FASB ASC Topic 605-25, <i>Revenue
 Recognition&#xA0;&#x2013;Multiple-Element Arrangements</i>, and ASC
 Topic 605-28, <i>Revenue Recognition&#x2013;Milestone Method</i>, in
 accounting for these agreements. In order to account for these
 agreements, the Company must identify the deliverables included
 within the agreement and evaluate which deliverables represent
 separate units of accounting based on the achievement of certain
 criteria, including whether the delivered element has stand-alone
 value to the collaborator. The consideration received is allocated
 among the separate units of accounting, and the applicable revenue
 recognition criteria are applied to each of the separate units.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For the periods presented, the Company had the following two types
 of agreements with the parties identified below: 1) exclusive
 development and commercialization licenses to use the
 Company&#x2019;s technology and/or certain other intellectual
 property to develop compounds against specified targets (referred
 to herein as exclusive licenses); and 2) Option/research agreements
 to secure on established terms, development and commercialization
 licenses to anticancer and other therapeutic product candidates to
 collaborator selected targets developed by the Company during an
 option period (referred to herein as right-to-develop
 agreements).</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 There are no performance, cancellation, termination or refund
 provisions in any of the arrangements that contain material
 financial consequences to the Company.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <i>Exclusive Licenses</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The deliverables under an exclusive license agreement generally
 include the exclusive license to the Company&#x2019;s DART
 technology with respect to a specified antigen target, and may also
 include deliverables related to rights to future technological
 improvements, research and pre-clinical development activities to
 be performed on behalf of the collaborator. In some cases the
 Company may have an option to participate in the co-development of
 product candidates that result from such agreements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Generally, exclusive license agreements contain nonrefundable terms
 for payments and, depending on the terms of the agreement, provide
 that the Company will (i)&#xA0;at the collaborator&#x2019;s request,
 provide research and pre-clinical development services at
 negotiated prices which are generally consistent with what other
 third parties would charge, (ii)&#xA0;earn payments upon the
 achievement of certain milestones, (iii)&#xA0;earn royalty
 payments, and (iv)&#xA0;in some cases grant the Company an option
 to participate in the development and commercialization of products
 that result from such agreements. Royalty rates may vary over the
 royalty term depending on the Company&#x2019;s intellectual property
 rights and whether the Company exercises any co-development and
 co-commercialization rights. The Company may provide technical
 assistance and share any technology improvements with its
 collaborators during the term of the collaboration agreements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company does not directly control when any collaborator will
 achieve milestones or become liable for royalty payments.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In determining the units of accounting, management evaluates
 whether the exclusive license has stand-alone value from the
 undelivered elements to the collaborator based on the consideration
 of the relevant facts and circumstances for each arrangement.
 Factors considered in this determination include the research and
 development capabilities of the partner and the availability of
 technology platform and product research expertise in the general
 marketplace. If the Company concludes that the license has
 stand-alone value and therefore will be accounted for as a separate
 unit of accounting, the Company then determines the estimated
 selling prices of the license and all other units of accounting
 based on market conditions, similar arrangements entered into by
 third parties, and entity-specific factors such as the terms of the
 Company&#x2019;s previous collaboration agreements, recent
 pre-clinical and clinical testing results of therapeutic product
 candidates that use the Company&#x2019;s technology platforms, the
 Company&#x2019;s pricing practices and pricing objectives, the
 likelihood that technological improvements will be made, the
 likelihood that technological improvements made will be used by the
 Company&#x2019;s collaborators and the nature of the research
 services to be performed on behalf of its collaborators and market
 rates for similar services.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upfront payments on exclusive licenses are deferred if facts and
 circumstances dictate that the license does not have stand-alone
 value. Prior to the adoption of Accounting Standards Update (ASU)
 No.&#xA0;2009-13, <i>Revenue Arrangements with Multiple
 Deliverables</i>, on January&#xA0;1, 2011, the Company determined
 that its licenses lacked stand-alone value because it did not have
 vendor-specific objective evidence of selling price (VSOE), and
 were combined with other elements of the arrangement and any
 amounts associated with the license were deferred and amortized
 over a certain period, which the Company refers to as the
 Company&#x2019;s period of substantial involvement. In making the
 determination of the length of the period over which to defer
 revenue for contracts entered into prior to the adoption of ASU
 No.&#xA0;2009-13, significant judgment and estimation is used by
 the Company and can have an impact on the amount of revenue
 recognized in a given period. Historically, the Company&#x2019;s
 involvement with the development of a collaborator&#x2019;s product
 candidate has been significant at the early stages of development,
 and lessens as it progresses into clinical trials. Accordingly, the
 Company generally estimates this period of substantial involvement
 to begin at the inception of the collaboration agreement and
 conclude at the end of the Company&#x2019;s substantial involvement.
 ASU No.&#xA0;2009-13 amends the criteria for separating and
 allocating consideration in a multiple element arrangement by
 modifying the fair value requirements for revenue recognition and
 eliminating the use of the residual value method. The selling
 prices of deliverables under an arrangement may be derived using
 third-party evidence (TPE), or a best estimate of selling price
 (BESP), if VSOE is not available. The objective of BESP is to
 determine the price at which the Company would transact a sale if
 the element within the license agreement was sold on a standalone
 basis. Establishing BESP involves management&#x2019;s judgment and
 considers multiple factors, including market conditions and
 company-specific factors, including those factors contemplated in
 negotiating the agreements, as well as internally developed models
 that include assumptions related to market opportunity, discounted
 cash flows, estimated development costs, probability of success and
 the time needed to commercialize a product candidate pursuant to
 the license. In validating the BESP, management considers whether
 changes in key assumptions used to determine the BESP will have a
 significant effect on the allocation of the arrangement
 consideration between the multiple deliverables. Deliverables under
 the arrangement are separate units of accounting if (i)&#xA0;the
 delivered item has value to the customer on a standalone basis and
 (ii)&#xA0;if the arrangement includes a general right of return
 relative to the delivered item, delivery or performance of the
 undelivered item is considered probable and substantially within
 the Company&#x2019;s control. The arrangement consideration that is
 fixed or determinable at the inception of the arrangement is
 allocated to the separate units of accounting based on their
 relative selling prices. The appropriate revenue recognition model
 is applied to each element and revenue is accordingly recognized as
 each element is delivered. Management exercises significant
 judgment in determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In determining the separate units of accounting, the Company
 evaluated whether the exclusive license had standalone value to the
 collaborator based on consideration of the relevant facts and
 circumstances for each arrangement. Factors considered in this
 determination included the research and development capabilities of
 the collaborator and the availability of relevant research
 expertise in the marketplace. In addition, the Company considered
 whether or not (i)&#xA0;the collaborator could use the license for
 its intended purpose without the receipt of the remaining
 deliverables, (ii)&#xA0;the value of the license was dependent on
 the undelivered items and (iii)&#xA0;the collaborator or other
 vendors could provide the undelivered items.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company reassesses its periods of substantial involvement over
 which the Company amortizes its upfront license fees and makes
 adjustments as appropriate. In the event a collaborator elects to
 discontinue development of a specific product candidate under a
 single target license, but retains its right to use the
 Company&#x2019;s technology to develop an alternative product
 candidate to the same target or a target substitute, the Company
 would cease amortization of any remaining portion of the upfront
 fee until there is substantial pre-clinical activity on another
 product candidate and its remaining period of substantial
 involvement can be estimated. In the event that a single target
 license were to be terminated, the Company would recognize as
 revenue any portion of the upfront fee that had not previously been
 recorded as revenue, but was classified as deferred revenue, at the
 date of such termination or through the remaining substantial
 involvement in the wind down of the agreement.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Upfront payments on exclusive licenses may be recognized upon
 delivery of the license if facts and circumstances dictate that the
 license has stand-alone value from the undelivered elements, which
 generally include rights to future technological improvements,
 research services and the manufacture of pre-clinical and clinical
 materials.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company recognizes revenue related to research and pre-clinical
 development services that represent separate units of accounting as
 they are performed, as long as there is persuasive evidence of an
 arrangement, the fee is fixed or determinable, and collection of
 the related receivable is probable. The Company recognizes revenue
 related to the rights to future technological improvements over the
 estimated term of the applicable license.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company typically performs research activities and pre-clinical
 development services, including generating and engineering product
 candidates, on behalf of its licensees during the early evaluation
 and pre-clinical testing stages of drug development under its
 exclusive licenses. The Company records amounts received for
 research materials produced or services performed as revenue from
 collaborative research.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s license agreements have milestone payments
 which for reporting purposes are aggregated into three categories:
 (i)&#xA0;development milestones, (ii)&#xA0;regulatory milestones,
 and (iii)&#xA0;sales milestones. Development milestones are
 typically payable when a product candidate initiates or advances
 into different clinical trial phases. Regulatory milestones are
 typically payable upon submission for marketing approval with the
 U.S. Food and Drug Administration (FDA) or other countries&#x2019;
 regulatory authorities or on receipt of actual marketing approvals
 for the compound or for additional indications. Sales milestones
 are typically payable when annual sales reach certain levels.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 At the inception of each agreement that includes milestone
 payments, the Company evaluates whether each milestone is
 substantive and at risk to both parties on the basis of the
 contingent nature of the milestone. This evaluation includes an
 assessment of whether (a)&#xA0;the consideration is commensurate
 with either (1)&#xA0;the entity&#x2019;s performance to achieve the
 milestone, or (2)&#xA0;the enhancement of the value of the
 delivered item(s) as a result of a specific outcome resulting from
 the entity&#x2019;s performance to achieve the milestone,
 (b)&#xA0;the consideration relates solely to past performance and
 (c)&#xA0;the consideration is reasonable relative to all of the
 deliverables and payment terms within the arrangement. The Company
 evaluates factors such as the scientific, regulatory, commercial
 and other risks that must be overcome to achieve the respective
 milestone, the level of effort and investment required to achieve
 the respective milestone and whether the milestone consideration is
 reasonable relative to all deliverables and payment terms in the
 arrangement in making this assessment.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Non-refundable development and regulatory milestones that are
 expected to be achieved as a result of the Company&#x2019;s efforts
 during the period of substantial involvement are considered
 substantive and are recognized as revenue upon the achievement of
 the milestone, assuming all other revenue recognition criteria are
 met. Milestones that are not considered substantive because the
 Company does not contribute effort to the achievement of such
 milestones are generally achieved after the period of substantial
 involvement and are recognized as revenue upon achievement of the
 milestone, as there are no undelivered elements remaining and no
 continuing performance obligations, assuming all other revenue
 recognition criteria are met.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; MARGIN-LEFT: 2%; FONT-SIZE: 10pt">
 <i>Right-to-Develop Agreements</i></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company&#x2019;s right-to-develop agreements provide
 collaborators with an exclusive option to obtain licenses to
 develop and commercialize in specified geographic territories
 product candidates developed by the Company under agreed upon
 research and pre-clinical development product programs. The product
 candidates resulting from each program are all directed to a
 specific target selected by the collaborator. Under these
 agreements, fees may be due to the Company (i)&#xA0;at the
 inception of the arrangement (referred to as &#x201C;upfront&#x201D;
 fees or payments), (ii)&#xA0;the selection of a target for a
 program, (iii)&#xA0;upon the exercise of an option to acquire a
 development and commercialization license (referred to as exercise
 fees or payments earned) for a program, or (iv)&#xA0;some
 combination of all of these fees.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The accounting for right-to-develop agreements is dependent on the
 nature of the options granted to the collaborator. Options are
 considered substantive if, at the inception of a right-to-develop
 agreement, the Company is at risk as to whether the collaborator
 will choose to exercise the options to secure development and
 commercialization licenses. Factors that are considered in
 evaluating whether options are substantive include the overall
 objective of the arrangement, the benefit the collaborator might
 obtain from the agreement without exercising the options, the cost
 to exercise the options relative to the total upfront
 consideration, and the additional financial commitments imposed on
 the collaborator as a result of exercising the options.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to a product program are
 considered substantive, the Company does not consider the
 development and commercialization licenses to be a deliverable at
 the inception of the agreement. For those right-to-develop
 agreements entered into prior to the adoption of ASU
 No.&#xA0;2009-13 where the options to secure development and
 commercialization licenses are considered substantive, the Company
 has deferred the upfront payments received and recognizes this
 revenue over the period during which the collaborator could elect
 to exercise options for development and commercialization licenses.
 These periods are specific to each collaboration agreement. If a
 collaborator selects a target for a product program, any
 substantive option fee is deferred and recognized over the life of
 the option, generally 12 months. Subsequent to the adoption of ASU
 No. 2009-13, the Company&#x2019;s evaluation of whether the option
 is substantive is consistent with pre-adoption of ASU
 No.&#xA0;2009-13. How the Company determines the selling price of
 the option is the only difference between pre and post adoption of
 ASU No.&#xA0;2009-13. Post adoption of ASU No.&#xA0;2009-13, the
 selling prices of deliverables under an arrangement may be derived
 using TPE or a BESP, if VSOE is not available. The objective of
 BESP is to determine the price at which the Company would transact
 a sale if the element within the right-to-develop agreement was
 sold on a standalone basis. Establishing BESP involves
 management&#x2019;s judgment and considers multiple factors,
 including market conditions and company-specific factors, including
 those factors contemplated in negotiating the agreements, as well
 as internally developed models that include assumptions related to
 market opportunity, discounted cash flows, estimated development
 costs, probability of success and the time needed to commercialize
 a product candidate pursuant to the right-to-develop agreement. In
 validating the BESP, management considers whether changes in key
 assumptions used to determine the BESP will have a significant
 effect on the allocation of the arrangement consideration between
 the multiple deliverables. Deliverables under the arrangement are
 separate units of accounting if (i)&#xA0;the delivered item has
 value to the customer on a standalone basis and (ii)&#xA0;if the
 arrangement includes a general right of return relative to the
 delivered item, delivery or performance of the undelivered item is
 considered probable and substantially within the Company&#x2019;s
 control. The arrangement consideration that is fixed or
 determinable at the inception of the arrangement is allocated to
 the separate units of accounting based on their relative selling
 prices. The appropriate revenue recognition model is applied to
 each element and revenue is accordingly recognized as each element
 is delivered. Management exercises significant judgment in
 determining whether a deliverable is a separate unit of
 accounting.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 If a collaborator exercises an option and acquires a development
 and commercialization license to a product program, the Company
 attributes the exercise fee to the development and
 commercialization license. The Company determines the selling price
 of the option license, upon exercise, through management&#x2019;s
 best estimate. Management&#x2019;s determination of selling price
 includes such factors as stage of development, market potential and
 cash flow models used during the negotiation with the collaborator.
 There have been no option license exercises to date for any period
 presented. Upon exercise of an option to acquire a development and
 commercialization license, the Company would also attribute any
 remaining deferred option fee to the development and
 commercialization license and apply the multiple-element revenue
 recognition criteria to the development and commercialization
 license and any other deliverables to determine the appropriate
 revenue recognition, which will be consistent with the
 Company&#x2019;s accounting policy for upfront payments on exclusive
 licenses event a right-to-develop agreement were to be terminated,
 the Company would recognize as revenue any portion of the upfront
 fee that had not previously been recorded as revenue, but was
 classified as deferred revenue, at the date of such termination.
 The Company&#x2019;s right-to-develop agreements have been
 determined to contain substantive options.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For right-to-develop agreements where the options to secure
 development and commercialization licenses to product programs are
 not considered substantive, the Company considers the development
 and commercialization licenses to be a deliverable at the inception
 of the agreement and applies the multiple-element revenue
 recognition criteria to determine the appropriate revenue
 recognition. The Company does not directly control when any
 collaborator will exercise its options for development and
 commercialization licenses.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Research and Development Costs</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Research and development expenditures are expensed as incurred.
 Research and development costs primarily consist of employee
 related expenses, including salaries and benefits, expenses
 incurred under agreements with contract research organizations,
 investigative sites and consultants that conduct the
 Company&#x2019;s clinical trials, the cost of acquiring and
 manufacturing clinical trial materials and other allocated
 expenses, license fees for and milestone payments related to
 in-licensed products and technologies, stock-based compensation
 expense, and costs associated with non-clinical activities and
 regulatory approvals.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Comprehensive Income (Loss)</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Effective January&#xA0;1, 2012, the Company adopted ASU2011-05,
 <i>Presentation of Comprehensive Income,</i> which amended ASC
 Topic 220, <i>Comprehensive Income.</i> The amendments in ASU
 2011-05 require the presentation of the comprehensive income (loss)
 and its components as part of the consolidated financial
 statements. Comprehensive income (loss) is comprised of the net
 income (loss) and other changes in equity that are excluded from
 net income (loss). Comprehensive income (loss) equals net income
 (loss) for the three and nine months ended September&#xA0;30, 2013
 and 2012.</p>
 <p style="MARGIN-TOP: 18px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Stock-based Compensation</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Stock-based payments are accounted for in accordance with the
 provisions of ASC&#xA0;718, <i>Compensation&#xA0;&#x2013; Stock
 Compensation</i>. The fair value of stock-based payments is
 estimated, on the date of grant, using the Black-Scholes model. The
 resulting fair value is recognized ratably over the requisite
 service period, which is generally the vesting period of the
 option.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 For all time-vesting awards granted, expense is amortized using the
 straight-line attribution method. For awards that contain a
 performance condition, expense is amortized using the accelerated
 attribution method. Recognition of stock-based compensation expense
 is based on the value of the portion of stock-based awards that is
 ultimately expected to vest during the period.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company utilizes the Black-Scholes model for estimating fair
 value of its stock options granted. Option valuation models,
 including the Black-Scholes model, require the input of highly
 subjective assumptions, and changes in the assumptions used can
 materially affect the grant-date fair value of an award. These
 assumptions include the risk-free rate of interest, expected
 dividend yield, expected volatility and the expected life of the
 award.</p>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Net Income (Loss) Per Share</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Income (loss) per share is calculated under the two-class method
 under which all earnings (distributed and undistributed) are
 allocated to each class of common stock and participating
 securities based on their respective rights to receive dividends.
 In the event that the Board of Directors shall declare a dividend
 payable in cash or other property on the then-outstanding shares of
 common stock, the holders of the Series&#xA0;A-1, A-2, B, C, D, and
 D-2 convertible preferred stock shall be entitled to receive the
 amount of dividends per share of Preferred Stock that would be
 payable on the largest number of whole shares of Common Stock into
 which each share of Preferred Stock could then be converted.
 Therefore, the Series A-1, A-2, B, C, D and D-2 are participating
 securities.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic net income (loss) per common share is determined by dividing
 the net income (loss) allocable to common stockholders by the
 weighted-average number of common shares outstanding during the
 period, without consideration of common stock equivalents. Diluted
 net income (loss) per share is computed by dividing the net income
 (loss) allocable to common stockholders by the weighted-average
 number of common stock equivalents outstanding for the period. The
 treasury stock method is used to determine the dilutive effect of
 the Company&#x2019;s stock option grants and the if-converted method
 is used to determine the dilutive effect of the Company&#x2019;s
 Series&#xA0;A-1, A-2, B, C, D, and D-2 convertible preferred
 stock.</p>
 <p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 &#xA0;</p>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Basic and diluted income (loss) per common share is computed as
 follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="51%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss)</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,603,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,600,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,944,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,466,582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less: undistributed earnings allocated to participating
 securities</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,434,756</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,600,514</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,944,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,466,582</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">169,226</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,184,507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,092,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,463,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,078,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>Basic income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>0.14</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">6,603,982</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,600,514</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,944,149</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,466,582</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less: undistributed earnings allocated to participating securities
 and other add-backs to net income (loss)</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(6,403,843</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,600,514</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(2,944,149</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(10,466,582</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Net income (loss) allocable to common shares</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">200,139</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">&#x2014;&#xA0;&#xA0;</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Basic weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,184,507</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,092,307</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,463,798</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,078,145</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Effect of dilutive securities</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,058,471</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,410,117</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,445,061</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">20,334,703</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Diluted weighted average common shares outstanding</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,242,978</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,502,424</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,908,859</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">21,412,848</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 <b>Diluted income (loss) per common share</b></p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>0.01</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"><b>$</b></td>
 <td valign="bottom" align="right"><b>&#x2014;&#xA0;&#xA0;</b></td>
 <td valign="bottom" nowrap="nowrap"><b>&#xA0;&#xA0;</b></td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following common stock equivalents are included in the
 calculation of diluted net income (loss) per share:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="60%"></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="2%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Three&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series A-1 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,156,114</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series A-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">392,274</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series B Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,336,037</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series C Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">5,909,906</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series D Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">769,468</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,391,991</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Warrants to purchase Series D-2 Preferred Stock</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">180,784</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Stock Options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,910,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,276,516</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,910,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,276,516</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>
 <p style="MARGIN-TOP: 18pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b><i>Recently Issued Accounting Standards Adopted</i></b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In May&#xA0;2011, the FASB issued ASU No.&#xA0;2011-04, which
 amended ASC Topic 820 to achieve common fair value measurements and
 disclosure requirements in U.S. GAAP and International Financial
 Reporting Standards (IFRS). The amendments in ASU No.&#xA0;2011-04
 result in common fair value measurement and disclosure requirements
 in U.S. GAAP and IFRS. Consequently, the amendments change the
 wording used to describe many of the requirements in U.S. GAAP for
 measuring fair value and for disclosing information about fair
 value measurements. This amendment is effective for fiscal years
 beginning after December&#xA0;15, 2011. The adoption of this
 amendment did not have a material impact on the Company&#x2019;s
 consolidated financial statements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 In June&#xA0;2011, the FASB issued ASU No.&#xA0;2011-05, which
 amended ASC Topic 220 regarding presentation of comprehensive
 income. The amendments in ASU No.&#xA0;2011-05 require that all
 nonowner changes in stockholders&#x2019; equity be presented either
 in a single continuous statement of comprehensive income or in two
 separate but consecutive statements. In the two-statement approach,
 the first statement should present total net income and its
 components followed consecutively by a second statement that should
 present total other comprehensive income, the components of other
 comprehensive income, and the total of comprehensive income. This
 amendment is effective for fiscal years beginning after
 December&#xA0;15, 2011. The adoption of this amendment did not have
 a material impact on the Company&#x2019;s consolidated financial
 statements.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The Company has evaluated all ASUs through the date the
 consolidated financials were issued and believes that the adoption
 of these will not have a material impact on the Company&#x2019;s
 consolidated financial statements.</p>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_AccountingPoliciesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SignificantAccountingPoliciesTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EQWAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Events - Additional Information (Detail) (USD $)<br>In Millions, except Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2013

</div>
          <div>Subsequent Event [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013

</div>
          <div>Subsequent Event [Member]

</div>
          <div>IPO [Member]</div>
        </th>
        <th class="th">
          <div>Oct. 16, 2013

</div>
          <div>Subsequent Event [Member]

</div>
          <div>IPO [Member]</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Initial public offering number of share sold</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">5,000,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Initial public offering price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 16<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption', window );">Additional shares sold under over-allotments Option to underwriter</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">750,000<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering net of expenses</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">$ 83.8<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump">2,124,624<span></span></td>
        <td class="nump">1,098,914<span></span></td>
        <td class="nump">25,020,288<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump">2,124,624<span></span></td>
        <td class="nump">1,098,914<span></span></td>
        <td class="nump">25,020,288<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable', window );">Milestone Payments Triggered</a></td>
        <td class="nump">5.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ResearchAndMaintenanceAmountReceivable', window );">Research Maintenance Payment Receivable</a></td>
        <td class="nump">$ 4.0<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ResearchAndMaintenanceAmountReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Research And Maintenance Amount Receivable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_ResearchAndMaintenanceAmountReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Revenue Recognition, Milestone Method, Revenue Receivable</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_RevenueRecognitionMilestoneMethodRevenueReceivable</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period, shares to underwriters for exercise of over allotment option.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesIssued</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PreferredStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ProceedsFromIssuanceInitialPublicOffering</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 820<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25499696&amp;loc=d3e19207-110258<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SharePrice</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_StockIssuedDuringPeriodSharesNewIssues</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_SubsequentEventLineItems</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EHEAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="2">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
        <td class="nump">$ 316,852<span></span></td>
        <td class="nump">$ 235,543<span></span></td>
        <td class="nump">$ 834,615<span></span></td>
        <td class="nump">$ 722,496<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DepreciationDepletionAndAmortization</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Property and equipment consists of the following:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="10%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>September&#xA0;30,&#xA0;2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>December&#xA0;31,&#xA0;2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Computer equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,172,535</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">2,003,706</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Software</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,323,081</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,323,081</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Furniture</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">599,650</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Lab equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,603,598</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">8,747,790</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Office equipment</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">51,360</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Leasehold improvements</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,893,770</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">4,881,706</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Property and equipment</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">19,643,994</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">17,607,293</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Less accumulated depreciation and amortization</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(15,174,112</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(14,339,497</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Property and equipment, net</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">4,469,882</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,267,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PropertyPlantAndEquipmentTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 <b>10. Employee Benefit Plan</b></p>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 On September&#xA0;25, 2002, the Company established the MacroGenics
 401(k) Plan (the Plan) for its employees under Section&#xA0;401(k)
 of the IRC. Under this Plan, all employees at least 21 years of age
 are eligible to participate in the Plan, starting on the first day
 of each month. Employees may contribute up to 100% of their salary,
 subject to government maximums.</p>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Employees are 100% vested in their contributions to the Plan. The
 Company&#x2019;s contribution to the Plan, as determined by the
 Board of Directors, is discretionary. The Company&#x2019;s
 contributions to the Plan totaled $55,311 and $48,891 for the three
 months ended September&#xA0;30, 2013 and 2012, respectively, and
 $194,498 and $179,966 for the nine months ended September&#xA0;30,
 2013 and 2012, respectively.</p>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CompensationAndRetirementDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for pension and other postretirement benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 715<br><br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Minimum Future Lease Payments Payables</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Future minimum lease payments under noncancelable operating leases
 at September&#xA0;30, 2013 are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="83%"></td>
 <td valign="bottom" width="6%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Twelve Months Ending September&#xA0;30,</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">3,460,609</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2015</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,396,780</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2016</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,385,321</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2017</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,486,881</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2018</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,035,013</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">625,540</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">17,390,144</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_CommitmentsAndContingenciesDisclosureAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of a lessee's leasing arrangements including: (1) the basis on which contingent rental payments are determined, (2) the existence and terms of renewal or purchase options and escalation clauses, (3) restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, (4) rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.  Disclosure may also include the specific period used to amortize material leasehold improvements made at the inception of the lease or during the lease term. Additionally, for operating leases having initial or remaining noncancelable lease terms in excess of one year: (a) future minimum rental payments required as of the date of the latest balance sheet presented, in the aggregate and for each of the five succeeding fiscal years, (b) the total of minimum rentals to be received in the future under noncancelable subleases as of the date of the latest balance sheet presented, and (c) for all operating leases, rental expense for each period for which an income statement is presented, with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month or less that were not renewed need not be included.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6851643&amp;loc=d3e12069-110248<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452660&amp;loc=d3e36991-112694<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 40<br><br> -Subparagraph (Note 1,3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Shared-Based Payments (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following stock-based compensation amounts were recognized for
 the periods indicated:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
 <tr>
 <td width="64%"></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="3%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Three Months Ended<br />
 September&#xA0;30</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"><b>Nine Months Ended<br />
 September&#xA0;30</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>2012</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Research and development</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">111,888</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">117,952</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">284,281</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">353,856</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 General and administrative</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">24,048</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">91,647</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">109,280</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">274,940</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Total stock-based compensation expense</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">135,936</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">209,599</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">393,561</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">628,796</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Option Award Estimated on the Date of Grant Using the Black-Scholes Option-Pricing Model</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 6pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The fair value of each option award is estimated on the date of
 grant using the Black-Scholes option-pricing model using the
 assumptions in the following table:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="75%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="3" align="center">
 <b>Nine&#xA0;Months&#xA0;Ended&#xA0;September&#xA0;30,</b></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2013</b></td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" align="center"><b>2012</b></td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected dividend yield</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">0%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected volatility</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">53%&#xA0;-&#xA0;58%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">51%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Risk-free interest rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">1.24%&#xA0;-&#xA0;2.05%</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">1.18%</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected average life of options</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">7&#xA0;years</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Fair market value of common stock at:</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center"><font style="WHITE-SPACE: nowrap">$1.50&#xA0;-&#xA0;$7.51</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">$1.50</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Expected forfeiture rate</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom" align="center">5.06%</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="center">5.57%</td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 The following table summarizes stock option activity under the Plan
 during the period then ended:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="84%" align="center"><!-- Begin Table Head -->
 <tr>
 <td width="59%"></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 <td valign="bottom" width="9%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Number&#xA0;of</b><br />
 <b>Options</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average&#xA0;Exercise</b><br />
 <b>Price</b></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"><b>Weighted-<br />
 Average</b><br />
 <b>Contractual&#xA0;Term</b><br />
 <b>(in Years)</b></td>
 <td valign="bottom">&#xA0;</td>
 </tr>
 <!-- End Table Head --><!-- Begin Table Body -->
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Outstanding, December&#xA0;31, 2012</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3,249,702</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.3</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Granted</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">687,183</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">3.19</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.0</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercised</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(1,025,933</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.75</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Forfeited or expired</p>
 </td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(33,949</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.13</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Outstanding, September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,877,003</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1.50</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">7.2</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 September&#xA0;30, 2013:</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Exercisable</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,855,178</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">0.94</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 Vested and Expected to Vest</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">918,600</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2.44</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <!-- End Table Body --></table>


 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E1AAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Sep. 30,
				 2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2013<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q3<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">MACROGENICS INC<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001125345<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-13<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Non-accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump">25,020,288<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_AmendmentFlag</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_CurrentFiscalYearEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalPeriodFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentFiscalYearFocus</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentPeriodEndDate</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_DocumentType</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCentralIndexKey</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityCommonStockSharesOutstanding</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityFilerCategory</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>dei_EntityRegistrantName</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>mgnx_DocumentAndEntityInformationAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>mgnx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <link rel="StyleSheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script></head>
  <body><span style="display: none;">v2.4.0.8</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Lease Exit Liability (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">9 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring And Related Activities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Lease Exit Liability</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 0pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Changes in the lease exit liability are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrual balance at December&#xA0;31, 2011</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">10,607,499</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(533,560</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrual balance at December 31, 2012</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">10,073,939</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Principal payments</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">(466,301</td>
 <td valign="bottom" nowrap="nowrap">)&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Accrual balance at September&#xA0;30, 2013</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,607,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 3px double">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Future Principal Payments Under Lease Agreement</a></td>
        <td class="text"><div>
 <p style="MARGIN-TOP: 12pt; TEXT-INDENT: 4%; FONT-FAMILY: Times New Roman; MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt">
 Future principal payments to be made under the lease agreement for
 the next five years and thereafter as of September&#xA0;30, 2013
 are as follows:</p>
 <p style="MARGIN-TOP: 0pt; MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt">
 &#xA0;</p>
 <table style="BORDER-COLLAPSE: collapse; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" border="0" cellspacing="0" cellpadding="0" width="68%" align="center">
 <tr>
 <td width="85%"></td>
 <td valign="bottom" width="5%"></td>
 <td></td>
 <td></td>
 <td></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Twelve Months Ending September&#xA0;30,</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 <td valign="bottom"></td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2014</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">1,229,454</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2015</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,589,410</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2016</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">1,808,119</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2017</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,049,273</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; FONT-SIZE: 10pt">
 2018</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">2,315,026</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt" bgcolor="#CCEEFF">
 <td valign="top">
 <p style="TEXT-INDENT: -1em; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; FONT-SIZE: 10pt">
 Thereafter</p>
 </td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">&#xA0;</td>
 <td valign="bottom" align="right">616,356</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 <tr style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
 <td valign="top"></td>
 <td valign="bottom"><font style="FONT-SIZE: 8pt">&#xA0;&#xA0;</font></td>
 <td valign="bottom">$</td>
 <td valign="bottom" align="right">9,607,638</td>
 <td valign="bottom" nowrap="nowrap">&#xA0;&#xA0;</td>
 </tr>
 <tr style="FONT-SIZE: 1px">
 <td valign="bottom"></td>
 <td valign="bottom">&#xA0;&#xA0;</td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td valign="bottom">
 <p style="BORDER-TOP: #000000 1px solid">&#xA0;</p>
 </td>
 <td>&#xA0;</td>
 </tr>
 </table>
 </div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_RestructuringAndRelatedActivitiesAbstract</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 420<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td><nobr>us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</nobr></td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;"><nobr><strong> Namespace Prefix:</strong></nobr></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
